PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hutchison, M; Berman, KS; Cobb, MH				Hutchison, M; Berman, KS; Cobb, MH			Isolation of TAO1, a protein kinase that activates MEKs in stress-activated protein kinase cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER-BEARING KINASE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; SIGNAL-TRANSDUCTION; STE20; YEAST; PATHWAY; HOMOLOG; IDENTIFICATION; SAPK/JNK	Several components of the budding yeast pheromone-response pathway are conserved in mammalian mitogen-activated protein (MAP) kinase pathways. Thus, we used degenerate oligonucleotides derived from the sequence of the Saccharomyces cerevisiae protein kinase Ste20p to amplify related sequences from the rat. One of these sequences was used to clone a rat Ste20p homolog, which we called TAO1 for its one thousand and one amino acids. Northern analysis shows TAO1 is highly expressed in brain, as is a homolog TAO2, Recombinant TAO1 was expressed and purified from Sf9 cells. In vitro, it activated MAP/extracellular signal-regulated protein kinase (ERR) kinases (MEKs) 3, 4, and 6 of the stress-responsive MAP kinase pathways, but not MEK1 or 2 of the classical MAP kinase pathway. TAO1 activated MEK3 but not MEK4 or MEK6 in transfected cells. MEK3 coimmunoprecipitated with TAO1 when they were expressed in 293 cells. In addition, immunoreactive MEK3 endogenous to Sf9 cells copurified with TAO1 produced from a recombinant baculovirus. The activation of and binding to MEK3 by TAO1 implicates TAO1 in the regulation of the p38-containing stress-responsive MAP kinase pathway.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	mcobb@mednet.swmed.edu		Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NIGMS NIH HHS [GM53032] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHALEFF DT, 1985, MOL CELL BIOL, V5, P1878, DOI 10.1128/MCB.5.8.1878; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; KATOH M, 1995, ONCOGENE, V10, P1447; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEVIN DE, 1993, J NIH RES, V5, P49; LEWIS TS, 1998, CANCER RES, P50; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984	47	106	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28625	28632		10.1074/jbc.273.44.28625	http://dx.doi.org/10.1074/jbc.273.44.28625			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786855				2022-12-25	WOS:000076691800016
J	Luneberg, J; Widmann, M; Dathe, M; Marti, T				Luneberg, J; Widmann, M; Dathe, M; Marti, T			Secondary structure of bacteriorhodopsin fragments - External sequence constraints specify the conformation of transmembrane helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; INTEGRAL MEMBRANE-PROTEIN; SYNTHETIC PEPTIDES; ALPHA-HELIX; STRUCTURE PREDICTION; NEURAL NETWORKS; MODEL; RECONSTITUTION; ENVIRONMENTS; DENATURATION	The secondary structure of bacteriorhodopsin polypeptides comprising two (AB, CD, DE, FG), three (AC, CE, EG), four (AD, DG), or five (AE, CG) of the seven transmembrane segments has been analyzed by circular dichroism spectroscopy. A comparison of the Lu-helix content with that predicted from the high resolution structure of the native protein revealed that the N-terminal AB, AC, AD, and AE fragments and the C-terminal CG fragment are completely refolded in the presence of mixed phospholipid micelles, In contrast, the DG, EG, FG, CD, CE, and DE fragments did not form alpha-helices of the expected lengths at pH 6, Each of the latter fragments displayed, however, an increased helicity upon lowering the pH to 4, Fluorescence measurements with the CD and FG fragments suggest that this helix formation occurs within transmembrane segments C and G, respectively, and thus is likely to originate from the protonation of carboxyl residues that participate in proton translocation, The partial misfolding at neutral pH observed for the shorter fragments from the central and C-terminal part of bacteriorhodopsin indicates that the conformation of some transmembrane segments is specified by interactions with neighboring helices in the assembled structure. Moreover, the data demonstrate that two stable helices at the N terminus of a multihelical membrane protein are sufficient as a folding template to induce a native conformation to the following transmembrane domains.	Bernard Nocht Inst, Dept Mol Biol, D-20359 Hamburg, Germany; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Res Inst Mol Pharmacol, D-10315 Berlin, Germany	Bernhard Nocht Institut fur Tropenmedizin; University of Zurich	Marti, T (corresponding author), Bernard Nocht Inst, Dept Mol Biol, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	marti@bni.uni-hamburg.de						Andersen NH, 1996, FEBS LETT, V399, P47, DOI 10.1016/S0014-5793(96)01279-3; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Blondelle SE, 1997, BIOPOLYMERS, V42, P489, DOI 10.1002/(SICI)1097-0282(19971005)42:4<489::AID-BIP11>3.3.CO;2-L; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Bohm G, 1996, BIOPHYS CHEM, V59, P1, DOI 10.1016/0301-4622(95)00120-4; Booth PJ, 1997, BIOCHEMISTRY-US, V36, P197, DOI 10.1021/bi962200m; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; COWAN R, 1990, Peptide Research, V3, P75; COWGILL RW, 1968, BIOCHIM BIOPHYS ACTA, V168, P431, DOI 10.1016/0005-2795(68)90176-1; DALMAS B, 1994, BIOCHEM MOL BIOL INT, V34, P17; Doak DG, 1996, J MOL BIOL, V258, P672, DOI 10.1006/jmbi.1996.0278; EFTINK MR, 1976, J PHYS CHEM-US, V80, P486, DOI 10.1021/j100546a014; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FASMAN GD, 1995, BIOPOLYMERS, V37, P339, DOI 10.1002/bip.360370505; GLAESER RM, 1985, BIOCHEMISTRY-US, V24, P6398, DOI 10.1021/bi00344a012; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; GRISSHAMMER R, 1995, Q REV BIOPHYS, V28, P315, DOI 10.1017/S0033583500003504; HANSEN OK, 1994, BIOL CHEM H-S, V375, P715; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; HOLLEY LH, 1991, METHOD ENZYMOL, V202, P204; HUANG KS, 1981, J BIOL CHEM, V256, P3802; Hunt JF, 1997, BIOCHEMISTRY-US, V36, P15177, DOI 10.1021/bi970147b; Hunt JF, 1997, BIOCHEMISTRY-US, V36, P15156, DOI 10.1021/bi970146j; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P8829, DOI 10.1021/bi00152a020; Kanaori K, 1997, EUR J BIOCHEM, V249, P878, DOI 10.1111/j.1432-1033.1997.00878.x; KHORANA HG, 1993, P NATL ACAD SCI USA, V90, P1166, DOI 10.1073/pnas.90.4.1166; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Lehrer S S, 1978, Methods Enzymol, V49, P222; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LI SC, 1994, NAT STRUCT BIOL, V1, P368, DOI 10.1038/nsb0694-368; LI SC, 1993, J BIOL CHEM, V268, P22975; LIAO MJ, 1983, J BIOL CHEM, V258, P9949; LONDON E, 1982, J BIOL CHEM, V257, P7003; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; MYSZKA DG, 1994, BIOCHEMISTRY-US, V33, P2363, DOI 10.1021/bi00175a003; NASSAL M, 1987, J BIOL CHEM, V262, P9264; Ozawa S, 1997, BBA-BIOMEMBRANES, V1323, P145, DOI 10.1016/S0005-2736(96)00182-4; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; PERVUSHIN KV, 1994, EUR J BIOCHEM, V219, P571, DOI 10.1111/j.1432-1033.1994.tb19973.x; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; POUNY Y, 1995, BIOCHEMISTRY-US, V34, P7712, DOI 10.1021/bi00023a018; Riley ML, 1997, BIOCHEMISTRY-US, V36, P192, DOI 10.1021/bi962199r; SahinToth M, 1996, BIOCHEMISTRY-US, V35, P2016, DOI 10.1021/bi952496g; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIGRIST H, 1988, EUR J BIOCHEM, V177, P125, DOI 10.1111/j.1432-1033.1988.tb14352.x; STOECKENIUS W, 1982, ANNU REV BIOCHEM, V51, P587, DOI 10.1146/annurev.bi.51.070182.003103; SWORDS NA, 1993, BIOCHEM J, V289, P215, DOI 10.1042/bj2890215; TAYLOR JW, 1987, METHOD ENZYMOL, V154, P473; VOGEL H, 1987, J BIOL CHEM, V262, P11464; WALLACE BA, 1987, BIOCHEMISTRY-US, V26, P65, DOI 10.1021/bi00375a010; Wigley WC, 1998, BIOCHEMISTRY-US, V37, P844, DOI 10.1021/bi972293n; Yamaguchi S, 1998, J BIOCHEM-TOKYO, V123, P78; YANG JT, 1986, METHOD ENZYMOL, V130, P208	63	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28822	28830		10.1074/jbc.273.44.28822	http://dx.doi.org/10.1074/jbc.273.44.28822			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786882	hybrid			2022-12-25	WOS:000076691800043
J	Ryu, K; Gilchrist, RL; Tung, CS; Ji, I; Ji, TH				Ryu, K; Gilchrist, RL; Tung, CS; Ji, I; Ji, TH			High affinity hormone binding to the extracellular N-terminal exodomain of the follicle-stimulating hormone receptor is critically modulated by exoloop 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; FUNCTIONAL EXPRESSION; ACTIVATION; GONADOTROPIN; SEQUENCE; DOMAIN; CDNA; RAT; CLONING	The human follicle-stimulating hormone receptor (FSH-R) consists of two distinct domains of >330 amino acids, the N-terminal extracellular exodomain and membrane-associated endodomain. The exodomain alone binds hormone with high affinity, whereas the endodomain is the site of receptor activation. Coordination of these two domains is essential for successful hormone action but little is known about their functional and structural relationship, In this communication, we report that exoloop 3 of FSH-R constrains follicle-stimulating hormone binding to the exodomain, When the FSH-R exodomain was prepared by truncating its endodomain, the hormone binding affinity of the exodomain was slightly improved, compared with the wild type receptor. The binding affinity was further improved by >3-fold when the exodomain was attached to the membrane-associated domain of CD8, These results suggest that the FSH-R endodomain attenuates hormone binding at the exodomain, As a first step to test this hypothesis, the II amino acids except Ala(589) of exoloop 3 were individually substituted with Ala, Ala substitution for Leu(583) or Ile(584) improved the hormone binding affinity by 4-6-fold while totally abolishing cAMP induction, indicating an inverse relationship. The Ala substitution for Lys(580) or Pro(582) had a similar trend but to a lesser extent. This significant improvement in the binding affinity suggests that the four residues at the N-terminal region of exoloop 3 interact with the exodomain and constrain the hormone binding in the wild type receptor. This effect is specific since substitutions for other than the 4 residues did not improve the hormone binding affinity. Computer modeling shows that the 4 residues can be positioned on one side of exoloop 3, This result and the apparent inverse relationship of hormone binding and cAMP induction suggest that these two essential functions may work against each other. Therefore, hormone binding might be compromised to preserve cAMP inducibility while maintaining a reasonably high, but below maximum, binding affinity.	Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA; Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA	University of Wyoming; United States Department of Energy (DOE); Los Alamos National Laboratory	Ji, TH (corresponding author), Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA.	Ji@uwyo.edu			NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI IH, 1995, J BIOL CHEM, V270, P15970, DOI 10.1074/jbc.270.27.15970; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; Osuga Y, 1997, MOL ENDOCRINOL, V11, P1659, DOI 10.1210/me.11.11.1659; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; Tung CS, 1997, BIOPHYS J, V72, P876, DOI 10.1016/S0006-3495(97)78722-8; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; XIE YB, 1990, J BIOL CHEM, V265, P21411	23	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28953	28958		10.1074/jbc.273.44.28953	http://dx.doi.org/10.1074/jbc.273.44.28953			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786899	hybrid			2022-12-25	WOS:000076691800060
J	Smith, RL; Szegedy, MA; Kucharski, LM; Walker, C; Wiet, RM; Redpath, A; Kaczmarek, MT; Maguire, ME				Smith, RL; Szegedy, MA; Kucharski, LM; Walker, C; Wiet, RM; Redpath, A; Kaczmarek, MT; Maguire, ME			The CorA Mg2+ transport protein of Salmonella typhimurium - Mutagenesis of conserved residues in the third membrane domain identifies a Mg2+ pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; MAGNESIUM TRANSPORT; SARCOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; REGULATORY CATION; ESCHERICHIA-COLI; ION; SEQUENCES; CLONING; SYSTEMS	The CorA transport system is the major Mg2+ influx pathway for bacteria and the Archaea. CorA contains three C-terminal transmembrane segments. No conserved charged residues are apparent within the membrane, suggesting that Mg2+ influx does not involve electrostatic interactions. We have mutated conserved residues within the third transmembrane segment to identify sites involved in transport. Mutation of conserved aromatic residues at either end of the membrane segment to alternative aromatic amino acids did not affect total cation uptake or cation affinity. Mutation to alanine greatly diminished uptake with little change in cation affinity implying that the conserved aromatic residues play a structural role in stabilizing this membrane segment of CorA at the interface between the bilayer and the aqueous environment. In contrast, mutation of Tyr(292), Met(299), and Tyr(307) greatly altered the transport properties of CorA. Y292F, Y292S, Y292C, or Y292I mutations essentially abolished transport, without effect on expression or membrane insertion. M299C and M299A mutants exhibited a decrease in cation affinity for Mg2+, Co2+, or Ni2+ Of 10-50-fold without a significant change in uptake capacity. Mutations at Tyr(307) had no significant effect on cation uptake capacity; however, the affinity of Y307F and Y307A mutations for Mg2+ and Co2+ was decreased 3-10-fold, while affinity for Ni2+ was unchanged compared with the wild type CorA. In contrast, the affinity of the Y307S mutant for all three cations was decreased 2-5-fold. Projection of the third transmembrane segment as an alpha-helix suggests that Tyr292, Met(299), and Tyr(307) all reside on the same face of the alpha-helix. Ne interpret the transport data to suggest that a hydroxyl group is important at Tyr(307), and that these three residues interact with Mg2+ during transport, forming part of the cation pore or channel within CorA.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	Maguire, ME (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	mem6@po.cwru.edu			NIDDK NIH HHS [DK07319] Funding Source: Medline; NIGMS NIH HHS [GM08056, GM39447] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039447] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEISENHOFER J, 1991, ANNU REV BIOPHYS BIO, V20, P247; DIEBLER H, 1969, Pure and Applied Chemistry, V20, P93, DOI 10.1351/pac196920010093; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GREEN NM, 1989, BIOCHEM SOC T, V17, P819, DOI 10.1042/bst0170819; GRUBBS RD, 1989, METHOD ENZYMOL, V173, P546; GRUBBS RD, 1987, MAGNESIUM, V6, P113; HMIEL SP, 1989, J BACTERIOL, V171, P4742, DOI 10.1128/jb.171.9.4742-4751.1989; HMIEL SP, 1986, J BACTERIOL, V168, P1444, DOI 10.1128/jb.168.3.1444-1450.1986; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; KEHRES D, 1998, COMP MICROB GENOM, V3, P151; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Lingrel JB, 1997, ANN NY ACAD SCI, V834, P194, DOI 10.1111/j.1749-6632.1997.tb52251.x; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAGUIRE ME, 1990, MET IONS BIOL SYST, V26, P135; MARTIN RB, 1990, MET IONS BIOL SYST, V26, P1; NELSON DL, 1971, J BIOL CHEM, V246, P3042; RAO R, 1993, J BIOL CHEM, V268, P6708; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; ROTH M, 1989, NATURE, V340, P659, DOI 10.1038/340659a0; SAIER MH, 1994, MICROBIOL REV, V58, P71, DOI 10.1128/MMBR.58.1.71-93.1994; SMITH RL, 1993, J BIOL CHEM, V268, P14071; Smith RL, 1998, MOL MICROBIOL, V28, P217, DOI 10.1046/j.1365-2958.1998.00810.x; SMITH RL, 1995, J BACTERIOL, V177, P1638, DOI 10.1128/jb.177.6.1638-1640.1995; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; SNAVELY MD, 1989, J BACTERIOL, V171, P4761, DOI 10.1128/jb.171.9.4761-4766.1989; Tao T, 1998, MICROBIOL-SGM, V144, P655, DOI 10.1099/00221287-144-3-655; TAO T, 1995, J BACTERIOL, V177, P2654, DOI 10.1128/jb.177.10.2654-2662.1995	29	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28663	28669		10.1074/jbc.273.44.28663	http://dx.doi.org/10.1074/jbc.273.44.28663			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786860	hybrid			2022-12-25	WOS:000076691800021
J	Eng, FCS; Barsalou, A; Akutsu, N; Mercier, I; Zechel, C; Mader, S; White, JH				Eng, FCS; Barsalou, A; Akutsu, N; Mercier, I; Zechel, C; Mader, S; White, JH			Different classes of coactivators recognize distinct but overlapping binding sites on the estrogen receptor ligand binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION FUNCTION AF-2; NUCLEAR-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; CBP; SUPERFAMILY; SEQUENCE; MEDIATOR; PROTEIN; BREAST; CANCER	We have analyzed interaction of coactivators with the wild-type estrogen receptor alpha (ER), HEG0, and a mutant, L536P-HEG0, which is constitutively active in several transiently transfected cells and a HeLa line that stably propagates an estrogen-sensitive reporter gene. Different classes of coactivators do not recognize the ER ligand binding domain (LBD) in the same manner. Steroid receptor coactivator-1 (SRC-1), amplified in breast cancer-1 (AIB-1), transcriptional intermediary factor-1 (TIF-1), transcriptional intermediary factor-2 (TIF-2), and receptor interacting protein 140 (RIP140) interacted with HEG0 and L536P-HEG0 in the presence of estradiol, but generally not in the presence of anti-estrogens. However, ICI164,384 stimulated some interaction of RIP140 with LBDs, SRC-1, AIB-1, and RIP140 interacted constitutively with the L536P ER, whereas TIF-1 and TIF-2 interacted only weakly in the absence of hormone. Reciprocal competition for binding to the ER LBD was observed between different classes of coactivators. Moreover, coexpression of RIP140 blocked enhanced transactivation by HEG0 observed in the presence of TIF-2, suggesting that RIP140 may play a negative role in ER signaling, We conclude that constitutive activity of L536P-HEG0 is manifested to similar degrees in different cell types and likely arises from constitutive coactivator binding; different classes of coactivators recognize distinct but overlapping binding sites on the ER LBD. Finally, the observation that L536P-HEG0 interacted constitutively with AIB-1, a coactivator that has been implicated in ER signaling in breast and ovarian cancer, suggests that similar mutations in the ER may contribute to hormone-independent proliferation of breast and ovarian cells.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Inst Genet & Biol Mol & Cellulaire, Illkirch, France	McGill University; McGill University; Universite de Montreal; Institut National de la Sante et de la Recherche Medicale (Inserm)	White, JH (corresponding author), McGill Univ, Dept Physiol, McIntyre Med Sci Bldg,3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	jwhite@physio.mcgill.ca	Mercier, Isabelle/C-5775-2011; white, john h/N-9782-2013	white, john h/0000-0002-4785-2687				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Eng FCS, 1997, MOL CELL BIOL, V17, P4644, DOI 10.1128/MCB.17.8.4644; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Montminy M, 1997, NATURE, V387, P654, DOI 10.1038/42594; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WHITE JH, 1994, BIO-TECHNOL, V12, P1003, DOI 10.1038/nbt1094-1003; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; Zhang QX, 1997, CANCER RES, V57, P1244	29	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28371	28377		10.1074/jbc.273.43.28371	http://dx.doi.org/10.1074/jbc.273.43.28371			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774463	hybrid			2022-12-25	WOS:000076549800083
J	Grishin, AV; Caplan, MJ				Grishin, AV; Caplan, MJ			ATP1AL1, a member of the non-gastric H,K-ATPase family, functions as a sodium pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING DUCT; RAT DISTAL COLON; ALPHA-SUBUNIT; GENE FAMILY; K-ATPASE; H+,K+-ATPASE; EXPRESSION; OUABAIN; NA+,K+-ATPASE; POTASSIUM	The human ATP1AL1-encoded protein (an alpha subunit of the human non-gastric H,K-ATPase) has previously been shown to assemble with the gastric H,K-ATPase beta subunit (gH,K beta) to form a functionally active ionic pump in HEK 293 cells. This pump has been found to be sensitive to both SCH 28080 and ouabain. However, the Rb-86(+)-influx mediated by the ATP1AL1-gH,K beta heterodimer in HEK 293 cells is at least 1 order of magnitude larger than the maximum ouabain-sensitive proton efflux detected in the same cells. In this study we find that the intracellular Na+ content in cells expressing ATP1AL1 and gH,K beta is two times lower than that in control HEK 293 cells in response to incubation for 3 h in the presence of 1 mu M ouabain. Moreover, analysis of net Na+ efflux in HEK 293 expressing the ATP1AL1-gH,K beta heterodimer reveals the presence of Na+ extrusion activity that is not sensitive to 1 mu M ouabain but can be inhibited by 1 mM of this drug. In contrast, ouabain-inhibitable Na+ efflux in control HEK 293 cells is similarly sensitive to either 1 mu M or 1 mM ouabain. Finally, Rb-86(+) influx through the ATP1AL1-gH,K beta complex is comparable to the 1 mM ouabain-sensitive Na+ efflux in the same cells. The data presented here suggest that the enzyme formed by ATP1AL1 and the gastric H,K-ATPase beta subunit in HEK 293 cells mediates primarily Na+,K+ rather than H+,K+ exchange.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Grishin, AV (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St,POB 208026, New Haven, CT 06520 USA.	grishin@biomed.med.yale.edu		Caplan, Michael/0000-0001-5768-4405	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-17433] Funding Source: Medline; NIGMS NIH HHS [GM-42136] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn KY, 1996, AM J PHYSIOL-RENAL, V271, pF314, DOI 10.1152/ajprenal.1996.271.2.F314; BuffinMeyer B, 1997, AM J PHYSIOL-RENAL, V272, pF124, DOI 10.1152/ajprenal.1997.272.1.F124; Codina J, 1998, J BIOL CHEM, V273, P7894, DOI 10.1074/jbc.273.14.7894; Codina J, 1996, J BIOL CHEM, V271, P29759, DOI 10.1074/jbc.271.47.29759; Cougnon M, 1998, P NATL ACAD SCI USA, V95, P6516, DOI 10.1073/pnas.95.11.6516; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; Doucet A, 1997, EXP NEPHROL, V5, P271; DUBOSE TD, 1995, AM J PHYSIOL-RENAL, V269, pF500, DOI 10.1152/ajprenal.1995.269.4.F500; EIAMONG S, 1993, J CLIN INVEST, V91, P2385, DOI 10.1172/JCI116471; EIAMONG S, 1993, KIDNEY INT, V43, P1015, DOI 10.1038/ki.1993.143; FEJESTOTH G, 1995, AM J PHYSIOL-RENAL, V269, pF551, DOI 10.1152/ajprenal.1995.269.4.F551; FERRONE RD, 1988, AM J PHYSIOL, V254, pG898; GRISHIN AV, 1994, FEBS LETT, V349, P144, DOI 10.1016/0014-5793(94)00655-5; Grishin AV, 1996, AM J PHYSIOL-RENAL, V271, pF539, DOI 10.1152/ajprenal.1996.271.3.F539; HAYSHI M, 1987, AM J PHYSIOL, V252, pF437; Jaisser F, 1996, AM J PHYSIOL-CELL PH, V270, pC679, DOI 10.1152/ajpcell.1996.270.2.C679; JAISSER F, 1993, PFLUG ARCH EUR J PHY, V425, P446, DOI 10.1007/BF00374871; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; Kone BC, 1998, J BIOL CHEM, V273, P2543, DOI 10.1074/jbc.273.5.2543; Kone BC, 1996, MINER ELECTROL METAB, V22, P349; Kraut JA, 1998, KIDNEY INT, V53, P958, DOI 10.1111/j.1523-1755.1998.00841.x; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Marsy S, 1996, PFLUG ARCH EUR J PHY, V432, P494, DOI 10.1007/s004240050161; MODYANOV NN, 1995, AM J PHYSIOL, V269, pF314; PANDIYAN V, 1992, GASTROENTEROLOGY, V102, P1846, DOI 10.1016/0016-5085(92)90304-H; POLVANI C, 1988, J BIOL CHEM, V263, P16757; POLVANI C, 1989, J BIOL CHEM, V264, P17854; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RABON EC, 1990, J BIOL CHEM, V265, P19594; RAJENDRAN VMD, 1991, AM J PHYSIOL, V261, pG1005; Sangan PC, 1997, AM J PHYSIOL-CELL PH, V272, pC685, DOI 10.1152/ajpcell.1997.272.2.C685; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKEGUCHI M, 1990, GASTROENTEROLOGY, V99, P1339, DOI 10.1016/0016-5085(90)91159-4; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; WATANABE T, 1990, AM J PHYSIOL, V258, pG506, DOI 10.1152/ajpgi.1990.258.4.G506; WINGO CS, 1995, AM J PHYSIOL-RENAL, V269, pF1, DOI 10.1152/ajprenal.1995.269.1.F1; ZHOU XM, 1992, AM J PHYSIOL, V263, pF1134; ZHOU XM, 1992, AM J PHYSIOL, V263, pF43, DOI 10.1152/ajprenal.1992.263.1.F43	40	51	51	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27772	27778		10.1074/jbc.273.43.27772	http://dx.doi.org/10.1074/jbc.273.43.27772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774385	hybrid			2022-12-25	WOS:000076549800005
J	Schaffer, DV; Lauffenburger, DA				Schaffer, DV; Lauffenburger, DA			Optimization of cell surface binding enhances efficiency and specificity of molecular conjugate gene delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR; IN-VIVO; NUCLEIC-ACIDS; CONDENSED DNA; FIBROBLASTS; TRANSFERRIN; VECTORS; LIGAND; SYSTEM	Molecular conjugates, or polyplexes, are promising synthetic vectors for targeted, in vivo gene delivery, if their efficiency can be improved. Gaining mechanistic information on conjugate gene delivery can potentially yield significant improvements in transfer efficiency by revealing barriers to conjugate transfer from the cell surface to the nucleus. We have developed an experimental system that employs epidermal growth factor as the ligand to direct delivery of DNA encoding the green fluorescent protein to mouse fibroblasts. We report here that the initial step of delivery, binding of the conjugate to the cell surface, is a barrier to gene transfer. We examined the effects of conjugate charge, ligand cross-linker spacer length, and ligand valency on polyplex cell surface binding, internalization, and gene transfer. We find that delivery is both efficient and specific only within a relatively narrow window of conjugate charge, results that correlate with binding and internalization of radiolabeled conjugate. In addition, increasing the cross-linker length can improve binding affinity and delivery. Finally, there is a significant optimum in gene delivery as a function of ligand valency, due to saturation of receptor binding and internalization. Optimizing parameters that affect surface binding therefore improves the efficiency and specificity of molecular conjugate gene delivery.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Ctr Biotechnol Proc Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Schaffer, DV (corresponding author), Salk Inst, LOG-G,POB 85800, San Diego, CA 92186 USA.							Ager S, 1996, HUM GENE THER, V7, P2157, DOI 10.1089/hum.1996.7.17-2157; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; CAO H, 1995, ENDOCRINOLOGY, V136, P3163, DOI 10.1210/en.136.7.3163; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CHIOU HC, 1994, NUCLEIC ACIDS RES, V22, P5439, DOI 10.1093/nar/22.24.5439; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; Goldman CK, 1997, NAT BIOTECHNOL, V15, P462, DOI 10.1038/nbt0597-462; HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012; HART SL, 1995, GENE THER, V2, P552; HOLT SJ, 1995, EXP CELL RES, V217, P554, DOI 10.1006/excr.1995.1122; JIANG LW, 1990, J CELL BIOL, V110, P559, DOI 10.1083/jcb.110.3.559; KING AC, 1980, P NATL ACAD SCI-BIOL, V77, P3283, DOI 10.1073/pnas.77.6.3283; Lee RJ, 1996, J BIOL CHEM, V271, P8481, DOI 10.1074/jbc.271.14.8481; Legendre JY, 1997, BIOCONJUGATE CHEM, V8, P57, DOI 10.1021/bc960076d; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; MARUYAMA K, 1995, BBA-BIOMEMBRANES, V1234, P74, DOI 10.1016/0005-2736(94)00263-O; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Ohno K, 1997, NAT BIOTECHNOL, V15, P763, DOI 10.1038/nbt0897-763; PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086; PLANK C, 1994, J BIOL CHEM, V269, P12918; Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437; REMY JS, 1995, P NATL ACAD SCI USA, V92, P1744, DOI 10.1073/pnas.92.5.1744; Schaffer DV, 1997, TISSUE ENG, V3, P53, DOI 10.1089/ten.1997.3.53; Sosnowski BA, 1996, J BIOL CHEM, V271, P33647, DOI 10.1074/jbc.271.52.33647; STANKOVICS J, 1994, HUM GENE THER, V5, P1095, DOI 10.1089/hum.1994.5.9-1095; STARBUCK C, 1990, CHEM ENG SCI, V45, P2367, DOI 10.1016/0009-2509(90)80117-W; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; ValsesiaWittmann S, 1996, J VIROL, V70, P2059, DOI 10.1128/JVI.70.3.2059-2064.1996; WADHWA MS, 1995, BIOCONJUGATE CHEM, V6, P283, DOI 10.1021/bc00033a008; WAGNER E, 1994, ADV DRUG DELIVER REV, V14, P113, DOI 10.1016/0169-409X(94)90008-6; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; Watkins SJ, 1997, GENE THER, V4, P1004, DOI 10.1038/sj.gt.3300511; Wilbur DS, 1997, BIOCONJUGATE CHEM, V8, P819, DOI 10.1021/bc970053e; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; Wolfert MA, 1996, HUM GENE THER, V7, P2123, DOI 10.1089/hum.1996.7.17-2123; WU GY, 1987, J BIOL CHEM, V262, P4429; Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474; Ziady AG, 1997, AM J PHYSIOL-GASTR L, V273, pG545, DOI 10.1152/ajpgi.1997.273.2.G545	41	128	132	1	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28004	28009		10.1074/jbc.273.43.28004	http://dx.doi.org/10.1074/jbc.273.43.28004			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774415	Green Published, hybrid			2022-12-25	WOS:000076549800035
J	Wang, W; Boffa, PB; Bajzar, L; Walker, JB; Nesheim, ME				Wang, W; Boffa, PB; Bajzar, L; Walker, JB; Nesheim, ME			A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; CARBOXY-TERMINAL LYSINE; CLOT LYSIS; PLASMA CARBOXYPEPTIDASE; PROCARBOXYPEPTIDASE-B; COAGULATION; BINDING; TAFI; IDENTIFICATION; PURIFICATION	TAFI (thrombin-activable fibrinolysis inhibitor) is a recently described plasma zsmogen that, when exposed to the thrombin-thrombomodulin complex, is converted by proteolysis at Arg(92) to a basic carboxypeptidase that inhibits fibrinolysis (TAFIa). The studies described here were undertaken to elucidate the molecular basis for the inhibition of fibrinolysis. When TAFIa is included in a clot undergoing fibrinolysis induced by tissue plasminogen activator and plasminogen, the time to achieve lysis is prolonged, and free arginine and lysine are released over time. In addition, TAFIa prevents a 2.5-fold increase in the rate constant for plasminogen activation which occurs when fibrin is modified by plasmin in the early course of fibrin degradation. The effect is specific for the Glu- form of plasminogen, TAFIa prevents or at least attenuates positive feedback expressed through Lys-plasminogen formation during the process of fibrinolysis initiated by tissue plasminogen activator and plasminogen. TAFIa also inhibits plasmin activity in a clot and prolongs fibrinolysis initiated with plasmin, We conclude that TAFIa suppresses fibrinolysis by removing COOH-terminal lysine and arginine residues from fibrin, thereby reducing its cofactor functions in both plasminogen activation and the positive feedback conversion of Glu-plasminogen to Lys-plasminogen. At relatively elevated concentrations, it also directly inhibits plasmin.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Univ Vermont, Dept Biochem, Burlington, VT 05405 USA; Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada	Queens University - Canada; Queens University - Canada; University of Vermont; McMaster University	Nesheim, ME (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.		Boffa, Michael/N-6539-2019	Boffa, Michael/0000-0003-1211-3064	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46703-6] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOKI N, 1993, METHOD ENZYMOL, V223, P185; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1998, J BIOL CHEM, V273, P2792, DOI 10.1074/jbc.273.5.2792; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Broze GJ, 1996, BLOOD, V88, P3815, DOI 10.1182/blood.V88.10.3815.bloodjournal88103815; CAMPBELL W, 1989, BIOCHEM BIOPH RES CO, V162, P933, DOI 10.1016/0006-291X(89)90762-6; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; EATON DL, 1991, J BIOL CHEM, V266, P21833; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; GAEDE G, 1975, ANAL BIOCHEM, V66, P393, DOI 10.1016/0003-2697(75)90606-5; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2176; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; KLUFT C, 1986, BLOOD, V67, P616; LENICH C, 1991, THROMB RES, V64, P69, DOI 10.1016/0049-3848(91)90206-C; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; NAKATANI Y, 1972, ANAL BIOCHEM, V49, P225, DOI 10.1016/0003-2697(72)90261-8; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NORRMAN B, 1985, EUR J BIOCHEM, V149, P193, DOI 10.1111/j.1432-1033.1985.tb08911.x; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; Redlitz A, 1996, CIRCULATION, V93, P1328, DOI 10.1161/01.CIR.93.7.1328; SAKHAROV DV, 1995, CIRCULATION, V92, P1883, DOI 10.1161/01.CIR.92.7.1883; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; SUENSON E, 1988, BIOCHEMISTRY-US, V27, P2435, DOI 10.1021/bi00407a029; SUENSON E, 1990, J BIOL CHEM, V265, P22228; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; WANG W, 1994, J BIOL CHEM, V269, P15937	32	336	347	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27176	27181		10.1074/jbc.273.42.27176	http://dx.doi.org/10.1074/jbc.273.42.27176			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765237	hybrid			2022-12-25	WOS:000076448000024
J	Anderson, RA; Joyce, C; Davis, M; Reagan, JW; Clark, M; Shelness, GS; Rudel, LL				Anderson, RA; Joyce, C; Davis, M; Reagan, JW; Clark, M; Shelness, GS; Rudel, LL			Identification of a form of acyl-CoA : cholesterol acyltransferase specific to liver and intestine in nonhuman primates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFRICAN-GREEN MONKEYS; CORONARY-ARTERY ATHEROSCLEROSIS; APO-B SECRETION; COENZYME-A; MOLECULAR-CLONING; DIETARY-CHOLESTEROL; ACYLCOENZYME-A; ACAT; EXPRESSION; PROTEIN	The present study demonstrates that two different forms of the intracellular cholesterol esterification enzyme acyl-CoA:cholesterol acyltransferase (ACAT) are present in the nonhuman primate hepatocyte; one is similar to that originally cloned from human genomic DNA, here termed ACAT1, while a second gene product, termed ACAT2, is reported here. The primate ACAT2 gene product was cloned from an African green monkey liver cDNA library. Sequence analysis of an isolated, full-length clone of ACAT2 cDNA identified an open reading frame encoding a 526-amino acid protein with essentially no sequence similarity to the ACAT1 cDNA over the N-terminal 101 amino acids but with 57% identity predicted over the remaining 425 amino acids. Transfection of the cloned ACAT2 cDNA into two different mammalian cell types resulted in the production of abundant ACAT activity which was sensitive to ACAT inhibitors. Northern blot analysis showed that the ACAT2 mRNA was expressed primarily in liver and intestine in monkeys. In contrast, ACAT1 mRNA was expressed in almost all tissues examined. Topologic predictions from the amino acid sequence of ACAT2 indicates that it has seven trans-membrane domains in a configuration that places the putative active site of the enzyme in the lumen of the endoplasmic reticulum. This orientation of ACAT2 in the endoplasmic reticulum membrane, in addition to its expression only in liver and intestine, suggests that this enzyme may have as a primary function, the secretion of cholesteryl esters into apoB-containing lipoproteins.	Wake Forest Univ, Sch Med, Dept Comparat Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Biochem, Arteriosclerosis Res Program, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	Rudel, LL (corresponding author), Wake Forest Univ, Sch Med, Dept Comparat Med, Winston Salem, NC 27157 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49373, HL-07115] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BILLHEIMER JT, 1990, ADV CHOLESTEROL RES, P7; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; CARR TP, 1995, J LIPID RES, V36, P25; CARR TP, 1992, ARTERIOSCLER THROMB, V12, P1274, DOI 10.1161/01.ATV.12.11.1274; CASES S, 1997, CIRCULATION S1, V96, P230; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; ESSER V, 1988, J BIOL CHEM, V263, P13282; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HUFF MW, 1994, ARTERIOSCLER THROMB, V14, P1498, DOI 10.1161/01.ATV.14.9.1498; KLEIN RL, 1983, J LIPID RES, V24, P343; LANFORD RE, 1989, IN VITRO CELL DEV B, V25, P174; LANFORD RE, 1997, MOL METHODS MED HEPA; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; PAPE ME, 1995, J LIPID RES, V36, P823; PURDY BH, 1984, J CLIN INVEST, V74, P351, DOI 10.1172/JCI111430; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1995, PROTEIN SCI, V4, P521; Rost B, 1996, METHOD ENZYMOL, V266, P525; RUDEL L, 1994, J CLIN INVEST, V93, P2463, DOI 10.1172/JCI117255; RUDEL LL, 1981, ARTERIOSCLEROSIS, V1, P144, DOI 10.1161/01.ATV.1.2.144; Rudel LL, 1997, J CLIN INVEST, V100, P74, DOI 10.1172/JCI119524; RUDEL LL, 1995, AM J CLIN NUTR, V62, p463S, DOI 10.1093/ajcn/62.2.463S; RUDEL LL, 1985, ANN NY ACAD SCI, V454, P248, DOI 10.1111/j.1749-6632.1985.tb11864.x; RUDEL LL, 1995, ARTERIOSCL THROM VAS, V15, P2101, DOI 10.1161/01.ATV.15.12.2101; RUDEL LL, 1980, USE NONHUMAN PRIMATE, P37; Sambrook J., 2002, MOL CLONING LAB MANU; STURLEY SL, 1997, CIRCULATION, V96, P441; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WONG MH, 1994, J BIOL CHEM, V269, P1340; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157	39	249	266	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26747	26754		10.1074/jbc.273.41.26747	http://dx.doi.org/10.1074/jbc.273.41.26747			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756918	hybrid			2022-12-25	WOS:000076373300072
J	Jensen, PH; Nielsen, MS; Jakes, R; Dotti, G; Goedert, M				Jensen, PH; Nielsen, MS; Jakes, R; Dotti, G; Goedert, M			Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; A-BETA COMPONENT; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MEMBRANE; NACP	The presynaptic protein alpha-synuclein has been implicated in the pathogenesis of Parkinson's disease. First, two missense mutations A30P and A53T cause inheritable early onset Parkinson's disease in some families. Secondly, alpha-synuclein is present in Lewy bodies of affected nerve cells in the predominant sporadic type of Parkinson's disease as well as in dementia with Lewy bodies. We demonstrate in the rat optic system that a portion of alpha-synuclein is carried by the vesicle-moving fast component of axonal transport and that it binds to rat brain vesicles through its amino-terminal repeat region. We find alpha-synuclein with the A30P mutation of familial Parkinson's disease devoid of vesicle-binding-activity and propose that mutant alpha-synuclein may accumulate, leading to assembly into Lewy body filaments.	Univ Aarhus, Dept Med Biochem, DK-8000 Aarhus C, Denmark; European Mol Biol Lab, D-69012 Heidelberg, Germany; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Aarhus University; European Molecular Biology Laboratory (EMBL); MRC Laboratory Molecular Biology	Jensen, PH (corresponding author), Univ Aarhus, Dept Med Biochem, Bldg 170, DK-8000 Aarhus C, Denmark.		Nielsen, Morten Schallburg/G-9498-2016; Dotti, Carlos G/I-5533-2015	Nielsen, Morten Schallburg/0000-0001-9863-9694; Dotti, Carlos G/0000-0003-4052-1719; Jensen, Poul Henning/0000-0002-4439-9020				Baba M, 1998, AM J PATHOL, V152, P879; BRADY ST, 1985, NEUROMETHODS, V1, P419; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; GOEDERT M, 1998, NEUROSCI NEWS, V1, P2; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Ince PG, 1998, BRAIN PATHOL, V8, P299; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; NAKAJO S, 1993, EUR J BIOCHEM, V217, P1057, DOI 10.1111/j.1432-1033.1993.tb18337.x; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	21	452	456	1	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26292	26294		10.1074/jbc.273.41.26292	http://dx.doi.org/10.1074/jbc.273.41.26292			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756856	hybrid			2022-12-25	WOS:000076373300010
J	Saleh, A; Schieltz, D; Ting, N; McMahon, SB; Litchfield, DW; Yates, JR; Lees-Miller, SP; Cole, MD; Brandl, CJ				Saleh, A; Schieltz, D; Ting, N; McMahon, SB; Litchfield, DW; Yates, JR; Lees-Miller, SP; Cole, MD; Brandl, CJ			Tra1p is a component of the yeast Ada center dot Spt transcriptional regulatory complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ACIDIC ACTIVATION DOMAINS; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE REPRESSION; GENE-EXPRESSION; DNA-REPAIR; IN-VIVO; GCN5	The yeast Ada and TBP class of Spt proteins interact in multiple complexes that are required for transcriptional regulation. We have identified Tra1p as a component of these complexes through tandem mass spectrometry analysis of proteins that associate with Ngg1p/Ada3p, TRA1 is an essential gene and encodes a 3744-amino acid protein that is a member of a group of proteins including the catalytic subunit of DNA-dependent protein kinase, ATM and TRRAP, with carboxyl-terminal regions related to phosphatidylinositol 3-kinases, The interaction between Tra1p and Ada/Spt components was verified by the reciprocal coimmunoprecipitation of Ada2p and Tra1p from whole cell extracts in one or more complexes containing Spt7p, Tra1p cofractionated with Ngg1p and Spt7p through consecutive chromatography on Mono Q, DNA-cellulose, and Superose 6 columns. Binding of Tra1p to DNA-cellulose required Ada components. The association of Tra1p with two Ada Spt complexes was suggested by its cofractionation with Ngg1p and Spt7p in two peaks on the Mono Q column. In the absence of Ada2p, the elution profile of Tra1p shifted to a distinct peak. Despite the similarity of Tra1p to a group of putative protein kinases, we have not detected protein kinase activity within immunoprecipitates of Tra1p or the Ada.Spt complexes.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Western University (University of Western Ontario); University of Washington; University of Washington Seattle; University of Calgary; Princeton University	Brandl, CJ (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	cbrandl@julian.uwo.ca	Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620; McMahon, Steven/0000-0002-3405-1768; Lees-Miller, Susan/0000-0001-5809-2516; Saleh, Ayman M/0000-0003-1126-6018	PHS HHS [118223-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Brandl CJ, 1996, J BIOL CHEM, V271, P9298, DOI 10.1074/jbc.271.16.9298; BRANDL CJ, 1993, EMBO J, V12, P5255, DOI 10.1002/j.1460-2075.1993.tb06221.x; Candau R, 1996, J BIOL CHEM, V271, P5237; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; ESTRUCH F, 1991, NUCLEIC ACIDS RES, V19, P4873, DOI 10.1093/nar/19.18.4873; GANSHEROFF LJ, 1995, GENETICS, V139, P523; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Hampsey M, 1997, TRENDS GENET, V13, P427, DOI 10.1016/S0168-9525(97)01292-4; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KENNEDY RT, 1989, ANAL CHEM, V61, P1128, DOI 10.1021/ac00185a016; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6742; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; Marcus GA, 1996, MOL CELL BIOL, V16, P3197; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Pemberton LF, 1997, J CELL BIOL, V139, P1645, DOI 10.1083/jcb.139.7.1645; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Roberts SM, 1997, GENETICS, V147, P451; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; SALEH A, 1998, IN PRESS J MOL BIOL; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIKORSKI RS, 1989, GENETICS, V122, P19; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; YATES JR, 1994, CELL BIOL LAB HDB, V3, P380; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	45	112	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26559	26565		10.1074/jbc.273.41.26559	http://dx.doi.org/10.1074/jbc.273.41.26559			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756893	hybrid			2022-12-25	WOS:000076373300047
J	Ohtani, K; Tsujimoto, A; Ikeda, M; Nakamura, M				Ohtani, K; Tsujimoto, A; Ikeda, M; Nakamura, M			Regulation of cell growth-dependent expression of mammalian CDC6 gene by the cell cycle transcription factor E2F	ONCOGENE			English	Article						mammalian CDC6; E2F; promoter; cell cycle; DNA synthesis	ORIGIN RECOGNITION COMPLEX; S-PHASE ENTRY; DNA-REPLICATION; MCM-PROTEINS; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; FISSION YEAST; DISTINCT ROLES; HUMAN HOMOLOG; HUMAN MEMBER	CDC6 of Saccharomyces cerevisiae regulates the DNA replication initiation through the origin recognition complex (ORC), Identification of a human homolog of the CDC6 gene (HsCdc6) suggests a universal role of the gene product in DNA replication. Expression of HsCdc6 is growth-regulated. We investigated the molecular basis of growth-regulated expression of mammalian Cdc6. The promoter activity of isolated HsCdc6 upstream region was activated at late G1 and G1/S boundary in the cell cycle of rat embryonic fibroblast REF52 cells by the addition of serum. The isolated promoter was activated by exogenous expression of E2F without serum stimulation. However a mutant promoter lacking the E2F recognition sites failed to respond to serum stimulation and exogenous expression of E2F, Expression of endogenous Cdc6 was induced by exogenous expression of E2F, Therefore, we concluded that the growth-regulated expression of mammalian Cdc6 was mediated by E2F, Moreover, we demonstrated that exogenous overexpression of either HsCdc6 or HsOrc1 failed to induce DNA synthesis unlike overexpression of E2F1, even though E2F1 induced both Cdc6 and Orc1, suggesting that E2F may regulate the expression of another gene(s), besides Cdc6 and Orc1, required for induction of cellular DNA synthesis in mammalian cells.	Tokyo Med & Dent Univ, Grad Sch Dent, Human Gene Sci Ctr, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch Dent, Dept Dev Biol, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Nakamura, M (corresponding author), Tokyo Med & Dent Univ, Grad Sch Dent, Human Gene Sci Ctr, Tokyo 1138510, Japan.							Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Fujita M, 1996, J BIOL CHEM, V271, P4349; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Geng Y, 1996, ONCOGENE, V12, P1173; Hardy CFJ, 1997, GENE, V187, P239, DOI 10.1016/S0378-1119(96)00761-5; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lin SY, 1996, MOL CELL BIOL, V16, P1668; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NEVINS JR, 1992, SCIENCE, V258, P424; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tsuruga H, 1997, GENES CELLS, V2, P381, DOI 10.1046/j.1365-2443.1997.1290327.x; Tsuruga H, 1997, BIOCHEM BIOPH RES CO, V236, P118, DOI 10.1006/bbrc.1997.6865; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	46	89	90	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1777	1785		10.1038/sj.onc.1202105	http://dx.doi.org/10.1038/sj.onc.1202105			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778043				2022-12-25	WOS:000076303300003
J	Tse, A; Moran, RG				Tse, A; Moran, RG			Cellular folates prevent polyglutamation of 5,10-dideazatetrahydrofolate - A novel mechanism of resistance to folate antimetabolites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; GLYCINAMIDE RIBONUCLEOTIDE FORMYLTRANSFERASE; MAMMALIAN FOLYLPOLYGLUTAMATE SYNTHETASE; THYMIDYLATE SYNTHASE INHIBITORS; NOVO PURINE SYNTHESIS; FOLIC-ACID; CCRF-CEM; SUBSTRATE-SPECIFICITY; MEMBRANE-TRANSPORT; POTENT INHIBITOR	Mouse L1210 cell variants were selected for resistance to 5,10-dideazatetrahydrofolate, a potent inhibitor of the first folate-dependent enzyme in de novo purine synthesis, glycinamide ribonucleotide formyltransferase. The drug-resistant phenotype selected was conditional to the folate compound used to support growth: grown on folic acid cells mere 400-fold resistant, whereas they were 2.5-fold more sensitive to 5,10-dideazatetrahydrofolate than wild-type L1210 cells when grown on folinic acid. In folic acid-containing media, polyglutamation of 5,10-dideazatetrahydrofolate was markedly reduced, yet folylpolyglutamate synthetase activity was not different from that in parental L1210 cells. Resistance was due to two changes in membrane transport: a minor increase in the K-m for 5,10-dideazatetrahydrofolate influx, and a major increase in folic acid transport. Enhanced folic acid transport resulted in an expanded cellular content of folates which blocked polyglutamation of 5,10-dideazatetrahydrofolate. We propose that polyglutamation of 5,10-dideazatetrahydrofolate is limited by feedback inhibition by cellular folates on folylpolyglutamate synthetase, an effect which reflects a mechanism in place to control the level of cellular folates. Although the primary alteration causative of resistance is different from those reported previously, all 5,10-dideazatetrahydrofolate resistance phenotypes result in decreased drug polyglutamation, reflecting the centrality of this reaction to the action of 5,10-dideazatetrahydrofolate.	Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Virginia Commonwealth University; Virginia Commonwealth University; University of Southern California	Moran, RG (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Box 980230, Richmond, VA 23298 USA.	rmoran@hsc.vcu.edu			NATIONAL CANCER INSTITUTE [R01CA027605] Funding Source: NIH RePORTER; NCI NIH HHS [CA 27605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alati T, 1996, CANCER RES, V56, P2331; ANTONSSON B, 1990, ANAL BIOCHEM, V186, P8, DOI 10.1016/0003-2697(90)90563-O; ASCHELE C, 1992, CANCER RES, V52, P1855; Assaraf YG, 1997, J BIOL CHEM, V272, P17460, DOI 10.1074/jbc.272.28.17460; BALDWIN SW, 1991, BIOCHEMISTRY-US, V30, P1997, DOI 10.1021/bi00221a037; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P513, DOI 10.1021/bi00376a025; Cunningham D, 1996, ANN ONCOL, V7, P961, DOI 10.1093/oxfordjournals.annonc.a010800; EVANS RM, 1981, CANCER RES, V41, P3288; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; HABECK LL, 1995, MOL PHARMACOL, V48, P326; HENDERSON GB, 1990, CANCER RES, V50, P1709; JACKMAN AL, 1991, ADV ENZYME REGUL, V31, P13, DOI 10.1016/0065-2571(91)90006-8; JACKMAN AL, 1991, CANCER RES, V51, P5579; JACKMAN AL, 1993, INHIBITION THYMIDYLA, P274; JANSEN G, 1990, CANCER RES, V50, P7544; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAN JLC, 1993, GENE, V137, P195, DOI 10.1016/0378-1119(93)90006-O; KAN JLC, 1995, J BIOL CHEM, V270, P1823, DOI 10.1074/jbc.270.4.1823; KESAVAN V, 1986, J BIOCHEM BIOPH METH, V12, P311, DOI 10.1016/0165-022X(86)90068-0; KEYOMARSI K, 1988, J BIOL CHEM, V263, P14402; KEYOMARSI K, 1986, CANCER RES, V46, P5229; MATHERLY LH, 1993, BIOCHEM PHARMACOL, V46, P2185, DOI 10.1016/0006-2952(93)90608-Y; MCGUIRE JJ, 1993, LEUKEMIA, V7, P1996; MORAN RG, 1984, ANAL BIOCHEM, V140, P326, DOI 10.1016/0003-2697(84)90174-X; MORAN RG, 1989, J BIOL CHEM, V264, P21047; MORAN RG, 1985, MOL PHARMACOL, V27, P156; MORAN RG, 1982, ANAL BIOCHEM, V122, P70, DOI 10.1016/0003-2697(82)90252-4; MORAN RG, 1976, J BIOL CHEM, V251, P3569; MORAN RG, 1979, P NATL ACAD SCI USA, V76, P1456, DOI 10.1073/pnas.76.3.1456; MORAN RG, 1984, BIOCHEMISTRY-US, V23, P4580, DOI 10.1021/bi00315a011; MORAN RG, 1992, NATIONAL CANCER I EU, V7, P91; OCONNOR BM, 1991, CANCER RES, V51, P3874; PIZZORNO G, 1995, CANCER RES, V55, P566; PIZZORNO G, 1993, J BIOL CHEM, V268, P1017; PIZZORNO G, 1991, MOL PHARMACOL, V39, P85; RAY MS, 1993, J NATL CANCER I, V85, P1154, DOI 10.1093/jnci/85.14.1154; RHEE MS, 1993, CANCER RES, V53, P2227; RINALDI DA, 1995, J CLIN ONCOL, V13, P2842, DOI 10.1200/JCO.1995.13.11.2842; Sanghani P., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P98; Sanghani SP, 1997, BIOCHEMISTRY-US, V36, P10506, DOI 10.1021/bi970825u; SCHMITZ JC, 1994, BIOCHEM PHARMACOL, V48, P319, DOI 10.1016/0006-2952(94)90103-1; Shih C, 1997, CANCER RES, V57, P1116; SIROTNAK FM, 1987, BIOCHEM PHARMACOL, V36, P1659, DOI 10.1016/0006-2952(87)90051-7; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P1241, DOI 10.1021/bi00508a029; Spinella MJ, 1996, BBA-GENE STRUCT EXPR, V1305, P11, DOI 10.1016/0167-4781(95)00193-X; TAYLOR EC, 1985, J MED CHEM, V28, P914, DOI 10.1021/jm00145a012; TAYLOR EC, 1992, J MED CHEM, V35, P4450, DOI 10.1021/jm00101a023; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; ULLMAN B, 1978, P NATL ACAD SCI USA, V75, P980, DOI 10.1073/pnas.75.2.980	51	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25944	25952		10.1074/jbc.273.40.25944	http://dx.doi.org/10.1074/jbc.273.40.25944			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748271	hybrid			2022-12-25	WOS:000076263100062
J	Jaakkola, P; Maatta, A; Jalkanen, M				Jaakkola, P; Maatta, A; Jalkanen, M			The activation and composition of FiRE (an FGF-inducible response element) differ in a cell type- and growth factor-specific manner	ONCOGENE			English	Article						AP-1; EGF; FGF; FIN-1; KGF; syndecan-1; transcription	HEPARAN-SULFATE PROTEOGLYCANS; LATE TRANSCRIPTION FACTOR; TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; GENE-EXPRESSION; SYNDECAN-1 GENE; WOUND REPAIR; IN-VIVO; C-FOS; PROMOTER	The expression of the heparan sulfate proteoglycan, syndecan-1, is induced both in keratinocytes and in fibroblasts during development and tissue regeneration. Here we report that in keratinocytes the syndecan-1 gene was stimulated by EGF but not by FGF-2, In fibroblasts it was stimulated by FGF-2 but not by EGF, Likewise, the recently discovered FGF-inducible response element (FiRE) on the gene of syndecan-1 was stimulated by FGF-2 in fibroblasts and by EGF in keratinocytes, but not vice vel sn. The FIRE has two binding sites for an activator protein-1 (AP-1), one for an FGF-inducible nuclear factor (FIN-1) and one for an upstream stimulatory factor-1 (USF-1), The growth factor-stimulated binding of these transcription factors, as well as their requirement for FiRE activation, varied between the two cell types. First, although AP-ls were required for activation of FIRE in both cell types, the binding of AP-1 to FiRE was increased by growth factor-stimulation only in fibroblasts and not in keratinocytes, Secondly, FiRE did not bind FIN-1 nor needed the FIN-1 binding site for EGF-stimulated activation in keratinocytes, in contrast to the FGF-stimulated activation of FiRE in fibroblasts, Thirdly, EGF, which did not activate FIRE in fibroblasts, failed to activate FIN-1 in these cells. Finally, an USF-1 binding site that was necessary for activation of FIRE in keratinocytes was not needed in fibroblasts, These data suggest mechanisms by which members of the EGF- and FGF-families can differentially stimulate transcription through AP-1 regulated elements in a cell type-specific manner.	Univ Turku, Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University	Jalkanen, M (corresponding author), Univ Turku, Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.		Jaakkola, Panu M/B-4355-2012	Maatta, Arto/0000-0003-3759-1310; Jaakkola, Panu/0000-0002-2365-4985				ANDREE C, 1994, P NATL ACAD SCI USA, V91, P12188, DOI 10.1073/pnas.91.25.12188; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; BENZEEV A, 1990, CELL REGUL, V1, P621, DOI 10.1091/mbc.1.9.621; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROWN GL, 1989, NEW ENGL J MED, V321, P76, DOI 10.1056/NEJM198907133210203; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON JM, 1991, ANN NY ACAD SCI, V638, P306, DOI 10.1111/j.1749-6632.1991.tb49041.x; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KLUCHER KM, 1990, J VIROL, V64, P4189, DOI 10.1128/JVI.64.9.4189-4198.1990; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LORET C, 1989, J BIOL CHEM, V264, P8319; PESTELL RG, 1995, J BIOL CHEM, V270, P18301, DOI 10.1074/jbc.270.31.18301; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994; VAINIO S, 1992, DEV DYNAM, V194, P105, DOI 10.1002/aja.1001940204; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; VIHINEN T, 1993, J BIOL CHEM, V268, P17261	32	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1279	1286		10.1038/sj.onc.1202002	http://dx.doi.org/10.1038/sj.onc.1202002			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771971				2022-12-25	WOS:000075803300010
J	Le Gall, M; Grall, D; Chambard, JC; Pouyssegur, J; Van Obberghen-Schilling, E				Le Gall, M; Grall, D; Chambard, JC; Pouyssegur, J; Van Obberghen-Schilling, E			An anchorage-dependent signal distinct from p42/44 MAP kinase activation is required for cell cycle progression	ONCOGENE			English	Article						anchorage; cell cycle; MAP kinase; cyclin D1; pRb; p21(Cip/Wafl)	PROTEIN-KINASE; EXTRACELLULAR-MATRIX; ADHESION COMPLEXES; GROWTH-FACTORS; D1 EXPRESSION; PROLIFERATION; PATHWAY; ARREST; CYTOSKELETON; FIBROBLASTS	Most normal cells require both mitogens and integrin-mediated attachment for growth. It is generally accepted that the p42/p44 MAP kinase module, which can be activated by both growth factors and adhesion, prays a critical role in G0 to S phase progression of quiescent cells, Studies on various cultured fibroblasts have shown that removal of anchorage leads to cell cycle arrest in G1 and it has been proposed that adhesion-dependent G1 progression requires the joint regulation of p42/p44 MAP kinase by integrins and growth factors. In quiescent CCL39 lung fibroblasts, MAP kinase activation in response to serum becomes compromised when cells are placed in suspension. Under these conditions, serum-stimulated cells arrest their growth in mid-G1 with reduced cyclin D1 expression and increased p21(Cip/Waf1) expression, as compared to their attached counterparts. To determine whether a casual link exists between suboptimal activation of MAP kinase in non-adherent cells and the observed G1 block,we used a variant of CCL39 stably expressing an estrogen-inducible activated-Raf-1 construct (Delta Raf-1:ER), We found that even strong and sustained activation of MAP kinase with estradiol, in addition to serum, is not able to boost cyclin D1 expression levels or stimulate hyperphosphorylation of pRb in suspended CCL39-Delta Raf-1:ER cells. These results indicate that p42/p44 MAP kinase activation is not a limiting factor for G1 to S phase transit in absence of anchorage. Thus, at least one adhesion-mediated signalling event, distinct from MAP kinase activation is required for maximal cyclin D1 induction and hyperphosphorylation of pRb.	CNRS, UMR 6543, Ctr Biochim, F-06108 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Van Obberghen-Schilling, E (corresponding author), CNRS, UMR 6543, Ctr Biochim, Parc Valrose, F-06108 Nice 2, France.		Le Gall, Maude/C-3917-2017; Van Obberghen-Schilling, Ellen/O-1581-2016; Van Obberghen-Schilling, Ellen/Q-4372-2019; Le Gall, Maude/W-2593-2019	Le Gall, Maude/0000-0002-5372-4585; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Le Gall, Maude/0000-0002-5372-4585; CHAMBARD, Jean Claude/0000-0003-4722-2308				Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bottazzi ME, 1997, TRENDS CELL BIOL, V7, P348, DOI 10.1016/S0962-8924(97)01114-8; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHULZE A, 1996, MOL CELL BIOL, V16, P4632; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VANOBBERGHENSCHILLING E, 1983, J CELL PHYSIOL, V115, P123, DOI 10.1002/jcp.1041150204; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	38	42	42	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1271	1277		10.1038/sj.onc.1202057	http://dx.doi.org/10.1038/sj.onc.1202057			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771970				2022-12-25	WOS:000075803300009
J	Ponzio, G; Loubat, A; Rochet, N; Turchi, L; Rezzonico, R; Far, DF; Dulic, V; Rossi, B				Ponzio, G; Loubat, A; Rochet, N; Turchi, L; Rezzonico, R; Far, DF; Dulic, V; Rossi, B			Early G(1) growth arrest of hybridoma B cells by DMSO involves cyclin D2 inhibition and p21([CIP1]) induction	ONCOGENE			English	Article						cyclin D2; cell cycle; DMSO; CDKs; p21([CIP1]); p27([KIP1])	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT KINASE-ACTIVITY; REVERSIBLE G1 ARREST; NEUROBLASTOMA-CELLS; DIMETHYL-SULFOXIDE; SUSCEPTIBILITY GENE; PHASE PROGRESSION; NUCLEAR-PROTEIN; MAMMALIAN-CELLS; DOWN-REGULATION	Dimethylsulfoxide (DMSO) was shown to inhibit the proliferation of several B cell lines including Raji, Daudi, and SKW6-CL4 but the mechanisms involved in this growth arrest are still unclear. We show that in 7TD1 mouse hybridoma cells a DMSO-induced reversible G(1) arrest involves inactivation of Rb kinases, cyclin D2/CDK4 and cyclin E/CDK2. This occurs by at least three distinct mechanisms. Inhibition of cyclin D2 neosynthesis leads to a dramatic decrease of cyclinD2/CDK4 complexes. This in turn enables the redistribution of p27([KIP1]) from cyclin D2/CDK4 to cyclin E/CDK2 complexes. In addition, the simultaneous accumulation of p21([CIP1]) entails increasing association with cyclin D3/CDK4 and cyclin E/CDK2. Thus, p21([CIP1]) and p27([KIP1]), act in concert to inhibit cyclin E/CDK2 activity which, together with CDK4 inactivation, confers a G(1)-phase arrest.	Fac Med, INSERM U364, F-06107 Nice 02, France; Hop Cantonal Geneva, Lab Immunol Clin, CH-1211 Geneva 14, Switzerland; CNRS, CRBM, ERS 155, F-34033 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Ponzio, G (corresponding author), Fac Med, INSERM U364, Ave Valombrose, F-06107 Nice 02, France.		ROCHET, Nathalie/N-1819-2018; ROCHET, Nathalie/S-3027-2019; Ponzio, Gilles/Q-1256-2016; REZZONICO, Roger/N-9626-2016	ROCHET, Nathalie/0000-0002-9995-6699; ROCHET, Nathalie/0000-0002-9995-6699; Ponzio, Gilles/0000-0003-2741-0248; REZZONICO, Roger/0000-0002-8460-1641; Dulic, Vjekoslav/0000-0003-1201-3901; Turchi, Laurent/0000-0003-2020-5831				BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BURGER C, 1994, J CELL SCI, V107, P2047; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Florenes VA, 1996, ONCOGENE, V13, P2447; GIRARD F, 1992, J CELL BIOL, V118, P785, DOI 10.1083/jcb.118.4.785; Gorospe M, 1996, MOL CELL BIOL, V16, P762; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HORIGUCHIYAMADA J, 1993, MOL CELL BIOCHEM, V119, P29, DOI 10.1007/BF00926850; JIANG HP, 1994, ONCOGENE, V9, P3397; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; KLINKEN SP, 1988, EXP CELL RES, V178, P185, DOI 10.1016/0014-4827(88)90390-4; KLUGE N, 1976, P NATL ACAD SCI USA, V73, P1237, DOI 10.1073/pnas.73.4.1237; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; MAEDA S, 1978, J CELL PHYSIOL, V94, P181, DOI 10.1002/jcp.1040940207; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Musgrove EA, 1997, MOL ENDOCRINOL, V11, P54, DOI 10.1210/me.11.1.54; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; PROUDFOOT AEI, 1993, J PROTEIN CHEM, V12, P489, DOI 10.1007/BF01025050; REAGAN LP, 1990, MOL PHARMACOL, V38, P878; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNERI LM, 1995, NEURAL PROCESS LETT, V2, P2, DOI 10.1007/BF02311571; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; SAWAI M, 1990, EXP CELL RES, V187, P4, DOI 10.1016/0014-4827(90)90108-M; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAKASE K, 1992, CELL GROWTH DIFFER, V3, P515; TAKASE K, 1994, CELL GROWTH DIFFER, V5, P1051; Teraoka H, 1996, EXP CELL RES, V222, P218, DOI 10.1006/excr.1996.0027; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Vadiveloo PK, 1996, ONCOGENE, V13, P599; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503	60	36	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1159	1166		10.1038/sj.onc.1202040	http://dx.doi.org/10.1038/sj.onc.1202040			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764826				2022-12-25	WOS:000075598400011
J	Yuan, J; Tirabassi, RS; Bush, AB; Cole, MD				Yuan, J; Tirabassi, RS; Bush, AB; Cole, MD			The C-elegans MDL-1 and MXL-1 proteins can functionally substitute for vertebrate MAD and MAX	ONCOGENE			English	Article						C-elegans; MAD; MAX	NEMATODE CAENORHABDITIS-ELEGANS; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; MYC-MAX; ONCOGENIC ACTIVITY; CELL-GROWTH; N-COR; COMPLEX; TRANSFORMATION; GENE	The genes of the myc/max/mad family play an important role in controlling cell proliferation and differentiation. We have identified the first homologues of the mad and max genes in the nematode C. elegans, which we have named mdl-1 and mxl-1 respectively. Like the vertebrate MAD proteins, MDL-1 binds an E-box DNA sequence (CACGTG) when dimerized with MXL-1. However, unlike vertebrate MAX, MXL-1 can not form homodimers and bind to DNA alone. Promoter fusions to a GFP reporter suggest that these genes are coexpressed in posterior intestinal and post-mitotic neuronal cells during larval development. The coexpression in the posterior intestinal cells occurs before their final division at the end of the L1 stage and persists afterwards, demonstrating that mad and max expression can be correlated directly to the cell cycle state of an individual cell type. These data also show that mxl-1 is an obligate partner for mdl-1 in vivo and in vitro and indicate that these genes may play an important role in post-embryonic development. Finally, MDL-1 can suppress activated c-MYC/RAS-induced focus formation in a rat embryo fibroblast transformation assay. Like the vertebrate MAD protein, MDL-1 activity in suppressing transformation is dependent on a functional SIN3 interaction domain.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Cole, MD (corresponding author), Merck & Co Inc, Dept Bioinformat, POB 2000,RY80A-1, Rahway, NJ 07065 USA.				NCI NIH HHS [CA55248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; ARMAND P, 1994, MOL CELL BIOL, V13, P383; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; AYER DE, 1993, CELL, V72, P1; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; CERNI C, 1995, ONCOGENE, V11, P587; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; MADURO M, 1995, GENETICS, V141, P977; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Wood WB, 1988, NEMATODE CAENORHABDI; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	44	31	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1109	1118		10.1038/sj.onc.1202036	http://dx.doi.org/10.1038/sj.onc.1202036			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764821				2022-12-25	WOS:000075598400006
J	Cadoret, A; Baron-Delage, S; Bertrand, F; Kornprost, M; Groyer, A; Gespach, C; Capeau, J; Cherqui, G				Cadoret, A; Baron-Delage, S; Bertrand, F; Kornprost, M; Groyer, A; Gespach, C; Capeau, J; Cherqui, G			Oncogene-induced up-regulation of Caco-2 cell proliferation involves IGF-II gene activation through a protein kinase C-mediated pathway	ONCOGENE			English	Article						Ha-ras; polyoma middle T; IGF-II gene; PKC; Spl; Caco-2 cells	GROWTH-FACTOR-I; MIDDLE-T-ONCOGENES; TRANSCRIPTION FACTOR SP1; MOUSE EMBRYO FIBROBLASTS; FACTOR BINDING-PROTEINS; COLON-CARCINOMA CELLS; HUMAN HA-RAS; MESSENGER-RNA; FACTOR (IGF)-II; DOWN-REGULATION	We previously reported that I as and polyoma middle T (PyMT), a constitutive activator of the src protooncogene product, up-regulated Caco-2 cell proliferation along with protein kinase C (PKC) alpha expression and PKC activity. We aimed to investigate whether oncogene-induced up-regulation of Caco-2 cell proliferation involved stimulation of the autocrine IGF-II/IGF-I receptor (IGF1R) loop described in these cells and if so, to analyse the role of overexpressed and activated PKC, Compared with control vector transfected Caco-2 cells, ras- and PyMT-transfected cells exhibited increased expression of the 6.0 and 4.8 kb IGF-II transcripts. This was due to increased activity of the P3 and P4 promoters of the IGF-II gene which correlated with increased expression and DNA-binding activity of Spl, a transcription factor interacting with several specific sites in P3 and P4 promoters. Oncogene-transfected cells displayed enhanced autocrine IGF-II production, which was fully responsible for the oncogene-induced increase in their proliferation since this increase was blunted by anti-human IGF-II and IGF1R (alpha IR3) antibodies. PKC mediated oncogene activation of the IGF-II gene presumably through action on Spl since (i) PKC activation by phorbol 12-myristate 13-acetate increased Spl expression, P3 and P4 activity and IGF-II mRNA in control but not in oncogene-transfected cells; and (ii) PKC inhibition by the PKC inhibitor Go6976 reduced Spl, P3 and P4 activity and IGF-II mRNA in all three cell lines. This is the first evidence that ras- and PyMT/src oncogenes up-regulate Caco-2 cell proliferation through a PKC-mediated pathway which stimulates IGF-II gene transcription and thereby increases autocrine IGF-II production, The mechanisms underlying IGF-II gene activation by PKC most probably involve action on Sp1.	Fac Med St Antoine, Biol Cellulaire Lab, INSERM, U402, F-75571 Paris 12, France; Fac Med Xavier Bichat, INSERM, U327, F-75018 Paris, France; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Cherqui, G (corresponding author), Fac Med St Antoine, Biol Cellulaire Lab, INSERM, U402, 27 Rue Chaligny, F-75571 Paris 12, France.		Cadoret, Axelle/L-2529-2017	Cadoret, Axelle/0000-0002-4283-6864				ADENIS A, 1995, EUR J CANCER, V31A, P50, DOI 10.1016/0959-8049(94)00368-F; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BaronDelage S, 1996, AM J PHYSIOL-GASTR L, V270, pG314, DOI 10.1152/ajpgi.1996.270.2.G314; BARONDELAGE S, 1994, J BIOL CHEM, V269, P18686; BASERGA R, 1995, CANCER RES, V55, P249; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BINOUX M, 1986, J CLIN ENDOCR METAB, V63, P1151, DOI 10.1210/jcem-63-5-1151; BISSONNETTE M, 1994, AM J PHYSIOL, V267, pG465, DOI 10.1152/ajpgi.1994.267.3.G465; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; CULOUSCOU JM, 1991, CANCER RES, V51, P2813; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DELAGE S, 1993, CANCER RES, V53, P2762; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GUO YS, 1992, GASTROENTEROLOGY, V102, P1101; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HOEFLICH A, 1994, MOL CELL ENDOCRINOL, V101, P141, DOI 10.1016/0303-7207(94)90228-3; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HOLTHUIZEN PE, 1993, REGUL PEPTIDES, V48, P77, DOI 10.1016/0167-0115(93)90337-8; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAHM H, 1994, INT J CANCER, V58, P452, DOI 10.1002/ijc.2910580325; LAMBERT S, 1990, INT J CANCER, V46, P405, DOI 10.1002/ijc.2910460313; LAMONERIE T, 1995, INT J CANCER, V61, P587, DOI 10.1002/ijc.2910610425; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Levy P, 1996, BRIT J CANCER, V74, P423, DOI 10.1038/bjc.1996.376; Marais R, 1996, CANCER SURV, V27, P101; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; NODA M, 1988, J BIOL CHEM, V263, P18574; OBEID LM, 1992, J BIOL CHEM, V267, P20804; Park JHY, 1996, J CELL PHYSIOL, V166, P396, DOI 10.1002/(SICI)1097-4652(199602)166:2<396::AID-JCP18>3.0.CO;2-9; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SUSSENBACH JS, 1991, MODERN CONCEPTS INSU, P639; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; TRICOLI JV, 1986, CANCER RES, V46, P6169; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Yurochko AD, 1997, J VIROL, V71, P4638, DOI 10.1128/JVI.71.6.4638-4648.1997; ZARRILLI R, 1994, CELL GROWTH DIFFER, V5, P1085; Zarrilli R, 1996, J BIOL CHEM, V271, P8108, DOI 10.1074/jbc.271.14.8108; Zenilman ME, 1997, CANCER INVEST, V15, P1, DOI 10.3109/07357909709018911; ZHANG Y, 1995, AM J PHYSIOL-ENDOC M, V269, pE804, DOI 10.1152/ajpendo.1995.269.5.E804	54	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					877	887		10.1038/sj.onc.1202013	http://dx.doi.org/10.1038/sj.onc.1202013			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780004				2022-12-25	WOS:000075448800009
J	Kaul, SC; Duncan, EL; Englezou, A; Takano, S; Reddel, RR; Mitsui, Y; Wadhwa, R				Kaul, SC; Duncan, EL; Englezou, A; Takano, S; Reddel, RR; Mitsui, Y; Wadhwa, R			Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein	ONCOGENE			English	Article						NIH3T3; malignant transformation; mot-2 protein	3' UNTRANSLATED REGION; MOUSE EMBRYO CELLS; SPONTANEOUS IMMORTALIZATION; REPLICATIVE SENESCENCE; CELLULAR MORTALITY; TUMOR SUPPRESSION; EPITHELIAL-CELLS; HSP70 FAMILY; FIBROBLASTS; EXPRESSION	The murine mortalin genes, mot-1 and mot-2, are members of the hsp70 family of proteins and differ from each other by only two amino acid residues. Mot-1 is expressed in normal cells and has pancytosolic cellular distribution whereas mot-2 is found in the perinuclear region of immortal cells. We report here that a high level of expression of mot-2 protein resulted in malignant transformation of cells as analysed by anchorage independent growth and nude mice assays. A high level of protein expression is attributed to the 900 bp 3' untranslated region of the cDNA which does not have any transforming activity per se. Mortalin cDNA clones isolated from human transformed cells were also found to have transforming activity in similar assays and a high level of expression was apparent in some of the human immortalized cells that showed non-pancytosolic mortalin immunofluorescence, Taken together, the data suggest that nonpancytosolic mortalin may have a role in tumorigenesis.	AIST, Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; Childrens Med Res Inst, Sydney, NSW 2145, Australia; Chugai Res Inst Mol Med, Niihari, Ibaraki 30041, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Children's Medical Research Institute - Australia; University of Sydney	Kaul, SC (corresponding author), AIST, Natl Inst Biosci & Human Technol, 1-1 Higashi, Tsukuba, Ibaraki 305, Japan.		Takano, Shuichi/I-6512-2013; Kaul, Sunil C/L-8671-2018; Reddel, Roger R/A-6635-2014; Wadhwa, Renu/L-8898-2018	Kaul, Sunil C/0000-0002-0046-3916; Reddel, Roger R/0000-0002-6302-6107; Wadhwa, Renu/0000-0001-8248-5192				BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Derventzi A, 1996, ANTICANCER RES, V16, P2901; DESILVA R, 1993, CELL MOL BIOL RES, V39, P101; DESILVA R, 1994, EXP CELL RES, V213, P418, DOI 10.1006/excr.1994.1218; Gallie DR, 1996, NUCLEIC ACIDS RES, V24, P1954, DOI 10.1093/nar/24.10.1954; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; Jupe ER, 1996, EXP CELL RES, V224, P128, DOI 10.1006/excr.1996.0120; Kaul SC, 1997, EXP CELL RES, V232, P56, DOI 10.1006/excr.1997.3503; Kaul SC, 1996, ONCOGENE, V13, P1231; KAUL SC, 1994, BBA-GEN SUBJECTS, V1201, P389, DOI 10.1016/0304-4165(94)90067-1; MEEK RL, 1977, EXP CELL RES, V107, P277, DOI 10.1016/0014-4827(77)90350-0; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; RITTLING SR, 1992, ONCOGENE, V7, P935; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Sambrook J., 2002, MOL CLONING LAB MANU; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; SUGHARA T, 1997, J BIOL CHEM, V273, P3033; SUGIHARA T, 1994, BBA-MOL CELL RES, V1224, P365, DOI 10.1016/0167-4889(94)90269-0; Takano S, 1997, EXP CELL RES, V237, P38, DOI 10.1006/excr.1997.3754; TOKUMITSU M, 1994, MOL CARCINOGEN, V10, P52, DOI 10.1002/mc.2940100109; WADHWA R, 1991, MUTAT RES, V256, P243, DOI 10.1016/0921-8734(91)90015-4; Wadhwa R, 1996, EXP CELL RES, V226, P381, DOI 10.1006/excr.1996.0239; WADHWA R, 1993, J BIOL CHEM, V268, P22239; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WADHWA R, 1995, INT J ONCOL, V7, P69; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; WORMINGTON M, 1994, BIOESSAYS, V16, P533, DOI 10.1002/bies.950160804	31	72	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					907	911		10.1038/sj.onc.1202017	http://dx.doi.org/10.1038/sj.onc.1202017			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780007				2022-12-25	WOS:000075448800012
J	Ogden, AT; Nunes, I; Ko, K; Wu, SJ; Hines, CS; Wang, AF; Hedge, RS; Lang, RA				Ogden, AT; Nunes, I; Ko, K; Wu, SJ; Hines, CS; Wang, AF; Hedge, RS; Lang, RA			GRIFIN, a novel lens-specific protein related to the galectin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTINS; ANIMAL LECTINS; STRUCTURAL PROTEIN; CRYSTALLINS; ENZYME; ACID; IDENTIFICATION; EMBRYOGENESIS; EXPRESSION; ENHANCER	The vertebrate lens is a relatively simple cellular structure that has evolved to refract light, The ability of the lens to focus light on the retina derives from a number of properties including the expression at high levels of a selection of soluble proteins referred to as the crystallins. In the present study, we have used differential cDNA display techniques to identify a novel, highly abundant and soluble lens protein. Though related to the family of soluble lectins called galectins, it does not bind beta-galactoside sugars and has atypical sequences at normally conserved regions of the carbohydrate-binding domain. Like some galectin family members, it can form a stable dimer. It is expressed only in the lens and is located at the interface between lens fiber cells despite the apparent lack of any membrane-targeting motifs. This protein is designated GRIFIN (galectin-related inter-fiber protein) to reflect its exclusion from the galectin family given the lack of affinity for beta-galactosides. Although the abundance, solubility, and lens-specific expression of GRIFIN would argue that it represents a new crystallin, its location at the fiber cell interface might suggest that its primary function is executed at the membrane.	NYU, Dept Cell Biol, Skirball Inst Biomol Med, Dev Genet Program,Med Ctr, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst Biomol Med, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst Biomol Med, Biochem Dept,Struct Biol Program, New York, NY 10016 USA	New York University; New York University; New York University	Lang, RA (corresponding author), NYU, Dept Cell Biol, Skirball Inst Biomol Med, Dev Genet Program,Med Ctr, 540 1st Ave, New York, NY 10016 USA.	lang@saturn.med.nyu.edu	Lang, Richard/E-5578-2011	Lang, Richard/0000-0002-5212-254X	NATIONAL CANCER INSTITUTE [R01CA066964] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011234, R01EY010559] Funding Source: NIH RePORTER; NCI NIH HHS [CA66964] Funding Source: Medline; NEI NIH HHS [R01 EY011234-09, R01 EY11234, R01 EY10559] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Colnot C, 1996, BIOCHEM SOC T, V24, P141, DOI 10.1042/bst0240141; Culling C. F. A., 1985, CELLULAR PATHOLOGY T, P642; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; DEWAARD A, 1976, J BIOL CHEM, V251, P7581; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FUNAHASHI J, 1993, DEVELOPMENT, V119, P433; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; HUGHES RC, 1994, GLYCOBIOLOGY, V4, P5, DOI 10.1093/glycob/4.1.5; KAMACHI Y, 1993, MOL CELL BIOL, V13, P5206, DOI 10.1128/MCB.13.9.5206; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LealPinto E, 1997, J BIOL CHEM, V272, P617; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; MAHANTHAPPA NK, 1994, DEVELOPMENT, V120, P1373; NOWAK TP, 1977, J BIOL CHEM, V252, P6026; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PIATIGORSKY J, 1984, CELL, V38, P620, DOI 10.1016/0092-8674(84)90254-X; Puche AC, 1996, DEV BIOL, V179, P274, DOI 10.1006/dbio.1996.0257; RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710; SOLIS D, 1994, EUR J BIOCHEM, V223, P107, DOI 10.1111/j.1432-1033.1994.tb18971.x; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Vyakarnam A, 1997, MOL CELL BIOL, V17, P4730, DOI 10.1128/MCB.17.8.4730; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; WISTOW GJ, 1990, GENE, V96, P263, DOI 10.1016/0378-1119(90)90262-P; WISTOW GJ, 1987, NATURE, V326, P622, DOI 10.1038/326622a0; WISTOW GJ, 1988, J CELL BIOL, V107, P2729, DOI 10.1083/jcb.107.6.2729; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; WOO HJ, 1991, J BIOL CHEM, V266, P18419	35	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28889	28896		10.1074/jbc.273.44.28889	http://dx.doi.org/10.1074/jbc.273.44.28889			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786891	hybrid			2022-12-25	WOS:000076691800052
J	Kato, K; Ito, H; Kamei, K; Inaguma, Y; Iwamoto, I; Saga, S				Kato, K; Ito, H; Kamei, K; Inaguma, Y; Iwamoto, I; Saga, S			Phosphorylation of alpha beta-crystallin in mitotic cells and identification enzymatic activities responsible for phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; B-CRYSTALLIN; IMMUNOREACTIVE ALPHA; CHAIN; ELECTROPHORESIS; PURIFICATION; SEPARATION; EVOLUTION; INHIBITOR; SUBUNITS	The immunofluorescence localization of alpha B-crystallin in U373 MG human glioma cells with an antibody specific for alpha B-crystallin that had been phosphorylated at Ser-45 revealed an intense staining of cells in the mitotic phase of the cell cycle. Phosphorylated forms of alpha B-crystallin in mitotic cells were detected in all cell lines examined and in tissue sections of mouse embryos. Increases in the levels of alpha B-crystallin that had been phosphorylated at Ser-45 and Ser-19, but not at Ser-59, were detected biochemically by isoelectric focusing or SDS-polyacrylamide gel electrophoresis and a subsequent Western blot analysis of extracts of cells collected at the mitotic phase. When we estimated the phosphorylation activity specific for alpha B-crystallin in extracts of mitotic U373 MG cells, using the amino-terminal 72-amino acid peptide derived from unphosphorylated alpha B2-crystallin as the substrate, we found that the activities responsible for the phosphorylation of Ser-45 and Ser-19 were markedly enhanced but that the activity responsible for the phosphorylation of Ser-59 was suppressed. The protein kinases responsible for the phosphorylation of Ser-45 and Ser-59 in the amino-terminal 72-amino acid peptide were partially purified from extracts of cells that had been stimulated by exposure to H2O2 in the presence of calyculin A. The activities responsible for the phosphorylation of Ser-45 and Ser-59 were eluted separately from a column of Superdex 200 at fractions corresponding to about 40 and 60 kDa, respectively, while the kinase for Ser-19 was unstable. p44/42 mitogen-activated protein (MAP) kinase and MAP kinase-activated protein (MAPKAP) kinase-2 were concentrated in the Ser-45 kinase fraction and Ser-59 kinase fraction, respectively. Recombinant human p44 MAP kinase and MAPKAP kinase-l purified from rabbit muscle selectively phosphorylated Ser-45 and -59, respectively. The Ser-45 kinase fraction and Ser-59 kinase fraction phosphorylated myelin basic protein and hsp27, respectively. These results suggest that the phosphorylations of Ser-45 and Ser-59 in alpha B-crystallin are catalyzed by p44/42 MAP kinase and MAPKAP kinase-a, respectively, in cells and that the phosphorylation of Ser-45 by p44/42 MAP kinase is enhanced while the phosphorylation of Ser-59 by MAPKAP kinase-a is suppressed during cell division.	Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Aichi 4800392, Japan; Aichi Med Univ, Dept Pathol, Aichi 48011, Japan	Aichi Medical University	Kato, K (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, 713-8 Kamiya, Aichi 4800392, Japan.	kato@inst-hsc.pref.aichi.jp		Ito, Hidenori/0000-0002-6527-477X				ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; Beall AC, 1997, J BIOL CHEM, V272, P11283; BLOEMENDAL H, 1981, ANAL BIOCHEM, V117, P327, DOI 10.1016/0003-2697(81)90787-9; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; CHIESA R, 1987, BIOCHEM BIOPH RES CO, V144, P1340, DOI 10.1016/0006-291X(87)91457-4; CHIESA R, 1988, EXP EYE RES, V46, P199, DOI 10.1016/S0014-4835(88)80077-0; CHIESA R, 1987, J BIOL CHEM, V262, P1438; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EHRNSPERGER M, 1997, MOL CHAPERONES LIFE, P533; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; KANTOROW M, 1995, J BIOL CHEM, V270, P17215, DOI 10.1074/jbc.270.29.17215; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; Kato K, 1996, J BIOL CHEM, V271, P26989, DOI 10.1074/jbc.271.43.26989; KATO K, 1994, J BIOL CHEM, V269, P15302; KATO K, 1992, J BIOL CHEM, V267, P7718; KIMURA G, 1975, P NATL ACAD SCI USA, V72, P673, DOI 10.1073/pnas.72.2.673; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Kozaki K, 1998, J BIOL CHEM, V273, P15125, DOI 10.1074/jbc.273.24.15125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMITH JB, 1992, PROTEIN SCI, V1, P601, DOI 10.1002/pro.5560010506; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; VANDEROU.FJ, 1974, EUR J BIOCHEM, V49, P157; VOORTER CEM, 1986, EUR J BIOCHEM, V160, P203; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; YOSHITAKE S, 1979, EUR J BIOCHEM, V101, P395, DOI 10.1111/j.1432-1033.1979.tb19731.x; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	35	110	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28346	28354		10.1074/jbc.273.43.28346	http://dx.doi.org/10.1074/jbc.273.43.28346			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774459	hybrid			2022-12-25	WOS:000076549800079
J	Xu, G; Kwon, G; Marshall, CA; Lin, TA; Lawrence, JC; McDaniel, ML				Xu, G; Kwon, G; Marshall, CA; Lin, TA; Lawrence, JC; McDaniel, ML			Branched-chain amino acids are essential in the regulation of PHAS-I and p70 S6 kinase by pancreatic beta-cells - A possible role in protein translation and mitogenic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TARGET; INSULIN RELEASE; PHOSPHORYLATION; RAPAMYCIN; ISLETS; INITIATION; TURNOVER; MUSCLE; GROWTH; INVOLVEMENT	Amino acids have been identified as important signaling molecules involved in pancreatic beta-cell proliferation, although the cellular mechanism responsible for this effect is not well defined. We previously reported that amino acids are required for glucose or exogenous insulin to stimulate phosphorylation of PHAS-I (phosphorylated heat- and acid-stable protein regulated by insulin), a recently discovered regulator of translation initiation during cell mitogenesis. Here we demonstrate that essential amino acids, in particular branched-chain amino acids (leucine, valine, and isoleucine), are largely responsible for mediating this effect. The transamination product of leucine, alpha-ketoisocaproic acid, also stimulates PHAS-I phosphorylation although the transamination products of isoleucine and valine are ineffective, Since amino acids are secretagogues for insulin secretion by beta-cells, we investigated whether endogenous insulin secreted by beta-cells is involved. Interestingly, branched-chain amino acids stimulate phosphorylation of PHAS-I independent of endogenous insulin secretion since genistein (10 mu M) and herbimycin A (1 mu M), two tyrosine kinase inhibitors in the insulin signaling pathway, exert no effect on amino acid-induced phosphorylation of PHAS-I, Furthermore, branched-chain amino acids retain their ability to induce phosphorylation of PHAS-I under conditions that block insulin secretion from beta-cells. In exploring the signaling pathway responsible for these effects, we find that rapamycin (25 nM) inhibits the ability of branched-chain amino acids to stimulate the phosphorylation of PHAS-I and p70(s6) kinase, suggesting that the mammalian target of rapamycin signaling pathway is involved. The branched-chain amino acid, leucine, also exerts similar effects on PHAS-I phosphorylation in isolated pancreatic islets. In addition, we find that amino acids are necessary for insulin-like growth factor (IGF-I) to stimulate the phosphorylation of PHAS-I indicating that a requirement for amino acids may be essential for other beta-cell growth factors in addition to insulin and IGF-I to activate this signaling pathway. We propose that amino acids, in particular branched-chain amino acids, may promote beta-cell proliferation either by stimulating phosphorylation of PHAS-I and p70(S6k) via the mammalian target of rapamycin pathway and/or by facilitating the proliferative effect mediated by growth factors such as insulin and IGF-I.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA	Washington University (WUSTL); University of Virginia	McDaniel, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 Euclid Ave,Box 8118, St Louis, MO 63110 USA.	mcdaniel@pathology.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052753, R01DK028312] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312, DK52753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BHATHENA SJ, 1982, DIABETES, V31, P521, DOI 10.2337/diabetes.31.6.521; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; BUSE MG, 1975, J CLIN INVEST, V56, P1250, DOI 10.1172/JCI108201; CORBETT JA, 1994, AM J PHYSIOL, V267, pC48, DOI 10.1152/ajpcell.1994.267.1.C48; Davoodi J, 1998, J BIOL CHEM, V273, P4982, DOI 10.1074/jbc.273.9.4982; ESCOLAR JC, 1987, J ENDOCRINOL, V115, P225, DOI 10.1677/joe.0.1150225; FLOYD JC, 1966, J CLIN INVEST, V45, P1487, DOI 10.1172/JCI105456; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HELLMAN B, 1971, BIOCHEM J, V123, P513, DOI 10.1042/bj1230513; HELLMAN B, 1971, ENDOCRINOLOGY, V89, P1432, DOI 10.1210/endo-89-6-1432; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; KUHARA T, 1991, AM J PHYSIOL, V260, pE21, DOI 10.1152/ajpendo.1991.260.1.E21; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; Lee ES, 1996, BIOL REPROD, V55, P1383, DOI 10.1095/biolreprod55.6.1383; LI JB, 1978, BIOCHIM BIOPHYS ACTA, V544, P351, DOI 10.1016/0304-4165(78)90103-4; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MAY ME, 1989, DIABETES METAB REV, V5, P227, DOI 10.1002/dmr.5610050303; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; MILNER RDG, 1969, LANCET, V1, P1075; Morley SJ, 1997, BIOCHEM SOC T, V25, P503, DOI 10.1042/bst0250503; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PRENTKI M, 1983, J BIOL CHEM, V258, P4239; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Renstrom E, 1996, J PHYSIOL-LONDON, V494, P41, DOI 10.1113/jphysiol.1996.sp021474; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; Tsuruzoe K, 1998, DIABETES, V47, P621, DOI 10.2337/diabetes.47.4.621; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Zhang Q, 1998, J ENDOCRINOL, V156, P573, DOI 10.1677/joe.0.1560573; Zheng XF, 1997, P NATL ACAD SCI USA, V94, P3070, DOI 10.1073/pnas.94.7.3070	45	196	200	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28178	28184		10.1074/jbc.273.43.28178	http://dx.doi.org/10.1074/jbc.273.43.28178			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774438	hybrid			2022-12-25	WOS:000076549800058
J	Taveggia, C; Pizzagalli, A; Feltri, ML; Grinspan, JB; Kamholz, J; Wrabetz, L				Taveggia, C; Pizzagalli, A; Feltri, ML; Grinspan, JB; Kamholz, J; Wrabetz, L			MEBA derepresses the proximal myelin basic protein promoter in oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-PROTEIN; SHIVERER MUTANT MICE; GENE-TRANSCRIPTION; NEGATIVE REGULATION; TRANSGENIC MICE; NERVOUS-SYSTEM; CELL-LINE; EXPRESSION; ELEMENTS; BRAIN	The central nervous system expression of myelin basic protein (MBP) is restricted to oligodendrocytes and is developmentally regulated; these regulatory features are transcriptionally mediated. We have previously shown that the proximal 149 nucleotides of the MBP promoter were both necessary and sufficient to activate the transcription of MBP in cultured oligodendrocytes, but not in other cell types. Sequences within the distal portion of this promoter, which contains a nuclear factor 1 (NF1) binding site, repressed activation of the MBP promoter in Cos-7 cells, but not in oligodendrocytes. We now describe a sequence upstream of and partially overlapping the NF1 site that activates the MBP promoter in oligodendrocytes, but not in Cos-7 cells. A protein complex binds to this site, designated MEBA (myelinating glia-enriched DNA binding activity), and is enriched in nuclear extracts prepared from the brain, oligodendrocytes, and Schwann cells, The amount of MEBA parallels MBP expression and myelinogenesis in the developing brain and parallels new MBP expression as purified oligodendrocytes differentiate. Mutational analyses of binding and function distinguish MEBA, an activator, from NF1, a repressor of MBP transcription, and suggest that MEBA consists of at least two proteins. Because the binding sites of MEBA and NF1 overlap, we suggest that MEBA may either compete with or modify NF1 binding, thereby activating the MBP promoter in oligodendrocytes.	San Raffaele Sci Inst, DIBIT, I-20132 Milan, Italy; San Raffaele Sci Inst, Dept Neurol, I-20132 Milan, Italy; Childrens Hosp Philadelphia, Div Neurosci Res, Philadelphia, PA 19104 USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Wayne State University	Wrabetz, L (corresponding author), San Raffaele Sci Inst, DIBIT, Via Olgettina 58, I-20132 Milan, Italy.		Feltri, Maria Laura/J-5286-2018; Taveggia, Carla/AAN-4784-2020					AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; ASIPU A, 1994, GENE, V150, P227, DOI 10.1016/0378-1119(94)90431-6; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DEVINEBEACH K, 1990, J BIOL CHEM, V265, P13830; FORAN DR, 1992, J NEUROSCI, V12, P4890; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Giesen K, 1997, DEVELOPMENT, V124, P2307; GOUJETZALC C, 1993, EUR J NEUROSCI, V5, P624, DOI 10.1111/j.1460-9568.1993.tb00528.x; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; GRINSPAN JB, 1990, J NEUROSCI, V10, P1866; HAAS S, 1995, J BIOL CHEM, V270, P12503, DOI 10.1074/jbc.270.21.12503; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; HAQUE NS, 1995, J CELL PHYSIOL, V163, P321, DOI 10.1002/jcp.1041630213; HAQUE NS, 1994, J BIOL CHEM, V269, P31149; INOUE T, 1990, J BIOL CHEM, V265, P19065; KAMHOLZ J, 1992, J NEUROSCI RES, V31, P231, DOI 10.1002/jnr.490310204; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MARTINI R, 1995, J NEUROSCI, V15, P4488; MISKIMINS R, 1992, DEV BRAIN RES, V65, P217, DOI 10.1016/0165-3806(92)90182-V; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; Osada S, 1997, J BIOCHEM, V121, P355; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; ROACH A, 1983, CELL, V34, P799, DOI 10.1016/0092-8674(83)90536-6; SALMINEN M, 1995, J MOL BIOL, V253, P17, DOI 10.1006/jmbi.1995.0532; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; Shy ME, 1996, J NEUROSCI RES, V43, P511, DOI 10.1002/(SICI)1097-4547(19960301)43:5<511::AID-JNR1>3.0.CO;2-L; STEPLEWSKI A, 1995, GENE, V154, P215, DOI 10.1016/0378-1119(94)00816-B; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; TAMURA TA, 1989, MOL CELL BIOL, V9, P3122, DOI 10.1128/MCB.9.7.3122; TONTSCH U, 1994, P NATL ACAD SCI USA, V91, P11616, DOI 10.1073/pnas.91.24.11616; WIKTOROWICZ M, 1991, DEV NEUROSCI-BASEL, V13, P143, DOI 10.1159/000112152; WRABETZ L, 1993, J NEUROSCI RES, V36, P455, DOI 10.1002/jnr.490360412; Wrabetz L, 1998, J NEUROBIOL, V34, P10, DOI 10.1002/(SICI)1097-4695(199801)34:1<10::AID-NEU2>3.0.CO;2-F; WRABETZ LG, 1990, ANN NY ACAD SCI, V605, P354, DOI 10.1111/j.1749-6632.1990.tb42410.x; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x	44	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27741	27748		10.1074/jbc.273.42.27741	http://dx.doi.org/10.1074/jbc.273.42.27741			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765312	hybrid			2022-12-25	WOS:000076448000099
J	Kamitani, T; Kito, K; Nguyen, HP; Wada, H; Fukuda-Kamitani, T; Yeh, ETH				Kamitani, T; Kito, K; Nguyen, HP; Wada, H; Fukuda-Kamitani, T; Yeh, ETH			Identification of three major sentrinization sites in PML	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; RETINOIC ACID; RAR-ALPHA; ZINC-FINGER; CONJUGATING ENZYME; RING FINGER; RECEPTOR; FUSION	Acute promyelocytic leukemia arises following a reciprocal chromosome translocation t(15;17), which generates PML-retinoic acid receptor alpha fusion proteins (PML-RAR alpha). We have shown previously that wild type PML, but not PML-RAR alpha, is covalently modified by the sentrin family of ubiquitin-like proteins (Kamitani, T., Nguyen, H. P., Kito, K., Fukuda-Kamitani, T., and Yeh, E. T. H. (1998) J. Biol. Chem. 273, 3117-3120). To understand the mechanisms underlying the differential sentrinization of PML versus PML-RAR alpha, extensive mutational analysis was carried out to determine which Lys residues are sentrinized, We show that Lys(65) in the RING finger domain, Lys(160) in the B1 Box, and Lys(490) in the nuclear localization signal contributes three major sentrinization sites. The PML mutant with Lys to Arg substitutions in all three sites is expressed normally, but cannot be sentrinized. Furthermore, the triple substitution mutant is localized predominantly to the nucleoplasm, in contrast to wild type PML, which is localized to the nuclear bodies. Thus, sentrinization of PML, in the context of the RING finger and the BI box, regulates nuclear body formation. Furthermore, we showed that sentrinization of PML-RAR alpha could be restored by overexpression of sentrin, but not by retinoic acid treatment. These studies provide novel insight into the pathobiochemistry of acute promyelocytic leukemia and the sentrinization pathway.	Univ Texas, Hlth Sci Ctr, Dept Internal Med,Res Ctr Cardiovasc Dis, Div Mol Med,Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Yeh, ETH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med,Res Ctr Cardiovasc Dis, Div Mol Med,Inst Mol Med Prevent Human Dis, 6431 Fannin,Suite 4-200, Houston, TX 77030 USA.	eyeh@heart.med.uth.tmc.edu	Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; Bloch DB, 1996, J BIOL CHEM, V271, P29198, DOI 10.1074/jbc.271.46.29198; Boddy MN, 1996, ONCOGENE, V13, P971; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FujimotoNishiyama A, 1997, GENE, V195, P267, DOI 10.1016/S0378-1119(97)00172-8; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KAMITANI T, 1991, CLIN IMMUNOL IMMUNOP, V58, P217, DOI 10.1016/0090-1229(91)90138-Z; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okura T, 1996, J IMMUNOL, V157, P4277; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yoshida H, 1996, CANCER RES, V56, P2945	44	267	269	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26675	26682		10.1074/jbc.273.41.26675	http://dx.doi.org/10.1074/jbc.273.41.26675			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756909	hybrid			2022-12-25	WOS:000076373300063
J	Rogers, MA; Winter, H; Wolf, C; Heck, M; Schweizer, J				Rogers, MA; Winter, H; Wolf, C; Heck, M; Schweizer, J			Characterization of a 190-kilobase pair domain of human type I hair keratin genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; EPITHELIAL CYTOKERATINS; EVOLUTIONARY CONSERVATION; DIFFERENTIAL EXPRESSION; INTERMEDIATE FILAMENTS; TRANSCRIPTION FACTOR; MAMMALIAN-TISSUES; BARRIER FUNCTION; SEQUENCE; IDENTIFICATION	Polymerase chain reaction-based screening of an arrayed human P1 artificial chromosome (PAC) library using primer pairs specific for the human type I hair keratins hHa3-II or hHaG, led to the isolation of two PAC clones, which covered 190 kilobase pairs (kbp) of genomic DNA and contained nine human type I hair keratin genes, one transcribed hair keratin pseudogene, as well as one orphan exon, The hair keratin genes are 4-7 kbp in size, exhibit intergenic distances of 5-8 kbp, and display the same direction of transcription. With one exception, all hair keratin genes are organized into 7 exons and 6 positionally conserved introns. On the basis of sequence homologies, the genes can be grouped into three subclusters of tandemly arranged genes. One subcluster harbors the highly related genes hHa1, hHa3-I, hHa3-II, and hHa4. A second subcluster of highly related genes comprises the novel genes hHa7 and hHa8, as well as pseudogene Psi hHaA, while the structurally less related genes hHaG, hHa5, and hHa2 are constituents of the third subcluster. As shown by reverse transcription-polymerase chain reaction, all hair keratin genes, including the pseudogene, are expressed in the human hair follicle. The transcribed pseudogene Psi hHaA contains a premature stop codon in exon 4 and exhibits aberrant pre-mRNA splicing. Evolutionary tree construction reveals an early divergence of hair keratin genes from cytokeratin genes, followed by the segregation of the genes into the three subclusters. We suspect that the 190-kbp domain contains the entire complement of human type I hair keratin genes.	German Canc Res Ctr, Res Program 2, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Rogers, MA (corresponding author), German Canc Res Ctr, Res Program 2, 5th Floor,Rm 522,Neuenheimerfeld 280, D-69120 Heidelberg, Germany.	m.rogers@dkfz-heidelberg.de	Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Attar PS, 1997, MOL ENDOCRINOL, V11, P792, DOI 10.1210/me.11.6.792; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BERTOLINO AP, 1988, J INVEST DERMATOL, V91, P541, DOI 10.1111/1523-1747.ep12476901; BERTOLINO AP, 1990, J INVEST DERMATOL, V94, P297, DOI 10.1111/1523-1747.ep12874436; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; Bowden P E, 1994, J Dermatol Sci, V7 Suppl, pS152, DOI 10.1016/0923-1811(94)90046-9; Bowden PE, 1998, J INVEST DERMATOL, V110, P158, DOI 10.1046/j.1523-1747.1998.00097.x; Ceratto N, 1997, CYTOGENET CELL GENET, V77, P169, DOI 10.1159/000134566; CHOSH LA, 1988, CELL, V53, P11; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; FINK P, 1995, BBA-GENE STRUCT EXPR, V1264, P12, DOI 10.1016/0167-4781(95)00122-W; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HEID HW, 1988, DIFFERENTIATION, V37, P215, DOI 10.1111/j.1432-0436.1988.tb00724.x; HEID HW, 1986, DIFFERENTIATION, V32, P101, DOI 10.1111/j.1432-0436.1986.tb00562.x; HU L, 1994, J BIOL CHEM, V269, P183; HUFF CA, 1993, J BIOL CHEM, V268, P377; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KAYTES PS, 1991, J INVEST DERMATOL, V97, P835, DOI 10.1111/1523-1747.ep12491511; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; LESSIN SR, 1988, J INVEST DERMATOL, V91, P572, DOI 10.1111/1523-1747.ep12477087; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; Mercier M, 1998, J INVEST DERMATOL, V111, P169, DOI 10.1046/j.1523-1747.1998.00234.x; Milisavljevic V, 1996, GENOMICS, V34, P134, DOI 10.1006/geno.1996.0252; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; Nishida K, 1997, AM J HUM GENET, V61, P1268, DOI 10.1086/301650; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; POWELL B, 1992, DEVELOPMENT, V114, P417; POWELL BC, 1986, P NATL ACAD SCI USA, V83, P5048, DOI 10.1073/pnas.83.14.5048; POWELL BC, 1994, J INVEST DERMATOL, V102, P171, DOI 10.1111/1523-1747.ep12371758; RAYCHAUDHURY A, 1986, MOL CELL BIOL, V6, P539, DOI 10.1128/MCB.6.2.539; REIS A, 1994, NAT GENET, V6, P174, DOI 10.1038/ng0294-174; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROGERS MA, 1995, EXP CELL RES, V220, P357, DOI 10.1006/excr.1995.1326; Rogers MA, 1997, DIFFERENTIATION, V61, P187, DOI 10.1046/j.1432-0436.1997.6130187.x; Rogers MA, 1996, J INVEST DERMATOL, V107, P633, DOI 10.1111/1523-1747.ep12584243; ROGERS MA, 1995, MOL BIOL REP, V20, P155, DOI 10.1007/BF00990548; ROMANO V, 1988, CYTOGENET CELL GENET, V48, P148, DOI 10.1159/000132612; ROMANO V, 1992, GENOMICS, V14, P495, DOI 10.1016/S0888-7543(05)80250-2; ROSENBERG M, 1988, MOL CELL BIOL, V8, P722, DOI 10.1128/MCB.8.2.722; ROSENBERG M, 1991, CYTOGENET CELL GENET, V57, P33, DOI 10.1159/000133109; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; SAVTCHENKO ES, 1990, GENOMICS, V7, P394, DOI 10.1016/0888-7543(90)90174-S; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; TOBIASCH E, 1992, DIFFERENTIATION, V50, P163, DOI 10.1111/j.1432-0436.1992.tb00671.x; TROYANOVSKY SM, 1992, EUR J CELL BIOL, V59, P127; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WASEEM A, 1990, GENOMICS, V7, P186; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; Winter H, 1997, J BIOL CHEM, V272, P32345, DOI 10.1074/jbc.272.51.32345; Winter H, 1997, HUM GENET, V101, P165, DOI 10.1007/s004390050607; Winter H, 1997, NAT GENET, V16, P372, DOI 10.1038/ng0897-372; Winter H, 1996, J INVEST DERMATOL, V106, P544, DOI 10.1111/1523-1747.ep12343976; WINTER H, 1994, EXP CELL RES, V212, P190, DOI 10.1006/excr.1994.1134; YU JL, 1993, J INVEST DERMATOL, V101, pS56, DOI 10.1111/1523-1747.ep12362635; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	68	67	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26683	26691		10.1074/jbc.273.41.26683	http://dx.doi.org/10.1074/jbc.273.41.26683			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756910	hybrid			2022-12-25	WOS:000076373300064
J	Tenneti, L; Gibbons, SJ; Talamo, BR				Tenneti, L; Gibbons, SJ; Talamo, BR			Expression and trans-synaptic regulation of P-2x4 and P-2z receptors for extracellular ATP in parotid acinar cells - Effects of parasympathetic denervation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SALIVARY-GLANDS; GATED ION CHANNELS; SUBSTANCE-P; MAST-CELLS; AMYLASE SECRETION; SUPER-SENSITIVITY; CYTOSOLIC CALCIUM; SENSORY NEURONS; P2X(7) RECEPTOR; PLASMA-MEMBRANE	Trans-synaptic regulation of muscarinic, peptidergic, and purinergic responses after denervation has been reported previously in rat parotid acinar cells (McMillian, M. K., Soltoff, S. P., Cantley, L. C., Rudel, R., and Talamo, B. R. (1993) Br. J. Pharmacol. 108, 453-461), Characteristics of the ATP-mediated responses and the effects of parasympathetic denervation were further analyzed through assay of Ca2+ influx, using fluorescence ratio imaging methods, and by analysis of P-2x receptor expression. ATP activates both a high affinity and a low affinity response with properties corresponding to the recently described P-2x4 and the P-2z (P-2x7)-type purinoceptors, respectively. Reverse transcription-polymerase chain reaction analysis reveals mRNA for P-2x4 as well as P-2x7 subtypes but not P-2x1, P-2x2, P-2x3, P-2x5, or P-2x6. P-2x4 protein also is detected by Western blotting. Distribution of the two types of ATP receptor responses on individual cells was stochastic, with both high and low affinity responses on some cells, and only a single type of response on others. Sensitivity to P-2x4-type activation also varied even among cells responsive to low concentrations of ATP. Parasympathetic denervation greatly enhanced responses, tripling the proportion of acinar cells with a P-2x4-type response and increasing the fraction of highly sensitive cells by 7-fold, Moreover, P-2x4 mRNA is significantly increased following parasympathetic denervation. These data indicate that sensitivity to ATP is modulated by neurotransmission at parasympathetic synapses, at least in part through increased expression of P-2x4 mRNA, and suggest that similar regulation may occur at other sites in the nervous system where P-2x4 receptors are widely expressed.	Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA	Tufts University	Talamo, BR (corresponding author), Tufts Univ, Sch Med, Dept Neurosci, 136 Harrison Ave, Boston, MA 02111 USA.	btalamo@opal.tufts.edu		Gibbons, Simon/0000-0001-5311-5993	NIDDK NIH HHS [P30 DK34928] Funding Source: Medline; NINDS NIH HHS [R01 NS-28556] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028556] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASKING B, 1989, ARCH ORAL BIOL, V34, P863, DOI 10.1016/0003-9969(89)90142-8; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; BOSCO D, 1988, AM J PHYSIOL, V254, pG664, DOI 10.1152/ajpgi.1988.254.5.G664; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; Butcher F R, 1980, Adv Cyclic Nucleotide Res, V13, P215; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; COCKCROFT S, 1980, BIOCHEM J, V188, P789, DOI 10.1042/bj1880789; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Collo G, 1996, J NEUROSCI, V16, P2495; Currie KPM, 1996, NEURON, V16, P1027, DOI 10.1016/S0896-6273(00)80126-9; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EKSTROM J, 1977, ACTA PHYSIOL SCAND, V101, P329, DOI 10.1111/j.1748-1716.1977.tb06014.x; EKSTROM J, 1983, ACTA PHYSIOL SCAND, V119, P169, DOI 10.1111/j.1748-1716.1983.tb07322.x; EKSTROM J, 1982, ACTA PHYSIOL SCAND, V115, P437, DOI 10.1111/j.1748-1716.1982.tb07102.x; EKSTROM J, 1980, ACTA PHYSIOL SCAND, V108, P253, DOI 10.1111/j.1748-1716.1980.tb06531.x; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Ferrari D, 1996, J IMMUNOL, V156, P1531; GRIERSON JP, 1995, J BIOL CHEM, V270, P4451, DOI 10.1074/jbc.270.9.4451; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HURLEY TW, 1993, AM J PHYSIOL, V265, pC1472, DOI 10.1152/ajpcell.1993.265.6.C1472; JORGENSEN TD, 1995, BIOCHEM J, V312, P457, DOI 10.1042/bj3120457; KATER SB, 1978, J CELL BIOL, V79, P20, DOI 10.1083/jcb.79.1.20; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; MCMILLIAN MK, 1993, BRIT J PHARMACOL, V108, P453, DOI 10.1111/j.1476-5381.1993.tb12825.x; MCMILLIAN MK, 1988, BIOCHEM J, V255, P291; MCMILLIAN MK, 1987, BIOCHEM BIOPH RES CO, V149, P523, DOI 10.1016/0006-291X(87)90399-8; MCMILLIAN MK, 1989, PEPTIDES, V10, P721, DOI 10.1016/0196-9781(89)90103-4; MEHANSHO H, 1985, J BIOL CHEM, V260, P4418; MERRITT JE, 1987, J BIOL CHEM, V262, P14912; Metioui M, 1996, J CELL PHYSIOL, V168, P462, DOI 10.1002/(SICI)1097-4652(199608)168:2<462::AID-JCP25>3.0.CO;2-3; MILNER P, 1990, BIOCHEM BIOPH RES CO, V170, P649, DOI 10.1016/0006-291X(90)92141-L; Moore D., 1995, CURRENT PROTOCOLS MO; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SCHNEYER CA, 1987, J AUTONOM NERV SYST, V18, P207, DOI 10.1016/0165-1838(87)90119-6; SCHNEYER CA, 1992, P SOC EXP BIOL MED, V200, P127; Schneyer LH, 1974, GASTROINTESTINAL PHY, P183; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Seguela P, 1996, J NEUROSCI, V16, P448; SOLTOFF SP, 1989, BIOCHEM BIOPH RES CO, V165, P1279, DOI 10.1016/0006-291X(89)92741-1; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; SOTO F, 1996, BIOCHEM BIOPH RES CO, V223, P46; SPEIRS RL, 1976, ARCH ORAL BIOL, V21, P539, DOI 10.1016/0003-9969(76)90019-4; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; TENNETI L, 1993, BIOCHEM J, V295, P255, DOI 10.1042/bj2950255; TURNER JT, 1998, IN PRESS CRIT REV OR; Ugur M, 1997, J PHYSIOL-LONDON, V498, P427, DOI 10.1113/jphysiol.1997.sp021869; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Virginio C, 1997, NEUROPHARMACOLOGY, V36, P1285, DOI 10.1016/S0028-3908(97)00141-X; VOLKNANDT W, 1986, J NEUROCHEM, V47, P1449, DOI 10.1111/j.1471-4159.1986.tb00778.x; WILEY JS, 1990, ARCH BIOCHEM BIOPHYS, V280, P263, DOI 10.1016/0003-9861(90)90328-V; WILLEMS PHGM, 1993, CELL CALCIUM, V14, P145, DOI 10.1016/0143-4160(93)90084-J	68	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26799	26808		10.1074/jbc.273.41.26799	http://dx.doi.org/10.1074/jbc.273.41.26799			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756924	hybrid			2022-12-25	WOS:000076373300078
J	Ferrandez, A; Minambres, B; Garcia, B; Olivera, ER; Luengo, JM; Garcia, JL; Diaz, E				Ferrandez, A; Minambres, B; Garcia, B; Olivera, ER; Luengo, JM; Garcia, JL; Diaz, E			Catabolism of phenylacetic acid in Escherichia coli - Characterization of a new aerobic hybrid pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENITRIFYING PSEUDOMONAS SP; BENZOYL-COENZYME-A; MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; PHENOL HYDROXYLASE; POSITIVE REGULATOR; COA LIGASE; GENE MAOA; PUTIDA U; PURIFICATION	The paa cluster of Escherichia coli W involved in the aerobic catabolism of phenylacetic acid (PA) has been cloned and sequenced. It was shown to map at min 31.0 of the chromosome at the right end of the mao region responsible for the transformation of 2-phenylethylamine into PA. The 14 paa genes are organized in three transcription units: paaZ and paaABCDEFGHIJK, encoding catabolic genes; and paaXY, containing the paaX regulatory gene. The paaK gene codes for a phenylacetyl-CoA ligase that catalyzes the activation of PA to phenylacetyl-CoA (PA-CoA). The paaABCDE gene products, which may constitute a multicomponent oxygenase, are involved in PA-CoA hydroxylation. The PaaZ protein appears to catalyze the third enzymatic step, with the paaFGHIJ gene products, which show significant similarity to fatty acid beta-oxidation enzymes, likely involved in further mineralization to Krebs cycle intermediates. Three promoters, Pt, Pa, and Pr, driven the expression of genes paaZ, paaABCDEFGHIJK, and paaX, respectively, have been identified. The Pa promoter is negatively controlled by the paaX gene product. As PA-CoA is the true inducer, PaaX becomes the first regulator of an aromatic catabolic pathway that responds to a CoA derivative. The aerobic catabolism of PA in E. coli represents a novel hybrid pathway that could be a widespread way of PA catabolism in bacteria.	CSIC, Ctr Invest Biol, Dept Mol Microbiol, Madrid 28006, Spain; Univ Leon, Fac Vet, Dept Biochem & Mol Biol, Leon 24007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Universidad de Leon	Diaz, E (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Microbiol, Velazquez 144, Madrid 28006, Spain.	cibdf4f@frenso.csic.es	OLIVERA, ELIAS RODRIGUEZ/H-6385-2016; Olivera, Elias Rodriguez/Q-1166-2019; Luengo, Jose M./E-1935-2016; Garcia Lopez, Jose Luis/G-9139-2015; Diaz, Eduardo/F-8605-2016	OLIVERA, ELIAS RODRIGUEZ/0000-0003-2315-8524; Olivera, Elias Rodriguez/0000-0003-2315-8524; Luengo, Jose M./0000-0002-4984-6256; Garcia Lopez, Jose Luis/0000-0002-9238-2485; Minambres Rodriguez, Baltasar/0000-0003-4590-4911; Diaz, Eduardo/0000-0002-9731-6524				Ahrazem O, 1997, CARBOHYD RES, V303, P67, DOI 10.1016/S0008-6215(97)00145-6; ALTENSCHMIDT U, 1993, J BACTERIOL, V175, P4851, DOI 10.1128/JB.175.15.4851-4858.1993; ALTENSCHMIDT U, 1992, EUR J BIOCHEM, V205, P721, DOI 10.1111/j.1432-1033.1992.tb16835.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARRECUBIETA C, 1994, J BACTERIOL, V176, P6375, DOI 10.1128/jb.176.20.6375-6383.1994; Barnes MR, 1997, J BACTERIOL, V179, P6145, DOI 10.1128/jb.179.19.6145-6153.1997; BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURLINGAME R, 1983, J BACTERIOL, V155, P113, DOI 10.1128/JB.155.1.113-121.1983; BURLINGAME RP, 1986, J BACTERIOL, V168, P55, DOI 10.1128/jb.168.1.55-64.1986; Chang KH, 1997, BIOCHEMISTRY-US, V36, P15650, DOI 10.1021/bi971262p; CHENG HP, 1994, J BACTERIOL, V176, P4034, DOI 10.1128/JB.176.13.4034-4042.1994; Chohnan S, 1997, APPL ENVIRON MICROB, V63, P553, DOI 10.1128/AEM.63.2.553-560.1997; COOPER RA, 1985, J GEN MICROBIOL, V131, P2753; COOPER RA, 1980, J BACTERIOL, V143, P302, DOI 10.1128/JB.143.1.302-306.1980; CORELL CC, 1992, SCIENCE, V258, P1604; CRIPPS RE, 1973, BIOCHEM J, V134, P353, DOI 10.1042/bj1340353; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DEFRANK JJ, 1977, J BACTERIOL, V129, P1356, DOI 10.1128/JB.129.3.1356-1364.1977; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; Diaz E, 1998, J BACTERIOL, V180, P2915; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; Dunaway-Mariano Debra, 1994, Biodegradation, V5, P259, DOI 10.1007/BF00696464; Egland PG, 1997, P NATL ACAD SCI USA, V94, P6484, DOI 10.1073/pnas.94.12.6484; Ferrandez A, 1997, FEBS LETT, V406, P23, DOI 10.1016/S0014-5793(97)00228-7; Ferrandez A, 1997, J BACTERIOL, V179, P2573, DOI 10.1128/jb.179.8.2573-2581.1997; FUJITA Y, 1989, J BIOL CHEM, V264, P4201; Gasson MJ, 1998, J BIOL CHEM, V273, P4163, DOI 10.1074/jbc.273.7.4163; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRUND E, 1992, APPL ENVIRON MICROB, V58, P1874, DOI 10.1128/AEM.58.6.1874-1877.1992; GUYER MS, 1983, METHOD ENZYMOL, V101, P362; Hanlon SP, 1997, MICROBIOL-UK, V143, P513, DOI 10.1099/00221287-143-2-513; Harwood CS, 1996, ANNU REV MICROBIOL, V50, P553, DOI 10.1146/annurev.micro.50.1.553; He XY, 1997, BIOCHEMISTRY-US, V36, P261, DOI 10.1021/bi961841e; HENSON JM, 1984, MOL GEN GENET, V193, P263, DOI 10.1007/BF00330678; Jaenecke S, 1996, MOL MICROBIOL, V21, P293, DOI 10.1046/j.1365-2958.1996.6411358.x; JOHNSON GR, 1995, APPL ENVIRON MICROB, V61, P3336, DOI 10.1128/AEM.61.9.3336-3346.1995; KOENIG K, 1989, APPL ENVIRON MICROB, V55, P1829, DOI 10.1128/AEM.55.7.1829-1834.1989; Kroger M, 1997, NUCLEIC ACIDS RES, V25, P39, DOI 10.1093/nar/25.1.39; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LANGKAU B, 1995, EUR J BIOCHEM, V230, P686; LIPSCOMB JD, 1994, ANNU REV MICROBIOL, V48, P371, DOI 10.1146/annurev.mi.48.100194.002103; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; MARTINEZBLANCO H, 1990, J BIOL CHEM, V265, P7084; MCNEIL D, 1981, J BACTERIOL, V146, P260; Minambres B, 1996, J BIOL CHEM, V271, P33531, DOI 10.1074/jbc.271.52.33531; MOHAMED MES, 1993, ARCH MICROBIOL, V159, P554, DOI 10.1007/BF00249035; MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x; Nakamura Y, 1997, NUCLEIC ACIDS RES, V25, P244, DOI 10.1093/nar/25.1.244; NAKATSU CH, 1995, MICROBIOL-UK, V141, P485, DOI 10.1099/13500872-141-2-485; NIEMETZ R, 1995, EUR J BIOCHEM, V227, P161, DOI 10.1111/j.1432-1033.1995.tb20372.x; OLIVERA ER, 1994, EUR J BIOCHEM, V221, P375, DOI 10.1111/j.1432-1033.1994.tb18749.x; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; Pikus JD, 1996, BIOCHEMISTRY-US, V35, P9106, DOI 10.1021/bi960456m; Powlowski J, 1997, J BIOL CHEM, V272, P945, DOI 10.1074/jbc.272.2.945; Prieto MA, 1996, J BACTERIOL, V178, P111, DOI 10.1128/jb.178.1.111-120.1996; PRIETO MA, 1993, J BACTERIOL, V175, P2162, DOI 10.1128/JB.175.7.2162-2167.1993; Prieto MA, 1997, BIOCHEM BIOPH RES CO, V232, P759, DOI 10.1006/bbrc.1997.6368; Qian H, 1997, BIOCHEMISTRY-US, V36, P495, DOI 10.1021/bi9619233; Rosche B, 1997, J BACTERIOL, V179, P3549, DOI 10.1128/jb.179.11.3549-3554.1997; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; Small FJ, 1997, J BIOL CHEM, V272, P24913, DOI 10.1074/jbc.272.40.24913; Spence EL, 1996, J BACTERIOL, V178, P5249, DOI 10.1128/jb.178.17.5249-5256.1996; STRINGFELLOW JM, 1995, GENE, V166, P73, DOI 10.1016/0378-1119(95)00596-8; SUGINO H, 1992, J BACTERIOL, V174, P2485, DOI 10.1128/jb.174.8.2485-2492.1992; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; Velasco A, 1998, J BACTERIOL, V180, P1063, DOI 10.1128/JB.180.5.1063-1071.1998; VITOVSKI S, 1993, FEMS MICROBIOL LETT, V108, P1; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; Yamashita M, 1996, J BACTERIOL, V178, P2941, DOI 10.1128/jb.178.10.2941-2947.1996; ZENK MH, 1980, ANAL BIOCHEM, V101, P182, DOI 10.1016/0003-2697(80)90058-5	75	171	193	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25974	25986		10.1074/jbc.273.40.25974	http://dx.doi.org/10.1074/jbc.273.40.25974			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748275	hybrid			2022-12-25	WOS:000076263100066
J	Okubo, Y; Blakesley, VA; Stannard, B; Gutkind, S; Le Roith, D				Okubo, Y; Blakesley, VA; Stannard, B; Gutkind, S; Le Roith, D			Insulin-like growth factor-I inhibits the stress-activated protein kinase/c-jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; INDUCED APOPTOSIS; MEDIATED APOPTOSIS; NEURONAL SURVIVAL; CELL-DEATH; RECEPTOR; RAS; JNK; PHOSPHORYLATION	The pathways involved in the cellular responses to the insulin-like growth factors (IGFs) are numerous and vary according to cell type. Following activation of the IGF-I receptor, the mitogen-activated protein kinase and phosphatidylinositide 3'-kinase (PI3'K) pathways are activated and result in cellular proliferation and inhibition of apoptosis. In this study, we analyzed the IGF-I effect on the stress-activated protein kinase/c-Jun N-terminal kinase (JNK) activity using human embryonic kidney 293 cells, 293 cells transiently expressing hemagglutinin-JNK, and 293 cells stably expressing a hemagglutinin-JNK transgene, In all cell types, endogenous or transfected JNK activity was strongly stimulated by anisomycin or tumor necrosis factor-alpha, and 10 nM IGF-I pretreatment suppressed the induced JNK activity. To determine whether the effect of IGF-I on JNK activity involves the mitogen-activated protein kinase or PI3'K pathway, we used the specific MEK1 inhibitor PD098059 and the PI3'K inhibitor LY 294002. PD098059 did not alter the IGF-I suppressive effect on stressor-induced JNK activity, but LY 294002 suppressed the IGF-I effect. Moreover, in transiently transfected parental 293 cells expressing dominant-negative Akt, anisomycin-increased JNK activity was not suppressed by pretreatment with IGF-I, Our results demonstrate that the action of IGF-I on JNK in these cells is via PI3'K and Akt.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; NIDR, Lab Cellular Dev & Oncol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Le Roith, D (corresponding author), NIDDK, Diabet Branch, NIH, Rm 8S235A,Bldg 10, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482				BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Butterfield L, 1997, J BIOL CHEM, V272, P10110; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cheng HL, 1998, J BIOL CHEM, V273, P14560, DOI 10.1074/jbc.273.23.14560; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156; Folli F, 1996, MOL NEUROBIOL, V13, P155, DOI 10.1007/BF02740639; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; Herrmann JL, 1997, EXP CELL RES, V234, P442, DOI 10.1006/excr.1997.3653; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Koval AP, 1998, BIOCHEM J, V330, P923; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Liu Q, 1997, J IMMUNOL, V159, P829; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Marais R, 1996, CANCER SURV, V27, P101; Miller BS, 1996, BIOCHEMISTRY-US, V35, P8769, DOI 10.1021/bi952651r; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RUBIN R, 1995, LAB INVEST, V73, P311; Sakakura C, 1996, J BIOL CHEM, V271, P946, DOI 10.1074/jbc.271.2.946; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Skov S, 1997, J CELL BIOL, V139, P1523, DOI 10.1083/jcb.139.6.1523; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tagami M, 1997, LAB INVEST, V76, P603; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	49	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25961	25966		10.1074/jbc.273.40.25961	http://dx.doi.org/10.1074/jbc.273.40.25961			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748273	hybrid			2022-12-25	WOS:000076263100064
J	Rencurel, F; Munoz-Alonso, MJ; Girard, J; Leturque, A				Rencurel, F; Munoz-Alonso, MJ; Girard, J; Leturque, A			An unusual high-K-m hexokinase is expressed in the mhAT3F hepatoma cell line.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; FATTY-ACID-SYNTHASE; GLUCOSE-TRANSPORTER; REGULATORY PROTEIN; PANCREATIC-ISLET; RAT HEPATOCYTES; GLUCOKINASE ACTIVITY; MESSENGER-RNA; III ISOZYME; LIVER	In most hepatoma cells, the high-K-m GLUT2/glucokinase proteins are replaced by the ubiquitous low-K-m GLUT1/hexokinase type I proteins. In the mhAT3F hepatoma cells, the stimulatory effect of glucose on gene expression and glycogen accumulation was not maximal at 5 mmol/liter glucose. This response to high glucose is observed in mhAT3F cells, where GLUT2 was expressed, but not glucokinase (assessed by Northern blotting and reverse transcription-polymerase chain reaction). A low-K-m hexokinase activity (19.6 +/- 3.8 milliunits/mg of protein) was present, but a high-K-m (40 mmol/liter) hexokinase activity (13.9 +/- 2.5 milliunits/mg) was also detected in mhAT3F cells. The high-K-m hexokinase activity was dependent on both ATP (or PP,) and glucose in the assay and was recovered in a 10-50-kDa fraction after filtration. A 30-kDa protein was detected using an anti-glucokinase antibody and localized by confocal microscopy at the same sites as glucokinase in hepatocytes. In FAO cells, the high-K-m hexokinase activity and 30-kDa protein were not found. We conclude that a high-K-m hexokinase activity is present in mhAT3F cells. This might explain why the effects of glucose on gene expression were not maximal at a glucose concentration of 5 mmol/liter. A 30-kDa protein identified using an antiglucokinase antibody may be responsible for this activity present in mhAT3F cells.	CNRS, UPR1524, F-92190 Meudon, France	Centre National de la Recherche Scientifique (CNRS)	Leturque, A (corresponding author), CNRS, UPR1524, 9 Rue Jules Hetzel, F-92190 Meudon, France.		Leturque, Armelle/Q-9437-2017	Leturque, Armelle/0000-0001-6570-6387				AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; AGIUS L, 1994, BIOCHEM J, V303, P841, DOI 10.1042/bj3030841; Antoine B, 1997, J BIOL CHEM, V272, P17937, DOI 10.1074/jbc.272.29.17937; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; ASANO T, 1992, DIABETES, V41, P22, DOI 10.2337/diabetes.41.1.22; BERRY MN, 1969, J CELL BIOL, V43, P606; Brown KS, 1997, DIABETES, V46, P179, DOI 10.2337/diabetes.46.2.179; BURCELIN R, 1992, BIOCHEM J, V288, P675, DOI 10.1042/bj2880675; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; DAVAGNINO J, 1980, J BIOL CHEM, V255, P2633; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Foster JD, 1997, P SOC EXP BIOL MED, V215, P314; GIFFHORNKATZ S, 1986, EUR J BIOCHEM, V159, P513, DOI 10.1111/j.1432-1033.1986.tb09916.x; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; Heimberg H, 1996, P NATL ACAD SCI USA, V93, P7036, DOI 10.1073/pnas.93.14.7036; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEVRAT F, 1993, EXP CELL RES, V209, P307, DOI 10.1006/excr.1993.1315; LIANG Y, 1991, J BIOL CHEM, V266, P6999; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MEIENHOFER MC, 1987, EUR J BIOCHEM, V169, P237, DOI 10.1111/j.1432-1033.1987.tb13603.x; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; NORDLIE RC, 1971, J BIOL CHEM, V246, P4807; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; POSTIC C, 1993, BIOCHEM J, V293, P119, DOI 10.1042/bj2930119; PRELLER A, 1992, ARCH BIOCHEM BIOPHYS, V294, P482, DOI 10.1016/0003-9861(92)90715-9; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; REYES A, 1983, BIOCHEM J, V221, P311; SCHWAB DA, 1991, ARCH BIOCHEM BIOPHYS, V285, P365, DOI 10.1016/0003-9861(91)90373-Q; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; TOYODA Y, 1995, BIOCHEM BIOPH RES CO, V215, P467, DOI 10.1006/bbrc.1995.2488; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VINUELA E, 1963, J BIOL CHEM, V238, P1175; Wilson JE, 1997, BIOCHEM SOC T, V25, P103, DOI 10.1042/bst0250103	41	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26187	26193		10.1074/jbc.273.40.26187	http://dx.doi.org/10.1074/jbc.273.40.26187			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748301	hybrid			2022-12-25	WOS:000076263100092
J	Husmann, K; Sers, C; Fietze, E; Mincheva, A; Lichter, P; Schafer, R				Husmann, K; Sers, C; Fietze, E; Mincheva, A; Lichter, P; Schafer, R			Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11-12	ONCOGENE			English	Article						expression genetics; cellular transformation; RAS; oncogenic signalling; transcriptional target	HRAS-TRANSFORMED CELLS; BREAST-CANCER CELLS; LYSYL OXIDASE; WILMS TUMOR; H-RAS; DIFFERENTIAL DISPLAY; PROTEIN-KINASE; MESSENGER-RNAS; EXPRESSION; GROWTH	The H-rev107 tumour suppressor was isolated as a gene specifically expressed in rat fibroblasts resistant toward malignant transformation by the activated HRAS gene (Sers et al., 1997; Hajnal et al., 1994), Here we describe the human homologue of the rat H-rev107 gene. The predicted rat and human proteins are highly conserved exhibiting an overall amino acid identity of 83%, The HREV107-1 gene is ubiquitously expressed with the exception of haematopoetic cells and tissues, In contrast, H-REV107-1 mRNA was found only in eight of 27 cell lines derived from mammary carcinoma, lung carcinoma, gastric carcinoma, kidney carcinoma, melanoma, neuroblastoma and other tumours, The H-REV107-1 protein was not detectable in any of these tumour cells. Loss of H-REV107-1 expression was not restricted to cultured human tumour cell lines, but also found in primary squamous cell carcinomas. Gross structural aberrations of the H-REV107-1 gene were absent in tumorigenic cell lines. Thus, the block to H-REV107-1 expression is achieved both at the level of transcription and translation. By fluorescence in situ hybridisation the human H-REV107-1 gene was localised to chromosome 11q11-12.	Univ Zurich, Dept Pathol, Div Canc Res, CH-8091 Zurich, Switzerland; Humboldt Univ, Univ Hosp Charite, Inst Pathol, D-10117 Berlin, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany	University of Zurich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ)	Schafer, R (corresponding author), Univ Zurich, Dept Pathol, Div Canc Res, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.		Schäfer, Reinhold/AAB-5110-2021; Sers, Christine/B-5438-2010	Schafer, Reinhold/0000-0001-7952-2124; Sers, christine/0000-0002-6219-1514				BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOAK AM, 1994, AM J RESP CELL MOL, V11, P751, DOI 10.1165/ajrcmb.11.6.7946403; BOS JL, 1989, CANCER RES, V49, P4682; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Gioeli D, 1997, CANCER RES, V57, P1157; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HAJNAL A, 1993, CANCER RES, V53, P4670; HAJNAL A, 1994, ONCOGENE, V9, P479; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; JANES PW, 1994, ONCOGENE, V9, P3601; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATZ E, 1986, J NATL CANCER I, V77, P909; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIESS M, 1995, ONCOGENE, V10, P61; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kuchinke W, 1995, NEUROIMMUNOMODULAT, V2, P347, DOI 10.1159/000097214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NEGRINI M, 1994, CANCER RES, V54, P1331; OBERHUBER H, 1995, MOL CARCINOGEN, V12, P198, DOI 10.1002/mc.2940120404; PENG JW, 1990, CANCER GENET CYTOGEN, V45, P101; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFER R, 1994, REV PHYSIOL BIOCH P, V124, P29, DOI 10.1007/BFb0031031; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHIPPER JH, 1991, CANCER RES, V51, P6328; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; Szpirer C, 1996, MAMM GENOME, V7, P701, DOI 10.1007/s003359900211; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	55	51	52	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1305	1312		10.1038/sj.onc.1202060	http://dx.doi.org/10.1038/sj.onc.1202060			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771974				2022-12-25	WOS:000075803300013
J	Oh, Y; Proctor, ML; Fan, YH; Su, LK; Hong, WK; Fong, KM; Sekido, YS; Gazdar, DF; Minna, JD; Mao, L				Oh, Y; Proctor, ML; Fan, YH; Su, LK; Hong, WK; Fong, KM; Sekido, YS; Gazdar, DF; Minna, JD; Mao, L			TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer	ONCOGENE			English	Article						non-small cell lung cancer; tumor suppressor	HUMAN BREAST-CANCER; P53 MUTATIONS; FHIT GENE; HETEROZYGOSITY; TUMORS; LINES; PHOSPHOPROTEIN; ONCOPROTEIN-18; CHROMOSOME-11; ABNORMALITIES	TSG101 is a candidate tumor suppressor gene whose deletion in NIH3T3 cells leads to spontaneous lung metastases in nude mice. Aberrant transcripts of TSG101 have been identified in 47% of primary breast carcinomas, without evidence of intragenic deletions at the TSG101 locus on 11p15, To investigate the possible role of TSG101 in lung cancer, which often shows 11p allele loss, we performed transcript analysis and mutational analysis of TSG101 in lung cancer cell lines. Reverse transcriptase RT-PCR and Northern analysis detected a common TSG101 transcript, shortened because of an internal deletion, which was expressed simultaneously with the wild-type transcript in 89% of small cell lung cancer (SCLC) lines. In contrast, the wild-type transcript was expressed alone in normal tissues, primary non-small cell lung cancer (NSCLC) specimens, and the majority of NSCLC cell lines. Sequence of the shortened SCLC transcript was identical to that of the most common aberrant transcript identified in breast cancer, consisting of a deletion of exons 2-4 and part of 1 and 5, Southern analysis of SCLC lines expressing the shortened transcript did not detect any intragenic deletions, Single strand conformational polymorphism (SSCP) analysis and direct sequencing of TSG101 cDNAs also identified no mutations or deletions. These results suggest that TSG101 is not mutated in lung cancer but that aberrant splicing of TSG101 occurs in SCLC.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Mao, Li/C-7570-2011; Fong, Kwun M/G-6369-2010	Mao, Li/0000-0001-7263-3358; Fong, Kwun/0000-0002-6507-1403; Sekido, Yoshitaka/0000-0002-2428-3848	NCI NIH HHS [5T32CA66187-03, CA 16672, P50 CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA066187, P50CA070907, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; COOK RM, 1993, CURR PROB CANCER, V17, P71; DAMICO D, 1992, ONCOGENE, V7, P339; DEVESA SS, 1991, CANCER EPIDEM BIOMAR, V1, P29; DiPaolo G, 1996, J CELL BIOL, V133, P1383, DOI 10.1083/jcb.133.6.1383; DOYE V, 1990, J BIOL CHEM, V265, P11650; Druck T, 1997, CANCER RES, V57, P504; FONG KM, 1994, GENE CHROMOSOME CANC, V10, P183, DOI 10.1002/gcc.2870100306; Fong KM, 1997, CANCER RES, V57, P2256; GRATIOTDEANS J, 1992, J CLIN INVEST, V90, P1576, DOI 10.1172/JCI116026; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HAILAT N, 1990, ONCOGENE, V5, P1615; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; Kim SK, 1997, CANCER RES, V57, P400; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; KOPPEL J, 1993, FEBS LETT, V331, P65, DOI 10.1016/0014-5793(93)80298-9; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Liang H., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P68; MAO L, 1994, CANCER RES, V54, P1634; Mao L, 1996, CANCER RES, V56, P5128; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MATTHEWS MJ, 1973, CANCER CHEMOTH REP 3, V4, P63; MILLER CW, 1992, CANCER RES, V52, P1695; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Roberts GC, 1996, EMBO J, V15, P6301, DOI 10.1002/j.1460-2075.1996.tb01020.x; ROOS G, 1993, LEUKEMIA, V7, P1538; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RYGAARD K, 1992, CANCER RES, V50, P5312; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Sundareshan TS, 1996, CANCER GENET CYTOGEN, V91, P53, DOI 10.1016/S0165-4608(96)00031-3; VIRMANI AK, 1998, IN PRESS GEN CHROM C; West CA, 1996, BONE, V19, P41, DOI 10.1016/8756-3282(96)00105-6; WINQVIST R, 1995, CANCER RES, V55, P2660	41	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1141	1148		10.1038/sj.onc.1202029	http://dx.doi.org/10.1038/sj.onc.1202029			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764824				2022-12-25	WOS:000075598400009
J	Wright, K; Wilson, PJ; Kerr, J; Do, K; Hurst, T; Khoo, SK; Ward, B; Chenevix-Trench, G				Wright, K; Wilson, PJ; Kerr, J; Do, K; Hurst, T; Khoo, SK; Ward, B; Chenevix-Trench, G			Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas	ONCOGENE			English	Article						loss of heterozygosity; ovarian adenocarcinomas; tumour suppressor gene	TUMOR-SUPPRESSOR GENE; PROSTATE-CANCER; ALLELIC LOSS; CARCINOMAS; ALLELOTYPE; DELETION	Many chromosomal regions undergo loss of heterozygosity (LOH) in ovarian adenocarcinomas but few of the target regions have been finely mapped. One of the chromosome arms likely to harbour one or more tumour suppressor genes inactivated in ovarian cancer is the short arm of chromosome 8 which is frequently deleted in many other solid tumours, We have examined a large panel of microsatellite markers on 8p for LOH in 53 ovarian adenocarcinomas. LOH was observed in 27 tumours (51%), with a significant trend towards a higher frequency of LOH in more advanced tumours, Detailed examination of nine tumours with partial deletions defined three regions of overlap, two in 8p23 and one in 8p22, which suggests that there might be as many as three tumour or metastasis suppressor genes on 8p which are inactivated during ovarian tumorigenesis. LOH on 8p was significantly associated with 9p LOH which suggests that inactivation of target genes on these chromosomes may be cooperative events.	Queensland Inst Med Res, Queensland Canc Res Unit, Brisbane, Qld 4029, Australia; Univ Queensland, Royal Brisbane Hosp, Dept Obstet & Gynaecol, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland	Chenevix-Trench, G (corresponding author), Queensland Inst Med Res, Queensland Canc Res Unit, Brisbane, Qld 4029, Australia.			Chenevix-Trench, Georgia/0000-0002-1878-2587				Becker SA, 1996, CANCER RES, V56, P5092; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; CLIBY W, 1993, CANCER RES, V53, P2393; FIELD JK, 1995, BRIT J CANCER, V72, P1180, DOI 10.1038/bjc.1995.483; Gustafson CE, 1996, CANCER RES, V56, P5238; ICHIKAWA T, 1994, CANCER RES, V54, P2299; IWABUCHI T, 1994, CANCER RES, V55, P6172; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; Takle LA, 1996, ONCOGENE, V12, P1083; TENERIELLO MG, 1993, CANCER RES, V53, P3103; Vocke CD, 1996, CANCER RES, V56, P2411; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V	21	61	62	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1185	1188		10.1038/sj.onc.1202028	http://dx.doi.org/10.1038/sj.onc.1202028			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764830				2022-12-25	WOS:000075598400015
J	Sawyer, C; Hiles, I; Page, M; Crompton, M; Dean, C				Sawyer, C; Hiles, I; Page, M; Crompton, M; Dean, C			Two erbB-4 transcripts are expressed in normal breast and in most breast cancers	ONCOGENE			English	Article						receptor tyrosine kinase; breast cancer; erbB-4; signal transduction; phosphatidylinositol 3-kinase	GROWTH-FACTOR RECEPTOR; DIFFERENTIATION FACTOR; MONOCLONAL-ANTIBODY; SIGNAL-TRANSDUCTION; CELLULAR-RESPONSE; HEREGULIN; CELLS; FAMILY; ACTIVATION; NEUREGULIN	ErbB-4 is a recently described member of the epidermal growth factor receptor (EGFR) family which together with erbB-3 acts as a receptor for a group of ligands known as the neuregulins (NRGs) or heregulins (HRGs), Unlike the EGFR and erbB-2 relatively little is known about the expression of erbB-4 in human tumours. Using RT-PCR and Southern blotting analysis we have investigated the expression of erbB-4 mRNA in a range of human tumour cell lines and in normal and malignant breast tissue. Using primers which amplified a 658 base pair (bp) region corresponding to part of the cytoplasmic domain of c-erbB-4 we found the receptor was expressed in some but not all breast and ovarian tumour cell lines and also in a glioma cell line. The highest level of erbB-4 expression was found in the ovarian carcinoma OVCAR-3 and the breast carcinoma T-47D, In all cell lines where the 'full-length' erbB-4 was detected, a second previously undescribed c-erbB-4 sequence was also found as a 610 bp PCR product. The alternative PCR product was identical in sequence to c-erbB-4 except for a deletion of 48 bp which encodes a consensus phosphatidylinositol 3-kinase (PI3K) binding site. This suggested that the two forms of erbB-4 might interact with different intracellular signalling pathways and therefore influence a wider variety of cellular responses to heregulin than previously thought. Expression of both erbB-4 variants was found in 7/7 normal breast tissues but only in 9/12 breast tumours analysed. In line with the terminology of Elenius et nl, (1997b) we have designated the two isoforms of the C-terminal transcripts as CT-a (full-length) and CT-b which lacks the PI3K binding motif, These results identify suitable cell lines for the further investigation of erbB-4 expression and function and suggest that the role of erbB-4 in breast cancer warrants further investigation with larger numbers of normal and malignant breast tissues.	Inst Canc Res, Immunol Sect, McElwain Labs, Sutton SM2 5NG, Surrey, England; Inst Canc Res, Sect Cell Biol & Expt Pathol, Sutton SM2 5NG, Surrey, England; Glaxo Wellcome Res Labs, Oncol Res Unit, Stevenage, Herts, England	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; GlaxoSmithKline; Wellcome Research Laboratories	Sawyer, C (corresponding author), Inst Canc Res, Immunol Sect, McElwain Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.			Box, Carol/0000-0002-8919-8724				ANDERSEN AS, 1992, BIOTECHNIQUES, V13, P678; Bacus SS, 1996, ONCOGENE, V12, P2535; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; CHAN SDH, 1995, J BIOL CHEM, V270, P22608, DOI 10.1074/jbc.270.38.22608; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Cohen BM, 1996, J BIOL CHEM, V271, P4813; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MODJTAHEDI H, 1994, INT J ONCOL, V4, P277; Modjtahedi H, 1996, BRIT J CANCER, V73, P228, DOI 10.1038/bjc.1996.40; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER C, 1997, THESIS U LONDON; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	33	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					919	924		10.1038/sj.onc.1202015	http://dx.doi.org/10.1038/sj.onc.1202015			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780009				2022-12-25	WOS:000075448800014
J	Edwards, CP; Fisher, KL; Presta, LG; Bodary, SC				Edwards, CP; Fisher, KL; Presta, LG; Bodary, SC			Mapping the intercellular adhesion molecule-1 and -2 binding site on the inserted domain of leukocyte function-associated antigen-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY MONOTHERAPY; INTEGRIN ALPHA-2-BETA-1 VLA-2; I-DOMAIN; LIGAND-BINDING; CRYSTAL-STRUCTURE; A-DOMAIN; RECOGNITION SITE; GRAFT-REJECTION; UNIQUE EPITOPE; CR3 CD11B/CD18	By extensive mutagenic analysis of the inserted domain (I-domain) of the alpha-chain (CD11a) of the leukocyte function-associated antigen-1 (LFA-1), we have defined a putative binding surface for intercellular adhesion molecules 1 and 2 (ICAM-1 and -2). This analysis showed that individually mutating Leu-205 or Glu-241 to alanine completely abolished LFA-1 binding to ICAM-1 or -2 without affecting I-domain structure, as assayed by antibody binding. Mutating Thr-243 to alanine also had a profound effect on LFA-1 binding to ICAM-1 and -2, as seen by complete loss of binding to ICAM-1 and a significant reduction (70% decrease) in binding to ICAM-2. Mutating Glu-146 to alanine reduced LFA-1 binding to ICAM-1 or -2 by 70%, and mutating His-264 or Glu-293 to alanine reduced binding to ICAM-1 or -2 by about 30-40%. Mutating Thr-175 to alanine reduced binding to ICAM-1 by about 30% and binding to ICAM-2 by about 70%. Interestingly, mutating Lys-263 to alanine preferentially abolished LFA-1 binding to ICAM-2 Using these data, we have generated a model of the interface between the LFA-1 I-domain and residues in the first domain of ICAM-1 that have been shown to be critical for this interaction. In addition, this model, together with the ICAM-2 crystal structure, has been used to map residues that are likely to mediate LFA-1 I-domain binding to ICAM-2.	Genentech Inc, Dept Immunol, San Francisco, CA USA	Roche Holding; Genentech	Bodary, SC (corresponding author), Genentech Inc, Dept Immunol, MS 34,1 DNA Way, San Francisco, CA USA.							ARNAOUT MA, 1990, BLOOD, V75, P1037; BAILLY P, 1994, P NATL ACAD SCI USA, V91, P5306, DOI 10.1073/pnas.91.12.5306; Bailly P, 1995, EUR J IMMUNOL, V25, P3316, DOI 10.1002/eji.1830251217; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; BERMAN PW, 1993, J CELL BIOCHEM, V52, P183, DOI 10.1002/jcb.240520210; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; Binnerts ME, 1996, J BIOL CHEM, V271, P9962, DOI 10.1074/jbc.271.17.9962; BINNERTS ME, 1994, EUR J IMMUNOL, V24, P2155, DOI 10.1002/eji.1830240933; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Casasnovas JM, 1997, NATURE, V387, P312, DOI 10.1038/387312a0; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; CAVAZZANACALVO M, 1995, TRANSPLANTATION, V59, P1576, DOI 10.1097/00007890-199506150-00013; CHAMPE M, 1995, J BIOL CHEM, V270, P1388, DOI 10.1074/jbc.270.3.1388; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Fabbri M, 1996, TISSUE ANTIGENS, V48, P47, DOI 10.1111/j.1399-0039.1996.tb02604.x; FISCHER A, 1991, BLOOD, V77, P249; Fisher KL, 1997, MOL BIOL CELL, V8, P501, DOI 10.1091/mbc.8.3.501; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HILDRETH JEK, 1985, J IMMUNOL, V134, P3272; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KERN A, 1994, J BIOL CHEM, V269, P22811; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; Knorr R, 1997, J EXP MED, V186, P719, DOI 10.1084/jem.186.5.719; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MARSTERS SA, 1995, P NATL ACAD SCI USA, V92, P5401, DOI 10.1073/pnas.92.12.5401; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; NAKAKURA EK, 1993, TRANSPLANTATION, V55, P412; Nakakura EK, 1996, TRANSPLANTATION, V62, P547, DOI 10.1097/00007890-199609150-00001; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; Tian L, 1997, J IMMUNOL, V158, P928; UCHIKOSHI F, 1995, TRANSPLANT P, V27, P1527; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; vanKooyk Y, 1996, J EXP MED, V183, P1247, DOI 10.1084/jem.183.3.1247; Woska JR, 1998, J BIOL CHEM, V273, P4725, DOI 10.1074/jbc.273.8.4725; ZENG YJ, 1994, TRANSPLANTATION, V58, P681; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	50	48	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28937	28944		10.1074/jbc.273.44.28937	http://dx.doi.org/10.1074/jbc.273.44.28937			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786897	hybrid			2022-12-25	WOS:000076691800058
J	Engelmann, B; Schaipp, B; Dobner, P; Stoeckelhuber, M; Kogl, C; Siess, W; Hermetter, A				Engelmann, B; Schaipp, B; Dobner, P; Stoeckelhuber, M; Kogl, C; Siess, W; Hermetter, A			Platelet agonists enhance the import of phosphatidylethanolamine into human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ACTIVATION; ARACHIDONIC-ACID; THROMBIN; MEMBRANE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; THROMBOMODULIN; LIPOPROTEIN; GENERATION; VESICLES	It is unknown whether the endocytosis-independent transfer of phospholipids from lipoproteins to platelets is regulated by platelet agonists such as thrombin. The movements of the choline phospholipids phosphatidylcholine and sphingomyelin (labeled with either C-14 or the fluorescent pyrenedecanoic acid) between low density lipoproteins and platelets were unaffected by thrombin (0.5 unit/ml). In contrast, thrombin accelerated the import of diacyl phosphatidylethanolamine (PE) and alkenylacyl phosphatidylethanolamine into platelets by about 4-fold. Similarly, thrombin receptor-activating peptide (15 mu M), collagen (10 mu g/ml), and ADP (10 mu M) enhanced PE uptake. High density lipoprotein particles and egg phosphatidylcholine vesicles were also donors for stimulation of platelet PE import. Part of the [C-14]arachidonic acid-labeled PE transferred from low density lipoprotein to platelets activated by thrombin and collagen was metabolized to C-14-eicosanoids, Inhibitors of protein kinase C partially prevented thrombin-induced [C-14]PE uptake, while direct activators of protein kinase C increased incorporation of [C-14]PE into platelets. Proteinaceous factor(s) recovered in the extracellular medium from ADP- and thrombin-activated platelet suspensions were found to accelerate the transfer of pyrenedecanoic acid-labeled PE between donor and acceptor lipid vesicles. The stimulation of import of ethanolamine phospholipids led to a 2-fold enhancement of the prothrombinase activity of thrombin-activated platelets. Our study demonstrates that physiological platelet stimuli increase specifically the transfer of ethanolamine phospholipids from lipoproteins to platelets through a secretion-dependent mechanism. This might contribute to the increase of procoagulant activity of stimulated platelets.	Univ Munich, Inst Physiol, D-80336 Munich, Germany; Univ Munich, Inst Prophylaxe Kreislaufkrankheiten, D-80336 Munich, Germany; Graz Univ Technol, Inst Biochem & Lebensmittelchem, A-8010 Graz, Austria	University of Munich; University of Munich; Graz University of Technology	Engelmann, B (corresponding author), Univ Munich, Inst Physiol, Pettenkoferstr 12, D-80336 Munich, Germany.	bernd.engelmann@med.uni-muenchen.de	Siess, Wolfgang/A-6430-2009	Siess, Wolfgang/0000-0003-0698-6416				BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARO IF, 1977, J CLIN INVEST, V60, P866, DOI 10.1172/JCI108841; COLARD O, 1989, BIOCHEM J, V259, P333, DOI 10.1042/bj2590333; Diaz C, 1996, J MEMBRANE BIOL, V151, P1, DOI 10.1007/s002329900051; EHRMAN ML, 1980, PROSTAGLANDINS, V20, P1103, DOI 10.1016/0090-6980(80)90063-5; Engelmann B, 1996, BIOCHEM J, V315, P781, DOI 10.1042/bj3150781; FENTON JW, 1989, SEMIN THROMB HEMOST, V15, P265, DOI 10.1055/s-2007-1002718; FREYSSINET JM, 1986, BIOCHEM J, V238, P151, DOI 10.1042/bj2380151; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GOODWIN CA, 1995, BIOCHEM J, V308, P15, DOI 10.1042/bj3080015; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; HABENICHT AJR, 1990, NATURE, V345, P634, DOI 10.1038/345634a0; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KOLLER E, 1989, J BIOL CHEM, V264, P12412; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; MYHER JJ, 1989, LIPIDS, V24, P408, DOI 10.1007/BF02535148; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NOZAWA Y, 1991, BIOCHIM BIOPHYS ACTA, V1082, P219, DOI 10.1016/0005-2760(91)90197-P; PALTAUF F, 1991, METHOD ENZYMOL, V197, P134; PURDON AD, 1987, BIOCHIM BIOPHYS ACTA, V920, P205, DOI 10.1016/0005-2760(87)90096-8; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; Smeets EF, 1996, THROMB RES, V81, P419, DOI 10.1016/0049-3848(96)00014-X; SPECTOR AA, 1970, J CLIN INVEST, V49, P1489, DOI 10.1172/JCI106366; TAKAMURA H, 1987, J BIOL CHEM, V262, P2262; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; THURNHOFER H, 1990, BIOCHIM BIOPHYS ACTA, V1024, P249, DOI 10.1016/0005-2736(90)90351-N; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; YAMASHITA T, 1991, J BIOL CHEM, V266, P3888	32	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27800	27808		10.1074/jbc.273.43.27800	http://dx.doi.org/10.1074/jbc.273.43.27800			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774389	hybrid			2022-12-25	WOS:000076549800009
J	Sato, Y; Ferguson, DG; Sako, H; Dorn, GW; Kadambi, VJ; Yatani, A; Hoit, BD; Walsh, RA; Kranias, EG				Sato, Y; Ferguson, DG; Sako, H; Dorn, GW; Kadambi, VJ; Yatani, A; Hoit, BD; Walsh, RA; Kranias, EG			Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; HEART-FAILURE; VENTRICULAR MYOCYTES; RYANODINE RECEPTORS; HUMAN MYOCARDIUM; GENE-EXPRESSION; CALCIUM CURRENT; GUINEA-PIG; PHOSPHOLAMBAN; CA2+	Calsequestrin is a high capacity Ca2+-binding protein in the sarcoplasmic reticulum (SR) lumen. To elucidate the functional role of calsequestrin in vivo, transgenic mice were generated that overexpressed mouse cardiac calsequestrin in the heart. Overexpression (20-fold) of calsequestrin was associated with cardiac hypertrophy and induction of a fetal gene expression program, Isolated transgenic cardiomyocytes exhibited diminished shortening fraction (46%), shortening rate (60%), and relengthening rate (60%). The Ca2+ transient amplitude was also depressed (45%), although the SR Ca2+ storage capacity was augmented, as suggested by caffeine application studies. These alterations were associated with a decrease in L-type Ca2+ current density and prolongation of this channel's inactivation kinetics without changes in Na+-Ca2+ exchanger current density. Furthermore, there were increases in protein levels of SR Ca2+-ATPase, phospholamban, and calreticulin and decreases in FKBP12, without alterations in ryanodine receptor, junctin, and triadin levels in transgenic hearts. Left ventricular function analysis in Langendorff perfused hearts and closed-chest anesthetized mice also indicated depressed rates of contraction and relaxation of transgenic hearts. These findings suggest that calsequestrin overexpression is associated with increases in SR Ca2+ capacity, but decreases in Ca2+-induced SR Ca2+ release, leading to depressed contractility in the mammalian heart.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Cincinnati, Div Cardiol, Cincinnati, OH 45267 USA; Case Western Reserve Univ, Dept Anat, Cleveland, OH 44106 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Case Western Reserve University	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, POB 670575,231 Bethesda Ave, Cincinnati, OH 45267 USA.	kraniaeg@email.uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026057, P01HL022619, R01HL026057] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26057, HL22619] Funding Source: Medline; PHS HHS [P50-52318] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARAI M, 1991, GENE, V109, P275, DOI 10.1016/0378-1119(91)90621-H; ARAI M, 1993, CIRC RES, V72, P463, DOI 10.1161/01.RES.72.2.463; ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; Balaguru D, 1997, J MOL CELL CARDIOL, V29, P2747, DOI 10.1006/jmcc.1997.0509; BEUCKELMANN DJ, 1992, CIRCULATION, V85, P1046, DOI 10.1161/01.CIR.85.3.1046; CARL SL, 1995, J CELL BIOL, V129, P673, DOI 10.1083/jcb.129.3.673; Chu GX, 1997, CIRC RES, V81, P485, DOI 10.1161/01.RES.81.4.485; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; DORN GW, 1994, AM J PHYSIOL, V267, pH400, DOI 10.1152/ajpheart.1994.267.1.H400; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; Gulick J, 1997, CIRC RES, V80, P655, DOI 10.1161/01.RES.80.5.655; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; GWATHMEY JK, 1993, CARDIOVASC RES, V27, P199, DOI 10.1093/cvr/27.2.199; Harrer JM, 1997, AM J PHYSIOL-HEART C, V272, pH57, DOI 10.1152/ajpheart.1997.272.1.H57; Hasenfuss G, 1996, BASIC RES CARDIOL, V91, P17, DOI 10.1007/BF00795357; Hasenfuss G, 1997, BASIC RES CARDIOL, V92, P87, DOI 10.1007/BF00794072; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; Hoit BD, 1997, AM J PHYSIOL-HEART C, V273, pH2528, DOI 10.1152/ajpheart.1997.273.5.H2528; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; JORGENSEN AO, 1985, J CELL BIOL, V101, P257, DOI 10.1083/jcb.101.1.257; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; MAHONY L, 1986, J BIOL CHEM, V261, P5257; Masaki H, 1997, AM J PHYSIOL-HEART C, V272, pH606, DOI 10.1152/ajpheart.1997.272.2.H606; McCall E, 1996, CIRC RES, V79, P1110, DOI 10.1161/01.RES.79.6.1110; MING Z, 1994, J MOL CELL CARDIOL, V26, P1133, DOI 10.1006/jmcc.1994.1132; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MOVSESIAN MA, 1994, CIRCULATION, V90, P653, DOI 10.1161/01.CIR.90.2.653; NUSS HB, 1991, J MOL CELL CARDIOL, V23, P717, DOI 10.1016/0022-2828(91)90981-Q; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; SANTOS PED, 1995, J CARDIOVASC ELECTR, V6, P1004; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SCHWINGER RHG, 1995, CIRCULATION, V92, P3220, DOI 10.1161/01.CIR.92.11.3220; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Sitsapesan R, 1997, J MEMBRANE BIOL, V159, P179, DOI 10.1007/s002329900281; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Tsutsui H, 1997, AM J PHYSIOL-HEART C, V272, pH168, DOI 10.1152/ajpheart.1997.272.1.H168; VAHL CF, 1994, CIRC RES, V74, P952, DOI 10.1161/01.RES.74.5.952; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; WANKERL M, 1995, J MOL MED-JMM, V73, P487; YANO K, 1994, MOL CELL BIOCHEM, V135, P61, DOI 10.1007/BF00925961; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	49	146	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28470	28477		10.1074/jbc.273.43.28470	http://dx.doi.org/10.1074/jbc.273.43.28470			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774476	hybrid			2022-12-25	WOS:000076549800096
J	Prabhakar, P; Thatte, HS; Goetz, RM; Cho, MR; Golan, DE; Michel, T				Prabhakar, P; Thatte, HS; Goetz, RM; Cho, MR; Golan, DE; Michel, T			Receptor-regulated translocation of endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; CAVEOLAE; LOCALIZATION; PROTEIN; PHOSPHORYLATION; PALMITOYLATION; SUBUNITS; CALCIUM; ENZYME; SITES	The endothelial nitric-oxide synthase (eNOS) is activated by transient increases in intracellular Ca2+ elicited by stimulation of diverse receptors, including bradykinin B-2 receptors on endothelial cells. eNOS and B-2 receptors are targeted to specialized signal-transducing domains in the plasma membrane termed plasmalemmal caveolae. Targeting to caveolae facilitates eNOS activation following receptor stimulation, but in resting cells, eNOS is tonically inhibited by its interactions with caveolin, the scaffolding protein in caveolae, We used a quantitative approach exploiting immunofluorescence microscopy to investigate regulation of the subcellular distribution of eNOS in endothelial cells by bradykinin and Ca2+. In resting cells, most of the eNOS is localized at the cell membrane. However, within 5 min following addition of bradykinin, nearly all the eNOS translocates to structures in the cell cytosol; following more protracted incubations with bradykinin, most of the cytosolic enzyme subsequently translocates back to the cell membrane. The bradykinin-induced internalization of eNOS is completely abrogated by the intracellular Ca2+ chelator BAPTA; conversely, Ca2+-mobilizing drugs and agonists promote eNOS translocation. These results establish that eNOS targeting to the membrane is labile and is subject to receptor-regulated Ca2+-dependent reversible translocation, providing another point for regulation of NO-dependent signaling in the vascular endothelium.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Michel, T (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol, Thorn Bldg,Rm 1210A,75 Francis St, Boston, MA 02115 USA.	degolan@warren.med.harvard.edu; michel@calvin.bwh.harvard.edu	Goetz, Regina/M-2411-2019	Goetz, Regina/0000-0003-3681-4703; Cho, Myoung Rae/0000-0002-8191-8045				ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DUDEK R, 1995, PHARMACOLOGY, V50, P257, DOI 10.1159/000139290; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FUKUDA S, 1995, BRAIN RES, V696, P30, DOI 10.1016/0006-8993(95)00704-T; HECKER M, 1994, BIOCHEM J, V299, P247, DOI 10.1042/bj2990247; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; KAO JPY, 1989, J BIOL CHEM, V264, P8179; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MOMBOULI JV, 1995, ANNU REV PHARMACOL, V35, P679, DOI 10.1146/annurev.pa.35.040195.003335; POLLOCK JS, 1993, AM J PHYSIOL, V265, pC1379, DOI 10.1152/ajpcell.1993.265.5.C1379; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Sase K, 1997, TRENDS CARDIOVAS MED, V7, P28, DOI 10.1016/S1050-1738(96)00121-1; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Venema VJ, 1996, BIOCHEM BIOPH RES CO, V226, P703, DOI 10.1006/bbrc.1996.1417	25	139	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27383	27388		10.1074/jbc.273.42.27383	http://dx.doi.org/10.1074/jbc.273.42.27383			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765266	hybrid			2022-12-25	WOS:000076448000053
J	Anfosso, F; Bardin, N; Frances, V; Vivier, E; Camoin-Jau, L; Sampol, J; Dignat-George, F				Anfosso, F; Bardin, N; Frances, V; Vivier, E; Camoin-Jau, L; Sampol, J; Dignat-George, F			Activation of human endothelial cells via S-endo-1 antigen (CD146) stimulates the tyrosine phosphorylation of focal adhesion kinase p125(FAK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; MOLECULAR-CLONING; HUMAN-MELANOMA; SH3 DOMAINS; PAXILLIN; PROTEIN; IDENTIFICATION; SRC; GLYCOPROTEIN; EXPRESSION	S-Endo-1 antigen (CD146), a transmembrane receptor also known as MUC18/MCAM, is a member of the immunoglobulin superfamily and belongs to a group of cell adhesion molecules. CD146 is highly expressed on the whole vascular tree. We demonstrate here that engagement of CD146 on human endothelial cells isolated from cord blood results in tyrosine phosphorylation of a large panel of cellular proteins, although no tyrosine phosphorylation of CD146 was detected, In particular, CD146 cross-linking induces the tyrosine phosphorylation of the protein tyrosine kinase p125(FAK) as well as p125(FAK) association with paxillin, both events being inhibited by cytochalasin D. No direct association of CD146 with p125(FAK) was observed. Consistent with these data, CD146 associates with p59(fyn), a Src family kinase known to phosphorylate p125(FAK), The identification of a signaling pathway initiated by CD146 engagement and which includes p59(fyn), p125(FAK) and paxillin indicates that CD146 participates in outside-in signaling in endothelial cells.	UFR Pharm, Lab Hematol Immunol, F-13385 Marseille 05, France; Inst Univ France, F-13288 Marseille, France; CNRS, Ctr Immunol, INSERM, Marseille, France	Institut Universitaire de France; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Anfosso, F (corresponding author), UFR Pharm, Lab Hematol Immunol, 27 Bd Jean Moulin, F-13385 Marseille 05, France.	hematim@pharmacie.univ-mrs.fr	bardin, nathalie/G-6414-2013; Bardin, Nathalie/AAL-3663-2020; DIGNAT-GEORGE, Françoise/R-1129-2016; Vivier, Eric/F-8939-2010	Bardin, Nathalie/0000-0003-3680-082X; DIGNAT-GEORGE, Françoise/0000-0001-7006-4462; Vivier, Eric/0000-0001-7022-8287				Bardin N, 1996, BIOCHEM BIOPH RES CO, V218, P210, DOI 10.1006/bbrc.1996.0037; Bardin N, 1996, TISSUE ANTIGENS, V48, P531, DOI 10.1111/j.1399-0039.1996.tb02666.x; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CAMPBELL IG, 1994, CANCER RES, V54, P5761; Cary LA, 1996, J CELL SCI, V109, P1787; DONNADIEU E, 1994, J BIOL CHEM, V269, P32828; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; ILLC D, 1995, NATURE, V377, P539; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Johnson JP, 1997, INT J CANCER, V73, P769; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAESSING U, 1994, DIFFERENTIATION, V56, P21, DOI 10.1007/s002580050017; Lampugnani MG, 1997, CURR OPIN CELL BIOL, V9, P674, DOI 10.1016/S0955-0674(97)80121-4; LEHMANN JM, 1987, CANCER RES, V47, P841; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; MING IE, 1994, CANCER RES, V54, P2514; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PATCH LA, 1995, J CELL SCI, V108, P1371; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEDUZZI JD, 1994, BRAIN RES, V640, P296, DOI 10.1016/0006-8993(94)91885-6; Pickl WF, 1997, J IMMUNOL, V158, P2107; Schaller MD, 1996, J ENDOCRINOL, V150, P1, DOI 10.1677/joe.0.1500001; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; SERS C, 1994, CANCER RES, V54, P5689; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Shih IM, 1997, AM J PATHOL, V151, P745; Shih IM, 1997, CANCER RES, V57, P3835; Shih IM, 1996, LAB INVEST, V75, P377; Shih IM, 1996, CLIN CANCER RES, V2, P569; SHIH IM, 1994, CANCER RES, V54, P2514; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TAIRA E, 1994, NEURON, V12, P861, DOI 10.1016/0896-6273(94)90338-7; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Vainio O, 1996, J CELL BIOL, V135, P1655, DOI 10.1083/jcb.135.6.1655	47	83	90	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26852	26856		10.1074/jbc.273.41.26852	http://dx.doi.org/10.1074/jbc.273.41.26852			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756930	hybrid			2022-12-25	WOS:000076373300084
J	Cantu, C; Palzkill, T				Cantu, C; Palzkill, T			The role of residue 238 of TEM-1 beta-lactamase in the hydrolysis of extended-spectrum antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; 3RD-GENERATION CEPHALOSPORINS; ACTIVE-SITE; SUBSTRATE-SPECIFICITY; MUTAGENESIS; RESISTANCE; SELECTION; AZTREONAM; MUTATIONS; MUTANTS	beta-Lactamases inactivate beta-lactam antibiotics by catalyzing the hydrolysis of the amide bond in the beta-lactam ring. The plasmid-encoded class A TEM-1 beta-lactamase is a commonly encountered beta-lactamase. It is able to inactivate penicillins and cephalosporins but not extended-spectrum antibiotics. However, TEM-1-derived natural variants containing the G238S amino acid substitution display increased hydrolysis of extended-spectrum antibiotics. Two models have been proposed to explain the role of the G238S substitution in hydrolysis of extended-spectrum antibiotics. The first proposes a direct hydrogen bond of the Ser(238) Side chain to the oxime group of extended-spectrum antibiotics. The second proposes that steric conflict with surrounding residues, due to increased side chain volume, leads to a more accessible active site pocket. To assess the validity of each model, TEM-1 mutants with amino acids substitutions of Ala, Ser, Cys, Thr, Asn, and Val have been constructed. Kinetic analysis of these enzymes with penicillins and cephalosporins suggests that a hydrogen bond is necessary but not sufficient to achieve the hydrolytic activity of the G238S enzyme for the extended-spectrum antibiotics cefotaxime and ceftazidime. In addition, it appears that the new hydrogen bond interaction is to a site on the enzyme rather than directly to the extended-spectrum antibiotic. The data indicate that, for the G238S substitution, a combination of an optimal side chain volume and hydrogen bonding potential results in the most versatile and advantageous antibiotic hydrolytic spectrum for bacterial resistance to extended-spectrum antibiotics.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Program Struct & Computat Biol & Mol Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Palzkill, T (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.				NIAID NIH HHS [AI32956] Funding Source: Medline; NIGMS NIH HHS [GM17581] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032956, R37AI032956, R56AI032956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM017581] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BUSH K, 1982, ANTIMICROB AGENTS CH, V22, P414, DOI 10.1128/AAC.22.3.414; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Cantu C, 1996, J BIOL CHEM, V271, P22538, DOI 10.1074/jbc.271.37.22538; Cantu C, 1997, J BIOL CHEM, V272, P29144, DOI 10.1074/jbc.272.46.29144; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P7; Fersht A., 1985, ENZYME STRUCTURE MEC, P99; HULETSKY A, 1993, J BIOL CHEM, V268, P3690; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABIA R, 1988, REV INFECT DIS, V10, P885; LENFANT F, 1990, BIOCHIMIE, V72, P495, DOI 10.1016/0300-9084(90)90073-P; Maveyraud L, 1996, J BIOL CHEM, V271, P10482, DOI 10.1074/jbc.271.18.10482; MINAMI S, 1980, ANTIMICROB AGENTS CH, V18, P382, DOI 10.1128/AAC.18.3.382; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; PALZKILL T, 1994, MOL MICROBIOL, V12, P217, DOI 10.1111/j.1365-2958.1994.tb01011.x; Petrosino JF, 1996, J BACTERIOL, V178, P1821, DOI 10.1128/jb.178.7.1821-1828.1996; RADIKA K, 1984, ANTIMICROB AGENTS CH, V25, P479, DOI 10.1128/AAC.25.4.479; RAQUET X, 1995, PROTEINS, V23, P63, DOI 10.1002/prot.340230108; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVES I, 1995, BIOCHEMISTRY-US, V34, P11660, DOI 10.1021/bi00037a003; SIEGEL EC, 1982, MUTAT RES, V93, P25, DOI 10.1016/0027-5107(82)90122-1; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; WIEDEMANN B, 1989, J ANTIMICROB CHEMOTH, V24, P1	26	39	39	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26603	26609		10.1074/jbc.273.41.26603	http://dx.doi.org/10.1074/jbc.273.41.26603			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756899	hybrid			2022-12-25	WOS:000076373300053
J	Crovello, CS; Lai, C; Cantley, LC; Carraway, KL				Crovello, CS; Lai, C; Cantley, LC; Carraway, KL			Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-RESPONSE; FACTOR RECEPTOR; ERBB RECEPTORS; NEU; HEREGULIN; EXPRESSION; DISTINCT; LIGANDS	The neuregulins comprise a subfamily of epidermal growth factor (EGF)-like growth factors that elicit diverse cellular responses by activating members of the ErbB family of receptor tyrosine kinases. Although neuregulin-1 and neuregulin-2 are both binding ligands for the ErbB3 and ErbB4 receptors, they exhibit distinct biological activities depending on cellular context. In MDA-MB-468 human mammary tumor cells, neuregulin-2 beta (NRG2 beta) inhibits cell growth, whereas neuregulin-1 beta (NRG1 beta) does not. In these cells, NRG2 beta appears to preferentially act through the EGF receptor, stimulating receptor tyrosine phosphorylation and the recruitment of phospholipase C-gamma, Cbl, SHP2, and Shc to that receptor. NRG1 beta preferentially acts through ErbB3 in these cells by stimulating the tyrosine phosphorylation and recruitment of phosphatidylinositol 3-kinase and Shc to that receptor. In MDA-MB-453 cells, both NRG1 beta and NRG2 beta stimulate the tyrosine phosphorylation of the ErbB2 and ErbB3 receptors to similar extents, but only NRG1 beta potently stimulates morphological changes consistent with their differentiation. The profiles of SH2 domain-containing proteins that are efficiently recruited to activated receptors differ for the two factors. These observations indicate that despite their overlapping receptor specificity, the neuregulins exhibit distinct biological and biochemical properties, Since both of these cell lines express only two of the known ErbB receptors, our results imply that EGF-like ligands might elicit differential signaling within the context of a single receptor heterodimer.	Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Scripps Research Institute	Carraway, KL (corresponding author), Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Signal Transduct, Rm 1018,330 Brookline Ave, Boston, MA 02215 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL CANCER INSTITUTE [R01CA071702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NCI NIH HHS [CA71702] Funding Source: Medline; NIGMS NIH HHS [GM18460, R01 GM041890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACUS SS, 1993, CANCER RES, V53, P5251; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; Busfield SJ, 1997, MOL CELL BIOL, V17, P4007, DOI 10.1128/MCB.17.7.4007; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; Carraway KL, 1996, BIOESSAYS, V18, P263, DOI 10.1002/bies.950180403; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Daly JM, 1997, CANCER RES, V57, P3804; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; Meyer D, 1997, DEVELOPMENT, V124, P3575; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Ozaki M, 1997, NATURE, V390, P691, DOI 10.1038/37795; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	41	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26954	26961		10.1074/jbc.273.41.26954	http://dx.doi.org/10.1074/jbc.273.41.26954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756944	hybrid			2022-12-25	WOS:000076373300098
J	Fujita, H; Kamiguchi, K; Cho, D; Shibanuma, M; Morimoto, C; Tachibana, K				Fujita, H; Kamiguchi, K; Cho, D; Shibanuma, M; Morimoto, C; Tachibana, K			Interaction of Hic-5, a senescence-related protein, with focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; BINDING-SITE; SH3 DOMAIN; V-CRK; PAXILLIN; VINCULIN; PP125(FAK); INTEGRINS	Hydrogen peroxide-inducible clone (Hic)-5 is induced during the senescent process in human fibroblasts, and the overexpression of Hic-5 induces a senescence-like phenotype. Structurally, Hic-5 and paxillin, a 68-kDa cytoskeletal protein, share homology such as the LD motifs in the N-terminal half and the LIM domains in the C-terminal half, Here we show that Hic-5 binds to focal adhesion kinase (FAR) by its N-terminal domain, and is localized to focal adhesions by its C-terminal LIM domains. However, Hic-5 is not tyrosine phosphorylated either by the coexpressed FAK in COS cells or by integrin stimulation in 293T cells. Furthermore, overexpression of Hic-5 results in a decreased tyrosine phosphorylation of paxillin. These findings suggest that putative functions of Hic-5 are the recruitment of FAK to focal adhesions and a competitive inhibition of tyrosine phosphorylation of paxillin.	Harvard Univ, Sch Med, Dept Med, Dana Farber Canc Inst,Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Tokyo 142, Japan; Univ Tokyo, Inst Med Sci, Dept Clin Immunol, Minato Ku, Tokyo, Japan; Univ Tokyo, Inst Med Sci, AIDS Res Ctr, Minato Ku, Tokyo, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Showa University; University of Tokyo; University of Tokyo	Tachibana, K (corresponding author), Harvard Univ, Sch Med, Dept Med, Dana Farber Canc Inst,Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.				NIAID NIH HHS [AI29530] Funding Source: Medline; NIAMS NIH HHS [AR33713] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033713] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; FELLER SM, 1995, ONCOGENE, V10, P1465; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SIMMON MA, 1991, CELL, V67, P701; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; WOOD CK, 1994, J CELL SCI, V107, P709	39	79	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26516	26521		10.1074/jbc.273.41.26516	http://dx.doi.org/10.1074/jbc.273.41.26516			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756887	hybrid			2022-12-25	WOS:000076373300041
J	Huang, YD; Liu, XQ; Rall, SC; Taylor, JM; von Eckardstein, A; Assmann, G; Mahley, RW				Huang, YD; Liu, XQ; Rall, SC; Taylor, JM; von Eckardstein, A; Assmann, G; Mahley, RW			Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-RELATED PROTEIN; FAMILIAL COMBINED HYPERLIPIDEMIA; CORONARY HEART-DISEASE; TRANSGENIC MICE; III HYPERLIPOPROTEINEMIA; LIPOLYTIC CONVERSION; E DEFICIENCY; APO-CIII	The molecular mechanisms of hypertriglyceridemia (HTG), a common lipid metabolic disorder in humans, often of genetic origin, are not well understood. In studying the effect of apolipoprotein (apo) E on the metabolism of triglyceride-rich lipoproteins, we found that expressing high plasma levels of human apoE3 in transgenic mice lacking endogenous mouse apoE caused HTG. These transgenic animals had 3-fold higher plasma triglyceride levels, higher very law density lipoproteins (VLDL), and lower high density lipoproteins than did non-transgenics, Removing one or both low density lipoprotein receptor alleles in the apoE3-overexpressing mice caused severe HTG (8-11-fold over nontransgenics) and increased VLDL and decreased low and high density lipoproteins, and apoE3-enriched VLDL were markedly depleted in apoC-II. At least two mechanisms could explain HTG associated with apoE3 overexpression: stimulated VLDL triglyceride production and impaired VLDL lipolysis. The apoE3 mice with HTG had a 50% increase in hepatic VLDL triglyceride production. Furthermore, overexpression of apoE (E2, E3, or E4) in cultured hepatocytes (McA-RH7777 cells) correlated positively with secretion of VLDL into the medium. However, apoE3 overexpression-associated HTG was only partially explained by VLDL overproduction, as lipoprotein lipase-mediated VLDL lipolysis was also decreased 20-86% depending on apoE3 levels, most likely by displacing or masking apoC-II on the particles. In human subjects, HTG correlated positively with increased VLDL triglyceride and plasma and VLDL apoE levels. However, plasma and VLDL apoE correlated negatively with VLDL apoC-II levels and lipoprotein lipase-mediated VLDL lipolysis. Thus, optimal expression of apoE is crucial for normal metabolism of triglyceride-rich lipoproteins, and overexpression and/or accumulation of apoE may contribute to ATG by stimulating VLDL triglyceride production and by impairing VLDL lipolysis. The apoE3-overexpressing mice will be useful for studying the pathophysiology of this disorder.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Munster, Inst Arteriosclerosis Res, D-48129 Munster, Germany	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Munster	Mahley, RW (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NHLBI NIH HHS [HL47660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Assmann G, 1996, AM J CARDIOL, V77, P1179, DOI 10.1016/S0002-9149(96)00159-2; BRUNZELL JD, 1983, J LIPID RES, V24, P147; BRUNZELL JD, 1976, METABOLISM, V25, P313, DOI 10.1016/0026-0495(76)90089-5; CHAIT A, 1978, METABOLISM, V27, P1055, DOI 10.1016/0026-0495(78)90151-8; CHAIT A, 1980, EUR J CLIN INVEST, V10, P17, DOI 10.1111/j.1365-2362.1980.tb00004.x; CHAIT A, 1977, LANCET, V1, P1176; CHUNG BH, 1983, J LIPID RES, V24, P1148; Cohn JS, 1996, ARTERIOSCL THROM VAS, V16, P149, DOI 10.1161/01.ATV.16.1.149; CONNELLY PW, 1994, J BIOL CHEM, V269, P20554; DESILVA HV, 1994, J LIPID RES, V35, P1297; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; EISENBERG S, 1984, J LIPID RES, V25, P1017; FAZIO S, 1992, J BIOL CHEM, V267, P6941; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; Fredrickson D. S., 1978, METABOLIC BASIS INHE, P604; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GOMEZCORONADO D, 1993, BIOCHIM BIOPHYS ACTA, V1167, P70, DOI 10.1016/0005-2760(93)90219-Y; HAVEL RJ, 1970, J CLIN INVEST, V49, P2017, DOI 10.1172/JCI106422; HORIE Y, 1992, J BIOL CHEM, V267, P1962; HOSPATTANKAR AV, 1984, J BIOL CHEM, V259, P318; Huang Y, 1997, ARTERIOSCL THROM VAS, V17, P2817, DOI 10.1161/01.ATV.17.11.2817; Huang YD, 1998, J BIOL CHEM, V273, P17483, DOI 10.1074/jbc.273.28.17483; Huang YD, 1996, J BIOL CHEM, V271, P29146, DOI 10.1074/jbc.271.46.29146; HUIPERS F, 1997, J CLIN INVEST, V100, P2915; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; KASHYAP ML, 1977, J CLIN INVEST, V60, P171, DOI 10.1172/JCI108753; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; MasucciMagoulas L, 1997, SCIENCE, V275, P391, DOI 10.1126/science.275.5298.391; Nikkila E A, 1974, Horm Metab Res, VSuppl 4, P29; NIKKILA EA, 1973, LANCET, V1, P954; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; Salah D, 1997, J LIPID RES, V38, P904; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	45	169	175	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26388	26393		10.1074/jbc.273.41.26388	http://dx.doi.org/10.1074/jbc.273.41.26388			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756870	hybrid			2022-12-25	WOS:000076373300024
J	Moreland, RJ; Hanas, JS; Conaway, JW; Conaway, RC				Moreland, RJ; Hanas, JS; Conaway, JW; Conaway, RC			Mechanism of action of RNA polymerase II elongation factor elongin - Maximal stimulation of elongation requires conversion of the early elongation complex to an elongin-activable form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-SIII; RIBONUCLEIC-ACID POLYMERASE; TUMOR-SUPPRESSOR PROTEIN; INITIATION FACTOR-ALPHA; MAJOR LATE PROMOTER; TERNARY COMPLEXES; ABORTIVE INITIATION; ESCHERICHIA-COLI; CHAIN ELONGATION; FUNCTIONAL-PROPERTIES	We previously identified and purified Elongin by its ability to stimulate the rate of elongation by RNA polymerase II in vitro (Bradsher, J. N., Jackson, K. W., Conaway, R. C., and Conaway, J. W. (1993) J. Biol. Chem. 268, 25587-25593), in this report, we present evidence that stimulation of elongation by Elongin requires that the early RNA polymerase II elongation complex undergoes conversion to an Elongin-activable form. We observe (i) that Elongin does not detectably stimulate the rate of promoter-specific transcription initiation by the fully assembled preinitiation complex and (ii) that early RNA polymerase II elongation intermediates first become susceptible to stimulation by Elongin after synthesizing 8-9-nucleotide-long transcripts. Furthermore, we show that the relative inability of Elongin to stimulate elongation by early elongation intermediates correlates not with the lengths of their associated transcripts but, instead, with the presence of transcription factor IIF (TFIIF) in transcription reactions. By exploiting adenovirus 2 major late promoter derivatives that contain premelted transcriptional start sites and do not require TFIIF, TFIIE, or TFIIH for transcription initiation, rye observe (i) that Elongin is capable of strongly stimulating the rate of synthesis of trinucleotide transcripts by a subcomplex of RNA polymerase II, TBP, and TFIIB and (ii) that the ability of Elongin to stimulate synthesis of these short transcripts is substantially reduced by addition of TFIIF to transcription reactions. Here we present these findings, which are consistent with the model that maximal stimulation of elongation by Elongin requires that early elongation intermediates undergo a structural transition that includes loss of TFIIF.	Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Howard Hughes Med Inst, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	Conaway, RC (corresponding author), Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA.			Conaway, Joan/0000-0002-2786-0663; Hanas, Jay/0000-0003-1922-5333	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CONAWAY JW, 1993, CELL MOL BIOL RES, V39, P323; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY JW, 1998, BIOCHIM BIOPHYS ACTA, V1337, pM47; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; LAVIALLE C, 1982, J BIOL CHEM, V257, P2458; LEWIS MK, 1982, ENZYMES, V15, P109; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; PAN GH, 1994, J BIOL CHEM, V269, P30101; PETERSON MG, 1991, NATURE, V354, P369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINES D, 1992, J BIOL CHEM, V267, P3795; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1991, J BIOL CHEM, V266, P10510; RHODES G, 1974, J BIOL CHEM, V249, P6675; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUELS M, 1984, J BIOL CHEM, V259, P2517; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; TAKAGI Y, 1995, J BIOL CHEM, V270, P24300, DOI 10.1074/jbc.270.41.24300; Takagi Y, 1996, J BIOL CHEM, V271, P25562, DOI 10.1074/jbc.271.41.25562; TAN SY, 1994, J BIOL CHEM, V269, P25684; TAN SY, 1994, BIOTECHNIQUES, V16, P824; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; UCKER DS, 1984, J BIOL CHEM, V259, P7416; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	64	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26610	26617		10.1074/jbc.273.41.26610	http://dx.doi.org/10.1074/jbc.273.41.26610			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756900	hybrid			2022-12-25	WOS:000076373300054
J	Lee, SJ; Dimtchev, A; Lavin, MF; Dritschilo, A; Jung, M				Lee, SJ; Dimtchev, A; Lavin, MF; Dritschilo, A; Jung, M			A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-kappa B	ONCOGENE			English	Article						ionizing radiation; NF-kappa B; I kappa B-alpha; ataxia-telangiectasia (AT); ATM	ATAXIA-TELANGIECTASIA CELLS; DNA-DAMAGE; ALPHA PROTEOLYSIS; KINASE COMPLEX; C-ABL; PHOSPHORYLATION; PROTEIN; DEGRADATION; INDUCTION; GENE	The signaling pathway through which ionizing radiation induces NF-kappa B activation is not fully understood. I kappa B-alpha, an inhibitory protein of NF-kappa B mediates the activation of NF-kappa B in response to various stimuli, including cytokines, mitogens, oxidants and other stresses. We have now identified an ionizing radiation-induced signaling pathway that is independent of TNF-alpha. I kappa B-alpha degradation is rapid in response to TNF-alpha induction, but it is absent in response to ionizing radiation exposure in cells from individuals with ataxia-telangiectasia (AT). Overexpression of wild-type ATM, the product of the gene defective in AT patients, restores radiation-induced degradation of I kappa B-alpha. Furthermore, phosphorylation of I kappa B-alpha. by immunoprecipitated ATM kinase is increased in control fibroblasts and transfected AT cells following ionizing radiation exposure. These data provide support for a novel ionizing radiation-induced signaling pathway for activation of NF-kappa B and a molecular basis for the sensitivity of AT patients to oxidative stresses.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Ctr, Dept Radiat Med,Div Radiat Res, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Microbiol, Washington, DC 20007 USA; Queensland Inst Med Res, Bancroft Ctr, Brisbane, Qld 4006, Australia	Georgetown University; Georgetown University; QIMR Berghofer Medical Research Institute	Jung, M (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Ctr, Dept Radiat Med,Div Radiat Res, Washington, DC 20007 USA.		Lavin, Martin/F-5961-2014	Lavin, Martin/0000-0002-5940-4769	NCI NIH HHS [CA45408, CA74175, CA 63023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045408, P01CA074175, R29CA063023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEG A, 1998, SCIENCE, V274, P782; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FUKS Z, 1993, RADIAT ONCOL INVEST, V1, P81; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jung M, 1997, CANCER RES, V57, P24; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MOHAN N, 1994, RADIAT RES, V140, P97, DOI 10.2307/3578574; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; TEOULE R, 1987, INT J RADIAT BIOL, V51, P573, DOI 10.1080/09553008414552111; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	37	117	120	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1821	1826		10.1038/sj.onc.1202088	http://dx.doi.org/10.1038/sj.onc.1202088			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778048				2022-12-25	WOS:000076303300008
J	Nason-Burchenal, K; Takle, G; Pace, U; Flynn, S; Allopenna, J; Martin, P; George, ST; Goldberg, AR; Dmitrovsky, E				Nason-Burchenal, K; Takle, G; Pace, U; Flynn, S; Allopenna, J; Martin, P; George, ST; Goldberg, AR; Dmitrovsky, E			Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells	ONCOGENE			English	Article						acute promyelocytic leukemia; PML/RAR alpha; retinoic acid; differentiation; apoptosis	RETINOIC ACID RECEPTOR; PML-RAR-ALPHA; INDUCED GRANULOCYTIC DIFFERENTIATION; BRONCHIAL EPITHELIAL-CELLS; FUSION PROTEIN; T(15-17) TRANSLOCATION; T(15,17) TRANSLOCATION; NONREARRANGED ALLELES; TRANSCRIPTION FACTOR; GROWTH SUPPRESSION	The t(15;17) rearrangement found in acute promyelocytic leukemia (APL) yields a fusion transcript, PML/RAR alpha. PML/RAR alpha. expression is linked to leukemogenesis and to clinical sensitivity to all-trans retinoic acid (RA), Paradoxically, RA treatment causes transient complete remissions in most t(15;17) APL cases. The precise roles of PML/RAR alpha in triggering leukemia or in causing a maturation block are not yet known. This study explores directly these PML/RAR alpha. functions in the growth and differentiation of APL cells using a hammerhead ribozyme to target PML/RAR alpha mRNA in the NB4 APL cell line. When the PML/RAR alpha cleaving but not the non-catalytic control ribozyme is introduced into the NB4 APL cell line, PML/RAR alpha protein expression is reduced. This catalysis signals growth suppression, cytotoxicity, and apoptosis without overcoming the maturation block found in these leukemic cells. These biologic effects depend on the selective pressure used to express the ribozyme from an episomal vector. Introduction of a non-catalytic, control ribozyme into NB4 cells caused no observed phenotype due to anti-sense activities, Expression of the catalytic or non-catalytic ribozymes in control cells lacking PML/RAR alpha mRNA yielded no apparent growth or differentiation effects. Thus, use of a hammerhead ribozyme that targets PML/RAR alpha. expression in APL cells reveals the anti-apoptotic function of this translocation product and demonstrates that PML/RAR alpha cleavage is insufficient to overcome the differentiation block observed in these leukemic cells. Taken together, these findings indicate that persistent PML/RAR alpha expression is required to maintain basal leukemic cell growth and point to the therapeutic potential of targeting PML/RAR alpha in APL.	Mem Hosp, Dept Med, Mol Med Lab, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA; Innovir Labs, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nason-Burchenal, K (corresponding author), Mem Hosp, Dept Med, Mol Med Lab, 1272 York Ave, New York, NY 10021 USA.				NCI NIH HHS [1F32CA61646-01A1, 2PO1-CA29502-14A2, R01-CA62275-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA061646, P01CA029502, R01CA062275] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn MJ, 1995, ONCOGENE, V11, P2357; AHN MJ, 1995, ONCOGENE, V10, P2307; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; BRUEL A, 1995, LEUKEMIA, V9, P1173; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chen GQ, 1996, BLOOD, V88, P1052; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DELIA D, 1993, CANCER RES, V53, P6036; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DUPREZ E, 1992, LEUKEMIA, V6, P1281; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Fu SQ, 1995, CLIN CANCER RES, V1, P583; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GRIGNANI F, 1995, CANCER RES, V55, P440; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; IKEDA K, 1994, AM J HEMATOL, V45, P212, DOI 10.1002/ajh.2830450304; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1080; LINRJ, 1998, NATURE, V391, P811; LOCOCO F, 1992, EUR J HAEMATOL, V48, P173; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Mangelsdorf David J., 1994, P319; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; MOASSER MM, 1995, ONCOGENE, V10, P1537; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NasonBurchenal K, 1997, DIFFERENTIATION, V61, P321, DOI 10.1046/j.1432-0436.1997.6150321.x; NASONBURCHENAL K, IN PRESS BLOOD; NERVI C, 1992, CANCER RES, V52, P3687; PACE U, 1994, CANCER RES, V54, P6365; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; REDDEL RR, 1988, CANCER RES, V48, P1904; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; ROGAIA D, 1995, LEUKEMIA, V9, P1467; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; TAIRA K, 1991, NUCLEIC ACIDS RES, V19, P5125, DOI 10.1093/nar/19.19.5125; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Yoshida H, 1996, CANCER RES, V56, P2945; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009	59	39	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1759	1768		10.1038/sj.onc.1202075	http://dx.doi.org/10.1038/sj.onc.1202075			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778041				2022-12-25	WOS:000076303300001
J	Zancai, P; Cariati, R; Rizzo, S; Boiocchi, M; Dolcetti, R				Zancai, P; Cariati, R; Rizzo, S; Boiocchi, M; Dolcetti, R			Retinoic acid-mediated growth arrest of EBV-immortalized B lymphocytes is associated with multiple changes in G(1) regulatory proteins: p27(Kip1) up-regulation is a relevant early event	ONCOGENE			English	Article						retinoic acid; cell cycle; p27(kip1); B lymphocytes; EBV	DEPENDENT KINASE INHIBITOR; ACUTE PROMYELOCYTIC LEUKEMIA; BREAST-CANCER CELLS; IN-VITRO; DIFFERENTIATION THERAPY; CARCINOMA CELLS; DNA-REPLICATION; DOWN-REGULATION; CDK INHIBITOR; HL-60 CELLS	EBV-immortalized lymphoblastoid B cell lines (LCLs) are a suitable in vitro model for the study of EBV-related lymphoproliferative disorders of immunosuppressed patients, We have previously shown that 9-cis-, 13-cis- and all-trans-retinoic acid (RA) powerfully inhibit LCL proliferation at concentrations corresponding to therapeutically achievable plasma levels (10(-6) M). Herein we show that RA-induced LCL accumulation in the G(0)/G(1) phases correlated with the loss of the catalytic activity of all three G(1)-associated CDKs (CDK2, CDK4 and CDK6) and with increased levels of underphosphorylated pRb and, in some LCLs, p130, LCLs arrested in G(0)/G(1) by RA also showed a significant decrease in the protein levels of cyclins D2, D3 and A, together with a reduction in the amount of cyclin D associated with CDK4 and CDK6, probably accounting for the inhibition of the relative kinase activity. In addition, RA-treated LCLs showed a marked upregulation of the CDK inhibitor (CKI) p27(Kip-1) at the protein but not mRNA level, which correlated with a progressive increase of p27(Kip-1) in CDK2 complexes (more than 2.5-fold) and with a reduction in the active phosphorylated form of CDK2, p27(Kip-1) may also contribute to the inhibition of CDK4 kinase activity, as the amount of CDK4-associated p27(Kip-1) was increased by 50% after RA exposure. p27(Kip-1) up-regulation stably persisted for more than one week after RA withdrawal concomitantly with the maintenance of the proliferative block. Moreover, neutralization of TGF beta did not affect the growth inhibitory activity of RA, suggesting that LCL growth arrest induced by these retinoids is probably not mediated by a pathway directly involving TGF beta. Overall, these results demonstrate that RA treatment of EBV-immortalized B lymphocytes is associated with multiple effects on G(1) regulatory proteins, including p27(Kip1) up-regulation, decreased levels of cyclins D2, D3 and A, and inhibition of CDK2, CDK4 and CDK6 activity, which ultimately result in reduced pRb phosphorylation and G(0)/G(1) growth arrest.	Ctr Riferimento Oncol, Div Expt Oncol 1, I-33081 Aviano, PN, Italy	IRCCS Aviano (CRO)	Boiocchi, M (corresponding author), Ctr Riferimento Oncol, Div Expt Oncol 1, I-33081 Aviano, PN, Italy.		Dolcetti, Riccardo/O-3832-2015; Rizzo, Silvana/AAW-1132-2020	Dolcetti, Riccardo/0000-0003-1625-9853; Rizzo, Silvana/0000-0002-7156-1783				Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; ASIEDU C, 1995, CANCER RES, V55, P3716; Blanchard DA, 1997, J IMMUNOL, V158, P3054; Bouchard C, 1997, J IMMUNOL, V159, P4155; CASTAIGNE S, 1990, BLOOD, V76, P1704; FALK LA, 1991, BLOOD, V77, P1248; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Florenes VA, 1996, ONCOGENE, V13, P2447; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; KALEMKERIAN GP, 1994, CELL GROWTH DIFFER, V5, P55; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kuniyasu H, 1997, CELL GROWTH DIFFER, V8, P47; Kwon TK, 1996, CELL GROWTH DIFFER, V7, P1305; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MIYATAKE S, 1995, J EXP MED, V182, P401, DOI 10.1084/jem.182.2.401; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; NALESNIK MA, 1988, AM J PATHOL, V133, P173; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Peng D, 1996, CANCER RES, V56, P3666; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pomponi F, 1996, BLOOD, V88, P3147, DOI 10.1182/blood.V88.8.3147.bloodjournal8883147; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; SHAO ZM, 1995, ONCOGENE, V11, P493; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; URBANI L, 1995, EXP CELL RES, V219, P159, DOI 10.1006/excr.1995.1216; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang QM, 1996, CANCER RES, V56, P264; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1994, SEMIN HEMATOL, V31, P1; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	47	28	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1827	1836		10.1038/sj.onc.1202089	http://dx.doi.org/10.1038/sj.onc.1202089			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778049				2022-12-25	WOS:000076303300009
J	Hourcade, DE; Mitchell, LM; Oglesby, TJ				Hourcade, DE; Mitchell, LM; Oglesby, TJ			A conserved element in the serine protease domain of complement factor B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; MOLECULAR-CLONING; SURFACE LOOPS; COMPONENT C2; BINDING-SITE; GENE; TRYPSIN; MHC; CHYMOTRYPSIN	Factor B and C2 are serine proteases that carry the catalytic sites of the complement C3 and C5 convertases. Their protease domains are activated by conformational changes that occur during convertase assembly and are deactivated upon convertase dissociation. Factor B and C2 share an 8-amino acid conserved sequence near their serine protease termini that is not seen in other serine proteases. To determine its importance, 24 factor B mutants were generated, each with a single amino acid substitution in this region. Whereas most mutants were functionally neutral, all five different substitutions of aspartic acid 715 and one phenylalanine 716 substitution severely reduced hemolytic activity. Several aspartic acid 715 mutants permitted the steps of convertase assembly including C3b-dependent factor D-mediated cleavage and activation of the high affinity C3b-binding site, but the resulting complexes did not cleave C3. Given that factor B and C2 share the same biological substrates and that part of the trypsin-like substrate specificity region is not apparent in either protein, we propose that the conserved region plays a critical role in the conformational regulation of the catalytic site and could offer a highly specific target for the therapeutic inhibition of complement.	Washington Univ, Sch Med, Div Rheumatol, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Hourcade, DE (corresponding author), Washington Univ, Sch Med, Div Rheumatol, Dept Med, 660 S Euclid,Box 8045, St Louis, MO 63110 USA.	dhourcad@im.wustl.edu						BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; BROWN JR, 1966, BIOCHEM J, V101, P214, DOI 10.1042/bj1010214; CAMPBELL RD, 1983, P NATL ACAD SCI-BIOL, V80, P4464, DOI 10.1073/pnas.80.14.4464; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; COLOMBATTI A, 1991, BLOOD, V77, P2305; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HORIUCHI T, 1991, J IMMUNOL, V147, P584; HOURCADE DE, 1995, J BIOL CHEM, V270, P19716, DOI 10.1074/jbc.270.34.19716; ISHIKAWA N, 1990, J BIOL CHEM, V265, P19040; KAM CM, 1987, J BIOL CHEM, V262, P3444; KATO Y, 1994, J IMMUNOL, V153, P4546; KRISTENSEN T, 1987, FASEB J, V46, P2463; Kuroda N, 1996, IMMUNOGENETICS, V44, P459, DOI 10.1007/BF02602808; LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MOLE JE, 1984, J BIOL CHEM, V259, P3407; NONAKA M, 1994, J IMMUNOL, V152, P2263; PERKINS SJ, 1993, BIOCHEM J, V295, P109, DOI 10.1042/bj2950109; PEROS JP, 1995, VITIS, V34, P189; POLLEY MJ, 1967, J EXP MED, V126, P1013, DOI 10.1084/jem.126.6.1013; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Seeger A, 1996, MOL IMMUNOL, V33, P511, DOI 10.1016/0161-5890(96)00002-8; SMITH CA, 1984, J EXP MED, V159, P324, DOI 10.1084/jem.159.1.324; TITANI K, 1975, BIOCHEMISTRY-US, V14, P1358, DOI 10.1021/bi00678a003; Tuckwell DS, 1997, BIOCHEMISTRY-US, V36, P6605, DOI 10.1021/bi963155l; UEDA A, 1987, J IMMUNOL, V138, P1143; Volanakis J., 1998, COMPLEMENT ENZYMES H, P49; Volanakis JE, 1998, HUMAN COMPLEMENT SYS, V20, P9, DOI DOI 10.1201/B14212-3	34	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25996	26000		10.1074/jbc.273.40.25996	http://dx.doi.org/10.1074/jbc.273.40.25996			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748277	hybrid			2022-12-25	WOS:000076263100068
J	Sawado, T; Hirose, F; Takahashi, Y; Sasaki, T; Shinomiya, T; Sakaguchi, K; Matsukage, A; Yamaguchi, M				Sawado, T; Hirose, F; Takahashi, Y; Sasaki, T; Shinomiya, T; Sakaguchi, K; Matsukage, A; Yamaguchi, M			The DNA replication-related element (DRE)/DRE-binding factor system is a transcriptional regulator of the Drosophila E2F gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; GROWTH-REGULATION; HOMEODOMAIN PROTEINS; POLYMERASE-ALPHA; FACTOR DREF; PROMOTER; EXPRESSION; BINDING; CYCLE; TRANSACTIVATION	Two mRNA species were observed for the Drosophila E2F (dE2F) gene, differing with regard to the first exons (exon I-a and exon 1-b), which were expressed differently during development. A single transcription initiation site for mRNA containing exon 1-b was mapped by primer extension analysis and numbered +1, We found three tandemly aligned sequences, similar 60 the DNA replication-related element (DRE; 5'-TATCGATA), which is commonly required for transcription of genes related to DNA replication and cell proliferation, in the region upstream of this site. Band mobility shift analyses using oligonucleotides containing the DRE-related sequences with or without various base substitutions revealed that two out of three DRE-related sequences are especially important for binding to the DRE-binding factor (DREF). On footprinting analysis with Kc cell nuclear extracts and a glutathione S-transferase fusion protein with the N-terminal fragment (1-125 amino acid residues) of DREF, all three DRE-related sequences were found to be protected. Transient luciferase expression assays in Kc cells demonstrated that the region containing the three DRE-related sequences is required for high promoter activity. We have established transgenic lines of Drosophila in which ectopic expression of DREF was targeted to the eye imaginal disc cells. Overexpression of DREF in eye imaginal disc cells enhanced the promoter activity of dE2F. The obtained results indicate that the DRE/DRBF system activates transcription of the dE2F gene.	Aichi Canc Ctr, Res Inst, Cell Biol Lab, Aichi 4648681, Japan; Sci Univ Tokyo, Fac Sci & Technol, Dept Appl Biol Sci, Chiba 2780022, Japan; Mitsubishi Kasei Inst Life Sci, Tokoyo 1948511, Japan	Aichi Cancer Center; Tokyo University of Science	Yamaguchi, M (corresponding author), Aichi Canc Ctr, Res Inst, Cell Biol Lab, Aichi 4648681, Japan.			Hirose, Fumiko/0000-0003-4586-4892; Yamaguchi, Masamitsu/0000-0002-6321-9750				BONDMATTHEWS B, 1988, GENE, V62, P289, DOI 10.1016/0378-1119(88)90566-5; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook A, 1996, EMBO J, V15, P3676, DOI 10.1002/j.1460-2075.1996.tb00737.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; Hayashi Y, 1997, J BIOL CHEM, V272, P22848, DOI 10.1074/jbc.272.36.22848; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; Hirose F, 1996, J BIOL CHEM, V271, P3930; HIROSE F, 1993, J BIOL CHEM, V268, P2092; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; LIGHTFOOT K, 1994, BRIT J CANCER, V69, P264, DOI 10.1038/bjc.1994.50; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; NEUMAN E, 1995, MOL CELL BIOL, V15, P4660; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; ROBERTSON HM, 1988, GENETICS, V118, P461; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Ryu JR, 1997, NUCLEIC ACIDS RES, V25, P794, DOI 10.1093/nar/25.4.794; Sambrook J., 2002, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Seum C, 1996, DEVELOPMENT, V122, P1949; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Spradling A. C, 1986, DROSOPHILA PRACTICAL; Takahashi Y, 1996, J BIOL CHEM, V271, P14541, DOI 10.1074/jbc.271.24.14541; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P25159, DOI 10.1074/jbc.270.42.25159; Yamaguchi M, 1996, GENES CELLS, V1, P47, DOI 10.1046/j.1365-2443.1996.03003.x	44	78	79	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26042	26051		10.1074/jbc.273.40.26042	http://dx.doi.org/10.1074/jbc.273.40.26042			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748283	hybrid			2022-12-25	WOS:000076263100074
J	Black, AF; Berthod, F; L'Heureux, N; Germain, L; Auger, FA				Black, AF; Berthod, F; L'Heureux, N; Germain, L; Auger, FA			In vitro reconstruction of a human capillary-like network in a tissue-engineered skin equivalent	FASEB JOURNAL			English	Article						angiogenesis; endothelial cell; extracellular matrix; inosculation; skin substitute	FIBROBLAST GROWTH-FACTOR; HUMAN-ENDOTHELIAL-CELLS; ANGIOGENESIS IN-VITRO; EXTRACELLULAR-MATRIX; SERUM-FREE; HUMAN KERATINOCYTES; TUBE FORMATION; ATHYMIC MICE; COLLAGEN; INVITRO	For patients with extensive burns, wound coverage with an autologous in vitro reconstructed skin made of both dermis and epidermis should be the best alternative to split-thickness graft. Unfortunately, various obstacles have delayed the widespread use of composite skin substitutes. Insufficient vascularization has been proposed as the most likely reason for their unreliable survival. Our purpose was to develop a vascular-like network inside tissue-engineered skin in order to improve graft vascularization. To reach this aim, we fabricated a collagen biopolymer in which three human cell types-keratinocytes, dermal fibroblasts, and umbilical vein endothelial cells-were cocultured. We demonstrated that the endothelialized skin equivalent (ESE) promoted spontaneous formation of capillary-like structures in a highly differentiated extracellular matrix. Immunohistochemical analysis and transmission electron microscopy of the ESE showed characteristics associated with the microvasculature in vivo (von Willebrand factor, Weibel-Palade bodies, basement membrane material, and intercellular junctions). We have developed the first endothelialized human tissue-engineered skin in which a network of capillary-like tubes is formed. The transplantation of this ESE on human should accelerate graft revascularization by inosculation of its preexisting capillary-like network with the patient's own blood vessels, as it is observed with autografts. In addition, the ESE turns out to be a promising in vitro angiogenesis model.	Univ Laval, Fac Med, Dept Surg, Quebec City, PQ G1S 4L8, Canada; Univ Laval, Ctr Hosp Affilie, Lab Organogenese Expt, Quebec City, PQ G1S 4L8, Canada	Laval University; Laval University	Auger, FA (corresponding author), Univ Lyon 1, Lab Substituts Cutanes, Federat Biochim, Hop Edouard Herriot, Batiment 5,5 Pl Arsonval, F-69437 Lyon 03, France.	Francois.auger@chg.ulaval.ca	; L'Heureux, Nicolas/K-8669-2015	Berthod, Francois/0000-0003-3580-0297; Germain, Lucie/0000-0001-8883-6491; L'Heureux, Nicolas/0000-0001-8602-3948				ARCHAMBAULT M, 1995, J INVEST DERMATOL, V104, P859, DOI 10.1111/1523-1747.ep12607034; AUGER FA, 1995, IN VITRO CELL DEV-AN, V31, P432; BALLAUN C, 1995, J INVEST DERMATOL, V104, P7, DOI 10.1111/1523-1747.ep12613450; BASSON CT, 1992, J CELL PHYSIOL, V153, P118, DOI 10.1002/jcp.1041530116; BELL E, 1983, J INVEST DERMATOL, V81, P2; Berthod F, 1996, J BIOMED MATER RES, V32, P87, DOI 10.1002/(SICI)1097-4636(199609)32:1<87::AID-JBM10>3.0.CO;2-F; Berthod F, 1997, J INVEST DERMATOL, V108, P737, DOI 10.1111/1523-1747.ep12292122; Berthod F, 1997, BRIT J DERMATOL, V136, P809, DOI 10.1111/j.1365-2133.1997.tb03917.x; Berthod F, 1997, SKIN SUBSTITUTE PROD, P23; BOYCE ST, 1995, J INVEST DERMATOL, V104, P345, DOI 10.1111/1523-1747.ep12665374; CHALUPOWICZ DG, 1995, J CELL BIOL, V130, P207, DOI 10.1083/jcb.130.1.207; COCKERILL GW, 1995, INT REV CYTOL, V159, P113, DOI 10.1016/S0074-7696(08)62106-3; ConradLapostolle V, 1996, CELL BIOL TOXICOL, V12, P189, DOI 10.1007/BF00438144; COOPER ML, 1991, SURGERY, V109, P198; CUONO CB, 1987, PLAST RECONSTR SURG, V80, P626, DOI 10.1097/00006534-198710000-00029; DAMOUR O, 1994, CLIN MATER, V15, P273, DOI 10.1016/0267-6605(94)90057-4; Deroanne CF, 1996, EXP CELL RES, V224, P215, DOI 10.1006/excr.1996.0131; DIAZFLORES L, 1994, HISTOL HISTOPATHOL, V9, P807; Foda HD, 1996, LAB INVEST, V74, P538; GERMAIN L, 1993, BURNS, V19, P99, DOI 10.1016/0305-4179(93)90028-7; GERMAIN L, 1995, ENCY HDB BIOMATERIAL, V1, P699; GORDON PB, 1983, IN VITRO CELL DEV B, V19, P661; Gupta K, 1997, EXP CELL RES, V230, P244, DOI 10.1006/excr.1996.3421; Hoying JB, 1996, IN VITRO CELL DEV-AN, V32, P409; Hoying JB, 1996, J CELL PHYSIOL, V168, P294, DOI 10.1002/(SICI)1097-4652(199608)168:2<294::AID-JCP8>3.0.CO;2-K; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; JACKSON CJ, 1991, EXP CELL RES, V192, P319, DOI 10.1016/0014-4827(91)90194-Y; KIENY M, 1984, J EXP ZOOL, V232, P327, DOI 10.1002/jez.1402320220; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LATTERA J, 1990, J CELL PHYSL, V144, P204; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; MACIAG T, 1982, J CELL BIOL, V94, P511, DOI 10.1083/jcb.94.3.511; MALLERY SR, 1994, CELL TISSUE RES, V279, P37; MARKS M, 1994, J CLIN INVEST, V93, P131; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MONTESANO R, 1993, J CELL SCI, V105, P1013; MONTESANO R, 1987, J CELL PHYSIOL, V130, P284, DOI 10.1002/jcp.1041300215; NICOSIA RF, 1990, LAB INVEST, V63, P115; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROUABHIA M, 1993, TRANSPLANTATION, V56, P259, DOI 10.1097/00007890-199308000-00001; Sahuc Florent, 1996, Wound Repair and Regeneration, V4, P93, DOI 10.1046/j.1524-475X.1996.40116.x; SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417, DOI 10.1002/jcp.1041530222; SHAHABEDDIN L, 1990, Skin Pharmacology, V3, P107; Trochon V, 1996, INT J CANCER, V66, P664, DOI 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4; VERNON RB, 1995, AM J PATHOL, V147, P873; VILLASCHI S, 1994, LAB INVEST, V71, P291; Young D. M., 1996, Journal of Burn Care and Rehabilitation, V17, P305, DOI 10.1097/00004630-199607000-00005	55	332	351	1	69	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1331	1340		10.1096/fasebj.12.13.1331	http://dx.doi.org/10.1096/fasebj.12.13.1331			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761776				2022-12-25	WOS:000076402000008
J	Connor, JX; Boileau, AJ; Czajkowski, C				Connor, JX; Boileau, AJ; Czajkowski, C			A GABA(A) receptor alpha(1) subunit tagged with green fluorescent protein requires a beta subunit for functional surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A RECEPTOR; CHANNEL EXPRESSION; MESSENGER-RNAS; ION CHANNELS; SUBTYPES; STOICHIOMETRY; HETEROGENEITY; LOCALIZATION; SYSTEM; SITES	gamma-Aminobutyric acid, type A (GABA(A)) receptors, the major inhibitory neurotransmitter receptors in the central nervous system, are heteropentameric proteins assembled from distinct subunit classes with multiple subtypes, alpha(1-6), beta(1-4), gamma(1-3), delta(1), and epsilon(1). To examine the process of receptor assembly and targeting, we tagged the carboxyl terminus of the GABA(A) receptor alpha(1) subunit with red-shifted enhanced green fluorescent protein (EGFP). Xenopus oocytes were injected with cRNA of this fusion protein, alpha(1)-EGFP, alone or in combination with cRNA of GABA(A) receptor beta(2), gamma(2), or beta(2) + gamma(2) subunits. Within 72 h after injection, EGFP fluorescence was visible in all fusion protein-injected cells. The fluorescence was associated with the plasmalemma only when the beta(2) subunit was co-injected with alpha(1)-EGFP. Texas Red-conjugated immunolabeling of EGFP on nonpermeabilized cells demonstrated that EGFP was localized extracellularly. Hence, the COOH terminus of the alpha(1) subunit is extracellular. Two-electrode voltage clamp of alpha(1)-EGFP beta(2)- and alpha(1)-EGFP beta(2)gamma(2)-injected oocytes demonstrates that these cells express functional receptors, with EC50 values for GABA and diazepam similar to wild-type receptors. Thus, a COOH-terminal tag of the alpha(1) subunit appears to be functionally silent, providing a useful marker for studies of GABA(A) receptor expression, assembly, transport, targeting, and clustering. Moreover, the beta(2) subunit is required for receptor assembly and surface expression.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Czajkowski, C (corresponding author), Univ Wisconsin, Dept Physiol, Rm 197 MSC,1300 Univ Ave, Madison, WI 53706 USA.				NINDS NIH HHS [NS34727] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034727, R56NS034727] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BLAIR LAC, 1988, SCIENCE, V242, P577, DOI 10.1126/science.2845583; Boileau AJ, 1998, MOL PHARMACOL, V53, P295, DOI 10.1124/mol.53.2.295; BULLER AL, 1994, MOL PHARMACOL, V46, P858; Chang YC, 1996, J NEUROSCI, V16, P5415; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connolly CN, 1996, P NATL ACAD SCI USA, V93, P9899, DOI 10.1073/pnas.93.18.9899; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; ENDO S, 1993, J NEUROCHEM, V60, P1388, DOI 10.1111/j.1471-4159.1993.tb03300.x; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; MALHERBE P, 1990, J NEUROSCI, V10, P2330; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; Moss SJ, 1996, INT REV NEUROBIOL, V39, P1, DOI 10.1016/S0074-7742(08)60662-5; NAYEEM N, 1994, J NEUROCHEM, V62, P815; Nusser Z, 1998, J NEUROSCI, V18, P1693; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; PEREZVELAZQUEZ JL, 1993, NATURE, V361, P457, DOI 10.1038/361457a0; POLLARD S, 1993, J BIOL CHEM, V268, P3753; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SIEGEL E, 1990, NEURON, V5, P703; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; Sperk G, 1997, NEUROSCIENCE, V80, P987, DOI 10.1016/S0306-4522(97)00146-2; Tretter V, 1997, J NEUROSCI, V17, P2728; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; Wisden W, 1997, BIOCHEM SOC T, V25, P820, DOI 10.1042/bst0250820; Wisden W, 1996, NEUROPHARMACOLOGY, V35, P1139, DOI 10.1016/S0028-3908(96)00076-7; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; WISDEN W, 1992, J NEUROSCI, V12, P1040; ZHANG JH, 1991, J COMP NEUROL, V308, P586, DOI 10.1002/cne.903080407	37	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28906	28911		10.1074/jbc.273.44.28906	http://dx.doi.org/10.1074/jbc.273.44.28906			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786893	hybrid			2022-12-25	WOS:000076691800054
J	Zhao, H; Butler, E; Rodgers, J; Spizzo, T; Duesterhoeft, S; Eide, D				Zhao, H; Butler, E; Rodgers, J; Spizzo, T; Duesterhoeft, S; Eide, D			Regulation of zinc homeostasis in yeast by binding of the ZAP1 transcriptional activator to zinc-responsive promoter elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINGER DNA RECOGNITION; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-CHARACTERIZATION; CONFERS RESISTANCE; LACZ FUSIONS; GENE ENCODES; PROTEIN; TRANSPORTER; SEQUENCE	Zinc homeostasis in yeast is controlled primarily through the regulation of zinc uptake. Transcription of the ZRT1 and ZRT2 zinc transporters increases in zinc-limited cells, and this induction is dependent on the ZAP1 gene. We hypothesized previously that ZAP1 encodes a zinc-responsive transcriptional activator. Expression of ZAP1 itself increases in zinc-limited cells. This response is also dependent on ZAP1 function through a potential positive autoregulatory mechanism. In this report, wk describe the characterization of zinc-responsive elements (ZREs) in the promoters of the ZRT1, ZRT2, and ZAP1 genes. A ZRE consensus sequence, 5'-ACCYYNAAGGT-3', was identified and found to be both necessary and sufficient for zinc-responsive transcriptional regulation. We also demonstrate that ZREs are DNA binding sites for ZAP1, First, a dominant ZAP1 mutation, ZAP1-1(up), which causes increased expression of ZAP1-regulated genes in zinc-replete cells, exerted its effects specifically through the ZREs, Second, electrophoretic mobility shift assays and in vitro DNase I footprint analyses indicated that ZAP1 binds to ZREs in a sequence-specific fashion, These studies demonstrate that ZAP1 plays a direct role in controlling zinc-responsive gene expression in yeast by binding to zinc-responsive elements in the promoters of genes that it regulates.	Univ Missouri, Nutr Sci Program, Columbia, MO 65211 USA; Univ Minnesota, Dept Biochem & Mol Biol, Sch Med, Duluth, MN 55812 USA	University of Missouri System; University of Missouri Columbia; University of Minnesota System; University of Minnesota Duluth	Eide, D (corresponding author), Univ Missouri, Nutr Sci Program, Columbia, MO 65211 USA.	eided@missouri.edu			NIGMS NIH HHS [GM48139, GM58265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058265, R29GM048139] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; Bohm S, 1997, NUCLEIC ACIDS RES, V25, P2464, DOI 10.1093/nar/25.12.2464; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HINNEBUSCH AG, 1985, P NATL ACAD SCI USA, V82, P498, DOI 10.1073/pnas.82.2.498; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kim CA, 1996, NAT STRUCT BIOL, V3, P940, DOI 10.1038/nsb1196-940; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PFEIFER K, 1987, CELL, V49, P19, DOI 10.1016/0092-8674(87)90751-3; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; Sherman F., 1986, METHODS YEAST GENETI; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	25	134	141	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28713	28720		10.1074/jbc.273.44.28713	http://dx.doi.org/10.1074/jbc.273.44.28713			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786867	hybrid			2022-12-25	WOS:000076691800028
J	Panchenko, MP; Saxena, K; Li, Y; Charnecki, S; Sternweis, PM; Smith, TF; Gilman, AG; Kozasa, T; Neer, EJ				Panchenko, MP; Saxena, K; Li, Y; Charnecki, S; Sternweis, PM; Smith, TF; Gilman, AG; Kozasa, T; Neer, EJ			Sites important for PLC beta(2) activation by the G protein beta gamma subunit map to the sides of the beta propeller structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; PHOSPHOLIPASE-C; CRYSTAL-STRUCTURE; SF9 CELLS; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; PURIFICATION; RESOLUTION; COMPLEX	The beta gamma subunits of the heterotrimeric GTP-binding proteins (G proteins) that couple heptahelical, plasma membrane-bound receptors to intracellular effector enzymes or ion channels directly regulate several types of effecters, including phospholipase C beta and adenylyl cyclase. The beta subunit is made up of two structurally different regions: an N-terminal alpha helix followed by a toroidal structure made up of 7 blades, each of which is a twisted beta sheet composed of four anti-parallel beta strands (Wall, M. A., Coleman, D. E., Lee, E., Iniguez-Lluhi, J. A, Posner, B. A, Oilman, A G., and Sprang, S. R. (1995) Cell 83, 1047-1058; Lambright, D. G., Sondek, J., Bohm, A., Skiba, N. P., Hamm, H. E., and Sigler, P. B. (1996) Nature 379, 311-319). We have previously shown that sites for activation of PLC beta(2), PLC beta(3), and adenylyl cyclase II overlap on the "top" surface of the propeller, where G alpha also binds (Li, Y., Sternweis, P. M., Charnecki, S., Smith, T. F., Oilman, A. G., Neer, E. J., and Kozasa, T. (1998) J. Biol. Chem. 273, 16265-16272). The present study was undertaken to identify the regions on the side of the torus that might be important for effector interactions. We made mutations in each of the outer beta strands of the G protein beta(1) propeller, as well as mutations in the loops that connect the outer strands to the adjacent beta strands. Our results suggest that activation of PLC beta(2) involves residues in the outer strands of blades 2, 6, and 7 of the propeller. We tested three of the mutations that most severely affected PLC beta(2) activity against two forms of adenylyl cyclase (ACI and ACII). Both inhibition of ACI and activation of ACII were unaffected by these mutations, suggesting that if ACI and ACII contact the outer strands, the sites of contact are different from those for PLC beta(2). We propose that distinct sets of contacts along the sides of the propeller will define the specificity of the interaction of beta gamma with effecters.	Brigham & Womens Hosp, Div Cardiovasc, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Boston Univ, Biomol Engn Res Ctr, Boston, MA 02111 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Boston University	Neer, EJ (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Dept Med, 75 Francis St, Boston, MA 02115 USA.	neer@calvin.bwh.harvard.edu			NIGMS NIH HHS [GM36259, GM34497] Funding Source: Medline; NLM NIH HHS [P1 LM05252] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497, R01GM036259, R37GM036259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLANK JL, 1993, J BIOL CHEM, V268, P25184; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CASEY PJ, 1991, METHOD ENZYMOL, V195, P315; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEE E, 1994, METHOD ENZYMOL, V237, P146; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Summers MD, 1987, TEXAS AGR EXPT STATI; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	26	78	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28298	28304		10.1074/jbc.273.43.28298	http://dx.doi.org/10.1074/jbc.273.43.28298			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774453	hybrid			2022-12-25	WOS:000076549800073
J	Tian, D; Huang, DL; Brown, RC; Jungmann, RA				Tian, D; Huang, DL; Brown, RC; Jungmann, RA			Protein kinase A stimulates binding of multiple proteins to a U-rich domain in the 3 '-untranslated region of lactate dehydrogenase A mRNA that is required for the regulation of mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; CYCLIC-AMP ELEVATION; ULTRAVIOLET-LIGHT; GENE-EXPRESSION; TUMOR PROMOTER; LLC-PK1 CELLS; OKADAIC ACID; STABILIZATION; DEGRADATION	We have explored the molecular basis of the cAMP-induced stabilization of lactate dehydrogenase A (LDH-A) mRNA and identified four cytoplasmic proteins of 96, 67, 52, and 50 kDa that specifically bind to a 30-nucleotide uridine rich sequence in the LDH 3'-untranslated region with a predicted stem-loop structure. Mutational analysis revealed that specific protein binding is dependent upon an intact primary nucleotide sequence in the loop as well as integrity of the adjoining double-stranded stem structure, thus indicating a high degree of primary and secondary structure specificity. The critical stem-loop region is located between nucleotides 1473 and 1502 relative to the mRNA cap site and contains a previously identified cAMP-stabilizing region (CSR) required for LDH-A mRNA stability regulation by the protein kinase A pathway. The 3'-untranslated region binding activity of the proteins is upregulated after protein kinase A activation, whereas protein dephosphorylation is associated with a loss of binding activity. These results imply a cause and effect relationship between LDH-A mRNA stabilization and CSR-phosphoprotein binding activity. We propose that the U-rich CSR is a recognition signal for CSR-binding proteins and for an mRNA processing pathway that specifically stabilizes LDH mRNA in response to activation of the protein kinase A signal transduction pathway.	Northwestern Univ, Sch Med, Dept Cellular & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Ctr Canc, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Jungmann, RA (corresponding author), Northwestern Univ, Sch Med, Dept Cellular & Mol Biol, Chicago, IL 60611 USA.	rjungman@nwu.edu			NIGMS NIH HHS [GM53115] Funding Source: Medline; NINDS NIH HHS [T32NS07140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BEALE EG, 1985, J BIOL CHEM, V260, P748; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; CHEN M, 1993, J BIOL CHEM, V268, P24138; CHRIST B, 1991, BIOCHEM BIOPH RES CO, V177, P1273, DOI 10.1016/0006-291X(91)90679-2; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GREENBERG JR, 1979, NUCLEIC ACIDS RES, V6, P715, DOI 10.1093/nar/6.2.715; GREENBERG JR, 1980, NUCLEIC ACIDS RES, V8, P5685, DOI 10.1093/nar/8.23.5685; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HUANG DL, 1995, MOL ENDOCRINOL, V9, P994, DOI 10.1210/me.9.8.994; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; NACHALIEL N, 1993, J BIOL CHEM, V268, P24203; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PENG H, 1995, J BIOL CHEM, V270, P20536, DOI 10.1074/jbc.270.35.20536; PENG H, 1995, J BIOL CHEM, V270, P23996, DOI 10.1074/jbc.270.41.23996; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; ROSS J, 1994, RNA PROCESSING PRACT, V2; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAKAUE M, 1991, J BIOL CHEM, V266, P5743; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH JD, 1988, EMBO J, V7, P3711, DOI 10.1002/j.1460-2075.1988.tb03254.x; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; THOLANIKUNNEL BG, 1995, J BIOL CHEM, V270, P12787, DOI 10.1074/jbc.270.21.12787; Tian D, 1998, J BIOL CHEM, V273, P24861, DOI 10.1074/jbc.273.38.24861; UHLER MD, 1987, J BIOL CHEM, V262, P15202; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	31	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28454	28460		10.1074/jbc.273.43.28454	http://dx.doi.org/10.1074/jbc.273.43.28454			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774474	hybrid			2022-12-25	WOS:000076549800094
J	Verdier, F; Chretien, S; Muller, O; Varlet, P; Yoshimura, A; Gisselbrecht, S; Lacombe, C; Mayeux, P				Verdier, F; Chretien, S; Muller, O; Varlet, P; Yoshimura, A; Gisselbrecht, S; Lacombe, C; Mayeux, P			Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation - Possible involvement of the ubiquitinated Cis protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOUBIQUITINATED ALPHA-GLOBIN; LEUKEMIC-CELL-LINE; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; ASSOCIATION; INTERLEUKIN-3; PATHWAY; GROWTH; DOMAIN; KINASE	Cis is an Src homology 2 domain-containing protein, which binds to the erythropoietin receptor and decreases erythropoietin-stimulated cell proliferation. We show that Cis associates with the second tyrosine residue of the intracellular domain of the erythropoietin receptor (Tyr(401)). TWO forms of Cis with molecular masses of 32 and 37 kDa were detected, and we demonstrate that the 37-kDa protein resulted from post-translational modifications of the 32-kDa form. Anti-ubiquitin antibodies recognized the 37-kDa form of Cis and the proteasome inhibitors N-acetyl-leucyl-leucyl-norleucinal and lactacystin inhibited its degradation, showing that the 37-kDa form of Cis is a ubiquitinated protein, which seems to be rapidly degraded by the proteasome. In erythropoietin-stimulated UT-7 cells, the activation of the erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) was transient and returned to basal levels after 30-60 min of erythropoietin stimulation. In contrast, these proteins remained strongly phosphorylated, and STAT5 remained activated for at least 120 min in the presence of proteasome inhibitors. These experiments demonstrate that the proteasomes are involved in the down-regulation of the erythropoietin receptor activation signals, Because the proteasome inhibitors induced the accumulation of both the ubiquitinated form of Cis and the Cis-erythropoietin receptor complexes, our results suggest that the ubiquitinated form of Cis could be involved in the proteasome-mediated inactivation of the erythropoietin receptor.	Univ Paris 05, INSERM, U363, Inst Cochin Genet Mol, F-75014 Paris, France; Inst Natl Transfus Sanguine, F-75015 Paris, France; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 839, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Kurume University	Mayeux, P (corresponding author), Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.		Chretien, Stany/M-5166-2018; Yoshimura, Akihiko/K-5515-2013					AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; COUX O, 1996, ANNU REV BIOCHEM, V65, P807; Damen JE, 1996, EXP HEMATOL, V24, P1455; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; HE TC, 1993, BLOOD, V82, P3530; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KITAMURA T, 1989, BLOOD, V73, P373; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOMATSU N, 1991, CANCER RES, V51, P341; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P96; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MAYEUX P, 1990, FEBS LETT, V269, P167, DOI 10.1016/0014-5793(90)81145-E; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MUI ALF, 1992, P NATL ACAD SCI USA, V89, P10812, DOI 10.1073/pnas.89.22.10812; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; SHAEFFER JR, 1994, J BIOL CHEM, V269, P22205; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017	45	150	154	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28185	28190		10.1074/jbc.273.43.28185	http://dx.doi.org/10.1074/jbc.273.43.28185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774439	hybrid			2022-12-25	WOS:000076549800059
J	Huang, SS; Huang, FW; Xu, J; Chen, SW; Hsu, CY; Huang, JS				Huang, SS; Huang, FW; Xu, J; Chen, SW; Hsu, CY; Huang, JS			Amyloid beta-peptide possesses a transforming growth factor-beta activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG EPITHELIAL-CELLS; ALZHEIMERS-DISEASE; CEREBRAL-HEMORRHAGE; NEURONAL CULTURES; RECEPTOR; PROTEIN; NEUROTOXICITY; AGGREGATION; TGF-BETA-1; GENE	Amyloid beta-peptide (A beta) of 39-42 amino acid residues is a major constituent of Alzheimer's disease neurite plaques. A beta aggregates (fibrils) are believed to be responsible for neuronal damage and dysfunction, as well as microglia and astrocyte activation in disease lesions by multiple mechanisms. Since A beta aggregates possess the multiple valencies of an FAED motif (20th to 23rd amino acid residues), which resembles the putative transforming growth factor-beta (TGF-beta) active site motif, we hypothesize that A beta monomers and A beta aggregates may function as TGF-beta antagonists and partial agonist, analogous to previously described monovalent and multivalent TGF-beta peptide antagonists and agonists (Huang, S. S., Liu, Q., Johnson, F. E., Konish, Y., and Huang, J. S. (1997) J. Biol. Chem. 272, 27155-27159). Here, we report that the Ap monomer, A beta-(1-40) and its fragment, containing the motif inhibit radiolabeled TGF-beta binding to cell-surface TGF-beta receptors in mink lung epithelial cells (Mv1Lu cells). A beta-(1-40)-bovine serum albumin conjugate (A beta-(1-40)-BSA), a multivalent synthetic analogue of A beta aggregates, exhibited cytotoxicity toward bovine cerebral endothelial cells and rat postmitotic differentiated hippocampal neuronal cells (H19-7 cells) and inhibitory activities of radiolabeled TGF-beta binding to TGF-beta receptors and TGF-beta-induced plasminogen activator inhibitor-1 expression, that were similar to 100-670 times more potent than those of A beta-(1-40) monomers, At less than micromolar concentrations, Ap(1-40)-BSA but not A beta-(1-40) monomers inhibited proliferation of Mv1Lu cells. Since TGF-beta is an organizer of responses to neurodegeneration and is also found in neurite plaques, the TGF-beta antagonist and partial agonist activities of A beta monomers and aggregates may play an important role in the pathogenesis of the disease.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA	Saint Louis University; Washington University (WUSTL); Washington University (WUSTL)	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangjs@wpogate.slu.edu		Hsu, Chung Y./0000-0002-5632-2733	NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATAYAKULCHANTLER S, 1994, J BIOL CHEM, V269, P27687; Auld DS, 1998, TRENDS NEUROSCI, V21, P43, DOI 10.1016/S0166-2236(97)01144-2; BURDICK D, 1992, J BIOL CHEM, V267, P546; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; FLOOD JF, 1991, P NATL ACAD SCI USA, V88, P3363, DOI 10.1073/pnas.88.8.3363; FLOOD JF, 1994, BRAIN RES, V663, P271, DOI 10.1016/0006-8993(94)91273-4; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; PERESS NS, 1995, J NEUROPATH EXP NEUR, V54, P802, DOI 10.1097/00005072-199511000-00007; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Prehn JHM, 1996, MOL PHARMACOL, V49, P319; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; PREHN JHM, 1993, J NEUROCHEM, V60, P1665, DOI 10.1111/j.1471-4159.1993.tb13389.x; Ren RF, 1996, BRAIN RES, V732, P16, DOI 10.1016/0006-8993(96)00458-1; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; VANDERWAL EA, 1993, NEUROREPORT, V4, P69, DOI 10.1097/00001756-199301000-00018; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yan SD, 1997, NATURE, V389, P689; YAN SD, 1996, NATURE, V382, P682; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	37	18	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27640	27644		10.1074/jbc.273.42.27640	http://dx.doi.org/10.1074/jbc.273.42.27640			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765299	hybrid			2022-12-25	WOS:000076448000086
J	Kimura, T; Christoffels, VM; Chowdhury, S; Iwase, K; Matsuzaki, H; Mori, M; Lamers, WH; Darlington, GJ; Takiguchi, M				Kimura, T; Christoffels, VM; Chowdhury, S; Iwase, K; Matsuzaki, H; Mori, M; Lamers, WH; Darlington, GJ; Takiguchi, M			Hypoglycemia-associated hyperammonemia caused by impaired expression of ornithine cycle enzyme genes in C/EBP alpha knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING-PROTEIN; PHOSPHATE SYNTHETASE-I; AMINO-ACID SEQUENCE; RAT ARGINASE GENE; ARGININOSUCCINATE LYASE; NUCLEOTIDE-SEQUENCE; LIVER ARGINASE; LEUCINE ZIPPER; MOUSE-LIVER; PROMOTER	Ammonia produced by amino acid metabolism is detoxified through conversion into urea by the ornithine cycle in the Liver, whereas carbon skeletons of amino acids are converted to glucose by gluconeogenic enzymes. Promoter and enhancer sequences of several genes for ornithine cycle enzymes interact with members of the CCAAT/enhancer-binding protein (C/EBP) transcription factor family. Disruption of the C/EBP alpha gene in mice causes hypoglycemia associated with the impaired expression of gluconeogenic enzymes. Here we examined the expression of ornithine cycle enzyme genes in the livers of C/EBP alpha-deficient mice. mRNA levels for the first, third, fourth, and fifth enzymes of five enzymes in the cycle were decreased in C/EBP alpha-deficient mice. Protein levels for the first, second, fourth, and fifth enzymes were also decreased. In situ hybridization analysis revealed that the enzyme mRNAs were distributed normally in the periportal region but were disordered in C/EBP alpha-deficient mice with relatively higher mRNA levels in the midlobular region. Blood ammonia concentrations in the mutant mice were severalfold higher than in wild-type mice. Thus, C/EBP alpha is crucial for ammonia detoxification by ornithine cycle enzymes and for coordination of gluconeogenesis and urea synthesis.	Kumamoto Univ, Sch Med, Dept Mol Genet, Kumamoto 8620976, Japan; Kumamoto Univ, Sch Med, Dept Internal Med, Kumamoto 8620976, Japan; Univ Amsterdam, Acad Med Ctr, Dept Anat & Embryol, NL-1105 AZ Amsterdam, Netherlands; Baylor Coll Med, Dept Pathol & Mol & Human Genet, Houston, TX 77030 USA	Kumamoto University; Kumamoto University; University of Amsterdam; Academic Medical Center Amsterdam; Baylor College of Medicine	Takiguchi, M (corresponding author), Chiba Univ, Sch Med, Dept Biochem, Inohana 1-8-1, Chiba 2608670, Japan.		Lamers, Wouter H./D-2965-2012		NIDDK NIH HHS [DK 45285] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045285] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMAYA Y, 1988, J BIOCHEM-TOKYO, V103, P177, DOI 10.1093/oxfordjournals.jbchem.a122227; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chowdhury S, 1996, EUR J BIOCHEM, V236, P500, DOI 10.1111/j.1432-1033.1996.00500.x; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Dingemanse MA, 1996, HEPATOLOGY, V24, P407; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; GOTOH T, 1994, J BIOCHEM-TOKYO, V115, P778, DOI 10.1093/oxfordjournals.jbchem.a124409; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HOWELL BW, 1989, MOL CELL BIOL, V9, P2928, DOI 10.1128/MCB.9.7.2928; IKEMOTO M, 1990, BIOCHEM J, V270, P697, DOI 10.1042/bj2700697; JUNGAS RL, 1992, PHYSIOL REV, V72, P419, DOI 10.1152/physrev.1992.72.2.419; Kanazawa M, 1997, J BIOCHEM-TOKYO, V121, P890; KAWAMOTO S, 1987, J BIOL CHEM, V262, P6280; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KOIZUMI T, 1990, LAB ANIM SCI, V40, P308; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; MATSUBASA T, 1994, J BIOCHEM, V116, P1044, DOI 10.1093/oxfordjournals.jbchem.a124626; Matsuno F, 1996, J BIOCHEM-TOKYO, V119, P524; MOORMAN AFM, 1988, J HISTOCHEM CYTOCHEM, V36, P751, DOI 10.1177/36.7.2898495; MOORMAN AFM, 1993, HISTOCHEM J, V25, P251, DOI 10.1007/BF00159117; MOORMAN AFM, 1991, FEBS LETT, V288, P133, DOI 10.1016/0014-5793(91)81019-5; MORI M, 1979, P NATL ACAD SCI USA, V76, P5071, DOI 10.1073/pnas.76.10.5071; MORRIS SM, 1989, ARCH BIOCHEM BIOPHYS, V269, P175, DOI 10.1016/0003-9861(89)90097-0; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; MURAWAKI Y, 1984, CLIN CHIM ACTA, V144, P195; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; Shneider Benjamin L., 1996, Current Opinion in Pediatrics, V8, P495, DOI 10.1097/00008480-199610000-00013; SURH LC, 1988, NUCLEIC ACIDS RES, V16, P9352, DOI 10.1093/nar/16.19.9352; TAKIGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P7412, DOI 10.1073/pnas.81.23.7412; Takiguchi M, 1995, BIOCHEM J, V312, P649, DOI 10.1042/bj3120649; TAKIGUCHI M, 1991, J BIOL CHEM, V266, P9186; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YU YJ, 1995, J BIOCHEM-TOKYO, V117, P952, DOI 10.1093/oxfordjournals.jbchem.a124826; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	45	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27505	27510		10.1074/jbc.273.42.27505	http://dx.doi.org/10.1074/jbc.273.42.27505			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765281	hybrid			2022-12-25	WOS:000076448000068
J	Quintana, DG; Thome, KC; Hou, ZH; Ligon, AH; Morton, CC; Dutta, A				Quintana, DG; Thome, KC; Hou, ZH; Ligon, AH; Morton, CC; Dutta, A			ORC5L, a new member of the human origin recognition complex, is deleted in uterine leiomyomas and malignant myeloid diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; YEAST ORIGIN; SACCHAROMYCES-CEREVISIAE; DROSOPHILA HOMOLOG; GENE; EXPRESSION; PROTEINS; XENOPUS; BINDING; SYSTEM	A new member of the human origin recognition complex (ORC) was cloned and identified as ORC5L, HsORC5p is a 50-kDa protein whose sequence is 38% identical and 62% similar to ORC5p from Drosophila melanogaster, Two alleles of ORC5L were identified, one with and one without an evolutionarily conserved purine nucleotide binding motif, HsORC5p is precipitated from cell extracts with HsORC2p and HsORC4p, indicating that it is part of the putative human ORC, The bulk of HsORC5p is in an insoluble nuclear fraction, whereas the other known human ORC subunits (HsORC1p, HsORC2p, and HsORC4p) are easily extracted in the nuclear-soluble fractions and in S100 (HsORC1p). In addition, we identified an alternatively spliced mRNA from the same locus (HsORC5T), HsORC5Tp also formed a complex with HsORC4p but not with HsORC2p, suggesting it may play a regulatory role in the assembly of different ORC subcomplexes, HsORC5, HsORC5T, and HsORC4 transcripts are abundant in spleen, ovary, and prostate in addition to tissues with high levels of DNA replication like testes and colon mucosa, implicating the human ORC proteins in functions besides DNA replication. Finally, the gene for ORC5L is located at chromosome 7, band q22, in the minimal region deleted in 10% of uterine leiomyomas and in 10-20% of acute myeloid leukemias and myelodysplastic syndromes.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Mol Oncol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Dutta, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Mol Oncol, Boston, MA 02115 USA.		Quintana, David G/M-5628-2018; Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Quintana, David G./0000-0002-4909-6686	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030498] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER; NCI NIH HHS [CA60499, R01 CA060499-05, R01 CA060499] Funding Source: Medline; NHLBI NIH HHS [T32 HL07627] Funding Source: Medline; NICHD NIH HHS [HD30498] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Brush GS, 1995, METHOD ENZYMOL, V262, P522; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; Fischer K, 1997, BLOOD, V89, P2036, DOI 10.1182/blood.V89.6.2036; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; Ishwad CS, 1997, GENE CHROMOSOME CANC, V19, P156, DOI 10.1002/(SICI)1098-2264(199707)19:3<156::AID-GCC4>3.0.CO;2-X; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; LeBeau MM, 1996, BLOOD, V88, P1930; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OZISIK YY, 1993, CANCER GENET CYTOGEN, V71, P1, DOI 10.1016/0165-4608(93)90195-R; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Schneider MC, 1996, GENOMICS, V38, P1, DOI 10.1006/geno.1996.0584; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018; Vanni R, 1997, GENE CHROMOSOME CANC, V18, P155, DOI 10.1002/(SICI)1098-2264(199703)18:3<155::AID-GCC1>3.0.CO;2-0; Williams AJ, 1997, AM J PATHOL, V150, P911; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Xing YP, 1997, CANCER GENET CYTOGEN, V98, P69; Zeng WR, 1997, ONCOGENE, V14, P2355, DOI 10.1038/sj.onc.1201076	36	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27137	27145		10.1074/jbc.273.42.27137	http://dx.doi.org/10.1074/jbc.273.42.27137			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765232	hybrid			2022-12-25	WOS:000076448000019
J	Aoki, K; Meng, GY; Suzuki, K; Takashi, T; Kameoka, Y; Nakahara, K; Ishida, R; Kasai, M				Aoki, K; Meng, GY; Suzuki, K; Takashi, T; Kameoka, Y; Nakahara, K; Ishida, R; Kasai, M			RP58 associates with condensed chromatin and mediates a sequence-specific transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; ACUTE PROMYELOCYTIC LEUKEMIA; TELOMERIC HETEROCHROMATIN; IMMUNOGLOBULIN ENHANCER; INTERACTION MOTIF; CONSERVED DOMAIN; ENCODING GENE; CELL LYMPHOMA; BTB DOMAIN; DROSOPHILA	An approximately 120-amino acid domain present generally at the NH2 termini, termed the POZ domain, is highly conserved in various proteins with zinc finger DNA binding motifs. We have isolated a novel protein sharing homology with the POZ domain of a number of zinc finger proteins, including the human BCL-6 protein. By using a binding site selection technique (CAST), a high affinity binding site of the protein was determined to be (A/C)ACATCTG(G/T) (A/C), containing the E box core sequence motif. The protein was shown to repress transcription from se promoter linked to its target sequences and was hence named RP58 (Repressor Protein with a predicted molecular mass of 58 kDa). Immunogold electron microscopic study revealed that almost all RP58 is localized in condensed chromatin regions. These observations demonstrate for the first time that a protein mediating a sequence-specific transcriptional repression associates with highly condensed chromatin. We suggest that RP58 may be involved in a molecular link between sequence-specific transcriptional repression and the organization of chromosomes in the nucleus.	Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Tokyo 162, Japan; Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo 162, Japan; Natl Inst Infect Dis, Div Genet Resources, Shinjuku Ku, Tokyo 162, Japan; Univ Tokyo, Sch Med, Dept Internal Med 1, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Sch Med, Dept Lab Med, Bunkyo Ku, Tokyo 113, Japan; Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, New Prod Res Labs 4, Edogawa Ku, Tokyo 134, Japan	National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID); University of Tokyo; University of Tokyo; Daiichi Sankyo Company Limited	Kasai, M (corresponding author), Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 162, Japan.							ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; AOKI K, 1994, ONCOGENE, V9, P1109; Aoki K, 1997, FEBS LETT, V401, P109, DOI 10.1016/S0014-5793(96)01444-5; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BORDEREAUX D, 1990, ONCOGENE, V5, P925; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DIBELLO PR, 1991, GENETICS, V129, P385; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; Kaplan J, 1997, NUCLEIC ACIDS RES, V25, P1108, DOI 10.1093/nar/25.6.1108; KASAI M, 1994, INT IMMUNOL, V6, P1017, DOI 10.1093/intimm/6.7.1017; KASAI M, 1992, MOL CELL BIOL, V12, P4751, DOI 10.1128/MCB.12.10.4751; Kasai M, 1997, J BIOL CHEM, V272, P11402; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MIKI T, 1994, BLOOD, V83, P26; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; SCHNEIDERGADICKE A, 1989, NATURE, V342, P708, DOI 10.1038/342708a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Seyfert VL, 1996, ONCOGENE, V12, P2331; SUGAWARA M, 1994, MOL CELL BIOL, V14, P8438, DOI 10.1128/MCB.14.12.8438; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	38	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26698	26704		10.1074/jbc.273.41.26698	http://dx.doi.org/10.1074/jbc.273.41.26698			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756912	hybrid			2022-12-25	WOS:000076373300066
J	Deguchi, M; Hata, Y; Takeuchi, M; Ide, N; Hirao, K; Yao, IK; Irie, M; Toyoda, A; Takai, Y				Deguchi, M; Hata, Y; Takeuchi, M; Ide, N; Hirao, K; Yao, IK; Irie, M; Toyoda, A; Takai, Y			BEGAIN (brain-enriched guanylate kinase-associated protein), a novel neuronal PSD-95/SAP90-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; POSTSYNAPTIC DENSITY; PSD-95 FAMILY; DOMAIN; INTERACTS; HOMOLOG; BINDING; SAP102; SAP90	PSD-95/SAP90 is a synaptic membrane-associated guanylate kinase with three PDZ, one SH3, and one guanylate kinase (GK) domain. PSD-95/SAP90 binds various proteins through the PDZ domains and organizes synaptic junctions. PSD-95/SAP90 also interacts with the postsynaptic density (PSD) fraction-enriched protein, named SAPAP (also called GKAP and DAP), through the GK domain. SAPAP is Triton X-100-insoluble and recruits PSD-95/SAP90 into the Triton X-100-insoluble fraction in the transfected cells, suggesting that SAPAP may fix PSD-95/SAP90 to the PSD. Here we report a novel protein interacting with the GK domain of PSD95/SAP90, BEGAIN. BEGAIN is specifically expressed in brain and enriched in the PSD fraction. BEGAIN is Triton X-100-soluble in the transfected cells but is recruited to the Triton X-100-insoluble fraction by SAPAP when coexpressed with PSD-95/SAP90. BEGAIN may be a novel PSD component associated with the core complex of PSD-95/SAP90 and SAPAP.	ERATO, Japan Sci & Technol Corp, JCR Pharmaceut Co Ltd, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan; Osaka Univ, Sch Med, Dept Biochem & Mol Biol, Suita, Osaka 565, Japan	Japan Science & Technology Agency (JST); Osaka University	Takai, Y (corresponding author), ERATO, Japan Sci & Technol Corp, JCR Pharmaceut Co Ltd, Takai Biotimer Project,Nishi Ku, 2-2-10 Murotani, Kobe, Hyogo 6512241, Japan.		Toyoda, Atsushi/AAA-5885-2020	Toyoda, Atsushi/0000-0002-0245-3244				CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; GARNER C, 1996, TRENDS CELL BIOL, V19, P429; Hata Y, 1996, J NEUROSCI, V16, P2488; HATA Y, 1998, IN PRESS NEUROSCI RE; HATTORI M, 1995, MOL CELL BIOL, V15, P552, DOI 10.1128/MCB.15.1.552; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lantz VA, 1998, J CELL BIOL, V140, P897, DOI 10.1083/jcb.140.4.897; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; ZIFF EB, 1997, CELL, V19, P1163	31	68	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26269	26272		10.1074/jbc.273.41.26269	http://dx.doi.org/10.1074/jbc.273.41.26269			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756850	hybrid			2022-12-25	WOS:000076373300004
J	Oh, JI; Bowien, B				Oh, JI; Bowien, B			Structural analysis of the fds operon encoding the NAD(+)-linked formate dehydrogenase of Ralstonia eutropha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; ELECTRON-PARAMAGNETIC RESONANCE; PROTON-TRANSLOCATING NADH; MITOCHONDRIAL COMPLEX-I; ESCHERICHIA-COLI K-12; AMINO-ACID-SEQUENCE; ALCALIGENES-EUTROPHUS; NUCLEOTIDE-SEQUENCE; REDUCING HYDROGENASE; PARACOCCUS-DENITRIFICANS	The fdsGBACD operon encoding the four subunits of the NAD(+)-reducing formate dehydrogenase of Ralstonia eutropha H16 was cloned and sequenced. Sequence comparisons indicated a high resemblance of FdsA (alpha-subunit) to the catalytic subunits of formate dehydrogenases containing a molybdenum (or tungsten) cofactor. The NH2-terminal region (residues 1-240) of FdsA, lacking in formate dehydrogenases not linked to NAD(P)(+), exhibited considerable similarity to that of NuoG of the NADH:ubiquinone oxidoreductase from Escherichia coli as well as to HoxU and the NH2-terminal segment of HndD of NAD(P)(+)-reducing hydrogenases. FdsB (beta-subunit) and FdsG (gamma-subunit) are closely related to NuoF and NuoE, respectively, as well as to HoxF and HndA. It is proposed that the NH2-terminal domain of FdsA together with FdsB and FdsG constitute a functional entity corresponding to the NADH dehydrogenase (diaphorase) part of NADH:ubiquinone oxidoreductase and the hydrogenases. No significant similarity to any known protein was observed for FdsD (delta-subunit). The predicted product of fdsC showed the highest resemblance to FdhD from E. coli, a protein required for the formation of active formate dehydrogenases in this organism. Transcription of the fds operon is subject to formate induction. A promoter structure resembling the consensus sequence of sigma(70)-dependent promoters from E. coli was identified upstream of the transcriptional start site determined by primer extension analysis.	Univ Gottingen, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany	University of Gottingen	Bowien, B (corresponding author), Univ Gottingen, Inst Mikrobiol & Genet, Grisebachstr 8, D-37077 Gottingen, Germany.	bbowien@gwdg.de						ABAIBOU H, 1995, J BACTERIOL, V177, P7141, DOI 10.1128/jb.177.24.7141-7149.1995; ALLEN SJ, 1995, GENE, V162, P99, DOI 10.1016/0378-1119(95)00347-9; Ausubel FM., 1988, CURRENT PROTOCOLS MO; AXLEY MJ, 1991, P NATL ACAD SCI USA, V88, P8450, DOI 10.1073/pnas.88.19.8450; BARBER MJ, 1983, J BIOL CHEM, V258, P839; BERG BL, 1991, J BIOL CHEM, V266, P22380; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1990, MOL GEN GENET, V222, P104, DOI 10.1007/BF00283030; BOKRANZ M, 1991, ARCH MICROBIOL, V156, P119, DOI 10.1007/BF00290984; BOWIEN B, 1990, FEMS MICROBIOL LETT, V87, P445, DOI 10.1016/0378-1097(90)90493-A; BOWIEN B, 1981, ANNU REV MICROBIOL, V35, P405, DOI 10.1146/annurev.mi.35.100181.002201; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; DESFRANCSSMALL CC, 1993, PLANT PHYSIOL, V102, P1171, DOI 10.1104/pp.102.4.1171; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I; FERRY JG, 1990, FEMS MICROBIOL LETT, V87, P377, DOI 10.1111/j.1574-6968.1990.tb04940.x; FRIEDEBOLD J, 1993, J BACTERIOL, V175, P4719, DOI 10.1128/JB.175.15.4719-4728.1993; FRIEDEBOLD J, 1995, BIOL CHEM H-S, V376, P561, DOI 10.1515/bchm3.1995.376.9.561; FRIEDRICH B, 1993, ANNU REV MICROBIOL, V47, P351, DOI 10.1146/annurev.mi.47.100193.002031; FRIEDRICH CG, 1979, J GEN MICROBIOL, V115, P185, DOI 10.1099/00221287-115-1-185; FU W, 1993, BIOCHEMISTRY-US, V32, P4813, DOI 10.1021/bi00069a016; Galkin A, 1995, APPL MICROBIOL BIOT, V44, P479, DOI 10.1007/BF00169947; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P7708, DOI 10.1073/pnas.91.16.7708; Gladyshev VN, 1996, J BIOL CHEM, V271, P8095, DOI 10.1074/jbc.271.14.8095; GLASER P, 1995, J BACTERIOL, V177, P1112, DOI 10.1128/jb.177.4.1112-1115.1995; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HOCHHEIMER A, 1995, X87969 GENBANKEMBLDD; HOLLENBERG CP, 1989, A06214 GENBANKEMBLDD; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; Kletzin A, 1996, FEMS MICROBIOL REV, V18, P5, DOI 10.1016/0168-6445(95)00025-9; KRAFFT T, 1992, EUR J BIOCHEM, V206, P503, DOI 10.1111/j.1432-1033.1992.tb16953.x; KUSIAN B, 1995, J BACTERIOL, V177, P4442, DOI 10.1128/jb.177.15.4442-4450.1995; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; Lenger R, 1997, EUR J BIOCHEM, V246, P646, DOI 10.1111/j.1432-1033.1997.t01-2-00646.x; LI XL, 1996, U73807 GENBANKEMBLDD; LOENEN WAM, 1980, GENE, V10, P249, DOI 10.1016/0378-1119(80)90054-2; MALKI S, 1995, J BACTERIOL, V177, P2628, DOI 10.1128/jb.177.10.2628-2636.1995; MANDRANDBERTHELOT MA, 1988, J GEN MICROBIOL, V134, P3129; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; MEYER J, 1991, BIOCHEMISTRY-US, V309, P3697; OELMULLER U, 1990, J MICROBIOL METH, V11, P73, DOI 10.1016/0167-7012(90)90050-G; PIERSON DE, 1990, J BACTERIOL, V172, P2194, DOI 10.1128/jb.172.4.2194-2198.1990; PILKINGTON SJ, 1991, BIOCHEMISTRY-US, V30, P2166, DOI 10.1021/bi00222a021; PILKINGTON SJ, 1989, BIOCHEMISTRY-US, V28, P3257, DOI 10.1021/bi00434a021; PLUNKETT G, 1993, NUCLEIC ACIDS RES, V21, P3391, DOI 10.1093/nar/21.15.3391; POPOV VO, 1994, BIOCHEM J, V301, P625, DOI 10.1042/bj3010625; POPOV VO, 1990, BIOORG KHIM+, V16, P324; PREIS D, 1991, BIOCHIM BIOPHYS ACTA, V1090, P133, DOI 10.1016/0167-4781(91)90049-R; RUNSWICK MJ, 1989, BIOCHEMISTRY-US, V28, P9452, DOI 10.1021/bi00450a031; Sambrook J., 2002, MOL CLONING LAB MANU; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; SCHMITZ O, 1995, EUR J BIOCHEM, V233, P266, DOI 10.1111/j.1432-1033.1995.266_1.x; SHUBER AP, 1986, J BIOL CHEM, V261, P2942; SIDDIQUI RA, 1993, J BACTERIOL, V175, P5867, DOI 10.1128/JB.175.18.5867-5876.1993; STEWART V, 1991, J BACTERIOL, V173, P4417, DOI 10.1128/JB.173.14.4417-4423.1991; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRANBETCKE A, 1990, J BACTERIOL, V172, P2920, DOI 10.1128/jb.172.6.2920-2929.1990; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; XU XM, 1992, ARCH BIOCHEM BIOPHYS, V296, P40, DOI 10.1016/0003-9861(92)90542-5; XU XM, 1991, BIOCHEMISTRY-US, V30, P8678, DOI 10.1021/bi00099a027; XU XM, 1991, BIOCHEMISTRY-US, V30, P6422, DOI 10.1021/bi00240a012; YAMAMOTO I, 1983, J BIOL CHEM, V258, P1826; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANO T, 1994, BIOCHEMISTRY-US, V33, P494, DOI 10.1021/bi00168a014; ZAMBRANO IC, 1989, J BIOL CHEM, V264, P20974; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	74	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26349	26360		10.1074/jbc.273.41.26349	http://dx.doi.org/10.1074/jbc.273.41.26349			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756865	hybrid			2022-12-25	WOS:000076373300019
J	Burchmore, RJS; Landfear, SM				Burchmore, RJS; Landfear, SM			Differential regulation of multiple glucose transporter genes in Leishmania mexicana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; MOLECULAR CHARACTERIZATION; AXENIC AMASTIGOTES; MESSENGER-RNAS; EXPRESSION; PROTEIN; ENRIETTII; DONOVANI; PROMASTIGOTES; CULTIVATION	We have studied the structure and expression of glucose transporter genes in the parasitic protozoan Leishmania mexicana. Three distinct glucose transporter isoforms, LmGT1, LmGT2, and LmGT3, are encoded by single copy genes that are clustered together at a single locus. Quantitation of Northern blots reveals that LmGT2 mRNA is present at similar to 15-fold higher level in promastigotes, the insect stage of the parasite life cycle, compared with amastigotes, the intracellular stage of the life cycle that lives within the mammalian host. In contrast, LmGT1 and LmGT3 mRNAs are expressed at similar levels in both life cycle stages. Transcription of the LmGT genes in promastigotes and axenically cultured amastigotes occurs at similar levels, as measured by nuclear run-on transcription. Consequently, the similar to 15-fold up-regulation of LmGT2 mRNA levels in promastigotes compared with amastigotes must be controlled at the post-transcriptional level. Measurement of LmGT2 RNA decay in promastigotes and axenic amastigotes treated with actinomycin D suggests that differential mRNA stability may play a role in regulating glucose transporter mRNA levels in the two life cycle stages.	Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA	Oregon Health & Science University	Landfear, SM (corresponding author), Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Burchmore, Richard/A-1896-2011	Landfear, Scott/0000-0002-1643-6664; Burchmore, Richard/0000-0003-1663-9004	NIAID NIH HHS [AI01162, AI25920] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025920] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; BLUM JJ, 1993, PARASITOL TODAY, V9, P118, DOI 10.1016/0169-4758(93)90168-F; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burchmore RJS, 1995, MOL BIOCHEM PARASIT, V74, P77, DOI 10.1016/0166-6851(95)02485-9; CAIRNS BR, 1989, P NATL ACAD SCI USA, V86, P7682, DOI 10.1073/pnas.86.20.7682; CHANG KP, 1980, SCIENCE, V209, P1240, DOI 10.1126/science.7403880; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; COMEAU AM, 1986, MOL BIOCHEM PARASIT, V21, P161, DOI 10.1016/0166-6851(86)90019-8; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; DOYLE PS, 1991, EXP PARASITOL, V73, P326, DOI 10.1016/0014-4894(91)90104-5; EHLERS B, 1987, MOL CELL BIOL, V7, P1242, DOI 10.1128/MCB.7.3.1242; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FONG D, 1984, P NATL ACAD SCI-BIOL, V81, P5782, DOI 10.1073/pnas.81.18.5782; GIBSON WC, 1988, J MOL BIOL, V201, P315, DOI 10.1016/0022-2836(88)90140-4; HART DT, 1982, EXP PARASITOL, V54, P397, DOI 10.1016/0014-4894(82)90049-2; HEHL A, 1994, P NATL ACAD SCI USA, V91, P370, DOI 10.1073/pnas.91.1.370; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; JEFFERIES D, 1991, MOL CELL BIOL, V11, P338, DOI 10.1128/MCB.11.1.338; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LAINSON R, 1978, NATURE, V273, P595, DOI 10.1038/273595a0; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; LANGFORD CK, 1994, J BIOL CHEM, V269, P17939; LANGFORD CK, 1992, MOL BIOCHEM PARASIT, V55, P51, DOI 10.1016/0166-6851(92)90126-5; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Moore LL, 1996, MOL BIOCHEM PARASIT, V80, P125, DOI 10.1016/0166-6851(96)02688-6; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; PAN AA, 1984, EXP PARASITOL, V58, P72, DOI 10.1016/0014-4894(84)90022-5; PAN AA, 1993, J EUKARYOT MICROBIOL, V40, P213, DOI 10.1111/j.1550-7408.1993.tb04906.x; PAYS E, 1990, EMBO J, V9, P3145, DOI 10.1002/j.1460-2075.1990.tb07512.x; PAYS E, 1989, MOL CELL BIOL, V9, P4018, DOI 10.1128/MCB.9.9.4018; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIPER RC, 1995, J CELL BIOL, V128, P499, DOI 10.1083/jcb.128.4.499; RAINEY PM, 1991, MOL BIOCHEM PARASIT, V49, P111, DOI 10.1016/0166-6851(91)90134-R; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAITO RM, 1994, EMBO J, V13, P5460, DOI 10.1002/j.1460-2075.1994.tb06881.x; Sambrook J., 2002, MOL CLONING LAB MANU; Snapp EL, 1997, J CELL BIOL, V139, P1775, DOI 10.1083/jcb.139.7.1775; STACK SP, 1990, MOL CELL BIOL, V10, P6785, DOI 10.1128/MCB.10.12.6785; TESH RB, 1984, AM J TROP MED HYG, V33, P41, DOI 10.4269/ajtmh.1984.33.41; TOBIN JF, 1991, P NATL ACAD SCI USA, V88, P864, DOI 10.1073/pnas.88.3.864; TRAUBCSEKO YM, 1993, MOL BIOCHEM PARASIT, V57, P101, DOI 10.1016/0166-6851(93)90248-V; WILSON K, 1991, NUCLEIC ACIDS RES, V19, P5787, DOI 10.1093/nar/19.20.5787; WILSON ME, 1993, J BIOL CHEM, V268, P15731; Wyler D. J., 1990, MODERN PARASITE BIOL	49	74	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29118	29126		10.1074/jbc.273.44.29118	http://dx.doi.org/10.1074/jbc.273.44.29118			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786920	hybrid			2022-12-25	WOS:000076691800081
J	Hoffman, MP; Nomizu, M; Rogue, E; Lee, S; Jung, DW; Yamada, Y; Kleinman, HK				Hoffman, MP; Nomizu, M; Rogue, E; Lee, S; Jung, DW; Yamada, Y; Kleinman, HK			Laminin-1 and laminin-2 G-domain synthetic peptides bind syndecan-1 and are involved in acinar formation of a human submandibular gland cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MOUSE SALIVARY EPITHELIUM; TERMINAL GLOBULAR DOMAIN; MEMBRANE-LIKE SUBSTRATUM; BRANCHING MORPHOGENESIS; NEURITE OUTGROWTH; ALPHA-CHAINS; SHORT ARM; IDENTIFICATION; ADHESION	The culture of human submandibular gland (HSG) cells on laminin-l induces acinar differentiation. me identified a site on laminin involved in acinar differentiation using synthetic peptides derived from the C-terminal G-domain of the laminin alpha 1 and alpha 2 chains. The alpha 1 chain peptide AG73 (RKRLQVQLSIRT) decreases the size of acini formed on laminin-1, Cells cultured with either AG73 or the homologous alpha 2 chain peptide MG73 (KNRLTIELEVRT) form structures that appear acinar-like, but the cell nuclei are not polarized to the basal surface and no lumen formation occurs, indicating that additional sites on laminin are required for complete differentiation. The G-domain of laminin-l contains both integrin and heparin binding sites, and anti-beta(1)-integrin antibodies disrupt acinar formation. Cell adhesion to the peptides and to E3, an elastase digest fragment of laminin-1 containing AG73, is specific, since other laminin peptides or EDTA do not compete the binding. Heparin and heparan sulfate decrease cell adhesion to AG73 and MG73 but anti-beta(1)-integrin antibodies have no effect. Treating the cell surface with heparitinase inhibits adhesion to both AG73 and MG73, We isolated cell surface ligands using both peptide affinity chromatography and laminin-l affinity chromatography, Treating the material bound to the affinity columns with heparitinase and chondroitinase enriches for a core protein identified as syndecan-1 by Western blot analysis, thus identifying a syndecan-1 binding site in the globular domain of laminin-2 and laminin-2, In summary, multiple interactions between laminin and HSG cells contribute to acinar differentiation, involving both beta(1)-integrins and syndecan-1.	NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Kleinman, HK (corresponding author), NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, 30-433,30 Convent Dr,MSC 4370, Bethesda, MD 20892 USA.	kleinman@yoda.nidr.nih.gov						BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROWN ML, 1995, BAS CLIN ON, V6, P69; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Carey DJ, 1996, J BIOL CHEM, V271, P15253, DOI 10.1074/jbc.271.25.15253; Colognato H, 1997, J BIOL CHEM, V272, P29330, DOI 10.1074/jbc.272.46.29330; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; Ekblom P, 1996, CURR OPIN CELL BIOL, V8, P700, DOI 10.1016/S0955-0674(96)80112-8; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; Hoffman MP, 1996, J CELL SCI, V109, P2013; Iida J, 1998, J BIOL CHEM, V273, P5955, DOI 10.1074/jbc.273.10.5955; KADOYA Y, 1995, J CELL BIOL, V129, P521, DOI 10.1083/jcb.129.2.521; Kadoya Y, 1998, DEV DYNAM, V212, P394; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Malinda KM, 1996, INT J BIOCHEM CELL B, V28, P957, DOI 10.1016/1357-2725(96)00042-8; MATTER ML, 1994, J CELL BIOL, V124, P1083, DOI 10.1083/jcb.124.6.1083; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; NOGAWA H, 1991, DEVELOPMENT, V112, P855; NOMIZU M, 1995, FEBS LETT, V365, P227, DOI 10.1016/0014-5793(95)00475-O; Nomizu M, 1996, FEBS LETT, V396, P37, DOI 10.1016/0014-5793(96)01060-5; Nomizu M, 1997, J BIOL CHEM, V272, P32198, DOI 10.1074/jbc.272.51.32198; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Richard BL, 1996, EXP CELL RES, V228, P98, DOI 10.1006/excr.1996.0304; ROYCE LS, 1993, DIFFERENTIATION, V52, P247, DOI 10.1111/j.1432-0436.1993.tb00637.x; SALMIVIRTA M, 1994, EXP CELL RES, V215, P180, DOI 10.1006/excr.1994.1330; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SHIRASUNA K, 1981, CANCER, V48, P745, DOI 10.1002/1097-0142(19810801)48:3<745::AID-CNCR2820480314>3.0.CO;2-7; Song SY, 1997, INT J CANCER, V71, P436, DOI 10.1002/(SICI)1097-0215(19970502)71:3<436::AID-IJC22>3.0.CO;2-C; STANLEY MJ, 1995, J BIOL CHEM, V270, P5077, DOI 10.1074/jbc.270.10.5077; TAKAHASHI Y, 1991, DEVELOPMENT, V111, P327; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q	36	171	171	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28633	28641		10.1074/jbc.273.44.28633	http://dx.doi.org/10.1074/jbc.273.44.28633			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786856	hybrid			2022-12-25	WOS:000076691800017
J	Leclerc, D; Burri, L; Kajava, AV; Mougeot, JL; Hess, D; Lustig, A; Kleemann, G; Hohn, T				Leclerc, D; Burri, L; Kajava, AV; Mougeot, JL; Hess, D; Lustig, A; Kleemann, G; Hohn, T			The open reading frame III product of cauliflower mosaic virus forms a tetramer through a N-terminal coiled-coil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MATRIX PROTEIN; AMINO-ACID; DNA; STABILITY; IDENTIFICATION; MUTAGENESIS; RESIDUES; SWITCH; DOMAIN	The open reading frame III product of cauliflower mosaic virus is a protein of 15 kDa (p15) that is essential for the virus life cycle. It was shown that the 34 N-terminal amino acids are sufficient to support protein-protein interaction with the full-length p15 in the yeast two-hybrid system. A corresponding peptide was synthesized and a recombinant p15 was expressed in Escherichia coli and purified. Circular dichroism spectroscopy showed that the peptide and the full-length protein can assume an iv-helical conformation Analytical centrifugation allowed to determine that p15 assembles as a rod-shaped tetramer. Oxidative cross-linking of N-terminal cysteines of the peptide generated specific covalent oligomers, indicating that the N terminus of p15 is a coiled-coil that assembles as a parallel tetramer. Mutation of Lys(22) into Asp destabilized the tetramer and put forward the presence of a salt bridge between Lys(22) and Asp(24) in a model building of the stalk. These results suggest a model in which the stalk segment of p15 is located at its N terminus, followed by a hinge that provides the space for presenting the C terminus for interactions with nucleic acids and/or proteins.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland; Swiss Inst Expt Canc Res, CH-10066 Epalinges, Switzerland; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	Friedrich Miescher Institute for Biomedical Research; Ludwig Institute for Cancer Research; Swiss Institute Experimental Cancer Research; University of Basel; MRC Laboratory Molecular Biology; University of Washington; University of Washington Seattle	Hohn, T (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	hohn@fmi.ch	Leclerc, Denis/AAG-6112-2019; Leclerc, Denis/P-1604-2019; Kajava, Andrey V/E-1107-2014	Kajava, Andrey V/0000-0002-2342-6886				Bartel P. L., 1993, CELLULAR INTERACTION, P153; Beck K, 1997, EMBO J, V16, P3767, DOI 10.1093/emboj/16.13.3767; BECKMAN RA, 1985, BIOCHEMISTRY-US, V24, P5810, DOI 10.1021/bi00342a019; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; CHENG RH, 1992, VIROLOGY, V186, P655, DOI 10.1016/0042-6822(92)90032-K; Chew MWK, 1995, J STRUCT BIOL, V115, P233, DOI 10.1006/jsbi.1995.1048; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; DAUTEL S, 1994, VIROLOGY, V202, P1043, DOI 10.1006/viro.1994.1435; DIXON LK, 1983, GENE, V25, P189, DOI 10.1016/S0378-1119(83)80001-8; Faix J, 1996, CELL, V86, P631, DOI 10.1016/S0092-8674(00)80136-1; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HUNTER I, 1992, J BIOL CHEM, V267, P6006; Jacquot E, 1997, VIROLOGY, V239, P352, DOI 10.1006/viro.1997.8859; Jacquot E, 1998, VIROLOGY, V242, P395, DOI 10.1006/viro.1997.8995; Kajava AV, 1996, PROTEINS, V24, P218, DOI 10.1002/(SICI)1097-0134(199602)24:2<218::AID-PROT8>3.3.CO;2-I; Kammerer RA, 1997, MATRIX BIOL, V15, P555, DOI 10.1016/S0945-053X(97)90031-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LEBEURIER G, 1980, GENE, V12, P139, DOI 10.1016/0378-1119(80)90024-4; LEBEURIER G, 1982, P NATL ACAD SCI-BIOL, V79, P2932, DOI 10.1073/pnas.79.9.2932; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; MCLACHLAN AD, 1975, J MOL BIOL, V98, P298; MONERA OD, 1993, J BIOL CHEM, V268, P19218; MOUGEOT JL, 1993, P NATL ACAD SCI USA, V90, P1470, DOI 10.1073/pnas.90.4.1470; NORTH ACT, 1994, PROTEINS, V20, P174, DOI 10.1002/prot.340200207; ROTHNIE HM, 1994, ADV VIRUS RES, V44, P1, DOI 10.1016/S0065-3527(08)60327-9; ROUSSEL A, 1993, TURBO FRODO VERSION; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; Terskikh AV, 1997, LETT PEPT SCI, V4, P297, DOI 10.1023/A:1008840603393; Terskikh AV, 1997, P NATL ACAD SCI USA, V94, P1663, DOI 10.1073/pnas.94.5.1663; VOGEL AM, 1994, MOL MICROBIOL, V12, P811, DOI 10.1111/j.1365-2958.1994.tb01067.x; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	37	40	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29015	29021		10.1074/jbc.273.44.29015	http://dx.doi.org/10.1074/jbc.273.44.29015			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786907	hybrid			2022-12-25	WOS:000076691800068
J	Schneider, B; Xu, YW; Janin, J; Veron, MM; Deville-Bonne, D				Schneider, B; Xu, YW; Janin, J; Veron, MM; Deville-Bonne, D			3 '-phosphorylated nucleotides are tight binding inhibitors of nucleoside diphosphate kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; CRYSTAL-STRUCTURE; TUMOR-METASTASIS; DROSOPHILA DEVELOPMENT; 2-ANGSTROM RESOLUTION; TRANSCRIPTION FACTOR; NM23 GENE; PROTEIN; CELLS; PHOSPHORYLATION	Nucleoside diphosphate (NDP) kinase catalyzes the phosphorylation of ribo- and deoxyribonucleosides diphosphates into triphosphates. NDP kinase is also involved in malignant tumors and was shown to activate in vitro transcription of the c-myc oncogene by binding to its NHE sequence, The structure of the complex of NDP kinase with bound ADP shows that the nucleotide adopts a different conformation from that observed in other phosphokinases with an internal H bond between the 3'-OH and the beta-O made free by the phosphate transfer. We use intrinsic protein fluorescence to investigate the inhibitory and binding potential of nucleotide analogues phosphorylated in 3'-OH position of the ribose to both wild type and F64W mutant NDP kinase from Dictyostelium discoideum. Due to their 3'-phosphate, 5'-phosphoadenosine 3'-phosphate (PAP) and adenosine 3'-phosphate 5'-phosphosulfate (PAPS) can be regarded as structural analogues of enzyme-bound ADP, The K-D of PAPS (10 mu M) is three times lower than the K-D of ADP. PAPS also acts as a competitive inhibitor toward natural substrates during catalysis, with a K-I in agreement with binding data, The crystal structure of the binary complex between Dictyostelium NDP kinase and PAPS was solved at 2.8-Angstrom resolution. It shows a new mode of nucleotide binding at the active site with the 3'-phosphate of PAPS located near the catalytic histidine, at the same position as the gamma-phosphate in the transition state. The sulfate group is directed toward the protein surface. PAPS will be useful for the design of high affinity drugs targeted to NDP kinases.	Inst Pasteur, Unite Regulat Enzymat Act Celulaires, CNRS, URA 1773, F-75724 Paris 15, France; CNRS, Lab Enzymol & Biochim Struct, UPR 9063, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Deville-Bonne, D (corresponding author), Inst Pasteur, Unite Regulat Enzymat Act Celulaires, CNRS, URA 1773, 25 Rue Dr Roux, F-75724 Paris 15, France.	ddeville@pasteur.fr	Janin, Joel/I-2958-2012; Schneider, Benoit/AAF-3850-2019	Schneider, Benoit/0000-0002-1377-2670				Anciaux K, 1997, FEBS LETT, V400, P75, DOI 10.1016/S0014-5793(96)01358-0; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; Bourdais J, 1996, J BIOL CHEM, V271, P7887, DOI 10.1074/jbc.271.14.7887; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; Deville-Bonne D, 1998, ADV EXP MED BIOL, V431, P569; DevilleBonne D, 1996, BIOCHEMISTRY-US, V35, P14643, DOI 10.1021/bi960945m; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; GEWIRTH D, 1996, XDISPLAYF SCALEPACK; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; Klaassen CD, 1997, FASEB J, V11, P404, DOI 10.1096/fasebj.11.6.9194521; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LASCU I, 1992, J BIOL CHEM, V267, P12775; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; Leonidas DD, 1997, BIOCHEMISTRY-US, V36, P5578, DOI 10.1021/bi9700330; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARTIN MW, 1995, BRIT J PHARMACOL, V115, P1080, DOI 10.1111/j.1476-5381.1995.tb15921.x; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Schneider B, 1998, J BIOL CHEM, V273, P11491, DOI 10.1074/jbc.273.19.11491; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1993, BREAST CANCER RES TR, V25, P175, DOI 10.1007/BF00662142; STRELKOV SV, 1995, J MOL BIOL, V249, P665, DOI 10.1006/jmbi.1995.0327; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; Timmons L, 1997, ADV GENET, V35, P207, DOI 10.1016/S0065-2660(08)60451-4; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; Yokoyama A, 1996, BLOOD, V88, P3555, DOI 10.1182/blood.V88.9.3555.bloodjournal8893555; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	47	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28773	28778		10.1074/jbc.273.44.28773	http://dx.doi.org/10.1074/jbc.273.44.28773			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786875	hybrid			2022-12-25	WOS:000076691800036
J	Walter, BN; Huang, ZD; Jakobi, R; Tuazon, PT; Alnemri, ES; Litwack, G; Traugh, JA				Walter, BN; Huang, ZD; Jakobi, R; Tuazon, PT; Alnemri, ES; Litwack, G; Traugh, JA			Cleavage and activation of pal-activated protein kinase gamma-PAK by CPP32 (Caspase 3) - Effects of autophosphorylation on activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-RNA; PHOSPHORYLATION; IDENTIFICATION; APOPTOSIS; PROTEOLYSIS; CLONING; BINDING; FAMILY; CELLS; PP12	p21-activated protein kinase gamma-PAK (Pak2, PAK I) is cleaved by CPP32 (caspase 3) during apoptosis and plays a key role in regulation of cell death, In vitro, CPP32 cleaves recombinant gamma-PAK into two peptides; 1-212 contains the majority of the regulatory domain whereas 213-524 contains 34 amino acids of the regulatory domain plus the entire catalytic domain. Following cleavage, both peptides become autophosphorylated with [gamma-P-32]ATP. Peptide 1-212 migrates at 27,000 daltons (p27) upon SDS-polyacrylamide gel electrophoresis and at 32,000 daltons following autophosphorylation on serine (p27P); the catalytic subunit migrates at 34,000 daltons (p34) before and after autophosphorylation on threonine, Following caspase cleavage, a significant lag (similar to 5 min) is observed before autophosphorylation and activity are detected. When gamma-PAK is autophosphorylated with ATP(Mg) alone and then cleaved, only p27 contains phosphate, and the enzyme is inactive with exogenous substrate. After autophosphorylation of gamma-PAK in the presence of Cdc42(GTP gamma S) or histone 4, both cleavage products contain phosphate and gamma-PAK is catalytically active. Mutation of the conserved Thr-402 to alanine greatly reduces autophosphorylation and protein kinase activity following cleavage. Thus activation of gamma-PAK via cleavage by CPP32 is a two-step mechanism wherein autophosphorylation of the regulatory domain is a priming step, and activation coincides with autophosphorylation of the catalytic domain.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	University of California System; University of California Riverside; Jefferson University; Jefferson University	Traugh, JA (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	jolinda.traugh@ucr.edu			NIAID NIH HHS [AI/HL 40976] Funding Source: Medline; NIA NIH HHS [AG 13487] Funding Source: Medline; NIGMS NIH HHS [GM26738] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040976] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FU XD, 1985, J BIOL CHEM, V260, P9941; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; Jakobi R, 1998, FASEB J, V12, pA1369; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; LEIS J, 1984, J BIOL CHEM, V259, P7726; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PENDERGAST AM, 1985, J BIOL CHEM, V260, P1769; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Ramos E, 1997, RECEPT SIGNAL TRANS, V7, P99; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; TAHARA SM, 1981, J BIOL CHEM, V256, P1558; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; TUAZON PT, 1984, J BIOL CHEM, V259, P541; Tuazon PT, 1998, FASEB J, V12, pA1408; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845	25	109	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28733	28739		10.1074/jbc.273.44.28733	http://dx.doi.org/10.1074/jbc.273.44.28733			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786869	hybrid			2022-12-25	WOS:000076691800030
J	Bracher, A; Eisenreich, W; Schramek, N; Ritz, H; Gotze, E; Herrmann, A; Gutlich, M; Bacher, A				Bracher, A; Eisenreich, W; Schramek, N; Ritz, H; Gotze, E; Herrmann, A; Gutlich, M; Bacher, A			Biosynthesis of pteridines - NMR studies on the reaction mechanisms of GTP cyclohydrolase I, pyruvoyltetrahydropterin synthase, and sepiapterin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE; DIHYDRONEOPTERIN TRIPHOSPHATE; TETRAHYDROBIOPTERIN; COFACTOR; ENZYME; INTERMEDIATE; PTERINS; SITE	GTP cyclohydrolase I catalyzes a ring expansion affording dihydroneopterin triphosphate from GTP. [1',2',3',4',5'-C-13(5),2'-H-2(1)]GTP was prepared enzymatically from [U-C-13(6)]glucose for use as enzyme substrate. Multinuclear NMR experiments showed that the reaction catalyzed by GTP cyclohydrolase I involves the release of a proton from C-2' of GTP that is exchanged with the bulk solvent. Subsequently, a proton is reintroduced stereospecifically from the bulk solvent. This is in line with an Amadori rearrangement mechanism. The proton introduced from solvent occupies the pro-7R position in the enzyme product. The data also confirm that the reaction catalyzed by pyruvoyltetrahydropterin synthase results in the incorporation of solvent protons into positions C-6 and C-3' of the enzyme product. On the other hand, the reaction catalyzed by sepiapterin reductase does not involve any detectable incorporation of solvent protons into tetrahydrobiopterin.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Bacher, A (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	Bacher@oc3gra.org.chemie.tu-muenchen.de	Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				ARMAREGO WLF, 1984, AUST J CHEM, V37, P355, DOI 10.1071/CH9840355; Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; BLAU N, 1983, ANAL BIOCHEM, V128, P446, DOI 10.1016/0003-2697(83)90399-8; Brown G. M., 1987, ESCHERICHIA COLI SAL, V1, P521; BURG AW, 1968, J BIOL CHEM, V243, P2349; BURGISSER DM, 1995, J MOL BIOL, V253, P358, DOI 10.1006/jmbi.1995.0558; DAWSON RCM, 1986, DATA BIOCH RES, P109; ESTELBERGER W, 1995, BBA-PROTEIN STRUCT M, V1249, P23, DOI 10.1016/0167-4838(95)00064-2; ESTELBERGER W, 1995, FEBS LETT, V357, P37, DOI 10.1016/0014-5793(94)01302-H; GHISLA S, 1990, EUR J BIOCHEM, V187, P651, DOI 10.1111/j.1432-1033.1990.tb15349.x; GHISLA S, 1987, UNCONJUGATED PTERINS, P67; HAASNOOT CAG, 1980, TETRAHEDRON, V36, P2783, DOI 10.1016/0040-4020(80)80155-4; KATOH S, 1984, BIOCHEM BIOPH RES CO, V118, P859, DOI 10.1016/0006-291X(84)91474-8; KATOH S, 1988, J BIOCHEM-TOKYO, V103, P286, DOI 10.1093/oxfordjournals.jbchem.a122262; KATOH S, 1987, J BIOCHEM-TOKYO, V101, P275, DOI 10.1093/oxfordjournals.jbchem.a121901; KELTJENS J T, 1988, Biofactors, V1, P95; KERLER F, 1990, J CELL PHYSIOL, V142, P268, DOI 10.1002/jcp.1041420208; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; KWON NS, 1989, J BIOL CHEM, V264, P20496; LOPEZ MD, 1977, CHEM BIOL PTERIDINES, P53; MILSTIEN S, 1989, BIOCHEM BIOPH RES CO, V165, P845, DOI 10.1016/S0006-291X(89)80043-9; Nar H, 1995, P NATL ACAD SCI USA, V92, P12120, DOI 10.1073/pnas.92.26.12120; NAR H, 1994, EMBO J, V13, P1255, DOI 10.1002/j.1460-2075.1994.tb06377.x; NAR H, 1995, STRUCTURE, V3, P459, DOI 10.1016/S0969-2126(01)00179-4; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; PALM D, 1963, Z NATURFORSCH PT B, VB 18, P419; PALM D, 1965, Z NATURFORSCH PT B, VB 20, P32; PARKIN DW, 1987, BIOCHEMISTRY-US, V26, P913, DOI 10.1021/bi00377a036; PFLEIDERER W, 1985, FOLATES PTERINS, V2, P43; Richter G, 1997, METHOD ENZYMOL, V280, P374; SHIOTA T, 1969, BIOCHIM BIOPHYS ACTA, V192, P205, DOI 10.1016/0304-4165(69)90357-2; SHIOTA T, 1967, J BIOL CHEM, V242, P1961; SIMON H., 1964, P327; Simon H., 1970, FORTSCHR CHEM FORSCH, V14, P430; SMITH GK, 1986, J BIOL CHEM, V261, P2725; SWITCHENKO AC, 1985, J BIOL CHEM, V260, P2945; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; THONY B, 1992, BIOCHEM BIOPH RES CO, V189, P1437, DOI 10.1016/0006-291X(92)90235-D; VAN QL, 1988, BIOCHEM BIOPH RES CO, V151, P512, DOI 10.1016/0006-291X(88)90623-7; WEYGAND F, 1961, ANGEW CHEM INT EDIT, V73, P402, DOI 10.1002/ange.19610731111; WOLF WA, 1969, BIOCHIM BIOPHYS ACTA, V192, P468, DOI 10.1016/0304-4165(69)90396-1	41	55	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28132	28141		10.1074/jbc.273.43.28132	http://dx.doi.org/10.1074/jbc.273.43.28132			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774432	hybrid			2022-12-25	WOS:000076549800052
J	Buxbaum, JD; Liu, KN; Luo, YX; Slack, JL; Stocking, KL; Peschon, JJ; Johnson, RS; Castner, BJ; Cerretti, DP; Black, RA				Buxbaum, JD; Liu, KN; Luo, YX; Slack, JL; Stocking, KL; Peschon, JJ; Johnson, RS; Castner, BJ; Cerretti, DP; Black, RA			Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN; KINASE-C; HUMAN-BRAIN; TNF-ALPHA; PHOSPHORYLATION; CELL; DISINTEGRIN; DERIVATIVES; ACTIVATION; ECTODOMAIN	The amyloid protein, A beta, which accumulates in the brains of Alzheimer patients, is derived by proteolysis of the amyloid protein precursor (APP). APP can undergo endoproteolytic processing at three sites, one at the amino terminus of the A beta domain (beta-cleavage), one within the A beta domain (alpha-cleavage), and one at the carboxyl terminus of the A beta domain (gamma-cleavage). The enzymes responsible for these activities have not been unambiguously identified. By the use of gene disruption (knockout), we now demonstrate that TACE (tumor necrosis factor alpha converting enzyme), a member of the ADAM family (a disintegrin and metalloprotease-family) of proteases, plays a central role in regulated alpha-cleavage of APP. Our data suggest that TACE may be the alpha-secretase responsible for the majority of regulated alpha-cleavage in cultured cells. Furthermore, we show that inhibiting this enzyme affects both APP secretion and A beta formation in cultured cells.	CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Neurobiol, New York, NY 10029 USA; Immunex Res & Dev Corp, Seattle, WA 98101 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Buxbaum, JD (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.		Buxbaum, Joseph D/G-6001-2010	Buxbaum, Joseph/0000-0001-8898-8313	NIA NIH HHS [AG14996] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014996, R55AG014996] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1996, BIOCHEM BIOPH RES CO, V225, P400, DOI 10.1006/bbrc.1996.1186; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BUXBAUM JD, 1993, BIOCHEM BIOPH RES CO, V197, P639, DOI 10.1006/bbrc.1993.2527; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Caputi A, 1997, J NEUROCHEM, V68, P2523; Desdouits F, 1996, J BIOL CHEM, V271, P24670, DOI 10.1074/jbc.271.40.24670; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; HUNG AY, 1993, J BIOL CHEM, V268, P22959; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Mills J, 1997, J NEUROSCI, V17, P9415; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Muller DM, 1997, LIFE SCI, V60, P985, DOI 10.1016/S0024-3205(97)00038-6; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; NITSCH RM, 1993, ANN NY ACAD SCI, V695, P122, DOI 10.1111/j.1749-6632.1993.tb23039.x; NITSCH RM, 1995, ARZNEIMITTEL-FORSCH, V45-1, P435; NITSCH RM, 1994, BIOCHEM PHARMACOL, V47, P1275, DOI 10.1016/0006-2952(94)90325-5; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SISODIA S S, 1990, New Biologist, V2, P66; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; VANNOSTRAND WE, 1991, P NATL ACAD SCI USA, V88, P10302, DOI 10.1073/pnas.88.22.10302; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Xu HX, 1996, P NATL ACAD SCI USA, V93, P4081, DOI 10.1073/pnas.93.9.4081; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	41	821	868	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27765	27767		10.1074/jbc.273.43.27765	http://dx.doi.org/10.1074/jbc.273.43.27765			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774383	hybrid			2022-12-25	WOS:000076549800003
J	Ding, HF; McGill, G; Rowan, S; Schmaltz, C; Shimamura, A; Fisher, DE				Ding, HF; McGill, G; Rowan, S; Schmaltz, C; Shimamura, A; Fisher, DE			Oncogene-dependent regulation of caspase activation by p53 protein in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-DEPENDENT APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; CYTOCHROME-C; MEDIATED APOPTOSIS; FUNCTIONAL DOMAINS; WILD-TYPE; IN-VIVO; DEATH; TRANSFORMATION; INDUCTION	The mechanism by which p53 modulates apoptosis in cancer therapy is incompletely understood. Here, cell-free extracts from irradiated tumor cells are described in which endogenous p53 protein is shown to participate in caspase activation. This apoptotic activity is also oncogene dependent, but independent of transcription in general or the presence of Bax or cytochrome c. A general use for this system is as a cell-free screen for apoptosis modulators. In this way, profound effects of protein kinase A were identified and corroborated in vivo by the protection conferred by cAMP against diverse triggers of p53-dependent apoptosis, This system provides direct biochemical evidence that p53 protein can transduce apoptotic signals through protein-protein interactions and reveals a modulator kinase pathway capable of regulating p53-dependent caspase activation.	Dana Farber Canc Inst, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard Medical School	Fisher, DE (corresponding author), Dana Farber Canc Inst, Dept Pediat, Boston, MA 02115 USA.	david_fisher@dfci.harvard.edu	Rowan, Sheldon/AAA-3271-2019	Rowan, Sheldon/0000-0002-1123-6743; Ding, Han-Fei/0000-0001-5702-3439				Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; ARMSTRONG R, 1995, MOL CELL BIOL, V15, P1826; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cao YA, 1997, CANCER RES, V57, P5584; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hengartner MO, 1998, NATURE, V391, P441, DOI 10.1038/35036; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RULEY HE, 1996, IMPORTANT ADV ONCOL, P87; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	44	81	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28378	28383		10.1074/jbc.273.43.28378	http://dx.doi.org/10.1074/jbc.273.43.28378			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774464	hybrid			2022-12-25	WOS:000076549800084
J	Hamilton, M; Wolfman, A				Hamilton, M; Wolfman, A			Oncogenic Ha-Ras-dependent mitogen-activated protein kinase activity requires signaling through the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; ACTIN STRESS FIBERS; TYROSINE KINASE; TRANSDUCTION PATHWAY; REGULATED KINASE; PLASMA-MEMBRANE; TGF-ALPHA; TRANSFORMATION; RAF-1; ASSOCIATION	C3H10T1/2 fibroblasts transformed by the minimal expression of oncogenic Ha-Ras (V12H10 cells) or N-Ras (K61N10 cells) have constitutive mitogen-activated protein kinase (IMAPK) activity and proliferate in serum-free medium. The constitutive MAPK activity and serum-independent proliferation of V12H10 cells are sensitive to the growth factor antagonist, suramin (Hamilton, M., and Wolfman, A. (1998) Oncogene 16, 1417-1428), suggesting that Ha-Ras-mediated regulation of the MAPK cascade is dependent upon the action of an autocrine factor. Serum-free medium conditioned by V12H10 cells contains an activity that stimulates MAPK activity in quiescent fibroblasts, This MAPK stimulatory activity could be specifically blocked by the epidermal growth factor receptor (EGFR) inhibitors, PD153035 and PD158780. These inhibitors also blocked the serum-independent proliferation of V12H10 cells. Immunodepletion of conditioned medium with antibodies to transforming growth factor alpha and EGF significantly inhibited its ability to stimulate MAPK activity. Stable transfection of EGFR-negative NR6 and EGFR-positive Swiss3T3 cells with oncogenic (G12V)Ha-Ras demonstrated that only the Ha-Ras-transfected Swiss 3T3 cells possessed constitutive MAPK activity, and this activity was sensitive to PD153035. These data suggest that autocrine activation of the EGFR is required for the regulation of the MAPK cascade in cells minimally expressing oncogenic Ha-Ras.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hamilton, M (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	hamiltm@cesmtp.ccf.org			NIGMS NIH HHS [GM49652] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM049652, R01GM049652] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berkowitz EA, 1996, ONCOGENE, V12, P1991; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; CASTELLI C, 1994, CANCER RES, V54, P4785; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; Dahring TK, 1997, J PHARMACOL EXP THER, V281, P1446; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FILMUS J, 1993, ONCOGENE, V8, P1017; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HOWE LR, 1993, J BIOL CHEM, V268, P20717; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KEHINDE EO, 1995, CANCER SURV, V23, P217; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PIRONIN M, 1992, INT J CANCER, V51, P980, DOI 10.1002/ijc.2910510624; PROPER JA, 1982, J CELL PHYSIOL, V110, P169, DOI 10.1002/jcp.1041100210; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; RAK J, 1995, CANCER RES, V55, P4575; RAPP UR, 1991, ONCOGENE, V6, P495; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	41	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28155	28162		10.1074/jbc.273.43.28155	http://dx.doi.org/10.1074/jbc.273.43.28155			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774435	hybrid			2022-12-25	WOS:000076549800055
J	Hess, MT; Naegeli, H; Capobianco, M				Hess, MT; Naegeli, H; Capobianco, M			Stereoselectivity of human nucleotide excision repair promoted by defective hybridization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-COUPLED REPAIR; DNA-REPAIR; PYRIMIDINE DIMERS; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; ACTIVE GENE; DHFR GENE; UV DAMAGE; ADDUCTS; NUCLEASE	To assess helical parameters that dictate fast or slow removal of carcinogen-DNA adducts, we probed human nucleotide excision repair (NER) activity with DNA containing L-deoxyriboses. Unlike natural lesions such as pyrimidine dimers or base adducts, L-deoxyribonucleosides (the mirror images of normal D-deoxyribonucleosides) involve neither the addition nor the loss of covalent bonds or functional groups and hence exclude modulation of repair efficiency by adduct chemistry and size. Previous studies showed that single L-deoxyribonucleosides distort DNA backbones but are accommodated in the double helix with intact hydrogen bonding between complementary strands. Here, we found that such single L-enantiomers are rejected as excision repair substrates in a NER-proficient cell extract. However, the same L-deoxyribose moiety stimulates NER activity upon incorporation into a nonhybridizing site of one or, more effectively, two base mismatches. In contrast to single L-deoxyriboses, multiple consecutive L-deoxyriboses interfere with normal hybridization; in this case, the intrinsic derangement of base pairing was sufficient to promote the excision of a cluster of three adjacent L-deoxyribonucleosides without any requirement for mismatches. Thus, using stereoselective substrates, we demonstrate the participation of a recognition subunit that guides human NER activity to sites of defective Watson-Crick strand pairing, This conformational sensor detects labile hydrogen bonds irrespective of the type of deoxyribonucleotide modification.	Univ Zurich Tierspital, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland; CNR, Ist Composti Carbonio Contenenti Eteroatom & Appl, I-40129 Bologna, Italy	University of Zurich; Consiglio Nazionale delle Ricerche (CNR)	Naegeli, H (corresponding author), Univ Zurich Tierspital, Inst Pharmacol & Toxicol, Winterthurerstr 260, CH-8057 Zurich, Switzerland.	naegelih@vetpharm.unizh.ch	Capobianco, Massimo L/A-7401-2010	Capobianco, Massimo L/0000-0002-4237-1198				BLOMMERS MJJ, 1994, BIOCHEMISTRY-US, V33, P7886, DOI 10.1021/bi00191a016; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; DAMHA MJ, 1994, BIOCHEMISTRY-US, V33, P7877, DOI 10.1021/bi00191a015; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FRITZ LK, 1995, BIOCHEMISTRY-US, V34, P13117, DOI 10.1021/bi00040a024; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GARBESI A, 1993, NUCLEIC ACIDS RES, V21, P4159, DOI 10.1093/nar/21.18.4159; Gunz D, 1996, J BIOL CHEM, V271, P25089, DOI 10.1074/jbc.271.41.25089; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HANSSON J, 1989, J BIOL CHEM, V264, P21788; Hess MT, 1996, NUCLEIC ACIDS RES, V24, P824, DOI 10.1093/nar/24.5.824; Hess MT, 1997, P NATL ACAD SCI USA, V94, P6664, DOI 10.1073/pnas.94.13.6664; Hess MT, 1996, CHEM BIOL, V3, P121, DOI 10.1016/S1074-5521(96)90288-4; Hess MT, 1997, MOL CELL BIOL, V17, P7069, DOI 10.1128/MCB.17.12.7069; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; LAN SY, 1985, BIOCHEMISTRY-US, V24, P7771, DOI 10.1021/bi00347a041; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; MU D, 1994, NUCLEIC ACIDS RES, V22, P4869, DOI 10.1093/nar/22.23.4869; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Naegeli H, 1997, MECHANISMS DNA DAMAG; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; SPADARI S, 1995, MOL PHARMACOL, V47, P1231; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; Tornaletti S, 1996, MOL CARCINOGEN, V17, P192, DOI 10.1002/(SICI)1098-2744(199612)17:4<192::AID-MC2>3.0.CO;2-G; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; URATA H, 1993, J AM CHEM SOC, V115, P9852, DOI 10.1021/ja00074a083; VENEMA J, 1992, J BIOL CHEM, V267, P8852; WEI D, 1995, P NATL ACAD SCI USA, V92, P2204, DOI 10.1073/pnas.92.6.2204; Wei D, 1996, MOL CELL BIOL, V16, P3714; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	41	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27867	27872		10.1074/jbc.273.43.27867	http://dx.doi.org/10.1074/jbc.273.43.27867			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774397	hybrid			2022-12-25	WOS:000076549800017
J	Kamei, T; Tanaka, K; Hihara, T; Umikawa, M; Imamura, H; Kikyo, M; Ozaki, K; Takai, Y				Kamei, T; Tanaka, K; Hihara, T; Umikawa, M; Imamura, H; Kikyo, M; Ozaki, K; Takai, Y			Interaction of Bnr1p with a novel Src homology 3 domain-containing Hof1p - Implication in cytokinesis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ACTIN CYTOSKELETON; EXCHANGE PROTEINS; CELL-DIVISION; YEAST; PROFILIN; BNI1P; GENE; MORPHOGENESIS; ENCODES	Proteins containing the formin homology (FH) domains FH1 and FH2 are involved in cytokinesis or establishment of cell polarity in a variety of organisms. We have shown that the FH proteins Bni1p and Bnr1p are potential targets of the Rho family small GTP-binding proteins and bind to an actin-binding protein, profilin, at their proline-rich FH1 domains to regulate reorganization of the actin cytoskeleton in the yeast Saccharomyces cerevisiae. We found here that a novel Src homology 3 (SH3) domain-containing protein, encoded by YMR032w, interacted with Bnr1p in a GTP-Rho4p-dependent manner through the FH1 domain of Bnrlp and the SH3 domain of Ymr032wp. Ymr032wp weakly bound to Bni1p. Ymr032wp was homologous to cdc15p, which is involved in cytokinesis in Schizosaccharomyces pombe, and we named this gene HOF1 (homolog of cdc 15). Both Bnrlp and Hof1p were localized at the bud neck, and both the bnr1 and hof1 mutations showed synthetic lethal interactions with the bni1 mutation. The hof1 mutant cells showed phenotypes similar to those of the septin mutants, indicating that HOF1 is involved in cytokinesis. These results indicate that Bnrlp directly interacts with Hof1p as well as with profilin to regulate cytoskeletal functions in S. cerevisiae.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Kuroda, Kumi O/A-3312-2013	Kuroda, Kumi O./0000-0001-7037-1753				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; BALASUBRAMANIAN MK, 1994, J CELL BIOL, V125, P1289, DOI 10.1083/jcb.125.6.1289; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chang F, 1997, J CELL BIOL, V137, P169, DOI 10.1083/jcb.137.1.169; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; Epp JA, 1997, CURR BIOL, V7, P921, DOI 10.1016/S0960-9822(06)00411-8; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; FANKHAUSER C, 1995, CELL, V82, P435, DOI 10.1016/0092-8674(95)90432-8; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Frazier JA, 1997, CURR BIOL, V7, pR414, DOI 10.1016/S0960-9822(06)00205-3; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUAN C, 1988, GENE, V67, P21; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDERS SL, 1994, CURR BIOL, V4, P907, DOI 10.1016/S0960-9822(00)00201-3; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Tanaka K, 1998, CURR OPIN CELL BIOL, V10, P112, DOI 10.1016/S0955-0674(98)80093-8; Umikawa M, 1998, ONCOGENE, V16, P2011, DOI 10.1038/sj.onc.1201724; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	41	131	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28341	28345		10.1074/jbc.273.43.28341	http://dx.doi.org/10.1074/jbc.273.43.28341			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774458	hybrid			2022-12-25	WOS:000076549800078
J	Pellegatta, F; Chierchia, SL; Zocchi, MR				Pellegatta, F; Chierchia, SL; Zocchi, MR			Functional association of platelet endothelial cell adhesion molecule-1 and phosphoinositide 3-kinase in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-MEDIATED ADHESION; KILLER-CELLS; PI-3-KINASE; ACTIVATION; WORTMANNIN; INHIBITOR; PECAM-1; SIGNALS; KINASE; CD31	In this paper we show that the engagement of the platelet-endothelial cell adhesion molecule-1 (PECAM-1/ CD31) up-regulates the adhesion of human neutrophils to the EA.hy926 endothelial cell line through a phosphoinositide S-kinase (PI3K)-dependent pathway. Indeed, LY294002 and wortmannin prevented the effect of PECAM-1/CD31 cross-linking on cell adhesion, at concentrations known to inhibit PI3K without affecting other kinases. Both compounds blocked neutrophil binding to murine fibroblasts transfected with human ICAM-1, to purified ICAM-1 protein, or to fibronectin, suggesting that PECAM-1/CD31-mediated up-regulation of beta 2 and beta 1 integrin-mediated adhesion is PI3K-sensitive. We also provide evidence for the association of PECAM-1/CD31 to PI3K, because PI3K was detectable in neutrophil lysates after PECAM-1/CD31 cross-linking and immunoprecipitation. PECAM-1/CD31-dependent recruitment of PI3K was suggested by the finding that the serine/threonine kinase p70 S6 kinase (S6K), a signaling protein downstream of PI3K, is activated in neutrophils upon PECAM-1/CD31 cross-linking, based on the appearance of serine phosphorylation in S6K immunoprecipitates. In turn, S6K is not directly involved in the up-regulation of integrin function because rapamycin, which can inhibit S6K independent of PI3K, did not block PECAM-1/CD31-induced adhesion of neutrophils to beta 1 and beta 2 integrin substrates. In conclusion, PECAM-1/CD31 appears to be one of the molecules functionally coupled to PI3K, suggesting that this enzyme may represent a common pathway of integrin and adhesiveness regulation in leukocytes.	San Raffaele Sci Inst, Dept Cardiol, Lab Cardiovasc Pathophysiol, Inst Ricovero & Cura Carattere Sci, I-20132 Milan, Italy; San Raffaele Sci Inst, Inst Ricovero & Cura Carattere, Lab Tumor Immunol, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Pellegatta, F (corresponding author), San Raffaele Sci Inst, Dept Cardiol, Lab Cardiovasc Pathophysiol, Inst Ricovero & Cura Carattere Sci, Via Olgettina 60, I-20132 Milan, Italy.	pellegatta.fabio@hsr.it		Zocchi, Maria Raffaella/0000-0002-0022-8385				BERNMAN ME, 1995, J IMMUNOL, V154, P299; BOWN EJ, 1996, CELL, V86, P517; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Ferrero E, 1996, CANCER RES, V56, P3211; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LEAVESLEY DI, 1994, J IMMUNOL, V153, P4673; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; Poggi A, 1996, EUR J IMMUNOL, V26, P817, DOI 10.1002/eji.1830260414; Poggi A, 1996, EUR J IMMUNOL, V26, P967, DOI 10.1002/eji.1830260502; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Varon D, 1998, BLOOD, V91, P500, DOI 10.1182/blood.V91.2.500.500_500_507; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Zell T, 1996, J IMMUNOL, V156, P883; Zocchi MR, 1996, EUR J IMMUNOL, V26, P759, DOI 10.1002/eji.1830260406	24	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27768	27771		10.1074/jbc.273.43.27768	http://dx.doi.org/10.1074/jbc.273.43.27768			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774384	hybrid			2022-12-25	WOS:000076549800004
J	Tantin, D				Tantin, D			RNA polymerase II elongation complexes containing the cockayne syndrome group B protein interact with a molecular complex containing the transcription factor IIH components xeroderma pigmentosum B and p62	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCISION-REPAIR; COUPLING FACTOR CSB/ERCC6; CDK-ACTIVATING KINASE; C-TERMINAL DOMAIN; DNA-REPAIR; ACTIVE GENES; SYNDROME CELLS; FACTOR TFIIH; PREFERENTIAL REPAIR; PROMOTER DNA	Transcription factor IIH (TFIIH) is involved both in transcription initiation by RNA polymerase II and in nucleotide excision-repair. Nucleotide excision-repair occurs at higher rates in transcriptionally active regions of the genome. Genetic studies indicate that this transcription-coupled repair is dependent on the Cockayne syndrome group A and B proteins, as well as TFIIH subunits. Previous work indicated that Cockayne syndrome group B interacts with RNA polymerase II molecules engaged in ternary complexes containing DNA and RNA. Evidence presented here indicates that this complex can interact with a factor containing the TFIIH core subunits p62 and xeroderma pigmentosum subunit B/excision repair cross-complementing 3. The targeting of TFIIH or a TFIIH-like repair factor to transcriptionally active DNA indicates a potential mechanism for transcription-coupled repair in human cells.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Tantin, D (corresponding author), MIT, Ctr Canc Res, 77 Massachusetts Ave,Bldg E17-529, Cambridge, MA 02139 USA.	dtantin@mit.edu			NIGMS NIH HHS [GM 46424, GM 07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046424] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Dianov GL, 1997, NUCLEIC ACIDS RES, V25, P3636, DOI 10.1093/nar/25.18.3636; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FLORES O, 1992, J BIOL CHEM, V267, P2786; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; Guzder SN, 1996, J BIOL CHEM, V271, P18314, DOI 10.1074/jbc.271.31.18314; He ZG, 1997, NUCLEIC ACIDS RES, V25, P1136, DOI 10.1093/nar/25.6.1136; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HOIEJMAKERS JHJK, 1996, CURR OPIN GENE DEV, V6, P26; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; ITOH T, 1994, MUTAT RES, V314, P233, DOI 10.1016/0921-8777(94)90068-X; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Larochelle S, 1998, GENE DEV, V12, P370, DOI 10.1101/gad.12.3.370; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; MAYNE LV, 1982, CANCER RES, V42, P1473; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nocentini S, 1997, J BIOL CHEM, V272, P22991, DOI 10.1074/jbc.272.37.22991; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; PAN GH, 1994, J BIOL CHEM, V269, P30101; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; REINBERG D, 1987, J BIOL CHEM, V262, P3310; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SCHMICKEL RD, 1977, PEDIATRICS, V60, P135; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TANTIN D, 1994, J BIOL CHEM, V269, P17397; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; vanOosterwijk MF, 1996, MOL CELL BIOL, V16, P4436; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; You ZY, 1998, MOL CELL BIOL, V18, P2668, DOI 10.1128/MCB.18.5.2668; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	64	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27794	27799		10.1074/jbc.273.43.27794	http://dx.doi.org/10.1074/jbc.273.43.27794			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774388	hybrid			2022-12-25	WOS:000076549800008
J	Busch, R; Reich, Z; Zaller, DM; Sloan, V; Mellins, ED				Busch, R; Reich, Z; Zaller, DM; Sloan, V; Mellins, ED			Secondary structure composition and pH-dependent conformational changes of soluble recombinant HLA-DM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN PEPTIDES; CLASS-II MOLECULES; ANTIGEN-PROCESSING MUTANT; DR MOLECULES; T-CELL; INTRACELLULAR-TRANSPORT; LYSOSOMAL PH; FC RECEPTOR; IN-VIVO	HLA-DM catalyzes the release of invariant chain fragments from newly synthesized major histocompatibility complex (MHC) class II molecules, stabilizes empty class II molecules, and edits class II-associated peptides by preferentially releasing those that are loosely bound. The ability of KLA-DM to carry out these functions in vitro is pH dependent, with an optimum at pH 4.5-5.5 and poor activity at pH 7, The structural basis for these properties of HLA-DM is unknown, Sequence homology suggests that HLA-DM resembles classical, peptide-binding MHC class II molecules. In this study, we examined whether HLA-DM has a secondary structure composition consistent with an MHC fold and whether HLA-DM changes conformation between pH 5 and pH 7. Far-UV circular dichroism (CD) spectra of recombinant soluble HLA-DM (sDM) indicate that HLA-DM belongs to the alpha/beta class of proteins and structurally resembles both MHC class I and class II molecules. The CD peak around 198 nm increases upon going from neutral to endosomal pH and drops sharply upon denaturation below pH 3.5, distinguishing at least three states of sDM: the denatured state and two highly similar folded states. Fluorescence emission spectra show a slight blue-shift and a approximate to 20% drop in intensity at pH 5 compared with pH 7. Unfolding experiments using guanidinium chloride show that the stability of sDM is somewhat reduced but not lost at pH 5. These results indicate that sDM undergoes a pH-dependent conformational change between neutral and endosomal pH. The change seems to involve both hydrogen bonding patterns and the hydrophobic core of sDM and may contribute to the pH dependence of DM activity.	Stanford Univ, Med Ctr, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; Merck Res Labs, Rahway, NJ 07065 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; Merck & Company	Busch, R (corresponding author), Stanford Univ, Med Ctr, Dept Pediat, 300 Pasteur Dr, Stanford, CA 94305 USA.			Mellins, Elizabeth/0000-0003-2577-139X; Busch, Robert/0000-0002-4132-0751	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028809, R29AI028809] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28809] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Boniface JJ, 1996, J EXP MED, V183, P119, DOI 10.1084/jem.183.1.119; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; Busch R, 1998, J IMMUNOL, V160, P734; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; Creighton T. E., 1993, PROTEINS STRUCTURES; Crowley MP, 1997, J EXP MED, V185, P1223, DOI 10.1084/jem.185.7.1223; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Denzin LK, 1997, SCIENCE, V278, P106, DOI 10.1126/science.278.5335.106; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORGA JC, 1989, P NATL ACAD SCI USA, V86, P2321, DOI 10.1073/pnas.86.7.2321; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GREEN JM, 1995, J IMMUNOL, V155, P3759; Guerra CB, 1998, J IMMUNOL, V160, P4289; Katz JF, 1996, J EXP MED, V184, P1747, DOI 10.1084/jem.184.5.1747; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; Kropshofer H, 1996, EMBO J, V15, P6144, DOI 10.1002/j.1460-2075.1996.tb01002.x; Kropshofer H, 1997, IMMUNOL TODAY, V18, P77, DOI 10.1016/S0167-5699(97)01006-2; Kropshofer H, 1997, IMMUNITY, V6, P293, DOI 10.1016/S1074-7613(00)80332-5; KROPSHOFER H, 1991, BIOCHEMISTRY-US, V30, P9177, DOI 10.1021/bi00102a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lightstone L, 1997, P NATL ACAD SCI USA, V94, P5772, DOI 10.1073/pnas.94.11.5772; Liljedahl M, 1998, IMMUNITY, V8, P233, DOI 10.1016/S1074-7613(00)80475-6; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; RADLEY E, 1994, J BIOL CHEM, V269, P18834; Reich Z, 1997, P NATL ACAD SCI USA, V94, P2495, DOI 10.1073/pnas.94.6.2495; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; Roche PA, 1996, SCIENCE, V274, P526, DOI 10.1126/science.274.5287.526; Runnels HA, 1996, J EXP MED, V183, P127, DOI 10.1084/jem.183.1.127; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; Stang E, 1998, J IMMUNOL, V160, P4696; STROYNOWSKI I, 1995, CURR OPIN IMMUNOL, V7, P97, DOI 10.1016/0952-7915(95)80034-4; Ullrich HJ, 1997, P NATL ACAD SCI USA, V94, P13163, DOI 10.1073/pnas.94.24.13163; vanHam SM, 1997, CURR BIOL, V7, P950, DOI 10.1016/S0960-9822(06)00414-3; Vogt AB, 1996, P NATL ACAD SCI USA, V93, P9724, DOI 10.1073/pnas.93.18.9724; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618	55	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27557	27564		10.1074/jbc.273.42.27557	http://dx.doi.org/10.1074/jbc.273.42.27557			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765288	hybrid			2022-12-25	WOS:000076448000075
J	Kraus, RL; Hering, S; Grabner, M; Ostler, D; Striessnig, J				Kraus, RL; Hering, S; Grabner, M; Ostler, D; Striessnig, J			Molecular mechanism of diltiazem interaction with L-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHENYLALKYLAMINE BLOCK; SENSITIVE CALCIUM-CHANNEL; SKELETAL-MUSCLE; 1,4-DIHYDROPYRIDINE SENSITIVITY; BINDING DOMAIN; DETERMINANTS; SUBUNIT; BENZOTHIAZEPINES; INACTIVATION; PORE	Benzothiazepine Ca2+ antagonists (such as (+)-cis-diltiazem) interact with transmembrane segments IIIS6 and TVS6 in the alpha(1) subunit of L-type Ca2+ channels, We investigated the contribution of individual IIIS6 amino acid residues for diltiazem sensitivity by employing alanine scanning mutagenesis in a benzothiazepine-sensitive alpha(1) subunit chimera (AL(DIL)) expressed in Xenopus laevis oocytes, The most dramatic decrease of block by 100 mu M diltiazem (AL(DIL) 45 +/- 4.8% inhibition) during trains of 100-ms pulses (0.1 Hz, -80 mV holding potential) was found after mutation of adjacent IIIS6 residues Phe(1164)(21 +/- 3%) and Val(1165) (8.5 +/- 1.4%). Diltiazem delayed current recovery by promoting a slowly recovering current component. This effect was similar in AL(DIL) and F1164A but largely prevented in V1165A. Both mutations slowed inactivation kinetics during a pulse. The reduced diltiazem block can therefore be explained by slowing of inactivation kinetics (F1164A and V1165A) and accelerated recovery from drug block (V1165A), The bulkier diltiazem derivative benziazem still efficiently blocked V1165A. From these functional and from additional radioligand binding studies with the dihydropyridine (+)-[H-3]isradipine we propose a model in which Val(1165) controls dissociation of the bound diltiazem molecule, and where bulky substituents on the basic nitrogen of diltiazem protrude toward the adjacent dihydropyridine binding domain.	Inst Biochem Pharmakol, A-6020 Innsbruck, Austria		Striessnig, J (corresponding author), Inst Biochem Pharmakol, Peter Mayrstr 1, A-6020 Innsbruck, Austria.	joerg.striessnig@uibk.ac.at	Striessnig, Joerg/S-9334-2017	Striessnig, Joerg/0000-0002-9406-7120	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 29632] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOYETT MR, 1994, PFLUG ARCH EUR J PHY, V428, P39, DOI 10.1007/BF00374750; Brauns T, 1997, BIOCHEMISTRY-US, V36, P3625, DOI 10.1021/bi9613584; BRAUNS T, 1995, BIOCHEMISTRY-US, V34, P3461, DOI 10.1021/bi00010a039; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GALIZZI JP, 1984, BIOCHEM BIOPH RES CO, V118, P239, DOI 10.1016/0006-291X(84)91092-1; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; HERING S, 1993, MOL PHARMACOL, V43, P820; Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Hille B., 1991, IONIC CHANNELS EXCIT; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Johnson BD, 1996, MOL PHARMACOL, V50, P1388; Hunt J T, 1993, Bioorg Med Chem, V1, P59, DOI 10.1016/S0968-0896(00)82134-3; KIMBALL SD, 1992, J MED CHEM, V35, P780, DOI 10.1021/jm00082a020; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Sinnegger MJ, 1997, J BIOL CHEM, V272, P27686, DOI 10.1074/jbc.272.44.27686; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7	24	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27205	27212		10.1074/jbc.273.42.27205	http://dx.doi.org/10.1074/jbc.273.42.27205			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765241	hybrid			2022-12-25	WOS:000076448000028
J	Mao, JH; Yuan, HD; Xie, W; Simon, MI; Wu, DQ				Mao, JH; Yuan, HD; Xie, W; Simon, MI; Wu, DQ			Specific involvement of G proteins in regulation of serum response factor-mediated gene transcription by different receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; BRUTONS-TYROSINE-KINASE; ALPHA-SUBUNITS; PHOSPHOLIPASE-C; TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; RGS PROTEINS; FAMILY; CELLS; RHO	Regulation of serum response factor (SRF)-mediated gene transcription by G protein subunits and G protein-coupled receptors was investigated in transfected NIH3T3 cells and in a cell line that was derived from mice lacking G alpha(q) and G alpha(11). We found that the constitutively active forms of the alpha subunits of the G(q) and G(12) class of G proteins, including G alpha(q), G alpha(11), G alpha(14), G alpha(16), G alpha(12), and G alpha(13), can activate SRF in NIH3T3 cells. me also found that the type 1 muscarinic receptor (m1R) and alpha(1)-adrenergic receptor (AR)-mediated SRF activation is exclusively dependent on G alpha(q/11), while the receptors for thrombin, lysophosphatidic acid (LPA), thromboxane A2, and endothelin can activate SRF in the absence of G alpha(q/11). Moreover, RGS12 but not RGS2, RGS4, or Axin was able to inhibit G alpha(12) and G alpha(13)-mediated SRF activation. And RGS12, but not other RGS proteins, blocked thrombin- and LPA-mediated SRF activation in the G alpha(q/11)-deficient cells. Therefore, the thrombin, LPA, thromboxane A2, and endothelin receptors may be able to couple to G alpha(12/13). On the contrary, receptors including beta(2)- and alpha(2)-ARs, m2R, the dopamine receptors type 1 and 2, angiotensin receptors types 1 and 2, and interleukin-8 receptor could not activate SRF in the presence or absence of G alpha(q/11), suggesting that these receptors cannot couple to endogenous G proteins of the G(12) or G(q) classes.	Univ Rochester, Dept Pharmacol & Physiol, Rochester, NY 14642 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	University of Rochester; California Institute of Technology	Wu, DQ (corresponding author), Univ Rochester, Dept Pharmacol & Physiol, Rochester, NY 14642 USA.	wud@pharmacol.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053162] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54167, GM53162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1995, J BIOL CHEM, V270, P9828, DOI 10.1074/jbc.270.17.9828; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	35	148	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27118	27123		10.1074/jbc.273.42.27118	http://dx.doi.org/10.1074/jbc.273.42.27118			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765229	hybrid			2022-12-25	WOS:000076448000016
J	Picha, KM; Patel, SS				Picha, KM; Patel, SS			Bacteriophage T7 DNA helicase binds dTTP, forms hexamers, and binds DNA in the absence of Mg2+ - The presence of dTTP is sufficient for hexamer formation and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; GENE-4 PROTEIN; OLIGOMERIC STRUCTURE; CRYSTAL-STRUCTURES; RAS P21; REPLICATION; RESOLUTION; HYDROLYSIS; ATP	The role of Mg2+ in dTTP hydrolysis, dTTP binding, hexamer formation, and DNA binding was studied in bacteriophage T7 DNA helicase (4A' protein). The steady state k(cat) for the dTTPase activity was 200-300-fold lower in the absence of MgCl2, but the K-m was only slightly affected, Direct dTTP binding experiments showed that the K-d of dTTP was unaffected, but the stoichiometry of dTTP binding was different in the absence of Mg2+. Two dTTPs were found to bind tightly in the absence of Mg2+ in contrast to three to four in the presence of Mg2+. I, the presence of DNA there was little difference in the stoichiometry of dTTP binding to 4A', These results indicate that Mg2+ is not necessary for dTTP binding, but Mg2+ is required for optimal hydrolysis of dTTP, Gel filtration of 4A' in the presence of dTTP without Mg2+ showed that Mg2+ was not necessary, and dTTP was sufficient for hexamer formation. The hexamers formed in the presence of dTTP without Mg2+ were capable of binding single-stranded DNA, However, the 4A' hexamers formed in the presence of dTDP with or without Mg2+ did not bind DNA, indicating that hexamer formation itself is not sufficient for DNA binding. The hexamers need to be in the correct conformation, in this case in the dTTP-bound state, to interact with the DNA. Thus, the gamma-phosphate of dTTP plays an important role in causing a conformational change in the protein that leads to stable interactions of 4A' with the DNA.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Patel, SS (corresponding author), Ohio State Univ, Dept Biochem, 484 W 12th Ave, Columbus, OH 43210 USA.	Patel.85@osu.edu			NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; Jezewska MJ, 1996, J BIOL CHEM, V271, P4261; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1995, BIOPHYS J, V68, pS186; PATEL SS, 1993, J BIOL CHEM, V268, P10668; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; SCHWEINS T, 1994, NAT STRUCT BIOL, V1, P476, DOI 10.1038/nsb0794-476; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740	34	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27315	27319		10.1074/jbc.273.42.27315	http://dx.doi.org/10.1074/jbc.273.42.27315			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765257	hybrid			2022-12-25	WOS:000076448000044
J	Takai, H; Kanematsu, M; Yano, K; Tsuda, E; Higashio, K; Ikeda, K; Watanabe, K; Yamada, Y				Takai, H; Kanematsu, M; Yano, K; Tsuda, E; Higashio, K; Ikeda, K; Watanabe, K; Yamada, Y			Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLAST-LIKE CELLS; MOUSE CALVARIA; CULTURES; OSTEOPETROSIS; RESORPTION; MICE; DIFFERENTIATION; OSTEOPOROSIS; CYTOKINES; DISEASE	Osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF) is a recently identified cytokine that belongs to the tumor necrosis factor receptor superfamily and regulates bone mass by inhibiting osteoclastic bone resorption. The present study was undertaken to determine whether OPG/OCIF is produced in bone microenvironment and how the expression is regulated. A transcript for OPG/OCIF at 3.1 kilobases was detected in bone marrow stromal cells (ST2 and MC3T3-G2/PA6) as well as in osteoblastic cells (MC3T3-E1). Transforming growth factor-beta 1 (TGF-beta 1) markedly increased the steady-state level of OPG/OCIF mRNA in a dose-dependent manner, while TGF-beta 1 suppressed the mRNA expression of tumor necrosis factor-related activation-induced cytokine (TRANCE)/receptor activator of NF-kappa B ligand (RANKL), a positive regulator of osteoclastogenesis to which OPG/OCIF binds. The effect of TGF-beta 1 on the expression of OPG/OCIF mRNA was transient, with a peak level at 3-6 h. The up-regulation of OPG/OCIF mRNA by TGF-beta 1 in ST2 cells did not require de novo protein synthesis and involved both a transcriptional and a post-transcriptional mechanism. Western blot analysis and an enzyme-linked immunosorbent assay revealed that TGF-beta 1 significantly increased the secretion of OPG/OCIF protein by ST2 cells at 6-24 h, In murine bone marrow cultures, TGF-beta 1 markedly inhibited the formation of tartrate-resistant acid phosphatase-positive multinucleated osteoclast like cells in the presence of 1,25-dihydroxyvitamin D-3, whose effect was significantly reversed by a neutralizing antibody against OPG/OCIF. These results suggest that TGF-beta 1 negatively regulates osteoclastogenesis, at least in part, through the induction of OPG/OCIF by bone marrow stromal cells and that the balance between OPG/OCIF and TRANCE/RANKL in local environment may be an important de terminant of osteoclastic bone resorption.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; Snow Brand Milk Prod Co Ltd, Life Sci Res Inst, Shimotsuga, Tochigi 3290521, Japan	Snow Brand Milk Products Co., Ltd.	Yamada, Y (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, 36-3 Gengo, Aichi 4748522, Japan.	yoyamada@nils.go.jp	Watanabe, Ken/I-3960-2013; Takai, Hiroyuki/B-8352-2011	Watanabe, Ken/0000-0003-0664-3915; 				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; CHENU C, 1988, P NATL ACAD SCI USA, V85, P5683, DOI 10.1073/pnas.85.15.5683; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIEUDONNE SC, 1991, J BONE MINER RES, V6, P479; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HATTERSLEY G, 1991, J BONE MINER RES, V6, P165; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KODAMA HA, 1982, J CELL PHYSIOL, V112, P89, DOI 10.1002/jcp.1041120114; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LU X, 1989, Nucleic Acids Research, V17, P442, DOI 10.1093/nar/17.1.442; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; Pacifici R, 1996, J BONE MINER RES, V11, P1043; PFEILSCHIFTER J, 1988, J CLIN INVEST, V82, P680, DOI 10.1172/JCI113647; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; SHINAR DM, 1990, ENDOCRINOLOGY, V126, P3153, DOI 10.1210/endo-126-6-3153; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TASHJIAN AH, 1985, P NATL ACAD SCI USA, V82, P4535, DOI 10.1073/pnas.82.13.4535; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; Yamaguchi K, 1998, J BIOL CHEM, V273, P5117, DOI 10.1074/jbc.273.9.5117; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	37	246	260	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27091	27096		10.1074/jbc.273.42.27091	http://dx.doi.org/10.1074/jbc.273.42.27091			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765225	hybrid			2022-12-25	WOS:000076448000012
J	Takei, N; Numakawa, T; Kozaki, S; Sakai, N; Endo, Y; Takahashi, M; Hatanaka, H				Takei, N; Numakawa, T; Kozaki, S; Sakai, N; Endo, Y; Takahashi, M; Hatanaka, H			Brain-derived neurotrophic factor induces rapid and transient release of glutamate through the non-exocytotic pathway from cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL-NEURONS; SYNAPTIC TRANSMISSION; NERVOUS-SYSTEM; PLASTICITY; CA2+; BDNF; NGF; NEUROTRANSMITTER; STIMULATION; SECRETION	There is increasing interest in the involvement of neurotrophins in neural transmission and plasticity. Thus, Re investigated the effects of brain-derived neurotrophic factor (BDNF) on glutamate release from cortical neurons, Treatment of cultured cortical neurons with BDNF induced rapid and transient release of glutamate, This effect was suggested to be mediated by TrkB activation because R252a inhibited the release of glutamate and BDNF phosphorylated TrkB within 30 s, BDNF-induced glutamate release was observed even when using Ca2+-free assay buffer but was inhibited by BAPTA-AM, a cell-permeable Ca2+ chelator, Therefore, BDNF-induced glutamate release was independent of extracelluar Ca2+ but dependent on intracellular Ca2+. Because normal neurotransmitter release is exocytotic, the involvement of the exocytotic pathway in BDNF-induced glutamate release was examined. As botulinum toxin is known to cleave exocytosis-associated proteins, thereby inhibiting exocytosis, it was applied to neurons prior to the release assay. Although botulinum toxin B cleaved VAMP2 and inhibited Ca2+-triggered glutamate release, it did not inhibit the BDNF-induced release of glutamate. These results strongly suggested that BDNF induces rapid and transient release of glutamate from cortical neurons through a non-exocytotic pathway.	Kyoto Inst Technol, Dept Appl Biol, Sakyo Ku, Kyoto 606, Japan; Osaka Univ, Inst Prot Res, Div Prot Biosynthesis, Suita, Osaka 565, Japan; Osaka Prefecture Univ, Coll Agr, Dept Vet Sci, Sakai, Osaka 593, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 194, Japan	Kyoto Institute of Technology; Osaka University; Osaka Metropolitan University	Takei, N (corresponding author), Niigata Univ, Brain Res Inst, Dept Mol Neurobiol, Asahimachi 1, Niigata 9518585, Japan.	nobtak@bri.niigata-u.ac.jp						ADAMVIZI V, 1992, J NEUROCHEM, V58, P395, DOI 10.1111/j.1471-4159.1992.tb09736.x; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Bennett MK, 1997, CURR OPIN NEUROBIOL, V7, P316, DOI 10.1016/S0959-4388(97)80058-X; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; Berninger B, 1996, CURR OPIN NEUROBIOL, V6, P324, DOI 10.1016/S0959-4388(96)80115-2; Blochl A, 1996, J BIOL CHEM, V271, P21100; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Goda Y, 1997, P NATL ACAD SCI USA, V94, P769, DOI 10.1073/pnas.94.3.769; Heymach JV, 1996, J BIOL CHEM, V271, P25430, DOI 10.1074/jbc.271.41.25430; Kanai Y, 1995, NEUROREPORT, V6, P2357, DOI 10.1097/00001756-199511270-00020; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KNIPPER M, 1994, NEUROREPORT, V5, P2433, DOI 10.1097/00001756-199412000-00007; LESSMANN V, 1994, NEUROREPORT, V6, P21; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; OHO C, 1995, NEUROSCI LETT, V186, P208, DOI 10.1016/0304-3940(95)11317-P; Sakai N, 1997, BRAIN RES, V778, P318, DOI 10.1016/S0006-8993(97)01052-4; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Takei N, 1997, J NEUROCHEM, V68, P370; TAKEI N, 1994, BRAIN RES, V652, P65, DOI 10.1016/0006-8993(94)90317-4; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Wildering WC, 1995, J NEUROPHYSIOL, V74, P2778, DOI 10.1152/jn.1995.74.6.2778	30	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27620	27624		10.1074/jbc.273.42.27620	http://dx.doi.org/10.1074/jbc.273.42.27620			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765296	hybrid			2022-12-25	WOS:000076448000083
J	Apletalina, E; Appel, J; Lamango, NS; Houghten, RA; Lindberg, I				Apletalina, E; Appel, J; Lamango, NS; Houghten, RA; Lindberg, I			Identification of inhibitors of prohormone convertases 1 and 2 using a peptide combinatorial library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUENCHED FLUOROGENIC SUBSTRATE; ENZYMATIC CHARACTERIZATION; PROCESSING ENZYME; HUMAN FURIN; NEUROENDOCRINE CELLS; CLEAVAGE; 7B2; ENDOPROTEASE; PURIFICATION; SEQUENCE	A positional scanning synthetic peptide combinatorial library containing approximately 52 million hexapeptides was used to identify potential inhibitory peptides for recombinant mouse prohormone convertase 1 (PC1) and PC2 and to provide information on the specificity of these enzymes. The library surveys revealed that a P6 Leu, a P4 Arg, a P2 Lys, and a P1 Arg were most inhibitory against PC1, and a P6 Ile and a P4 Arg were most inhibitory against PC2, Using information derived from the library surveys, hexapeptide sets were synthesized and screened for inhibition of PC1 and PC2, The data obtained revealed the preference of both enzymes for a P3 Val, At P5, many substitutions were well tolerated. PC1 and PC2 proved to differ mainly in the selectivity of their S6 subsites, In PC1, this subsite displayed a strong preference toward occupation by Leu; the K-i value for peptide Ac-Leu-Leu-Arg-Val-Lys-Arg-NH2 was 28 times lower than that for peptide Ac-Ile-Ile-Arg-Val-Lys-Arg-NH2. In contrast, PC2 discriminated little between Leu and lie at P6, as evidenced by the small (1.5-fold) difference in K-i values for these two peptides, Several hexapeptides synthesized as a result of the screen were found to represent potent inhibitors of PC2 (with K-i values in the submicromolar range) and, particularly, of PC1 (with K-i values in the low nanomolar range). The most potent inhibitor, Ac-Leu-Leu-Arg-Val-Lys-Arg-NH2, proved to be the same peptide for both enzymes and inhibited PC1 and PC2 in a competitive, fast-binding manner with K-i values of 3.2 and 360 nm, respectively, The four most potent peptide inhibitors of PC1 and PC2 were also tested against soluble human furin and found to exhibit a different rank order of inhibition; for example, Ac-Leu-Leu-Arg-Val-Lys-Arg-NH2, was 440-fold less potent against furin than against PC1, with a K-i of 1400 nM.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA	Louisiana State University System; Torrey Pines Institute for Molecular Studies, California	Lindberg, I (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	ilindb@lsumc.edu	Lindberg, Iris/Q-3825-2019; Lamango, Nazarius/W-8459-2019		NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [DA05084, DA00204, R56 DA005084, R01 DA005084] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; ANGLIKER H, 1995, ANAL BIOCHEM, V224, P409, DOI 10.1006/abio.1995.1058; ANGLIKER H, 1995, J MED CHEM, V38, P4014, DOI 10.1021/jm00020a016; BASAK A, 1995, INT J PEPT PROT RES, V46, P228; BASAK A, 1994, INT J PEPT PROT RES, V44, P253; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; Dahlen JR, 1998, J BIOL CHEM, V273, P1851, DOI 10.1074/jbc.273.4.1851; EICHLER J, 1993, BIOCHEMISTRY-US, V32, P11035, DOI 10.1021/bi00092a013; EICHLER J, 1994, PEPTIDE RES, V7, P300; Eichler J, 1996, MOL DIVERS, V1, P233, DOI 10.1007/BF01715527; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; INOUYE M, 1991, ENZYME, V45, P314, DOI 10.1159/000468904; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; Jutras I, 1997, J BIOL CHEM, V272, P15184, DOI 10.1074/jbc.272.24.15184; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; Ledgerwood EC, 1996, BIOCHEM MOL BIOL INT, V39, P1167; Lindberg I, 1998, DNA CELL BIOL, V17, P727, DOI 10.1089/dna.1998.17.727; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; LU WY, 1993, J BIOL CHEM, V268, P14583; MISUMI Y, 1990, J BIOCHEM-TOKYO, V108, P230, DOI 10.1093/oxfordjournals.jbchem.a123185; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; PINILLA C, 1994, DRUG DEVELOP RES, V33, P133, DOI 10.1002/ddr.430330210; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; PINILLA C, 1995, BIOPOLYMERS, V37, P221, DOI 10.1002/bip.360370306; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SEIDAH NG, 1994, METHOD ENZYMOL, V244, P171; VANHORSSEN AM, 1995, J BIOL CHEM, V270, P14292; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU Y, 1994, J BIOL CHEM, V269, P18408; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	45	64	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26589	26595		10.1074/jbc.273.41.26589	http://dx.doi.org/10.1074/jbc.273.41.26589			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756897	hybrid			2022-12-25	WOS:000076373300051
J	Cases, S; Novak, S; Zheng, YW; Myers, HM; Lear, SR; Sande, E; Welch', CB; Lusis, AJ; Spencer, TA; Krause, BR; Erickson, SK; Farese, RV				Cases, S; Novak, S; Zheng, YW; Myers, HM; Lear, SR; Sande, E; Welch', CB; Lusis, AJ; Spencer, TA; Krause, BR; Erickson, SK; Farese, RV			ACAT-2, a second mammalian acyl-CoA : cholesterol acyltransferase - Its cloning, expression, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR LXR; COENZYME-A; MOLECULAR-CLONING; APOLIPOPROTEIN-B; LIPOPROTEIN METABOLISM; ESTERIFICATION ENZYMES; FUNCTIONAL EXPRESSION; OXIDIZED CHOLESTEROL; OXYGENATED STEROLS; LIVER	The synthesis of cholesterol esters by acyl-CoA:cholesterol acyltransferase (ACAT, EC 2.3.1.26) is an important component of cellular cholesterol homeostasis, Cholesterol ester formation also is hypothesized to be important in several physiologic processes, including intestinal cholesterol absorption, hepatic lipoprotein production, and macrophage foam cell formation in atherosclerotic lesions. Mouse tissue expression studies and the disruption of the mouse ACAT gene (Acact) have indicated that more than one ACAT exists in mammals and specifically that another enzyme is important in mouse liver and intestine. We now describe a second mammalian ACAT enzyme, designated ACAT-2, that is 44% identical to the first cloned mouse ACAT (henceforth designated ACAT-1), Infection of H5 insect cells with an ACAT-2 recombinant baculovirus resulted in expression of a similar to 46-kDa protein in cell membranes that was associated with high levels of cholesterol esterification activity. Both ACAT-1 and ACAT-2 also catalyzed the esterification of the SP-hydroxyl group of a variety of oxysterols, Cholesterol esterification activities for ACAT-1 and ACAT-2 exhibited different IC50 values when assayed in the presence of several ACAT-specific inhibitors, demonstrating that ACAT inhibitors can selectively target specific forms of ACAT, ACAT-2 was expressed primarily in mouse liver and small intestine, supporting the hypothesis that ACAT-2 contributes to cholesterol esterification in these tissues. The mouse ACAT-S gene (Acact2) maps to chromosome 15 in a region containing a quantitative trait locus influencing plasma cholesterol levels. The identification and cloning of ACAT-S will facilitate molecular approaches to understanding the role of ACAT enzymes in mammalian biology.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Vet Adm Med Ctr, San Francisco, CA 94121 USA; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA; Parke Davis Pharmaceut Res, Ann Arbor, MI 48105 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Dartmouth College; Pfizer	Farese, RV (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042488, R01HL052069, R01HL057170, R37HL042488] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42488, HL52069, HL57170, R01 HL057170] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; BOCAN TMA, 1991, ARTERIOSCLER THROMB, V11, P1830, DOI 10.1161/01.ATV.11.6.1830; Brown AJ, 1996, J LIPID RES, V37, P320; BROWN MS, 1975, J BIOL CHEM, V250, P4025; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; CARR TP, 1995, J LIPID RES, V36, P25; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; CORNELL R, 1977, EXP CELL RES, V109, P299, DOI 10.1016/0014-4827(77)90009-X; DIXON JL, 1993, J LIPID RES, V34, P167; DOMINICK MA, 1993, TOXICOL PATHOL, V21, P54, DOI 10.1177/019262339302100107; EMANUEL HA, 1991, J FOOD SCI, V56, P843, DOI 10.1111/j.1365-2621.1991.tb05396.x; ERICKSON SK, 1980, J LIPID RES, V21, P930; ERICKSON SK, 1986, J LIPID RES, V27, P875; Farese RV, 1996, J LIPID RES, V37, P347; FIELD FJ, 1990, GASTROENTEROLOGY, V99, P539, DOI 10.1016/0016-5085(90)91040-D; GOLDSTEIN JL, 1978, P NATL ACAD SCI USA, V75, P1877, DOI 10.1073/pnas.75.4.1877; GOODMAN DS, 1965, PHYSIOL REV, V45, P747, DOI 10.1152/physrev.1965.45.4.747; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; HAUGEN R, 1976, SCAND J GASTROENTERO, V11, P615; HUFF MW, 1994, ARTERIOSCLER THROMB, V14, P1498, DOI 10.1161/01.ATV.14.9.1498; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JIALAL I, 1991, ARTERIOSCLER THROMB, V11, P482, DOI 10.1161/01.ATV.11.3.482; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KINNUNEN PM, 1988, BIOCHEMISTRY-US, V27, P7344, DOI 10.1021/bi00419a025; Krause B.R., 1995, INFLAMMATION MEDIATO, P173; KRAUSE BR, 1993, J PHARMACOL EXP THER, V267, P734; Lee HT, 1996, J MED CHEM, V39, P5031, DOI 10.1021/jm960674d; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LICHTENSTEIN AH, 1983, BIOCHIM BIOPHYS ACTA, V751, P340, DOI 10.1016/0005-2760(83)90292-8; MADUSKUIE TP, 1995, J MED CHEM, V38, P1067, DOI 10.1021/jm00007a004; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; Meiner V, 1997, J LIPID RES, V38, P1928; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; NELSON JA, 1981, J BIOL CHEM, V256, P1067; NELSON JA, 1981, J AM CHEM SOC, V103, P6974, DOI 10.1021/ja00413a040; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; OSADA K, 1994, LIPIDS, V29, P555, DOI 10.1007/BF02536627; OSADA K, 1994, BIOSCI BIOTECH BIOCH, V58, P782, DOI 10.1271/bbb.58.782; PENG SK, 1987, ATHEROSCLEROSIS, V64, P1, DOI 10.1016/0021-9150(87)90047-5; PRASAD VVK, 1984, J STEROID BIOCHEM, V21, P733, DOI 10.1016/0022-4731(84)90038-4; PURCELLHUYNH DA, 1995, J CLIN INVEST, V96, P1845, DOI 10.1172/JCI118230; RICHERT L, 1983, BIOCHEM BIOPH RES CO, V117, P851, DOI 10.1016/0006-291X(83)91674-1; SAUCIER SE, 1989, J BIOL CHEM, V264, P6863; SMITH JL, 1995, J LIPID RES, V36, P641; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; SUCKLING KE, 1985, J LIPID RES, V26, P647; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; Vora Jayesh, 1997, Pharmaceutical Research (New York), V14, pS505; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; Welch CL, 1996, J LIPID RES, V37, P1406; WILSON MD, 1994, J LIPID RES, V35, P943; WOLFGANG GHI, 1995, LIFE SCI, V56, P1089, DOI 10.1016/0024-3205(95)00045-8; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yang HY, 1997, J BIOL CHEM, V272, P3980, DOI 10.1074/jbc.272.7.3980; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157; ZHANG HF, 1990, J LIPID RES, V31, P1361	59	323	340	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26755	26764		10.1074/jbc.273.41.26755	http://dx.doi.org/10.1074/jbc.273.41.26755			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756919	hybrid			2022-12-25	WOS:000076373300073
J	Konstantinidis, AK; Radhakrishnan, R; Gu, F; Rao, RN; Yeh, WK				Konstantinidis, AK; Radhakrishnan, R; Gu, F; Rao, RN; Yeh, WK			Purification, characterization, and kinetic mechanism of cyclin D1 center dot CDK4, a major target for cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; DEPENDENT KINASES; PROTEIN; PHOSPHORYLATION; INHIBITION; STAUROSPORINE; BINDING; E2F; IDENTIFICATION; SUBSTRATE	The cyclin D1 . CDK4-pRb (retinoblastoma protein) pathway plays a central role iu the cell cycle, and its deregulation is correlated with many types of cancers. As a major drug target, we purified dimeric cyclin D1 . CDK4 complex to near-homogeneity by a four-step procedure from a recombinant baculovirus-infected insect culture, We optimized the kinase activity and stability and developed a reproducible assay. We examined several catalytic and kinetic properties of the complex and, via steady-state kinetics, derived a kinetic mechanism with a peptide (Rb-ING) and subsequently investigated the mechanistic implications with a physiologically relevant protein (Rb-21) as the phosphoacceptor. The complex bound ATP 130-fold tighter when Rb-21 instead of Rb-ING was used as the phosphoacceptor, By using staurosporine and ADP as inhibitors, the kinetic mechanism of the complex appeared to be a "single displacement or Bi-Bi" with Mg2+. ATP as the leading substrate and phosphorylated Rb-ING as the last product released. In addition, we purified a cyclin D1-CDK4 fusion protein to homogeneity by a three-step protocol from another recombinant baculovirus culture and observed similar kinetic properties and mechanisms as those from the complex. We attempted to model staurosporine in the ATP-binding site of CDK4 according to our kinetic data. Our biochemical and modeling data provide validation of both the complex and fusion protein as highly active kinases and their usefulness in antiproliferative inhibitor discovery.	Lilly Res Labs, Res Technol & Prot, Indianapolis, IN 46285 USA; Lilly Res Labs, Canc Res, Indianapolis, IN 46285 USA	Eli Lilly; Eli Lilly	Yeh, WK (corresponding author), Lilly Res Labs, Res Technol & Prot, Indianapolis, IN 46285 USA.							BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHURGAY LM, 1995, TECHNIQUES PROTEIN C, P837; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Furet P, 1995, J COMPUT AID MOL DES, V9, P465, DOI 10.1007/BF00124317; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; GREER J, 1980, P NATL ACAD SCI-BIOL, V77, P3393, DOI 10.1073/pnas.77.6.3393; GULBINSKY JS, 1968, BIOCHEMISTRY-US, V7, P566, DOI 10.1021/bi00842a009; HAMEL PA, 1992, ONCOGENE, V7, P693; HAMMES GG, 1962, J AM CHEM SOC, V84, P2069, DOI 10.1021/ja00870a012; Heitz F, 1997, BIOCHEMISTRY-US, V36, P4995, DOI 10.1021/bi962349y; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HIGASHI H, 1995, BIOCHEM BIOPH RES CO, V216, P520, DOI 10.1006/bbrc.1995.2653; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KITAGAWA M, 1992, ONCOGENE, V7, P1067; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lawrie AM, 1997, NAT STRUCT BIOL, V4, P796, DOI 10.1038/nsb1097-796; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUNBERG AS, 1998, MOL CELL BIOL, V18, P753; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORRISON JF, 1965, BIOCHEM J, V97, P37, DOI 10.1042/bj0970037; MOURAD N, 1966, J BIOL CHEM, V241, P271; NOBUYUKI F, 1994, TETRAHEDRON LETT, V35, P1251; OTTO KA, 1996, KEYST S MOL CELL BIO; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; RICE JW, 1993, BIOTECHNIQUES, V15, P1052; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SEGEL IH, 1993, ENZYME KINETICS BEHA, P505; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; Wallace AC, 1996, PROTEIN SCI, V5, P1001; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WHITAKER JR, 1963, ANAL CHEM, V35, P1950, DOI 10.1021/ac60205a048; WOOD HG, 1966, J BIOL CHEM, V241, P5692; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	55	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26506	26515		10.1074/jbc.273.41.26506	http://dx.doi.org/10.1074/jbc.273.41.26506			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756886	hybrid			2022-12-25	WOS:000076373300040
J	Kotera, J; Fujishige, K; Akatsuka, H; Imai, Y; Yanaka, N; Omori, K				Kotera, J; Fujishige, K; Akatsuka, H; Imai, Y; Yanaka, N; Omori, K			Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; N-TERMINAL DOMAIN; PROTEIN-KINASE; MESSENGER-RNA; NUCLEOTIDE PHOSPHODIESTERASES; MEMBRANE ASSOCIATION; CATALYTIC SUBUNIT; RPDE-6 RNPDE4A5; SMOOTH-MUSCLE; RAT-TISSUES	After our recent findings that the amino-terminal portion of rat cGMP-binding, cGMP-specific phosphodiesterase (cGB-PDE) differs from those of bovine and human cGB-PDEs, we found two forms of canine cGB-PDE cDNAs (CFPDEA1 and CFPDE5A2) in canine lung, Each contained a distinct amino-terminal sequence, CFPDE5A1, possessing an amino-terminal portion with sequence similar to those of bovine and human, and CFPDE5A2, having one similar to that of rat, Other portions coding for the cGMP binding domains and the catalytic domain mere conserved. Both CFPDE5A1 and CFPDE5A2 transcripts were detected in the cerebellum, hippocampus, retina, lung, heart, spleen, and thoracic artery. CFPDE5A1 transcripts were particularly abundant in the pylorus, whereas CFPDE5A2 transcripts were quite low in this tissue. CFPDE5A1 and CFPDE5A2 expressed in COS-7 cells had cGMP K-m values of 2.68 and 1.97 mu M, respectively, and both were inhibited by a low concentration of a cGB-PDE inhibitor, Zaprinast. Both CFPDE5A1 and CFPDE5A2 bound cGMP to their allosteric cGMP binding domains, and this cGMP binding was stimulated by 3-isobutyl-1-methylxanthine. Thus, two types of alternative splice variants of canine cGB-PDE have been identified and shown to have similar biological properties in vitro.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Toda, Saitama 3358505, Japan	Mitsubishi Tanabe Pharma Corporation	Omori, K (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, 2-50 Kawagishi-2-chome, Toda, Saitama 3358505, Japan.		Yanaka, Noriyuki/P-9096-2016					AHN HS, 1989, BIOCHEM PHARMACOL, V38, P331; BEAVO AJ, 1990, CYCLIC NUCLEOTIDE PH, V2; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; BURNS F, 1992, BIOCHEM BIOPH RES CO, V189, P1389, DOI 10.1016/0006-291X(92)90228-D; BURNS F, 1992, BIOCHEM J, V283, P487, DOI 10.1042/bj2830487; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; COQUIL JF, 1985, BIOCHEM BIOPH RES CO, V127, P226, DOI 10.1016/S0006-291X(85)80148-0; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; FRANCIS SH, 1988, METHOD ENZYMOL, V159, P722; HAMET P, 1978, J CYCLIC NUCL PROT, V4, P281; HAMET P, 1988, METHOD ENZYMOL, V159, P710; Han P, 1997, J BIOL CHEM, V272, P16152, DOI 10.1074/jbc.272.26.16152; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; Kotera J, 1997, EUR J BIOCHEM, V249, P434, DOI 10.1111/j.1432-1033.1997.t01-1-00434.x; KUKOVETZ WR, 1979, N-S ARCH PHARMACOL, V310, P129, DOI 10.1007/BF00500277; LINCOLN TM, 1983, ADV CYCL NUCL RES<D>, V15, P139; LINCOLN TM, 1976, P NATL ACAD SCI USA, V73, P2559, DOI 10.1073/pnas.73.8.2559; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Lochhead A, 1997, J BIOL CHEM, V272, P18397, DOI 10.1074/jbc.272.29.18397; MARTIN W, 1986, J PHARMACOL EXP THER, V237, P539; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; POLLI JW, 1994, J NEUROSCI, V14, P1251, DOI 10.1523/JNEUROSCI.14-03-01251.1994; REINHARDT RR, 1995, J CLIN INVEST, V95, P1528, DOI 10.1172/JCI117825; SCHRAMM M, 1984, SCIENCE, V225, P1350, DOI 10.1126/science.6147897; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SOUNESS JE, 1989, BRIT J PHARMACOL, V98, P725, DOI 10.1111/j.1476-5381.1989.tb14599.x; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; Turko IV, 1998, BIOCHEM J, V329, P505; YAN C, 1994, J NEUROSCI, V14, P973; Yan C, 1996, J BIOL CHEM, V271, P25699, DOI 10.1074/jbc.271.41.25699; Yanaka N, 1998, EUR J BIOCHEM, V255, P391, DOI 10.1046/j.1432-1327.1998.2550391.x; Yanaka N, 1996, EUR J BIOCHEM, V237, P25, DOI 10.1111/j.1432-1033.1996.0025n.x	42	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26982	26990		10.1074/jbc.273.41.26982	http://dx.doi.org/10.1074/jbc.273.41.26982			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756948	hybrid			2022-12-25	WOS:000076373300102
J	Prekeris, R; Hernandez, RM; Mayhew, MW; White, MK; Terrian, DM				Prekeris, R; Hernandez, RM; Mayhew, MW; White, MK; Terrian, DM			Molecular analysis of the interactions between protein kinase C-epsilon and filamentous actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; TERMINAL RESIDUES; BINDING MOTIF; MUSCLE ACTIN; ACTIVATION; CELLS; LOCALIZATION; DOMAINS; IDENTIFICATION; TRANSLOCATION	Protein kinase C-epsilon (PKC-epsilon) contains a putative actin binding motif that is unique to this individual member of the PKC gene family. me have used deletion mutagenesis to determine whether this hexapeptide motif is required for the physical association of PKC-epsilon and actin. Full-length recombinant PKC-epsilon, but not PKC-beta II, -delta, -eta, or -zeta bound to filamentous actin in a phorbol ester-dependent manner. Deletion of PKC-epsilon amino acids 222-230, encompassing a putative actin binding motif, completely abrogated this binding activity. When NIH 3T3 cells overexpressing either PKC-epsilon off the deletion mutant of this isozyme were treated with phorbol ester only wild-type PKC-epsilon colocalized with actin in tomes of cell adhesion. in binary reactions, it was possible to demonstrate that purified filamentous actin is capable of directly stimulating PKC-epsilon phosphotransferase activity. These and other findings support the hypothesis that a conformationally hidden actin binding motif in the PKC-epsilon sequence becomes exposed upon activation of this isozyme aad functions as a dominant localization signal in NIH 3T3 fibroblasts. This protein-protein interaction is sufficient to maintain PKC-epsilon ire a catalytically active conformation.	E Carolina Univ, Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	University of North Carolina; East Carolina University; Jefferson University	Terrian, DM (corresponding author), E Carolina Univ, Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA.	dterrian@brody.med.ecu.edu	Hernández, Rosa/GRF-5998-2022		NIDDK NIH HHS [DK45718] Funding Source: Medline; NIEHS NIH HHS [ES8397] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008397] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKITA Y, 1994, J BIOL CHEM, V269, P4653; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BETTACHE N, 1989, P NATL ACAD SCI USA, V86, P6028, DOI 10.1073/pnas.86.16.6028; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Cacace AM, 1996, ONCOGENE, V13, P2517; Chun J, 1997, J CELL PHYSIOL, V173, P361, DOI 10.1002/(SICI)1097-4652(199712)173:3<361::AID-JCP8>3.0.CO;2-L; Chun JS, 1996, J BIOL CHEM, V271, P13008, DOI 10.1074/jbc.271.22.13008; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; GOMEZ J, 1995, EUR J IMMUNOL, V25, P2673, DOI 10.1002/eji.1830250941; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Horowitz A, 1996, AM J PHYSIOL-CELL PH, V271, pC589, DOI 10.1152/ajpcell.1996.271.2.C589; Huang XP, 1997, J CELL SCI, V110, P1625; Hurley JH, 1997, PROTEIN SCI, V6, P477; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P221; Lee HW, 1997, MOL PHARMACOL, V51, P439; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MORNET D, 1984, P NATL ACAD SCI-BIOL, V81, P3680, DOI 10.1073/pnas.81.12.3680; MOSSAKOWSKA M, 1993, BIOCHEM J, V289, P897, DOI 10.1042/bj2890897; ODONOGHUE SI, 1992, ARCH BIOCHEM BIOPHYS, V293, P110, DOI 10.1016/0003-9861(92)90372-4; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; Perletti G, 1996, BIOCHEM BIOPH RES CO, V221, P688, DOI 10.1006/bbrc.1996.0657; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; QUEST AFG, 1994, J BIOL CHEM, V269, P2000; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ReifelMiller AE, 1996, J BIOL CHEM, V271, P21666, DOI 10.1074/jbc.271.35.21666; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; SHARKEY NA, 1985, CANCER RES, V45, P19; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; VUORI K, 1993, J BIOL CHEM, V268, P21459	41	106	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26790	26798		10.1074/jbc.273.41.26790	http://dx.doi.org/10.1074/jbc.273.41.26790			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756923	hybrid			2022-12-25	WOS:000076373300077
J	Tolon, RM; Castillo, AI; Aranda, A				Tolon, RM; Castillo, AI; Aranda, A			Activation of the prolactin gene by peroxisome proliferator-activated receptor-alpha appears to be DNA binding-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X-RECEPTOR; RAT GROWTH-HORMONE; TRANSCRIPTION FACTOR; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; RESPONSE ELEMENTS; FATTY-ACIDS; PPAR-GAMMA; CROSS-TALK	Although the effects of the peroxisome proliferator-activated receptors (PPARs) have been studied primarily in adipocytes and liver, the wide distribution of these receptors suggests that they might also play a role in other cell types, We present evidence that PPAR activators stimulate the expression of the prolactin gene in pituitary GH4C1 cells. Transfection assays in non-pituitary HeLa cells showed that stimulation of the prolactin promoter by PPAR alpha requires the presence of the transcription factor GHF-1 (or Pit-1), Proximal promoter sequences confer responsiveness to PPAR alpha, and activation by this receptor is lost concomitantly with the response to GHF-1. Surprisingly, expression of the retinoid X receptor (RXR) abolishes stimulation by PPAR alpha, Furthermore, the promoter region that confers PPAR alpha responsiveness does not contain a PPAR response element. This suggests that the transcriptional effect of PPAR alpha might be mediated by protein-protein interactions rather than by binding of PPAR/RXR to the promoter. A direct interaction between PPAR alpha and GHF-1 was confirmed by in vitro binding studies, Expression of the coactivators SRC-1 and CREB-binding protein, which bind to PPAR, also enhanced the responsiveness of the prolactin promoter to PPAR alpha. Furthermore, CREB-binding protein also significantly increased activation by GHF-1, and both proteins associated in vitro, Thus, PPAR alpha, a receptor that normally acts as a ligand-dependent transcription factor by binding to specific DNA sequences in one context, can also stimulate the prolactin promoter by association with GHF-1 and coactivator proteins.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	aaranda@iib.uam.es	Aranda, Ana/ABG-8820-2020; Castillo, Ana/I-1269-2017; Tolón, Rosa/AAA-9401-2019; Tolón, Rosa M M/N-4364-2015	Aranda, Ana/0000-0002-8338-9589; Castillo, Ana/0000-0002-2873-1206; Tolón, Rosa M M/0000-0003-1087-4505				BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; ELSHOLTZ HP, 1992, SEMIN REPROD ENDOCR, V10, P183, DOI 10.1055/s-2007-1018875; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GarciaVillalba P, 1996, MOL CELL BIOL, V16, P318; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GUBBINS EJ, 1980, J BIOL CHEM, V255, P8655; GUTIERREZHARTMANN A, 1994, MOL ENDOCRINOL, V8, P1447, DOI 10.1210/me.8.11.1447; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; ING NH, 1992, J BIOL CHEM, V267, P17617; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JACOB KK, 1994, J BIOL CHEM, V269, P25515; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KELLER H, 1993, TRENDS ENDOCRIN MET, V4, P291, DOI 10.1016/1043-2760(93)90048-J; KELLER H, 1995, MOL ENDOCRINOL, V9, P794, DOI 10.1210/me.9.7.794; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MONTE D, 1995, ONCOGENE, V11, P771; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PALOMINO T, 1998, IN PRESS FASEB J; QI JS, 1995, MOL CELL BIOL, V15, P1817; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sanchez-Pacheco A, 1998, FEBS LETT, V422, P103, DOI 10.1016/S0014-5793(97)01609-8; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218	60	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26652	26661		10.1074/jbc.273.41.26652	http://dx.doi.org/10.1074/jbc.273.41.26652			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756906	hybrid			2022-12-25	WOS:000076373300060
J	Wan, HS; Dawson, MI; Hong, WK; Lotan, R				Wan, HS; Dawson, MI; Hong, WK; Lotan, R			Overexpressed activated retinoid X receptors can mediate growth inhibitory effects of retinoids in human carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; ACID RECEPTORS; CANCER CHEMOPREVENTION; SELECTIVE RETINOIDS; HORMONE RECEPTORS; RESPONSE PATHWAYS; RXR HETERODIMERS; ORPHAN RECEPTORS; BINDING; BETA	Retinoic acid receptors (RARs) and retinoid X receptors (RXRs) mediate the effects of retinoids on gene expression by binding to response elements in retinoid-sensitive genes. RAR- but not RXR-selective retinoids were found in many previous studies to suppress the growth of various cells, implicating RXR-RAR in these effects. Using a co-expression vector for identifying cells that expressed retinoid receptors transiently and 5'-bromo 2'-deoxyuridine incorporation for labeling DNA-synthesizing cells, we found that RXR-selective retinoids inhibited DNA synthesis in squamous carcinoma 1483 cells transfected with RXR alpha but not with RARs. Ligand-induced transcription of the reporter luciferase gene via the activation of RXR-RXR but not RXR-RAR correlated with growth suppression. Studies with RXR alpha deletion mutants indicated that the DNA binding and the ligand binding domains are essential for mediating growth inhibition. A point mutation in the ligand binding domain (L430F) that decreased RXR alpha homodimerization compromised its growth inhibitory function. Further, RXR alpha mutant (F313A), which functions as a constitutively active receptor, inhibited DNA synthesis in the absence of ligand. These results demonstrate that RXR homodimer activation leads to growth inhibition and suggest that transfection of RXR alpha and treatment with RXR-selective retinoids or the transfection of constitutively activated RXR alpha mutant alone may have a therapeutic potential.	Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; SRI Int, Retinoid Program, Menlo Pk, CA 94025 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; SRI International	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Box 108, Houston, TX 77030 USA.	rlotan@notes.mdacc.tmc.edu			NCI NIH HHS [P30 CA16672, P01 CA52051, P01 CA51993] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051, P01CA051993, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; DAVIS KD, 1994, MOL CELL BIOL, V14, P7105, DOI 10.1128/MCB.14.11.7105; DAWSON MI, 1994, BLOOD, V84, P446; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FRANGIONI JV, 1994, J CELL SCI, V107, P827; GENDIMENICO GJ, 1994, J INVEST DERMATOL, V102, P676, DOI 10.1111/1523-1747.ep12374092; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gudas Lorraine J., 1994, P443; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; JIANG H, 1995, BIOCHEM PHARMACOL, V50, P669, DOI 10.1016/0006-2952(95)00183-Z; Kersten S, 1997, J BIOL CHEM, V272, P12771, DOI 10.1074/jbc.272.19.12771; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LeDouarin B, 1996, PHILOS T R SOC B, V351, P569, DOI 10.1098/rstb.1996.0056; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; Li C, 1996, DNA CELL BIOL, V15, P955, DOI 10.1089/dna.1996.15.955; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; Lipkin SM, 1996, J VIROL, V70, P7182, DOI 10.1128/JVI.70.10.7182-7189.1996; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOTAN R, 1995, CANCER RES, V55, P232; LOTAN R, 1995, RETINOIDS ONCOLOGY, P27; MADER S, 1993, J BIOL CHEM, V268, P591; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MEDIN JA, 1994, MOL CELL ENDOCRINOL, V105, P27, DOI 10.1016/0303-7207(94)90032-9; Mehta K, 1996, CELL GROWTH DIFFER, V7, P179; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; Pignatello MA, 1997, TOXICOL APPL PHARM, V142, P319, DOI 10.1006/taap.1996.8047; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SACKS PG, 1988, CANCER RES, V48, P2858; Stroup D, 1997, J BIOL CHEM, V272, P9833; Sun SY, 1997, CANCER RES, V57, P4931; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; UNDERHILL TM, 1994, MOL ENDOCRINOL, V8, P274, DOI 10.1210/me.8.3.274; Vivat V, 1997, EMBO J, V16, P5697, DOI 10.1093/emboj/16.18.5697; Willhite CC, 1996, DRUG METAB REV, V28, P105, DOI 10.3109/03602539608993994; XIAO JH, 1995, J BIOL CHEM, V270, P3001, DOI 10.1074/jbc.270.7.3001; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZOU CP, 1994, CANCER RES, V54, P5479	48	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26915	26922		10.1074/jbc.273.41.26915	http://dx.doi.org/10.1074/jbc.273.41.26915			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756939	hybrid			2022-12-25	WOS:000076373300093
J	Yamamoto, M; Toya, Y; Schwencke, C; Lisanti, MP; Myers, MG; Ishikawa, Y				Yamamoto, M; Toya, Y; Schwencke, C; Lisanti, MP; Myers, MG; Ishikawa, Y			Caveolin is an activator of insulin receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE CELLS; TYROSINE PHOSPHORYLATION; MEMBRANE DOMAINS; 3T3-L1 CELLS; GENE FAMILY; EXPRESSION; PROTEIN; PURIFICATION; KINASE	Recent data have demonstrated that caveolin, a major structural protein of caveolae, negatively regulates signaling molecules localized to caveolae, The interaction of caveolin with several caveolae-associated signaling proteins is mediated by the binding of the scaffolding region of caveolin to a hydrophobic amino acid-containing region within the regulated proteins. The presence of a similar motif within the insulin receptor kinase prompted us to investigate the caveolar localization and regulation of the insulin receptor by caveolin, We found that overexpression of caveolin-3 augmented insulin-stimulated phosphorylation of insulin receptor substrate-1 in 293T cells but not the phosphorylation of insulin receptor. Peptides corresponding to the scaffolding domain of caveolin potently stimulated insulin receptor kinase activity toward insulin receptor substrate-1 or a Src-derived peptide in vitro and in a caveolin subtype-dependent fashion. Peptides from caveolin-2 exhibited no effect, whereas caveolin-1 and -3 stimulated activity 10- and 17-fold, respectively. Peptides which increased insulin receptor kinase activity did so without affecting insulin receptor auto-phosphorylation. Furthermore, the insulin receptor bound to immobilized caveolin peptides, and this binding was inhibited in the presence of free caveolin-3 peptides. Thus, we have identified a novel mechanism by which the insulin receptor is bound and activated by specific caveolin subtypes, Furthermore, these data define a new role for caveolin as an activator of signaling.	Allegheny Univ Hlth Sci, Cardiovasc & Pulm Res Inst, Pittsburgh, PA 15212 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA	Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Ishikawa, Y (corresponding author), Allegheny Univ Hlth Sci, Cardiovasc & Pulm Res Inst, Pittsburgh, PA 15212 USA.	yishikaw@pgh.auhs.edu	Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; 	NHLBI NIH HHS [HL59139, HL59729] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL059729, P01HL059139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN J, 1998, J BIOL CHEM, V268, P7571; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; Huppertz C, 1996, DIABETOLOGIA, V39, P1432, DOI 10.1007/s001250050595; ISHIKAWA Y, 1992, NUCLEIC ACIDS RES, V20, P4367, DOI 10.1093/nar/20.16.4367; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, MOL MEMBR BIOL, V12, P121, DOI 10.3109/09687689509038506; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; Munoz P, 1996, J BIOL CHEM, V271, P8133, DOI 10.1074/jbc.271.14.8133; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; PIKE LJ, 1986, J BIOL CHEM, V261, P3782; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Scherer PE, 1997, J BIOL CHEM, V272, P20698, DOI 10.1074/jbc.272.33.20698; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SIMIONESCU N, 1983, PHYSIOL REV, V63, P1536, DOI 10.1152/physrev.1983.63.4.1536; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; SUN XJ, 1992, J BIOL CHEM, V267, P22662; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; VILLALBA M, 1989, P NATL ACAD SCI USA, V86, P7848, DOI 10.1073/pnas.86.20.7848; WHITE MF, 1994, J BIOL CHEM, V269, P1	42	254	261	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26962	26968		10.1074/jbc.273.41.26962	http://dx.doi.org/10.1074/jbc.273.41.26962			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756945	hybrid			2022-12-25	WOS:000076373300099
J	Zhang, FX; Rubin, R; Rooney, TA				Zhang, FX; Rubin, R; Rooney, TA			N-methyl-D-aspartate inhibits apoptosis through activation of phosphatidylinositol 3-kinase in cerebellar granule neurons - A role for insulin receptor substrate-1 in the neurotrophic action of N-methyl-D-aspartate and its inhibition by ethanol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCITATORY AMINO-ACIDS; CENTRAL-NERVOUS-SYSTEM; FETAL ALCOHOL SYNDROME; PROTEIN-KINASE AKT; IGF-I RECEPTOR; GROWTH-FACTOR; GLUTAMATE RECEPTORS; CELL-DEATH; SURVIVAL; NMDA	Primary cultured rat cerebellar granule neurons underwent apoptosis when switched from medium containing 25 mM K+ to one containing 5 mM K+, N-methyl-D-aspartate (NMDA) protected granule neurons from apoptosis in medium containing 5 mM K+. Inhibition of apoptosis by NMDA was blocked by the phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor LY294002, but it was unaffected by the mitogen-activated protein kinase kinase inhibitor PD 98059. The antiapoptotic action of NMDA was associated with an increase in the tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), an increase in the binding of the regulatory subunit of PI 3-kinase to IRS-1, and a stimulation of PI 3-kinase activity. In the absence of extracellular Ca2+, NMDA was unable to prevent apoptosis or to phosphorylate IRS-1 and activate PI 3-kinase. Significant inhibition of NMDA-mediated neuronal survival by ethanol (10-15%) was observed at 1 mM, and inhibition was half-maximal at 45-50 rmM. Inhibition of neuronal survival by ethanol corresponded with a marked reduction in the capacity of NMDA to increase the concentration of intracellular Ca2+, phosphorylate IRS-1, and activate PI 3-kinase, These data demonstrate that the neurotrophic action of NMDA and its inhibition by ethanol are mediated by alterations in the activity of a PI 3-kinase-dependent antiapoptotic signaling pathway.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Rooney, TA (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 1020 Locust St, Philadelphia, PA 19107 USA.	rooneyt@jeflin.tju.edu			NIAAA NIH HHS [K02 AA123, AA09976, AA10413] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009976, R29AA010413] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BALAZS R, 1992, MOL NEUROPHARMACOL, V2, P203; Barnard EA, 1997, TRENDS PHARMACOL SCI, V18, P141, DOI 10.1016/S0165-6147(97)01053-5; BAUERMOFFETT C, 1977, BRAIN RES, V119, P249, DOI 10.1016/0006-8993(77)90310-9; Bhave SV, 1997, J NEUROCHEM, V68, P578, DOI 10.1046/j.1471-4159.1997.68020578.x; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; CHOI DW, 1994, PROG BRAIN RES, V100, P47; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FARR KL, 1988, ALCOHOL, V5, P125, DOI 10.1016/0741-8329(88)90009-2; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GALLO V, 1987, J NEUROSCI, V7, P2203; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; JONES KL, 1973, LANCET, V2, P999; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; KATO H, 1993, J BIOL CHEM, V268, P2655; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MANEV H, 1989, MOL PHARMACOL, V36, P106; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; MARCUS JC, 1987, NEUROPEDIATRICS, V18, P158, DOI 10.1055/s-2008-1052471; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Miller TM, 1997, J BIOL CHEM, V272, P9847; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MORRISETT RA, 1989, ALCOHOL, V6, P415, DOI 10.1016/0741-8329(89)90013-X; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Ono T, 1997, J BIOL CHEM, V272, P14404, DOI 10.1074/jbc.272.22.14404; PANTAZIS NJ, 1995, ALCOHOL CLIN EXP RES, V19, P846, DOI 10.1111/j.1530-0277.1995.tb00957.x; PANTAZIS NJ, 1993, ALCOHOL CLIN EXP RES, V17, P1014, DOI 10.1111/j.1530-0277.1993.tb05657.x; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; QUEEN SA, 1993, ALCOHOL CLIN EXP RES, V17, P887, DOI 10.1111/j.1530-0277.1993.tb00859.x; RESNICOFF M, 1994, LAB INVEST, V71, P657; RESNICOFF M, 1993, J BIOL CHEM, V268, P21777; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLK B, 1984, ACTA NEUROPATHOL, V63, P57, DOI 10.1007/BF00688471; WEGELIUS K, 1995, ACTA PHYSIOL SCAND, V154, P25, DOI 10.1111/j.1748-1716.1995.tb09882.x; WOODWARD JJ, 1990, J NEUROCHEM, V54, P712, DOI 10.1111/j.1471-4159.1990.tb01931.x; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; YAN GM, 1994, BRAIN RES, V656, P43, DOI 10.1016/0006-8993(94)91364-1; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang FX, 1998, J NEUROCHEM, V71, P196, DOI 10.1046/j.1471-4159.1998.71010196.x; ZOU JY, 1995, ALCOHOL CLIN EXP RES, V19, P840, DOI 10.1111/j.1530-0277.1995.tb00956.x	61	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26596	26602		10.1074/jbc.273.41.26596	http://dx.doi.org/10.1074/jbc.273.41.26596			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756898	hybrid			2022-12-25	WOS:000076373300052
J	Elliott, J; Jones, MD; Griffin, BE; Krauzewicz, N				Elliott, J; Jones, MD; Griffin, BE; Krauzewicz, N			Regulation of cytoskeletal association by a basic amino acid motif in polyoma virus middle T antigen	ONCOGENE			English	Article						CaaX box; cytoskeleton; green fluorescent protein; middle T antigen	MEDIUM TUMOR-ANTIGEN; SRC GENE-PRODUCT; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL KINASE; ONCOGENIC TRANSFORMATION; SIGNAL-TRANSDUCTION; STRUCTURAL PROTEINS; COMPLEX-FORMATION; CELL-MEMBRANES; EARLY REGION	The subcellular localization of many oncogenic proteins is thought to be important for their function. In the case of the middle T antigen of the DNA tumour virus, polyoma, localization to membranes in a specific manner is essential for its cellular transforming activity. To investigate factors that influence this localization, heterologous membrane targetting sequences were substituted for the middle T antigen transmembrane domain and the properties of the resulting proteins studied. Whereas G-terminal lipid modification derived from the H-ras CaaX box restored oncogenic activity to nontransforming truncated middle T antigen species, N-terminal myristylation from pp60c-src did not. Furthermore, a region, rich in basic amino acids and adjacent to the middle T transmembrane domain, was found to mediate association with detergent-insoluble cytoskeleton. Go-operation between the basic motif and neighbouring membrane binding domains resulted in specific localization of proteins to particular membrane sites, characterized by the association with subcellular structures, likely to be cytoskeletal in nature. These results demonstrate that the cellular localization of MT is regulated by at least two determinants, a transmembrane sequence which confers membrane binding and a basic motif which specifies a particular site within the membrane.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis, London W12 0NN, England	Imperial College London	Krauzewicz, N (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis, 7th Floor,Du Cane Rd, London W12 0NN, England.							ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; BALLMERHOFER K, 1987, VIRUS RES, V6, P345, DOI 10.1016/0168-1702(87)90066-9; BOLEN JB, 1984, J BIOL CHEM, V259, P1686; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1989, ONCOGENE RES, V4, P75; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DAHL J, 1992, MOL CELL BIOL, V12, P5050, DOI 10.1128/MCB.12.11.5050; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; DILWORTH SM, 1986, EMBO J, V5, P491, DOI 10.1002/j.1460-2075.1986.tb04238.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; Doherty J, 1997, ONCOGENE, V14, P1923, DOI 10.1038/sj.onc.1201025; FORSTOVA J, 1993, J VIROL, V67, P1405; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRIFFIN BE, 1979, J VIROL, V31, P645, DOI 10.1128/JVI.31.3.645-656.1979; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; ITO Y, 1977, P NATL ACAD SCI USA, V74, P4666, DOI 10.1073/pnas.74.10.4666; JANIAK F, 1994, J BIOL CHEM, V269, P9842; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KRAUZEWICZ N, 1994, ONCOGENE, V9, P2283; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Messerschmitt A, 1996, J GEN VIROL, V77, P17, DOI 10.1099/0022-1317-77-1-17; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; PALLAS DC, 1989, J VIROL, V63, P4533, DOI 10.1128/JVI.63.11.4533-4539.1989; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SCHAFFHAUSEN BS, 1982, MOL CELL BIOL, V2, P1187, DOI 10.1128/MCB.2.10.1187; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SOEDA E, 1980, NATURE, V283, P445, DOI 10.1038/283445a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STRAUSS M, 1986, GENE, V49, P331, DOI 10.1016/0378-1119(86)90369-0; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TEMPLETON D, 1984, MOL CELL BIOL, V4, P282, DOI 10.1128/MCB.4.2.282; Topp WC, 1981, DNA TUMOR VIRUSES 2, P205; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1987, J VIROL, V61, P405, DOI 10.1128/JVI.61.2.405-410.1987; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WYSS A, 1990, J VIROL, V64, P5163, DOI 10.1128/JVI.64.10.5163-5166.1990; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	61	9	9	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1797	1806		10.1038/sj.onc.1202083	http://dx.doi.org/10.1038/sj.onc.1202083			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778045				2022-12-25	WOS:000076303300005
J	Fujii, M; Hayashi, K; Niki, M; Chiba, N; Meguro, K; Endo, K; Kameoka, J; Ito, S; Abe, K; Watanabe, T; Satake, M				Fujii, M; Hayashi, K; Niki, M; Chiba, N; Meguro, K; Endo, K; Kameoka, J; Ito, S; Abe, K; Watanabe, T; Satake, M			Overexpression of AML1 renders a T hybridoma resistant to T cell receptor-mediated apoptosis	ONCOGENE			English	Article						AML1/PEBP2 alpha B/CBFA2; T lymphocyte; apoptosis; transcription factor; Fas-ligand	ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; PROTEIN-PROTEIN INTERACTIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; RUNT DOMAIN; TRANSCRIPTION FACTOR; FUSION TRANSCRIPT; DNA-BINDING; PROTOONCOGENE PRODUCT; DELTA-ENHANCER	The AML1 gene, which encodes the DNA binding subunit of the heterodimeric transcription factor, PEBP2/CBF, is involved in several types of chromosomal translocations associated with human acute myeloid leukemia, and has been shown by gene targeting to be essential for the development of definitive hematopoiesis in the murine fetal liver. In addition, the gene is expressed abundantly in T lymphocytes and has been implicated in T cell specific gene expression. In the present study we examined the function of AML1 in T cell receptor (TCR)-mediated, Fas/Fas-ligand dependent apoptosis of a T hybridoma Line, DO11.10, Several independent cell clones overexpressing the AML1 protein were isolated by transfecting AML1 cDNA into these cells. These clones possessed an increased level of PEBP2/CBF DNA binding activity and were found to be resistant to apoptosis induced by anti-CD3 antibody treatment. Northern blot analysis revealed that induction of the Fas-ligand transcript was markedly suppressed in the anti-CD3 treated clones. Instead, expression of IL-2 receptor alpha subunit (IL-2R alpha), which is a manifestation of proliferative TCR signaling, was induced. This was in contrast to the parental, anti-CD3 treated DO11.10 cells where induction of Fas-ligand but not of IL-2R alpha was observed. Resistance of the AML1 overexpressing cell clones to TCR-mediated apoptosis is most likely attributable to the lack of Fas-ligand induction, since simultaneous treatment with anti-CD3 and anti-Fas antibodies caused apoptosis of the clones. The overall results suggest that the AML1 protein may play a pivotal role in switching TCR signaling between apoptosis and cell proliferation in T lymphocytes.	Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Dept Internal Med 2, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University	Satake, M (corresponding author), Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Seiryo Machi, Sendai, Miyagi 9808575, Japan.		Ito, Sadayoshi/A-3933-2015	Ito, Sadayoshi/0000-0002-5092-3626				BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CALNAN BJ, 1995, IMMUNITY, V3, P273; Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; Cui HL, 1996, CELL IMMUNOL, V167, P276, DOI 10.1006/cimm.1996.0036; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ERICKSON P, 1992, BLOOD, V80, P1825; Frank R, 1995, ONCOGENE, V11, P2667; Fujioka M, 1996, GENES CELLS, V1, P741, DOI 10.1111/j.1365-2443.1996.tb00014.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Latinis KM, 1997, J IMMUNOL, V158, P4602; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OKABE T, 1995, J IMMUNOL, V154, P3871; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SHIMIZU A, 1985, NUCLEIC ACIDS RES, V139, P1505; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Tanaka Y, 1997, ONCOGENE, V15, P677, DOI 10.1038/sj.onc.1201235; Uchida H, 1997, J IMMUNOL, V158, P2251; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WARGNIER A, 1995, P NATL ACAD SCI USA, V92, P6930, DOI 10.1073/pnas.92.15.6930; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WIJMENGA C, 1995, GENOMICS, V26, P611, DOI 10.1016/0888-7543(95)80185-O; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Zhang H, 1996, J AUTOM REASONING, V16, P1, DOI 10.1007/BF00244457	67	24	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1813	1820		10.1038/sj.onc.1202087	http://dx.doi.org/10.1038/sj.onc.1202087			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778047				2022-12-25	WOS:000076303300007
J	Mohan, R; Rinehart, WB; Bargagna-Mohan, P; Fini, ME				Mohan, R; Rinehart, WB; Bargagna-Mohan, P; Fini, ME			Gelatinase B/lacZ transgenic mice, a model for mapping gelatinase B expression during developmental and injury related tissue remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE GENE; MATRIX METALLOPROTEINASES; TRANSCRIPTION FACTOR; KERATIN GENE; 92-KDA; CELLS; MIGRATION; 72-KDA; MACROPHAGES; PHENOTYPE	Matrix metalloproteinases (MMPs) drive normal tissue remodeling and are implicated in a wide range of pathologies, Although MMP activity is controlled at multiple levels, the primary regulation of MMP activity is transcriptional. The transcriptional promoter elements required for MMP gene expression in cultured cells have been defined, but this has not been extended to the in vivo situation. In this paper, we show that the DNA sequences between -522 and +19 of the rabbit gelatinase B gene (MMP-9) (as characterized in the transgenic mouse line 3445) constitute a minimal promoter that drives appropriate developmental and injury-induced reporter gene expression in transgenic mice. We further show that the expression and activity of three transcription factors (NF-kappa B, AP-2, and Sp1) that control the activity of the gelatinase B promoter are selectively induced in the epithelium migrating to heal a wound. Although promoter activity parallels expression of the endogenous gene in cell cultures, we show by several criteria that cell cultures cannot model many aspects of promoter regulation in vivo. This study reveals that the transgenic mouse line 3445 might be a useful model for investigating the regulation of gelatinase B expression in vivo and for identifying and characterizing new drugs that can control gelatinase B gene transcription.	New England Med Ctr, Vis Res Labs, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Anat, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Cell Biol, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University; Tufts University	Fini, ME (corresponding author), New England Med Ctr, Vis Res Labs, 750 Washington St,POB 450, Boston, MA 02111 USA.	efini@opal.tufts.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042981] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42981] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Backstrom JR, 1996, J NEUROSCI, V16, P7910; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BRINCKERHOFF C E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P145; BROWN PD, 1997, MATRIX METALLOPROTEI, P243; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CANETESOLER R, 1995, DEV DYNAM, V204, P30, DOI 10.1002/aja.1002040105; CANETESOLER R, 1995, DEV BRAIN RES, V88, P37; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; Chin JR, 1997, DEVELOPMENT, V124, P1519; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; CUI CQ, 1994, TRANSGENIC RES, V3, P182, DOI 10.1007/BF01973986; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINI ME, 1995, INVEST OPHTH VIS SCI, V36, P622; FINI ME, 1994, J BIOL CHEM, V269, P28620; FINI ME, 1990, INVEST OPHTH VIS SCI, V31, P1779; Fini ME, 1996, AM J PATHOL, V149, P1287; FINI ME, 1997, MATRIX METALLOPROTEI, P299; FISHER SJ, 1989, J CELL BIOL, V109, P891, DOI 10.1083/jcb.109.2.891; FREESTONE T, 1995, ARTERIOSCL THROM VAS, V15, P1145, DOI 10.1161/01.ATV.15.8.1145; FUJIKAWA LS, 1984, J CELL BIOL, V98, P128, DOI 10.1083/jcb.98.1.128; GEORGESCU HI, 1988, IN VITRO CELL DEV B, V24, P1015; GIRARD MT, 1991, INVEST OPHTH VIS SCI, V32, P2441; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Harlow E., 1988, ANTIBODIES LAB MANUA; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; Lelievre S, 1996, RECENT PROG HORM RES, V51, P417; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; MATSUBARA M, 1991, INVEST OPHTH VIS SCI, V32, P92; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NGUYEN Q, 1993, BIOCHEM J, V295, P595, DOI 10.1042/bj2950595; Obana N, 1996, J DERMATOL SCI, V13, P83, DOI 10.1016/0923-1811(95)00506-4; OIKARINEN A, 1993, J INVEST DERMATOL, V101, P205, DOI 10.1111/1523-1747.ep12363823; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; REPONEN P, 1995, DEV DYNAM, V202, P388, DOI 10.1002/aja.1002020408; SALO T, 1991, J BIOL CHEM, V266, P11436; SALO T, 1994, LAB INVEST, V70, P176; Sambrook J., 2002, MOL CLONING LAB MANU; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shipley JM, 1996, J BIOL CHEM, V271, P4335; Sorbi D, 1996, ARTHRITIS RHEUM-US, V39, P1747, DOI 10.1002/art.1780391019; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Sullivan RW, 1998, J MED CHEM, V41, P413, DOI 10.1021/jm970671g; VU TH, 1997, MATRIX METALLOPROTEI, P115; WASSERMAN PM, 1993, METHOD ENZYMOL, V225, P319; West-Mays J. A., 1996, Investigative Ophthalmology and Visual Science, V37, pS354; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WOESSNER JF, 1997, MATRIX METALLOPROTEI, P1	56	88	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25903	25914		10.1074/jbc.273.40.25903	http://dx.doi.org/10.1074/jbc.273.40.25903			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748266	hybrid			2022-12-25	WOS:000076263100057
J	Ohno, H; Aguilar, RC; Yeh, D; Taura, D; Saito, T; Bonifacino, JS				Ohno, H; Aguilar, RC; Yeh, D; Taura, D; Saito, T; Bonifacino, JS			The medium subunits of adaptor complexes recognize distinct but overlapping sets of tyrosine-based sorting signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; FACTOR-II RECEPTOR; MEMBRANE-PROTEIN; INTERNALIZATION SIGNALS; RAPID INTERNALIZATION; TRANSFERRIN RECEPTOR; CYTOPLASMIC TAIL; PLASMA-MEMBRANE; AP-2 COMPLEXES; MEDIUM CHAINS	Tyrosine-based sorting signals conforming to the motif YXXO (Y is tyrosine, X is any amino acid, and O is an amino acid with a bulky hydrophobic side chain (leucine, isoleucine, phenylalanine, methionine, valine)) interact with the medium (mu) subunits of clathrin adaptor (AP) complexes. We have analyzed the selectivity of interaction between YXXO signals and the mu 1, mu 2, and mu 3 (A or B) subunits of the AP-1, AP-2, and AP-3 complexes, respectively, by screening a combinatorial XYXYXXO library using the yeast two-hybrid system. All the medium subunits were found to prefer proline at position Y+2, suggesting that YXXO signals are stabilized by a bend in the polypeptide backbone. Other than for this common preference, each medium subunit favored specific sets of residues at the X and O positions; these preferences were consistent with the proposed roles of the different adaptor complexes in rapid endocytosis and lysosomal targeting. A considerable specificity overlap was also revealed by these analyses, suggesting that additional factors, such as the context of the signals, must be important determinants of recognition.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Chiba Univ, Grad Sch Med, Div Mol Genet, Chuo Ku, Chiba 2608670, Japan	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Chiba University	Bonifacino, JS (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bldg 18T Rm 101,18 Lib Dr,MSC 5430, Bethesda, MD 20892 USA.	juan@helix.nih.gov	Ohno, Hiroshi/L-7899-2014; Saito, Takashi/C-9684-2009	Ohno, Hiroshi/0000-0001-8776-9661; Saito, Takashi/0000-0001-9495-3547; Bonifacino, Juan S./0000-0002-5673-6370				Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chuang E, 1997, J IMMUNOL, V159, P144; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Gough NR, 1997, J CELL BIOL, V137, P1161, DOI 10.1083/jcb.137.5.1161; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JADOT M, 1992, J BIOL CHEM, V267, P11069; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Medley QG, 1996, P NATL ACAD SCI USA, V93, P685, DOI 10.1073/pnas.93.2.685; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Motulsky H., 1995, INTUITIVE BIOSTATIST; NAIM HY, 1994, J BIOL CHEM, V269, P3928; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OHNO H, 1998, GENE AMST, V2, P187; Ooi CE, 1997, EMBO J, V16, P4508; PEVSNER J, 1994, GENE, V146, P279, DOI 10.1016/0378-1119(94)90306-9; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Seymour AB, 1997, MOL BIOL CELL, V8, P1316; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; Stephens DJ, 1997, J BIOL CHEM, V272, P14104, DOI 10.1074/jbc.272.22.14104; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P9273, DOI 10.1073/pnas.94.17.9273; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	202	205	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25915	25921		10.1074/jbc.273.40.25915	http://dx.doi.org/10.1074/jbc.273.40.25915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748267	hybrid			2022-12-25	WOS:000076263100058
J	Zimmer, KP; Naim, H; Weber, P; Ellis, HJ; Ciclitira, PJ				Zimmer, KP; Naim, H; Weber, P; Ellis, HJ; Ciclitira, PJ			Targeting of gliadin peptides, CD8, alpha/beta-TCR, and gamma/delta-TCR to Golgi complexes and vacuoles within celiac disease enterocytes	FASEB JOURNAL			English	Article						endoplasmic reticulum; T cell receptor; trans-Golgi network	T-CELL-RECEPTOR; MAJOR HISTOCOMPATIBILITY COMPLEX; INTESTINAL EPITHELIAL-CELLS; HLA-DR; MONOCLONAL-ANTIBODIES; ORGAN-CULTURE; EXPRESSION; ANTIGEN; LYMPHOCYTES; ASSOCIATION	Celiac disease (CD) is characterized by autodestruction of enterocytes after exposure of genetically susceptible individuals to dietary gluten. To define the transport pathways of proteins involved in the celiac immune response, we wished to determine the subcellular compartments of the intestinal mucosa where wheat gliadin peptides colocalize with receptors of T lymphocytes, including alpha/beta-TCR, gamma/delta-TCR, and CD8. Semithin and ultrathin frozen section of jejunal biopsies from CD patients and controls were used to perform immunofluorescence and immunogold labeling as well as in situ hybridization experiments. In patients with active CD, we detected gliadin peptides in vacuoles and Golgi complexes of enterocytes. CD8, alpha/beta-TCR, and gamma/delta-TCR were found in vacuoles and Golgi complexes within these enterocytes in addition to the surface of intraepithelial and mucosal T lymphocytes. In contrast, we observed that the localization of CD4, CD3, T cell-restricted intracellular antigen (TIA.), and leukocyte common antigen (LCA) was restricted to lymphocytes in CD patients. We further detected labeling signals for gliadin peptides, CD8, alpha/beta-TCR, and gamma/delta-TCR at the basal membrane of enterocytes that were interdigitated by extensions of lymphocytes. In situ hybridization experiments revealed that CD8 and gamma/delta-TCR were not expressed by CD enterocytes. We conclude that CD8, alpha/beta-TCR, and y/6TCR are targeted to Golgi complexes and vacuoles of small intestinal enterocytes in active CD. The observed process may be involved in the pathogenesis of CD enterocytes. We propose a mechanism for the uptake of CD8, alpha/beta-TCR, and gamma/delta-TCR by the basolateral membrane of small intestinal enterocytes.	Univ Munster, Kinderklin, D-48149 Munster, Germany; Tierarztlichen Hsch Hannover, Inst Physiol Chem, D-30559 Hannover, Germany; United Med & Dent Sch Guys & St Thomas Hosp, St Thomas Hosp, Gastroenterol Unit, London SE1 7EH, England	University of Munster; University of Veterinary Medicine Hannover, Foundation; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Zimmer, KP (corresponding author), Univ Munster, Kinderklin, Albert Schweitzer Str 33, D-48149 Munster, Germany.	zimmerp@uni-muenster.de	Zimmer, Klaus-Peter/AAY-9261-2020; Zimmer, Klaus-Peter/AAY-9351-2020		NIDDK NIH HHS [R01 DK47716] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZIL V, 1995, IMMUNOL TODAY, V16, P135, DOI 10.1016/0167-5699(95)80130-8; BLANCO A, 1995, ADV EXP MED BIOL, V371, P1355; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; CICLITIRA PJ, 1985, BRIT J NUTR, V53, P39, DOI 10.1079/BJN19850008; CICLITIRA PJ, 1986, CLIN EXP IMMUNOL, V63, P101; DERITIS G, 1988, GASTROENTEROLOGY, V94, P41, DOI 10.1016/0016-5085(88)90607-5; ELLIS HJ, 1993, SCAND J GASTROENTERO, V28, P212, DOI 10.3109/00365529309096074; FAIS S, 1992, GUT, V33, P472, DOI 10.1136/gut.33.4.472; FRIIS S, 1992, GUT, V33, P1498; GJERTSEN HA, 1994, HUM IMMUNOL, V39, P243, DOI 10.1016/0198-8859(94)90267-4; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; HALSTENSEN TS, 1991, IMMUNOL RES, V10, P493, DOI 10.1007/BF02919747; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HOLM K, 1992, LANCET, V339, P1500, DOI 10.1016/0140-6736(92)91262-7; MARLEY NJE, 1987, CLIN EXP IMMUNOL, V70, P386; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; Moss SF, 1996, GUT, V39, P811, DOI 10.1136/gut.39.6.811; MOTHES T, 1989, BIOMED BIOCHIM ACTA, V48, P137; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NORMENT AM, 1989, J IMMUNOL, V142, P3312; PETERS PJ, 1990, IMMUNOL TODAY, V11, P28; REGOECZI E, 1982, P NATL ACAD SCI-BIOL, V79, P2226, DOI 10.1073/pnas.79.7.2226; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; RUST C, 1992, SCAND J IMMUNOL, V35, P459, DOI 10.1111/j.1365-3083.1992.tb02881.x; SCRIVASTAVA MD, 1995, RES COMMUN MOL PATH, V87, P21; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STURGESS R, 1994, LANCET, V343, P758, DOI 10.1016/S0140-6736(94)91837-6; STURGESS R, 1993, CURR OPIN GASTROEN, V9, P242, DOI 10.1097/00001574-199303000-00009; TAKAHASHIIWANAGA H, 1995, CELL TISSUE RES, V280, P491; TOKUYASU KT, 1978, J ULTRA MOL STRUCT R, V63, P287, DOI 10.1016/S0022-5320(78)80053-7; TONER PG, 1971, J ULTRA MOL STRUCT R, V34, P329, DOI 10.1016/S0022-5320(71)80076-X; TREJDOSIEWICZ LK, 1995, BAILLIERE CLIN GASTR, V9, P251, DOI 10.1016/0950-3528(95)90031-4; TRIER JS, 1991, NEW ENGL J MED, V325, P1709, DOI 10.1056/NEJM199112123252406; TRUGNAN G, 1987, J CELL BIOL, V104, P1199, DOI 10.1083/jcb.104.5.1199; TUCKOVA L, 1995, CLIN IMMUNOL IMMUNOP, V74, P170, DOI 10.1006/clin.1995.1025; ULMER JB, 1994, EUR J IMMUNOL, V24, P1590, DOI 10.1002/eji.1830240721; VOLZ B, 1995, J CELL BIOL, V130, P537, DOI 10.1083/jcb.130.3.537; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909; WIESER H, 1986, Z LEBENSM UNTERS FOR, V182, P115, DOI 10.1007/BF01454241; YEH CJG, 1990, PLACENTA, V11, P253, DOI 10.1016/S0143-4004(05)80272-3; ZIMMER KP, 1995, GUT, V36, P703, DOI 10.1136/gut.36.5.703	43	27	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1349	1357		10.1096/fasebj.12.13.1349	http://dx.doi.org/10.1096/fasebj.12.13.1349			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761778				2022-12-25	WOS:000076402000010
J	Townsend, KJ; Trusty, JL; Traupman, MA; Eastman, A; Craig, RW				Townsend, KJ; Trusty, JL; Traupman, MA; Eastman, A; Craig, RW			Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C	ONCOGENE			English	Article						MCL1; BCL2; mitogen activated protein kinase; extracellular signal-regulated kinase	MYELOID-LEUKEMIA CELLS; NECROSIS-FACTOR-ALPHA; HAMSTER OVARY CELLS; MAP KINASE; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; TRANSCRIPTIONAL REGULATION; INDUCED APOPTOSIS; FAMILY MEMBER; DNA-SYNTHESIS	Members of both the mitogen activated protein (MAP) kinase and BCL2 gene families, acting in concert with other gene products, are involved in the regulation of cell viability. However, the relationship between these families, and the signal transduction networks that control viability-regulating genes, are only beginning to be elucidated, MCL1 is a viability-promoting member of the BCL2 family that exhibits a rapid increase in expression in response to specific differentiation- and apoptosis-inducing stimuli. The signal transduction pathway involved in eliciting this increase has now been investigated. In the ML-1 human myeloblastic leukemia cell line, a rapid and sustained increase in phosphorylation of the extracellular signal-regulated kinase (ERK) members of the MAP kinase family was found to precede the increase in MCL1 expression produced by 12-O-tetradecanoylphorbol 13-acetate (TPA) or the microtubule-disrupting agents colchicine and vinblastine. ERK activation was necessary for the increase in MCL1, as inhibition of the increase in ERK phosphorylation (with the inhibitor PD 98059) prevented the increase in MCL1 expression and caused rapid cell death by apoptosis, In addition, other agents that markedly increased ERK phosphorylation (lipopolysaccharide, okadaic acid) also increased MCL1 expression. In contrast, agents that did not have this marked effect did not increase MCL1, Upstream components in this ERK-mediated pathway were also identified, where the pathway was found to be stimulated by microtubule disruption acting through protein kinase C (PKC). These results indicate that expression of the MCL1 viability-enhancing gene is regulated through a cytoskeletal disruption-induced ERK-mediated signal, transduction pathway. They therefore suggest a mechanism through which the cytoskeleton and MAP kinases can exert effects on cell viability.	Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	Craig, RW (corresponding author), Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.				NATIONAL CANCER INSTITUTE [R01CA057359, T32CA009658, R55CA050224, R01CA050224] Funding Source: NIH RePORTER; NCI NIH HHS [CA57359, CA50224, CA09658, R01 CA057359] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BASU A, 1992, BIOCHEMISTRY-US, V31, P3824, DOI 10.1021/bi00130a013; BHALLA K, 1993, LEUKEMIA, V7, P563; Blagosklonny MV, 1997, CANCER RES, V57, P130; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BRADSHAW TD, 1992, INT J CANCER, V51, P144, DOI 10.1002/ijc.2910510125; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; CARNEY DH, 1986, ANN NY ACAD SCI, V466, P919, DOI 10.1111/j.1749-6632.1986.tb38477.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; CRAIG RW, 1984, CANCER RES, V44, P2421; CROSSIN KL, 1981, CELL, V23, P61, DOI 10.1016/0092-8674(81)90270-1; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Ding AH, 1996, J EXP MED, V183, P1899, DOI 10.1084/jem.183.4.1899; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Duke R. C., 1991, CURRENT PROTOCOLS IM, V1; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; Glanz J, 1997, SCIENCE, V276, P678; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; Guan X P, 1989, Cancer Commun, V1, P111; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1997, CANCER RES, V57, P229; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Itoh T, 1996, J BIOL CHEM, V271, P27931, DOI 10.1074/jbc.271.44.27931; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KILEY SC, 1995, J CELL SCI, V108, P1003; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; LIU MK, 1994, J IMMUNOL, V153, P2642; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MANIE S, 1993, J BIOL CHEM, V268, P13675; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MAY WS, 1994, J BIOL CHEM, V269, P26865; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; Plevin R, 1996, BIOCHEM J, V318, P657, DOI 10.1042/bj3180657; REYNOLDS JE, 1994, CANCER RES, V54, P6348; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; SAKAGAMI H, 1984, CANCER RES, V44, P3330; SAKAMAKI K, 1994, FEBS LETT, V353, P133, DOI 10.1016/0014-5793(94)01024-2; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SHINOHARAGOTOH Y, 1991, EXP CELL RES, V193, P161, DOI 10.1016/0014-4827(91)90551-5; SORENSON CM, 1988, CANCER RES, V48, P4484; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wilkie N, 1996, J BIOL CHEM, V271, P32447, DOI 10.1074/jbc.271.50.32447; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	69	94	96	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1223	1234		10.1038/sj.onc.1202035	http://dx.doi.org/10.1038/sj.onc.1202035			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771965				2022-12-25	WOS:000075803300004
J	Stucki, M; Pascucci, B; Parlanti, E; Fortini, P; Wilson, SH; Hubscher, U; Dogliotti, E				Stucki, M; Pascucci, B; Parlanti, E; Fortini, P; Wilson, SH; Hubscher, U; Dogliotti, E			Mammalian base excision repair by DNA polymerases delta and epsilon	ONCOGENE			English	Article						DNA repair; DNA polymerases; abasic sites	CELL NUCLEAR ANTIGEN; REPLICATION PROTEIN-A; MISMATCH REPAIR; ESCHERICHIA-COLI; CALF THYMUS; LIGASE-I; FACTOR-C; BETA; REQUIREMENT; BINDING	Two distinct pathways for completion of base excision repair (BER) have been discovered in eukaryotes: the DNA polymerase beta (Pol beta)-dependent short-patch pathway that involves the replacement of a single nucleotide and the long-patch pathway that entails the resynthesis of 2-6 nucleotides and requires PCNA, We have used cell extracts from Pol beta-deleted mouse fibroblasts to separate subfractions containing either Pol delta or Pol epsilon. These fractions were then tested for their ability to perform both short- and long-patch BER in an in vitro repair assay, using a circular DNA template, containing a single abasic site at a defined position. Remarkably, both Pol delta and Pol epsilon were able to replace a single nucleotide at the lesion site, but the repair reaction is delayed compared to single nucleotide replacement by Pol beta, Furthermore, our observations indicated, that either Pol delta and/or Pol epsilon participate in the long-patch BER. PCNA and RF-C, but not RP-A are required for this process. Our data show for the first time that Pol delta and/or Pol epsilon are directly involved in the long-patch BER of abasic sites and might function as back-up system for Pol beta in one-gap filling reactions.	Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy; Univ Zurich, Inst Vet Biochem, CH-8057 Zurich, Switzerland; NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA	Istituto Superiore di Sanita (ISS); University of Zurich; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Dogliotti, E (corresponding author), Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, Vle Regina Elena 299, I-00161 Rome, Italy.		Stucki, Manuel/H-4739-2017; Parlanti, Eleonora/AAC-5978-2021; Fortini, Paola/K-1197-2018; Wilson, Samuel H/E-6644-2019	Fortini, Paola/0000-0001-6206-8498; Wilson, Samuel H/0000-0002-1702-5293; PASCUCCI, BARBARA/0000-0002-8383-8751				CHEN M, 1992, P NATL ACAD SCI USA, V89, P2516, DOI 10.1073/pnas.89.7.2516; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; CULLMANN G, 1993, GENE, V134, P191, DOI 10.1016/0378-1119(93)90093-I; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FROSINA G, 1994, BIOCHEM J, V304, P699, DOI 10.1042/bj3040699; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P6284, DOI 10.1073/pnas.76.12.6284; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; JONSSON ZO, 1998, IN PRESS EMBO J; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Longley MJ, 1997, J BIOL CHEM, V272, P10917; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; UITTO L, 1995, NUCLEIC ACIDS RES, V23, P244, DOI 10.1093/nar/23.2.244; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wang ZG, 1997, J BIOL CHEM, V272, P24064, DOI 10.1074/jbc.272.38.24064; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WEISER T, 1991, J BIOL CHEM, V266, P10420; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919	38	158	162	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					835	843		10.1038/sj.onc.1202001	http://dx.doi.org/10.1038/sj.onc.1202001			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780000				2022-12-25	WOS:000075448800005
J	Suzuki, M; Okuyama, S; Okamoto, S; Shirasuna, K; Nakajima, T; Hachiya, T; Nojima, H; Sekiya, S; Oda, K				Suzuki, M; Okuyama, S; Okamoto, S; Shirasuna, K; Nakajima, T; Hachiya, T; Nojima, H; Sekiya, S; Oda, K			A novel E2F binding protein with Myc-type HLH motif stimulates E2F-dependent transcription by forming a heterodimer	ONCOGENE			English	Article						human EC cells; E2F binding protein; E2F-dependent transcription	EMBRYONAL CARCINOMA-CELLS; RETINOBLASTOMA PROTEIN; MAMMALIAN-CELLS; IN-VIVO; FACTOR DRTF1/E2F; CYCLE CONTROL; DP FAMILY; DIFFERENTIATION; CLONING; GENE	The human embryonal carcinoma cells NEC14 can be induced to differentiate morphologically by the addition of 10(-2) M N, N'-hexamethylene-bis-acetamide and cease to grow in several days. Transcription factors of the E2F/DP family have been shown to be closely related to the regulation of cell proliferation. To analyse cellular proteins which interact with E2F in NEC14 cells, cDNA clones encoding E2F binding proteins were isolated from a lambda ZAP II NEC14 cell library with the P-32-labeled GST (Glutathione S-transferase)-E2F-l fusion protein as a probe. One of the clones encodes E2FBP1 which has the helix-loop-helix (HLH) motif, but lacks the basic domain and the zipper structure usually found at N- and C-terminal sides to the HLH motif, respectively, The arrangement of amino acids in the helix 1 and helix 2 regions is quite similar to those of Mxi and Mad, but different from those of E2F-1 and DP-1, Western blot analysis of the immunoprecipitates prepared with anti-E2FBP1 antibody showed that E2FBP1 associates with both E2F-1 and DP-1 in vivo. E2FBP1 alone has no DNA binding activity, but bind to the E2F site through heterodimerization with E2F-1 but not with DP-1, Although E2FBP1 lacks the transactivation domain, it stimulates E2F site-dependent transcription in cooperation with E2F-1.	Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan; MBL Co Ltd, Ina Labs, Nagano 396, Japan; Osaka Univ, Microbial Dis Res Inst, Suita, Osaka 565, Japan; Chiba Univ, Sch Med, Dept Obstet & Gynecol, Chiba 280, Japan	Tokyo University of Science; Osaka University; Chiba University	Oda, K (corresponding author), Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BUCK V, 1995, ONCOGENE, V11, P31; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBEIL HB, 1995, ONCOGENE, V11, P909; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; ELIZABETH AK, 1987, J BIOL CHEM, V262, P9136; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARA E, 1993, ONCOGENE, V8, P1023; HARA E, 1991, NUCLEIC ACIDS RES, V19, P7097, DOI 10.1093/nar/19.25.7097; HARA E, 1995, METH NEUROSCI, V26, P262; HASEGAWA T, 1991, DIFFERENTIATION, V47, P107, DOI 10.1111/j.1432-0436.1991.tb00228.x; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; NEVINS JR, 1992, SCIENCE, V258, P424; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; PEASON BE, 1991, MOL CELL BIOL, V11, P2081; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SEKIYA S, 1990, GYNECOL ONCOL, V36, P69, DOI 10.1016/0090-8258(90)90111-W; SEKIYA S, 1985, DIFFERENTIATION, V29, P259, DOI 10.1111/j.1432-0436.1985.tb00325.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU CL, 1995, MOL CELL BIOL, V15, P2536; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; ZAMANIAN M, 1993, MOL CELL BIOL, V13, P389; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	35	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					853	865		10.1038/sj.onc.1202163	http://dx.doi.org/10.1038/sj.onc.1202163			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780002				2022-12-25	WOS:000075448800007
J	Borsch-Haubold, AG; Pasquet, S; Watson, SP				Borsch-Haubold, AG; Pasquet, S; Watson, SP			Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059 - SB 203580 also inhibits thromboxane synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CYTOSOLIC PHOSPHOLIPASE A(2); STIMULATED HUMAN PLATELETS; ARACHIDONIC-ACID; CELLULAR STRESSES; ENDOTHELIAL-CELLS; MAP KINASE; PHOSPHORYLATION; AGGREGATION; COLLAGEN	The kinase inhibitors SE 203580 and PD 98059 have been reported to be specific inhibitors of the 38- and 42/44-kDa mitogen-activated protein kinase (MAPK) pathways, respectively. In this study, the two inhibitors were found to decrease platelet aggregation induced by low concentrations of arachidonic acid, suggesting that they also interfere with the metabolism of arachidonic acid to thromboxane A(2). In support of this, SE 203580 and PD 98059 inhibited the conversion of exogenous [H-3]arachidonic acid to [H-3]thromboxane in intact platelets. Measurement of platelet cyclooxygenase-1 activity following immunoprecipitation revealed that SE 203580 and PD 98059 are direct inhibitors of this enzyme. Both compounds were shown to inhibit purified cyclooxygenase-1 and -2 by a reversible mechanism, In addition, SE 203580 (but not PD 98059) inhibited platelet aggregation induced by prostaglandin H-2 and the conversion of prostaglandin H-2 to thromboxane A(2) in intact platelets. SE 203580 also inhibited this pathway in platelet microsome preparations, suggesting a direct inhibitory effect on thromboxane synthase. These results demonstrate that direct effects of the two kinase inhibitors on active arachidonic acid metabolites have to be excluded before using these compounds for the investigation of MAPKs in signal transduction pathways. This is of particular relevance to studies on the regulation of cytosolic phospholipase A(2) as these two MAPKs are capable of phosphorylating cytosolic phospholipase A(2), thereby increasing its intrinsic activity.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Borsch-Haubold, AG (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DARET D, 1993, J LIPID RES, V34, P1473; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GORMAN RR, 1983, PROSTAGLANDINS, V26, P325, DOI 10.1016/0090-6980(83)90099-0; GRESELE P, 1991, TRENDS PHARMACOL SCI, V12, P158, DOI 10.1016/0165-6147(91)90533-X; HABIB A, 1992, ARCH BIOCHEM BIOPHYS, V298, P544, DOI 10.1016/0003-9861(92)90448-6; HABIB A, 1993, J BIOL CHEM, V268, P23448; HALENDA SP, 1985, J BIOL CHEM, V260, P2484; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Karim S, 1996, J BIOL CHEM, V271, P12042, DOI 10.1074/jbc.271.20.12042; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KRAMER RM, 1994, SIGNAL ACTIVATED PHO, P13; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACLOUF J, 1981, METHOD ENZYMOL, V86, P273; MARSHALL PJ, 1991, BIOCHEM PHARMACOL, V42, P813, DOI 10.1016/0006-2952(91)90041-3; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; VEZZA R, 1993, BLOOD, V82, P2704	30	246	249	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28766	28772		10.1074/jbc.273.44.28766	http://dx.doi.org/10.1074/jbc.273.44.28766			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786874	hybrid			2022-12-25	WOS:000076691800035
J	Malmendal, A; Evenas, J; Thulin, E; Gippert, GP; Drakenberg, T; Forsen, S				Malmendal, A; Evenas, J; Thulin, E; Gippert, GP; Drakenberg, T; Forsen, S			When size is important - Accommodation of magnesium in a calcium binding regulatory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; CARBOXY-TERMINAL DOMAIN; TRYPTIC FRAGMENTS; NUCLEOTIDE PHOSPHODIESTERASE; TRANSFER SPECTROSCOPY; COHERENCE TRANSFER; CROSS-RELAXATION; NMR-SPECTROSCOPY; APO-CALMODULIN; CA2+ BINDING	The accommodation of Mg2+ in the N-terminal domain of calmodulin was followed through amide H-1 and N-15 chemical shifts and line widths in heteronuclear single-quantum coherence spectroscopy NMR spectra. Mg2+ binds sequentially to the two Ca2+-binding loops in this domain, with affinities such that nearly half of the loops would be occupied by Mg2+ in resting eukaryotic cells. Mg2+ binding seems to occur without ligation to the residue in the 12th loop position, previously proven largely responsible for the major rearrangements induced by binding of the larger Ca2+. Consequently, smaller Mg2+-induced structural changes are indicated throughout the protein. The two Ca2+-binding loops have different Mg2+ binding characteristics. Ligands in the N-terminal loop I are better positioned for cation binding, resulting in higher affinity and slower binding kinetics compared with the C-terminal loop II (k(off) = 380 +/- 40 s(-1) compared with similar to 10,000 s(-1) at 25 degrees C). The Mg2+-saturated loop II undergoes conformational exchange on the 100-mu s time scale. Available data suggest that this exchange occurs between a conformation providing a ligand geometry optimized for Mg2+ binding and a conformation more similar to that of the empty loop.	Lund Univ, S-22100 Lund, Sweden	Lund University	Malmendal, A (corresponding author), Lund Univ, POB 124, S-22100 Lund, Sweden.	anders@bor.fkem2.lth.se	Malmendal, Anders/S-2014-2019; Malmendal, Anders/F-1198-2017	Malmendal, Anders/0000-0002-8413-9717; Malmendal, Anders/0000-0002-8413-9717				Andersson M, 1997, PROTEIN SCI, V6, P1139, DOI 10.1002/pro.5560060602; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bentrop D, 1997, BIOCHEMISTRY-US, V36, P11605, DOI 10.1021/bi971022+; Biekofsky RR, 1998, BIOCHEMISTRY-US, V37, P7617, DOI 10.1021/bi9800449; Birch NG, 1993, MAGNESIUM CELL; BRAUNSCHWEILER L, 1983, MOL PHYS, V48, P535, DOI 10.1080/00268978300100381; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Campbell I D, 1979, Methods Biochem Anal, V25, P1, DOI 10.1002/9780470110454.ch1; CAVANAGH J, 1992, J MAGN RESON, V96, P670, DOI 10.1016/0022-2364(92)90357-D; CHAO SH, 1984, MOL PHARMACOL, V26, P75; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; CHAZIN WJ, 1988, J MOL BIOL, V202, P603, DOI 10.1016/0022-2836(88)90290-2; Cowan JA., 1995, BIOL CHEM MAGNESIUM; DECLERCQ JP, 1991, J MOL BIOL, V220, P1017, DOI 10.1016/0022-2836(91)90369-H; DRABIKOWSKI W, 1982, J BIOL CHEM, V257, P1584; DRABIKOWSKI W, 1977, BIOCHIM BIOPHYS ACTA, V485, P124, DOI 10.1016/0005-2744(77)90199-1; Drake SK, 1996, BIOCHEMISTRY-US, V35, P1753, DOI 10.1021/bi952335c; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; Evenas J, 1998, CURR OPIN CHEM BIOL, V2, P293, DOI 10.1016/S1367-5931(98)80072-0; Evenas J, 1998, BIOCHEMISTRY-US, V37, P13744, DOI 10.1021/bi9806448; Evenas J, 1997, BIOCHEMISTRY-US, V36, P3448, DOI 10.1021/bi9628275; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FINN BE, 1995, NAT STRUCT BIOL, V2, P777, DOI 10.1038/nsb0995-777; FINN BE, 1993, FEBS LETT, V336, P368, DOI 10.1016/0014-5793(93)80839-M; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; GIPPERT G, 1995, THESIS SCRIPPS RES I; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1987, FEBS LETT, V219, P17, DOI 10.1016/0014-5793(87)81182-1; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; LINSE S, 1991, J BIOL CHEM, V266, P8050; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; Malmendal A, 1998, BIOCHEMISTRY-US, V37, P2586, DOI 10.1021/bi971798a; MCCONNELL HM, 1958, J CHEM PHYS, V28, P430, DOI 10.1063/1.1744152; NEEDHAM JV, 1993, BIOCHEMISTRY-US, V32, P3363, DOI 10.1021/bi00064a020; Nelson MR, 1998, PROTEIN SCI, V7, P270; OHKI S, 1993, J BIOL CHEM, V268, P12388; Ohki SY, 1997, BIOCHEMISTRY-US, V36, P4309, DOI 10.1021/bi962759m; PRESS WH, 1986, NUMERICAL RECIPES AR; Sandstrom J., 1982, DYNAMIC NMR SPECTROS; SEAMON KB, 1980, BIOCHEMISTRY-US, V19, P207, DOI 10.1021/bi00542a031; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TANOKURA M, 1986, FEBS LETT, V209, P77, DOI 10.1016/0014-5793(86)81087-0; TELEMAN A, 1986, BIOCHIM BIOPHYS ACTA, V873, P204, DOI 10.1016/0167-4838(86)90047-6; TSAI MD, 1987, BIOCHEMISTRY-US, V26, P3635, DOI 10.1021/bi00386a057; WAGNER G, 1983, J MAGN RESON, V55, P151, DOI 10.1016/0022-2364(83)90284-6; WALSH M, 1977, J BIOL CHEM, V252, P7440; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	59	51	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28994	29001		10.1074/jbc.273.44.28994	http://dx.doi.org/10.1074/jbc.273.44.28994			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786904	hybrid			2022-12-25	WOS:000076691800065
J	Tammi, R; MacCallum, D; Hascall, VC; Pienimaki, JP; Hyttinen, M; Tammi, M				Tammi, R; MacCallum, D; Hascall, VC; Pienimaki, JP; Hyttinen, M; Tammi, M			Hyaluronan bound to CD44 on keratinocytes is displaced by hyaluronan decasaccharides and not hexasaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TRYPSIN INHIBITOR; HUMAN MESOTHELIAL CELLS; SKIN ORGAN-CULTURE; EXTRACELLULAR-MATRIX; CHONDROITIN SULFATE; CARTILAGE PROTEOGLYCANS; CONTAINING COATS; BINDING PROTEIN; LINK PROTEIN; VI COLLAGEN	Abundant hyaluronan is present between epidermal keratinocytes. However, virtually nothing is known regarding its organization in the limited extracellular space between these cells. We have used metabolic labeling with [H-3]glucosamine and [S-35]sulfate and a hyaluronan-specific biotinylated probe to study the metabolism of hyaluronan and its localization in monolayer cultures of a rat epidermal keratinocyte cell line. Hyaluronan (similar to 20 fg/cell) was present on the apical and lateral surfaces of the cells in two nearly equal pools, either in patches (similar to 160/cell) or diffusely spread. The hyaluronan in the patches is bound to CD44 as indicated by co-localization with an antibody to CD44, and by displacement with hyaluronan decasaccharides as well as with an antibody that blocks hyaluronan binding to CD44. The inability of hyaluronan oligomers shorter than 10 monosaccharides to displace hyaluronan suggests that CD44 dimerization or cooperative interactions are required for tight binding. The diffuse hyaluronan pool is likely bound to hyaluronan synthase during its biosynthesis.	Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland; Cleveland Clin, Res Inst, Connect Tissue Biol Sect, Dept Biomed Engn, Cleveland, OH 44106 USA; Univ Michigan, Dept Anat & Cell Biol, Ann Arbor, MI 48109 USA	University of Eastern Finland; Cleveland Clinic Foundation; University of Michigan System; University of Michigan	Tammi, R (corresponding author), Univ Kuopio, Dept Anat, POB 1627, FIN-70211 Kuopio, Finland.	rtammi@messi.uku.fi	Tammi, Markku/AAQ-7878-2021					AGREN UM, 1995, J CELL PHYSIOL, V164, P240, DOI 10.1002/jcp.1041640204; BADEN HP, 1983, J INVEST DERMATOL, V80, P124, DOI 10.1111/1523-1747.ep12532899; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; CHEN L, 1994, J BIOL CHEM, V269, P28282; CLARRIS BJ, 1968, EXP CELL RES, V49, P181, DOI 10.1016/0014-4827(68)90530-2; DOEGE K, 1987, J BIOL CHEM, V262, P17757; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOLDBERG RL, 1984, J CELL BIOL, V99, P2114, DOI 10.1083/jcb.99.6.2114; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HARDINGHAM TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2; HASCALL VC, 1974, J BIOL CHEM, V249, P4232; HAYDOCK PV, 1993, J INVEST DERMATOL, V101, P118, DOI 10.1111/1523-1747.ep12363609; HELDIN P, 1995, J CELL PHYSIOL, V165, P54, DOI 10.1002/jcp.1041650107; HELDIN P, 1993, EXP CELL RES, V208, P422, DOI 10.1006/excr.1993.1264; HUA Q, 1993, J CELL SCI, V106, P365; HUANG L, 1993, J BIOL CHEM, V268, P26725; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; KIELTY CM, 1992, J CELL BIOL, V118, P979, DOI 10.1083/jcb.118.4.979; KITCHEN JR, 1995, BIOCHEM J, V309, P649, DOI 10.1042/bj3090649; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; Knudson CB, 1998, WENN GR INT, V72, P161; Knudson W, 1996, EXP CELL RES, V228, P216, DOI 10.1006/excr.1996.0320; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LAURENT TC, 1986, BIOCHEM J, V234, P653, DOI 10.1042/bj2340653; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LESLEY J, 1993, EUR J IMMUNOL, V23, P1902, DOI 10.1002/eji.1830230826; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIAO HX, 1995, J IMMUNOL, V155, P3938; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; MACCALLUM D K, 1990, Skin Pharmacology, V3, P86; MCDEVITT CA, 1991, FEBS LETT, V294, P167, DOI 10.1016/0014-5793(91)80660-U; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; MILSTONE LM, 1994, J CELL SCI, V107, P3183; MUNAIM SI, 1991, DEV BIOL, V143, P297, DOI 10.1016/0012-1606(91)90080-M; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PERSCHL A, 1995, EUR J IMMUNOL, V25, P495, DOI 10.1002/eji.1830250228; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; QIN Y, 1992, DEV DYNAM, V193, P145, DOI 10.1002/aja.1001930206; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; Takahashi K, 1996, J BIOL CHEM, V271, P9490, DOI 10.1074/jbc.271.16.9490; TAMMI R, 1991, J INVEST DERMATOL, V97, P126, DOI 10.1111/1523-1747.ep12478553; TAMMI R, 1989, J INVEST DERMATOL, V92, P326, DOI 10.1111/1523-1747.ep12277125; TAMMI R, 1994, PROG HISTOCHEM CYTOC, V29, P1; TAMMI R, 1988, J INVEST DERMATOL, V90, P412, DOI 10.1111/1523-1747.ep12456530; TAMMI R, 1990, ARCH ORAL BIOL, V35, P219, DOI 10.1016/0003-9969(90)90058-I; TURLEY EA, 1993, EXP CELL RES, V207, P277, DOI 10.1006/excr.1993.1194; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; Wang C, 1996, AM J PATHOL, V148, P1861; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485	60	119	119	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28878	28888		10.1074/jbc.273.44.28878	http://dx.doi.org/10.1074/jbc.273.44.28878			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786890	hybrid			2022-12-25	WOS:000076691800051
J	Toikka, J; Aalto, J; Hayrinen, J; Pelliniemi, LJ; Finne, J				Toikka, J; Aalto, J; Hayrinen, J; Pelliniemi, LJ; Finne, J			The polysialic acid units of the neural cell adhesion molecule N-CAM form filament bundle networks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG OLIGOSACCHARIDE SEGMENT; GROUP-B; NEISSERIA-MENINGITIDIS; MICROSCOPY; BRAIN; POLYSACCHARIDES; BACTERIA; GLYCOPROTEINS; CLEAVAGE; EPITOPE	Polysialic acid is a developmentally regulated component in the neural cell, adhesion molecule N-CAM which also occurs as the capsular polysaccharide of bacteria causing meningitis. Polysialic acid has been considered as a repulsive element that regulates intermolecular and intercellular adhesion. Using atomic force microscopy we unexpectedly find that oligomers of polysialic acid assemble with each other into filament bundle networks. Filaments were formed from oligomers containing 12 or more N-acetylneuraminic acid residues, and they were sensitive to sialidase digestion. The networks were also formed by the polysialic acid-containing carbohydrate units of N-CAM. The formation of filament bundles is a novel and unexpected property of polysialic acid and of short carbohydrate oligomers in general and represents a previously unrecognized molecular interaction mechanism which impacts both eukaryotic and prokaryotic cell-cell adhesions.	Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Utrecht, Bijvoet Res Ctr, Dept Bioorgan Chem, NL-3584 CH Utrecht, Netherlands; Univ Turku, Electron Microscopy Lab, FIN-20520 Turku, Finland	University of Turku; Utrecht University; University of Turku	Finne, J (corresponding author), Univ Turku, Dept Med Biochem, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	finne@utu.fi	Finne, Jukka/B-6881-2008	Finne, Jukka/0000-0002-8076-3344				ACHESON A, 1988, J CELL BIOL, V106, P479, DOI 10.1083/jcb.106.2.479; ADLAM C, 1987, FEMS MICROBIOL LETT, V42, P23, DOI 10.1111/j.1574-6968.1987.tb02293.x; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; FINNE J, 1985, J BIOL CHEM, V260, P1265; FINNE J, 1982, J BIOL CHEM, V257, P1966; FINNE J, 1983, LANCET, V2, P355; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; GALE M, 1995, BIOPHYS J, V68, P2124, DOI 10.1016/S0006-3495(95)80393-0; HALLENBECK PC, 1987, ANAL BIOCHEM, V161, P181, DOI 10.1016/0003-2697(87)90670-1; HAYRINEN J, 1989, MOL IMMUNOL, V26, P523, DOI 10.1016/0161-5890(89)90003-5; HAYRINEN J, 1995, J INFECT DIS, V171, P1481, DOI 10.1093/infdis/171.6.1481; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; JENNINGS HJ, 1989, J IMMUNOL, V142, P3585; JENNINGS HJ, 1985, J IMMUNOL, V134, P2651; JENNINGS HJ, 1984, PURE APPL CHEM, V56, P893, DOI 10.1351/pac198456070893; KIRBY AR, 1995, BIOPHYS J, V68, P360, DOI 10.1016/S0006-3495(95)80195-5; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; LYUBCHENKO YL, 1995, SCANNING MICROSCOPY, V9, P705; MARSH TC, 1995, NUCLEIC ACIDS RES, V23, P696, DOI 10.1093/nar/23.4.696; PELKONEN S, 1988, J BACTERIOL, V170, P2646, DOI 10.1128/jb.170.6.2646-2653.1988; PELKONEN S, 1989, J VIROL, V63, P4409, DOI 10.1128/JVI.63.10.4409-4416.1989; Popescu O, 1997, NATURE, V386, P231, DOI 10.1038/386231b0; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Round AN, 1997, CARBOHYD RES, V303, P251, DOI 10.1016/S0008-6215(97)00175-4; Rutishauser U, 1996, CURR OPIN CELL BIOL, V8, P679, DOI 10.1016/S0955-0674(96)80109-8; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SCOTT JE, 1991, BIOCHEM J, V274, P699, DOI 10.1042/bj2740699; Song Y, 1998, J BIOL CHEM, V273, P2517, DOI 10.1074/jbc.273.5.2517	28	30	30	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28557	28559		10.1074/jbc.273.44.28557	http://dx.doi.org/10.1074/jbc.273.44.28557			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786844	hybrid			2022-12-25	WOS:000076691800005
J	Frost, JA; Khokhlatcheva, A; Stippec, S; White, MA; Cobb, MH				Frost, JA; Khokhlatcheva, A; Stippec, S; White, MA; Cobb, MH			Differential effects of PAK1-activating mutations reveal activity-dependent and -independent effects on cytoskeletal regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; BINDING PROTEIN-RHO; MOLECULAR-CLONING; ADAPTER PROTEIN; ACTIVATION; FAMILY; ACTIN; CDC42; PAK1; IDENTIFICATION	PARs are serine/threonine protein kinases that are activated by binding to Rac or Cdc42hs, Different forms of activated PAK1 have been reported to either promote membrane ruffling and focal adhesion assembly or cause focal adhesion disassembly and stress fiber dissolution. To understand the basis for these distinct morphological effects, we have examined the mechanism of mutational activation of PAK1, and characterized the effects of different active PAK1 proteins on cytoskeletal structure in vivo, We find that PAK1 contains an autoinhibitory domain that overlaps with its small G protein binding domain and that two separate activating mutations within this regulatory region each decrease autoinhibitory activity. Because only one of these mutations affects Cdc42hs binding activity, this indicates that activation of PAK1 by these mutations results from interference with the function of the autoinhibitory domain and not with small G protein binding activity. When we examined the morphological effects of these different forms of PAK1 in vivo, we found that PAK1 kinase activity was associated with disassembly of focal adhesions and actin stress fibers and that this may require interaction with potential SH3 domain-containing proteins. Lamellipodia formation and membrane ruffling caused by active PAK1 expression, however, was independent of PAK1 catalytic activity and likely requires interaction among multiple proteins binding to the PARI regulatory domain.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Frost, JA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Frost, Jeffrey/0000-0001-9722-1536; Cobb, Melanie/0000-0003-0833-5473	NCI NIH HHS [CA71443] Funding Source: Medline; NIGMS NIH HHS [GM53032] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Leung T, 1996, MOL CELL BIOL, V16, P5313; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	25	167	171	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28191	28198		10.1074/jbc.273.43.28191	http://dx.doi.org/10.1074/jbc.273.43.28191			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774440	hybrid			2022-12-25	WOS:000076549800060
J	Sorgen, PL; Caviston, TL; Perry, RC; Cain, BD				Sorgen, PL; Caviston, TL; Perry, RC; Cain, BD			Deletions in the second stalk of F1F0-ATP synthase in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; B-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; MUTAGENIC ANALYSIS; CROSS-LINKING; DELTA-SUBUNIT; F1-ATPASE; MUTATIONS; F1; TRANSPORT	In Escherichia coli F1F0-ATP synthase, the two b subunits form the second stalk spanning the distance between the membrane F-0 sector and the bulk of F-1. Current models predict that the stator should be relatively rigid and engaged in contact with F-1 at fixed points. To test this hypothesis, we constructed a series of deletion mutations in the uncF(b) gene to remove segments from the middle of the second stalk of the subunit, Mutants with deletions of 7 amino acids were essentially normal, and those with deletions of up to 11 amino acids retained considerable activity. Membranes prepared from these strains had readily detectable levels of F-1-ATPase activity and proton pumping activity. Removal of 12 or more amino acids resulted in loss of oxidative phosphorylation. Levels of membrane-associated F-1-ATPase dropped precipitously for the longer deletions, and immunoblot analysis indicated that reductions in activity correlated with reduced levels of b subunit in the membranes, Assuming the likely alpha-helical conformation for this area of the b subunit, the 11-amino acid deletion would result in shortening the subunit by approximately 16 Angstrom. Since these deletions did not prevent the b subunit from participating in productive interactions with F-1, we suggest that the b subunit is not a rigid rodlike structure, but has an inherent flexibility compatible with a dynamic role in coupling.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Cain, BD (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.				NIGMS NIH HHS [GM43495] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043495] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARIS JP, 1983, J BIOL CHEM, V258, P4599; ARIS JP, 1985, J BIOL CHEM, V260, P1207; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Caviston TL, 1998, FEBS LETT, V429, P201, DOI 10.1016/S0014-5793(98)00597-3; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12364; DECKERSHEBESTREIT G, 1986, EUR J BIOCHEM, V161, P225, DOI 10.1111/j.1432-1033.1986.tb10146.x; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Fillingame RH, 1997, J EXP BIOL, V200, P217; HARTZOG PE, 1994, J BIOL CHEM, V269, P32313; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; Howitt SM, 1996, J BIOL CHEM, V271, P7038, DOI 10.1074/jbc.271.12.7038; JANS DA, 1984, BIOCHEM J, V221, P43, DOI 10.1042/bj2210043; JANS DA, 1983, BIOCHEM J, V211, P717, DOI 10.1042/bj2110717; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PORTER ACG, 1985, J BIOL CHEM, V260, P8182; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Sabbert D, 1997, P NATL ACAD SCI USA, V94, P4401, DOI 10.1073/pnas.94.9.4401; Sawada K, 1997, J BIOL CHEM, V272, P30047, DOI 10.1074/jbc.272.48.30047; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; TAMARAPPOO BK, 1992, J BIOL CHEM, V267, P2370; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WILKENS S, 1994, FEBS LETT, V354, P37, DOI 10.1016/0014-5793(94)01059-5; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908	37	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27873	27878		10.1074/jbc.273.43.27873	http://dx.doi.org/10.1074/jbc.273.43.27873			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774398	hybrid			2022-12-25	WOS:000076549800018
J	Zhang, LJ; Schwartz, JJ; Miller, J; Liu, J; Fritze, LMS; Shworak, NW; Rosenberg, RD				Zhang, LJ; Schwartz, JJ; Miller, J; Liu, J; Fritze, LMS; Shworak, NW; Rosenberg, RD			The retinoic acid and cAMP-dependent up-regulation of 3-O-sulfotransferase-1 leads to a dramatic augmentation of anticoagulantly active heparan sulfate biosynthesis in F9 embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; ANTITHROMBIN-BINDING SEQUENCE; CARDIOVASCULAR-SYSTEM; CONFORMATIONAL CHANGE; FETAL DEVELOPMENT; PROTEOGLYCANS; THROMBOMODULIN; IDENTIFICATION; FETOMODULIN; PRECURSOR	Retinoic acid (RA) and dibutyryl cAMP plus theophilline (CT) trigger F9 cells to differentiate into parietal endoderm, The differentiation induces a 9-fold increase in total heparan sulfate (HStotal) biosynthesis and a 170-fold increase in anticoagulantly active HS (HSact) biosynthesis, Measurement of 3-O-sulfotransferase-1 mRNA and enzymatic activity demonstrated an increase of over 100-fold whereas determination of N-, 2-O, and 6-O-sulfotransferase enzymatic activities showed elevations of 2-, 3.5-, and 3.7-fold, respectively. HSact precursor pool measurements reveal that 30% of control F9 HStotal can be converted into HSact while only an additional 10% of RACT F9 HStotal can be transformed into HSact. Disaccharide analysis of metabolic labeled HS indicated that 32% 3-O-sulfate containing disaccharides, i.e. GlcA-anMan(R)3S and GlcA-anMan(R)3S6S, are present in HSact and 68% GlcA-anMan(R)3S and GlcA-anMan(R)3S6S are found in anticoagulantly inactive HS (HSinact). By using adenosine S'-phosphate 5'-phosphosulfate and purified 3-O-sulfotransferase-1, 30% of 3-O-sulfation occurs in HSact and 70% of 3-O-sulfation occurs in HSinact. The similar ratio of 3-O-sulfate distribution in HSact versus HSinact suggests that HSact production in the F9 system is determined by the abundance of 3-O-sulfotransferase-1 as well as the size of the HSact precursor pool. Extensively 3-O-sulfated HSinact may play an important functional role under in vivo conditions within the murine placenta.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Dept Med, Boston, MA 02215 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rosenberg, RD (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave,Bldg 68-480, Cambridge, MA 02139 USA.	rdrrosen@MIT.EDU	Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NHLBI NIH HHS [5-PO1-HL41484, HL66385] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066385, P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BAME KJ, 1989, J BIOL CHEM, V264, P8059; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; IMADA M, 1987, DEV BIOL, V122, P483, DOI 10.1016/0012-1606(87)90312-5; IMADA S, 1990, DEV BIOL, V140, P113, DOI 10.1016/0012-1606(90)90058-Q; KAPOOR R, 1983, EUR J BIOCHEM, V137, P589, DOI 10.1111/j.1432-1033.1983.tb07866.x; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; PEJLER G, 1987, J BIOL CHEM, V262, P5036; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V77, P6551; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; WEILERGUETTLER H, 1992, P NATL ACAD SCI USA, V89, P2155, DOI 10.1073/pnas.89.6.2155; WLAD H, 1994, J BIOL CHEM, V269, P24538; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	29	29	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27998	28003		10.1074/jbc.273.43.27998	http://dx.doi.org/10.1074/jbc.273.43.27998			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774414	hybrid			2022-12-25	WOS:000076549800034
J	Dumais, N; Barbeau, B; Olivier, M; Tremblay, MJ				Dumais, N; Barbeau, B; Olivier, M; Tremblay, MJ			Prostaglandin E-2 up-regulates HIV-1 long terminal repeat-driven gene activity in T cells via NF-kappa B-dependent and -independent signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-KINASE; ARACHIDONIC-ACID; IMMUNE-RESPONSE; HUMAN MONOCYTES; SYNTHASE CYCLOOXYGENASE; PSEUDOMONAS-AERUGINOSA; ALVEOLAR MACROPHAGES; INDUCED ACTIVATION; ADENYLATE-CYCLASE	Replication of human immunodeficiency virus type-1 (HIV-1) is highly dependent on the state of activation of the infected cells and is modulated by interactions between viral and host cellular factors. Prostaglandin E-2 (PGE(2)), a pleiotropic immunomodulatory molecule, is observed at elevated levels during HIV-1 infection as well as during the course of other pathogenic infections. in 1G5, a Jurkat-derived T cell line stably transfected with a luciferase gene driven by HIV-1 long terminal repeat (LTR), we found that PGE2 markedly enhanced HIV-1 LTR-mediated reporter gene activity. Experiments have been conducted to identify second messengers involved in this PGE(2)-dependent up-regulating effect on the regulatory element of HIV-1. In this study, we present evidence indicating that signal transduction pathways induced by PGE(2) necessitate the participation of cyclic AMP, protein kinase A, and Ca2+. Experiments conducted with different HIV-1 LTR-based vectors suggested that PGE(2)-mediated activation effect on HIV-1 transcription was transduced via both NF-KB-dependent and -independent signaling pathways. The involvement of NF-KB in the PGE(2)-dependent activating effect on HIV-1 transcription was further confirmed using a KB-regulated luciferase encoding vector and by electrophoretic mobility shift assays. Results from Northern blot and flow cytometric analyses, as well as the use of a selective antagonist indicated that PGE(2) modulation of HIV-1 LTR-driven reporter gene activity in studied T lymphoid cells is transduced via the EP4 receptor subtype. These results suggest that secretion of PGE(2) by macrophages in response to infection or inflammatory activators could induce signaling events resulting in activation of proviral DNA present into T cells latently infected with HIV-1.	Ctr Hosp Univ Quebec, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Biol Med, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Olivier, M (corresponding author), Ctr Hosp Univ Quebec, Ctr Rech Infectiol, RC-709,Pavillon CHUL,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	Martin.Olivier@crchul.ulaval.ca	Barbeau, Benoit/A-1174-2010	Barbeau, Benoit/0000-0002-4108-8155				ABEL PM, 1992, FEMS MICROBIOL IMMUN, V105, P317; AGUILARCORDOVA E, 1994, AIDS RES HUM RETROV, V10, P295, DOI 10.1089/aid.1994.10.295; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AUBERGER P, 1989, CELL SIGNAL, V1, P289, DOI 10.1016/0898-6568(89)90046-6; BAKER PE, 1981, CELL IMMUNOL, V61, P52, DOI 10.1016/0008-8749(81)90353-1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; BenHur T, 1996, J NEUROVIROL, V2, P279, DOI 10.3109/13550289609146891; Bernier R, 1998, J IMMUNOL, V160, P2881; Bernier R, 1998, J GEN VIROL, V79, P1353, DOI 10.1099/0022-1317-79-6-1353; BERNIER R, 1995, J VIROL, V69, P7282, DOI 10.1128/JVI.69.11.7282-7285.1995; Berube P, 1996, J VIROL, V70, P4009; Blaschke V, 1996, FEBS LETT, V394, P39, DOI 10.1016/0014-5793(96)00928-3; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOWDHURY MIH, 1990, LANCET, V336, P247; COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; CORREIADESA P, 1994, EUR J PHARMACOL, V271, P349, DOI 10.1016/0014-2999(94)90793-5; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEVRIES GW, 1995, BRIT J PHARMACOL, V115, P1231; FARRELL JP, 1987, J IMMUNOL, V138, P902; Fedyk ER, 1996, P NATL ACAD SCI USA, V93, P10978, DOI 10.1073/pnas.93.20.10978; FOLEY P, 1992, IMMUNOLOGY, V75, P391; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FREY J, 1986, EUR J BIOCHEM, V158, P85, DOI 10.1111/j.1432-1033.1986.tb09724.x; FU JY, 1990, J BIOL CHEM, V265, P16737; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GOLDYNE ME, 1987, PROSTAGLANDINS, V34, P783, DOI 10.1016/0090-6980(87)90060-8; GOODWIN JS, 1980, CLIN IMMUNOL IMMUNOP, V15, P106, DOI 10.1016/0090-1229(80)90024-0; GOODWIN JS, 1977, J EXP MED, V146, P1719, DOI 10.1084/jem.146.6.1719; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; GRIFFIN DE, 1994, ANN NEUROL, V35, P592, DOI 10.1002/ana.410350513; GUELLAEN G, 1977, BIOCHIM BIOPHYS ACTA, V484, P465, DOI 10.1016/0005-2744(77)90102-4; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HARAGUCHI S, 1995, IMMUNOL TODAY, V16, P595, DOI 10.1016/0167-5699(95)80083-2; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; HEINEN E, 1986, ANN INST PASTEUR IMM, VD137, P369; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; HENKE A, 1992, RES IMMUNOL, V143, P65, DOI 10.1016/0923-2494(92)80081-U; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOFMANN B, 1993, AIDS, V7, P659, DOI 10.1097/00002030-199305000-00008; HUI RT, 1995, J VIROL, V69, P8020, DOI 10.1128/JVI.69.12.8020-8026.1995; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KERNACKI KA, 1994, J OCUL PHARMACOL, V10, P281, DOI 10.1089/jop.1994.10.281; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; KOH WS, 1995, BIOCHEM BIOPH RES CO, V206, P703, DOI 10.1006/bbrc.1995.1099; KUNO S, 1986, P NATL ACAD SCI USA, V83, P3487, DOI 10.1073/pnas.83.10.3487; KURLAND JI, 1978, J EXP MED, V147, P952, DOI 10.1084/jem.147.3.952; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; Li W, 1996, BIOCHEM BIOPH RES CO, V219, P96, DOI 10.1006/bbrc.1996.0187; LINGK DS, 1990, J IMMUNOL, V145, P449; MARGOLICK JB, 1987, J IMMUNOL, V138, P1719; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MIDULLA F, 1989, AM REV RESPIR DIS, V140, P771, DOI 10.1164/ajrccm/140.3.771; Mori K, 1996, J MOL MED-JMM, V74, P333, DOI 10.1007/BF00207510; MUNOZ E, 1990, J EXP MED, V172, P95, DOI 10.1084/jem.172.1.95; MUROI M, 1993, CELL SIGNAL, V5, P289, DOI 10.1016/0898-6568(93)90019-I; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL GJ, 1994, HIV ADV RES THERAPY, V4, P1; NISHIGAKI N, 1995, FEBS LETT, V364, P339, DOI 10.1016/0014-5793(95)00421-5; NOKTA M, 1991, VIROLOGY, V181, P211, DOI 10.1016/0042-6822(91)90486-U; NOKTA MA, 1992, AIDS RES HUM RETROV, V8, P1255, DOI 10.1089/aid.1992.8.1255; ONTA T, 1993, MICROBIOL IMMUNOL, V37, P573, DOI 10.1111/j.1348-0421.1993.tb01679.x; PHIPPS RP, 1988, J LEUKOCYTE BIOL, V43, P271, DOI 10.1002/jlb.43.3.271; PHIPPS RP, 1990, IMMUNOL REV, V117, P135, DOI 10.1111/j.1600-065X.1990.tb00571.x; PINTER A, 1989, J VIROL, V63, P2674, DOI 10.1128/JVI.63.6.2674-2679.1989; RAMIS I, 1992, J CHROMATOGR-BIOMED, V575, P143, DOI 10.1016/0378-4347(92)80515-R; RAPPAPORT RS, 1982, J EXP MED, V155, P943, DOI 10.1084/jem.155.3.943; RASTOGI N, 1992, FEMS MICROBIOL IMMUN, V89, P273, DOI 10.1111/j.1574-6968.1992.tb05006.x; REINER WE, 1984, CELL IMMUNOL, V134, P556; RINCON M, 1988, EUR J IMMUNOL, V18, P1791, DOI 10.1002/eji.1830181121; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Roper R L, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P101; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SORRELL TC, 1989, IMMUNOL CELL BIOL, V67, P169, DOI 10.1038/icb.1989.27; STENSON WF, 1982, PROSTAGLANDINS, P39; Sun SC, 1996, MOL CELL BIOL, V16, P1058; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WALKER C, 1983, J IMMUNOL, V130, P1770; WANG W, 1995, INFECT IMMUN, V63, P1089, DOI 10.1128/IAI.63.3.1089-1094.1995; WANG W, 1992, IMMUNOLOGY, V76, P242; Yasui H, 1997, J BIOL CHEM, V272, P28762, DOI 10.1074/jbc.272.45.28762; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	88	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27306	27314		10.1074/jbc.273.42.27306	http://dx.doi.org/10.1074/jbc.273.42.27306			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765256	hybrid			2022-12-25	WOS:000076448000043
J	Li, XD; Rhodes, TE; Ikebe, R; Kambara, T; White, HD; Ikebe, M				Li, XD; Rhodes, TE; Ikebe, R; Kambara, T; White, HD; Ikebe, M			Effects of mutations in the gamma-phosphate binding site of myosin on its motor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; ACTOMYOSIN ADENOSINE-TRIPHOSPHATASE; LIGHT-CHAIN KINASE; 3-DIMENSIONAL STRUCTURE; 2-HEADED STRUCTURE; MOLECULAR MOTOR; ACTIVE-SITE; SUBFRAGMENT-1; ATPASE; HYDROLYSIS	The role of the highly conserved residues in the gamma-phosphate binding site of myosin upon myosin motor function was studied. Each of five residues (Ser(181), Lys(185), Asn(235), Ser(236), and Arg(238)) in smooth muscle myosin was mutated. K185Q has neither a steady state ATPase nor an initial P-i burst. Although ATP and actin bind to K185Q, it is not dissociated from actin by ATP. These results indicate that the hydrolysis of bound ATP by K185Q is inhibited. S236T has nearly normal basal Mg2+-ATPase activity, initial P-i burst, ATP-induced enhancement of intrinsic tryptophan fluorescence, and ATP-induced dissociation from actin, However, the actin activation of the Mg2+-ATPase activity and actin translocation of S236T were blocked. In contrast S236A has nearly normal enzymatic properties and actin-translocating activity. These results indicate that 1) the hydroxyl group of Ser(236) is not critical as an intermediary of proton transfer during the ATP hydrolysis step, and 2) the bulk of the extra methyl group of the threonine residue in S236T blocks the acceleration of product release from the active site by actin, Arg(238), which interacts with Glu(459) at the Switch II region, was mutated to Lye and ne, respectively, R238K has essentially normal enzymatic activity and motility. In contrast, R238I does not hydrolyze ATP or support motility, although it still binds ATP. These results indicate that the charge interaction between Glu(459) and Arg(238) is critical for ATP hydrolysis by myosin, Other mutants, S181A, S181T, and N235I, showed nearly normal enzymatic and motile activity.	Univ Massachusetts, Med Ctr, Dept Physiol, Worcester, MA 01655 USA; Eastern Virginia Med Sch, Dept Biochem, Norfolk, VA 23507 USA	University of Massachusetts System; University of Massachusetts Worcester; Eastern Virginia Medical School	Ikebe, M (corresponding author), Univ Massachusetts, Med Ctr, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	mitsuo.ikebe@ummed.edu			NHLBI NIH HHS [HL56218, HL47530] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047530, R01HL056218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CREMO CR, 1989, J BIOL CHEM, V264, P6608; DYSON RD, 1971, BIOCHEMISTRY-US, V15, P5818; ECCLESTON JF, 1979, BIOCHEMISTRY-US, V18, P2896, DOI 10.1021/bi00580a034; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GEEVES MA, 1992, PHILOS T ROY SOC B, V336, P63, DOI 10.1098/rstb.1992.0045; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; GRAMMER JC, 1993, BIOCHEMISTRY-US, V32, P5725, DOI 10.1021/bi00073a001; Higashihara M, 1989, J BIOL CHEM, V264, P5218; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; JIANG W, 1995, THESIS E VIRGINIA ME; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARUTA H, 1981, J BIOL CHEM, V256, P499; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Onishi H, 1997, BIOCHEMISTRY-US, V36, P3767, DOI 10.1021/bi9630772; ORIELLY DR, 1992, BACULOVIRUS EXPRESSI; PATE E, 1993, J BIOL CHEM, V268, P10046; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1994, TRENDS BIOCHEM SCI, V19, P129, DOI 10.1016/0968-0004(94)90206-2; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SLEEP JA, 1981, J MUSCLE RES CELL M, V2, P373, DOI 10.1007/BF00711966; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; TAYLOR EW, 1977, BIOCHEMISTRY-US, V16, P732, DOI 10.1021/bi00623a027; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TRENTHAM DR, 1976, Q REV BIOPHYS, V9, P217, DOI 10.1017/S0033583500002419; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WHITE HD, 1993, BIOCHEMISTRY-US, V32, P9859, DOI 10.1021/bi00088a042; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WHITE HD, 1993, J BIOL CHEM, V268, P10039; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044; YOUNT RG, 1995, BIOPHYS J, V68, pS44	41	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27404	27411		10.1074/jbc.273.42.27404	http://dx.doi.org/10.1074/jbc.273.42.27404			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765269	hybrid			2022-12-25	WOS:000076448000056
J	Nakonechny, WS; Teschke, CM				Nakonechny, WS; Teschke, CM			GroEL and GroES control of substrate flux in the in vivo folding pathway of phage P22 coat protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; ESCHERICHIA-COLI; IN-VITRO; SALMONELLA PHAGE-P22; SCAFFOLDING PROTEIN; STRUCTURAL PROTEINS; CHAPERONINS; HEAD; SUBUNITS; BACTERIOPHAGE-T4	Our present understanding of the action of the chaperonins GroEL/S on protein folding is based primarily on in vitro studies, whereas the folding of proteins in the cellular milieu has not been as thoroughly investigated. We have developed a means of examining in vivo protein folding and assembly that utilizes the coat protein of bacteriophage P22, a naturally occurring substrate of GroEL/S. Here we show that amino acid substitutions in coat protein that cause a temperature-sensitive-folding (tsf) phenotype slowed assembly rates upon increasing the temperature of cell growth. Raising cellular concentrations of GroEL/S increased the rate of assembly of the tsf mutant coat proteins to nearly that of wild-type (WT) coat protein by protecting a thermolabile folding intermediate from aggregation, thereby increasing the concentration of assembly competent coat protein. The rate of release of the tsf coat proteins from the GroEL/S-coat protein ternary complex was approximately a-fold slower at non-permissive temperatures when compared with the release of WT coat protein. However, the rate of release of WT Or tsf coat proteins at each temperature remained constant regardless of GroEL/S levels. Thus, raising the cellular concentration of GroEL/S increased the amount of assembly-competent tsf coat proteins not by altering the rates of folding but by increasing the probability of GroEL/S-coat protein complex formation.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	University of Connecticut	Teschke, CM (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, 75 N Eagleville Rd,U-125, Storrs, CT 06269 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053567, R29GM053567] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53567] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZINET C, 1988, J MOL BIOL, V202, P77, DOI 10.1016/0022-2836(88)90520-7; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CASJENA S, 1974, J SUPRAMOL STRU T, V2, P22; CASJENS S, 1979, J MOL BIOL, V131, P1, DOI 10.1016/0022-2836(79)90298-5; DYK TKV, 1989, NATURE, V342, P451; EARNSHAW W, 1978, J MOL BIOL, V126, P721, DOI 10.1016/0022-2836(78)90017-7; EARNSHAW W, 1976, J MOL BIOL, V104, P387, DOI 10.1016/0022-2836(76)90278-3; EWAIT KL, 1997, CELL, V90, P491; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; Fenton WA, 1997, PROTEIN SCI, V6, P743; GALISTEO ML, 1993, BIOPHYS J, V65, P227, DOI 10.1016/S0006-3495(93)81073-7; GALISTEO ML, 1995, J BIOL CHEM, V270, P16595, DOI 10.1074/jbc.270.28.16595; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GORDON CL, 1993, J BIOL CHEM, V268, P9358; GORDON CL, 1994, GENETICS, V136, P427; Greene B, 1996, VIROLOGY, V225, P82, DOI 10.1006/viro.1996.0577; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; KING J, 1973, J MOL BIOL, V80, P697, DOI 10.1016/0022-2836(73)90205-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; Miller J. H., 1972, EXPT MOL GENETICS, P431; NEAL BL, 1993, J BACTERIOL, V175, P7115, DOI 10.1128/jb.175.21.7115-7118.1993; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; PREVELIGE PE, 1993, BIOPHYS J, V64, P824, DOI 10.1016/S0006-3495(93)81443-7; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; SERWER P, 1978, J VIROL, V28, P917, DOI 10.1128/JVI.28.3.917-928.1978; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TESCHKE CM, 1995, BIOCHEMISTRY-US, V34, P6815, DOI 10.1021/bi00020a028; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10839, DOI 10.1021/bi00091a040; Teschke CM, 1996, BIOCHEMISTRY-US, V35, P14831, DOI 10.1021/bi960860l; WINSTON F, 1979, J BACTERIOL, V137, P433, DOI 10.1128/JB.137.1.433-439.1979; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993	40	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27236	27244		10.1074/jbc.273.42.27236	http://dx.doi.org/10.1074/jbc.273.42.27236			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765246	hybrid			2022-12-25	WOS:000076448000033
J	Radebaugh, CA; Kubaska, WM; Hoffman, LH; Stiffler, K; Paule, MR				Radebaugh, CA; Kubaska, WM; Hoffman, LH; Stiffler, K; Paule, MR			A novel transcription initiation factor (TIF), TIF-IE, is required for homogeneous Acanthamoeba castellanii TIF-IB (SL1) to form a committed complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-I; TATA-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; RDNA TRANSCRIPTION; PREINITIATION COMPLEX; GEL-ELECTROPHORESIS; FACTOR UBF; DNA; PROMOTER; TBP	The fundamental transcription initiation factor (TIF) for ribosomal RNA expression by eukaryotic RNA polymerase I, TIF-IB, has been purified to near homogeneity from Acanthamoeba castellanii using standard techniques. The purified factor consists of the TATA-binding protein and four TATA-binding protein-associated factors with relative molecular weights of 145,000, 99,000, 96,000, and 91,000. This yields a calculated native molecular weight of 460,000, which compares well with its mass determined by scanning transmission electron microscopy (493,000) and its sedimentation rate, which is close to RNA polymerase I (515,000). Both impure and nearly homogeneous TIF-IB exhibit an apparent equilibrium dissociation constant of 56 +/- 3 pM. However, although impure TIF-IB can form a promoter-DNA complex resistant to challenge by other promoter-containing DNAs, near homogeneous TIF-IB cannot do so. An additional transcription factor, dubbed TIF-IE, restores the ability of near homogeneous TIF-IB to sequester DNA into a committed complex.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Radebaugh, CA (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	mpaule@vines.colostate.edu			NIGMS NIH HHS [GM22580] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022580] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATEMAN E, 1985, P NATL ACAD SCI USA, V82, P8004, DOI 10.1073/pnas.82.23.8004; BATEMAN E, 1989, MOL BIOL RNA DNA PRO, P259; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bodeker M, 1996, MOL CELL BIOL, V16, P5572; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DALESSIO JM, 1979, J BIOL CHEM, V254, P4085; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Garfin DE, 1990, METHOD ENZYMOL, P425; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GONG XL, 1995, MOL CELL BIOL, V15, P4956; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; GRUMMT I, 1998, TRANSCRIPTION EUKARY, V1, P135; Hanada K, 1996, EMBO J, V15, P2217, DOI 10.1002/j.1460-2075.1996.tb00575.x; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; IIDA CT, 1985, P NATL ACAD SCI USA, V82, P1668, DOI 10.1073/pnas.82.6.1668; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; Keys DA, 1996, GENE DEV, V10, P887, DOI 10.1101/gad.10.7.887; KOWNIN P, 1988, MOL CELL BIOL, V8, P747, DOI 10.1128/MCB.8.2.747; KOWNIN P, 1987, CELL, V50, P693, DOI 10.1016/0092-8674(87)90327-8; KUHN A, 1998, TRANSCRIPTION EUKARY, V1, P201; Lalo D, 1996, J BIOL CHEM, V271, P21062, DOI 10.1074/jbc.271.35.21062; Lin CW, 1996, MOL CELL BIOL, V16, P6436; LOFQUIST AK, 1993, NUCLEIC ACIDS RES, V21, P3233; MANIATIS T, 1982, MOL CLONING LABORATO, P348; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MURAMATSU M, 1998, TRANSCRIPTION EUKARY, V1, P95; MURAMATSU M, 1998, TRANSCRIPTION EUKARY, V1, P295; Nomura M., 1998, TRANSCRIPTION EUKARY, P155; PAULE MR, 1990, NATURE, V344, P819, DOI 10.1038/344819a0; PAULE MR, 1998, TRANSCRIPTION EUKARY, V1, P107; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PAULE MR, 1998, TRANSCRIPTION EUKARY, V1; Perna Peter J., 1992, Gene Expression, V2, P71; PUTNAM CD, 1994, MOL CELL BIOL, V14, P6476, DOI 10.1128/MCB.14.10.6476; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; Radebaugh CA, 1997, J BIOL CHEM, V272, P3141, DOI 10.1074/jbc.272.6.3141; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Smith S. David, 1993, Gene Expression, V3, P229; SPINDLER SR, 1978, J BIOL CHEM, V253, P4669; Steffan JS, 1996, GENE DEV, V10, P2551, DOI 10.1101/gad.10.20.2551; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yamamoto RT, 1996, EMBO J, V15, P3964, DOI 10.1002/j.1460-2075.1996.tb00770.x; ZOMERDIJK JCB, 1998, TRANSCRIPTION RIBOSO, V1, P121; ZOMERDIJK JCB, 1998, TRANSCRIPTION EUKARY, V1, P67	51	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27708	27715		10.1074/jbc.273.42.27708	http://dx.doi.org/10.1074/jbc.273.42.27708			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765308	hybrid			2022-12-25	WOS:000076448000095
J	Thompson, J; Pikis, A; Ruvinov, SB; Henrissat, B; Yamamoto, H; Sekiguchi, J				Thompson, J; Pikis, A; Ruvinov, SB; Henrissat, B; Yamamoto, H; Sekiguchi, J			The gene glvA of Bacillus subtilis 168 encodes a metal-requiring, NAD (H)-dependent 6-phospho-alpha-glucosidase - Assignment to family 4 of the glycosylhydrolase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; D-PHOSPHOGALACTOSIDE GALACTOHYDROLASE; FUSOBACTERIUM-MORTIFERUM ATCC-25557; SUGAR PHOSPHOTRANSFERASE SYSTEM; AGROBACTERIUM BETA-GLUCOSIDASE; ACID-SEQUENCE SIMILARITIES; ACTIVE-SITE NUCLEOPHILE; ESCHERICHIA-COLI K-12; NUCLEOTIDE-SEQUENCE; AMINO-ACID	The gene gluA (formerly glu-1) from Bacillus subtilis has been cloned and expressed in Escherichia coli. The purified protein GlvA (449 residues, M-r = 50,513) is a unique 6-phosphoryl-O-alpha-D-glucopyranosyl:phosphoglucohydrolase (6-phospho-alpha-glucosidase) that requires both NAD(H) and divalent metal (Mn2+, Fe2+, Co2+, or Ni2+) for activity. 6-Phospho-alpha-glucosidase (EC 3.2.1.122) from B. subtilis cross-reacts with polyclonal antibody to maltose 6-phosphate hydrolase from Fusobacterium mortiferum, and the two proteins exhibit amino acid sequence identity of 73%. Estimates for the M-r of GlvA determined by SDS-polyacrylamide gel electrophoresis (51,000) and electrospray-mass spectroscopy (50,510) were in excellent agreement with the molecular weight of 50,513 deduced from the amino acid sequence. The sequence of the first 37 residues from the N terminus determined by automated analysis agreed precisely with that predicted by translation of gluA. The chromogenic and fluorogenic substrates, p-nitrophenyl-alpha-D-glucopyranoside 6-phosphate and 4-methylumbelliferyl-alpha-D-glucopyranoside 6-phosphate were used for the discontinuous assay and in situ detection of enzyme activity, respectively. Site directed mutagenesis shows that three acidic residues, Asp(41), Glu(111), and Glu(359), are required for GlvA activity. Asp(41) is located at the C terminus of a beta alpha beta fold that may constitute the dinucleotide binding domain of the protein. Glu(111) and GlU(359) may function as the catalytic acid (proton donor) and nucleophile (base), respectively, during hydrolysis of 6-phospho-alpha-glucoside substrates including maltose 6-phosphate and trehalose 6-phosphate, In metal-free buffer, GlvA exists as an inactive dimer, but in the presence of Mn2+ ion, these species associate to form the NAD(H)-dependent catalytically active tetramer, By comparative sequence alignment with its homologs, the novel 6-phospho-alpha-glucosidase from B. subtilis can be assigned to the nine-member family 4 of the glycosylhydrolase superfamily.	NIDR, Oral Infect & Immun Branch, Microbial Biochem & Genet Unit, NIH, Bethesda, MD 20892 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Childrens Natl Med Ctr, Dept Infect Dis, Washington, DC 20010 USA; CNRS, Struct Enzymol & Glycobiol Grp, F-13402 Marseille, France; Shinshu Univ, Fac Text Sci & Technol, Dept Appl Biol, Ueda, Nagano 386, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Children's National Health System; Centre National de la Recherche Scientifique (CNRS); Shinshu University	Thompson, J (corresponding author), NIDR, Oral Infect & Immun Branch, Microbial Biochem & Genet Unit, NIH, Bldg 30,Rm 528,Convent Dr,MSC-4350, Bethesda, MD 20892 USA.	jthompson@yoda.nidr.nih.gov	PIKIS, ANDREAS/AFU-1192-2022; Henrissat, Bernard/J-2475-2012; Sekiguchi, Junichi/F-9963-2010	Henrissat, Bernard/0000-0002-3434-8588; 				BAKER PJ, 1992, J MOL BIOL, V228, P662, DOI 10.1016/0022-2836(92)90848-E; BHUMIRATANA A, 1974, J BACTERIOL, V119, P484, DOI 10.1128/JB.119.2.484-493.1974; Bibel M, 1998, FEMS MICROBIOL LETT, V158, P9, DOI 10.1111/j.1574-6968.1998.tb12793.x; BOIZET B, 1988, GENE, V62, P249, DOI 10.1016/0378-1119(88)90563-X; Bouma CL, 1997, J BACTERIOL, V179, P4129, DOI 10.1128/jb.179.13.4129-4137.1997; BREIDT F, 1987, APPL ENVIRON MICROB, V53, P969, DOI 10.1128/AEM.53.5.969-973.1987; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; BURSTEIN C, 1971, BIOCHIM BIOPHYS ACTA, V230, P52, DOI 10.1016/0304-4165(71)90053-5; CALMES R, 1979, INFECT IMMUN, V23, P68, DOI 10.1128/IAI.23.1.68-79.1979; CASE GS, 1973, BIOCHEM J, V133, P99, DOI 10.1042/bj1330099; DANCHIN A, 1989, FEMS MICROBIOL LETT, V63, P1; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; ELHASSOUNI M, 1992, J BACTERIOL, V174, P765, DOI 10.1128/jb.174.3.765-777.1992; ERNI B, 1992, INT REV CYTOL, V137A, P127; GOTSCHE S, 1995, J BACTERIOL, V177, P2721, DOI 10.1128/jb.177.10.2721-2726.1995; GRABNITZ F, 1991, EUR J BIOCHEM, V200, P301, DOI 10.1111/j.1432-1033.1991.tb16186.x; HELFERT C, 1995, MOL MICROBIOL, V16, P111, DOI 10.1111/j.1365-2958.1995.tb02396.x; HENGSTENBERG W, 1993, FEMS MICROBIOL REV, V12, P149; HENGSTENBERG W, 1989, FEMS MICROBIOL LETT, V63, P35, DOI 10.1016/0168-6445(89)90006-5; HENGSTENBERG W, 1970, EUR J BIOCHEM, V14, P27, DOI 10.1111/j.1432-1033.1970.tb00256.x; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Ishikawa S, 1998, J BACTERIOL, V180, P1375, DOI 10.1128/JB.180.6.1375-1380.1998; JOHNSON KG, 1974, J BACTERIOL, V117, P667, DOI 10.1128/JB.117.2.667-674.1974; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; LENGELER JW, 1990, PHILOS T ROY SOC B, V326, P489, DOI 10.1098/rstb.1990.0027; LILJESTROM PL, 1987, NUCLEIC ACIDS RES, V15, P2213, DOI 10.1093/nar/15.5.2213; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; MAURIZI MR, 1986, ARCH BIOCHEM BIOPHYS, V246, P494, DOI 10.1016/0003-9861(86)90496-0; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MIKI T, 1987, PROTEIN ENG, V1, P327, DOI 10.1093/protein/1.4.327; Nosworthy NJ, 1998, BIOCHEMISTRY-US, V37, P6718, DOI 10.1021/bi980126x; PARKER LL, 1990, GENETICS, V124, P455; PORTER EV, 1988, GENE, V62, P263; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PRASAD I, 1973, J BACTERIOL, V114, P909, DOI 10.1128/JB.114.3.909-915.1973; RAFFERTY JB, 1995, STRUCTURE, V3, P927, DOI 10.1016/S0969-2126(01)00227-1; REIZER J, 1994, PROTEIN SCI, V3, P440; REIZER J, 1988, CRC CR REV MICROBIOL, V15, P297, DOI 10.3109/10408418809104461; RIMMELE M, 1994, J BACTERIOL, V176, P5654, DOI 10.1128/JB.176.18.5654-5664.1994; ROBRISH SA, 1994, J BACTERIOL, V176, P3250, DOI 10.1128/jb.176.11.3250-3256.1994; ROJAS A, 1995, BIOCHEM MOL BIOL INT, V35, P1223; ROSEMAN S, 1989, FEMS MICROBIOL LETT, V63, P3, DOI 10.1016/0168-6445(89)90003-X; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1994, MOL MICROBIOL, V13, P755; SAIER MH, 1996, RES MICROBIOL, V147, P435; SCHAEFLER S, 1968, P NATL ACAD SCI USA, V59, P285, DOI 10.1073/pnas.59.1.285; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SINNOTT ML, 1978, BIOCHEM J, V175, P539, DOI 10.1042/bj1750539; STAEDTLER P, 1995, EUR J BIOCHEM, V232, P658, DOI 10.1111/j.1432-1033.1995.658zz.x; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; TENU JP, 1972, EUR J BIOCHEM, V26, P112, DOI 10.1111/j.1432-1033.1972.tb01746.x; THOMPSON J, 1989, J BIOL CHEM, V264, P9592; Thompson J, 1997, J BACTERIOL, V179, P1636, DOI 10.1128/jb.179.5.1636-1645.1997; THOMPSON J, 1995, J BACTERIOL, V177, P2505, DOI 10.1128/jb.177.9.2505-2512.1995; Thompson J., 1987, SUGAR TRANSPORT META, P13; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tobisch S, 1997, J BACTERIOL, V179, P496, DOI 10.1128/jb.179.2.496-506.1997; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WIESMANN C, 1995, STRUCTURE, V3, P961, DOI 10.1016/S0969-2126(01)00230-1; WILSON G, 1974, J BIOL CHEM, V249, P5586; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; WITT E, 1993, PROTEIN ENG, V6, P913, DOI 10.1093/protein/6.8.913; Yamamoto H, 1996, MICROBIOL-SGM, V142, P1417, DOI 10.1099/13500872-142-6-1417; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; ZHANG JK, 1994, GENE, V140, P85, DOI 10.1016/0378-1119(94)90735-8	71	67	70	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27347	27356		10.1074/jbc.273.42.27347	http://dx.doi.org/10.1074/jbc.273.42.27347			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765262	hybrid			2022-12-25	WOS:000076448000049
J	Wong, CW; Privalsky, ML				Wong, CW; Privalsky, ML			Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RAR alpha, and BCL-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; NUCLEAR HORMONE RECEPTORS; PROTEIN INTERACTION MOTIF; ZINC-FINGER GENE; CENTER B-CELLS; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; N-COR; MOLECULAR PATHOGENESIS	Many transcription factors function by repressing gene transcription. For a variety of these transcription factors the ability to physically recruit auxiliary proteins, denoted corepressors, is crucial for the ability to silence gene expression. We and others have previously implicated the SMRT corepressor in the actions of the PLZF transcription factor and in the function of its oncogenic derivative, PLZF-retinoic acid receptor (RAR alpha), in promyelocytic leukemia. We report here that PLZF, and a structurally similar transcriptional repressor, BCL-6, can interact with a variety of corepressor proteins in addition to SMRT, including the mSin3A protein and (for PLZF) histone deacetylase-l. Unexpectedly, these additional interactions with corepressor components are nonequivalent for these otherwise similar oncoproteins, suggesting that transcriptional repression by BCL-6 and by PLZF may differ in mechanism. Furthermore, we demonstrate that the oncogenic PLZF-RAR alpha chimera lacks several important corepressor interaction sites that are present in the native PLZF protein. Thus the t(11;17) translocation that creates the PLZF-RAR alpha chimera generates an oncoprotein with potentially novel regulatory properties distinct from those of either parental protein. Our results demonstrate that otherwise similar transcription factors can differ notably in their interactions with the corepressor machinery.	Univ Calif Davis, Microbiol Sect, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Microbiol Sect, Div Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu			NATIONAL CANCER INSTITUTE [R37CA053394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053528] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA-53394] Funding Source: Medline; NIDDK NIH HHS [R01 DK-53528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AVANTAGGIATO V, 1995, J NEUROSCI, V15, P4927; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; Chen Z, 1996, GENE CHROMOSOME CANC, V15, P147, DOI 10.1002/(SICI)1098-2264(199603)15:3<147::AID-GCC1>3.0.CO;2-2; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; DALLAFAVERA R, 1994, COLD SPRING HARB SYM, V59, P117, DOI 10.1101/SQB.1994.059.01.015; DERURBERTIS F, 1991, NATURE, V384, P589; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Downes M, 1996, NUCLEIC ACIDS RES, V24, P4379, DOI 10.1093/nar/24.22.4379; FLENGHI L, 1995, AM J PATHOL, V147, P405; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zamir I, 1996, MOL CELL BIOL, V16, P5458; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	60	137	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27695	27702		10.1074/jbc.273.42.27695	http://dx.doi.org/10.1074/jbc.273.42.27695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765306	hybrid			2022-12-25	WOS:000076448000093
J	Angove, HC; Yoo, SJ; Munck, E; Burgess, BK				Angove, HC; Yoo, SJ; Munck, E; Burgess, BK			An all-ferrous state of the Fe protein of nitrogenase - Interaction with nucleotides and electron transfer to the MoFe protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; MOLYBDENUM-IRON PROTEIN; KLEBSIELLA-PNEUMONIAE NITROGENASE; PARAMAGNETIC RESONANCE; P-CLUSTERS; ADENOSINE 5'-TRIPHOSPHATE; CONFORMATIONAL-CHANGES; CIRCULAR-DICHROISM; EPR SPECTROSCOPY; FE4S4 CLUSTER	The MoFe protein of nitrogenase catalyzes the six-electron reduction of dinitrogen to ammonia. It has long been believed that this protein receives the multiple electrons it requires one at a time, from the [4Fe-4S](2+/+) couple of the Fe protein. Recently an all-ferrous [4Fe4S](0) state of the Fe protein was demonstrated suggesting instead a series of two electron steps involving the [4Fe-4S](2+/0) couple. We have examined the interactions of the [4Fe-4S](0) Fe protein with nucleotides and its ability to transfer electrons to the MoFe protein. The [4Fe45](0) Fe protein binds both MgATP and MgADP and undergoes the MgATP induced conformational change and then binds properly to the MoFe protein, as evidenced by the fact that the behavior of the 0 and +1 oxidation states in the chelation and chelation protection assays are indistinguishable. Nucleotide binding does not effect the distinctive UV/Vis, CD, or Mossbauer spectra exhibited by the [4Fe-4S](0) Fe protein; however, because the intensity of the g = 16.4 EPR signal of the [4Fe-4S](0) Fe protein is extremely sensitive to minor variations of the rhombicity parameter E/D, the EPR signal is sensitive to the binding of nucleotides. A 50:50 mixture of [4Fe-4S](2+) and [4Fe-4S](0) Fe protein results in electron self-exchange and 100% production of [4Fe-4S](2+) Fe protein, demonstrating that the +1/0 couple is fully reversible. MgATP is absolutely required for electron transfer from the [4Fe-4S](0) Fe protein to the reduced state of the MoFe protein. In that reaction both electrons are transferred and are used to reduce substrate.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA	University of California System; University of California Irvine; Carnegie Mellon University	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	bburgess@uci.edu			NIGMS NIH HHS [GM-45209] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045209] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angove HC, 1997, J AM CHEM SOC, V119, P8730, DOI 10.1021/ja9712837; ASHBY GA, 1987, BIOCHEM J, V246, P455, DOI 10.1042/bj2460455; BOLIN JT, 1993, ACS SYM SER, V535, P186; BUI PT, 1968, P NATL ACAD SCI USA, V61, P1021, DOI 10.1073/pnas.61.3.1021; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; CHEN L, 1994, J BIOL CHEM, V269, P3290; DEITS TL, 1989, J BIOL CHEM, V264, P6619; Duyvis MG, 1996, FEBS LETT, V380, P233, DOI 10.1016/0014-5793(96)00019-1; FISHER K, 1991, BIOCHEM J, V279, P81, DOI 10.1042/bj2790081; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HAGEN WR, 1985, FEBS LETT, V189, P250, DOI 10.1016/0014-5793(85)81033-4; HEERING HA, 1995, EUR J BIOCHEM, V232, P811, DOI 10.1111/j.1432-1033.1995.811zz.x; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; IMAM S, 1980, FEBS LETT, V110, P35, DOI 10.1016/0014-5793(80)80016-0; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; Lanzilotta WN, 1997, BIOCHEMISTRY-US, V36, P12976, DOI 10.1021/bi9715371; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P16770, DOI 10.1021/bi962286j; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LINDAHL PA, 1985, J BIOL CHEM, V260, P1160; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; Lowe D. J., 1995, Nitrogen fixation: fundamentals and applications. Proceedings of the 10th International Congress on Nitrogen Fixation, St. Petersburg, Russia, May 28-June 3 1995., P103; LOWE DJ, 1993, BIOCHEM J, V292, P93, DOI 10.1042/bj2920093; LOWERY RG, 1989, BIOCHEMISTRY-US, V28, P1206, DOI 10.1021/bi00429a038; Ma L, 1996, J BIOL CHEM, V271, P10528, DOI 10.1074/jbc.271.18.10528; MORGAN TV, 1990, BIOCHEMISTRY-US, V29, P3077, DOI 10.1021/bi00464a026; MUNCK E, 1975, BIOCHIM BIOPHYS ACTA, V400, P32, DOI 10.1016/0005-2795(75)90124-5; ODONNELL MJ, 1978, BIOCHEM J, V173, P831, DOI 10.1042/bj1730831; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; Renner KA, 1996, BIOCHEMISTRY-US, V35, P5353, DOI 10.1021/bi960441o; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; Ryle MJ, 1996, J BIOL CHEM, V271, P1551, DOI 10.1074/jbc.271.3.1551; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Seefeldt LC, 1997, ACCOUNTS CHEM RES, V30, P260, DOI 10.1021/ar960260e; SEEFELDT LC, 1994, ANAL BIOCHEM, V221, P379, DOI 10.1006/abio.1994.1429; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SMITH BE, 1974, BIOCHEM J, V137, P169, DOI 10.1042/bj1370169; SMITH BE, 1972, BIOCHEM J, V130, P641, DOI 10.1042/bj1300641; STEPHENS PJ, 1979, P NATL ACAD SCI USA, V76, P2585, DOI 10.1073/pnas.76.6.2585; STOCCHI V, 1985, ANAL BIOCHEM, V146, P118, DOI 10.1016/0003-2697(85)90405-1; SURERUS KK, 1992, J AM CHEM SOC, V114, P8579, DOI 10.1021/ja00048a034; THORNELEY RN, 1974, BIOCHIM BIOPHYS ACTA, V333, P487, DOI 10.1016/0005-2728(74)90133-9; THORNELEY RNF, 1984, BIOCHEM J, V224, P887, DOI 10.1042/bj2240887; Thorneley RNF, 1996, J BIOL INORG CHEM, V1, P576, DOI 10.1007/s007750050095; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; THORNELEY RNF, 1993, ACS SYM SER, V535, P290; THORNELEY RNF, 1991, BIOCHEM J, V277, P735, DOI 10.1042/bj2770735; TITTSWORTH RC, 1993, J AM CHEM SOC, V115, P9763, DOI 10.1021/ja00074a050; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WATT GD, 1989, BIOCHEMISTRY-US, V28, P1844, DOI 10.1021/bi00430a062; WATT GD, 1994, J INORG BIOCHEM, V53, P281, DOI 10.1016/0162-0134(94)85115-8; WATT GD, 1986, BIOCHEMISTRY-US, V25, P8156, DOI 10.1021/bi00373a005; WATT GD, 1980, BIOCHEMISTRY-US, V19, P4926, DOI 10.1021/bi00562a035; WATT GD, 1985, BIOCHEMISTRY-US, V24, P7226, DOI 10.1021/bi00346a031; WILLING AH, 1989, J BIOL CHEM, V264, P8499; Yates M. G., 1992, BIOL NITROGEN FIXATI, P685; ZIMMERMANN R, 1978, BIOCHIM BIOPHYS ACTA, V537, P185, DOI 10.1016/0005-2795(78)90504-4; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9	64	68	68	4	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26330	26337		10.1074/jbc.273.41.26330	http://dx.doi.org/10.1074/jbc.273.41.26330			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756863	hybrid			2022-12-25	WOS:000076373300017
J	Noronkoski, T; Stoineva, IB; Ivanov, IP; Petkov, DD; Mononen, I				Noronkoski, T; Stoineva, IB; Ivanov, IP; Petkov, DD; Mononen, I			Glycosylasparaginase-catalyzed synthesis and hydrolysis of beta-aspartyl peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTYLGLYCOSAMINURIA; MECHANISM; ASPARTYLGLUCOSAMINIDASE; ASSAY	beta-Aspartyl di- and tripeptides are common constituents of mammalian metabolism, but their formation and catabolism are not fully understood. In this study we provide evidence that glycosylasparaginase (aspartylglucosaminidase), an N-terminal nucleophile hydrolase involved in the hydrolysis of the N-glycosidic bond in glycoproteins, catalyzes the hydrolysis of beta-aspartyl peptides to form L-aspartic acid and amino acids or peptides. The enzyme also effectively catalyzes the synthesis of beta-aspartyl peptides by transferring the beta-aspartyl moiety from other beta-aspartyl peptides or beta-aspartylglycosylamine to a variety of amino acids and peptides. Furthermore, the enzyme can use L-asparagine as the beta-aspartyl donor in the formation of beta-aspartyl peptides, The data show that synthesis and degradation of beta-aspartyl peptides are new, significant functions of glycosylasparaginase and suggest that the enzyme could have an important role in the metabolism of beta-aspartyl peptides.	Bulgarian Acad Sci, Inst Organ Chem, Lab Biocatalysis, BG-1113 Sofia, Bulgaria; Kuopio Univ Hosp, Dept Clin Chem, FIN-70211 Kuopio, Finland; Univ Sofia, Fac Biol, Lab Bioorgan Synth, BG-1421 Sofia, Bulgaria	Bulgarian Academy of Sciences; Kuopio University Hospital; University of Sofia	Mononen, I (corresponding author), Bulgarian Acad Sci, Inst Organ Chem, Lab Biocatalysis, BG-1113 Sofia, Bulgaria.	ilkka.mononen@messi.uku.fi						Aronson NN, 1997, LYSOSOMAL STORAGE DI, P55; Arvio M, 1997, LYSOSOMAL STORAGE DI, P19; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; BUCHANAN DL, 1962, BIOCHEMISTRY-US, V1, P612, DOI 10.1021/bi00910a011; COHENANISFELD ST, 1993, J AM CHEM SOC, V115, P10531, DOI 10.1021/ja00076a010; FASTREZ J, 1973, BIOCHEMISTRY-US, V12, P2025, DOI 10.1021/bi00735a001; HANSON RW, 1964, J CHEM SOC, P836, DOI 10.1039/jr9640000836; KAARTINEN V, 1992, J BIOL CHEM, V267, P6855; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; Kaartinen V, 1996, NAT MED, V2, P1375, DOI 10.1038/nm1296-1375; KAARTINEN V, 1990, ANAL BIOCHEM, V190, P98, DOI 10.1016/0003-2697(90)90140-5; MAKINO M, 1966, BIOCHEM BIOPH RES CO, V24, P961, DOI 10.1016/0006-291X(66)90344-5; MAKINO M, 1968, J BIOCHEM, V63, P186, DOI 10.1093/oxfordjournals.jbchem.a128760; MONONEN I, 1995, FASEB J, V9, P428, DOI 10.1096/fasebj.9.5.7896015; Mononen I, 1996, BIOCHEM BIOPH RES CO, V218, P510, DOI 10.1006/bbrc.1996.0091; MONONEN IT, 1993, ANAL BIOCHEM, V208, P372, DOI 10.1006/abio.1993.1063; Noronkoski T, 1997, FEBS LETT, V412, P149, DOI 10.1016/S0014-5793(97)00761-8; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Perakyla M, 1997, J AM CHEM SOC, V119, P1189, DOI 10.1021/ja9628967; SANDBERG M, 1994, ANAL BIOCHEM, V217, P48, DOI 10.1006/abio.1994.1082; TANAKA T, 1978, J BIOCHEM-TOKYO, V84, P1147, DOI 10.1093/oxfordjournals.jbchem.a132230; TARENTINO AL, 1969, ARCH BIOCHEM BIOPHYS, V130, P295, DOI 10.1016/0003-9861(69)90036-8; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; Thomas GH, 1995, METABOLIC MOL BASES, P2529	24	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26295	26297		10.1074/jbc.273.41.26295	http://dx.doi.org/10.1074/jbc.273.41.26295			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756857	hybrid			2022-12-25	WOS:000076373300011
J	Simizu, S; Takada, M; Umezawa, K; Imoto, M				Simizu, S; Takada, M; Umezawa, K; Imoto, M			Requirement of caspase-3(-like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RESPIRATORY BURST OXIDASE; INDUCED CELL-DEATH; KINASE-C; ICE/CED-3 PROTEASE; CYSTEINE PROTEASE; CARCINOMA CELLS; ACTIVATION; CLEAVAGE; OXYGEN	Caspase-3 (-like) proteases play important roles in controlling mammalian apoptosis. However, the downstream events from the caspase-3(-like) protease activation to death of cells are still unclear. Previously, we reported that hydrogen peroxide (H2O2) was generated by the activation of caspase-3(-like) proteases in the process of tyrosine kinase inhibitor-induced apoptosis in human small cell lung carcinoma Ms-1. cells. In the present study, we examined whether generation of H2O2 is a critical event for the apoptotic pathway downstream of caspase-3(-like) protease activation by various anticancer drugs. Anticancer drugs such as camptothecin, vinblastine, inostamycin, and adriamycin induced activation of caspase-3(-like) proteases and apoptosis. Generation of H2O2 was commonly detected after treatment with each of the four anticancer drugs, and scavenging of H2O2 caused cells to fail to undergo apoptosis. Moreover, anticancer drug-induced H2O2 production was inhibited not only by san inhibitor of caspase-3(-like) proteases but also by diphenyleneiodonium chloride, an inhibitor of flavonoid-containing enzymes such as NADPH oxidase. However, activation of caspase-3(-like) proteases was not inhibited by diphenyleneiodonium chloride. These findings suggest that activation of caspase-3(-like) proteases by various anticancer drugs causes generation of H2O2 presumably through the activation of NADPH oxidase, thereby inducing apoptosis. Therefore, H2O2 may function as a common mediator for apoptosis induced by various anticancer drugs.	Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan; Rinku Gen Med Ctr, Izumisano, Osaka 5988577, Japan	Keio University	Imoto, M (corresponding author), Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2238522, Japan.	imoto@applc.keio.ac.jp		Simizu, Siro/0000-0003-2949-2427				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; ElBenna J, 1996, J BIOL CHEM, V271, P6374; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; EPSTEIN RJ, 1990, J CLIN ONCOL, V8, P2062, DOI 10.1200/JCO.1990.8.12.2062; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IMOTO M, 1990, J NAT PROD, V53, P825, DOI 10.1021/np50070a008; IMOTO M, 1992, J BIOCHEM-TOKYO, V112, P299, DOI 10.1093/oxfordjournals.jbchem.a123894; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Islam KN, 1997, FREE RADICAL BIO MED, V22, P1007, DOI 10.1016/S0891-5849(96)00493-5; ISRAEL N, 1992, J IMMUNOL, V149, P3386; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JIAN N, 1996, CANCER, V77, P1797; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicolau JM, 1996, GEOMORPHOLOGY, V14, P297, DOI 10.1016/0169-555X(95)00043-5; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scala S, 1996, CANCER RES, V56, P3737; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHNEIDER E, 1988, BIOCHIM BIOPHYS ACTA, V949, P264, DOI 10.1016/0167-4781(88)90151-0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schulz JB, 1996, J NEUROSCI, V16, P4696; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Simizu S, 1996, CANCER RES, V56, P4978; Simizu S, 1998, EXP CELL RES, V238, P197, DOI 10.1006/excr.1997.3823; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Tamura K, 1997, JPN J CANCER RES, V88, P218, DOI 10.1111/j.1349-7006.1997.tb00369.x; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V187, P940, DOI 10.1016/0006-291X(92)91288-2; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	55	233	237	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26900	26907		10.1074/jbc.273.41.26900	http://dx.doi.org/10.1074/jbc.273.41.26900			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756937	hybrid			2022-12-25	WOS:000076373300091
J	Gu, XJ; Trigatti, B; Xu, SZ; Acton, S; Babitt, J; Krieger, M				Gu, XJ; Trigatti, B; Xu, SZ; Acton, S; Babitt, J; Krieger, M			The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain (vol 273, pg 26343, 1998)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction													Eckhardt, Erik/G-1567-2010; Krieger, Marco/AAE-8611-2020	Trigatti, Bernardo (Dino) L./0000-0002-4556-119X	NHLBI NIH HHS [HL52212, HL41484] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338	1	198	204	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					35388	35388		10.1074/jbc.273.41.26338	http://dx.doi.org/10.1074/jbc.273.41.26338			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9756864	hybrid			2022-12-25	WOS:000077719700100
J	Cavallius, J; Merrick, WC				Cavallius, J; Merrick, WC			Site-directed mutagenesis of yeast eEF1A - Viable mutants with altered nucleotide specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR 1-ALPHA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; RABBIT RETICULOCYTES; FACTOR-TU; FACTOR-I; PROTEIN; SEQUENCE; EF-1-ALPHA	Site directed mutants of eEF1A (formerly eEF-1 alpha) were generated using a modification of a highly versatile yeast shuttle vector (Cavallius, J., Popkie, A. P., and Merrick, W. C. (1997) Biochim. Biophys, Acta 1350, 345-358), The nucleotide specificity sequence NKMD (residues number 153-156) was targeted for mutagenesis, and the following mutants were obtained: N153D (DKMD), N153T (TKMD), D156N (NKMN), D156W (NKMW), and the double mutant N153T,D156E (TKNE), All of the yeast strains containing the mutant eEF1As as the sole source of eEF1A were viable except for the N153D mutant. Most of the purified mutant eEF1As had specific activities in the poly(U)-directed synthesis of polyphenylalanine similar to wild type, although with a K-m for GTP increased by 1-2 orders of magnitude. The mutants showed a reduced rate of GTP hydrolysis, and most displayed misincorporation rates greater than wild type. The mutant NKMW eEF1A showed unusual properties. The yeast strain was temperature sensitive for growth, although the purified protein was not. Second, this form of eEF1A was 10-fold more accurate in protein synthesis, and its rate of GTP hydrolysis was about 20% of wild type. In total, the wild-type protein contains the most optimal nucleotide specificity sequence, NKMD, and even subtle changes in this sequence have drastic consequences on eEF1A function in vitro or yeast viability.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Merrick, WC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 07319] Funding Source: Medline; NIGMS NIH HHS [GM 26796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARVALHO JF, 1984, ARCH BIOCHEM BIOPHYS, V234, P591, DOI 10.1016/0003-9861(84)90309-6; CARVALHO MDD, 1984, ARCH BIOCHEM BIOPHYS, V234, P603, DOI 10.1016/0003-9861(84)90310-2; Cavallius J, 1997, BBA-GENE STRUCT EXPR, V1350, P345, DOI 10.1016/S0167-4781(96)00181-9; CAVALLIUS J, 1993, BIOCHIM BIOPHYS ACTA, V1163, P75, DOI 10.1016/0167-4838(93)90281-U; CAVALLIUS J, 1993, HDB EXPT PHARM, V108, P115; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JONES S, 1995, J CELL BIOL, V130, P1051, DOI 10.1083/jcb.130.5.1051; KANG C, 1994, J BIOL CHEM, V269, P24046; KINZY TG, 1995, GENETICS, V141, P481; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KURLAND CG, 1990, RIBOSOME, P513; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; MAIER T, 1995, EUR J BIOCHEM, V230, P133, DOI 10.1111/j.1432-1033.1995.tb20543.x; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick WC., 1996, TRANSLATION CONTROL, P31; Rose MD., 1990, METHODS YEAST GENETI; RUUSALA T, 1984, EMBO J, V3, P2575, DOI 10.1002/j.1460-2075.1984.tb02176.x; SANDBAKEN MG, 1988, GENETICS, V120, P923; SELIGER LS, 1987, J BIOL CHEM, V262, P16289; SIKORSKI RS, 1989, GENETICS, V122, P19; STOFFEL M, 1993, HUM MOL GENET, V2, P1, DOI 10.1093/hmg/2.1.1; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; WEIJLAND A, 1994, BIOCHEMISTRY-US, V33, P10711, DOI 10.1021/bi00201a019; YAMADA M, 1989, J BIOL CHEM, V264, P19192; ZAGARI A, 1994, J MOL BIOL, V242, P175, DOI 10.1006/jmbi.1994.1568	28	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28752	28758		10.1074/jbc.273.44.28752	http://dx.doi.org/10.1074/jbc.273.44.28752			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786872	hybrid			2022-12-25	WOS:000076691800033
J	Kim, HJ; Kim, JH; Lee, JW				Kim, HJ; Kim, JH; Lee, JW			Steroid receptor coactivator-1 interacts with serum response factor and coactivates serum response element-mediated transactivations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX-FORMATION; PROTEIN-BINDING SITE; C-FOS PROMOTER; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; NUCLEAR RECEPTORS; FACTOR P62TCF; FACTORS ELK-1; CBP; P300	Steroid receptor coactivator-l (SRC-1) specifically bound to serum response factor (SRF), as demonstrated by glutathione S-transferase pull down assays, and the yeast and mammalian two hybrid tests. In mammalian cells, SRC-1 potentiated serum response element (SRE)-mediated transactivations in a dose-dependent manner. Coexpression of p300 synergistically enhanced this SRC-1-potentiated level of transactivations, consistent with the recent finding (Ramirez, S., All, S. A. S., Robin, P., Trouche, D., and Harel-Bellan, A. (1997) J. Biol. Chem. 272, 31016-31021) in which the p300 homologue CREB-binding protein was shown to be a transcription coactivator of SRF. Thus, we concluded that at least two distinct classes of coactivator molecules may cooperate to regulate SRF-dependent transactivations in vivo.	Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Hallym Univ, Inst Environm & Life Sci, Chunchon, South Korea	Chonnam National University; Chonnam National University; Hallym University	Lee, JW (corresponding author), Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea.	jlee@chonnam.chonnam.ac.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim HJ, 1998, MOL ENDOCRINOL, V12, P1038, DOI 10.1210/me.12.7.1038; KIM JH, 1994, J BIOL CHEM, V269, P13740; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LIU SH, 1993, J BIOL CHEM, V268, P21147; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moore DD, 1995, GLOB MOB SURV; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NORMAN C, 1988, CELL, V55, P898; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	61	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28564	28567		10.1074/jbc.273.44.28564	http://dx.doi.org/10.1074/jbc.273.44.28564			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786846	hybrid			2022-12-25	WOS:000076691800007
J	Tatsumi, S; Miyamoto, K; Kouda, T; Motonaga, K; Katai, K; Ohkido, I; Morita, K; Segawa, H; Tani, Y; Yamamoto, H; Taketani, Y; Takeda, E				Tatsumi, S; Miyamoto, K; Kouda, T; Motonaga, K; Katai, K; Ohkido, I; Morita, K; Segawa, H; Tani, Y; Yamamoto, H; Taketani, Y; Takeda, E			Identification of three isoforms for the Na+-dependent phosphate cotransporter (NaPi-2) in rat kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA/P-I-COTRANSPORTER; FUNCTIONAL EXPRESSION; MOLECULAR MECHANISMS; MESSENGER-RNA; CLONING; TRANSPORTER; CORTEX; MURINE; SYSTEM; MOUSE	We have isolated three unique NaPi-2-related protein cDNAs (NaPi-2 alpha, NaPi-2 beta, and NaPi-2 gamma) from a rat kidney library. NaPi-2 alpha cDNA encodes 337 amino acids which have high homology to the N-terminal half of NaPi-2 containing 3 transmembrane domains. NaPi-2 beta encodes 327 amino acids which are identical to the N-terminal region of NaPi-2 containing 4 transmembrane domains, whereas the 146 amino acids in the C-terminal region are completely different. In contrast, NaPi-2 gamma encodes 268 amino acids which are identical to the C-terminal half of NaPi-2, An analysis of phage and cosmid clones indicated that the three related proteins were produced by alternative splicing in the NaPi-2 gene. In a rabbit reticulocyte lysate system, NaPi-2 alpha, beta, and gamma were found to be 36, 36, and 29 kDa amino acid polypeptides, respectively. NaPi-2 alpha: and NaPi-2 gamma were glycosylated and revealed to be 45- and 35-kDa proteins, respectively. In isolated brush-border membrane vesicles, an N-terminal antibody was reacted with 45- and 40-kDa, and a C-terminal antibody was reacted with 37-kDa protein. The sizes of these proteins corresponded to those in glycosylated forms. A functional analysis demonstrated that NaPi-2 gamma and -2 alpha markedly inhibited NaPi-2 activity in Xenopus oocytes, The results suggest that these short isoforms may function as a dominant negative inhibitor of the full-length transporter.	Univ Tokushima, Sch Med, Dept Clin Nutr, Tokushima 770, Japan	Tokushima University	Miyamoto, K (corresponding author), Univ Tokushima, Sch Med, Dept Clin Nutr, Kuramoto Cho 3, Tokushima 770, Japan.	miyamoto@nutr.med.tokushima-u.ac.jp		Tatsumi, Sawako/0000-0002-4862-2955				ADHAM ML, 1995, AM J PHYSIOL, V269, pF93; Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372; Biber J, 1996, KIDNEY INT, V49, P981, DOI 10.1038/ki.1996.139; Boyer CJC, 1996, BBA-BIOMEMBRANES, V1281, P117, DOI 10.1016/0005-2736(96)00033-8; BUSCH A, 1994, P NATL ACAD SCI USA, V91, P8205, DOI 10.1073/pnas.91.17.8205; COLLINS JF, 1995, AM J PHYSIOL-GASTR L, V268, pG917, DOI 10.1152/ajpgi.1995.268.6.G917; COLLINS JF, 1994, FASEB J, V8, P862, DOI 10.1096/fasebj.8.11.8070635; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Hartmann CM, 1996, P NATL ACAD SCI USA, V93, P7409, DOI 10.1073/pnas.93.14.7409; HARTMANN CM, 1995, PFLUG ARCH EUR J PHY, V430, P830, DOI 10.1007/BF00386183; HAYES G, 1994, J BIOL CHEM, V269, P24143; Katai K, 1997, J BIOCHEM-TOKYO, V121, P50, DOI 10.1093/oxfordjournals.jbchem.a021569; Kohl B, 1998, J PHYSIOL-LONDON, V508, P341, DOI 10.1111/j.1469-7793.1998.341bq.x; Kohl B., 1996, FASEB Journal, V10, pA90; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MICHAEL PK, 1996, KIDNEY INT, V49, P959; MINAMI H, 1993, GASTROENTEROLOGY, V105, P692, DOI 10.1016/0016-5085(93)90884-F; Miyamoto K, 1997, MOL ENDOCRINOL, V11, P1165, DOI 10.1210/me.11.8.1165; Miyamoto K, 1997, BIOCHEM J, V327, P735, DOI 10.1042/bj3270735; MIYAMOTO KI, 1995, BIOCHEM J, V305, P81, DOI 10.1042/bj3050081; Murer H, 1996, ANNU REV PHYSIOL, V58, P607, DOI 10.1146/annurev.physiol.58.1.607; Murer H, 1997, PFLUG ARCH EUR J PHY, V433, P379, DOI 10.1007/s004240050292; MURRER H, 1992, KIDNEY PATHOPHYSIOLO, P2481; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; SORRIBAS V, 1994, J BIOL CHEM, V269, P6615; Taketani Y, 1997, BIOCHEM J, V324, P927, DOI 10.1042/bj3240927; Tenenhouse HS, 1997, J BONE MINER RES, V12, P159, DOI 10.1359/jbmr.1997.12.2.159; VERRI T, 1995, AM J PHYSIOL-RENAL, V268, pF626, DOI 10.1152/ajprenal.1995.268.4.F626; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WERNER A, 1994, J BIOL CHEM, V269, P6637; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; Xiao YS, 1997, BIOCHEM J, V323, P401, DOI 10.1042/bj3230401	33	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28568	28575		10.1074/jbc.273.44.28568	http://dx.doi.org/10.1074/jbc.273.44.28568			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786847	hybrid			2022-12-25	WOS:000076691800008
J	Wolf, I; Pevzner, V; Kaiser, E; Bernhardt, G; Claudio, E; Siebenlist, U; Forster, R; Lipp, M				Wolf, I; Pevzner, V; Kaiser, E; Bernhardt, G; Claudio, E; Siebenlist, U; Forster, R; Lipp, M			Downstream activation of a TATA-less promoter by Oct-2, Bob1, and NF-kappa B directs expression of the homing receptor BLR1 to mature B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; TRANSCRIPTION FACTORS; FUNCTIONAL-CHARACTERIZATION; MURINE HOMOLOG; POU DOMAIN; COACTIVATOR; DIFFERENTIATION; CLONING; GENE; LYMPHOMA	The chemokine receptor, BLR1, is a major regulator of the microenvironmental homing of B cells in lymphoid organs. In vitro studies identify three essential elements of the TATA-less blr1 core promoter that confer cell type- and differentiation-specific expression in the B cells of both humans and mice, a functional promoter region (-36 with respect to the transcription start site), a NF-kappa B motif (+44), and a noncanonical octamer motif (+157), The importance of these sites was confirmed by in vivo studies in gene-targeted mice deficient of either Oct-2, Bob1, or both NF-kappa B subunits p50 and p52, In all of these animals, the expression of BLR1 was reduced or absent. In mice deficient only of p52/NF-KB, BLR1 expression was unaffected. Thus our data demonstrate that BLR1 is a target gene for Oct-2, Bob1, and members of the NF-kappa B/Rel family and provides a link to the impaired B cell functions in mice deficient for these factors.	Max Delbruck Ctr Mol Med, Dept Tumorgenet & Immunogenet, D-13122 Berlin, Germany; Univ Munich, Inst Biochem, D-81377 Munich, Germany; NICHD, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Munich; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Lipp, M (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumorgenet & Immunogenet, Robert Rossle Str 10, D-13122 Berlin, Germany.		Bernhardt, Günter/F-6946-2012; Lipp, Martin/G-2235-2010; Förster, Reinhold/D-6770-2011	Bernhardt, Günter/0000-0002-0510-2853; Lipp, Martin/0000-0002-0087-2672; Forster, Reinhold/0000-0001-6190-7923				ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; FORSTER R, 1994, BLOOD, V84, P830; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; KAISER E, 1993, EUR J IMMUNOL, V23, P2532, DOI 10.1002/eji.1830231023; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; KONIG H, 1995, GENE DEV, V9, P1598, DOI 10.1101/gad.9.13.1598; KOUBA M, 1993, FEBS LETT, V321, P173, DOI 10.1016/0014-5793(93)80102-Z; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; Pfisterer P, 1996, MOL CELL BIOL, V16, P6160; PFISTERER P, 1995, J BIOL CHEM, V270, P29870, DOI 10.1074/jbc.270.50.29870; PFISTERER P, 1994, EMBO J, V13, P1655; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; Schubart DB, 1996, NUCLEIC ACIDS RES, V24, P1913, DOI 10.1093/nar/24.10.1913; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Shah PC, 1997, EMBO J, V16, P7105, DOI 10.1093/emboj/16.23.7105; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	35	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28831	28836		10.1074/jbc.273.44.28831	http://dx.doi.org/10.1074/jbc.273.44.28831			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786883	hybrid			2022-12-25	WOS:000076691800044
J	Bauer, A; Lickert, H; Kemler, R; Stappert, J				Bauer, A; Lickert, H; Kemler, R; Stappert, J			Modification of the E-cadherin-catenin complex in mitotic Madin-Darby canine kidney epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; EPIDERMAL GROWTH-FACTOR; BETA-CATENIN; ALPHA-CATENIN; FACTOR RECEPTOR; PHOSPHORYLATED EPITOPE; MONOCLONAL-ANTIBODIES; CYCLE PROGRESSION; ADHESION COMPLEX; SRC GENE	One of the hallmarks of polarized epithelial cells undergoing mitosis is their rounded morphology, This phenotype correlates with a reduced cell-substratum adhesion, apparently caused by a modulation of integrin function. However, it is still unclear whether the cadherin-mediated cell-cell adhesion is affected as well. To address this question, the cadherin complex was analyzed in different cell cycle stages of Madin-Darby canine kidney cells. By immunofluorescence, mitotic Madin-Darby canine kidney cells showed an increased staining of E-cadherin and the catenins (alpha-catenin, beta-catenin, plakoglobin, p120(ctn)) in the cytosol, suggesting a reorganization of the cadherin-catenin complex during mitosis. Biochemical analysis revealed that the overall amount of these components, as well as the proportion of the complex associated with the actin cytoskeleton, remained unchanged in mitotic cells. However, we found evidence for an internalization of E-cadherin during mitosis, In addition, the cadherin-catenin complex was analyzed for mitosis-specific changes in phosphorylation. We report a decrease in the tyrosine phosphorylation of beta-catenin, plakoglobin, and p120(ctn) during mitosis. Moreover, we observed a mitosis-specific Ser/Thr-phosphorylation of p120(ctn), as detected by the MPM-2 antibody. Hence, the cadherin/catenin complex is a target for different posttranslational modifications during mitosis, which may also have a profound impact on cadherin-mediated cell-cell adhesion.	Max Planck Inst Immunbiol, Dept Mol Embryol, D-79108 Freiburg, Germany	Max Planck Society	Stappert, J (corresponding author), Max Planck Inst Immunbiol, Dept Mol Embryol, Stubeweg 51, D-79108 Freiburg, Germany.	stappert@immunbio.mpg.de	Lickert, Heiko/K-9045-2013					Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; BAKER J, 1993, J CELL SCI, V104, P415; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bhattacharjee RN, 1996, BIOCHEM BIOPH RES CO, V220, P192, DOI 10.1006/bbrc.1996.0379; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; BUTZ S, 1994, FEBS LETT, V355, P195, DOI 10.1016/0014-5793(94)01205-9; CAO LG, 1990, J CELL BIOL, V111, P1905, DOI 10.1083/jcb.111.5.1905; Che SL, 1997, FEBS LETT, V413, P417, DOI 10.1016/S0014-5793(97)00948-4; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DAVIS FM, 1989, CELL STRUCT FUNCT, V14, P271, DOI 10.1247/csf.14.271; ENGLE DB, 1988, CELL MOTIL CYTOSKEL, V10, P432, DOI 10.1002/cm.970100310; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Hughes TA, 1996, EXP CELL RES, V222, P275, DOI 10.1006/excr.1996.0035; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kiyokawa N, 1997, J BIOL CHEM, V272, P18656, DOI 10.1074/jbc.272.30.18656; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUANG J, 1989, P NATL ACAD SCI USA, V86, P4982, DOI 10.1073/pnas.86.13.4982; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nagafuchi A, 1993, Semin Cell Biol, V4, P175, DOI 10.1006/scel.1993.1021; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Obama H, 1997, J BIOL CHEM, V272, P11017; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; Orsulic S, 1996, CURR BIOL, V6, P1363, DOI 10.1016/S0960-9822(96)00731-2; OUHIBI N, 1994, INT J DEV BIOL, V38, P731; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; REINSCH S, 1994, J CELL BIOL, V126, P1509, DOI 10.1083/jcb.126.6.1509; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SANDIG M, 1990, CELL MOTIL CYTOSKEL, V17, P133, DOI 10.1002/cm.970170208; SMITH KJ, 1994, CANCER RES, V54, P3672; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TAAGEPERA S, 1994, MOL BIOL CELL, V5, P1243, DOI 10.1091/mbc.5.11.1243; Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TZUUSHUH J, 1995, P NATL ACAD SCI USA, V92, P5067; URBANI L, 1995, EXP CELL RES, V219, P159, DOI 10.1006/excr.1995.1216; VANDRE DD, 1986, EUR J CELL BIOL, V41, P72; VANDRE DD, 1991, J CELL SCI, V98, P577; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	58	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28314	28321		10.1074/jbc.273.43.28314	http://dx.doi.org/10.1074/jbc.273.43.28314			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774455	hybrid			2022-12-25	WOS:000076549800075
J	Hime, NJ; Barter, PJ; Rye, KA				Hime, NJ; Barter, PJ; Rye, KA			The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TRANSFER PROTEIN; A-II; APOA-II; ENZYMIC ACTIVITY; HUMAN-PLASMA; ACTIVATION; SIZE; PHOSPHATIDYLCHOLINE; TRIGLYCERIDE; CHOLESTEROL	This study describes the influence of apolipoproteins on the hepatic lipase (HL)-mediated hydrolysis of phospholipids and triacylglycerol in high density lipoproteins (HDL), HL-mediated hydrolysis was assessed in well characterized, homogeneous preparations of spherical reconstituted high density lipoproteins (rHDL), The rHDL were comparable in size and lipid composition and contained either apoA-I ((A-I)rHDL) or apoA-II ((AII)rHDL) as their sole apolipoprotein constituent. Preparations of rHDL containing only cholesteryl esters (CE) in their core, (A-I/CE)rHDL and (A-II/CE)rHDL, were used to assess phospholipid hydrolysis, Preparations of rHDL that contained triacylglycerol as their predominant core lipid, (A-I/TG)rHDL and (A-II/TG)rHDL, were used to assess both triacylglycerol and phospholipid hydrolysis, The rHDL contained trace amounts of either radiolabeled phospholipid or radiolabeled triacylglycerol, Hydrolysis was measured as the release of radiolabeled nonesterified fatty acids (NEFA) from the rHDL, Kinetic analysis showed that HL had a greater affinity for the phospholipids in (A-II/CE)rHDL (K-m(app) = 0.2 mM) than in (A-I/CE)rHDL (K-m(app) = 3.1 mM). This was also evident when hydrolysis was measured directly by quantitating NEFA mass. HL also had a greater affinity for the phospholipids and triacylglycerol in (A-II/TG)rHDL than in (A-I/TG)rHDL. The V-max for phospholipid hydrolysis was, by contrast, greater for (A-I/CE)rHDL than for (A-II/CE)rHDL: 309.3 versus 49.1 nmol of NEFA formed/ml of HL/h. Comparable V-max values were obtained for the hydrolysis of the phospholipids in (A-II/TG)rHDL and (A-I/TG)rHDL. In the case of triacylglycerol hydrolysis, the respective V-max values for (A-I/TG)rHDL and (A-II/TG)rHDL were 1154.8 and 240.2 nmol of NEFA formed/ml of HL/h, These results show that apolipoproteins have a major influence on the kinetics of HL-mediated phospholipid and triacylglycerol hydrolysis in rHDL.	Hanson Ctr Canc Res, Lipid Res Lab, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5005, Australia; Royal Adelaide Hosp, Div Cardiovasc Serv, Adelaide, SA 5000, Australia	University of Adelaide; Royal Adelaide Hospital	Rye, KA (corresponding author), Hanson Ctr Canc Res, Lipid Res Lab, Level 1,Frome Rd, Adelaide, SA 5000, Australia.	karye@camtech.net.au						APPLEBAUMBOWDEN D, 1985, ARTERIOSCLEROSIS, V5, P273, DOI 10.1161/01.ATV.5.3.273; BEKAERT ED, 1992, BIOCHIM BIOPHYS ACTA, V1126, P105, DOI 10.1016/0005-2760(92)90223-I; BURSTEIN M, 1970, J LIPID RES, V11, P583; DATTA S, 1988, J BIOL CHEM, V263, P1107; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DUVERGER N, 1994, ARTERIOSCLER THROMB, V14, P1594, DOI 10.1161/01.ATV.14.10.1594; EUGUI J, 1994, CLIN BIOCHEM, V27, P310, DOI 10.1016/0009-9120(94)90035-3; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FOLCH J, 1957, J BIOL CHEM, V226, P497; JAHN CE, 1981, FEBS LETT, V131, P366, DOI 10.1016/0014-5793(81)80405-X; JAHN CE, 1983, EUR J BIOCHEM, V131, P25, DOI 10.1111/j.1432-1033.1983.tb07227.x; JENSEN GL, 1982, BIOCHIM BIOPHYS ACTA, V710, P464, DOI 10.1016/0005-2760(82)90130-8; KOHLMEIER M, 1986, CLIN CHEM, V32, P63; KUBO M, 1982, J BIOCHEM-TOKYO, V92, P365; KUUSI T, 1980, ATHEROSCLEROSIS, V36, P589, DOI 10.1016/0021-9150(80)90251-8; LABODA HM, 1988, BIOCHEMISTRY-US, V27, P2313, DOI 10.1021/bi00407a011; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MOWRI HO, 1992, J LIPID RES, V33, P1269; Mowri HO, 1996, ARTERIOSCL THROM VAS, V16, P755, DOI 10.1161/01.ATV.16.6.755; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PIRAN U, 1979, J LIPID RES, V20, P1040; RYE KA, 1989, J LIPID RES, V30, P335; RYE KA, 1994, J BIOL CHEM, V269, P10298; Rye KA, 1996, J BIOL CHEM, V271, P4243; Rye KA, 1998, J LIPID RES, V39, P613; Rye KA, 1997, J BIOL CHEM, V272, P3953, DOI 10.1074/jbc.272.7.3953; RYE KA, 1995, J BIOL CHEM, V270, P189, DOI 10.1074/jbc.270.1.189; RYE KA, 1992, J LIPID RES, V33, P215; Sanan DA, 1997, J LIPID RES, V38, P1002; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; Tansey JT, 1997, BIOCHEMISTRY-US, V36, P12227, DOI 10.1021/bi970356w; THUREN T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P217, DOI 10.1016/0005-2760(91)90046-K; THUREN T, 1991, J BIOL CHEM, V266, P4853; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE894, DOI 10.1152/ajpendo.1988.255.6.E894; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VERGER R, 1976, ANNU REV BIOPHYS BIO, V5, P77, DOI 10.1146/annurev.bb.05.060176.000453; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; ZHONG SB, 1994, J CLIN INVEST, V94, P2457, DOI 10.1172/JCI117614	39	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27191	27198		10.1074/jbc.273.42.27191	http://dx.doi.org/10.1074/jbc.273.42.27191			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765239	hybrid			2022-12-25	WOS:000076448000026
J	Guo, SY; Ives, DH				Guo, SY; Ives, DH			Functional assignment by chimera construction of the domain affecting heterotropic activation of deoxyadenosine kinase from Lactobacillus acidophilus R-26	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; DEOXYGUANOSINE KINASE; THYMIDINE KINASE; DEOXYCYTIDINE KINASE; DIRECTED MUTAGENESIS; EXPRESSION; CLONING; CDNA; BINDING; SITE	The heterodimeric subunits of deoxyadenosine kinase (dAK)-deoxyguanosine kinase (dGrK) from Lactobacillus acidophilus R-26 exhibit contrasting conformations manifested in the nearly unidirectional heterotropic activation of dAK when dGK binds deoxyguanosine. This is mediated, in part, by the conserved Ras switch I-like sequence (residues 153-161) [Guo et at. (1997) J. Biol. Chem. 272, 6890-6897]. In an attempt to identify domains differentiating the specificities of dAK and dGK, we constructed several chimeras splicing heterodimeric dAK within this region. In Chimera-III, dAK residues 120-170 were replaced by the homologous section of dGK. dAK activity was elevated 40%, but although it retained its original specificity and K-m values, it could no longer be activated by deoxyguanosine. Moreover, both the activated dAK; and the "dAK" of Chimera-ID exhibited (i) an increased K-s for the leading substrate ATP-Mg2+, suggesting the formation of intermediate enzyme species along their respective kinetic pathways, and (ii) broadened and lower pH optima for the dAK activities, These observations further indicate the importance of dAK residues 120-170, including the Ras-like segment, in catalysis and heterotropic activation. The other conformational properties of dAK (e.g. self-inactivity and MgATP being the leading substrate) were unaltered by this substitution, thus localizing the responsible domains even further upstream.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	Ohio State University	Ives, DH (corresponding author), Ohio State Univ, Dept Biochem, 776 Biosci,484 W 12th Ave, Columbus, OH 43210 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049635] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49635] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; CHAKRAVARTY R, 1984, BIOCHEMISTRY-US, V23, P6235, DOI 10.1021/bi00320a053; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEIBEL MR, 1977, J BIOL CHEM, V252, P8240; DEIBEL MR, 1977, J BIOL CHEM, V252, P8235; DEIBEL MR, 1977, DEOXYNUCLEOSIDE KINA; DURHAM JP, 1971, BIOCHIM BIOPHYS ACTA, V228, P9, DOI 10.1016/0005-2787(71)90542-9; Eriksson S, 1997, NUCLEOS NUCLEOT, V16, P653, DOI 10.1080/07328319708002930; Guo SY, 1997, J BIOL CHEM, V272, P6890, DOI 10.1074/jbc.272.11.6890; Higuchi R., 1989, PCR TECHNOLOGY, P61; HONG YS, 1995, J BIOL CHEM, V270, P6602, DOI 10.1074/jbc.270.12.6595; IKEDA S, 1986, J BIOL CHEM, V261, P5836; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P13373, DOI 10.1021/bi00249a025; IKEDA S, 1985, J BIOL CHEM, V260, P2659; Ives DH, 1998, PROG NUCLEIC ACID RE, V59, P205; IVES DH, 1984, ANAL BIOCHEM, V136, P416, DOI 10.1016/0003-2697(84)90237-9; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; MA GT, 1995, J BIOL CHEM, V270, P6595, DOI 10.1074/jbc.270.12.6602; Ma N, 1996, P NATL ACAD SCI USA, V93, P14385, DOI 10.1073/pnas.93.25.14385; MUNIR KM, 1992, J BIOL CHEM, V267, P6584; Segel I. H., 1975, ENZYME KINETICS, P273; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Wang LY, 1996, FEBS LETT, V390, P39, DOI 10.1016/0014-5793(96)00623-0; WILD K, 1995, FEBS LETT, V368, P289, DOI 10.1016/0014-5793(95)00680-8; Wild K, 1997, PROTEIN SCI, V6, P2097; YAN HG, 1991, BIOCHEMISTRY-US, V30, P5539, DOI 10.1021/bi00236a029	30	0	0	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26624	26630		10.1074/jbc.273.41.26624	http://dx.doi.org/10.1074/jbc.273.41.26624			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756902	hybrid			2022-12-25	WOS:000076373300056
J	Nakamura, M; Kudo, T; Narimatsu, H; Furukawa, Y; Kikuchi, J; Asakura, S; Yang, W; Iwase, S; Hatake, K; Miura, Y				Nakamura, M; Kudo, T; Narimatsu, H; Furukawa, Y; Kikuchi, J; Asakura, S; Yang, W; Iwase, S; Hatake, K; Miura, Y			Single glycosyltransferase, core 2 beta 1 -> 6-N-acetylglucosaminyltransferase, regulates cell surface sialyl-Le(x) expression level in human pre-B lymphocytic leukemia cell line KM3 treated with phorbolester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIN GLYCOPROTEIN LIGAND-1; LEUKOCYTE ADHESION MOLECULE-1; NEOLACTO-SERIES GANGLIOSIDES; ASN-LINKED OLIGOSACCHARIDES; POLY-N-ACETYLLACTOSAMINE; P-SELECTIN; GRANULOCYTIC DIFFERENTIATION; MONOCLONAL-ANTIBODIES; INTERLEUKIN-3 GENE; ENDOTHELIAL-CELLS	Sialyl-Le(x) (sLe(x)) antigen expression recognized by KM93 monoclonal antibody was significantly down-regulated during differentiation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in human pre-B lymphocytic leukemia cell line KM3. The sLe(x) determinants were almost exclusively expressed on O-linked oligosaccharide chains of an O-glycosylated 150-kDa glycoprotein (gp150). A low shear force cell adhesion assay showed that TPA treatment significantly inhibited E-selectin-mediated cell adhesion. Transcript and/or enzyme activity levels of alpha 1-->3-fucosyltransferase, alpha 2-->3-sialyltransferase, beta 1-->4-galactosyltransferase, and elongation beta 1-->3-N-acetylglucosaminyltransferase did not correlate with sLe(x) expression levels. However, transcript and enzyme activity levels of core 2 GlcNAc-transferase (C2GnT) were significantly down-regulated during TPA treatment. Following transfection and constitutive expression of full-length exogenous C2GnT transcript, C2GnT enzyme activities were maintained at high levels even after TPA treatment and down-regulation of cell surface sLe(x) antigen expression by TPA was completely abolished. Furthermore, in the transfected cells, the KM93 reactivity of gp150 was not reduced by TPA treatment, and the inhibition of cell adhesion by TPA was also blocked. These results suggest that sLe(x) expression is critically regulated by a single glycosyltransferase, C2GnT, during differentiation of KM3 cells.	Jichi Med Sch, Inst Hematol, Div Hemopoiesis, Minami Kawachi, Tochigi 32904, Japan; Jichi Med Sch, Div Hemostasis & Thrombosis, Res Inst Hematol, Minami Kawachi, Tochigi 32904, Japan; Soka Univ, Inst Life Sci, Div Cell Biol, Hachioji, Tokyo 192, Japan; Hitachi Koki Co Ltd, Katsuta Res Lab, Katsuta, Ibaraki 312, Japan; Jikei Univ, Sch Med, Dept Internal Med, Tokyo 105, Japan	Jichi Medical University; Jichi Medical University; Soka University; Hitachi Limited; Jikei University	Nakamura, M (corresponding author), Jichi Med Sch, Inst Hematol, Div Hemopoiesis, Minami Kawachi, Tochigi 32904, Japan.	owlmnaka@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Breton C, 1996, GLYCOBIOLOGY, V6, pR7; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; Clarke JL, 1996, J BIOL CHEM, V271, P10317, DOI 10.1074/jbc.271.17.10317; DECLERCK LS, 1994, J IMMUNOL METHODS, V172, P115, DOI 10.1016/0022-1759(94)90384-0; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; GOELZ S, 1994, J BIOL CHEM, V269, P1033; HANAI N, 1990, ANTICANCER RES, V10, P1579; IUPAC-IUB Commission on Biochemical Nomenclature, 1977, LIPIDS, V12, P455; KAWASHIMA H, 1993, J BIOL CHEM, V268, P27118; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KITAGAWA S, 1989, J BIOL CHEM, V264, P16149; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KUDO T, 1995, GLYCOBIOLOGY, V5, P397, DOI 10.1093/glycob/5.4.397; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LEE N, 1990, J BIOL CHEM, V265, P20476; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NAKAMURA M, 1992, J BIOL CHEM, V267, P23507; Nakamura M, 1996, GLYCOCONJUGATE J, V13, P255, DOI 10.1007/BF00731500; NAKAMURA M, 1991, CANCER RES, V51, P1940; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PILARSKI LM, 1991, J IMMUNOL, V147, P136; SAKAGAMI H, 1984, LEUKEMIA RES, V8, P187, DOI 10.1016/0145-2126(84)90142-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SCHLOSSMAN SF, 1995, LEUKOCYTE TYPING, V5, P1524; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; Snapp KR, 1997, BLOOD, V89, P896, DOI 10.1182/blood.V89.3.896; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; Tsuboi S, 1997, EMBO J, V16, P6364, DOI 10.1093/emboj/16.21.6364; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; TSUNODA A, 1995, BIOCHEMISTRY-US, V34, P9356, DOI 10.1021/bi00029a011; UEMURA M, 1992, CANCER RES, V52, P6153	47	34	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26779	26789		10.1074/jbc.273.41.26779	http://dx.doi.org/10.1074/jbc.273.41.26779			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756922	hybrid			2022-12-25	WOS:000076373300076
J	Wang, J; Ducret, A; Tu, YP; Kozasa, T; Aebersold, R; Ross, EM				Wang, J; Ducret, A; Tu, YP; Kozasa, T; Aebersold, R; Ross, EM			RGSZ1, a G(z)-selective RGS protein in brain - Structure, membrane association, regulation by G alpha(z) phosphorylation, and relationship to a G(z) GTPase-activating protein subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE STRING PROTEIN; AMINO-ACID-SEQUENCES; ALPHA-SUBUNIT; PHOSPHOLIPASE C-BETA-1; KINASE-C; TRANSITION-STATE; ADP-RIBOSYLATION; BINDING PROTEIN; PERTUSSIS TOXIN; MAMMALIAN-CELLS	We cloned the cDNA for human RGSZ1, the major G(z)-selective GTPase-activating protein (GAP) in brain (Wang, J., Tu, Y., Woodson, J., Song, IL, and Ross, E. M. (1997) J. Biol, Chem. 272, 5732-5740) and a member of the RGS family of G protein GAPs. Its sequence is 83% identical to RET-RGS1 (except its N-terminal extension) and 56% identical to GAIP. Purified, recombinant RGSZ1, RET-RGS1, and GAIP each accelerated the hydrolysis of G alpha(z)-GTP over 400-fold with K-m values of similar to 2 nM. RGSZ1 was 100-fold selective for G alpha(z) over G alpha(i), unusually specific among RGS proteins. Other enzymological properties of RGSZ1, brain G(z) GAP, and RET-RGS1 were identical; GAIP differed only in Mg2+ dependence and in its slightly lower selectivity for G alpha(z). RGSZ1, RET-RGS1, and GAIP thus define a subfamily of G(z) GAPs within the RGS proteins. RGSZ1 has no obvious membrane-spanning region but is tightly membrane-bound in brain. Its regulatory activity in membranes depends on stable bilayer association. When co-reconstituted into phospholipid vesicles with G(z) and m2 muscarinic receptors, RGSZ1 increased agonist-stimulated GTPase >15-fold with EC50 <12 nM, but RGSZ1 added to the vesicle suspension was <0.1% as active. RGSZ1, RET-RGS1, and GAIP share a cysteine string sequence, perhaps targeting them to secretory vesicles and allowing them to participate in the proposed control of secretion by G(z). Phosphorylation of G alpha(z) by protein kinase C inhibited the GAP activity of RGSZ1 and other RGS proteins, providing a mechanism for potentiation of G(z) signaling by protein kinase C.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Ross, EM (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BLEASBY AJ, 1994, NUCLEIC ACIDS RES, V22, P3574; BRANDT DR, 1985, J BIOL CHEM, V260, P266; BRAUN JEA, 1995, NEUROPHARMACOLOGY, V34, P1361, DOI 10.1016/0028-3908(95)00114-L; Buchner E, 1997, TRENDS NEUROSCI, V20, P223, DOI 10.1016/S0166-2236(96)10082-5; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; DUCRET A, 1997, P 45 ASMS C MASS SPE, P14; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GARIBAY JLR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P193, DOI 10.1016/0167-4889(91)90008-L; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; HALLAK H, 1994, J BIOL CHEM, V269, P4571; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HINTON DR, 1990, J NEUROSCI, V10, P2763; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; INGI T, 1998, IN PRESS J NEUROCHEM; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; Natochin M, 1998, J BIOL CHEM, V273, P6731, DOI 10.1074/jbc.273.12.6731; NAVON SE, 1984, J BIOL CHEM, V259, P6686; NGAI PK, 1991, BIOCHEM J, V280, P805, DOI 10.1042/bj2800805; PARKER EM, 1991, J BIOL CHEM, V266, P519; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; vandeGoor J, 1996, FEBS LETT, V380, P251, DOI 10.1016/0014-5793(96)00026-9; vanOostveen I, 1997, ANAL BIOCHEM, V247, P310, DOI 10.1006/abio.1997.2052; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; WANG J, 1995, J BIOL CHEM, V270, P6488, DOI 10.1074/jbc.270.12.6488; WANG J, 1998, G PROTEINS TECHNIQUE; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	65	109	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26014	26025		10.1074/jbc.273.40.26014	http://dx.doi.org/10.1074/jbc.273.40.26014			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748280	hybrid			2022-12-25	WOS:000076263100071
J	Hase, M; Yoshimi, T; Ishikawa, Y; Ohba, A; Guo, L; Mima, S; Makise, M; Yamaguchi, Y; Tsuchiya, T; Mizushima, T				Hase, M; Yoshimi, T; Ishikawa, Y; Ohba, A; Guo, L; Mima, S; Makise, M; Yamaguchi, Y; Tsuchiya, T; Mizushima, T			Site-directed mutational analysis for the membrane binding of DnaA protein - Identification of amino acids involved in the functional interaction between DnaA protein and acidic phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; INITIATION PROTEIN; ATP BINDING; IN-VITRO; REPLICATION; ORIGIN	DnaA protein, the initiator of chromosomal DNA replication in Escherichia coli, interacts with acidic phospholipids, such as cardiolipin, and its activity seems to be regulated by membrane binding in cells. In this study we introduced site-directed mutations at the positions of hydrophobic or basic amino acids which are conserved among various bacteria species and which are located in the putative membrane-binding region of DnaA protein (from Asp(357) to, Val(374)). All mutant DnaA proteins showed much the same ATP and ADP binding activity as that of the wild-type protein. The release of ATP bound to the mutant DnaA protein, in which three hydrophobic amino acids were mutated to hydrophilic ones, was stimulated by cardiolipin, as in the case of the wild-type protein. On the other hand, the release of ATP bound to another mutant DnaA protein, in which three basic amino acids were mutated to acidic ones, was not stimulated by cardiolipin, These results suggest not only that the region is a membrane-binding domain of DnaA protein but also that these basic amino acids are important for the binding and the ionic interaction between the basic amino acids and acidic residues of cardiolipin and is involved in the interaction between DnaA protein and cardiolipin.	Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan; Oita Univ, Fac Engn, Oita 8701192, Japan; Kyushu Univ, Fac Pharmaceut Sci, Fukuoka 8128581, Japan; Japan Sci & Technol, PRESTO, Kawaguchi 3320012, Japan	Okayama University; Oita University; Kyushu University; Japan Science & Technology Agency (JST)	Mizushima, T (corresponding author), Okayama Univ, Fac Pharmaceut Sci, 1-1-1 Tsushima Naka, Okayama 7008530, Japan.	mizushima@pheasant.pharm.okayama-u.ac.jp	Guo, Lei/E-9232-2011	guo, lei/0000-0002-0402-4152				BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Carr KM, 1996, MOL MICROBIOL, V20, P1307, DOI 10.1111/j.1365-2958.1996.tb02649.x; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; Garner J, 1998, J BIOL CHEM, V273, P5167, DOI 10.1074/jbc.273.9.5167; Garner J, 1996, EMBO J, V15, P3477, DOI 10.1002/j.1460-2075.1996.tb00714.x; Hase M, 1998, J BIOCHEM-TOKYO, V123, P680; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HUPP TR, 1993, J BIOL CHEM, V268, P13128; HWANG DS, 1988, J BIOL CHEM, V263, P10633; HWANG DS, 1990, J BIOL CHEM, V265, P19244; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KATAYAMA T, 1994, J BIOL CHEM, V269, P12698; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; Kubota T, 1997, BIOCHEM BIOPH RES CO, V232, P130, DOI 10.1006/bbrc.1997.6244; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kurokawa K, 1998, BIOCHEM BIOPH RES CO, V243, P90, DOI 10.1006/bbrc.1997.8069; Mizushima T, 1997, EMBO J, V16, P3724, DOI 10.1093/emboj/16.12.3724; Mizushima T, 1996, J BIOL CHEM, V271, P3633; Mizushima T, 1996, J BIOL CHEM, V271, P25178, DOI 10.1074/jbc.271.41.25178; Mizushima T, 1996, BIOCHEMISTRY-US, V35, P11512, DOI 10.1021/bi953088f; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	29	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28651	28656		10.1074/jbc.273.44.28651	http://dx.doi.org/10.1074/jbc.273.44.28651			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786858	hybrid			2022-12-25	WOS:000076691800019
J	Rumbaugh, JA; Fuentes, GM; Bambara, RA				Rumbaugh, JA; Fuentes, GM; Bambara, RA			Processing of an HIV replication intermediate by the human DNA replication enzyme FEN1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEOTIDE EXCISION-REPAIR; CENTRAL POLYPURINE TRACT; CALF RTH-1 NUCLEASE; ESCHERICHIA-COLI; MAMMALIAN 5'-EXONUCLEASE; SACCHAROMYCES-CEREVISIAE; REVERSE TRANSCRIPTION; ENDONUCLEASE ACTIVITY; NUCLEOCAPSID PROTEIN	The role of human FEN1 (flap endonuclease-l), an RTH1 (RAD two homolog-l) class nuclease, in the replication of human immunodeficiency virus (HIV) type 1 has been examined using model substrates, FEN1 is able to endonucleolytically cleave a primer annealed to a template, but with a 5'-unannealed tail. The HIV (+)-strand is synthesized as two discontinuous segments, with the upstream segment displacing the downstream segment to form a central (+)-strand overlap. Given a substrate with the exact HIV nucleotide sequence, FEN1 was able to remove the overlap. After extension of the upstream primer with DNA polymerase epsilon, human DNA ligase I was able to complete the continuous double strand as would occur for an integrated provirus, FEN1 may represent a target for new therapeutic interventions.	Univ Rochester, Sch Med & Dent, Dept Biochem, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Microbiol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem, Rochester, NY 14642 USA.				NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573, R01GM024441] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198] Funding Source: Medline; NIGMS NIH HHS [GM24441, GM49573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arts EJ, 1998, PROG NUCLEIC ACID RE, V58, P339; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; CHAKRABARTI L, 1987, NATURE, V328, P543, DOI 10.1038/328543a0; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fuentes GM, 1996, J BIOL CHEM, V271, P29605, DOI 10.1074/jbc.271.47.29605; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Huang L, 1996, BIOCHEMISTRY-US, V35, P9266, DOI 10.1021/bi9603074; HUNGNES O, 1992, VIROLOGY, V190, P440, DOI 10.1016/0042-6822(92)91230-R; HUNGNES O, 1991, ARCH VIROL, V116, P133, DOI 10.1007/BF01319237; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; JUNGHANS RP, 1982, J VIROL, V43, P544, DOI 10.1128/JVI.43.2.544-554.1982; KAHN R, 1992, J BIOL CHEM, V267, P6689; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Kornberg A., 1992, DNA REPLICATION; MILLER MD, 1995, J VIROL, V69, P3938, DOI 10.1128/JVI.69.6.3938-3944.1995; MONTECUCCO A, 1995, EMBO J, V14, P5379, DOI 10.1002/j.1460-2075.1995.tb00222.x; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURANTE RS, 1994, J BIOL CHEM, V269, P18191; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; REENAN RAG, 1992, GENETICS, V132, P975; REPASKE R, 1989, J VIROL, V63, P1460, DOI 10.1128/JVI.63.3.1460-1464.1989; Rumbaugh JA, 1997, J BIOL CHEM, V272, P22591, DOI 10.1074/jbc.272.36.22591; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SONIGO P, 1985, CELL, V42, P369, DOI 10.1016/S0092-8674(85)80132-X; TERAOKA H, 1993, J BIOL CHEM, V268, P24156; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; YOU JC, 1993, J BIOL CHEM, V268, P16519	47	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28740	28745		10.1074/jbc.273.44.28740	http://dx.doi.org/10.1074/jbc.273.44.28740			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786870	hybrid			2022-12-25	WOS:000076691800031
J	Wang, F; Nelson, ME; Kuryatov, A; Olale, F; Cooper, J; Keyser, K; Lindstrom, J				Wang, F; Nelson, ME; Kuryatov, A; Olale, F; Cooper, J; Keyser, K; Lindstrom, J			Chronic nicotine treatment up-regulates human alpha 3 beta 2 but not alpha 3 beta 4 acetylcholine receptors stably transfected in human embryonic kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPOSURE DIFFERENTIALLY AFFECTS; MONOCLONAL-ANTIBODIES; MYASTHENIA-GRAVIS; CILIARY GANGLION; DOPAMINE RELEASE; XENOPUS OOCYTES; BINDING-SITES; EXPRESSION; SUBUNIT; SUBTYPES	Human nicotinic acetylcholine receptor (AChR) subtypes alpha 3 beta 2, alpha 3 beta 2 alpha 5, alpha 3 beta 4, and alpha 3 beta 4 alpha 5 were stably expressed in cells derived from the human embryonic kidney cell line 293. alpha 3 beta 4 AChRs were found in prominent 2-mu m patches on the cell surface, whereas most alpha 3 beta 2 AChRs were more diffusely distributed. The functional properties of the alpha 3 AChRs in tsA201 cells were characterized by whole cell patch clamp using both acetylcholine and nicotine as agonists, Nicotine was a partial agonist on alpha 3 beta 4 AChRs and nearly a full agonist on alpha 3 beta 2 alpha 5 AChRs. Chronic exposure of cells expressing alpha 3 beta 2 AChRs or alpha 3 beta 2 alpha 5 AChRs to nicotine or carbamylcholine increased their amount up to 24-fold but had no effect on the amount of alpha 3 beta 4 or alpha 3 beta 4 alpha 5 AChRs, ie. the up-regulation of alpha 3 AChRs depended on the presence of beta 2 but not beta 4 subunits in the AChRs. This was also found to be true of alpha 3 AChRs in the human neuroblastoma SH-SY5Y, In the absence of nicotine, alpha 3 beta 2 AChRs were expressed at much lower levels than alpha 3 beta 4 AChRs, but in the presence of nicotine, the amount of alpha 3 beta 2 AChRs exceeded that of alpha 3 beta 4 AChRs, Up-regulation was seen for both total AChRs and surface AChRs. Up-regulated alpha 3 beta 2 AChRs were functional. The nicotinic antagonists curare and dihydro-p-erythroidine also up-regulated alpha 3 beta 2 AChRs, but only by 3-5-fold. The channel blocker mecamylamine did not cause up-regulation of alpha 3 beta 2 AChRs and inhibited up-regulation by nicotine. Our data suggest that up-regulation of alpha 3 beta 2 AChRs in these lines by nicotine results from both increased subunit assembly and decreased AChR turnover.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Alabama Birmingham, Dept Physiol & Opt, Birmingham, AL 35294 USA	University of Pennsylvania; University of Alabama System; University of Alabama Birmingham	Lindstrom, J (corresponding author), Univ Penn, Sch Med, Dept Neurosci, 217 Stemmler Hall, Philadelphia, PA 19104 USA.				NINDS NIH HHS [NS10333, NS11323] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010333, R01NS011323] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bannon AW, 1998, SCIENCE, V279, P77, DOI 10.1126/science.279.5347.77; Benowitz N. L, 1990, NICOTINE PSYCHOPHARM, P112; Benowitz NL, 1996, ANNU REV PHARMACOL, V36, P597, DOI 10.1146/annurev.pa.36.040196.003121; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; CamposCaro A, 1997, J NEUROCHEM, V68, P488; ChavezNoriega LE, 1997, J PHARMACOL EXP THER, V280, P346; CHINI B, 1992, P NATL ACAD SCI USA, V89, P1572, DOI 10.1073/pnas.89.5.1572; COHEN BN, 1995, J GEN PHYSIOL, V105, P745, DOI 10.1085/jgp.105.6.745; Collins AC, 1996, DRUG DEVELOP RES, V38, P231, DOI 10.1002/(SICI)1098-2299(199607/08)38:3/4<231::AID-DDR12>3.0.CO;2-1; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; Flores CM, 1997, J NEUROCHEM, V69, P2216; Gerzanich V, 1998, J PHARMACOL EXP THER, V286, P311; GERZANICH V, 1995, MOL PHARMACOL, V48, P774; GILLESPIE A, 1997, NEUR SOC M ABSTR NEW; Gopalakrishnan M, 1997, MOL PHARMACOL, V52, P524, DOI 10.1124/mol.52.3.524; GOPALAKRISHNAN M, 1995, EUR J PHARM-MOLEC PH, V290, P237, DOI 10.1016/0922-4106(95)00083-6; GRANDO SA, 1995, J INVEST DERMATOL, V105, P774, DOI 10.1111/1523-1747.ep12325606; Grando SA, 1996, J INVEST DERMATOL, V107, P412, DOI 10.1111/1523-1747.ep12363399; GREEN WN, 1991, P NATL ACAD SCI USA, V88, P854, DOI 10.1073/pnas.88.3.854; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Horch HLW, 1995, J NEUROSCI, V15, P7778; Hsu YN, 1996, J NEUROCHEM, V66, P667; Kaiser SA, 1998, J NEUROCHEM, V70, P1069; Kulak JM, 1997, J NEUROSCI, V17, P5263; KUNTZWEILER T, 1997, NEUR SOC M ABSTR NEW; Lindstrom J, 1998, ANN NY ACAD SCI, V841, P71, DOI 10.1111/j.1749-6632.1998.tb10910.x; Lindstrom J, 1996, Ion Channels, V4, P377; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; Marshall DL, 1997, J NEUROCHEM, V68, P1511; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MIHOVILOVIC M, 1993, J IMMUNOL, V151, P6517; Olale F, 1997, J PHARMACOL EXP THER, V283, P675; Pauly JR, 1996, J PHARMACOL EXP THER, V278, P361; Peng X, 1997, MOL PHARMACOL, V51, P776, DOI 10.1124/mol.51.5.776; PENG X, 1994, MOL PHARMACOL, V46, P523; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHWARTZ RD, 1985, J NEUROCHEM, V45, P427, DOI 10.1111/j.1471-4159.1985.tb04005.x; SHYNG SL, 1991, NEURON, V6, P469, DOI 10.1016/0896-6273(91)90254-W; Stauderman KA, 1998, J PHARMACOL EXP THER, V284, P777; Stetzer E, 1996, FEBS LETT, V397, P39, DOI 10.1016/S0014-5793(96)01115-5; TZARTOS S, 1987, J NEUROIMMUNOL, V15, P185, DOI 10.1016/0165-5728(87)90092-0; Ullian EM, 1997, J NEUROSCI, V17, P7210; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; VIJAYARAGHAVAN S, 1990, J NEUROSCI, V10, P3255; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; Wang F, 1996, J BIOL CHEM, V271, P17656, DOI 10.1074/jbc.271.30.17656; WHEELER SV, 1994, J NEUROCHEM, V63, P1891; WHITING PJ, 1988, J NEUROSCI, V8, P3395; WHITING PJ, 1987, J NEUROSCI, V7, P4005; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z; Wonnacott S, 1996, DRUG DEVELOP RES, V38, P149, DOI 10.1002/(SICI)1098-2299(199607/08)38:3/4<149::AID-DDR3>3.0.CO;2-M; XIAO Y, 1997, NEUR SOC M ABSTR; Zia S, 1997, RES COMMUN MOL PATH, V97, P243	59	140	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28721	28732		10.1074/jbc.273.44.28721	http://dx.doi.org/10.1074/jbc.273.44.28721			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786868	hybrid			2022-12-25	WOS:000076691800029
J	Asada, A; Zhao, Y; Kondo, S; Iwata, M				Asada, A; Zhao, Y; Kondo, S; Iwata, M			Induction of thymocyte apoptosis by Ca2+-independent protein kinase C (nPKC) activation and its regulation by calcineurin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-INDUCED APOPTOSIS; CD4(+)CD8(+) THYMOCYTES; T-CELLS; NEGATIVE SELECTION; POSITIVE SELECTION; DIFFERENTIAL REGULATION; SIGNALING EVENTS; CLONAL DELETION; PHORBOL ESTERS; MOUSE THYMUS	Glucocorticoids appear to participate in apoptosis of unselected CD4(+)CD8(+) thymocytes, Activation of Ca2+-independent novel protein kinase C (nPKC) precedes glucocorticoid-induced thymocyte apoptosis, while proper levels of Ca2+-dependent protein kinase C (cPKC) and calcineurin activities contribute to rescue thymocytes. To clarify the role of nPKC in thymocyte apoptosis, murine thymocytes were stimulated with the diterpene diester, ingenol 3,20-dibenzoate (IDB). IDB induced selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induced morphologically typical apoptosis through de novo synthesis of macromolecules. The apoptosis was also induced by thymeleatoxin, a diterpene ester, at relatively high concentrations that induced translocation of cPKC, nPKC-theta, and PKC-mu. The IDB- or thymeleatoxin-induced death was inhibited by non-isoform-selective PKC inhibitors, but not by their structural analogs with weak PKC-inhibitory activity or the selective inhibitor of cPKC and PKC-mu, Go 6976. The death was also inhibited by calcium ionophore ionomycin at concentrations within a narrow range. The range corresponded to the concentration range that contributes to the inhibition of glucocorticoid-induced apoptosis. The antiapoptotic effect was canceled by the immunosuppressant FK506 but not by rapamycin, These results indicate that activation of nPKC, especially nPKC-theta, induces apoptosis in thymocytes and that calcineurin activation regulates the apoptosis.	Mitsubishi Kasei Inst Life Sci, Integrat Project, Machida, Tokyo 194, Japan; Mitsubishi Kasei Inst Life Sci, Electron Microscopy Sect, Machida, Tokyo 194, Japan		Iwata, M (corresponding author), Mitsubishi Kasei Inst Life Sci, Integrat Project, 11 Minamiooya, Machida, Tokyo 194, Japan.							Amasaki Y, 1998, J IMMUNOL, V160, P2324; ANDERSON G, 1995, J IMMUNOL, V154, P3636; Cidlowski JA, 1996, RECENT PROG HORM RES, V51, P457; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1984, J IMMUNOL, V132, P38; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; DEUSCH K, 1990, J IMMUNOL, V144, P2851; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FREIREMOAR J, 1991, J IMMUNOL, V147, P405; GILLILAND LK, 1991, J IMMUNOL, V146, P1759; GONZALO JA, 1993, J EXP MED, V177, P1239, DOI 10.1084/jem.177.5.1239; GRATIOTDEANS J, 1994, P NATL ACAD SCI USA, V91, P10685, DOI 10.1073/pnas.91.22.10685; GRUBER J, 1994, EUR J IMMUNOL, V24, P1115, DOI 10.1002/eji.1830240516; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOMO F, 1980, J STEROID BIOCHEM, V13, P135, DOI 10.1016/0022-4731(80)90184-3; HUGO P, 1991, EUR J IMMUNOL, V21, P2655, DOI 10.1002/eji.1830211103; IWATA M, 1994, INT IMMUNOL, V6, P431, DOI 10.1093/intimm/6.3.431; Iwata M, 1996, STEM CELLS, V14, P632, DOI 10.1002/stem.140632; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; Iwata M, 1996, EUR J IMMUNOL, V26, P2081, DOI 10.1002/eji.1830260918; Iwata M, 1995, Curr Top Microbiol Immunol, V200, P81; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; LOVE SW, 1993, NATURE, V362, P847; Lui J., 1991, CELL, V66, P807; Marchetti P, 1996, J IMMUNOL, V157, P4830; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; MUID RE, 1991, FEBS LETT, V293, P169, DOI 10.1016/0014-5793(91)81178-B; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohoka Y, 1996, INT IMMUNOL, V8, P297, DOI 10.1093/intimm/8.3.297; Ohoka Y, 1997, J IMMUNOL, V158, P5707; PUNT JA, 1994, J EXP MED, V179, P709, DOI 10.1084/jem.179.2.709; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; SHORTMAN K, 1974, CELL IMMUNOL, V12, P230, DOI 10.1016/0008-8749(74)90075-6; Squier MKT, 1997, J IMMUNOL, V158, P3690; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VACCHIO MS, 1994, J EXP MED, V179, P1835, DOI 10.1084/jem.179.6.1835; VEIS DJ, 1993, J IMMUNOL, V151, P2546; WANG CR, 1995, J EXP MED, V181, P927, DOI 10.1084/jem.181.3.927; WILLIE AH, 1984, J PATHOL, V142, P67; ZHAO Y, 1995, INT IMMUNOL, V7, P1387, DOI 10.1093/intimm/7.9.1387; ZHAO Y, 1995, J IMMUNOL, V154, P6346; Zhou T, 1996, J EXP MED, V183, P1879, DOI 10.1084/jem.183.4.1879	51	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28392	28398		10.1074/jbc.273.43.28392	http://dx.doi.org/10.1074/jbc.273.43.28392			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774466	hybrid			2022-12-25	WOS:000076549800086
J	Brockstedt, E; Rickers, A; Kostka, S; Laubersheimer, A; Dorken, B; Wittmann-Liebold, B; Bommert, K; Otto, A				Brockstedt, E; Rickers, A; Kostka, S; Laubersheimer, A; Dorken, B; Wittmann-Liebold, B; Bommert, K; Otto, A			Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line - Cleavage of heterogeneous nuclear ribonucleoprotein A1 by caspase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-DIMENSIONAL ELECTROPHORESIS; MASS-SPECTROMETRY; C-MYC; BINDING; PROTEASES; DOMAIN; LOCALIZATION; HOMOLOG; ENZYME; ACTIN	Apoptosis or programmed cell death is essential in the process of controlling lymphocyte growth and selection. We identified proteins that are involved in anti-IgM antibody-mediated apoptosis using a subclone of the human Burkitt lymphoma cell line BL60, Apoptosis-associated proteins were detected by high resolution two-dimensional gel electrophoresis on a micropreparative scale. Comparison of the high resolution two dimensional gel electrophoresis protein patterns from apoptotic and non-apoptotic cells showed differences in similar to 80 spots including protein modifications. Analysis of the predominantly altered proteins was performed by internal Edman microsequencing and/or by peptide mass fingerprinting using matrix-assisted laser desorption/ionization mass spectrometry, Analysis was significantly improved by using new micropreparative high resolution two-dimensional gels employing high protein concentrations. The following 12 apoptosis-associated proteins were identified: heterogeneous nuclear ribonucleoprotein (hnRNP) A1, hnRNP C1/C2, FUSE-binding protein, dUTPase, lymphocyte-specific protein LSP1, UV excision repair protein RAD23 homologue B (HHR23B), 60 S acidic ribosomal protein P0 (L10E), heterochromatin protein 1 homologue alpha (HP1 alpha), nucleolin, lamin, neutral calponin, and actin, Fragmentation of actin, hnRNP A1, hnRNP C1/C2, 60 S acidic ribosomal protein P0, lamin, and nucleolin could be inhibited by benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethyl ketone, a selective irreversible inhibitor of CPP32 (caspase 3).	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Humboldt Univ, Charite, Robert Rossle Klin, D-13125 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Wittmann-Liebold, B (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.		Bommert, Kurt/G-9247-2011					AEBERSOLD R, 1990, ELECTROPHORESIS, V11, P540; BAZAR L, 1995, ONCOGENE, V10, P2229; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DUDLEY B, 1992, J BIOL CHEM, V267, P11964; ECKERSKORN C, 1988, ELECTROPHORESIS, V9, P830, DOI 10.1002/elps.1150091208; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; Gevaert K, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P15; GRABOWSKI DT, 1991, NUCLEIC ACIDS RES, V19, P4297, DOI 10.1093/nar/19.15.4297; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; JONGSTRABILEN J, 1992, J CELL BIOL, V118, P1443, DOI 10.1083/jcb.118.6.1443; KLOSE J, 1975, HUMANGENETIK, V26, P231; KLOSE J, 1995, ELECTROPHORESIS, V16, P1034, DOI 10.1002/elps.11501601175; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Ladner RD, 1997, J BIOL CHEM, V272, P19072, DOI 10.1074/jbc.272.30.19072; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Masuda H, 1996, J BIOCHEM-TOKYO, V120, P415; MELTZER NM, 1987, ANAL BIOCHEM, V160, P356, DOI 10.1016/0003-2697(87)90060-1; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Otto A, 1996, ELECTROPHORESIS, V17, P1643, DOI 10.1002/elps.1150171027; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rickers A, 1998, EUR J IMMUNOL, V28, P296, DOI 10.1002/(SICI)1521-4141(199801)28:01<296::AID-IMMU296>3.0.CO;2-4; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sugasawa K, 1997, MOL CELL BIOL, V17, P6924, DOI 10.1128/MCB.17.12.6924; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; Sugimoto K, 1996, J BIOCHEM, V120, P153; Thiede B, 1996, ELECTROPHORESIS, V17, P588, DOI 10.1002/elps.1150170330; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X; WITTMANNLIEBOLD B, 1994, CONCEPTS PROTEIN ENG, P47; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983; YOKOTE Y, 1986, ANAL BIOCHEM, V152, P245, DOI 10.1016/0003-2697(86)90405-7	41	156	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28057	28064		10.1074/jbc.273.43.28057	http://dx.doi.org/10.1074/jbc.273.43.28057			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774422	hybrid			2022-12-25	WOS:000076549800042
J	Clement, AM; Nadanaka, S; Masayama, K; Mandl, C; Sugahara, K; Faissner, A				Clement, AM; Nadanaka, S; Masayama, K; Mandl, C; Sugahara, K; Faissner, A			The DSD-1 carbohydrate epitope depends on sulfation, correlates with chondroitin sulfate D motifs, and is sufficient to promote neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; EXTRACELLULAR-MATRIX MOLECULES; FIBROBLAST GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; HEPARAN-SULFATE; IN-VITRO; IMMUNOCYTOCHEMICAL LOCALIZATION; MONOCLONAL-ANTIBODIES; INHIBITORY MOLECULES; NEURONAL POLARITY	The neural chondroitin sulfate (CS) proteoglycan (PG) DSD-1-PG was originally identified with the monoclonal antibody (mAb) 473HD. It promotes neurite outgrowth of hippocampal neurons when coated as a substrate in the presence of polycations. This effect is inhibited by mAb 473HD that specifically recognizes the DSD-1 epitope. The DSD-1 epitope is also detectable in CS-C and CS-D preparations from shark cartilage but not in other chondroitin sulfates that are structurally related and differ in their sulfation patterns. Non-sulfated DSD-1-PG and chemically desulfated CS-D were not recognized by mAb 473HD, suggesting that the DSD-1 epitope depends on sulfation. It was possible to enrich DSD-1 epitope-bearing carbohydrates and D disaccharide units from CS-C and CS-D preparations on a mAb 473HD affinity matrix. This indicates that the DSD-1 epitope represents a distinct glycosaminoglycan structure containing D units. The analysis of glycosaminoglycan digestion products by high pressure liquid chromatography revealed that DSD-1-PG preparations contain a unique D disaccharide unit as well as an A, a C, and a non-sulfated disaccharide unit. In neurite outgrowth assays with hippocampal neurons, substrate-bound CS-D promoted neurite outgrowth, whereas CS-A, CS-B, or CS-C did not. This effect of CS-D was inhibited by mAb 473HD. DSD-1 epitope enriched fractions obtained from CS-D and CS-C promoted neurite outgrowth, whereas CS-C had no such effect prior to enrichment on the mAb 473HD matrix. Based on these findings we conclude that the DSD-1 epitope by itself is sufficient to promote neurite outgrowth and that this activity is possibly associated with D motifs.	Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany; Kobe Pharmaceut Univ, Dept Biochem, Kobe, Hyogo 6588558, Japan; CNRS, Ctr Neurochim, Lab Neurobiol Dev & Regenerat, UPR 1352, F-67084 Strasbourg, France; Univ Strasbourg 1, F-67084 Strasbourg, France	Ruprecht Karls University Heidelberg; Kobe Pharmaceutical University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Faissner, A (corresponding author), Univ Heidelberg, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.	faissner@sun0.urz.uni-heidelberg.de	Faissner, Andreas/A-5314-2008	Faissner, Andreas/0000-0002-2211-8259				AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BOVOLENTA P, 1993, NEUROREPORT, V5, P345, DOI 10.1097/00001756-199312000-00042; BRAUNEWELL KH, 1995, EUR J NEUROSCI, V7, P792, DOI 10.1111/j.1460-9568.1995.tb00682.x; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; CATERSON B, 1990, J CELL SCI, V97, P411; CHALLACOMBE JF, 1995, EXP NEUROL, V134, P126, DOI 10.1006/exnr.1995.1043; DAVIDSON S, 1990, J BIOL CHEM, V265, P12324; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Deller T, 1997, NEUROSCIENCE, V81, P829, DOI 10.1016/S0306-4522(97)00194-2; DMITRIEV BA, 1973, CARBOHYD RES, V29, P451, DOI 10.1016/S0008-6215(00)83031-1; Dou CL, 1995, J NEUROSCI, V15, P8053; FAISSNER A, 1985, EMBO J, V4, P3105, DOI 10.1002/j.1460-2075.1985.tb04052.x; FAISSNER A, 1995, GLIA, V13, P233, DOI 10.1002/glia.440130402; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; Faissner A, 1997, CELL TISSUE RES, V290, P331, DOI 10.1007/s004410050938; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; Faissner A, 1996, SEMIN NEUROSCI, V8, P347, DOI 10.1006/smns.1996.0043; FERNAUDESPINOSA I, 1994, J CELL SCI, V107, P1437; FernaudEspinosa I, 1996, J NEUROBIOL, V30, P410, DOI 10.1002/(SICI)1097-4695(199607)30:3<410::AID-NEU9>3.0.CO;2-7; FLACCUS A, 1991, J NEUROCHEM, V56, P1608, DOI 10.1111/j.1471-4159.1991.tb02058.x; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; Gates MA, 1996, J NEUROSCI, V16, P8005; Goslin K., 1991, CULTURING NERVE CELL, P251; Grumet M, 1996, PERSPECT DEV NEUROBI, V3, P319; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; HEYMAN I, 1995, DEV DYNAM, V204, P301, DOI 10.1002/aja.1002040308; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; IIJIMA N, 1991, J NEUROCHEM, V56, P706, DOI 10.1111/j.1471-4159.1991.tb08207.x; IWATA H, 1969, IPPON SEIKEIGEKA GAK, V43, P455; JUNG M, 1995, EUR J NEUROSCI, V7, P1245, DOI 10.1111/j.1460-9568.1995.tb01115.x; Kappler J, 1997, EUR J NEUROSCI, V9, P306, DOI 10.1111/j.1460-9568.1997.tb01401.x; Kempf M, 1996, J NEUROSCI, V16, P5583; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFONT F, 1992, DEVELOPMENT, V114, P17; LAFONT F, 1994, DEV BIOL, V165, P453, DOI 10.1006/dbio.1994.1267; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; Letourneau PC, 1992, CURR OPIN GENET DEV, V2, P625, DOI 10.1016/S0959-437X(05)80183-2; LIPS K, 1995, J NEUROCYTOL, V24, P449, DOI 10.1007/BF01181606; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MARK M P, 1990, International Journal of Developmental Biology, V34, P191; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Miao HQ, 1996, J BIOL CHEM, V271, P4879; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; PERRIS R, 1991, DEVELOPMENT, V111, P583; PINDZOLA RR, 1993, DEV BIOL, V156, P34, DOI 10.1006/dbio.1993.1057; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; Schnadelbach O, 1998, GLIA, V23, P99, DOI 10.1002/(SICI)1098-1136(199806)23:2<99::AID-GLIA2>3.0.CO;2-Z; SCHNITZER J, 1981, J NEUROIMMUNOL, V1, P471, DOI 10.1016/0165-5728(81)90024-2; Shum DKY, 1996, J NEUROSCI RES, V46, P465, DOI 10.1002/(SICI)1097-4547(19961115)46:4<465::AID-JNR8>3.0.CO;2-E; SMITHTHOMAS LC, 1994, J CELL SCI, V107, P1687; Snow DM, 1996, INT J DEV NEUROSCI, V14, P331, DOI 10.1016/0736-5748(96)00017-2; SORRELL JM, 1990, J HISTOCHEM CYTOCHEM, V38, P393, DOI 10.1177/38.3.1689338; STEINDLER DA, 1990, EXP NEUROL, V109, P35, DOI 10.1016/S0014-4886(05)80007-X; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; Sugahara K, 1996, EUR J BIOCHEM, V239, P871, DOI 10.1111/j.1432-1033.1996.0871u.x; Sugahara K, 1996, EUR J BIOCHEM, V239, P865, DOI 10.1111/j.1432-1033.1996.0865u.x; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERNA JM, 1989, INT J DEV NEUROSCI, V7, P389, DOI 10.1016/0736-5748(89)90060-9; Xiao ZC, 1997, J BIOL CHEM, V272, P32092, DOI 10.1074/jbc.272.51.32092; Yamada H, 1997, J NEUROSCI, V17, P7784; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4	77	166	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28444	28453		10.1074/jbc.273.43.28444	http://dx.doi.org/10.1074/jbc.273.43.28444			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774473	hybrid			2022-12-25	WOS:000076549800093
J	Ota, K; Sakaguchi, M; Hamasaki, N; Mihara, K				Ota, K; Sakaguchi, M; Hamasaki, N; Mihara, K			Assessment of topogenic functions of anticipated transmembrane segments of human band 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYTOPIC MEMBRANE-PROTEINS; SIGNAL-ANCHOR SEQUENCES; ENDOPLASMIC-RETICULUM; ANION-EXCHANGER; P-GLYCOPROTEIN; INTEGRATION; TRANSLOCATION; REQUIREMENTS; ORIENTATION; BIOGENESIS	Band 3 protein is a typical multispanning membrane protein whose membrane topology has been extensively studied from various protein chemical approaches. To clarify the membrane topogenesis of this multispanning protein on the endoplasmic reticulum, the topogenic functions of the anticipated transmembrane segments were individually assessed in an in vitro system using two series of model proteins in which each segment was placed in either a "stop-transfer" context or a "translocation initiation" context. They were expressed in a cell-free system containing rough microsomal membranes, and their topologies were evaluated by taking advantage of either sensitivity to protease or accessibility to N-glycosylation, We found that some segments seem to possess insufficient topogenic functions for membrane integration: the second transmembrane segment (TM2) is insufficient for the stop-transfer sequence, and TM3, TM5, and TM7 are not sufficient for the translocation initiation. In contrast to these phenomena, we herein demonstrate that TM2 shows an efficient stop-transfer function when it is near the preceding TM1 and suggest that TM3, TM5, and TM7 are followed by TM segments with a strong topogenic function to form N-exo/C-cyt topology, via which the preceding segments are integrated into the membrane. From these results, we propose that the interactions between the TMs should be operative during membrane integration, and that the segments with a weak topogenic function are given a transmembrane orientation by their following TMs.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Dept Clin Chem & Lab Med, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Sakaguchi, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							Bibi E, 1998, TRENDS BIOCHEM SCI, V23, P51, DOI 10.1016/S0968-0004(97)01134-1; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GROVES JD, 1995, J BIOL CHEM, V270, P9097, DOI 10.1074/jbc.270.16.9097; Hamasaki N, 1997, J BIOCHEM-TOKYO, V122, P577; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1993, J BIOL CHEM, V268, P26745; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; KUROIWA T, 1990, J BIOCHEM, V108, P829, DOI 10.1093/oxfordjournals.jbchem.a123288; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; LOCKER JK, 1992, J BIOL CHEM, V267, P21911; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; SAKAGUCHI M, 1992, J BIOCHEM, V112, P243, DOI 10.1093/oxfordjournals.jbchem.a123884; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; Sakaguchi M, 1997, MEMBRANE PROTEINS - STRUCTURE, FUNCTION AND EXPRESSION CONTROL: INTERNATIONAL SYMPOSIUM, P101; SAKAGUCHI M, 1997, MOL B INT U, P135; SKACH WR, 1994, CANCER RES, V54, P3202; TAM LY, 1994, J BIOL CHEM, V269, P32542; Tanner MJA, 1997, MOL MEMBR BIOL, V14, P155, DOI 10.3109/09687689709048178; Wang L, 1997, J BIOL CHEM, V272, P10631; WOOD PG, 1992, PROGR CELL RES, V2, P325; Zhang JT, 1996, MOL BIOL CELL, V7, P1709, DOI 10.1091/mbc.7.11.1709; Zhang JT, 1998, MOL BIOL CELL, V9, P853, DOI 10.1091/mbc.9.4.853	29	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28286	28291		10.1074/jbc.273.43.28286	http://dx.doi.org/10.1074/jbc.273.43.28286			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774451	hybrid			2022-12-25	WOS:000076549800071
J	Song, YH; Ray, K; Liebhaber, SA; Cooke, NE				Song, YH; Ray, K; Liebhaber, SA; Cooke, NE			Vitamin D-binding protein gene transcription is regulated by the relative abundance of hepatocyte nuclear factors 1 alpha and 1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FETOPROTEIN GENE; GC-GLOBULIN GENE; FACTOR-I GENE; ALBUMIN GENE; MESSENGER-RNA; MAMMALIAN-CELLS; EXPRESSION; LIVER; PROMOTER; ENHANCER	Vitamin D-binding protein (DBP)/Gc-globulin, the major carrier of vitamin D and its metabolites in blood, is synthesized predominantly in the liver in a developmentally regulated fashion. By transient transfection analysis, we identified three regions in the 5'-flanking region of the rat DBP gene, segments F-2, B, and A, that contain tissue-specific transcriptional determinants. Gel mobility shift and DNase I footprinting analyses showed that all three regions contained binding sites for the hepatocyte nuclear factor 1 (HNF1), a transcriptional regulator composed of HNF1 alpha and HNF1 beta hetero- and homodimers, The activity of the most proximal segment A (coordinates -141 to -43) was DBP promoter-specific, position-dependent, and positively controlled by HNF1 alpha, In contrast, the two more distal determinants (segments F-2 and B; coordinates -1844 to -1621 and -254 to -140, respectively) acted as classical enhancers in transfected hepatocyte-derived HepG2 cells; their activities were promoter- and orientation-independent, and disruption of their respective HNF1-binding sites resulted in marked loss of DBP gene expression, Remarkably, the activities of these two distal elements depended upon the relative levels of HNF1 alpha and HNF1 beta; HNF1 alpha had a major stimulatory effect, whereas HNF1 beta acted as a trans-dominant inhibitor of HNF1 alpha-mediated enhancer activity. These results suggested that the net expression of the DBP gene reflected a balance between the two major HNF1 species; the relative abundance of HNF1 alpha and HNF1 beta proteins in a cell may thus play a critical role in determining the pattern of gene expression.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Cooke, NE (corresponding author), Univ Penn, Dept Med, 700 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.		Ray, Kunal/E-6515-2011	Ray, Kunal/0000-0001-9989-1760; Song, Young-Han/0000-0002-0758-3654	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032035] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM32035] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACH I, 1993, EMBO J, V12, P4229, DOI 10.1002/j.1460-2075.1993.tb06107.x; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BELANGER L, 1994, J BIOL CHEM, V269, P5481; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; BOISJOYEUX B, 1994, BIOCHEM J, V301, P49, DOI 10.1042/bj3010049; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIN AC, 1987, P NATL ACAD SCI USA, V84, P1614, DOI 10.1073/pnas.84.6.1614; CHOW BKC, 1991, J BIOL CHEM, V266, P18927; COOKE NE, 1987, CYTOGENET CELL GENET, V44, P98, DOI 10.1159/000132351; COOKE NE, 1986, HUM GENET, V73, P225, DOI 10.1007/BF00401232; COOKE NE, 1986, J BIOL CHEM, V261, P3441; COOKE NE, 1985, J CLIN INVEST, V76, P2420, DOI 10.1172/JCI112256; COOKE NE, 1989, ENDOCR REV, V10, P294, DOI 10.1210/edrv-10-3-294; COOKE NE, 1991, J STEROID BIOCHEM, V40, P787, DOI 10.1016/0960-0760(91)90304-N; COOKE NE, 1995, ENDOCRINE REV MONOGR, V4, P125; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; ENAMI KH, 1995, MOL CELL BIOL, V15, P5906; Faust DM, 1996, MOL CELL BIOL, V16, P3125; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GUHA C, 1995, HEPATOLOGY, V21, P1675; HARBOMEL P, 1989, MOL CELL BIOL, V9, P4750; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JOHNSON DR, 1995, BIOTECHNIQUES, V19, P193; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; KRITIS AA, 1993, NUCLEIC ACIDS RES, V21, P5882, DOI 10.1093/nar/21.25.5882; Ktistaki E, 1997, SCIENCE, V277, P109, DOI 10.1126/science.277.5322.109; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; LICHENSTEIN HS, 1994, J BIOL CHEM, V269, P18149; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LIU SY, 1995, DNA CELL BIOL, V14, P285, DOI 10.1089/dna.1995.14.285; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maniatis T., 1989, MOL CLONING LAB MANU; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041; MUGLIA L, 1984, NUCLEIC ACIDS RES, V12, P6751, DOI 10.1093/nar/12.17.6751; NEGRI R, 1991, ANAL BIOCHEM, V197, P389, DOI 10.1016/0003-2697(91)90409-M; NOLTEN LA, 1995, MOL ENDOCRINOL, V9, P1488, DOI 10.1210/me.9.11.1488; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; RAY K, 1991, J BIOL CHEM, V266, P6221; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; ROLLIER A, 1993, MOL BIOL CELL, V4, P59, DOI 10.1091/mbc.4.1.59; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SMALE ST, 1994, CORE PROMOTER ARCHIT, P63; SMITHIES O, 1995, BIOCHEM J, V61, P629; Sourdive DJD, 1997, NUCLEIC ACIDS RES, V25, P1476, DOI 10.1093/nar/25.8.1476; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; WRIGHT APH, 1993, J STEROID BIOCH MOL, V47, P1; WU GD, 1994, J BIOL CHEM, V269, P17080; YASUDA H, 1994, MOL CELL BIOL, V14, P1395, DOI 10.1128/MCB.14.2.1395	63	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28408	28418		10.1074/jbc.273.43.28408	http://dx.doi.org/10.1074/jbc.273.43.28408			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774468	hybrid			2022-12-25	WOS:000076549800088
J	Strehlow, I; Schindler, C				Strehlow, I; Schindler, C			Amino-terminal signal transducer and activator of transcription (STAT) domains regulate nuclear translocation and STAT deactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-ALPHA; TYROSINE PHOSPHORYLATION; DNA-BINDING; IFN-GAMMA; FACTOR ISGF-3; PROTEIN; RECEPTOR; GENE; PATHWAY; PHOSPHATASE	The first similar to 100 amino acids of the STAT (Signal transducer and activator of transcription) family of transcription factors share a high degree of sequence similarity. To determine whether they encode a functionally conserved domain, amino-terminal chimeric STATs were created. These chimeric STATs share a number of properties with wild-type Stat1, including a predominately cytoplasmic pattern of expression in unstimulated cells. Upon stimulation with ligand, the chimeric STATs rapidly become tyrosine-phosphorylated, dimerize, and are able to bind DNA, They are also able to heterodimerize with coexpressed wild-type Stat1. Yet in contrast to wild-type Stat1, the chimeric STATs exhibit a marked defect in deactivation. Moreover, the persistence of active chimeras correlates directly with an inability to translocate to the nucleus. The defects both in nuclear translocation and in deactivation are rescued by heterodimerization with coexpressed wild-type Stat1. This study indicates that STAT amino termini provide a signal that is important for nuclear translocation and, subsequently, deactivation, It also suggests that deactivation may depend on a prior nuclear localization event.	Columbia Univ, Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University	Schindler, C (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Microbiol, HHSC 1208,701 W 168th St, New York, NY 10032 USA.							AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Barahmand-Pour F, 1998, J BIOL CHEM, V273, P12567, DOI 10.1074/jbc.273.20.12567; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; BECKER S, 1998, SCIENCE, V394, P145; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; EILERS A, 1993, MOL CELL BIOL, V13, P3245, DOI 10.1128/MCB.13.6.3245; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Lee CK, 1997, J BIOL CHEM, V272, P21872, DOI 10.1074/jbc.272.35.21872; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Pawson T, 1997, NATURE, V385, P582, DOI 10.1038/385582b0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; SEKIMOTO T, 1997, EMBO J, V16, P7076; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; STREHLOW I, 1997, GAMMA INTERFERON ANT, P61; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; YAN H, 1996, MOL CELL BIOL, V16, P2974; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	49	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28049	28056		10.1074/jbc.273.43.28049	http://dx.doi.org/10.1074/jbc.273.43.28049			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774421	hybrid			2022-12-25	WOS:000076549800041
J	Storms, SD; Rutishauser, U				Storms, SD; Rutishauser, U			A role for polysialic acid in neural cell adhesion molecule heterophilic binding to proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; MONOCLONAL-ANTIBODY EPITOPES; PROTEIN-TYROSINE-PHOSPHATASE; EMBRYONIC BRAIN MEMBRANES; N-CAM; HOMOPHILIC BINDING; FUNCTIONAL DETERMINANTS; NCAM; NEURONS; DOMAIN	The neural cell adhesion molecule (NCAM) is known to participate in both homophilic and heterophilic binding, the latter including mechanisms that involve interaction with proteoglycans. The polysialic acid (PSA) moiety of NCAM can serve as a negative regulator of homophilic binding, but indirect evidence has suggested that PSA can also be involved in heterophilic binding. We have examined this potential positive role for PSA in terms of the adhesion of PSA-expressing mouse F11 cells and chick embryonic brain cells to substrates composed of the purified heparan sulfate proteoglycans agrin and 6C4. This adhesion was specifically inhibited by polyclonal anti-NCAM Fab antibodies, monoclonal anti-PSA antibodies, PSA itself, and enzymatic removal of either PSA or heparan sulfate side chains. By contrast, the adhesion was not affected by chondroitinase, and cell binding to laminin was not inhibited by any of these treatments. A specific NCAM-heparan sulfate interaction in this adhesion was further indicated by its inhibition with monoclonal anti-NCAM Feb antibodies that recognize the known heparin-binding domain of NCAM and with the HBD-2 peptide derived from this region, but not with antibodies directed against other regions of the protein including the homophilic binding region. Together, the results suggest that PSA can act in vitro either as a receptor in NCAM heterophilic adhesion or as a promoter of binding between heparan sulfate proteoglycans and the NCAM heparin-binding domain.	Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Rutishauser, U (corresponding author), Mem Sloan Kettering Canc Ctr, Program Cellular Biochem & Biophys, 1275 York Ave,POB 290, New York, NY 10021 USA.	urs@ski.mskcc.org			NEI NIH HHS [EY06107] Funding Source: Medline; NICHD NIH HHS [HD18369] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD018369, R01HD018369] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY006107] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; BURG MA, 1995, J NEUROSCI RES, V41, P49, DOI 10.1002/jnr.490410107; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; COLE GJ, 1986, J CELL BIOL, V103, P1730; FRELINGER AL, 1986, J CELL BIOL, V103, P1729, DOI 10.1083/jcb.103.5.1729; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; HALFTER W, 1993, J NEUROSCI, V13, P2863; HALFTER W, 1994, EXP CELL RES, V214, P285, DOI 10.1006/excr.1994.1260; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MURRAY BA, 1992, J CELL BIOL, V117, P1311, DOI 10.1083/jcb.117.6.1311; PLATIKA D, 1985, P NATL ACAD SCI USA, V82, P3499, DOI 10.1073/pnas.82.10.3499; Rabinowitz JE, 1996, P NATL ACAD SCI USA, V93, P6421, DOI 10.1073/pnas.93.13.6421; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RAO Y, 1994, J BIOL CHEM, V269, P27540; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; RUTISHAUSER U, 1982, P NATL ACAD SCI-BIOL, V79, P685, DOI 10.1073/pnas.79.2.685; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Storms SD, 1996, CELL ADHES COMMUN, V3, P497, DOI 10.3109/15419069609081026; Storms SD, 1996, EXP CELL RES, V223, P385, DOI 10.1006/excr.1996.0093; STORMS SD, 1994, EXP CELL RES, V214, P100, DOI 10.1006/excr.1994.1238; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721	36	106	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27124	27129		10.1074/jbc.273.42.27124	http://dx.doi.org/10.1074/jbc.273.42.27124			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765230	hybrid			2022-12-25	WOS:000076448000017
J	Brekken, DL; Phillips, MA				Brekken, DL; Phillips, MA			Trypanosoma brucei gamma-glutamylcysteine synthetase - Characterization of the kinetic mechanism and the role of Cys-319 in cystamine inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ACTIVE-SITE THIOL; GLUTATHIONE SYNTHESIS; GENE; TRYPANOTHIONE; INHIBITION; BIOSYNTHESIS; PURIFICATION; SULFOXIMINE; REDUCTASE	The parasitic protozoan Trypanosoma brucei utilizes a conjugate of glutathione and spermidine, termed trypanothione, in place of glutathione to maintain cellular redox balance. The first committed step in the biosynthesis of glutathione and thereby trypanothione, is catalyzed by gamma-glutamylcysteine synthetase (gamma-GCS), We have determined the kinetic mechanism for T. brucei gamma-GCS. The kinetics are best described by a rapid equilibrium random ter-reactant mechanism, in which the model derived K-d values for the binding of L-Glu, L-alpha-aminobutyrate, and ATP to free enzyme are 2.6, 5.1, and 1.4 mM, respectively. However, significant dependences exist between the binding of some of the substrate pairs, The binding of either ATP or L-Glu to the enzyme increases the binding affinity of the other by 18-fold, whereas the binding of L-Glu or L-alpha-aminobutyrate decreases the binding affinity of the other by 6-fold, Similarly to the mammalian enzyme, cystamine is a time-dependent, irreversible inhibitor of T. brucei gamma-GCS. It has been suggested by several studies that cystamine labels an active site Cys residue essential for catalysis. Among the enzymes reported to be inactivated by cystamine, only one Cys residue is invariant (Cys-319 in T. brucei gamma-GCS). Mutation of Cys-319 to Ala in T. brucei gamma-GCS renders the enzyme insensitive to cystamine inactivation without significantly affecting the enzyme's catalytic efficiency, kinetic mechanism, or substrate affinities, These studies suggest that cystamine inactivates the enzyme by blocking substrate access to the active site and not by labeling an essential active site residue.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Brekken, Deirdre/I-7999-2012	Brekken, Deirdre/0000-0003-2790-0108	NIAID NIH HHS [R01 AI34432] Funding Source: Medline; NIGMS NIH HHS [T32 GM07062] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRICK BA, 1981, J EXP MED, V153, P720, DOI 10.1084/jem.153.3.720; COBLENZ A, 1995, YEAST, V11, P1171, DOI 10.1002/yea.320111207; Coulson A, 1996, BIOCHEM SOC T, V24, P289, DOI 10.1042/bst0240289; DAVIS JS, 1973, BIOCHEM J, V133, P667, DOI 10.1042/bj1330667; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; Fairlamb Alan H., 1997, P149; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1979, J BIOL CHEM, V254, P1205; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; HUANG CS, 1988, P NATL ACAD SCI USA, V85, P2464, DOI 10.1073/pnas.85.8.2464; HUSSEIN AS, 1995, MOL BIOCHEM PARASIT, V72, P57, DOI 10.1016/0166-6851(94)00064-T; KOEING K, 1997, J BIOL CHEM, V272, P11908; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEBO RV, 1978, J BIOL CHEM, V253, P2615; Lueder DV, 1996, J BIOL CHEM, V271, P17485, DOI 10.1074/jbc.271.29.17485; Mehlotra RK, 1996, CRIT REV MICROBIOL, V22, P295, DOI 10.3109/10408419609105484; MEISTER A, 1989, GLUTATHIONE CHEM BIO, P368; MESHNICK SR, 1977, BIOCHEM PHARMACOL, V26, P1923, DOI 10.1016/0006-2952(77)90167-8; OHTAKE Y, 1991, YEAST, V7, P953, DOI 10.1002/yea.320070907; ORLOWSKI M, 1971, J BIOL CHEM, V246, P7095; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; SCHANDLE VB, 1981, J BIOL CHEM, V256, P7590; SCHOR NF, 1990, BIOCHEM J, V267, P291, DOI 10.1042/bj2670291; SEELIG GF, 1984, J BIOL CHEM, V259, P3534; SEELIG GF, 1982, J BIOL CHEM, V257, P5092; Segel IH, 1975, ENZYME KINETICS BEHA; SEKURA R, 1977, J BIOL CHEM, V252, P2599; SIMONDSEN RP, 1986, J BIOL CHEM, V261, P7134; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; VANBUSKIRK GE, 1978, EUR J BIOCHEM, V85, P589; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521; YAN N, 1990, J BIOL CHEM, V265, P1588; YIP B, 1976, J BIOL CHEM, V251, P3563	37	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26317	26322		10.1074/jbc.273.41.26317	http://dx.doi.org/10.1074/jbc.273.41.26317			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756861	hybrid			2022-12-25	WOS:000076373300015
J	Colussi, PA; Harvey, NL; Shearwin-Whyatt, LM; Kumar, S				Colussi, PA; Harvey, NL; Shearwin-Whyatt, LM; Kumar, S			Conversion of procaspase-3 to an autoactivating caspase by fusion to the caspase-2 prodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; PROTEASE; APOPTOSIS; CED-3; INHIBITION; ENCODES; COMPLEX; CRMA; GENE; P35	Caspases are cysteine proteases that play an essential role in apoptosis. Initial activation of caspases defines the hey step in apoptotic execution. Based on primary structure, caspases can be divided into two groups, those with long amino-terminal prodomains (class I), and those with relatively short prodomains (class Il). On overexpression in mammalian cells, class I caspases can induce cell death that is dependent on their autocatalytic activity. Recent studies suggest that the long prodomains in some class I caspases are able to mediate dimerization of procaspase molecules, thereby promoting autoprocessing. In this communication, we demonstrate that fusion of the prodomain of a class I caspase (Nedd2/caspase-2) with procaspase-3 greatly augments autocatalysis and apoptosis induction by the chimeric caspase-3 molecule. The chimeric caspase-3 molecules were able to form homodimers in Saccharomyces cerevisiae and were efficiently processed in transfected mammalian cells. These results provide direct evidence for a role of a class I caspase prodomain in caspase autoactivation and processing and establish a basis for functional hierarchy among the two classes of caspases.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Frome Rd,POB 14,Rundle Mall, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Kumar, Sharad/AAX-7787-2020; Shearwin, Linda/AAD-5594-2020	Kumar, Sharad/0000-0001-7126-9814; Shearwin, Linda/0000-0002-4504-6534; Harvey, Natasha/0000-0001-9839-8966				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Dorstyn L, 1997, CELL DEATH DIFFER, V4, P570, DOI 10.1038/sj.cdd.4400281; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5	25	70	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26566	26570		10.1074/jbc.273.41.26566	http://dx.doi.org/10.1074/jbc.273.41.26566			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756894	hybrid			2022-12-25	WOS:000076373300048
J	Tamura, K; Nyui, N; Tamura, N; Fujita, T; Kihara, M; Toya, Y; Takasaki, I; Takagi, N; Ishii, M; Oda, K; Horiuchi, M; Umemura, S				Tamura, K; Nyui, N; Tamura, N; Fujita, T; Kihara, M; Toya, Y; Takasaki, I; Takagi, N; Ishii, M; Oda, K; Horiuchi, M; Umemura, S			Mechanism of angiotensin II-mediated regulation of fibronectin gene in rat vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CONVERTING ENZYME; COLLAGEN-SYNTHESIS; MOLECULAR-CLONING; CARDIAC MYOCYTES; TYROSINE KINASE; MESANGIAL CELLS; TYPE-1 RECEPTOR; AT(1) RECEPTOR; DEFICIENT MICE	This study was performed to investigate a mechanism of angiotensin II (Ang II)-mediated activation of the fibronectin (FN) gene in rat vascular smooth muscle cells. Actinomycin D and CV11974 completely inhibited Ang II-mediated increase in FN mRNA levels. Inhibitors of protein kinase C (PKC), protein-tyrosine kinase (PTK), phosphatidylinositol-specific phospholipase C, Ras, phosphatidylinositol 3-kinase, p70 S6 kinase, and Ca2+/calmodulin kinase also decreased Ang II-induced activation of FN mRNA. In contrast, cycloheximide; PD123319; or inhibitors of G(i), protein kinase A, or mitogen-activated protein kinase kinase did not affect the induction. FN promoter contained a putative AP-1 binding site (rFN/AP-1; -463 to -437), and the results of a transient transfection and electrophoretic mobility shift assay showed that Ang II enhanced rFN/AP-1 activity. CV11974 and inhibitors of PKC or PTK suppressed Ang II-mediated increases in rFN/AP-1 activity, although neither PD123319 nor a protein kinase A inhibitor affected the induction. Furthermore, mutation of rFN/AP-1 that disrupted nuclear binding suppressed Ang II-induced transcription in the native FN promoter (-1908 to +136) context. Thus, Ang II activates transcription of the FN gene through the Ang II type 1 receptor in vascular smooth muscle cells, at least in part, via the activation of AP-1 by a signaling mechanism dependent on PKC and PTK.	Yokohama City Univ, Sch Med, Dept Internal Med 2, Kanazawa Ku, Yokohama, Kanagawa 236, Japan; Yokohama City Univ, Sch Med, Dept Dermatol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan; Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Boston, MA 02115 USA	Yokohama City University; Yokohama City University; Tokyo University of Science; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Tamura, K (corresponding author), Yokohama City Univ, Sch Med, Dept Internal Med 2, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 236, Japan.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bardy N, 1996, CIRC RES, V79, P70, DOI 10.1161/01.RES.79.1.70; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P59; CHOBANIAN AV, 1992, AM J CARDIOL, V69, pE3; CHOBANIAN AV, 1990, HYPERTENSION, V15, P666, DOI 10.1161/01.HYP.15.6.666; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CONTARD F, 1993, HYPERTENSION, V22, P665, DOI 10.1161/01.HYP.22.5.665; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1476; Dunn FW, 1997, J PHARMACOL EXP THER, V280, P447; DZAU VJ, 1993, J CARDIOVASC PHAR S1, V21, P1; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; FOLKOW B, 1982, PHYSIOL REV, V62, P347, DOI 10.1152/physrev.1982.62.2.347; FUKAMIZU A, 1991, BIOMED BIOCHIM ACTA, V50, P659; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; GLAGOV S, 1994, CIRCULATION, V89, P2888, DOI 10.1161/01.CIR.89.6.2888; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; GRANDE JP, 1989, ARTERIOSCLEROSIS, V9, P446, DOI 10.1161/01.ATV.9.4.446; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; Griendling KK, 1997, HYPERTENSION, V29, P366, DOI 10.1161/01.HYP.29.1.366; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIMENO H, 1994, HYPERTENSION, V23, P823, DOI 10.1161/01.HYP.23.6.823; Holzmeister J, 1997, AM J PHYSIOL-HEART C, V273, pH655, DOI 10.1152/ajpheart.1997.273.2.H655; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KATO H, 1991, J HYPERTENS, V9, P17; Kijima K, 1996, CIRC RES, V79, P887, DOI 10.1161/01.RES.79.4.887; KIM S, 1994, BRIT J PHARMACOL, V113, P662, DOI 10.1111/j.1476-5381.1994.tb17042.x; KIM SK, 1995, CIRCULATION, V92, P88, DOI 10.1161/01.CIR.92.1.88; KOHARA K, 1992, AM J PHYSIOL, V262, pE651, DOI 10.1152/ajpendo.1992.262.5.E651; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; LEVY BI, 1988, CIRC RES, V63, P227, DOI 10.1161/01.RES.63.1.227; Li JY, 1996, MOL ENDOCRINOL, V10, P252, DOI 10.1210/me.10.3.252; MAMUYA W, 1992, CIRC RES, V71, P1341, DOI 10.1161/01.RES.71.6.1341; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MULVANY MJ, 1993, AM J MED, V94, pS20; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAKAJIMA T, 1992, MOL CELL BIOL, V12, P2837, DOI 10.1128/MCB.12.6.2837; NISHIZUKA Y, 1988, NATURE, V351, P662; ODERMATT E, 1985, P NATL ACAD SCI USA, V82, P6571, DOI 10.1073/pnas.82.19.6571; OHKUBO H, 1983, P NATL ACAD SCI-BIOL, V80, P2196, DOI 10.1073/pnas.80.8.2196; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; RAKUGI H, 1994, CIRCULATION, V90, P449, DOI 10.1161/01.CIR.90.1.449; RAKUGI H, 1993, CIRCULATION, V87, P283, DOI 10.1161/01.CIR.87.1.283; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; RuizOrtega M, 1997, KIDNEY INT, V52, P1497, DOI 10.1038/ki.1997.480; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; Seewald S, 1998, HYPERTENSION, V31, P1151, DOI 10.1161/01.HYP.31.5.1151; SHIOTA N, 1992, HYPERTENSION, V20, P168, DOI 10.1161/01.HYP.20.2.168; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STUDER RK, 1995, KIDNEY INT, V48, P422, DOI 10.1038/ki.1995.310; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TAKASAKI I, 1990, J BIOL CHEM, V265, P21935; TAKASAKI I, 1991, J BIOL CHEM, V266, P17686; TAKASAKI I, 1992, HYPERTENSION, V20, P20, DOI 10.1161/01.HYP.20.1.20; TAKEUCHI K, 1990, BIOCHEM BIOPH RES CO, V172, P1189, DOI 10.1016/0006-291X(90)91574-C; TAMURA K, 1993, J BIOL CHEM, V268, P15024; Tamura K, 1998, AM J PHYSIOL-REG I, V275, pR1, DOI 10.1152/ajpregu.1998.275.1.R1; Tamura K, 1995, Hypertens Res, V18, P7, DOI 10.1291/hypres.18.7; TAMURA K, 1994, J CLIN INVEST, V93, P1370, DOI 10.1172/JCI117113; Tamura K, 1998, HYPERTENSION, V32, P223, DOI 10.1161/01.HYP.32.2.223; Tamura K, 1997, J BIOL CHEM, V272, P16845, DOI 10.1074/jbc.272.27.16845; TANIMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V302, P409, DOI 10.1006/abbi.1993.1232; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; Wang DH, 1997, HYPERTENSION, V29, P1104, DOI 10.1161/01.HYP.29.5.1104; Wang DH, 1998, J HYPERTENS, V16, P467, DOI 10.1097/00004872-199816040-00008; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879	78	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26487	26496		10.1074/jbc.273.41.26487	http://dx.doi.org/10.1074/jbc.273.41.26487			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756884	hybrid			2022-12-25	WOS:000076373300038
J	Kim, JC; Yoon, JB; Koo, HS; Chung, IK				Kim, JC; Yoon, JB; Koo, HS; Chung, IK			Cloning and characterization of the 5 '-flanking region for the human topoisomerase III gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; LOOP-HELIX PROTEIN; RNA POLYMERASE-II; DNA TOPOISOMERASE; ACTIVATES TRANSCRIPTION; BINDING PROTEIN; REVERSE GYRASE; YY1; YEAST; PROMOTER	The human DNA topoisomerase III (hTOP3) gene encodes a topoisomerase homologous to the Escherichia coli DNA topoisomerase I subfamily. To understand the mechanisms responsible for regulating hTOP3 expression, we have cloned the 5'-flanking region of the gene coding for the hTOP3 and analyzed its promoter activity, The presence of a single transcription initiation site was suggested by primer extension analysis. The hTOP3 gene promoter is moderately high in GC content and lacks a canonical TATA box, suggesting that hTOP3 promoter has overall similarity 60 promoters of a number of housekeeping genes. Examination of the promoter sequence indicated the presence of four Sp-1 consensus binding sequences and a putative initiator element surrounding the transcription initiation site. Transient expression of a luciferase reporter gene under the control of serially deleted 5'-flanking sequences revealed that the 52-base pair region from -326 to -275 upstream of the transcription initiation site includes a positive cis-acting element(s) for the efficient expression of hTOP3 gene. On the basis of gel mobility shift and supershift assays, we demonstrated that both YY1 and USF1 transcription factors can bind 60 the 52-base pair region. When HeLa cells were transiently transfected with a mutant construct which had disabled both YY1- and USF1-binding sites, the luciferase activity was greatly reduced, suggesting that these binding elements play a functional role in the basal activation of the hTOP3 promoter. Transfection studies with mutations that selectively impaired YY1 or USF1 binding suggested that both YY1 and USF1 function as activators in the hTOP3 promoter.	Yonsei Univ, Coll Sci, Dept Biol, Bioprod Res Ctr, Seoul 120749, South Korea; Yonsei Univ, Coll Sci, Dept Biochem, Bioprod Res Ctr, Seoul 120749, South Korea	Yonsei University; Yonsei University	Chung, IK (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Bioprod Res Ctr, 134 Shinchon Dong, Seoul 120749, South Korea.	topoviro@bubble.yonsei.ac.kr		Yoon, Jong-Bok/0000-0002-3563-0702				BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; Fritz E, 1997, P NATL ACAD SCI USA, V94, P4538, DOI 10.1073/pnas.94.9.4538; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; HYDEDERUYSCHER RL, 1991, MOL CELL BIOL, V11, P5090; KIM RA, 1995, P NATL ACAD SCI USA, V92, P2667, DOI 10.1073/pnas.92.7.2667; KIM RA, 1992, J BIOL CHEM, V267, P17178; LEE TC, 1992, MOL CELL BIOL, V12, P4209; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SAMBROOK J, 1989, MOL CLONING, V9, P14; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; Seki T, 1998, BBA-GENE STRUCT EXPR, V1396, P127, DOI 10.1016/S0167-4781(97)00192-9; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SHYAMALA V, 1993, METHOD ENZYMOL, V217, P436; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG JC, 1991, J BIOL CHEM, V266, P6659; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1996, GENETICS, V144, P936; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	51	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26130	26137		10.1074/jbc.273.40.26130	http://dx.doi.org/10.1074/jbc.273.40.26130			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748294	hybrid			2022-12-25	WOS:000076263100085
J	Schulteis, CT; Nagaya, N; Papazian, DM				Schulteis, CT; Nagaya, N; Papazian, DM			Subunit folding and assembly steps are interspersed during shaker potassium channel biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED K+ CHANNELS; ENDOPLASMIC-RETICULUM; XENOPUS-OOCYTES; BETA-SUBUNITS; ELECTROSTATIC INTERACTIONS; TRANSMEMBRANE SEGMENTS; CYSTEINE RESIDUES; ALPHA-SUBUNITS; TEA BLOCKADE; VOLTAGE	In the voltage-dependent Shaker K+ channel, distinct regions of the protein form the voltage sensor, contribute to the permeation pathway, and recognize compatible subunits for assembly. To investigate channel biogenesis, we disrupted the formation of these discrete functional domains with mutations, including an aminoterminal deletion, Delta 97-196, which is likely to disrupt subunit oligomerization; D316K and K374E, which prevent proper folding of the voltage sensor; and E418K and C462K which are likely to disrupt pore formation. We determined whether these mutant subunits undergo three previously identified assembly events as follows: 1) tetramerization of Shaker subunits, 2) assembly of Shaker (alpha) and cytoplasmic beta subunits, and 3) association of the amino and carboxyl termini of adjacent Shaker subunits. Delta 97-196 subunits failed to establish any of these quaternary interactions, The Delta 97-196 deletion also prevented formation of the pore. The other mutant subunits assembled into tetramers and associated with the beta subunit but did not establish proximity between the amino and carboxyl termini of adjacent subunits. The results indicate that oligomerization mediated by the amino terminus is required for subsequent pore formation and either precedes or is independent of folding of the voltage sensor. In contrast, the amino and carboxyl termini of adjacent subunits associate late during biogenesis. Because subunits with folding defects oligomerize, we conclude that Shaker channels need not assemble from pre-folded monomers. Furthermore, association with native subunits can weakly promote the proper folding of some mutant subunits, suggesting that steps of folding and assembly alternate during channel biogenesis.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Interdept Program Neurosci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Papazian, DM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Box 951751, Los Angeles, CA 90095 USA.	papazian@physiology.medsch.ucla.edu			NIGMS NIH HHS [R01 GM043459-15, GM43459, R01 GM043459-09, R01 GM043459-13, R01 GM043459, R01 GM043459-10, R01 GM043459-15S1, R01 GM043459-12, R01 GM043459-16, R01 GM043459-11, R01 GM043459-14, R01 GM043459-17] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043459] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Hille B., 1992, IONIC CHANNELS EXCIT; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; Papazian DM, 1997, NEWS PHYSIOL SCI, V12, P203; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PARCEJ DN, 1989, BIOCHEM J, V257, P899, DOI 10.1042/bj2570899; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PEROZO E, 1994, BIOPHYS J, V66, P345, DOI 10.1016/S0006-3495(94)80783-0; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; RHODES KJ, 1995, J NEUROSCI, V15, P5360; Rowling P J, 1993, Subcell Biochem, V21, P41; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; SCHULTEIS CT, 1995, BIOCHEMISTRY-US, V34, P1725, DOI 10.1021/bi00005a029; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SCHWARZ TL, 1990, NEURON, V4, P119, DOI 10.1016/0896-6273(90)90448-O; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEN NV, 1993, NEURON, V11, P67; Sheng ZF, 1997, BIOCHEMISTRY-US, V36, P15501; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; Tang CY, 1998, BIOPHYS J, V75, P1263, DOI 10.1016/S0006-3495(98)74046-9; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; VERRALL S, 1992, CELL, V68, P21; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	56	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26210	26217		10.1074/jbc.273.40.26210	http://dx.doi.org/10.1074/jbc.273.40.26210			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748304	hybrid			2022-12-25	WOS:000076263100095
J	Estevez, R; Camps, M; Rojas, AM; Testar, X; Deves, R; Hediger, MA; Zorzano, A; Palacin, M				Estevez, R; Camps, M; Rojas, AM; Testar, X; Deves, R; Hediger, MA; Zorzano, A; Palacin, M			The amino acid transport system y(+)L/4F2hc is a heteromultimeric complex	FASEB JOURNAL			English	Article						oocyte; mutagenesis; erythrocyte; y(+)L transport activity; homologous protein	XENOPUS-LAEVIS OOCYTES; RENAL CYSTINE TRANSPORTER; MONOCLONAL-ANTIBODY 4F2; MINK POTASSIUM CHANNELS; CELL-SURFACE ANTIGEN; HEAVY-CHAIN; RAT-KIDNEY; EXPRESSION CLONING; HUMAN ERYTHROCYTES; HIGH-AFFINITY	4F2hc is an almost ubiquitous transmembrane protein in mammalian cells; upon expression in Xenopus laevis oocytes, it induces amino acid transport with characteristics of system y(+)L. Indirect evidence fostered speculation that function requires the association of 4F2hc with another protein endogenous to oocytes and native tissues. We show that expression of system y(+)L-like amino acid transport activity by 4F2hc in oocytes is Limited by an endogenous factor and that direct covalent modification of external cysteine residue(s) of an oocyte membrane protein blocks system y(+)L/4F2hc transport activity, based on the following. I) Induction of system y(+)L-like activity saturates at very low doses of human 4F2hc cRNA (0.1 ng/oocyte). This saturation occurs with very low expression of 4F2hc at the oocyte surface, and further increased expression of the protein at the cell surface does not result in higher induction of system y(+)L-like activity. 2) Human 4F2hc contains only two cysteine residues (C109 and C330). We mutated these residues, singly and in combination, to serine (C109S; CS1, C330S; CS2 and C109S-C330S, Cys-less). Mutation CS2 had no effect on the expressed system y(+)L-like transport activity, whereas C109S-containing mutants (CS1 and Cys-less) retained only partial y(+)L-like transport activity (30 to 50% of wild type). 3) Hg2+, the organic mercury com pounds pCMB, and the membrane-impermeant pCMBS almost completely inactivated system y(+)L-like induced by human 4F2hc wild type and all the mutants studied. This was reversed by P-mercaptoethanol, indicating that external cysteine residue(s) are the target of this inactivation. 4) Sensitivity to Hg2+ inactivation is increased by pretreatment of oocytes with P-mercaptoethanol or in the C109S-containing mutants (CS1 and Cys-less). The increased Hg2+ reactivity of C109S-containing mutants supports the possibility that C109 may be linked by a disulfide bond to the Hg2+-targeted cysteine residue of the associated protein. These results indicate that 4F2hc is intimately associated with a membrane oocyte protein for the expression of system y(+)L amino acid transport activity. To our knowledge, this is the first direct evidence for a heteromultimeric protein structure of an organic solute carrier in mammals.	Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Brigham & Womens Hosp, Div Renal, Harvard Inst Med, Boston, MA 02115 USA; Univ Chile, Fac Med, Dept Fisiol & Biofis, Santiago 7, Chile	University of Barcelona; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Universidad de Chile	Palacin, M (corresponding author), Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, Avda Diagonal 645, E-08028 Barcelona, Spain.		Camps, Marta/F-6557-2016; Palacín, Manuel/G-9786-2015; Zorzano, Antonio/R-5479-2018; Estevez, Raul/D-8610-2015	Camps, Marta/0000-0001-5392-1792; Estevez, Raul/0000-0003-1579-650X; Palacin, Manuel/0000-0002-8670-293X; Hediger, Matthias/0000-0003-1946-027X				Ahmed A, 1997, J BIOL CHEM, V272, P125; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Bisceglia L, 1997, AM J HUM GENET, V60, P611; Broeer S., 1997, Amino Acids (Vienna), V13, P45; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; BROER S, 1994, BBA-BIOMEMBRANES, V1192, P95, DOI 10.1016/0005-2736(94)90147-3; Broer S, 1997, BIOCHEM J, V324, P535, DOI 10.1042/bj3240535; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chillaron J, 1997, J BIOL CHEM, V272, P9543; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; DEVES R, 1993, J PHYSIOL-LONDON, V468, P753, DOI 10.1113/jphysiol.1993.sp019799; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; FEI YJ, 1995, BIOCHEMISTRY-US, V34, P8744, DOI 10.1021/bi00027a025; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; GEERING K, 1989, AM J PHYSIOL, V257, P851; HAYNES BF, 1981, J IMMUNOL, V126, P1409; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HEMLER ME, 1982, J IMMUNOL, V129, P623; Kakuda DK, 1993, TRANSGENE, V1, P91; LEE WS, 1993, J CLIN INVEST, V91, P1959, DOI 10.1172/JCI116415; Miyamoto K, 1996, J BIOL CHEM, V271, P16758, DOI 10.1074/jbc.271.28.16758; Mora C, 1996, J BIOL CHEM, V271, P10569, DOI 10.1074/jbc.271.18.10569; MORA S, 1996, THESIS U BARCELONA S; MOSCKOVITZ R, 1994, FASEB J, V8, P1069, DOI 10.1096/fasebj.8.13.7926373; Palacin M, 1996, BIOCHEM SOC T, V24, P856, DOI 10.1042/bst0240856; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; Peter GJ, 1996, BIOCHEM J, V318, P915, DOI 10.1042/bj3180915; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SEGAL S, 1995, METABOLIC MOL BASES, P3581; Tai KK, 1997, J BIOL CHEM, V272, P1654, DOI 10.1074/jbc.272.3.1654; Tate SS, 1996, AMINO ACIDS, V11, P209, DOI 10.1007/BF00813861; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; WALDEGGER S, 1995, KIDNEY INT, V47, P1677, DOI 10.1038/ki.1995.232; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; Wartenfeld R, 1997, AM J HUM GENET, V60, P617; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	47	67	68	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1319	1329		10.1096/fasebj.12.13.1319	http://dx.doi.org/10.1096/fasebj.12.13.1319			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761775				2022-12-25	WOS:000076402000007
J	Guo, XYD; Cuillerot, JM; Wang, T; Wu, Y; Arlinghaus, R; Claxton, D; Bachier, C; Greenberger, J; Colombowala, I; Deisseroth, AB				Guo, XYD; Cuillerot, JM; Wang, T; Wu, Y; Arlinghaus, R; Claxton, D; Bachier, C; Greenberger, J; Colombowala, I; Deisseroth, AB			Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210(bcr-abl) positive 32D myeloid leukemia cells	ONCOGENE			English	Article						p210(bcr-abl) oncoprotein; tetramerization; BCR; CML	ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; C-ABL; PHILADELPHIA-CHROMOSOME; ONCOGENIC ACTIVATION; HEMATOPOIETIC-CELLS; FUSION PROTEINS; GENE-PRODUCT; BINDING; INHIBITION	We first showed that the introduction of a bcr-abl transcription unit into the 32D murine myeloid cell line (P210bcrab132D) converts this cell line from an IL3 dependent cell line to an IL3 growth independent cell line, We next cloned a fragment of the bcr-abl cDNA, which codes for the bcr oligomerization domain and neighboring regions, To test for a transformation inhibitory effect of this oligomerization inhibitory peptide transcription unit on the p210(bcr-abl) mediated IL3 independent growth of the P210bcrab132D cell line, we transiently co-electroporated into the growth factor dependent 32D cells, mixtures of plasmids which contained varying ratios of the plasmid expression vectors for the bcr oligomerization inhibitory peptide along with a smaller amount of the plasmid expression vector for the full length p210(bcr-abl). (The P210(bcr-abl) protein converts the 32D from a growth factor dependent into a growth factor independent cell line.) We then showed that the oligomerization domain containing fragment from the bcr and bcr-abl proteins, can be used to inhibit the IL3 independent growth of p210(bcr-abl) positive 32D cells, These studies may be of eventual interest for those investigators whose goal is to design molecular therapeutic approaches to CML based on the use of peptidomimetic chemical functionalities, which mimic the structure and the inhibitory binding properties of the oligomerization domain containing fragment so as to inhibit the transforming function of the P210(bcr-abl) oncoprotein.	Yale Univ, Sch Med, Dept Internal Med, Med Oncol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Canc Ctr, Gene Therapy Program, New Haven, CT 06520 USA; Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA; Univ Pittsburgh, Med Ctr, Hanover, NH USA; Dartmouth Coll, Hanover, NH 03755 USA; S Texas Canc Inst, San Antonio, TX USA	Yale University; Yale University; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Dartmouth College	Deisseroth, AB (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Med Oncol Sect, 333 Cedar St, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 55162, P01 CA49639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDI A, 1994, BLOOD, V83, P2038; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; CARLESSO N, 1994, ONCOGENE, V9, P149; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBERGER JS, 1983, P NATL ACAD SCI USA, V80, P2391; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HOEVE J, 1994, BLOOD, V86, P1731; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Liu JX, 1996, MOL CELL BIOL, V16, P998; LU D, 1993, BLOOD, V82, P1257; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MITINORI S, 1995, NATURE, V374, P159; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUVRE C, 1989, CELL, V56, P777; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; USALA SJ, 1988, MOL ENDOCRINOL, V2, P1217, DOI 10.1210/mend-2-12-1217; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZAVACKI AM, 1993, MOL ENDOCRINOL, V7, P1319, DOI 10.1210/me.7.10.1319	55	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	1998	17	7					825	833		10.1038/sj.onc.1201999	http://dx.doi.org/10.1038/sj.onc.1201999			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9779999				2022-12-25	WOS:000075448800004
J	Kumar, A; Dhawan, S; Aggarwal, BB				Kumar, A; Dhawan, S; Aggarwal, BB			Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-kappa B activation, I kappa B degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells	ONCOGENE			English	Article						emodin; TNF; NF-kappa B; adhesion; I kappa-B alpha; endothelial cells	TYROSINE KINASE INHIBITOR; CANCER CELLS; MOLECULE-1; PHOSPHORYLATION; GENE	Most inflammatory agents activate nuclear transcription factor-kappa B (NF-kappa B) which results in expression of genes for cytokines, adhesion molecules, and enzymes involved in amplification and perpetuation of inflammation. Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) is an active component from the roots of Polygonum cuspidatum that has been reported to exhibit antiinflammatory properties but the mechanism is not known. In the present study we investigated the effects of emodin on the activation of NF-kappa B in human umbelical vein endothelial cells (EC), Treatment of EC with TNF activated NF-kappa B; preincubation with emodin inhibited this activation in a dose- and time-dependent manner. Emodin did not chemically modify NF-kappa B subunits but rather inhibited degradation of I kappa B, an inhibitory subunit of NF-kappa B. Since the promoter regions of ICAM-1, VCAM-1, and ELAM-1 contain NF-kappa B binding sites and these adhesion molecules are involved in the attachment of leukocytes to EC, the effect of emodin on the adhesion of monocytes to EC and the expression of these adhesion molecules was also studied. Treatment of EC with TNF for 6 h increased the adhesion of monocytes to EC, which correlated with increases in cell surface expression of ICAM-1, VCAM-1 and ELAM-1. Pretreatment of EC for Ih with emodin inhibited both monocyte-EC attachment and expression of ICAM-1, ELAM-1 and VCAM-1, These results indicate that emodin is a potent inhibitor of NF-kappa B activation and expression of adhesion molecules and thus could be useful in treating various inflammatory diseases.	Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Cytokine Res Sect, Houston, TX 77030 USA; US FDA, Lab Immunochem, Div Transfus Transmitted Dis, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	University of Texas System; UTMD Anderson Cancer Center; US Food & Drug Administration (FDA)	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Cytokine Res Sect, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; CARLOS TM, 1994, BLOOD, V84, P2068; CHAN TCK, 1993, BIOCHEM BIOPH RES CO, V193, P1152, DOI 10.1006/bbrc.1993.1746; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; Dhawan S, 1997, BLOOD, V90, P1535; FREDENHAGEN A, 1995, J ANTIBIOT, V48, P1355, DOI 10.7164/antibiotics.48.1355; FREW T, 1994, ANTICANCER RES, V14, P2425; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUANG HC, 1992, EUR J PHARMACOL, V211, P359, DOI 10.1016/0014-2999(92)90393-I; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; JAYASURIYA H, 1992, J NAT PROD, V55, P696, DOI 10.1021/np50083a026; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Lin CC, 1996, J ETHNOPHARMACOL, V52, P107, DOI 10.1016/0378-8741(96)01397-9; MCCARTY JM, 1995, FEBS LETT, V372, P194, DOI 10.1016/0014-5793(95)00976-G; Natarajan K, 1998, ARCH BIOCHEM BIOPHYS, V352, P59, DOI 10.1006/abbi.1998.0576; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; VORABERGER G, 1991, J IMMUNOL, V147, P2777; ZHANG LS, 1995, CANCER RES, V55, P3890; Zhang LS, 1996, ONCOGENE, V12, P571	26	141	168	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	1998	17	7					913	918		10.1038/sj.onc.1201998	http://dx.doi.org/10.1038/sj.onc.1201998			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780008				2022-12-25	WOS:000075448800013
J	Groppe, J; Rumpel, K; Economides, AN; Stahl, N; Sebald, W; Affolter, M				Groppe, J; Rumpel, K; Economides, AN; Stahl, N; Sebald, W; Affolter, M			Biochemical and biophysical characterization of refolded Drosophila DPP, a homolog of bone morphogenetic proteins 2 and 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MULLERIAN-INHIBITING SUBSTANCE; HUMAN OSTEOGENIC PROTEIN-1; IN-VITRO; TRANSFORMING GROWTH-FACTOR-BETA-1; 3-DIMENSIONAL STRUCTURE; DISTINCT MECHANISMS; BIOLOGICAL-ACTIVITY; SUBUNIT INTERFACES; CRYSTAL-STRUCTURE	The mature C-terminal signaling domain of the Drosophila Decapentaplegic proprotein (DPP) can be efficiently refolded from chaotrope-solubilized inclusion bodies with the aid of a membrane protein solubilizing detergent, high concentrations (0.75-2 M) of NaCl, and low temperatures (5-15 degrees C), The disulfide-linked homodimeric product contains N-terminal heparin-binding sites that were utilized as intrinsic affinity tags to obtain a highly enriched preparation in one chromatographic step. A subsequent C4 reverse phase high pressure liquid chromatography step provides high purity, salt-free protein that is amenable to biophysical and structural studies at a yield of approximately 3 mg/liter of bacterial culture. The dimeric protein is correctly folded as determined by electrophoretic, spectroscopic, chemical, and proteolytic analyses. Refolded DPP is also bioactive as shown by induction of chondrogenesis in embryonic chick limb bud cells and by high affinity binding to Noggin, an antagonist of bone morphogenetic protein signaling. In contrast to bone morphogenetic proteins extracted from demineralized bone or overexpressed in cell culture, the refolded Escherichia coli-expressed protein is not glycosylated at a conserved N-linked site and is therefore homogeneous. The C-terminal domain dimer is more hydrophobic and thus less soluble than its unfolded or partially folded forms, necessitating highly solubilizing conditions for recovery after folding in vitro. Hence solubilization of the mature ligand may be one of the principal roles of the large (250-400 amino acids) N-terminal prodomains of transforming growth factor-beta superfamily members, shown to act as intramolecular chaperones in vivo.	Univ Basel, Biozentrum, Dept Cell Biol, CH-4056 Basel, Switzerland; Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Biozentrum, Theodor Boveri Inst, D-97074 Wurzburg, Germany	University of Basel; University of Basel; Regeneron; University of Wurzburg	Groppe, J (corresponding author), Univ Basel, Biozentrum, Dept Cell Biol, Klingelbergstr 70, CH-4056 Basel, Switzerland.			Economides, Aris/0000-0002-6508-8942; Affolter, Markus/0000-0002-5171-0016				AMBROSIUS D., 1996, U.S. Patent, Patent No. [5,578,710, 5578710]; AONO A, 1995, BIOCHEM BIOPH RES CO, V210, P670, DOI 10.1006/bbrc.1995.1712; ARAKAWA T, 1985, METHOD ENZYMOL, V114, P49; ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CARRINGTON JL, 1991, DEV BIOL, V146, P406, DOI 10.1016/0012-1606(91)90242-U; Cerletti N., 1991, European Patent Application, Patent No. 0433225; CERLETTI N, 1995, Patent No. 9502718; CHEN P, 1993, EXP CELL RES, V206, P119, DOI 10.1006/excr.1993.1127; CHEN P, 1992, EXP CELL RES, V200, P110, DOI 10.1016/S0014-4827(05)80078-3; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Creighton T. E., 1989, PROTEIN STRUCTURE PR, P155; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P155; Daopin Sun, 1993, Proteins Structure Function and Genetics, V17, P176, DOI 10.1002/prot.340170207; DEKKER N, 1995, EUR J BIOCHEM, V232, P214, DOI 10.1111/j.1432-1033.1995.tb20801.x; Ellis RJ, 1998, TRENDS BIOCHEM SCI, V23, P43, DOI 10.1016/S0968-0004(98)01175-X; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HAMMONDS RG, 1991, MOL ENDOCRINOL, V5, P149, DOI 10.1210/mend-5-1-149; Han B, 1997, PROTEIN EXPRES PURIF, V11, P169, DOI 10.1006/prep.1997.0784; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lijnzaad P, 1997, PROTEINS, V28, P333; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; Nachtigal MW, 1996, P NATL ACAD SCI USA, V93, P7711, DOI 10.1073/pnas.93.15.7711; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Newfeld SJ, 1997, DEVELOPMENT, V124, P3167; Newfeld SJ, 1997, GENETICS, V145, P297; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; REUTER R, 1990, DEVELOPMENT, V110, P1031; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; ROARK EF, 1994, DEV DYNAM, V200, P103, DOI 10.1002/aja.1002000203; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; RUDOLPH R, 1996, PROTEIN STRUCTURE PR, P57; Ruppert R, 1996, EUR J BIOCHEM, V237, P295, DOI 10.1111/j.1432-1033.1996.0295n.x; SAMPATH TK, 1987, P NATL ACAD SCI USA, V84, P7109, DOI 10.1073/pnas.84.20.7109; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SAMUELSSON E, 1994, BIOCHEMISTRY-US, V33, P4207, DOI 10.1021/bi00180a013; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHMID FX, 1996, PROTEIN STRUCTURE PR, P261; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Vincent S, 1997, DEVELOPMENT, V124, P2741; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WILSON CA, 1993, MOL ENDOCRINOL, V7, P247, DOI 10.1210/me.7.2.247; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	77	45	45	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29052	29065		10.1074/jbc.273.44.29052	http://dx.doi.org/10.1074/jbc.273.44.29052			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786911	hybrid			2022-12-25	WOS:000076691800072
J	Haniu, M; Arakawa, T; Bures, EJ; Young, Y; Hui, JO; Rohde, MF; Welcher, AA; Horan, T				Haniu, M; Arakawa, T; Bures, EJ; Young, Y; Hui, JO; Rohde, MF; Welcher, AA; Horan, T			Human leptin receptor - Determination of disulfide structure and N-glycosylation sites of the extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; HUMAN VONWILLEBRAND-FACTOR; AMINO-ACID-SEQUENCE; CYTOKINE RECEPTORS; OBESE GENE; OB-R; CHAIN; IDENTIFICATION; ACTIVATION; CLONING	The leptin receptor (OB-R) is a member of the class I cytokine receptor family and mediates the weight regulatory effects of its ligand through interaction with cytoplasmic kinases, The extracellular domain of this receptor is comprised of two immunoglobulin-like and cytokine-receptor homology domains each and type III fibronectin domains. The extracellular domain of human leptin receptor was expressed in and purified from Chinese hamster ovary cells and was found to contain extensive N-glycosylation (approximately 36% of the total protein). The purified protein had a molecular weight of approximately 145,000 and exhibited ligand binding ability as evidenced by formation of ligand-receptor complex, followed by chemical cross-linking. The determined disulfide motif of the soluble leptin receptor contained several distinct cystine knots as well as 10 free cysteines, The N-glycosylation analysis revealed that Asn(624) Of the WSXWS motif (residues 622-626) within the C-terminal cytokine receptor homology domain was glycosylated, indicating that this region is solvent-exposed, On the other hand, the N-terminal WSXWS motif was not glycosylated.	Amgen Inc, Dept Prot Struct, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Prot Chem, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Immunol, Thousand Oaks, CA 91320 USA	Amgen; Amgen; Amgen	Haniu, M (corresponding author), Amgen Inc, Dept Prot Struct, Thousand Oaks, CA 91320 USA.	mhaniu@amgen.com						AGNES H, 1986, ADV METHODS MICROSEQ, P244; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Haniu M, 1996, BIOCHEMISTRY-US, V35, P13040, DOI 10.1021/bi960213u; HANIU M, 1994, INT J PEPT PROT RES, V43, P81; Kalai M, 1996, EUR J BIOCHEM, V238, P714, DOI 10.1111/j.1432-1033.1996.0714w.x; KEHRY M, 1979, P NATL ACAD SCI USA, V76, P2932, DOI 10.1073/pnas.76.6.2932; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Rajotte D, 1997, J EXP MED, V185, P1939, DOI 10.1084/jem.185.11.1939; STENFLO J, 1982, J BIOL CHEM, V257, P2180; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; Vance BA, 1997, J BIOL CHEM, V272, P23117, DOI 10.1074/jbc.272.37.23117; White BD, 1997, P SOC EXP BIOL MED, V214, P222, DOI 10.3181/00379727-214-44090; White David W., 1996, Cytokine and Growth Factor Reviews, V7, P303, DOI 10.1016/S1359-6101(96)00040-8; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	25	47	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28691	28699		10.1074/jbc.273.44.28691	http://dx.doi.org/10.1074/jbc.273.44.28691			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786864	hybrid			2022-12-25	WOS:000076691800025
J	Sano, Y; Tokitou, F; Dai, P; Maekawa, T; Yamamoto, T; Ishii, S				Sano, Y; Tokitou, F; Dai, P; Maekawa, T; Yamamoto, T; Ishii, S			CBP alleviates the intramolecular inhibition of ATF-2 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; AMP RESPONSE ELEMENT; TRANSCRIPTIONAL COACTIVATOR CBP; RUBINSTEIN-TAYBI SYNDROME; DNA-BINDING; LEUCINE-ZIPPER; HISTONE ACETYLTRANSFERASE; GLUCOCORTICOID RECEPTOR; C-MYB; DROSOPHILA CBP	The transcription factor ATF-2 (also called CRE-BP1), whose DNA-binding domain consists of a basic amino acid cluster and a leucine zipper (b-ZIP) region, binds to the cAMP response element as a homodimer or as a heterodimer with c-Jun. The amino-terminal region of ATF-2 containing the transcriptional activation domain is phosphorylated by stress-activated kinases, which leads to activation of ATF-2. We report here that CBP, which was originally identified as a co-activator of CREB, directly binds to the b-ZIP region of ATF-2 via a Cys/His rich region termed C/H2, and potentiates transactivation by ATF-2. The b-ZIP region of ATF-2 was previously shown to interact with the amino-terminal region intramolecularly and to inhibit trans-activating capacity. The binding of CBP to the b-ZIP region abrogates this intramolecular interaction. The adenovirus 13S E1A protein which binds to the b-ZIP region of ATF-2 also inhibited this intramolecular interaction, suggesting that both CBP and 135 E1A share a similar function as positive regulators of ATF-2. We found that the b-ZIP regions of c-Jun and CREB also interact with the C/H2 domain of CBP, suggesting that CBP acts as a regulator for a group of b-ZIP-containing proteins. These results shed light on a novel aspect of CBP function as a regulator for a group of b-ZIP containing proteins.	RIKEN, Tsukuba Life Sci Ctr, Genet Mol Lab, Tsukuba, Ibaraki 305, Japan; Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1080071, Japan; Univ Tsukuba, Inst Med Sci, Tsukuba, Ibaraki 3050006, Japan	RIKEN; University of Tokyo; University of Tsukuba	Ishii, S (corresponding author), RIKEN, Tsukuba Life Sci Ctr, Genet Mol Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 305, Japan.	sishii@rtc.riken.go.jp	Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DUBRIDGE RB, 1987, P NATL ACAD SCI USA, V84, P156; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3461; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; NOMURA N, 1993, J BIOL CHEM, V268, P4259; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okuda A, 1998, EMBO J, V17, P2019, DOI 10.1093/emboj/17.7.2019; ONATE SA, 1995, SCIENCE, V270, P1354; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TAKEDA J, 1991, ONCOGENE, V6, P1009; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; ZU YL, 1991, J BIOL CHEM, V266, P24134	55	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29098	29105		10.1074/jbc.273.44.29098	http://dx.doi.org/10.1074/jbc.273.44.29098			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786917	hybrid			2022-12-25	WOS:000076691800078
J	Schaffer, K; McBride, EW; Beinborn, M; Kopin, AS				Schaffer, K; McBride, EW; Beinborn, M; Kopin, AS			Interspecies polymorphisms confer constitutive activity to the Mastomys cholecystokinin-B/gastrin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B GASTRIN RECEPTOR; HUMAN BRAIN; ALPHA-1B-ADRENERGIC RECEPTOR; FUNCTIONAL EXPRESSION; THYROTROPIN RECEPTOR; ACTIVATING MUTATION; MOLECULAR-CLONING; HORMONE RECEPTOR; AMINO-ACID; SUBTYPE	The enteroendocrine hormone, gastrin, exerts trophic effects on the gastric mucosa through the CCK-B/gastrin receptor (CCK-BR), To varying degrees in different species, excess circulating gastrin leads to proliferation of enterochromaffin-like cells and to the development of gastric carcinoid tumors. The African rodent, Mastomys natalensis, is distinguished from other mammals by its propensity toward CCR-BR-mediated growth even in the absence of hypergastrinemia. Here, we report that the Mastomys CCK-BR, when expressed in COS-7 cells, differs from the respective human, canine, and rat receptor homologs by its ability to trigger ligand-independent (i.e., constitutive) inositol phosphate formation. To define the molecular basis of this observation, a series of Mastomys-human chimeric receptors was investigated. Functional characterization of these constructs revealed that a limited segment of the Mastomys CCK-BR, transmembrane domain VI through the C-terminal end, is sufficient to confer constitutive activity to the human protein. Mutagenesis studies within this CCK-BR region defined a combination of three Mastomys amino acids that, when introduced into the human receptor, together conferred a level of ligand-independent signaling comparable with the Mastomys CCK-BR. Complementing prior observations that single point mutations can lead to ligand-independent signaling, our findings suggest that multiple naturally occurring amino acid polymorphisms and/or mutations may together result in an enhanced basal level of receptor activity.	Tufts Univ, New England Med Ctr, Sch Med, Tupper Res Inst,Div Gastroenterol, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Sch Med, Tupper Res Inst,GRASP Digest Dis Ctr, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University	Kopin, AS (corresponding author), Tufts Univ, New England Med Ctr, Sch Med, Tupper Res Inst,Div Gastroenterol, 750 Wshington St, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928, R01DK046767] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46767, P30 DK34928] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BARKER EL, 1994, J BIOL CHEM, V269, P11687; Beinborn M, 1998, J BIOL CHEM, V273, P14146, DOI 10.1074/jbc.273.23.14146; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BLUEML K, 1994, J BIOL CHEM, V269, P18870; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Hasegawa H, 1996, J BIOL CHEM, V271, P1857, DOI 10.1074/jbc.271.4.1857; ITO M, 1993, J BIOL CHEM, V268, P18300; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Johnson LR., 1987, PHYSL GASTROINTESTIN; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; Kopin AS, 1997, P NATL ACAD SCI USA, V94, P11043, DOI 10.1073/pnas.94.20.11043; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; Langhans N, 1997, GASTROENTEROLOGY, V112, P280, DOI 10.1016/S0016-5085(97)90000-7; LEE YM, 1993, J BIOL CHEM, V268, P8164; MATUSLEIBOVITCH N, 1995, J BIOL CHEM, V270, P1041, DOI 10.1074/jbc.270.3.1041; Modlin IM, 1996, GASTROENTEROLOGY, V111, P783, DOI 10.1053/gast.1996.v111.agast961110783; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; NAKATA H, 1992, BIOCHEM BIOPH RES CO, V187, P1151, DOI 10.1016/0006-291X(92)91317-J; Parent JL, 1996, J BIOL CHEM, V271, P7949, DOI 10.1074/jbc.271.14.7949; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; RAVARD S, 1990, TRENDS PHARMACOL SCI, V11, P271, DOI 10.1016/0165-6147(90)90004-R; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; TIBERI M, 1994, J BIOL CHEM, V269, P27925; Walsh J. H., 1994, GUT PEPTIDES; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WIERTELAK EP, 1992, SCIENCE, V256, P830, DOI 10.1126/science.1589765	36	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28779	28784		10.1074/jbc.273.44.28779	http://dx.doi.org/10.1074/jbc.273.44.28779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786876	hybrid			2022-12-25	WOS:000076691800037
J	Rovner, AS				Rovner, AS			A long, weakly charged actin-binding loop is required for phosphorylation-dependent regulation of smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-MEROMYOSIN; LIGHT-CHAIN; CHIMERIC SUBSTITUTIONS; ENZYMATIC-PROPERTIES; GIZZARD MYOSIN; MOTOR DOMAIN; SUBFRAGMENT-1; MECHANISM; MOVEMENT; ATPASE	Chimeric substitution of the weak actin-binding loop (ABL) from chicken skeletal muscle myosin for that of gizzard smooth muscle heavy meromyosin (HMM) causes activation of the dephosphorylated mutant (SABL HMM; Rovner, A. S., Freyzon, Y., and Trybus, K. M. (1995) J, Biol. Chem. 270, 30260-30263). The present study determined whether this loss of regulation is due to the greater positive charge density (5 versus 3 clustered lysine residues) or lesser length (14 versus 26 residues) of the mutant ABL, Charge augmentation had little effect on regulation of expressed mutants, but elimination of the 12 N-terminal amino acids from the wild-type ABL significantly increased actin-activated ATPase activity of the dephosphorylated relative to the phosphorylated molecule while conferring the ability to move actin filaments in vitro on the former. Addition of the same 12 residues to the SABL mutant increased the ratio of phosphorylated to dephosphorylated ATPase activity while imparting mild type-like regulation to motility, However, full actin activation of dephosphorylated ATPase activity required both the shorter length and greater positive charge density found in the SABL loop. These results demonstrate that, compared with skeletal, both the greater length and lesser positive charge density of the smooth muscle myosin ABL are required for proper phosphorylation-mediated regulation of the molecule.	Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	University of Vermont	Rovner, AS (corresponding author), Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA.							CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Guilford William H., 1996, Biophysical Journal, V70, pA127; Higuchi R., 1992, PCR TECHNOLOGY, P61; IKEBE M, 1994, J BIOL CHEM, V269, P28173; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Sata M, 1997, P NATL ACAD SCI USA, V94, P91, DOI 10.1073/pnas.94.1.91; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; SEIDEL JC, 1980, J BIOL CHEM, V255, P4355; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; Trybus KM, 1998, J BIOL CHEM, V273, P18423, DOI 10.1074/jbc.273.29.18423; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WAGNER PD, 1987, J BIOL CHEM, V262, P15556; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0; YANG ZH, 1995, J BIOL CHEM, V270, P24646, DOI 10.1074/jbc.270.42.24646	30	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27939	27944		10.1074/jbc.273.43.27939	http://dx.doi.org/10.1074/jbc.273.43.27939			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774407	hybrid			2022-12-25	WOS:000076549800027
J	Shields, MJ; Kubota, R; Hodgson, W; Jacobson, S; Biddison, WE; Ribaudo, RK				Shields, MJ; Kubota, R; Hodgson, W; Jacobson, S; Biddison, WE; Ribaudo, RK			The effect of human beta(2)-microglobulin on major histocompatibility complex I peptide loading and the engineering of a high affinity variant - Implications for peptide-based vaccines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOCYTE EPITOPES; TRANSGENIC MICE; MHC MOLECULES; CELL-SURFACE; DNA VACCINES; HAPLOTYPE FREQUENCIES; ENDOGENOUS PEPTIDES; MATRIX PEPTIDE; VIABLE CELLS; HLA GENE	The ability to directly load cell surface major histocompatibility complex (MHC) class I molecules with peptides provides a potentially powerful approach toward the development of vaccines to generate cell-mediated immunity. We demonstrate that exogenous beta(2)-microglobulin (beta(2)m) stabilizes human cell surface MHC I molecules and facilitates their loading with exogenous peptides, Additionally, using three-dimensional crystal structures and known interaction sites between MHC I heavy chains and beta(2)m, we engineered variants of human beta(2)m (h beta(2)m) with a single serine substitution at residue 55, This alteration was predicted to promote hydrophobic interactions at the MHC I heavy chain/beta(2)m interface and displace an ordered water molecule. Compared with h beta(2)m, the serine to valine substitution at residue 55 had improved ability to bind to cell surface HLA-A1, HLA-A2, and HLA-A3 molecules, facilitate exogenous peptide loading, and promote recognition by peptide-specific T cells. The inclusion of h beta(2)m or higher affinity variants when pulsing cells with MHC-restricted peptides increases the efficiency of peptide loading 50-80-fold. Therefore, the inclusion of h beta(2)m in peptide-based vaccines may increase cell surface antigen densities above thresholds that allow recognition of peptide antigens by the immune system, particularly for cryptic, subdominant, or marginally antigenic peptides.	NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA; NINDS, Neuroimmunol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Ribaudo, RK (corresponding author), Mol Applicat Grp, 11800 Dewey Rd, Silver Spring, MD 20906 USA.	rkr@mag.com	Ribaudo, Randall/AAH-7094-2021; Kubota, Ryuji/A-7139-2009	Kubota, Ryuji/0000-0002-4158-3471				ABASTADO JP, 1993, J IMMUNOL, V151, P3569; ANDERSON KS, 1993, J IMMUNOL, V151, P3407; [Anonymous], INTRO PROTEIN STRUCT; BARRA C, 1993, J IMMUNOL, V150, P3681; Biddison WE, 1997, J IMMUNOL, V159, P2018; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BREMERS AJA, 1995, J IMMUNOTHER, V18, P77, DOI 10.1097/00002371-199508000-00001; BRODSKY FM, 1982, J IMMUNOL, V128, P129; Cook JR, 1996, J IMMUNOL, V157, P2256; DANLICZYK UG, 1994, J IMMUNOL, V153, P3533; Day PM, 1997, P NATL ACAD SCI USA, V94, P8064, DOI 10.1073/pnas.94.15.8064; DELGUERCIO MF, 1995, J IMMUNOL, V154, P685; Deng YP, 1997, J IMMUNOL, V158, P1507; Depierreux C, 1997, J IMMUNOL METHODS, V203, P77, DOI 10.1016/S0022-1759(97)00015-X; DIBRINO M, 1994, J IMMUNOL, V152, P620; DIBRINO M, 1993, J IMMUNOL, V151, P5930; DIBRINO M, 1993, P NATL ACAD SCI USA, V90, P1508, DOI 10.1073/pnas.90.4.1508; Eberl G, 1996, EUR J IMMUNOL, V26, P2709, DOI 10.1002/eji.1830261124; Edidin M, 1997, IMMUNOGENETICS, V46, P41, DOI 10.1007/s002510050240; EPSTEIN H, 1989, EUR J IMMUNOL, V19, P1575, DOI 10.1002/eji.1830190909; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Evans DT, 1997, J IMMUNOL, V159, P1374; FUKAZAWA T, 1994, J IMMUNOL, V153, P3543; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; Hansen TH, 1997, ADV IMMUNOL, V64, P105, DOI 10.1016/S0065-2776(08)60888-3; HOCHMAN JH, 1988, J IMMUNOL, V140, P2322; Honma K, 1997, J NEUROIMMUNOL, V73, P7, DOI 10.1016/S0165-5728(96)00161-0; Horig H, 1997, P NATL ACAD SCI USA, V94, P13826, DOI 10.1073/pnas.94.25.13826; JAULIN C, 1992, INT IMMUNOL, V4, P945, DOI 10.1093/intimm/4.8.945; KANE KP, 1991, EUR J IMMUNOL, V21, P2289, DOI 10.1002/eji.1830210945; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; Lustgarten J, 1997, HUM IMMUNOL, V52, P109, DOI 10.1016/S0198-8859(96)00292-3; MAN S, 1994, J IMMUNOL, V153, P4458; Manickan E, 1997, CRIT REV IMMUNOL, V17, P139, DOI 10.1615/CritRevImmunol.v17.i2.20; Montgomery DL, 1997, PHARMACOL THERAPEUT, V74, P195, DOI 10.1016/S0163-7258(97)82003-7; Mori M, 1997, TRANSPLANTATION, V64, P1017, DOI 10.1097/00007890-199710150-00014; Moss B, 1996, P NATL ACAD SCI USA, V93, P11341, DOI 10.1073/pnas.93.21.11341; OTTEN GR, 1992, J IMMUNOL, V148, P3723; PARKER KC, 1995, IMMUNOL RES, V14, P34, DOI 10.1007/BF02918496; PARKER KC, 1992, J IMMUNOL, V149, P3580; PARKER KC, 1994, J IMMUNOL, V152, P163; PEDERSEN LO, 1995, EUR J IMMUNOL, V25, P1609, DOI 10.1002/eji.1830250621; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; RIBAUDO RK, 1995, J IMMUNOL, V155, P3481; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P301, DOI 10.1073/pnas.88.1.301; ROCK KL, 1993, J IMMUNOL, V150, P1244; Schipper RF, 1997, HUM IMMUNOL, V52, P54, DOI 10.1016/S0198-8859(96)00257-1; Shields MJ, 1998, J IMMUNOL, V160, P2297; Shields MJ, 1998, TISSUE ANTIGENS, V51, P567, DOI 10.1111/j.1399-0039.1998.tb02994.x; Shiver JW, 1997, VACCINE, V15, P884, DOI 10.1016/S0264-410X(96)00251-4; Sidney J, 1996, HUM IMMUNOL, V45, P79, DOI 10.1016/0198-8859(95)00173-5; SIDNEY J, 1995, J IMMUNOL, V154, P247; Sidney J, 1996, J IMMUNOL, V157, P3480; SMITH JD, 1992, P NATL ACAD SCI USA, V89, P7767, DOI 10.1073/pnas.89.16.7767; SOUSA CRE, 1995, J EXP MED, V182, P841, DOI 10.1084/jem.182.3.841; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; SUGAWARA S, 1987, J IMMUNOL METHODS, V100, P83; Suhrbier A, 1997, IMMUNOL CELL BIOL, V75, P402, DOI 10.1038/icb.1997.63; TATAKE RJ, 1993, IMMUNOGENETICS, V38, P318; TAUROG JD, 1993, J IMMUNOL, V150, P4168; Trymbulak WP, 1997, IMMUNOGENETICS, V46, P418, DOI 10.1007/s002510050296; Trymbulak WP, 1997, TRANSPLANTATION, V64, P640, DOI 10.1097/00007890-199708270-00016; vanderBurg SH, 1995, HUM IMMUNOL, V44, P189, DOI 10.1016/0198-8859(95)00105-0; VITIELLO A, 1991, J EXP MED, V173, P1007, DOI 10.1084/jem.173.4.1007; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; Waldburger CD, 1996, P NATL ACAD SCI USA, V93, P2629, DOI 10.1073/pnas.93.7.2629; Weiskirch LM, 1997, IMMUNOL REV, V158, P159, DOI 10.1111/j.1600-065X.1997.tb01002.x; WINTER CC, 1991, J IMMUNOL, V146, P3508; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; Zhang C, 1997, VACCINE, V15, P1291, DOI 10.1016/S0264-410X(97)00040-6; ZHU X, 1995, SCAND J IMMUNOL, V42, P557, DOI 10.1111/j.1365-3083.1995.tb03696.x	74	24	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28010	28018		10.1074/jbc.273.43.28010	http://dx.doi.org/10.1074/jbc.273.43.28010			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774416	hybrid			2022-12-25	WOS:000076549800036
J	Guan, LS; Rauchman, M; Wang, ZY				Guan, LS; Rauchman, M; Wang, ZY			Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; NEGATIVE REGULATOR; EXPRESSION; HYBRIDIZATION; TRANSCRIPTION; POLYPEPTIDE; RECEPTOR; LOCUS; YEAST; RAS	The Wilms' tumor suppressor gene, wt1, encodes a zinc-finger transcription factor, WT1, that plays an important role in controlling urogenital development. Previously, WT1 has been shown to inhibit cell growth and to repress transcription initiated from the promoters of a number of growth-promoting genes. However, few physiological target genes that are transcriptionally activated by WT1 have been established. Using suppression subtractive hybridization polymerase chain reaction, we isolated a WT1 target gene that is up-regulated about 15-fold in cells expressing WT1. The gene was identified as retinoblastoma suppressor (Rb)-associated protein 46 (RbAp46), a nuclear protein that interacts physically with Rb and is a component of the human mSin3 co-repressor complex. Cells transfected with RbAp46 cDNA formed fewer colonies than the control cells, and RbAp46 suppressed the growth rate (by about a-fold) of transfected cells. In the developing kidney and gonad, RbAp46 exhibits an expression pattern similar to that of WT1. We conclude that RbAp46 has strong growth inhibition activity and may function as an important mediator of WT1's function.	Beth Israel Deaconess Med Ctr, Dept Med, Div Growth Regulat, Boston, MA 02215 USA; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	Wang, ZY (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Growth Regulat, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R29CA076632] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA76632] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ach RA, 1997, PLANT CELL, V9, P1595, DOI 10.1105/tpc.9.9.1595; AUSUBEL FM, 1996, CURRENT PROTOCOLS S, V36; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; KINANE TB, 1996, J BIOL CHEM, V271, P30760; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; NICHOLS KE, 1995, CANCER RES, V55, P4540; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1995, MOL CELL BIOL, V15, P3516; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	24	55	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27047	27050		10.1074/jbc.273.42.27047	http://dx.doi.org/10.1074/jbc.273.42.27047			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765217	hybrid			2022-12-25	WOS:000076448000004
J	Gunasinghe, SK; Hubbs, AE; Wright, CF				Gunasinghe, SK; Hubbs, AE; Wright, CF			A vaccinia virus late transcription factor with biochemical and molecular identity to a human cellular protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; LATE GENE; LATE PROMOTER; PURIFICATION; OVEREXPRESSION; IDENTIFICATION; SEQUENCE; MUTANTS; COMPLEX; PRODUCT	A factor designated VLTF-X is required to support vaccinia virus late transcription in vitro. It has been found that a late promoter DNA binding activity cochromatographs and cosediments with VLTF-X activity. Current experiments show that VLTF-X activity is present in a variety of uninfected mammalian cell types and is indistinguishable from that recovered from infected cells based upon several criteria. VLTF-X activity from both sources displays the same purification profile over phosphocellulose and DNA affinity resins and has the same sedimentation coefficient, In addition, the factors purified from both infected and uninfected cells form protein-DNA complexes of identical electrophoretic mobility in the presence of vaccinia virus late promoter-containing DNA The affinity of these factors for the late promoter probes is identical and late promoter-specific based on competition experiments. Moreover, VLTF-X purified from both sources bound to late promoter containing DNA in the presence or absence of MgCl2 and ATP and formed complexes resistant to heat inactivation. These experiments offer proof that vaccinia virus factor VLTF-X is a host cell protein that supports transcription of the viral late genes.	Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA	Medical University of South Carolina; United States Department of Defense	Wright, CF (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 171 Ashley Ave, Charleston, SC 29425 USA.			Wright, Cynthia/0000-0003-0442-1665				ABMAYR SM, 1996, CURRENT PROTOCOLS MO; BERTHOLET C, 1986, EMBO J, V5, P1951, DOI 10.1002/j.1460-2075.1986.tb04449.x; Black EP, 1996, J VIROL, V70, P47, DOI 10.1128/JVI.70.1.47-54.1996; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1991, J BIOL CHEM, V266, P15545; CHODOSH LA, 1996, CURRENT PROTOCOLS MO; Condit RC, 1996, VIROLOGY, V220, P10, DOI 10.1006/viro.1996.0280; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; Hubbs AE, 1996, J VIROL, V70, P327, DOI 10.1128/JVI.70.1.327-331.1996; KECK JG, 1993, J VIROL, V67, P5740, DOI 10.1128/JVI.67.10.5740-5748.1993; KERRIGAN LA, 1996, CURRENT PROTOCOLS MO; Kovacs GR, 1996, J VIROL, V70, P6796, DOI 10.1128/JVI.70.10.6796-6802.1996; KOVACS GR, 1994, J VIROL, V68, P3443, DOI 10.1128/JVI.68.5.3443-3447.1994; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MOSS B, 1991, J BIOL CHEM, V266, P1355; Passarelli AL, 1996, J VIROL, V70, P4444, DOI 10.1128/JVI.70.7.4444-4450.1996; ROSALES R, 1994, P NATL ACAD SCI USA, V91, P3794, DOI 10.1073/pnas.91.9.3794; ROSALES R, 1994, J BIOL CHEM, V269, P14260; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; VOS JC, 1991, EMBO J, V10, P2552; WEIR JP, 1987, J VIROL, V61, P75, DOI 10.1128/JVI.61.1.75-80.1987; WRIGHT CF, 1987, P NATL ACAD SCI USA, V84, P8883, DOI 10.1073/pnas.84.24.8883; Wright CF, 1998, J VIROL, V72, P1446, DOI 10.1128/JVI.72.2.1446-1451.1998; WRIGHT CF, 1993, J VIROL, V67, P7264, DOI 10.1128/JVI.67.12.7264-7270.1993; Zhu M, 1998, J VIROL, V72, P3893, DOI 10.1128/JVI.72.5.3893-3899.1998	27	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27524	27530		10.1074/jbc.273.42.27524	http://dx.doi.org/10.1074/jbc.273.42.27524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765284	hybrid			2022-12-25	WOS:000076448000071
J	Liao, JF; Barthel, A; Nakatani, K; Roth, RA				Liao, JF; Barthel, A; Nakatani, K; Roth, RA			Activation of protein kinase B/Akt is sufficient to repress the glucocorticoid and cAMP induction of phosphoenolpyruvate carboxykinase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; S6 KINASE; INSULIN; EXPRESSION; AKT; TRANSLOCATION; INHIBITION; SEQUENCE; GTP	A rat hepatoma cell line, H4IIE, was stably transfected with a tamoxifen regulatable Akt-1 construct. Treatment of these cells with tamoxifen caused a rapid stimulation of Akt enzymatic activity that was comparable with the activity observed with the endogenous Akt after insulin stimulation. Prior studies have extensively documented that insulin can repress the glucocorticoid and cAMP-stimulated increase in phosphoenolpyruvate carboxykinase (PEPCK) gene transcription. Activation of this regulatable Akt with tamoxifen was found to mimic the dominant inhibitory effect of insulin on PEPCK gene transcription. Dose response curves to insulin and tamoxifen demonstrated that this response was very sensitive to Akt activation although the maximal response observed with tamoxifen activation was slightly less than that observed with insulin, indicating that the response to insulin mag also involve other sig naling cascades. The regulation of PEPCK transcription via Akt was, like that previously described for insulin, not dependent upon 70 kDa S6 kinase activity in that it was not inhibited by rapamycin, Finally, the expression of a kinase dead Akt was able to partially inhibit the ability of insulin to stimulate this response. in summary, the present results indicate that activation of Akt alone is sufficient to repress the glucocorticoid and cAMP-stimulated increase in PEPCK gene transcription.	Stanford Univ, Med Ctr, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA	Stanford University	Roth, RA (corresponding author), Stanford Univ, Med Ctr, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA.	roth@cmgm.stanford.edu		Nakatani, Kaname/0000-0001-6709-541X	NIDDK NIH HHS [DK34926, DK09293] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009293, R37DK034926, R01DK034926] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BEALE EG, 1985, J BIOL CHEM, V260, P748; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Krook A, 1997, DIABETES, V46, P2110, DOI 10.2337/diabetes.46.12.2110; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	32	113	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27320	27324		10.1074/jbc.273.42.27320	http://dx.doi.org/10.1074/jbc.273.42.27320			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765258	hybrid			2022-12-25	WOS:000076448000045
J	Mattila, P; Salminen, H; Hirvas, L; Niittymaki, J; Salo, H; Niemela, R; Fukuda, M; Renkonen, O; Renkonen, R				Mattila, P; Salminen, H; Hirvas, L; Niittymaki, J; Salo, H; Niemela, R; Fukuda, M; Renkonen, O; Renkonen, R			The centrally acting beta 1,6N-acetylglucosaminyltransferase (GlcNAc to Gal) - Functional expression, purification, and acceptor specificity of a human enzyme involved in midchain branching of linear poly-N-acetyllactosamines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; BLOOD-GROUP-I; ENDO-BETA-GALACTOSIDASE; L-SELECTIN; LYMPHOCYTE ADHESION; POLYLACTOSAMINE BACKBONES; CARBOHYDRATE STRUCTURE; GASTRIC-MUCOSA; HUMAN-SERUM; BIOSYNTHESIS	In the present experiments the cDNA coding for a truncated form of the beta 1,6N-acetylglucosaminyltransferase responsible for the conversion of linear to branched polylactosamines in human PA1 cells was expressed in Sf9 insect cells. The catalytic ectodomain of the enzyme was fused to glutathione S-transferase, allowing effective one-step purification of the glycosylated 67-74-kDa fusion protein. Typically a yield of 750 mu g of the purified protein/liter of suspension culture was obtained. The purified recombinant protein catalyzed the transfer of GlcNAc from UDP-GlcNAc to the linear tetrasaccharide Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4-GlcNAc, converting the acceptor to the branched pentasaccharide Gal beta 1-4GlcNAc beta 1-3(GlcNAc beta 1-6)Gal beta 1-4-GlcNAc as shown by matrix-assisted laser desorption/ionization time of-flight mass spectrometry, degradative experiments, and H-1 NMR spectroscopy of the product. By contrast, the recombinant enzyme did not catalyze any reaction when incubated with UDP-GlcNAc and the trisaccharide GlcNAc beta 1-3Gal beta 1-4GlcNAc. Accordingly, we call the recombinant beta 1,6-GlcNAc transferase cIGnT6 to emphasize its action at central rather than peridistal galactose residues of linear polylactosamines in the biosynthesis of blood group I antigens, Taken together this in vitro expression of I-branching enzyme, in combination with the previously cloned enzymes, beta 1,4galactosyltransferase and beta 1,3N-acetylglucosaminyltransferase, should allow the general synthesis of polylactosamines based totally on the use of recombinant enzymes.	Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, SF-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, SF-00014 Helsinki, Finland; Burnham Inst, La Jolla, CA 92037 USA	University of Helsinki; University of Helsinki; Sanford Burnham Prebys Medical Discovery Institute	Mattila, P (corresponding author), Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, POB 21,Haartmaninkatu 3, SF-00014 Helsinki, Finland.	pirkko.mattila@helsinki.fi						BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; DABROWSKI U, 1984, J BIOL CHEM, V259, P7648; FEIZI T, 1979, J EXP MED, V149, P975, DOI 10.1084/jem.149.4.975; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; GU J, 1992, J BIOL CHEM, V267, P2994; Helin J, 1997, FEBS LETT, V412, P637, DOI 10.1016/S0014-5793(97)00818-1; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KOENDERMAN AHL, 1987, EUR J BIOCHEM, V166, P199, DOI 10.1111/j.1432-1033.1987.tb13502.x; Leppanen A, 1997, BIOCHEMISTRY-US, V36, P7026, DOI 10.1021/bi9627673; Leppanen A, 1998, J BIOL CHEM, V273, P17399, DOI 10.1074/jbc.273.28.17399; LEPPANEN A, 1991, BIOCHEMISTRY-US, V30, P9287, DOI 10.1021/bi00102a022; Leppanen A, 1997, BIOCHEMISTRY-US, V36, P13729, DOI 10.1021/bi9712807; Maaheimo H, 1997, CARBOHYD RES, V297, P145, DOI 10.1016/S0008-6215(96)00259-5; MAAHEIMO H, 1995, EUR J BIOCHEM, V234, P616, DOI 10.1111/j.1432-1033.1995.616_b.x; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; MURAMATSU T, 1978, P NATL ACAD SCI USA, V75, P2315, DOI 10.1073/pnas.75.5.2315; MURAMATSU T, 1979, SOMAT CELL GENET, V5, P753, DOI 10.1007/BF01542639; Niemela R, 1995, CARBOHYD RES, V279, P331, DOI 10.1016/0008-6215(95)00299-5; PILLER F, 1984, J BIOL CHEM, V259, P3385; Rabina J, 1997, CARBOHYD RES, V305, P491, DOI 10.1016/S0008-6215(97)00260-7; RASILO ML, 1982, EUR J BIOCHEM, V123, P397, DOI 10.1111/j.1432-1033.1982.tb19782.x; RASILO ML, 1980, PURE APPL CHEM, V52, P55, DOI 10.1351/pac198052010055; RASILO ML, 1980, CAN J BIOCHEM CELL B, V58, P384, DOI 10.1139/o80-050; RENKONEN O, 1983, BIOCHEM SOC T, V11, P265, DOI 10.1042/bst0110265; Renkonen O, 1997, GLYCOBIOLOGY, V7, P453, DOI 10.1093/glycob/7.4.453-c; RENKONEN O, 1988, BIOCHEM CELL BIOL, V66, P449, DOI 10.1139/o88-054; RENKONEN O, 1991, GLYCOCONJUGATE J, V8, P376, DOI 10.1007/BF00731351; ROMANS DG, 1980, J IMMUNOL, V124, P2807; ROPP PA, 1991, J BIOL CHEM, V266, P23863; Sakamoto Y, 1998, J BIOL CHEM, V273, P27625, DOI 10.1074/jbc.273.42.27625; Salminen H, 1997, FEBS LETT, V419, P220, DOI 10.1016/S0014-5793(97)01462-2; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Seppo A, 1996, GLYCOBIOLOGY, V6, P65, DOI 10.1093/glycob/6.1.65; SEPPO A, 1990, BIOCHEM CELL BIOL, V68, P44, DOI 10.1139/o90-006; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; Toppila S, 1997, EUR J IMMUNOL, V27, P1360, DOI 10.1002/eji.1830270610; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; VANDENEIJNDEN DH, 1983, J BIOL CHEM, V258, P3435; ZDEBSKA E, 1983, CARBOHYD RES, V120, P113, DOI 10.1016/0008-6215(83)88011-2; ZIELENSKI J, 1983, FEBS LETT, V158, P164, DOI 10.1016/0014-5793(83)80700-5; ZIELENSKI J, 1983, FEBS LETT, V163, P114, DOI 10.1016/0014-5793(83)81175-2	46	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27633	27639		10.1074/jbc.273.42.27633	http://dx.doi.org/10.1074/jbc.273.42.27633			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765298	hybrid			2022-12-25	WOS:000076448000085
J	Bae, SH; Choi, E; Lee, KH; Park, JS; Lee, SH; Seo, YS				Bae, SH; Choi, E; Lee, KH; Park, JS; Lee, SH; Seo, YS			Dna2 of Saccharomyces cerevisiae possesses a single-stranded DNA-specific endonuclease activity that is able to act on double-stranded DNA in the presence of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINTS; RECBCD ENZYME; HELICASE; REPLICATION; REPAIR; RECOMBINATION; NUCLEASE; PROTEIN; BINDING; DAMAGE	To gain further insights into the biological functions of Dnaa, previously known as a cellular replicative helicase in Saccharomyces cerevisiae, we examined biochemical properties of the recombinant Dnaa protein purified to homogeneity, Besides the single-stranded (Ss) DNA-dependent ATPase activity as reported previously, we were able to demonstrate that ssDNA-specific endonuclease activity is intrinsically associated with Dna2, Moreover, Dnaa was capable of degrading duplex DNA in an ATP-dependent fashion. ATP and dATP, the only nucleotides hydrolyzed by Dnaa, served to stimulate Dnaa to utilize duplex DNA, indicating their hydrolysis is required. Dna2 was able to unwind short duplex only under the condition where the endonuclease activity was minimized. This finding implies that Dna2 unwinds only partially the 3'-end of duplex DNA and generates a stretch of ssDNA of limited length, which is subsequently cleaved by the ssDNA-specific endonuclease activity, A point mutation at the conserved ATP-binding site of Dna2 inactivated concurrently ssDNA-dependent ATPase, ATP-dependent nuclease, and helicase activities, indicating that they all reside in Dna2 itself, By virtue of its nucleolytic activities, the Dnaa protein may function in the maintenance of chromosomal integrity, such as repair or other related process, Father than in propagation of cellular replication forks.	Samsung Biomed Res Inst, Basic Res Ctr, Nucleic Acid Biochem Lab, Seoul 135230, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center	Seo, YS (corresponding author), Samsung Biomed Res Inst, Basic Res Ctr, Nucleic Acid Biochem Lab, 50 Ilwon-Dong,Kangnam-Ku, Seoul 135230, South Korea.		Seo, Yeonsoo/C-1605-2011					Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; EGGLESTON AK, 1993, J MOL BIOL, V231, P605, DOI 10.1006/jmbi.1993.1313; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fiorentino DF, 1997, MOL BIOL CELL, V8, P2519, DOI 10.1091/mbc.8.12.2519; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Haijema BJ, 1996, J BACTERIOL, V178, P5130, DOI 10.1128/jb.178.17.5130-5137.1996; HARLOW E, 1988, ANTIBODIES LABORATOR, P309; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hunt T, 1993, CELL CYCLE, P135; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KAROUI ME, 1998, P NATL ACAD SCI USA, V95, P626; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kooistra J, 1997, MOL MICROBIOL, V23, P137, DOI 10.1046/j.1365-2958.1997.1991570.x; Kornberg A., 1992, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Lydall D, 1996, CURR OPIN GENET DEV, V6, P4, DOI 10.1016/S0959-437X(96)90003-9; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MONIKA L, 1993, J BIOL CHEM, V268, P15795; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; Park JS, 1997, J BIOL CHEM, V272, P18910, DOI 10.1074/jbc.272.30.18910; Rumbaugh JA, 1997, J BIOL CHEM, V272, P22591, DOI 10.1074/jbc.272.36.22591; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMMES P, 1992, CHROMOSOMA, V101, P467, DOI 10.1007/BF00352468; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tuteja N, 1996, NAT GENET, V13, P11, DOI 10.1038/ng0596-11; WAGA S, 1994, J BIOL CHEM, V269, P10923; Weinert T, 1997, CANCER SURV, V29, P109; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4	38	111	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26880	26890		10.1074/jbc.273.41.26880	http://dx.doi.org/10.1074/jbc.273.41.26880			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756935	hybrid			2022-12-25	WOS:000076373300089
J	Gerken, TA; Owens, CL; Pasumarthy, M				Gerken, TA; Owens, CL; Pasumarthy, M			Site-specific core 1 O-glycosylation pattern of the porcine submaxillary gland mucin tandem repeat - Evidence for the modulation of glycan length by peptide sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; AMINO-ACID-SEQUENCE; LINKED GLYCOSYLATION; MASS-SPECTROMETRY; CELL-ADHESION; UDP-GALNAC; GLYCOPROTEINS; GLYCOPEPTIDE; OLIGOSACCHARIDES; CONFORMATION	The sequence-specific O-linked core 1 ([R-1, R-2]-beta-Gal(1-3)-alpha-GalNAc-O-Ser/Thr) glycosylation pattern has been quantitatively determined for 30 of the 31 Ser/Thr residues in the 81-residue porcine submaxillary gland mucin tandem repeat. This was achieved by Edman amino acid sequencing of the isolated tandem repeat after selective removal of non-C3-substituted, peptide-linked GalNAc residues by periodate oxidation and subsequent trimming of the remaining oligosaccharides to peptide-linked GalNAc residues by mild trifluoromethanesulfonic acid/anisole treatment. The sequencing reveals 61% (range, 12-95%) of the peptide alpha-N-acetylgalactosamine (GalNAc) residues to be substituted by core 1 chains, a value in agreement with the carbon-13 NMR analysis of the native mucin, Residues with the lowest C3 substitution were typically clustered in regions of sequence with the highest densities of (glycosylated) serine or threonine. This suggests that the porcine beta 3-Gal, core 1, transferase is sensitive to peptide sequence and/or neighboring core GalNAc glycosylation in vivo, in keeping with earlier in vitro enzymatic glycosylation studios (Granovsky, M., Blielfeldt, T., Peters, S,, Paulsen, II., Meldal, M., Brockhausen, J,, and Brockhausen, I, (1994) fur. J, Biochem. 221, 1039-1046), These results demonstrate that the O-glycan structures in mucin domains are not necessarily uniformly distributed along the polypeptide core and that their lengths can be modulated by peptide sequence. The data further suggest that hydroxyamino acid spacing may contribute to the regulation of glycan length, thereby, providing a mechanism for maintaining an optimally expanded, protease resistant, mucin conformation.	Case Western Reserve Univ, Dept Pediat, WA Bernbaum Ctr Cyst Fibrosis Res, Sch Med BRB, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Mol & Microbiol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Gerken, TA (corresponding author), Case Western Reserve Univ, Dept Pediat, WA Bernbaum Ctr Cyst Fibrosis Res, Sch Med BRB, Cleveland, OH 44106 USA.	tag@glycocon.cwru.edu			NCI NIH HHS [P30-CA43703, R01 CA078834] Funding Source: Medline; NIDDK NIH HHS [R01-DK-39918, P30-DK-27651] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA078834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651, R01DK039918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APOSTOLOPOULOS V, 1994, CRIT REV IMMUNOL, V14, P293, DOI 10.1615/CritRevImmunol.v14.i3-4.40; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BERMAN E, 1980, J BIOL CHEM, V255, P4407; BROCKHAUSEN I, 1990, BIOCHEMISTRY-US, V29, P10206, DOI 10.1021/bi00496a008; Bruneau N, 1997, J BIOL CHEM, V272, P27353, DOI 10.1074/jbc.272.43.27353; Burdick MD, 1997, J BIOL CHEM, V272, P24198, DOI 10.1074/jbc.272.39.24198; CARLSON DM, 1968, J BIOL CHEM, V243, P616; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; DEVRIES AL, 1970, J BIOL CHEM, V245, P2901; DO KY, 1994, J BIOL CHEM, V269, P23456; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; GERKEN TA, 1992, BIOCHEMISTRY-US, V31, P639, DOI 10.1021/bi00118a002; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; GERKEN TA, 1987, BIOCHEMISTRY-US, V26, P4689, DOI 10.1021/bi00389a015; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GERKEN TA, 1997, TECHNIQUES GLYCOBIOL, P247; Goletz S, 1997, RAPID COMMUN MASS SP, V11, P1387; Goletz S, 1997, GLYCOBIOLOGY, V7, P881, DOI 10.1093/glycob/7.7.881; Gooley AA, 1997, NATURE, V385, P557, DOI 10.1038/385557a0; GRANOVSKY M, 1994, EUR J BIOCHEM, V221, P1039, DOI 10.1111/j.1432-1033.1994.tb18822.x; GUPTA R, 1989, BIOCHEMISTRY-US, V28, P6114, DOI 10.1021/bi00440a058; HILKENS J, 1988, Cancer Reviews, V11-12, P25; Iwase H, 1996, J BIOCHEM-TOKYO, V120, P393; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Kim YS, 1996, GLYCOCONJUGATE J, V13, P693, DOI 10.1007/BF00702333; KUWANO M, 1991, J CELL SCI, V98, P131; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Muller S, 1997, J BIOL CHEM, V272, P24780, DOI 10.1074/jbc.272.40.24780; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; PISANO A, 1997, TECHNIQUES GLYCOBIOL, P299; PLANTNER JJ, 1975, ANAL BIOCHEM, V65, P153, DOI 10.1016/0003-2697(75)90501-1; REDDY P, 1989, J BIOL CHEM, V264, P17329; REMALEY AT, 1993, J BIOL CHEM, V268, P6785; RHJU TS, 1994, MOL BIOL INT, V34, P943; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SHOGREN RL, 1987, CARBOHYD RES, V160, P317; SHOGREN RL, 1986, BIOPOLYMERS, V25, P1505, DOI 10.1002/bip.360250809; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; TAKAYASU T, 1982, BIOCHEM BIOPH RES CO, V105, P1066, DOI 10.1016/0006-291X(82)91078-6; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; WILLIAMSON G, 1992, EUR J BIOCHEM, V207, P661, DOI 10.1111/j.1432-1033.1992.tb17093.x; WILLIAMSON G, 1992, BIOCHEM J, V282, P423, DOI 10.1042/bj2820423; Yeh JC, 1997, GLYCOBIOLOGY, V7, P241, DOI 10.1093/glycob/7.2.241; Yoshida A, 1997, J BIOL CHEM, V272, P16884, DOI 10.1074/jbc.272.27.16884; ZHANG W, 1994, IMMUNOLOGY, V81, P137	54	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26580	26588		10.1074/jbc.273.41.26580	http://dx.doi.org/10.1074/jbc.273.41.26580			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756896	hybrid			2022-12-25	WOS:000076373300050
J	Max, M; Surya, A; Takahashi, JS; Margolskee, RF; Knox, BE				Max, M; Surya, A; Takahashi, JS; Margolskee, RF; Knox, BE			Light-dependent activation of rod transducin by pineal opsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLTRANSFERASE MESSENGER-RNA; BOVINE PHOTORECEPTOR-MEMBRANES; AVIAN MELATONIN SYNTHESIS; CHICK PINEAL; VISUAL PIGMENTS; PHOTOENDOCRINE TRANSDUCTION; RHODOPSIN GENE; CIRCADIAN OSCILLATOR; MOLECULAR-PROPERTIES; BINDING PROTEIN	The pinneal gland expresses a unique member of the opsin family (P-opsin; Max, M., McKinnon, P, J., Seidenman, K. J, Barrett, R. K., Applebury, M. L., Takahaslai, J. S., and Margolskee, R. F. (1995) Science 267, 1502-1506) that may play a role in circadian entrainment and photo-regulation of melatonin synthesis. To study the function of this protein, are epitope-tagged P-opsin was stably expressed in anembryonic chicken pineal cell line. When incubated with 11-cis-retinal, a light-sensitive pigment was formed with a lambda(max) at 462 +/- 2 nm, P-opsin bleached slowly in the dark (t(1/2) = 2 h) in the presence of 50 mM hydroxylamine. Purified P-opsin in dodecyl maltoside activated rod transducin in a light-dependent manner, catalyzing the exchange of more than 300 mol of GTP gamma S (guanosine 5'-O-(3-thiotriphosphate))/mol of P-opsin. The initial rate for activation (75 mol of GTP gamma S bound/mol of P-opsin/min at 7 mu M) increased with increasing concentrations of transducin. The addition of egg phosphatidylcholine to P-opsin had little effect on the activation kinetics; however, the intrinsic rate of decay in the absence of transducin was accelerated. These results demonstrate that P-opsin is ale efficient catalyst for activation of rod transducin and suggest that the pineal gland may contain a rodlike phototransduction cascade.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA; Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Howard Hughes Medical Institute; Northwestern University	Max, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1677,1425 Madison Ave, New York, NY 10029 USA.	max@msvax.mssm.edu	Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012	Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878; Margolskee, Robert/0000-0002-9572-2887	NEI NIH HHS [EY09409, EY11256, EY08467] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008467, R55EY009409, R01EY009409, R01EY011256] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; Batni S, 1996, J BIOL CHEM, V271, P3179, DOI 10.1074/jbc.271.6.3179; Bernard M, 1997, J NEUROCHEM, V68, P213; Bernard M, 1997, P NATL ACAD SCI USA, V94, P304, DOI 10.1073/pnas.94.1.304; BINKLEY S, 1973, SCIENCE, V181, P273, DOI 10.1126/science.181.4096.273-a; Blackshaw S, 1997, J NEUROSCI, V17, P8083; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; BROWN MF, 1994, CHEM PHYS LIPIDS, V73, P159, DOI 10.1016/0009-3084(94)90180-5; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DEGUCHI T, 1981, NATURE, V290, P706, DOI 10.1038/290706a0; DEGUCHI T, 1979, SCIENCE, V203, P1245, DOI 10.1126/science.424750; DEGUCHI T, 1979, NATURE, V282, P94, DOI 10.1038/282094a0; EBREY TG, 1977, VISION RES, V17, P147, DOI 10.1016/0042-6989(77)90213-9; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FOSTER RG, 1987, CELL TISSUE RES, V248, P161, DOI 10.1007/BF01239977; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hao WS, 1996, BIOCHEMISTRY-US, V35, P6251, DOI 10.1021/bi952420k; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Hisatomi O, 1997, PHOTOCHEM PHOTOBIOL, V66, P792, DOI 10.1111/j.1751-1097.1997.tb03226.x; IMAI H, 1995, BIOCHEMISTRY-US, V34, P10525, DOI 10.1021/bi00033a026; Kawamura S, 1997, VISION RES, V37, P1867, DOI 10.1016/S0042-6989(96)00309-4; Kawamura S, 1996, GENE, V182, P213, DOI 10.1016/S0378-1119(96)00476-3; Kawamura S, 1998, VISION RES, V38, P37, DOI 10.1016/S0042-6989(97)00160-0; KHORANA HG, 1988, P NATL ACAD SCI USA, V85, P7917, DOI 10.1073/pnas.85.21.7917; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KITO Y, 1968, NATURE, V218, P955, DOI 10.1038/218955a0; KNOX BE, 1993, J PHYSIOL-LONDON, V466, P157; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; LOLLEY RN, 1992, NEUROCHEM RES, V17, P81, DOI 10.1007/BF00966868; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; MASUDA H, 1994, TISSUE CELL, V26, P101, DOI 10.1016/0040-8166(94)90086-8; MAX M, 1995, SCIENCE, V267, P1502, DOI 10.1126/science.7878470; NATHANS J, 1992, ANNU REV GENET, V26, P403, DOI 10.1146/annurev.ge.26.120192.002155; NIKAIDO SS, 1989, NEURON, V3, P609, DOI 10.1016/0896-6273(89)90271-7; Okano T, 1997, J MOL EVOL, V44, pS91, DOI 10.1007/PL00000057; Okano T, 1997, MOL BRAIN RES, V50, P190, DOI 10.1016/S0169-328X(97)00184-8; OKANO T, 1989, BIOCHEMISTRY-US, V28, P8848, DOI 10.1021/bi00448a025; OKANO T, 1994, NATURE, V372, P94, DOI 10.1038/372094a0; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PANDEY S, 1994, EXP EYE RES, V58, P605, DOI 10.1006/exer.1994.1055; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROBERTSON LM, 1988, J NEUROSCI, V8, P22; ROBERTSON LM, 1990, THESIS NW U EVANSTON; SHAN D, 1994, BIOCHEMISTRY-US, V33, P13117; SHESHBERADARAN H, 1994, MOL CELL NEUROSCI, V5, P309, DOI 10.1006/mcne.1994.1037; SHICHIDA Y, 1994, BIOCHEMISTRY-US, V33, P9040, DOI 10.1021/bi00197a002; Soni BG, 1997, FEBS LETT, V406, P279, DOI 10.1016/S0014-5793(97)00287-1; Soni BG, 1998, NATURE, V394, P27, DOI 10.1038/27794; Starace DM, 1998, EXP EYE RES, V67, P209, DOI 10.1006/exer.1998.0507; Starace DM, 1997, J BIOL CHEM, V272, P1095, DOI 10.1074/jbc.272.2.1095; SUN JH, 1991, NEUROSCI LETT, V133, P97, DOI 10.1016/0304-3940(91)90066-3; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; VANVEEN T, 1986, P NATL ACAD SCI USA, V83, P912; VANVEEN T, 1986, EXP BIOL, V45, P15; VIGH B, 1981, CELL TISSUE RES, V221, P451, DOI 10.1007/BF00216748; WANG SZ, 1992, BIOCHEMISTRY-US, V31, P3309, DOI 10.1021/bi00128a002; YOKOYAMA R, 1995, INVEST OPHTH VIS SCI, V36, P939; Yokoyama S, 1997, GENE, V202, P89, DOI 10.1016/S0378-1119(97)00458-7; Yoshikawa T, 1998, FEBS LETT, V424, P69, DOI 10.1016/S0014-5793(98)00139-2; YOSHIZAWA T, 1994, BIOPHYS CHEM, V50, P17, DOI 10.1016/0301-4622(94)85016-X; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6; ZATZ M, 1989, BRAIN RES, V477, P14, DOI 10.1016/0006-8993(89)91389-9; ZATZ M, 1988, BRAIN RES, V438, P199, DOI 10.1016/0006-8993(88)91339-X; ZATZ M, 1988, BRAIN RES, V453, P51, DOI 10.1016/0006-8993(88)90142-4	72	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26820	26826		10.1074/jbc.273.41.26820	http://dx.doi.org/10.1074/jbc.273.41.26820			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756926	hybrid			2022-12-25	WOS:000076373300080
J	Mutoh, T; Tokuda, A; Inokuchi, J; Kuriyama, M				Mutoh, T; Tokuda, A; Inokuchi, J; Kuriyama, M			Glucosylceramide synthase inhibitor inhibits the action of nerve growth factor in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; TYROSINE KINASE-ACTIVITY; GANGLIOSIDE GM1; RETINOIC ACID; GLYCOSPHINGOLIPID SYNTHESIS; NEURITE OUTGROWTH; I RECEPTORS; PHOSPHORYLATION; PROTEIN; NEURONS	Previous studies have shown that the ceramide analogue, D-threo-1-phenyl-2-decanoylamin-3-morpholinopropanol (D-PDMP), inhibits glucosylceramide synthase and thus leads to extensive depletion of glycosphingolipids derived from glucosyl ceramide, Our previous studies have shown that cholera toxin B subunit, which specifically binds to the cell surface ganglioside GM1, and GM1 itself can enhance the action of nerve growth factor (NGF) in responsive cells by enhancing the NGF-induced autophosphorylation of the high affinity NGF receptor, Trk, Using D-PDMP, we examined the effects of the inhibition of the biosynthesis of glycosphingolipids on intracellular NGF signaling pathway. D-PDMP was found to inhibit NGF-induced neurite outgrowth of PC12 cells. Moreover, D-PDMP clearly inhibited NGF-induced autophosphorylation of Trk and prevented the activation of phosphatidylinositol 3-kinase and mitogen-activated protein kinase, downstream targets of Trk-initiated intracellular protein kinase cascades. These effects of D-PDMP were abolished by the addition of GM1 but not by the addition of other ganglioside subspecies to the culture medium. Furthermore, the effect of D-PDMP seemed to be specific for the Trk receptor, because intracellular signaling pathway of epidermal growth factor was not affected by D-PDMP, Dimethylsphingosine and the cell-permeable analogue, C-2-ceramide, did not show such a strong inhibitory effect on neurite outgrowth or on the autophosphorylation of Trk, The present results and our previous observations clearly demonstrate that Trk requires endogenous gangliosides, especially GM1, for its normal function in mediating the neurotrophic activity of NGF at least in PC12 cells.	Fukui Med Univ, Fac Med, Dept Internal Med 2, Div Neurol, Fukui 9101198, Japan; Seikagaku Corp, Tokyo Res Inst, Tokyo 207, Japan	University of Fukui; Seikagaku Corporation	Mutoh, T (corresponding author), Fukui Med Univ, Fac Med, Dept Internal Med 2, Div Neurol, 23 Shimoaizuki Matsuoka Cho, Fukui 9101198, Japan.	mutho@fmsrsa.fukui-med.ac.jp	Mutoh, Tatsuro/H-4317-2019; Inokuchi, Jin-ichi/AAW-9964-2020	Mutoh, Tatsuro/0000-0001-7712-8481; Inokuchi, Jin-ichi/0000-0002-0703-5746				CANNELLA MS, 1990, BRAIN RES, V513, P286, DOI 10.1016/0006-8993(90)90469-R; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; CUELLO AC, 1989, P NATL ACAD SCI USA, V86, P2056, DOI 10.1073/pnas.86.6.2056; DAHMS NM, 1983, J NEUROSCI, V3, P806; DOHERTY P, 1985, J NEUROCHEM, V44, P1259, DOI 10.1111/j.1471-4159.1985.tb08752.x; Farooqui T, 1997, J NEUROCHEM, V68, P2348; FELDINGHABERMANN B, 1990, BIOCHEMISTRY-US, V29, P6314, DOI 10.1021/bi00478a028; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FERRARI G, 1983, BRAIN RES, V261, P215; Freischutz B, 1997, J NEUROCHEM, V68, P2070; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; INOKUCHI JI, 1987, J LIPID RES, V28, P565; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KATO H, 1993, J BIOL CHEM, V268, P2655; KATOHSEMBA R, 1984, J NEUROSCI RES, V12, P299, DOI 10.1002/jnr.490120217; Li RX, 1997, J BIOL CHEM, V272, P1349, DOI 10.1074/jbc.272.2.1349; LOEB DM, 1993, J NEUROSCI, V13, P2919; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; Mizutani A, 1996, BIOCHEM BIOPH RES CO, V222, P494, DOI 10.1006/bbrc.1996.0772; MOSKAL JR, 1980, CELL SURFACE GLYCOLI, P241; MUTOH T, 1993, J NEUROCHEM, V60, P1540, DOI 10.1111/j.1471-4159.1993.tb03319.x; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; MUTOH T, 1992, J NEUROCHEM, V58, P175, DOI 10.1111/j.1471-4159.1992.tb09293.x; RABIN SJ, 1995, J NEUROCHEM, V65, P347; RADIN NS, 1993, ADV LIPID RES, V26, P183; ROBSON JA, 1985, NEUROSCIENCE, V14, P1149, DOI 10.1016/0306-4522(85)90284-2; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SVENNERHOLM L, 1989, BIOCHIM BIOPHYS ACTA, V1005, P109, DOI 10.1016/0005-2760(89)90175-6; TOFFANO G, 1983, BRAIN RES, V261, P163, DOI 10.1016/0006-8993(83)91298-2; UEMURA K, 1991, J BIOCHEM-TOKYO, V110, P96, DOI 10.1093/oxfordjournals.jbchem.a123549; WU GS, 1995, J NEUROCHEM, V65, P1419; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; YANO H, 1993, J BIOL CHEM, V268, P25846; ZADOR IZ, 1993, J CLIN INVEST, V91, P797, DOI 10.1172/JCI116299	38	69	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26001	26007		10.1074/jbc.273.40.26001	http://dx.doi.org/10.1074/jbc.273.40.26001			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748278	hybrid			2022-12-25	WOS:000076263100069
J	Sanjay, A; Fu, J; Kreibich, G				Sanjay, A; Fu, J; Kreibich, G			DAD1 is required for the function and the structural integrity of the oligosaccharyltransferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE OLIGOSACCHARYLTRANSFERASE; N-LINKED GLYCOSYLATION; APOPTOTIC CELL-DEATH; RIBOPHORIN-I; MAMMALIAN OLIGOSACCHARYLTRANSFERASE; MOLECULAR-CLONING; RIBOSOME BINDING; PROTEIN; MEMBRANE	Asparagine-linked glycosylation is a highly conserved protein modification reaction that occurs in all eukaryotic organisms. The oligosaccharyltransferase (OST), which has its active site exposed on the luminal face of the endoplasmic reticulum (ER), catalyzes the transfer of preassembled high mannose oligosaccharides onto certain asparagine residues of nascent polypeptides. The mammalian OST complex was initially thought to be composed of three transmembrane proteins, ribophorin I (RI), ribophorin II (RII), and OST48, Most recently, a small integral membrane protein of 12 kDa called DAD1 has been identified as an additional member of the mammalian OST complex. A point mutation in the DAD1 gene is responsible for the temperature-sensitive phenotype of a baby hamster kidney-derived cell line (tsBN7) that undergoes apoptosis at the non-permissive temperature. Furthermore, the mutant protein DAD1 is not detectable in tsBN7 cells 6 h after shifting the cells to the non-permissive temperature. This temperature-sensitive cell Line offered unique opportunities to study the effects caused by the loss of one OST subunit on the other three subunits and also on N-linked glycosylation, Western blot analysis of cell lysates showed that after 6 h at the non-permissive temperature, steady-state levels of the ribophorins were reduced by about 50%, and OST48 was barely detectable. On the other hand, steady-state levels of other components of the rough ER, such as the alpha-subunits of the TRAP (translocon-associated membrane protein) and the Sec61 complex, which are components of the translocation apparatus, are not affected by the instability of the OST subunits, Furthermore, N-glycosylation of the ribophorins was seriously affected 6 h after shifting the cells to the non-permissive temperature, and after 12 h they were synthesized only in the non-glycosylated form. As may be expected, this defect in the OST complex at the non-permissive temperature caused also the underglycosylation of a secretory glycoprotein, We concluded that degradation of DAD1 at the non-permissive temperature not only affects the stability of OST48 and the ribophorins but also results in the functional inactivation of the OST complex.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	New York University	Kreibich, G (corresponding author), NYU, Sch Med, Dept Cell Biol, 550 1st Ave, New York, NY 10016 USA.	kreibg01@mcrcr6.med.nyu.edu						BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; Fu J, 1997, J BIOL CHEM, V272, P29687, DOI 10.1074/jbc.272.47.29687; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; IVESSA NE, 1992, J CELL BIOL, V117, P949, DOI 10.1083/jcb.117.5.949; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; KREIBICH G, 1978, J CELL BIOL, V77, P488, DOI 10.1083/jcb.77.2.488; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; KUMAR V, 1994, J BIOL CHEM, V269, P13451; LEE AS, 1992, CURR OPIN CELL BIOL, V13, P877; Makishima T, 1997, GENES CELLS, V2, P129, DOI 10.1046/j.1365-2443.1997.1070303.x; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; PEREZSALA D, 1995, J CELL PHYSIOL, V163, P523, DOI 10.1002/jcp.1041630312; PIROZZI G, 1991, BIOCHEM BIOPH RES CO, V176, P1482, DOI 10.1016/0006-291X(91)90454-F; RAPOPORT T, 1966, ANNU REV BIOCHEM, V65, P271; Reiss G, 1997, EMBO J, V16, P1164, DOI 10.1093/emboj/16.6.1164; ROSENFELD MG, 1984, J CELL BIOL, V99, P1076, DOI 10.1083/jcb.99.3.1076; SABATINI DD, 1995, METABOLIC BASIS INHE, P459; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335; [No title captured]	37	45	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26094	26099		10.1074/jbc.273.40.26094	http://dx.doi.org/10.1074/jbc.273.40.26094			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748289	hybrid			2022-12-25	WOS:000076263100080
J	Xue, BZ; Moustaid-Moussa, N; Wilkison, WO; Zemel, MB				Xue, BZ; Moustaid-Moussa, N; Wilkison, WO; Zemel, MB			The agouti gene product inhibits lipolysis in human adipocytes via a Ca2+-dependent mechanism	FASEB JOURNAL			English	Article						calcium; agouti polypeptide; MSH; melanocortin receptor	MELANOCYTE-STIMULATING-HORMONE; CYTOSOLIC FREE CALCIUM; RAT ADIPOCYTES; INSULIN RESISTANCE; OBESITY; PROTEIN; RECEPTOR; MICE; EXPRESSION	Overexpression of the murine agouti gene results in obesity, The human homologue of agouti is expressed primarily in human adipocytes, and we have shown recombinant agouti protein to increase adipocyte intracellular Ca2+([Ca2+](i)) and thereby stimulate Lipogenesis. However, since recent data demonstrate that increasing adipocyte [Ca2+](i) may also inhibit Lipolysis, we have investigated the role of agouti-induced [Ca2+](i) increases in regulating lipolysis in human adipocytes, Short-term (1 h) exposure to recombinant agouti (100 nM) protein had no effect on basal lipolysis, although longer term treatment (24 h) caused a 60% decrease in basal lipolysis (P<0.0001), Short-term agouti treatment totally inhibited ACTH-induced lipolysis (P<0.05), Since melanocortin receptors (MCR) are involved in some actions of agouti, we next determined whether agouti's antilipolytic effect is exerted through competitive antagonism of the ACTH receptor (MCR-2), Forskolin (1 mu M), an adenylate cyclase activator, induced a 48% increase in Lipolysis in human adipocytes (P<0.05); this effect was reversed by 100 nM agouti (P<005), demonstrating that the antilipolytic effect of agouti is distal to the ACTH receptor, To determine the role of [Ca2+]i in the antilipolytic effect of agouti, human adipocytes were treated with KCI or arginine vasopressin to stimulate voltage- and receptor-stimulated Ca2+ influx, respectively, Both agents caused inhibition of forskolin-induced lipolysis (P<0.005), Furthermore, agouti's antilipolytic effect was also blocked by the Ca2+ channel blocker nitrendipine. These data demonstrate that agouti exerts a potent antilipolytic effect in human adipocytes via a Ca2+-dependent mechanism. This effect, combined with agouti-induced lipogenesis, represents a coordinate control of adipocyte lipid metabolism that may contribute to an agouti-induced obesity syndrome.	Univ Tennessee, Dept Nutr, Knoxville, TN 37996 USA; Univ Tennessee, Dept Med, Knoxville, TN 37996 USA; ZenBio Inc, Res Triangle Pk, NC 27709 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Health Science Center	Zemel, MB (corresponding author), Univ Tennessee, Dept Nutr, 1215 W Cumberland Ave,Rm 229, Knoxville, TN 37996 USA.	mzemel@utk.edu	Moustaid-Moussa, Naima/B-9067-2014	Moustaid-Moussa, Naima/0000-0002-7508-8030; Zemel, Michael/0000-0003-4104-5750				BOOBIS LH, 1983, CLIN CHIM ACTA, V132, P173, DOI 10.1016/0009-8981(83)90245-0; Boston BA, 1997, SCIENCE, V278, P1641, DOI 10.1126/science.278.5343.1641; Boston BA, 1996, ENDOCRINOLOGY, V137, P2043, DOI 10.1210/en.137.5.2043; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; BYYNY RL, 1992, AM J HYPERTENS, V5, P459, DOI 10.1093/ajh/5.7.459; Claycombe K. J., 1997, FASEB Journal, V11, pA352; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; GALBRAITH DB, 1964, J EXP ZOOL, V155, P71, DOI 10.1002/jez.1401550106; HUNT G, 1995, J ENDOCRINOL, V147, pR1, DOI 10.1677/joe.0.147R001; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; IZAWA T, 1994, AM J PHYSIOL, V266, pE418, DOI 10.1152/ajpendo.1994.266.3.E418; JACKSON IJ, 1991, BIOESSAYS, V13, P439, DOI 10.1002/bies.950130903; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; KATOCS AS, 1974, J BIOL CHEM, V249, P2000; Kim JH, 1997, AM J PHYSIOL-ENDOC M, V272, pE379, DOI 10.1152/ajpendo.1997.272.3.E379; Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558; KLEBIG ML, 1994, MOL GENETIC ASPECTS; KWON HY, 1994, P NATL ACAD SCI USA, V91, P9760, DOI 10.1073/pnas.91.21.9760; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Moustaid N, 1996, J NUTR, V126, P865, DOI 10.1093/jn/126.4.865; OELOFSEN W, 1983, ARCH BIOCHEM BIOPHYS, V225, P414, DOI 10.1016/0003-9861(83)90048-6; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; Silvers W. K., 1979, COAT COLORS MICE, P6; SILVERS WK, 1958, J EXP ZOOL, V137, P189, DOI 10.1002/jez.1401370110; STEELEY RJ, 1997, NATURE, V390, P349; Tebar F, 1996, ENDOCRINOLOGY, V137, P4181, DOI 10.1210/en.137.10.4181; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274; YEN T T T, 1970, Hormone and Metabolic Research, V2, P200; YEN TT, 1984, INT J OBESITY, V8, P65; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; YEN TT, 1983, LIFE SCI, V32, P1515, DOI 10.1016/0024-3205(83)90918-9; ZEMEL MB, 1998, IN PRESS INT J OBESI; ZEMEL MB, 1995, OBES RES, V3, pS338	36	130	150	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1391	1396		10.1096/fasebj.12.13.1391	http://dx.doi.org/10.1096/fasebj.12.13.1391			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761782				2022-12-25	WOS:000076402000014
J	Ma, L; Broomfield, S; Lavery, C; Lin, SL; Xiao, W; Bacchetti, S				Ma, L; Broomfield, S; Lavery, C; Lin, SL; Xiao, W; Bacchetti, S			Up-regulation of CIR1/CROC1 expression upon cell immortalization and in tumor-derived human cell lines	ONCOGENE			English	Article						CIR1; CROC1; UEV-1; immortalization; tumorigenesis differential display	COMPARATIVE GENOMIC HYBRIDIZATION; BREAST-CANCER; HUMAN TELOMERASE; SV40-MEDIATED IMMORTALIZATION; REPLICATIVE SENESCENCE; DIFFERENTIAL DISPLAY; HUMAN FIBROBLASTS; GENE-EXPRESSION; T-ANTIGEN; AMPLIFICATION	Acquisition of the immortal phenotype by tumor cells represents an essential and potentially rate-limiting step in tumorigenesis, To identify changes in gene expression that are associated with the early stages of cell immortalization, we compared genetically matched pairs of pre-immortal and immortal human cell clones by mRNA differential display. Two transcripts, denoted CIR1 and CIR2, were identified which were up-regulated in immortal cells. Sequence analysis revealed CIR1 to be identical to the recently cloned CROC1/UEV-1 gene, whereas CIR2 corresponds to an as yet uncharacterized 1.2 kb mRNA, A 5-6-fold elevation in CIR1/CROC1 expression and a 2-3-fold elevation in CIR2 expression were observed in SV40-transformed human enbryonic kidney cells immediately following proliferative crisis, suggesting a potential role for these genes in immortalization, Expression of CIR1/CROC1 was found to be elevated also in a variety of immortal human tumor-derived cell lines, as compared to their normal tissue counterparts. These results are compatible with induction of CIR1/CROC1 being an early event in the acquisition of immortality and with a role for this gene in the immortal phenotype of tumor cells.	McMaster Univ, Dept Pathol, Canc Res Grp, Hamilton, ON L8N 3Z5, Canada; Univ Saskatchewan, Dept Microbiol, Saskatoon, SK S7N 5E5, Canada; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA	McMaster University; University of Saskatchewan; Rutgers State University New Brunswick; Rutgers State University Medical Center	Broomfield, S (corresponding author), McMaster Univ, Dept Pathol, Canc Res Grp, HSC-4H30,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			Xiao, Wei/0000-0001-7568-0782				Avilion AA, 1996, CANCER RES, V56, P645; Bacchetti S, 1996, CANCER SURV, V28, P197; Brinkmann U, 1996, GENOME RES, V6, P187, DOI 10.1101/gr.6.3.187; BROOMFIELD S, 1998, IN PRESS P NATL ACAD; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; EDWARDS PAW, 1993, CANCER SURV, V16, P79; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Harley CB, 1997, CANCER SURV, V29, P263; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; IMAI S, 1992, BIOCHEM BIOPH RES CO, V189, P148, DOI 10.1016/0006-291X(92)91537-Z; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; Pardinas J, 1997, J CELL PHYSIOL, V171, P325, DOI 10.1002/(SICI)1097-4652(199706)171:3<325::AID-JCP11>3.0.CO;2-9; Rothofsky ML, 1997, GENE, V195, P141, DOI 10.1016/S0378-1119(97)00097-8; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; SASAKI M, 1994, CANCER RES, V54, P6090; SATOH Y, 1994, MUTAT RES, V316, P25, DOI 10.1016/0921-8734(94)90005-1; Savelieva E, 1997, ONCOGENE, V14, P551, DOI 10.1038/sj.onc.1200868; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163	34	29	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1321	1326		10.1038/sj.onc.1202058	http://dx.doi.org/10.1038/sj.onc.1202058			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771976				2022-12-25	WOS:000075803300015
J	Dhulipala, PDK; Lee, L; Rao, VN; Reddy, ESP				Dhulipala, PDK; Lee, L; Rao, VN; Reddy, ESP			Fli-1b is generated by usage of differential splicing and alternative promoter	ONCOGENE			English	Article						Fli-1; Fli-1b; alternative splicing; alternative promoter; onco-protein; translocation; transcriptional activator	PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; ETS-RELATED PROTEIN; DNA-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; T-CELL; C-ETS; C-ETS-1 PROTOONCOGENE; EWING SARCOMA	The proto-oncogene Fli-1, a member of Ets family is rearranged or activated through proviral integration in erythroleukemias, induced by Friends' Murine Leukemia Virus. The DNA binding domain (ETS domain) of Fli-1 is fused to the RNA binding domain of EWS by t(11q24:22q12) chromosomal translocation in Ewing's sarcoma and primitive neuroectodermal tumors. Screening of human cDNA libraries has identified two different 5'-termini and alternatively spliced forms of the human Fli-1 gene (Fli-1b), suggesting the possible existence of two independent promoters. The genomic sequence adjacent to the alternate exon of human Fli-1b gene shows functional promoter activity when cloned in promoter-less CAT expression vector and transfected into QT-6 cells. The transcription initiation (CAP) site and minimum promoter region necessary for function were localized. The 5'-flanking regions of human Fli-1b and mouse Fli-1 show 80% homology suggesting conserved promoter regulatory elements. The Fli-1b 5'-flanking sequence lacks canonical TATA or CCAAT boxes but contains a partially conserved TATA-like sequence at position 242. Several transcription factor binding sequences like ATF/CREB, E2A-PBX1, EBP, PEA-3, ETS-2, Sp-1, c-Myc, TBP, GATA-1 and Oct-3 were conserved in the promoter sequence. Functional promoter assays revealed that Fli-1b promoter shows very strong transcriptional activation compared to Fli-1 promoter. We also showed that variant Fli-1b has transcriptional activation properties similar to those of Fli-1. Fli-1b and Fli-1 show differential expression in various hematopoietic cell lines. This differential expression and promoter activities of Fli-1 and Fli-1b suggests that several mechanisms are involved in Fli-1 gene regulation which are mediated by many transcription factors.	Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Philadelphia, PA 19102 USA; SAIC, Frederick, MD 21702 USA	Drexel University; Science Applications International Corporation (SAIC); SAIC-Frederick	Reddy, ESP (corresponding author), Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Broad & Vine St, Philadelphia, PA 19102 USA.				NATIONAL CANCER INSTITUTE [P01CA051083, R01CA058642, R01CA057322] Funding Source: NIH RePORTER; NCI NIH HHS [CA57322, CA 58642, CA 51083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Barbeau B, 1996, BBA-GENE STRUCT EXPR, V1307, P220, DOI 10.1016/0167-4781(96)00060-7; BAUD V, 1991, GENOMICS, V11, P223, DOI 10.1016/0888-7543(91)90124-W; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BROWN TA, 1992, GENE DEV, V6, P2500; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HIPSKIND RA, 1991, NATURE, V354, P53534; HROMAS R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P155, DOI 10.1016/0167-4781(93)90283-J; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JEON IS, 1995, ONCOGENE, V10, P1229; JORCYK CL, 1991, ONCOGENE, V6, P523; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MELTON DA, 1987, METHOD ENZYMOL, V152, P288; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OHNO T, 1993, CANCER RES, V53, P5859; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRIBYL LS, 1988, ONCOGENE, V6, P1175; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; SELLERI L, 1991, P NATL ACAD SCI USA, V88, P887, DOI 10.1073/pnas.88.3.887; SETH A, 1993, ONCOGENE, V8, P1783; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YE K, 1993, P NATL ACAD SCI USA, V90, P2295, DOI 10.1073/pnas.90.6.2295; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; YUNIS JJ, 1989, GENOMICS, V5, P84, DOI 10.1016/0888-7543(89)90090-6	62	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1149	1157		10.1038/sj.onc.1202030	http://dx.doi.org/10.1038/sj.onc.1202030			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764825				2022-12-25	WOS:000075598400010
J	Seki, T; Seki, M; Onodera, R; Katada, T; Enomoto, T				Seki, T; Seki, M; Onodera, R; Katada, T; Enomoto, T			Cloning of cDNA encoding a novel mouse DNA topoisomerase III (Topo III beta) possessing negatively supercoiled DNA relaxing activity, whose message is highly expressed in the testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; REVERSE GYRASE; SYNDROME GENE; INTERACTS; PRODUCT; HOMOLOG; RECQ; SGS1	We cloned cDNA encoding a novel mouse homologue of DNA topoisomerase III (mTOP3 beta). The nucleotide sequence contains an open reading frame of 863 amino acids, and the deduced molecular mass of the coded protein is 96.9 kDa. The overall sequence of mTOP3 beta has a 48 and 36% identity with mouse TOP3 alpha at the nucleotide and amino acid level, respectively. DNA topoisomerase III beta was expressed using a baculovirus expression system and purified. The purified DNA topoisomerase mp had activity to relax negatively supercoiled DNA. Relaxation of supercoiled DNA was partial at 37 degrees C and complete relaxation was observed at higher temperatures. mTOP3 beta mRNA was strongly expressed in the testis and relatively strongly in the brain. The levels of TOP3 beta mRNA in the testis increased slightly 14 days and considerably 17 days after birth, when the cells in the pachytene phase bean to appear and increase.	Tohoku Univ, Fac Pharmaceut Sci, Dept Mol Cell Biol, Aoba Ku, Sendai, Miyagi 9808578, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo 1138654, Japan	Tohoku University; University of Tokyo	Enomoto, T (corresponding author), Tohoku Univ, Fac Pharmaceut Sci, Dept Mol Cell Biol, Aoba Ku, Sendai, Miyagi 9808578, Japan.							Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; Kawasaki K, 1997, GENOME RES, V7, P250, DOI 10.1101/gr.7.3.250; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIM RA, 1992, J BIOL CHEM, V267, P17178; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; Seki T, 1998, BBA-GENE STRUCT EXPR, V1396, P127, DOI 10.1016/S0167-4781(97)00192-9; Seki T, 1998, BBA-GENE STRUCT EXPR, V1398, P377, DOI 10.1016/S0167-4781(98)00066-9; TSEDINH YC, 1986, J MOL BIOL, V191, P321, DOI 10.1016/0022-2836(86)90129-4; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	19	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28553	28556		10.1074/jbc.273.44.28553	http://dx.doi.org/10.1074/jbc.273.44.28553			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786843	hybrid			2022-12-25	WOS:000076691800004
J	Amann, KJ; Renley, BA; Ervasti, JM				Amann, KJ; Renley, BA; Ervasti, JM			A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; GLYCOPROTEIN COMPLEX; ALPHA-ACTININ; IN-VITRO; UTROPHIN; EXPRESSION; PROTEIN; MODEL; MICE; IDENTIFICATION	The dystrophin rod domain is composed of 24 spectrin-like repeats and was thought to act mainly as a flexible spacer between the amino-terminal actin binding domain and carboxyl-terminal membrane-associated domains, We previously demonstrated that a fragment of the dystrophin rod domain also binds F-actin, However, the nature and extent of rod domain association with F-actin is presently unclear. To begin addressing these questions, we characterized two recombinant proteins representing adjacent regions of the dystrophin rod, DYS1416 (amino acids 1416-1880) bound F-actin with a K-d of 14.2 +/- 5.2 mu M and a stoichiometry of 1 mol:mol of actin, However, DYS1030 (amino acids 1030-1494) failed to bind F-actin, suggesting that not all rod domain repeats are capable of binding F-actin, Interestingly, DYS1416 corresponds to a unique region of the dystrophin rod rich in basic amino acids, whereas DYS1030 is composed mainly of acidic repeats, This observation suggested that DYS1416 may interact with acidic actin filaments through an electrostatic interaction. Supporting this hypothesis, actin binding by DYS1416 was dramatically inhibited by increasing ionic strength. We suggest that electrostatic interactions between basic spectrin-like repeats and actin filaments may contribute to the actin binding activity of other members of the actin cross-linking protein family.	Univ Wisconsin, Dept Physiol, Serv Mem Inst 127, Sch Med, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Grad Program Cellular & Mol Biol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ervasti, JM (corresponding author), Univ Wisconsin, Dept Physiol, Serv Mem Inst 127, Sch Med, 1300 Univ Ave, Madison, WI 53706 USA.	ervasti@facstaff.wisc.edu	Ervasti, James/AAZ-4786-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042423, K02AR001985] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42423, AR01985] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; Blake DJ, 1996, BRAIN PATHOL, V6, P37, DOI 10.1111/j.1750-3639.1996.tb00781.x; BREMER A, 1992, Current Opinion in Cell Biology, V4, P20, DOI 10.1016/0955-0674(92)90054-G; Calvert R, 1996, BIOPHYS J, V71, P1605, DOI 10.1016/S0006-3495(96)79363-3; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Chan YM, 1997, FEBS LETT, V410, P153, DOI 10.1016/S0014-5793(97)00454-7; CORRADO K, 1994, FEBS LETT, V344, P255, DOI 10.1016/0014-5793(94)00397-1; CROSS RA, 1990, FEBS LETT, V262, P87, DOI 10.1016/0014-5793(90)80160-K; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Deconinck N, 1997, NAT MED, V3, P1216, DOI 10.1038/nm1197-1216; DeWolf C, 1997, BIOPHYS J, V72, P2599, DOI 10.1016/S0006-3495(97)78903-3; Durbeej M, 1997, DEV BIOL, V181, P156, DOI 10.1006/dbio.1996.8430; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; KAHANA E, 1994, J MOL BIOL, V235, P1271, DOI 10.1006/jmbi.1994.1080; Kahana E, 1997, CELL MOTIL CYTOSKEL, V36, P246; KOENIG M, 1990, J BIOL CHEM, V265, P4560; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KUHLMAN PA, 1992, FEBS LETT, V304, P201, DOI 10.1016/0014-5793(92)80619-R; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; Li XL, 1996, J BIOL CHEM, V271, P15695, DOI 10.1074/jbc.271.26.15695; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; PACE CN, 1989, PROTEIN STRUCTURE PR, P253; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; RENLEY BA, 1998, IN PRESS CELL MOTIL; ROSENBERG S, 1981, J BIOL CHEM, V256, P2986; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Rybakova IN, 1997, J BIOL CHEM, V272, P28771, DOI 10.1074/jbc.272.45.28771; Tang JX, 1997, EUR J BIOCHEM, V247, P432, DOI 10.1111/j.1432-1033.1997.00432.x; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; Winder S. J., 1997, P27; WINDER SJ, 1995, J CELL SCI, V108, P63; WINDER SJ, 1995, FEBS LETT, V369, P27, DOI 10.1016/0014-5793(95)00398-S; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097	42	126	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28419	28423		10.1074/jbc.273.43.28419	http://dx.doi.org/10.1074/jbc.273.43.28419			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774469	hybrid			2022-12-25	WOS:000076549800089
J	Berestetskaya, YV; Faure, MP; Ichijo, H; Voyno-Yasenetskaya, TA				Berestetskaya, YV; Faure, MP; Ichijo, H; Voyno-Yasenetskaya, TA			Regulation of apoptosis by alpha-subunits of G12 and G13 proteins via apoptosis signal-regulating kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; CELL-DEATH; COS-7 CELLS; BCL-2; ACTIVATION; PATHWAYS; RAS; MITOGEN; INDUCTION; PHOSPHORYLATION	Many growth factors and G protein-coupled receptors activate mitogen-activated protein (MAP) kinase pathways. The MAP kinase pathways are involved in the regulation of the ubiquitous process of apoptosis or programmed cell death. Two related MAP kinase kinase kinases, apoptosis-signal regulating kinase 1 (ASK1) and MAP kinase kinase kinase 1 (MEKK1), stimulate c-Jun kinase (JNK) activity and induce apoptosis, Transient transfection of dominant negative and constitutively active components of the JNK pathway in COS-7 cells showed that two G protein subunits, G alpha 12 and G alpha 13, stimulated the JNK pathway in a ASK1- and MEKK1-dependent manner. Moreover, the mutationally activated G alpha 12 and G alpha 13 stimulated the kinase activity of ASK1. Both G alpha 12 and G alpha 13 employ small GTPases, Cdc42 and Rac1, to transduce signal to MEKK1 and, subsequently, to JNK, However, activation of JNK by Cdc42 and Rac1 did not require ASK1. Additionally, ASK1 and MEKK1 are involved in the apoptosis induced by G alpha 12 and G alpha 13, We conclude that G alpha 12 and G alpha 13 can induce apoptosis using two separate MAP kinase pathways; one is initiated by ASK1, and the other is initiated by MEKK1, Furthermore, Bcl-2 can block apoptosis induced by G alpha 12 and G alpha 13. This death-sparing function was associated with increased Bcl-2 phosphorylation, suggesting that phosphorylation of Bcl-2 may be a critical mechanism protecting cells from G alpha 12- and G alpha 13-induced apoptosis.	Univ Illinois, Coll Med, Dept Pharmacol MC 868, Chicago, IL 60612 USA; Inst Canc, Dept Oral Pathol, Tokyo 113, Japan; Sugen Inc, Redwood City, CA 94063 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Voyno-Yasenetskaya, TA (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol MC 868, 835 S Wollcott Ave, Chicago, IL 60612 USA.	tvy@uic.edu		Ichijo, Hidenori/0000-0002-5005-6438				Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Apasov SG, 1997, J IMMUNOL, V158, P5095; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; FAURE M, 1994, J BIOL CHEM, V269, P7851; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JIMENEZ B, 1995, ONCOGENE, V10, P811; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OLTAVI ZN, 1993, CELL, V74, P609; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sharma K, 1996, MOL ENDOCRINOL, V10, P1688, DOI 10.1210/me.10.12.1688; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Ucker D S, 1997, Adv Pharmacol, V41, P179, DOI 10.1016/S1054-3589(08)61059-5; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WANG YS, 1993, ONCOGENE, V8, P3427; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; YAN GM, 1995, MOL PHARMACOL, V47, P248; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	48	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27816	27823		10.1074/jbc.273.43.27816	http://dx.doi.org/10.1074/jbc.273.43.27816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774391	hybrid			2022-12-25	WOS:000076549800011
J	Chan, CHT; Wang, JS; French, RR; Glennie, MJ				Chan, CHT; Wang, JS; French, RR; Glennie, MJ			Internalization of the lymphocytic surface protein CD22 is controlled by a novel membrane proximal cytoplasmic motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL ACTIVATION; DENSITY-LIPOPROTEIN RECEPTOR; ANTIGEN RECEPTOR; IMMUNOGLOBULIN SUPERFAMILY; CD22-DEFICIENT MICE; MOLECULE CD22; AMINO-ACIDS; TYROSINE; SIGNAL; ENDOCYTOSIS	CD22 is a key receptor on B-lymphocytes that modulates signaling during antigenic stimulation. We have defined a novel cytoplasmic motif in human CD22 that controls its unusually rapid turnover at the plasma membrane. Chimeric and mutated CD22 alpha cDNA vectors were constructed and stably transfected in CD22-negative Jurkat T-lymphocytic cells. Two assays were employed to measure CD22 alpha internalization: first, cytoplasmic uptake of radioiodinated anti-CD22 monoclonal antibody; and second, lethal targeting of a toxin, saporin, into cells via CD22 using bispecific F(ab')(2) ([anti-CD22 x anti-saporin]) antibody, Results showed that CD22 alpha lacking a cytoplasmic tail was not internalized and that replacement of the cytoplasmic tail of CD19 with that of CD22 alpha resulted in a chimeric molecule that behaved like CD22 alpha and internalized rapidly. Step-wise deletion of the cytoplasmic tail of CD22 alpha located the internalization motif to a polar region of 11 residues (QRRWKRTQSQQ) proximal to the plasma membrane, a part of the molecule predicted to form a coil or turn structure; Interestingly, additional CD22 mutants showed that the two glutamine residues sandwiching the serine are critical to internalization but that the serine itself is not.	Southampton Gen Hosp, Tenovus Canc Lab, Lymphoma Res Unit, Southampton SO16 6YD, Hants, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Southampton; MRC Laboratory Molecular Biology	Glennie, MJ (corresponding author), Southampton Gen Hosp, Tenovus Canc Lab, Lymphoma Res Unit, Tremona Rd, Southampton SO16 6YD, Hants, England.							AMLOT PL, 1993, BLOOD, V82, P2624; ANDREASON GL, 1988, BIOTECHNIQUES, V6, P650; BONARDI MA, 1993, CANCER RES, V53, P3015; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; ELLIS JH, 1995, J IMMUNOL, V155, P925; FRENCH RR, 1991, CANCER RES, V51, P2353; French RR, 1996, LEUKEMIA RES, V20, P607, DOI 10.1016/0145-2126(96)00007-0; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GHETIE MA, 1988, CANCER RES, V48, P2610; GLENNIE MJ, 1988, J IMMUNOL, V141, P3662; GLENNIE MJ, 1993, TUMOUR IMMUNOBIOLOGY, P225; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAW CL, 1993, J IMMUNOL, V151, P175; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; MASON DY, 1987, BLOOD, V69, P836; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; NAIM HY, 1994, J BIOL CHEM, V269, P3928; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PELCHENMATTEWS A, 1991, J EXP MED, V173, P578; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; SCHWARTZALBIEZ R, 1991, INT IMMUNOL, V3, P623, DOI 10.1093/intimm/3.7.623; SHAN DM, 1995, J IMMUNOL, V154, P4466; Sherbina NV, 1996, J IMMUNOL, V157, P4390; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; TEDDER TF, 1989, J IMMUNOL, V143, P712; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Vely F, 1997, J IMMUNOL, V159, P2075; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	43	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27809	27815		10.1074/jbc.273.43.27809	http://dx.doi.org/10.1074/jbc.273.43.27809			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774390	hybrid			2022-12-25	WOS:000076549800010
J	Li, N; Seetharam, B				Li, N; Seetharam, B			A 69-base pair fragment derived from human transcobalamin II promoter is sufficient for high bidirectional activity in the absence of a TATA box and an initiator element in transfected cells - Role of an E box in transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; ADENOVIRUS MAJOR LATE; RNA POLYMERASE-II; FACTOR USF; DNA-BINDING; SYNTHASE PROMOTER; MAMMALIAN-CELLS; MULTIPLE FORMS; PROTEIN; GENE	A 69-base pair (bp) (-581/-513) fragment derived from human transcobalamin II distal promoter constructed upstream of a chloramphenicol acetyltransferase reporter gene demonstrated high bidirectional promoter activity in transfected epithelial Caco-2 cells. DNase I footprinting, gel mobility shift, supershift, and mutagenesis studies with the 69-bp fragment demonstrated that a GC box (-568/-559) and an E box (-523/-528), which interacted with Sp1/Sp3 and USF1/USF2 (where USF is upstream stimulatory factor), respectively, were required for the full transcriptional activity of this fragment. Whereas mutations in the GC box reduced the promoter activity by 50%, mutations in the E box alone or in both the E box and GC box resulted in 90% loss of transcriptional activity. The essential role of the E box in the bidirectional promoter activity was further demonstrated by transient transfection in Caco-2, K-562, and HeLa cells using a 29-bp (-541/-513) fragment that contained only the E box. Based on these results we suggest that 1) the E box is essential for both the GC box-dependent and -independent promoter activity of the 69-bp fragment, 2) cooperative interactions between Sp1/Sp3 and USFs are required for the full activation of the BS-bp promoter activity, and 3) the single E box is able to mediate bidirectional transcription in transfected cells in the absence of an obvious TATA box or a known initiator element.	Med Coll Wisconsin, Dept Med, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Vet Adm Med Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Seetharam, B (corresponding author), Med Coll Wisconsin, MACC Fund Ctr, Rm 6061,8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	seethara@post.itsmcw.edu			NIDDK NIH HHS [DK-50052] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050052] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; Bradford MM, 1976, ANAL BIOCHEM, V112, P195; BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; COOPER BA, 1987, ANNU REV NUTR, V7, P291, DOI 10.1146/annurev.nu.07.070187.001451; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Ebara S, 1997, BIOCHEM BIOPH RES CO, V240, P136, DOI 10.1006/bbrc.1997.7618; FABER PW, 1993, J BIOL CHEM, V268, P9296; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALLE JP, 1995, J BIOL CHEM, V270, P21307, DOI 10.1074/jbc.270.36.21307; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Ikeda K, 1997, BIOCHEM BIOPH RES CO, V236, P765, DOI 10.1006/bbrc.1997.7046; JACOB E, 1980, PHYSIOL REV, V60, P918, DOI 10.1152/physrev.1980.60.3.918; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LI N, 1995, BIOCHEM BIOPH RES CO, V208, P756, DOI 10.1006/bbrc.1995.1402; Li N, 1998, J BIOL CHEM, V273, P16104, DOI 10.1074/jbc.273.26.16104; LIAO WC, 1994, GENE, V146, P183, DOI 10.1016/0378-1119(94)90291-7; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; VANDERZEE CA, 1994, J BIOL CHEM, V269, P6972; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	51	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28170	28177		10.1074/jbc.273.43.28170	http://dx.doi.org/10.1074/jbc.273.43.28170			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774437	hybrid			2022-12-25	WOS:000076549800057
J	Wong, BR; Josien, R; Lee, SY; Vologodskaia, M; Steinman, RM; Choi, YW				Wong, BR; Josien, R; Lee, SY; Vologodskaia, M; Steinman, RM; Choi, YW			The TRAF family of signal transducers mediates NF-kappa B activation by the TRANCE receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-RECEPTOR; TERMINAL KINASE; TNF RECEPTOR; CONTAINS 2; T-CELLS; CD40; INDUCTION; APOPTOSIS; PROTEINS; LIGAND	Tumor necrosis factor (TNF)-related activation-induced cytokine (TRANCE), a member of the TNF family expressed on activated T-cells, bone marrow stromal cells, and osteoblasts, regulates the function of dendritic cells (DC) and osteoclasts. The TRANCE receptor (TRANCE-R), recently identified as receptor activator of NF-kappa beta (RANK), activates NF-kappa B, a transcription factor critical in the differentiation and activation of those cells. In this report we identify the TNF receptor-associated factor (TRAF) family of signal transducers as important components of TRANCE-R-mediated NF-kappa B activation. Coimmunoprecipitation experiments suggested potential interactions between the cytoplasmic tail of TRANCE-R with TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6. Dominant negative forms of TRAF2, TRAF5, and TRAF6 and an endogenous inhibitor of TRAF2, TRAF-interacting protein (TRIP), substantially inhibited TRANCE-R-mediated NF-kappa B activation, suggesting a role of TRAFs in regulating DC and osteoclast function. Overexpression of combinations of TRAF dominant negative proteins revealed competition between TRAF proteins for the TRANCE-R and the possibility of a TRAF-independent NF-kappa B pathway. Analysis of TRANCE-R deletion mutants suggested that the TRAF2 and TRAF5 interaction sites were restricted to the C-terminal 93 amino acids (C-region). TRAF6 also complexed to the C-region in addition to several regions N-terminal to the TRAF2 and TRAF5 association sites. Furthermore, transfection experiments with TRANCE-R deletion mutants revealed that multiple regions of the TRANCE-R can mediate NF-kappa B activation.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Immunol Lab, New York, NY 10021 USA; Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA; Hallym Univ, Dept Pathol, Chunchon 200702, Kangwon Do, South Korea	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Rockefeller University; Hallym University	Choi, YW (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.	choi@rockvax.rcckefeller.edu	Josien, Regis/L-7468-2015; Steinman, Ralph/F-7729-2012; Josien, Regis/U-4405-2019	Josien, Regis/0000-0001-7900-7413; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013013, R01AI013013, R01AI041082] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41082, AI13013] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Horie R, 1998, INT IMMUNOL, V10, P203, DOI 10.1093/intimm/10.2.203; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697; Oyama T, 1998, J IMMUNOL, V160, P1224; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Speiser DE, 1997, J EXP MED, V185, P1777, DOI 10.1084/jem.185.10.1777; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	36	395	426	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28355	28359		10.1074/jbc.273.43.28355	http://dx.doi.org/10.1074/jbc.273.43.28355			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774460	Green Published, hybrid			2022-12-25	WOS:000076549800080
J	Sakamoto, Y; Taguchi, T; Tano, Y; Ogawa, T; Leppanen, A; Kinnunen, M; Aitio, O; Parmanne, P; Renkonen, O; Taniguchi, N				Sakamoto, Y; Taguchi, T; Tano, Y; Ogawa, T; Leppanen, A; Kinnunen, M; Aitio, O; Parmanne, P; Renkonen, O; Taniguchi, N			Purification and characterization of UDP-GlcNAc : Gal beta 1-4-GlcNAc beta 1-3*Gal beta 1-4Glc (NAc)-R(GlcNAc to *Gal) beta 1, 6N-acetylglucosaminyltransferase from hog small intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP-I; UDP-N-ACETYLGLUCOSAMINE; BETA-1,6-GLCNAC TRANSFERASE; STRUCTURAL REQUIREMENTS; CARBOHYDRATE STRUCTURE; CELL-DIFFERENTIATION; BACTEROIDES-FRAGILIS; GASTRIC-MUCOSA; MOUSE KIDNEY; BIOSYNTHESIS	A beta 1,6N-acetylglucosaminyltransferase (beta 1-6GnT) responsible for the formation of the beta 1,6-branched poly-N-acetyllactosamine structure has been purified 210,000-fold in 2.4% yield from a homogenate of hog small intestine by successive column chromatographies involving CM-Sepharose FF, Ni2+-chelating Sepharose FF, and UDP-hexanolamine-agarose, using an assay wherein pyridylaminated lacto-N-neotetraose (Gal beta 1-4GlcNAc beta 1-3Galp1-4Glc-PA) was used as an acceptor substrate, and the reaction product was Gal beta 1-4GlcNAc beta 1-3(GlcNAc beta 1-6)Gal beta 1-4Glc-PA. The apparent molecular weight of the purified enzyme was 76,000 under nonreducing conditions. The enzyme has a pH optimum at 7.0 and has no requirement for any divalent metal ions. The K-m values for pyridylaminated lacto-N-neotetraose and UDP-GlcNAc were 0.96 and 2.59 mM, respectively, For its activity, this enzyme was shown to have an absolute requirement of at least a complete LacNAc (LacNAc = Gal beta 1-4GlcNAc) residue bound to position 3 of the acceptor Gal residues, i.e. it is capable of acting only on the Gal residues of internal LacNAc units. The data strongly suggest that this enzyme could be involved in generating branches to central positions of preformed as well as growing polylactosamine chains, but not in synthesizing the distal branches to growing polylactosamine chains.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	Osaka University; Osaka University; RIKEN; University of Helsinki; University of Helsinki	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan.		Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968; Parmanne, Pinja/0000-0002-4691-2107				BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1994, TRENDS GLYCOSCI GLYC, V6, P17; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; GU J, 1992, J BIOL CHEM, V267, P2994; HASHIMOTO Y, 1993, J BIOL CHEM, V268, P25857; Helin J, 1997, FEBS LETT, V412, P637, DOI 10.1016/S0014-5793(97)00818-1; KAPADIA A, 1981, EXP CELL RES, V131, P185, DOI 10.1016/0014-4827(81)90418-3; KEMLER R, 1977, P NATL ACAD SCI USA, V74, P4449, DOI 10.1073/pnas.74.10.4449; KOENDERMAN AHL, 1987, EUR J BIOCHEM, V166, P199, DOI 10.1111/j.1432-1033.1987.tb13502.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leppanen A, 1997, BIOCHEMISTRY-US, V36, P7026, DOI 10.1021/bi9627673; Leppanen A, 1998, J BIOL CHEM, V273, P17399, DOI 10.1074/jbc.273.28.17399; LEPPANEN A, 1991, BIOCHEMISTRY-US, V30, P9287, DOI 10.1021/bi00102a022; Leppanen A, 1997, BIOCHEMISTRY-US, V36, P13729, DOI 10.1021/bi9712807; Maaheimo H, 1997, CARBOHYD RES, V297, P145, DOI 10.1016/S0008-6215(96)00259-5; MURAMATSU T, 1978, P NATL ACAD SCI USA, V75, P2315, DOI 10.1073/pnas.75.5.2315; Natunen J, 1997, GLYCOBIOLOGY, V7, P711, DOI 10.1093/glycob/7.5.711; NIEMANN H, 1978, BIOCHEM BIOPH RES CO, V81, P1286, DOI 10.1016/0006-291X(78)91275-5; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; Oguri S, 1997, J BIOL CHEM, V272, P22721, DOI 10.1074/jbc.272.36.22721; PILLER F, 1984, J BIOL CHEM, V259, P3385; RENKONEN O, 1991, GLYCOCONJUGATE J, V8, P376, DOI 10.1007/BF00731351; ROPP PA, 1991, J BIOL CHEM, V266, P23863; SABESAN S, 1992, J AM CHEM SOC, V114, P8363, DOI 10.1021/ja00048a004; SCUDDER P, 1984, J BIOL CHEM, V259, P6586; SEKINE M, 1994, J BIOL CHEM, V269, P31143; SEKINE M, 1990, J BIOCHEM-TOKYO, V108, P103, DOI 10.1093/oxfordjournals.jbchem.a123147; SEPPO A, 1995, BIOCHEMISTRY-US, V34, P4655, DOI 10.1021/bi00014a019; VANDENEIJNDEN DH, 1993, CURR OPIN STRUC BIOL, V3, P711, DOI 10.1016/0959-440X(93)90054-O; WATANABE K, 1979, J BIOL CHEM, V254, P3221	33	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27625	27632		10.1074/jbc.273.42.27625	http://dx.doi.org/10.1074/jbc.273.42.27625			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765297	hybrid			2022-12-25	WOS:000076448000084
J	Sanchez-Mejorada, G; Rosales, C				Sanchez-Mejorada, G; Rosales, C			Fc gamma receptor-mediated mitogen-activated protein kinase activation in monocytes is independent of Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; SIGNAL-TRANSDUCTION PATHWAY; NF-KAPPA-B; TYROSINE PHOSPHORYLATION; MAP KINASE; CROSS-LINKING; FUNCTIONAL ASSOCIATION; EXTRACELLULAR SIGNALS; HIGH-AFFINITY; MOTIF ITAM	Receptors for the Fc portion of immunoglobulin molecules (FcR) present on leukocyte cell membranes mediate a large number of cellular responses that are very important in host defense, including phagocytosis, cell cytotoxicity, production and secretion of inflammatory mediators, and modulation of the immune response. Cross-linking of FcR with immune complexes leads, first to activation of protein-tyrosine kinases. The molecular events that follow and that transduce signals from these receptors to the nucleus are still poorly defined. We have investigated the signal transduction pathway from Fc receptors that leads to gene activation and production of cytokines in monocytes, Cross-linking of FcR, on the THP-1 monocytic cell line, by immune complexes resulted in both activation of the transcription factor NF-kappa B and interleukin 1 production. These responses were completely blocked by tyrosine kinase inhibitors. In contrast, expression of dominant negative mutants of Res and Raf-1, in these cells, did not have any effect on FcR-mediated nuclear factor activation, suggesting that the mitogen-activated protein kinase (MAPK) signaling pathway was not used by these receptors, However, MAPK activation was easily detected by in vitro kinase assays, after FcR cross-linking with immune complexes. Using the specific MAPK/extracellular signal-regulated kinase kinase (MAPK kinase) inhibitor PD98059, we found that MAPK activation is necessary for FcR-dependent activation of the nuclear factor NF-kappa B. These results strongly suggest that the signaling pathway from Fc receptors leading to expression of different genes important to leukocyte biology, initiates with tyrosine kinases and requires MAPK activation; but in contrast to other tyrosine kinase receptors, FcR-mediated MAPK activation does not involve Ras and Raf.	Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Immunol, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Rosales, C (corresponding author), Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Immunol, Apto Postal 70228,Cd Univ, Mexico City 04510, DF, Mexico.	carosal@servidor.unam.mx	ROSALES, CARLOS/AAA-5206-2019	ROSALES, CARLOS/0000-0003-2568-5723				AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANEGON I, 1988, J EXP MED, V167, P452, DOI 10.1084/jem.167.2.452; AZZONI L, 1992, J EXP MED, V176, P1745, DOI 10.1084/jem.176.6.1745; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CAMBIER JC, 1995, IMMUNOL LETT, V44, P77, DOI 10.1016/0165-2478(94)00196-X; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CASILLAS A, 1991, J BIOL CHEM, V266, P19088; CHEN SY, 1994, ONCOGENE, V9, P2691; COGSWELL JP, 1994, J IMMUNOL, V153, P712; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DARBY C, 1994, J IMMUNOL, V152, P5429; DURDEN DL, 1995, J IMMUNOL, V154, P4039; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ERBE DV, 1991, J IMMUNOL, V146, P3145; Galandrini R, 1996, J EXP MED, V183, P179, DOI 10.1084/jem.183.1.179; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAY JG, 1993, MOL CELL BIOL, V13, P6678, DOI 10.1128/MCB.13.11.6678; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; HASKILL S, 1988, J IMMUNOL, V140, P1690; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Isakov N, 1997, J LEUKOCYTE BIOL, V61, P6, DOI 10.1002/jlb.61.1.6; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; JabrilCuenod B, 1996, J BIOL CHEM, V271, P16268, DOI 10.1074/jbc.271.27.16268; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KANAKARAJ P, 1994, J EXP MED, V179, P551, DOI 10.1084/jem.179.2.551; Karimi K, 1998, INFLAMMATION, V22, P67, DOI 10.1023/A:1022347808042; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Milella M, 1997, J IMMUNOL, V158, P3148; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POLAT GL, 1993, IMMUNOLOGY, V80, P287; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Rosales C, 1996, CANCER RES, V56, P2302; SALCEDO TW, 1993, J EXP MED, V177, P1475, DOI 10.1084/jem.177.5.1475; Sanchez-Mejorada G, 1998, J LEUKOCYTE BIOL, V63, P521, DOI 10.1002/jlb.63.5.521; Santana C, 1996, J LEUKOCYTE BIOL, V60, P433, DOI 10.1002/jlb.60.4.433; SCHOONK LB, 1987, MONOCLONAL ANTIBODY; SHEN ZH, 1994, J IMMUNOL, V152, P3017; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; SPORN SA, 1990, J IMMUNOL, V144, P4434; TING AT, 1992, J EXP MED, V176, P1751, DOI 10.1084/jem.176.6.1751; Trotta R, 1996, J EXP MED, V184, P1027, DOI 10.1084/jem.184.3.1027; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; UNKELESS JC, 1992, INFLAMMATION BASIC P, P497; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VIVIER E, 1993, EUR J IMMUNOL, V23, P1872, DOI 10.1002/eji.1830230821; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; ZOLA H, 1987, MONOCLONAL ANTIBODIE	64	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27610	27619		10.1074/jbc.273.42.27610	http://dx.doi.org/10.1074/jbc.273.42.27610			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765295	hybrid			2022-12-25	WOS:000076448000082
J	Valnickova, Z; Enghild, JJ				Valnickova, Z; Enghild, JJ			Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases - Evidence for transglutaminase-catalyzed cross-linking to fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; PLASMA CARBOXYPEPTIDASE-B; ALPHA-2-PLASMIN INHIBITOR; STABILIZING FACTOR; GLU-PLASMINOGEN; DEGRADED FIBRIN; BINDING-SITES; FACTOR-XIIIA; PROTEIN-C; AFFINITY	Procarboxypeptidase U (EC 3.4.17.20) (pro-CpU), also known as plasma procarboxypeptidase B and thrombin-activable fibrinolysis inhibitor, is a human plasma protein that has been implicated in the regulation of fibrinolysis. In this study, we show that pro-CpU serves as a substrate for transglutaminases. Both factor XIIIa and tissue transglutaminase catalyzed the polymerization of pro-CpU and the cross-linking to fibrin as well as the incorporation of 5-dimethylaminonaphthalene-1-sulfonyl cadaverine (dansylcadaverine), [C-14]putrescine, and dansyl-PGGQQIV. These findings show that pro-CpU contains both amine acceptor (Gln) and amine donor (Lys) residues. The amine acceptor residues were identified as Gln(2), Gln(5), and Gln(292), suggesting that both the activation peptide and the mature enzyme participate in the cross-linking reaction. These observations imply that transglutaminases may mediate covalent binding of pro-CpU to other proteins and cell surfaces in vivo. In particular, factor XIIIa may cross-link pro-CpU to fibrin during the latter part of the coagulation cascade, thereby helping protect the newly formed fibrin clot from premature plasmin degradation. Moreover, the cross-linking may facilitate the activation of pro-CpU, stabilize the enzymatic activity, and protect the active enzyme from further degradation.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University	Enghild, JJ (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	enghi001@mc.duke.edu		Enghild, Jan Johannes/0000-0001-9292-9172	NHLBI NIH HHS [HL49542] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AESCHLIMANN D, 1992, J BIOL CHEM, V267, P11316; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BALE MD, 1986, BIOCHEMISTRY-US, V25, P5667, DOI 10.1021/bi00367a048; BENDIXEN E, 1995, J BIOL CHEM, V270, P17929, DOI 10.1074/jbc.270.30.17929; BENDIXEN E, 1993, J BIOL CHEM, V268, P21962; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Broze GJ, 1996, BLOOD, V88, P3815, DOI 10.1182/blood.V88.10.3815.bloodjournal88103815; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CHRISTENSEN U, 1985, FEBS LETT, V182, P43, DOI 10.1016/0014-5793(85)81150-9; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EATON DL, 1991, J BIOL CHEM, V266, P21833; ENGHILD JJ, 1993, BIOCHEM J, V291, P933, DOI 10.1042/bj2910933; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; FRANCIS RT, 1986, J BIOL CHEM, V261, P9787; HADA M, 1986, BLOOD, V68, P95; HARPEL PC, 1985, J BIOL CHEM, V260, P4432; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; ICHINOSE A, 1983, FEBS LETT, V153, P369, DOI 10.1016/0014-5793(83)80645-0; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; KLUFT C, 1984, THROMB RES, V33, P419, DOI 10.1016/0049-3848(84)90081-1; LORAND L, 1991, P NATL ACAD SCI USA, V88, P82, DOI 10.1073/pnas.88.1.82; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1968, BIOCHEMISTRY-US, V7, P1214, DOI 10.1021/bi00843a043; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; SKORSTENGAARD K, 1990, FEBS LETT, V262, P269, DOI 10.1016/0014-5793(90)80208-Z; SUNDQVIST B, 1984, BIOMED MASS SPECTROM, V11, P242, DOI 10.1002/bms.1200110509; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; TRANTHANG C, 1986, EUR J BIOCHEM, V160, P599, DOI 10.1111/j.1432-1033.1986.tb10080.x; Valnickova Z, 1996, J BIOL CHEM, V271, P12937, DOI 10.1074/jbc.271.22.12937; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229	44	99	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27220	27224		10.1074/jbc.273.42.27220	http://dx.doi.org/10.1074/jbc.273.42.27220			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765243	hybrid			2022-12-25	WOS:000076448000030
J	Gu, XJ; Trigatti, B; Xu, SZ; Acton, S; Babitt, J; Krieger, M				Gu, XJ; Trigatti, B; Xu, SZ; Acton, S; Babitt, J; Krieger, M			The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE GLYCOPROTEIN; CHOLESTERYL ESTER TRANSFER; APOLIPOPROTEIN-A-I; SR-BI; SELECTIVE UPTAKE; HEPATIC LIPASE; HDL-RECEPTOR; ADRENAL-CELLS; ANIONIC PHOSPHOLIPIDS; INTRACELLULAR EVENTS	The class B type I scavenger receptor, (SR-BI), is a member of the CD36 superfamily of proteins and is a physiologically relevant, high affinity cell surface high density lipoprotein (HDL) receptor that mediates selective lipid uptake. The mechanism of selective lipid uptake is fundamentally different from that of classic receptor-mediated uptake via coated pits and vesicles (e.g. the low density lipoprotein receptor pathway) in that it involves efficient transfer of the lipids, but not the outer shell proteins, from HDL to cells. The abilities of SR-SI and CD36, both of which are class B scavenger receptors, to bind HDL and mediate cellular uptake of HDL-associated lipid when transiently expressed in COS cells were examined. For these experiments, the binding of HDL to cells was assessed using either I-125- or Alexa (a fluorescent dye)-HDL in which the apolipoproteins on the surface of the HDL particles were covalently modified, Lipid transfer was measured using HDL noncovalently labeled by the fluorescent lipid l,l'-dioctadecyl-3,3,3',3'-tetramethylindoearbocyanine perchlorate. Although both mSR-BI and human CD36 (hCD36) could mediate the binding of HDL in a punctate pattern across the surfaces of cells, only mSR-BI efficiently mediated the transfer of lipid to the cells. Analysis of point mutants established that the major sites of fatty acylation of mSR-BI are Cys(462) and Cys(470) and that fatty acylation is not required for receptor clustering, HDL binding, or efficient lipid transfer. Generation of mSR-BI/hCD36 domain swap chimeras showed that the differences in lipid uptake activities between mSR-BI and hCD36 were not due to differences between their two sets of transmembrane and cytoplasmic domains brit rather result from differences in their large extracellular loop domains. These results shaw that high affinity binding to a cell surface receptor is not sufficient to ensure efficient cellular lipid uptake from HDL. Thus, SR-BI-mediated binding combined with SR-BI-dependent facilitated transfer of lipid from the HDL particle to the cell appears to be the most likely mechanism for the bulk of the selective uptake of cholesteryl esters from HDL to the fiver and steroidogenic tissues.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Krieger, M (corresponding author), MIT, Dept Biol, Rm 68-483, Cambridge, MA 02139 USA.	krieger@mit.edu	Eckhardt, Erik/G-1567-2010; Krieger, Marco/AAE-8611-2020	Trigatti, Bernardo (Dino) L./0000-0002-4556-119X	NHLBI NIH HHS [HL52212, HL41484] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Alessio M, 1996, J BIOL CHEM, V271, P1770, DOI 10.1074/jbc.271.3.1770; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Azhar S, 1998, J CLIN ENDOCR METAB, V83, P983, DOI 10.1210/jc.83.3.983; AZHAR S, 1989, J LIPID RES, V30, P1799; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BAMBERGER M, 1983, J LIPID RES, V24, P869; Benoist F, 1997, J BIOL CHEM, V272, P23572, DOI 10.1074/jbc.272.38.23572; Calvo D, 1998, J LIPID RES, V39, P777; CALVO D, 1993, J BIOL CHEM, V268, P18929; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; deFaria E, 1996, J LIPID RES, V37, P197; Dichek HL, 1998, J BIOL CHEM, V273, P1896, DOI 10.1074/jbc.273.4.1896; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; EISENBERG S, 1984, J LIPID RES, V25, P1017; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Fielding CJ, 1997, J LIPID RES, V38, P1503; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; Fluiter K, 1998, J BIOL CHEM, V273, P8434, DOI 10.1074/jbc.273.14.8434; Foger B, 1997, J BIOL CHEM, V272, P27393, DOI 10.1074/jbc.272.43.27393; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDBERG DI, 1991, J CLIN INVEST, V87, P331, DOI 10.1172/JCI114991; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREENWALT DE, 1992, BLOOD, V80, P1105; GWYNNE JT, 1976, P NATL ACAD SCI USA, V73, P4329, DOI 10.1073/pnas.73.12.4329; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HART K, 1993, J MOL BIOL, V234, P249, DOI 10.1006/jmbi.1993.1580; Hatzopoulos AK, 1998, J LIPID RES, V39, P495; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Johnson MSC, 1998, ENDOCRINOLOGY, V139, P72, DOI 10.1210/en.139.1.72; Komaromy M, 1996, J BIOL CHEM, V271, P16906, DOI 10.1074/jbc.271.28.16906; KOVANEN PT, 1979, J BIOL CHEM, V254, P5498; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1998, P NATL ACAD SCI USA, V95, P4077, DOI 10.1073/pnas.95.8.4077; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LEITERSDORF E, 1984, BIOCHIM BIOPHYS ACTA, V796, P72, DOI 10.1016/0005-2760(84)90240-6; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu JQ, 1997, J CLIN ENDOCR METAB, V82, P2522, DOI 10.1210/jc.82.8.2522; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORRISON JR, 1994, J BIOL CHEM, V269, P13911; MOWRI HO, 1992, J LIPID RES, V33, P1269; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; Panzenboeck U, 1997, J LIPID RES, V38, P239; PEARCE SFA, 1994, BLOOD, V84, P384; PIETERS MN, 1994, BBA-MOL BASIS DIS, V1225, P125, DOI 10.1016/0925-4439(94)90069-8; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Rajapaksha WRAKJS, 1997, MOL CELL ENDOCRINOL, V134, P59, DOI 10.1016/S0303-7207(97)00173-1; REAVEN E, 1995, J LIPID RES, V36, P1602; Reaven E, 1996, J BIOL CHEM, V271, P16208, DOI 10.1074/jbc.271.27.16208; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P275, DOI 10.1016/0005-2760(93)90108-L; RINNINGER F, 1988, J LIPID RES, V29, P1179; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P284, DOI 10.1016/0005-2760(93)90109-M; Rogers ME, 1997, J BIOL CHEM, V272, P14792, DOI 10.1074/jbc.272.23.14792; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536; Schorsch F, 1997, FEBS LETT, V414, P507, DOI 10.1016/S0014-5793(97)01061-2; SCHOUTEN D, 1990, ARTERIOSCLEROSIS, V10, P1127, DOI 10.1161/01.ATV.10.6.1127; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; Tao NB, 1996, J BIOL CHEM, V271, P22315, DOI 10.1074/jbc.271.37.22315; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; VEGA MA, 1991, J BIOL CHEM, V266, P16818; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Webb NR, 1997, J LIPID RES, V38, P1490; Wyne KL, 1998, J LIPID RES, V39, P518; Xu SZ, 1997, J LIPID RES, V38, P1289; ZANNIS VI, 1993, ADV HUM GENET, V21, P145	88	198	204	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26338	26348		10.1074/jbc.273.41.26338	http://dx.doi.org/10.1074/jbc.273.41.26338			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756864	hybrid			2022-12-25	WOS:000076373300018
J	Huang, LJS; Taylor, SS				Huang, LJS; Taylor, SS			Dissecting cAMP binding domain A in the R-I alpha subunit of cAMP-dependent protein kinase - Distinct subsites for recognition of cAMP and the catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; CYCLIC-AMP; HOLOENZYME FORMATION; PREDICTED STRUCTURES; KINETIC MECHANISM; INHIBITOR PROTEIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MUTATIONS; SITES	The two gene-duplicated cAMP binding domains in the regulatory subunits of cAMP dependent protein kinase are each comprised of an A helix, an eight-stranded beta-barrel, and a B and C helix (1). The A domain is required for high affinity binding to C, while the B domain regulates access to the A domain. Using a combination of a yeast two-hybrid screen coupled with deletion analysis, cAMP binding domain A of R-1 was dissected into two structurally and functionally distinct subsites, one that binds cAMP and another that binds the C subunit, The minimum stable subdomain required for binding to C in the 1-3 micromolar range is composed of residues 94-169, while residues 236-244, mapped to the C helix of cAMP binding domain A, were defined as a second surface necessary for high affinity (5-10 nanomolar) binding to C. This portion of the C helix, due to its position directly between the two subsites, serves as a molecular switch for either a cAMP-bound conformation or a C-bound conformation and can thus modulate interactions of cAMP binding domain A with cAMP, with C, and with cAMP binding domain B.	Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, 9500 Gilman Dr 0654, La Jolla, CA 92093 USA.	staylor@ucsd.edu			NIGMS NIH HHS [GM34921, 2T32GM07240-21A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007240, R01GM034921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; Gibson RM, 1997, J BIOL CHEM, V272, P31998, DOI 10.1074/jbc.272.51.31998; Gibson RM, 1997, PROTEIN SCI, V6, P1825, DOI 10.1002/pro.5560060903; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GORMAN KB, 1994, SOMAT CELL MOLEC GEN, V20, P301, DOI 10.1007/BF02254719; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; JIBUECHLER Y, 1993, J BIOL CHEM, V268, P16495; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; OGREID D, 1981, FEBS LETT, V129, P282, DOI 10.1016/0014-5793(81)80184-6; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REED J, 1989, BIOCHEM J, V264, P371, DOI 10.1042/bj2640371; RINGHEIM GE, 1990, J BIOL CHEM, V265, P4800; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASWAT LD, 1988, J BIOL CHEM, V263, P18241; SARASWAT LD, 1988, METHOD ENZYMOL, V159, P325; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; Scott SP, 1996, PROTEIN ENG, V9, P333, DOI 10.1093/protein/9.4.333; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SYMCOX MM, 1994, J BIOL CHEM, V269, P23025; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WEBER IT, 1982, P NATL ACAD SCI-BIOL, V79, P7679, DOI 10.1073/pnas.79.24.7679; WEN W, 1994, J BIOL CHEM, V269, P8423; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; Wilson JE, 1997, BIOCHEM SOC T, V25, P103, DOI 10.1042/bst0250103; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171	47	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26739	26746		10.1074/jbc.273.41.26739	http://dx.doi.org/10.1074/jbc.273.41.26739			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756917	hybrid			2022-12-25	WOS:000076373300071
J	Myers, MG; Mendez, R; Shi, P; Pierce, JH; Rhoads, R; White, MF				Myers, MG; Mendez, R; Shi, P; Pierce, JH; Rhoads, R; White, MF			The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; RECEPTOR SUBSTRATE FAMILY; GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; PHOSPHOTYROSINE PROTEIN; PHOSPHATASE SHP-2; SH2 DOMAINS; YMXM MOTIFS; SH-PTP2	Activation of tyrosine kinases by numerous growth factor and cytokine receptors leads to tyrosine phosphorylation of the insulin receptor substrate (IRS)-proteins. Tyrosine-phosphorylated motifs on the IRS proteins bind to the SH2 domains in proteins that mediate down-stream signals, including phosphatidylinositol 3'-kinase, GRB-2, and SHP-2. We investigated the function of the two SHP-2 binding COOH-terminal tyrosines of IRS-l by replacing them with phenylalanine (IRS-1(FCT)). IRS-1(FCT) failed to bind SHP-2 or mediate its tyrosine phosphorylation during insulin stimulation. Although several reports suggest a critical role for SHP-2 in insulin stimulated mitogen-activated protein kinase activation and cell proliferation, IRS-1(FCT) mediated these effects normally in 32D cells. indeed, IRS-1(FCT) exhibited increased tyrosine phosphorylation, phosphatidylinositol 3'-kinase binding and activation of protein synthesis in response to insulin. These results suggest that SHP-2 attentuates the phosphorylation and downstream signal transmission of IRS-1 and that the interaction of IRS-1 and SHP-2 is an important regulatory event which attenuates insulin metabolic responses.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; NIH, Lab Cell & Mol Biol, Bethesda, MD 20892 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; National Institutes of Health (NIH) - USA	Myers, MG (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	myersmg@joslab.harvard.edu		Mendez, Raul/0000-0002-1952-6905	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43808] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Comu S, 1997, J NEUROSCI, V17, P8702; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MYERS MG, 1995, DIABETES, V44, pA49; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Myers MG, 1996, MOL CELL BIOL, V16, P4147; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; PONS S, 1995, MOL CELL BIOL, V15, P4453; Rocchi S, 1996, ENDOCRINOLOGY, V137, P4944, DOI 10.1210/en.137.11.4944; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Servidei T, 1998, J BIOL CHEM, V273, P6233, DOI 10.1074/jbc.273.11.6233; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Yenush L, 1996, MOL CELL BIOL, V16, P2509	55	127	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26908	26914		10.1074/jbc.273.41.26908	http://dx.doi.org/10.1074/jbc.273.41.26908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756938	hybrid, Green Submitted			2022-12-25	WOS:000076373300092
J	Thelen, JJ; Muszynski, MG; Miernyk, JA; Randall, DD				Thelen, JJ; Muszynski, MG; Miernyk, JA; Randall, DD			Molecular analysis of two pyruvate dehydrogenase kinases from maize	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; PLANT-MITOCHONDRIA; COMPLEX; SEQUENCE; CLONING; FAMILY; PHOSPHORYLATION; EXPRESSION; IMPORT	Two maize cDNAs were isolated and sequenced that had open reading frames with approximately 37% amino acid identity to mammalian pyruvate dehydrogenase kinases. Both maize kinase sequences contain the five domains with conserved signature residues typical of procaryotic two-component histidine kinases. Sequence comparisons identified six other highly conserved motifs that are proposed to be specific to pyruvate dehydrogenase kinases. In addition, specific Trp and Cys residues are also invariant in these sequences. The maize cDNAs are 1332 (PDK1) and 1602 (PDK2) nucleotides in length, encoding polypeptides with calculated molecular masses of 38,867 and 41,327 Da that share 77% amino acid identity, Reverse transcriptase-polymerase chain reaction analysis with oligonucleotide-specific primers revealed a differential expression pattern for the two isoforms, PDK1 and PDK2 were expressed in Escherichia coli with N-terminal His(6) tags to facilitate purification. The recombinant proteins migrated at 44 and 48 kDa, respectively, during SDS-polyacrylamide gel electrophoresis. Anti-PDK1 antibodies immunoprecipitated 75% of pyruvate dehydrogenase kinase activity from a maize mitochondrial matrix fraction, and recognized a matrix protein of 43 kDa. Recombinant PDK2, expressed as a fusion with the maltose-binding protein, inactivated kinase-depleted maize pyruvate dehydrogenase complex when incubated with MgATP, coincident with incorporation of P-32 from [gamma-P-32]ATP into the alpha subunit of pyruvate dehydrogenase.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Univ Missouri, Dept Sci Biol, Columbia, MO 65211 USA; Pioneer Hi Bred Int Inc, Johnston, IA 50131 USA; USDA, Mycotoxin Res Unit, NCAUR, Peoria, IL 61604 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; DuPont; Pioneer Hi-Bred International, Inc.; United States Department of Agriculture (USDA)	Randall, DD (corresponding author), Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA.	behemdr@showme.missouri.edu	Muszynski, Michael G./L-2843-2016	Muszynski, Michael G./0000-0002-0817-7594; Thelen, Jay/0000-0001-5995-1562				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMEMURA M, 1990, J BACTERIOL, V172, P6300, DOI 10.1128/jb.172.11.6300-6307.1990; BUDDE RJA, 1990, P NATL ACAD SCI USA, V87, P673, DOI 10.1073/pnas.87.2.673; CAMP PJ, 1985, PLANT PHYSIOL, V77, P571, DOI 10.1104/pp.77.3.571; GEMEL J, 1992, PLANT PHYSIOL, V100, P908, DOI 10.1104/pp.100.2.908; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; HARRIS RA, 1995, ADV ENZYME REGUL, V35, P147, DOI 10.1016/0065-2571(94)00020-4; Katsube T, 1997, DNA CELL BIOL, V16, P335, DOI 10.1089/dna.1997.16.335; Luethy MH, 1996, ALPHA KETO ACID DEHY, P71; MOORE AL, 1994, ANNU REV PLANT PHYS, V45, P545, DOI 10.1146/annurev.pp.45.060194.002553; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Popov K M, 1991, Protein Expr Purif, V2, P278, DOI 10.1016/1046-5928(91)90084-V; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; Randall D. D., 1996, V39, P87; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHULLER KA, 1993, PLANT PHYSIOL, V102, P139, DOI 10.1104/pp.102.1.139; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Thelen JJ, 1998, PLANT PHYSIOL, V116, P1443, DOI 10.1104/pp.116.4.1443; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; Whelan J, 1997, PLANT MOL BIOL, V33, P771, DOI 10.1023/A:1005755505738; WILLIAMS M, 1979, PLANT PHYSIOL, V64, P1099, DOI 10.1104/pp.64.6.1099; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	26	37	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26618	26623		10.1074/jbc.273.41.26618	http://dx.doi.org/10.1074/jbc.273.41.26618			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756901	hybrid			2022-12-25	WOS:000076373300055
J	Gitan, RS; Luo, H; Rodgers, J; Broderius, M; Eide, D				Gitan, RS; Luo, H; Rodgers, J; Broderius, M; Eide, D			Zinc-induced inactivation of the yeast ZRT1 zinc transporter occurs through endocytosis and vacuolar degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASE; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; GENE ENCODES; CATABOLITE INACTIVATION; CONFERS RESISTANCE; URACIL PERMEASE; PROTEIN; IRON; SIGNALS	The ZRT1 gene encodes the transporter responsible for high affinity zinc uptake in yeast. ZRT1 is transcribed in zinc-limited cells and its transcription is repressed in zinc-replete cells. In this report, we describe a second, post-translational mechanism that regulates ZRT1 activity. In zinc-limited cells, ZRT1 is a stable, N-glycosylated plasma membrane protein. Exposure to high levels of extracellular zinc triggers a rapid loss of ZRT1 uptake activity. Our results demonstrate that this inactivation occurs through zinc-induced endocytosis of the protein and its subsequent degradation in the vacuole, Mutations that inhibit the internalization step of endocytosis also inhibited zinc-induced ZRT1 inactivation and the major vacuolar proteases were required to degrade ZRT1 in response to zinc. Furthermore, immunofluorescence microscopy showed that ZRT1 is localized to the plasma membrane in zinc-limited cells and that the protein is transferred to the vacuole via an endosome-like compartment upon exposure to zinc. ZRT1 inactivation is a relatively specific response to zinc; cadmium and cobalt ions trigger the response but less effectively than zinc, Moreover, zinc does not alter the stability of several other plasma membrane proteins, Therefore, zinc-induced ZRT1 inactivation is a specific regulatory system to shut off zinc uptake activity in cells exposed to high extracellular zinc levels thereby preventing overaccumulation of this potentially toxic metal.	Univ Missouri, Nutr Sci Program, Columbia, MO 65211 USA; Univ Minnesota, Dept Biochem & Mol Biol, Duluth, MN 55812 USA	University of Missouri System; University of Missouri Columbia; University of Minnesota System; University of Minnesota Duluth	Eide, D (corresponding author), Univ Missouri, Nutr Sci Program, 217 Gwynn Hall, Columbia, MO 65211 USA.	deide@showme.missouri.edu						ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; Bohm S, 1997, NUCLEIC ACIDS RES, V25, P2464, DOI 10.1093/nar/25.12.2464; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Chiang HL, 1996, J BIOL CHEM, V271, P9934, DOI 10.1074/jbc.271.17.9934; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; DIX DR, 1994, J BIOL CHEM, V269, P26092; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; EIDE D, 1992, J BIOL CHEM, V267, P20774; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; Harlow E., 1988, ANTIBODIES LAB MANUA; Hein C, 1997, MOL MICROBIOL, V24, P607, DOI 10.1046/j.1365-2958.1997.3771735.x; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horak J, 1997, J BACTERIOL, V179, P1541, DOI 10.1128/jb.179.5.1541-1549.1997; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KAISER CA, 1997, MOL CELLULAR BIOL YE, V3, P91; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; LIU HP, 1992, GENETICS, V132, P665; Medintz I, 1996, J BACTERIOL, V178, P2245, DOI 10.1128/jb.178.8.2245-2254.1996; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; RIBALLO E, 1995, J BACTERIOL, V177, P5622, DOI 10.1128/jb.177.19.5622-5627.1995; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; THOMAS TC, 1990, METHOD ENZYMOL, V182, P499; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; VOLLAND C, 1994, FOLIA MICROBIOL, V39, P554, DOI 10.1007/BF02814106; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	49	161	161	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28617	28624		10.1074/jbc.273.44.28617	http://dx.doi.org/10.1074/jbc.273.44.28617			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786854	hybrid			2022-12-25	WOS:000076691800015
J	Shapiro, MJ; Coughlin, SR				Shapiro, MJ; Coughlin, SR			Separate signals for agonist-independent and agonist-triggered trafficking of protease-activated receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL THROMBIN RECEPTOR; VEIN ENDOTHELIAL-CELLS; COUPLED RECEPTOR; PROTEOLYTIC MECHANISM; RESENSITIZATION; INTERNALIZATION; SEQUESTRATION; SPECIFICITY; ENDOCYTOSIS; PEPTIDES	Protease-activated receptor 1 (PAR1), a G protein-coupled, protease-activated receptor for the serine protease thrombin, is activated when thrombin cleaves its aminoterminal exodomain. This irreversible mechanism of activation may have necessitated an unusual pattern of receptor trafficking. Unactivated PAR1 cycles tonically between the cell surface and an intracellular pool, providing an intracellular store of uncleaved receptors and allowing repopulation of the surface with uncleaved receptors after thrombin exposure without new receptor synthesis. Activated PAR1 internalizes rapidly and is degraded in lysosomes. We report characterization of a PAR1 mutant that trafficked like the wild-type receptor when activated but did not internalize and recycle in the absence of agonist. This complements a previous study in which a mutant with normal tonic internalization but defective agonist-triggered internalization was described, These observations suggest that the trafficking behaviors of unactivated and activated PAR1 are specified by distinct signals within the receptor and imply that PAR1 internalization in the presence or absence of agonist may be mediated by distinct molecular machinery. PAR1 mutants that did not internalize in the absence of agonist were also shown to localize exclusively to the cell surface and to be defective in their ability to repopulate the cell surface with uncleaved receptors after thrombin exposure. These observations suggest that tonic internalization is necessary for maintenance of the intracellular PAR1 pool.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Coughlin, SR (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, HSE-1300,505 Parnassus Ave, San Francisco, CA 94143 USA.	shaun_coughlin@quickmail.ucsf.edu			NHLBI NIH HHS [HL44907] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; HEIN L, 1994, J BIOL CHEM, V269, P27719; HORVAT R, 1995, J CELL SCI, V108, P1155; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; ISHII K, 1993, J BIOL CHEM, V268, P9780; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Krueger KM, 1997, J BIOL CHEM, V272, P5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; TSENG MJ, 1995, J BIOL CHEM, V270, P18858, DOI 10.1074/jbc.270.32.18858; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	33	50	51	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29009	29014		10.1074/jbc.273.44.29009	http://dx.doi.org/10.1074/jbc.273.44.29009			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786906	hybrid			2022-12-25	WOS:000076691800067
J	Wen, W; Weiss, SL; Sunde, RA				Wen, W; Weiss, SL; Sunde, RA			UGA codon position affects the efficiency of selenocysteine incorporation into glutathione peroxidase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IODOTHYRONINE DEIODINASE; 3' UNTRANSLATED REGION; MESSENGER-RNA; ESCHERICHIA-COLI; COTRANSLATIONAL INCORPORATION; FUNCTIONAL-CHARACTERIZATION; SELENOPROTEIN SYNTHESIS; 3'-UNTRANSLATED REGION; DIETARY SELENIUM; SECIS ELEMENTS	A UGA codon and a selenocysteine insertion sequence in the 3'-untranslated region are the only established mRNA elements necessary for selenocysteine (Sec or U) incorporation during translation. These two elements, however, do not universally confer efficient Sec incorporation, The objective of this study was to systematically examine the effect of UGA codon position on efficiency of Sec insertion. In a glutathione peroxidase-1 (F-GPX1) expression vector, the UGA at the native position (U47) was mutated to a cysteine codon, and codons for Ser-7, Ser-12, Ser-18, Ser-29, Ser-45, Ser-93, Cys-154, Val-172, Ser-178, and Ser-195 were individually mutated to UGA and transiently expressed in COS-7 cells. Se-75 incorporation at the 11 positions was 31, 72, 54, 105, 90, 100, 146, 135, 13, 11, and 43%, respectively, of Se-75 incorporation at U47, suggesting that Sec is more efficiently incorporated at UGA codons positioned in the middle of the coding region rather than close to the 5' or 3' ends. Ribonuclease protection showed that these differences were not due to differences in mRNA level. When the green fluorescence protein (GFP) coding region was placed in-frame at the 5' or 3' ends of the coding region in F-GPX1 to produce chimeric 50-51-kDa GFP/GPX1 proteins, Sec incorporation at UGA codons, formerly close to the 5' or 3' ends, was increased to levels comparable to the UGA at U47, Insertion of GFP after the UAA-stop was just as effective in increasing Sec insertion efficiency as GFP inserted before the stop. These studies used a recombinant expression model that incorporated Sec at non-native UGA codons at rates equal to those of endogenous glutathione peroxidase-1 and showed that the efficiency of Sec incorporation can be modulated by UGA position; Sec incorporation at high efficiency appears to require that the UGA be >21 nucleotides from the AUG-start and >204 nucleotides from the selenocysteine insertion sequence element.	Univ Missouri, Nutr Sci Program, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Sunde, RA (corresponding author), Univ Missouri, Nutr Sci Program, 217 Gwynn Hall, Columbia, MO 65211 USA.	sunder@missouri.edu						AKASAKA M, 1990, NUCLEIC ACIDS RES, V18, P4619, DOI 10.1093/nar/18.15.4619; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; AXLEY MJ, 1989, ANNU REV NUTR, V9, P127, DOI 10.1146/annurev.nu.09.070189.001015; BERRY MJ, 1991, ENDOCRINOLOGY, V129, P550, DOI 10.1210/endo-129-1-550; BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BOCK A, 1994, SELENIUM BIOL HUMAN, P9; Brigelius-Flohe R, 1997, BIOCHEM J, V328, P199, DOI 10.1042/bj3280199; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHU FF, 1993, J BIOL CHEM, V268, P2571; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gu QP, 1997, GENE, V193, P187, DOI 10.1016/S0378-1119(97)00113-3; Guimaraes MJ, 1996, P NATL ACAD SCI USA, V93, P15086, DOI 10.1073/pnas.93.26.15086; Hatfield D.L., 1994, SELENOCYSTEINE TRNA; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Hubert N, 1996, NUCLEIC ACIDS RES, V24, P464, DOI 10.1093/nar/24.3.464; Huttenhofer A, 1996, NUCLEIC ACIDS RES, V24, P3903, DOI 10.1093/nar/24.20.3903; Kim IY, 1997, P NATL ACAD SCI USA, V94, P418, DOI 10.1073/pnas.94.2.418; Kollmus H, 1996, NUCLEIC ACIDS RES, V24, P1195, DOI 10.1093/nar/24.7.1195; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Kromayer M, 1996, J MOL BIOL, V262, P413, DOI 10.1006/jmbi.1996.0525; LARSEN PR, 1995, ANNU REV NUTR, V15, P323, DOI 10.1146/annurev.nu.15.070195.001543; LAWRENCE RA, 1974, EXP EYE RES, V18, P563, DOI 10.1016/0014-4835(74)90062-1; Leonard JL, 1996, J CELL BIOCHEM, V61, P410, DOI 10.1002/(SICI)1097-4644(19960601)61:3<410::AID-JCB8>3.0.CO;2-W; Lesoon A, 1997, MOL CELL BIOL, V17, P1977, DOI 10.1128/MCB.17.4.1977; LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIORINO M, 1991, J BIOL CHEM, V266, P7728; Martin GW, 1996, RNA, V2, P171; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; Moriarty PM, 1997, RNA, V3, P1369; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Morley SJ, 1997, RNA, V3, P1085; *PROM CORP, 1993, TECH B PROM CORP, V97; ROCHER C, 1992, EUR J BIOCHEM, V205, P955, DOI 10.1111/j.1432-1033.1992.tb16862.x; ROCHER C, 1991, GENE, V98, P193, DOI 10.1016/0378-1119(91)90173-9; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; SAEDI MS, 1988, BIOCHEM BIOPH RES CO, V153, P855, DOI 10.1016/S0006-291X(88)81174-4; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; Shen QC, 1998, J BIOL CHEM, V273, P5443, DOI 10.1074/jbc.273.10.5443; Shen QC, 1995, J BIOL CHEM, V270, P30448, DOI 10.1074/jbc.270.51.30448; SHEN QC, 1993, J BIOL CHEM, V268, P11463; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Sunde R. A., 1997, Handbook of nutritionally essential mineral elements., P493; SUNDE RA, 1987, J BIOL CHEM, V262, P933; SUNDE RA, 1993, BIOCHEM BIOPH RES CO, V193, P905, DOI 10.1006/bbrc.1993.1711; TAMURA T, 1996, P NATL ACAD SCI USA, V93, P106; Tormay P, 1997, J BACTERIOL, V179, P576, DOI 10.1128/jb.179.3.576-582.1997; Tormay P, 1996, MOL MICROBIOL, V21, P1253, DOI 10.1046/j.1365-2958.1996.881450.x; VENDELAND SC, 1995, P NATL ACAD SCI USA, V92, P8749, DOI 10.1073/pnas.92.19.8749; Weiss SL, 1998, RNA, V4, P816, DOI 10.1017/S1355838298971990; Weiss SL, 1997, J NUTR, V127, P1304, DOI 10.1093/jn/127.7.1304; WILLIAM BJ, 1979, METHOD ENZYMOL, V58, P1	65	35	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28533	28541		10.1074/jbc.273.43.28533	http://dx.doi.org/10.1074/jbc.273.43.28533			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774484	hybrid			2022-12-25	WOS:000076549800104
J	Inoue, S; Lin, SL; Chang, TN; Wu, SH; Yao, CW; Chu, TY; Troy, FA; Inoue, Y				Inoue, S; Lin, SL; Chang, TN; Wu, SH; Yao, CW; Chu, TY; Troy, FA; Inoue, Y			Identification of free deaminated sialic acid (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid) in human red blood cells and its elevated expression in fetal cord red blood cells and ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; CARBOHYDRATE ANTIGENS; NEURAMINIC ACID; TUMOR; GLYCOSYLATION; CHAINS; KDN; POLYSIALOGLYCOPROTEIN; SYNTHETASE; ASSAY	Chemical studies have shown the occurrence of the deaminated sialic acid 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN) in paired samples of blood obtained from mothers and newborns of healthy human individuals. Most of the KDN was found in red blood cells, although low levels were detected in mononuclear cells. No N-glycolylneuraminic acid was detected. Unexpectedly, nearly all of the KDN in fetal cord and matched maternal red blood cells was present as the free sugar and comparatively little occurred conjugated or as cytidine 5'-KDN phosphate, The amount of free KDN in fetal newborn red blood cells was 2.4-fold higher than in red blood cells from the mothers or from healthy nonpregnant women. Free KDN was also identified in normal human ovaries, in ovarian tumors, and in ascites cells obtained from ovarian cancer patients. Importantly, as in fetal cord red blood cells, a distinguishing feature of KDN expression in ovarian tumor cells was an elevated level of free KDN compared with normal controls. A positive correlation was found between an increase in the ratio of free KDN/N-acetylneuraminic acid in ovarian adenocarcinomas and the stage of malignancy. This was particularly evident in tumor cells isolated from the ascites fluid. The central importance of these new findings is a-fold. First, they show that free KDN is a minor but ubiquitous sialic acid in human red blood cells and that its elevated expression in red blood cells from fetal cord blood compared with maternal red blood cells may be developmentally related to blood cell formation during embryogenesis, Second, the enhanced expression of KDN in ovarian cancer cells suggests that this sialic acid, like the alpha 2,8-linked polysialic acid glycotope, may be an oncofetal antigen in these tumors and thus could be an "early warning" signal for onset of disease and/or a marker for detection of recurrence of disease. These new findings highlight the importance of elucidating the role that KDN and KDN-containing glycoconjugates may play in normal development and malignancy.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Def Med Ctr, Triserv Gen Hosp, Taipei 115, Taiwan; Univ Calif Davis, Sch Med, Dept Biol Chem, Livermore, CA 95616 USA	Academia Sinica - Taiwan; National Defense Medical Center; Tri-Service General Hospital; University of California System; University of California Davis	Inoue, Y (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	syinoue@gate.sinica.edu.tw		Chu, Tang-Yuan/0000-0003-2717-2681	NHLBI NIH HHS [DOH88-HR-805] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGATA T, 1998, 19 INT CARB S CP022; ANGATA T, 1997, THESIS U TOKYO; Feijoo C, 1997, CANCER LETT, V112, P155, DOI 10.1016/S0304-3835(96)04564-8; Fukuda M, 1996, CANCER RES, V56, P2237; GANDOUREDWARDS R, 1985, MED PATHOL, V8, P101; GLICK MC, 1991, PROG CLIN BIOL RES, V366, P267; GROGAN T, 1994, LAB INVEST, V70, pA110; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HIGASHI H, 1985, CANCER RES, V45, P3796; Inoue S, 1996, J BIOL CHEM, V271, P24341, DOI 10.1074/jbc.271.40.24341; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KERN WF, 1993, LEUKEMIA LYMPHOMA, V12, P1, DOI 10.3109/10428199309059565; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MUCHMORE EA, 1989, J BIOL CHEM, V264, P20216; MUCHMORE EA, 1992, GLYCOBIOLOGY, V2, P337, DOI 10.1093/glycob/2.4.337; MURAMATSU T, 1993, GLYCOBIOLOGY, V3, P294; NADANO D, 1986, J BIOL CHEM, V261, P1550; Panneerselvam K, 1997, J BIOL CHEM, V272, P23123, DOI 10.1074/jbc.272.37.23123; PETRIE CR, 1983, ANAL BIOCHEM, V131, P153, DOI 10.1016/0003-2697(83)90147-1; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; Schauer R, 1997, N COMP BIOC B, V29, P243; SCOTT AA, 1994, LAB INVEST, V70, pA120; SONG Y, 1995, GLYCOBIOLOGY, V5, P207, DOI 10.1093/glycob/5.2.207; SONG Y, 1991, J BIOL CHEM, V266, P21929; SPIEGEL LB, 1992, J CHROMATOGR-BIOMED, V573, P23, DOI 10.1016/0378-4347(92)80469-7; TAKANO R, 1994, GLYCOBIOLOGY, V4, P665, DOI 10.1093/glycob/4.5.665; TERADA T, 1993, J BIOL CHEM, V268, P2640; Troy F.A., 1995, BIOL SIALIC ACIDS, P95; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25	30	65	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27199	27204		10.1074/jbc.273.42.27199	http://dx.doi.org/10.1074/jbc.273.42.27199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765240	hybrid			2022-12-25	WOS:000076448000027
J	Kupershmidt, S; Snyders, DJ; Raes, A; Roden, DM				Kupershmidt, S; Snyders, DJ; Raes, A; Roden, DM			A K+ channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly activating delayed rectifier current	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; I-KR; HERG; RECTIFICATION; INACTIVATION; MYOCYTES; VOLTAGE; MECHANISMS	We have cloned HERG(USO), a C-terminal splice variant of the human ether-g-go-go-related gene (HERG), the gene encoding the rapid component of the delayed rectifier (I-Kr), from human heart, and we find that its mRNA is similar to 2-fold more abundant than that for HERG(1) (the originally described cDNA). After transfection of HERG(USO) in Ltk(-) cells, no current was observed, However, coexpression of HERG(USO) with HERG(1) modified I-Kr by decreasing its amplitude, accelerating its activation, and shifting the voltage dependence of activation 8.8 mV negative. As with HERG(USO), HERG(Delta C) (a HERG(1), construct lacking the C-terminal 462 amino acids) also produced no current in transfected cells. However, I-Kr was rescued by ligation of 104 amino acids from the C terminus of HERG(1) to the C terminus of HERG(Delta C), indicating that the C terminus of HERG(1) includes a domain (less than or equal to 104 amino acids) that is critical for faithful recapitulation of I-Kr. The lack of this C-terminal domain not only explains the finding that HERG(USO) does not generate I-Kr but also indicates a similar mechanism for hitherto-uncharacterized long QT syndrome HERG mutations that disrupt the splice site or the C-terminal. We suggest that the amplitude and gating of cardiac I-Kr depends on expression of both HERG(1) and HERG(USO).	Vanderbilt Univ, Med Ctr, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Kupershmidt, S (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Pharmacol, 532 Med Res Bldg I, Nashville, TN 37232 USA.		Kupershmidt, Sabina/AAO-5464-2021; Snyders, Dirk/A-2713-2013; Roden, Dan/ABD-5412-2021	Kupershmidt, Sabina/0000-0002-8119-2723; Snyders, Dirk/0000-0001-7142-6672; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046681, R01HL049989, R01HL047599] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47599, HL49989, HL46681] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackerman MJ, 1997, NEW ENGL J MED, V336, P1575, DOI 10.1056/NEJM199705293362207; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOY AMJ, 1996, CIRCULATION, V94, P164; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; LeesMiller JP, 1997, CIRC RES, V81, P719; Li GR, 1996, CIRC RES, V78, P689, DOI 10.1161/01.RES.78.4.689; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; London B, 1997, CIRC RES, V81, P870; Ludwig J, 1997, EMBO J, V16, P6337, DOI 10.1093/emboj/16.21.6337; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; Sambrook J., 2002, MOL CLONING LAB MANU; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1991, CIRC RES, V68, P77, DOI 10.1161/01.RES.68.1.77; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Snyders DJ, 1996, MOL PHARMACOL, V49, P949; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; VESELY MR, 1997, CIRCULATION, V96, P56; Wang SM, 1996, FEBS LETT, V389, P167, DOI 10.1016/0014-5793(96)00570-4; WANG ZG, 1994, CARDIOVASC RES, V28, P1540, DOI 10.1093/cvr/28.10.1540; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Yang T, 1997, CIRC RES, V80, P782; YANG T, 1995, CIRC RES, V77, P1246, DOI 10.1161/01.RES.77.6.1246	33	125	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27231	27235		10.1074/jbc.273.42.27231	http://dx.doi.org/10.1074/jbc.273.42.27231			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765245	hybrid			2022-12-25	WOS:000076448000032
J	Xirasagar, S; Elliott, MB; Bartolini, W; Gollnick, P; Gottlieb, PA				Xirasagar, S; Elliott, MB; Bartolini, W; Gollnick, P; Gottlieb, PA			RNA structure inhibits the TRAP (trp RNA-binding attenuation protein) RNA interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS BINDS; LEADER RNA; CRYSTAL-STRUCTURE; TELOMERIC DNA; OPERON; NUCLEOTIDES; REPRESSOR; SUBSTITUTION; TRANSCRIPTS; RECOGNITION	TRAP (trp RNA-binding attenuation protein) regulates expression of the tryptophan biosynthetic genes in response to tryptophan in Bacillus subtilis by binding to two sites containing a series of 9 or 11 (G/U)AG triplet repeats that are generally separated by two or three spacer nucleotides. Previous mutagenesis experiments have identified three TRAP residues, Lys-37, Lys-56, and Arg-58 that are essential for RNA binding. The location of these residues on the TRAP oligomer supports the proposal that RNA binds TRAP by encircling the TRAP oligomer, In this work, we show that RNAs containing 11 GAG or UAG repeats separated by CC dinucleotide spacers (((G/U)AGCC)(11)) form stable structures that inhibit binding to TRAP. This conclusion is based on the effects of temperature and Mg2+ on the affinity of TRAP for RNAs with CC spacers combined with UV hyperchromicity and circular dichroism. Furthermore, introducing the base analogue 7-deazaguanosine in the ((G/U)AGCC)(11) RNAs stabilized the TRAP-RNA interaction, This effect was associated with decreased stability of the RNA structure as measured by circular dichroism spectroscopy. The precise nature of the structure of the ((G/U)AGCC)(11) RNAs is not known but evidence is presented that it involves noncanonical interactions, We also observed that substitution of Arg-58 with Lys further reduced the ability of TRAP to interact with structured RNAs. Since in vivo function of TRAP may involve binding to structured RNAs, we suggest a potential function for this residue, which is conserved in TRAP from three different bacilli.	SUNY Buffalo, Dept Sci Biol, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Gottlieb, PA (corresponding author), SUNY Buffalo, Dept Sci Biol, Buffalo, NY 14260 USA.		Gottlieb, Philip/C-3113-2019	Gottlieb, Philip/0000-0003-3764-9885	NIGMS NIH HHS [GM52033] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052033] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P907, DOI 10.1021/bi00676a006; ANTSON AA, 1994, J MOL BIOL, V244, P1, DOI 10.1006/jmbi.1994.1698; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Babitzke P, 1996, J BACTERIOL, V178, P5159, DOI 10.1128/jb.178.17.5159-5163.1996; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; Babitzke P, 1997, MOL MICROBIOL, V26, P1, DOI 10.1046/j.1365-2958.1997.5541915.x; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; Baumann C, 1997, J BIOL CHEM, V272, P19863, DOI 10.1074/jbc.272.32.19863; BRAHMS J, 1966, J MOL BIOL, V15, P467, DOI 10.1016/S0022-2836(66)80122-5; Brion P, 1997, ANNU REV BIOPH BIOM, V26, P113, DOI 10.1146/annurev.biophys.26.1.113; BROYDE S, 1978, NUCLEIC ACIDS RES, V5, P2729, DOI 10.1093/nar/5.8.2729; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; Du HS, 1997, J BACTERIOL, V179, P2582, DOI 10.1128/jb.179.8.2582-2586.1997; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283; HOFFMAN RJ, 1995, J BACTERIOL, V177, P839, DOI 10.1128/jb.177.3.839-842.1995; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; MAZZARELLI JM, 1992, BIOCHEMISTRY-US, V31, P5925, DOI 10.1021/bi00140a032; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; RAMASAMY K, 1987, TETRAHEDRON LETT, V28, P5107, DOI 10.1016/S0040-4039(00)95603-X; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SEELA F, 1982, BIOCHEMISTRY-US, V21, P4338, DOI 10.1021/bi00261a024; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VARANI G, 1994, RNA PROTEIN INTERACT, P1; WIECZOREK A, 1994, BIOORG MED CHEM LETT, V4, P987, DOI 10.1016/S0960-894X(01)80668-5; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149; ZHANG XL, 1993, BIOCHEMISTRY-US, V32, P11374, DOI 10.1021/bi00093a014; ZHANG XL, 1995, NUCLEIC ACIDS RES, V23, P1502, DOI 10.1093/nar/23.9.1502; Ziehler WA, 1996, BIOTECHNIQUES, V20, P622	38	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27146	27153		10.1074/jbc.273.42.27146	http://dx.doi.org/10.1074/jbc.273.42.27146			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765233	hybrid			2022-12-25	WOS:000076448000020
J	Gribble, FM; Proks, P; Corkey, BE; Ashcroft, FM				Gribble, FM; Proks, P; Corkey, BE; Ashcroft, FM			Mechanism of cloned ATP-sensitive potassium channel activation by oleoyl-CoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN ACYL-COA; PANCREATIC BETA-CELLS; SULFONYLUREA RECEPTOR; INSULIN-SECRETION; K+ CURRENTS; GUANINE-NUCLEOTIDES; SKELETAL-MUSCLE; ADP/ATP CARRIER; SMOOTH-MUSCLE; MALONYL-COA	Insulin secretion from pancreatic beta cells is coupled to cell metabolism through closure of ATP-sensitive potassium (K-ATP,) channels, which comprise Kir6.2 and sulfonylurea receptor (SUR1) subunits. Although metabolic regulation of K-ATP, channel activity is believed to be mediated principally by the adenine nucleotides, other metabolic intermediates, including long chain acyl-CoA esters, may also be involved. We recorded macroscopic and single-channel currents from Xenopus oocytes expressing either Kir6.2/SUR1 or Kir6.2 Delta C36 (which forms channels in the absence of SUR1), Oleoyl-CoA (1 mu M) activated both wild-type Kir6.2/SUR1 and Kir6.2 Delta C36 macroscopic currents, similar to 2-fold, by increasing the number and open probability of Kir6.2/SUR1 and Kir6.2 Delta C36 channels. It was ineffective on the related Kir subunit Kir1.1a. Oleoyl-CoA also impaired channel inhibition by ATP, increasing the K-i values for both Kir6.2/SUR1 and Kir6.2 Delta C36 currents by similar to 3-fold. Our results indicate that activation of K-ATP channels by oleoyl-CoA results from an interaction with the Kir6.2 subunit, unlike the stimulatory effects of MgADP and diazoxide which are mediated through SUR1. The increased activity and reduced ATP sensitivity of K-ATP, channels by oleoyl-CoA might contribute to the impaired insulin secretion observed in non-insulin-dependent diabetes mellitus.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Boston Univ, Med Ctr, Boston, MA 02118 USA	University of Oxford; Boston University	Ashcroft, FM (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.	frances.ashcroft@physiol.ox.ac.uk	; Corkey, Barbara/E-7712-2015	Gribble, Fiona/0000-0002-4232-2898; Corkey, Barbara/0000-0002-5467-1630; Proks, Peter/0000-0001-6097-3646	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035914, R01DK035914, R56DK035914] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35914] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Branstrom R, 1997, J BIOL CHEM, V272, P17390, DOI 10.1074/jbc.272.28.17390; Chutkow WA, 1996, DIABETES, V45, P1439, DOI 10.2337/diabetes.45.10.1439; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FINDLAY I, 1986, PFLUG ARCH EUR J PHY, V407, P238, DOI 10.1007/BF00580683; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Karschin C, 1997, FEBS LETT, V401, P59, DOI 10.1016/S0014-5793(96)01438-X; KOZLOWSKI RZ, 1989, BRIT J PHARMACOL, V97, P1039, DOI 10.1111/j.1476-5381.1989.tb12560.x; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; OHNOSHOSAKU T, 1987, PFLUG ARCH EUR J PHY, V408, P133, DOI 10.1007/BF00581342; Paucek P, 1996, J BIOL CHEM, V271, P32084, DOI 10.1074/jbc.271.50.32084; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; PRENTKI M, 1997, DIABETOLOGIA, V40, P32; PROKS P, 1993, PFLUG ARCH EUR J PHY, V424, P63, DOI 10.1007/BF00375103; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; RUOHO AE, 1989, J BIOL CHEM, V264, P4168; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Trapp S, 1997, P NATL ACAD SCI USA, V94, P8872, DOI 10.1073/pnas.94.16.8872; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; WOLDEGIORGIS G, 1989, BIOCHEM BIOPH RES CO, V161, P502, DOI 10.1016/0006-291X(89)92627-2	38	116	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26383	26387		10.1074/jbc.273.41.26383	http://dx.doi.org/10.1074/jbc.273.41.26383			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756869	hybrid			2022-12-25	WOS:000076373300023
J	Ohnuma, S; Hirooka, K; Tsuruoka, N; Yano, M; Ohto, C; Nakane, H; Nishino, T				Ohnuma, S; Hirooka, K; Tsuruoka, N; Yano, M; Ohto, C; Nakane, H; Nishino, T			A pathway where polyprenyl diphosphate elongates in prenyltransferase - Insight into a common mechanism of chain length determination of prenyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNDECAPRENYL PYROPHOSPHATE SYNTHETASE; ASPARTATE-RICH MOTIF; ESCHERICHIA-COLI; MOLECULAR-CLONING; MICROCOCCUS-LUTEUS; SACCHAROMYCES-CEREVISIAE; BIOSYNTHETIC-PATHWAY; PARTIAL-PURIFICATION; PRENYL TRANSFERASES; BACILLUS-SUBTILIS	Prenyltransferases catalyze the consecutive condensations of isopentenyl diphosphate to produce linear polyprenyl diphosphates. Each enzyme forms the final product with a specific chain length. The product specificity of an enzyme is thought to be determined by the structure around the unknown path through which the product elongates in the enzyme. To explore the path, we introduced a few mutations at the 5th, the 8th, and/or the 11th positions before the first aspartate-rich motif of geranylgeranyl-diphosphate synthase or farnesyl-diphosphate synthase, The side chains of these amino acids are situated on the same side of an alpha-helix. In geranylgeranyl-diphosphate synthase, a single mutated enzyme (F77S) mainly produces a C-25 product (Ohnuma, S.-I., Hirooka, K., Hemmi, H., Ishida, C., Ohto, C., and Nishino, T. (1996) J. Biol. Chem. 271, 18831-18837). A double mutated enzyme (L74G and F77G) mainly produces a C-35 compound with significant amounts of C-35 and C-40. A triple mutated enzyme (I71G, L74G, and F77G) mainly produces a C-40 compound with C-35 and C-45. Mutated farnesyl-diphosphate synthases also show similar patterns. These findings indicate that the elongating product passages on a surface of the side chains of the mutated amino acids, the original bulky amino acids had blocked the elongation, and the path is conserved in prenyltransferases. Moreover, the fact that some double and triple mutated enzymes can also form small amounts of products longer than C-50 indicates that the paths in these mutated enzymes can partially access the outer surface of the enzymes.	Tohoku Univ, Dept Biochem & Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan; Toyota Motor Corp, Bio Res Labs, Toyota 4718572, Japan	Tohoku University; Toyota Motor Corporation	Ohnuma, S (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.		Hirooka, Kazutake/K-9827-2017; Tsuruoka, Naoki/L-1192-2018; Ohto, Chikara/GQB-4702-2022	Hirooka, Kazutake/0000-0001-5879-936X; Tsuruoka, Naoki/0000-0003-4052-3327; Ohnuma, Shin-ichi/0000-0002-3305-5126				ALLEN CM, 1976, ARCH BIOCHEM BIOPHYS, V175, P236, DOI 10.1016/0003-9861(76)90504-X; ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BABA T, 1980, ARCH BIOCHEM BIOPHYS, V200, P474, DOI 10.1016/0003-9861(80)90379-3; BREMS DN, 1981, BIOCHEMISTRY-US, V20, P3711, DOI 10.1021/bi00516a007; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CHEN AJ, 1994, ARCH BIOCHEM BIOPHYS, V314, P399, DOI 10.1006/abbi.1994.1459; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CORNISH K, 1993, EUR J BIOCHEM, V218, P267, DOI 10.1111/j.1432-1033.1993.tb18374.x; ERICSSON J, 1991, J BIOL CHEM, V266, P10602; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; FUJII H, 1982, J BIOL CHEM, V257, P4610; FUJISAKI S, 1986, J BIOCHEM-TOKYO, V99, P1327, DOI 10.1093/oxfordjournals.jbchem.a135600; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; HEIDE L, 1989, ARCH BIOCHEM BIOPHYS, V273, P331, DOI 10.1016/0003-9861(89)90491-8; ISHII K, 1983, BIOCHEM BIOPH RES CO, V116, P500, DOI 10.1016/0006-291X(83)90551-X; KOIKETAKESHITA A, 1995, J BIOL CHEM, V270, P18396, DOI 10.1074/jbc.270.31.18396; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; OHNUMA S, 1992, J BIOCHEM-TOKYO, V112, P743, DOI 10.1093/oxfordjournals.jbchem.a123969; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; Ohnuma S, 1996, J BIOL CHEM, V271, P30748, DOI 10.1074/jbc.271.48.30748; Ohnuma S, 1997, J BIOL CHEM, V272, P5192, DOI 10.1074/jbc.272.8.5192; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; Ohnuma S, 1997, J BIOCHEM-TOKYO, V121, P696; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; Okada K, 1997, J BACTERIOL, V179, P5992, DOI 10.1128/jb.179.19.5992-5998.1997; POULTER CD, 1982, BIOSYNTHESIS ISOPREN, P161; SAGAMI H, 1977, BIOCHEMISTRY-US, V16, P4616, DOI 10.1021/bi00640a014; Sambrook J., 2002, MOL CLONING LAB MANU; Suzuki K, 1997, J BIOCHEM, V121, P496; TAKAHASHI I, 1982, J BIOCHEM-TOKYO, V92, P1527, DOI 10.1093/oxfordjournals.jbchem.a134077; TAKAHASHI I, 1980, J BIOL CHEM, V255, P4539; TANAKA Y, 1988, Journal of Natural Rubber Research, V3, P177; TANAKA Y, 1989, J APPL POLYM SCI APP, V44, P1; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607	43	76	77	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26705	26713		10.1074/jbc.273.41.26705	http://dx.doi.org/10.1074/jbc.273.41.26705			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756913	hybrid			2022-12-25	WOS:000076373300067
J	Fujita, N; Nagahashi, A; Nagashima, K; Rokudai, S; Tsuruo, T				Fujita, N; Nagahashi, A; Nagashima, K; Rokudai, S; Tsuruo, T			Acceleration of apoptotic cell death after the cleavage of Bcl-X-L protein by caspase-3-like proteases	ONCOGENE			English	Article						Bcl-X-L; apoptosis; IL-2; caspase-3	CYTOCHROME-C; ICE/CED-3 PROTEASE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; PROTOONCOGENE BCL-2; MAMMALIAN HOMOLOG; FAMILY PROTEASES; GENE CED-3; ELEGANS; BCL-X(L)	Interleukin-2 (IL-2)-dependent T cell clone CTLL-2 underwent apoptosis by deprivation of IL-2 from culture medium. The decrease in the anti-apoptotic Bcl-X-L protein level was observed during apoptosis after IL-2 withdrawal, We found that Bcl-X-L protein was cleaved to produce two 18 kDa fragments during CTLL-2 cell apoptosis. When the activation of caspases was suppressed by overexpressing human Bcl-2 protein or by the addition of caspase inhibitors, cleavage of Bcl-X-L protein was suppressed in vivo. Bcl-X-L protein cleavage by incubation with apoptosed CTLL-2 cell lysate was suppressed by the caspase-3/CPP32-specific tetrapeptide inhibitor in vitro. Therefore, caspase-3/CPP32-like proteases were activated and involved in the cleavage of Bcl-X-L protein during CTLL-2 cell apoptosis. We found that Bcl-X-L protein was cleaved by caspase-3/CPP32 at two sites in the loop domain (i.e., HLAD(61 down arrow)S and SSLD(76 down arrow)A), The transfection of the carboxy-terminal 18 kDa Bcl-X-L fragment increased the sensitivity to apoptosis. These results indicate that caspase-3/CPP32-like proteases cleaved anti-apoptotic Bcl-X-L protein and resulted in accelerated apoptotic cell death.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Rokudai, Susumu/O-6771-2018; Fujita, Naoya/A-7349-2010	Rokudai, Susumu/0000-0003-0300-0391; Fujita, Naoya/0000-0002-9631-9264				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boulakia CA, 1996, ONCOGENE, V12, P529; BROOME HE, 1995, J IMMUNOL, V155, P2311; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FADOK VA, 1992, J IMMUNOL, V148, P2207; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Frankel A, 1997, CANCER RES, V57, P2388; FUJITA N, 1993, CANCER RES, V53, P5022; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu CKA, 1997, EXP CELL RES, V232, P17, DOI 10.1006/excr.1997.3509; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee SH, 1996, ONCOGENE, V13, P2131; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Naito M, 1997, CELL DEATH DIFFER, V4, P617, DOI 10.1038/sj.cdd.4400287; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Noguchi K, 1996, ONCOGENE, V13, P39; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Shimizu S, 1996, ONCOGENE, V12, P2251; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	54	140	143	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1295	1304		10.1038/sj.onc.1202065	http://dx.doi.org/10.1038/sj.onc.1202065			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771973				2022-12-25	WOS:000075803300012
J	Maouche-Chretien, L; Deleu, N; Badoual, C; Fraissignes, P; Berger, R; Gaulard, P; Romeo, PH; Leroy-Viard, K				Maouche-Chretien, L; Deleu, N; Badoual, C; Fraissignes, P; Berger, R; Gaulard, P; Romeo, PH; Leroy-Viard, K			Identification of a novel cDNA, encoding a cytoskeletal associated protein, differentially expressed in diffuse large B cell lymphomas	ONCOGENE			English	Article						lymphoma; cytoskeleton; cloning; DDRT	NON-HODGKINS-LYMPHOMA; GERMINAL CENTER FORMATION; MESSENGER-RNA; CHROMOSOMAL-ABNORMALITIES; CLINICAL CORRELATIONS; CYTOGENETIC ANALYSIS; KIEL CLASSIFICATION; ACTIN CYTOSKELETON; BTB/POZ DOMAIN; CROSS-LINKING	Diffuse large B-cell lymphomas (DLBL) constitute an heterogeneous clinico-pathological entity. To characterize molecular events related to histological subtypes, clinical presentation or outcome, we compared the mRNAs expressed in a limited series of DLBL by Differential display-reverse transcription (DDRT) and cloned a differential cDNA, that we called LB1, LB1 open reading frame encodes a 683 amino-acid polypeptide that does not show significant homology upon comparison to protein databases, nor any structural domain relating LB1 to an already known protein family, Immunofluorescence analysis of transfected COS cells showed a cytoplasmic filamentous staining, indicating that LB1 protein is tightly associated with cytoskeletal fibers, Two LB1 transcripts, a major 3,6 - 3.9 Kb and a minor 2.2 Kb transcripts, were detected among human haematopoietic and non-haematopoietic lines and tissues, LB1 transcripts were abundant in testis, thymus and in tumour derived cell lines, while barely detectable in liver, prostate and kidney, Concerning DLBL, LB1 expression was high in two cases of DLBL, and low or undetectable in four others, confirming the differential expression previously observed in the DDRT experiment. Furthermore, LB1 gene mapped to chromosome 13q14, a region that has been involved as a chromosomal breakpoint in DLBL, The cellular function of LB1 and its relationship with B cell maturation and/or oncogenesis remain to be established.	Hop Henri Mondor, INSERM, U474, F-94010 Creteil, France; Hop St Louis, Ctr G Hayem, INSERM, U301, F-75475 Paris, France; Hop Henri Mondor, Dept Pathol, F-94010 Creteil, France; Hop Henri Mondor, EA 2348, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Leroy-Viard, K (corresponding author), Hop Henri Mondor, INSERM, U474, 51 Av Mal De Lattre De Tassigny, F-94010 Creteil, France.		Romeo, Paul-Henri/L-5989-2017; maouche, leila/E-3887-2017; Leroy, Karen/E-9235-2011	Romeo, Paul-Henri/0000-0002-8294-0367; Leroy, Karen/0000-0002-4379-0140; CHRETIEN, LEILA/0000-0001-5747-9719; Badoual, Cecile/0000-0002-1143-3085				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; BASTARD C, 1994, BLOOD, V83, P2423; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Engelhard M, 1997, BLOOD, V89, P2291; Foisner R, 1996, MOL BIOL CELL, V7, P273, DOI 10.1091/mbc.7.2.273; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Gomez J, 1997, J IMMUNOL, V158, P1516; HAILAT N, 1990, ONCOGENE, V5, P1615; HARRIS NL, 1994, BLOOD, V84, P1361; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; JACOBSON JO, 1993, CANCER, V72, P231, DOI 10.1002/1097-0142(19930701)72:1<231::AID-CNCR2820720141>3.0.CO;2-5; Jugloff LS, 1997, J IMMUNOL, V159, P1096; JUNEJA S, 1990, BRIT J HAEMATOL, V76, P231, DOI 10.1111/j.1365-2141.1990.tb07877.x; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOCIALKOWSKI S, 1995, BRIT J HAEMATOL, V89, P55, DOI 10.1111/j.1365-2141.1995.tb08911.x; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LADANYI M, 1991, BLOOD, V77, P1057; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LO CF, 1994, BLOOD, V83, P1757; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; OFFIT K, 1991, BLOOD, V77, P1508; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; SCHOUTEN HC, 1990, BLOOD, V75, P1841; STANSFELD AG, 1988, LANCET, V1, P292; STAUDER R, 1995, BLOOD, V85, P2885, DOI 10.1182/blood.V85.10.2885.bloodjournal85102885; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VILLUENDAS R, 1993, BLOOD, V82, P3151; WHANGPENG J, 1995, BLOOD, V85, P203, DOI 10.1182/blood.V85.1.203.bloodjournal851203; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	42	34	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1245	1251		10.1038/sj.onc.1202048	http://dx.doi.org/10.1038/sj.onc.1202048			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771967				2022-12-25	WOS:000075803300006
J	Ding, GJF; Fischer, PA; Boltz, RC; Schmidt, JA; Colaianne, JJ; Gough, A; Rubin, RA; Miller, DK				Ding, GJF; Fischer, PA; Boltz, RC; Schmidt, JA; Colaianne, JJ; Gough, A; Rubin, RA; Miller, DK			Characterization and quantitation of NF-kappa B nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha - Development and use of a high capacity fluorescence cytometric system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR; RECEPTOR ANTAGONIST; PROTEIN-KINASE; ACTIVATION; PHOSPHORYLATION; PRECURSOR; BINDING; SIGNAL; FORM	A new quantitative cytometric technique, termed the ArrayScan(TM), is described and used to measure NF-KB nuclear translocation induced by interleukin (IL)-1 and tumor necrosis factor-alpha (TNF alpha). The amount of p65 staining is measured in both the nuclei defined by Hoechst 33342 labeling and in the surrounding cytoplasmic area within a preselected number of cells/well in 96-well plates. Using this technique in synchronously activated human chondrocytes or HeLa cells, NF-kappa B was found to move to the nucleus with a half-time of 7-8 min for HeLa and 12-13 min for chondrocytes, a rate in each case about 4-5 min slower than that of I kappa B alpha degradation. IL-1 receptor antagonist and anti-TypeI IL-1 receptor antiserum on the one hand and anti-TNF alpha and monoclonal anti-TNF receptor 1 antibodies on the other hand could be shown to respectively inhibit IL-1 and TNF alpha stimulation in both cell types. In contrast, a polyclonal anti-TNF receptor 1 antiserum exhibited both a 50% agonism and a 50% antagonism to a TNF alpha stimulation in a dose-dependent fashion, indicating that subtle functional responses to complex agonist and antagonist stimuli could be measured. The effects of different proteasome inhibitors to prevent I kappa B alpha degradation and subsequent NF-kappa B translocation could also be discriminated; Leu-Leu-Leu aldehyde was only a partial inhibitor with an IC50 of 2 mu M, while clastolactacystin beta-lactone was a complete inhibitor with an IC50 of 10 mu M. The nonselective kinase inhibitor K252a completely inhibited both IL-1 and TNF alpha stimulation in both cell types with an IC50 of 0.4 mu M. This concentration determined after a 20-min stimulation, was shown to be comparable with that obtained for inhibition of IL-6 production induced by a 100-fold lower IL-1 and TNF alpha concentration measured after 17 h of stimulation. These results suggest that the ArrayScan(TM) technology provides a rapid, sensitive, quantitative technique for measuring early events in the signal transduction of NF-kappa B.	Merck Res Labs, Dept Immunol & Inflammat, Rahway, NJ 07065 USA; Merck Res Labs, Dept Biometr Res, Rahway, NJ 07065 USA; Cellom Inc, Pittsburgh, PA 15238 USA	Merck & Company; Merck & Company	Miller, DK (corresponding author), Merck Res Labs, Dept Immunol & Inflammat, POB 2000,R80N-A32, Rahway, NJ 07065 USA.	douglas_miller@merck.com	Gough, Albert/K-2490-2019	Gough, Albert/0000-0001-6456-0195				AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; AREND W P, 1990, Progress in Growth Factor Research, V2, P193, DOI 10.1016/0955-2235(90)90018-F; AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIN J, 1987, J EXP MED, V165, P70, DOI 10.1084/jem.165.1.70; Dick LR, 1997, J BIOL CHEM, V272, P182; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Dinarello C A, 1992, Semin Immunol, V4, P133; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; Giuliano KA, 1997, J BIOMOL SCREEN, V2, P249, DOI 10.1177/108705719700200410; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MCINTYRE KW, 1991, J EXP MED, V173, P931, DOI 10.1084/jem.173.4.931; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIMS JE, 1994, EUR CYTOKINE NETW, V5, P539; SMITH RA, 1987, J BIOL CHEM, V262, P6951; Sonoda Y, 1997, J BIOL CHEM, V272, P15366, DOI 10.1074/jbc.272.24.15366; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	46	185	207	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28897	28905		10.1074/jbc.273.44.28897	http://dx.doi.org/10.1074/jbc.273.44.28897			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786892	Green Submitted, hybrid			2022-12-25	WOS:000076691800053
J	Sperling, P; Zahringer, U; Heinz, E				Sperling, P; Zahringer, U; Heinz, E			A sphingolipid desaturase from higher plants - Identification of a new cytochrome b(5) fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID DESATURASE; LONG-CHAIN BASES; SACCHAROMYCES; DOMAIN; ENZYME; DIHYDROCERAMIDE; MONOOXYGENASE; HYDROXYLATION; EXPRESSION; LEAVES	A recently cloned cDNA from sunflower codes for a fusion protein composed of an N-terminal cytochrome b(5) and a domain similar to membrane-bound acyl lipid desaturases. For a functional identification, homologous cDNAs from Brassica napus and Arabidopsis thaliana were expressed in Saccharomyces cerevisiae, and sphingolipid long chain bases were analyzed. The expression of the heterologous enzyme results in significant proportions of new Delta(8,9)-cis/trans-phytosphingenines that accompany the residual C-18-phytosphinganine predominating in wild-type yeast cells. These results represent the first identification of a gene coding for a sphingolipid desaturase and for a stereounselective desaturase showing trans-activity from any organism. Furthermore, this fusion protein is a new member of the cytochrome b(5) superfamily. The formation of the two regioisomeric phytosphingenines in the transformed yeast sheds new light on the factors controlling regioselectivity.	Univ Hamburg, Inst Allgemeine Bot, D-22609 Hamburg, Germany; Forschungszentrum Borstel, Lab Grp Immunchem, D-23845 Borstel, Germany	University of Hamburg; Forschungszentrum Borstel	Heinz, E (corresponding author), Univ Hamburg, Inst Allgemeine Bot, Ohnhorststr 18, D-22609 Hamburg, Germany.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSSON BA, 1974, LIPIDS, V9, P185, DOI 10.1007/BF02532690; ASUBEL FM, 1995, CURRENT PROTOCOLS MO; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; FROST DJ, 1975, CHEM PHYS LIPIDS, V15, P53, DOI 10.1016/0009-3084(75)90032-8; Fulda M, 1997, PLANT MOL BIOL, V33, P911, DOI 10.1023/A:1005780529307; Gallagher SC, 1997, EUR J BIOCHEM, V247, P635, DOI 10.1111/j.1432-1033.1997.00635.x; Gilchrist DG, 1997, CELL DEATH DIFFER, V4, P689, DOI 10.1038/sj.cdd.4400312; Girke T, 1998, PLANT J, V15, P39, DOI 10.1046/j.1365-313X.1998.00178.x; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; HASCHKE HP, 1990, BOT ACTA, V103, P32, DOI 10.1111/j.1438-8677.1990.tb00122.x; Imai H, 1997, BIOSCI BIOTECH BIOCH, V61, P351, DOI 10.1271/bbb.61.351; Itoh R, 1998, CURR GENET, V33, P165, DOI 10.1007/s002940050323; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; KARLSSON KA, 1970, CHEM PHYS LIPIDS, V5, P6, DOI 10.1016/0009-3084(70)90008-3; KARLSSON KA, 1970, LIPIDS, V5, P878, DOI 10.1007/BF02531119; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; Kok JW, 1997, J BIOL CHEM, V272, P21128, DOI 10.1074/jbc.272.34.21128; LEMIEUX RU, 1955, CAN J CHEM, V33, P1710, DOI 10.1139/v55-209; LESTER RL, 1993, J BIOL CHEM, V268, P845; LEVIN RJ, 1989, NUCLEIC ACIDS RES, V17, P6349, DOI 10.1093/nar/17.15.6349; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Mitchell AG, 1997, J BIOL CHEM, V272, P28281, DOI 10.1074/jbc.272.45.28281; MITCHELL AG, 1995, J BIOL CHEM, V270, P29766; MORRISON WR, 1970, BIOCHIM BIOPHYS ACTA, V202, P460, DOI 10.1016/0005-2760(70)90116-5; Napier JA, 1998, BIOCHEM J, V330, P611; OHNISHI M, 1983, BIOCHIM BIOPHYS ACTA, V752, P416; OKULEY J, 1994, PLANT CELL, V6, P147, DOI 10.1105/tpc.6.1.147; Sayanova O, 1997, P NATL ACAD SCI USA, V94, P4211, DOI 10.1073/pnas.94.8.4211; Scheffler JA, 1997, THEOR APPL GENET, V94, P583, DOI 10.1007/s001220050454; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; SIEBERTZ HP, 1980, EUR J BIOCHEM, V108, P177, DOI 10.1111/j.1432-1033.1980.tb04710.x; SPERLING P, 1995, EUR J BIOCHEM, V232, P798, DOI 10.1111/j.1432-1033.1995.0798a.x; SPERLING P, 1993, J BIOL CHEM, V268, P26935; Wise ML, 1997, BIOCHEMISTRY-US, V36, P2985, DOI 10.1021/bi962158v; Zahringer U, 1997, J BIOL CHEM, V272, P26262, DOI 10.1074/jbc.272.42.26262	40	144	149	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28590	28596		10.1074/jbc.273.44.28590	http://dx.doi.org/10.1074/jbc.273.44.28590			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786850	hybrid			2022-12-25	WOS:000076691800011
J	Bowman, EP; Campbell, JJ; Druey, KM; Scheschonka, A; Kehrl, JH; Butcher, EC				Bowman, EP; Campbell, JJ; Druey, KM; Scheschonka, A; Kehrl, JH; Butcher, EC			Regulation of chemotactic and proadhesive responses to chemoattractant receptors by RGS (Regulator of G-protein Signaling) family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; FORMYL PEPTIDE RECEPTOR; FUNCTIONAL EXPRESSION; CHEMOKINE RECEPTORS; LEUKOCYTE ADHESION; COUPLED RECEPTORS; TRANSITION-STATE; GENE-EXPRESSION; ALPHA-SUBUNITS; LYMPHOID-CELLS	Serpentine G alpha(i)-linked receptors support rapid adhesion and directed migration of leukocytes and other cell types. The intracellular mechanisms mediating and regulating chemoattractant-directed adhesion and locomotion are only now beginning to be explored. RGS (for regulator of G-protein signaling) proteins are a recently described family that regulate G alpha(i)-stimulated pathways by acting as GTPase-activating proteins. Little is known about the GTPase activity of the G alpha(i) proteins involved in adhesion and chemotaxis, or the significance of their regulation to these responses. Using transiently transfected lymphoid cells as a model system, we show that expression of RGS1, RGS3, and RGS4 inhibits chemoattractant-induced migration. In contrast, RGS2, a regulator of G alpha(q) activity, had no effect on cell migration to any chemoattractant. RGS1, RGS3, and RGS4 also reduced rapid chemoattractant-triggered adhesion, although the proadhesive response appears quantitatively less sensitive to RGS action than chemotaxis, The results suggest that the duration of the G alpha(i) signal may be a particularly important parameter in the chemotactic responses of leukocytes, and demonstrate the potential for RGS family members to regulate cellular adhesive and migratory behaviors.	Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Ctr Digest Dis, Dept Med, Stanford, CA 94305 USA; Dept Vet Affairs, Palo Alto Hlth Care Syst, Foothill Res Ctr, Ctr Mol Biol & Med, Palo Alto, CA 94305 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Butcher, EC (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA.		Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X; Campbell, James/0000-0003-4252-5182	NCI NIH HHS [5T32CA090302] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline; NIGMS NIH HHS [GM56527] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056527] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BARGATZE RF, 1987, J EXP MED, V166, P1125, DOI 10.1084/jem.166.4.1125; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Campbell JJ, 1997, EUR J IMMUNOL, V27, P2571, DOI 10.1002/eji.1830271016; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Grant KR, 1997, IMMUNOLOGY, V90, P564, DOI 10.1046/j.1365-2567.1997.00196.x; Hall AL, 1997, J LEUKOCYTE BIOL, V62, P535, DOI 10.1002/jlb.62.4.535; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HONDA S, 1994, J IMMUNOL, V152, P4026; HONG JX, 1993, J IMMUNOL, V150, P3895; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Kitayama J, 1997, J IMMUNOL, V158, P2340; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Mackay CR, 1996, J EXP MED, V184, P799, DOI 10.1084/jem.184.3.799; MATSUOKA M, 1993, AM J MED SCI, V306, P89, DOI 10.1097/00000441-199308000-00004; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; PALERMO DP, 1991, J BIOTECHNOL, V19, P35, DOI 10.1016/0168-1656(91)90073-5; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Sabroe I, 1997, J IMMUNOL, V158, P1361; Sagoo MS, 1997, NATURE, V389, P392, DOI 10.1038/38750; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAKAI Y, 1993, CIBA F SYMP, V176, P128; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WALTZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wieland T, 1997, J BIOL CHEM, V272, P8853; WITTE ON, 1978, P NATL ACAD SCI USA, V75, P2488, DOI 10.1073/pnas.75.5.2488; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1989, J IMMUNOL, V142, P1956; Yu JH, 1996, EMBO J, V15, P5184, DOI 10.1002/j.1460-2075.1996.tb00903.x	63	108	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28040	28048		10.1074/jbc.273.43.28040	http://dx.doi.org/10.1074/jbc.273.43.28040			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774420	hybrid			2022-12-25	WOS:000076549800040
J	Talla, E; de Mendonca, RL; Degand, I; Goffeau, A; Ghislain, M				Talla, E; de Mendonca, RL; Degand, I; Goffeau, A; Ghislain, M			Schistosoma mansoni Ca2+-ATPase SMA2 restores viability to yeast Ca2+-ATPase-deficient strains and functions in calcineurin-mediated Ca2+ tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; PLASMA-MEMBRANE; SARCOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CA-2+ PUMP; CALCIUM PUMPS; SARCO/ENDOPLASMIC RETICULUM; CHROMOSOMAL LOCALIZATION; TISSUE DISTRIBUTION	The sarco(endo)plasmic reticulum of animal cells contains an ATP-powered Ca2+ pump that belongs to the P-type family of membrane-bound cation-translocating enzymes. In Schistosoma mansoni, the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) is encoded by the SMA1 and SMA2 genes. A full-length SMA2 cDNA clone was isolated, sequenced, and expressed into a yeast Ca2+-ATPase-deficient strain requiring plasmid-borne rabbit SERCA1a for viability. The S. mansoni Ca2+-ATPase supports growth of mutant cells lacking SERCA1a, indicating functional expression in yeast and a role in calcium sequestration. Subcellular fractionation showed that the SMA2 ATPase is localized in yeast internal membranes. SMA2 expression was found to be associated with thapsigargin-sensitive, Ca2+-dependent ATPase activity. The activity increased 2-fold upon calcineurin inactivation, which correlates with in vivo stimulated contribution of SMA2 in calcium tolerance. These results suggest that calcineurin controls calcium homeostasis by inhibiting Ca2+-ATPase activity in an internal compartment.	Catholic Univ Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium	Universite Catholique Louvain	Ghislain, M (corresponding author), Catholic Univ Louvain, Unite Biochim Physiol, Pl Croix Sud 2-20, B-1348 Louvain, Belgium.	ghislain@fysa.ucl.ac.be		TALLA, Emmanuel/0000-0002-7775-8296				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAPIEAUX E, 1989, J BIOL CHEM, V264, P7437; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CIOLI D, 1995, PHARMACOL THERAPEUT, V68, P35, DOI 10.1016/0163-7258(95)00026-7; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CUNHA VM, 1997, LIFE SCI, V60, P289; CUNHA VMN, 1992, MOL BIOCHEM PARASIT, V52, P167, DOI 10.1016/0166-6851(92)90049-P; CUNHA VMN, 1988, FEBS LETT, V241, P65, DOI 10.1016/0014-5793(88)81032-9; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DAVIES TW, 1983, PARASITOLOGY, V87, P55, DOI 10.1017/S0031182000052410; DEMEIS L, 1981, TRANSPORT LIFE SCI, V2, P1; DEMENDONCA RL, 1995, MOL BIOCHEM PARASIT, V72, P129, DOI 10.1016/0166-6851(95)00078-F; DEXAERDE AD, 1995, J BIOL CHEM, V270, P23828, DOI 10.1074/jbc.270.40.23828; Dode L, 1996, BIOCHEM J, V318, P689, DOI 10.1042/bj3180689; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; ENOUF J, 1988, J BIOL CHEM, V263, P13922; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALLON PG, 1994, PARASITOL RES, V80, P623, DOI 10.1007/BF00933013; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; FOOR F, 1992, NATURE, V360, P682; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; HAMILTON BA, 1991, NUCLEIC ACIDS RES, V19, P1951, DOI 10.1093/nar/19.8.1951; JAMES P, 1988, J BIOL CHEM, V263, P2905; KNIGHT M, 1984, EMBO J, V3, P213, DOI 10.1002/j.1460-2075.1984.tb01786.x; LIMA SF, 1994, PARASITOLOGY, V109, P57, DOI 10.1017/S0031182000077763; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MAGYAR A, 1990, BIOCHEM BIOPH RES CO, V173, P872, DOI 10.1016/S0006-291X(05)80867-8; Mair GR, 1998, PARASITOL TODAY, V14, P73, DOI 10.1016/S0169-4758(97)01182-4; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NECHAY BR, 1980, J PARASITOL, V66, P596, DOI 10.2307/3280515; PALMERO I, 1989, J MOL BIOL, V210, P737, DOI 10.1016/0022-2836(89)90106-X; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; Redman CA, 1996, PARASITOL TODAY, V12, P14, DOI 10.1016/0169-4758(96)80640-5; REVELARD P, 1991, MOL BIOCHEM PARASIT, V46, P241, DOI 10.1016/0166-6851(91)90048-B; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Sillen L, 1964, STABILITY CONSTANTS; SMITHERS SR, 1965, PARASITOLOGY, V55, P695, DOI 10.1017/S0031182000086248; Sorin A, 1997, J BIOL CHEM, V272, P9895; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; THAPSTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WACH A, 1990, EUR J BIOCHEM, V189, P675, DOI 10.1111/j.1432-1033.1990.tb15536.x; WACH A, 1991, EUR J BIOCHEM, V201, P91, DOI 10.1111/j.1432-1033.1991.tb16260.x; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WELLS KE, 1991, EXP PARASITOL, V73, P295, DOI 10.1016/0014-4894(91)90101-2; Withee JL, 1998, GENETICS, V149, P865; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	81	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27831	27840		10.1074/jbc.273.43.27831	http://dx.doi.org/10.1074/jbc.273.43.27831			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774393	hybrid			2022-12-25	WOS:000076549800013
J	Suo, ZC; Johnson, KA				Suo, ZC; Johnson, KA			Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-phosphonylmethoxypropyl)adenine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; HUMAN-IMMUNODEFICIENCY-VIRUS; DEFICIENCY SYNDROME AIDS; STATE KINETIC-ANALYSIS; BASE-EXCISION-REPAIR; MITOCHONDRIAL-DNA; NUCLEAR EXTRACT; HTLV-III; FIDELITY; MECHANISM	(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA) is an acyclic nucleoside phosphonate that has been shown to be effective in the treatment of AIDS although it has a shorter separation between the adenine and phosphorus than dideoxy-AMP and dAMP. By using presteady state kinetic methods, we examined the incorporation of the diphosphate of PMPA 2',3'-dideoxyadenosine 5'-triphosphate (ddATP), and dATP catalyzed by wild-type human immunodeficiency virus type 1 (HIV-1) reverse transcriptase, an exonuclease-deficient T7 DNA polymerase (T7 exo(-)), and wild-type rat DNA polymerase beta in order to evaluate the selectivity of PMPA as an antiviral inhibitor. With a DNA/DNA or DNA/RNA 22/43-mer duplex, the diphosphate of PMPA (PMPApp) is as effective as ddATP in reactions catalyzed by HIV-1 reverse transcriptase in that both analogs have similar substrate specificity constants (k(p)/K-d) which are only 5-fold lower than dATP. In contrast, PMPApp is a much weaker inhibitor of the reaction catalyzed by T7 exo(-) (with the DNA/DNA 22/43-mer duplex) in that PMPApp has a 5 x 10(-4)-fold lower k(d)/K-d than ddATP and dATP. The lower k(p)/K-d of PMPApp is due to a 1000-2000-fold lower incorporation rate (k(p)) and a 35-45-fold lower binding constant (K-d). Similarly, PMPApp is 800-fold less inhibitory toward polymerase beta with the DNA/DNA 22/43-mer duplex, whereas in studies with a single nucleotide gapped DNA (22-20/43-mer) PMPApp is 13-fold less inhibitory than ddATP. Although parallel studies will need to be performed using appropriate human polymerases, these results begin to define the mechanistic basis for the reported lower toxicity of PMPA in the treatment of AIDS.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Johnson, KA (corresponding author), Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA.	kajl@psu.edu			NIGMS NIH HHS [GM44613] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044613] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; Amaudo E, 1991, LANCET, V337, P508; BALZARINI J, 1993, ANTIMICROB AGENTS CH, V37, P332, DOI 10.1128/AAC.37.2.332; BALZARINI J, 1991, BIOCHEM BIOPH RES CO, V178, P329, DOI 10.1016/0006-291X(91)91818-W; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; CHEN CH, 1989, J BIOL CHEM, V264, P11934; Cherrington JM, 1996, ANTIMICROB AGENTS CH, V40, P2212, DOI 10.1128/AAC.40.9.2212; CHERRINGTON JM, 1995, ANTIVIR CHEM CHEMOTH, V6, P217, DOI 10.1177/095632029500600403; Cohen J, 1997, SCIENCE, V277, P32, DOI 10.1126/science.277.5322.32; Dawson R., 1987, BIOCHEM EDUC, V15, P97; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; ISAACS NS, 1987, PHYSICA ORGANIC CHEM; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KATI WM, 1992, J BIOL CHEM, V267, P25988; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; Kornberg A., 1992, DNA REPLICATION; LARDER BA, 1993, REVERSE TRANSCRIPTAS, P205; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743; Mulato AS, 1997, ANTIVIR RES, V36, P91, DOI 10.1016/S0166-3542(97)00043-0; PARKER WB, 1994, J NIH RES, V6, P57; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SENGUPTA DN, 1986, BIOCHEM BIOPH RES CO, V136, P341, DOI 10.1016/0006-291X(86)90916-2; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; vanRompay KKA, 1996, ANTIMICROB AGENTS CH, V40, P2586, DOI 10.1128/AAC.40.11.2586; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j	50	63	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27250	27258		10.1074/jbc.273.42.27250	http://dx.doi.org/10.1074/jbc.273.42.27250			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765248	hybrid			2022-12-25	WOS:000076448000035
J	Badea, TC; Niculescu, FI; Soane, L; Shin, ML; Rus, H				Badea, TC; Niculescu, FI; Soane, L; Shin, ML; Rus, H			Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TERMINAL COMPLEMENT; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; COMPLEXES; PROTEINS; ATTACK; MYELIN; ABSENCE; C5B-9	Sublytic complement activation on oligodendrocytes (OLG) down-regulates expression of myelin genes and induces cell cycle in culture. Differential display (DD) was used to search for new genes whose expression is altered in response to complement and that may be involved in cell cycle activation. DD bands showing either increased or decreased mRNA expression in response to complement were identified and designated Response Genes to Complement (RGC) 1-32, RGC-1 is identical with heat shock protein 105, RGC-2 with poly(ADP-ribose) polymerase, and RGC-10 with IP-10, A new gene, RGC-32, that encodes a protein of 137 amino acids was cloned. RGC-32 has no homology with other known proteins, and contains no motif that would indicate its function. In OLG, the mRNA expression was increased by complement activation and by terminal complement complex assembly. RGC-32 protein was localized in the cytoplasm and co-immunoprecipitated with cdc2 kinase. Overexpression of RGC-32 increased DNA synthesis in OLGxC6 glioma cell hybrids. These results suggest that RGC-32 may play a role in cell cycle activation.	Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Rus, H (corresponding author), Univ Maryland, Sch Med, Dept Pathol, 10 S Pine St, Baltimore, MD 21201 USA.		Badea, Tudor Constantin/B-1654-2018; Rus, Horea/AAF-2583-2020	Badea, Tudor Constantin/0000-0003-3086-6713; 	NIAID NIH HHS [R01 AI 19006] Funding Source: Medline; NINDS NIH HHS [R0-1 NS 19906] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985; CARNEY DF, 1990, J IMMUNOL, V145, P623; COMPSTON DAS, 1989, NEUROPATH APPL NEURO, V15, P307, DOI 10.1111/j.1365-2990.1989.tb01231.x; COMPSTON DAS, 1986, NEUROLOGY, V36, P1503, DOI 10.1212/WNL.36.11.1503; HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418; Lang TJ, 1997, J NEUROCHEM, V68, P1581; LININGTON C, 1989, BRAIN, V112, P895, DOI 10.1093/brain/112.4.895; LININGTON C, 1989, ACTA NEUROPATHOL, V79, P78, DOI 10.1007/BF00308961; LIU WT, 1983, J IMMUNOL, V131, P778; NICULESCU F, 1994, J BIOL CHEM, V269, P4417; NICULESCU F, 1993, J IMMUNOL, V150, P214; Niculescu F, 1997, J IMMUNOL, V158, P4405; PIDDLESDEN SJ, 1994, J IMMUNOL, V152, P5477; Rus H, 1997, IMMUNOPHARMACOLOGY, V38, P177, DOI 10.1016/S0162-3109(97)00063-5; Rus HG, 1996, J IMMUNOL, V156, P4892; SANDERS ME, 1986, J IMMUNOL, V136, P4456; SCOLDING NJ, 1989, J NEUROL SCI, V89, P289, DOI 10.1016/0022-510X(89)90030-0; SHEARER WT, 1975, J EXP MED, V141, P736; SHIRAZI Y, 1989, J IMMUNOL, V142, P4385; SHIRAZI Y, 1993, J IMMUNOL, V150, P4581; VANGURI P, 1982, P NATL ACAD SCI-BIOL, V79, P3290, DOI 10.1073/pnas.79.10.3290; VANGURI P, 1988, J BIOL CHEM, V263, P7228; WIEDMER T, 1987, J BIOL CHEM, V262, P13674; WREN DR, 1989, P NATL ACAD SCI USA, V86, P9025, DOI 10.1073/pnas.86.22.9025	24	84	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26977	26981		10.1074/jbc.273.41.26977	http://dx.doi.org/10.1074/jbc.273.41.26977			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756947	hybrid			2022-12-25	WOS:000076373300101
J	Kallen, CB; Billheimer, JT; Summers, SA; Stayrook, SE; Lewis, M; Strauss, JF				Kallen, CB; Billheimer, JT; Summers, SA; Stayrook, SE; Lewis, M; Strauss, JF			Steroidogenic acute regulatory protein (StAR) is a sterol transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOID ADRENAL-HYPERPLASIA; CARRIER PROTEIN-2; CELLS; EXPRESSION; GENE; PHOSPHOPROTEIN; PURIFICATION; BIOSYNTHESIS; CHOLESTEROL	Steroidogenic acute regulatory protein (StAR) plays a critical role in steroidogenesis by enhancing the delivery of substrate cholesterol from the outer mitochondrial membrane to the cholesterol side chain cleavage enzyme system on the inner membrane. A recombinant StAR protein lacking the first N-terminal 62 amino acid residues that includes the mitochondrial targeting sequence was shown to stimulate the transfer of cholesterol and beta-sitosterol from liposomes to heat-treated mitochondria in a dose-, time-, and temperature-dependent manner. A recombinant mutant StAR protein that cannot stimulate steroidogenesis by isolated mitochondria did not promote sterol transfer. Unlike the more promiscuous lipid transfer protein, sterol carrier protein 2 (SCP2), StAR did not stimulate phosphatidylcholine transfer in our assay system. The recombinant StAR protein increased cholesterol transfer to heat-treated microsomes as well as to heat- and trypsin-treated mitochondria. These observations demonstrate that StAR has sterol transfer activity, which may reflect an ability to enhance desorption of cholesterol from sterol-rich donor membranes. We suggest that the ability of StAR to promote sterol transfer explains its steroidogenic activity.	Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Dupont Merck Pharmaceut Co, Wilmington, DE 19880 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; DuPont	Strauss, JF (corresponding author), 778 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	jfs3@mail.med.upenn.edu	/AAE-5384-2020	Stayrook, Steven/0000-0002-1677-8293; Kallen, Caleb/0000-0002-4156-6719	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD034449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009375] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-34449, HD-06274] Funding Source: Medline; NIDDK NIH HHS [DK-09375] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; BILLHEIMER JT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P136, DOI 10.1016/0005-2760(90)90180-6; BLOJ B, 1977, J BIOL CHEM, V252, P1613; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; HARTIGAN JA, 1995, J STEROID BIOCHEM, V53, P95, DOI 10.1016/0960-0760(95)00026-V; KRUEGER RJ, 1983, J BIOL CHEM, V258, P159; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MARTINEZ F, 1997, SUBCELL BIOCH, V28, P208; MATSUURA JE, 1993, BIOCHEMISTRY-US, V32, P567, DOI 10.1021/bi00053a023; Nakae J, 1997, HUM MOL GENET, V6, P571, DOI 10.1093/hmg/6.4.571; PON LA, 1986, J BIOL CHEM, V261, P3309; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	20	171	175	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26285	26288		10.1074/jbc.273.41.26285	http://dx.doi.org/10.1074/jbc.273.41.26285			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756854	hybrid			2022-12-25	WOS:000076373300008
J	Pal, S; Claffey, P; Cohen, HT; Mukhopadhyay, D				Pal, S; Claffey, P; Cohen, HT; Mukhopadhyay, D			Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; RENAL-CELL CARCINOMA; FACTOR EXPRESSION; V-SRC; SP1; ANGIOGENESIS; PRODUCT; RECEPTORS; ONCOGENES; MUTATIONS	The transcription factor Sp1 is ubiquitously expressed and plays a significant role in the constitutive and induced expression of a variety of mammalian genes and may even contribute to tumorigenesis. Here, we describe a novel pathway whereby Sp1 promotes the transcription of vascular permeability factor/vascular endothelial growth factor (VPF/NEGF), a potent angiogenic factor, by interacting directly and specifically with protein kinase C zeta (PKC zeta) isoform in renal cell carcinoma. PKC zeta binds and phosphorylates the zinc finger region of Sp1. Moreover, in the presence of the wild type von Hippel-Lindau gene product, the interaction of Sp1 with PKC zeta is inhibited, and in this manner steady state levels of Sp1 phosphorylation are decreased significantly. Co-transfection of renal cell carcinoma cells and human fibrosarcoma cells with a plasmid overexpressing PKC zeta and VPF/VEGF promoter luciferase constructs results in activation of Sp1-mediated transcription, whereas expression of a dominant-negative mutant of PKC zeta repressed this activation. Taken together, our results suggest a new pathway of cell signaling through PKC zeta and provide an insight into PKC zeta and Sp1-dependent transcriptional regulation of VPF/VEGF expression and thus tumor angiogenesis,	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA; Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston University	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, RN 270H,99 Brookline Ave, Boston, MA 02215 USA.							Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BROWN LF, 1993, AM J PATHOL, V143, P1255; CHEN F, 1995, CANCER RES, V55, P4804; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1996, SCI AM, V275, P150, DOI 10.1038/scientificamerican0996-150; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GNARRA JR, 1993, UROL CLIN N AM, V20, P207; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MURATA Y, 1994, J BIOL CHEM, V269, P20674; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RAK J, 1995, CANCER RES, V55, P4575; RICHARDS FM, 1995, HUM MOL GENET, V4, P2139, DOI 10.1093/hmg/4.11.2139; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367	29	157	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26277	26280		10.1074/jbc.273.41.26277	http://dx.doi.org/10.1074/jbc.273.41.26277			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756852	hybrid			2022-12-25	WOS:000076373300006
J	Herrmann, C; Block, C; Geisen, C; Haas, K; Weber, C; Winde, G; Moroy, T; Muller, O				Herrmann, C; Block, C; Geisen, C; Haas, K; Weber, C; Winde, G; Moroy, T; Muller, O			Sulindac sulfide inhibits Ras signaling	ONCOGENE			English	Article						non-steroidal anti-inflammatory drugs; sulindac; p21ras	GTPASE-ACTIVATING PROTEIN; FAMILIAL ADENOMATOUS POLYPOSIS; GUANINE-NUCLEOTIDE EXCHANGE; COLON-CANCER CELLS; MALIGNANT TRANSFORMATION; DIFFERENTIAL REGULATION; PLASMA-MEMBRANE; GENE-PRODUCT; IN-VIVO; HA-RAS	The non-steroidal anti-inflammatory drug sulindac is used in cancer prevention and therapy, but the molecular aspects of its anti-tumor effect remain unresolved. In vivo the prodrug sulindac, is converted into the metabolite sulindac sulfide. We found that sulindac sulfide strongly inhibits Ras induced malignant transformation and Ras/Raf dependent transactivation, Sulindac sulfide decreases the Ras induced activation of its main effector, the c-Raf-1 kinase, In vitro sulindac sulfide directly binds to the Ras gene product p21ras in a non-covalent manner. Moreover, we can show that sulindac sulfide inhibits the interaction of p21ras with the p21ras binding domain of the Raf protein. In addition, sulindac sulfide can impair the nucleotide exchange on p21ras by CDC25 as well as the acceleration of the p21ras GTPase reaction by p120GAP. Due to its action at the most critical site in Ras signaling me propose sulindac sulfide as a lead compound in the search for novel anti-cancer drugs which directly inhibit Ras mediated cell proliferation and malignant transformation.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44139 Dortmund, Germany; Univ Essen Gesamthsch Klinikum, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany; Univ Wurzburg, Inst Med Strahltnkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Munster, Chirurg Klin, D-48129 Munster, Germany	Max Planck Society; University of Duisburg Essen; University of Wurzburg; University of Munster	Muller, O (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Rheinlanddamm 201, D-44139 Dortmund, Germany.		Moroy, Tarik/D-9923-2011; Winde, Guenther/AAA-3610-2020					Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; Chiu CH, 1997, CANCER RES, V57, P4267; CRAVCHIK A, 1993, GENE, V137, P139, DOI 10.1016/0378-1119(93)90262-2; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; GIARDIELLO FM, 1994, CANCER METAST REV, V13, P279, DOI 10.1007/BF00666098; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; Goldberg Y, 1996, ONCOGENE, V12, P893; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; LOVEC H, 1994, ONCOGENE, V9, P323; Luk GD, 1996, SCHWEIZ MED WSCHR, V126, P801; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2909; Piazza GA, 1997, CANCER RES, V57, P2452; QIAO L, 1995, BBA-LIPID LIPID MET, V1258, P215, DOI 10.1016/0005-2760(95)00100-Q; RAO CV, 1995, CANCER RES, V55, P1464; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14225, DOI 10.1021/bi961118o; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Thompson HJ, 1997, CANCER RES, V57, P267; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vane JR, 1996, SCAND J RHEUMATOL, P9; WINDE G, 1995, DIS COLON RECTUM, V38, P813, DOI 10.1007/BF02049838; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Wright JD, 1996, CLIN PHARMACOKINET, V30, P445, DOI 10.2165/00003088-199630060-00003	44	107	113	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1769	1776		10.1038/sj.onc.1202085	http://dx.doi.org/10.1038/sj.onc.1202085			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778042				2022-12-25	WOS:000076303300002
J	Bennoun, M; Grimber, G; Couton, D; Seye, A; Molina, T; Briand, P; Joulin, V				Bennoun, M; Grimber, G; Couton, D; Seye, A; Molina, T; Briand, P; Joulin, V			The amino-terminal region of SV40 large T antigen is sufficient to induce hepatic tumours in mice	ONCOGENE			English	Article						pRb; p300; p53; transgenic mice; hepatic tumour; SV40 large T-antigen	SIMIAN-VIRUS-40 LARGE-T; INDUCED TUMORIGENESIS; P53-DEFICIENT MICE; PROTEINS P130; J-DOMAIN; P53; P300; GENE; RETINOBLASTOMA; BINDING	The transforming activity of SV40 large T-antigen (Tag) depends on its binding to cellular proteins involved in the control of the cell cycle (p53, pRb, p300..) and on the J-domain region in the amino-terminus. We established transgenic lines expressing wild-type or Tag mutant proteins lacking one of the three transforming domains, to determine the respective contributions of these domains to hepatic tumour formation. Tag mutants with no pRb-binding domain or N-terminal fragment did not cause neoplastic liver abnormalities. The dl1137 Tag mutant protein, which inhibits pRb function without affecting p53, induced hepatic tumours, These tumours grew significantly faster than those induced by wild-type Tag. Our results demonstrate different requirements for each of the inactivating functions of SV40 Tag in hepatocyte transformation and show that the loss of p53 function has only a moderate effect on hepatic tumour formation.	Inst Cochin Genet Mol, INSERM, U380, F-75014 Paris, France; Lab Univ Rech Histopathol, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Joulin, V (corresponding author), Inst Cochin Genet Mol, INSERM, U380, 22 Rue Mechain, F-75014 Paris, France.		Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754; JOULIN, Virginie/0000-0003-1091-7819				Allemand I, 1995, ONCOGENE, V11, P2583; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; CHEN JD, 1992, ONCOGENE, V7, P1167; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eckner R, 1996, MOL CELL BIOL, V16, P3454; FAN GS, 1995, CELL GROWTH DIFFER, V6, P1463; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Williams BO, 1996, CURR OPIN GENET DEV, V6, P65; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116	29	16	16	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1253	1259		10.1038/sj.onc.1202047	http://dx.doi.org/10.1038/sj.onc.1202047			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771968				2022-12-25	WOS:000075803300007
J	Navarre, WW; Ton-That, H; Faull, KF; Schneewind, O				Navarre, WW; Ton-That, H; Faull, KF; Schneewind, O			Anchor structure of staphylococcal surface proteins II. COOH-terminal structure of muramidase and amidase-solubilized surface protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; CELL-WALL; METHICILLIN-RESISTANT; BACILLUS-SUBTILIS; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; PEPTIDOGLYCAN COMPOSITION; AUREUS STRAIN; CLONING; GENE	Surface proteins of the Gram-positive organism Staphylococcus aureus are anchored to the bacterial cell wall by a transpeptidation mechanism during which the polypeptide is cleaved between the threonine (T) and the glycine (G) of the LPXTG motif. The carboxyl of threonine is subsequently amide linked to the amino of the pentaglycyl cross-bridge within the staphylococcal peptidoglycan, Previous work examined the anchor structure of surface proteins solubilized from the peptidoglycan by treatment with lysostaphin or phi 11 hydrolase and identified COOH-terminally linked triglycyl or L-AZa-D-iGln-L-Lys(Gly(5))-D-Ala and MurNAc-[L-Ala-D-iGln-L-Lys(Gly(5))-D-Ala](beta 1-4)-GlcNAc, respectively, Here, we report the anchor structure of surface proteins solubilized with N-acetylmuramidase and N-acetylmuramyI-L-alanine amidase. N-Acetylmuramidase-released surface protein was linked to MurNAc-[L-Ala-D-iGln-L-Lys(Gly(5))-D-Ala](beta 1-4)-GlcNAc, whereas N-acetylmuramyl-L-alanine amidase treatment of the cell wall solubilized surface proteins linked to L-Ala-D-iGln-L-Lys(Gly(5))-D-Ala. Most, but not all, anchor structures were cross-linked to other cell wall subunits, in which the D-alanyl at position four was amide linked to the pentaglycyl of a neighboring wall peptide.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schneewind, O (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Ton-That, Hung/AAB-6155-2020	Navarre, William/0000-0002-9293-9220; Ton-That, Hung/0000-0003-1611-0469	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033985, R01AI038897] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 38897, AI 33985] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baba T, 1998, EMBO J, V17, P4639, DOI 10.1093/emboj/17.16.4639; Boneca IG, 1997, J BIOL CHEM, V272, P29053, DOI 10.1074/jbc.272.46.29053; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CALANDRA GB, 1980, INFECT IMMUN, V28, P1033; DEJONGE BLM, 1993, J BACTERIOL, V175, P2779, DOI 10.1128/JB.175.9.2779-2782.1993; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11255; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FOSTER SJ, 1991, J GEN MICROBIOL, V137, P1987, DOI 10.1099/00221287-137-8-1987; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GHUYSEN JM, 1963, BIOCHEMISTRY-US, V2, P1119, DOI 10.1021/bi00905a036; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GLAUNER B, 1990, J BIOL CHEM, V265, P18988; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; HANDWERGER S, 1994, J BACTERIOL, V176, P260, DOI 10.1128/JB.176.1.260-264.1994; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kopp U, 1996, MICROB DRUG RESIST, V2, P29, DOI 10.1089/mdr.1996.2.29; KURODA A, 1990, J GEN MICROBIOL, V136, P2209, DOI 10.1099/00221287-136-11-2209; KURODA A, 1991, FEMS MICROBIOL LETT, V81, P9, DOI 10.1016/S0378-1097(99)00506-6; Lebrun M, 1996, MOL MICROBIOL, V21, P579, DOI 10.1111/j.1365-2958.1996.tb02566.x; MATSUHAS.M, 1967, J BIOL CHEM, V242, P3191; MATSUHASHI M, 1965, P NATL ACAD SCI USA, V54, P587, DOI 10.1073/pnas.54.2.587; MEDAGLINI D, 1995, P NATL ACAD SCI USA, V92, P6868, DOI 10.1073/pnas.92.15.6868; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; OSHIDA T, 1995, P NATL ACAD SCI USA, V92, P285, DOI 10.1073/pnas.92.1.285; PANCHOLI V, 1988, J BACTERIOL, V170, P2618, DOI 10.1128/jb.170.6.2618-2624.1988; SAMUELSON P, 1995, J BACTERIOL, V177, P1470, DOI 10.1128/jb.177.6.1470-1476.1995; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; SJOQUIST J, 1972, EUR J BIOCHEM, V29, P572, DOI 10.1111/j.1432-1033.1972.tb02023.x; SJOQUIST J, 1972, EUR J BIOCHEM, V30, P190, DOI 10.1111/j.1432-1033.1972.tb02086.x; SLOAN GL, 1977, BIOCHEM J, V167, P293, DOI 10.1042/bj1670293; SNOWDEN MA, 1989, J GEN MICROBIOL, V135, P3015; STROMINGER JL, 1967, SCIENCE, V156, P213, DOI 10.1126/science.156.3772.213; STROMINGER JL, 1967, FED PROC, V26, P9; TIPPER DJ, 1969, BIOCHEMISTRY-US, V8, P2183, DOI 10.1021/bi00833a060; TIPPER DJ, 1967, BIOCHEMISTRY-US, V6, P906, DOI 10.1021/bi00855a035; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; TIPPER DJ, 1965, BIOCHEMISTRY-US, V4, P468, DOI 10.1021/bi00879a015; TIPPER DJ, 1968, BIOCHEMISTRY-US, V7, P1441, DOI 10.1021/bi00844a029; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; WANG X, 1991, GENE, V102, P105; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xu NX, 1997, ANAL BIOCHEM, V248, P7, DOI 10.1006/abio.1997.2073; YOKOGAWA K, 1974, ANTIMICROB AGENTS CH, V6, P156, DOI 10.1128/AAC.6.2.156	48	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29135	29142		10.1074/jbc.273.44.29135	http://dx.doi.org/10.1074/jbc.273.44.29135			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786922	hybrid			2022-12-25	WOS:000076691800083
J	Howe, AK; Juliano, RL				Howe, AK; Juliano, RL			Distinct mechanisms mediate the initial and sustained phases of integrin-mediated activation of the Raf/MEK/mitogen-activated protein kinase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR ACTIVATION; FOCAL ADHESION KINASE; CELL-ADHESION; SIGNAL-TRANSDUCTION; MAP KINASE; PLASMA-MEMBRANE; RAF-1 KINASE; IN-VITRO; TYROSINE PHOSPHORYLATION; PHOSPHATIDIC-ACID	Integrin-mediated adhesion to the extracellular matrix activates the canonical mitogen-activated protein kinase cascade, although the exact mechanism is not fully resolved. We show that integrin-mediated activation of Raf-l, an upstream regulator of mitogen-activated protein kinase, occurs in two phases. Efficient early activation of Raf required Raf-Ras interaction but was not affected by protein kinase C (PKC) inhibitors, while a lower, sustained level of activity was independent of Raf-Ras interaction but was reduced by PEC inhibitors. The combination of PEC inhibition and lack of Ras binding completely blocked integrin-mediated Raf activity. The activity of a membrane-bound Raf mutant that is deficient in Ras binding (Raf-R89L-CAAX) was also regulated by adhesion. Raf-R89L-CAAX activity was low in nonadherent cells, was rapidly stimulated to wild-type levels by cell. adhesion, and remained at nearly maximal levels longer than wild-type activity. The activation of wild-type and mutant Raf proteins was ablated by cytochalasin D, demonstrating that cytoskeletal organization is required for activation of Raf, even when targeted to the membrane. These data suggest distinct initial and sustained phases of integrin-mediated Raf activation that require Raf membrane localization and possibly PKC activity, respectively, and that integrin-mediated adhesion may regulate a cytoskeleton-associated factor(s) responsible for Raf activation.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Juliano, RL (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Mary Ellen Jones Bldg 920,CB 7365, Chapel Hill, NC 27599 USA.	arjay@med.unc.edu			NATIONAL CANCER INSTITUTE [T32CA009156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026165] Funding Source: NIH RePORTER; NCI NIH HHS [CA09156-23] Funding Source: Medline; NIGMS NIH HHS [GM26165] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aplin AE, 1998, PHARMACOL REV, V50, P197; Arai H, 1996, MOL PHARMACOL, V50, P522; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Couchman JR, 1996, J CELL BIOCHEM, V61, P578, DOI 10.1002/(SICI)1097-4644(19960616)61:4<578::AID-JCB11>3.0.CO;2-C; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; Downward J, 1996, CANCER SURV, V27, P87; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FINNEY R, 1995, METHOD ENZYMOL, V255, P310; Ghosh S, 1997, BIOCHEM SOC T, V25, P561, DOI 10.1042/bst0250561; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Gille J, 1996, ANN NY ACAD SCI, V797, P93, DOI 10.1111/j.1749-6632.1996.tb52952.x; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; VUORI K, 1993, J BIOL CHEM, V268, P21459; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	53	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27268	27274		10.1074/jbc.273.42.27268	http://dx.doi.org/10.1074/jbc.273.42.27268			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765250	Green Published, hybrid			2022-12-25	WOS:000076448000037
J	Resnick, MS; Kang, BS; Luu, D; Wickham, JT; Sando, JJ; Hahn, CS				Resnick, MS; Kang, BS; Luu, D; Wickham, JT; Sando, JJ; Hahn, CS			Differential downstream functions of protein kinase C eta and -theta in EL4 mouse thymoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; T-CELLS; PROTEOLYTIC ACTIVATION; ENDOPLASMIC-RETICULUM; GROWTH-INHIBITION; DOWN-REGULATION; ACTIN; LYMPHOCYTES; EXPRESSION; APOPTOSIS	Sensitive EW mouse thymoma cells (s-EL4) respond to phorbol esters with growth inhibition, adherence to substrate, and production of cytokines including interleukin 2. Since these cells express several of the phorbol ester-sensitive protein kinase C (PKC) isozymes, the function of each isozyme remains unclear. Previous studies demonstrated that s-EL4 cells expressed substantially more PKC eta and PKC theta than did EL4 cells resistant to phorbol esters (r-EL4). To examine potential roles for PKC eta and PKC theta in EL4 cells, wild type and constitutively active versions of the isozymes were transiently expressed using a Sindbis virus system, Expression of constitutively active PKC eta, but not PKC theta, in sand r-EL4 cells altered cell morphology and cytoskeletal structure in a manner similar to that of phorbol ester treatment, suggesting a role for PKC eta in cytoskeletal organization. Prolonged treatment of s-EL4 cells with phorbol esters results in inhibition of cell cycling along with a decreased expression of most of the PKC isozymes, including PKC theta. Introduction of virally expressed PKC theta, but not PKC eta, overcame the inhibitory effects of the prolonged phorbol ester treatment on cell cycle progression, suggesting a possible involvement of PKC theta in cell cycle regulation. These results support differential functions for PKC eta and PKC theta in T cell activation.	Univ Virginia, Bierne B Carter Ctr Immunol Res, Hlth Sci Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Hlth Sci Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Hlth Sci Ctr, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Hahn, CS (corresponding author), Univ Virginia, Bierne B Carter Ctr Immunol Res, Hlth Sci Ctr, Box MR4-4012, Charlottesville, VA 22908 USA.	csh2s@virginia.edu			NIGMS NIH HHS [GM54572, GM31184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054572, R01GM031184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Basu A, 1998, MOL PHARMACOL, V53, P105, DOI 10.1124/mol.53.1.105; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; Desrivieres S, 1997, J BIOL CHEM, V272, P2470; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; FREIREMOAR J, 1992, ANN NY ACAD SCI, V660, P288, DOI 10.1111/j.1749-6632.1992.tb21088.x; GENDLOFF EH, 1990, PLANT MOL BIOL, V14, P575, DOI 10.1007/BF00027503; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; Haverstick DM, 1997, J BIOL CHEM, V272, P15426, DOI 10.1074/jbc.272.24.15426; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; KELLER H, 1995, EUR J CELL BIOL, V66, P157; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mihalik R, 1996, INT J BIOCHEM CELL B, V28, P925, DOI 10.1016/1357-2725(96)00020-9; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PHATAK PD, 1988, J IMMUNOL, V141, P2929; PHATAK PD, 1994, J CELL PHYSIOL, V159, P365, DOI 10.1002/jcp.1041590220; Resnick MS, 1997, CANCER RES, V57, P2209; RICE CM, 1982, J MOL BIOL, V154, P325, DOI 10.1016/0022-2836(82)90067-5; SANDO JJ, 1982, CANCER RES, V42, P1676; Sansbury HM, 1997, CARCINOGENESIS, V18, P1817, DOI 10.1093/carcin/18.9.1817; SAVART M, 1992, INT J CANCER, V52, P399, DOI 10.1002/ijc.2910520312; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Stewart MP, 1996, J IMMUNOL, V156, P1810; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TRACHSEL S, 1995, J LEUKOCYTE BIOL, V57, P587, DOI 10.1002/jlb.57.4.587; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101	44	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27654	27661		10.1074/jbc.273.42.27654	http://dx.doi.org/10.1074/jbc.273.42.27654			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765301	hybrid			2022-12-25	WOS:000076448000088
J	Yamakuni, T; Yamamoto, T; Hoshino, M; Song, SY; Yamamoto, H; Kunikata-Sumitomo, M; Minegishi, A; Kubota, M; Ito, M; Konishi, S				Yamakuni, T; Yamamoto, T; Hoshino, M; Song, SY; Yamamoto, H; Kunikata-Sumitomo, M; Minegishi, A; Kubota, M; Ito, M; Konishi, S			A novel protein containing cdc10/SWI6 motifs regulates expression of mRNA encoding catecholamine biosynthesizing enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE GENE; DOPAMINE-BETA-HYDROXYLASE; NERVE GROWTH-FACTOR; PHENYLETHANOLAMINE N-METHYLTRANSFERASE; PHEOCHROMOCYTOMA CELL-LINE; CYCLIC-AMP; MESSENGER-RNA; ELONGATION FACTOR-1-ALPHA; PROMOTER ACTIVITY; NEURONS EXPRESS	Catecholaminergic (dopaminergic, noradrenergic, and adrenergic) transmitter phenotypes require the cooperative actions of four biosynthetic enzymes: tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine beta-hydroxylase, and phenylethanolamine N-methyltransferase, Mechanisms that control expression of these enzymes in a transmitter phenotype-specific manner, however, are poorly understood. Here, we provide evidence that overexpression of a novel cdc10/SWI6 motif-containing protein, V-1, elicits the coordinate up regulation of tyrosine hydroxylase, aromatic L-amino acid decarboxylase, and dopamine beta-hydroxylase mRNAs in the neuronal cell line PC12D, and as a result, catecholamine levels are increased. Furthermore, V-1 is strongly expressed in the cytoplasm of rat chromaffin cells of adrenal medulla, Thus, V-1 may act as a cytoplasmic protein/protein adapter and be involved in control of the catecholaminergic phenotype expression via an intracellular pathway signaling to the nucleus.	Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Lab Mol Recognit, Kanazawa Ku, Yokohama, Kanagawa 2360027, Japan; Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 1130021, Japan; Tokyo Inst Psychiat, Dept Psychopharmacol, Setagaya Ku, Tokyo 1560057, Japan	Yokohama City University; Tokyo Metropolitan Institute of Medical Science; Tokyo Institute of Psychiatry	Yamakuni, T (corresponding author), Mitsubishi Kasei Inst Life Sci, 11 Minamiooya, Machida, Tokyo 1948511, Japan.		Yamakuni, Tohru/AAE-3541-2019	Yamakuni, Tohru/0000-0003-3968-7949				AXELROD J, 1962, J BIOL CHEM, V237, P1657; BAETGE EE, 1981, P NATL ACAD SCI-BIOL, V78, P1269, DOI 10.1073/pnas.78.2.1269; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; Cooper J.R., 1996, BIOCH BASIS NEUROPHA, Vseventh; EBERT SN, 1994, J BIOL CHEM, V269, P20885; FRIEDMAN S, 1965, J BIOL CHEM, V240, P4763; Fujigasaki H, 1996, MOL BRAIN RES, V40, P203, DOI 10.1016/0169-328X(96)00005-8; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HATANAKA H, 1984, Neuroscience Research, V1, P253, DOI 10.1016/S0168-0102(84)80004-8; HIREMAGALUR B, 1993, J BIOL CHEM, V268, P23704; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; KANEDA N, 1987, BIOCHEM BIOPH RES CO, V146, P971, DOI 10.1016/0006-291X(87)90742-X; KATO T, 1981, EXPERIENTIA, V37, P809, DOI 10.1007/BF01985652; KATOHSEMBA R, 1987, J NEUROSCI RES, V17, P36, DOI 10.1002/jnr.490170106; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KIM KS, 1993, P NATL ACAD SCI USA, V90, P3471, DOI 10.1073/pnas.90.8.3471; KIRSHNER N, 1957, BIOCHIM BIOPHYS ACTA, V24, P658, DOI 10.1016/0006-3002(57)90271-8; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; Kumer SC, 1996, J NEUROCHEM, V67, P443; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LI XM, 1994, NEUROCHEM RES, V19, P591, DOI 10.1007/BF00971335; LOVENBERG W, 1962, J BIOL CHEM, V237, P89; Menezes A, 1996, J NEUROCHEM, V67, P2316; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; MORITA S, 1992, MOL BRAIN RES, V13, P313, DOI 10.1016/0169-328X(92)90214-V; NagamotoCombs K, 1997, J BIOL CHEM, V272, P6051, DOI 10.1074/jbc.272.9.6051; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NANKOVA B, 1994, P NATL ACAD SCI USA, V91, P5937, DOI 10.1073/pnas.91.13.5937; SABBAN EL, 1983, J BIOL CHEM, V258, P7819; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; Song SY, 1996, ENDOCRINOLOGY, V137, P1423, DOI 10.1210/en.137.4.1423; TANAKA T, 1989, P NATL ACAD SCI USA, V86, P8142, DOI 10.1073/pnas.86.20.8142; TAOKA M, 1994, J BIOL CHEM, V269, P9946; TAOKA M, 1992, EUR J BIOCHEM, V207, P615, DOI 10.1111/j.1432-1033.1992.tb17088.x; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	42	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27051	27054		10.1074/jbc.273.42.27051	http://dx.doi.org/10.1074/jbc.273.42.27051			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765218	hybrid			2022-12-25	WOS:000076448000005
J	Becker, DF; Leartsakulpanich, U; Surerus, KK; Ferry, JG; Ragsdale, SW				Becker, DF; Leartsakulpanich, U; Surerus, KK; Ferry, JG; Ragsdale, SW			Electrochemical and spectroscopic properties of the iron-sulfur flavoprotein from Methanosarcina thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; ELECTRON-PARAMAGNETIC-RES; COMPLETE GENOME SEQUENCE; ACETYL COENZYME-A; METHANOBACTERIUM-THERMOAUTOTROPHICUM; HETERODISULFIDE REDUCTASE; 8-HYDROXY-5-DEAZAFLAVIN-REDUCING HYDROGENASE; SPECTROELECTROCHEMICAL CELL; CLOSTRIDIUM-THERMOACETICUM; ENZYME COMPLEX	An iron-sulfur flavoprotein (Isf) from the methanoarchaeaon Methanosarcina thermophila, which participates in electron transfer reactions required for the fermentation of acetate to methane, was characterized by electrochemistry and EPR and Mossbauer spectroscopy. The midpoint potential (E-m) of the FMN/FMNH2 couple was -0.277 V. No flavin semiquinone was observed during potentiometric titrations; however, low amounts of the radical were observed when Isf was quickly frozen after reaction with CO and the CO dehydrogenase/acetyl-CoA synthase complex from M. thermophila. Isf contained a [4Fe-4S](2+/1+) cluster with g values of 2.06 and 1.93 and an unusual split signal with g values at 1.86 and 1.82. The unusual morphology was attributed to microheterogeneity among Isf molecules. The E-m value for the 2+/1+ redox couple of the cluster was -0.394 V, Extracts from H-2-CO2-grown Methanobacterium thermoautotrophicum cells catalyzed either the H-2- or CO-dependent reduction of M. thermophila Isf, In addition, Isf homologs were found in the genomic sequences of the CO2-reducing methanoarchaea M. thermoautotrophicum and Methanococcus jannaschii. These results support a general role for Isf in electron transfer reactions of both acetate-fermenting and CO2-reducing methanoarchaea, It is suggested that Isf functions to couple electron transfer from ferredoxin to membrane-bound electron carriers, such as methanophenazine and/or b-type cytochromes.	Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA; Penn State Univ, Eberly Coll Sci, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Wisconsin, Dept Chem, Milwaukee, WI 53201 USA	University of Nebraska System; University of Nebraska Lincoln; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Wisconsin System; University of Wisconsin Milwaukee	Ragsdale, SW (corresponding author), Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA.				NIGMS NIH HHS [1-R15-GM52666-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM052666] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abken HJ, 1998, J BACTERIOL, V180, P2027, DOI 10.1128/JB.180.8.2027-2032.1998; BARON SF, 1989, J BACTERIOL, V171, P3846, DOI 10.1128/jb.171.7.3846-3853.1989; BONAM D, 1987, J BIOL CHEM, V262, P2980; BRUSCHI M, 1988, FEMS MICROBIOL LETT, V54, P155, DOI 10.1111/j.1574-6968.1988.tb02741.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHRISTNER JA, 1983, J BIOL CHEM, V258, P1157; CLEMENTS AP, 1994, J BACTERIOL, V176, P2689, DOI 10.1128/JB.176.9.2689-2693.1994; DANIELS L, 1977, J BACTERIOL, V132, P118, DOI 10.1128/JB.132.1.118-126.1977; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; Ferry J.G, 2012, METHANOGENESIS ECOLO; FOX JA, 1987, BIOCHEMISTRY-US, V26, P4219, DOI 10.1021/bi00388a007; HARDER SR, 1989, ANAL BIOCHEM, V181, P283, DOI 10.1016/0003-2697(89)90244-3; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; HEDDERICH R, 1990, EUR J BIOCHEM, V193, P255, DOI 10.1111/j.1432-1033.1990.tb19331.x; HEIDEN S, 1994, EUR J BIOCHEM, V221, P855, DOI 10.1111/j.1432-1033.1994.tb18800.x; HEMMING A, 1985, TRENDS BIOCHEM SCI, V10, P198, DOI 10.1016/0968-0004(85)90191-4; JABLONSKI PE, 1993, J BIOL CHEM, V268, P325; JOHNSON MK, 1994, ENCY INORGANIC CHEM, P1896; KAY CJ, 1988, BIOCHEMISTRY-US, V27, P6142, DOI 10.1021/bi00416a047; KUHN W, 1983, EUR J BIOCHEM, V135, P89, DOI 10.1111/j.1432-1033.1983.tb07621.x; Kunkel A, 1997, EUR J BIOCHEM, V244, P226, DOI 10.1111/j.1432-1033.1997.00226.x; Kyrpides N C, 1996, Microb Comp Genomics, V1, P329; Latimer MT, 1996, J BIOL CHEM, V271, P24023, DOI 10.1074/jbc.271.39.24023; LINDAHL PA, 1985, J BIOL CHEM, V260, P1160; LU WP, 1994, J BIOL CHEM, V269, P9736; MaupinFurlow JA, 1996, J BACTERIOL, V178, P6849, DOI 10.1128/jb.178.23.6849-6856.1996; MEYER J, 1988, TRENDS ECOL EVOL, V3, P222, DOI 10.1016/0169-5347(88)90162-0; MIDDLETON P, 1978, EUR J BIOCHEM, V88, P135, DOI 10.1111/j.1432-1033.1978.tb12430.x; MOON BY, 1992, J MAGN RESON, V46, P247; Muh U, 1996, BIOCHEMISTRY-US, V35, P11710, DOI 10.1021/bi9601363; MUTH E, 1987, EUR J BIOCHEM, V169, P571, DOI 10.1111/j.1432-1033.1987.tb13647.x; NOLLING J, 1995, EUR J BIOCHEM, V231, P628, DOI 10.1111/j.1432-1033.1995.0628d.x; PEER CW, 1994, J BACTERIOL, V176, P6974, DOI 10.1128/JB.176.22.6974-6979.1994; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; SCHAUER NL, 1983, J BACTERIOL, V155, P467, DOI 10.1128/JB.155.2.467-472.1983; SCHONHEIT P, 1980, ARCH MICROBIOL, V127, P59, DOI 10.1007/BF00414356; Simianu M, 1998, BIOCHEMISTRY-US, V37, P10027, DOI 10.1021/bi9726483; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STANKOVICH M, 1983, BIOCHEMISTRY-US, V22, P4466, DOI 10.1021/bi00288a018; STANKOVICH MT, 1980, ANAL BIOCHEM, V109, P295, DOI 10.1016/0003-2697(80)90652-1; Stiefel EI, 1994, BIOINORG CHEM, P365; WASSERFALLEN A, 1995, J BACTERIOL, V177, P2436, DOI 10.1128/jb.177.9.2436-2441.1995	43	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26462	26469		10.1074/jbc.273.41.26462	http://dx.doi.org/10.1074/jbc.273.41.26462			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756881	hybrid			2022-12-25	WOS:000076373300035
J	Berman, HK; O'Doherty, RM; Anderson, P; Newgard, CB				Berman, HK; O'Doherty, RM; Anderson, P; Newgard, CB			Overexpression of protein targeting to glycogen (PTG) in rat hepatocytes causes profound activation of glycogen synthesis independent of normal hormone- and substrate-mediated regulatory mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; LIVER-GLYCOGEN; HEXOKINASE-I; GLUCOSE; GLUCOKINASE; ADENOVIRUS; TRANSLOCATION; SYNTHASE; PHOSPHATASE-1; GENE	Protein targeting to glycogen (PTG), also known as PPP1R5, is a widely expressed member of a growing family of proteins that target protein phosphatase-1 (PP-1) to glycogen particles. Because PTG also binds to glycogen synthase and phosphorylase kinase, it has been suggested that it serves as a "scaffold" for efficient activation of glycogen synthesis. However, very little is known about the metabolic effects of PTG, In this study, we have used recombinant adenovirus to overexpress PTG in primary rat hepatocytes, a cell type with high glycogenic capacity. We find that overexpression of PTG potently activates glycogen synthesis in cultured hepatocytes. Surprisingly, the glycogenic effect of PTG is observed even in the complete absence of carbohydrates or insulin in the culture medium. Furthermore, glycogenolytic agents such as forskolin or glucagon are largely ineffective at activating glycogen degradation in PTG overexpressing hepatocytes, even though large increases in cAMP levels are demonstrated. These metabolic effects of PTG overexpression are accompanied by a 3.6-fold increase in glycogen synthase activation state and a 40% decrease in glycogen phosphorylase activity. Our results are consistent with a model in which PTG overexpression "locks" the hepatocyte in a glycogenic mode, presumably via its ability to promote interaction of enzymes of glycogen metabolism with PP-1.	Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Newgard, CB (corresponding author), Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Room Y8-212,5323 Harry Hines Blvd, Dallas, TX 75235 USA.	newgard@utsw.swmed.edu			PHS HHS [1P50H2598801] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Berman HK, 1998, BIOCHEMISTRY-US, V37, P4543, DOI 10.1021/bi9726133; Brown KS, 1997, DIABETES, V46, P179, DOI 10.2337/diabetes.46.2.179; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; FernandezNovell JM, 1997, BIOCHEM J, V321, P227, DOI 10.1042/bj3210227; FernandezNovell JM, 1996, EUR J BIOCHEM, V238, P570, DOI 10.1111/j.1432-1033.1996.0570z.x; Ferrer JC, 1997, FEBS LETT, V415, P249, DOI 10.1016/S0014-5793(97)01136-8; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; MCGARRY JD, 1987, ANNU REV NUTR, V7, P51, DOI 10.1146/annurev.nu.07.070187.000411; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; NEWGARD CB, 1983, J BIOL CHEM, V258, P8046; NOEL RJ, 1996, DIABET ANN, V10, P65; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; TANG PM, 1991, J BIOL CHEM, V266, P15782; TOYODA Y, 1994, BIOCHEM BIOPH RES CO, V204, P252, DOI 10.1006/bbrc.1994.2452; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; WILSON JE, 1984, REGULATION CARBOHYDR, P45	27	64	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26421	26425		10.1074/jbc.273.41.26421	http://dx.doi.org/10.1074/jbc.273.41.26421			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756875	hybrid			2022-12-25	WOS:000076373300029
J	Hao, DY; Ohme-Takagi, M; Sarai, A				Hao, DY; Ohme-Takagi, M; Sarai, A			Unique mode of GCC box recognition by the DNA-binding domain of ethylene-responsive element-binding factor (ERF domain) in plant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AP2 DOMAIN; PROTEINS; ARABIDOPSIS; GENE; EXPRESSION; SEQUENCE; APETALA2; INTERACTS; REPRESSOR	Ethylene-responsive element-binding proteins (EREBPs)have novel DNA-binding domains (ERF domains), which are widely conserved in plants, and interact specifically with sequences containing AGCCGCC motifs (GCC box). Deletion experiments show that some flanking region at the N terminus of the conserved 59-amino acid ERF domain is required for stable binding to the GCC box. Three ERF domain-containing fragments of EREBP2, EREBP4, and AtERF1 from tobacco and Arabidopsis, bind to the sequence containing the GCC box with a high binding affinity in the pM range. The high affinity binding is conferred by a monomeric ERF domain fragment, and DNA truncation experiments show that only 11-base pair DNA containing the GCC box is sufficient for stable ERF domain interaction. Systematic DNA mutation analyses demonstrate that the specific amino acid contacts are confined within the B-base pair GCCGCC region of the GCC box, and the first G, the fourth G, and the sixth C exhibit highest binding specificity common in all three ERF domain-containing fragments studied. Other bases within the GCC box exhibit modulated binding specificity varying from protein to protein, implying that these positions are important for differential binding by different EREBPs, The conserved N-terminal half is likely responsible for formation of a stable complex with the GCC box and the divergent C-terminal half for modulating the specificity.	Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan; Natl Inst Biosci & Human Technol, Plant Mol Biol Lab, Tsukuba, Ibaraki 3050046, Japan	RIKEN; National Institute of Advanced Industrial Science & Technology (AIST)	Sarai, A (corresponding author), Inst Phys & Chem Res, Tsukuba Life Sci Ctr, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.			Ohme-Takagi, Masaru/0000-0003-2700-4119				Abeles F, 1992, ETHYLENE PLANT BIOL; Buttner M, 1997, P NATL ACAD SCI USA, V94, P5961, DOI 10.1073/pnas.94.11.5961; EYAL Y, 1993, PLANT J, V4, P225, DOI 10.1046/j.1365-313X.1993.04020225.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HART CM, 1993, PLANT MOL BIOL, V21, P121, DOI 10.1007/BF00039623; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; OHMETAKAGI M, 1990, PLANT MOL BIOL, V15, P941, DOI 10.1007/BF00039434; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; Okamuro JK, 1997, P NATL ACAD SCI USA, V94, P7076, DOI 10.1073/pnas.94.13.7076; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Sato F, 1996, PLANT CELL PHYSIOL, V37, P249, DOI 10.1093/oxfordjournals.pcp.a028939; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stockinger EJ, 1997, P NATL ACAD SCI USA, V94, P1035, DOI 10.1073/pnas.94.3.1035; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; WEIGEL D, 1995, PLANT CELL, V7, P388, DOI 10.1105/tpc.7.4.388; ZHOU J, 1997, EMBO J, V16, P3217	18	294	391	4	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26857	26861		10.1074/jbc.273.41.26857	http://dx.doi.org/10.1074/jbc.273.41.26857			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756931	hybrid			2022-12-25	WOS:000076373300085
J	Okano, H; Cyert, MS; Ohya, Y				Okano, H; Cyert, MS; Ohya, Y			Importance of phenylalanine residues of yeast calmodulin for target binding and activations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; SPINDLE POLE BODY; SACCHAROMYCES-CEREVISIAE; CENTRAL HELIX; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN-KINASES; PEPTIDE COMPLEX; GENES; CALCINEURIN; RESOLUTION	Recent genetic studies of yeast calmodulin (yCaM) have shown that alterations of different sets of Phe residues result in distinct functional defects (Ohya, Y., and Botstein, D. (1994) Science 263, 963-966). To examine the importance of Phe residues for target binding and activation, we purified mutant yCaMs containing single or double Phe to Ala substitutions and determined their ability to bind and activate two target proteins, calcineurin and CaM-dependent protein kinase (CaMK). Binding assays using the gel overlay technique and quantitative analyses using surface plasmon resonance measurements indicated that the binding of yCaM to calcineurin is impaired by either double mutations of F16A/F19A or a single mutation of F140A, while binding to CaMX is impaired by F89A, F92A, or F140A. These same mutant yCaMs fail to activate calcineurin and CaMK, respectively, in vitro. In addition, F19A exhibited a severe defect in activation of both enzymes. F12A activated calcineurin to only 50% of the level achieved by wild-type calmodulin but fully activated CaMX. These results suggest that each target protein requires a specific and distinct subset of Phe residues in yCaM for target binding and activation.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Tokyo, Grad Sch Sci, Japan Sci & Technol Corp, PRESTO,Unit Proc & Combined Circuit,Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; Stanford University; Japan Science & Technology Agency (JST); University of Tokyo	Ohya, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan.	ohya@biol.s.u-tokyo.ac.jp		Cyert, Martha/0000-0003-3825-7437				BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BROCKERHOFF SE, 1994, J CELL BIOL, V124, P315, DOI 10.1083/jcb.124.3.315; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Chin D, 1997, J BIOL CHEM, V272, P5510, DOI 10.1074/jbc.272.9.5510; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1995, NAT STRUCT BIOL, V2, P943, DOI 10.1038/nsb1195-943; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Meyer DF, 1996, J BIOL CHEM, V271, P11284, DOI 10.1074/jbc.271.19.11284; Moser NJ, 1996, MOL CELL BIOL, V16, P4824; OHYA Y, 1991, J BIOL CHEM, V266, P12784; OHYA Y, 1994, GENETICS, V138, P1041; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sekiya-Kawasaki M, 1998, GENETICS, V150, P43; SHACTERNOIMAN E, 1983, J BIOL CHEM, V258, P4214; SIKORSKI RS, 1989, GENETICS, V122, P19; STIRLING DA, 1994, EMBO J, V13, P4329, DOI 10.1002/j.1460-2075.1994.tb06753.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKANO E, 1994, FEBS LETT, V352, P247, DOI 10.1016/0014-5793(94)00965-1; TAYLOR DA, 1991, J BIOL CHEM, V266, P21375; TITANJI VPK, 1977, BIOCHIM BIOPHYS ACTA, V481, P140, DOI 10.1016/0005-2744(77)90145-0; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; Withee JL, 1997, MOL BIOL CELL, V8, P263, DOI 10.1091/mbc.8.2.263; ZHANG MJ, 1994, J BIOL CHEM, V269, P15546	36	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26375	26382		10.1074/jbc.273.41.26375	http://dx.doi.org/10.1074/jbc.273.41.26375			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756868	hybrid			2022-12-25	WOS:000076373300022
J	Yano, M; Kanazawa, M; Terada, K; Takeya, M; Hoogenraad, N; Mori, M				Yano, M; Kanazawa, M; Terada, K; Takeya, M; Hoogenraad, N; Mori, M			Functional analysis of human mitochondrial receptor Tom20 for protein import into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; HUMAN HOMOLOG; IN-VITRO; SUBUNIT; MAS20P; MOM19; TRANSLOCATION; PREPROTEINS	The mitochondrial import receptor translocase of the outer membrane of mitochondria (Tom20) consists of five segments, an N-terminal membrane-anchor segment, a linker segment rich in charged amino acids, a tetratricopeptide repeat motif a glutamine-rich segment, and a c-terminal segment, To assess the role of each segment, four C-terminally truncated mutants of the human receptor (hTom20) were constructed, and the effect of their overexpression in COS-7 cells was analyzed, Expression of a mutant lacking the tetratricopeptide repeat motif inhibited preornithine transcarbamylase (pOTC) import to the same extent as the wild-type receptor. Thus, overexpression of the membrane-anchor and the linker segments is sufficient for the inhibition of import. Expression of either the wild-type receptor or a mutant lacking the C-terminal end of 20 amino acid residues stimulated import of pOTC-green fluorescent protein (GFP), a fusion protein in which the presequene of pOTC was fused to green fluorescent protein. On the other hand, expression of mutants lacking either the glutamine-rich segment or larger deletions inhibited pOTC-GFP import. In. vitro import of pOTC was inhibited by the wild-type hTom20 and the mutant lacking the C-terminal end, but much less strongly by the mutant lacking the glutamine-rich segment. On the other hand, import of pOTC-GFP was little affected by any of the forms of hTom20. In binding assays, pOTC binding to hTom20 was only moderately decreased by the deletion of the glutamine-rich segment, whereas pOTC-GFP binding was completely lost by this deletion. Binding of pOTCN-GFP a construct that contains am additional 58 N-terminal residues of mature OTC, resembled that of pOTC, All of these results indicate that the region 106-125 containing the glutamine-rich segment of hTom20 is essential for binding and import stimulation in vivo of pOTC-GFP and for inhibition of in vitro import of pOTC. The results also indicate that this region is important for mitochondrial aggregation. The different behaviors of pOTC and the pOTC-GFP chimera toward hTom20 mutants is explicable on the basis of the conformation of the precursor proteins.	Kumamoto Univ, Sch Med, Dept Mol Genet, Kumamoto 862, Japan; Kumamoto Univ, Sch Med, Dept Pathol 2, Kumamoto 862, Japan; La Trobe Univ, Dept Biochem, Bundoora, Vic 3083, Australia	Kumamoto University; Kumamoto University; La Trobe University	Mori, M (corresponding author), Kumamoto Univ, Sch Med, Dept Mol Genet, Kuhonji 4-24-1, Kumamoto 862, Japan.		Hoogenraad, Nicholas J/C-7505-2011					GOPING IS, 1995, FEBS LETT, V373, P45; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Hajek P, 1997, MOL CELL BIOL, V17, P7169, DOI 10.1128/MCB.17.12.7169; Hanson B, 1996, EUR J BIOCHEM, V235, P750, DOI 10.1111/j.1432-1033.1996.t01-1-00750.x; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Iwahashi J, 1997, J BIOL CHEM, V272, P18467, DOI 10.1074/jbc.272.29.18467; Kanazawa M, 1997, J BIOCHEM-TOKYO, V121, P890; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; LITHGOW T, 1995, J BIOL CHEM, V270, P14267, DOI 10.1074/jbc.270.24.14267; McBride HM, 1996, J CELL BIOL, V134, P307, DOI 10.1083/jcb.134.2.307; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; Schleiff E, 1997, J BIOL CHEM, V272, P17784, DOI 10.1074/jbc.272.28.17784; SEKI N, 1995, FEBS LETT, V375, P307, DOI 10.1016/0014-5793(95)01229-8; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; TAKEYA M, 1988, ULTRASTRUCT PATHOL, V12, P651, DOI 10.3109/01913128809056490; Terada K, 1997, FEBS LETT, V403, P309, DOI 10.1016/S0014-5793(97)00070-7; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459	28	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26844	26851		10.1074/jbc.273.41.26844	http://dx.doi.org/10.1074/jbc.273.41.26844			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756929	hybrid			2022-12-25	WOS:000076373300083
J	Goodier, JL; Maraia, RJ				Goodier, JL; Maraia, RJ			Terminator-specific recycling of a B1-Alu transcription complex by RNA polymerase III is mediated by the RNA terminus-binding protein La	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FETOPROTEIN GENE; INITIATION-FACTOR; EXPRESSION; SEQUENCES; ELEMENTS; PROMOTER; REGION; DOWNSTREAM; PRECURSOR; INCREASE	Efficient synthesis of many small abundant RNAs is achieved by the proficient recycling of RNA polymerase (pol) III and stable transcription complexes. Cellular Alu and related retroposons represent unusual pol III genes that are normally repressed but are activated by viral infection and other conditions. The core sequences of these elements contain pol III promoters but must rely on fortuitous downstream oligo(dT) tracts for terminator function, me show that a B1-Alu gene differs markedly from a classical pol III gene (tRNA(i)(Met)) in terminator sequence requirements. B1-Alu genes that differ only in terminator sequence context direct differential RNA 3' end formation. These genes are assembled into stable transcription complexes but differ in their ability to be recycled in the presence of the La transcription termination factor. La binds to the nascent RNA 3' UUUOH end motif that is generated by transcriptional termination within the pol III termination signal, oligo(dT). We found that the recycling efficiency of the B1-Alu genes is correlated with the ability of La to access the 3' end of the nascent transcript and protect it from 3'-5' exonucleolytic processing. These results illuminate a relationship between RNA 3' end formation and transcription termination, and La-mediated reinitiation by pol III.	NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Maraia, RJ (corresponding author), NICHD, Lab Mol Growth Regulat, NIH, 6-416,MSC-2753,9000 Rockville Pike, Bethesda, MD 20892 USA.		Maraia, Richard/ABC-1442-2020	Maraia, Richard/0000-0002-5209-0066				ADENIYIJONES S, 1985, NATURE, V317, P81, DOI 10.1038/317081a0; ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; ARIAS JA, 1989, J BIOL CHEM, V264, P3223; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; Chu WM, 1997, NUCLEIC ACIDS RES, V25, P2077, DOI 10.1093/nar/25.11.2077; CHU WM, 1995, NUCLEIC ACIDS RES, V23, P1750, DOI 10.1093/nar/23.10.1750; Chu WM, 1998, MOL CELL BIOL, V18, P58, DOI 10.1128/MCB.18.1.58; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Goodier JL, 1997, MOL CELL BIOL, V17, P5823, DOI 10.1128/MCB.17.10.5823; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LIU WM, 1995, NUCLEIC ACIDS RES, V23, P1758, DOI 10.1093/nar/23.10.1758; MARAIA R, 1988, MOL CELL BIOL, V8, P4433, DOI 10.1128/MCB.8.10.4433; MARAIA RJ, 1992, MOL CELL BIOL, V12, P1500, DOI 10.1128/MCB.12.4.1500; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; MARAIA RJ, 1991, NUCLEIC ACIDS RES, V19, P5695, DOI 10.1093/nar/19.20.5695; PANNING B, 1993, MOL CELL BIOL, V13, P3231, DOI 10.1128/MCB.13.6.3231; RUSSANOVA VR, 1995, MOL CELL BIOL, V15, P4282; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; Van Horn DJ, 1997, RNA, V3, P1434; Wang ZX, 1996, MOL CELL BIOL, V16, P6841; Wang ZX, 1997, GENE DEV, V11, P2371, DOI 10.1101/gad.11.18.2371; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; WILSON ET, 1988, MOL CELL BIOL, V8, P624, DOI 10.1128/MCB.8.2.624; WILSON ET, 1985, J MOL BIOL, V183, P153, DOI 10.1016/0022-2836(85)90209-8; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2; YOUNG LS, 1991, MOL CELL BIOL, V11, P1382, DOI 10.1128/MCB.11.3.1382; YOUNG PR, 1982, NUCLEIC ACIDS RES, V10, P3099, DOI 10.1093/nar/10.10.3099; ZASLOFF M, 1982, J BIOL CHEM, V257, P7857	39	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26110	26116		10.1074/jbc.273.40.26110	http://dx.doi.org/10.1074/jbc.273.40.26110			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748291	hybrid			2022-12-25	WOS:000076263100082
J	Greco, A; Fusetti, L; Villa, R; Sozzi, G; Minoletti, F; Mauri, P; Pierotti, MA				Greco, A; Fusetti, L; Villa, R; Sozzi, G; Minoletti, F; Mauri, P; Pierotti, MA			Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans	ONCOGENE			English	Article						dermatofibrosarcoma; gene rearrangement; transformation; PDGFB gene	SIMIAN SARCOMA-VIRUS; CHRONIC MYELOMONOCYTIC LEUKEMIA; IN-SITU HYBRIDIZATION; SOFT-TISSUE TUMORS; CELL-LINES; TYROSINE KINASES; HUMAN GLIOMA; EXPRESSION; RECEPTORS; PROLIFERATION	As a consequence of a reciprocal translocation t(17;22)(q22;q13) and of supernumerary ring chromosomes derived from the t(17;22), a fusion between the platelet-derived growth factor b-chain (PDGF, c-sis proto-oncogene) and the collagen type 1A1 (COL1A1) genes has been recently described in dermatofibrosarcoma protuberans (DP), an infiltrating skin tumor (Simon ct al,, 1997), Although PDGFB has been implicated in transforming processes via autocrine and paracrine pathways, by the activation of the cognate receptor, no direct evidence of its involvement in neoplastic transformation of human tumours has been so far provided. In this report, we have tested the DNA from four DPs in the classical DNA transfection assay onto NIH3T3 fibroblast cell line. All the DNAs induced the formation of transformed foci in the transfected cultures whose derived cell lines were shown to contain a fused sequence comprising the human COL1A1 and PDGF genes. The relative breakpoint regions have been sequenced revealing that this gene fusion deleted exon 1 of PDGF and released the growth factor from its normal regulation, All the biochemical and biological assays were consistent with the model of an autocrine mechanism for NIH3T3 transformation by the human rearranged PDGFB gene involving the activation of the endogeneous PDGF receptor.	Ist Nazl Tumori, Div Expt Oncol A, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Greco, A (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Milan, Italy.		sozzi, gabriella/G-8259-2011; Greco, Angela/C-1953-2017; Pierotti, Marco Alessandro/AAC-4728-2022	sozzi, gabriella/0000-0001-9360-6914; Greco, Angela/0000-0003-2994-0349; Pierotti, Marco Alessandro/0000-0002-7431-8332; Villa, Riccardo/0000-0001-8385-800X				BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CAMBY I, 1994, PROSTATE, V24, P187, DOI 10.1002/pros.2990240404; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Chin LS, 1997, CLIN CANCER RES, V3, P771; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRECO A, 1992, ONCOGENE, V7, P237; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; HERMANSON M, 1992, CANCER RES, V52, P3213; KIKUCHI K, 1993, BIOCHEM BIOPH RES CO, V196, P409, DOI 10.1006/bbrc.1993.2264; MAXWELL M, 1986, J CLIN INVEST, P131; MINOLETTI F, 1995, GENE CHROMOSOME CANC, V13, P62, DOI 10.1002/gcc.2870130110; Pedeutour F, 1996, CYTOGENET CELL GENET, V72, P171, DOI 10.1159/000134178; PEDEUTOUR F, 1993, CANCER GENET CYTOGEN, V67, P149, DOI 10.1016/0165-4608(93)90171-H; PERES R, 1987, CANCER RES, V47, P3425; ROBBINS KC, 1982, SCIENCE, V218, P1131, DOI 10.1126/science.6293053; Sambrook J., 2002, MOL CLONING LAB MANU; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; TAPLEY P, 1992, ONCOGENE, V7, P371; TSAI LH, 1994, BLOOD, V83, P51; WANG J, 1994, CANCER RES, V54, P560; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEINER TM, 1994, ANN SURG ONCOL, V1, P18, DOI 10.1007/BF02303537; WEINSTEIN IB, 1987, J CELL BIOCHEM, V33, P213, DOI 10.1002/jcb.240330308; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; WESTERMARK B, 1993, CYTOKINES, P1	34	80	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1313	1319		10.1038/sj.onc.1202051	http://dx.doi.org/10.1038/sj.onc.1202051			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771975				2022-12-25	WOS:000075803300014
J	Ishikawa, T; Casini, AF; Nishikimi, M				Ishikawa, T; Casini, AF; Nishikimi, M			Molecular cloning and functional expression of rat liver glutathione-dependent dehydroascorbate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBIC-ACID; PURIFICATION; IDENTIFICATION; THIOLTRANSFERASE; GLUTAREDOXIN; ACCUMULATION; TRANSPORT; PROTEINS; NADH; RNA	We have isolated a cDNA clone for a novel glutathione-dependent dehydroascorbate reductase from a rat liver cDNA library in lambda gt11 by immunoscreening, The authenticity of the clone was confirmed as follows: first, the antibody that had been purified through affinity for the protein expressed by the cloned lambda gt11 phage recognized only the enzyme in a crude extract from rat liver; and second, two internal amino acid sequences of purified enzyme were identified in the protein sequence predicted from the cDNA, The predicted protein consists of 213 amino acids with a molecular weight of 24,929, which is smaller by similar to 3,000 than the value obtained by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, This discrepancy of the molecular weight was explained by post-translational modification because the recombinant protein expressed by a mammalian system (Chinese hamster ovary cells) was of the same size as rat liver enzyme but larger than the protein expressed by a bacterial system (Escherichia coli), Chinese hamster ovary cells, originally devoid of glutathione-dependent dehydroascorbate reductase activity, was made to elicit the enzyme activity (1.5 nmol/min/mg of cytosolic protein) by expression of the recombinant protein. Additionally, the cells expressing the enzyme were found to accumulate 1.7 times as much ascorbate as the parental cells after incubation with dehydroascorbate, This result points to the importance of the dehydroascorbic acid reductase in maintaining a high concentration of ascorbate in the cell.	Wakayama Med Coll, Dept Biochem, Wakayama 6410012, Japan; Univ Pisa, Dept Expt Pathol, I-56126 Pisa, Italy	Wakayama Medical University; University of Pisa	Nishikimi, M (corresponding author), Wakayama Med Coll, Dept Biochem, 811-1 Kimiidera, Wakayama 6410012, Japan.							BIGLEY R, 1981, BIOCHIM BIOPHYS ACTA, V659, P15, DOI 10.1016/0005-2744(81)90266-7; Borsook H, 1937, J BIOL CHEM, V117, P237; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELBELLO B, 1994, BIOCHEM J, V304, P385, DOI 10.1042/bj3040385; GREEN RC, 1973, BIOCHIM BIOPHYS ACTA, V293, P334, DOI 10.1016/0005-2744(73)90341-0; HARA T, 1971, J BIOCHEM-TOKYO, V69, P325, DOI 10.1093/oxfordjournals.jbchem.a129470; HORVATH E, 1989, J NEUROSCI RES, V24, P398, DOI 10.1002/jnr.490240309; ITO A, 1981, BIOCHEM BIOPH RES CO, V101, P591, DOI 10.1016/0006-291X(81)91300-0; KODAKA K, 1985, BITAMIN, V59, P451; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAELLARO E, 1994, BIOCHEM J, V301, P471, DOI 10.1042/bj3010471; May JM, 1997, J BIOL CHEM, V272, P22607, DOI 10.1074/jbc.272.36.22607; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; Paolicchi A, 1996, ARCH BIOCHEM BIOPHYS, V333, P489, DOI 10.1006/abbi.1996.0419; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; WELCH RW, 1995, J BIOL CHEM, V270, P12584, DOI 10.1074/jbc.270.21.12584; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; Xu DP, 1996, BIOCHEM BIOPH RES CO, V221, P117, DOI 10.1006/bbrc.1996.0555	25	65	70	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28708	28712		10.1074/jbc.273.44.28708	http://dx.doi.org/10.1074/jbc.273.44.28708			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786866	hybrid			2022-12-25	WOS:000076691800027
J	Lee, TH; Rhim, T; Kim, SS				Lee, TH; Rhim, T; Kim, SS			Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; AMINO-ACID-SEQUENCE; ANGIOGENESIS INHIBITOR; HUMAN-PLASMINOGEN; BINDING; PURIFICATION; ANGIOSTATIN; PROLIFERATION; FRAGMENT-2; EXPRESSION	Recently, O'Reilly et al. (O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A, Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. (1994) Cell 79, 315-328; O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R, Olsen, B. R., and Folkman, J. (1997) Cell 88, 277-285) developed a simple in vitro angiogenesis assay system using bovine capillary endothelial cell proliferation and purified potent angiogenic inhibitors, including angiostatin and endostatin. Using a simple in vitro assay for angiogenesis, we purified a protein molecule that showed antiendothelial cell proliferative activity from the serum of New Zealand White rabbits, which was stimulated by lipopolysaccharide. The purified protein showed only bovine capillary endothelial cell growth inhibition and not any cytotoxicity. This molecule was identified as a prothrombin kringle-2 domain (fragment-2) using Edman degradation and the amino acid sequence deduced from the cloned cDNA. Both the prothrombin kringle-2 domain released from prothrombin by factor Xa cleavage and the angiogenic inhibitor purified from rabbit sera exhibited anti-endothelial cell proliferative activity. The recombinant rabbit prothrombin kringle-2 domain showed potent inhibitory activity with half-maximal concentrations (ED50) of 2 mu g/ml media. As in angiostatin, the recombinant rabbit prothrombin kringle-2 domain also inhibited angiogenesis in the chorioallantoic membrane of chick embryos.	Yonsei Univ, Dept Biochem, Coll Sci, Seoul 120749, South Korea; Yonsei Univ, Bioprod Res Ctr, Seoul 120749, South Korea	Yonsei University; Yonsei University	Kim, SS (corresponding author), Yonsei Univ, Dept Biochem, Coll Sci, Seoul 120749, South Korea.							ABE S, 1985, FEBS LETT, V180, P203, DOI 10.1016/0014-5793(85)81071-1; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CHOMCZYNSHI P, 1972, P NATL ACAD SCI USA, V69, P1408; Deguchi H, 1997, BIOCHEM J, V321, P729, DOI 10.1042/bj3210729; DEMARCO A, 1982, J BIOL CHEM, V257, P2716; DEUTSCH DG, 1970, SCIENCE, V170, P1096; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V127, P121, DOI 10.1002/jcp.1041270116; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; KARPATKIN M, 1991, THROMB RES, V62, P757, DOI 10.1016/0049-3848(91)90379-B; KAUFMANN E, 1984, FEBS LETT, V170, P81, DOI 10.1016/0014-5793(84)81373-3; Lee TH, 1998, IMMUNOL LETT, V60, P97, DOI 10.1016/S0165-2478(97)00134-X; LUKKER NA, 1994, PROTEIN ENG, V7, P895; LYNCH SE, 1989, J CLIN INVEST, V84, P640, DOI 10.1172/JCI114210; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PADMANABHAN K, 1994, PROTEIN SCI, V3, P898; PENNICA D, 1983, NATURE, V301, P579; PHAM DQD, 1992, GENE, V122, P345, DOI 10.1016/0378-1119(92)90224-D; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; RUFF MR, 1980, J IMMUNOL, V125, P1671; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEIGERER L, 1987, BIOCHEM BIOPH RES CO, V143, P997, DOI 10.1016/0006-291X(87)90350-0; SENGER DR, 1990, CANCER RES, V50, P1774; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VALI Z, 1984, J BIOL CHEM, V259, P3690; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WALZ DA, 1977, P NATL ACAD SCI USA, V74, P1969, DOI 10.1073/pnas.74.5.1969; WEINSTEIN RE, 1990, THROMB RES, V59, P759, DOI 10.1016/0049-3848(90)90057-J	47	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28805	28812		10.1074/jbc.273.44.28805	http://dx.doi.org/10.1074/jbc.273.44.28805			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786880	hybrid			2022-12-25	WOS:000076691800041
J	Liu, YF				Liu, YF			Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; PROTEIN-KINASE; C-JUN; DISEASE; DEATH; TRANSCRIPTION; ASSOCIATION; GLUTAMATE; MICE	Huntington's disease is one of a growing number of hereditary neurodegenerative disorders caused by expansion of a polyglutamine stretch at the NH2 terminus of huntingtin. To explore whether polyglutamine-expanded huntingtin induces neuronal toxicity, I examined the expression of the full-length of huntingtin with 16, 48, or 89 polyglutamine repeats in a rat hippocampal neuronal cell (HN33). Expression of mutated huntingtin with 48 or 89 polyglutamine repeats stimulated c-Jun amino-terminal kinases (JNKs) activity and induced apoptotic cell death in HN33 cells while expression of normal huntingtin with 16 polyglutamine repeats had no toxic effect. The JNK activation precedes apoptotic cell death and co-expression of a dominant negative mutant form of stress-signaling kinase (SEK1) nearly completely blocked activation of JNKs and neuronal apoptosis mediated by mutated huntingtin. Taken together, my studies demonstrate that expression of polyglutamine-expanded huntingtin induces neuronal apoptosis via activation of the SEK1-JNK pathway.	Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA	Northeastern University	Liu, YF (corresponding author), Northeastern Univ, Dept Pharmaceut Sci, 312 Mugar Hall,360 Huntington Ave, Boston, MA 02115 USA.							ANDERSON AJ, 1994, EXP NEUROL, V125, P286, DOI 10.1006/exnr.1994.1031; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAMMOND DN, 1990, BRAIN RES, V512, P190, DOI 10.1016/0006-8993(90)90626-M; Harper PS, 1991, HUNTINGTONS DIS; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; SANCHEZ I, 1994, NATURE, V380, P75; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; Schwarzschild MA, 1997, J NEUROSCI, V17, P3455; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; XIA Z, 1995, SCIENCE, V2370, P1326; YAN MH, 1994, NATURE, V372, P798; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	30	112	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28873	28877		10.1074/jbc.273.44.28873	http://dx.doi.org/10.1074/jbc.273.44.28873			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786889	hybrid			2022-12-25	WOS:000076691800050
J	Ton-That, H; Labischinski, H; Berger-Bachi, B; Schneewind, O				Ton-That, H; Labischinski, H; Berger-Bachi, B; Schneewind, O			Anchor structure of staphylococcal surface proteins III. Role of the femA, femB, and femX factors in anchoring surface proteins to the bacterial cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN-BINDING PROTEIN; GRAM-POSITIVE BACTERIA; METHICILLIN RESISTANCE; MOLECULAR-CLONING; AUREUS STRAINS; PEPTIDOGLYCAN; EXPRESSION; ENCODES; LEVEL; LOCUS	Surface proteins of Staphylococcus aureus are covalently linked to the bacterial cell wall by a mechanism requiring a COOH-terminal sorting signal with a conserved LPXTG motif, Cleavage between the threonine and the glycine of the LPXTG motif liberates the carboxyl of threonine to form an amide bond with the pentaglycyl cross-bridge in the staphylococcal peptidoglycan. Here, we asked whether altered peptidoglycan cross-bridges interfere with the sorting reaction and investigated surface protein anchoring in staphylococcal fem mutants. S. aureus strains carrying mutations in the femA, femB, femAB, or the femAX genes synthesize altered cross-bridges, and each of these strains displayed decreased sorting activity. Characterization of cell wall anchor structures purified from the fem mutants revealed that surface proteins were linked to cross-bridges containing one, three, or five glycyl residues, but not to the epsilon-amino of lysyl in muropeptides without glycine, When tested in a femAB strain synthesizing cross-bridges with mono-, tri-, and pentaglycyl as well as tetraglycyl-monoseryl, surface proteins were found anchored mostly to the five-residue cross-bridges (pentaglycyl or tetraglycyl-monoseryl). Thus, although mild-type peptidoglycan appears to be the preferred substrate for the sorting reaction, altered cell wall cross-bridges can be linked to the COOH-terminal end of surface proteins.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Bayer AG, Pharma Res Antiinfect I, D-42096 Wuppertal, Germany; Univ Zurich, Inst Med Microbiol, CH-8028 Zurich, Switzerland	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Bayer AG; University of Zurich	Schneewind, O (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	olafs@ucla.edu	Ton-That, Hung/AAB-6155-2020	Ton-That, Hung/0000-0003-1611-0469	NIAID NIH HHS [AI 38897, AI 33985] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033985, R01AI038897] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berger-Bachi Brigitte, 1994, Trends in Microbiology, V2, P389, DOI 10.1016/0966-842X(94)90617-3; BERGERBACHI B, 1983, FEMS MICROBIOL LETT, V20, P305; BERGERBACHI B, 1989, MOL GEN GENET, V219, P263; BERGERBACHI B, 1992, ANTIMICROB AGENTS CH, V36, P1367, DOI 10.1128/AAC.36.7.1367; DEJONGE BLM, 1993, J BACTERIOL, V175, P2779, DOI 10.1128/JB.175.9.2779-2782.1993; DELENCASTRE H, 1994, ANTIMICROB AGENTS CH, V38, P2590, DOI 10.1128/AAC.38.11.2590; Ehlert K, 1997, J BACTERIOL, V179, P7573, DOI 10.1128/jb.179.23.7573-7576.1997; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FOSTER TJ, 1994, FEMS MICROBIOL LETT, V118, P199, DOI 10.1016/0378-1097(94)90504-5; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GHUYSEN JM, 1963, BIOCHEMISTRY-US, V2, P1119, DOI 10.1021/bi00905a036; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GREEN CJ, 1993, J BACTERIOL, V175, P5091, DOI 10.1128/JB.175.16.5091-5096.1993; GUSTAFSON J, 1994, J BACTERIOL, V176, P1460, DOI 10.1128/jb.176.5.1460-1467.1994; HARTMAN BJ, 1984, J BACTERIOL, V158, P513, DOI 10.1128/JB.158.2.513-516.1984; HENZE U, 1993, J BACTERIOL, V175, P1612, DOI 10.1128/JB.175.6.1612-1620.1993; Jolly L, 1997, J BACTERIOL, V179, P5321, DOI 10.1128/jb.179.17.5321-5325.1997; KEHOE MA, 1994, BACTERIAL CELL WALL, P217; Kopp U, 1996, MICROB DRUG RESIST, V2, P29, DOI 10.1089/mdr.1996.2.29; KOZARICH JW, 1978, J BIOL CHEM, V253, P1272; MAIDHOF H, 1991, J BACTERIOL, V173, P3507, DOI 10.1128/jb.173.11.3507-3513.1991; MATSUHAS.M, 1967, J BIOL CHEM, V242, P3191; MATSUHASHI M, 1965, P NATL ACAD SCI USA, V54, P587, DOI 10.1073/pnas.54.2.587; MATSUHASHI M, 1986, J BACTERIOL, V167, P975, DOI 10.1128/jb.167.3.975-980.1986; Navarre WW, 1996, J BACTERIOL, V178, P441, DOI 10.1128/jb.178.2.441-446.1996; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; Niemeyer DM, 1996, J BACTERIOL, V178, P5464, DOI 10.1128/jb.178.18.5464-5471.1996; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; PETIT JF, 1966, BIOCHEMISTRY-US, V5, P2764, DOI 10.1021/bi00872a037; ROBERTS RJ, 1974, J BIOL CHEM, V249, P4781; ROBERTS RJ, 1974, J BIOL CHEM, V249, P4787; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; STEWART TS, 1971, NATURE, V230, P36, DOI 10.1038/230036a0; Stranden AM, 1997, J BACTERIOL, V179, P9, DOI 10.1128/jb.179.1.9-16.1997; STROMINGER JL, 1967, FED PROC, V26, P9; TESCH W, 1988, ANTIMICROB AGENTS CH, V32, P1494, DOI 10.1128/AAC.32.10.1494; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; UTSUI Y, 1985, ANTIMICROB AGENTS CH, V28, P397, DOI 10.1128/AAC.28.3.397	42	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29143	29149		10.1074/jbc.273.44.29143	http://dx.doi.org/10.1074/jbc.273.44.29143			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786923	hybrid			2022-12-25	WOS:000076691800084
J	Yu, H; Jetzt, AE; Ron, Y; Preston, BD; Dougherty, JP				Yu, H; Jetzt, AE; Ron, Y; Preston, BD; Dougherty, JP			The nature of human immunodeficiency virus type 1 strand transfers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; RETROVIRAL RECOMBINATION; GENETIC-RECOMBINATION; INFECTED CELL; DNA-SYNTHESIS; RNA; CONSTRUCTION; GENOMES	The diploid nature of human immunodeficiency virus type 1 (HIV-1) suggests that recombination serves a central function in virus replication and evolution. A system was developed to examine HIV-1 strand transfers, including the obligatory DNA primer strand transfers as well as recombinational crossovers during reverse transcription. Sequence heterogeneity between different strains of HIV-1 was exploited for examining primer transfer events. Both intra- and intermolecular primer transfers were observed at similar frequencies during minus-strand DNA synthesis, whereas primer transfers during plus-strand DNA synthesis were primarily intramolecular. Sequence analysis of long terminal repeats from progeny proviruses also revealed a high rate of homologous recombination during minus-strand synthesis, corresponding to an overall rate of approximately three crossovers per HIV-1 genome per cycle of replication. These results imply that both viral genomic RNAs serve as templates during HIV-1 reverse transcription and that primer strand transfers and recombination may contribute substantially to the rapid genetic variation of HIV-1.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Rutgers State Univ, Grad Program Microbiol & Mol Genet, New Brunswick, NJ 08903 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Inst Human Genet, Dept Radiat Oncol, Salt Lake City, UT 84112 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Dougherty, JP (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, 675 Hoes Ln, Piscataway, NJ 08854 USA.	doughejp@umdnj.edu			NCI NIH HHS [CA50777] Funding Source: Medline; NIAID NIH HHS [AI34834] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050777, R29CA050777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034834, R21AI034834] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; Coffin JM, 1996, VIROLOGY, P1767; FENYO EM, 1989, AIDS, V3, pS5, DOI 10.1097/00002030-198901001-00002; Gao F, 1996, J VIROL, V70, P7013, DOI 10.1128/JVI.70.10.7013-7029.1996; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Hunter E, 1978, Curr Top Microbiol Immunol, V79, P295; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JONES JS, 1994, J VIROL, V68, P207, DOI 10.1128/JVI.68.1.207-216.1994; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Mansky LM, 1996, VIROLOGY, V222, P391, DOI 10.1006/viro.1996.0436; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994; SCHWARTZ O, 1995, J VIROL, V69, P4053, DOI 10.1128/JVI.69.7.4053-4059.1995; Sharp PM, 1996, NATURE, V383, P586, DOI 10.1038/383586a0; SKALKA AM, 1982, J CELL BIOCHEM, V19, P293, DOI 10.1002/jcb.240190311; Strickberger MW., 1976, GENETICS; TEMIN HM, 1991, TRENDS GENET, V7, P71, DOI 10.1016/0168-9525(91)90048-U; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; Vogt P., 1973, POSSIBLE EPISOMES EU; Vogt V. M., 1997, P27; WAINHOBSON S, 1993, CURR OPIN GENET DEV, V3, P878, DOI 10.1016/0959-437X(93)90008-D; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wooley DP, 1997, J VIROL, V71, P9650, DOI 10.1128/JVI.71.12.9650-9653.1997; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Yu H, 1996, J VIROL, V70, P4530, DOI 10.1128/JVI.70.7.4530-4537.1996; ZHANG JY, 1994, J VIROL, V68, P2409, DOI 10.1128/JVI.68.4.2409-2414.1994	36	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28384	28391		10.1074/jbc.273.43.28384	http://dx.doi.org/10.1074/jbc.273.43.28384			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774465	hybrid			2022-12-25	WOS:000076549800085
J	Geng, Y; Zhou, L; Thompson, WJ; Lotz, M				Geng, Y; Zhou, L; Thompson, WJ; Lotz, M			Cyclic GMP and cGMP-binding phosphodiesterase are required for interleukin-1-induced nitric oxide synthesis in human articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GUANYLYL CYCLASE RECEPTORS; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; NUCLEOTIDE PHOSPHODIESTERASES; SIGNAL-TRANSDUCTION; MURINE MACROPHAGES; INTRACELLULAR CA2+; MOLECULAR-CLONING; SYNTHASE ACTIVITY	This study addressed the role of guanylyl cyclase (GC) and phosphodiesterase (PDE) in interleukin (IL)-1 activation of human articular chondrocytes, The GC inhibitors LY83583 and methylene blue dose dependently inhibited IL-1-induced nitric oxide (NO) production, inducible NO synthase (iNOS) protein, and mRNA expression. These effects of GC inhibition were consistent with the rapid induction of cGMP by IL-1, which reached maximal levels after 5 min. The effects of GC inhibitors were selective as they did not reduce IL-1-induced cyclooxygenase II protein and mRNA. An inhibitor specific for soluble GC did not affect IL-1-induced NO production, and activators of soluble GC did not induce NO. However, the expression of iNOS mRNA was induced by atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP), activators of particulate GC, indicating that particulate rather than soluble guanylyl cyclases were involved in iNOS induction. The expression of iNOS mRNA and the production of NO were induced by a slowly hydrolyzable analog of cGMP, 8-bromo-cGMP, but not by nonhydrolyzable analog, dibutyryl cGMP, suggesting that PDE rather than cGMP-dependent protein kinase mediates the cGMP effects. Chondrocytes contained extensive cGMP PDE activity. This had PDE5 biochemical features and an inhibitor profile consistent with PDES, Furthermore, the nonisoform-specific PDE inhibitor IBMX and PDES specific inhibitors suppressed IL-1-induced NO release and iNOS mRNA expression, PDE5 mRNA was constitutively expressed in chondrocytes. In addition to increasing PDE5 activities, IL-1 treatment reduced the sensitivity of PDE5 to several pharmacological inhibitors by up to 50-fold. In summary, inhibitors of either GC or PDE5 prevented IL-1 induction of iNOS; IL-1 increased the rates of both cGMP generation and hydrolysis; and exogenous PDE hydrolyzable cGMP analog induced iNOS and NO. These results suggest that increased cGMP metabolic flux is sufficient to induce iNOS, and GC and PDE5 activities are required for IL-1 induction of iNOS expression via increases in coupled cGMP synthesis and hydrolysis.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ S Alabama, Coll Med, Dept Pharmacol, Mobile, AL 36688 USA	Scripps Research Institute; University of South Alabama	Lotz, M (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.	mlotz@scripps.edu			NIAMS NIH HHS [AR42438, AR43872] Funding Source: Medline; NIA NIH HHS [AG13242] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043872, R01AR042438] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMES A, 1986, J BIOL CHEM, V261, P3034; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BEASLEY D, 1994, J EXP MED, V179, P71, DOI 10.1084/jem.179.1.71; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BIANCO FJ, 1995, AM J PATHOL, V146, P75; BLANCO FJ, 1995, EXP CELL RES, V218, P319, DOI 10.1006/excr.1995.1161; BULUT V, 1993, BIOCHEM BIOPH RES CO, V195, P1134, DOI 10.1006/bbrc.1993.2162; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CICIRELLI MF, 1985, DEV BIOL, V108, P254, DOI 10.1016/0012-1606(85)90029-6; CONQUER JA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P1, DOI 10.1016/0167-4889(92)90021-3; DAWIS SM, 1988, J BIOL CHEM, V263, P8771; DONG ZY, 1993, J IMMUNOL, V151, P2717; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GENG Y, 1995, J CELL PHYSIOL, V163, P545, DOI 10.1002/jcp.1041630315; GENG Y, 1995, J CELL BIOL, V129, P1651, DOI 10.1083/jcb.129.6.1651; GENG Y, 1995, J IMMUNOL, V155, P796; GOLDBERG ND, 1983, J BIOL CHEM, V258, P9213; GREEN D, 1993, GERIATRICS, V48, P46; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; HABY C, 1994, J NEUROCHEM, V62, P496; HAGIWARA H, 1994, J BIOL CHEM, V269, P10729; HARTZELL HC, 1986, NATURE, V323, P273, DOI 10.1038/323273a0; HORTELANO S, 1993, FEBS LETT, V320, P135, DOI 10.1016/0014-5793(93)80078-9; HORTELANO S, 1992, J BIOL CHEM, V267, P24937; HULKOWER KI, 1991, BIOCHEM J, V276, P157, DOI 10.1042/bj2760157; HULKOWER KI, 1991, J RHEUMATOL, V18, P110; KOIDE M, 1993, J BIOL CHEM, V268, P24959; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kotera J, 1997, EUR J BIOCHEM, V249, P434, DOI 10.1111/j.1432-1033.1997.t01-1-00434.x; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; LOTZ M, 1995, J RHEUMATOL, V22, P104; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; MAIER R, 1994, BBA-PROTEIN STRUCT M, V1208, P145, DOI 10.1016/0167-4838(94)90171-6; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; Martin MU, 1997, EUR CYTOKINE NETW, V8, P5; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MITCHELL PG, 1993, BIOCHEM BIOPH RES CO, V196, P1133, DOI 10.1006/bbrc.1993.2369; Moro MA, 1996, P NATL ACAD SCI USA, V93, P1480, DOI 10.1073/pnas.93.4.1480; MUNOZ E, 1992, EUR J IMMUNOL, V22, P1391, DOI 10.1002/eji.1830220610; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; PALMER RMJ, 1993, BIOCHEM BIOPH RES CO, V193, P398, DOI 10.1006/bbrc.1993.1637; Rediske J J, 1994, Osteoarthritis Cartilage, V2, P199, DOI 10.1016/S1063-4584(05)80069-X; RODBARD D, 1974, P S RAD REL PROC MED; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Schulz S, 1998, J BIOL CHEM, V273, P1032, DOI 10.1074/jbc.273.2.1032; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; STADLER J, 1991, J IMMUNOL, V147, P3915; Tamai KT, 1997, RECENT PROG HORM RES, V52, P121; THOMPSON WJ, 1991, PHARMACOL THERAPEUT, V51, P13, DOI 10.1016/0163-7258(91)90039-O; Vesely DL, 1997, AM J MED SCI, V314, P311, DOI 10.1097/00000441-199711000-00008; Wedel BJ, 1997, FEBS LETT, V410, P29, DOI 10.1016/S0014-5793(97)00358-X; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	66	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27484	27491		10.1074/jbc.273.42.27484	http://dx.doi.org/10.1074/jbc.273.42.27484			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765278	hybrid			2022-12-25	WOS:000076448000065
J	McDowall, A; Leitinger, B; Stanley, P; Bates, PA; Randi, AM; Hogg, N				McDowall, A; Leitinger, B; Stanley, P; Bates, PA; Randi, AM; Hogg, N			The I domain of integrin leukocyte function-associated antigen-1 is involved in a conformational change leading to high affinity binding to ligand intercellular adhesion molecule 1 (ICAM-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DIVALENT-CATION; CELL-ADHESION; A-DOMAIN; ALPHA-2-BETA-1 VLA-2; ALPHA-SUBUNITS; CR3 CD11B/CD18; LFA-1; SITE; IDENTIFICATION	On T cells the leukocyte integrin leukocyte function-associated antigen-1 (LFA-1) (CD11a/CD18) can be induced to bind its ligand intercellular adhesion molecule 1 (ICAM-1) (CD54) either by increasing the affinity of the receptor with Mg2+ and EGTA or by receptor clustering following activation with phorbol ester, The existence of these two adhesion-inducing pathways implies that alternative mechanisms might exist by which LFA-1 engages ICAM-1. The LFA-1 alpha subunit I domain contains a major binding site for ICAM-1. In this study me show that soluble LFA-1 I domain blocks ICAM-1 binding of the high affinity Mg2+-induced form of LFA-1 but not the phorbol ester-induced form. Under conditions of Mg2+-activation, the soluble I domain also prevents expression of an activation dependent epitope on LFA-1, implying that it inhibits a conformational change necessary for conversion to the high affinity form of this integrin. In addition, the binding of Mg2+-activated LFA-1 to ICAM-1 is blocked by peptides covering the alpha 4-beta 3 loop, the beta 3-alpha 5 loop, and the alpha 5 helix of the I domain, whereas none of the peptides tested blocks phorbol ester-mediated adhesion. The blocking peptides localize to the same face of the crystal structure of the LFA-1 I domain and define an area that, during activation, may be involved in association of the I domain with another region of LFA-1, potentially the beta-propeller domain. This is the first evidence Linking a structural domain of an integrin, in this case the I domain, with a particular activation mechanism.	Imperial Canc Res Fund, Leukocyte Adhes Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Biomolec Modelling Lab, London WC2A 3PX, England	Cancer Research UK; Cancer Research UK	Hogg, N (corresponding author), Imperial Canc Res Fund, Leukocyte Adhes Lab, Lincolns Inn Fields, London WC2A 3PX, England.	hogg@europa.lif.icnet.uk	Bates, Paul/A-1651-2011; Bates, Paul A/AAF-8561-2020	Bates, Paul A/0000-0003-0621-0925; McDowall, Alison/0000-0003-2018-1462				BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BERGELSON JM, 1995, CURR BIOL, V5, P615, DOI 10.1016/S0960-9822(95)00124-2; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; DRANSFIELD I, 1990, IMMUNOL REV, V114, P29, DOI 10.1111/j.1600-065X.1990.tb00560.x; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; GRAVES BJ, 1995, NAT STRUCT BIOL, V2, P181, DOI 10.1038/nsb0395-181; HOGG N, 1997, LEUCOCYTE TYPING, V6, P343; Hogg Nancy, 1994, Trends in Cell Biology, V4, P379, DOI 10.1016/0962-8924(94)90044-2; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; Rieu P, 1996, J BIOL CHEM, V271, P15858, DOI 10.1074/jbc.271.27.15858; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Stanley P, 1998, J BIOL CHEM, V273, P3358, DOI 10.1074/jbc.273.6.3358; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Stewart MP, 1996, J IMMUNOL, V156, P1810; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; STORMS SD, 1994, EXP CELL RES, V214, P100, DOI 10.1006/excr.1994.1238; TUCKWELL D, 1995, J CELL SCI, V108, P1629; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; Zhang L, 1996, J BIOL CHEM, V271, P29953, DOI 10.1074/jbc.271.47.29953; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	47	87	95	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27396	27403		10.1074/jbc.273.42.27396	http://dx.doi.org/10.1074/jbc.273.42.27396			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765268	hybrid			2022-12-25	WOS:000076448000055
J	Shi, DQ; Kellems, RE				Shi, DQ; Kellems, RE			Transcription factor AP-2 gamma regulates murine adenosine deaminase gene expression during placental development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GONADOTROPIN ALPHA-SUBUNIT; HUMAN CHORIONIC-GONADOTROPIN; HUMAN TISSUE INHIBITOR; GROWTH-FACTOR; FACTOR AP-2; MOUSE EMBRYOGENESIS; CELL-DEATH; TROPHOBLAST; MICE; AP-2-BETA	Trophoblast cells are specialized extra-embryonic cells present only in eutherian mammals. They play a major role in the implantation and placentation processes. To understand better the molecular mechanisms that control the development and function of trophoblast cells, we sought to identify the transcription factors that regulate murine adenosine deaminase (ADA) gene expression in the placenta. Here we report a detailed characterization of a placenta-specific footprinting region (FP1) in the Ada placental regulatory element. The sequence of FP1 was mapped by DNase I footprinting and was found to match a consensus AP-2 transcription factor-binding site. Electrophoretic mobility shift assays demonstrated that FP1 interacted with AP-a-like proteins. Further analysis using AP-2 antibody confirmed that AP-2 protein was indeed present in the placenta and bound to FP1. Mutation at the AP-2 site in FP1 abolished the ability of the Ada placental regulatory element to bind AP-2 proteins and failed to target chloramphenicol acetyltransferase reporter gene expression to placentas in transgenic mice, indicating that AP-2 is required for Ada expression in the placenta. In addition, RNase protection assays demonstrated that AP-S gamma was the predominant AP-2 family member expressed in the placenta. In situ hybridization analysis revealed that AP-S gamma expression was enriched in the trophoblast lineage throughout development, suggesting that AP-2 gamma may be critical for trophoblast development and differentiation.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	University of Texas System; Baylor College of Medicine	Shi, DQ (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin St, Houston, TX 77030 USA.				NICHD NIH HHS [HD34130] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034130] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R56HD034130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; ANSELL JD, 1975, EARLY DEV MANNALS, P107; Berkowitz EA, 1997, ONCOGENE, V14, P2229, DOI 10.1038/sj.onc.1201051; BILLINGTON WD, 1971, ADV REPROD PHYSIOL, V5, P27; Bischof P, 1997, Early Pregnancy, V3, P81; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; Blackburn MR, 1997, DEVELOPMENT, V124, P3089; Blackburn MR, 1996, PROG NUCLEIC ACID RE, V55, P195, DOI 10.1016/S0079-6603(08)60194-4; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; CROSS JC, 1995, DEVELOPMENT, V121, P2513; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; ENDERS AC, 1993, J EXP ZOOL, V266, P578, DOI 10.1002/jez.1402660608; FINI ME, 1994, J BIOL CHEM, V269, P28620; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Hammani K, 1996, J BIOL CHEM, V271, P25498, DOI 10.1074/jbc.271.41.25498; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; Johnson W, 1997, J BIOL CHEM, V272, P15405, DOI 10.1074/jbc.272.24.15405; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1988, BIOL REPROD, V39, P937, DOI 10.1095/biolreprod39.4.937; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Ma GT, 1997, DEVELOPMENT, V124, P907; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097-0177(199701)208:1<115::AID-AJA11>3.0.CO;2-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; Nakayama H, 1997, DEV GENET, V21, P21, DOI 10.1002/(SICI)1520-6408(1997)21:1<21::AID-DVG3>3.3.CO;2-R; NG YK, 1994, DEVELOPMENT, V120, P3257; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; PIJNENBORG R, 1981, PLACENTA, V2, P71, DOI 10.1016/S0143-4004(81)80042-2; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SHI D, 1997, J BIOL CHEM, V272, P3334; Silins G, 1997, BIOCHEM BIOPH RES CO, V230, P413, DOI 10.1006/bbrc.1996.5979; Soares MJ, 1996, PLACENTA, V17, P277, DOI 10.1016/S0143-4004(96)90051-X; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; STEGER DJ, 1993, MOL ENDOCRINOL, V7, P1579, DOI 10.1210/me.7.12.1579; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; Tanaka M, 1997, DEV BIOL, V190, P55, DOI 10.1006/dbio.1997.8685; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	53	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27331	27338		10.1074/jbc.273.42.27331	http://dx.doi.org/10.1074/jbc.273.42.27331			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765260	hybrid			2022-12-25	WOS:000076448000047
J	Izban, MG; Parsons, MA; Sinden, RR				Izban, MG; Parsons, MA; Sinden, RR			Template end-to-end transposition by RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RNA; ELONGATION FACTOR-SII; FACILITATED TRANSCRIPT CLEAVAGE; PROMOTE READ-THROUGH; FACTOR-S-II; TERNARY COMPLEXES; NASCENT TRANSCRIPT; CALF THYMUS; DNA; ARREST	On 5'-template strand protruding templates, promoter-initiated run-off transcription by RNA polymerase II generates discrete, 15-16-nucleotide (nt) longer than expected products whose production is abrogated by elongation factor SII (Parsons, M. A., Sinden, R. R., and Izban, M. G. (1998) J. Biol. Chem. 273, 26998-27008). We demonstrate that template terminal complexes produce these RNAs and that transcript extension is a general and salt-sensitive (250 mM) feature of run-off transcription. On 5'-overhung templates the extended run-off transcripts appear to be retained within an RNA-DNA-enzyme ternary complex, and SII facilitates resumption of transcript elongation via a dinucleotide truncation intermediate. Moreover, on one of the 5-overhung templates, the initially extended complexes spontaneously resumed transcript extension and were uniquely resistant to salt (250 mM) challenge. However, SII did not facilitate this long distance extension on all template ends. Run-off transcripts on a blunt-ended template were initially extended by 2-11 nt (roughly in 2-nt increments); SII addition either before or after extension resulted in the accumulation of a 4-5-nt extension product. Based on these findings, we propose that the initial and continuously extended RNAs reflect intermediates and successful completion of template end-to-end transposition (template switching) by RNA polymerase II, respectively. Both the template end sequence and structure influenced the success of such an event.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Dept Obstet & Gynecol, Galveston, TX 77555 USA; Texas A&M Univ, Ctr Genome Res, Inst Biosci & Technol, Dept Biochem & Biophys, Houston, TX 77030 USA	University of Texas System; University of Texas Medical Branch Galveston; Texas A&M University System	Izban, MG (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Dept Obstet & Gynecol, Galveston, TX 77555 USA.		Sinden, Richard/AAE-3086-2019		NIGMS NIH HHS [GM50719, GM52982] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GUO HL, 1993, J BIOL CHEM, V268, P18762; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Parsons MA, 1998, J BIOL CHEM, V273, P26998, DOI 10.1074/jbc.273.41.26998; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; Rudd MD, 1996, J BIOL CHEM, V271, P21549, DOI 10.1074/jbc.271.35.21549; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; Umehara T, 1995, GENE, V167, P297, DOI 10.1016/0378-1119(95)00634-6; Uptain SM, 1997, P NATL ACAD SCI USA, V94, P13548, DOI 10.1073/pnas.94.25.13548; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; Wang DG, 1997, J BIOL CHEM, V272, P5989, DOI 10.1074/jbc.272.9.5989; WIEST DK, 1992, J BIOL CHEM, V267, P7733; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	61	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					27009	27016		10.1074/jbc.273.41.27009	http://dx.doi.org/10.1074/jbc.273.41.27009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756951	hybrid			2022-12-25	WOS:000076373300105
J	Jung, H; Rubenhagen, R; Tebbe, S; Leifker, K; Tholema, N; Quick, M; Schmid, R				Jung, H; Rubenhagen, R; Tebbe, S; Leifker, K; Tholema, N; Quick, M; Schmid, R			Topology of the Na+/Proline transporter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOA FUSION ANALYSIS; MEMBRANE TOPOLOGY; LACTOSE PERMEASE; PSEUDOMONAS-FRAGI; NA+/H+ ANTIPORTER; PROLINE UPTAKE; PROTEINS; EXPRESSION; PROMOTER; VECTORS	Hydropathy profile analysis of the amino acid sequence of the Na+/proline transporter of Escherichia coli (PutP) suggests that the protein consists of 12 transmembrane domains (TMs) which are connected by hydrophilic loops (Nakao, T., Yamato, I., and Anraku, Y. (1987) Mol Gen., Genet. 208, 70-75). We have tested this prediction by applying a gene fusion approach in combination with a Cys accessibility analysis and site-specific proteolysis, Characterization of a series of PutP-alkaline phosphatase (PhoA) and PutP-beta-galactosidase (LacZ) hybrid proteins yields a reciprocal activity pattern of the reporter proteins that is in agreement with the topology of TMs III to XII of the 12-helix model. Placement of the PutP-PhoA and PutP-LacZ junction sites closer to the N terminus does not yield conclusive results. As a prerequisite for further topology studies, a functional PutP molecule devoid of all five native Cys residues (Cys-free PutP) is generated. Subsequently, amino acids in Cys-free PutP are replaced individually with Cys, and the accessibility of the sulfhydryl groups is analyzed. Surprisingly, Cys residues placed close to the N terminus of PutP (Ile-3 --> Cys, Thr-5 --> Cys) or into putative TM II (Ser-71 --> Cys, Glu-75 --> Cys) are highly accessible to membrane permeant and impermeant thiol reagents in intact cells. In contrast, Cys at the C terminus (Ser-502 --> Cys) reacts only with the membrane permeant but not with the impermeant reagent in intact cells. These results contradict the 12-helix motif and indicate a periplasmic location of the N terminus whereas the C terminus faces the cytoplasm. In addition, a transporter with Cys in place of Leu-37 (putative periplasmic loop (pL2) shows the same accessibility pattern as the Cys at the C terminus. Furthermore, PutP which has been purified and reconstituted into proteoliposomes in an inside-out orientation, is readily cleaved by the endoproteinase AspN before Asp-33 (pL2), Asp-112 (putative cytoplasmic loop (cL3), Asp-262 (cL7), and Asp-356 (cL9), These results suggest a cytosolic location of Asp-33 and Leu-37, thereby implying the formation of an additional TM formed by amino acids of pL2. Based on these observations, a new secondary structure model is proposed according to which the protein consists of 13 TMs with the N terminus on the outside and the C terminus facing the cytoplasm. The 13-helix structure is discussed as a common topological motif for all members of the Na+/solute cotransporter family.	Univ Osnabruck, Fachbereich Biol Chem, Arbeitsgrp Mikrobiol, D-49069 Osnabruck, Germany	University Osnabruck	Jung, H (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Arbeitsgrp Mikrobiol, Barbarastr 11, D-49069 Osnabruck, Germany.		Jung, Heinrich/K-3790-2014	Jung, Heinrich/0000-0002-5450-3063				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1994, MEMBRANE PROTEIN STR; BUHR A, 1993, J BIOL CHEM, V268, P11599; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CAO GQ, 1994, EMBO J, V13, P4662, DOI 10.1002/j.1460-2075.1994.tb06789.x; CHEN CC, 1985, J MEMBRANE BIOL, V84, P157, DOI 10.1007/BF01872213; Delgado-Partin VM, 1998, J BIOL CHEM, V273, P9927, DOI 10.1074/jbc.273.16.9927; DRAPEAU GR, 1980, J BIOL CHEM, V255, P839; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Haardt M, 1996, J BACTERIOL, V178, P5370, DOI 10.1128/jb.178.18.5370-5381.1996; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; KABACK HR, 1993, J BIOENERG BIOMEMBR, V25, P627; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; KOMEIJI Y, 1989, FEBS LETT, V256, P135, DOI 10.1016/0014-5793(89)81733-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MILLER JH, 1972, EXPT MOL GENETICS, P54; MILLER JH, 1992, SHORT COURSE BACTERI, P439; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; NOREAU J, 1979, J BACTERIOL, V140, P911, DOI 10.1128/JB.140.3.911-916.1979; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; Quick M, 1996, EUR J BIOCHEM, V239, P732, DOI 10.1111/j.1432-1033.1996.0732u.x; Quick M, 1997, BIOCHEMISTRY-US, V36, P4631, DOI 10.1021/bi963063w; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmid R, 1997, MICROBIOL-UK, V143, P991, DOI 10.1099/00221287-143-3-991; STALMACH ME, 1983, J BACTERIOL, V156, P481, DOI 10.1128/JB.156.2.481-486.1983; STEWART LMD, 1983, FEMS MICROBIOL LETT, V19, P161, DOI 10.1111/j.1574-6968.1983.tb00533.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; UJWAL ML, 1995, BIOCHEMISTRY-US, V34, P14909, DOI 10.1021/bi00045a036; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; Weissborn AC, 1997, BBA-BIOMEMBRANES, V1329, P237, DOI 10.1016/S0005-2736(97)00116-8; Yamato I., 1993, ALKALI CATION TRANSP, P53; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26400	26407		10.1074/jbc.273.41.26400	http://dx.doi.org/10.1074/jbc.273.41.26400			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756872	hybrid			2022-12-25	WOS:000076373300026
J	Melkonyan, H; Hofmann, HA; Nacken, W; Sorg, C; Klempt, M				Melkonyan, H; Hofmann, HA; Nacken, W; Sorg, C; Klempt, M			The gene encoding the myeloid-related protein 14 (MRP14), a calcium-binding protein expressed in granulocytes and monocytes, contains a potent enhancer element in the first intron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; CELL-DIFFERENTIATION; MAMMALIAN-CELLS; 27E10 ANTIGEN; S100 FAMILY; HL-60 CELLS; MOUSE MRP8; KAPPA-B; DNA; MACROPHAGES	Myeloid-related proteins 8 and 14 (MRP8 and MRP14) are two Ca2+-binding proteins of the S-100 family highly abundant in myelomonocytic cells, The expression is mot only dependent on the developmental status of the cell but also on the inflammatory situation in the tissue. in order to identify regulatory elements responsible for the high expression of MRP14 in myeloid cells, reporter gene constructs have been transfected into HL-60 cells, Mono Mac 6 cells, and L132 cells, We demonstrated that a DNA element in the first intron (positions 153-361) enhances the transcriptional activity of the homologous promoter and of the heterologous herpes simplex virus thymidine kinase promoter up to 37-fold. To further identify the functional site, the region between positions 153 and 192 was analyzed functionally using the thymidine kinase promoter, The region increased the expression in the same magnitude as the complete intron. This enhancer is highly conserved in time human and murine MRP genes, indicative of its involvement in the transcription of MRPs, Protein binding to the region is demonstrated using EMSA, DNA cross-linking, Southwestern blotting, and affinity purification. Affinity purification confirms that four proteins bind to the enhancer element.	Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany	University of Munster	Klempt, M (corresponding author), Univ Munster, Inst Expt Dermatol, von Esmarchstr 56, D-48149 Munster, Germany.	Klempt@uni-muenster.de						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BHARDWAJ RS, 1992, EUR J IMMUNOL, V22, P1891, DOI 10.1002/eji.1830220732; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURWINKEL F, 1994, HISTOCHEMISTRY, V101, P113, DOI 10.1007/BF00269357; CHEN X, 1993, BIOCHEM BIOPH RES CO, V191, P18, DOI 10.1006/bbrc.1993.1178; CHOMCZYNSKI P, 1897, ANN BIOCH, V162, P156; CICCARONE VC, 1990, J IMMUNOL, V144, P725; COLLINS SJ, 1987, BLOOD, V70, P1233; DELABIE J, 1990, CLIN EXP IMMUNOL, V81, P123; EDGEWORTH J, 1989, NATURE, V342, P189, DOI 10.1038/342189a0; GOEBELER M, 1994, TRANSPLANTATION, V58, P355; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HENKEL G, 1992, J IMMUNOL, V149, P3239; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; KIHARANEGISHI F, 1993, MOL CELL BIOL, V13, P7747, DOI 10.1128/MCB.13.12.7747; Klempt M, 1997, FEBS LETT, V408, P81, DOI 10.1016/S0014-5793(97)00394-3; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; KUDO S, 1994, J BIOL CHEM, V269, P22969; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAGASSE E, 1992, BLOOD, V79, P1907; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lefebvre V, 1996, ANN NY ACAD SCI, V785, P284, DOI 10.1111/j.1749-6632.1996.tb56285.x; LUGERING N, 1995, CLIN EXP IMMUNOL, V101, P249; LUGERING N, 1995, EUR J CLIN INVEST, V25, P659, DOI 10.1111/j.1365-2362.1995.tb01982.x; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; METCALF D, 1995, EXP HEMATOL, V23, P569; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; MURAO S, 1990, CELL GROWTH DIFFER, V1, P447; Nacken W, 1996, BBA-MOL BASIS DIS, V1315, P1, DOI 10.1016/0925-4439(95)00108-5; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; ORKIN SH, 1992, BLOOD, V80, P575; Rammes A, 1997, J BIOL CHEM, V272, P9496; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; ROTH J, 1993, BIOCHEM BIOPH RES CO, V191, P565, DOI 10.1006/bbrc.1993.1255; ROTH J, 1992, INT ARCH ALLERGY IMM, V98, P140, DOI 10.1159/000236177; ROTH J, 1994, BIOCHEM J, V301, P655, DOI 10.1042/bj3010655; ROTH J, 1993, BLOOD, V82, P1875; Sambrock J, 1989, MOL CLONING LAB MANU; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Siegenthaler G, 1997, J BIOL CHEM, V272, P9371; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; Tulchinsky E, 1997, J BIOL CHEM, V272, P4828, DOI 10.1074/jbc.272.8.4828; vandenBos C, 1996, J IMMUNOL, V156, P1247; WARNERBARTNICKI AL, 1993, EXP CELL RES, V204, P241, DOI 10.1006/excr.1993.1030; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	52	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					27026	27032		10.1074/jbc.273.41.27026	http://dx.doi.org/10.1074/jbc.273.41.27026			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756953	hybrid			2022-12-25	WOS:000076373300107
J	Rice, JC; Massey-Brown, KS; Futscher, BW				Rice, JC; Massey-Brown, KS; Futscher, BW			Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells	ONCOGENE			English	Article						BRCA1; CpG island; 5-methylcytosine; breast cancer; tumor suppressor	CLONAL CHROMOSOME-ABNORMALITIES; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; OVARIAN-CANCER; MESSENGER-RNA; LUNG-CANCER; MGMT GENE; CARCINOMAS; MUTATIONS; SITES	BRCA1 mRNA is reduced in sporadic breast cancer cells despite the lack of mutations. Because a CpG island is found at the 5' end of the BRCA1 gene, we hypothesized that the decreased BRCA1 mRNA in sporadic breast cancer was associated with aberrant cytosine methylation of the CpG island. We examined BRCA1 mRNA expression in normal human mammary epithelial cells (HMECs), peripheral blood lymphocytes (PBLs) and six sporadic breast cancer cell lines using RT-PCR. The normal breast cells expressed high levels of BRCA1 mRNA. The sporadic breast cancer cell lines and PBLs expressed lower levels of BRCA1 mRNA ranging from a 3-16-fold decrease compared to the normal breast cells. We identified a 600 bp region of the BRCA1 CpG island that possessed strong promoter activity (similar to 40-fold above control), and determined the cytosine methylation patterns of the 30 CpG sites within this region by sodium bisulfite genomic sequencing. The HMECs, PBLs and five of the sporadic breast cancer cell lines were largely unmethylated. However, one sporadic breast cancer cell line, UACC3199, was greater than or equal to 60% methylated at all 30 CpG sites (18 sites were 100% methylated) and was associated with an eightfold decrease in BRCA1 mRNA compared to normal breast cells. These findings suggest that aberrant cytosine methylation of the BRCA1 CpG island promoter may be one mechanism of BRCA1 repression in sporadic breast cancer.	Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Arizona Canc Ctr, Tucson, AZ 85724 USA; Arizona Canc Ctr, Bone Marrow Transplant Program, Tucson, AZ 85724 USA	University of Arizona; Arizona Center Cancer Care; Arizona Center Cancer Care	Futscher, BW (corresponding author), Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.		Rice, Judd C/B-7806-2009		NATIONAL CANCER INSTITUTE [R01CA065662, R29CA065662, P30CA023074] Funding Source: NIH RePORTER; NCI NIH HHS [CA65662, 3P30 CA23074-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dobrovic A, 1997, CANCER RES, V57, P3347; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREGER V, 1994, HUM GENET, V94, P491; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MELTZER P, 1991, BRIT J CANCER, V63, P727, DOI 10.1038/bjc.1991.164; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OTTERSON GA, 1995, ONCOGENE, V11, P1211; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; Pieper RO, 1996, J BIOL CHEM, V271, P13916, DOI 10.1074/jbc.271.23.13916; Qian XLC, 1997, CANCER RES, V57, P3672; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Stirzaker C, 1997, CANCER RES, V57, P2229; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; WELLS D, 1985, P NATL ACAD SCI USA, V82, P2834, DOI 10.1073/pnas.82.9.2834; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	36	202	212	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1807	1812		10.1038/sj.onc.1202086	http://dx.doi.org/10.1038/sj.onc.1202086			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778046				2022-12-25	WOS:000076303300006
J	Mukhopadhyay, T; Multani, AS; Roth, JA; Pathak, S				Mukhopadhyay, T; Multani, AS; Roth, JA; Pathak, S			Reduced telomeric signals and increased telomeric associations in human lung cancer cell lines undergoing p53-mediated apoptosis	ONCOGENE			English	Article						p53; lung cancer; apoptosis; telomere; gene expression	WILD-TYPE P53; ACTIVATION; DEATH; INDUCTION; LENGTH; GROWTH	Transduction of a p53-negative H1299 human non-small cell lung cancer cell line with an adenoviral vector containing wild-type p53 (Ad5p53) induced apoptosis, Analysis of the Ad5p53-infected H1299 cells showed high levels of telomeric association prior to apoptotic nuclear fragmentation. Similar telomeric association was observed in stably transfected clones of the wtH226b cell line, which expressed exogenous wild-type p53 protein and also showed complex chromosomal abnormalities including dicentrics, rings and fragments, Fluorescence ill situ hybridization (FISH) analysis using a human telomeric DNA probe indicated reductions in telomere signals in both Ad5p53-infected H1299 cells and wtH226b-S cells. In contrast, stably transfected wtH226b-AS clones expressing antisense p53 cDNA showed no telomeric association and had high levels of telomeric signals associated with a faster growing phenotype, These results suggest that wild-type p53 is involved in shortening telomeres, a possibly early event in the p53-mediated apoptotic process and in the subsequent telomeric association that predisposes a cell to genetic instability and DNA fragmentation resulting in apoptotic cell death. Moreover, loss of telomeric signals may indicate a cell's decision to undergo programmed cell death and, if so, could, serve as a sensitive marker of p53-mediated apoptosis.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [R01 CA45187, P50-CA70907, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA070907, R01CA045187] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; HEALY KC, 1995, ONCOL RES, V7, P121; HIYAMA K, 1995, ONCOGENE, V10, P937; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; PATHAK S, 1994, INT J ONCOL, V4, P323; Pathak S., 1994, In Vivo (Attiki), V8, P843; Pathak S., 1996, Archivos de Zootecnia, V45, P141; PATHAK S, 1976, J REPROD MED, V17, P25; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Seegers JC, 1997, J STEROID BIOCHEM, V62, P253, DOI 10.1016/S0960-0760(97)00043-5; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	24	21	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					901	906		10.1038/sj.onc.1202011	http://dx.doi.org/10.1038/sj.onc.1202011			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780006				2022-12-25	WOS:000075448800011
J	Zhang, N; Chen, P; Gatei, M; Scott, S; Khanna, KK; Lavin, MF				Zhang, N; Chen, P; Gatei, M; Scott, S; Khanna, KK; Lavin, MF			An anti-sense construct of full-length ATM cDNA imposes a radiosensitive phenotype on normal cells	ONCOGENE			English	Article						ataxia-telangiectasia; ATM; anti-sense cDNA; radiosensitivity; cell cycle	ATAXIA-TELANGIECTASIA CELLS; CYCLE CHECKPOINT PATHWAY; ABL TYROSINE KINASE; IONIZING-RADIATION; DNA-SYNTHESIS; GENE-PRODUCT; C-ABL; DEFICIENT MICE; PROTEIN; DAMAGE	The cloning of a full-length cDNA for the gene (ATM) mutated in the human genetic disorder ataxia-telangiectasia (A-T) has been described recently. This cDNA, as well as a fragment representing a functional region from ATM, are capable of rescuing various aspects of the radiosensitive phenotype in A-T cells. We have subcloned full-length ATM cDNA in the opposite orientation in an EBV-based vector under the control of an inducible promoter to determine whether this anti-sense construct might sensitize control lymphoblastoid cells to ionizing radiation, The effectiveness of expression of this construct in control cells was monitored by loss of ATM protein which was evident over a period 6-12 h after induction. Under these conditions radiosensitivity was enhanced approximately threefold in control cells, approaching the degree of radiosensitivity observed in A-T cells. Expression of the anti-sense construct also increased the number of radiation-induced chromosomal breaks and led to the appearance of radioresistant DNA synthesis in these cells. Abrogation of the G1/S checkpoint was evident from the loss of the p53 response and that of its downstream effector, p21/WAF1, post-irradiation. The extent of accumulation of transfected cells in G2/M phase at 24 h post-irradiation was similar to that observed in A-T cells and the induction of stress-activated protein kinase by ionizing radiation was prevented by antisense ATM cDNA expression. These data demonstrate that full-length ATM anti-sense cDNA, by reducing the amount of ATM protein, is effective in imposing a series of known defects characteristic of the A-T phenotype, This inducible system provides an experimental model to further investigate mechanisms underlying radiosensitivity and cell cycle control.	Queensland Canc Fund, Res Labs, Brisbane, Qld 4029, Australia; Queensland Inst Med Res, Dept Surg, Brisbane, Qld 4029, Australia	Cancer Council Queensland; QIMR Berghofer Medical Research Institute	Lavin, MF (corresponding author), Queensland Canc Fund, Res Labs, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.		Khanna, Kum Kum/I-1747-2013; Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BODER E, 1985, ATAXIA TELANGIECTASI, V19, P1; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CANMAN CE, 1994, CANCER RES, V54, P5054; Chen P, 1996, INT J RADIAT BIOL, V69, P385, DOI 10.1080/095530096145940; CHEN P, 1994, CANCER GENET CYTOGEN, V76, P43, DOI 10.1016/0165-4608(94)90069-8; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; COLE J, 1988, INT J RADIAT BIOL, V54, P929, DOI 10.1080/09553008814552331; COQUERELLE TM, 1987, INT J RADIAT BIOL, V51, P209, DOI 10.1080/09553008714550711; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; FORAY N, 1997, IN PRESS INT J RAD B; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khanna KK, 1997, J BIOL CHEM, V272, P9489; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lakin ND, 1996, ONCOGENE, V13, P2707; LAVIN MF, 1992, CANCER GENET CYTOGEN, V60, P183, DOI 10.1016/0165-4608(92)90014-Y; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LAVIN MF, 1988, MUTAT RES, V193, P193, DOI 10.1016/0167-8817(88)90030-2; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MCFARLIN DE, 1972, MEDICINE, V51, P281, DOI 10.1097/00005792-197207000-00002; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; ROSIN MP, 1986, HUM GENET, V74, P335, DOI 10.1007/BF00280482; RUDOLPH NS, 1989, MUTAT RES, V211, P19, DOI 10.1016/0027-5107(89)90103-6; SANFORD KK, 1990, CHROMOSOMAL ABERRATI, P113; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SCOTT D, 1994, INT J RADIAT BIOL, V66, pS157, DOI 10.1080/09553009414551991; SCOTT D, 1982, INT J RADIAT BIOL, V42, P679, DOI 10.1080/09553008214551661; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHILOH Y, 1986, LANCET, V1, P689; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TAYLOR AMR, 1982, ATAXIA TELANGIECTASI, P53; Telatar M, 1996, AM J HUM GENET, V59, P40; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; ZIV Y, 1995, SOMAT CELL MOLEC GEN, V21, P99, DOI 10.1007/BF02255785	66	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	1998	17	7					811	818		10.1038/sj.onc.1202007	http://dx.doi.org/10.1038/sj.onc.1202007			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9779997				2022-12-25	WOS:000075448800002
J	Ameyar, M; Atfi, A; Cai, ZZ; Stancou, R; Shatrov, V; Bettaieb, A; Chouaib, S				Ameyar, M; Atfi, A; Cai, ZZ; Stancou, R; Shatrov, V; Bettaieb, A; Chouaib, S			Analysis of human breast adenocarcinoma MCF7 resistance to tumor necrosis factor-induced cell death - Lack of correlation between JNK activation and ceramide pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION PATHWAYS; JUN NH2-TERMINAL KINASE; C-JUN; PROTEIN-KINASE; FACTOR-ALPHA; TNF RECEPTOR-1; INDUCED APOPTOSIS; DIFFERENTIAL ACTIVATION	Considerable progress has been made in the understanding of tumor necrosis factor (TNF) signaling; however, the molecular and biochemical basis of tumor resistance to the cytotoxic action of TNF are still not definitively identified yet. Although a role of c-Jun N-terminal kinase (JNK) pathway has been suggested as an effector in TNF signaling, its exact relative contribution and its interaction with ceramide pathway and tumor resistance to TNF remain unknown. The relationship between JNK activation and human breast adenocarcinoma MCF7 resistance acquisition to the cytotoxic action of TNF was therefore investigated. We demonstrate that TNF triggers JNK activation in both TNF-sensitive MCF7 cells and its resistant derivative, RA1/1001, In addition, when MCF7 cells were stably transfected with mitogen-activated protein kinase kinase 4 (MKK4) dominant-negative cDNA or transiently transfected with a dominant-negative c-Jun mutant (TAM: 67), their susceptibility to the cytotoxic action of TNF remains comparable with control cells. We also demonstrated that JNK activation does not require ceramide generation since in MCF7 cells transfected with a dominant-negative derivative of FADD (FADD-DN), which are resistant to the cytotoxic action of TNF, TNF induced JNK activation in the absence of ceramide generation. Furthermore, our data indicate that exogenous permeable synthetic ceramide C-6 induced the killing of MCF7 cells transfected with MKK4 dominant-negative cDNA. These results provide strong evidence indicating that tumor acquisition of resistance to the cytotoxic action of TNF may occur either independently or at a level downstream of JNK activation and suggest that JNK activation is not linked to ceramide pathway in TNF-mediated apoptosis.	Inst Gustave Roussy, INSERM U487 Cytokines & Immunol Tumeurs Humaines, F-94805 Villejuif, France; Ctr Hosp Univ St Antoine, Inst Federat Rech, INSERM U482, F-75012 Paris, France; Inst Claudius Regaud, INSERM CJF 95 03, F-31052 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Chouaib, S (corresponding author), Inst Gustave Roussy, INSERM U487 Cytokines & Immunol Tumeurs Humaines, Rue Camille Desmoulins, F-94805 Villejuif, France.	chouaib@igr.fr	Chouaib, Salem/F-7939-2016	Bettaieb, Ali/0000-0002-6018-9592				Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1995, P NATL ACAD SCI USA, V92, P12110, DOI 10.1073/pnas.92.26.12110; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHOUAIB S, 1991, IMMUNOL TODAY, V12, P141, DOI 10.1016/0167-5699(91)90076-6; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Haimovitz-Friedman A, 1997, BRIT MED BULL, V53, P539; Hannun YA, 1997, ADV EXP MED BIOL, V407, P145; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; HSU J, 1996, CELL, V84, P299; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; KIM MY, 1991, J BIOL CHEM, V266, P484; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1995, CELL, V81, P1159; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RAPP UR, 1994, ONCOGENE, V9, P3493; RATNER A, 1993, J IMMUNOL, V150, P4303; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SHUTZE S, 1992, CELL, V71, P765; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; ZYAD A, 1994, CANCER RES, V54, P825	62	21	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29002	29008		10.1074/jbc.273.44.29002	http://dx.doi.org/10.1074/jbc.273.44.29002			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786905	hybrid			2022-12-25	WOS:000076691800066
J	Rosenfeld, SS; Xing, J; Cheung, HC; Brown, F; Kar, S; Sweeney, HL				Rosenfeld, SS; Xing, J; Cheung, HC; Brown, F; Kar, S; Sweeney, HL			Structural and kinetic studies of phosphorylation-dependent regulation in smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN PHOSPHORYLATION; ENZYMATIC-ACTIVITY; HEAVY-MEROMYOSIN; IONIC-STRENGTH; CROSS-LINKING; 2 HEADS; SUBFRAGMENT-1; ACTIN; MOTOR; CONFORMATION	In this study, we have examined the mechanism of phosphorylation-dependent regulation in smooth muscle myosin through the use of structural and kinetic methodologies applied to several myosin fragments. Fluorescence anisotropy decay measurements demonstrate that regulatory light chain phosphorylation significantly reduces the rotational correlation time of regulatable myosin preparations, whereas minimally regulated ones show little effect in this assay. Sedimentation equilibrium studies show that the regulatory domain can dimerize with a dissociation constant that is unaffected by regulatory light chain phosphorylation. Finally, kinetic studies on the interactions of myosin-ADP constructs with actin are also consistent with a model in which interactions occur between the two heads, which are lost with regulatory light chain phosphorylation. We propose that in the absence of regulatory light chain phosphorylation, the two heads of myosin interact with each other, due to a weak intrinsic dimerization of the regulatory domains that is significantly stabilized by the proximal rod. Regulatory light chain phosphorylation abolishes the stabilizing effect of the proximal rod, leading to a loss of this interaction.	Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Grad Program Biophys Sci, Birmingham, AL 35294 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Pennsylvania	Rosenfeld, SS (corresponding author), Univ Alabama, Dept Neurol, UAb Stn, Birmingham, AL 35294 USA.	s_rosenfeld@email.neuro.uab.edu	Sweeney, H Lee/F-1862-2010		NIAMS NIH HHS [AR 35661] Funding Source: Medline; NINDS NIH HHS [NS 34856, NS 31096] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035661] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031096, P01NS034856] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; Blanchoin L, 1996, J BIOL CHEM, V271, P12380, DOI 10.1074/jbc.271.21.12380; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; GREENE LE, 1987, J BIOL CHEM, V262, P4177; HAI CM, 1988, AM J PHYSIOL, V254, pC99, DOI 10.1152/ajpcell.1988.254.1.C99; HIGHSMITH S, 1978, BIOCHEMISTRY-US, V17, P22, DOI 10.1021/bi00594a004; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; IKEBE M, 1994, P NATL ACAD SCI USA, V91, P9096, DOI 10.1073/pnas.91.19.9096; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; Katoh T, 1996, J BIOL CHEM, V271, P9992, DOI 10.1074/jbc.271.17.9992; KATOH T, 1995, EUR J BIOCHEM, V233, P123, DOI 10.1111/j.1432-1033.1995.123_1.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEPNIEKS JJ, 1979, J BIOL CHEM, V254, P1677; Malmqvist U, 1997, P NATL ACAD SCI USA, V94, P7655, DOI 10.1073/pnas.94.14.7655; MCRORIE DK, 1993, SELF ASS SYSTEMS ANA, V2; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; PERESCHINI A, 1983, BIOCHEMISTRY-US, V22, P470; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rosenfeld SS, 1996, J BIOL CHEM, V271, P30212, DOI 10.1074/jbc.271.47.30212; ROSENFELD SS, 1994, J BIOL CHEM, V269, P30187; ROSENFELD SS, 1987, J BIOL CHEM, V262, P9984; ROWE T, 1993, EMBO J, V12, P4877, DOI 10.1002/j.1460-2075.1993.tb06177.x; Sata M, 1997, P NATL ACAD SCI USA, V94, P91, DOI 10.1073/pnas.94.1.91; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1983, J BIOL CHEM, V258, P4181; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUMMERS MD, 1987, TEX AGR EXP SIN B, V1555; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; Trybus KM, 1991, CURR OPIN CELL BIOL, V3, P105, DOI 10.1016/0955-0674(91)90172-U; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; VYAS TB, 1992, AM J PHYSIOL, V263, pC210, DOI 10.1152/ajpcell.1992.263.1.C210; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; XLE X, 1994, NATURE, V368, P306; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0; YANG ZH, 1995, J BIOL CHEM, V270, P24646, DOI 10.1074/jbc.270.42.24646	45	26	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28682	28690		10.1074/jbc.273.44.28682	http://dx.doi.org/10.1074/jbc.273.44.28682			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786863	hybrid			2022-12-25	WOS:000076691800024
J	Sabourin, M; Byl, JAW; Hannah, SE; Nitiss, JL; Osheroff, N				Sabourin, M; Byl, JAW; Hannah, SE; Nitiss, JL; Osheroff, N			A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINE; DNA TOPOISOMERASES; ESCHERICHIA-COLI; TARGETING DRUGS; RESISTANCE; ETOPOSIDE; INHIBITORS; AMSACRINE; APOPTOSIS; IDENTIFICATION	To further characterize the mechanistic basis for cellular resistance/hypersensitivity to anticancer drugs, a yeast genetic system was used to select a mutant type II topoisomerase that conferred cellular resistance to CP-115,953, amsacrine, etoposide, and ellipticine, The mutant enzyme contained a single point mutation that converted Gly(437) --> Ser (top2G437S), Purified top2G437S displayed wild-type enzymatic activity in the absence of drugs but exhibited two properties that were not predicted by the cellular resistance phenotype, First, in the absence of ATP, it was hypersensitive to all of the drugs examined and hypersensitivity correlated with increased drug affinity. Second, in the presence of ATP, top2G437S lost its hypersensitivity and displayed wildtype drug sensitivity. Since the resistance of yeast harboring top2G437S could not be explained by alterations in enzyme-drug interactions, physiological levels of topoisomerase II were determined. The Gly(437) --> Ser mutation reduced the stability of topoisomerase II and decreased the cellular concentration of the enzyme. These findings suggest that the physiological drug resistance phenotype conferred by top2G437S results primarily from its decreased stability. This study highlights the need to analyze both the biochemistry and the physiology of topoisomerase II mutants with altered drug sensitivity in order to define the mechanistic bridge that links enzyme function to cellular phenotype.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Oncol, Nashville, TN 37232 USA; St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38101 USA	Vanderbilt University; Vanderbilt University; St Jude Children's Research Hospital	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Med Res Bldg 1, Nashville, TN 37232 USA.	osheron@ctrvax.vanderbilt.edu	Nitiss, John/E-9974-2010	Nitiss, John/0000-0002-1013-4972	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA052814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA52814] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTON PA, 1993, BRIT J HAEMATOL, V85, P241, DOI 10.1111/j.1365-2141.1993.tb03162.x; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BUGG BY, 1991, P NATL ACAD SCI USA, V88, P7654, DOI 10.1073/pnas.88.17.7654; Burden DA, 1996, J BIOL CHEM, V271, P29238, DOI 10.1074/jbc.271.46.29238; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; CHAN VTW, 1993, J BIOL CHEM, V268, P2160; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; D'Arpa P, 1994, Adv Pharmacol, V29B, P127; Danks M K, 1989, Cancer Commun, V1, P101; DAVIES SM, 1990, MUTAT RES, V235, P111, DOI 10.1016/0921-8777(90)90064-C; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; ELSEA SH, 1992, J BIOL CHEM, V267, P13150; EVANS CD, 1994, CANCER CHEMOTH PHARM, V34, P242; FELDHOFF PW, 1994, CANCER RES, V54, P756; FERGUSON LR, 1994, ENVIRON MOL MUTAGEN, V24, P245, DOI 10.1002/em.2850240402; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Halicka HD, 1997, APOPTOSIS, V2, P25, DOI 10.1023/A:1026431524236; HARRISON DJ, 1995, J PATHOL, V175, P7, DOI 10.1002/path.1711750103; HASEGAWA S, 1995, BRIT J CANCER, V71, P907, DOI 10.1038/bjc.1995.177; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; JANNATIPOUR M, 1993, J BIOL CHEM, V268, P18586; KIM R, 1992, ANTICANCER RES, V12, P241; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; Li W, 1997, J BIOL CHEM, V272, P31190, DOI 10.1074/jbc.272.49.31190; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1994, ADV PHARM, V29; LIU YX, 1994, CANCER RES, V54, P2943; Malonne H, 1997, ANTI-CANCER DRUG, V8, P811, DOI 10.1097/00001813-199710000-00001; McPherson JP, 1997, ANTICANCER RES, V17, P4243; Negri C, 1995, BIOCHIMIE, V77, P893, DOI 10.1016/0300-9084(95)90009-8; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; NITISS JL, 1994, CANCER CHEMOTH PHARM, V34, pS6, DOI 10.1007/BF00684857; Nitiss JL, 1996, ANN NY ACAD SCI, V803, P32, DOI 10.1111/j.1749-6632.1996.tb26374.x; NITISS JL, 1993, CANCER RES, V53, P89; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; NITISS JL, 1992, CANCER RES, V52, P4467; NITISS JL, 1994, MOL PHARMACOL, V46, P773; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; Patel S, 1997, MOL PHARMACOL, V52, P658, DOI 10.1124/mol.52.4.658; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; POMMIER Y, 1997, CANC THERAPEUTICS EX, V1, P153; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; POTMESIL M, 1990, DNA TOPOLOGY ITS BIO, P391; Potmesil M., 1991, DNA TOPOISOMERASES C; RITKE MK, 1994, MOL PHARMACOL, V46, P605; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROY C, 1992, EXP CELL RES, V200, P416, DOI 10.1016/0014-4827(92)90190-J; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SINHA BK, 1995, DRUGS, V49, P11, DOI 10.2165/00003495-199549010-00002; SMITH PJ, 1994, ANN HEMATOL, V69, pS7, DOI 10.1007/BF01757348; SOLARY E, 1994, LEUKEMIA LYMPHOMA, V15, P21, DOI 10.3109/10428199409051674; Son YS, 1998, CANCER CHEMOTH PHARM, V41, P353, DOI 10.1007/s002800050751; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; SULLIVAN DM, 1989, BIOCHEMISTRY-US, V28, P5680, DOI 10.1021/bi00439a051; SULLIVAN DM, 1987, CANCER RES, V47, P3973; TARTOF KD, 1987, FOCUS, V9, P2; WALKER PR, 1991, CANCER RES, V51, P1078; Wang HK, 1997, MED RES REV, V17, P367, DOI 10.1002/(SICI)1098-1128(199707)17:4<367::AID-MED3>3.0.CO;2-U; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1994, CANCER RES, V54, P1795; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; Wessel I, 1997, CANCER RES, V57, P4451; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; ZWELLING LA, 1989, J BIOL CHEM, V264, P16411	74	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29086	29092		10.1074/jbc.273.44.29086	http://dx.doi.org/10.1074/jbc.273.44.29086			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786915	hybrid			2022-12-25	WOS:000076691800076
J	Arni, S; Keilbaugh, SA; Ostermeyer, AG; Brown, DA				Arni, S; Keilbaugh, SA; Ostermeyer, AG; Brown, DA			Association of GAP-43 with detergent-resistant membranes requires two palmitoylated cysteine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; KIDNEY EPITHELIAL-CELLS; NEURONAL GROWTH CONE; KINASE-C SUBSTRATE; TYROSINE KINASE; ALPHA-SUBUNIT; NEUROMODULIN GAP-43; SIGNAL-TRANSDUCTION; MDCK CELLS; T-CELLS	GAP-43 is an abundant protein in axonal growth cones of developing and regenerating neurons. We found that GAP-43 was enriched in detergent-resistant membranes (DRMs) isolated by Triton X-100 extraction from PC12 pheochromocytoma cells and could be detected in detergent-insoluble plasma membrane remnants after extraction of cells in situ, GAP-43 is palmitoylated at Cys-3 and Cys-4. Mutation of either Cys residue prevented association with DRMs. A hybrid protein containing the first 20 amino acid residues of GAP-43 fused to beta-galactosidase was targeted to DRMs even more efficiently than GAP-43 itself. We conclude that tandem palmitoylated Cys residues can target GAP-43 to DRMs, defining a new signal for DRM targeting. We propose that tandem or closely spaced saturated fatty acyl chains partition into domains or "rafts" in the liquid-ordered phase, or a phase with similar properties, in cell membranes. These rafts are isolated as DRMs after detergent extraction. The brain-specific heterotrimeric G protein G(o), which may be regulated by GAP-43 in vitro, was also enriched in DRMs from PC12 cells, Targeting of GAP-43 to rafts may function to facilitate signaling through G(o), In addition, raft association may aid in sorting of GAP-43 into axonally directed vesicles in the trans-Golgi network.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Brown, DA (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	dbrown@mcbsgi.bio.sunysb.edu		Arni, Stephan/0000-0001-5497-8256	NIGMS NIH HHS [GM 47897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; ARREAZA G, 1995, J BIOL CHEM, V270, P23641, DOI 10.1074/jbc.270.40.23641; BENOWITZ LI, 1983, J NEUROSCI, V3, P2153; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DECAMILLI P, 1993, NATURE, V364, P387; DEGRAAN PNE, 1993, BIOCHEM SOC T, V21, P406, DOI 10.1042/bst0210406; DEHOOP MJ, 1993, J CELL SCI, P85; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; DOTTI CG, 1993, J CELL SCI S15, V100, P75; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; GISPEN WH, 1991, MOL NEUROBIOL, V5, P61, DOI 10.1007/BF02935540; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; GORDONWEEKS PR, 1989, TRENDS NEUROSCI, V12, P363, DOI 10.1016/0166-2236(89)90073-8; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; GOSLIN K, 1990, J NEUROSCI, V10, P588; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; HSU WH, 1990, J BIOL CHEM, V265, P11220; Jouvin M H, 1995, Semin Immunol, V7, P29, DOI 10.1016/1044-5323(95)90005-5; Lane SR, 1997, J NEUROCHEM, V69, P1864; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; LIU YC, 1994, J NEUROSCI, V14, P5807; Maekawa S, 1997, BBA-BIOMEMBRANES, V1323, P1, DOI 10.1016/S0005-2736(96)00222-2; MATEO CR, 1995, BIOPHYS J, V68, P978, DOI 10.1016/S0006-3495(95)80273-0; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; MEIRI KF, 1990, J NEUROSCI, V10, P256; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; RIETVELD A, 1998, IN PRESS BIOCH BIOPH; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROSE JK, 1982, CELL, V30, P753, DOI 10.1016/0092-8674(82)90280-X; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHMIDT CF, 1978, NATURE, V271, P775, DOI 10.1038/271775a0; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SHI YG, 1994, J CELL BIOL, V124, P927, DOI 10.1083/jcb.124.6.927; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SKENE JHP, 1981, J CELL BIOL, V89, P96, DOI 10.1083/jcb.89.1.96; SPICHER K, 1991, BIOCHEM BIOPH RES CO, V175, P473, DOI 10.1016/0006-291X(91)91588-4; Stauffer TP, 1997, J CELL BIOL, V139, P1447, DOI 10.1083/jcb.139.6.1447; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1992, J NEUROBIOL, V23, P507, DOI 10.1002/neu.480230506; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; THOMAS JL, 1994, J CELL BIOL, V125, P795, DOI 10.1083/jcb.125.4.795; VANHOOFF COM, 1989, J CELL BIOL, V108, P1115, DOI 10.1083/jcb.108.3.1115; Zhang P, 1997, J BIOL CHEM, V272, P9609; ZHANG W, 1998, IN PRESS IMMUNITY; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	73	122	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28478	28485		10.1074/jbc.273.43.28478	http://dx.doi.org/10.1074/jbc.273.43.28478			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774477	hybrid			2022-12-25	WOS:000076549800097
J	Nishida, Y; Shima, F; Sen, H; Tanaka, Y; Yanagihara, C; Yamawaki-Kataoka, Y; Kariya, K; Kataoka, T				Nishida, Y; Shima, F; Sen, H; Tanaka, Y; Yanagihara, C; Yamawaki-Kataoka, Y; Kariya, K; Kataoka, T			Coiled-coil interaction of N-terminal 36 residues of cyclase-associated protein with adenylyl cyclase is sufficient for its function in Saccharomyces cerevisiae Ras pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH REGION; SCHIZOSACCHAROMYCES-POMBE; YEAST; CAP; BINDING; HOMOLOG; GENES; DNA; IDENTIFICATION; ACTIVATION	In the budding yeast Saccharomyces cerevisiae, association with the 70-kDa cyclase-associated protein (CAP) is required for proper response of adenylyl cyclase to Pas proteins. We show here that a small segment comprising the N-terminal 36 amino acid residues of CAP is sufficient for association with adenylyl cyclase as well as for its function in the Ras-adenylyl cyclase pathway as assayed by the ability to confer RAS2(Val-19)-dependent heat shock sensitivity to yeast cells. The CAP-binding site of adenylyl cyclase was mapped to a segment of 119 amino acid residues near its C terminus. Both of these regions contained tandem repetitions of a heptad motif alpha XX alpha XXX (where alpha represents a hydrophobic amino acid and X represents any amino acid), suggesting a coiled-coil interaction. When mutants of CAP defective in associating with adenylyl cyclase were isolated by screening of a pool of randomly mutagenized CAP, they were found to carry substitution mutations in one of the key hydrophobic residues in the heptad repeats. Furthermore, mutations of the key hydrophobic residues in the heptad repeats of adenylyl cyclase also resulted in loss of association with CAP. These results indicate the coiled-coil mechanism as a basis of the CAP-adenylyl cyclase interaction.	Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Kataoka, T (corresponding author), Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, 7-5-1 Kusunoki-cho, Kobe, Hyogo 6500017, Japan.	kataoka@kobe-u.ac.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Freeman NL, 1996, MOL CELL BIOL, V16, P548; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GRAM H, 1992, P NATL ACAD SCI USA, V89, P3576, DOI 10.1073/pnas.89.8.3576; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KAWAMUKAI M, 1992, MOL BIOL CELL, V3, P167, DOI 10.1091/mbc.3.2.167; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIMBERGER RJ, 1990, MOL BIOCHEM PARASIT, V38, P271, DOI 10.1016/0166-6851(90)90030-P; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MATVIW H, 1992, MOL CELL BIOL, V12, P5033, DOI 10.1128/MCB.12.11.5033; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MINATO T, 1994, J BIOL CHEM, V269, P20845; Rose MD., 1990, METHODS YEAST GENETI; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Shima F, 1997, MOL CELL BIOL, V17, P1057, DOI 10.1128/MCB.17.3.1057; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; VOJTEK AB, 1993, J CELL SCI, V105, P777; WANG J, 1993, MOL CELL BIOL, V13, P4087, DOI 10.1128/MCB.13.7.4087; YAMAWAKIKATAOKA Y, 1989, P NATL ACAD SCI USA, V86, P5693, DOI 10.1073/pnas.86.15.5693; Yanagihara C, 1997, BIOCHEM BIOPH RES CO, V232, P503, DOI 10.1006/bbrc.1997.6326; Zelicof A, 1996, J BIOL CHEM, V271, P18243, DOI 10.1074/jbc.271.30.18243; ZELICOF A, 1993, J BIOL CHEM, V268, P13448	40	43	43	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28019	28024		10.1074/jbc.273.43.28019	http://dx.doi.org/10.1074/jbc.273.43.28019			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774417	hybrid			2022-12-25	WOS:000076549800037
J	Tsakiridis, T; Bergman, A; Somwar, R; Taha, C; Aktories, K; Cruz, TF; Klip, M; Downey, GP				Tsakiridis, T; Bergman, A; Somwar, R; Taha, C; Aktories, K; Cruz, TF; Klip, M; Downey, GP			Actin filaments facilitate insulin activation of the Src and collagen homologous/mitogen-activated protein kinase pathway leading to DNA synthesis and c-fos expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; AMINO-ACID-TRANSPORT; NERVE GROWTH-FACTOR; P70 S6 KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; GLUCOSE TRANSPORTERS; GLYCOGEN-SYNTHASE; MUSCLE-CELLS; PHOSPHOINOSITIDE 3-KINASE	The exact mechanism of the spatial organization of the insulin signaling pathway leading to nuclear events remains unknown, Here, we investigated the involvement of the actin cytoskeleton in propagation of insulin signaling events leading to DNA synthesis and expression of the immediate early genes c-fos and c-jun in L6 muscle cells. Insulin reorganized the cellular actin network and increased the rate of DNA synthesis and the levels of c-fos mRNA, but not those of c-jun mRNA, in undifferentiated L6 myoblasts. Similarly, insulin markedly elevated the levels of c-fos mRNA but not of c-jun mRNA in differentiated L6 myotubes. Disassembly of the actin filaments by cytochalasin D, latrunculin B, or botulinum Ca toxin significantly inhibited insulin-mediated DNA synthesis in myoblasts and abolished stimulation of c-fos expression by the hormone in myoblasts and myotubes, Actin disassembly abolished insulin-induced phosphorylation and activation of extracellulor signal-regulated kinases, activation of a 65-kda member of the pal-activated kinases, and phosphorylation of p38 mitogen-activated protein kinases but did not prevent activation of phosphatidylinositol 3-kinase and p70(S6k). Under these conditions, insulin-induced Ras activation was also abolished, and Grb2 association with the Src and collogen homologous (Shc) molecule was inhibited without inhibition of the tyrosine phosphorylation of Shc, We conclude that the actin filament network plays an essential role in insulin regulation of She-dependent signaling events governing gene expression by facilitating the interaction of Shc with Grb2.	Univ Toronto, Dept Med, Div Resp, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Freiburg	Downey, GP (corresponding author), Univ Toronto, Dept Med, Div Resp, Rm 6264,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	gregory.downey@utoronto.ca	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Downey, Gregory P/0000-0003-3253-5862				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AHN NG, 1991, J BIOL CHEM, V266, P4220; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; COPPER JA, 1987, J CELL BIOL, V105, P1473; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOSHIMA K, 1984, J CELL BIOL, V98, P801, DOI 10.1083/jcb.98.3.801; Harada S, 1996, J BIOL CHEM, V271, P30222, DOI 10.1074/jbc.271.47.30222; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Ishihara H, 1997, J BIOL CHEM, V272, P9581; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kao AW, 1997, ENDOCRINOLOGY, V138, P2474, DOI 10.1210/en.138.6.2474; KIM SJ, 1994, J BIOL CHEM, V269, P11887; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LENORMAND P, 1993, ADV SEC MESS PHOSPH, V28, P237; Lin TH, 1997, J BIOL CHEM, V272, P8849; MELAMED I, 1991, J IMMUNOL, V147, P1139; Miller BS, 1996, BIOCHEMISTRY-US, V35, P8769, DOI 10.1021/bi952651r; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; MUSGROVE EA, 1994, SEMIN CANCER BIOL, V5, P381; MYERS MG, 1994, J BIOL CHEM, V269, P28783; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SueAQuan AK, 1997, J CELL PHYSIOL, V172, P94, DOI 10.1002/(SICI)1097-4652(199707)172:1<94::AID-JCP11>3.0.CO;2-O; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; TORTI M, 1993, P NATL ACAD SCI USA, V90, P7553, DOI 10.1073/pnas.90.16.7553; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Waldmann V, 1996, PATHOL RES PRACT, V192, P883, DOI 10.1016/S0344-0338(96)80067-7; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	59	67	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28322	28331		10.1074/jbc.273.43.28322	http://dx.doi.org/10.1074/jbc.273.43.28322			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774456	hybrid			2022-12-25	WOS:000076549800076
J	Zong, CS; Zeng, LY; Jiang, YX; Sadowski, HB; Wang, LH				Zong, CS; Zeng, LY; Jiang, YX; Sadowski, HB; Wang, LH			Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced Anchorage-independent growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; DNA-BINDING ACTIVITY; SIGNAL-TRANSDUCTION PATHWAYS; CONSTITUTIVE ACTIVATION; INTERFERON-GAMMA; CELL-LINES; TRANSCRIPTION FACTORS; TARGETED DISRUPTION; ABL ONCOGENE; C-ROS	The role of signal transducers and activators of transcription (STATs) in receptor protein-tyrosine kinase (PTH)-induced cell growth and transformation was investigated using an inducible epidermal growth factor receptor-Res chimeric receptor called ER2 and a constitutively activated insulin-like growth factor I receptor called NM1, both of which are able to induce anchorage-independent growth of NM 3T3 cells. ER2 and NM1 receptor PTKs are able to cause Stat3 activation. Coexpressing the dominant negative Stat3 mutant with ER2 or NM1 in transiently or stable transfected cells resulted in a dramatic inhibition of colonies induced by these receptor PTKs and a moderate inhibition of their mitogenicity in monolayer. Therefore, Stat3 is not only important for initiation of transformation, as demonstrated by inhibition of the epidermal growth factor-inducible colony formation of the ER2 cells by the mutant, but it is also required for the maintenance of transformation, as evidenced by reversion of the NM1 transformed cells, The DNA binding and transcriptional activities of the endogenous Stat3 were greatly inhibited in the ER2 and NM1 cells co-expressing the Stat3 mutants. We conclude that activated function of Stat3 is required for the establishment and maintenance of Ros and insulin-like growth factor I receptor PTK-induced cell transformation.	Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Zong, CS (corresponding author), Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.	zongc01@doc.mssm.edu			NATIONAL CANCER INSTITUTE [R01CA029339, R01CA055054] Funding Source: NIH RePORTER; NCI NIH HHS [CA55054, CA29339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAHMANDPOUR F, 1995, FEBS LETT, V360, P29, DOI 10.1016/0014-5793(95)00072-H; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; CACACE AM, 1993, ONCOGENE, V8, P2095; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Coffer PJ, 1997, ONCOGENE, V15, P2529, DOI 10.1038/sj.onc.1201429; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GouilleuxGruart V, 1996, BLOOD, V87, P1692; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Kang JS, 1996, MOL CELL BIOL, V16, P3370; KRAUSS RS, 1992, MOL CELL BIOL, V12, P3117, DOI 10.1128/MCB.12.7.3117; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULI AL, 1995, EMBO J, V14, P1166; MULI AL, 1996, EMBO J, V15, P2425; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J., 1989, MOL CLONING, P1666; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; Shuai K, 1996, ONCOGENE, V13, P247; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WeberNordt RM, 1996, BLOOD, V88, P809; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xiong QH, 1996, MOL CELL BIOL, V16, P1509; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x; ZONG CS, 1993, J VIROL, V67, P6453, DOI 10.1128/JVI.67.11.6453-6462.1993; ZONG CS, 1994, P NATL ACAD SCI USA, V91, P10982, DOI 10.1073/pnas.91.23.10982; Zong CS, 1997, J BIOL CHEM, V272, P1500, DOI 10.1074/jbc.272.3.1500	55	81	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28065	28072		10.1074/jbc.273.43.28065	http://dx.doi.org/10.1074/jbc.273.43.28065			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774423	hybrid			2022-12-25	WOS:000076549800043
J	Mallat, A; Gallois, C; Tao, JC; Habib, A; Maclouf, J; Mavier, P; Preaux, AM; Lotersztajn, S				Mallat, A; Gallois, C; Tao, JC; Habib, A; Maclouf, J; Mavier, P; Preaux, AM; Lotersztajn, S			Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation - Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN ITO CELLS; SMOOTH-MUSCLE CELLS; FAT-STORING CELLS; INHIBITORY PROPERTIES; MEDIATED PATHWAY; LIVER-INJURY; EXPRESSION; CULTURE; CYCLOOXYGENASE	Proliferation of myofibroblastic hepatic stellate cells (HSC) in response to growth factors is essential for the development of liver fibrosis, We have reported that prostaglandins (PG) and cyclic AMP (cAMP) inhibit growth of human HSC, This PG/cAMP pathway transduces the endothelin (ET) B-mediated antiproliferative effect of endothelin-1 (ET-1) and up-regulates ETB receptors, Here, we show that platelet derived growth factor (PDGF)-BB and thrombin, although mitogenic, generate growth inhibitory PGE, in myofibroblastic human HSC, The two peptides elicit early PGE(2) and cAMP synthesis, and also promote delayed induction of cyclooxygenase (COX)-2. Both early and delayed production of PGE, counteract the mitogenic effect of PDGF-BB and thrombin because: (i) pretreatment with the COX inhibitor ibuprofen markedly enhances the mitogenic effect of both peptides; (ii) blocking early synthesis of PGE, greatly enhances extracellular signal-regulated kinase (ERK) activation by both growth factors; (iii) enhancement of DNA synthesis by ibuprofen is only lost when the inhibitor is added after COX-2 induction has occurred. Finally, PDGF-BB and thrombin raise ETB receptors through the PG pathway. Thus, ibuprofen blunts growth factor-induced increase in ETB receptors, Up regulation of the growth inhibitory ETB receptors by both mitogens may enhance the antiproliferative effect of ET-1 and thereby establish a negative feedback of their mitogenic effect. Our results shed light on novel growth inhibitory signals evoked by two mitogenic growth factors expressed during liver injury.	Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France; Hop Lariboisiere, Inst Federat Rech Circulat Lariboisiere, U348, INSERM, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mallat, A (corresponding author), Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France.	mallat@im3.inserm.fr	Lotersztajn, Sophie/K-9160-2017; Habib, Aida/H-8647-2019	Habib, Aida/0000-0001-6027-0043; lotersztajn, Sophie/0000-0002-0053-7807				Albrecht DE, 1997, J BIOL CHEM, V272, P2236; Asselin E, 1996, J CELL PHYSIOL, V168, P600, DOI 10.1002/(SICI)1097-4652(199609)168:3<600::AID-JCP12>3.0.CO;2-2; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016/0005-2760(94)00196-6; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; DAVIS BH, 1991, BIOCHEM J, V278, P43, DOI 10.1042/bj2780043; DEBLAQUIERE J, 1994, J BIOL CHEM, V269, P4812; FAILLI P, 1995, AM J PHYSIOL-CELL PH, V269, pC1133, DOI 10.1152/ajpcell.1995.269.5.C1133; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GEERTS A, 1991, HEPATOLOGY, V13, P1193, DOI 10.1002/hep.1840130628; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; HABIB A, 1993, J BIOL CHEM, V268, P23448; Houglum K, 1997, J CLIN INVEST, V99, P1322, DOI 10.1172/JCI119291; JOUNEAUX C, 1994, J BIOL CHEM, V269, P1845; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MALLAT A, 1995, J CLIN INVEST, V96, P42, DOI 10.1172/JCI118052; MALLAT A, 1995, HEPATOLOGY, V21, P1003, DOI 10.1016/0270-9139(95)90247-3; Mallat A, 1996, J HEPATOL, V25, P405, DOI 10.1016/S0168-8278(96)80130-9; Mallat A, 1996, J CLIN INVEST, V98, P2771, DOI 10.1172/JCI119103; MALLAT A, 1994, HEPATOLOGY, V20, P1589, DOI 10.1002/hep.1840200631; MANCINI R, 1992, J HEPATOL, V15, P361, DOI 10.1016/0168-8278(92)90069-2; MARRA F, 1995, HEPATOLOGY, V22, P780, DOI 10.1002/hep.1840220314; Marra F, 1997, GASTROENTEROLOGY, V112, P1297, DOI 10.1016/S0016-5085(97)70144-6; Marra F, 1998, HEPATOLOGY, V27, P462, DOI 10.1002/hep.510270221; McAnulty RJ, 1997, BIOCHEM J, V321, P639, DOI 10.1042/bj3210639; Pinzani M, 1996, GASTROENTEROLOGY, V110, P534, DOI 10.1053/gast.1996.v110.pm8566602; PINZANI M, 1994, HEPATOLOGY, V19, P701, DOI 10.1002/hep.1840190323; PINZANI M, 1992, J CLIN INVEST, V90, P642, DOI 10.1172/JCI115905; Pinzani M, 1996, AM J PATHOL, V148, P785; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SCHMITTGRAFF A, 1991, AM J PATHOL, V138, P1233; Throckmorton DC, 1996, BIOCHEM BIOPH RES CO, V220, P692, DOI 10.1006/bbrc.1996.0466; VIDAL C, 1994, MOL PHARMACOL, V45, P97; VITTET D, 1992, J CELL PHYSIOL, V150, P65, DOI 10.1002/jcp.1041500110; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121; WONG L, 1994, J CLIN INVEST, V94, P1563, DOI 10.1172/JCI117497	40	89	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27300	27305		10.1074/jbc.273.42.27300	http://dx.doi.org/10.1074/jbc.273.42.27300			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765255	hybrid			2022-12-25	WOS:000076448000042
J	Thomas, D; Lipp, P; Berridge, MJ; Bootman, MD				Thomas, D; Lipp, P; Berridge, MJ; Bootman, MD			Hormone-evoked elementary Ca2+ signals are not stereotypic, but reflect activation of different size channel clusters and variable recruitment of channels within a cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE; XENOPUS OOCYTES; HELA-CELLS; ENDOTHELIAL-CELLS; CARDIAC MYOCYTES; CALCIUM; EVENTS; RELEASE; PATTERNS; SPIKES	Precious studies of (InsP(3))-evoked elementary Ca2+ events suggested a hierarchy of signals; fundamental events ("Ca2+ blips") arising from single InsP(3) receptors (InsP(3)Rs), and intermediate events ("Ca2+ puffs") reflecting the coordinated opening of a cluster of InsP(3)Rs, The characteristics of such elementary Ca2+ release signals provide insights into the functional interaction and distribution of InsP(3)Rs in living cells. Therefore we investigated whether elementary Ca2+ signaling is truly represented by such stereotypic release events. A histogram of >900 events revealed a wide spread of signal amplitudes (20-600 nM; mean 216 +/- 4 nM; n = 206 cells), which cannot be explained by stochastic variation of a stereotypic Ca2+ release site. We identified elementary Ca2+ release sites with consistent amplitudes (<20% difference) and locations with variable amplitudes (similar to 500% difference). importantly, within single cells, distinct sites displayed events with significantly different mean amplitudes, Additional determinants affecting the magnitude of elementary Ca2+ release were identified to be (i) hormone concentration, (ii) day-to day variability, and (iii) a progressively decreasing Ca2+ release during prolonged stimulation. We therefore suggest that elementary Ca2+ events are not stereotypic, instead a continuum of signals can be achieved by either recruitment of entire clusters with different numbers of InsP(3)Rs or by a graded recruitment of InsP(3)Rs within a cluster.	Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	Lipp, P (corresponding author), Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England.	peterlipp@bbsrc.ac.uk	Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; Bootman MD, 1996, CURR BIOL, V6, P855, DOI 10.1016/S0960-9822(02)00609-7; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; Callamaras N, 1998, J PHYSIOL-LONDON, V509, P81, DOI 10.1111/j.1469-7793.1998.081bo.x; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Huser J, 1997, AM J PHYSIOL-CELL PH, V273, pC1775, DOI 10.1152/ajpcell.1997.273.5.C1775; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; Lipp P, 1996, PROG BIOPHYS MOL BIO, V65, P265, DOI 10.1016/S0079-6107(96)00014-4; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; Lipp P, 1998, J PHYSIOL-LONDON, V508, P801, DOI 10.1111/j.1469-7793.1998.801bp.x; Lipp P, 1996, J PHYSIOL-LONDON, V492, P31, DOI 10.1113/jphysiol.1996.sp021286; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; Marchant JS, 1998, J PHYSIOL-LONDON, V506P, p70P; Parker I, 1996, CELL CALCIUM, V20, P105, DOI 10.1016/S0143-4160(96)90100-1; Parker I, 1997, J PHYSIOL-LONDON, V505, P337, DOI 10.1111/j.1469-7793.1997.337bb.x; Parker I, 1996, J PHYSIOL-LONDON, V491, P663, DOI 10.1113/jphysiol.1996.sp021247; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; Reber BFX, 1996, PFLUG ARCH EUR J PHY, V432, P893, DOI 10.1007/s004240050213; Shirokova N, 1997, J PHYSIOL-LONDON, V502, P3, DOI 10.1111/j.1469-7793.1997.003bl.x; Sun XP, 1998, J PHYSIOL-LONDON, V509, P67, DOI 10.1111/j.1469-7793.1998.067bo.x; Swillens S, 1998, CELL CALCIUM, V23, P291, DOI 10.1016/S0143-4160(98)90025-2; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; Tovey SC, 1998, J PHYSIOL-LONDON, V509P, p200P; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538	31	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27130	27136		10.1074/jbc.273.42.27130	http://dx.doi.org/10.1074/jbc.273.42.27130			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765231	hybrid			2022-12-25	WOS:000076448000018
J	Zhu, XG; Hanover, JA; Hager, GL; Cheng, SY				Zhu, XG; Hanover, JA; Hager, GL; Cheng, SY			Hormone-induced translocation of thyroid hormone receptors in living cells visualized using a receptor green fluorescent protein chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; L-TRIIODOTHYRONINE; GLUCOCORTICOID RECEPTOR; BINDING; LOCALIZATION; DOMAIN; GROWTH; DNA; MODULATION; MUTANTS	Thyroid hormone nuclear receptors (TRs) are ligand-dependent transcription factors that regulate growth, differentiation, and development. To understand the role of the hormone, 3,3',5-triiodo-L-thyronine (T-3), in the nuclear translocation and targeting of TRs to the regulatory sites in chromatin, we appended green fluorescent protein (GFP) to the human TR subtype beta 1 (TR beta 1). The fusion of GFP to the amino terminus of TR beta 1 protein did not alter T-3 binding or transcriptional activities of the receptor. The subcellular localization of GFP-TR beta 1 in living cells was visualized by laser-scanning confocal microscopy. In the presence of T-3, the expressed GFP-TR beta 1 was predominately localized in the nucleus, exhibiting a nuclear/cytoplasmic ratio of similar to 5.5. No GFP-TR beta 1 was detected in the nucleolus. In the absence of T-3, more GFP-TR beta 1 was present in the cytoplasm, exhibiting a nuclear/cytoplasmic ratio of similar to 1.5. In these cells, cytoplasmic GFP-TR beta 1 could be induced to enter the nucleus by T-3. The T-3-induced translocation was blocked when Lys(184)-Arg(185) in domain D of TR beta 1 was mutated to Ala(184)-Ala(185). Furthermore, the inability of the mutant TR to translocate to the nucleus correlated with the loss of most of its transcriptional activity. These results suggest that TR functions may, in part, be regulated by T-3-induced nuclear entry.	NCI, Mol Biol Lab, Bethesda, MD 20892 USA; NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20892 USA; NIDDK, Lab Cellular Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Cheng, SY (corresponding author), Bldg 37,Rm 2D24,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.							ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BHAT MK, 1993, BIOCHEM BIOPH RES CO, V195, P385, DOI 10.1006/bbrc.1993.2055; Cheng Sheue-Yann, 1995, Journal of Biomedical Science, V2, P77, DOI 10.1007/BF02253060; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DEFESI CR, 1985, ENDOCRINOLOGY, V116, P2062, DOI 10.1210/endo-116-5-2062; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; HELM R, 1995, NATURE, V373, P663; HOLLEY SJ, 1995, MOL BIOL CELL, V6, P1833, DOI 10.1091/mbc.6.12.1833; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; LEE Y, 1993, J BIOL CHEM, V268, P2021; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; Lin KH, 1996, ENDOCRINOLOGY, V137, P4073, DOI 10.1210/en.137.10.4073; LIN KH, 1991, ENDOCRINOLOGY, V128, P2601, DOI 10.1210/endo-128-5-2601; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; MEIER CA, 1993, J CLIN INVEST, V92, P1986, DOI 10.1172/JCI116793; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; OPPENHEIMER JH, 1975, ENDOCR RES COMMUN, V2, P309, DOI 10.1080/07435807509089004; OPPENHEIMER JH, 1994, EUR J ENDOCRINOL, V130, P15, DOI 10.1530/eje.0.1300015; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; PUYMIRAT J, 1992, NEUROSCI LETT, V135, P239, DOI 10.1016/0304-3940(92)90445-D; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SAMUELS HH, 1976, P NATL ACAD SCI USA, V73, P3877, DOI 10.1073/pnas.73.11.3877; SAMUELS HH, 1979, J CLIN INVEST, V63, P1229, DOI 10.1172/JCI109418; SPINDLER BJ, 1975, J BIOL CHEM, V250, P4113; STRAIT KA, 1991, P NATL ACAD SCI USA, V88, P3887, DOI 10.1073/pnas.88.9.3887; SURKS MI, 1975, J CLIN INVEST, V55, P50, DOI 10.1172/JCI107917; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; Zhu XG, 1997, J BIOL CHEM, V272, P9048	32	92	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27058	27063		10.1074/jbc.273.42.27058	http://dx.doi.org/10.1074/jbc.273.42.27058			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765220	hybrid			2022-12-25	WOS:000076448000007
J	Chevalier, M; King, L; Wang, CY; Gething, MJ; Elguindi, E; Blond, SY				Chevalier, M; King, L; Wang, CY; Gething, MJ; Elguindi, E; Blond, SY			Substrate binding induces depolymerization of the C-terminal peptide binding domain of murine GRP78/BiP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE HSC70; SHOCK COGNATE PROTEIN; ATPASE ACTIVITY; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; CIRCULAR-DICHROISM; SELF-ASSOCIATION; SECONDARY STRUCTURE; UNFOLDED PROTEINS; BIP	To investigate the role of each domain in BiP/GRP78 function, we have used a full-length recombinant BiP engineered to contain two enterokinase sites; one site is located after an N-terminal FLAG epitope, and a second site has been inserted at the junction between the N- and C-terminal domains (FLAG-BiP,ent), FLAG-BiP.ent oligomerizes into multiple species that interconvert with each other in a slow, concentration- and temperature-dependent equilibrium. Binding of ATP or AMP-PNP (adenosine 5'-(beta,gamma-imino)triphosphate), but not ADP, or of a peptidic substrate induces depolymerization of FLAG-BiP,ent and stabilization of monomeric species. Enterokinase cleavage of monomeric, nucleotide-free BiP,ent results in the physical dissociation of the 44-kDa N-terminal ATPase fragment (N44,ent) from the 30-kDa C-terminal substrate binding domain (C30.ent), Upon dissociation, the freed C-terminal substrate binding domain readily undergoes self-association while N44,ent remains monomeric, Enterokinase cleavage performed in the presence of a synthetic peptide prevents oligomerization of the freed C30,ent domain. Addition of ATP during enterokinase cleavage has no effect on C30.ent oligomerization, Our data clearly indicate that binding of a specific peptide onto the C-terminal domain, or ATP onto the N-terminal domain, induces internal conformational change(s) within the C30 domain that result(s) in BiP depolymerization.	Univ Illinois, Coll Pharm, Ctr Pharmaceut Biotechnol M C 870, Chicago, IL 60607 USA; Univ Melbourne, Dept Biochem & Mol Bol, Parkville, Vic 3052, Australia	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Melbourne	Blond, SY (corresponding author), Univ Illinois, Coll Pharm, Ctr Pharmaceut Biotechnol M C 870, Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA.	Blond@uic.edu						Azem A, 1997, J BIOL CHEM, V272, P20901, DOI 10.1074/jbc.272.33.20901; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; BENAROUDJ N, 1995, BIOCHEMISTRY-US, V34, P15282, DOI 10.1021/bi00046a037; Benaroudj N, 1996, J BIOL CHEM, V271, P18471, DOI 10.1074/jbc.271.31.18471; Benaroudj N, 1997, J BIOL CHEM, V272, P8744, DOI 10.1074/jbc.272.13.8744; BENAROUDJ N, 1994, EUR J BIOCHEM, V221, P121, DOI 10.1111/j.1432-1033.1994.tb18720.x; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1994, BIOL HEAT SHOCK PROT, P85; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Gao BC, 1996, J BIOL CHEM, V271, P16792, DOI 10.1074/jbc.271.28.16792; GAO BC, 1995, BIOCHEMISTRY-US, V34, P11882, DOI 10.1021/bi00037a028; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOZUTSUMI Y, 1989, J CELL SCI, P115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, FEBS LETT, V336, P124, DOI 10.1016/0014-5793(93)81624-9; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PARK K, 1993, PROTEIN SCI, V2, P325; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SEALS JR, 1978, ANAL BIOCHEM, V90, P785, DOI 10.1016/0003-2697(78)90169-0; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; WANG TF, 1993, J BIOL CHEM, V268, P26049; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; WIECH H, 1993, J BIOL CHEM, V268, P7414; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]; [No title captured]	60	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26827	26835		10.1074/jbc.273.41.26827	http://dx.doi.org/10.1074/jbc.273.41.26827			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756927	hybrid			2022-12-25	WOS:000076373300081
J	Soteropoulos, P; Perlin, DS				Soteropoulos, P; Perlin, DS			Genetic probing of the stalk segments associated with M2 and M3 of the plasma membrane H+-ATPase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; CYTOPLASMIC DOMAINS; MUTATIONS; REVERTANTS; CA-2+-ATPASE; NA,K-ATPASE; BINDING; REGIONS; PUMPS	The stalk region of the H+-ATPase from Saccharomyces cerevisiae has been proposed to play a role in coupling ATP hydrolysis to proton transport. Genetic probing was used to examine the role of stalk segments S2 and S3, associated with M2 and M3, respectively. Saturation mutagenesis was used to explore the role of side group character at position Ile(183) in S2, at which an alanine substitution was shown previously to partially uncouple the enzyme (Wang, G., Tamas, M. J., Hall, BI. J., Pascual-Ahuir, A., and Perlin, D. S, (1996) J, Biol, Chem, 271, 25438-25445). Diverse side group substitutions were tolerated at this position, although three substitutions, I183N, I183R, and I183Y required second site mutations at the C terminus of the enzyme for stabilization. Substitution of glycine and proline at Ile(183) resulted in lethal phenotypes, suggesting that the backbone may be more important than side group at this position. Proline/glycine mutagenesis was used to study additional sites in S2 and S3. The substitution of proline at Gly(186) resulted in a lethal phenotype, whereas substitutions in S3 of proline or serine at Gly(270) and proline or glycine at Thr(287) resulted in viable mutants. Mutations G270P and T287P resulted in mutant enzymes that produced pronounced growth defects and ATP hydrolysis rates that were 35% and 60% lower than wild type enzyme, respectively. The mutant enzymes transported protons at rates consistent with their ATPase activity, suggesting that the growth defects observed were due to a reduced rate of ATP hydrolysis and not to uncoupling of proton transport. The prominent growth phenotypes produced by mutations G270P and T287P permitted the isolation of suppressor mutations, which restored wild type growth, Most of the suppressors either replaced the primary site mutation with alanine or restored the mild type residue by ectopic recombination with PMA2, both of which restore alpha-helical tendency. This study suggests that maintaining alpha-helical character is essential to S2 and may play an important role in S3.	Publ Hlth Res Inst City New York Inc, New York, NY 10016 USA		Perlin, DS (corresponding author), Publ Hlth Res Inst City New York Inc, 455 1st Ave, New York, NY 10016 USA.	perlin@phri.nyu.edu	Perlin, David S/K-4013-2015		NIGMS NIH HHS [GM 38225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANAND S, 1995, BBA-BIOMEMBRANES, V1234, P127, DOI 10.1016/0005-2736(94)00281-S; ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Bandell M, 1996, BBA-BIOMEMBRANES, V1280, P81, DOI 10.1016/0005-2736(95)00280-4; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; ERASO P, 1994, J BIOL CHEM, V269, P10393; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NA SQ, 1993, J BIOL CHEM, V268, P11792; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERLIN DS, 1986, ARCH BIOCHEM BIOPHYS, V248, P53, DOI 10.1016/0003-9861(86)90400-5; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SETOYOUNG D, 1992, BIOCHIM BIOPHYS ACTA, V1102, P213, DOI 10.1016/0167-4838(92)90512-C; SETOYOUNG D, 1994, J BIOL CHEM, V269, P23988; SetoYoung D, 1996, J BIOL CHEM, V271, P581, DOI 10.1074/jbc.271.1.581; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; Wach A, 1996, BIOCHEMISTRY-US, V35, P883, DOI 10.1021/bi951998r; Wang GF, 1996, J BIOL CHEM, V271, P25438, DOI 10.1074/jbc.271.41.25438; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	34	10	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26426	26431		10.1074/jbc.273.41.26426	http://dx.doi.org/10.1074/jbc.273.41.26426			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756876	hybrid			2022-12-25	WOS:000076373300030
J	Casamassima, A; Rozengurt, E				Casamassima, A; Rozengurt, E			Insulin-like growth factor I stimulates tyrosine phosphorylation of p130(Cas), focal adhesion kinase, and paxillin - Role of phosphatidylinositol 3 '-kinase and formation of a p130(Cas)center dot Crk complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SWISS 3T3 CELLS; PHOSPHOINOSITIDE 3-KINASE; RECEPTOR SUBSTRATE-1; ACTIN CYTOSKELETON; LYSOPHOSPHATIDIC ACID; EXTRACELLULAR-MATRIX; SIGNALING PATHWAYS; DNA-SYNTHESIS; V-SRC	Addition of insulin growth factor-I (IGF-I) to quiescent Swiss 3T3 cells rapidly induced tyrosine phosphorylation of the p130Crk-associated substrate (p130(Cas)), a novel adaptor protein localized at focal adhesions. Half-maximal effect was obtained at 0.6 nM. IGF-I also promoted the formation of a complex between p130(Cas) and c-Crk and elicited a parallel increase in the tyrosine phosphorylation of p125(Fak) and paxillin. IGF-I-induced p130(Cas), p125Fak, and paxillin tyrosine phosphorylation could be dissociated from mitogen-activated protein kinase kinase, p70(S6K), and protein kinase C activation. In contrast, the structurally unrelated phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 markedly attenuated the increase in tyrosine phosphorylation of p130(Cas), p125(Fak) and paxillin induced by IGF-I. Cytochalasin D, which disrupts the network of actin microfilaments, completely prevented tyrosine phosphorylation of p130(Cas), p125(Fak), and paxillin and the formation of a p130(Cas).Crk complex in response to IGF-I. Thus, our results identified a phosphatidylinositol 3-kinase-dependent pathway that requires the integrity of the actin cytoskeleton to induce tyrosine phosphorylation of p130(Cas), p125(Fak) and paxillin in response to IGF-I and suggest that tyrosine phosphorylation of these focal adhesion proteins, together with the recruitment of c-Crk into a complex with p130(Cas), may play a novel role in IGF-I signal transduction.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Imperial Canc Res Fund, Lincolns Inn Fields, London WC2A 3PX, England; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cancer Research UK; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Baron V, 1998, J BIOL CHEM, V273, P7162, DOI 10.1074/jbc.273.12.7162; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1997, VITAM HORM, V53, P65, DOI 10.1016/S0083-6729(08)60704-9; Baserga R, 1997, BBA-REV CANCER, V1332, pF105, DOI 10.1016/S0304-419X(97)00007-3; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Burnham MR, 1996, ONCOGENE, V12, P2467; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Cary LA, 1996, J CELL SCI, V109, P1787; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Grammer TC, 1996, CANCER SURV, V27, P271; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Ilic D, 1997, J CELL SCI, V110, P401; ILLE D, 1995, NATURE, V377, P539; KasusJacobi A, 1997, J BIOL CHEM, V272, P17166, DOI 10.1074/jbc.272.27.17166; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Konstantopoulos N, 1996, J BIOL CHEM, V271, P28960, DOI 10.1074/jbc.271.46.28960; Konstantopoulos N, 1996, BIOCHEM J, V314, P387, DOI 10.1042/bj3140387; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LeRoith D, 1996, BAILLIERE CLIN ENDOC, V10, P49, DOI 10.1016/S0950-351X(96)80298-9; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; OKADA T, 1994, J BIOL CHEM, V269, P3563; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; OWENS LV, 1995, CANCER RES, V55, P2752; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Rozengurt E, 1997, ESSAYS BIOCHEM, V32, P73; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, CANCER SURV, V24, P81; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Tobe K, 1996, MOL CELL BIOL, V16, P4765; TOKER A, 1997, NATURE, V387; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1994, J CELL SCI, V107, P1583; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VUORI K, 1993, J BIOL CHEM, V268, P21459; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; Withers DJ, 1997, J BIOL CHEM, V272, P2509; YANO H, 1993, J BIOL CHEM, V268, P25846; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	79	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26149	26156		10.1074/jbc.273.40.26149	http://dx.doi.org/10.1074/jbc.273.40.26149			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748296	hybrid			2022-12-25	WOS:000076263100087
J	Iwabuchi, K; Li, B; Massa, HF; Trask, BJ; Date, T; Fields, S				Iwabuchi, K; Li, B; Massa, HF; Trask, BJ; Date, T; Fields, S			Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; DNA-BINDING SITE; TUMOR SUPPRESSION; MUTANT P53; CELL-LINE; CHECKPOINT; GROWTH; GENE; TRANSFORMATION; DOMAINS	p53 is a tumor suppressor protein that controls cell proliferation by regulating the expression of growth control genes. In a previous study, we identified two proteins, 53BP1 and 53BP2, that are able to bind to wild type but not to mutant p53 via the DNA-binding domain of p53. We isolated cDNAs expressing a full-length human 53BP1 clone, which predicts a protein of 1972 residues that can be detected in the H358 human lung carcinoma cell line. The 53BP1 and 53BP2 genes were mapped to chromosomes 15q15-21 and 1q41-42, respectively. Immunofluorescence studies showed three types of staining patterns for 53BP1 as follows: both cytoplasmic and nuclear, homogeneous nuclear, and a nuclear dot pattern. In contrast, 53BP2 localized exclusively to the cytoplasm, and this pattern did not change upon coexpression of wild type p53. Although our previous study revealed that p53 is not able to bind simultaneously to either 53BP1 or 53BP2 and to DNA carrying a consensus binding site, both 53BP1 and 53BP2 enhanced p53-mediated transcriptional activation and induced the expression of a p53-dependent protein, suggesting that these proteins might function in signal transduction pathways to promote p53 activity.	Univ Washington, Dept Genet, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Med, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Kanazawa Med Univ, Dept Biochem, Uchinada, Ishikawa 92002, Japan; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Kanazawa Medical University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Fields, S (corresponding author), Univ Washington, Dept Genet, Howard Hughes Med Inst, Box 357360, Seattle, WA 98195 USA.				NATIONAL CANCER INSTITUTE [R01CA054699, P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA28146, CA54699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Maniatis T., 1982, MOL CLONING LAB MANU; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reed Michael, 1993, Gene Expression, V3, P95; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; TRASK BJ, 1997, GENOME ANAL LAB MANU; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	55	162	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26061	26068		10.1074/jbc.273.40.26061	http://dx.doi.org/10.1074/jbc.273.40.26061			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748285	hybrid			2022-12-25	WOS:000076263100076
J	Tse, A; Brigle, K; Taylor, SM; Moran, RG				Tse, A; Brigle, K; Taylor, SM; Moran, RG			Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENOVO PURINE SYNTHESIS; LEUKEMIA-CELL LINE; L1210 CELLS; FOLIC-ACID; MAMMALIAN-CELLS; TRANSPORT; METHOTREXATE; MURINE; 5,10-DIDEAZA-5,6,7,8-TETRAHYDROFOLATE; EXPRESSION	L1210/D3 mouse leukemia cells are resistant to 5,10-dideazatetrahydrofolate due to expansion of cellular folate pools which block polyglutamation of the drug (Tse, A., and Moran, R. G, (1998) J. Biol. Chem. 273, 25944-25952). These cells were found to have two point mutations in the reduced folate carrier (RFC), resulting in a replacement of isoleucine 48 by phenylalanine and of tryptophan 105 by glycine. Each mutation contributes to the resistance phenotype. Genomic DNA from resistant cells contained both the wild-type and mutant alleles, but wild-type message was not detected. Folic acid was a much better substrate, and 5-formyltetrahydrofolate was a poorer substrate for transport in L1210/D3 cells relative to L1210 cells. Enhanced transport of folic acid was due to a marked, approximate to 20-fold, decrease in the influx K-m. Influx of methotrexate and 5,10-dideazatetrahydrofolate were minimally altered. Transfection of mutated rfc cDNA into RFC-null L1210/A cells produced the substrate specificity and 5,10-dideazatetrahydrofolate resistance observed in the L1210/D3 line. Transfection of the mutant cDNA into wild-type cells also conferred resistance to 5,10-dideazatetrahydrofolate. We conclude that the I48F and W105G mutations in RFC caused resistance to 5,10-dideazatetrahydrofolate, that the region of the RFC protein near these two positions defines the substrate-binding site, that the wild-type allele was silenced during the multistep development of resistance, and that this mutant phenotype represents a genetically dominant trait.	Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol Immunol, Richmond, VA 23298 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; University of Southern California	Moran, RG (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Box 980230, Richmond, VA 23298 USA.				NATIONAL CANCER INSTITUTE [R01CA027605] Funding Source: NIH RePORTER; NCI NIH HHS [CA 27605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALATI T, 1996, CANCER RES, V56, P331; Assaraf YG, 1997, J BIOL CHEM, V272, P17460, DOI 10.1074/jbc.272.28.17460; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; DIXON KH, 1994, J BIOL CHEM, V269, P17; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1984, J BIOL CHEM, V259, P1526; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KEYOMARSI K, 1986, CANCER RES, V46, P5229; Laohavinij S, 1996, INVEST NEW DRUG, V14, P325, DOI 10.1007/BF00194536; MATHERLY LH, 1993, BIOCHEM PHARMACOL, V46, P2185, DOI 10.1016/0006-2952(93)90608-Y; MORAN RG, 1989, J BIOL CHEM, V264, P21047; MORAN RG, 1976, J BIOL CHEM, V251, P3569; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1987, BIOCHEM PHARMACOL, V36, P1659, DOI 10.1016/0006-2952(87)90051-7; TAYLOR EC, 1985, J MED CHEM, V28, P914, DOI 10.1021/jm00145a012; Tolner B, 1997, GENE, V189, P1, DOI 10.1016/S0378-1119(96)00676-2; Tse A, 1998, J BIOL CHEM, V273, P25944, DOI 10.1074/jbc.273.40.25944; YOUNG C W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P406; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873	24	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25953	25960		10.1074/jbc.273.40.25953	http://dx.doi.org/10.1074/jbc.273.40.25953			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748272	hybrid			2022-12-25	WOS:000076263100063
J	Minshall, RD; Miyagawa, K; Chadwick, CC; Novy, MJ; Hermsmeyer, K				Minshall, RD; Miyagawa, K; Chadwick, CC; Novy, MJ; Hermsmeyer, K			In vitro modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones	FASEB JOURNAL			English	Article						estrogen; progesterone; coronary artery reactivity; ischemic heart disease	PROTEIN-KINASE-C; FUNCTIONAL ESTROGEN-RECEPTORS; SMOOTH-MUSCLE; ARTERY SPASM; POSTMENOPAUSAL WOMEN; RHESUS-MONKEYS; HEART-DISEASE; PROGESTERONE; 17-BETA-ESTRADIOL; PROLIFERATION	Susceptibility to drug-induced coronary vasospasm in rhesus monkeys increases after removal of the ovaries and can be normalized by adding back physiological levels of estradiol-17 beta (E-2) and/or natural progesterone (P) in vivo as reported recently by our group. Furthermore, the reactivity status (Ca2+ and protein kinase C responses) of freshly isolated and primary culture coronary artery vascular muscle cells (VMC) mimic the intact coronary artery responses to 5-HT + U46619. Since coronary reactivity is maintained in the isolated VMC, we hypothesized that the reactivity state inherent in the VMC was modulated directly by ovarian steroids in vitro as in the whole animal. To test this hypothesis, we treated hyperreactive VMC from ovariectomized (ovx) mon keys in vitro with Ea or P and measured VMC reactivity to combined stimulation with 5-HT and U46619, as determined by the amplitude and especially the duration of intracellular Ca2+ signals, as well as protein kinase C (PKC) activation/translocation. VMC were treated for 12-96 h with 3-100 pg/ml E-2 (10-365 pM) and/or 0.3-3 ng/ml P (0.95-9.5 nM). Hyperreactive responses to the combination of 5-HT and U46619 in untreated VMC were significantly and dose-dependently reduced by treatment in vitro with physiological levels of either Ep or P for at least 24 h, Both the early transient and late sustained increases in intracellular Ca2+ and PKC translocation were blunted, and the effects of 0.2 nM E-2 and 3.2 nM P were specifically antagonized by the receptor blockers ICI 182,780 (200 nM) and RU486 (15 nM), respectively. Antibodies to the estrogen receptor and progesterone receptor labeled nuclei in VMC, which were also positively labeled by a smooth muscle myosin heavy chain monoclonal antibody. These data indicate that natural ovarian steroids directly reduce hyperreactive 5-HT and thromboxane A(2)-stimulated Ca2+ and PKC responses of coronary artery VMC from surgically menopausal rhesus macaques, We hypothesize that vascular hyperreactivity, which may be a critical factor involved in the increased incidence of coronary artery vasospasm and ischemic heart disease in postmenopausal women, can be normalized by E-2 and/or P through direct actions on coronary artery vascular muscle cells.	Oregon Reg Primate Res Ctr, Div Reprod Sci, Beaverton, OR 97006 USA; Wyeth Ayerst Res, Dept Endocrinol, Womens Hlth Res Inst, Radnor, PA 19084 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Dev & Cell Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon National Primate Research Center; Pfizer; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Hermsmeyer, K (corresponding author), Oregon Reg Primate Res Ctr, Div Reprod Sci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	rkh@compuserve.com			NHLBI NIH HHS [HL 51723] Funding Source: Medline; NICHD NIH HHS [HD18185, HD06159] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD006159, R01HD006159] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051723] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BAYARD F, 1995, ENDOCRINOLOGY, V136, P1523, DOI 10.1210/en.136.4.1523; Bei M, 1996, J STEROID BIOCHEM, V58, P83, DOI 10.1016/0960-0760(96)00005-2; BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Bhalla RC, 1997, AM J PHYSIOL-HEART C, V272, pH1996, DOI 10.1152/ajpheart.1997.272.4.H1996; Bielefeldt K, 1996, AM J PHYSIOL-GASTR L, V271, pG370, DOI 10.1152/ajpgi.1996.271.2.G370; Bory M, 1996, EUR HEART J, V17, P1015; Duckles SP, 1996, J PHARMACOL EXP THER, V279, P1; ELLIS EF, 1976, SCIENCE, V193, P1135, DOI 10.1126/science.959827; Espinosa E, 1996, BIOCHEM BIOPH RES CO, V221, P8, DOI 10.1006/bbrc.1996.0535; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; FORESTA C, 1995, BIOCHEM BIOPH RES CO, V206, P408, DOI 10.1006/bbrc.1995.1056; GILLIGAN DM, 1994, CIRCULATION, V90, P786, DOI 10.1161/01.CIR.90.2.786; GOLINO P, 1989, CIRCULATION, V79, P154, DOI 10.1161/01.CIR.79.1.154; GRABER R, 1993, CELL SIGNAL, V5, P181, DOI 10.1016/0898-6568(93)90069-X; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; HARDER DR, 1979, J CELL PHYSIOL, V100, P375, DOI 10.1002/jcp.1041000218; Hermsmeyer K, 1997, J AM COLL CARDIOL, V29, P671, DOI 10.1016/S0735-1097(96)00524-4; HERMSMEYER K, 1977, AM J PHYSIOL, V233, pC172, DOI 10.1152/ajpcell.1977.233.5.C172; HERMSMEYER K, 1996, J VASC RES, P33; HERMSMEYER K, 1997, ENDOTHELIAL CELL RES, V3, P237; HESS DL, 1981, BIOL REPROD, V24, P609, DOI 10.1095/biolreprod24.3.609; HORWITZ KB, 1982, J CLIN INVEST, V69, P750, DOI 10.1172/JCI110513; INGEGNO MD, 1988, LAB INVEST, V59, P353; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KALSNER S, 1995, BIOCHEM PHARMACOL, V49, P859, DOI 10.1016/0006-2952(94)00447-T; KARAS RH, 1994, CIRCULATION, V89, P1943, DOI 10.1161/01.CIR.89.5.1943; KASKI JC, 1989, J AM COLL CARDIOL, V14, P1456, DOI 10.1016/0735-1097(89)90382-3; KHALIL RA, 1991, CIRC RES, V69, P1626, DOI 10.1161/01.RES.69.6.1626; Kitazawa T, 1997, J PHYSIOL-LONDON, V499, P497, DOI 10.1113/jphysiol.1997.sp021944; Kolodgie FD, 1996, AM J PATHOL, V148, P969; Lee WS, 1997, NAT MED, V3, P1005, DOI 10.1038/nm0997-1005; LIOU YM, 1994, AM J PHYSIOL-CELL PH, V267, pC980, DOI 10.1152/ajpcell.1994.267.4.C980; LOSORDO DW, 1994, CIRCULATION, V89, P1501, DOI 10.1161/01.CIR.89.4.1501; MARVIN WJ, 1979, CIRC RES, V45, P528, DOI 10.1161/01.RES.45.4.528; MASERI A, 1990, CIRCULATION, V81, P1983, DOI 10.1161/01.CIR.81.6.1983; MEIZEL S, 1991, MOL CELL ENDOCRINOL, V11, pR1; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Minshall RD, 1998, J CLIN ENDOCR METAB, V83, P649, DOI 10.1210/jc.83.2.649; Miyagawa K, 1997, NAT MED, V3, P324, DOI 10.1038/nm0397-324; Miyagawa K, 1997, AM J PHYSIOL-HEART C, V272, pH2645, DOI 10.1152/ajpheart.1997.272.6.H2645; Moraghan T, 1996, ENDOCRINOLOGY, V137, P5174, DOI 10.1210/en.137.11.5174; NAKAO J, 1981, ATHEROSCLEROSIS, V38, P75, DOI 10.1016/0021-9150(81)90105-2; ORIMO A, 1993, BIOCHEM BIOPH RES CO, V195, P730, DOI 10.1006/bbrc.1993.2106; PERROTAPPLANAT M, 1995, CIRCULATION, V92, P2975, DOI 10.1161/01.CIR.92.10.2975; PRESS MF, 1988, ENDOCRINOLOGY, V122, P1165, DOI 10.1210/endo-122-3-1165; PRICE RJ, 1994, CIRC RES, V75, P520, DOI 10.1161/01.RES.75.3.520; RESKO JA, 1974, ENDOCRINOLOGY, V94, P128, DOI 10.1210/endo-94-1-128; RESKO JA, 1975, ENDOCRINOLOGY, V97, P425, DOI 10.1210/endo-97-2-425; Ruehlmann Dietrich O., 1997, Biochemical Society Transactions, V25, p112S; RUSCH NJ, 1995, PHYSL PATHOPHYSIOLOG, P999; RUSCH NJ, 1994, ION TRANSPORT HYPERT, P197; RYLANCE PB, 1985, BRIT MED J, V290, P13, DOI 10.1136/bmj.290.6461.13; SELF DA, 1994, J VASC RES, V31, P359, DOI 10.1159/000159064; SLAYDEN OD, 1993, ENDOCRINOLOGY, V132, P1845, DOI 10.1210/en.132.4.1845; STANCZYK FZ, 1995, MENOPAUSE, V2, P137; STANCZYK FZ, 1984, TREATMENT POSTMENOPA, P69; TAKAHASHI I, 1989, BIOCHEM BIOPH RES CO, V165, P1207, DOI 10.1016/0006-291X(89)92730-7; VANHOUTTE PM, 1985, CIRCULATION, V72, P728, DOI 10.1161/01.CIR.72.4.728; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; WILLERSON JT, 1986, J AM COLL CARDIOL, V8, P245, DOI 10.1016/S0735-1097(86)80121-8; WILLIAMS JK, 1994, J AM COLL CARDIOL, V24, P1757, DOI 10.1016/0735-1097(94)90184-8; ZHANG F, 1994, AM J PHYSIOL, V266, pC975, DOI 10.1152/ajpcell.1994.266.4.C975; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	66	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1998	12	13					1419	1429		10.1096/fasebj.12.13.1419	http://dx.doi.org/10.1096/fasebj.12.13.1419			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761786				2022-12-25	WOS:000076402000018
J	Thate, C; Englert, C; Gessler, M				Thate, C; Englert, C; Gessler, M			Analysis of WT1 target gene expression in stably transfected cell lines	ONCOGENE			English	Article						Wilms' tumour; WT1; zinc finger protein; differential display PCR; CSF1	WILMS-TUMOR GENE-WT1; DENYS-DRASH-SYNDROME; GROWTH-FACTOR-A; PRODUCT; BINDING; DNA; TRANSCRIPTION; MUTATIONS; RECEPTOR; SEQUENCE	The Wilms' tumour suppressor gene WT1 encodes a zinc finger protein that is mutated in a subset of Wilms' tumours. Mutation screening and animal studies revealed essential roles during development and later function of the kidneys and the entire genitourinary system. Sequence similarity suggested a possible role for WT1 as a transcription factor. Indeed, sequence specific DNA binding and transcriptional activation or repression potential could be demonstrated in transient transfection assays with various reporter constructs. To identify endogenous WT1 target genes we established HEK293 cell lines expressing the different WT1 isoforms in a tetracycline dependent manner. Differential display PCR (ddPCR) was performed on RNA from stable WT1 transfected HEK293 cell lines and two other WT1 transfected lines (G401 and Saos-2), In an extended survey of several thousand ddPCR bands only few differences in intensity were seen and none of these could unambiguously be verified as being WT1 regulated by subsequent Northern blot analysis, In addition, almost none of the WT1 target genes identified to date in transient co-transfection assays could be confirmed by either ddPCR or Northern hybridization in the three stable transfected cell lines. Among the nine genes expressed, the only exceptions were CSF1 and to a lesser extent IGF1R being induced in Saos-2/G401 and HEK293 cells, respectively. At least two of the cell lines tested had previously shown clear biological effects though - either WT1 dependent apoptosis (Saos-2) or greatly reduced tumorigenicity (G401). This suggests that WT1 may regulate only a very small set of genes that escape the detection methods used or it may not act as a transcription factor that influences steady state levels of mRNA.	Univ Wurzburg, Theodor Boveri Inst Biowissensch, D-97074 Wurzburg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	University of Wurzburg; Helmholtz Association; Karlsruhe Institute of Technology	Gessler, M (corresponding author), Univ Wurzburg, Theodor Boveri Inst Biowissensch, Hubland, D-97074 Wurzburg, Germany.			Thaete, Claudia/0000-0002-2739-5669; Gessler, Manfred/0000-0002-7915-6045; Englert, Christoph/0000-0002-5931-3189				Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Charlieu JP, 1995, J CELL SCI, P95; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; KENT J, 1995, ONCOGENE, V11, P1781; Kikuchi H, 1998, J MED GENET, V35, P45, DOI 10.1136/jmg.35.1.45; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; Klamt B, 1998, HUM MOL GENET, V7, P709, DOI 10.1093/hmg/7.4.709; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LANGERAK AW, 1995, GENE CHROMOSOME CANC, V12, P87, DOI 10.1002/gcc.2870120203; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LINSKENS MHK, 1995, NUCLEIC ACIDS RES, V23, P3244, DOI 10.1093/nar/23.16.3244; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MCMASTER ML, 1995, CELL GROWTH DIFFER, V6, P1609; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY JC, 1995, J BIOL CHEM, V270, P29976; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Vicanek C, 1997, KIDNEY INT, V52, P614, DOI 10.1038/ki.1997.374; Wan JS, 1996, NAT BIOTECHNOL, V14, P1685, DOI 10.1038/nbt1296-1685; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1992, J BIOL CHEM, V267, P21999	36	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	1998	17	10					1287	1294		10.1038/sj.onc.1202055	http://dx.doi.org/10.1038/sj.onc.1202055			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771972				2022-12-25	WOS:000075803300011
J	Cazaux, C; Blanchet, JS; Dupuis, D; Villani, G; Defais, M; Johnson, NP				Cazaux, C; Blanchet, JS; Dupuis, D; Villani, G; Defais, M; Johnson, NP			Investigation of the secondary DNA-binding site of the bacterial recombinase RecA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; GENETIC-RECOMBINATION; PROTEIN; COMPLEXES; EXCHANGE; ASSOCIATION; FILAMENTS	The L2 loop is a DNA-binding site of RecA protein, a recombinase from Eschericha coil. Two DNA-binding sites have been functionally defined in this protein. To determine whether the L2 loop of RecA protein is part of the primary or secondary binding site, we have constructed proteins with site-specific mutations in the loop and investigated their biological, biochemical, and DNA binding properties. The mutation E207Q inhibits DNA repair and homologous recombination in vivo and prevents DNA strand exchange in vitro (Larminat, F., Cazaux, C., Germanier, M., and Defais, M. (1992) J. Bacteriol. 174, 6264-6269; Cazaux, C., Larminat, F., Villani, G., Johnson, N. P., Schnarr, M., and Defais, M. (1994) J. Biol. Chem. 269, 8246-8254). We have found that mutant protein RecA(E207Q) lacked one of the two single stranded DNA-binding sites of wild type RecA. The remaining site was functional, and biochemical activities of the mutant protein were the same as wild type RecA with ssDNA in the primary binding site. The second mutation, E207K, reduced but did not eliminate DNA repair, SOS induction, and homologous recombination in vivo. In the presence of ATP, mutant protein RecA(E207K) catalyzed DNA strand exchange in vitro at a slower rate than wild type protein, and ssDNA binding at site I was competitively inhibited. These results show that the L2 loop is or is part of the functional secondary DNA-binding site of RecA protein.	CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Johnson, NP (corresponding author), CNRS, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.							BLANCO M, 1975, MOL MECHANISMS REPAI, P379; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; CALSOU P, 1985, MOL GEN GENET, V201, P1162; CAZAUX C, 1991, BIOCHIMIE, V73, P281, DOI 10.1016/0300-9084(91)90214-L; CAZAUX C, 1994, J BIOL CHEM, V269, P8246; CAZAUX C, 1992, J MOL BIOL, V223, P823, DOI 10.1016/0022-2836(92)90243-D; CAZENAVE C, 1983, EMBO J, V2, P2247, DOI 10.1002/j.1460-2075.1983.tb01730.x; EGELMAN EH, 1993, MICRON, V24, P309, DOI 10.1016/0968-4328(93)90056-7; Fersht A, 1985, ENZYME STRUCTURE MEC, P108; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; Johnson NP, 1996, J BIOL CHEM, V271, P19675, DOI 10.1074/jbc.271.33.19675; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P44; LARMINAT F, 1992, J BACTERIOL, V174, P6264, DOI 10.1128/JB.174.19.6264-6269.1992; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; Mazin AV, 1996, P NATL ACAD SCI USA, V93, P10673, DOI 10.1073/pnas.93.20.10673; MENETSKI JP, 1992, J BIOL CHEM, V267, P10400; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; Miller J. H ., 1971, EXPT MOL GENETICS; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SILVER MS, 1982, BIOCHEMISTRY-US, V21, P6066, DOI 10.1021/bi00267a007; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TAKAHASHI M, 1989, J BIOL CHEM, V264, P288; Voloshin ON, 1996, SCIENCE, V272, P868, DOI 10.1126/science.272.5263.868; Wang Y, 1996, BIOCHEMISTRY-US, V35, P3563, DOI 10.1021/bi952438v; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; ZLOTNICK A, 1993, J BIOL CHEM, V268, P22525	31	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28799	28804		10.1074/jbc.273.44.28799	http://dx.doi.org/10.1074/jbc.273.44.28799			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786879	hybrid			2022-12-25	WOS:000076691800040
J	Edskes, HK; Ohtake, Y; Wickner, RB				Edskes, HK; Ohtake, Y; Wickner, RB			Mak21p of Saccharomyces cerevisiae, a homolog of human CAATT-binding protein, is essential for 60 S ribosomal subunit biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; POL FUSION PROTEIN; MESSENGER-RNA; SUPERKILLER MUTATIONS; ANTIVIRAL SYSTEM; KILLER VIRUS; YEAST; EXPRESSION; TRANSLATION; POLY(A)	Mak21-1 mutants are unable to propagate M-1 double-stranded RNA, a satellite of the L-A double-stranded RNA virus, encoding a secreted protein toxin lethal to yeast strains that do not carry M-1. We cloned MAK21 using its map location and found that Mak21p is homologous to a human and mouse CAATT-binding protein and open reading frames in Schizosaccharomyces pombe and Caenorhabditis elegans, Although the human protein regulates Hsp70 production, Mak21p is essential for growth and necessary for 60 S ribosomal subunit biogenesis. mak21-1 mutants have decreased levels of L-A coat protein and L-A double-stranded RNA. Electroporation with reporter mRNAs shows that mak21-1 cells cannot optimally express mRNAs which, like L-A viral mRNA, lack 3'-poly(A) or 5'-cap structures but can normally express mRNA with both cap and poly(A), The virus propagation phenotype of mak21-1 is suppressed by ski2 or ski6 mutations, each of which derepresses translation of non-poly(A) mRNA.	NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wickner, RB (corresponding author), NIDDK, Lab Biochem & Genet, NIH, Bldg 8,Rm 225,8 Ctr Dr,MSC0830, Bethesda, MD 20892 USA.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Benard L, 1998, MOL CELL BIOL, V18, P2688, DOI 10.1128/MCB.18.5.2688; BOSTIAN KA, 1980, J BACTERIOL, V143, P463, DOI 10.1128/JB.143.1.463-470.1980; BRUENN J, 1976, NUCLEIC ACIDS RES, V3, P2427, DOI 10.1093/nar/3.10.2427; CARROLL K, 1995, J BACTERIOL, V177, P2887, DOI 10.1128/jb.177.10.2887-2891.1995; CHENG RH, 1994, J MOL BIOL, V244, P255, DOI 10.1006/jmbi.1994.1726; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Cui Y, 1998, MOL CELL BIOL, V18, P1506, DOI 10.1128/MCB.18.3.1506; DINMAN JD, 1995, GENETICS, V141, P95; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; Dinman JD, 1997, RNA, V3, P870; DINMAN JD, 1994, GENETICS, V136, P75; ERICKSON JR, 1993, GENETICS, V134, P151; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; ESTEBAN R, 1988, J VIROL, V62, P1278, DOI 10.1128/JVI.62.4.1278-1285.1988; FABIAN GR, 1987, J BACTERIOL, V169, P1571, DOI 10.1128/jb.169.4.1571-1578.1987; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; Hoeppner MA, 1996, NUCLEIC ACIDS RES, V24, P1091, DOI 10.1093/nar/24.6.1091; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; ICHO T, 1989, J BIOL CHEM, V264, P6716; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; JOHNSON AW, 1995, MOL CELL BIOL, V15, P2719; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; MASISON DC, 1995, MOL CELL BIOL, V15, P2763; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; OHTAKE Y, 1995, MOL CELL BIOL, V15, P2772; OHTAKE Y, 1995, GENETICS, V140, P129; Ribas JC, 1998, J BIOL CHEM, V273, P9306, DOI 10.1074/jbc.273.15.9306; RIBAS JC, 1994, J BIOL CHEM, V269, P28420; RIDLEY SP, 1984, MOL CELL BIOL, V4, P761, DOI 10.1128/MCB.4.4.761; RILES L, 1993, GENETICS, V134, P81; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS A, 1980, J BIOL CHEM, V255, P3080; STEVENS A, 1987, ARCH BIOCHEM BIOPHYS, V252, P339, DOI 10.1016/0003-9861(87)90040-3; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; THIELE DJ, 1984, VIROLOGY, V137, P20, DOI 10.1016/0042-6822(84)90004-7; TOHE A, 1978, J BACTERIOL, V136, P1002, DOI 10.1128/JB.136.3.1002-1007.1978; TOHE A, 1980, P NATL ACAD SCI-BIOL, V77, P527, DOI 10.1073/pnas.77.1.527; Tumer NE, 1998, J VIROL, V72, P1036, DOI 10.1128/JVI.72.2.1036-1042.1998; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WERNERWASHBURNE M, 1989, GENOME, V31, P684, DOI 10.1139/g89-125; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; WICKNER RB, 1979, J BACTERIOL, V140, P154, DOI 10.1128/JB.140.1.154-160.1979; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; WICKNER RB, 1982, P NATL ACAD SCI-BIOL, V79, P4706, DOI 10.1073/pnas.79.15.4706; WICKNER RB, 1996, FIELDS VIROLOGY, V1, P557; WIDNER WR, 1993, MOL CELL BIOL, V13, P4331, DOI 10.1128/MCB.13.7.4331; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Zanchin NIT, 1997, MOL CELL BIOL, V17, P5001, DOI 10.1128/MCB.17.9.5001	51	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28912	28920		10.1074/jbc.273.44.28912	http://dx.doi.org/10.1074/jbc.273.44.28912			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786894	hybrid			2022-12-25	WOS:000076691800055
J	Fu, SL; Dean, R; Southan, M; Truscott, R				Fu, SL; Dean, R; Southan, M; Truscott, R			The hydroxyl radical in lens nuclear cataractogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED PROTEIN OXIDATION; METAL-CATALYZED OXIDATION; HYDROGEN-PEROXIDE; AMINO-ACIDS; OXYGEN RADICALS; O-TYROSINE; PRODUCTS; DAMAGE; DEGRADATION; DITYROSINE	Cataract is the major cause of blindness; the most common form is age-related, or senile, cataract, The reasons for the development of cataract are unknown, Here we demonstrate that nuclear cataract is associated with the extensive hydroxylation of protein-bound amino acid residues, which increases with the development of cataract by up to 15-foId in the case of DOPA, The relative abundance of the oxidized amino acids in lens protein (assessed per parent amino acid) is DOPA > o- and m-tyrosine > 3-hydroxyvaline, 5-hydroxyleucine > dityrosine, Nigrescent cataracts, in which the normally transparent lens becomes black and opaque, contain the highest level of hydroxylated amino acids yet observed in a biological tissue: for example, per 1000 parent amino acid residues, DOPA, 15; 3-hydroxyvaline, 0.3; compared with dityrosine, 0.05, The products include representatives of the hydroperoxide and DOPA pathways of protein oxidation, which can give rise to secondary reactive species, radical and otherwise. The observed relative abundance corresponds closely with that of products of hydroxyl radical or metal-dependent oxidation of isolated proteins, and not with the patterns resulting from hypochlorite or tyrosyl-radical oxidation, Although very Little light in the 300-400-nm range passes the cornea and the filter compounds of the eye, we nevertheless also demonstrate that photoxidation of lens proteins with light of 310 nm, the part of the spectrum in which protein aromatic residues have residual absorbance, does not give rise to the hydroxylated aliphatic amino acids. Thus the post-translational modification of crystallins by hydroxyl radicals/Fenton systems seems to dominate their in vivo oxidation, and it could explain the known features of such nuclear cataractogenesis.	Heart Res Inst, Cell Biol Grp, Camperdown, NSW 2050, Australia; Univ Wollongong, Australian Cataract Res Fdn, Wollongong, NSW 2522, Australia	University of Sydney; Heart Research Institute; University of Wollongong	Dean, R (corresponding author), Heart Res Inst, Cell Biol Grp, Camperdown, NSW 2050, Australia.	r.dean@hri.org.au	Fu, Shanlin/D-8286-2013	Fu, Shanlin/0000-0002-6238-3612; Dean, Roger Thornton/0000-0002-8859-8902				ARMSTRONG SG, 1995, REDOX REP, V1, P291, DOI 10.1080/13510002.1995.11747000; BUCKINGHAM RH, 1972, EXP EYE RES, V14, P123, DOI 10.1016/0014-4835(72)90057-7; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; Davies M.J., 1997, RADICAL MEDIATED PRO; DAVIES MJ, 1995, BIOCHEM J, V305, P643, DOI 10.1042/bj3050643; Dean RT, 1997, BIOCHEM J, V324, P1; DEAN RT, 1993, TRENDS BIOCHEM SCI, V18, P437, DOI 10.1016/0968-0004(93)90145-D; DEAN RT, 1986, BIOMED BIOCHIM ACTA, V45, P1563; DEAN RT, 1996, FREE RADICALS PRACTI, P171; DUNCAN G, 1981, MECHANISMS CATARACT, P1; Fu S, 1998, BIOCHEM J, V333, P519, DOI 10.1042/bj3330519; Fu SL, 1998, BIOCHEM J, V330, P233, DOI 10.1042/bj3300233; Fu SL, 1997, BIOCHEM J, V324, P41, DOI 10.1042/bj3240041; FU SL, 1995, FREE RADICAL BIO MED, V19, P281, DOI 10.1016/0891-5849(95)00021-O; GARCIACASTINEIRAS S, 1978, EXP EYE RES, V26, P461, DOI 10.1016/0014-4835(78)90132-X; GARLAND D, 1990, EXP EYE RES, V50, P677, DOI 10.1016/0014-4835(90)90113-9; GARNER MH, 1980, P NATL ACAD SCI-BIOL, V77, P1274, DOI 10.1073/pnas.77.3.1274; GARRISON WM, 1987, CHEM REV, V87, P381, DOI 10.1021/cr00078a006; GIBLIN FJ, 1985, EXP EYE RES, V40, P827, DOI 10.1016/0014-4835(85)90128-9; GIESEG SP, 1993, BIOCHEMISTRY-US, V32, P4780, DOI 10.1021/bi00069a012; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Harding J., 1991, CATARACT BIOCH EPIDE; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HUGGINS TG, 1993, J BIOL CHEM, V268, P12341; ISHIMITSU S, 1990, CHEM PHARM BULL, V38, P1417; Javitt JC, 1996, ANNU REV PUBL HEALTH, V17, P159; JOSCHEK HI, 1966, J AM CHEM SOC, V88, P3273, DOI 10.1021/ja00966a019; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; MARAINI G, 1973, HUMAN LENS RELATION, P79; MARCANTONIO JM, 1980, EXP EYE RES, V31, P227, DOI 10.1016/0014-4835(80)90080-9; MCNAMARA M, 1984, EXP EYE RES, V38, P45, DOI 10.1016/0014-4835(84)90137-4; MCNAMARA MK, 1980, EXP EYE RES, V30, P319, DOI 10.1016/0014-4835(80)90014-7; MINASSIAN DC, 1990, BRIT J OPHTHALMOL, V74, P341, DOI 10.1136/bjo.74.6.341; MONNIER VM, 1983, BIOCHIM BIOPHYS ACTA, V760, P97, DOI 10.1016/0304-4165(83)90129-0; Morin B, 1998, BIOCHEM J, V330, P1059, DOI 10.1042/bj3301059; NAGARAJ RH, 1992, BIOCHIM BIOPHYS ACTA, V1116, P34, DOI 10.1016/0304-4165(92)90125-E; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; Obara Yoshitaka, 1995, Nippon Ganka Gakkai Zasshi, V99, P1303; PIRIE A, 1968, INVEST OPHTH VISUAL, V7, P634; SLIGHT SH, 1990, BIOCHIM BIOPHYS ACTA, V1038, P367, DOI 10.1016/0167-4838(90)90250-J; Sliney DH, 1995, J PHOTOCH PHOTOBIO B, V31, P69, DOI 10.1016/1011-1344(95)07171-5; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STUTCHBURY GM, 1993, EXP EYE RES, V57, P149, DOI 10.1006/exer.1993.1110; Takemoto L, 1996, EXP EYE RES, V63, P585, DOI 10.1006/exer.1996.0149; TRUSCOTT RJW, 1977, EXP EYE RES, V25, P139, DOI 10.1016/0014-4835(77)90126-9; TRUSCOTT RJW, 1977, BIOCHIM BIOPHYS ACTA, V492, P43, DOI 10.1016/0005-2795(77)90212-4; TRUSCOTT RJW, 1977, EXP EYE RES, V24, P159, DOI 10.1016/0014-4835(77)90256-1; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; WELLSKNECHT MC, 1993, J BIOL CHEM, V268, P12348; Wolff S P, 1989, Prog Clin Biol Res, V304, P259; WOLFF SP, 1987, BIOELECTROCH BIOENER, V18, P283, DOI 10.1016/0302-4598(87)85030-4; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8; WOLFF SP, 1986, BIOCHEM J, V234, P399, DOI 10.1042/bj2340399; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; WOOD AM, 1994, VISION RES, V34, P1369, DOI 10.1016/0042-6989(94)90135-X; ZIGLER JS, 1989, INVEST OPHTH VIS SCI, V30, P2195; [No title captured]	64	141	142	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28603	28609		10.1074/jbc.273.44.28603	http://dx.doi.org/10.1074/jbc.273.44.28603			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786852	hybrid			2022-12-25	WOS:000076691800013
J	Hanson, RW				Hanson, RW			Biological role of the isoforms of C/EBP minireview series	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material									Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Hanson, RW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.							LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021	3	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28543	28543		10.1074/jbc.273.44.28543	http://dx.doi.org/10.1074/jbc.273.44.28543			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786840	hybrid			2022-12-25	WOS:000076691800001
J	Saenko, EL; Scandella, D; Yakhyaev, AV; Greco, NJ				Saenko, EL; Scandella, D; Yakhyaev, AV; Greco, NJ			Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; SURFACE-PLASMON RESONANCE; COAGULATION FACTOR-VIII; PHOSPHATIDYL-L-SERINE; PORCINE FACTOR-VIII; LIGHT-CHAIN; FACTOR-IXA; FACTOR-X; VONWILLEBRAND-FACTOR; BLOOD-COAGULATION	Membrane-bound thrombin-activated factor VIII (fVIIIa) functions as a cofactor for factor IXa in the factor Xase complex. We found that binding of heterotrimeric fVIIIa (A1.A2.A3-C1-C2) to synthetic vesicles with a physiologic content of 4% phosphatidylserine (PS), 76% phosphatidylcholine, and 20% phosphatidylethanolamine occurs with a 10-fold higher affinity than that of factor VIII (fVIII), The increased affinity of fVIIIa for PS-containing membranes resulted from the reduced rate of fVIIIa dissociation from the vesicles compared with that of fVIII, Similar affinities of A3-C1-C2, A1.A2.A3-C1-C2, and A3-C1-C2.heavy chain for interaction with PS-containing membranes demonstrate that removal of the light chain (LCh) acidic region by thrombin is responsible for these increased affinities of fVIIIa and its derivatives. Similar kinetic parameters of fVIII and its LCh and C2 domain for binding to PS-containing membranes and to activated platelets indicated that the C2 domain is entirely responsible for the interaction of fVIII with membranes. We conclude that the increased fVIIIa affinity for PS-containing membranes is a result of conformational change(s) within the C2 domain upon removal of the acidic region of the LCh, This conclusion is based on the finding that binding of the monoclonal antibody ESH8 to the C2 domain, which is known to prevent this conformational transition, resulted in fVIIIa binding to PS/phosphatidylcholine/phosphatidylethanolamine vesicles (4/76/20) with a lower affinity similar to that of fVIII, In addition, stabilization of the low affinity binding conformation of the C2 domain of fVIIIa by this antibody led to an inhibition of the fVIIIa activity in the factor X activation complex.	Amer Red Cross, Jerome H Holland Lab, Rockville, MD 20855 USA	American Red Cross	Saenko, EL (corresponding author), Amer Red Cross, Jerome H Holland Lab, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055273] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55273] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT AJ, 1987, BIOCHEMISTRY-US, V26, P7994, DOI 10.1021/bi00398a067; AHMAD SS, 1989, J BIOL CHEM, V264, P3244; AHMAD SS, 1989, J CLIN INVEST, V84, P824, DOI 10.1172/JCI114242; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; ATKINS JS, 1992, MOL CELL BIOCHEM, V112, P61; BARDELLE C, 1993, J BIOL CHEM, V268, P8815; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FAY PJ, 1987, BIOCHIM BIOPHYS ACTA, V952, P181; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1995, J BIOL CHEM, V270, P18500, DOI 10.1074/jbc.270.31.18500; GILBERT GE, 1992, J BIOL CHEM, V267, P15861; Gilbert GE, 1996, J BIOL CHEM, V271, P11120, DOI 10.1074/jbc.271.19.11120; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; GRECO NJ, 1991, J BIOL CHEM, V266, P13627; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Li X, 1997, BIOCHEMISTRY-US, V36, P10760, DOI 10.1021/bi970052+; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1988, BLOOD, V71, P137; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PLANT AL, 1995, ANAL BIOCHEM, V226, P342, DOI 10.1006/abio.1995.1234; SAENKO EL, 1995, J BIOL CHEM, V270, P13826, DOI 10.1074/jbc.270.23.13826; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; SPAARGAREN J, 1995, BIOCHEM J, V310, P539, DOI 10.1042/bj3100539; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0; ZWAAL RFA, 1993, BIOCHEM SOC T, V21, P248, DOI 10.1042/bst0210248	52	76	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27918	27926		10.1074/jbc.273.43.27918	http://dx.doi.org/10.1074/jbc.273.43.27918			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774404	hybrid			2022-12-25	WOS:000076549800024
J	Okamoto, H; Takuwa, N; Gonda, K; Okazaki, H; Chang, K; Yatomi, Y; Shigematsu, H; Takuwa, Y				Okamoto, H; Takuwa, N; Gonda, K; Okazaki, H; Chang, K; Yatomi, Y; Shigematsu, H; Takuwa, Y			EDG1 is a functional sphingosine-l-phosphate receptor that is linked via a G(i/o) to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING; COUPLED RECEPTORS; MEMBRANE-RECEPTOR; SURFACE-RECEPTOR; 2ND MESSENGER; HIGH-AFFINITY; S-PHASE; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE	In Chinese hamster ovary (CHO) cells transiently transfected with an expression vector for EDG1, but not an empty vector, sphingosine-l-phosphate (SP) at a concentration as low as 10(-10) M caused an increase in the intracellular free Ca2+ concentration ([Ca2+](i)) as a result of mobilization of Ca2+ from both intracellular and extracellular pools. In a CHO clone stably expressing EDG1 receptor (CBO-EDG1 cells), SP induced increases in the production of inositol phosphates and the [Ca2+](i) and inhibited forskolin-induced increase in the cellular cAMP content, all in a manner sensitive to pertussis toxin. SP also activated mitogen-activated protein kinase in CHO-EDG1 cells in pertussis toxin-sensitive and Ras-dependent manners. To evaluate the spectrum of agonists for EDG1, we used human erythroleukemia (HEL) cells, which at naive state do not respond to SP or structurally related lipids with an increase in the [Ca2+](i). In HEL cells stably expressing EDG1 receptor (HEL-EDG1 cells), SP dose-dependently increased the [Ca2+](i) with half-maximal and maximal concentration values of 10(-9) and 3 x 10(-7) M, respectively; sphingosylphosphorylcholine at exclusively high concentrations, but not sphingosine at all, also increased the [Ca2+](i). HEL-EDG1 cells bound P-32-labeled SP, which was displaced dose dependently by unlabeled SP, These results indicate that EDG1, a member of the EDG family G protein-coupled receptors, is a specific, high-affinity SP receptor.	Univ Tokyo, Sch Med, Dept Mol & Cellular Physiol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Vasc Surg, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Plast Surg, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Biol, Tokyo 1130033, Japan; Yamanashi Med Univ, Dept Lab Med, Yamanashi 4093898, Japan; Fdn Advancement Int Sci, Ibaraki 3050006, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Yamanashi	Takuwa, Y (corresponding author), Univ Tokyo, Sch Med, Dept Mol & Cellular Physiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yohtakwa@m.u-tokyo.ac.jp		Yatomi, Yutaka/0000-0003-1719-4297; TAKUWA, Noriko/0000-0002-4278-2704				An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Heringdorf DMZ, 1997, FEBS LETT, V410, P34, DOI 10.1016/S0014-5793(97)00320-7; HLA T, 1990, J BIOL CHEM, V265, P9308; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	32	235	245	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27104	27110		10.1074/jbc.273.42.27104	http://dx.doi.org/10.1074/jbc.273.42.27104			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765227	hybrid			2022-12-25	WOS:000076448000014
J	Shalom-Barak, T; Quach, J; Lotz, M				Shalom-Barak, T; Quach, J; Lotz, M			Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE PRODUCTION; C-JUN; GLUCOCORTICOID RECEPTOR; TRANSCRIPTIONAL ACTIVATION; CYTOKINE BIOSYNTHESIS; FUNCTIONAL ANTAGONISM; TERMINAL KINASE; AP-1 ACTIVITY; T-CELL; OSTEOARTHRITIS	This study examines intracellular signaling events associated with the activation of chondrocytes by the cytokine interleukin-17 (IL-17). Stimulation of normal human articular chondrocytes with IL-17 induced nitric oxide (NO) production, concomitant with an increase in transcripts and de novo translation products of the inducible nitric oxide synthase (iNOS) and cyclooxygenase-a (COX-2) genes. Several other genes associated with inflammation and cartilage degradation, such as IL-1 beta, IL-6, and stromelysin, were also up-regulated in IL-17-treated chondrocytes. Among signaling events displaying early response to IL-17 in chondrocytes were the mitogen-activated protein (MAP) kinases ERK1, ERK2, JNK, and p38. DNA binding activity of NF-kappa B was also significantly induced. IL-17 effects on NO release, as well, as iNOS, COX-2, and IL-6 protein expression, were inhibited by the anti-inflammatory drug dexamethasone, Importantly, dexamethasone blunted IL-17-dependent activation of MAP kinases, suggesting a mechanistic relationship between these activities and the aforementioned gene expression responses. Similar effects of a lesser extent were observed with the p38-specific inhibitor SB203580, These results suggest that IL-17 activation of chondrocytes is associated with and depends at least in part on the activation of MAP kinases and NF-kappa B.	Scripps Res Inst, Div Arthrit Res, La Jolla, CA 92037 USA	Scripps Research Institute	Lotz, M (corresponding author), Scripps Res Inst, Div Arthrit Res, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mlotz@scripps.edu			NIAMS NIH HHS [AR43872] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043872] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; AMIN AR, 1995, J EXP MED, V182, P2097, DOI 10.1084/jem.182.6.2097; Attur MG, 1997, ARTHRITIS RHEUM, V40, P1050, DOI 10.1002/art.1780400609; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BIANCO FJ, 1995, AM J PATHOL, V146, P75; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; Grabowski PS, 1996, BRIT J RHEUMATOL, V35, P207; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LOTZ M, 1995, J RHEUMATOL, V22, P104; LOTZ M, 1992, INT MED, V13, P55; PALMER RMJ, 1993, BIOCHEM BIOPH RES CO, V193, P398, DOI 10.1006/bbrc.1993.1637; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rediske J J, 1994, Osteoarthritis Cartilage, V2, P199, DOI 10.1016/S1063-4584(05)80069-X; Rider LG, 1996, J IMMUNOL, V157, P2374; ROUVIER E, 1993, J IMMUNOL, V150, P5445; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Scherle PA, 1997, BIOCHEM BIOPH RES CO, V230, P573, DOI 10.1006/bbrc.1996.5985; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STADLER J, 1991, J IMMUNOL, V147, P3915; Stein B, 1996, ANNU REP MED CHEM, V31, P289, DOI 10.1016/S0065-7743(08)60468-6; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Westacott CI, 1996, SEMIN ARTHRITIS RHEU, V25, P254, DOI 10.1016/S0049-0172(96)80036-9; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; YOO ZB, 1995, J IMMUNOL, V155, P5483	46	325	365	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27467	27473		10.1074/jbc.273.42.27467	http://dx.doi.org/10.1074/jbc.273.42.27467			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765276	hybrid			2022-12-25	WOS:000076448000063
J	Stennicke, HR; Jurgensmeier, JM; Shin, H; Deveraux, Q; Wolf, BB; Yang, XH; Zhou, Q; Ellerby, HM; Ellerby, LM; Bredesen, D; Green, DR; Reed, JC; Froelich, CJ; Salvesen, GS				Stennicke, HR; Jurgensmeier, JM; Shin, H; Deveraux, Q; Wolf, BB; Yang, XH; Zhou, Q; Ellerby, HM; Ellerby, LM; Bredesen, D; Green, DR; Reed, JC; Froelich, CJ; Salvesen, GS			Pro-caspase-3 is a major physiologic target of caspase-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PROTEASE GRANZYME-B; CYTOCHROME-C; MITOCHONDRIAL CONTROL; APOPTOSIS; DEATH; ACTIVATION; BCL-2; CPP32; PATHWAYS	The apoptotic signal triggered by ligation of members of the death receptor family is promoted by sequential activation of caspase zymogens, We show here that in a purified system, the initiator caspases-8 and -10 directly process the executioner pro-caspase-3 with activation rates (k(cat)/K-m) of 8.7 x 10(5) and 2.8 x 10(5) M-1 s(-1), respectively, These rates are of sufficient magnitude to indicate direct processing in vivo. Differentially processed forms of caspase-3 that accumulate during its activation have similar rates of activation, activities, and specificities. The pattern and rate of caspase-3 induced activation of pro-caspase-3 in cytosolic extracts was the same as in a purified system. Moreover, immunodepletion of a putative intermediary in the pathway to activation, procaspase-9, was without consequence. Taken together these data demonstrate that the initiator caspase-8 can directly activate pro-caspase-3 without the requirement for an accelerator. The in vitro data thus help to deconvolute previous in vivo transfection studies which have debated the role of a direct versus indirect transmission of the apoptotic signal generated by ligation of death receptors.	Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA; Northwestern Univ, Evanston Hosp, Dept Med, Evanston, IL 60201 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92110 USA	Sanford Burnham Prebys Medical Discovery Institute; NorthShore University Health System; Northwestern University; La Jolla Institute for Immunology	Salvesen, GS (corresponding author), Burnham Inst, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Green, Douglas R/N-8083-2018; Yang, Jim/B-3776-2010; Juergensmeier, Juliane/I-4117-2013	Green, Douglas R/0000-0002-7332-1417; 	NCI NIH HHS [CA72994] Funding Source: Medline; NHLBI NIH HHS [HL51399] Funding Source: Medline; NINDS NIH HHS [NS37878] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072994] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037878] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Ellerby HM, 1997, J NEUROSCI, V17, P6165; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krajewska M, 1997, CANCER RES, V57, P1605; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w; Zhou Q, 1997, BIOCHEM J, V324, P361, DOI 10.1042/bj3240361; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	45	613	642	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27084	27090		10.1074/jbc.273.42.27084	http://dx.doi.org/10.1074/jbc.273.42.27084			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765224	hybrid			2022-12-25	WOS:000076448000011
J	Erlenbach, I; Wess, J				Erlenbach, I; Wess, J			Molecular basis of V2 vasopressin receptor/G(s) coupling selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; RANDOM SATURATION MUTAGENESIS; G-PROTEIN ACTIVATION; FUNCTIONAL EXPRESSION; CLONING; BINDING; DOMAINS; PALMITOYLATION; RHODOPSIN; RAT	The molecular mechanisms governing the coupling selectivity of G protein-coupled receptors activated by peptide ligands are not well understood. To shed light on this issue, we have used the G(q/11)-linked V1a and the G(s)-coupled V2 vasopressin peptide receptors as model systems. To explore the structural basis underlying the ability of the V2 receptor to selectively recognize G(s), we systematically substituted distinct V2 receptor segments (or single amino acids) into the V1a receptor and studied whether the resulting hybrid receptors gained the ability to mediate hormone-dependent cAMP production. This strategy appeared particularly attractive since hormone stimulation of the Via receptor has virtually no effect on intracellular cAMP levels. Functional analysis of a large number of mutant receptors transiently expressed in COS-7 cells indicated that the presence of V2 receptor sequence at the N terminus of the third intracellular loop is critical for efficient activation of G(s). More detailed mutational analysis of this receptor region showed that two polar V2 receptor residues, Gln(225) and Glu(231), play key roles in G(s) recognition. In addition, a short sequence at the N terminus of the cytoplasmic tail was found to make an important contribution to V2 receptor/G(s) coupling selectivity. We also made the novel observation that the efficiency of V2 receptor/G(s) coupling can be modulated by the length of the central portion of the third intracellular loop (rather than the specific amino acid sequence within this domain). These findings provide novel insights into the molecular mechanisms regulating peptide receptor/G protein coupling selectivity.	NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05, Bethesda, MD 20892 USA.	jwess@helix.nih.gov						Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BIRNBAUMER M, 1995, J RECEPT SIGNAL TR R, V15, P131, DOI 10.3109/10799899509045213; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BOUVIER M, 1995, METHOD ENZYMOL, V250, P300; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Higuchi R., 1989, PCR TECHNOLOGY, P61; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; Innamorati G, 1996, BIOCHEM J, V314, P710; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LASZLO FA, 1991, PHARMACOL REV, V43, P73; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; LIU J, 1995, J BIOL CHEM, V270, P19532, DOI 10.1074/jbc.270.33.19532; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; LOLAIT SJ, 1995, P NATL ACAD SCI USA, V92, P6783, DOI 10.1073/pnas.92.15.6783; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; ROSENTHAL W, 1993, J BIOL CHEM, V268, P13030; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAVARESE TM, 1992, BIOCHEM J, V283, P1; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; WATSON S, 1994, G PROTEIN LINKED REC, P1; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	42	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26549	26558		10.1074/jbc.273.41.26549	http://dx.doi.org/10.1074/jbc.273.41.26549			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756892	hybrid			2022-12-25	WOS:000076373300046
J	Glaab, WE; Risinger, JI; Umar, A; Kunkel, TA; Barrett, JC; Tindall, KR				Glaab, WE; Risinger, JI; Umar, A; Kunkel, TA; Barrett, JC; Tindall, KR			Characterization of distinct human endometrial carcinoma cell lines deficient in mismatch repair that originated from a single tumor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA; CANCER; HETERODIMER; MSH3; MUTATIONS; GENE; HOMOLOGS; PROTEINS; BINDING; DEFECTS	The role of specific mismatch repair (MMR) gene products was examined by observing several phenotypic end points in two MMR-deficient human endometrial carcinoma cell lines that were originally isolated from the same tumor. The first cell Line, HEC-1-A, contains a nonsense mutation ire the hPMS2 gene, which results in premature termination and a truncated hPMS2 protein. In addition, REC-1-A cells carry a splice mutation in the hMSH6 gene and lack wild-type hMSH6 protein, The second cell line, HEC-1-B, possesses thee same defective hMSH6 locus, However, HEC-1-B cells are heterozygous at the hPMS2 locus; that is, along with carrying the same nonsense mutation in hPMS2 as in HEC-1-A, HEC-1-B cells also contain a wild-type hPMS2 gene. initial recognition of mismatches in DNA requires either the hMSH2/hMSH6 or hMSH2/hMSH3 heterodimer, with hPMS2 functioning downstream of damage recognition. Therefore, cells defective in hPMS2 should completely lack MMR (HEC-1-A), whereas cells mutant in hMSH6 only (HEC-1-B) can potentially repair damage via the hMSH2/hMSH3 heterodimer. The data presented here in HEC-1-B cells illustrate (i) the reduction of instability at microsatellite sequences, (ii) a significant decrease in frameshift mutation rate at HPRT, and (iii) the in vitro repair of looped substrates, relative to HEC-1-A cells, illustrating the repair of frameshift intermediates by hMSH2/hMSH3 heterodimer. Furthermore, the role of hMSH2/hMSH3 heterodimer in the repair of base:base mismatches is supported by observing the reduction in base substitution mutation rate at HPRT in HEC-1-B cells (hMSH6-defective but possessing wild-type hPMS2), as compared with HEC-1-A (hMSH6/hPMS2-defective) cells, These data support a critical role for hPMS2 in human MMR, while further defining the role of the hMSH2/hMSH3 heterodimer in maintaining genomic stability in the absence of a wild-type hMSH2/hMSH6 heterodimer.	NIEHS, Lab Environm Carcinogenesis & Mutagenesis, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Glaab, WE (corresponding author), Merck Res Labs, WP45-320, W Point, PA 19486 USA.	warren_glaab@merck.com	Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788				Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Cariello NF, 1996, NUCLEIC ACIDS RES, V24, P119, DOI 10.1093/nar/24.1.119; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; Greene CN, 1997, MOL CELL BIOL, V17, P2844, DOI 10.1128/MCB.17.5.2844; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; HORII A, 1994, BIOCHEM BIOPH RES CO, V204, P1257, DOI 10.1006/bbrc.1994.2598; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KOI M, 1994, CANCER RES, V54, P4308; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KURAMOTO H, 1972, AM J OBSTET GYNECOL, V114, P1012, DOI 10.1016/0002-9378(72)90861-7; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Marra G, 1996, GASTROENTEROL CLIN N, V25, P755, DOI 10.1016/S0889-8553(05)70273-9; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Prolla TA, 1996, SEMIN CANCER BIOL, V7, P241, DOI 10.1006/scbi.1996.0032; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Risinger JI, 1998, CANCER RES, V58, P2978; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; THOMASHOW LS, 1995, PLANT MICROBE INTERA, V1, P187; Tindall KR, 1998, MUTAT RES-FUND MOL M, V402, P15, DOI 10.1016/S0027-5107(97)00277-7; Umar A, 1998, GENETICS, V148, P1637; Umar A, 1997, CANCER RES, V57, P3949; YANG JL, 1989, GENE, V83, P347, DOI 10.1016/0378-1119(89)90121-2	34	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26662	26669		10.1074/jbc.273.41.26662	http://dx.doi.org/10.1074/jbc.273.41.26662			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756907	hybrid			2022-12-25	WOS:000076373300061
J	Hamada, K; Terashima, H; Arisawa, N; Kitada, K				Hamada, K; Terashima, H; Arisawa, N; Kitada, K			Amino acid sequence requirement for efficient incorporation of glycosylphosphatidylinositol-associated proteins into the cell wall of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AGGLUTININ; PLASMA-MEMBRANE; ASPARTYL PROTEASE; ANCHORED PROTEIN; CROSS-LINKING; GAS1 PROTEIN; GPI ANCHOR; SIDE-CHAIN; YEAST; GENE	During cell wall biogenesis in Saccharomyces cerevisiae, some glycosylphosphatidylinositol (GPI)-attached proteins are detached from GPI moieties and bound to beta-1,6-glucan of the cell wall. The amino acid sequence requirement for the incorporation of GPI-attached proteins into the cell wall was studied by using reporter fusion proteins. Only the short omega-minus region composed of five amino acids, which is located upstream of the omega site for GPI attachment, determined the cellular localization of the GPI-associated proteins. Within the omega-minus region, amino acid residues at the omega-4 or -5 and omega-2 sites were important for the cell wall incorporation. Yap3p, a well characterized GPI-anchored plasma membrane aspartic protease, was localized in the cell wall when the omega-minus region was mutated to sequences containing Val or lie at the omega-4 or -5 site and Val or Tyr at the omega-2 site.	Nippon Roche Res Ctr, Dept Mycol, Kamakura, Kanagawa 247, Japan	Roche Holding	Kitada, K (corresponding author), Nippon Roche Res Ctr, Dept Mycol, 200 Kajiwara, Kamakura, Kanagawa 247, Japan.	kunio.kitada@roche.com						ASH J, 1995, J BIOL CHEM, V270, P20847, DOI 10.1074/jbc.270.35.20847; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; Bourdineaud JP, 1998, MOL MICROBIOL, V27, P85, DOI 10.1046/j.1365-2958.1998.00660.x; BROWN JL, 1993, GENETICS, V133, P837; Caro LHP, 1997, YEAST, V13, P1477, DOI 10.1002/(SICI)1097-0061(199712)13:15<1477::AID-YEA184>3.0.CO;2-L; CAWLEY NX, 1995, BIOCHEMISTRY-US, V34, P7430, DOI 10.1021/bi00022a016; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; De Nobel Hans, 1994, Trends in Cell Biology, V4, P42, DOI 10.1016/0962-8924(94)90003-5; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; FIELD MC, 1993, LIPID MODIFICATIONS, P83; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Hamada K, 1998, MOL GEN GENET, V258, P53, DOI 10.1007/s004380050706; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Kapteyn JC, 1997, J BACTERIOL, V179, P6279, DOI 10.1128/JB.179.20.6279-6284.1997; Kapteyn JC, 1996, GLYCOBIOLOGY, V6, P337, DOI 10.1093/glycob/6.3.337; Kinoshita T, 1995, ADV IMMUNOL, V60, P57, DOI 10.1016/S0065-2776(08)60584-2; Kitada K, 1997, CURR GENET, V31, P122, DOI 10.1007/s002940050185; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kitagaki H, 1997, EUR J BIOCHEM, V249, P343, DOI 10.1111/j.1432-1033.1997.t01-1-00343.x; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; KONDO K, 1991, J BIOL CHEM, V266, P17537; KOWALSKI LRZ, 1995, MOL MICROBIOL, V15, P341, DOI 10.1111/j.1365-2958.1995.tb02248.x; LIPKE PN, 1989, MOL CELL BIOL, V9, P3155, DOI 10.1128/MCB.9.8.3155; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; LU CF, 1994, MOL CELL BIOL, V14, P4825, DOI 10.1128/MCB.14.7.4825; Maniatis T., 1982, MOL CLONING LAB MANU; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MONTIJN RC, 1994, J BIOL CHEM, V269, P19338; Moukadiri I, 1997, J BACTERIOL, V179, P2154, DOI 10.1128/jb.179.7.2154-2162.1997; Muller G, 1996, MOL CELL BIOL, V16, P442; Nosjean O, 1997, BBA-REV BIOMEMBRANES, V1331, P153, DOI 10.1016/S0304-4157(97)00005-1; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; ROY A, 1991, MOL CELL BIOL, V11, P4196, DOI 10.1128/MCB.11.8.4196; SCHREUDER MP, 1993, YEAST, V9, P399, DOI 10.1002/yea.320090410; Sherman F., 1986, METHODS YEAST GENETI; SHIMOI H, 1995, J BIOCHEM, V118, P302, DOI 10.1093/oxfordjournals.jbchem.a124907; SIKORSKI RS, 1989, GENETICS, V122, P19; TEUNISSEN AWRH, 1995, YEAST, V11, P1001, DOI 10.1002/yea.320111102; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VAI M, 1991, J BIOL CHEM, V266, P12242; VANBERKEL MAA, 1994, FEBS LETT, V349, P135, DOI 10.1016/0014-5793(94)00631-8; VanderVaart JM, 1997, APPL ENVIRON MICROB, V63, P615, DOI 10.1128/AEM.63.2.615-620.1997; VANDERVAART JM, 1995, J BACTERIOL, V177, P3104, DOI 10.1128/jb.177.11.3104-3110.1995; VanderVaart JM, 1996, FEMS MICROBIOL LETT, V145, P401, DOI 10.1016/S0378-1097(96)00440-5; Vossen JH, 1997, J BACTERIOL, V179, P2202, DOI 10.1128/jb.179.7.2202-2209.1997; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554	50	66	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26946	26953		10.1074/jbc.273.41.26946	http://dx.doi.org/10.1074/jbc.273.41.26946			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756943	hybrid			2022-12-25	WOS:000076373300097
J	Jung, K; Altendorf, K				Jung, K; Altendorf, K			Individual substitutions of clustered arginine residues of the sensor kinase KdpD of Escherichia coli modulate the ratio of kinase to phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCTION MUTATIONS; SIGNAL TRANSDUCTION; OPERON EXPRESSION; KDPABC OPERON; PROTEIN; POTASSIUM; ATPASE; TURGOR; SYSTEM; INACTIVATION	Escherichia coli responds to K+ limitation or high osmolarity by induction of the kdpFABC operon coding for the high affinity K+-translocating Kdp-ATPase, KdpD, the sensor kinase of this system, is a bifunctional enzyme catalyzing the autophosphorylation by ATP and the dephosphorylation of the corresponding response regulator KdpE, Here we demonstrate that individual replacements of clustered arginine residues located close to transmembrane domain TM4 modulate the ratio of kinase to phosphatase activity. Thus KdpD-Arg(511) --> Gln is characterized by an increase in the kinase activity and a loss of the phosphatase activity. However, when Arg at position 511 is replaced with Lys, activities of the corresponding protein are comparable with wildtype KdpD, In contrast, replacement of arginine residues at positions 503, 506, or 508 with glutamine or lysine causes a decrease of the kinase and an increase of the phosphatase activities. Changes of the activities of these KdpD proteins correspond with alterations in kdpFABC expression. Thus KdpD-Arg511 --> Gin causes constitutive expression of kdpFABC. KdpD proteins with Arg replacements at positions 503, 506, or 508 are unable to respond to osmolarity, whereas the sensing of K+ limitation is not influenced. Simultaneous replacement of arginine residues 508 and 511 or 506, 508, and 511 with glutamine leads to a decrease of the phosphatase activity. However, kdpFABC expression is dependent on K+ and osmolarity, Finally, when Arg(513) is replaced with glutamine the amount of KdpD detected in the membrane is drastically reduced. These results imply that there is an equilibrium between the kinase and phosphatase activities of KdpD, which can be shifted by the replacement of one arginine residue. An electrostatic switch mechanism within the protein is proposed through which the ratio of kinase to phosphatase is regulated. Finally, these results lend support to the notion that KdpD can be activated by two distinct stimuli, K+ limitation and osmolarity.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany	University Osnabruck	Jung, K (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany.							ALTENDORF K, 1996, BIOMEMBR, V5, P403; ASHA H, 1993, J BACTERIOL, V175, P4528, DOI 10.1128/JB.175.14.4528-4537.1993; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; EPSTEIN W, 1992, ACTA PHYSIOL SCAND, V146, P193; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Jung K, 1998, J BIOL CHEM, V273, P17406, DOI 10.1074/jbc.273.28.17406; Jung K, 1997, J BIOL CHEM, V272, P10847; Jung K, 1998, BBA-BIOMEMBRANES, V1372, P311, DOI 10.1016/S0005-2736(98)00070-4; KALMAN LV, 1990, J BACTERIOL, V172, P7049, DOI 10.1128/jb.172.12.7049-7056.1990; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; Kondoh S, 1997, J BIOL CHEM, V272, P19333, DOI 10.1074/jbc.272.31.19333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MILLER JF, 1992, J BACTERIOL, V174, P970, DOI 10.1128/jb.174.3.970-979.1992; Miller JH., 1992, SHORT COURSE BACTERI, P72; NAKASHIMA K, 1993, MOL MICROBIOL, V7, P109, DOI 10.1111/j.1365-2958.1993.tb01102.x; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POLAREK JW, 1992, J BACTERIOL, V174, P2145, DOI 10.1128/JB.174.7.2145-2151.1992; Puppe W, 1996, J BIOL CHEM, V271, P25027, DOI 10.1074/jbc.271.40.25027; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUGIURA A, 1992, MOL MICROBIOL, V6, P1769, DOI 10.1111/j.1365-2958.1992.tb01349.x; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; SUTHERLAND L, 1986, J BACTERIOL, V168, P805, DOI 10.1128/jb.168.2.805-814.1986; VOELKNER P, 1993, EUR J BIOCHEM, V217, P1019, DOI 10.1111/j.1432-1033.1993.tb18333.x; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	33	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26415	26420		10.1074/jbc.273.41.26415	http://dx.doi.org/10.1074/jbc.273.41.26415			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756874	hybrid			2022-12-25	WOS:000076373300028
J	Lind, T; Tufaro, F; McCormick, C; Lindahl, U; Lidholt, K				Lind, T; Tufaro, F; McCormick, C; Lindahl, U; Lidholt, K			The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY MULTIPLE EXOSTOSES; GENE; CELLS; GLUCURONOSYLTRANSFERASE; IDENTIFICATION; PROTEOGLYCANS; LOCALIZATION; CLONING; FAMILY	Hereditary multiple exostoses, characterized by multiple cartilaginous tumors, is ascribed to mutations at three distinct loci, denoted EXT1-3. Here, we report the purification of a protein from bovine serum that harbored the D-glucuronyl (GlcA) and N-acetyl-D-glucosaminyl (GlcNAc) transferase activities required for biosynthesis of the glycosaminoglycan, heparan sulfate (HS). This protein was identified as EXT2. Expression of EXT2 yielded a protein with both glycosyltransferase activities. Moreover, EXT1, previously found to rescue defective HS biosynthesis (McCormick, C., Leduc, Y., Martindale, D., Mattison, K., Esford, L. E., Dyer, A. P., and Tufaro, F. (1998) Nat. Genet. 19, 158-161), was shown to elevate the low GlcA and GlcNAc transferase levels of mutant cells. Thus at least two members of the EXT family of tumor suppressors encode glycosyltransferases involved in the chain elongation step of HS biosynthesis.	Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	Uppsala University; University of British Columbia	Lind, T (corresponding author), Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, Box 575, S-75123 Uppsala, Sweden.	Thomas.Lind@medkem.uu.se	McCormick, Craig/AAH-9069-2019	McCormick, Craig/0000-0003-2794-3722; Lind, Thomas/0000-0003-2791-688X				AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; COOK A, 1993, AM J HUM GENET, V53, P71; GRUENHEID S, 1993, J VIROL, V67, P93, DOI 10.1128/JVI.67.1.93-100.1993; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HENNEKAM RCM, 1991, J MED GENET, V28, P262, DOI 10.1136/jmg.28.4.262; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; LEMERRER M, 1994, HUM MOL GENET, V3, P717, DOI 10.1093/hmg/3.5.717; LEONE NC, 1987, J HERED, V78, P171, DOI 10.1093/oxfordjournals.jhered.a110351; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIND T, 1993, J BIOL CHEM, V268, P20705; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; NAKANISHI H, 1992, BIOCHEM J, V288, P215, DOI 10.1042/bj2880215; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Safaiyan F, 1998, EUR J BIOCHEM, V252, P576, DOI 10.1046/j.1432-1327.1998.2520576.x; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SCHMALE GA, 1994, J BONE JOINT SURG AM, V76A, P986, DOI 10.2106/00004623-199407000-00005; SOLOMON L, 1963, J BONE JOINT SURG BR, V45, P292, DOI 10.1302/0301-620X.45B2.292; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; UhlinHansen L, 1997, J BIOL CHEM, V272, P3200, DOI 10.1074/jbc.272.6.3200; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; VLODAVSKY I, 1994, INVAS METAST, V14, P290; WICKLUND CL, 1995, AM J MED GENET, V55, P43, DOI 10.1002/ajmg.1320550113; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; WU YQ, 1994, HUM MOL GENET, V3, P167, DOI 10.1093/hmg/3.1.167; Wuyts W, 1997, EUR J HUM GENET, V5, P382, DOI 10.1159/000484796; Wuyts W, 1996, HUM MOL GENET, V5, P1547, DOI 10.1093/hmg/5.10.1547	35	335	349	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26265	26268		10.1074/jbc.273.41.26265	http://dx.doi.org/10.1074/jbc.273.41.26265			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756849	hybrid			2022-12-25	WOS:000076373300003
J	Osherov, N; Yamashita, RA; Chung, YS; May, GS				Osherov, N; Yamashita, RA; Chung, YS; May, GS			Structural requirements for in vivo myosin I function in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONVENTIONAL MYOSINS; YEAST; MITOSIS; ENDOCYTOSIS; PROTEINS; BINDING; DOMAIN; MODEL; GENES; ACTS	We have investigated the minimal requirements of the tail region for myosin I function in vivo using the filamentous fungus Aspergillus nidulans. The CL3 strain (McGoldrick, C. A., Gruver, C., and May, G. S. (1995) J. Cell Biol. 128, 577-587) was transformed with a variety of myoA constructs containing mutations in the IQ, TH-1-like, SH3, and proline-rich domains by frameshift or in-frame deletions of the tail domains. The resulting strains contained wild type myoA driven by the alcA promoter and a mutant myoA driven by its endogenous promoter. This strategy allowed for selective expression of the wild type and/or mutant form of MYOA by the choice of growth medium. Proper septation and hyphal branching were found to be dependent on the interaction of the IQ motifs with calmodulin, as well as, the presence of its proline-rich domain, Additionally, a single proline-rich motif was sufficient for nearly wild type MYOA function. Most surprisingly, the SH3 domain was not essential for MYOA function. These studies expand our previous knowledge of the function of MYOA to include roles in hyphal morphogenesis, septal wall formation, and cell polarity, laying the groundwork for more detailed investigations on the function of the various tail domains in MYOA.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	May, GS (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	gsmay@bcm.tmc.edu						BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; Brown SS, 1997, CURR OPIN CELL BIOL, V9, P44, DOI 10.1016/S0955-0674(97)80150-0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIDDY C, 1976, J GEN MICROBIOL, V97, P169, DOI 10.1099/00221287-97-2-169; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; HASSON T, 1995, CURR OPIN CELL BIOL, V7, P587, DOI 10.1016/0955-0674(95)80017-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; Kalabokis VN, 1996, J BIOL CHEM, V271, P26779, DOI 10.1074/jbc.271.43.26779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAY GS, 1985, J CELL BIOL, V101, P712, DOI 10.1083/jcb.101.3.712; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; MIRABITO PM, 1993, J CELL BIOL, V120, P959, DOI 10.1083/jcb.120.4.959; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WARING RB, 1989, GENE, V79, P119, DOI 10.1016/0378-1119(89)90097-8; Wolkow TD, 1996, J CELL SCI, V109, P2179; Yamashita RA, 1998, J BIOL CHEM, V273, P14644, DOI 10.1074/jbc.273.23.14644	27	27	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					27017	27025		10.1074/jbc.273.41.27017	http://dx.doi.org/10.1074/jbc.273.41.27017			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756952	hybrid			2022-12-25	WOS:000076373300106
J	Pascuzzi, P; Hamilton, D; Bodily, K; Arias, J				Pascuzzi, P; Hamilton, D; Bodily, K; Arias, J			Auxin-induced stress potentiates trans-activation by a conserved plant basic/leucine-zipper factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; TISSUE-SPECIFIC EXPRESSION; DEFENSE GENE PROMOTER; DNA-BINDING; ARABIDOPSIS-THALIANA; SALICYLIC-ACID; OCS-ELEMENT; TRANSCRIPTION FACTORS; NUCLEAR FACTOR; TOBACCO	The promoter element activation sequence-1 (as-1) confers tissue-specific and signal-responsive transcription in plants. Hormone and chemical stress cues are thought to activate as-1-dependent transcription through specific basic/leucine-zipper proteins, termed TGA factors, that bind this element. We report here that a highly conserved TGA factor of tobacco, TGA1a, can selectively activate transcription in response to micromolar concentrations of auxin hormones or their analogs. This induction is chemically specific, as a range of other compounds tested at similar concentrations had little or no effect. Auxin was found to augment the transactivation potential of TGA1a through carboxyl-terminal residues. The amino-terminal domain of TGA1a, by gain-of-function assays, was found to both constitutively activate transcription and maximize the response to auxin, Further evidence indicates that the trans-activation potential of this domain in TGA1a is repressed, under basal conditions, by carboxyl-terminal residues. Because TGA1a and endogenous TGA factors are stimulated by auxin only at concentrations that inhibited cell growth, this response is likely to involve chemical stress.	Univ Maryland, Ctr Agr Biotechnol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Arias, J (corresponding author), Univ Maryland, Ctr Agr Biotechnol, 5115 Plant Sci Bldg, College Pk, MD 20742 USA.		Pascuzzi, Pete/T-5378-2019; Hamilton, D/AAA-4616-2020	Pascuzzi, Pete/0000-0002-9316-4404				Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; AN GH, 1990, PLANT CELL, V2, P225, DOI 10.1105/tpc.2.3.225; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARIAS JA, 1993, PLANT CELL, V5, P485, DOI 10.1105/tpc.5.4.485; BENFEY PN, 1990, EMBO J, V9, P1677, DOI 10.1002/j.1460-2075.1990.tb08291.x; BILANG J, 1993, PLANT PHYSIOL, V102, P29, DOI 10.1104/pp.102.1.29; BOUCHEZ D, 1989, EMBO J, V8, P4197, DOI 10.1002/j.1460-2075.1989.tb08605.x; Chen WQ, 1996, PLANT J, V10, P955, DOI 10.1046/j.1365-313X.1996.10060955.x; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DRON M, 1988, P NATL ACAD SCI USA, V85, P6738, DOI 10.1073/pnas.85.18.6738; Droog F, 1995, PLANT MOL BIOL, V29, P413, DOI 10.1007/BF00020974; Droog F, 1997, J PLANT GROWTH REGUL, V16, P95, DOI 10.1007/PL00006984; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUILFOYLE TJ, 1993, AUST J PLANT PHYSIOL, V20, P489, DOI 10.1071/PP9930489; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KATAGIRI F, 1992, MOL CELL BIOL, V12, P4809, DOI 10.1128/MCB.12.11.4809; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KIM YH, 1994, PLANT MOL BIOL, V24, P105, DOI 10.1007/BF00040578; LAM E, 1995, NUCLEIC ACIDS RES, V23, P3778, DOI 10.1093/nar/23.18.3778; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIU XJ, 1994, J BIOL CHEM, V269, P668; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MIAO ZH, 1995, PLANT J, V7, P887, DOI 10.1046/j.1365-313X.1995.07060887.x; MIAO ZH, 1995, PLANT J, V7, P359, DOI 10.1046/j.1365-313X.1995.7020359.x; NEUHAUS G, 1994, PLANT CELL, V6, P827, DOI 10.1105/tpc.6.6.827; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PRESTERA T, 1993, ADV ENZYME REGUL, V33, P281; RIEPING M, 1994, PLANT CELL, V6, P1087, DOI 10.1105/tpc.6.8.1087; SCHINDLER U, 1992, PLANT CELL, V4, P1309, DOI 10.1105/tpc.4.10.1309; TAKAHASHI Y, 1990, P NATL ACAD SCI USA, V87, P8013, DOI 10.1073/pnas.87.20.8013; ULMASOV T, 1994, PLANT MOL BIOL, V26, P1055, DOI 10.1007/BF00040688; vanderKop DAM, 1996, PLANT MOL BIOL, V30, P839, DOI 10.1007/BF00019016; vanderZaal BJ, 1996, PLANT PHYSIOL, V110, P79, DOI 10.1104/pp.110.1.79; WATANABE Y, 1986, VIROLOGY, V152, P414, DOI 10.1016/0042-6822(86)90143-1; Xiang CB, 1996, PLANT MOL BIOL, V32, P415, DOI 10.1007/BF00019093; YAMAZAKI K, 1990, P NATL ACAD SCI USA, V87, P7035, DOI 10.1073/pnas.87.18.7035; ZETTL R, 1994, P NATL ACAD SCI USA, V91, P689, DOI 10.1073/pnas.91.2.689; ZHANG B, 1994, P NATL ACAD SCI USA, V91, P2507, DOI 10.1073/pnas.91.7.2507	47	35	36	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26631	26637		10.1074/jbc.273.41.26631	http://dx.doi.org/10.1074/jbc.273.41.26631			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756903	hybrid			2022-12-25	WOS:000076373300057
J	Rayner, JC; Munro, S				Rayner, JC; Munro, S			Identification of the MNN2 and MNN5 mannosyltransferases required for forming and extending the mannose branches of the outer chain mannans of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II MEMBRANE-PROTEIN; GLYCOPROTEIN-BIOSYNTHESIS; GENETIC-CONTROL; MPK1-MEDIATED PATHWAYS; CHEMICAL-STRUCTURE; GOLGI COMPARTMENT; CANDIDA-ALBICANS; N-GLYCOSYLATION; YEAST; MUTANTS	The mannan structure found on the N-linked glycans of the yeast Saccharomyces cerevisiae is composed of a long backbone of alpha-1,6-linked mannose to which are attached branches consisting of two alpha-1,2-linked mannoses followed by an alpha-1,3-linked mannose. In the mutants mnn2 and mnn5, the addition of the first and second of these two mannoses, respectively, is defective. in this paper, we report the identification of the genes corresponding to these mutations. The two genes encode closely related proteins with distant homology to the known Mnn1p alpha-1,3-mannosyltransferase. We show that these proteins are localized in an early compartment of the yeast Golgi and that they are not physically associated with each other or with the two protein complexes known to be involved in synthesizing the alpha-1,6-linked backbone. The identification of Mnn2p and Mmnn5p allows us to assign Golgi proteins to all of the catalytic steps in S. cerevisiae mannan synthesis.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Munro, S (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Rayner, Julian/0000-0002-9835-1014; Munro, Sean/0000-0001-6160-5773				BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU CE, 1973, J BIOL CHEM, V248, P4667; BALLOU DL, 1975, J BACTERIOL, V123, P616, DOI 10.1128/JB.123.2.616-619.1975; BALLOU L, 1995, P NATL ACAD SCI USA, V92, P2790, DOI 10.1073/pnas.92.7.2790; BALLOU L, 1990, P NATL ACAD SCI USA, V87, P3368, DOI 10.1073/pnas.87.9.3368; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Calderone Richard A., 1993, Trends in Microbiology, V1, P55, DOI 10.1016/0966-842X(93)90033-N; COHEN RE, 1980, J BIOL CHEM, V255, P7700; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; Dean N, 1996, GLYCOBIOLOGY, V6, P73, DOI 10.1093/glycob/6.1.73; ESMON B, 1984, J BIOL CHEM, V259, P322; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Guthrie C, 1991, GUIDE YEAST GENETICS; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; Iwahara S, 1996, BIOSCI BIOTECH BIOCH, V60, P957, DOI 10.1271/bbb.60.957; JIMENEZBARBERO J, 1995, CARBOHYD RES, V272, P121, DOI 10.1016/0008-6215(95)00023-M; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; LEHLE L, 1995, FEBS LETT, V370, P41, DOI 10.1016/0014-5793(95)00789-C; Lussier M, 1997, YEAST, V13, P267, DOI 10.1002/(SICI)1097-0061(19970315)13:3<267::AID-YEA72>3.0.CO;2-K; Lussier M, 1997, J BIOL CHEM, V272, P15527, DOI 10.1074/jbc.272.24.15527; LUSSIER M, 1995, J CELL BIOL, V131, P913, DOI 10.1083/jcb.131.4.913; Manas P, 1997, GLYCOBIOLOGY, V7, P487, DOI 10.1093/glycob/7.4.487; Mondesert G, 1997, GENETICS, V147, P421; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; NAGASU T, 1992, YEAST, V8, P535, DOI 10.1002/yea.320080705; NAKAJIMA T, 1994, J FERMENT BIOENG, V78, P472, DOI 10.1016/0922-338X(94)90050-7; NAKAJIMA T, 1975, P NATL ACAD SCI USA, V72, P3912, DOI 10.1073/pnas.72.10.3912; Nakamura T, 1997, MOL GEN GENET, V256, P481, DOI 10.1007/s004380050592; Nakamura T, 1996, MOL GEN GENET, V251, P211; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Neiman AM, 1997, GENETICS, V145, P637; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; PEAT S, 1961, J CHEM SOC, P3918, DOI 10.1039/jr9610003918; Ram AFJ, 1998, J BACTERIOL, V180, P1418, DOI 10.1128/JB.180.6.1418-1424.1998; RASCHKE WC, 1973, J BIOL CHEM, V248, P4660; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROEMER T, 1994, J CELL BIOL, V127, P567, DOI 10.1083/jcb.127.2.567; ROMERO PA, 1994, YEAST, V10, P1111, DOI 10.1002/yea.320100813; Schwappach B, 1998, J BIOL CHEM, V273, P15110, DOI 10.1074/jbc.273.24.15110; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; SIPOS G, 1995, J BIOL CHEM, V270, P19709, DOI 10.1074/jbc.270.34.19709; STRATFORD M, 1992, YEAST, V8, P635, DOI 10.1002/yea.320080807; STRAVER MH, 1993, TRENDS BIOTECHNOL, V11, P228, DOI 10.1016/0167-7799(93)90133-T; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; VEROSTEK MF, 1995, GLYCOBIOLOGY, V5, P671, DOI 10.1093/glycob/5.7.671; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wang XH, 1997, J BIOL CHEM, V272, P18117, DOI 10.1074/jbc.272.29.18117; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723	58	97	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26836	26843		10.1074/jbc.273.41.26836	http://dx.doi.org/10.1074/jbc.273.41.26836			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756928	hybrid			2022-12-25	WOS:000076373300082
J	Rimon, A; Gerchman, Y; Kariv, Z; Padan, E				Rimon, A; Gerchman, Y; Kariv, Z; Padan, E			A point mutation (G338S) and its suppressor mutations affect both the pH response of the NhaA-Na+/H+ antiporter as well as the growth phenotype of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; EXPRESSION; ANT; HISTIDINE-226; SENSITIVITY; INCREASES; RESIDUES; CELLS; LYSR	pH controls the activity of the NhaA Na+/H+ antiporter of Escherichia coli. In the present work we show that replacement of glycine 338 of NhaA with serine (G338S) alleviates the pH control of the antiporter. Monitoring Na+-dependent collapse of Delta pH, to assess antiporter activity in isolated membrane vesicles, shows that the mutant protein is practically independent of pH, between pH 7 and 9, and even at pH 6 is 70% active. Similarly the purified reconstituted mutant protein catalyzes pH-independent passive efflux of Na-22 from proteoliposomes as well as Delta pH-driven influx. Whereas the native NhaA in isolated membrane vesicles is exposed to digestion by trypsin only above pH 7, the mutated protein is degraded already at pH 6.5. Delta nhaA Delta nhaB cells transformed with a plasmid encoding the pH-independent antiporter are sensitive to Na+ but not to K+ at alkaline pH, while growing in the presence of both ions at neutral pH. Several possibilities that could explain the Na+ sensitivity of the mutant at alkaline pH were excluded; Western analysis and measurement of Na+/H+ antiporter activity in membrane vesicles, isolated from cells shifted to the non-permissive growth conditions, showed neither reduced expression of G338S-NhaA nor defective activity. The finding that the mutated protein is electrogenic led to the retraction of the idea that the protein is active in vitro but not in vivo at alkaline pH, when only Delta psi exists in the cells. The Na+ concentration needed for half-maximal activity of G338S in isolated everted membrane vesicles is similar to that of the wild type. Therefore an increase in intracellular Na+ due to a reduced antiporter affinity could not explain the results. It is suggested that the loss of growth. at alkaline pH in the presence of Na+ is due to the loss of the pH control of the mutated NhaA, Indeed, in the four mutations suppressing G338S phenotype, growth at alkaline pH was restored together with the pH regulation of NhaA, Three of the four suppressor mutations cluster in helix IV,whereas the original mutation is in helix XI, suggesting that the two helixes interact.	Hebrew Univ Jerusalem, Div Microbial & Mol Ecol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Padan, E (corresponding author), Hebrew Univ Jerusalem, Div Microbial & Mol Ecol, IL-91904 Jerusalem, Israel.		Gerchman, Yoram/F-5226-2015; Gerchman, Yoram/H-4698-2019	Gerchman, Yoram/0000-0002-8637-9589; 				CARMEL O, 1994, EMBO J, V13, P1981, DOI 10.1002/j.1460-2075.1994.tb06467.x; Carmel O, 1997, EMBO J, V16, P5922, DOI 10.1093/emboj/16.19.5922; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HARELBRONSTEIN M, 1994, J BIOL CHEM, V269, P3816; INOUE H, 1995, FEBS LETT, V363, P264, DOI 10.1016/0014-5793(95)00331-3; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KARPEL R, 1991, J BIOL CHEM, V266, P21753; Noumi T, 1997, J BIOCHEM-TOKYO, V121, P661; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; PADAN E, 1993, J BIOENERG BIOMEMBR, V25, P647; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PADAN E, 1992, ALKALI CATION TRANSP, P3; PADAN E, 1998, MICROBIOLOGY BIOCH H; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1993, J BIOL CHEM, V268, P1729; PINNER E, 1994, J BIOL CHEM, V269, P26274; RAHAVMANOR O, 1992, J BIOL CHEM, V267, P10433; RIMON A, 1995, J BIOL CHEM, V270, P26813, DOI 10.1074/jbc.270.45.26813; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; ROTHMAN A, 1997, BIOCHEMISTRY-US, V36, P14577; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; Schuldiner S., 1992, ALKALI CATION TRANSP, P25; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; TOKUDA H, 1982, J BIOL CHEM, V257, P7; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	32	63	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26470	26476		10.1074/jbc.273.41.26470	http://dx.doi.org/10.1074/jbc.273.41.26470			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756882	hybrid			2022-12-25	WOS:000076373300036
J	Stitt, BL; Xu, YM				Stitt, BL; Xu, YM			Sequential hydrolysis of ATP molecules bound in interacting catalytic sites of Escherichia coli transcription termination protein Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; RNA-DNA HELICASE; PHYSICAL-PROPERTIES; PARTITION ANALYSIS; BINDING DOMAINS; POLYMERASE; F1-ATPASE; HEXAMER; PROCESSIVITY; COFACTORS	Escherichia coli transcription termination protein Rho, an RNA-dependent ATPase, disrupts transcription complexes, releasing RNA and allowing RNA polymerase to recycle. Homohexameric Rho binds three molecules of MgATP in a single class of catalytically competent sites. In rapid mix chemical quench experiments, when Rho saturated with ATP was mixed with RNA and the reaction was quenched after various times, hydrolysis of the three bound ATP molecules was not simultaneous. A hydrolysis burst of one molecule of ATP per hexamer occurred at >300 s(-1), followed by steady-state hydrolysis at 30 s(-1) per hexamer, The burst also shows that a step following ATP hydrolysis is rate-limiting for overall catalysis and requires communication among the three catalytic sites during net ATP hydrolysis. The rate of hydrolysis of radiolabeled ATP when one labeled and two unlabeled ATP molecules are bound indicates a sequential pattern of hydrolysis. Positive cooperativity of catalysis occurs among the catalytic sites of Rho; when only one ATP molecule is bound per hexamer, ATP hydrolysis upon addition of RNA is 30-fold slower than when ATP is saturating. These behaviors are comparable to those of F-1-type ATPases, with which Rho shares a number of structural features.	Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Stitt, BL (corresponding author), Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA.							ALIFANO P, 1991, CELL, V64, P553; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1911, DOI 10.1073/pnas.82.7.1911; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; Horiguchi T, 1997, J MOL BIOL, V269, P514, DOI 10.1006/jmbi.1997.1059; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; LADINE JR, 1988, J CELL BIOL, V107, P854; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LOWERYGO.C, 1974, P NATL ACAD SCI USA, V71, P2003, DOI 10.1073/pnas.71.5.2003; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NEHRKE KW, 1992, NUCLEIC ACIDS RES, V20, P6107, DOI 10.1093/nar/20.22.6107; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; O IS, 1994, J BIOL CHEM, V269, P5009; ODA T, 1972, J MOL BIOL, V71, P799; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; Rose I A, 1980, Methods Enzymol, V64, P47; ROSE IA, 1995, METHOD ENZYMOL, V249, P315; SEIFRIED SE, 1991, J MOL BIOL, V221, P1139; STEINMETZ EJ, 1994, P NATL ACAD SCI USA, V91, P1401, DOI 10.1073/pnas.91.4.1401; STITT BL, 1988, J BIOL CHEM, V263, P11130; STITT BL, 1986, J BIOL CHEM, V261, P5906; Walstrom KM, 1997, BIOCHEMISTRY-US, V36, P7993, DOI 10.1021/bi963180r; WANG Y, 1993, J BIOL CHEM, V268, P13947; Washburn RS, 1996, J MOL BIOL, V260, P332, DOI 10.1006/jmbi.1996.0404; WASHBURN RS, 1997, THESIS TEMPLE U; WEBB MR, 1982, METHOD ENZYMOL, V87, P301; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740	56	46	46	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26477	26486		10.1074/jbc.273.41.26477	http://dx.doi.org/10.1074/jbc.273.41.26477			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756883	hybrid			2022-12-25	WOS:000076373300037
J	Becker, W; Weber, Y; Wetzel, K; Eirmbter, K; Tejedor, FJ; Joost, HG				Becker, W; Weber, Y; Wetzel, K; Eirmbter, K; Tejedor, FJ; Joost, HG			Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME CRITICAL REGION; DOWN-SYNDROME; HUMAN HOMOLOG; SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; TYROSINE RESIDUES; DROSOPHILA; IDENTIFICATION; CHROMOSOME-21; GENE	DYRK1 is a dual specificity protein kinase presumably involved in brain development. Here we show that the kinase belongs to a new family of protein kinases comprising at least seven mammalian isoforms (DYRK1A, DYRK1B, DYRK1C, DYRK2, DYRK3, DYRK4A, and DYRK4B), the yeast homolog Yak1p, and the Drosophila kinase minibrain (MNB). In rat tissues, DYRK1A is expressed ubiquitously, whereas transcripts for DYRK1B, DYRK2, DYRK3, and DYRK4 were detected predominantly in testes of adult but not prepuberal rats. By fluorescence microscopy and subcellular fractionation, a green fluorescent protein (GFP) fusion protein of DYRK1A was found to accumulate in the nucleus of transfected COS-7 and HEK293 cells, whereas GFP-DYRK2 was predominantly detected in the cytoplasm. DYRK1A exhibited a punctate pattern of GFP fluorescence inside the nucleus and was co-purified with the nuclear matrix. Analysis of GFP-DYRK1A deletion constructs showed that the nuclear localization of DYRK1A was mediated by its nuclear targeting signal (amino acids 105-139) but that its characteristic subnuclear distribution depended on additional N-terminal elements (amino acids 1-104). When expressed in Escherichia coli, DYRK1A DYRK2, DYRK3, MNB, and Yak1p catalyzed their autophosphorylation on tyrosine residues. The kinases differed in their substrate specificity in that DYRK2 and DYRK3, but not DYRK1A and MNB, catalyzed phosphorylation of histone H2B, The heterogeneity of their subcellular localization and substrate specificity suggests that the kinases are involved in different cellular functions.	Rhein Westfal TH Aachen, Fak Med, Inst Pharmakol & Toxikol, D-52057 Aachen, Germany; Univ Miguel Hernandez, Inst Neurosci, Alicante 03550, Spain; CSIC, Inst Cajal, Alicante 03550, Spain	RWTH Aachen University; Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Becker, W (corresponding author), Rhein Westfal TH Aachen, Fak Med, Inst Pharmakol & Toxikol, Wendlingweg 2, D-52057 Aachen, Germany.		Becker, Walter/B-8889-2008; Joost, Hans-Georg/J-4462-2013	Becker, Walter/0000-0002-0347-4768; Joost, Hans-Georg/0000-0002-5860-606X; Tejedor, Francisco J/0000-0003-1942-2580				Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; Begley DA, 1997, GENE, V200, P35, DOI 10.1016/S0378-1119(97)00350-8; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Chen HM, 1997, HUM GENET, V99, P262, DOI 10.1007/s004390050350; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Delabar Jean-Maurice, 1993, European Journal of Human Genetics, V1, P114; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHBACH KF, 1984, J EXP BIOL, V112, P65; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; GARRETT S, 1991, MOL CELL BIOL, V11, P4045, DOI 10.1128/MCB.11.8.4045; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Guimera J, 1996, HUM MOL GENET, V5, P1305, DOI 10.1093/hmg/5.9.1305; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MCCORMICK MK, 1989, GENOMICS, V5, P325, DOI 10.1016/0888-7543(89)90065-7; Nickerson JA, 1995, INT REV CYTOL, V162A, P67; Ohira M, 1997, GENOME RES, V7, P47, DOI 10.1101/gr.7.1.47; Pennisi E, 1996, SCIENCE, V274, P2008; PINES J, 1995, TRENDS GENET, V11, P326, DOI 10.1016/S0168-9525(00)89092-7; RAHMANI Z, 1989, P NATL ACAD SCI USA, V86, P5958, DOI 10.1073/pnas.86.15.5958; SANDER A, 1995, AM J HUM GENET, V56, P310; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Smith DJ, 1997, NAT GENET, V16, P28, DOI 10.1038/ng0597-28; Song WJ, 1997, BIOCHEM BIOPH RES CO, V231, P640, DOI 10.1006/bbrc.1997.6154; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; WADA K, 1991, NUCLEIC ACIDS RES, V19, P1981, DOI 10.1093/nar/19.suppl.1981; WANDEL S, 1994, FEBS LETT, V348, P114, DOI 10.1016/0014-5793(94)00558-3	39	227	242	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25893	25902		10.1074/jbc.273.40.25893	http://dx.doi.org/10.1074/jbc.273.40.25893			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748265	hybrid			2022-12-25	WOS:000076263100056
J	Cook, T; Gebelein, B; Mesa, K; Mladek, A; Urrutia, R				Cook, T; Gebelein, B; Mesa, K; Mladek, A; Urrutia, R			Molecular cloning and characterization of TIEG2 reveals a new subfamily of transforming growth factor-beta-inducible Sp1-like zinc finger-encoding genes involved in the regulation of cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; BOX-BINDING PROTEIN; RICH ACTIVATION DOMAINS; KRUPPEL-LIKE FACTOR; PROMOTER REGION; RECEPTOR GENE; TGF-BETA; CYCLE REGULATION; MULTIGENE FAMILY; GC BOXES	Sp1-like zinc finger transcription factors are involved in the regulation of cell growth and differentiation. Recent evidence demonstrating that mammalian cells express novel, yet uncharacterized, Sp1-like proteins has stimulated a search for new members of this family. We and others have recently reported that the transforming growth factor (TGF)-beta-regulated gene TIEG encodes a new Sp1-like protein that inhibits cell growth in cultured cells. Here we report the identification, nuclear localization, DNA binding activity, transcriptional repression activity, and growth inhibitory effects of TIEG2, a novel TGF-beta-inducible gene related to TIEG. TIEG2 is ubiquitously expressed in human tissues, with an enrichment in pancreas and muscle. TIEG2 shares 91% homology with TIEG1 within the zinc finger region and 44% homology within the N terminus. Biochemical characterization reveals that TIEG2 is a nuclear protein, which, as predicted from the primary structure, specifically binds to an Sp1-like DNA sequence in vitro and can repress a promoter containing Sp1-Like binding sites in transfected Chinese hamster ovary epithelial cells. Furthermore, functional studies using [H-3]thymidine uptake and MTS (3-(4,3-dimethyltiazol-2 yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl) -2H-tetrazolium) assays demonstrate that the overexpression of TIEG2 in Chinese hamster ovary cells inhibits cell proliferation. Thus, TIEG2, together with TIEG1, defines a new subfamily of TGF-beta-inducible Sp1-Like proteins involved in the regulation of cell growth.	Mayo Clin & Mayo Fdn, St Marys Hosp, GI Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Neurosci, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Urrutia, R (corresponding author), Mayo Clin & Mayo Fdn, St Marys Hosp, GI Res Unit, 200 1st St SW, Rochester, MN 55905 USA.			Cook, Tiffany/0000-0002-3100-5248	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052913, T32DK007198, R56DK052913] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07198, DK52913, R01 DK052913-03, R01 DK052913] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams PD, 1997, METHOD ENZYMOL, V283, P59; Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; ARAKI E, 1991, J BIOL CHEM, V266, P3944; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BALDWIN RL, 1993, GROWTH FACTORS, V8, P23, DOI 10.3109/08977199309029131; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BIRNBAUM MJ, 1995, BIOCHEMISTRY-US, V34, P7648, DOI 10.1021/bi00023a011; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Chiarugi V, 1997, PHARMACOL RES, V35, P257, DOI 10.1006/phrs.1997.0140; Clare SE, 1997, J BIOL CHEM, V272, P33028, DOI 10.1074/jbc.272.52.33028; Cook T, 1996, J NEUROCHEM, V67, P927; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; ElRouby S, 1996, ONCOGENE, V13, P2623; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; Faraldo MLM, 1997, MOL CARCINOGEN, V20, P33, DOI 10.1002/(SICI)1098-2744(199709)20:1<33::AID-MC5>3.0.CO;2-J; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GEISER AG, 1993, GENE, V129, P223, DOI 10.1016/0378-1119(93)90272-5; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Gum JR, 1997, BIOCHEM J, V325, P259, DOI 10.1042/bj3250259; HAGAN G, 1992, NUCLEIC ACIDS RES, V20, P5519; Hamel W, 1996, CYTOMETRY, V25, P173, DOI 10.1002/(SICI)1097-0320(19961001)25:2<173::AID-CYTO6>3.0.CO;2-I; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Horie N, 1997, J BIOL CHEM, V272, P18375, DOI 10.1074/jbc.272.29.18375; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Imoto M, 1998, J CELL SCI, V111, P1341; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kawachi Y, 1996, IMMUNOGENETICS, V44, P358, DOI 10.1007/BF02602780; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; Kojima S, 1997, J BIOCHEM, V121, P389; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Laniel MA, 1997, BIOCHEM CELL BIOL, V75, P427, DOI 10.1139/bcb-75-4-427; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LIN XH, 1992, J BIOL CHEM, V267, P25614; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; PAGES G, 1995, J BIOL CHEM, V270, P26986, DOI 10.1074/jbc.270.45.26986; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; Philippe J, 1997, CYTOMETRY, V29, P242, DOI 10.1002/(SICI)1097-0320(19971101)29:3<242::AID-CYTO7>3.3.CO;2-Z; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Rolland V, 1996, J BIOL CHEM, V271, P21297, DOI 10.1074/jbc.271.35.21297; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Tau KR, 1998, ENDOCRINOLOGY, V139, P1346, DOI 10.1210/en.139.3.1346; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Yajima S, 1997, J NEUROSCI, V17, P8657; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; Zhang Y, 1997, BBA-GENE STRUCT EXPR, V1353, P307, DOI 10.1016/S0167-4781(97)00063-8; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	71	160	166	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25929	25936		10.1074/jbc.273.40.25929	http://dx.doi.org/10.1074/jbc.273.40.25929			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748269	hybrid			2022-12-25	WOS:000076263100060
J	Hu, ZZ; Zhuang, L; Meng, JP; Dufau, ML				Hu, ZZ; Zhuang, L; Meng, JP; Dufau, ML			Transcriptional regulation of the generic promoter III of the rat prolactin receptor gene by C/EBP beta and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; BINDING PROTEINS; FACTOR-I; EXPRESSION; MULTIPLE; ACTIVATION; ELEMENT; CLONING; DOMAIN; SITES	Three promoters are operative in the rat prolactin receptor gene as follows: promoter I (PI) and II (PII) are specific for the gonads and liver, respectively, and promoter III (PILI) is common to several tissues. To investigate the mechanisms controlling the activity of promoter III, its regulatory elements and transcription factors were characterized in gonadal and non-gonadal cells. The TATA-less PIII domain was localized to the region -437 to -179 (ATG + 1) containing the 5'-flanking region and part of the non-coding first exon, Within the promoter domain, a functional CAAT-box/enhancer binding protein (C/EBP) (-398) and an Sp1 element (-386), which bind C/EBP beta and Sp1/Sp3, respectively, contribute individually to promoter activation in gonadal and non-gonadal cells. However, significant redundancy was demonstrated between these elements in non-gonadal cells. Additionally, an element within the non-coding exon 1 (-338) is also required for promoter activity. Activation of PIII by the widely expressed Spl and C/EBP beta factors explains its common utilization in multiple tissues. Moreover, whereas the rat and mouse PIII share similar structure and function, the mouse PI lacks the functional SF-1 element and hence is inactive. These findings indicate that promoter III is of central importance in prolactin receptor gene transcription across species.	NICHD, Sect Mol Endocrinol, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dufau, ML (corresponding author), NICHD, Sect Mol Endocrinol, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A36,49 Convent Dr,MSC 4510, Bethesda, MD 20892 USA.	dufau@helix.nih.gov						ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ASSELIN C, 1989, ONCOGENE, V4, P549; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; Bonifacino J.S., 1984, Serono Symposia Publications from Raven Press, V9, P149; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DOPPLER W, 1994, REV PHYSIOL BIOCH P, V124, P93, DOI 10.1007/BFb0031032; Eberhardt W, 1998, J IMMUNOL, V160, P4961; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; Hoppe KL, 1998, J LIPID RES, V39, P969; Hu ZZ, 1996, J BIOL CHEM, V271, P10242, DOI 10.1074/jbc.271.17.10242; HU ZZ, 1991, BIOCHEM BIOPH RES CO, V181, P219, DOI 10.1016/S0006-291X(05)81405-6; Hu ZZ, 1997, J BIOL CHEM, V272, P14263, DOI 10.1074/jbc.272.22.14263; Hu ZZ, 1998, TRENDS ENDOCRIN MET, V9, P94, DOI 10.1016/S1043-2760(98)00027-7; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Moldrup A, 1996, MOL ENDOCRINOL, V10, P661, DOI 10.1210/me.10.6.661; NICOLL CS, 1974, HDB PHYSIOLOGY, V4, P253; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Pang HL, 1998, BIOCHEM J, V333, P209, DOI 10.1042/bj3330209; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1994, RAV S MOL C, V3, P63; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; TSAIMORRIS CH, 1995, J BIOL CHEM, V270, P7487, DOI 10.1074/jbc.270.13.7487; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402	44	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26225	26235		10.1074/jbc.273.40.26225	http://dx.doi.org/10.1074/jbc.273.40.26225			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748306	hybrid			2022-12-25	WOS:000076263100097
J	Schacke, H; Schumann, H; Hammami-Hauasli, N; Raghunath, M; Bruckner-Tuderman, L				Schacke, H; Schumann, H; Hammami-Hauasli, N; Raghunath, M; Bruckner-Tuderman, L			Two forms of collagen XVII in keratinocytes - A full-length transmembrane protein and a soluble ectodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULLOUS PEMPHIGOID ANTIGEN; BENIGN EPIDERMOLYSIS-BULLOSA; BASEMENT-MEMBRANE ZONE; EXTRACELLULAR DOMAIN; BP180; GENE; AUTOANTIBODIES; AUTOANTIGEN; BPAG2; DERMATOSIS	The cDNA sequence of human collagen XVII predicts an unusual type II transmembrane protein, but a biochemical characterization of this structure has not been accomplished yet. Using domain-specific antibodies against recombinant collagen XVII fragments, we identified two molecular forms of the collagen in human skin and epithelial cells. Full-length collagen XVII appeared as a homotrimeric transmembrane molecule of three 180-kDa alpha 1(XVII) chains. The globular intracellular domain was disulfide-linked, and the N-glycosylated extracellular domain of three 120-kDa polypeptides was triple-helical at physiological temperatures. A second, soluble form of collagen XVII in keratinocyte culture media was recognized with antibodies to the ectodomain, but not the endodomain, The soluble form exhibited molecular properties of the collagen XVII ectodomain: a triple-helical, N-glycosylated molecule of three 120-kDa polypeptides, Northern blot analysis with probes spanning either the distal 5' or the distal 3' end of the collagen XVII cDNA revealed an identical 6-kb mRNA, suggesting that both the 180- and 120-kDa polypeptides were translated from the same mRNA, and that the 120-kDa polypeptide was generated post-translationally, In concert, keratinocytes harboring a homozygous nonsense mutation in the COL17A1 gene synthesized neither the 180-kDa alpha 1(XVII) chain nor the 120-kDa polypeptide. Finally, treatment of normal keratinocytes with a synthetic inhibitor of furin proprotein convertases, decanoyl-RVKR-chloromethyl ketone, prevented the generation of the 120-kDa polypeptide. These data strongly suggest that the soluble 120-kDa polypeptide represents a specifically cleaved ectodomain of collagen XVII, generated through furin-mediated proteolytic processing. Thus, collagen XVII is not only an unusual type II transmembrane collagen, but the first collagen with a specifically processed, soluble triple-helical ectodomain.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany	University of Munster	Bruckner-Tuderman, L (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 56, D-48149 Munster, Germany.		Raghunath, Michael/E-6483-2010; Raghunath, Michael/M-2727-2019	Raghunath, Michael/0000-0002-2138-6614; 				ACTON S, 1993, J BIOL CHEM, V268, P3530; Balding SD, 1997, BIOCHEMISTRY-US, V36, P8821, DOI 10.1021/bi970675n; Balding SD, 1996, J INVEST DERMATOL, V106, P141, DOI 10.1111/1523-1747.ep12329728; Borradori L, 1997, J CELL BIOL, V136, P1333, DOI 10.1083/jcb.136.6.1333; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Chavanas S, 1997, J INVEST DERMATOL, V109, P74, DOI 10.1111/1523-1747.ep12276614; Darling TN, 1998, J INVEST DERMATOL, V110, P165, DOI 10.1046/j.1523-1747.1998.00103.x; Darling TN, 1997, J INVEST DERMATOL, V108, P463, DOI 10.1111/1523-1747.ep12289718; Darling TN, 1998, J INVEST DERMATOL, V110, P170, DOI 10.1046/j.1523-1747.1998.00101.x; FLOETH M, 1998, IN PRESS J INVEST DE; GAO SQ, 1994, ARCH DERMATOL, V130, P873, DOI 10.1001/archderm.130.7.873; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; Gatalica B, 1997, AM J HUM GENET, V60, P352; GIUDICE GJ, 1994, J INVEST DERMATOL, V102, P878, DOI 10.1111/1523-1747.ep12382738; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; Hirako Y, 1996, J BIOL CHEM, V271, P13739, DOI 10.1074/jbc.271.23.13739; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HOPKINSON SB, 1995, J CELL BIOL, V130, P117, DOI 10.1083/jcb.130.1.117; ISHIKO A, 1993, J CLIN INVEST, V91, P1608, DOI 10.1172/JCI116368; Jonkman MF, 1996, ARCH DERMATOL, V132, P145, DOI 10.1001/archderm.132.2.145; Jonkman MF, 1997, CELL, V88, P543, DOI 10.1016/S0092-8674(00)81894-2; JONKMAN MF, 1995, J CLIN INVEST, V95, P1345, DOI 10.1172/JCI117785; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KONIG A, 1992, J CELL BIOL, V117, P679, DOI 10.1083/jcb.117.3.679; LI KH, 1993, J BIOL CHEM, V268, P8825; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; Marinkovich MP, 1996, J INVEST DERMATOL, V106, P734, DOI 10.1111/1523-1747.ep12345782; Masunaga T, 1997, J INVEST DERMATOL, V109, P200, DOI 10.1111/1523-1747.ep12319337; McGrath JA, 1996, J INVEST DERMATOL, V106, P771, DOI 10.1111/1523-1747.ep12345821; McGrath JA, 1996, AM J PATHOL, V148, P1787; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; MEYER LJ, 1991, J INVEST DERMATOL, V96, P991, DOI 10.1111/1523-1747.ep12476575; NISHIZAWA Y, 1993, J BIOCHEM-TOKYO, V113, P493, DOI 10.1093/oxfordjournals.jbchem.a124072; Pas HH, 1997, J INVEST DERMATOL, V108, P423, DOI 10.1111/1523-1747.ep12289703; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RAGHUNATH M, 1994, J MOL BIOL, V236, P940, DOI 10.1006/jmbi.1994.1199; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Schumann H, 1997, AM J HUM GENET, V60, P1344, DOI 10.1086/515463; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; STAHLEBACKDAHL M, 1994, J CLIN INVEST, V93, P2022, DOI 10.1172/JCI117196; Zillikens D, 1997, J INVEST DERMATOL, V109, P573, DOI 10.1111/1523-1747.ep12337492; Zone JJ, 1998, J INVEST DERMATOL, V110, P207, DOI 10.1046/j.1523-1747.1998.00129.x; ZONE JJ, 1990, J CLIN INVEST, V85, P812, DOI 10.1172/JCI114508	51	127	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25937	25943		10.1074/jbc.273.40.25937	http://dx.doi.org/10.1074/jbc.273.40.25937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748270	hybrid			2022-12-25	WOS:000076263100061
J	Turner, SJ; Domin, J; Waterfield, MD; Ward, SG; Westwick, J				Turner, SJ; Domin, J; Waterfield, MD; Ward, SG; Westwick, J			The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOATTRACTANT PROTEIN-1 RECEPTOR; MYELOID-DERIVED CELLS; BETA-GAMMA-SUBUNITS; SWISS 3T3 CELLS; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; STIMULATED SYNTHESIS; FUNCTIONAL LIGAND; KINASE-ACTIVITY; FACTOR MCAF	The cellular effects of MCP-1 are mediated primarily by binding to CC chemokine receptor-2. We report here that MCP-1 stimulates the formation of the lipid products of phosphatidylinositol (PI) 3-kinase, namely phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate (PI 3,4,5-P-3) in THP-1 cells that can be inhibited by pertussis toxin but not wortmannin. MCP-1 also stimulates an increase in the in vitro lipid kinase activity present in immunoprecipitates of the class 1(A) p85/p110 heterodimeric PI 3-kinase, although the kinetics of activation were much slower than observed for the accumulation of PI 3,4,5-P-3. In addition, this in vitro lipid kinase activity was inhibited by wortmannin (IC50 = 4.47 +/- 1.88 nM, n = 4), and comparable concentrations of wortmannin also inhibited MCP-stimulated chemotaxis of THP-1 cells (IC50 = 11.8 +/- 4.2 nM, n = 4), indicating that p85/p110 PI 3-kinase activity is functionally relevant. MCP-1 also induced tyrosine phosphorylation of three proteins in these cells, and a fourth tyrosine-phosphorylated protein co-precipitates with the p85 subunit upon MCP-1 stimulation. In addition, MCP-1 stimulated lipid kinase activity present in immunoprecipitates of a class II PI 3-kinase (PI3K-C2 alpha) with kinetics that closely resembled the accumulation of PI 3,4,5-P-3. Moreover, this MCP-1-induced increase in PI3K-C2 alpha activity was insensitive to wortmannin but was inhibited by pertussis toxin pretreatment. Since this mirrored the effects of these inhibitors on MCP-1-stimulated increases in D-3 phosphatidylinositol lipid accumulation in vivo, these results suggest that activation of PI3K-C2 alpha rather than the p85/p110 heterodimer is responsible for mediating the in vivo formation of D-3 phosphatidylinositol lipids. These data demonstrate that MCP-1 stimulates protein tyrosine kinases as well. as at least two separate PI 3-kinase isoforms, namely the p85/p110 PI 3-kinase and PI3K-C2 alpha. This is the first demonstration that MCP-1 can stimulate PI 3-kinase activation and is also the first indication of an agonist-induced activation of the PI3K-C2 alpha enzyme. These two events may play important roles in MCP-1-stimulated signal transduction and biological consequences.	Univ Bath, Sch Pharm & Pharmacol, Pharmacol Grp, Bath BA2 7AY, Avon, England; Ludwig Inst Canc Res, London W1P 8BT, England	University of Bath; Ludwig Institute for Cancer Research	Ward, SG (corresponding author), Univ Bath, Sch Pharm & Pharmacol, Pharmacol Grp, Claverton Down, Bath BA2 7AY, Avon, England.	prssgw@bath.ac.uk	Ward, Stephen/AAE-4341-2020	Ward, Stephen G./0000-0002-6795-6002	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Chensue SW, 1996, J IMMUNOL, V157, P4602; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Dubois PM, 1996, J IMMUNOL, V156, P1356; FRANCI C, 1995, J IMMUNOL, V154, P6511; FUENTES ME, 1995, J IMMUNOL, V155, P5769; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GNN MD, 1997, J IMMUNOL, V159, P401; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; Grewal IS, 1997, J IMMUNOL, V159, P401; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Matsuo T, 1996, BIOCHEM J, V315, P505, DOI 10.1042/bj3150505; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NELKEN NA, 1991, J CLIN INVEST, V90, P772; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sarafi MN, 1997, J EXP MED, V185, P99, DOI 10.1084/jem.185.1.99; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; SOZZANI S, 1993, J IMMUNOL, V150, P1544; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Taub DD, 1996, J LEUKOCYTE BIOL, V59, P81, DOI 10.1002/jlb.59.1.81; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TURNER L, 1995, J IMMUNOL, V155, P2437; TURNER SJ, 1995, BRIT J PHARMACOL, V114, pP211; WARD SG, 1992, J BIOL CHEM, V267, P23862; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Wright K, 1997, J BIOL CHEM, V272, P12626, DOI 10.1074/jbc.272.19.12626; ZACHARIAE COC, 1990, J EXP MED, V171, P2177, DOI 10.1084/jem.171.6.2177; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	62	140	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25987	25995		10.1074/jbc.273.40.25987	http://dx.doi.org/10.1074/jbc.273.40.25987			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748276	hybrid			2022-12-25	WOS:000076263100067
J	Iglesias, M; Yen, K; Gaiotti, D; Hildesheim, A; Stoler, MH; Woodworth, CD				Iglesias, M; Yen, K; Gaiotti, D; Hildesheim, A; Stoler, MH; Woodworth, CD			Human papillomavirus type 16 E7 protein sensitizes cervical keratinocytes to apoptosis and release of interleukin-1 alpha	ONCOGENE			English	Article						apoptosis; cervical carcinoma; human; papillomavirus; interleukin-1; keratinocyte	EPITHELIAL-CELLS; GENE-EXPRESSION; DIFFERENTIAL REGULATION; GROWTH-FACTOR; DNA; CARCINOMA; RECEPTOR; PROLIFERATION; FIBROBLASTS; INFECTION	Interleukin-1 alpha. (IL-1 alpha) is a multifunctional cytokine that promotes inflammation, tissue remodeling and epithelial hyperplasia, Keratinocytes produce and sequester large amounts of biologically active IL-1 alpha which can be released after injury or infection. We show that high level expression of human papillomavirus (HPV) type 16 E6 and E7 oncoproteins enhanced release of IL-1 alpha from cultures of normal cervical keratinocytes (relative effectiveness E7>E6/E7 much greater than E6> control). The amount of IL-1 alpha. released was directly related to the ability of E7 or E6/E7 to stimulate apoptosis, E7 proteins that bound the retinoblastoma protein (Rb) strongly (HPV-16 and -18) induced more IL-1 alpha release than those that bound poorly (HPV-6 and an HPV-16 E7 24gly mutant). Furthermore, overexpression of the E2F-1 transcription factor, a downstream target of Rb, induced extensive apoptosis and IL-1 alpha release. Apoptosis and IL-1 alpha release in response to growth factor removal occurred in part through a p53-independent pathway as coexpression of E6 and downregulation of p53 did not prevent either response. Immunohistochemical analyses showed that IL-1 alpha. was expressed by keratinocytes in normal cervical epithelia, low and high grade dysplasias, and cervical carcinomas. However, HPV-16 E6/E7 RNA expression and apoptosis increased in parallel in proliferating keratinocytes in severe dysplasias and carcinomas suggesting that IL-1 alpha release is associated with progression to high grade disease. Thus, high level expression of the HPV-16 E7 protein sensitizes keratinocytes to apoptosis which results in release of IL-1 alpha.	NCI, Biol Lab, Bethesda, MD 20892 USA; NCI, Environm Epidemiol Branch, Bethesda, MD 20892 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22901 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Virginia	Woodworth, CD (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, Bldg 37,Room 3B25, Bethesda, MD 20892 USA.							ANSEL JC, 1988, J IMMUNOL, V140, P2274; Brown J, 1997, J CELL BIOCHEM, V66, P245, DOI 10.1002/(SICI)1097-4644(19970801)66:2<245::AID-JCB11>3.0.CO;2-G; BRYAN D, 1995, CELL GROWTH DIFFER, V6, P1245; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; Castrilli G, 1997, BRIT J CANCER, V75, P855, DOI 10.1038/bjc.1997.152; COLLINS RH, 1987, NEW ENGL J MED, V316, P1654, DOI 10.1056/NEJM198706253162609; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CORREA P, 1992, CANCER RES, V52, P6735; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FAN TPD, 1993, BRIT J PHARMACOL, V110, P43, DOI 10.1111/j.1476-5381.1993.tb13769.x; Frazer IH, 1996, CURR OPIN IMMUNOL, V8, P484, DOI 10.1016/S0952-7915(96)80035-5; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Isacson C, 1996, CANCER RES, V56, P669; Kim CY, 1997, CANCER RES, V57, P4200; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KUPPER TS, 1995, J INVEST DERMATOL, V105, pS62, DOI 10.1111/1523-1747.ep12316087; Li DQ, 1997, J CELL PHYSIOL, V172, P361, DOI 10.1002/(SICI)1097-4652(199709)172:3<361::AID-JCP10>3.0.CO;2-9; Merrick DT, 1996, CELL GROWTH DIFFER, V7, P1661; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Montague JW, 1996, EXPERIENTIA, V52, P957, DOI 10.1007/BF01920104; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; OBERYSZYN TM, 1993, MOL CARCINOGEN, V7, P238, DOI 10.1002/mc.2940070406; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; Riethdorf L, 1996, AM J PATHOL, V149, P1469; RORKE EA, 1995, EXP CELL RES, V216, P65, DOI 10.1006/excr.1995.1008; ROSL F, 1994, J VIROL, V68, P2142; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shoji Y, 1996, J CLIN PATHOL, V49, P134, DOI 10.1136/jcp.49.2.134; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; STONE KM, 1995, CLIN INFECT DIS   S1, V20, P591; VIDALVANACLOCHA F, 1994, CANCER RES, V54, P2667; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Wood LC, 1996, J INVEST DERMATOL, V106, P397, DOI 10.1111/1523-1747.ep12343392; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WOODWORTH CD, 1993, AM J PATHOL, V142, P1544; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840; Woodworth CD, 1996, CELL GROWTH DIFFER, V7, P811; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	52	52	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1195	1205		10.1038/sj.onc.1202054	http://dx.doi.org/10.1038/sj.onc.1202054			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771962				2022-12-25	WOS:000075803300001
J	Stoppler, H; Stoppler, MC; Johnson, E; Simbulan-Rosenthal, CM; Smulson, ME; Iyer, S; Rosenthal, DS; Schlegel, R				Stoppler, H; Stoppler, MC; Johnson, E; Simbulan-Rosenthal, CM; Smulson, ME; Iyer, S; Rosenthal, DS; Schlegel, R			The E7 protein of human papillomavirus type 16 sensitizes primary human keratinocytes to apoptosis	ONCOGENE			English	Article						HPV E6 and E7 oncogenes; apoptosis; p53; primary keratinocytes; extended life span	MAMMARY EPITHELIAL-CELLS; RAT EMBRYO FIBROBLASTS; S-PHASE ENTRY; E6 ONCOPROTEIN; P53 PROTEIN; MUTATIONAL ANALYSIS; TRANSFORMING GENE; WILD-TYPE; HA-RAS; IMMORTALIZATION	The 'high risk' human papillomaviruses are associated with the development of anogenital carcinomas and their E6 and E7 genes possess immortalizing and transforming functions in several in vitro culture systems, Recently the E6 gene has also been shown to enhance the apoptosis of human mammary epithelial cells, To determine the apoptotic activity of these oncogenes in the natural host cell, we infected genital keratinocytes with retroviruses expressing either HPV-16 E6, E7, or both the E6 and E7 (E6/7) genes. Apoptosis was quantitated under normal growth conditions or when induced by tumor necrosis factor alpha/cycloheximide or sulfur mustard. In contrast to previous findings with mammary epithelial cells, the E6 gene did not significantly augment either spontaneous or induced apoptosis, E6 also did not suppress apoptosis in normal keratinocytes (despite dramatically reducing their p53 levels), suggesting that p53-independent events mediated this effect, In contrast, E7 increased both spontaneous and induced apoptosis as well as the cellular levels of p53 and p21 protein. Interestingly, coexpression of E6 abrogated E7-facilitated apoptosis by tumor necrosis factor alpha nearly completely, but had only a minor protective effect on sulfur mustard induced apoptosis in these cells, demonstrating at least in part the p53-dependence and -independence of these two apoptotic pathways, Finally, our results indicate that the apoptosis of normal and E7-expressing keratinocytes is differentially affected by E6 expression and that E7, when unaccompanied by E6, sensitizes keratinocytes to apoptosis.	Georgetown Univ, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Univ Marburg, Inst Pharmacol & Toxicol, D-35033 Marburg, Germany; Univ Marburg, Klinikum Lahnberge, Dept Pathol, D-35043 Marburg, Germany; Georgetown Univ, Dept Pathol, Mol Pathol Program, Washington, DC 20007 USA	Georgetown University; Philipps University Marburg; Philipps University Marburg; Georgetown University	Rosenthal, DS (corresponding author), Georgetown Univ, Dept Biochem & Mol Biol, 3900 Reservoir Rd, Washington, DC 20007 USA.		Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014	Rosenthal, Dean/0000-0002-7624-0209; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342	NATIONAL CANCER INSTITUTE [R01CA053371] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA53371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Dabrowska MI, 1996, TOXICOL APPL PHARM, V141, P568, DOI 10.1006/taap.1996.0324; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; LIU ZJ, 1994, VIROLOGY, V201, P388, DOI 10.1006/viro.1994.1306; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUNGER K, 1989, J VIROL, V63, P4417; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PEACOCK JW, 1990, ONCOGENE, V5, P1769; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rosenthal DS, 1998, J INVEST DERMATOL, V111, P64, DOI 10.1046/j.1523-1747.1998.00250.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; Stoppler H, 1997, J BIOL CHEM, V272, P13332, DOI 10.1074/jbc.272.20.13332; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; TANAKA A, 1989, J VIROL, V63, P1465, DOI 10.1128/JVI.63.3.1465-1469.1989; Thomas M, 1996, ONCOGENE, V13, P265; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; VILLA LL, 1991, VIROLOGY, V181, P374; VILLA LL, 1992, MOL CARCINOGEN, V6, P5, DOI 10.1002/mc.2940060103; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; Yu YJ, 1997, ONCOGENE, V14, P1661, DOI 10.1038/sj.onc.1201026	68	88	92	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	1998	17	10					1207	1214		10.1038/sj.onc.1202053	http://dx.doi.org/10.1038/sj.onc.1202053			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771963				2022-12-25	WOS:000075803300002
J	Kasahara, M; Maeda, M				Kasahara, M; Maeda, M			Contribution to substrate recognition of two aromatic amino acid residues in putative transmembrane segment 10 of the yeast sugar transporters Gal2 and Hxt2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLUCOSE TRANSPORTERS; GALACTOSE; PROTEINS; FAMILY	The comprehensive study of chimeras between the Gal2 galactose transporter and the Hxt2 glucose transporter of Saccharomyces cerevisiae has shown that Tyr(446) is essential and Trp(455) is important for galactose recognition by Gal2, Consistent with this finding, replacement of the corresponding Phe(431) and Tyr(440) residues of Hxt2 with Tyr and Trp, respectively, allowed Hxt2 to transport galactose, suggesting that the two amino acid residues in putative transmembrane segment 10 play a definite role in galactose recognition (Kasahara, M., Shimoda, E., and Maeda, M. (1997) J. Biol. Chem. 272, 16721-16724), Replacement of Trp(455) of Gal2 with any of the other 19 amino acids was shown to reduce galactose transport activity to between 0 and <20% of that of wild-type Gal2, The role of Phe(431) in Hxt2 was similarly studied. Other than Phe, only Tyr at position 431 was able to support glucose transport activity, at the reduced level of <20%. In contrast, replacement of Tyr(440) Of Hxt2 with Other amino acids revealed that most replacements, with the exception of Pro and charged amino acids, supported glucose transport activity. The importance of residue 431 in sugar recognition was more pronounced in a modified Hxt2 in which Tyr440 was replaced with Trp, Glucose transport was supported only by the aromatic amino acids Phe, Tyr, and Trp at position 431, and galactose transport was supported only by Tyr, These results suggest that an aromatic amino acid located in the middle of transmembrane segment 10 (Tyr(446) in Gal2 and Phe(431) in Hxt2) plays a critical role in substrate recognition in the yeast sugar transporter family to which Gal2 and Hxt2 belong.	Teikyo Univ, Sch Med, Biophys Lab, Hachioji, Tokyo 1920395, Japan	Teikyo University	Kasahara, M (corresponding author), Teikyo Univ, Sch Med, Biophys Lab, Hachioji, Tokyo 1920395, Japan.	kasahara@main.teikyo-u.ac.jp						BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; Dutzler R, 1996, STRUCTURE, V4, P127, DOI 10.1016/S0969-2126(96)00016-0; Forst D, 1998, NAT STRUCT BIOL, V5, P37, DOI 10.1038/nsb0198-37; Kasahara M, 1996, FEBS LETT, V389, P174, DOI 10.1016/0014-5793(96)00567-4; Kasahara M, 1997, J BIOL CHEM, V272, P16721, DOI 10.1074/jbc.272.27.16721; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; Liang H, 1998, MOL CELL BIOL, V18, P926, DOI 10.1128/MCB.18.2.926; NEHLIN JO, 1989, GENE, V85, P313, DOI 10.1016/0378-1119(89)90423-X; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; PONTKINGDON G, 1994, BIOTECHNIQUES, V16, P1010; QUIOCHO FA, 1993, BIOCHEM SOC T, V21, P442, DOI 10.1042/bst0210442; VYAS MN, 1994, BIOCHEMISTRY-US, V33, P4762, DOI 10.1021/bi00182a003; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; [No title captured]	16	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29106	29112		10.1074/jbc.273.44.29106	http://dx.doi.org/10.1074/jbc.273.44.29106			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786918	hybrid			2022-12-25	WOS:000076691800079
J	MacRae, IJ; Rose, AB; Segel, IH				MacRae, IJ; Rose, AB; Segel, IH			Adenosine 5 '-phosphosulfate kinase from Penicillium chrysogenum - Site-directed mutagenesis at putative phosphoryl-accepting and ATP P-loop residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-ACTIVATING ENZYMES; ADENOSINE-5'-PHOSPHOSULFATE KINASE; RAT CHONDROSARCOMA; FILAMENTOUS FUNGI; APS KINASE; PURIFICATION; SULFURYLASE; BINDING; IDENTIFICATION; DISSOCIATION	The properties of Penicillium chrysogenum adenosine 5'-phosphosulfate (APS) kinase mutated at Ser-107 were examined. Ser-107 is analogous to a serine of the E. coli enzyme that has been shown to serve as an intermediate acceptor in the transfer of a phosphoryl group from ATP to APS, Replacement of Ser-107 with alanine yielded an active enzyme with kinetic characteristics similar to those of wild-type APS kinase, Another mutant form of the enzyme in which Ser-107 was replaced by cysteine was also active. Covalent modification of Cys-107 eliminated catalytic activity, and substrates protected against modification. Mutation of Ser-97, of Ser-99, of Thr-103, of Ser-104 to alanine, or of Tyr-109 to phenylalanine also yielded an active enzyme. The cumulative results indicate that Ser-107 may reside in the substrate binding pocket of fungal APS kinase, but neither it nor any nearby hydroxy amino acid serves as an obligatory phophoryl acceptor in the 3'-phosphoadenylylsulfate synthesis reaction. The results also indicate that the absence of a serine at position 478 in the APS kinase-like C-terminal region of fungal ATP sulfurylase does not account for the lack of APS kinase activity in that enzyme. However, mutating the ATP P-loop residues in APS kinase to those found in the analogous C-terminal region of fungal ATP sulfurylase eliminated enzyme activity.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Segel, IH (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA.			Rose, Alan/0000-0003-0765-8887				Biondi RM, 1996, ANAL BIOCHEM, V242, P165, DOI 10.1006/abio.1996.0449; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; HOMMES FA, 1987, BIOCHIM BIOPHYS ACTA, V924, P270, DOI 10.1016/0304-4165(87)90022-5; JENDER HG, 1984, ARCH MICROBIOL, V138, P9, DOI 10.1007/BF00425399; KANNO N, 1990, BOT MAR, V33, P369, DOI 10.1515/botm.1990.33.4.369; LYLE S, 1994, BIOCHEMISTRY-US, V33, P5920, DOI 10.1021/bi00185a032; LYLE S, 1994, BIOCHEM J, V301, P355, DOI 10.1042/bj3010355; MacRae I, 1997, ARCH BIOCHEM BIOPHYS, V337, P17, DOI 10.1006/abbi.1996.9751; Maniatis T, 1982, MOL CLONING LABORATO, P68; Onda M, 1996, BIOSCI BIOTECH BIOCH, V60, P134, DOI 10.1271/bbb.60.134; RENOSTO F, 1985, J BIOL CHEM, V260, P1535; RENOSTO F, 1985, J BACTERIOL, V164, P674, DOI 10.1128/JB.164.2.674-683.1985; RENOSTO F, 1990, J BIOL CHEM, V265, P10300; RENOSTO F, 1984, J BIOL CHEM, V259, P2113; RENOSTO F, 1991, ARCH BIOCHEM BIOPHYS, V284, P30, DOI 10.1016/0003-9861(91)90258-K; RENOSTO F, 1985, J BIOL CHEM, V260, P1903; ROBBINS PW, 1958, J BIOL CHEM, V233, P681; ROSENTHAL E, 1995, GENE, V165, P243, DOI 10.1016/0378-1119(95)00450-K; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SATISHCHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P11684, DOI 10.1021/bi00162a003; SATISHCHANDRAN C, 1989, J BIOL CHEM, V264, P15012; SATISHCHANDRAN C, 1990, FASEB J, V4, pA2119; Segel I.H, 1993, ENZYME KINETICS; SEGEL IH, 1987, METHOD ENZYMOL, V143, P334; SEGEL IH, 1976, BIOCH CALCULATIONS, P334; VIEILLE C, 1990, MOL PLANT MICROBE IN, V3, P389, DOI 10.1094/MPMI-3-389; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	29	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28583	28589		10.1074/jbc.273.44.28583	http://dx.doi.org/10.1074/jbc.273.44.28583			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786849	hybrid			2022-12-25	WOS:000076691800010
J	Tang, D; Kidd, VJ				Tang, D; Kidd, VJ			Cleavage of DFF-45/ICAD by multiple caspases is essential for its function during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; DNA FRAGMENTATION; MICE DEFICIENT; CELL-DEATH; PROTEASE; DOMAIN; ENZYME	Apoptosis involves the proteolysis of specific cellular proteins by a group of cysteine proteases known as caspases. Many of these cellular targets are either functionally inactivated (e.g. poly(ADP-ribose) polymerase) or activated (e.g, other caspases, gelsolin) by such processing, thereby facilitating the cell death process. Caspase 3 is involved in the processing of many of these proteins. Recently, however, it was reported that caspase 3 is dispensable for the cleavage of a large number of cellular caspase substrates during apoptosis. Among these substrates is DFB-45/ICAD, a subunit of the heterodimeric DNA fragmentation factor (DFF), otherwise known as caspase-activated DNase (CAD), that mediates genomic DNA degradation during apoptosis. Conversely, others have reported that caspase 3 is essential for the cleavage and activation of DFF-45/ICAD. To resolve this controversy we examined DFF-45/ICAD processing during apoptosis in MCF-7 breast carcinoma cells that lack functional caspase 3 and in MCF-7 cells expressing caspase 3. We found that DFF-45/ICAD is cleaved by two distinct caspases, one of which is caspase 3. Furthermore, cleavage of the carboxyl-terminal region of DFF-45/ICAD, which is necessary for activation of the enzyme, requires functional caspase 3. In the absence of caspase 3 cleavage of the amino-terminal region of DFF-45/ICAD by another caspase occurs, but the DFF-45 enzyme remains inactive.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA	St Jude Children's Research Hospital	Kidd, VJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38101 USA.		Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 44088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDUS T, 1987, EUR J IMMUNOL, V17, P1193, DOI 10.1002/eji.1830170817; BELLAMY COC, 1995, CANC BIOL, V6, P3; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1996, CURR BIOL, V6, P55; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Tang DM, 1998, J BIOL CHEM, V273, P16601, DOI 10.1074/jbc.273.26.16601; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; YUAN JY, 1995, CURR OPIN CELL BIOL, V7, P211, DOI 10.1016/0955-0674(95)80030-1	30	148	153	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28549	28552		10.1074/jbc.273.44.28549	http://dx.doi.org/10.1074/jbc.273.44.28549			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786842	hybrid			2022-12-25	WOS:000076691800003
J	Twigg, SM; Kiefer, MC; Zapf, J; Baxter, RC				Twigg, SM; Kiefer, MC; Zapf, J; Baxter, RC			Insulin-like growth factor-binding protein 5 complexes with the acid-labile subunit - Role of the carboxyl-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMED HUMAN FIBROBLASTS; ADULT HUMAN SERUM; MOLECULAR-CLONING; FACTOR IGF; HEPARIN-BINDING; SOMATOMEDIN-C; FACTOR-I; AFFINITY; PURIFICATION; IDENTIFICATION	We have recently shown that insulin-like growth factor (IGF)-binding protein 5 forms ternary complexes with IGF-I or IGF-II and the acid-labile subunit (ALS) (Twigg, S, M., and Baxter, R. C. (1998) J. Biol. Chem. 273, 6074-6079). Because IGF-binding protein 3 (IGFBP-3) binds to ALS through its basic carboxyl-terminal domain, we tested whether a homologous region present in IGFBP-5 is involved in IGFBP-5 binding to ALS. Chimeric peptides were generated by carboxyl-terminal domain interchange between recombinant human IGFBP-5 and IGFBP-6, producing two IGFBP peptides designated 5-5-6 and 6-6-5, Determined by immunoprecipitation and by Superose chromatography, 6-6-5 formed ternary complexes, albeit less potently than IGFBP-5, In contrast, 5-5-6, like IGFBP-6, did not form ternary complexes by these methods, Whereas 6-6-5, like IGFBP-6, had a marked preference for binary complex formation with IGF-II rather than IGF-I, it formed ternary complexes more efficiently with IGF-I, like IGFBP-5. The glycosaminoglycans heparin and heparan sulfate bind to IGFBP-5 through its basic carboxyl-terminal domain. At high concentrations, these glycosaminoglycans inhibited ALS binding to binary complexed IGFBP-5, In addition, in the absence of IGFs, IGFBP-5, a synthetic peptide representing the basic carboxyl-terminal sequence IGFBP-5(201-218), and the corresponding IGFBP-3 basic sequence IGFBP-3(215-232), competed weakly for ALS binding to covalent IGF-IGFBP-5 complex, as did a random-sequence synthetic peptide with the same composition as IGFBP-5(201-218). These findings are consistent with the basic carboxyl-terminal domain on IGFBP-5 being the principal site in IGFBP-5 that binds to ALS.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia; Chiron Corp, Emeryville, CA 94608 USA; Univ Zurich Hosp, Div Endocrinol & Metab, CH-8091 Zurich, Switzerland	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; Novartis; University of Zurich; University Zurich Hospital	Baxter, RC (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	robaxter@med.usyd.edu.au	Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142				Abrass CK, 1997, AM J PHYSIOL-RENAL, V273, pF899, DOI 10.1152/ajprenal.1997.273.6.F899; ARAI T, 1994, J BIOL CHEM, V269, P20388; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; BAXTER RC, 1988, J CLIN ENDOCR METAB, V67, P265, DOI 10.1210/jcem-67-2-265; BAXTER RC, 1990, BIOCHEM J, V271, P773, DOI 10.1042/bj2710773; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1992, J BIOL CHEM, V267, P60; BINOUX M, 1988, J CLIN ENDOCR METAB, V67, P509, DOI 10.1210/jcem-67-3-509; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; BUSBY WH, 1989, ENDOCRINOLOGY, V125, P773, DOI 10.1210/endo-125-2-773; Campbell PG, 1997, AM J PHYSIOL-ENDOC M, V273, pE1005, DOI 10.1152/ajpendo.1997.273.5.E1005; CAMPBELL PG, 1997, AM J PHYSIOL, V273, pF996; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CLEMMONS DR, 1983, J CLIN ENDOCR METAB, V56, P384, DOI 10.1210/jcem-56-2-384; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; FURLANETTO RW, 1980, J CLIN ENDOCR METAB, V51, P12, DOI 10.1210/jcem-51-1-12; Hashimoto R, 1997, J BIOL CHEM, V272, P27936, DOI 10.1074/jbc.272.44.27936; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; HODGKINSON SC, 1994, J MOL ENDOCRINOL, V13, P105, DOI 10.1677/jme.0.0130105; JONES JI, 1996, ENDOCR REV, V16, P3; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; LEE CY, 1995, ENDOCRINOLOGY, V136, P668, DOI 10.1210/en.136.2.668; LeRoith D, 1997, NEW ENGL J MED, V336, P633, DOI 10.1056/NEJM199702273360907; LEWITT MS, 1994, ENDOCRINOLOGY, V134, P2404, DOI 10.1210/en.134.6.2404; MARTIN JL, 1994, J BIOL CHEM, V269, P11470; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; Nam TJ, 1997, ENDOCRINOLOGY, V138, P2972, DOI 10.1210/en.138.7.2972; NICOLAS V, 1995, CALCIFIED TISSUE INT, V57, P206, DOI 10.1007/BF00310260; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; RECHLER MM, 1992, GROWTH REGULAT, V2, P55; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; Twigg SM, 1998, J BIOL CHEM, V273, P6074, DOI 10.1074/jbc.273.11.6074; WINZOR DJ, 1992, J CHROMATOGR, V597, P67, DOI 10.1016/0021-9673(92)80097-E; ZAPF J, 1990, J BIOL CHEM, V265, P14892	42	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28791	28798		10.1074/jbc.273.44.28791	http://dx.doi.org/10.1074/jbc.273.44.28791			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786878	hybrid			2022-12-25	WOS:000076691800039
J	Zaina, S; Squire, S				Zaina, S; Squire, S			The soluble type 2 insulin-like growth factor (IGF-II) receptor reduces organ size by IGF-II-mediated and IGF-II-independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; PERINATAL LETHALITY; SERUM; MICE; GENE; BINDING; ACID; DNA	The soluble type 2 insulin-like growth factor (IGF) receptor or IGF-II/mannose B-phosphate receptor (sIGF2R) is produced in vivo by proteolytic deletion of the transmembrane and intracellular domains of the cellular form of the receptor (IGF2R). There is evidence that sIGF2R is a negative regulator of growth. We have shown that transgenic mice expressing an Igf2r cDNA with a deleted transmembrane domain sequence (s Delta Igf2r) show reduced local organ size. In the present study, we investigate whether s Delta IGF2R can slow the growth induced by an excess of IGF-II and whether the biological activity of s Delta IGF2R is due solely to its interactions with IGF-II. To this end, we crossed s Delta Igf2r transgenics by mice overexpressing IGF-II (Blast line) or by mice carrying a disrupted paternal (active) allele of the Igf2 gene (Igf2(m+/p-)). Analysis of the phenotypes revealed that the soluble IGF2R affects the size of some organs (colon and cecum) exclusively by reducing the biological activity of IGF-II, whereas in other organs (stomach and skin) the biological activity of the receptor is at least in part independent of IGF-II and must involve an interaction with other factor(s).	Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Zaina, S (corresponding author), Univ Lund, Malmo Gen Hosp, Wallenberg Lab, 1st Floor, S-20502 Malmo, Sweden.		Zaina, Silvio/C-5255-2017	Zaina, Silvio/0000-0001-6589-076X				CAUSIN C, 1988, BIOCHEM J, V252, P795, DOI 10.1042/bj2520795; DACOSTA THM, 1994, J ENDOCRINOL, V143, P433, DOI 10.1677/joe.0.1430433; Dahms NM, 1996, BIOCHEM SOC T, V24, P136, DOI 10.1042/bst0240136; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Folkman J, 1998, ENDOCRINOLOGY, V139, P441, DOI 10.1210/en.139.2.441; Franck-Lissbrant I, 1998, ENDOCRINOLOGY, V139, P451, DOI 10.1210/en.139.2.451; Gemmell NJ, 1996, TRENDS GENET, V12, P338, DOI 10.1016/S0168-9525(96)80005-9; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; KIESS W, 1987, P NATL ACAD SCI USA, V84, P7720, DOI 10.1073/pnas.84.21.7720; KIESS W, 1989, J BIOL CHEM, V264, P4710; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; OKA Y, 1985, J BIOL CHEM, V260, P9435; Ouyang H, 1997, CANCER RES, V57, P1851; Scott CD, 1996, ENDOCRINOLOGY, V137, P873, DOI 10.1210/en.137.3.873; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; VALENZANO KJ, 1995, J BIOL CHEM, V270, P16441, DOI 10.1074/jbc.270.27.16441; Volpert O, 1996, ENDOCRINOLOGY, V137, P3871, DOI 10.1210/en.137.9.3871; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WARD A, 1994, P NATL ACAD SCI USA, V91, P10365, DOI 10.1073/pnas.91.22.10365; Xu Y, 1998, J CLIN ENDOCR METAB, V83, P437, DOI 10.1210/jc.83.2.437; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351; ZAINA S, 1998, IN PRESS ENDOCRINOLO	31	51	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28610	28616		10.1074/jbc.273.44.28610	http://dx.doi.org/10.1074/jbc.273.44.28610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786853	hybrid			2022-12-25	WOS:000076691800014
J	Zeng, YY; Tang, CM; Yao, YL; Yang, WM; Seto, E				Zeng, YY; Tang, CM; Yao, YL; Yang, WM; Seto, E			Cloning and characterization of the mouse histone deacetylase-2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; FACTOR-INDUCIBLE GENE; BINDING PROTEIN; N-COR; REPRESSION; PROMOTER; COMPLEX; YEAST; MAX; MYC	Histone deacetylase-2 (HDAC2) is a component of a complex that mediates transcriptional repression in mammalian cells. A mouse HDAC2 cDNA was used to identify several recombinant clones containing the entire mouse HDAC2 gene. The mouse HDAC2 gene spans over 36 kilobase pairs and is composed of 14 exons (ranging from 58 to 362 nucleotides in length) and 13 introns (ranging from 75 base pairs to 19 kilobase pairs in length). Primer extension analysis with total RNA from NIH3T3 cells revealed a major transcriptional start site at 221 base pairs 5' of the ATG translational start codon. Upstream of the transcriptional start site, no canonical TATA box was found, but binding sites for several known transcription factors were identified. Transient transfection studies with 5' deletion mutants localized the promoter to no more than 76 base pairs upstream from the major transcriptional start site. Fluorescence in situ hybridization mapped mouse HDAC2 to chromosomal location 10B1, which is in close proximity to the growth factor-inducible gene fisp-12. Information concerning the genomic organization and promoter of HDAC2 will be useful in studies of the regulation of histone deacetylase activities, which in turn are important in studies of the regulation of transcriptional repression in mammalian cells.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Coll Med,Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Seto, E (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Coll Med,Dept Med Microbiol & Immunol, 12902 Magnolia Dr, Tampa, FL 33612 USA.			Yang, Wen-Ming/0000-0002-5871-5979				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; BEECHEY CV, 1994, MOUSE GENOME, V92, P336; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOYER TG, 1990, J BIOL CHEM, V265, P20524; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; CATTANACH BM, 1995, MOUSE GENOME, V93, P853; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1477; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; FARNHAM P, 1996, MOL CELL BIOL, V6, P2392; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGOLIA DE, 1986, MOL CELL BIOL, V6, P4458, DOI 10.1128/MCB.6.12.4458; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; LUQUE T, 1994, EUR J BIOCHEM, V225, P985, DOI 10.1111/j.1432-1033.1994.0985b.x; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; LUZI P, 1995, GENOMICS, V26, P407, DOI 10.1016/0888-7543(95)80230-J; MAGNAGHIJAULIN, 1998, NATURE, V391, P601; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PARKS CL, 1988, J VIROL, V62, P54, DOI 10.1128/JVI.62.1.54-67.1988; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STENLUND A, 1987, SCIENCE, V236, P1666, DOI 10.1126/science.3037693; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TEASE C, 1992, MOUSE GENOME, V90, P671; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WALTER MH, 1994, EUR J BIOCHEM, V224, P999, DOI 10.1111/j.1432-1033.1994.t01-1-00999.x; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; [No title captured]	70	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28921	28930		10.1074/jbc.273.44.28921	http://dx.doi.org/10.1074/jbc.273.44.28921			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786895	hybrid			2022-12-25	WOS:000076691800056
J	Lee, LF; Li, GX; Templeton, DJ; Ting, JPY				Lee, LF; Li, GX; Templeton, DJ; Ting, JPY			Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-jun NH2-terminal kinase (JNK/SAPK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; SIGNAL-TRANSDUCTION PATHWAY; PROTEIN-KINASE; INDUCED APOPTOSIS; MAMMALIAN-CELLS; HUMAN OVARIAN; TRANSCRIPTIONAL ACTIVATION; ANTINEOPLASTIC AGENT; MURINE MACROPHAGES	Paclitaxel (Taxol) is a novel anti-cancer drug that has shown efficacy toward several malignant tumors, particularly ovarian tumors. We reported previously that paclitaxel can induce interleukin IL-8 promoter activation in subgroups of ovarian cancer through the activation of both AP-1 and nuclear factor kappa B. Further analysis of paclitaxel analogs indicates that the degree of IL-8 induction by analysis correlates with the extent of cell death; however, IL-8 itself is not the cause of cell death. This suggests that pathways that lead to IL-8 and cell death may overlap, although IL-8 per se does not kill tumor cells. To decipher the upstream signals for paclitaxel-induced transcriptional activation and cell death, we studied the involvement of protein kinases that lead to the activation of AP-1, specifically the c-Jun NH2-terminal kinase (JNK1), p38, and the extracellular signal-regulated kinase 1 (ERK1). The role of I kappa B in paclitaxel-induced cell death was also analyzed. Paclitaxel activated JNK, and to a lesser degree p38, but not ERK1. Paclitaxel-induced IL-8 promoter activation was inhibited by dominant-inhibitory mutants of JNK p38, and the super-repressor form of I kappa B alpha, but not by dominant-inhibitory forms of ERK1. Dominant-inhibitory mutants of JNK1 also greatly reduced paclitaxel-induced cell death, and the kinetics of JNK induction was closely followed by DNA fragmentation. These results indicate (i) that paclitaxel activates the JNK signaling pathway and (ii) that JNK activation is a common point of paclitaxel-induced gene induction and cell death.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Case Western Reserve University	Ting, JPY (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	panyun@med.unc.edu	Templeton, Dennis J/F-7695-2011		NIAID NIH HHS [AI41751] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041751] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN JN, 1993, J LAB CLIN MED, V122, P374; Amato SF, 1998, CANCER RES, V58, P241; ANTWERP DJV, 1996, SCIENCE, V274, P787; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Belotti D, 1996, CLIN CANCER RES, V2, P1725; BOGDAN C, 1992, J LEUKOCYTE BIOL, V52, P119, DOI 10.1002/jlb.52.1.119; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ETTINGER DS, 1993, J NATL CANC I MONOGR, V15, P177; FORASTIERE AA, 1993, SEMIN ONCOL, V20, P56; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; HUIZING MT, 1995, CANCER INVEST, V13, P381, DOI 10.3109/07357909509031919; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ITOHLINDSTROM Y, 1995, MOL CELL BIOL, V15, P282, DOI 10.1128/MCB.15.1.282; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAYE SB, 1995, SEMIN ONCOL, V22, P30; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; Lee LF, 1996, CANCER RES, V56, P1303; Li YS, 1996, MOL CELL BIOL, V16, P5947; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANTHEY CL, 1994, J IMMUNOL, V152, P825; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; MANTHEY CL, 1993, J EXP MED, V178, P695, DOI 10.1084/jem.178.2.695; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAMAKRISHNAN S, 1989, J CLIN INVEST, V83, P921, DOI 10.1172/JCI113977; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TERUI Y, 1995, J CELL PHYSIOL, V164, P74, DOI 10.1002/jcp.1041640110; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Watson JM, 1998, CANCER CHEMOTH PHARM, V41, P391, DOI 10.1007/s002800050756; Westerlund A, 1997, CLIN EXP METASTAS, V15, P318, DOI 10.1023/A:1018481617275; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; White CM, 1998, CANCER IMMUNOL IMMUN, V46, P104, DOI 10.1007/s002620050468; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WINSTON BW, 1995, J BIOL CHEM, V270, P27391, DOI 10.1074/jbc.270.46.27391; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yu R, 1996, CANCER RES, V56, P2954; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	72	188	194	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28253	28260		10.1074/jbc.273.43.28253	http://dx.doi.org/10.1074/jbc.273.43.28253			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774447	Green Published, hybrid			2022-12-25	WOS:000076549800067
J	Lee, SF; Mahasneh, A; de la Roche, M; Cote, GP				Lee, SF; Mahasneh, A; de la Roche, M; Cote, GP			Regulation of the p21-activated kinase-related Dictyostelium myosin I heavy chain kinase by autophosphorylation, acidic phospholipids, and Ca2+-calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; CATALYTIC DOMAIN; PHOSPHORYLATION; BINDING; ACTIN; ACTIVATION; YEAST; PAK	The Dictyostelium myosin I heavy chain kinase (MIHCK) is a member of the p21-activated kinase family (Lee, S.-F., Egelhoff, T. T,, Mahasneh, A., and Cote, G. P. (1996) J. Biol. Chem. 271, 27044-27048). MIHCK incubated with MgATP in the absence of effecters incorporates 1 mol of phosphate/mol, resulting in an similar to 40-fold increase in kinase activity, Sequence analysis of tryptic peptides has identified the major site of phosphorylation as Ser-8, A peptide and a glutathione S-transferase fusion protein containing the Ser-8 phosphorylation site were good substrates for MIHCK, indicating that MIHCK can catalyze its own activation. Guanosine 5'-3-O-(thio)triphosphate (GTP gamma S)-Rac1 stimulates MIHCK autophosphorylation and kinase activity 10-fold, Phosphatidylserine, phosphatidylinositol, and phosphatidylinositol 4,5-bisphosphate, but not phosphatidylcholine or sphingosine, were as effective as GTP gamma S-Rac1 in enhancing MIHCK autophosphorylation and activity. Acidic lipids and GTP gamma S-Rac1 induced the autophosphorylation of a similar set of sites as judged by two-dimensional tryptic peptide maps. It is proposed that GTP-Rac and acidic phospholipids function cooperatively to associate MIHCK with membranes. Ca2+-calmodulin bound MIHCK and inhibited activation by acidic phospholipids but not by GTP gamma S-Rac1. These studies reveal a number of similarities between the regulatory properties of the Dictyostelium and Acanthamoeba MIHCK, suggesting that the signaling pathways that control myosin I are conserved.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Cote, GP (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.		Mahasneh, Amjad/AAA-1732-2022	Mahasneh, Amjad/0000-0002-4931-8699				Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; BRZESKA H, 1992, J BIOL CHEM, V267, P23870; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; BRZESKA H, 1992, J BIOL CHEM, V267, P4949; Coluccio LM, 1997, AM J PHYSIOL-CELL PH, V273, pC347, DOI 10.1152/ajpcell.1997.273.2.C347; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KIM JY, 1994, J BIOL CHEM, V269, P28214; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; LEE SF, 1993, J BIOL CHEM, V268, P20923; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; LINDE S, 1990, J CHROMATOGR-BIOMED, V530, P29, DOI 10.1016/S0378-4347(00)82299-9; MANSER E, 1995, METHOD ENZYMOL, V256, P130; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; Szczepanowska J, 1997, P NATL ACAD SCI USA, V94, P8503, DOI 10.1073/pnas.94.16.8503; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Wu C, 1997, J BIOL CHEM, V272, P30623, DOI 10.1074/jbc.272.49.30623; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	47	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27911	27917		10.1074/jbc.273.43.27911	http://dx.doi.org/10.1074/jbc.273.43.27911			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774403	hybrid			2022-12-25	WOS:000076549800023
J	McFall, AJ; Rapraeger, AC				McFall, AJ; Rapraeger, AC			Characterization of the high affinity cell-binding domain in the cell surface proteoglycan syndecan-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; PROTEIN-KINASE-C; MOLECULAR-CLONING; N-SYNDECAN; ADHESION; EXPRESSION; FAMILY	The syndecan family of cell surface proteoglycans regulates cell adhesion via their glycosaminoglycan chains and discrete domains of their core proteins. Core protein domains that are variable between syndecan family members may regulate syndecan-specific associations, thereby endowing individual syndecans with unique functions. A syndecan-4-specific domain has been identified in the extracellular syndecan-4 protein. This region mediates cell adhesion when provided as an artificial substratum and is localized within amino acids 56-109 of the recombinant extracellular protein domain of mouse syndecan-4 (mS4ED) (McFall, A. J., and Rapraeger, A. C. (1997) J, Biol, Chem, 272, 12901-12904), To characterize its interaction with the cell surface, radiolabeled ligand binding studies were performed. A single high affinity interaction, with a dissociation constant of 2 x 10(-9) M, was observed between mS4ED and both human and mouse cells. Both chicken S4ED and mS4ED compete for this interaction, although they are only 34% identical within the cell-binding domain sequence. The extracellular protein domains of syndecan-1, -2, and -3, however, fail to compete. The interaction is also observed with native syndecan-4 shed from cell surfaces. Interestingly, the extracellular protein domain of syndecan-1 also mediates cell adhesion, suggesting a similar but discrete interaction for this family member.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Rapraeger, AC (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave, Madison, WI 53706 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021881, R23HD021881] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21881] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMAGAI M, 1995, J INVEST DERMATOL, V104, P146, DOI 10.1111/1523-1747.ep12613668; ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Carey DJ, 1997, J BIOL CHEM, V272, P2873, DOI 10.1074/jbc.272.5.2873; Carey DJ, 1997, BIOCHEM J, V327, P1; Cheresh D.A., 1993, ADV MOL CELL BIOL, V6, P225; Couchman JR, 1996, J CELL BIOCHEM, V61, P578, DOI 10.1002/(SICI)1097-4644(19960616)61:4<578::AID-JCB11>3.0.CO;2-C; DARNELL J, 1990, MOL CELL BIOL TRANSP; DAVID G, 1993, DEVELOPMENT, V119, P841; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Harlow E., 1988, ANTIBODIES LAB MANUA; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; Maurer P, 1996, CURR OPIN CELL BIOL, V8, P609, DOI 10.1016/S0955-0674(96)80101-3; McFall AJ, 1997, J BIOL CHEM, V272, P12901, DOI 10.1074/jbc.272.20.12901; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; SAITO K, 1994, DYNAMICS TRACE ELEME, V31; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; STANLEY MJ, 1995, J BIOL CHEM, V270, P5077, DOI 10.1074/jbc.270.10.5077; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713	25	55	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28270	28276		10.1074/jbc.273.43.28270	http://dx.doi.org/10.1074/jbc.273.43.28270			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774449	hybrid			2022-12-25	WOS:000076549800069
J	Archambault, J; Pan, GH; Dahmus, GK; Cartier, M; Marshall, N; Zhang, S; Dahmus, ME; Greenblatt, J				Archambault, J; Pan, GH; Dahmus, GK; Cartier, M; Marshall, N; Zhang, S; Dahmus, ME; Greenblatt, J			FCP1, the RAP74-interacting subunit of a human protein phosphatase that dephosphorylates the carboxyl-terminal domain of RNA polymerase IIO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION PREINITIATION COMPLEX; ESCHERICHIA-COLI SIGMA-70; MAJOR LATE PROMOTER; ACTIVATION DOMAINS; INITIATION; ELONGATION; HOLOENZYME; PHOSPHORYLATION; BINDING; PURIFICATION	TFIIF (RAP30/74) is a general initiation factor that also increases the rate of elongation by RNA polymerase II. A two-hybrid screen for RAP74 interacting proteins produced cDNAs encoding FCP1a, a novel, ubiquitously expressed human protein that interacts with the carboxyl-terminal evolutionarily conserved domain of RAP74. Related cDNAs encoding FCP1b lack a carboxyl-terminal RAP74-binding domain of FCP1a, FCP1 is an essential subunit of a RAP74-stimulated phosphatase that processively dephosphorylates the carboxyl-terminal domain of the largest RNA polymerase II subunit, FCP1 is also a stoichiometric component of a human RNA polymerase II holoenzyme complex.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada; Hosp Sick Children, Res Inst, Dept Genet, Toronto, ON M5G 1X8, Canada; Univ Calif Davis, Div Biol Sci, Sect Mol & Cellular Biol, Livermore, CA 95616 USA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of California System; University of California Davis	Greenblatt, J (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.			Archambault, Jacques/0000-0001-8107-3428	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33300] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Blau J, 1996, MOL CELL BIOL, V16, P2044; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KANG ME, 1993, J BIOL CHEM, V268, P25033; KANG ME, 1995, J BIOL CHEM, V270, P23390, DOI 10.1074/jbc.270.40.23390; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KIM WY, 1988, J BIOL CHEM, V263, P18880; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MARUYAMA IN, 1995, NUCLEIC ACIDS RES, V23, P3796, DOI 10.1093/nar/23.18.3796; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; SCHEISTL RH, 1989, CURR GENET, V16, P339; Sherman F, 1986, LAB COURSE MANUAL ME; SOPTA M, 1985, J BIOL CHEM, V260, P353; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; TAN SY, 1994, J BIOL CHEM, V269, P25684; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YONAHA M, 1993, NUCLEIC ACIDS RES, V21, P273, DOI 10.1093/nar/21.2.273; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	58	128	131	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27593	27601		10.1074/jbc.273.42.27593	http://dx.doi.org/10.1074/jbc.273.42.27593			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765293	hybrid			2022-12-25	WOS:000076448000080
J	DeMott, MS; Zigman, S; Bambara, RA				DeMott, MS; Zigman, S; Bambara, RA			Replication protein A stimulates long patch DNA base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-TERMINAL DEOXYRIBOSE PHOSPHATE; POLYMERASE-BETA; ESCHERICHIA-COLI; DAMAGED DNA; PURIFIED PROTEINS; REQUIREMENT; RESIDUES; CELLS; RECONSTITUTION; EXPRESSION	Two pathways for completion of DNA base excision repair (BER) have recently emerged. In one, called short patch BER, only the damaged nucleotide is replaced, whereas in the second, known as long patch BER, the monobasic lesion is removed along with additional downstream nucleotides. Flap endonuclease 1, which preferentially cleaves unannealed 5'-flap structures in DNA, has been shown to play a crucial role in the long patch mode of repair. This nuclease will efficiently release 5'-terminal abasic lesions as part of an intact oligonucleotide when cleavage is combined with strand displacement synthesis, Further gap filling and ligation complete repair. We reconstituted the final steps of long patch base excision repair in vitro using calf DNA polymerase epsilon to provide strand displacement synthesis, human flap endonuclease 1, and human DNA ligase I. Replication protein A is an important constituent of the DNA replication machinery. It also has been shown to interact with an early component of base excision repair: uracil glycosylase. Here we show that human replication protein A greatly stimulates long patch base excision repair.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Ophthalmol, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NEI NIH HHS [EY00459] Funding Source: Medline; NIGMS NIH HHS [GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Biswas EE, 1997, BIOCHEMISTRY-US, V36, P5955, DOI 10.1021/bi962890u; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GEORGAKI A, 1993, NUCLEIC ACIDS RES, V21, P3659, DOI 10.1093/nar/21.16.3659; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Krokan HE, 1997, BIOCHEM J, V325, P1; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Nakamura J, 1998, CANCER RES, V58, P222; Nealon K, 1996, NUCLEIC ACIDS RES, V24, P3763, DOI 10.1093/nar/24.19.3763; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; Sandigursky M, 1998, NUCLEIC ACIDS RES, V26, P1282, DOI 10.1093/nar/26.5.1282; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; TERAOKA H, 1993, J BIOL CHEM, V268, P24156; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; Umezu K, 1998, GENETICS, V148, P989; Wang ZG, 1997, J BIOL CHEM, V272, P24064, DOI 10.1074/jbc.272.38.24064; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	35	79	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27492	27498		10.1074/jbc.273.42.27492	http://dx.doi.org/10.1074/jbc.273.42.27492			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765279	hybrid			2022-12-25	WOS:000076448000066
J	Ghosh, JK; Peisajovich, SG; Ovadia, M; Shai, Y				Ghosh, JK; Peisajovich, SG; Ovadia, M; Shai, Y			Structure-function study of a heptad repeat positioned near the transmembrane domain of Sendai virus fusion protein which blocks virus-cell fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENTLY LABELED ANALOGS; BIOLOGICALLY-ACTIVE PEPTIDES; LEUCINE-ZIPPER STRUCTURE; PHOSPHOLIPID-MEMBRANES; PARAMYXOVIRUS FUSION; INFLUENZA-VIRUS; ENVELOPE GLYCOPROTEIN; MUTATIONAL ANALYSIS; SYNTHETIC PEPTIDES; POTENT INHIBITORS	A synthetic heptad repeat, SV-473, derived from Sendal virus fusion protein is a potent inhibitor of virus-cell fusion. In order to understand the mechanism of the inhibitory effect, we synthesized and fluorescently labeled SV-465, an extended version of SV-473 by one more heptad, its mutant peptide A(17,24)-SV-465, in which two heptadic leucines were substituted with two alanines, and its enatiomer D-SV-465, composed entirely of D-amino acids. Similar mutations in the homologous fusion protein of the Newcastle disease virus drastically reduced its activity. The data revealed that SV-465, but not A(17,24)-SV-465 or. its enantiomer, is highly active in inhibiting Sendai virus-induced hemolysis of red blood cells. None of the peptides interfere with the binding of virions to the target red blood cells as demonstrated by hemagglutinin assay. Fluorescence and circular dichroism (CD) spectroscopy indicated that: (i) only SV-465 could self-assemble in aqueous environment; (ii) only SV-465 could co-assemble with two other biologically active heptad repeats derived from Sendai virus fusion protein; (iii) SV-465 has a higher helical content than A(17,24)-SV-465 in solution, and (iv) all the peptides bind strongly to zwitterionic and negatively charged phospholipids. Polarized attenuated total reflection infrared spectroscopy revealed that they bound as monomers onto the surface of zwitterionic membranes with predominantly alpha-helical structures. The functional role of the amino acid 465-497 domain in Sendai virus-mediated membrane fusion is discussed in light of these findings.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Zool, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bmshai@weizmann.weizmann.ac.il	Peisajovich, Sergio/C-6641-2011					BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERNSTEIN HB, 1995, J VIROL, V69, P2745, DOI 10.1128/JVI.69.5.2745-2750.1995; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; BUCKLAND R, 1992, J GEN VIROL, V73, P1703, DOI 10.1099/0022-1317-73-7-1703; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAMBERS P, 1992, J GEN VIROL, V73, P1717, DOI 10.1099/0022-1317-73-7-1717; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; Fringeli U P, 1981, Mol Biol Biochem Biophys, V31, P270; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; Furuta RA, 1998, NAT STRUCT BIOL, V5, P612, DOI 10.1038/871; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P12363, DOI 10.1021/bi00097a013; Gazit E, 1996, J MOL BIOL, V258, P860, DOI 10.1006/jmbi.1996.0293; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; Ghosh JK, 1998, J BIOL CHEM, V273, P7252, DOI 10.1074/jbc.273.13.7252; Ghosh JK, 1997, BIOCHEMISTRY-US, V36, P15451, DOI 10.1021/bi971152i; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARRICK NJ, 1967, INT REFLECTION SPECT; HOMMA M, 1973, J VIROL, V12, P1457, DOI 10.1128/JVI.12.6.1457-1465.1973; HORVATH CM, 1992, J VIROL, V66, P2443, DOI 10.1128/JVI.66.4.2443-2455.1992; ISHIGURO R, 1993, BIOCHEMISTRY-US, V32, P9792, DOI 10.1021/bi00088a034; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; KENNEDY DW, 1983, J CELL PHYSIOL, V114, P257, DOI 10.1002/jcp.1041140302; KENNER RA, 1971, BIOCHEMISTRY-US, V10, P4433, DOI 10.1021/bi00800a013; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; LAMB RA, 1993, VIROLOGY, V197, P1, DOI 10.1006/viro.1993.1561; Lambert DM, 1996, P NATL ACAD SCI USA, V93, P2186, DOI 10.1073/pnas.93.5.2186; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LOYTER A, 1982, CELL SURF REV, V8, P215; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; MARTIN I, 1991, BIOCHEM BIOPH RES CO, V175, P872, DOI 10.1016/0006-291X(91)91646-T; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; MURATA M, 1987, J BIOCHEM-TOKYO, V102, P957, DOI 10.1093/oxfordjournals.jbchem.a122137; NUSSBAUM O, 1984, VIROLOGY, V138, P185, DOI 10.1016/0042-6822(84)90344-1; PERETZ H, 1974, J CELL BIOL, V63, P1, DOI 10.1083/jcb.63.1.1; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; RAPAPORT D, 1994, J BIOL CHEM, V269, P15124; RAPAPORT D, 1995, EMBO J, V14, P5524, DOI 10.1002/j.1460-2075.1995.tb00239.x; REITTER JN, 1995, J VIROL, V69, P5995, DOI 10.1128/JVI.69.10.5995-6004.1995; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; ROTHSCHILD KJ, 1979, SCIENCE, V204, P311, DOI 10.1126/science.432645; ROTT R, 1977, CELL SURF REV, P47; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; SCHEID A, 1977, VIROLOGY, V80, P54, DOI 10.1016/0042-6822(77)90380-4; SCHEID A, 1972, VIROLOGY, V50, P640, DOI 10.1016/0042-6822(72)90418-7; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SHAI Y, 1991, J BIOL CHEM, V266, P22346; SHIMIZU YK, 1976, VIROLOGY, V71, P48, DOI 10.1016/0042-6822(76)90093-3; SLEPUSHKIN VA, 1990, BIOCHEM BIOPH RES CO, V172, P952, DOI 10.1016/0006-291X(90)90768-I; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375; VANINI S, 1993, AIDS, V7, P167, DOI 10.1097/00002030-199302000-00003; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P75; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; YAMADA KM, 1975, P NATL ACAD SCI USA, V72, P3158, DOI 10.1073/pnas.72.8.3158; YANG PW, 1987, BIOCHEM BIOPH RES CO, V145, P298, DOI 10.1016/0006-291X(87)91320-9; YEAGLE PL, 1993, FUSION SENDAI VIRUS; Young JK, 1998, VIROLOGY, V243, P21, DOI 10.1006/viro.1998.9044	81	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27182	27190		10.1074/jbc.273.42.27182	http://dx.doi.org/10.1074/jbc.273.42.27182			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765238	hybrid			2022-12-25	WOS:000076448000025
J	Hu, Y; Fisette, PL; Denlinger, LC; Guadarrama, AG; Sommer, JA; Proctor, RA; Bertics, PJ				Hu, Y; Fisette, PL; Denlinger, LC; Guadarrama, AG; Sommer, JA; Proctor, RA; Bertics, PJ			Purinergic receptor modulation of lipopolysaccharide signaling and inducible nitric-oxide synthase expression in RAW 264.7 macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; BACTERIAL LIPOPOLYSACCHARIDE; NUCLEOTIDE RECEPTOR; MYELOID LEUKOCYTES; MURINE MACROPHAGES; PROTEIN-KINASES; P-2X RECEPTOR; CELL-GROWTH; ACTIVATION; DIFFERENTIATION	Previous studies have suggested that the P2Z/P2X(7), purinergic receptor can participate in nucleotide-induced modulation of lipopolysaccharide (LPS) stimulated inflammatory mediator production. To test this hypothesis, we evaluated whether antagonism of the P2Z/P2X(7), receptor can influence LPS signaling and expression of the inducible form of nitric-oxide synthase (iNOS) in RAW 264.7 macrophages, In the present study, we demonstrate that pretreatment of RAW 264.7 macrophages with a P2Z/P2X(7) receptor antagonist, periodate oxidized adenosine 5'-triphosphate (o-ATP), substantially inhibits LPS-stimulated NO production and iNOS expression without altering cell viability. This effect on LPS-induced iNOS expression is mimicked by a pyridoxal-phosphate-based antagonist (pyridoxal-phosphate-6-azophenyl-2',4'-disuIfonic acid) of the P2Z/P2X(7) purinergic receptor, indicating that these results are not unique to o-ATP, Additionally, o-ATP prevents cell death induced by P2Z/P2X(7) receptor agonists, To ascertain how P2Z/P2X(7), receptor antagonists influence LPS signaling, we evaluated the capacity of o-ATP to regulate LPS-mediated activation of the transcription factor, nuclear factor-kappa B, and the mitogen-activated protein kinases, extracellular signal-regulated kinase (ERK) 1 and ERK2. These experiments reveal that pretreatment of RAW 264.7 cells with o-ATP attenuates the LPS stimulation of a nuclear factor-kappa B-like binding activity. Moreover, the activation of ERK1 and ERK2 by LPS, but not by the phorbol ester, phorbol Ig-myristate 13-acetate, is also blocked in RAW 264.7 cells by o-ATP pretreatment, In summary, these data suggest that the P2Z/P2X(7), receptor modulates LPS-induced macrophage activation as assessed by iNOS expression and NO production. This report implicates the P2Z/P2X(7) receptor in the control of protein kinase cascades and transcriptional processes, and these observations are likely to be important for the development of selective purinergic receptor antagonists for the treatment of septic shock.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Cellular & Mol Biol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med Microbiol & Immunol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Mol & Cellular Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Bertics, PJ (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215, T32GM008349] Funding Source: NIH RePORTER; NICHD NIH HHS [5 T32 HD07259] Funding Source: Medline; NIGMS NIH HHS [T32-GM08349, T32-GM07215] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BROWN C, 1995, BRIT J PHARMACOL, V116, P2413, DOI 10.1111/j.1476-5381.1995.tb15088.x; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Denlinger LC, 1996, J BIOL CHEM, V271, P337, DOI 10.1074/jbc.271.1.337; Denlinger LC, 1998, INFECT IMMUN, V66, P1638, DOI 10.1128/IAI.66.4.1638-1647.1998; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; Dubyak GR, 1996, DRUG DEVELOP RES, V39, P269, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<269::AID-DDR6>3.0.CO;2-P; ELMOATASSIM C, 1993, J BIOL CHEM, V268, P15571; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Fisette PL, 1996, DRUG DEVELOP RES, V39, P377, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<377::AID-DDR19>3.0.CO;2-Z; Gargett CE, 1996, BIOCHEM J, V313, P529, DOI 10.1042/bj3130529; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Humphreys BD, 1996, J IMMUNOL, V157, P5627; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Lambrecht G, 1996, J AUTON PHARMACOL, V16, P341, DOI 10.1111/j.1474-8673.1996.tb00049.x; Martin KA, 1997, MOL PHARMACOL, V51, P97, DOI 10.1124/mol.51.1.97; MURGIA M, 1993, J BIOL CHEM, V268, P8199; PROCTOR RA, 1995, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 2ND EDITION, P173; PROCTOR RA, 1994, P NATL ACAD SCI USA, V91, P6017, DOI 10.1073/pnas.91.13.6017; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; RESTA R, 1993, GENE, V133, P171, DOI 10.1016/0378-1119(93)90635-G; Sanghera JS, 1996, J IMMUNOL, V156, P4457; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; TONETTI M, 1995, BIOCHEM BIOPH RES CO, V214, P125, DOI 10.1006/bbrc.1995.2265; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; XIE QW, 1994, J BIOL CHEM, V269, P4705; ZIEGLERHEITBROCK HWL, 1995, IMMUNOBIOLOGY, V193, P217	36	117	119	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27170	27175		10.1074/jbc.273.42.27170	http://dx.doi.org/10.1074/jbc.273.42.27170			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765236	hybrid			2022-12-25	WOS:000076448000023
J	Rajakumar, RA; Thamotharan, S; Menon, RK; Devaskar, SU				Rajakumar, RA; Thamotharan, S; Menon, RK; Devaskar, SU			Sp1 and Sp3 regulate transcriptional activity of the facilitative glucose transporter isoform-3 gene in mammalian neuroblasts and trophoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; SV40 EARLY PROMOTER; GROWTH-FACTOR-I; RECEPTOR GENE; BINDING-SITES; DEVELOPMENTAL EXPRESSION; MESSENGER-RNA; MUSCLE-CELLS; MOUSE-BRAIN; RAT-BRAIN	The murine facilitative glucose transporter isoform 3 (Glut 3) is developmentally regulated and is predominantly expressed in neurons and trophoblasts. Employing the primer extension and RNase protection assays, the transcription start site (denoted as +1) of the murine Glut 3 gene was localized to 305 base pairs (bp) 5' to the ATG translation start codon. Transient transfection assays in N2A, H19-7 neuroblasts, and HRP.1 trophoblasts using sequential 5'-deletions of the murine Glut 3-luciferase fusion gene indicated that the -203 to +237 bp region with reference to the transcriptional start site contained promoter activity. Repressor function was limited to the -137 to -130 bp region within the transcriptional activation domain. The nuclear factors Spl and Sp3 bound this GC-rich region in N2A, H19-7, and HRP.1 cells. Dephosphorylation of Sp1 was essential for Glut 3 DNA binding. The related Sp3 protein also bound this same region of mouse Glut 3 in all three cell lines. Mutations of the Sp1-binding site employed in transient transfection and mobility shift assays confirmed the nature of the DNA-binding proteins, while supershift assays with anti-Sp1 and anti-Sp3 IgGs characterized the differences in the two DNA-binding proteins. Co-transfection of the Glut 3-luciferase fusion gene with or without mutations of the Sp1-binding site along with the Spl or Sp3 expression vectors in Drosophila SL2 cells confirmed a reciprocal effect, with Sp1 suppressing and Sp3 activating Glut 3 gene transcription.	Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Dept Pediat,Div Neonatol & Dev Biol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Dept Pediat,Div Endocrinol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Devaskar, SU (corresponding author), Magee Womens Hosp, Dept Pediat, 300 Halket St, Pittsburgh, PA 15213 USA.	sdevaskar@mail.magee.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD025024, R01HD033997, R01HD025024] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33997, HD25024] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMMENDOLA R, 1992, J BIOL CHEM, V267, P17944; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; BELL GI, 1993, J BIOL CHEM, V268, P19161; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; BOILEAU P, 1995, J CLIN INVEST, V96, P309, DOI 10.1172/JCI118036; BONNY C, 1995, MOL ENDOCRINOL, V9, P1413, DOI 10.1210/me.9.10.1413; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; Chen JP, 1997, J BIOL CHEM, V272, P23144, DOI 10.1074/jbc.272.37.23144; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DEVASKAR SU, 1992, PEDIATR RES, V31, P1, DOI 10.1203/00006450-199201000-00001; DEVASKAR SU, 1994, AM J OBSTET GYNECOL, V171, P1316, DOI 10.1016/0002-9378(94)90154-6; DEVASKAR SU, 1994, J BIOL CHEM, V269, P8445; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EHRHARDT RA, 1997, AM J PHYSIOL, V42, pR1132; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Gao JG, 1996, MOL ENDOCRINOL, V10, P613, DOI 10.1210/me.10.6.613; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; HAAS S, 1993, MOL CELL BIOL, V13, P3103, DOI 10.1128/MCB.13.5.3103; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; KIM HS, 1995, MOL ENDOCRINOL, V9, P178, DOI 10.1210/me.9.2.178; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; LIU ML, 1992, J BIOL CHEM, V267, P11673; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MAHER F, 1994, MOL CELL NEUROSCI, V5, P369, DOI 10.1006/mcne.1994.1044; MANTYCH GJ, 1993, ENDOCRINOLOGY, V133, P600, DOI 10.1210/en.133.2.600; MANTYCH GJ, 1992, ENDOCRINOLOGY, V131, P1270, DOI 10.1210/en.131.3.1270; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Maxam A M, 1980, Methods Enzymol, V65, P499; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MENON RK, 1995, J BIOL CHEM, V270, P8851, DOI 10.1074/jbc.270.15.8851; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; NAGAMATSU S, 1994, BIOCHEM J, V300, P125, DOI 10.1042/bj3000125; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; OFIR R, 1995, EUR J IMMUNOL, V25, P3070, DOI 10.1002/eji.1830251113; Pantaleon M, 1997, P NATL ACAD SCI USA, V94, P3795, DOI 10.1073/pnas.94.8.3795; POSTIC C, 1994, AM J PHYSIOL, V266, pE548, DOI 10.1152/ajpendo.1994.266.4.E548; Rajakumar RA, 1996, MOL ENDOCRINOL, V10, P867, DOI 10.1210/me.10.7.867; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schroeder RE, 1997, PEDIATR RES, V41, P11, DOI 10.1203/00006450-199701000-00002; SENGUPTA PK, 1994, AM J HEMATOL, V46, P169, DOI 10.1002/ajh.2830460302; SOARES MJ, 1987, DEV BIOL, V124, P134, DOI 10.1016/0012-1606(87)90466-0; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; Uehara Y, 1997, AM J PHYSIOL-ENDOC M, V272, pE716, DOI 10.1152/ajpendo.1997.272.4.E716; Urabe T, 1996, J NEUROCHEM, V67, P265; VANNUCCI SJ, 1994, AM J PHYSIOL-ENDOC M, V267, pE605, DOI 10.1152/ajpendo.1994.267.4.E605; VANNUCCI SJ, 1994, J NEUROCHEM, V62, P240; WILDEMAN AG, 1984, EMBO J, V3, P3129, DOI 10.1002/j.1460-2075.1984.tb02269.x	62	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27474	27483		10.1074/jbc.273.42.27474	http://dx.doi.org/10.1074/jbc.273.42.27474			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765277	hybrid			2022-12-25	WOS:000076448000064
J	Waterborg, JH				Waterborg, JH			Dynamics of histone acetylation in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN STRUCTURE; CHICKEN ERYTHROCYTES; ACTIVE CHROMATIN; BINDING-SITE; CELL-CYCLE; TRANSCRIPTION; NUCLEOSOME; ALFALFA; YEAST; IDENTIFICATION	The dynamic character of core histone post-translational acetylation in the unicellular green alga Chlamydomonas reinhardtii was studied by tritiated acetate incorporation. Histone H3 is the major target of acetylation, steady state, and in pulse and pulse-chase analyses. Acetylation turnover rates were measured by tracer labeling under steady-state conditions. Half-Lives of 1.5-3 min were found for penta- to mono-acetylation of H3, dynamically acetylated to the 30% level. Twenty percent of H3 was multi-acetylated, on average with 3.2 acetyl-lysines, all with rapid turnover. Deacetylase inhibitor trichostatin A (TSA) caused doubling of average acetylation levels, primarily as penta-acetylated H3, but half of H3 was not acetylated at all. The level of histone H4 acetylation was only half that of H3 and a major fraction of mono- and di-acetylated forms appeared static. The dynamic fraction had an average half-life of 3.5 min with higher turnover rates for more highly acetylated H4 forms. TSA, inhibiting less effectively deacetylases active on H4, strongly increased multi-acetylated H4 levels and doubled average acetylation. As for H3, half of histone H4 remained unacetylated. Acetylation of histone H2B was low and of H2A was barely measurable. Despite turnover with half-lives of approximately 2 min, no increase beyond di-acetylation was seen upon TSA treatment.	Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Waterborg, JH (corresponding author), Rm 414 BSB,5007 Rockhill Rd, Kansas City, MO 64110 USA.	waterborg@cctr.umkc.edu	Waterborg, Jakob H./J-5479-2013	Waterborg, Jakob H./0000-0002-2881-4634				ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; Allfrey V. G, 1977, CHROMATIN CHROMOSOME, P167; ALMOUZNI G, 1994, DEV BIOL, V165, P654, DOI 10.1006/dbio.1994.1283; An WJ, 1998, P NATL ACAD SCI USA, V95, P3396, DOI 10.1073/pnas.95.7.3396; Belyaev ND, 1997, CHROMOSOMA, V106, P193, DOI 10.1007/s004120050239; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; COVAULT J, 1980, J BIOL CHEM, V255, P9110; DarkinRattray SJ, 1996, P NATL ACAD SCI USA, V93, P13143, DOI 10.1073/pnas.93.23.13143; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; FABRY S, 1995, CURR GENET, V28, P333, DOI 10.1007/BF00326431; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hayes JJ, 1996, BIOCHEMISTRY-US, V35, P11931, DOI 10.1021/bi961590+; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; JACKSON V, 1975, J BIOL CHEM, V250, P4856; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KUROCHKINA L, 1992, BIOCHEM BIOPH RES CO, V187, P261, DOI 10.1016/S0006-291X(05)81486-X; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Lechner T, 1996, BBA-PROTEIN STRUCT M, V1296, P181, DOI 10.1016/0167-4838(96)00069-6; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; LOPEZRODAS G, 1991, J BIOL CHEM, V266, P18745; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Lusser A, 1997, SCIENCE, V277, P88, DOI 10.1126/science.277.5322.88; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; Matthews HR, 1985, ENZYMOLOGY POSTTRANS, V2, P125; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; NELSON DA, 1982, J BIOL CHEM, V257, P1565; NELSON DA, 1983, BIOCHIM BIOPHYS ACTA, V741, P269, DOI 10.1016/0167-4781(83)90068-4; PANTAZIS P, 1982, J CELL BIOCHEM, V20, P225, DOI 10.1002/jcb.240200303; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; SENDRA R, 1988, PLANT MOL BIOL, V11, P857, DOI 10.1007/BF00019525; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; THOMAS JO, 1984, J CELL SCI, P1; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; van Holde KE., 1989, SPRINGER SERIES MOL; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WALTHER Z, 1995, NUCLEIC ACIDS RES, V23, P3756, DOI 10.1093/nar/23.18.3756; WATERBORG JH, 1991, PLANT PHYSIOL, V96, P453, DOI 10.1104/pp.96.2.453; WATERBORG JH, 1992, PLANT MOL BIOL, V18, P181, DOI 10.1007/BF00034947; WATERBORG JH, 1993, J BIOL CHEM, V268, P4912; WATERBORG JH, 1983, BIOCHEMISTRY-US, V22, P1489, DOI 10.1021/bi00275a025; WATERBORG JH, 1990, J BIOL CHEM, V265, P17157; WATERBORG JH, 1995, PLANT PHYSIOL, V109, P393, DOI 10.1104/pp.109.2.393; WATERBORG JH, 1992, BIOCHEMISTRY-US, V31, P6211, DOI 10.1021/bi00142a006; WATERBORG JH, 1990, BIOCHIM BIOPHYS ACTA, V1049, P324, DOI 10.1016/0167-4781(90)90105-B; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; ZHANG DE, 1988, BIOCHEM J, V250, P241, DOI 10.1042/bj2500241; ZHANG DE, 1988, BIOCHEM J, V250, P233, DOI 10.1042/bj2500233	56	30	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27602	27609		10.1074/jbc.273.42.27602	http://dx.doi.org/10.1074/jbc.273.42.27602			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765294	hybrid			2022-12-25	WOS:000076448000081
J	Oelkers, P; Behari, A; Cromley, D; Billheimer, JT; Sturley, SL				Oelkers, P; Behari, A; Cromley, D; Billheimer, JT; Sturley, SL			Characterization of two human genes encoding acyl coenzyme A: Cholesterol acyltransferase-related enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; RADIATION INACTIVATION; FUNCTIONAL EXPRESSION; SUBSTRATE-SPECIFICITY; ACAT INHIBITORS; COA; CELLS; ESTERIFICATION; METABOLISM; CDNA	The enzyme acyl coenzyme A:cholesterol acyltransferase 1 (ACAT1) mediates sterol esterification, a crucial component of intracellular lipid homeostasis. Two enzymes catalyze this activity in Saccharomyces cerevisiae (yeast), and several lines of evidence suggest multigene families may also exist in mammals. Using the human ACAT1 sequence to screen data bases of expressed sequence tags, we identified two novel and distinct partial human cDNAs. Full-length cDNA clones for these ACAT related gene products (ARGP) 1 and 2 were isolated from a hepatocyte (HepG2) cDNA library. ARGP1 was expressed in numerous human adult tissues and tissue culture cell lines, whereas expression of ARGP2 was more restricted, In vitro microsomal assays in a yeast strain deleted for both esterification genes and completely deficient in sterol esterification indicated that ARGP2 esterified cholesterol while ARGP1 did not, In contrast to ACAT1 and similar to liver esterification, the activity of ARGP2 was relatively resistant to a histidine active site modifier, ARGP1 is therefore a tissue-specific sterol esterification enzyme which we thus designated ACAT2, We speculate that ARGP1 participates in the coenzyme A-dependent acylation of substrate(s) other than cholesterol, Consistent with this hypothesis, ARGP1, unlike any other member of this multigene family, possesses a predicted diacylglycerol binding motif suggesting that it may perform the last acylation in triglyceride biosynthesis,	Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol & Mol Biophys, New York, NY 10032 USA; DuPont Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA	Columbia University; Columbia University; Columbia University; DuPont	Sturley, SL (corresponding author), Columbia Univ Coll Phys & Surg, Inst Human Nutr, 650 W 168th St, New York, NY 10032 USA.			Oelkers, Peter/0000-0002-2421-472X	NHLBI NIH HHS [HL07343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL007343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BILLHEIMER JT, 1990, J BIOL CHEM, V265, P8632; BILLHEIMER JT, 1992, ADV CHOLESTEROL RES; BOTHAM KM, 1992, BIOCHEM SOC T, V20, P454, DOI 10.1042/bst0200454; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; CARR TP, 1995, J LIPID RES, V36, P25; CARR TP, 1992, ARTERIOSCLER THROMB, V12, P1275; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG CCY, 1994, SOMAT CELL MOLEC GEN, V20, P71, DOI 10.1007/BF02257489; CIVEN M, 1982, J STEROID BIOCHEM, V16, P817, DOI 10.1016/0022-4731(82)90040-1; CORTON JM, 1992, EUR J BIOCHEM, V204, P203, DOI 10.1111/j.1432-1033.1992.tb16625.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; DOOLITTLE GM, 1982, BIOCHEMISTRY-US, V21, P674, DOI 10.1021/bi00533a014; EINARSSON K, 1989, J LIPID RES, V30, P739; ERICKSON SK, 1994, J LIPID RES, V35, P763; FIELD FJ, 1990, GASTROENTEROLOGY, V99, P539, DOI 10.1016/0016-5085(90)91040-D; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; GUO Z, 1996, CIRCULATION, V94, P35; HUFF MW, 1994, ARTERIOSCLER THROMB, V14, P1498, DOI 10.1161/01.ATV.14.9.1498; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINNUNEN PM, 1988, BIOCHEMISTRY-US, V27, P7344, DOI 10.1021/bi00419a025; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MADUSKUIE TP, 1995, J MED CHEM, V38, P1067, DOI 10.1021/jm00007a004; Maniatis T., 1987, MOL CLONING LAB MANU; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; Matsuda H, 1996, BBA-LIPID LIPID MET, V1301, P76, DOI 10.1016/0005-2760(96)00020-3; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHOONDERWOERD K, 1990, BIOCHEM J, V268, P487, DOI 10.1042/bj2680487; Sturley SL, 1997, CURR OPIN LIPIDOL, V8, P167, DOI 10.1097/00041433-199706000-00007; TABAS I, 1996, CIRCULATION, V94, P35; TAVANI DM, 1982, J LIPID RES, V23, P774; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; VELDHUIS JD, 1985, ENDOCRINOLOGY, V116, P25, DOI 10.1210/endo-116-1-25; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yang HY, 1997, J BIOL CHEM, V272, P3980, DOI 10.1074/jbc.272.7.3980; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157	45	320	359	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26765	26771		10.1074/jbc.273.41.26765	http://dx.doi.org/10.1074/jbc.273.41.26765			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756920	hybrid			2022-12-25	WOS:000076373300074
J	Wang, ZY; Melmed, S				Wang, ZY; Melmed, S			Functional map of a placenta-specific enhancer of the human leukemia inhibitory factor receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; TISSUE-SPECIFIC ENHANCER; ELEMENT-BINDING PROTEIN; IL-6 SIGNAL TRANSDUCER; FACTOR LIF RECEPTOR; CHORIONIC SOMATOMAMMOTROPIN; ADENOSINE-DEAMINASE; TARGETED DISRUPTION; CYTOKINE RECEPTORS; HUMAN ENDOMETRIUM	We recently reported a placenta-specific enhancer in the human leukemia inhibitory factor receptor (LIFR) gene and now show detailed characterization of the 226-base pair enhancer (-4625/-4400 nucleotides). Four of twenty-two mutants in linker analysis showed reduced promoter activities to 45, 30, 10, and 10%, respectively. Specific binding of region A (-4617/-4602) with nuclear extract was competed by a known Oct-1 oligo and supershifted by Oct-1 antibody. Specific binding of region B (-4549/-4535) was competed by a GATA oligo, but could not be supershifted by four GATA antibodies. Nevertheless, mutagenesis showed that critical bases in region B were identical to the GATA core motif, indicating that region B may bind to a novel GATA family transcription factor. The other two adjacent regions designated as region C (-4464/-4445) showed no known consensus binding sites, and their specific placental JEG-3 nuclear extract binding was not evident in nonplacental nuclear extracts and was not competed by a trophoblast specific element (TSE), indicating that region C is a novel placenta-specific element (PSE, CATTTCCTGAACTAGTTTTT). Footprinting localized the binding boundary of PSE-binding protein (PSEB), and three Gs were found to be important for specific PSE binding. UV cross-linking showed that PSEB had a molecular mass of similar to 160 kDa, substituting the PSE with two previously reported placenta elements TSE or chorionic somatomammotropin enhancer factor 1 (CSEF-1) motifs resulted in markedly different promoter activities, indicating that PSEB is indeed different from TSE binding protein or CSEF-1. These results are the first demonstration that a novel PSE is the major element for placenta-specific enhancer activity in human LIFR gene.	Univ Calif Los Angeles, Sch Med, Cedar Sinai Res Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Melmed, S (corresponding author), Cedars Sinai Med Ctr, Div Endocrinol, 8700 Beverly Blvd,B-131, Los Angeles, CA 90048 USA.							ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BARSH GS, 1983, NUCLEIC ACIDS RES, V11, P3939, DOI 10.1093/nar/11.12.3939; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; CHARNOCKJONES DS, 1994, J REPROD FERTIL, V101, P421; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; CHEM EY, 1989, GENOMICS, V4, P479; Chesnokova V, 1998, ENDOCRINOLOGY, V139, P2209, DOI 10.1210/en.139.5.2209; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; HECKERT LL, 1995, J BIOL CHEM, V270, P26497, DOI 10.1074/jbc.270.44.26497; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; Jiang SW, 1997, MOL ENDOCRINOL, V11, P1223, DOI 10.1210/me.11.9.1223; KENDALL SK, 1995, GENE DEV, V9, P2007, DOI 10.1101/gad.9.16.2007; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOJIMA K, 1995, HUM REPROD, V10, P1907, DOI 10.1093/oxfordjournals.humrep.a136205; KOJIMA K, 1994, BIOL REPROD, V50, P882, DOI 10.1095/biolreprod50.4.882; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; NICKEL BE, 1990, BIOCHEM J, V267, P653, DOI 10.1042/bj2670653; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Pennica Diane, 1996, Cytokine and Growth Factor Reviews, V7, P81, DOI 10.1016/1359-6101(96)00007-X; PITTMAN RH, 1994, J BIOL CHEM, V269, P19360; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; STEGER DJ, 1993, MOL ENDOCRINOL, V7, P1579, DOI 10.1210/me.7.12.1579; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TARTAGLIA LA, 1995, CELL, V83, P1363; THOMPSON EA, 1974, J BIOL CHEM, V249, P5373; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WALKER WH, 1990, J BIOL CHEM, V265, P12940; Wang ZY, 1997, J BIOL CHEM, V272, P27957, DOI 10.1074/jbc.272.44.27957; WARE CB, 1995, DEVELOPMENT, V121, P1283; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YAMADA K, 1995, J BIOL CHEM, V270, P25064, DOI 10.1074/jbc.270.42.25064	55	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26069	26077		10.1074/jbc.273.40.26069	http://dx.doi.org/10.1074/jbc.273.40.26069			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748286	hybrid			2022-12-25	WOS:000076263100077
J	Faure, S; Morin, N; Doree, M				Faure, S; Morin, N; Doree, M			Inactivation of protein kinase A is not required for c-mos translation during meiotic maturation of Xenopus oocytes	ONCOGENE			English	Article						c-mos oncogene; protein kinase A translation; oocyte maturation	MAP KINASE; CYTOPLASMIC POLYADENYLATION; MESSENGER-RNA; FROG OOCYTES; SOMATIC-CELLS; ACTIVATION; CYCLIN; PHOSPHATASE; METAPHASE; NUCLEAR	It has been shown previously that protein kinase A (PKA) maintains Xenopus oocytes arrested at G2, at least in part by preventing c-mos translation, but how PKA controls c-mos translation is not known. Using microinjection of recombinant c-mos, which still activates MAP kinase in the presence of active PKA, we have found that PKA does not exert any effect on translation of endogenous c-mos if MAP kinase is first activated, Even though they accumulate c-mos and contain MAP kinase activity as high as control oocytes, oocytes do not exit G2 in the presence of active PKA, These results are discussed in connection with recent findings on regulation of c-raf activity.	CNRS, Ctr Rech Biochim Macromol, Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Doree, M (corresponding author), CNRS, Ctr Rech Biochim Macromol, 1919 Route Mende, F-34293 Montpellier 5, France.		FAURE, Sandrine/N-6506-2018	FAURE, Sandrine/0000-0002-8902-8274; Morin, Nathalie/0000-0001-8677-1401				Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DAAR I, 1993, J CELL BIOL, V120, P1197, DOI 10.1083/jcb.120.5.1197; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; GABRIELLI BG, 1993, SCIENCE, V259, P1766, DOI 10.1126/science.8456304; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GEBAUER F, 1994, EMBO J, V13, P5712, DOI 10.1002/j.1460-2075.1994.tb06909.x; GODEAU F, 1978, CR ACAD SCI D NAT, V286, P685; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; HUCHON D, 1979, BIOL CELLULAIRE, V35, P15; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KISHIMOTO T, 1982, EXP CELL RES, V137, P121, DOI 10.1016/0014-4827(82)90014-3; Kuge H, 1995, EMBO J, V14, P6301, DOI 10.1002/j.1460-2075.1995.tb00320.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1991, METHOD ENZYMOL, V201, P291; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MALLER J, 1977, J BIOL CHEM, V525, P1712; MALLER JL, 1983, ADV CYCL NUCL RES<D>, V15, P295; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; MELTON DA, 1979, CELL, V18, P1165, DOI 10.1016/0092-8674(79)90229-0; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; RIME H, 1994, BIOL CELL, V82, P11, DOI 10.1016/0248-4900(94)90061-2; RIME H, 1992, DEV BIOL, V151, P105, DOI 10.1016/0012-1606(92)90217-5; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; Shibuya EK, 1996, CELL GROWTH DIFFER, V7, P235; SPEAKER MG, 1977, NATURE, V267, P848, DOI 10.1038/267848a0; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666	44	19	20	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1215	1221		10.1038/sj.onc.1202056	http://dx.doi.org/10.1038/sj.onc.1202056			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771964				2022-12-25	WOS:000075803300003
J	Guan, ZH; Buckman, SY; Miller, BW; Springer, LD; Morrison, AR				Guan, ZH; Buckman, SY; Miller, BW; Springer, LD; Morrison, AR			Interleukin-1 beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE-2 GENE-EXPRESSION; NITRIC-OXIDE; GROWTH-FACTOR; STRESS; INDUCTION	The inflammatory cytokine interleukin-1 beta (IL-1 beta) induces cyclooxygenase-a (Cox-a) expression with a concomitant release of prostaglandins from glomerular mesangial cells. We reported previously that IL-1 beta rapidly activates the c-Jun NH2-terminal/stress-activated protein kinases (JNK/SAPK) and p38 mitogen-activated protein kinase (MAPK) and also induces Cox-a expression and prostaglandin E-2 (PGE(2)) production. The current study demonstrates that overexpression of the dominant negative form of JNK1 or p54 JNK2/SAPK beta reduces Cox-a expression and PGE(2) production stimulated by IL-1 beta. Similarly, overexpression of the kinase-dead form of p38 MAPK also inhibits IL-1 beta-induced Cox-a expression and PGE(2) production. These results suggest that activation of both JMK/SAPK and p38 MAPK is required for Cox-a expression after IL-1 beta activation. Furthermore, our experiments confirm that IL-1 beta activates MAP kinase kinase-4 (MKK4)/SEK1, MKK3, and MKK6 in renal mesangial cells. Overexpression of the dominant negative form of MKK4/SEK1 decreases IL-1 beta- induced Cox-2 expression with inhibition of both JNK/SAPK and p38 MAPK phosphorylation. Overexpression of the kinase-dead form of MKK3 or MKK6 demonstrated that either of these two mutant kinases inhibited IL-1 beta-induced p38 MAPK phosphorylation and Cox-a expression but not JNK/SAPK phosphorylation and activation. This study suggests that the activation of both JNK/SAPK and p38 MAPK signaling cascades is required for IL-1 beta-induced Cox-a expression and PGE(2) synthesis.	Washington Univ, Sch Med, Dept Med & Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Guan, ZH (corresponding author), Barnes Jewish Hosp, Div Renal, 216 S Kingshighway,Box 8305, St Louis, MO 63110 USA.				NIDDK NIH HHS [DK 50606] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050606] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Guan ZH, 1996, AM J PHYSIOL-RENAL, V270, pF634, DOI 10.1152/ajprenal.1996.270.4.F634; HABENICHT AJR, 1985, J CLIN INVEST, V75, P1381, DOI 10.1172/JCI111839; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MARNETT LJ, 1992, CANCER RES, V52, P5575; Miller BW, 1997, AM J PHYSIOL-CELL PH, V273, pC130, DOI 10.1152/ajpcell.1997.273.1.C130; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Taub D D, 1994, Ther Immunol, V1, P229; Tetsuka T, 1996, J CLIN INVEST, V97, P2051, DOI 10.1172/JCI118641; Tetsuka T, 1996, J BIOL CHEM, V271, P11689, DOI 10.1074/jbc.271.20.11689; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742	28	216	224	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28670	28676		10.1074/jbc.273.44.28670	http://dx.doi.org/10.1074/jbc.273.44.28670			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786861	hybrid			2022-12-25	WOS:000076691800022
J	Lim, K; Owens, SM; Arnold, L; Sacchettini, JC; Linthicum, DS				Lim, K; Owens, SM; Arnold, L; Sacchettini, JC; Linthicum, DS			Crystal structure of monoclonal 6B5 fab complexed with phencyclidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; PROTEIN STRUCTURES; BINDING SITE; FRAGMENT; RESOLUTION; RECEPTOR; IMMUNOGLOBULINS; PERSPECTIVES; DISPOSITION; RATS	The crystal structure of monoclonal antibody (mAb) 6B5 Fab fragment complexed with 1-(1-phenylcyclohexyl)piperidine (PCP or phencyclidine) was determined at 2.2-Angstrom resolution, 6B5 was originally produced from a mouse immunized with a phencyclidine analogue hapten 5-[N-(1' phenylcyclohexyl) amino]pentanoic acid conjugated to bovine serum albumin. This mAb was selected for further study because of its high affinity (K-d = 2 x 10(-9) M/liter) for PCP and usefulness in reversing PCP induced central nervous system toxicity in laboratory animals. The dominant feature of the 6B5 Fab PCP complex is the deep binding site and hydrophobic nature of the interaction. The ligand binding pocket of 6B5 Fab has numerous aromatic side chains, as compared with other known Fab structures. The most notable feature of the binding site is a Trp at position 97H (H-chain), and the side chain of this residue appears to act as a hydrophobic umbrella on the ligand in the antigen binding pocket. There are only two other known Fabs found with a Trp at the 97H position in complementarity determining region (CDR) H3, but they do not play a major role in the interaction with their respective antigens; in both Fab TE33 and R6.5 the Trp 97H side chain is positioned away from the bound antigen. Comparison of the CDR residues of 6B5 with other Fab structures with similar CDR sizes and amino acid compositions reveals a number of important patterns of residue substitutions that appear to be critical for specific PCP ligand interactions.	Texas A&M Univ, Dept Biochem & Biophys, Ctr Struct Biol, College Stn, TX 77843 USA; Univ Arkansas Med Sci, Coll Med, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27514 USA	Texas A&M University System; Texas A&M University College Station; University of Arkansas System; University of Arkansas Medical Sciences; University of North Carolina; University of North Carolina Chapel Hill	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, Ctr Struct Biol, College Stn, TX 77843 USA.	sacchett@tamu.edu			NIDA NIH HHS [K02 DA00110, R01 DA07610] Funding Source: Medline; NIGMS NIH HHS [R01 GM46535] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046535] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000110, R01DA007610] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; ANILINE O, 1982, CRC CR REV TOXICOL, V10, P145, DOI 10.3109/10408448209041322; ARGOS P, 1970, ACTA CRYSTALL B-STRU, VB 26, P53, DOI 10.1107/S0567740870001917; BRUNGER AT, 1991, J MOL BIOL, V221, P239, DOI 10.1016/0022-2836(91)90817-P; BURNS RS, 1976, CLIN TOXICOL, V9, P477; CHAUDIEU I, 1989, PHARMACOL BIOCHEM BE, V32, P699, DOI 10.1016/0091-3057(89)90020-8; Cohen GH, 1996, ACTA CRYSTALLOGR D, V52, P315, DOI 10.1107/S0907444995014855; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COOK CE, 1982, CLIN PHARMACOL THER, V31, P625; DANDLIKER WB, 1967, IMMUNOCHEMISTRY, V5, P171; DAVIES DR, 1983, ANNU REV IMMUNOL, V1, P87, DOI 10.1146/annurev.iy.01.040183.000511; Droupadi P. R., 1992, Journal of Molecular Recognition, V5, P173, DOI 10.1002/jmr.300050407; FAUMAN MA, 1979, AM J PSYCHIAT, V136, P1584; FERRERMONTIEL AV, 1995, P NATL ACAD SCI USA, V92, P8021, DOI 10.1073/pnas.92.17.8021; GUDDAT LW, 1994, J MOL BIOL, V236, P247, DOI 10.1006/jmbi.1994.1133; Hardin JS, 1998, J PHARMACOL EXP THER, V285, P1113; HERRON JN, 1994, BIOPHYS J, V67, P2167, DOI 10.1016/S0006-3495(94)80738-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat E. A., 1991, SEQUENCES PROTEINS I; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KLEYWEGT GJ, 1995, ESF CCP4 NEWSLETT, V31, P45; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCCLURKAN MB, 1993, J PHARMACOL EXP THER, V266, P1439; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OWENS SM, 1988, J PHARMACOL EXP THER, V246, P472; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; POKKULURI PR, 1994, J MOL BIOL, V243, P283, DOI 10.1006/jmbi.1994.1654; POLJAK RJ, 1973, P NATL ACAD SCI USA, V70, P3305, DOI 10.1073/pnas.70.12.3305; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; Tetin SY, 1996, BIOCHEMISTRY-US, V35, P1258, DOI 10.1021/bi951576h; TETIN SY, 1992, BIOCHEMISTRY-US, V31, P12029, DOI 10.1021/bi00163a010; Valentine JL, 1996, J PHARMACOL EXP THER, V278, P709; VARGASMADRAZO E, 1995, J MOL BIOL, V254, P497, DOI 10.1006/jmbi.1995.0633; VIGNON J, 1982, EUR J PHARMACOL, V81, P531, DOI 10.1016/0014-2999(82)90342-9; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; ZUKIN SR, 1979, P NATL ACAD SCI USA, V76, P5372, DOI 10.1073/pnas.76.10.5372	41	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28576	28582		10.1074/jbc.273.44.28576	http://dx.doi.org/10.1074/jbc.273.44.28576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786848	hybrid, Green Published			2022-12-25	WOS:000076691800009
J	Luo, ZD; Camp, S; Mutero, A; Taylor, P				Luo, ZD; Camp, S; Mutero, A; Taylor, P			Splicing of 5 ' introns dictates alternative splice selection of acetylcholinesterase pre-mRNA and specific expression during myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; MESSENGER-RNA; MAMMALIAN ACETYLCHOLINESTERASE; MOUSE ACETYLCHOLINESTERASE; DEVELOPMENTAL REGULATION; GENE-EXPRESSION; MOLECULAR-FORMS; INVITRO; EXON; SITE	Splicing of alternative exon 6 to invariant exons 2, 3, and 4 in acetylcholinesterase (AChE) pre-mRNA results in expression of the prevailing enzyme species in the nervous system and at the neuromuscular junction of skeletal muscle. The structural determinants controlling splice selection are examined in differentiating C2-C12 muscle cells by selective intron deletion from and site-directed mutagenesis in the Ache gene. Transfection of a plasmid lacking two invariant introns (introns II and III) within the open reading: frame of the Ache gene, located 5' of the alternative splice region, resulted in alternatively spliced mRNAs encoding enzyme forms not found endogenously in myotubes, Retention of either intron II or III is sufficient to control the tissue-specific pre-mRNA splicing pattern prevalent in situ. Further deletions and branch point mutations revealed that upstream splicing, but not the secondary structure of AChE pre-mRNA, is the determining factor in the splice selection. In addition, deletion of the alternative intron between the splice donor site and alternative acceptor sites resulted in aberrant upstream splicing. Thus, selective splicing of AChE pre-mRNA during myogenesis occurs in an ordered recognition sequence in which the alternative intron influences the fidelity of correct upstream splicing, which, in turn, determines the downstream splice selection of alternative exons.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NHLBI NIH HHS [F32HL09848] Funding Source: Medline; NIGMS NIH HHS [GM 18360] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1995, RNA, V1, P763; Coleman BA, 1996, J BIOL CHEM, V271, P4410; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FU XD, 1995, RNA, V1, P663; FUENTES ME, 1993, NEURON, V10, P679, DOI 10.1016/0896-6273(93)90169-R; GIBNEY G, 1988, J BIOL CHEM, V263, P1140; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; INESTROSA NC, 1983, EXP CELL RES, V147, P393, DOI 10.1016/0014-4827(83)90221-5; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KARPEL R, 1994, EXP CELL RES, V210, P268, DOI 10.1006/excr.1994.1039; KELLER EB, 1984, P NATL ACAD SCI-BIOL, V81, P7417, DOI 10.1073/pnas.81.23.7417; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; LEGAY C, 1995, EUR J NEUROSCI, V7, P1803, DOI 10.1111/j.1460-9568.1995.tb00699.x; LEICHT BG, 1995, GENETICS, V139, P299; LI Y, 1993, J BIOL CHEM, V268, P3563; LI Y, 1993, J BIOL CHEM, V268, P5790; LI Y, 1991, J BIOL CHEM, V266, P23083; Lodish H., 1995, MOL CELL BIOL; Luo ZD, 1996, J NEUROCHEM, V67, P111; LUO ZG, 1994, J BIOL CHEM, V269, P27216; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MASSOULIE J, 1995, ENZYMES OF THE CHOLINESTERASE FAMILY, P29; Moore M., 1993, RNA WORLD, P303; NASIM FH, 1990, GENE DEV, V4, P1172, DOI 10.1101/gad.4.7.1172; PADGETT RA, 1985, P NATL ACAD SCI USA, V82, P8349, DOI 10.1073/pnas.82.24.8349; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; RANDALL WR, 1994, J BIOL CHEM, V269, P12367; RAUTMANN G, 1985, NATURE, V315, P430, DOI 10.1038/315430a0; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; RUSKIN B, 1985, CELL, V43, P131, DOI 10.1016/0092-8674(85)90018-2; RUSKIN B, 1985, CELL, V41, P833, DOI 10.1016/S0092-8674(85)80064-7; Sambrook J., 2002, MOL CLONING LAB MANU; SILMAN I, 1978, FEBS LETT, V94, P166, DOI 10.1016/0014-5793(78)80929-6; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433	44	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28486	28495		10.1074/jbc.273.43.28486	http://dx.doi.org/10.1074/jbc.273.43.28486			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774478	hybrid			2022-12-25	WOS:000076549800098
J	Penc, SF; Pomahac, B; Winkler, T; Dorschner, RA; Eriksson, E; Herndon, M; Gallo, RL				Penc, SF; Pomahac, B; Winkler, T; Dorschner, RA; Eriksson, E; Herndon, M; Gallo, RL			Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-LIKE MOLECULES; HUMAN-LUNG FIBROBLASTS; CELL-SURFACE; EXTRACELLULAR-MATRIX; HIGH-AFFINITY; FACTOR-ALPHA; COFACTOR-II; PROTEOGLYCANS; BINDING; EXPRESSION	Proteoglycans have been shown in vitro to bind multiple components of the cellular microenvironment that function during wound healing. To study the composition and function of these molecules when derived from an in vivo source, soluble proteoglycans released into human wound fluid were characterized and evaluated for influence on fibroblast growth factor-2 activity. Immunoblot analysis of wound fluid revealed the presence of syndecan-1, syndecan-4, glypican, decorin, perlecan, and versican. Sulfated glycosaminoglycan concentrations ranged from 15 to 65 mu g/ml, and treatment with chondroitinase B showed that a large proportion of the glycosaminoglycan was dermatan sulfate. The total glycosaminoglycan mixture present in wound fluid supported the ability of fibroblast growth factor-a to signal cell proliferation. Dermatan sulfate, and not heparan sulfate, was the major contributor to this activity, and dermatan sulfate bound FGF-2 with K-d = 2.48 mu M. These data demonstrate that proteoglycans released during wound repair are functionally active and provide the first evidence that dermatan sulfate is a potent mediator of fibroblast growth factor-2 responsiveness.	Boston Childrens Hosp, Div Dev & Newborn Baby, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Plast Surg, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Expt Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center	Gallo, RL (corresponding author), Boston Childrens Hosp, Div Dev & Newborn Baby, Enders 950,300 Longwood Ave, Boston, MA 02115 USA.	GAllo@A1.TCH.Harvard.edu	Pomahac, Bohdan/AAH-1792-2019; Gallo, Richard L/A-8931-2009	Pomahac, Bohdan/0000-0003-3703-8240; Gallo, Richard L/0000-0002-1401-7861				ABRAHAM J, 1996, MOL CELLULAR BIOL WO; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; ASHER R, 1991, J NEUROSCI RES, V28, P410, DOI 10.1002/jnr.490280314; Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; CELLA G, 1992, ANGIOLOGY, V43, P59, DOI 10.1177/000331979204300107; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; COOPER DM, 1994, ANN SURG, V219, P688, DOI 10.1097/00000658-199406000-00012; DAVID G, 1993, DEVELOPMENT, V119, P841; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; HAGGERTY JG, 1992, J INVEST DERMATOL, V99, P374, DOI 10.1111/1523-1747.ep12616087; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HEREMANS A, 1988, J BIOL CHEM, V263, P4731; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LORIES V, 1992, J BIOL CHEM, V267, P1116; LORIES V, 1989, J BIOL CHEM, V264, P7009; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MASCELLANI G, 1993, BIOCHEM J, V296, P639, DOI 10.1042/bj2960639; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PRIGLINGER U, 1994, J BIOL CHEM, V269, P14705; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Stringer SE, 1997, INT J BIOCHEM CELL B, V29, P709, DOI 10.1016/S1357-2725(96)00170-7; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	48	172	178	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28116	28121		10.1074/jbc.273.43.28116	http://dx.doi.org/10.1074/jbc.273.43.28116			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774430	hybrid			2022-12-25	WOS:000076549800050
J	Xu, X; Croy, JT; Zeng, WZ; Zhao, LP; Davignon, I; Popov, S; Yu, K; Jiang, HP; Offermanns, S; Muallem, S; Wilkie, TM				Xu, X; Croy, JT; Zeng, WZ; Zhao, LP; Davignon, I; Popov, S; Yu, K; Jiang, HP; Offermanns, S; Muallem, S; Wilkie, TM			Promiscuous coupling of receptors to Gq class alpha subunits and effector proteins in pancreatic and submandibular gland cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROTROPIN RECEPTOR; HETEROTRIMERIC G-PROTEINS; PHOSPHOLIPASE-C-BETA; SALIVARY-GLAND; SIGNAL-TRANSDUCTION; CA2+ RELEASE; FAMILY; G(Q); CHANNELS; EXPRESSION	Mice with deficiencies in one or more Gq class alpha subunit genes were used to examine the role of the a subunit in regulating Ca2+ signaling in pancreatic and submandibular gland cells. Western blot analysis showed that these cells express three of the four Gq class subunits, G alpha q, G alpha 11, and G alpha 14 but not G alpha 15. Surprisingly, all parameters of Ca2+ signaling were identical in cells from wild type and four lines of mutant mice: 1) G alpha 11-/-, 2) G alpha 11-/-/G alpha 14-/-, 3) G alpha 14-/-/Ga15-/-, and 4) G alpha q-/-/G alpha 15-/-. These parameters included the K-app for several Gq class coupled receptors, induction of [Ca2+](i) oscillations by weak stimulation, and a biphasic [Ca2+](i) response by strong stimulation. Furthermore, Ca2+ release from internal stores and Ca2+ entry were not affected in cells from any of the mutant mice. We conclude that G alpha q, G alpha 11, and G alpha 14 promiscuously couple several receptors (m(3) muscarinic, bombesin, cholecystokinin, and alpha 1 adrenergic) to effector proteins that activate both Ca2+ release from internal stores and Ca2+ entry.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Astra Arcus USA Inc, Rochester, NY 14602 USA; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmacol, D-14195 Berlin, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	smuall@mednet.swmed.edu	Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805	NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK38938] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07062] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; BERRIDGE MJ, 1994, BIOCHEM J, V302, P545, DOI 10.1042/bj3020545; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Davignon I, 1996, GENOMICS, V31, P359, DOI 10.1006/geno.1996.0059; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; GalvinParton PA, 1997, J BIOL CHEM, V272, P4335, DOI 10.1074/jbc.272.7.4335; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HEPLER JR, 1994, METHOD ENZYMOL, V237, P191; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kuhn B, 1996, MOL ENDOCRINOL, V10, P1697, DOI 10.1210/me.10.12.1697; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEE CH, 1992, J BIOL CHEM, V267, P16044; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; MacrezLepretre N, 1997, J BIOL CHEM, V272, P5261, DOI 10.1074/jbc.272.8.5261; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; NAKAMURA F, 1995, J BIOL CHEM, V270, P6246, DOI 10.1074/jbc.270.11.6246; Obukhov AG, 1996, EMBO J, V15, P5833, DOI 10.1002/j.1460-2075.1996.tb00970.x; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; VALDEZ IH, 1991, AM J PHYSIOL, V261, pG359, DOI 10.1152/ajpgi.1991.261.2.G359; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; XU X, 1995, J BIOL CHEM, V270, P29169, DOI 10.1074/jbc.270.49.29169; Xu X, 1997, CELL CALCIUM, V22, P217, DOI 10.1016/S0143-4160(97)90015-4; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; ZENG W, 1998, IN PRESS J BIOL CHEM	35	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27275	27279		10.1074/jbc.273.42.27275	http://dx.doi.org/10.1074/jbc.273.42.27275			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765251	hybrid			2022-12-25	WOS:000076448000038
J	Swaren, P; Maveyraud, L; Raquet, X; Cabantous, S; Duez, C; Pedelacq, JD; Mariotte-Boyer, S; Mourey, L; Labia, R; Nicolas-Chanoine, MH; Nordmann, P; Frere, JM; Samama, JP				Swaren, P; Maveyraud, L; Raquet, X; Cabantous, S; Duez, C; Pedelacq, JD; Mariotte-Boyer, S; Mourey, L; Labia, R; Nicolas-Chanoine, MH; Nordmann, P; Frere, JM; Samama, JP			X-ray analysis of the NMC-A beta-lactamase at 1.64-angstrom resolution, a class A carbapenemase with broad substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS PC1; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; 3RD-GENERATION CEPHALOSPORINS; ENTEROBACTER-CLOACAE; SERRATIA-MARCESCENS; MOLECULAR-STRUCTURE; EXTENDED-SPECTRUM; ACTIVE-SITE; MEROPENEM	The treatment of infectious diseases by penicillin and cephalosporin antibiotics is continuously challenged by the emergence and the dissemination of the numerous TEM and SHV mutant beta-lactamases with extended substrate profiles. These class A beta-lactamases nevertheless remain inefficient against carbapenems, the most effective antibiotics against clinically relevant pathogens. A new member of this enzyme class, NMC-A, was recently reported to hydrolyze at high rates, and hence destroy, all known beta-lactam antibiotics, including carbapenems and cephamycins. The crystal structure of NMC-A was solved to 1.64-Angstrom resolution, and reveals modifications in the topology of the substrate-binding site. While preserving the geometry of the essential catalytic residues, the active site of the enzyme presents a disulfide bridge between residues 69 and 238, and certain other structural differences compared with the other beta-lactamases. These unusual features in class A beta-lactamases involve amino acids that participate in enzyme-substrate interactions, which suggested that these structural factors should be related to the very broad substrate specificity of this enzyme. The comparison of the NMC-A structure with those of other class A enzymes and enzyme-ligand complexes, indicated that the position of Asn-132 in NMC-A provides critical additional space in the region of the protein where the poorer substrates for class A beta-lactamases, such as cephamycins and carbapenems, need to be accommodated.	Inst Pharmacol & Biol Struct, Grp Cristallog Biol, CNRS, UPR 9062, F-31077 Toulouse, France; Univ Liege, Inst Chim B6, Ctr Ingn Prot, B-4000 Liege, Belgium; Hop Lariboisiere, Serv Bacteriol Virol, F-75475 Paris 10, France; MNHN, CNRS, UMR 175, F-29000 Quimper, France; Univ Paris 05, Fac Med Paris Ouest, Microbiol Lab, F-92100 Boulogne, France; Hop Bicetre, Serv Bacteriol & Virol, F-94275 Le Kremlin Bicetre, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Liege; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Samama, JP (corresponding author), Inst Pharmacol & Biol Struct, Grp Cristallog Biol, CNRS, UPR 9062, 205 Route Narbonne, F-31077 Toulouse, France.	samama@ipbs.fr	Cabantous, Stephanie/AAB-5113-2020; Cabantous, Stephanie/M-3282-2014; Pedelacq, Jean-Denis/C-6053-2011; Maveyraud, Laurent/C-6066-2011; Mourey, Lionel/B-5662-2009	Cabantous, Stephanie/0000-0002-8406-9421; Cabantous, Stephanie/0000-0002-8406-9421; Maveyraud, Laurent/0000-0003-4610-8319; Mourey, Lionel/0000-0002-8259-1259; PEDELACQ, Jean-Denis/0000-0002-3202-2517				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banerjee S, 1998, BIOCHEMISTRY-US, V37, P3286, DOI 10.1021/bi972127f; BLUMER JL, 1995, SCAND J INFECT DIS, P38; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P374; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; EDWARDS JR, 1995, J ANTIMICROB CHEMOTH, V36, P1; FELICI A, 1995, ANTIMICROB AGENTS CH, V39, P192, DOI 10.1128/AAC.39.1.192; GALLENI M, 1988, BIOCHEM J, V255, P123, DOI 10.1042/bj2550123; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; HUTLESKY A, 1993, J BIOL CHEM, V268, P3690; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; KNOX JR, 1991, J MOL BIOL, V220, P435, DOI 10.1016/0022-2836(91)90023-Y; Knox JR, 1996, CHEM BIOL, V3, P937, DOI 10.1016/S1074-5521(96)90182-9; LABIA R, 1989, J ANTIMICROB CHEMOTH, V24, P219, DOI 10.1093/jac/24.suppl_A.219; LESLIE AGW, 1987, COMPUTATIONAL ASPECT, P39; LIVERMORE DM, 1992, J ANTIMICROB CHEMOTH, V29, P609, DOI 10.1093/jac/29.6.609; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MariotteBoyer S, 1996, FEMS MICROBIOL LETT, V143, P29, DOI 10.1016/0378-1097(96)00288-1; Maveyraud L, 1998, BIOCHEMISTRY-US, V37, P2622, DOI 10.1021/bi972501b; Maveyraud L, 1996, J AM CHEM SOC, V118, P7435, DOI 10.1021/ja9609718; Miyashita K, 1996, BIOORG MED CHEM LETT, V6, P319, DOI 10.1016/0960-894X(96)00022-4; NAAS T, 1994, ANTIMICROB AGENTS CH, V38, P1262, DOI 10.1128/AAC.38.6.1262; NORDMANN P, 1993, ANTIMICROB AGENTS CH, V37, P939, DOI 10.1128/AAC.37.5.939; OSUNA J, 1995, J BIOL CHEM, V270, P775, DOI 10.1074/jbc.270.2.775; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Raquet X, 1997, PROTEINS, V27, P47, DOI 10.1002/(SICI)1097-0134(199701)27:1<47::AID-PROT6>3.0.CO;2-K; RAQUET X, 1994, J MOL BIOL, V244, P625, DOI 10.1006/jmbi.1994.1756; Rasmussen BA, 1996, ANTIMICROB AGENTS CH, V40, P2080, DOI 10.1128/AAC.40.9.2080; Rasmussen BA, 1997, ANTIMICROB AGENTS CH, V41, P223, DOI 10.1128/AAC.41.2.223; Sougakoff W, 1996, J STRUCT BIOL, V116, P313, DOI 10.1006/jsbi.1996.0046; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P688, DOI 10.1038/nsb0896-688; TAIBI P, 1995, J AM CHEM SOC, V117, P7600, DOI 10.1021/ja00134a003; WILSON AJC, 1949, ACTA CRYSTALLOGR, V2, P318, DOI 10.1107/S0365110X49000813; YANG YJ, 1995, J ANTIMICROB CHEMOTH, V35, P75, DOI 10.1093/jac/35.1.75; Zawadzke LE, 1995, PROTEIN ENG, V8, P1275, DOI 10.1093/protein/8.12.1275; Zawadzke LE, 1996, BIOCHEMISTRY-US, V35, P16475, DOI 10.1021/bi962242a	44	77	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26714	26721		10.1074/jbc.273.41.26714	http://dx.doi.org/10.1074/jbc.273.41.26714			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756914	Green Published, hybrid			2022-12-25	WOS:000076373300068
J	Chen, ZQ; Banerjee, R				Chen, ZQ; Banerjee, R			Purification of soluble cytochrome b(5) as a component of the reductive activation of porcine methionine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PLASMA HOMOCYST(E)INE; MEGALOBLASTIC-ANEMIA; P450 REDUCTASE; RISK FACTOR; PIG-LIVER; COBALAMIN; HOMOCYSTINURIA; METABOLISM; MECHANISM	In mammals, methionine synthase plays a central role in the detoxification of the rogue metabolite homocysteine. It catalyzes a transmethylation reaction in which a methyl group is transferred from methyltetrahydrofolate to homocysteine to generate tetrahydrofolate and methionine. The vitamin B-12 cofactor cobalamin plays a direct role in this reaction by alternately accepting and donating the methyl group that is in transit from one substrate (methyltetrahydrofolate) to another (homocysteine). The reactivity of the cofactor intermediate cob(I)alamin renders the enzyme susceptible to oxidative damage. The oxidized enzyme may be returned to the catalytic turnover cycle via a reductive methylation reaction that requires S-adenosylmethionine as a methyl group donor, and a source of electrons. In this study, we have characterized an NADPH-dependent pathway for the reductive activation of porcine methionine synthase. Two proteins are required for the transfer of electrons from NADPH, one of which is microsomal and the other cytoplasmic. The cytoplasmic protein has been purified to homogeneity and is soluble cytochrome b(5). It supports methionine synthase activity in the presence of NADPH and the microsomal component in a saturable manner. In addition, purified microsomal cytochrome P450 reductase and soluble cytochrome b(5) reconstitute the activity of the porcine methionine synthase. Identification of soluble cytochrome b(5) as a member of the reductive activation system for methionine synthase describes a function for this protein in non-erythrocyte cells. In erythrocytes, soluble cytochrome b(5) functions in methemoglobin reduction. In addition, it identifies an additional locus in which genetic polymorphisms may play a role in the etiology of hyperhomocysteinemia, which is correlated with cardiovascular diseases.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rbanerje@unlinfo2.unl.edu			NIDDK NIH HHS [DK45776] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; Baginski ES, 1974, METH ENZYMOL; Banerjee R, 1997, CHEM BIOL, V4, P175, DOI 10.1016/S1074-5521(97)90286-6; Banerjee R, 1997, METHOD ENZYMOL, V281, P189; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BRATTSTROM LE, 1984, STROKE, V15, P1012, DOI 10.1161/01.STR.15.6.1012; CHEN ZQ, 1995, J BIOL CHEM, V270, P19246, DOI 10.1074/jbc.270.33.19246; CHEN ZQ, 1994, J BIOL CHEM, V269, P27193; Dallner G, 1974, Methods Enzymol, V31, P191; DRUMMOND JT, 1993, BIOCHEMISTRY-US, V32, P9290, DOI 10.1021/bi00087a005; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; FUJII K, 1974, J BIOL CHEM, V249, P6745; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; Gulati S, 1997, J BIOL CHEM, V272, P19171, DOI 10.1074/jbc.272.31.19171; Gulati S, 1996, HUM MOL GENET, V5, P1859, DOI 10.1093/hmg/5.12.1859; HULTQUIST DE, 1971, NATURE-NEW BIOL, V229, P252, DOI 10.1038/newbio229252a0; Jarrett JT, 1997, BIOCHEMISTRY-US, V36, P15739, DOI 10.1021/bi971987t; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; Jenkins CM, 1998, BIOCHEMISTRY-US, V37, P6106, DOI 10.1021/bi973076p; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KRAUS JP, 1994, J INHERIT METAB DIS, V17, P383, DOI 10.1007/BF00711354; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; Leclerc D, 1996, HUM MOL GENET, V5, P1867, DOI 10.1093/hmg/5.12.1867; LLOYD E, 1994, BIOCHEMISTRY-US, V33, P11432, DOI 10.1021/bi00204a005; Ludwig ML, 1997, ANNU REV BIOCHEM, V66, P269, DOI 10.1146/annurev.biochem.66.1.269; MALINOW MR, 1995, CLIN CHEM, V41, P173; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MANGUM JH, 1971, BIOCHEMISTRY-US, V10, P3765, DOI 10.1021/bi00796a019; MATTHEWS RG, 1986, METHIONINE BIOSYNTHE, P697; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MCCULLY KS, 1983, ATHER REV, V11, P157; OZOLS J, 1990, METHOD ENZYMOL, V182, P225; PASSON PG, 1972, BIOCHIM BIOPHYS ACTA, V275, P51, DOI 10.1016/0005-2728(72)90023-0; Peterson JA, 1986, CYTOCHROME P 450 STR, P89; POMPON D, 1984, J BIOL CHEM, V259, P5377; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; Rivera M, 1998, BIOCHEMISTRY-US, V37, P1485, DOI 10.1021/bi972390g; ROSENBLATT DS, 1984, J CLIN INVEST, V74, P2149, DOI 10.1172/JCI111641; SCHUH S, 1984, NEW ENGL J MED, V310, P686, DOI 10.1056/NEJM198403153101104; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; VanDerMark PK, 1997, BIOCHEM BIOPH RES CO, V240, P80, DOI 10.1006/bbrc.1997.7599; WALKER FA, 1988, J AM CHEM SOC, V110, P6234, DOI 10.1021/ja00226a045; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438	50	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26248	26255		10.1074/jbc.273.40.26248	http://dx.doi.org/10.1074/jbc.273.40.26248			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748308	hybrid			2022-12-25	WOS:000076263100099
J	Pai, JT; Guryev, O; Brown, MS; Goldstein, JL				Pai, JT; Guryev, O; Brown, MS; Goldstein, JL			Differential stimulation of cholesterol and unsaturated fatty acid biosynthesis in cells expressing individual nuclear sterol regulatory element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; STEAROYL-COA DESATURASE; BOUND TRANSCRIPTION FACTOR; DIPHOSPHATE SYNTHASE GENE; LEUCINE ZIPPER PROTEIN; COENZYME-A REDUCTASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; CULTURED-CELLS; ADIPOCYTE DETERMINATION	Three sterol regulatory element-binding proteins (SREBP-1a, -1c, and -2) stimulate transcription of genes involved in synthesis and receptor-mediated uptake of cholesterol and fatty acids. Here, we explore the individual roles of each SREBP by preparing lines of Chinese hamster ovary (CHO) cells that express graded amounts of nuclear forms of each SREBP (designated nSREBPs) under control of a muristerone-inducible nuclear receptor system. The parental hamster cell line (M19 cells) lacks its own nSREBPs, owing to a deletion in the gene encoding the Site-a protease, which releases nSREBPs from cell membranes. By varying the concentration of muristerone, we obtained graded expression of individual nSREBPs in the range that restored lipid synthesis to near physiologic levels. The results show that nSREBP-2 produces a higher ratio of synthesis of cholesterol over fatty acids than does nSREBP-1a. This is due in part to a selective ability of low levels of nSREBP-2, but not nSREBP-1a, to activate the promoter for squalene synthase. nSREBP-1a and -2 both activate transcription of the genes encoding stearoyl-CoA desaturase-l and -2, thereby markedly enhancing the production of monounsaturated fatty acids. nSREBP-1c was inactive in stimulating any transcription at the concentrations achieved in these studies. The current data support the emerging view that the nSREBPs act in complementary ways to modulate the lipid composition of cell membranes.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Belarus Acad Sci, Inst Bioorgan Chem, Minsk 220141, BELARUS	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Academy of Sciences of Belarus (NASB); Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus	Pai, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; AOYAMA Y, 1994, BIOCHEM BIOPH RES CO, V201, P1320, DOI 10.1006/bbrc.1994.1848; BOLLAG DM, 1991, PROTEIN METHODS, P100; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1978, J BIOL CHEM, V253, P1121; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; GIL G, 1986, J BIOL CHEM, V261, P3717; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Guan GM, 1998, J BIOL CHEM, V273, P12526, DOI 10.1074/jbc.273.20.12526; Guan GM, 1997, J BIOL CHEM, V272, P10295; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KRIEGER M, 1979, J SUPRAMOL STR CELL, V10, P467, DOI 10.1002/jss.400100409; KUSANO M, 1995, BIOL PHARM BULL, V18, P195; LIMANEK JS, 1978, P NATL ACAD SCI USA, V75, P5452, DOI 10.1073/pnas.75.11.5452; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magana MM, 1997, J LIPID RES, V38, P1630; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Miserez AR, 1997, GENOMICS, V40, P31, DOI 10.1006/geno.1996.4525; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rosenfeld JM, 1998, J BIOL CHEM, V273, P16112, DOI 10.1074/jbc.273.26.16112; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO R, 1994, J BIOL CHEM, V269, P17267; SEGE RD, 1986, MOL CELL BIOL, V6, P3268, DOI 10.1128/MCB.6.9.3268; Sessler AM, 1996, J BIOL CHEM, V271, P29854, DOI 10.1074/jbc.271.47.29854; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Waters KM, 1997, BBA-LIPID LIPID MET, V1349, P33, DOI 10.1016/S0005-2760(97)00069-6; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	62	185	192	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26138	26148		10.1074/jbc.273.40.26138	http://dx.doi.org/10.1074/jbc.273.40.26138			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748295	hybrid			2022-12-25	WOS:000076263100086
J	Zhang, LJ; Zhan, SL; Navid, F; Li, QD; Choi, YH; Kim, M; Seth, P; Helman, LJ				Zhang, LJ; Zhan, SL; Navid, F; Li, QD; Choi, YH; Kim, M; Seth, P; Helman, LJ			AP-2 may contribute to IGF-II overexpression in rhabdomyosarcoma	ONCOGENE			English	Article						IGF-II; AP-2; tumor cells	TRANSCRIPTION FACTOR AP-2; GROWTH FACTOR-II; GENE-EXPRESSION; INDUCIBLE ENHANCER; MAMMARY-CARCINOMA; CYCLIC-AMP; CELL-LINE; PROMOTER; EMBRYOGENESIS; ACTIVATION	The human insulin-like growth factor II gene is regulated in a development-dependent manner and is not expressed in most adult tissues. However, high levels of insulin-like growth factor II mRNA are detected in many human tumors including rhabdomyosarcoma, an embryonal tumor of skeletal muscle origin. In this study, we demonstrate that the developmentally regulated transcription factor AP-2 is expressed at higher levels in human fetal skeletal muscle and rhabdomyosarcoma cells compared to human adult skeletal muscle, Endogenous insulin-like growth factor II mRNA derived from the P3 as well as transfected P3 promoter activity were modestly and consistently increased to the same extent following treatment of the rhabdomyosarcoma cell line RD with forskolin, a compound implicated in AP-2 transactivation, This effect of AP-2 on increased transcriptional activity was confirmed by nuclear run-on assays. Expression of AP-2B, a dominant-negative inhibitor of AP-2, suppressed the P3 promoter activity in AP-2 expressing RD cells. Furthermore, five AP-2 protected regions corresponding to six AP-2 specific binding sites were detected in the insulin-like growth factor II P3 promoter. These data together suggest that AP-2 may contribute to the high expression of IGF-II in rhabdomyosarcoma cells.	NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; NCI, Med Ovarian Canc Sect, NIH, Bethesda, MD 20892 USA; NCI, Cell Signaling & Oncogenesis Sect, NIH, Bethesda, MD 20892 USA; NCI, Med Breast Canc Sect, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Helman, LJ (corresponding author), NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bldg 10,Rm 13N240, Bethesda, MD 20892 USA.			Choi, Yung Hyun/0000-0002-1454-3124				BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CROUCH GD, 1993, EXP CELL RES, V204, P210, DOI 10.1006/excr.1993.1026; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; ELBADRY OM, 1989, J CLIN INVEST, V84, P829, DOI 10.1172/JCI114243; Gong DW, 1996, J BIOL CHEM, V271, P3971; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MINNITI CP, 1994, AM J CLIN PATHOL, V101, P198, DOI 10.1093/ajcp/101.2.198; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; RAJ NBK, 1983, P NATL ACAD SCI-BIOL, V80, P3923, DOI 10.1073/pnas.80.13.3923; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhang LJ, 1996, CANCER RES, V56, P1367	31	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1261	1270		10.1038/sj.onc.1202050	http://dx.doi.org/10.1038/sj.onc.1202050			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771969				2022-12-25	WOS:000075803300008
J	Katoh, H; Aoki, J; Yamaguchi, Y; Kitano, Y; Ichikawa, A; Negishi, M				Katoh, H; Aoki, J; Yamaguchi, Y; Kitano, Y; Ichikawa, A; Negishi, M			Constitutively active G alpha(12), G alpha(13), and G alpha(q) induce rho-dependent neurite retraction through different signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; LYSOPHOSPHATIDIC ACID; INOSITOL 1,4,5-TRISPHOSPHATE; ADP-RIBOSYLTRANSFERASE; EXCHANGE FACTOR; ALPHA-SUBUNITS; PC12 CELLS; ACTIVATION; RECEPTOR; KINASE	In neuronal cells, activation of a certain heterotrimeric G protein-coupled receptor causes neurite retraction and cell rounding via the small GTPase Rho, However, the specific heterotrimeric G proteins that mediate Rho dependent neurite retraction and cell rounding have not yet been identified. Here we investigated the effects of expression of constitutively active G alpha subunits on the morphology of differentiated PC12 cells, Expression of GTPase-deficient G alpha(12), G alpha(13), and G alpha(q), but not G alpha(i2), caused neurite retraction and cell rounding in differentiated PC12 cells. These morphological changes induced by G alpha(12), G alpha(13), and G alpha(q) were completely inhibited by C3 exoenzyme, which specifically ADP-ribosylates and inactivates Rho, The tyrosine kinase inhibitor tyrphostin A25 blocked the neurite retraction and cell rounding induced by G alpha(13) and G alpha(q). However, tyrphostin A25 failed to inhibit the G alpha(12)-induced neuronal morphological changes. On the other hand, inhibition of protein kinase C or elimination of extracellular Ca2+ blocked the neurite retraction and cell rounding induced by G alpha q, whereas the morphological effects of G alpha(12) and G alpha(13) did not require activation of protein kinase C and extracellular Ca2+, These results demonstrate that activation of G alpha(12), G alpha(13), and G alpha(q) induces Rho-dependent morphological changes in PC12 cells through different signaling pathways.	Kyoto Univ, Fac Pharmaceut Sci, Dept Mol Neurobiol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Fac Pharmaceut Sci, Dept Mol Neurobiol, Sakyo Ku, Kyoto 6068501, Japan.		Yamaguchi, Yoshiaki/K-9418-2013	Yamaguchi, Yoshiaki/0000-0003-4126-542X				AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GOODMAN CS, 1993, CELL S, V10, P77; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Jin Z, 1997, J NEUROSCI, V17, P6256; Katoh H, 1996, J BIOL CHEM, V271, P29780, DOI 10.1074/jbc.271.47.29780; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MOCHIZUKIODA N, 1994, J BIOL CHEM, V269, P9651; NOBES CD, 1995, J CELL SCI, V108, P225; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; Tigyi G, 1996, J NEUROCHEM, V66, P549; Tigyi G, 1996, J NEUROCHEM, V66, P537; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	44	157	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28700	28707		10.1074/jbc.273.44.28700	http://dx.doi.org/10.1074/jbc.273.44.28700			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786865	hybrid			2022-12-25	WOS:000076691800026
J	Rokaw, MD; Wang, JM; Edinger, RS; Weisz, OA; Hui, D; Middleton, P; Shlyonsky, V; Berdiev, BK; Ismailov, I; Eaton, DC; Benos, DJ; Johnson, JP				Rokaw, MD; Wang, JM; Edinger, RS; Weisz, OA; Hui, D; Middleton, P; Shlyonsky, V; Berdiev, BK; Ismailov, I; Eaton, DC; Benos, DJ; Johnson, JP			Carboxylmethylation of the beta subunit of xENaC regulates channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; PROTEIN CARBOXYL METHYLTRANSFERASES; PLANAR LIPID BILAYERS; SODIUM-CHANNELS; APICAL MEMBRANE; ALPHA-SUBUNIT; METHYLATION; ALDOSTERONE; A6	The action of aldosterone to increase apical membrane permeability in responsive epithelia is thought to be due to activation of sodium channels. Aldosterone stimulates methylation of a 95-kDa protein in apical membrane of A6 cells, and we have previously shown that methylation of a 95-kDa protein in the immunopurified Na+ channel complex increases open probability of these channels in planar lipid bilayers. We report here that aldosterone stimulates carboxylmethylation of the beta subunit of xENaC in A6 cells. In vitro translated beta subunit, but not alpha or gamma, serves as a substrate for carboxylmethylation. Carboxylmethylation of ENaC reconstituted in planar lipid bilayers leads to an increase in open probability only when beta subunit is present. When the channel complex is immunoprecipitated from A6 cells and analyzed by Western blot with antibodies to the three subunits of xENaC, all three subunits are recognized as constituents of the complex. The results suggest that Na+ channel activity in A6 cells is regulated, in part, by carboxylmethylation of the beta subunit of xENaC.	Univ Pittsburgh, Med Ctr, Dept Med, Lab Epithelial Cell Biol, Pittsburgh, PA 15213 USA; Emory Univ, Dept Physiol, Atlanta, GA 30322 USA; Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Emory University	Johnson, JP (corresponding author), Univ Pittsburgh, Med Ctr, Dept Med, Lab Epithelial Cell Biol, 937 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15213 USA.		Hui, Daniel J/H-8855-2013	Hui, Daniel J/0000-0003-0294-3582; Shlyonsky, Vadim/0000-0003-2999-6553; Eaton, Douglas/0000-0002-2686-6692	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206, R01DK052991, R01DK047874, R56DK037206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52991, DK47874, DK37206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; COUPAYEGERARD B, 1993, J MEMBRANE BIOL, V135, P225; EATON DC, 1995, KIDNEY INT, V48, P941, DOI 10.1038/ki.1995.375; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Harlow E., 1988, ANTIBODIES LABORATOR, P511; ISMAILOV II, 1994, J BIOL CHEM, V269, P22193; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; ISMAILOV II, 1995, J GEN PHYSIOL, V106, P445, DOI 10.1085/jgp.106.3.445; May A, 1997, J AM SOC NEPHROL, V8, P1813; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rokaw MD, 1996, J BIOL CHEM, V271, P4491; SARIBANSOHRABY S, 1993, J BIOL CHEM, V268, P26613; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WEISMANN WP, 1985, AM J PHYSIOL, V248, pF43	23	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28746	28751		10.1074/jbc.273.44.28746	http://dx.doi.org/10.1074/jbc.273.44.28746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786871	hybrid			2022-12-25	WOS:000076691800032
J	Schultheis, PJ; Lorenz, JN; Meneton, P; Nieman, ML; Riddle, TM; Flagella, M; Duffy, JJ; Doetschman, T; Miller, ML; Shull, GE				Schultheis, PJ; Lorenz, JN; Meneton, P; Nieman, ML; Riddle, TM; Flagella, M; Duffy, JJ; Doetschman, T; Miller, ML; Shull, GE			Phenotype resembling Gitelman's syndrome in mice lacking the apical Na+-Cl- cotransporter of the distal convoluted tubule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOKALEMIC ALKALOSIS; ANGIOTENSIN-II; BARTTERS-SYNDROME; RENAL-CORTEX; TRANSPORT; CELLS; ADAPTATION; MUTATIONS; KIDNEY; RAT	Mutations in the gene encoding the thiazide-sensitive Na+-Cl- cotransporter (NCC) of the distal convoluted tubule cause Gitelman's syndrome, an inherited hypokalemic alkalosis with hypomagnesemia and hypocalciuria, These metabolic abnormalities are secondary to the deficit in NaCl reabsorption, but the underlying mechanisms are unclear. To gain a better understanding of the role of NCC in sodium and fluid volume homeostasis and in the pathogenesis of Gitelman's syndrome, we used gene targeting to prepare an NCC-deficient mouse. Null mutant (Ncc(-/-)) mice appear healthy and are normal with respect to acid-base balance, plasma electrolyte concentrations, serum aldosterone levels, and blood pressure. Ncc(-/-) mice retain Na+ as well as wild-type mice when fed a Na+-depleted diet; however, after 2 weeks of Na+ depletion the mean arterial blood pressure of Ncc(-/-) mice was significantly lower than that of wild-type mice. In addition, Ncc(-/-) mice exhibited increased renin mRNA levels in kidney, hypomagnesemia and hypocalciuria, and morphological changes in the distal convoluted tubule, These data indicate that the loss of NCC activity in the mouse causes only subtle perturbations of sodium and fluid volume homeostasis, but renal handling of Mg2+ and Ca2+ are altered, as observed in Gitelman's syndrome.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethseda Ave, Cincinnati, OH 45267 USA.	shullge@ucmail.uc.edu	Meneton, Pierre/T-1216-2019		NHLBI NIH HHS [HL41496] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050594, R37DK050594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BETTINELLI A, 1992, J PEDIATR-US, V120, P38, DOI 10.1016/S0022-3476(05)80594-3; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Costanzo LS, 1992, KIDNEY PHYSL PATHOPH, P2375; CUSHNER HM, 1990, AM J KIDNEY DIS, V16, P495, DOI 10.1016/S0272-6386(12)80067-9; Dai LJ, 1997, KIDNEY INT, V51, P1008, DOI 10.1038/ki.1997.141; DORUP J, 1985, J ULTRA MOL STRUCT R, V92, P101, DOI 10.1016/0889-1605(85)90132-6; ELLISON DH, 1993, AM J PHYSIOL, V264, pF141, DOI 10.1152/ajprenal.1993.264.1.F141; ELLISON DH, 1989, J CLIN INVEST, V83, P113, DOI 10.1172/JCI113847; GAMBA G, 1994, J BIOL CHEM, V269, P17713; GESEK FA, 1992, J CLIN INVEST, V90, P429, DOI 10.1172/JCI115878; GULLNER HG, 1981, AM J MED, V71, P578, DOI 10.1016/0002-9343(81)90209-6; Hummler E, 1997, P NATL ACAD SCI USA, V94, P11710, DOI 10.1073/pnas.94.21.11710; KAISSLING B, 1985, AM J PHYSIOL, V248, pF374, DOI 10.1152/ajprenal.1985.248.3.F374; KAISSLING B, 1988, AM J PHYSIOL, V255, pF1256, DOI 10.1152/ajprenal.1988.255.6.F1256; Kaplan MR, 1996, ANNU REV PHYSIOL, V58, P649, DOI 10.1146/annurev.ph.58.030196.003245; Loffing J, 1996, KIDNEY INT, V50, P1180, DOI 10.1038/ki.1996.426; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; MADSEN KM, 1986, AM J PHYSIOL, V250, pF1, DOI 10.1152/ajprenal.1986.250.1.F1; Mastroianni N, 1996, AM J HUM GENET, V59, P1019; Meneton P, 1998, J CLIN INVEST, V101, P536, DOI 10.1172/JCI1720; Navar LG, 1997, SEMIN NEPHROL, V17, P412; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Plotkin MD, 1996, KIDNEY INT, V50, P174, DOI 10.1038/ki.1996.300; Quamme GA, 1997, KIDNEY INT, V52, P1180, DOI 10.1038/ki.1997.443; Quan A, 1997, SEMIN NEPHROL, V17, P423; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Simon DB, 1996, AM J PHYSIOL-RENAL, V271, pF961, DOI 10.1152/ajprenal.1996.271.5.F961; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; STANTON BA, 1988, AM J PHYSIOL, V255, pF1269, DOI 10.1152/ajprenal.1988.255.6.F1269; WHANG R, 1985, ARCH INTERN MED, V145, P1686, DOI 10.1001/archinte.145.9.1686; YANAGAWA N, 1991, KIDNEY INT, V39, pS33	33	237	239	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29150	29155		10.1074/jbc.273.44.29150	http://dx.doi.org/10.1074/jbc.273.44.29150			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786924	hybrid			2022-12-25	WOS:000076691800085
J	Adam, L; Vadlamudi, R; Kondapaka, SB; Chernoff, J; Mendelsohn, J; Kumar, R				Adam, L; Vadlamudi, R; Kondapaka, SB; Chernoff, J; Mendelsohn, J; Kumar, R			Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; BREAST-CANCER; GENE-PRODUCT; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; PROTO-ONCOGENE; EXPRESSION	The mechanisms through which heregulin (HRG) regulates the activities of breast cancer cells are currently unknown. We demonstrate that HRG stimulation of noninvasive breast cancer cells enhanced the conversion of globular to filamentous actin and the formation of membrane ruffles, stress fibers, filopodia, and lamellipodia and accompanied by increased cell migration, In addition, HRG; triggered a rapid stimulation of p21-activated kinasel (PAK1) activity and its redistribution into the leading edges of motile cells. The HRG-induced stimulation of PAK1 kinase activity followed phosphatidylinositol-3 kinase (PI-3 kinase) activation. Inhibition of PI-3 kinase activity blocked the activation of PAK1 kinase and also blocked cell migration in response to HRG., Furthermore, direct inhibition of PAK1 functions by the dominant-negative mutant suppressed the capacity of HRG to reorganize actin cytoskeleon structures. We also demonstrated that HRG stimulation promoted physical interactions between PAK1, actin, and human epidermal growth factor receptor 2 (HER2) receptors, and these interactions were dependent on the activation of PI-3 kinase, The blockade of HER2 receptor by an anti-HERB monoclonal antibody resulted in the inhibition of HRG-mediated stimulation of PI-3 kinase/PAK pathway and also the formation of motile actin cytoskeleton structures but not extracellular signal-regulated kinases, These findings suggest a role of PI-3 kinase/PAK1-dependent reorganization of the cortical actin cytoskeleton in HRG-mediated increased cell migration, and these changes may have significant consequences leading to enhanced invasion by breast cancer cells.	Univ Texas, MD Anderson Cancer Ctr, Cell Growth Regulat Sect, Cell Growth Regulat Lab, Houston, TX 77030 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	University of Texas System; UTMD Anderson Cancer Center; Fox Chase Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Cell Growth Regulat Sect, Cell Growth Regulat Lab, 1515 Holcombe Blvd,Box 36, Houston, TX 77030 USA.	rkumar@notes.mdacc.tmc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NATIONAL CANCER INSTITUTE [U01CA065746, R01CA065746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054168] Funding Source: NIH RePORTER; NCI NIH HHS [CA65746] Funding Source: Medline; NIGMS NIH HHS [GM54168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM L, 1994, INT J CANCER, V59, P262, DOI 10.1002/ijc.2910590219; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; FAN Z, 1993, J BIOL CHEM, V268, P21073; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; KIM HH, 1994, J BIOL CHEM, V269, P24747; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; KUMAR R, 1995, J CELL BIOCHEM, V62, P102; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	38	258	262	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28238	28246		10.1074/jbc.273.43.28238	http://dx.doi.org/10.1074/jbc.273.43.28238			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774445	hybrid			2022-12-25	WOS:000076549800065
J	Hua, CT; Gamble, JR; Vadas, MA; Jackson, DE				Hua, CT; Gamble, JR; Vadas, MA; Jackson, DE			Recruitment and activation of SHP-1 protein-tyrosine phosphatase by human platelet endothelial cell adhesion molecule-1 (PECAM-1) - Identification of immunoreceptor tyrosine-based inhibitory motif-like binding motifs and substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; ANTIGEN RECEPTOR; MEMBRANE GLYCOPROTEIN; CONTAINING PEPTIDES; CYTOPLASMIC DOMAIN; PHOSPHORYLATION; INTEGRIN; PTP1C; AGGREGATION; ASSOCIATION	Stimulation of platelet aggregation leads to tyrosine phosphorylation of a number of receptors and signaling molecules including platelet endothelial cell adhesion molecule-1 (PECAM-1). In this report, we demonstrate that both protein-tyrosine phosphatases SHP-1 and SHP-2 physically associate with different kinetics of assembly with tyrosine-phosphorylated human PECAM-1 during integrin alpha(IIb)beta(3)-mediated platelet aggregation. Peptido-precipitation analysis revealed that tyrosine phosphorylated peptides encompassing residues 658-668 and 681-691 of PECAM-1 bound specifically to both protein-tyrosine phosphatases SHP-1 and SHP-2, We further show that the association of SHP-1 with PECAM-1 occurs through the direct interaction of the src homology region 2 domains of SHP-1 with two highly conserved phosphotyrosine binding motifs within PECAM-1 having the sequences NSDVQpY(663)TEVQV and DTETVpY(686)SEVRK (where pY represents phosphotyrosine). In vitro dephosphorylation experiments using phosphotyrosyl PECAM-1 peptides encompassing either Tyr-663 or Tyr-686 revealed induction of SHP-1 catalytic activity, suggesting that PECAM-1 serves as a SHP-1 substrate. Surface plasmon resonance studies reveal that recombinant SHP-2 binds PECAM-1 phosphopeptides with 5-fold higher affinity than recombinant SHP-1, These data suggest that in hematopoietic cells such as platelets, PECAM-1 cellular signaling is regulated by the selective recruitment and activation of two distinct protein-tyrosine phosphatases, SHP-1 and SHP-2, via a common immunoreceptor tyrosine-based inhibitory-like motif.	Inst Med & Vet Sci, Div Human Immunol, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia	Jackson, DE (corresponding author), Inst Med & Vet Sci, Div Human Immunol, Hanson Ctr Canc Res, POB 14,Rundle Mall, Adelaide, SA 5000, Australia.	Denise.Jackson@imvs.sa.gov.au	Vadas, Mathew/R-1378-2019	Gamble, Jennifer/0000-0002-0179-9964				BERMAN ME, 1995, J IMMUNOL, V154, P299; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GOLDBERGER A, 1994, J BIOL CHEM, V269, P17183; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LEAVESLEY DI, 1994, J IMMUNOL, V153, P4673; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; LI RY, 1994, FEBS LETT, V343, P89, DOI 10.1016/0014-5793(94)80613-6; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; Lu TT, 1997, J BIOL CHEM, V272, P14442, DOI 10.1074/jbc.272.22.14442; Masuda M, 1997, FEBS LETT, V408, P331, DOI 10.1016/S0014-5793(97)00457-2; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Olcese L, 1996, J IMMUNOL, V156, P4531; Osawa M, 1997, EUR J CELL BIOL, V72, P229; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Sagawa K, 1997, J BIOL CHEM, V272, P13412, DOI 10.1074/jbc.272.20.13412; Sagawa K, 1997, J BIOL CHEM, V272, P31086, DOI 10.1074/jbc.272.49.31086; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; Sun QH, 1996, J BIOL CHEM, V271, P11090, DOI 10.1074/jbc.271.19.11090; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VANZANT G, 1989, EXP HEMATOL, V17, P81; Varon D, 1998, BLOOD, V91, P500, DOI 10.1182/blood.V91.2.500.500_500_507; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Vely F, 1997, J IMMUNOL, V159, P2075; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	62	99	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28332	28340		10.1074/jbc.273.43.28332	http://dx.doi.org/10.1074/jbc.273.43.28332			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774457	hybrid			2022-12-25	WOS:000076549800077
J	Rae, TD; Goff, HM				Rae, TD; Goff, HM			The heme prosthetic group of lactoperoxidase - Structural characteristics of heme 1 and heme 1-peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; NATURAL PORPHYRIN DERIVATIVES; HUMAN MYELOPEROXIDASE; ELECTRONIC-STRUCTURE; AUTOLYTIC CLEAVAGE; PROTOHEME-IX; ACTIVE-SITE; PEROXIDASE; COMPLEXES; SPECTROSCOPY	The heme prosthetic group from the bovine milk enzyme lactoperoxidase (LPO), termed heme 1, is isolated through an approach that combines proteolytic hydrolysis and reverse-phase high performance liquid chromatographic separation of the resulting digest. Application of different proteases yields either a peptide-bound heme (with trypsin and chymotrypsin) or a peptide-free heme (with proteinase K). Both heme 1 and heme 1-peptide species were investigated by paramagnetic H-1 NMR spectroscopy, electrospray mass spectrometry, and peptide sequence analysis. Paramagnetic H-1 MMR experiments on the low spin bis(cyano)-Fe(III)heme 1 complex conclusively define the heme 1 structure as a 1,5-bis(hydroxymethyl) derivative of heme b. The electrospray mass spectrum of heme 1 confirms the two-site hydroxyl functionalization on this heme, Paramagnetic H-1 NMR spectra of the high spin bis(dimethyl sulfoxide)-Fe(III) complexes of the isolated heme species provide information regarding peptide content. Sequence analyses of peptides released from two heme 1-peptide species by base hydrolysis suggest that heme-protein ester linkages in lactoperoxidase occur between the two hydroxyl groups of heme 1 and the carboxylic side chains of glutamate 275 and aspartate 125, These results confirm the earlier reported structural proposal (Rae, T, D., and Goff, H. M. (1996) J. Am. Chem. Soc. 118, 2103-2104).	Univ Iowa, Dept Chem, Iowa City, IA 52242 USA	University of Iowa	Goff, HM (corresponding author), Univ Iowa, Dept Chem, Iowa City, IA 52242 USA.							Andersson LA, 1996, J BIOL CHEM, V271, P3406, DOI 10.1074/jbc.271.7.3406; BANCI L, 1992, COORDIN CHEM REV, V120, P1, DOI 10.1016/0010-8545(92)80045-S; Borhan B, 1996, FRESEN J ANAL CHEM, V354, P490; BUDD DL, 1979, J AM CHEM SOC, V101, P6091, DOI 10.1021/ja00514a036; CALS MM, 1991, EUR J BIOCHEM, V198, P733, DOI 10.1111/j.1432-1033.1991.tb16073.x; CARLSTROM A, 1969, ACTA CHEM SCAND, V23, P171, DOI 10.3891/acta.chem.scand.23-0171; CHATFIELD MJ, 1988, J AM CHEM SOC, V110, P6352, DOI 10.1021/ja00227a013; DePillis GD, 1997, J BIOL CHEM, V272, P8857; DEROPP JS, 1991, J AM CHEM SOC, V113, P4348, DOI 10.1021/ja00011a058; DUGAD LB, 1990, J AM CHEM SOC, V112, P1386, DOI 10.1021/ja00160a015; DUGAD LB, 1990, J BIOL CHEM, V265, P7173; DULL TJ, 1990, DNA CELL BIOL, V9, P499, DOI 10.1089/dna.1990.9.499; EDMAN LW, 1984, J IMMUNOASSY, V5, P29; Everse J.E.K.E., 1991, PEROXIDASES CHEM BIO, VI; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; GIOIA L, 1996, J BIOL INORG CHEM, V1, P476; GOFF HM, 1985, BIOCHEM BIOPH RES CO, V133, P794, DOI 10.1016/0006-291X(85)90974-X; HULTQUIST DE, 1963, J BIOL CHEM, V238, P2843; HURST JK, 1991, PEROXIDASES CHEM BIO, V1, P37; ISAAC MF, 1993, INORG CHEM, V32, P4030, DOI 10.1021/ic00071a011; KOHLER H, 1988, ARCH BIOCHEM BIOPHYS, V264, P438, DOI 10.1016/0003-9861(88)90309-8; Kooter IM, 1997, J AM CHEM SOC, V119, P11542, DOI 10.1021/ja9725460; La Mar G.N., 1993, BIOL MAGN RESON, P1; LAMAR GN, 1978, J AM CHEM SOC, V100, P8085, DOI 10.1021/ja00494a010; LICOCCIA S, 1989, J AM CHEM SOC, V111, P6087, DOI 10.1021/ja00198a017; MORELL DB, 1963, BIOCHIM BIOPHYS ACTA, V71, P157, DOI 10.1016/0006-3002(63)90994-6; NICHOL AW, 1987, BIOCHEM J, V247, P147, DOI 10.1042/bj2470147; Pruitt K.M., 1985, IMMUNOLOGY SERIES, V27; Rae TD, 1996, J AM CHEM SOC, V118, P2103, DOI 10.1021/ja952650m; SIEVERS G, 1979, BIOCHIM BIOPHYS ACTA, V579, P181, DOI 10.1016/0005-2795(79)90097-7; TAYLOR KL, 1992, J BIOL CHEM, V267, P25282; TAYLOR KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P635, DOI 10.1006/abbi.1995.1083; VANGEET AL, 1970, ANAL CHEM, V42, P679, DOI 10.1021/ac60288a022; YONETANI T, 1967, J BIOL CHEM, V242, P5008; YU C, 1986, J MAGN RESON, V67, P346, DOI 10.1016/0022-2364(86)90440-3; [No title captured]	36	55	58	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27968	27977		10.1074/jbc.273.43.27968	http://dx.doi.org/10.1074/jbc.273.43.27968			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774411	hybrid			2022-12-25	WOS:000076549800031
J	Spurney, RF				Spurney, RF			Role of C-terminal serines in desensitization and phosphorylation of the mouse thromboxane receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; AGONIST-DEPENDENT PHOSPHORYLATION; HUMAN PLATELETS; A(2) RECEPTOR; EXPRESSION; CLONING; BETA; PROSTAGLANDIN; INHIBITOR; ISOFORMS	To investigate the role of C-terminal hydroxyamino acids in desensitization of the receptor for thromboxane A(2) (TxA(2)), we created a mutant TxA(2) receptor (TP receptor) in which serines at positions 321, 322, and 328 were replaced with either alanine or glycine. Mutant and wild type receptors were expressed in a mesangial cell line, and clones expressing similar numbers of receptors were studied. Affinity and specificity of TxA(2) binding to the mutant receptor were identical to wild type receptors. In contrast, TxA(2)-induced inositol trisphosphate generation by the mutant receptor was enhanced compared with the wild type. Prior treatment with the TxA(2) agonist U46619 reduced subsequent U46619-induced increases in inositol trisphosphate generation by both receptors; however, the extent of desensitization was significantly reduced in the receptor mutant. Protein kinase C (PKC) inhibitors attenuated TxA(2)-induced desensitization of wild type receptors, but had little effect on TxA(2)-induced desensitization of mutant receptors, Pretreatment with the phorbol ester phorbol 12,13-dybutyrate (PDBu) (100 nM) decreased subsequent responsiveness of wild type but not mutant TP receptors, U46619-induced desensitization of wild type receptors was associated with enhanced phosphorylation of receptor proteins. This agonist-specific phosphorylation of the TP receptor was largely prevented by inhibitors of PKC. Treatment with 100 nM PDBu increased phosphorylation of both wild type and mutant TP receptors, but the extent of phosphorylation of the receptor mutant was reduced compared with the wild type. Increasing the concentration of PDBu from 100 nM to 1 mu M PDBu reduced responsiveness of both mutant and wild type receptors without enhancing phosphorylation of either of the receptor proteins. These data suggest that 1) phosphorylation of C-terminal serines contributes to agonist-specific desensitization of the TP receptor, 2) PKC-induced desensitization of TP receptors is caused, in part, by phosphorylation of C-terminal serines, and 3) desensitization of TP receptors by PKC is complex and involves mechanisms that may not require direct phosphorylation of receptor proteins.	Duke Univ, Med Ctr, Dept Med, Div Nephrol, Durham, NC 27710 USA; Vet Adm Med Ctr, Durham, NC 27710 USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Spurney, RF (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Nephrol, Box 3014, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047333] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29-DK47333] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE T, 1995, J CLIN INVEST, V96, P657, DOI 10.1172/JCI118108; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; COLEMAN RA, 1981, BRIT J PHARMACOL, V73, P773, DOI 10.1111/j.1476-5381.1981.tb16814.x; DOLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653; DORN GW, 1992, AM J PHYSIOL, V263, pC864, DOI 10.1152/ajpcell.1992.263.4.C864; FITZGERALD GA, 1987, FASEB J, V46, P154; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; JANSSEN K, 1993, CURRENT PROTOCOLS MO; KINSELLA BT, 1994, J BIOL CHEM, V269, P29914; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; MORINELLI TA, 1989, J PHARMACOL EXP THER, V251, P557; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OGLETREE ML, 1985, J PHARMACOL EXP THER, V234, P435; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PEARSON RB, 1991, METHOD ENZYMOL, V200, P63; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; RYU SH, 1990, J BIOL CHEM, V265, P17941; Sambrook J., 2002, MOL CLONING LAB MANU; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHENKER A, 1991, J BIOL CHEM, V266, P9309; Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698; Spurney RF, 1997, J PHARMACOL EXP THER, V283, P207; SPURNEY RF, 1994, AM J PHYSIOL, V267, pF467, DOI 10.1152/ajprenal.1994.267.3.F467; SPURNEY RF, 1997, J AM SOC NEPHROL, V8, pA447; STORK JE, 1986, AM J MED, V80, P34, DOI 10.1016/0002-9343(86)90930-7; TAKANO T, 1994, J BIOL CHEM, V269, P22453; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1	37	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28496	28503		10.1074/jbc.273.43.28496	http://dx.doi.org/10.1074/jbc.273.43.28496			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774479	hybrid			2022-12-25	WOS:000076549800099
J	Bouzier, AK; Goodwin, R; de Gannes, FMP; Valeins, H; Voisin, P; Canioni, P; Merle, M				Bouzier, AK; Goodwin, R; de Gannes, FMP; Valeins, H; Voisin, P; Canioni, P; Merle, M			Compartmentation of lactate and glucose metabolism in C6 glioma cells - A C-13 and H-1 NMR study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASTROCYTES; HEART; <1-C-13>GLUCOSE; MITOCHONDRIAL; FLUORESCENCE; NEURONS; FATE	C-13 and H-1 NMR spectroscopy was used to investigate the metabolism of L-lactate and D-glucose in C6 glioma cells, The changing of lactate and glucose concentration in the extracellular medium of C6 glioma cells incubated with 5.5 mM glucose and 11 mM lactate indicated a net production of lactate as the consequence of an active aerobic glycolysis. The C-13 enrichments of various metabolites were determined after 4-h cell incubation in media containing both substrates, each of them being alternatively labeled in the form of either [3-C-13]L-lactate or [1-C-13]D-glucose. Using 11 mM [3-C-13]L-lactate, the enrichment of glutamate C4, 69%, was found higher than that of alanine C3, 32%, when that of acetyl-CoA C2 was 78%. These results indicated that exogenous lactate was the major substrate for the oxidative metabolism of the cells, Nevertheless, an active glycolysis occurred, leading to a net lactate production. This lactate was, however, metabolically different from the exogenous lactate as both lactate species did not mix into a unique compartment, The results were actually consistent with the concept of the existence of two pools of both lactate and pyruvate, wherein one pool was closely connected with exogenous lactate and was the main fuel for the oxidative metabolism, and the other pool was closely related to aerobic glycolysis.	Univ Victor Segalen, CNRS, UMR 5536, Lab Res Magnet Syst Biol, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Canioni, P (corresponding author), Univ Victor Segalen, CNRS, UMR 5536, Lab Res Magnet Syst Biol, 146 Rue Leo Saignat, F-33076 Bordeaux, France.		de Gannes, Florence Poulletier/B-9827-2011	Bouzier-Sore, Anne-Karine/0000-0002-3470-0940				ARGILES JM, 1988, MOL CELL BIOCHEM, V81, P3; Brand K, 1997, J BIOENERG BIOMEMBR, V29, P355, DOI 10.1023/A:1022498714522; CLEGG JS, 1990, ARCH BIOCHEM BIOPHYS, V278, P452, DOI 10.1016/0003-9861(90)90284-6; Damico LA, 1996, J MOL CELL CARDIOL, V28, P989, DOI 10.1006/jmcc.1996.0092; DRINGEN R, 1995, DEV NEUROSCI-BASEL, V17, P63, DOI 10.1159/000111275; HENRIKSON RL, 1984, DEV NEUROSCI, V1, P226; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; LIU ZJ, 1987, PLANT PHYSIOL, V84, P1385, DOI 10.1104/pp.84.4.1385; Lovry O.H., 1951, J BIOL CHEM, V193, P265; LUST WD, 1975, MOL CELL BIOCHEM, V8, P169, DOI 10.1007/BF01792767; Magistretti PJ, 1996, CEREB CORTEX, V6, P50, DOI 10.1093/cercor/6.1.50; MALLOY CR, 1990, BIOCHEMISTRY-US, V29, P6756, DOI 10.1021/bi00481a002; MARTIN M, 1993, EUR J BIOCHEM, V217, P617, DOI 10.1111/j.1432-1033.1993.tb18284.x; McKenna MC, 1996, J NEUROCHEM, V66, P386; Merle M, 1996, EUR J BIOCHEM, V239, P742, DOI 10.1111/j.1432-1033.1996.0742u.x; MUSGROVE E, 1986, CYTOMETRY, V7, P347, DOI 10.1002/cyto.990070409; OVADI J, 1996, CHANNELLING INTERMED, P237; PEUHKURINEN KJ, 1983, BIOCHEM J, V210, P193, DOI 10.1042/bj2100193; PIANET I, 1991, EUR J BIOCHEM, V195, P87, DOI 10.1111/j.1432-1033.1991.tb15679.x; Portais JC, 1996, BIOCHIMIE, V78, P155, DOI 10.1016/0300-9084(96)89500-9; PORTAIS JC, 1993, EUR J BIOCHEM, V217, P457, DOI 10.1111/j.1432-1033.1993.tb18265.x; Ross B D, 1988, NMR Biomed, V1, P20, DOI 10.1002/nbm.1940010105; SCHWARTZ JP, 1975, MOL CELL BIOCHEM, V9, P67, DOI 10.1007/BF01732197; STJOHN PA, 1986, J NEUROSCI, V6, P1492; THOLEY G, 1981, J NEUROCHEM, V36, P77, DOI 10.1111/j.1471-4159.1981.tb02379.x; VAUPEL P, 1992, NMR BIOMED, V5, P220, DOI 10.1002/nbm.1940050505; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309	27	58	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27162	27169		10.1074/jbc.273.42.27162	http://dx.doi.org/10.1074/jbc.273.42.27162			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765235	hybrid			2022-12-25	WOS:000076448000022
J	Pfeiffer, S; Mayer, B				Pfeiffer, S; Mayer, B			Lack of tyrosine nitration by peroxynitrite generated at physiological pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE AUTOXIDATION; CARBON-DIOXIDE; AQUEOUS-SOLUTION; CATALYZED OXIDATION; IN-VIVO; SUPEROXIDE; KINETICS; NITROTYROSINE; HYDROXYLATION; MECHANISM	Nitration of tyrosine residues of proteins has been suggested as a marker of peroxynitrite-mediated tissue injury in inflammatory conditions. The nitration reaction has been extensively studied in vitro by bolus addition of authentic peroxynitrite, an experimental approach hardly reflecting in vivo situations in which the occurrence of peroxynitrite is thought to result from continuous generation of (NO)-N-. and O-2(radical anion) at physiological pH, In the present study, we measured the nitration of free tyrosine by (NO)-N-. and O-2(radical anion) generated at web defined rates from the donor compound (Z)-1-[N-[3-aminopropyl]-N-[4-(3-aminopropylammonio)butyl]-amino]-diazen-1-ium-1,2-diolate] (spermine NONOate) and the xanthine oxidase reaction, respectively. The results were compared with the established nitration reaction triggered by authentic peroxynitrite, Bolus addition of peroxynitrite (1 mM) to tyrosine (1 mM) at pH 7.4 yielded 36.77 +/- 1.67 mu M 3-nitrotyrosine, corresponding to a recovery of about 4%. However, peroxynitrite formed from (NO)-N-. and O-2(radical anion), which were generated at equal rates (similar to 5 mu M X min(-1)) from 1 mM spermine NONOate, 28 milliunits/ml xanthine oxidase, and 1 mM hypoxanthine was much less efficient (0.67 +/- 0.01 mu M; similar to 0.07% of total product flow). At O-2(radical anion) fluxes exceeding the (NO)-N-. release rates, 3-nitrotyrosine formation was below the detection limit of the high performance Liquid chromatography method (<0.06 mu M) Nitration was most efficient (similar to 0.3%) with the (NO)-N-. donor alone, i.e. without concomitant generation of O-2(radical anion). Nitration by (NO)-N-. had a pH optimum of 8.2, increased progressively with increasing tyrosine concentrations (0.1-2 mM), and was not enhanced by NaHCO3 (up to 20 mar), indicating that it was mediated by (NO2)-N-. rather than peroxynitrite, Our results argue against peroxynitrite produced from (NO)-N-. and O-2(radical anion) as a mediator of tyrosine nitration in vivo.	Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria	University of Graz	Pfeiffer, S (corresponding author), Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, Univ Platz 2, A-8010 Graz, Austria.	silvia.pfeiffer@kfunigraz.ac.at	Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494				Akaike T, 1996, P NATL ACAD SCI USA, V93, P2448, DOI 10.1073/pnas.93.6.2448; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Berlett BS, 1998, P NATL ACAD SCI USA, V95, P2784, DOI 10.1073/pnas.95.6.2784; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CROW JP, 1994, FREE RADICAL BIO MED, V16, P331, DOI 10.1016/0891-5849(94)90034-5; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; Feelisch M., 1989, J CARDIOVASC PHARM, V14, P13; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; Goodwin DC, 1998, J BIOL CHEM, V273, P8903, DOI 10.1074/jbc.273.15.8903; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; HADDAD IY, 1993, AM J PHYSIOL, V265, pL555, DOI 10.1152/ajplung.1993.265.6.L555; HALFPENNY E, 1952, J CHEM SOC, P939, DOI 10.1039/jr9520000939; Halliwell B, 1997, FEBS LETT, V411, P157, DOI 10.1016/S0014-5793(97)00469-9; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; Kelm M, 1997, J BIOL CHEM, V272, P9922; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KIGUGAWA K, 1994, FREE RADICAL BIO MED, V16, P273; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KUKOVETZ WR, 1989, J CARDIOVASC PHARM, V14, pS40, DOI 10.1097/00005344-198914110-00008; Lemercier JN, 1997, ARCH BIOCHEM BIOPHYS, V345, P160, DOI 10.1006/abbi.1997.0240; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, CHEM RES TOXICOL, V9, P845, DOI 10.1021/tx960046z; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; Mannick EE, 1996, CANCER RES, V56, P3238; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MAYER B, 1992, J NEUROCHEM, V59, P2024; MAYER B, 1997, TRENDS BIOCHEM SCI, V22, P453; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763, DOI 10.1164/ajrccm.155.5.9154889; Schmidt K, 1997, N-S ARCH PHARMACOL, V355, P457, DOI 10.1007/PL00004969; TSAI JHM, 1994, J AM CHEM SOC, V116, P4115, DOI 10.1021/ja00088a072; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9; Wink DA, 1997, J BIOL CHEM, V272, P11147; XIE QW, 1994, J LEUKOCYTE BIOL, V56, P576, DOI 10.1002/jlb.56.5.576	58	156	157	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27280	27285		10.1074/jbc.273.42.27280	http://dx.doi.org/10.1074/jbc.273.42.27280			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765252	hybrid			2022-12-25	WOS:000076448000039
J	Diarra-Mehrpour, M; Sarafan, N; Bourguignon, J; Bonnet, F; Bost, F; Martin, JP				Diarra-Mehrpour, M; Sarafan, N; Bourguignon, J; Bonnet, F; Bost, F; Martin, JP			Human inter-alpha-trypsin inhibitor heavy chain H3 gene - Genomic organization, promoter analysis, and gene linkage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUMULUS EXTRACELLULAR-MATRIX; COVALENTLY CROSS-LINKS; AMINO-ACID-SEQUENCE; HUMAN-PLASMA; CELL-LINE; HEPG2 CELLS; PROTEIN; FAMILY; ALPHA-1-MICROGLOBULIN; PRECURSOR	To understand more about the human inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) expression and the relationship between this gene and the family of other ITI heavy chain genes, an analysis of the structure of the ITIH3 gene and its promoter region was performed. This gene is a single copy gene, 14 kilobase pair in length and consists of 22 exons, ITIH3 shares highly conserved exon size and intron-exon borders with other ITI heavy chain genes. We determined that the human ITIH1, ITIH3, and ITIH4 genes are closely linked within a 45-kilobase pair. They are arranged in the order of H1-H3-H4, with the ITIH4 gene transcribed in the opposite direction. A model for the evolution of the ITI heavy chain gene family is presented that involves multiple rounds of gene duplication plus inversion events. The minimum promoter region (-135 to +75) is identified in HepG2 cells. The transient transfection study in various cell lines indicates that the activity of the ITIH3 promoter is not liver-specific. DNase I footprinting, mobility shift assays, and cotransfection experiments reveal a functional CCAAT/enhancer-binding protein site (C/EBP, -1344 to -1305) which interacts with C/EBP alpha and C/EBP beta factors. The latter factors control the transcription of the ITIH3 gene positively.	Fac Med, INSERM, U295, Lab Physiopathol & Genet Renale & Pulm, F-76183 Rouen, France; Univ Rouen, IFR Physicochim & Biol Syst Integres 61, F-76821 Mont St Aignan, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Diarra-Mehrpour, M (corresponding author), Fac Med, INSERM, U295, Lab Physiopathol & Genet Renale & Pulm, 22 Blvd Gambetta, F-76183 Rouen, France.	maryam.diarra-mehropour@univ-rouen.fr	BOST, Frederic/AAN-4691-2020; Mehrpour, Maryam/D-8640-2017	BOST, Frederic/0000-0003-4509-4701; mehrpour, maryam/0000-0002-5002-1366				ALLROBYN JA, 1990, MOL CELL BIOL, V10, P6544, DOI 10.1128/MCB.10.12.6544; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BOST F, 1993, EUR J BIOCHEM, V218, P283, DOI 10.1111/j.1432-1033.1993.tb18376.x; Bost F, 1998, EUR J BIOCHEM, V252, P339, DOI 10.1046/j.1432-1327.1998.2520339.x; BOURGUIGNON J, 1989, BIOCHEM J, V261, P305, DOI 10.1042/bj2610305; BOURGUIGNON J, 1993, EUR J BIOCHEM, V212, P771, DOI 10.1111/j.1432-1033.1993.tb17717.x; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P743; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1994, J BIOL CHEM, V269, P28282; CHIAO PJ, 1992, MOL CARCINOGEN, V5, P219, DOI 10.1002/mc.2940050309; CHOIMIURA NH, 1995, J BIOCHEM, V117, P400, DOI 10.1093/jb/117.2.400; DAVEAU M, 1993, BIOCHEM J, V292, P485, DOI 10.1042/bj2920485; DIARRAMEHRPOUR M, 1994, BBA-GENE STRUCT EXPR, V1219, P551, DOI 10.1016/0167-4781(94)90087-6; DIARRAMEHRPOUR M, 1989, EUR J BIOCHEM, V179, P147, DOI 10.1111/j.1432-1033.1989.tb14532.x; DIARRAMEHRPOUR M, 1990, EUR J BIOCHEM, V191, P131, DOI 10.1111/j.1432-1033.1990.tb19102.x; DIARRAMEHRPOUR M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P114, DOI 10.1016/0167-4781(92)90065-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GEBHARD W, 1988, FEBS LETT, V229, P63, DOI 10.1016/0014-5793(88)80798-1; GONZALEZRAMON N, 1995, FEBS LETT, V371, P227, DOI 10.1016/0014-5793(95)00882-A; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HELLER DL, 1988, MOL CELL BIOL, V8, P2797, DOI 10.1128/MCB.8.7.2797; HERON A, 1994, BIOCHEM J, V302, P573, DOI 10.1042/bj3020573; HOCHSTRASSER K, 1976, H-S Z PHYSIOL CHEM, V357, P153, DOI 10.1515/bchm2.1976.357.1.153; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; JESSEN TE, 1988, FEBS LETT, V230, P195, DOI 10.1016/0014-5793(88)80670-7; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; KOBAYASHI H, 1995, J BIOL CHEM, V270, P8361, DOI 10.1074/jbc.270.14.8361; KOBAYASHI H, 1995, INT J CANCER, V63, P455, DOI 10.1002/ijc.2910630326; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; MAESTRO R, 1993, CANCER RES, V53, P5775; Maniatis T., 1982, MOL CLONING LAB MANU; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; NISHIMURA H, 1995, FEBS LETT, V357, P207; ODUM L, 1992, INT J BIOCHEM, V24, P215, DOI 10.1016/0020-711X(92)90249-Z; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POTEMPA J, 1989, J BIOL CHEM, V264, P15109; PU PX, 1994, BIOCHIM BIOPHYS ACTA, V1208, P338; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; RAYMONDJEAN M, 1991, NUCLEIC ACIDS RES, V19, P6145, DOI 10.1093/nar/19.22.6145; ROUET P, 1992, J BIOL CHEM, V267, P20765; ROUET P, 1995, NUCLEIC ACIDS RES, V23, P395, DOI 10.1093/nar/23.3.395; Saguchi K, 1996, J BIOCHEM, V119, P898; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; Samadani U, 1996, MOL CELL BIOL, V16, P6273; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAFAN N, 1995, EUR J BIOCHEM, V227, P808, DOI 10.1111/j.1432-1033.1995.tb20205.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700; TOBE T, 1995, CYTOGENET CELL GENET, V71, P296, DOI 10.1159/000134130; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657	57	15	16	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26809	26819		10.1074/jbc.273.41.26809	http://dx.doi.org/10.1074/jbc.273.41.26809			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756925	hybrid			2022-12-25	WOS:000076373300079
J	Kobayashi, M; Ohara-Nemoto, Y; Kaneko, M; Hayakawa, H; Sekiguchi, M; Yamamoto, K				Kobayashi, M; Ohara-Nemoto, Y; Kaneko, M; Hayakawa, H; Sekiguchi, M; Yamamoto, K			Potential of Escherichia coli GTP cyclohydrolase II for hydrolyzing 8-oxo-dGTP, a mutagenic substrate for DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUS MUTATIONS; ENDONUCLEASE-VIII; OXYGEN RADICALS; MTH1 PROTEIN; MUTT PROTEIN; CLONING; GENE; GUANINE; CDNA; PURIFICATION	MutT protein of Escherichia coli prevents the occurrence of A:T --> C:G transversion by hydrolyzing an oxidized form of dGTP, 8-oxo-7,8-dihydro-2'-deoxyguanosine 5'-triphosphate (8-oxo-dGTP), which is produced by active oxygen species. In a search for mutT-related genes, we found that the ribA gene, encoding GTP cyclohydrolase II, is able to reduce the increased level of mutation frequency of the mutT strain to almost the normal level, provided that the gene product is overproduced. Purified preparations of Escherichia coli GTP cyclohydrolase II protein as well as the histidine hexamer-tagged recombinant GTP cyclohydrolase II protein efficiently hydrolyze 8-oxo-dGTP and 8-oxo-GTP, producing 8-oxo-dGMP and 8-oxo-GMP, respectively. dGTP was not hydrolyzed by these preparations; GTP cyclohydrolase II catalyzes conversion of GTP to 2,5-diamino-6-hydroxy-4-(5-phosphoribosylamino)-pyrimidine, which constitutes the first step for riboflavin synthesis. The K-m values for the three types of guanine nucleotides, GTP, 8-oxo-GTP, and 8-oxo-dGTP, were almost the same. In the mutT(-) background, ribA(-) cells showed higher spontaneous mutation frequencies as compared with that of ribA(+) cells. Thus, GTP cyclohydrolase II, the ribA gene product, has a potential to protect genetic material from the untoward effects of endogenous oxygen radicals.	Tohoku Univ, Grad Sch Sci, Inst Biol, Sendai, Miyagi 9808578, Japan; Iwate Med Univ, Sch Dent, Dept Microbiol, Morioka, Iwate 0208505, Japan; Kyushu Univ, Sch Med, Dept Biochem, Fukuoka 8128582, Japan; Fukuoka Dent Coll, Dept Biol, Fukuoka 8140193, Japan	Tohoku University; Iwate Medical University; Kyushu University; Fukuoka Dental College (FDC)	Yamamoto, K (corresponding author), Tohoku Univ, Grad Sch Sci, Inst Biol, Sendai, Miyagi 9808578, Japan.							Aburatani H, 1997, CANCER RES, V57, P2151; AKASAKA S, 1992, MOL GEN GENET, V235, P173, DOI 10.1007/BF00279358; AKASAKA S, 1991, MUTAT RES, V254, P27, DOI 10.1016/0921-8777(91)90037-P; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BESSHO T, 1993, P NATL ACAD SCI USA, V90, P8901, DOI 10.1073/pnas.90.19.8901; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; COX EC, 1969, J BACTERIOL, V100, P390, DOI 10.1128/JB.100.1.390-397.1969; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; FOOR F, 1975, J BIOL CHEM, V250, P3545; Foor F, 1980, Methods Enzymol, V66, P303; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KASAI H, 1984, JPN J CANCER RES, V75, P1037; Koh YS, 1996, MOL GEN GENET, V251, P591, DOI 10.1007/s004380050206; Luria SE, 1943, GENETICS, V28, P491; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MEDIGUE C, 1991, J MOL BIOL, V222, P851, DOI 10.1016/0022-2836(91)90575-Q; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; RICHTER G, 1993, J BACTERIOL, V175, P4045, DOI 10.1128/JB.175.13.4045-4051.1993; Saito Y, 1997, J BACTERIOL, V179, P3783, DOI 10.1128/jb.179.11.3783-3785.1997; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SHIBUTANI S, 1991, NATURE, V349, P432; SLATER TF, 1984, BIOCHEM J, V222, P1; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; Yakushiji H, 1997, MUTAT RES-DNA REPAIR, V384, P181, DOI 10.1016/S0921-8777(97)00025-6; Yamamoto K, 1997, J RADIAT RES, V38, P1, DOI 10.1269/jrr.38.1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	36	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26394	26399		10.1074/jbc.273.41.26394	http://dx.doi.org/10.1074/jbc.273.41.26394			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756871	hybrid			2022-12-25	WOS:000076373300025
J	Mounkes, LC; Zhong, W; Cipres-Palacin, G; Heath, TD; Debs, RJ				Mounkes, LC; Zhong, W; Cipres-Palacin, G; Heath, TD; Debs, RJ			Proteoglycans mediate cationic Liposome-DNA complex-based gene delivery in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-RELATED PROTEIN; FIBROBLAST GROWTH; CELL-SURFACE; EXPRESSION; MATRIX; DEGRADATION; MECHANISM; RELEASE; BINDING	The factors controlling cationic liposome-DNA complex (CLDC)-based gene transfer in cells and in animals are poorly understood. me found that cell surface heparin/heparan sulfate-bearing proteoglycans mediate CLDC-based gene transfer and expression both in cultured cells and following intravenous gene delivery into animals. CLDC did not transfect Raji cells, which lack proteoglycans, but did efficiently transfect Raji cells stably transfected with the proteoglycan, syndecan-1, Fucoidan, heparin, or dextran sulfate, all of which are highly anionic polysaccharides, each blocked CLDC-mediated transfection both in cultured cells and following intravenous injection into mice, but had no effect on transfection by either recombinant adenovirus infection or electroporation. Intravenous pretreatment of mice with heparinases, which specifically cleave heparan sulfate molecules from cell surface proteoglycans, blocked intravenous, CLDC-mediated transfection in mice, confirming that proteoglycans mediate CLDC gene delivery in vivo. Modulation of proteoglycan expression may prove useful in controlling the efficiency of, as well as targeting the sites of, CLDC-based gene transfer in animals.	Calif Pacific Med Res Inst, San Francisco, CA 94115 USA; Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of Wisconsin System; University of Wisconsin Madison	Debs, RJ (corresponding author), Calif Pacific Med Res Inst, Stern Bldg,2330 Clay St, San Francisco, CA 94115 USA.				NATIONAL CANCER INSTITUTE [R01CA058914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049550, R01DK045917] Funding Source: NIH RePORTER; NCI NIH HHS [CA58914] Funding Source: Medline; NIDDK NIH HHS [DK49550, DK45917] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Batra RK, 1997, J BIOL CHEM, V272, P11736, DOI 10.1074/jbc.272.18.11736; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CANONICO AE, 1994, J APPL PHYSIOL, V77, P415, DOI 10.1152/jappl.1994.77.1.415; Cole GJ, 1996, PERSPECT DEV NEUROBI, V3, P359; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Friend DS, 1996, BBA-BIOMEMBRANES, V1278, P41, DOI 10.1016/0005-2736(95)00219-7; GALLAGHER JT, 1994, EUR J CLIN CHEM CLIN, V32, P239; GOTTE M, 1995, EUR J CELL BIOL, V66, P226; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; JI ZS, 1995, J LIPID RES, V36, P583; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; LabatMoleur F, 1996, GENE THER, V3, P1010; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; Mamo JCL, 1996, BIOCHEMISTRY-US, V35, P10210, DOI 10.1021/bi960188s; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; MUIR H, 1995, BIOESSAYS, V17, P1039, DOI 10.1002/bies.950171208; NIETFELD JJ, 1993, EXPERIENTIA, V49, P456, DOI 10.1007/BF01923589; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; PRICE P, 1995, IMMUNOL CELL BIOL, V73, P308, DOI 10.1038/icb.1995.47; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; ROUGHLEY PJ, 1994, MICROSC RES TECHNIQ, V28, P385, DOI 10.1002/jemt.1070280505; Sambrook J., 2002, MOL CLONING LAB MANU; Sawitzky D, 1996, MED MICROBIOL IMMUN, V184, P155, DOI 10.1007/BF02456129; SIVARAM P, 1995, J BIOL CHEM, V270, P29760; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; Thierry AR, 1997, GENE THER, V4, P226, DOI 10.1038/sj.gt.3300350; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	46	203	210	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26164	26170		10.1074/jbc.273.40.26164	http://dx.doi.org/10.1074/jbc.273.40.26164			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748298	hybrid			2022-12-25	WOS:000076263100089
J	Rao, S; Karray, S; Gackstetter, ER; Koshland, ME				Rao, S; Karray, S; Gackstetter, ER; Koshland, ME			Myocyte enhancer factor-related B-MEF2 is developmentally expressed in B cells and regulates the immunoglobulin J chain promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX TRANSCRIPTION FACTORS; DNA-BINDING SPECIFICITY; GENE-EXPRESSION; MEF2 PROTEIN; MUSCLE; ACTIVATION; DIFFERENTIATION; ELEMENT; KINASE; SEQUENCE	Immunoglobulin J chain gene expression is induced by the delivery of a lymphokine signal to antigen-activated B cells in a primary immune response. A major interleukin 2 (IL-2)-responsive region that contains two adjacent control elements (JA and JB) exists within the J chain promoter. Transcription factor PU.1 positively regulates J chain gene expression by binding to one of the control elements (JB) in the J chain promoter. In the present study we have determined that a myocyte enhancer factor 2 (MEF2)-related nuclear factor, named B-MEF2, positively regulates the J chain gene promoter activity via the second control element (JA), An in vitro translated MEF2 family member, MEF2C, was found to bind the JA site with identical properties as endogenously expressed B-MEF2 in B cell lines. Moreover, in vivo experiments showed that a dominant negative mutant of MEF2C blocked B-MEF2 regulation of the J chain promoter. Consistent with its role as positive regulator of J chain gene expression, B-MEF2 levels were enhanced in highly differentiated B cells. In addition, induction of an IL-2-responsive presecretor cell line BCL1 with IL-2 or IL-5 (which up-regulates J chain gene expression) resulted in an increased expression of B-MEF2. We conclude that a MEF2-related transcriptional factor, B-MEF2, acts as a stage-specific positive regulator of J chain gene expression in the B cell lineage.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA; Inst Pasteur, Dept Immunol, F-75015 Paris, France	University of California System; University of California Berkeley; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Rao, S (corresponding author), PE Appl Biosyst, 850 Lincoln Ctr Dr, Foster City, CA 94404 USA.	RaoSU@PEABD.com		Karray, Saoussen/0000-0003-0107-4039				BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BLACKMAN M, 1986, CELL, V46, P609; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DODUO E, 1995, NUCLEIC ACIDS RES, V23, P4267; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Kang CJ, 1998, IMMUNITY, V8, P285, DOI 10.1016/S1074-7613(00)80534-8; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KOSHLAND ME, 1985, ANNU REV IMMUNOL, V3, P425; LANSFORD RD, 1992, P NATL ACAD SCI USA, V89, P5966, DOI 10.1073/pnas.89.13.5966; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MCFADDEN HJ, 1991, P NATL ACAD SCI USA, V88, P11027, DOI 10.1073/pnas.88.24.11027; MINIE ME, 1986, MOL CELL BIOL, V6, P4031, DOI 10.1128/MCB.6.11.4031; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NAKANISHI K, 1984, J EXP MED, V160, P1736, DOI 10.1084/jem.160.6.1736; NILES MJ, 1995, P NATL ACAD SCI USA, V92, P2884, DOI 10.1073/pnas.92.7.2884; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Subramanian SV, 1996, MECH DEVELOP, V57, P103, DOI 10.1016/0925-4773(96)00542-4; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUN K, 1996, CURR OPIN CELL BIOL, V6, P877	37	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26123	26129		10.1074/jbc.273.40.26123	http://dx.doi.org/10.1074/jbc.273.40.26123			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748293	hybrid			2022-12-25	WOS:000076263100084
J	Tlapak-Simmons, VL; Kempner, ES; Baggenstoss, BA; Weigel, PH				Tlapak-Simmons, VL; Kempner, ES; Baggenstoss, BA; Weigel, PH			The active streptococcal hyaluronan synthases (HASs) contain a single HAS monomer and multiple cardiolipin molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION TARGET ANALYSIS; GROUP-A STREPTOCOCCI; ACID SYNTHASE; PROTEIN-KINASE; INACTIVATION; MEMBRANE; CLONING; SUBUNIT; BINDING; WEIGHT	The functional sizes of the two streptococcal hyaluronan synthases (HASs) were determined by radiation inactivation analysis of isolated membranes. The native enzymes in membranes from Group A Streptococcus pyogenes HAS and Group C Streptococcus equisimilis HAS were compared with the recombinant proteins expressed in Escherichia coli membranes. Based on their amino acid sequences, the masses of these four proteins as monomers are similar to 48 kDa. In all cases, loss of enzyme activity was a simple single exponential function with increasing radiation dose. The functional sizes calculated from these data were identical for the four HASs at similar to 64 kDa. In contrast, the sizes of the proteins estimated by the loss of antibody reactivity on Western blots were essentially identical at 41 kDa for the four RAS species, consistently lower than the functional size by similar to 23 kDa. Matrix-assisted laser desorption time of flight mass spectrometry analysis of purified S. pyogenes HAS-H-6 and S. equisimilis HAS-H-6 gave masses that differed by <0.07% from the predicted monomer sizes, which confirms that neither protein is posttranslationally modified or covalently attached to another protein. Ongoing studies indicate that the purified HAS enzymes require cardiolipin (CL) for maximal activity and stability. When irradiated membranes were detergent solubilized and the extracts were incubated with exogenous CL, the residual level of HAS activity increased. Consequently, the calculated functional size decreased by similar to 23 kDa to the expected size of the RAS monomer. The similar to 23-kDa larger size of the functional HAS enzyme, compared with the HAS monomer, is due, therefore, to CL molecules. We propose that the active streptococcal IIA syntheses are monomers in complex with similar to 16 CL molecules.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; NIAMS, Phys Biol Lab, NIH, Bethesda, MD 20892 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.				NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUREGARD G, 1980, BIOCHEM BIOPH RES CO, V96, P1290, DOI 10.1016/0006-291X(80)90091-1; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BOYER TD, 1992, ANAL BIOCHEM, V207, P51, DOI 10.1016/0003-2697(92)90498-V; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUPIN V, 1995, FEBS LETT, V373, P239, DOI 10.1016/0014-5793(95)01054-I; CRATER DL, 1995, J BIOL CHEM, V270, P18452, DOI 10.1074/jbc.270.31.18452; DeAngelis PL, 1997, SCIENCE, V278, P1800, DOI 10.1126/science.278.5344.1800; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DeAngelis PL, 1995, DEV BIOL STAND, V85, P225; DeAngelis PL, 1996, BIOCHEMISTRY-US, V35, P9768, DOI 10.1021/bi960154k; DEVES R, 1998, PHYSIOL REV, V78, P545; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Fulop C, 1997, ARCH BIOCHEM BIOPHYS, V337, P261, DOI 10.1006/abbi.1996.9793; HARMON JT, 1985, METHOD ENZYMOL, V117, P65; Harwood C., 1990, MOL BIOL METHODS BAC, P1; HELDERMON C, 1996, MOL BIOL CELL, V7, P55; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; HOFFMANN B, 1994, J BIOL CHEM, V269, P1940; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; ITO K, 1977, CELL, V11, P551, DOI 10.1016/0092-8674(77)90073-3; KASTRAU DHW, 1994, EUR J BIOCHEM, V222, P293, DOI 10.1111/j.1432-1033.1994.tb18868.x; KEMPNER ES, 1993, TRENDS BIOCHEM SCI, V18, P236, DOI 10.1016/0968-0004(93)90169-N; KEMPNER ES, 1986, ANAL BIOCHEM, V156, P140, DOI 10.1016/0003-2697(86)90165-X; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Kumari K, 1997, J BIOL CHEM, V272, P32539, DOI 10.1074/jbc.272.51.32539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Malhotra R, 1996, BIOCHEM J, V314, P297, DOI 10.1042/bj3140297; Matsushima H, 1996, J NEUROCHEM, V67, P317; MCINTYRE JO, 1983, J BIOL CHEM, V258, P953; Meyer K, 1934, J BIOL CHEM, V107, P629; Miller JH, 1998, ARCH BIOCHEM BIOPHYS, V352, P281, DOI 10.1006/abbi.1998.0604; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; Paradies G, 1997, BBA-BIOENERGETICS, V1319, P5, DOI 10.1016/S0005-2728(97)00012-1; Peng B, 1996, J BIOL CHEM, V271, P32233, DOI 10.1074/jbc.271.50.32233; PESTKA S, 1983, J BIOL CHEM, V258, P9706; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; POTIER M, 1991, BIOCHEMISTRY-US, V30, P8151, DOI 10.1021/bi00247a009; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; ROSS AC, 1993, J LIPID RES, V34, P1201; Schmidt KH, 1996, MED MICROBIOL IMMUN, V184, P169, DOI 10.1007/PL00008248; Schwarz D, 1996, J BIOL CHEM, V271, P12840, DOI 10.1074/jbc.271.22.12840; Sheng YH, 1996, J IMMUNOL, V157, P3744; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Spicer AP, 1997, J BIOL CHEM, V272, P8957; STEVENS BR, 1990, P NATL ACAD SCI USA, V87, P1456, DOI 10.1073/pnas.87.4.1456; SUGAHARA K, 1979, J BIOL CHEM, V254, P6252; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRISCOTT MX, 1986, J BIOL CHEM, V261, P6004; VANDERIJN I, 1992, J BIOL CHEM, V267, P24302; VIA DP, 1992, P NATL ACAD SCI USA, V89, P6780, DOI 10.1073/pnas.89.15.6780; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317	61	70	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26100	26109		10.1074/jbc.273.40.26100	http://dx.doi.org/10.1074/jbc.273.40.26100			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748290	hybrid			2022-12-25	WOS:000076263100081
J	Trevino, RJ; Tsalkova, T; Kramer, G; Hardesty, B; Chirgwin, JM; Horowitz, PM				Trevino, RJ; Tsalkova, T; Kramer, G; Hardesty, B; Chirgwin, JM; Horowitz, PM			Truncations at the NH2 terminus of rhodanese destabilize the enzyme and decrease its heterologous expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; INTRACELLULAR PROTEIN DEGRADATION; ESCHERICHIA-COLI; TRANSCRIPTION TRANSLATION; RAPID DEGRADATION; PRECURSOR PROTEIN; BACTERIAL-CELLS; STABILITY; INACTIVATION; GROEL	Rhodanese mutants containing sequential NH2-terminal deletions were constructed to test the distinct contributions of this region of the protein to expression, folding, and stability. The results indicate that the first 11 residues are nonessential for folding to the active conformation, but they are necessary for attaining an active, stable structure when expressed in Escherichia coli, Rhodanese species with up to 9 residues deleted were expressed and purified. Kinetic parameters for the mutants were similar to those of the full-length enzyme. Compared with shorter truncations, mutants missing 7 or 9 residues were (a) increasingly inactivated by urea denaturation, (b) more susceptible to inactivation by dithiothreitol, (c) less able to be reactivated, and (d) less rapidly inactivated by incubation at 37 degrees C, Immunoprecipitation showed that mutants lacking 10-23 NH2-terminal amino acids were expressed as inactive species of the expected size but were rapidly eliminated. Cell-free transcription/translation at 37 degrees C showed mutants deleted through residue 9 were enzymatically active, but they were inactive when deleted further, just as in vivo, However, at 30 degrees C in vitro, both Delta 1-10 and Delta 1-11 showed considerable activity. Truncations in the NH2 terminus affect the chemical stability of the distantly located active site. Residues Ser-11 through Gly-22, which form the NH2-proximal alpha-helix, contribute to folding to an active conformation, to resisting degradation during heterologous expression, and to chemical stability in vitro.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Med Endocrinol, San Antonio, TX 78284 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Austin	Horowitz, PM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.	horowitz@bioc02.uthscsa.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIRD BA, 1988, J BIOL CHEM, V263, P15270; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BALTSCHEFFSKY H, 1981, MITOCHONDRIA MICROSO, P519; BOGGARAM V, 1985, BIOCHEM BIOPH RES CO, V130, P407, DOI 10.1016/0006-291X(85)90431-0; CANNELLA C, 1983, FEBS LETT, V162, P180, DOI 10.1016/0014-5793(83)81074-6; COSTA M, 1977, BIOCHEM BIOPH RES CO, V78, P596, DOI 10.1016/0006-291X(77)90221-2; DUNGAN JM, 1993, J PROTEIN CHEM, V12, P311, DOI 10.1007/BF01028193; Gliubich F, 1996, J BIOL CHEM, V271, P21054, DOI 10.1074/jbc.271.35.21054; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLDBERG AL, 1974, ANNU REV BIOCHEM, V43, P835, DOI 10.1146/annurev.bi.43.070174.004155; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HOL WGJ, 1983, FUND APPL TOXICOL, V3, P370, DOI 10.1016/S0272-0590(83)80007-4; HOROWITZ PM, 1989, J BIOL CHEM, V264, P3311; HOROWITZ PM, 1993, ACS SYM SER, V516, P167; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; KANDROR O, 1995, EMBO J, V14, P6021, DOI 10.1002/j.1460-2075.1995.tb00290.x; KANDROR O, 1994, J BIOL CHEM, V269, P23575; KIM SK, 1975, BIOCHEM BIOPH RES CO, V67, P433, DOI 10.1016/0006-291X(75)90334-4; KUDLICKI W, 1995, J BIOL CHEM, V270, P10650, DOI 10.1074/jbc.270.18.10650; KUDLICKI W, 1992, ANAL BIOCHEM, V206, P389, DOI 10.1016/0003-2697(92)90383-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO GX, 1993, J BIOL CHEM, V268, P10246; MARGULIS L, 1970, ORIGIN EUKARYOTIC CE, P178; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1994, J PROTEIN CHEM, V13, P15, DOI 10.1007/BF01891988; MERRILL GA, 1993, J BIOL CHEM, V268, P15611; MERRILL GA, 1992, J PROTEIN CHEM, V11, P193, DOI 10.1007/BF01025225; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MILLERMARTINI DM, 1994, J BIOL CHEM, V269, P12414; MILLERMARTINI DM, 1994, J BIOL CHEM, V269, P3423; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHERMAN MY, 1992, EMBO J, V11, P71; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TREVINO RJ, 1993, BIOTECHNIQUES, V15, P366; TSALKOVA T, 1993, BIOCHEMISTRY-US, V32, P3377, DOI 10.1021/bi00064a022; Waltner M, 1996, J BIOL CHEM, V271, P21226, DOI 10.1074/jbc.271.35.21226; WALTNER M, 1995, J BIOL CHEM, V270, P26311, DOI 10.1074/jbc.270.44.26311; Westley J, 1981, Methods Enzymol, V77, P285; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	50	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27841	27847		10.1074/jbc.273.43.27841	http://dx.doi.org/10.1074/jbc.273.43.27841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774394	hybrid			2022-12-25	WOS:000076549800014
J	Wu, CL; Leeuw, T; Leberer, E; Thomas, DY; Whiteway, M				Wu, CL; Leeuw, T; Leberer, E; Thomas, DY; Whiteway, M			Cell cycle- and Cln2p-Cdc28p-dependent phosphorylation of the yeast Ste20p protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; PHEROMONE RESPONSE; S-PHASE; MOLECULAR CHARACTERIZATION; TRANSDUCIN HOMOLOG; FILAMENTOUS GROWTH; BINDING PROTEIN; DNA-SYNTHESIS; G1 CYCLINS	Ste20p from Saccharomyces cerevisiae is a member of the Ste20/p21-activated protein kinase family of protein kinases. The Ste20p kinase is post-translationally modified by phosphorylation in a cell cycle-dependent manner, as judged by the appearance of phosphatase-sensitive species with reduced mobility on SDS-polyacrylamide gel electrophoresis. This modification is maximal during S phase, and correlates with the accumulation of Ste20p fused to green fluorescent protein at the site of bud emergence. Overexpression of Cln2p, but not Clb2p or Clb5p, causes a quantitative shift of Ste20p to the reduced mobility form, and this shift is dependent on Cdc28p activity. The post-translational mobility shift can be generated in vitro by incubation of Ste20p with immunoprecipitated Cln2p kinase complexes, but not by immunoprecipitated Clb2p or Clb5p kinase complexes. Ste20p is therefore a substrate for the Cdc28p kinase, and undergoes a Cln2p-Cdc28p mediated mobility shift as cells initiate budding and DNA replication. In cells that express only the Cln2p G(1) cyclin, minor overexpression of Ste20p causes aberrant morphology, suggesting a proper coordination of Ste20p and Cln-Cdc28p activity may be required for the control of cell shape.	Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 2B2, Canada	National Research Council Canada; McGill University; McGill University; McGill University	Whiteway, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.		Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				BUCKINGTHROM E, 1973, EXP CELL RES, V76, P99, DOI 10.1016/0014-4827(73)90424-2; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; HARTWELL LH, 1973, EXP CELL RES, V76, P111, DOI 10.1016/0014-4827(73)90425-4; HARTWELL LH, 1985, GENETICS, V110, P381; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; IMIGER S, 1995, CELL, V81, P269; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; Lim HH, 1996, MOL GEN GENET, V253, P138, DOI 10.1007/s004380050306; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Maniatis T., 1982, MOL CLONING LAB MANU; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OEHLEN LJWM, 1994, GENE DEV, V8, P1058, DOI 10.1101/gad.8.9.1058; PATTERSON M, 1986, MOL CELL BIOL, V6, P1590, DOI 10.1128/MCB.6.5.1590; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rose MD., 1990, METHODS YEAST GENETI; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Wassmann K, 1997, J BIOL CHEM, V272, P13180, DOI 10.1074/jbc.272.20.13180; Wittenberg C, 1996, CURR OPIN CELL BIOL, V8, P223, DOI 10.1016/S0955-0674(96)80069-X; Wu C, 1997, J BIOL CHEM, V272, P30623, DOI 10.1074/jbc.272.49.30623; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YOON HJ, 1991, P NATL ACAD SCI USA, V88, P3574, DOI 10.1073/pnas.88.9.3574	59	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28107	28115		10.1074/jbc.273.43.28107	http://dx.doi.org/10.1074/jbc.273.43.28107			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774429	hybrid			2022-12-25	WOS:000076549800049
J	Cessna, SG; Chandra, S; Low, PS				Cessna, SG; Chandra, S; Low, PS			Hypo-osmotic shock of tobacco cells stimulates Ca2+ fluxes deriving first from external and then internal Ca2+ stores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY VOLUME DECREASE; CALCIUM-RELEASE CHANNEL; DEPENDENT ANION CHANNEL; CYCLIC ADP-RIBOSE; PLASMA-MEMBRANE; ABSCISIC-ACID; GUARD-CELLS; ENDOPLASMIC-RETICULUM; CYTOSOLIC CALCIUM; OXIDATIVE BURST	Hypo-osmotic shock of aequorin-transformed tobacco cells induces a biphasic cytosolic Ca2+ influx. Because both phases of Ca2+ entry are readily blocked by Ca2+ channel inhibitors, we conclude that the Ca2+ transients are mediated by Ca2+ channels. Evidence that the first but not second Ca2+ transient derives from external Ca2+ stores is that the first but not second influx is (i) eliminated by membrane-impermeable Ca2+ chelators, (ii) enlarged by supplementation of the medium with excess Ca2+, and (iii) reduced by the addition of competitive cations such as Mg2+ and Mn2+. Furthermore, entry of Ca-45 during osmotic shock is prevented by inhibitors of the first but not second phase of Ca2+ entry. Evidence that the second wave of Ca2+ influx stems from release of intracellular Ca2+ is based on the above data plus observations that probable modulators of intracellular Ca2+ channels selectively block this phase of Ca2+ influx. Finally, a mechanism of communication between the two Ca2+ release pathways has become apparent, since perturbations that elevate or reduce the first Ca2+ transient lead to a compensating diminution/elevation of the second and vice versa. These data thus suggest that osmotic shock leads to the sequential opening of extracellular followed by intracellular Ca2+ stores and that these Ca2+ release pathways are internally compensated.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Low, PS (corresponding author), Purdue Univ, Dept Chem, 1393 Brown Bldg, W Lafayette, IN 47907 USA.	lowps@omni.cc.purdue.edu		Low, Philip/0000-0001-9042-5528; Cessna, Stephen/0000-0001-7233-8711				ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; ATKINSON MM, 1990, PLANT PHYSIOL, V92, P215, DOI 10.1104/pp.92.1.215; BarbierBrygoo H, 1997, TRENDS PLANT SCI, V2, P214, DOI 10.1016/S1360-1385(97)89546-5; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Borle A B, 1986, Methods Enzymol, V124, P90; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; CALVERT CM, 1995, J BIOL CHEM, V270, P7272, DOI 10.1074/jbc.270.13.7272; Chandra S, 1997, J BIOL CHEM, V272, P28274, DOI 10.1074/jbc.272.45.28274; Chen XF, 1997, PLANT J, V11, P363, DOI 10.1046/j.1365-313X.1997.11030363.x; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COSGROVE DJ, 1991, PLANTA, V186, P143, DOI 10.1007/BF00201510; Digonnet C, 1997, DEVELOPMENT, V124, P2867; DING JP, 1993, PLANT J, V3, P83, DOI 10.1111/j.1365-313X.1993.tb00013.x; GELLI A, 1993, PLANT PHYSIOL, V102, P1139, DOI 10.1104/pp.102.4.1139; Gelli A, 1997, PLANT PHYSIOL, V113, P269, DOI 10.1104/pp.113.1.269; GILROY S, 1993, J CELL SCI, V106, P453; Gong M, 1998, PLANT PHYSIOL, V116, P429, DOI 10.1104/pp.116.1.429; Grabov A, 1997, PLANT J, V12, P203, DOI 10.1046/j.1365-313X.1997.12010203.x; Haussinger D, 1996, BIOCHEM J, V313, P697; Hirschi KD, 1996, P NATL ACAD SCI USA, V93, P8782, DOI 10.1073/pnas.93.16.8782; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Ishii T, 1996, J PHYSIOL-LONDON, V493, P371, DOI 10.1113/jphysiol.1996.sp021389; JOHANNES E, 1995, J MEMBRANE BIOL, V146, P211; KLUSENER B, 1995, EMBO J, V14, P2708, DOI 10.1002/j.1460-2075.1995.tb07271.x; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; Knight H, 1997, PLANT J, V12, P1067, DOI 10.1046/j.1365-313X.1997.12051067.x; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; KONISHI M, 1987, J PHYSIOL-LONDON, V383, P269; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Leckie CP, 1998, J EXP BOT, V49, P339, DOI 10.1093/jexbot/49.suppl_1.339; Legue V, 1997, PLANT PHYSIOL, V114, P789, DOI 10.1104/pp.114.3.789; LEMTIRICHLIEH F, 1994, J MEMBRANE BIOL, V137, P99; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; MA JJ, 1993, J GEN PHYSIOL, V102, P1031, DOI 10.1085/jgp.102.6.1031; MARTEN I, 1992, EMBO J, V11, P3569, DOI 10.1002/j.1460-2075.1992.tb05440.x; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; MCCARTY NA, 1991, J MEMBRANE BIOL, V123, P149, DOI 10.1007/BF01998085; Muir SR, 1997, J EXP BOT, V48, P589, DOI 10.1093/jxb/48.Special_Issue.589; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PEETERS GA, 1989, AM J PHYSIOL, V256, pC351, DOI 10.1152/ajpcell.1989.256.2.C351; Pierson ES, 1996, DEV BIOL, V174, P160, DOI 10.1006/dbio.1996.0060; Pineros M, 1997, J EXP BOT, V48, P551, DOI 10.1093/jxb/48.Special_Issue.551; PRICE AH, 1994, PLANT CELL, V6, P1301, DOI 10.1105/tpc.6.9.1301; Pugin A, 1997, PLANT CELL, V9, P2077, DOI 10.1105/tpc.9.11.2077; RATHORE KS, 1991, DEV BIOL, V148, P612, DOI 10.1016/0012-1606(91)90278-B; Roberts DM, 1993, CURR OPIN CELL BIOL, V5, P242, DOI 10.1016/0955-0674(93)90110-C; Schulz-Lessdorf B, 1994, Symp Soc Exp Biol, V48, P99; SCHWARTZ A, 1995, PLANT PHYSIOL, V109, P651, DOI 10.1104/pp.109.2.651; SEDBROCK JC, PLANT PHYSL, V111, P243; SUBBAIAH CC, 1994, PLANT CELL, V6, P1747, DOI 10.1105/tpc.6.12.1747; Tahtiharju S, 1997, PLANTA, V203, P442, DOI 10.1007/s004250050212; Takahashi K, 1997, PLANT PHYSIOL, V113, P587, DOI 10.1104/pp.113.2.587; Taylor AR, 1996, PLANT CELL, V8, P2015; Thomine S, 1997, J MEMBRANE BIOL, V159, P71, DOI 10.1007/s002329900270; TINEL H, 1994, AM J PHYSIOL, V267, pF130, DOI 10.1152/ajprenal.1994.267.1.F130; WARD JM, 1995, PLANT CELL, V7, P833, DOI 10.1105/tpc.7.7.833; Wu X, 1997, J MEMBRANE BIOL, V158, P127, DOI 10.1007/s002329900250; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; Xu HX, 1998, PLANT CELL, V10, P585, DOI 10.1105/tpc.10.4.585; YAHRAUS T, 1995, PLANT PHYSIOL, V109, P1259, DOI 10.1104/pp.109.4.1259; ZHA XH, 1995, AM J PHYSIOL-CELL PH, V269, pC923, DOI 10.1152/ajpcell.1995.269.4.C923; Zimmermann S, 1997, P NATL ACAD SCI USA, V94, P2751, DOI 10.1073/pnas.94.6.2751; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	67	59	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27286	27291		10.1074/jbc.273.42.27286	http://dx.doi.org/10.1074/jbc.273.42.27286			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765253	hybrid			2022-12-25	WOS:000076448000040
J	Chiaberge, S; Cassarino, E; Mangiarotti, G				Chiaberge, S; Cassarino, E; Mangiarotti, G			The phosphorylation of protein S6 modulates the interaction of the 40 S ribosomal subunit with the 5 '-untranslated region of a Dictyostelium pre-spore-specific mRNA and controls its stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISCOIDEUM MESSENGER-RNAS; CELL-DIFFERENTIATION; STALK CELL; CAMP; EXPRESSION; KINASE; GENES	AC914 mRNA, a pre-spore-specific mRNA that accumulates only in the post-aggregation stage of development, is transcribed constitutively as shown by nuclear run-off experiments and by fusing its promoter to the luciferase reporter gene. The same mRNA disappears quickly from disaggregated cells. If the 5'-untranslated region (5'UTR) of the constitutively expressed Actin 15 mRNA is substituted for the 5'UTR of AC914 mRNA, this can no longer be destabilized and accumulates both in growing and disaggregated cells. If the 5'UTR of AC914 mRNA is substituted for the 5'UTR of Actin 15 mRNA, the latter accumulates only in aggregated cells. Pactamycin, but not other inhibitors of protein synthesis, prevents AC914 mRNA from being destabilized in disaggregated cells, suggesting a role of 40 S subunits in the destabilization. This has been confirmed by using an in vitro system in which the in vice stability of different mRNAs is reproduced. A protein kinase A-dependent phosphorylation of ribosomal protein S6 determines whether 40 S subunits are capable or not of destabilizing AC914 mRNA in the in vitro system.	Univ Turin, Dept Clin & Biol Sci, Osped S Luigi, I-10043 Orbassano, To, Italy	University of Turin	Mangiarotti, G (corresponding author), Univ Turin, Dept Clin & Biol Sci, Osped S Luigi, I-10043 Orbassano, To, Italy.							ANJARD C, 1992, DEVELOPMENT, V115, P785; BARKLIS E, 1983, CELL, V32, P1139, DOI 10.1016/0092-8674(83)90297-0; BLUMBERG DD, 1980, DEV BIOL, V78, P285, DOI 10.1016/0012-1606(80)90337-1; BOZZARO S, 1984, EMBO J, V3, P193, DOI 10.1002/j.1460-2075.1984.tb01783.x; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; CECCARELLI A, 1987, NUCLEIC ACIDS RES, V15, P7463, DOI 10.1093/nar/15.18.7463; Chattopadhyay S, 1996, P NATL ACAD SCI USA, V93, P8284, DOI 10.1073/pnas.93.16.8284; CHUNG S, 1981, CELL, V24, P785, DOI 10.1016/0092-8674(81)90104-5; COLOMA A, 1980, CELL, V28, P346; Das B, 1996, EUR J BIOCHEM, V235, P613, DOI 10.1111/j.1432-1033.1996.00613.x; HOPPER NA, 1993, DEVELOPMENT, V119, P147; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JULIANI MH, 1983, FEBS LETT, V154, P400, DOI 10.1016/0014-5793(83)80191-4; KAEMPFER R, 1970, NATURE, V228, P534, DOI 10.1038/228534a0; KAEMPFER R, 1968, J MOL BIOL, V31, P273; Kudlicki W, 1997, FOLD DES, V2, P101, DOI 10.1016/S1359-0278(97)00014-X; LLOYD M, 1988, DEV GENET, V11, P391; MANGIAROTTI G, 1971, J MOL BIOL, V60, P441, DOI 10.1016/0022-2836(71)90180-X; MANGIAROTTI G, 1981, NUCLEIC ACIDS RES, V9, P947, DOI 10.1093/nar/9.4.947; Mangiarotti G, 1997, J BIOL CHEM, V272, P19682, DOI 10.1074/jbc.272.32.19682; MANGIAROTTI G, 1982, DEV BIOL, V89, P82, DOI 10.1016/0012-1606(82)90296-2; MANGIAROTTI G, 1983, NATURE, V301, P616, DOI 10.1038/301616a0; MANGIAROTTI G, 1989, DEVELOPMENT, V106, P473; MANGIAROTTI G, 1985, P NATL ACAD SCI USA, V82, P5786, DOI 10.1073/pnas.82.17.5786; MANGIAROTTI G, 1967, J MOL BIOL, V29, P395, DOI 10.1016/0022-2836(67)90107-6; ROSS J, 1987, J BIOL CHEM, V262, P9374; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLESSINGER D, 1967, P NATL ACAD SCI USA, V58, P1782, DOI 10.1073/pnas.58.4.1782; SOMMERMAN J, 1991, J BIOL CHEM, V266, P23091; VREKEN P, 1992, NUCLEIC ACIDS RES, V20, P2503, DOI 10.1093/nar/20.10.2503	32	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27070	27075		10.1074/jbc.273.42.27070	http://dx.doi.org/10.1074/jbc.273.42.27070			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765222	hybrid			2022-12-25	WOS:000076448000009
J	Franco, P; Massa, O; Garcia-Rocha, R; Chiaradonna, F; Iaccarino, C; Correas, I; Mendez, E; Avila, J; Blasi, F; Stoppelli, MP				Franco, P; Massa, O; Garcia-Rocha, R; Chiaradonna, F; Iaccarino, C; Correas, I; Mendez, E; Avila, J; Blasi, F; Stoppelli, MP			Protein kinase C-dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; CARCINOMATOUS CELL-LINE; UROKINASE RECEPTOR; PRO-UROKINASE; BINDING; CLEAVAGE; GENE; VITRONECTIN; SPECIFICITY; SENSITIVITY	We recently reported that in vivo phosphorylation of urokinase-type plasminogen activator on Ser(138/303) prevents its catalytic independent ability to promote myelomonocytic cell adherence and motility, me now show that Ca2+ activated, phospholipid-dependent protein kinase C from rat brain phosphorylates in vitro a peptide corresponding to prourokinase residues 133-143 (DGKKPSSPPEE) and the full-length molecule on Ser(138/139). The in vivo involvement of the protein kinase C isoenzyme family is supported by the finding that inhibition of kinase C activity prevents prourokinase phosphorylation on Ser(138/303) in A431 human carcinoma cells. Conversely, a short treatment of A431 cells with phorbol myristate acetate increases the extent of phosphorylated prourokinase and, concomitantly, affects its function; under these conditions, the capability of prourokinase to up-regulate U937 monocyte-like cell adherence is severely impaired, although receptor binding is unaltered. By the aid of a "phosphorylation-like" variant (Se-138 to Glu) we show that modification of Ser(138) is sufficient to confer to prourokinase the antagonistic properties observed following in vivo stimulation of protein kinase C activity. These observations provide the first evidence that protein kinase C directs the formation of a receptor competitive antagonist by regulating the in vivo phosphorylation state of prourokinase.	IIGB, CNR, I-80125 Naples, Italy; Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol, E-28049 Madrid, Spain; Univ Milan, Dipartimento Genet, I-20132 Milan, Italy; Ist Sci San Raffaele, Dept Biol & Biotechnol, I-20132 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Autonomous University of Madrid; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Stoppelli, MP (corresponding author), IIGB, CNR, Via Marconi 10, I-80125 Naples, Italy.	stoppelli@iigbna.iigb.na.cnr.it	Avila, Jesus/I-2610-2015; Correas, Isabel/O-4061-2018; Franco, Paola/O-5897-2015; CHIARADONNA, Ferdinando/K-4959-2016	Avila, Jesus/0000-0002-6288-0571; Correas, Isabel/0000-0002-2286-186X; Franco, Paola/0000-0002-3289-7284; CHIARADONNA, Ferdinando/0000-0001-8529-2732; IACCARINO, Ciro/0000-0003-1619-7146; Blasi, Francesco/0000-0001-9406-1784				Ando Y, 1996, J CELL PHYSIOL, V167, P500, DOI 10.1002/(SICI)1097-4652(199606)167:3<500::AID-JCP14>3.0.CO;2-7; ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; BARLATI S, 1991, FEBS LETT, V281, P137, DOI 10.1016/0014-5793(91)80377-F; BARLATI S, 1995, FEBS LETT, V363, P170, DOI 10.1016/0014-5793(95)00312-W; BASTANI B, 1995, BBA-MOL CELL RES, V1269, P307, DOI 10.1016/0167-4889(95)00120-0; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; BLASI F, 1994, FIBRINOLYSIS, V8, P182, DOI 10.1016/0268-9499(94)90716-1; Carriero MV, 1997, CLIN CANCER RES, V3, P1299; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Ellis V, 1996, J BIOL CHEM, V271, P14779, DOI 10.1074/jbc.271.25.14779; Franco P, 1997, J CELL BIOL, V137, P779, DOI 10.1083/jcb.137.3.779; FRANCO P, 1992, J BIOL CHEM, V267, P19369; Gechtman Z, 1997, EUR J BIOCHEM, V243, P493, DOI 10.1111/j.1432-1033.1997.0493a.x; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; HOGAN MV, 1995, J NEUROCHEM, V65, P2022; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Li CH, 1995, J BIOL CHEM, V270, P30282, DOI 10.1074/jbc.270.51.30282; MASTRONICOLA MR, 1990, FEBS LETT, V266, P109, DOI 10.1016/0014-5793(90)81519-T; MASTRONICOLA MR, 1992, FIBRINOLYSIS, V6, P117; MIMURO J, 1987, BLOOD, V70, P721; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOLLI ML, 1986, THROMB HAEMOSTASIS, V56, P214; NOWAK UK, 1993, BIOCHEMISTRY-US, V32, P298, DOI 10.1021/bi00052a038; ORSINI G, 1991, EUR J BIOCHEM, V195, P691, DOI 10.1111/j.1432-1033.1991.tb15755.x; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; RAND MD, 1994, BLOOD, V83, P2180; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Schreuder H, 1997, NATURE, V386, P194, DOI 10.1038/386194a0; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; STOPPELLI MP, 1986, J CELL BIOL, V102, P1035; TAKAHASHI K, 1992, BIOCHEM BIOPH RES CO, V182, P1473, DOI 10.1016/0006-291X(92)91900-B; TAKAHASHI K, 1992, BIOCHEM BIOPH RES CO, V182, P1466, DOI 10.1016/0006-291X(92)91899-2; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WALSH MP, 1984, BIOCHEM J, V224, P117, DOI 10.1042/bj2240117; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360	46	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27734	27740		10.1074/jbc.273.42.27734	http://dx.doi.org/10.1074/jbc.273.42.27734			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765311	hybrid			2022-12-25	WOS:000076448000098
J	Lin, Y; Tang, H; Nomura, T; Dorjsuren, D; Hayashi, N; Wei, WX; Ohta, T; Roeder, R; Murakami, S				Lin, Y; Tang, H; Nomura, T; Dorjsuren, D; Hayashi, N; Wei, WX; Ohta, T; Roeder, R; Murakami, S			The hepatitis B virus X protein is a co-activator of activated transcription that modulates the transcription machinery and distal binding activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; LONG TERMINAL REPEAT; NF-KAPPA-B; HBX PROTEIN; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAY; TRANS-ACTIVATION; GENE PRODUCT; KINASE-C; PROMOTER	Hepatitis B virus X protein (HBx) transactivates viral and cellular genes through a wide variety of cis-elements, but the mechanism has not been well elucidated. Evidence for nuclear events in HBx transactivation has been reported. Here we examine the role of HBx in modulation of transcription with a transient transfection system and an in vitro transcription assay. Reporters bearing Gal4-binding sites were applied to avoid the effects of endogenous transcription factors with or without signaling processes. The Gal4-DNA binding domain fused form of HBx exhibited no effect on Gal4-responsive reporters. However, HBx augmented activated transcription by transcriptional activators, suggesting HBx retains a co-activator but not a transcriptional activator function. The functional domain for co-activation was the same as that for HBx transactivation, and the transcription factor IIB and RNA polymerase II subunit B-interacting sites of HBx, which were critical for HBx transactivation, were shown to be crucial for the co-activation function. Importantly, HBx stimulated transcription on templates bearing the X responsive elements in vitro with endogenous activators. These results imply that HBx acts as a co-activator that modulates transcriptional machinery and distal-binding activators, which may explain one of the mechanisms of transactivation by HBx when localized in nuclei.	Kanazawa Univ, Canc Res Inst, Dept Mol Biol, Kanazawa, Ishikawa 9200934, Japan; Rockefeller Univ, New York, NY 10021 USA; Natl Inst Genet, Mishima, Shizuoka 4110801, Japan	Kanazawa University; Rockefeller University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Murakami, S (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Biol, Takara Machi 13-1, Kanazawa, Ishikawa 9200934, Japan.	semuraka@kenroku.kanazawa-u.ac.jp		Hayashi, Naoyuki/0000-0001-9626-3689				ANTUNOVIC J, 1993, CELL MOL BIOL RES, V39, P463; ASPINALL S, 1986, J GEN VIROL, V67, P2315, DOI 10.1099/0022-1317-67-11-2315; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Blau J, 1996, MOL CELL BIOL, V16, P2044; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P142; Chou S, 1997, MOL CELL BIOL, V17, P6794, DOI 10.1128/MCB.17.12.6794; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; DUFLOT A, 1995, HEPATOLOGY, V21, P1483, DOI 10.1016/0270-9139(95)90448-4; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FISCHER M, 1995, VIRUS GENES, V10, P99, DOI 10.1007/BF01724303; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Lin Y, 1997, CANCER RES, V57, P5137; LIU X, 1995, MOL CELL BIOL, V15, P6474; LUBER B, 1991, VIROLOGY, V184, P808, DOI 10.1016/0042-6822(91)90458-N; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; MURAKAMI S, 1994, VIROLOGY, V199, P243, DOI 10.1006/viro.1994.1119; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SETO E, 1989, VIROLOGY, V173, P764, DOI 10.1016/0042-6822(89)90594-1; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; TUGIZOV SM, 1993, VIRUS RES, V30, P189, DOI 10.1016/0168-1702(93)90006-9; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	55	46	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27097	27103		10.1074/jbc.273.42.27097	http://dx.doi.org/10.1074/jbc.273.42.27097			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765226	hybrid			2022-12-25	WOS:000076448000013
J	Walkey, CJ; Yu, LQ; Agellon, LB; Vance, DE				Walkey, CJ; Yu, LQ; Agellon, LB; Vance, DE			Biochemical and evolutionary significance of phospholipid methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; CHOLINE-DEFICIENCY; RAT HEPATOCYTES; LIVER; CHOLESTEROL; PLASMA; BRAIN; MONOMETHYLETHANOLAMINE; DIMETHYLETHANOLAMINE; ETHANOLAMINE	All nucleated mammalian cells synthesize phosphatidylcholine from choline via the CDP-choline pathway. Hepatocytes have a second pathway for the synthesis of phosphatidylcholine, a stepwise methylation of phosphatidylethanolamine, catalyzed by phosphatidylethanolamine N-methyltransferase and encoded by the Pempt gene. We report that when Pempt deficient mice were fed a choline-deficient diet for 3 days, severe liver pathology occurred apparently due to a lack of phosphatidylcholine biosynthesis. The hepatic concentration of phosphatidylcholine decreased by 50% compared with wild type mice on the diet. The levels of plasma triacylglycerols and cholesterol were decreased by greater than 90% in the Pempt-deficient mice. We suggest that the Pempt gene has been maintained during evolution to provide phosphatidylcholine when dietary choline is insufficient, as might occur during starvation or pregnancy.	Univ Alberta, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada.							Albright CD, 1996, FASEB J, V10, P510, DOI 10.1096/fasebj.10.4.8647350; ANDRIAMAMPANDRY C, 1992, BIOCHEM J, V288, P267, DOI 10.1042/bj2880267; ANDRIAMAMPANDRY C, 1989, BIOCHEM J, V264, P555, DOI 10.1042/bj2640555; ANDRIAMAMPANDRY C, 1991, J NEUROCHEM, V56, P1845, DOI 10.1111/j.1471-4159.1991.tb03439.x; BARTLETT GR, 1959, J BIOL CHEM, V234, P366; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREMER J, 1960, BIOCHIM BIOPHYS ACTA, V43, P477, DOI 10.1016/0006-3002(60)90470-4; BREMER J, 1960, BIOCHIM BIOPHYS ACTA, V37, P173, DOI 10.1016/0006-3002(60)90104-9; Glickman Robert M., 1994, P391; HAINES DSM, 1966, CAN J BIOCHEM CELL B, V44, P45, DOI 10.1139/o66-006; Houweling M, 1997, BBA-LIPID LIPID MET, V1346, P1, DOI 10.1016/S0005-2760(97)00011-8; KENNEDY EP, 1989, PHOSPHATIDYLCHOLINE, P1; KIEFT KA, 1991, J LIPID RES, V32, P859; Kuipers F, 1997, Subcell Biochem, V28, P295; MARSHALL WJ, 1995, CLIN CHEM, P231; Savendahl L, 1997, AM J CLIN NUTR, V66, P622, DOI 10.1093/ajcn/66.3.622; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shin OH, 1997, J CELL BIOCHEM, V64, P196, DOI 10.1002/(SICI)1097-4644(199702)64:2<196::AID-JCB3>3.0.CO;2-S; SNYDER F, 1959, BIOCHIM BIOPHYS ACTA, V34, P244; Torchia EC, 1997, EUR J CELL BIOL, V74, P190; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; YAO Z, 1990, BIOCHEM CELL BIOL, V68, P552, DOI 10.1139/o90-079; YAO ZM, 1988, J BIOL CHEM, V263, P2998; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1995, J NUTR, V125, P3049; ZEISEL SH, 1990, J NUTR BIOCHEM, V1, P332, DOI 10.1016/0955-2863(90)90001-2	28	180	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27043	27046		10.1074/jbc.273.42.27043	http://dx.doi.org/10.1074/jbc.273.42.27043			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765216	hybrid			2022-12-25	WOS:000076448000003
J	Dietrich, J; Geisler, C				Dietrich, J; Geisler, C			T cell receptor zeta allows stable expression of receptors containing the CD3 gamma leucine-based receptor-sorting motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; ANTIGEN RECEPTOR; DOWN-REGULATION; ALPHA-CHAIN; COMPLEX; MICE; CONSEQUENCES; TRANSDUCTION; SYNTHESIZE; ACTIVATION	The leucine-based motif in the T cell receptor (TCR) subunit CD3 gamma constitutes a strong internalization signal. In fully assembled TCR this motif is inactive unless phosphorylated, In contrast, the motif is constitutively active in CD4/CD3 gamma and Tac/CD3 gamma chimeras independently of phosphorylation and leads to rapid internalization and sorting of these chimeras to lysosomal degradation. Because the TCR zeta chain rescues incomplete TCR complexes from lysosomal degradation and allows stable surface expression of fully assembled TCR, we addressed the question whether TCR zeta has the potential to mask the CD3 gamma leucine-based motif. By studying CD4/CD3 gamma and CD16/CD3 gamma chimeras, we found that CD16/CD3 gamma chimeras associated with TCR zeta. The CD16/CD3 gamma-TCR zeta complexes were stably expressed at the cell surface and had a low spontaneous internalization rate, indicating that the leucine-based motif in these complexes was inactive. In contrast, the CD4/CD3 gamma chimeras did not associate with TCR zeta, and the leucine-based motif in these chimeras was constitutively active resulting in a high spontaneous internalization rate and low expression of the chimeras at the cell surface. Thus, our data demonstrate that TCR zeta allows stable cell surface expression of receptors containing CD3 gamma leucine-based motifs by its potential to mask such motifs.	Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, DK-2200 Copenhagen, Denmark	University of Copenhagen	Geisler, C (corresponding author), Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, Bldg 18-3,Blegdamsvej 3C, DK-2200 Copenhagen, Denmark.	cgtcr@biobase.dk	Geisler, Carsten/A-7056-2012	Geisler, Carsten/0000-0002-8472-0771				ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; Backstrom BT, 1997, EUR J IMMUNOL, V27, P1433; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dietrich J, 1996, J BIOL CHEM, V271, P11441, DOI 10.1074/jbc.271.19.11441; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; GEISLER C, 1992, J IMMUNOL, V148, P2437; GEISLER C, 1992, J IMMUNOL, V148, P3469; Hou XH, 1996, J BIOL CHEM, V271, P22815, DOI 10.1074/jbc.271.37.22815; KLAUSNER RD, 1990, CURR TOP MEMBR TRANS, V36, P31; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; Luton F, 1997, J IMMUNOL, V158, P4162; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MOINGEON P, 1992, P NATL ACAD SCI USA, V89, P1492, DOI 10.1073/pnas.89.4.1492; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; SAITO T, 1987, J IMMUNOL, V139, P625; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TRANSY C, 1989, P NATL ACAD SCI USA, V86, P7108, DOI 10.1073/pnas.86.18.7108; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	30	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26281	26284		10.1074/jbc.273.41.26281	http://dx.doi.org/10.1074/jbc.273.41.26281			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756853	hybrid			2022-12-25	WOS:000076373300007
J	Kelley, LL; Hicks, GG; Hsieh, FF; Prasher, JM; Green, WF; Miller, MD; Eide, EJ; Ruley, HE				Kelley, LL; Hicks, GG; Hsieh, FF; Prasher, JM; Green, WF; Miller, MD; Eide, EJ; Ruley, HE			Endogenous p53 regulation and function in early stage Friend virus-induced tumor progression differs from that following DNA damage	ONCOGENE			English	Article						p53; p21; activation; differentiation; erythroleukemia	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; CELL-CYCLE ARREST; ERYTHROPOIETIN RECEPTOR; ERYTHROLEUKEMIA-CELLS; TRANSCRIPTION FACTOR; TRANSGENIC MICE; GROWTH ARREST; GLOBIN GENE; E7 GENE	Erythroleukemia induced by the anemia strain of Friend virus occurs in two stages, The first stage results in rapid expansion of pre-leukemic proerythroblasts (FVA cells) dependent on erythropoietin (Epo) for differentiation and survival in vitro. The second stage is characterized by emergence of erythroleukemic clones (MEL cells) which typically bear activation of the ets-oncogene, PU.1/spi.1, and loss of functional p53. We developed a Friend virus-sensitive, p53-deficient mouse model to investigate the biological advantage conferred by p53-loss during tumor progression. Here we report p53 was not required for cell survival or growth arrest during differentiation of FVA cells, nor was p53 required for induction of apoptosis upon Epo withdrawal. However, we detected induction of the p21(Cip1) cyclin-dependent kinase inhibitor gene during differentiation, which was markedly enhanced in the presence of p53. p53-dependent expression of p21(Cip1) occurred in the absence of an increase in p53 mRNA and protein levels and was specific for p21(Cip1) since expression of gadd45, mdm-2, cyclin G and bax were unaffected by p53. In contrast, treatment of FVA cells with DNA damaging agents led to rapid accumulation of p53 protein resulting in transcription of multiple p53-regulated genes, leading to either apoptosis or growth arrest, depending on the agent used. These data demonstrate that p53-dependent activities during differentiation of preleukemic erythroblasts are distinct from those observed in response to genotoxic agents. We propose that enhancement of p53-dependent gene expression during differentiation may represent a tumor suppressor function which is necessary to monitor differentiation of preleukemic cells and which is selected against during tumor progression.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Oncol Sci, Salt Lake City, UT 84132 USA; Vanderbilt Univ, Dept Microbiol & Immunol, Nashville, TN 37212 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Vanderbilt University	Kelley, LL (corresponding author), Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA.			Hicks, Geoffrey/0000-0003-4688-2312	NCI NIH HHS [R01CA69169, 5P30CA42014] Funding Source: Medline; NIDDK NIH HHS [P50DK49219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069169, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONDURANT MC, 1985, MOL CELL BIOL, V5, P675, DOI 10.1128/MCB.5.4.675; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLEY LL, 1992, J CELL PHYSIOL, V151, P487, DOI 10.1002/jcp.1041510307; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KELLEY LL, 1993, BLOOD, V82, P2340; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOURY MJ, 1984, J CELL PHYSIOL, V121, P526, DOI 10.1002/jcp.1041210311; KOURY ST, 1988, EXP HEMATOL, V16, P758; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI JP, 1995, J VIROL, V69, P1714, DOI 10.1128/JVI.69.3.1714-1719.1995; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Ruley H. Earl, 1996, P37; SAWYER ST, 1987, METHOD ENZYMOL, V147, P340; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WEINBERG WC, 1995, ONCOGENE, V10, P2271; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	53	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1119	1130		10.1038/sj.onc.1202037	http://dx.doi.org/10.1038/sj.onc.1202037			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764822				2022-12-25	WOS:000075598400007
J	McHenry, JZ; Leon, A; Matthaei, KI; Cohen, DR				McHenry, JZ; Leon, A; Matthaei, KI; Cohen, DR			Overexpression of fra-2 in transgenic mice perturbs normal eye development	ONCOGENE			English	Article						AP-1; fra-2; anterior segment dysgenesis; transgenic	HELIX-ZIPPER PROTEIN; C-FOS; GENE; JUN; TRANSCRIPTION; EXPRESSION; CELLS; PHOSPHORYLATION; TRANSFORMATION; AP-1	The major components of transcription factor AP-1 (Activator Protein 1) are encoded by the two families of genes related to the proto-oncogenes c-fos and c-jun. The fos-related antigen-2 (fra-2) gene is the most recently described member of the Fos family. To determine the oncogenic potential of fra-2, transgenic mice were generated which over-express fra-2 in a number of tissues. No tumours were evident in any transgenic mice up to 18 months of age, although eye development was severely disrupted in these animals. Corneal abnormalities could be observed histologically as early as embryonic day 15.5 and eyelid fusion failed to occur. Adult eyes were characterized by generalized anterior segment dysgenesis similar to that previously reported in transgenic mice over-expressing transforming growth factor alpha (TGF alpha), and occasionally microphthalmia. Expression of fra-2 was shown to increase following TGF alpha. treatment of cells in vitro, suggesting that AP-1 complexes containing Fra-2 contribute to TGF alpha signalling events.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Cell Biol, Canberra, ACT 0200, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Neurosci, Canberra, ACT 0200, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; John Curtin School of Medical Research; Australian National University; John Curtin School of Medical Research	Cohen, DR (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Cell Biol, Canberra, ACT 0200, Australia.		Klaus, Matthaei/D-8691-2011	Cohen, Donna/0000-0002-0419-9542				BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CARRASCO D, 1995, ONCOGENE, V10, P1069; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; FOLETTA VC, 1994, ONCOGENE, V9, P3305; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; GOTZ W, 1995, OPHTHALMIC GENET, V16, P85, DOI 10.3109/13816819509059967; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OEHLER T, 1993, ONCOGENE, V8, P1141; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; RENEKER LXW, 1995, DEVELOPMENT, V121, P1669; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	27	22	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1131	1140		10.1038/sj.onc.1202044	http://dx.doi.org/10.1038/sj.onc.1202044			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764823				2022-12-25	WOS:000075598400008
J	Schwahn, DJ; Medina, D				Schwahn, DJ; Medina, D			p96, a MAPK-related protein, is consistently downregulated during mouse mammary carcinogenesis	ONCOGENE			English	Article						mammary carcinogenesis; p96; mammary epithelium; hyperplasia	PHOSPHOTYROSINE INTERACTION DOMAIN; COLONY-STIMULATING FACTOR-1; GROWTH-FACTOR RECEPTOR; DIFFERENTIAL DISPLAY; GENE-EXPRESSION; MESSENGER-RNA; PRODUCT; BINDING; CSF-1; PROTOONCOGENE	Differential display PCR [DD-PCR] was applied to identify mRNAs differentially expressed between two consecutive stages of an in vivo model of mouse mammary carcinogenesis. The extended life 12 [EL12] and transformed mammary 12 [TM12] outgrowths differ in morphology, ovarian hormone dependence, and tumorigenicity, yet the TM12 outgrowth arose spontaneously from the EL12 outgrowth. A fragment of the mouse p96 gene was identified using DD-PCR. The differential expression of p96 was confirmed using RNase protection assays. Examination of the RNA expression patterns of the p96 isoforms during normal mammary gland development showed high levels in the involuting mammary gland and in preneoplastic hyperplasias. In contrast, p96 isoform mRNA levels were consistently decreased in mammary tumors derived from the in vivo hyperplasias. Examination of p96 protein levels revealed a decrease in p96 protein in a number of mammary tumors as compared to their hyperplastic precursors further supporting the observations that p96 gene expression is consistently downregulated in mammary tumors. The functional activity of p96 protein has not been resolved, however the observation that p96 gene expression is downregulated in two different tumor systems (human ovarian tumors and mouse mammary tumors) warrants more extensive investigation on its role in normal and neoplastic cell growth.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Medina, D (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA63137] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063137] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BORYCKI AG, 1995, ONCOGENE, V10, P1799; CALLARD D, 1994, BIOTECHNIQUES, V16, P1096; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P15; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; Jackowski S, 1997, MOL REPROD DEV, V46, P24; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MEDINA D, 1993, CANCER RES, V53, P668; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; MEDINA D, 1993, CANCER RES, V53, P663; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Nowicki A, 1996, INT J CANCER, V65, P112, DOI 10.1002/(SICI)1097-0215(19960103)65:1<112::AID-IJC19>3.3.CO;2-R; POLLARD JW, 1994, P NATL ACAD SCI USA, V91, P9312, DOI 10.1073/pnas.91.20.9312; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; ZHANG LX, 1993, MOL CARCINOGEN, V8, P123, DOI 10.1002/mc.2940080209	24	45	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1173	1178		10.1038/sj.onc.1202038	http://dx.doi.org/10.1038/sj.onc.1202038			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764828				2022-12-25	WOS:000075598400013
J	Grombacher, T; Eichhorn, U; Kaina, B				Grombacher, T; Eichhorn, U; Kaina, B			P53 is involved in regulation of the DNA repair gene O-6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents	ONCOGENE			English	Article						p53; alkyltransferase; MGMT; DNA repair; inducible response	WILD-TYPE P53; CELL NUCLEAR ANTIGEN; RAT HEPATOMA-CELLS; NUCLEOTIDE EXCISION-REPAIR; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; MAMMALIAN-CELLS; IONIZING-RADIATION; MESSENGER-RNA; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; TRANSGENIC MICE	The DNA repair protein O-6-methlguanine-DNA methyltransferase (MGMT) is inducible stress. MGMT induction results from activation of the MGMT gene which Is a specific response to DNA damage, A possible factor involved in triggering MGMT induction might be p53, because both p53 and MGMT are activated by DNA breaks, To study the effect of p53 on induction of the MGMT gene, we compared the presence of functional wild-type (wt) and mutant p53 with MGMT expression level in various mouse fibroblasts and rat hepatoma cell lines upon genotoxic treatment. Cells which responded to ionizing radiation (IR) by MGMT induction displayed functional p53, whereas in cells not expressing wt p53, MGMT induction was not observed. Also, the cloned MGMT promoter was inducible by IR upon transfection into p53 wt cells, but not in cells deficient for p53, Thus, expression of wt p53 appears to be required for induction of MGMT mRNA and protein by IR, On the other hand, transfection of a MGMT-promoter-CAT construct together with p53 (either wt or mutant) in cells expressing wt p53 markedly reduced the basal activity of the MGMT promoter whereas cotransfection with a p53 antisense construct slightly increased MGMT promoter activity. Furthermore, cotransfection of MGMT promoter with wt or mutant p53 in p53 wt cells reduced radiation evoked MGMT promoter induction. Thus, transfection mediated high level expression of p53 has inhibitory effect both on basal MGMT promoter activity and its activation by IR, The results give evidence for involvement of p53 in DNA damage-induced MGMT promoter activation.	Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Kaina, B (corresponding author), Univ Mainz, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.							Becker K, 1996, CANCER RES, V56, P3244; Becker K, 1997, CANCER RES, V57, P3335; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN CL, 1990, CARCINOGENESIS, V11, P1217, DOI 10.1093/carcin/11.7.1217; CHAN CL, 1992, CANCER RES, V52, P1804; DINCALCI M, 1988, CANC TREAT REV, V15, P5723; Dosch J, 1996, ONCOGENE, V13, P1927; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FRITZ G, 1992, BIOCHIM BIOPHYS ACTA, V1171, P35, DOI 10.1016/0167-4781(92)90137-O; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; FUKUHARA M, 1992, JPN J CANCER RES, V83, P72, DOI 10.1111/j.1349-7006.1992.tb02354.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Grombacher T, 1996, CARCINOGENESIS, V17, P2329, DOI 10.1093/carcin/17.11.2329; GROMBACHER T, 1995, BBA-MOL BASIS DIS, V1270, P63, DOI 10.1016/0925-4439(94)00073-Y; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; HARRIS LC, 1992, CANCER RES, V52, P6404; Harris LC, 1996, CANCER RES, V56, P2029; KAINA B, 1993, ENVIRON MOL MUTAGEN, V22, P283, DOI 10.1002/em.2850220418; Kaina B, 1997, CANCER RES, V57, P2721; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; LAVAL F, 1991, BIOCHEM BIOPH RES CO, V176, P1086, DOI 10.1016/0006-291X(91)90395-N; LAVAL F, 1990, MUTAT RES, V233, P211, DOI 10.1016/0027-5107(90)90164-Y; LEFEBVRE P, 1993, DNA CELL BIOL, V12, P233, DOI 10.1089/dna.1993.12.233; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Margan U, 1996, BERL MUNCH TIERARZTL, V109, P1; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PEGG AE, 1990, CANCER RES, V50, P6119; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Rafferty JA, 1996, ONCOGENE, V12, P693; SCHMEROLD I, 1986, CANCER RES, V46, P245; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; WILSON RE, 1993, CARCINOGENESIS, V14, P679, DOI 10.1093/carcin/14.4.679; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Yurochko AD, 1997, J VIROL, V71, P4638, DOI 10.1128/JVI.71.6.4638-4648.1997	48	117	121	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					845	851		10.1038/sj.onc.1202000	http://dx.doi.org/10.1038/sj.onc.1202000			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780001				2022-12-25	WOS:000075448800006
J	Lin, RY; Vera, JC; Chaganti, RSK; Golde, DW				Lin, RY; Vera, JC; Chaganti, RSK; Golde, DW			Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDNA CLONING; MULTIDRUG-RESISTANCE; LACTATE TRANSPORT; CELLS; LOCALIZATION; MEMBRANE; EXPRESSION; SUBSTRATE; KINETICS; TISSUES	The transport of pyruvate and lactate across cellular membranes is an essential process in mammalian cells and is mediated by the H+/monocarboxylate transporters (MCTs). We have molecularly cloned and characterized a novel human monocarboxylate transporter, MCT2. The cDNA is 1,907 base pairs long and encodes a polypeptide of 478 amino acids with 12 predicted transmembrane domains. Human MCT2 is the product of a single gene that mapped to chromosome 12q13 by fluorescence in situ hybridization, The kinetic properties of human MCT2 fulfill the criteria to establish it as a H(+/)monocarboxylate transporter; however, the unique biochemical feature of human MCT2 is its high affinity for the transport of pyruvate (apparent K-m of 25 mu M), implying that it is a primary pyruvate transporter in man. Comparison of human MCT1 and MCT2 with regard to tissue distribution and RNA transcript variants disclosed substantial differences. Human MCT2 mRNA expression was restricted in normal human tissues but widely expressed in cancer cell lines, suggesting that MCT2 may be pre-translationally regulated in neoplasia. We found co-expression of human MCT1 and MCT2 at the mRNA level in human cancer cell lines, including the hematopoietic lineages HL60, K562, MOLT-4, and Burkitt's lymphoma Raji, and solid tumor cells such as SW480, A549, and G361, These findings suggest that the two monocarboxylate transporters, MCT1 and MCT2, have distinct biological roles.	Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Golde, DW (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, 1275 York Ave, New York, NY 10021 USA.	d-golde@ski.mskcc.org			NATIONAL CANCER INSTITUTE [R37CA030388, R01CA030388, P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042107] Funding Source: NIH RePORTER; NCI NIH HHS [CA08748, CA30388] Funding Source: Medline; NHLBI NIH HHS [HL42107] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Broer S, 1997, J BIOL CHEM, V272, P30096, DOI 10.1074/jbc.272.48.30096; Carpenter L, 1996, BBA-BIOMEMBRANES, V1279, P157, DOI 10.1016/0005-2736(95)00254-5; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Denton R M, 1979, Essays Biochem, V15, P37; DEUTICKE B, 1982, J MEMBRANE BIOL, V70, P89, DOI 10.1007/BF01870219; DEUTICKE B, 1989, METHOD ENZYMOL, V173, P300; GARCIA CK, 1994, GENOMICS, V23, P500, DOI 10.1006/geno.1994.1532; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HALESTRAP AP, 1976, BIOCHEM J, V156, P181, DOI 10.1042/bj1560181; Halestrap AP, 1997, AM J CARDIOL, V80, pA17, DOI 10.1016/S0002-9149(97)00454-2; HALESTRAP AP, 1990, BIOCHEM SOC T, V18, P1132, DOI 10.1042/bst0181132; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HINTZ M, 1977, DEV BIOL, V57, P375, DOI 10.1016/0012-1606(77)90222-6; Jackson VN, 1996, J BIOL CHEM, V271, P861, DOI 10.1074/jbc.271.2.861; Jackson VN, 1997, BIOCHEM J, V324, P447, DOI 10.1042/bj3240447; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Pellerin L, 1998, P NATL ACAD SCI USA, V95, P3990, DOI 10.1073/pnas.95.7.3990; POITRYYAMATE CL, 1995, J NEUROSCI, V15, P5179; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; REITHMEIER RAF, 1996, TRANSPORT PROCESSES, V2, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schurr A, 1997, J NEUROCHEM, V69, P423; TAKANAGA H, 1995, BIOCHEM BIOPH RES CO, V217, P370, DOI 10.1006/bbrc.1995.2786; TAMAI I, 1995, BIOCHEM BIOPH RES CO, V214, P482, DOI 10.1006/bbrc.1995.2312; VOET D, 1990, BIOCHEMISTRY-US, P599; Yoon HY, 1997, BIOCHEM BIOPH RES CO, V234, P90, DOI 10.1006/bbrc.1997.6588	33	163	183	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28959	28965		10.1074/jbc.273.44.28959	http://dx.doi.org/10.1074/jbc.273.44.28959			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786900	hybrid			2022-12-25	WOS:000076691800061
J	Swagemakers, SMA; Essers, J; de Wit, J; Hoeijmakers, JHJ; Kanaar, R				Swagemakers, SMA; Essers, J; de Wit, J; Hoeijmakers, JHJ; Kanaar, R			The human Rad54 recombinational DNA repair protein is a double-stranded DNA-dependent ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-F; SACCHAROMYCES-CEREVISIAE; YEAST RAD51; RECA; HELICASE; EXCHANGE; BINDING; RESISTANCE; DISRUPTION; SEQUENCES	DNA double-strand break repair through the RAD52 homologous recombination pathway in the yeast Saccharomyces cerevisiae requires, among others, the RAD51, RAD52, and RAD54 genes. The biological importance of homologous recombination is underscored by the conservation of the RAD52 pathway from fungi to humans. The critical roles of the RAD52 group proteins in the early steps of recombination, the search for DNA homology and strand exchange, are now becoming apparent. Here, we report the purification of the human Rad54 protein. We showed that human Rad54 has ATPase activity that is absolutely dependent on double-stranded DNA. Unexpectedly, the ATPase activity appeared not absolutely required for the DNA repair function of human Rad54 in vivo. Despite the presence of amino acid sequence motifs that are conserved in a large family of DNA helicases, no helicase activity of human Rad54 was observed on a variety of different DNA substrates. Possible functions of human Rad54 in homologous recombination that couple the energy gained from ATP hydrolysis to translocation along DNA, rather than disruption of base pairing, are discussed.	Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Dr Daniel Den Hoed Canc Ctr, Dept Radiotherapy, Div Clin Radiobiol, NL-3008 AE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Kanaar, R (corresponding author), Erasmus Univ, Dept Cell Biol & Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.	kanaar@pop.fgg.eur.nl	Hoeijmakers, Jan/AAX-6972-2021					Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Citterio E, 1998, J BIOL CHEM, V273, P11844, DOI 10.1074/jbc.273.19.11844; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P291, DOI 10.1016/0968-0004(93)90037-N; Ivanov EL, 1997, CURR BIOL, V7, pR492, DOI 10.1016/S0960-9822(06)00246-6; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; Kanaar R, 1998, NATURE, V391, P335, DOI 10.1038/34790; Kanaar Roland, 1997, Genes and Function, V1, P165; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; Mezard C, 1997, J MOL BIOL, V271, P704, DOI 10.1006/jmbi.1997.1225; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; RESNICK MA, 1976, MOL GEN GENET, V143, P119, DOI 10.1007/BF00266917; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weeda G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960-9822(06)00190-4; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; WHITBY MC, 1994, EMBO J, V13, P5220, DOI 10.1002/j.1460-2075.1994.tb06853.x	51	109	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28292	28297		10.1074/jbc.273.43.28292	http://dx.doi.org/10.1074/jbc.273.43.28292			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774452	Green Published, hybrid			2022-12-25	WOS:000076549800072
J	Renne, C; Kallen, KJ; Mullberg, J; Jostock, T; Grotzinger, J; Rose-John, S				Renne, C; Kallen, KJ; Mullberg, J; Jostock, T; Grotzinger, J; Rose-John, S			A new type of cytokine receptor antagonist directly targeting gp130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY; HUMAN MYELOMA CELLS; HUMAN INTERLEUKIN-6; ONCOSTATIN-M; HUMAN IL-6; SOLUBLE RECEPTORS; TRANSGENIC MICE; GROWTH-FACTORS; ACTIVATION	The interleukin-6-type family of cytokines bind to receptor complexes that share gp130 as a common signal-transducing subunit. So far, receptor antagonists for interleukin-6-type cytokines have been constructed that still bind to the specific ligand binding subunit of the receptor complex, but have lost the ability to stimulate gp130. Such receptor antagonists compete for a specific receptor of a member of the cytokine family. Interleukin 6 only binds to gp130 when complexed with the interleukin-6 receptor that exists as a membrane bound and soluble molecule. Here we have constructed fusion proteins that consist of the soluble form of the human interleukin-6 receptor covalently linked to interleukin-6 receptor antagonists. These fusion proteins directly bind to gp130, Moreover, at concentrations of 10-50 nM they completely neutralize not only the biological activity of interleukin-6 but also of other cytokines of the interleukin-6-type family that act via gp130 homodimers or gp130/LIF-R heterodimers. Therefore, these gp130 targeting cytokine antagonists might be useful therapeutic tools in disease states that are related to cytokines of the interleukin-g family.	Univ Mainz, Abt Pathophysiol, Med Klin 1, D-55101 Mainz, Germany; Klinikum RWTH Aachen, Inst Biochem, D-52057 Aachen, Germany	Johannes Gutenberg University of Mainz; RWTH Aachen University; RWTH Aachen University Hospital	Rose-John, S (corresponding author), Univ Mainz, Med Klin Pathophysiol 1, Obere Zahlbacher Str 63, D-55101 Mainz, Germany.		Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ALI SA, 1995, BIOTECHNIQUES, V18, P745; Baumann H, 1996, J IMMUNOL, V157, P284; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CASTELL J, 1990, EUR J BIOCHEM, V189, P113, DOI 10.1111/j.1432-1033.1990.tb15466.x; Ciapponi L, 1995, J BIOL CHEM, V270, P31249, DOI 10.1074/jbc.270.52.31249; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DEBETS R, 1994, IMMUNOL TODAY, V15, P455, DOI 10.1016/0167-5699(94)90187-2; DEHON FD, 1994, J EXP MED, V180, P2395, DOI 10.1084/jem.180.6.2395; Ehlers M, 1996, J INTERF CYTOK RES, V16, P569, DOI 10.1089/jir.1996.16.569; EHLERS M, 1994, J IMMUNOL, V153, P1744; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; HIRATA Y, 1989, J IMMUNOL, V143, P2900; Ichihara M, 1997, BLOOD, V90, P165; Kallen K J, 1997, Expert Opin Investig Drugs, V6, P237, DOI 10.1517/13543784.6.3.237; KLEIN B, 1991, BLOOD, V78, P1198; Krebs B, 1998, J BIOL CHEM, V273, P2858, DOI 10.1074/jbc.273.5.2858; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; Marz P, 1998, P NATL ACAD SCI USA, V95, P3251, DOI 10.1073/pnas.95.6.3251; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; Oppmann B, 1996, J IMMUNOL METHODS, V195, P153, DOI 10.1016/0022-1759(96)00110-X; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Sambrook J., 2002, MOL CLONING LAB MANU; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; Sporeno E, 1996, BLOOD, V87, P4510, DOI 10.1182/blood.V87.11.4510.bloodjournal87114510; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; Vernallis AB, 1997, J BIOL CHEM, V272, P26947, DOI 10.1074/jbc.272.43.26947; WENDLING D, 1993, J RHEUMATOL, V20, P259; Xu GY, 1997, J MOL BIOL, V268, P468, DOI 10.1006/jmbi.1997.0933; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	42	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27213	27219		10.1074/jbc.273.42.27213	http://dx.doi.org/10.1074/jbc.273.42.27213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765242	hybrid			2022-12-25	WOS:000076448000029
J	An, WJ; van Holde, K; Zlatanova, J				An, WJ; van Holde, K; Zlatanova, J			The non-histone chromatin protein HMG1 protects linker DNA on the side opposite to that protected by linker histones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY JUNCTION DNA; CHROMOSOMAL-PROTEINS; H1; TRANSCRIPTION; COMPETITION; NUCLEOSOMES; BINDING; B4	Linker histones and HMG1/2 constitute the two major proteins that bind to linker DNA in chromatin. While the location of linker histones on the nucleosome has attracted considerable research effort, only a few studies have addressed the location of HMG1 in the particles. In this study, we use a procedure based on micrococcal nuclease digestion of reconstituted nucleosomal particles to which HMG1 has been bound, followed by analysis of the protected DNA by restriction nuclease digestion, to locate the HMG1 binding site. Nucleosomal particles were reconstituted on a 235-base pair DNA fragment, which is known to be a strong nucleosome positioning sequence. The results unequivocally show that HMG1 protects linker DNA on one side of the core particle. Importantly, and possibly of physiological relevance, the linker DNA site protected by HMG1 was located on the side opposite to that already shown to be protected by linker histone binding.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Bulgarian Acad Sci, Inst Genet, BU-1113 Sofia, Bulgaria	Oregon State University; Bulgarian Academy of Sciences	Zlatanova, J (corresponding author), Argonne Natl Lab, Bldg 202-A253,9700 S Cass Ave, Argonne, IL 60439 USA.	zlatanoj@everest.bim.anl.gov	Zlatanova, Jordanka/B-3273-2009		FOGARTY INTERNATIONAL CENTER [R03TW000568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050276] Funding Source: NIH RePORTER; FIC NIH HHS [TW00568] Funding Source: Medline; NIGMS NIH HHS [GM50276] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1990, J CHROMATOGR-BIOMED, V530, P39, DOI 10.1016/S0378-4347(00)82300-2; ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; An WJ, 1998, NUCLEIC ACIDS RES, V26, P4042, DOI 10.1093/nar/26.17.4042; An WJ, 1998, P NATL ACAD SCI USA, V95, P3396, DOI 10.1073/pnas.95.7.3396; CraneRobinson C, 1997, TRENDS BIOCHEM SCI, V22, P75, DOI 10.1016/S0968-0004(97)01013-X; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; JACKSON JB, 1981, BIOCHEMISTRY-US, V20, P1042, DOI 10.1021/bi00507a060; JACKSON JB, 1979, BIOCHEMISTRY-US, V18, P3739, DOI 10.1021/bi00584a015; Nightingale K, 1996, EMBO J, V15, P548, DOI 10.1002/j.1460-2075.1996.tb00387.x; Sera T, 1998, MOL CELL BIOL, V18, P3668, DOI 10.1128/MCB.18.7.3668; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; VARGAWEISZ P, 1994, BIOCHEM BIOPH RES CO, V203, P1904, DOI 10.1006/bbrc.1994.2410; Wong JM, 1997, EMBO J, V16, P7130, DOI 10.1093/emboj/16.23.7130; Yaneva J, 1997, P NATL ACAD SCI USA, V94, P13448, DOI 10.1073/pnas.94.25.13448; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X; ZLATANOVA J, 1992, J CELL SCI, V103, P889	19	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26289	26291		10.1074/jbc.273.41.26289	http://dx.doi.org/10.1074/jbc.273.41.26289			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756855	hybrid			2022-12-25	WOS:000076373300009
J	Brown, GM; Huckerby, TN; Bayliss, MT; Nieduszynski, IA				Brown, GM; Huckerby, TN; Bayliss, MT; Nieduszynski, IA			Human aggrecan keratan sulfate undergoes structural changes during adolescent development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; AGE-RELATED-CHANGES; ANION-EXCHANGE CHROMATOGRAPHY; JOINT DISEASE; II DIGESTION; ALPHA(1-3)-LINKED FUCOSE; PROTEOGLYCAN STRUCTURE; SYNOVIAL-FLUID; OLIGOSACCHARIDES; OSTEOARTHRITIS	Alkaline borohydride-reduced keratan sulfate chains were isolated from human articular cartilage aggrecan from individuals of various ages (0-85 years old). The chains were structurally characterized using H-1 NMR spectroscopy, gel permeation chromatography, and oligosaccharide profiling (after digestion with the enzymes keratanase and keratanase II). The results show that from birth to early adolescence (0-9 years) the levels of alpha(l-3)-fucosylation, alpha(2-3)-sialylation, and galactose sulfation increase. Also, the weight-average molecular weight of the chains increases. During maturation (9-18 years) the levels of fucosylation and galactose sulfation continue to increase and alpha(2-6)-sialylation of the chains occurs. In adult life (18-85 years) there is little change in the weight-average molecular weight of the chains, and the levels of fucosylation, sialylation, and sulfation remain fairly constant.	Univ Lancaster, Inst Environm & Biol Sci, Dept Biol Sci, Lancaster LA1 4YQ, England; Univ Lancaster, Sch Phys & Chem, Ctr Polymer, Lancaster LA1 4YA, England; Univ London Royal Vet Coll, Dept Vet Basic Sci, London NW1 0TU, England	Lancaster University; Lancaster University; University of London; University of London Royal Veterinary College	Brown, GM (corresponding author), Univ Lancaster, Inst Environm & Biol Sci, Dept Biol Sci, Lancaster LA1 4YQ, England.							ALWAN WH, 1990, RES VET SCI, V49, P56, DOI 10.1016/S0034-5288(18)31046-4; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BAYLISS MT, 1978, BIOCHEM J, V176, P683, DOI 10.1042/bj1760683; BAYLISS MT, 1990, BIOCHEM SOC T, V18, P799, DOI 10.1042/bst0180799; BAYLISS MT, 1980, STUDIES JOINT DISEAS, V1, P2; BAYLISS MT, 1985, DEGENERATIVE JOINTS, V2, P13; BHAVANANDAN VP, 1968, J BIOL CHEM, V243, P1052; BJELLE A, 1975, CONNECT TISSUE RES, V3, P141, DOI 10.3109/03008207509152172; BROWN GM, 1992, BIOCHEM J, V286, P235, DOI 10.1042/bj2860235; BROWN GM, 1994, EUR J BIOCHEM, V224, P281, DOI 10.1111/j.1432-1033.1994.00281.x; BROWN GM, 1994, BIOCHEMISTRY-US, V33, P4836, DOI 10.1021/bi00182a012; BROWN GM, 1995, GLYCOBIOLOGY, V5, P311, DOI 10.1093/glycob/5.3.311; Brown GM, 1996, BIOCHEM J, V319, P137, DOI 10.1042/bj3190137; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CARROLL G, 1991, RHEUMATOL INT, V11, P63, DOI 10.1007/BF00291147; DICKENSON JM, 1990, ANAL BIOCHEM, V190, P271, DOI 10.1016/0003-2697(90)90192-C; DICKENSON JM, 1990, BIOCHEM J, V269, P55, DOI 10.1042/bj2690055; DINGLE JT, 1975, ANN RHEUM DIS, V34, P303, DOI 10.1136/ard.34.4.303; Fawthrop F, 1997, ANN RHEUM DIS, V56, P119, DOI 10.1136/ard.56.2.119; FEIZI T, 1989, KERATAN SULPHATE CHE, P21; GREILING H, 1973, CONNECTIVE TISSUE AG, P160; HARDINGHAM T, 1990, SEMIN ARTHRITIS RHEU, V20, P12, DOI 10.1016/0049-0172(90)90044-G; HASCALL VC, 1972, J BIOL CHEM, V247, P4529; HEINEGARD D, 1985, SCAND J CLIN LAB INV, V45, P421, DOI 10.1080/00365518509155238; HEINEGARD D, 1977, J BIOL CHEM, V252, P1971; HELMINEN HJ, 1987, JOINT LOADING, P29; HONDA S, 1981, ANAL BIOCHEM, V113, P130, DOI 10.1016/0003-2697(81)90055-5; HUCKERBY TN, 1991, GLYCOCONJUGATE J, V8, P39, DOI 10.1007/BF00731641; KAPLAN D, 1959, NATURE, V182, P1267; LIEPOLD HR, 1989, ARTHRITIS RHEUM, V32, P312; LOHMANDER LS, 1986, ANAL BIOCHEM, V154, P75, DOI 10.1016/0003-2697(86)90498-7; LOHMANDER LS, 1980, J BIOL CHEM, V255, P6084; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; MEHRABAN F, 1991, ARTHRITIS RHEUM, V34, P383, DOI 10.1002/art.1780340403; NIEDUSZYNSKI IA, 1990, BIOCHEM J, V271, P243, DOI 10.1042/bj2710243; RATCLIFFE A, 1988, ANN RHEUM DIS, V47, P826, DOI 10.1136/ard.47.10.826; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; SANTER V, 1982, BIOCHIM BIOPHYS ACTA, V716, P277, DOI 10.1016/0304-4165(82)90017-4; SPECTOR TD, 1992, ANN RHEUM DIS, V51, P1134, DOI 10.1136/ard.51.10.1134; SWEET MBE, 1979, ARCH BIOCHEM BIOPHYS, V198, P439, DOI 10.1016/0003-9861(79)90518-6; TAI GH, 1994, CARBOHYD RES, V255, P303, DOI 10.1016/S0008-6215(00)90987-X; TAI GH, 1991, BIOCHEM J, V273, P307, DOI 10.1042/bj2730307; THEOCHARIS DA, 1985, BIOCHIM BIOPHYS ACTA, V841, P131, DOI 10.1016/0304-4165(85)90283-1; THONAR EJMA, 1991, J RHEUMATOL, V18, P24; THONAR EJMA, 1981, ARCH BIOCHEM BIOPHYS, V208, P535, DOI 10.1016/0003-9861(81)90542-7; THONAR EJMA, 1985, ARTHRITIS RHEUM, V28, P1367, DOI 10.1002/art.1780281209; THORNTON DJ, 1989, BIOCHEM J, V260, P277, DOI 10.1042/bj2600277	47	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26408	26414		10.1074/jbc.273.41.26408	http://dx.doi.org/10.1074/jbc.273.41.26408			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756873	hybrid			2022-12-25	WOS:000076373300027
J	Morel, Y; Barouki, R				Morel, Y; Barouki, R			Down-regulation of cytochrome P450 1A1 gene promoter by oxidative stress - Critical contribution of nuclear factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; NF-KAPPA-B; TRANSCRIPTION FACTOR; FACTOR-I; HYDROGEN-PEROXIDE; REDOX REGULATION; CONSENSUS SEQUENCE; HUMAN HEPATOCYTES; PRIMARY CULTURE; PROTEIN-KINASE	Oxidative stress interferes with several cellular functions, in particular transcriptional regulation, We show here that the human cytochrome P450 1A1 (CYP1A1) is down-regulated at the transcriptional level by oxidative stress. Basal as well as 2,3,7,8-tetrachloro-p-dioxin-induced promoter activities are strongly impaired by H2O2 treatment or glutathione depletion with L-buthionine-(S,R)-sulfoximine. Tumor necrosis factor cu inhibits CYP1A1 expression, and this inhibition is prevented by the antioxidant pyrrolidine dithiocarbamate, We show that these regulations depend on the integrity of the nuclear factor 1 (NFI) site located in the proximal promoter. We therefore examined the redox regulation of this transcription factor. Treatment of human HepG2 or rat H4 hepatoma cells with H2O2 or L-buthionine-(S,R)-sulfoximine inactivates the binding of the NFI transcription factor to its DNA consensus sequence. Furthermore, H2O2 treatment leads to a dose-dependent decrease of reporter gene expressions driven by promoters containing NFI binding sites. Glutathione depletion and catalase inhibition also repress a NFI-driven promoter. Under the same conditions, the CP-1 transcription factor activity is not affected by oxidative stress. Thus, NFI seems particularly sensitive to oxidative stress. This accounts, at least partially, for the regulation of cyp1A1 gene expression.	Ctr Univ St Peres, INSERM, U490, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Barouki, R (corresponding author), Ctr Univ St Peres, INSERM, U490, 45 Rue Saints Peres, F-75006 Paris, France.		morel, yves/C-4757-2017					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABDELRAZZAK Z, 1994, MOL PHARMACOL, V46, P1100; ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; AEBI HE, 1974, METHOD ENZYMAT AN, P277; Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANANIA FA, 1995, HEPATOLOGY, V21, P1640, DOI 10.1002/hep.1840210624; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; BARKER CW, 1994, J BIOL CHEM, V269, P3985; BOISJOYEUX B, 1994, BIOCHEM J, V301, P49, DOI 10.1042/bj3010049; BOUCHER PD, 1995, MOL CELL BIOL, V15, P5144; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; DESCHATRETTE J, 1980, CELL, V19, P1043, DOI 10.1016/0092-8674(80)90095-1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Duval DL, 1996, MOL PHARMACOL, V50, P277; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; FEILLEUXDUCHE S, 1994, BIOCHEM J, V297, P497, DOI 10.1042/bj2970497; Gao B, 1996, MOL CELL BIOL, V16, P5997; Garlatti M, 1996, J BIOL CHEM, V271, P32629, DOI 10.1074/jbc.271.51.32629; Gergel D, 1997, ARCH BIOCHEM BIOPHYS, V337, P239, DOI 10.1006/abbi.1996.9765; GERGEL D, 1995, J BIOL CHEM, V270, P20922, DOI 10.1074/jbc.270.36.20922; GRANTLEY DC, 1997, BIOCHEM BIOPH RES CO, V238, P338; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; GRONOSTAJSKI RM, 1985, P NATL ACAD SCI USA, V81, P4013; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES KW, 1990, MOL CELL BIOL, V10, P5098, DOI 10.1128/MCB.10.10.5098; Kadlubar F.F., 1987, MAMMALIAN CYTOCHROME, P81; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Massaad C, 1997, MOL PHARMACOL, V51, P285, DOI 10.1124/mol.51.2.285; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; MICHIELS C, 1988, EUR J BIOCHEM, V177, P435, DOI 10.1111/j.1432-1033.1988.tb14393.x; MIHM S, 1995, FASEB J, V9, P246, DOI 10.1096/fasebj.9.2.7781927; MUNTANERELAT J, 1995, HEPATOLOGY, V22, P1143; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; Nose K, 1996, BIOCHEM J, V316, P381, DOI 10.1042/bj3160381; NOVAK A, 1992, J BIOL CHEM, V267, P12986; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Osada S, 1997, BIOCHEM BIOPH RES CO, V238, P744, DOI 10.1006/bbrc.1997.7382; Park JYK, 1996, P NATL ACAD SCI USA, V93, P2322, DOI 10.1073/pnas.93.6.2322; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; Pennisi E, 1997, SCIENCE, V275, P1567, DOI 10.1126/science.275.5306.1567; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Vasiliou V, 1995, BIOCHEM PHARMACOL, V50, P2057, DOI 10.1016/0006-2952(95)02108-6; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157; [No title captured]	63	166	168	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26969	26976		10.1074/jbc.273.41.26969	http://dx.doi.org/10.1074/jbc.273.41.26969			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756946	hybrid			2022-12-25	WOS:000076373300100
J	Wu, SK; Luan, P; Matteson, J; Zeng, K; Nishimura, N; Balch, WE				Wu, SK; Luan, P; Matteson, J; Zeng, K; Nishimura, N; Balch, WE			Molecular role for the Rab binding platform of guanine nucleotide dissociation inhibitor in endoplasmic reticulum to Golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; QUANTITATIVE-ANALYSIS; MEMBRANE ASSOCIATION; PROTEIN-TRANSPORT; GDP/GTP EXCHANGE; GDP; GTP; CHOROIDEREMIA; COMPARTMENTS; COMPLEX	Guanine nucleotide dissociation inhibitor (GDI) regulates the recycling of Rab GTPases involved in vesicle targeting and fusion. We have analyzed the requirement for conserved amino acid residues in the binding of Rab1A and the function of GDI in transport of cargo between the endoplasmic reticulum (ER) and the Golgi apparatus. Using a new approach to monitor GDI-Rab interactions based on the change in fluorescence associated with the release of methylanthraniloyl guanosine di(tri)phosphate-GDP (mGDP) from Rab, we show that residues previously implicated in the binding of the synapse-specific Rab3A, including Gln-236, Arg-240, and Thr-248, are essential for the binding of Rab1A. Mutation of each of these residues has potent effects on the ability of GDI to remove Rab1A from membranes and inhibit ER to Golgi transport in vitro, Given the sequence divergence between Rab1A and 3A (35% identity), these residues are proposed to play a general role in GDI function in the cell. In contrast, several other residues found within or flanking the Rab-binding region were found to have differential effects in the recognition and recycling of Rab1A and 3A, and therefore direct selective interaction of GDI with individual Rab proteins. Intriguingly, mutation of one residue, Arg-70, led to a reduction of Rab1A binding, failed to extract Rab1A from membranes in vitro, yet bound membranes tightly and potently inhibited ER to Golgi transport. These results provide evidence that novel membrane-associated factor(s) mediate Rab-independent GDI interaction with membranes.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Balch, WE (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM33301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDERS DA, 1993, CELL, V73, P1091; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; D'Adamo P, 1998, NAT GENET, V19, P134, DOI 10.1038/487; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; NOUFFER C, 1997, MOL BIOL CELL, V8, P1305; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1995, METHOD ENZYMOL, V257, P3; Overmeyer JH, 1998, MOL BIOL CELL, V9, P223, DOI 10.1091/mbc.9.1.223; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SHAPIRO AD, 1995, J BIOL CHEM, V270, P11085, DOI 10.1074/jbc.270.19.11085; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; SHISHEVA A, 1995, EUR J CELL BIOL, V68, P143; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STEELEMORTIMER O, 1993, FEBS LETT, V329, P313, DOI 10.1016/0014-5793(93)80244-O; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; WALDHERR M, 1993, NAT GENET, V3, P193, DOI 10.1038/ng0393-193; WILSON AL, 1993, J BIOL CHEM, V268, P14561; WILSON CN, 1996, SOUTH CULT, V2, P271, DOI 10.1353/scu.1996.0002; Wu SK, 1996, TRENDS BIOCHEM SCI, V21, P472, DOI 10.1016/S0968-0004(96)10062-1; YANG CZ, 1994, J BIOL CHEM, V269, P31891	45	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26931	26938		10.1074/jbc.273.41.26931	http://dx.doi.org/10.1074/jbc.273.41.26931			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756941	hybrid			2022-12-25	WOS:000076373300095
J	Brake, RL; Kees, UR; Watt, PM				Brake, RL; Kees, UR; Watt, PM			Multiple negative elements contribute to repression of the HOX11 proto-oncogene	ONCOGENE			English	Article						HOX11 promoter; negative element; repressor; silencing; transcription	ACUTE LYMPHOBLASTIC-LEUKEMIA; T-CELL RECEPTOR; BETA-INTERFERON GENE; RNA-POLYMERASE-II; C-MYB EXPRESSION; DROSOPHILA DEVELOPMENT; REGULATORY ELEMENTS; HOMEOBOX GENE; TRANSCRIPTIONAL REPRESSION; CHROMOSOME-TRANSLOCATION	The HOX11 proto-oncogene is normally expressed in embryogenesis where it directs the synthesis of the spleen. In adult tissues, HOX11 expression is silenced by an unknown mechanism. Aberrant expression of HOX11 occurs in T-cell acute lymphoblastic leukaemia (T-ALL), where it is thought to be involved in T-cell immortalization, The deregulated expression of HOX11 is frequently associated with chromosomal translocations which juxtapose a T-cell receptor (TCR) gene upstream of the HOX11 gene. In these cases, it is presumed that the activation of HOX11 expression results from bringing the gene under the control of TCR enhancer elements. However, activation of HOX11 also occurs in the absence of an associated translocation in both T-ALL and erythroleukaemia cells, implying that an alternative activation mechanism may exist, We hypothesized that HOX11 may be repressed in normal T-cells and erythroid cells by the action of negative elements which may be deleted or mutated in leukaemia. We therefore conducted a search for negative elements in the human HOX11 promoter which may function to silence its expression in normal cells of the haematopoietic lineages. Since little sequence of the HOX11 promoter was available, we began our investigation by sequencing over 4.5 kilobases of untranslated DNA from upstream of HOX11, The human sequence that overlaps with the 2.1 kb of murine Hox11 is highly conserved, suggesting that a large region of DNA upstream of HOX11 may have a regulatory function. We then used transfection assays to test the ability of portions of the promoter to drive transcription of a reporter gene. These studies identified four negative elements. Two of them (NRE2 and NRE4) function in all cell lines tested, while the remaining two (NRE1 and NRE3) appear to be cell-type specific. The DNA sequences of three elements are conserved between the human and mouse HOX11/Hox11 promoters, We propose a model in which the combined action of these negative elements contributes to the overall repression of HOX11 expression in normal blood cells.	TVW, Telethon Inst Child Hlth Res, Perth, WA 6872, Australia	Telethon Kids Institute; University of Western Australia	Kees, UR (corresponding author), TVW, Telethon Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.							ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Arai Y, 1997, GENE, V193, P73, DOI 10.1016/S0378-1119(97)00088-7; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BROWN WM, 1994, INT J BIOCHEM, V26, P1403, DOI 10.1016/0020-711X(94)90184-8; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVEL, V121, P2929; DUBE ID, 1991, BLOOD, V78, P2996; Gerard M, 1996, GENE DEV, V10, P2326, DOI 10.1101/gad.10.18.2326; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; Gottgens B, 1997, ONCOGENE, V15, P2419, DOI 10.1038/sj.onc.1201426; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; GUERRA J, 1995, BLOOD, V86, P1873, DOI 10.1182/blood.V86.5.1873.bloodjournal8651873; GUTMAN A, 1994, MOL CELL BIOL, V14, P8143, DOI 10.1128/MCB.14.12.8143; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Ip YT, 1997, CURR BIOL, V7, pR216, DOI 10.1016/S0960-9822(06)00104-7; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAGAN J, 1994, CANCER RES, V54, P226; Kees UR, 1998, CANCER GENET CYTOGEN, V100, P159, DOI 10.1016/S0165-4608(97)00030-7; KEES UR, 1994, GENE CHROMOSOME CANC, V9, P129, DOI 10.1002/gcc.2870090209; KEES UR, 1989, BLOOD, V74, P369; KEES UR, 1987, LEUKEMIA RES, V11, P489, DOI 10.1016/0145-2126(87)90082-8; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; LANEY JD, 1996, DEVEL, V122, P2302; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MACINTYRE EA, 1992, BLOOD, V80, P1511; Martin CS, 1996, BIOTECHNIQUES, V21, P520; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MILLER CW, 1984, BLOOD, V63, P195; MING L, 1992, ONCOGENE, V7, P1325; MOTUM PI, 1993, EXP HEMATOL, V21, P852; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; PIRROTTA V, 1991, ADV GENET, V29, P301, DOI 10.1016/S0065-2660(08)60110-8; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; SALVATI PD, 1995, ONCOGENE, V11, P1333; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WOODRUFF KA, 1995, ONCOGENE, V10, P1335; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	59	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1787	1795		10.1038/sj.onc.1202078	http://dx.doi.org/10.1038/sj.onc.1202078			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778044				2022-12-25	WOS:000076303300004
J	Dong, ZG; Huang, CS; Ma, WY; Malewicz, B; Baumann, WJ; Kiss, Z				Dong, ZG; Huang, CS; Ma, WY; Malewicz, B; Baumann, WJ; Kiss, Z			Increased synthesis of phosphocholine is required for UV-induced AP-1 activation	ONCOGENE			English	Article						AP-1; UV irradiation; phosphocholine phosphatidylcholine; MAP kinase	PROTEIN-KINASE-C; NUCLEAR MAGNETIC-RESONANCE; NIH 3T3 FIBROBLASTS; SIGNAL-TRANSDUCTION; GROWTH-FACTORS; ULTRAVIOLET-LIGHT; CHOLINE-PHOSPHATE; PHOSPHOLIPASE-D; PHORBOL ESTER; DNA-SYNTHESIS	Exposure of mammalian cells to UV irradiation stimulates phosphatidylcholine hydrolysis and activates the transcription factor AP-1. Since phosphocholine (PCho), a phospholipid metabolite, is a potential regulator of mitogenesis and carcinogenesis, we examined the effect of UV exposure on the formation of PCho and the possible mediatory role of PCho in UVB-and UVC-induced activation of AP-1 in mouse JB6 epidermal cells. We found that both UVB and UVC irradiation resulted in increased PCho levels. Hemicholinium-3 (HC-3), an inhibitor of choline kinase, strongly inhibited UV-induced AP-1 activity. By contrast, relatively low levels of PCho (80 mu M) or choline (20 mu M) nearly doubled UV-induced AP-1 activity, while higher (2-20 mM) concentrations of PCho alone stimulated AP-1 activity 6-8-fold. Importantly, HC-3 inhibited only the stimulatory effect of choline, but not of PCho, on AP-1 activity. Of the mitogen-activated protein (MAP) kinases involved in the regulation of AP-1 activity, UVC stimulated the MAP kinase family ERK-1/ERK-2, JNK as well as p38 kinase activity. These UVC effects were all inhibited by HC-3. With UVB, by contrast, only the activation of ERK-1/ERK-2 was inhibited by HC-3. The data suggest that increased formation of PCho is required for UV-induced activation of AP-1 by an ERK-1/ERK-2-dependent mechanism.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16Th Ave NE, Austin, MN 55912 USA.			Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R29CA074916] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004654] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009292] Funding Source: NIH RePORTER; NCI NIH HHS [CA74916] Funding Source: Medline; NCRR NIH HHS [RR04654] Funding Source: Medline; NIAAA NIH HHS [AA09292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1995, INDUCED GENE EXPRESS, P63; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; CARSBERG CJ, 1995, BIOCHEM J, V305, P471, DOI 10.1042/bj3050471; Chung TW, 1997, J BIOL CHEM, V272, P3064, DOI 10.1074/jbc.272.5.3064; CUADRADO A, 1993, ONCOGENE, V8, P2959; DALY PF, 1987, J BIOL CHEM, V262, P14875; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DONG ZG, 1995, INT J ONCOL, V7, P359; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; EVANS FE, 1977, P NATL ACAD SCI USA, V74, P4909, DOI 10.1073/pnas.74.11.4909; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; *IARC, 1992, IARC MON EV CARC RIS, V55; ISHIDATE K, 1980, BIOCHEM BIOPH RES CO, V96, P946, DOI 10.1016/0006-291X(80)91446-1; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kiss Z, 1996, ARCH BIOCHEM BIOPHYS, V335, P191, DOI 10.1006/abbi.1996.0497; KISS Z, 1995, FEBS LETT, V358, P243, DOI 10.1016/0014-5793(94)01434-3; KISS Z, 1994, BIOCHEM J, V300, P751, DOI 10.1042/bj3000751; Kiss Z, 1997, FEBS LETT, V412, P197, DOI 10.1016/S0014-5793(97)00776-X; KISS Z, 1995, FEBS LETT, V357, P279, DOI 10.1016/0014-5793(94)01371-7; Kiss Z, 1996, BIOCHEM BIOPH RES CO, V218, P505, DOI 10.1006/bbrc.1996.0090; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAVON G, 1977, P NATL ACAD SCI USA, V74, P87, DOI 10.1073/pnas.74.1.87; PAULSON BK, 1989, BIOCHIM BIOPHYS ACTA, V1004, P274, DOI 10.1016/0005-2760(89)90278-6; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; RONAI ZA, 1988, J VIROL, V62, P1057, DOI 10.1128/JVI.62.3.1057-1060.1988; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; TOMONO M, 1995, BIOCHEM BIOPH RES CO, V213, P980, DOI 10.1006/bbrc.1995.2225; WARDEN CH, 1985, J BIOL CHEM, V260, P6006	46	16	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1845	1853		10.1038/sj.onc.1202084	http://dx.doi.org/10.1038/sj.onc.1202084			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778051				2022-12-25	WOS:000076303300011
J	Alberti, L; Borrello, MG; Ghizzoni, S; Torriti, F; Rizzetti, MG; Pierotti, M				Alberti, L; Borrello, MG; Ghizzoni, S; Torriti, F; Rizzetti, MG; Pierotti, M			Grb2 binding to the different isoforms of Ret tyrosine kinase	ONCOGENE			English	Article						Ret; Grb2; receptor tyrosine kinase; oncogene	PAPILLARY THYROID CARCINOMAS; GROWTH-FACTOR RECEPTOR; CELL-LINE; NEUROTROPHIC FACTOR; PHOSPHOTYROSINE PHOSPHATASE; DOCKING SITE; GDNFR-ALPHA; RI-ALPHA; PROTOONCOGENE; SHC	The RET proto-oncogene encodes two isoforms of a receptor tyrosine kinase which plays a role in neural crest and kidney development. Ret ligands have been recently identified as the neuron survival factor GDNF (Glial-Derived Neurotrophic Factor) and Neurturin. Somatic rearrangements of RET, designated RET/PTCs, have been frequently detected in papillary thyroid carcinomas. In addition, distinct germ-line mutations of RET gene have been associated with the inherited cancer syndromes MEN (Multiple Endocrine Neoplasia) 2A, 2B and FMTC (Familial Medullar Thyroid Carcinomas) as well as with the congenital megacolon or Hirschsprung's disease, thus enlightening a significant role of this receptor gene in diverse human pathologic conditions. In this study, by performing classical inhibition experiments using synthetic phosphopeptides and by site-directed mutagenesis of the putative docking site, we have determined that for Grb2 the latter is provided by the tyrosine 620 of Ret/ptc2 long isoform (corresponding to Tyr 1096 on proto-Ret). However, in intact cells, the interaction of Grb2 with the two short and long Ret isoforms expressed separately is of similar strength, thus suggesting that Ret short isoform interaction with Grb2 could be mediated not only by Shc but also by a molecule that binds preferentially to this isoform. This possibility is supported by the evidence that the mutant Ret/ptc2Y620F long isoform displays a weak coimmunoprecipitation with Grb2 and that this mutant, lacking the docking site for Grb2 but owing all the others phosphotyrosines, surprisingly displays a reduced transforming activity compared to that of the two WTs oncogenes. We thus conclude that in intact cells both Ret isoforms bind to Grb2, although with different modalities, In addition, the present results are in agreement with the possibility that different signal transduction pathways are associated with the two isoforms of Ret.	Ist Nazl Tumori, Div Expt Oncol A, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Borrello, MG (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Via Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Borrello, Maria Grazia/C-3161-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Borrello, Maria Grazia/0000-0002-6854-2848				Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; LANZI C, 1992, ONCOGENE, V7, P2189; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LORENZO MJ, 1995, ONCOGENE, V10, P1377; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MYERS SM, 1995, ONCOGENE, V11, P2039; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Suvanto P, 1997, HUM MOL GENET, V6, P1267, DOI 10.1093/hmg/6.8.1267; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; Tortora G, 1997, ONCOGENE, V14, P923, DOI 10.1038/sj.onc.1200906; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	75	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1079	1087		10.1038/sj.onc.1202046	http://dx.doi.org/10.1038/sj.onc.1202046			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764818				2022-12-25	WOS:000075598400003
J	Jones, N; Dumont, DJ				Jones, N; Dumont, DJ			The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R	ONCOGENE			English	Article						signal transduction; endothelial cells; angiopoietins; Tek/Tie2; receptor tyrosine kinase	GTPASE-ACTIVATING PROTEIN; IRS-1 PTB DOMAIN; TYROSINE KINASE; INSULIN-RECEPTOR; ENDOTHELIAL-CELLS; ADAPTER PROTEIN; TIE2 RECEPTOR; MOLECULAR-CLONING; 2-HYBRID SYSTEM; VASCULAR SYSTEM	Tek/Tie2 is an endothelial cell-specific receptor tyrosine kinase that has been shown to play a role in vascular development of the mouse. Targeted mutagenesis of both Tek and its agonistic ligand, Angiopoietin-1, result in embryonic lethality, demonstrating that the signal transduction pathway(s) mediated by this receptor are crucial for normal embryonic development. In an attempt to identify downstream signaling partners of the Tek receptor, we have used the yeast two-hybrid system to identify phosphotyrosine-dependent interactions. Using this approach, we have identified a novel docking molecule called Dok-R, which has sequence and structural homology to p62(dok) and IRS-3. Mapping of the phospho tyrosine-interaction domain within Dok-R shows that Dok-R interacts with Tek through a PTB domain. Dok-R is coexpressed with Tek in a number of endothelial cell lines. We show that coexpression of Dok-R with activated Tek results in tyrosine phosphorylation of Dok-R and that rasGAP and Nck coimmunoprecipitate with phosphorylated Dok-R. Furthermore, Dok-R is constitutively bound to Crk presumably through the proline rich tail of Dok-R. The cloning of Dok-R represents the first downstream substrate of the activated Tek receptor, and suggests that Tek can signal through a multitude of pathways.	Univ Toronto, AMGEN, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Dumont, DJ (corresponding author), Univ Toronto, AMGEN, Toronto, ON M5G 2C1, Canada.							Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HUANG LW, 1995, ONCOGENE, V11, P2097; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PANDEY A, 1994, J BIOL CHEM, V269, P30154; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rockow S, 1996, ONCOGENE, V12, P2351; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TANAKA S, 1993, MOL CELL BIOL, V14, P5495; Tang JP, 1997, ONCOGENE, V15, P1823, DOI 10.1038/sj.onc.1201351; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIEGLER SF, 1993, ONCOGENE, V8, P663	66	125	132	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1097	1108		10.1038/sj.onc.1202115	http://dx.doi.org/10.1038/sj.onc.1202115			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764820				2022-12-25	WOS:000075598400005
J	Li, M; Xie, YH; Kong, YY; Wu, X; Zhu, L; Wang, Y				Li, M; Xie, YH; Kong, YY; Wu, X; Zhu, L; Wang, Y			Cloning and characterization of a novel human hepatocyte transcription factor, hB1F, which finds and activates enhancer II of hepatitis B virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RECEPTOR SUPERFAMILY; NUCLEAR RECEPTOR; GENE-EXPRESSION; NUCLEOCAPSID PROMOTER; STEROIDOGENIC FACTOR-1; INSITU HYBRIDIZATION; ORPHAN RECEPTORS; ESCHERICHIA-COLI; MAMMALIAN-CELLS; BINDING-PROTEIN	Enhancer II (ENII) of hepatitis B virus (HBV) is one of the essential cis-elements for the transcriptional regulation of HBV gene expression. Its function is highly liver-specific, suggesting that liver-enriched transcriptional factors play critical roles in regulating the activity of ENII. In this report, a novel hepatocyte transcription factor, which binds specifically to the B1 region (AACGACCGACCTTGAG) within the major functional unit (B unit) of ENII, has been cloned from a human liver cDNA library by yeast one-hybrid screening, and demonstrated to trans-activate EMI via the B1 region. We named this factor hB1F, for human B1-binding factor. Amino acid analysis revealed this factor structurally belongs to nuclear receptor superfamily. Based on the sequence similarities, hB1F is characterized to be a novel human homolog of the orphan receptor fushi tarazu factor I (FTZ-F1). Using reverse transcription-polymerase chain reaction, a splicing isoform of hB1F (hB1F-2) was identified, which has an extra 46 amino acid residues in the A/B region. Examination of the tissue distribution has revealed an abundant 5.2-kilobase transcript of hB1F is present specifically in human pancreas and liver. Interestingly, an additional transcript of 3.8 kilobases was found to be present in hepatoma cells HepG2. Fluorescent in situ hybridization has mapped the gene locus of hB1F to the region q31-32.1 of human chromosome 1. Altogether, this study provides the first report that a novel human homolog of FTZ-F1 binds and regulates ENII of HBV. The potential roles of this FTZ-F1 homolog in tissue-specific gene regulation, in embryonic development, as web as in liver carcinogenesis are discussed.	Chinese Acad Sci, Shanghai Inst Biochem, Shanghai 200031, Peoples R China; Clontech Lab Inc, Div Mol Biol, Palo Alto, CA 94303 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Wang, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	wangyuan@server.shcnc.ac.cn		Li, Mei/0000-0003-4225-6699				Alexandre Cyrille, 1993, Methods (Orlando), V5, P147, DOI 10.1006/meth.1993.1019; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AYER S, 1993, NUCLEIC ACIDS RES, V21, P1619, DOI 10.1093/nar/21.7.1619; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; ELLINGERZIEGELBAUER H, 1994, MOL CELL BIOL, V14, P2786, DOI 10.1128/MCB.14.4.2786; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; GAN RB, 1987, SCI CHINA SER B, V30, P507; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUO WT, 1993, MOL CELL BIOL, V13, P443, DOI 10.1128/MCB.13.1.443; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HONDA S, 1993, J BIOL CHEM, V268, P7494; HONIGWACHS J, 1989, J VIROL, V63, P919, DOI 10.1128/JVI.63.2.919-924.1989; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; JOHNSON JL, 1995, VIROLOGY, V208, P147, DOI 10.1006/viro.1995.1138; KAISER P, 1993, BIOTECHNIQUES, V14, P552; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Li M, 1995, VIROLOGY, V214, P371, DOI 10.1006/viro.1995.0046; Liu D, 1997, MOL ENDOCRINOL, V11, P877, DOI 10.1210/me.11.7.877; LOPEZCABRERA M, 1990, P NATL ACAD SCI USA, V87, P5069, DOI 10.1073/pnas.87.13.5069; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; OHNO CK, 1993, MECH DEVELOP, V40, P13, DOI 10.1016/0925-4773(93)90084-B; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Raney AK, 1997, J VIROL, V71, P1058, DOI 10.1128/JVI.71.2.1058-1071.1997; Raney AK, 1991, MOL BIOL HEPATITIS B, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHALLER H, 1991, CURR TOP MICROBIOL, V168, P21; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SU H, 1992, P NATL ACAD SCI USA, V89, P2708, DOI 10.1073/pnas.89.7.2708; SUN GC, 1994, DEV BIOL, V162, P426, DOI 10.1006/dbio.1994.1099; TAKETO M, 1995, GENOMICS, V25, P565, DOI 10.1016/0888-7543(95)80059-U; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOGNONI A, 1985, NUCLEIC ACIDS RES, V13, P7457, DOI 10.1093/nar/13.20.7457; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; TUGWOOD JD, 1991, M81385 GENB; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wang WX, 1998, RES VIROLOGY, V149, P99, DOI 10.1016/S0923-2516(98)80085-X; WANG Y, 1990, J VIROL, V64, P3977, DOI 10.1128/JVI.64.8.3977-3981.1990; Wong M, 1996, J MOL ENDOCRINOL, V17, P139, DOI 10.1677/jme.0.0170139; WU X, 1992, VIROLOGY, V191, P490, DOI 10.1016/0042-6822(92)90217-D; XIE YH, 1997, THESIS SHANGHAI I BI; XIE YH, 1997, MOL BIOL HEPATITIS B, P5; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; Yu XM, 1997, J VIROL, V71, P9366, DOI 10.1128/JVI.71.12.9366-9374.1997; YUH CH, 1993, J VIROL, V67, P142, DOI 10.1128/JVI.67.1.142-149.1993; ZHANG P, 1993, J VIROL, V67, P1472, DOI 10.1128/JVI.67.3.1472-1481.1993	60	97	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29022	29031		10.1074/jbc.273.44.29022	http://dx.doi.org/10.1074/jbc.273.44.29022			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786908	hybrid			2022-12-25	WOS:000076691800069
J	Oorni, K; Hakala, JK; Annila, A; Ala-Korpela, M; Kovanen, PT				Oorni, K; Hakala, JK; Annila, A; Ala-Korpela, M; Kovanen, PT			Sphingomyelinase induces aggregation and fusion, but phospholipase A(2) only aggregation, of low density lipoprotein (LDL) particles - Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTERYL ESTER ACCUMULATION; HUMAN ATHEROSCLEROTIC LESIONS; HUMAN PLASMA-LIPOPROTEINS; MAST-CELL GRANULES; APOLIPOPROTEIN-B; LYSINE RESIDUES; MACROPHAGES; RETENTION; GLYCOSAMINOGLYCANS; ATHEROGENESIS	During atherogenesis, low density lipoprotein (LDL) particles bind to extracellular matrix proteoglycans in the arterial wall, become modified, and appear as aggregated and fused particles, Sphingomyelinase (SMase) and phospholipase A(2) (PLA(2)) have been found in the arterial wall, and, moreover, lesional LDL shows signs of hydrolysis of both sphingomyelin and phosphatidylcholine, We have now studied the effects of these two lipolytic modifications on the aggregation and fusion of LDL particles by hydrolyzing the particles with Bacillus cereus SMase or bee venom PLA(2). In addition, the binding strengths of the modified LDL to human aortic proteoglycans (PG) were analyzed on an affinity column, We found that SMase induced aggregation and fusion of LDL, but PLA(2) induced only aggregation of the particles, In addition, the SMase-induced aggregation and fusion of LDL was promoted by pretreatment of LDL with PLA(2). Determination of the binding strengths of the hydrolyzed LDL revealed that mere lipolysis of LDL without aggregation or fusion, either by SMase or PLA(2), did not affect the binding of the particles to PG. Aggregation and fusion of lipolyzed LDL particles, however, increased their strength of binding to PG, Active lysine residues in apolipoprotein B-100 (apoB-100) appear to be involved in the binding of LDL to PG, and, in fact, quantitative C-13 NMR analysis revealed that, in the fused LDL particles, the number of active lysine residues per apoB-100 moiety was increased. Moreover, aggregation and fusion of LDL increased the number of apoB-100 copies and, consequently, the number of active lysine residues per aggregate or fused particle. Our present findings therefore (i) show that treatment of LDL with SMase and PLA, generates modified LDL particles, which then bind to human aortic PG with increased strength, and (ii) suggest that SMase- and PLA(2)-induced aggregation and fusion of LDL are potential mechanisms leading to focal retention of extracellular lipid in the arterial wall.	Wihuri Res Inst, FIN-00140 Helsinki, Finland; State Tech Res Ctr Finland, FIN-02044 Espoo, Finland	Wihuri Research Institute	Kovanen, PT (corresponding author), Wihuri Res Inst, Kalliolinnantie 4, FIN-00140 Helsinki, Finland.	Petri.kovanen@wihuri.fimnet.fi	Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250; Ala-Korpela, Mika/0000-0001-5905-1206				AVIRAM M, 1992, BIOCHEM BIOPH RES CO, V185, P465, DOI 10.1016/S0006-291X(05)81008-3; BARTOLD PM, 1985, ANAL BIOCHEM, V150, P320, DOI 10.1016/0003-2697(85)90517-2; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CAMEJO G, 1993, J BIOL CHEM, V268, P14131; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAO FF, 1990, AM J PATHOL, V136, P169; FENSKE DB, 1990, BIOCHEMISTRY-US, V29, P3973, DOI 10.1021/bi00468a026; Forte T, 1972, Adv Lipid Res, V10, P1; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Huang HW, 1996, BIOCHEM BIOPH RES CO, V220, P834, DOI 10.1006/bbrc.1996.0490; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P1011, DOI 10.1161/01.ATV.17.6.1011; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KLEINMAN Y, 1988, J LIPID RES, V29, P729; KOKKONEN JO, 1989, J BIOL CHEM, V264, P10749; KOVANEN PT, 1991, J BIOL CHEM, V266, P4430; Krug E L, 1981, Methods Enzymol, V72, P347; Laatikainen R, 1996, MAGN RESON MED, V36, P359, DOI 10.1002/mrm.1910360306; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1991, J BIOL CHEM, V266, P2701; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; MACEK J, 1987, J CHROMATOGR-BIOMED, V414, P156, DOI 10.1016/0378-4347(87)80034-8; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Menschikowski M, 1995, ATHEROSCLEROSIS, V118, P173, DOI 10.1016/0021-9150(95)05604-1; Oorni K, 1997, J BIOL CHEM, V272, P21303, DOI 10.1074/jbc.272.34.21303; PAANANEN K, 1994, J BIOL CHEM, V269, P2023; PAANANEN K, 1995, J BIOL CHEM, V270, P12257, DOI 10.1074/jbc.270.20.12257; PIHA M, 1995, BIOCHEMISTRY-US, V34, P10120, DOI 10.1021/bi00032a004; RADDING CM, 1960, J CLIN INVEST, V39, P1560, DOI 10.1172/JCI104177; Romano M, 1998, ARTERIOSCL THROM VAS, V18, P519, DOI 10.1161/01.ATV.18.4.519; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHUMAKER VN, 1994, ADV PROTEIN CHEM, V45, P205; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SMITH EB, 1990, EUR HEART J, V11, P72, DOI 10.1093/eurheartj/11.suppl_E.72; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; TAILLEUX A, 1993, J LIPID RES, V34, P719; Vijayagopal P, 1996, ATHEROSCLEROSIS, V127, P195, DOI 10.1016/S0021-9150(96)05954-0; VIJAYAGOPAL P, 1992, ARTERIOSCLER THROMB, V12, P237, DOI 10.1161/01.ATV.12.2.237; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; XU XX, 1991, J BIOL CHEM, V266, P24849	49	110	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29127	29134		10.1074/jbc.273.44.29127	http://dx.doi.org/10.1074/jbc.273.44.29127			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786921	hybrid			2022-12-25	WOS:000076691800082
J	Tang, H; Zhao, K; Pizzolato, JF; Fonarev, M; Langer, JC; Manfredi, JJ				Tang, H; Zhao, K; Pizzolato, JF; Fonarev, M; Langer, JC; Manfredi, JJ			Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; DNA-BINDING FUNCTION; MUTANT P53; MONOCLONAL-ANTIBODIES; CELL-GROWTH; ACTIVATION; ONCOGENE; MDM2; INDUCTION; DAMAGE	The tumor suppressor protein p53 has been implicated in the response of cells to DNA damage. Studies to date have demonstrated a role for p53 in the transcriptional activation of target genes in the cellular response to DNA damage that results in either growth arrest or apoptosis, In contrast, here is demonstrated a role for p53 in regulating the basal level of expression of the cyclin-dependent kinase inhibitor p21 in the absence of treatment with DNA-damasng agents. Wild-type p53-expressing MCF10F cells had detectable levels of p21 mRNA and protein, whereas the p53-negative Saos-2 cells did not. Saos-2 cells were infected with recombinant retrovirus to establish a proliferating pool of cells with a comparable constitutive level of expression of wild-type p53 protein to that seen in untreated MCF10F cells. Restoration of wild-type but not mutant p53 expression recovered a basal level of expression of p21 in these cells. Constitutive expression of luciferase reporter constructs containing the p21 promoter was inhibited by co-transfection with the human MDM2 protein or a dominant-negative p53 protein and was dependent on the presence of p53 response elements in the reporter constructs. Furthermore, p53 in nuclear extracts of untreated cells was capable of binding to DNA in a sequence-specific manner. These results implicate a role for p53 in regulating constitutive levels of expression of p21 and demonstrate that the p53 protein is capable of sequence-specific DNA binding and transcriptional activation in untreated, proliferating cells.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Brookdale Ctr Mol & Dev Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Manfredi, JJ (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box1130, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R29CA069161] Funding Source: NIH RePORTER; NCI NIH HHS [CA-69161] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABARZUA P, 1995, CANCER RES, V55, P3490; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN YM, 1991, ONCOGENE, V6, P1799; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FAN SJ, 1995, CANCER RES, V55, P1649; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guillot C, 1997, ONCOGENE, V14, P45, DOI 10.1038/sj.onc.1200803; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Isaacs JS, 1997, CANCER RES, V57, P2986; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIAO K, 1995, J BIOL CHEM, V270, P12123, DOI 10.1074/jbc.270.20.12123; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; RAMIREZ VD, 1975, MOL CELL ENDOCRINOL, V3, P339, DOI 10.1016/0303-7207(75)90035-0; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TANG HY, 1994, RADIAT RES, V138, pS109, DOI 10.2307/3578775; WEINBERG WC, 1994, CANCER RES, V54, P5584; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	51	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29156	29163		10.1074/jbc.273.44.29156	http://dx.doi.org/10.1074/jbc.273.44.29156			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786925	hybrid			2022-12-25	WOS:000076691800086
J	Eder, AM; Dominguez, L; Franke, TF; Ashwell, JD				Eder, AM; Dominguez, L; Franke, TF; Ashwell, JD			Phosphoinositide 3-kinase regulation of T cell receptor-mediated interleukin-2 gene expression in normal T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; PHOSPHATIDYLINOSITOL 3-KINASE; IL-2 GENE; SIGNAL-TRANSDUCTION; BOVINE BRAIN; ACTIVATION; WORTMANNIN; AKT; INHIBITION	Phosphoinositide (PI) 3-kinase has been implicated in T cell receptor (TCR) signaling, either as a positive or a negative regulatory molecule. Here, we show that for normal mouse lymph node T cells, PI 3-kinase activity is required for interleukin-2 (IL-2) production following TCR-mediated activation. Furthermore, in normal T cells, inhibition of PI 3-kinase prevented activation of enzymes in the extracellular signal-regulated protein kinase (ERK) signaling pathway (MEK-1 and ERK-2). Overexpression of a dominant-negative mutant of PI 3-kinase and pharmacological inhibitors of PI 3-kinase prevented transcriptional activation of AP-1 and NF-AT, transcription factors regulated by ERK-2 and pivotal for IL-2 gene expression. Although a constitutively active form of Akt kinase, a downstream mediator of PI 3-kinase function, enhanced TCR-induced IL-2 gene transcription, it could not bypass the requirement for PI 3-kinase activity. Therefore, PI 3-kinase is likely to be involved in signaling for IL-2 production in at least two steps in the TCR-initiated signaling pathway.	NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA; Univ Santiago de Compostela, Dept Biochem & Mol Biol, Santiago De Compostela 15706, Spain; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universidade de Santiago de Compostela; Columbia University	Ashwell, JD (corresponding author), NCI, Lab Immune Cell Biol, NIH, Bldg 10,Rm 1B40, Bethesda, MD 20892 USA.							Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CARRERA AC, 1994, J BIOL CHEM, V269, P19435; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; deAos I, 1997, J BIOL CHEM, V272, P25310, DOI 10.1074/jbc.272.40.25310; delPeso L, 1997, SCIENCE, V278, P687; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; EXLEY M, 1994, J BIOL CHEM, V269, P15140; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; LIPS DL, 1989, J BIOL CHEM, V264, P8759; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; OKADA T, 1994, J BIOL CHEM, V269, P3563; PETRAK D, 1994, J IMMUNOL, V153, P2046; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Reif K, 1997, CURR BIOL, V7, P285, DOI 10.1016/S0960-9822(06)00151-5; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; Shi J, 1997, J IMMUNOL, V158, P4688; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRUITT KE, 1995, J IMMUNOL, V155, P4702; UEDA Y, 1995, INT IMMUNOL, V7, P957, DOI 10.1093/intimm/7.6.957; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YANO H, 1993, J BIOL CHEM, V268, P25846	50	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28025	28031		10.1074/jbc.273.43.28025	http://dx.doi.org/10.1074/jbc.273.43.28025			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774418	hybrid			2022-12-25	WOS:000076549800038
J	Schumacher, B; Staeheli, P				Schumacher, B; Staeheli, P			Domains mediating intramolecular folding and oligomerization of MxA GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED HUMAN PROTEIN; INFLUENZA-VIRUS; ANTIVIRAL ACTIVITY; INTERFERON; INHIBITION; BINDING; RESISTANCE; HOMOLOGY; MICE	MxA is an interferon-induced GTPase of human cells that inhibits the multiplication of several RNA viruses by a still poorly understood mechanism. Previous biochemical studies indicated that the C terminus of MxA folds back to form a functional GTP-binding pocket, and that an internal fragment contains a domain required for oligomerization. Using the yeast two-hybrid system, we have now mapped these domains. MxA sequences located downstream of amino acid 564 were found to strongly interact with an internal domain that includes amino acids 372 to 540, This interaction was abolished by mutating phenylalanine 382 or leucine 612, which is part, of a leucine zipper motif. Neither the C-terminal nor the internal MxA fragments formed homo-oligomers. Using a mammalian nuclear transport assay that can detect protein-protein interactions, we further found that full-length MxA forms complexes with MxA fragments that include amino acids 372 to 540. This interaction was not observed when phenylalanine 382 was exchanged for alanine or arginine. Furthermore, interaction of two full-length MxA molecules occurred only if at least one of them carried a functional C-terminal leucine zipper motif, These results suggest that C-terminal back-folding and oligomerization are two alternative outcomes of the same type of interaction between the C-terminal and the internal domains of MxA. Intramolecular interaction is believed to result in the formation of MxA monomers, whereas intermolecular interaction may induce the formation of large MxA oligomers.	Univ Freiburg, Dept Virol, Inst Med Mikrobiol & Hyg, Abt Virol, D-79008 Freiburg, Germany	University of Freiburg	Staeheli, P (corresponding author), Univ Freiburg, Dept Virol, Inst Med Mikrobiol & Hyg, Abt Virol, Hermann Herder Str 11, D-79008 Freiburg, Germany.	staeheli@ukl.uni-freiburg.de						AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; Ausubel FM, 1992, CURRENT PROTOCOLS MO; FRESE M, 1995, J VIROL, V69, P3904, DOI 10.1128/JVI.69.6.3904-3909.1995; Frese M, 1996, J VIROL, V70, P915, DOI 10.1128/JVI.70.2.915-923.1996; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; Landis H, 1998, J VIROL, V72, P1516, DOI 10.1128/JVI.72.2.1516-1522.1998; Li YL, 1997, J CLIN INVEST, V100, P2873, DOI 10.1172/JCI119836; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MELEN K, 1992, J BIOL CHEM, V267, P25898; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PAVLOVIC J, 1995, J VIROL, V69, P4506, DOI 10.1128/JVI.69.7.4506-4510.1995; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; Ponten A, 1997, J VIROL, V71, P2591, DOI 10.1128/JVI.71.4.2591-2599.1997; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SCHNEIDERSCHAULIES S, 1994, J VIROL, V68, P6910, DOI 10.1128/JVI.68.11.6910-6917.1994; SCHNORR JJ, 1993, J VIROL, V67, P4760, DOI 10.1128/JVI.67.8.4760-4768.1993; SCHWEMMLE M, 1995, VIROLOGY, V206, P545, DOI 10.1016/S0042-6822(95)80071-9; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; STAEHELI P, 1985, MOL CELL BIOL, V5, P2150, DOI 10.1128/MCB.5.8.2150; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Zhao H, 1996, VIROLOGY, V220, P330, DOI 10.1006/viro.1996.0321; ZURCHER T, 1992, EMBO J, V11, P1657, DOI 10.1002/j.1460-2075.1992.tb05212.x; ZURCHER T, 1992, J VIROL, V66, P5059	26	53	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28365	28370		10.1074/jbc.273.43.28365	http://dx.doi.org/10.1074/jbc.273.43.28365			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774462	hybrid			2022-12-25	WOS:000076549800082
J	Chiba, Y; Suzuki, M; Yoshida, S; Yoshida, A; Ikenaga, H; Takeuchi, M; Jigami, Y; Ichishima, K				Chiba, Y; Suzuki, M; Yoshida, S; Yoshida, A; Ikenaga, H; Takeuchi, M; Jigami, Y; Ichishima, K			Production of human compatible high mannose-type (Man(5)GlcNAc(2)) sugar chains in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ERYTHROPOIETIN; LUMINAL ER PROTEINS; 1,2-ALPHA-D-MANNOSIDASE GENE; GLYCOPROTEIN-BIOSYNTHESIS; LINKED OLIGOSACCHARIDES; NUCLEOTIDE-SEQUENCE; ASPERGILLUS-SAITOI; MEDIATED RETRIEVAL; CARBOXYPEPTIDASE-Y; MOLECULAR-CLONING	A yeast mutant capable of producing Man(5)GlNAc(2) human compatible sugar chains ore glycoproteins was constructed. An expression vector for alpha-1,2-mannosidase with the "HDEL" endoplasmic reticulum retention/retrieval tag was designed and expressed in Saccharomyces cerevisiae. An in vitro alpha-1,2-mannosidase assay and Western blot analysis showed that it was successfully localized in the endoplasmic reticulum. A triple mutant yeast lacking three glycosyltransferase activities was then transformed with an alpha-1,2-mannosidase expression vector. The oligosaccharide structures of carboxypeptidase Y as well as cell surface glycoproteins were analyzed, and the recombinant yeast was shown to produce a series of high mannose-type sugar chains including Man(5)GlcNAc(2). This is the first report of a recombinant S. cerevisiae able to produce Man(5)GlcNAc(2)-oligosaccharides, the intermediate for hybrid-type and complex-type sugar chains.	Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Natl Inst Biosci & Human Technol, Ibaraki 3050046, Japan; Sohka Univ, Fac Engn, Dept Bioengn, Tokyo 1920003, Japan	Kirin Brewery Company Limited; National Institute of Advanced Industrial Science & Technology (AIST)	Takeuchi, M (corresponding author), Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, 1-13-5 Fukuura, Yokohama, Kanagawa 2360004, Japan.		Chiba, Yasunori/L-7993-2018	Chiba, Yasunori/0000-0002-6401-5071				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; Fujita A, 1997, BIOCHEM BIOPH RES CO, V238, P779, DOI 10.1006/bbrc.1997.7389; FUKUDA MN, 1989, BLOOD, V73, P84; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; INOUE T, 1995, BBA-PROTEIN STRUCT M, V1253, P141, DOI 10.1016/0167-4838(95)00195-6; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHANSEN JT, 1976, CARLSBERG RES COMMUN, V41, P1, DOI 10.1007/BF02908689; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL A, 1994, J BIOL CHEM, V269, P9872; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LUSSIER M, 1995, J CELL BIOL, V131, P913, DOI 10.1083/jcb.131.4.913; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; PEAT S, 1961, J CHEM SOC, P29, DOI 10.1039/jr9610000029; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SIKORSKI RS, 1989, GENETICS, V122, P19; SPIVAK JL, 1989, BLOOD, V73, P90; TAKEUCHI M, 1989, P NATL ACAD SCI USA, V86, P7819, DOI 10.1073/pnas.86.20.7819; TAKEUCHI M, 1991, Glycobiology, V1, P337, DOI 10.1093/glycob/1.4.337; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tremblay LO, 1998, GLYCOBIOLOGY, V8, P585, DOI 10.1093/glycob/8.6.585; TRIMBLE RB, 1983, J BIOL CHEM, V258, P2562; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; WANG JL, 1981, J TOXICOL ENV HEALTH, V8, P639, DOI 10.1080/15287398109530098; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723; YOSHIDA T, 1995, BBA-GENE STRUCT EXPR, V1263, P159, DOI 10.1016/0167-4781(95)00101-L	37	102	145	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26298	26304		10.1074/jbc.273.41.26298	http://dx.doi.org/10.1074/jbc.273.41.26298			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756858	hybrid			2022-12-25	WOS:000076373300012
J	Overkleeft, HS; Renkema, GH; Neele, J; Vianello, P; Hung, IO; Strijland, A; van der Burg, AM; Koomen, GJ; Pandit, UK; Aerts, JMFG				Overkleeft, HS; Renkema, GH; Neele, J; Vianello, P; Hung, IO; Strijland, A; van der Burg, AM; Koomen, GJ; Pandit, UK; Aerts, JMFG			Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAUCHER DISEASE; N-BUTYLDEOXYNOJIRIMYCIN; GLYCOLIPID BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; GLUCOCEREBROSIDASE; PURIFICATION; GLUCOSIDASE; CELLS; 2ND	The existence of a non-lysosomal glucosylceramidase in human cells has been documented (van Weely, S,, Brandsma, M., Strijland, A., Tager, J, M., and Aerts, J. M, F, G. (1993) Biochim, Biophys, Acta 1181, 55-62), Hypothetically, the activity of this enzyme, which is localized near the cell surface, may influence ceramide-mediated signaling processes. To obtain insight in the physiological importance of the non-lysosomal glucosylceramidase, the availability of specific inhibitors would be helpful. Here we report on the generation of hydrophobic deoxynojirimycin (DNM) derivatives that potently inhibit the enzyme. The inhibitors were designed on the basis of the known features of the non-lysosomal glucosylceramidase and consist of a DNM moiety, an N-alkyl spacer, and a large hydrophobic group that promotes insertion in membranes, In particular, N-(5-adamantane-1-yl-methoxy)pentyl)-DNM is a very powerful inhibitor of the non-lysosomal glucosylceramidase at nanomolar concentrations. At such concentrations, the lysosomal glucocerebrosidase and alpha-glucosidase, the glucosylceramide synthase, and the N-linked glycan-trimming alpha-glucosidases of the endoplasmic reticulum are not affected.	Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Dept Organ Chem, NL-1100 DE Amsterdam, Netherlands; Univ Milan, Ist Chim Farmaceut & Tossicol, Milan, Italy	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; University of Milan	Aerts, JMFG (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Biochem, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Renkema, Herma/L-1489-2015; Aerts, Johannes/A-1028-2009	Renkema, Herma/0000-0002-8174-6538; Aerts, Johannes/0000-0001-8168-2565; Overkleeft, Herman/0000-0001-6976-7005				Abe A, 1996, BBA-LIPID LIPID MET, V1299, P333, DOI 10.1016/0005-2760(95)00217-0; BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913; Beutler E., 1995, METABOLIC MOL BASES, P2641; BOESHAGEN H, 1989, Patent No. 315017; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; FURBISH FS, 1981, BIOCHIM BIOPHYS ACTA, V673, P425, DOI 10.1016/0304-4165(81)90474-8; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HETTKAMP H, 1984, EUR J BIOCHEM, V142, P85, DOI 10.1111/j.1432-1033.1984.tb08253.x; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; LEGLER G, 1985, BIOL CHEM H-S, V366, P1113, DOI 10.1515/bchm3.1985.366.2.1113; OSIECKINEWMAN KM, 1986, ENZYME, V35, P147, DOI 10.1159/000469336; OVERKLEEFT HS, 1994, TETRAHEDRON, V50, P4215, DOI 10.1016/S0040-4020(01)86715-6; PLATT FM, 1994, J BIOL CHEM, V269, P27108; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; PLATT FM, 1994, J BIOL CHEM, V269, P8362; STOTZ H, 1990, THESIS U BONN BONN G; TULP A, 1993, ELECTROPHORESIS, V14, P1295, DOI 10.1002/elps.11501401198; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VANWEELY S, 1991, BIOCHIM BIOPHYS ACTA, V1096, P301, DOI 10.1016/0925-4439(91)90066-I; VANWEELY S, 1993, BIOCHIM BIOPHYS ACTA, V1181, P55, DOI 10.1016/0925-4439(93)90090-N; WANNER MJ, 1995, J ORG CHEM, V60, P5634, DOI 10.1021/jo00122a052	23	151	172	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26522	26527		10.1074/jbc.273.41.26522	http://dx.doi.org/10.1074/jbc.273.41.26522			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756888	hybrid, Green Published			2022-12-25	WOS:000076373300042
J	Straub, T; Grue, P; Uhse, A; Lisby, M; Knudsen, BR; Tange, TO; Westergaard, O; Boege, F				Straub, T; Grue, P; Uhse, A; Lisby, M; Knudsen, BR; Tange, TO; Westergaard, O; Boege, F			The RNA-splicing factor PSF/p54(nrb) controls DNA-topoisomerase I activity by a direct interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; BINDING; PURIFICATION; ASSOCIATION; MODULATION; CLONING; PSF	DNA-topoisomerase I has been implied in RNA splicing because it catalyzes RNA strand transfer and activates serine/arginine-rich RNA-splicing factors by phosphorylation. Here, we demonstrate a direct interaction between topoisomerase I and pyrimidine tract binding protein-associated splicing factor (PSF), a cofactor of RNA splicing, which forms heterodimers with its smaller homolog, the nuclear RNA-binding protein of 54 kDa (p54(nrb)), Topoisomerase I, PSF, and p54(nrb) copurified in a 1:1:1 ratio from human A431 cell nuclear extracts. Specific binding of topoisomerase I to PSF (but not p54(nrb)) was demonstrated by coimmunoprecipitation and by far Western blotting, in which renatured blots were probed with biotinylated topoisomerase I. Chemical cross-linking of pure topoisomerase I revealed monomeric, dimeric, and trimeric enzyme forms, whereas in the presence of PSF/p54(nrb) the enzyme was cross-linked into complexes larger than homotrimers. When topoisomerase I was complexed with PSF/p54(nrb) it was 16-fold more active than the pure enzyme, which could be stimulated 5- and 16-fold by the addition of recombinant PSF or native PSF/p54(nrb), respectively. A physiological role of this stimulatory mechanism seems feasible, because topoisomerase I and PSF showed a patched colocalization in A431 cell nuclei, which varied with cell cycle.	Univ Wurzburg, Med Poliklin, D-97070 Wurzburg, Germany; Univ Aarhus, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark	University of Wurzburg; Aarhus University	Boege, F (corresponding author), Univ Wurzburg, Med Poliklin, Klin Str 6-8, D-97070 Wurzburg, Germany.		Straub, Tobias/B-2023-2009; Lisby, Michael/K-9814-2014; Boege, Fritz/H-3261-2019	Straub, Tobias/0000-0002-0547-0453; Lisby, Michael/0000-0002-4830-5247; Knudsen, Birgitta Ruth/0000-0002-3484-3802				Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Boege F, 1996, J BIOL CHEM, V271, P2262, DOI 10.1074/jbc.271.4.2262; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; Knudsen BR, 1996, J CHROMATOGR B, V684, P307, DOI 10.1016/0378-4347(96)00152-1; KORDIYAK GJ, 1994, BIOCHEMISTRY-US, V33, P13484, DOI 10.1021/bi00249a037; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; LIU LF, 1983, METHOD ENZYMOL, V100, P171; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; PEREZ I, 1997, EUKARYOTIC MRNA PROC, P127; POMMIER Y, 1995, MUTAT RES-DNA REPAIR, V337, P135, DOI 10.1016/0921-8777(95)00019-G; ROSE KM, 1988, CHROMOSOMA, V96, P411, DOI 10.1007/BF00303034; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; SAALEM A, 1998, P AM ASSOC CANC RES, V39, P373; Sekiguchi J, 1997, J BIOL CHEM, V272, P15721, DOI 10.1074/jbc.272.25.15721; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1841, DOI 10.1093/carcin/14.9.1841; TSAO YP, 1993, CANCER RES, V53, P5908; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060; ZHANG WW, 1993, BIOCHEM J, V290, P267, DOI 10.1042/bj2900267	23	74	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26261	26264		10.1074/jbc.273.41.26261	http://dx.doi.org/10.1074/jbc.273.41.26261			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756848	hybrid			2022-12-25	WOS:000076373300002
J	Huang, SS; Cerullo, MA; Huang, FW; Huang, JS				Huang, SS; Cerullo, MA; Huang, FW; Huang, JS			Activated thyroglobulin possesses a transforming growth factor-beta activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY-DNA; CRYSTAL-STRUCTURE; RECEPTOR; CELLS; GROWTH-FACTOR-BETA-2; THYROCYTES; RESOLUTION; SEQUENCE; KINASE	Thyroglobulin (Tg), the thyroid hormone precursor, is a major protein component in the thyroid gland and may have other important functions. Here, we show that bovine Tg inhibited I-125-labeled transforming growth factor-beta(1) (I-125-TGF-beta(1)) binding to cell-surface TGF-beta receptors in mink lung epithelial cells with an IC50 of similar to 300 nM. After disuccinimidyl suberate (DSS) modification, reduction/alkylation, treatment with 8 M urea, 0.1% SDS, or acidic pH (pH 4-5), Tg exhibited a similar to 5-10-fold increase of I-125-TGF-beta(1) binding inhibitory activity with IC50 of similar to 30-60 nM. This inhibitory activity was an intrinsic property of the Tg and could not be segregated from Tg protein by 5% SDS-polyacrylamide gel electrophoresis or by immunoprecipitation using antiserum to Tg. Untreated Tg did not affect DNA synthesis but blocked the TGF-beta-induced inhibition of DNA synthesis in mink lung epithelial cells. After DSS activation, Tg possessed TGF-beta agonist activity and inhibited DNA synthesis of mink lung epithelial cells and rat thyroid cells. The activated Tg also exerted a small but significant TGF-beta agonist activity in transcriptional activation of plasminogen activator inhibitor-1. These results suggest that Tg possesses an authentic TGF-beta activity which can be induced by chemical modifications and treatments with denaturing agents and acidic pH.	St Louis Univ, Med Ctr, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Huang, JS (corresponding author), St Louis Univ, Med Ctr, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NCI NIH HHS [CA 38808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVINO CG, 1995, ENDOCRINOLOGY, V136, P3179, DOI 10.1210/en.136.8.3179; Berndorfer U, 1996, J CLIN ENDOCR METAB, V81, P1918, DOI 10.1210/jc.81.5.1918; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; HUANG SS, 1988, J BIOL CHEM, V263, P1535; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; LEMANSKY P, 1992, EUR J BIOCHEM, V209, P111, DOI 10.1111/j.1432-1033.1992.tb17267.x; LISSITZKY S, 1984, J ENDOCRINOL INVEST, V7, P65, DOI 10.1007/BF03348380; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MALTHIERY Y, 1989, BIOCHIMIE, V71, P195, DOI 10.1016/0300-9084(89)90057-6; MARRIQ C, 1980, EUR J BIOCHEM, V111, P33; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MERCKEN L, 1985, NATURE, V316, P647, DOI 10.1038/316647a0; MIQUELIS R, 1993, J CELL BIOL, V123, P1695, DOI 10.1083/jcb.123.6.1695; Mziaut H, 1996, ENDOCRINOLOGY, V137, P1370, DOI 10.1210/en.137.4.1370; ODA Y, 1993, J BIOL CHEM, V268, P27318; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, V1, P419; SALVATORE G, 1964, J BIOL CHEM, V239, P3267; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VANHERLE AJ, 1979, NEW ENGL J MED, V301, P307, DOI 10.1056/NEJM197908093010605; WOHL SM, 1994, J EXP MED, V180, P1587; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; Zheng G, 1998, ENDOCRINOLOGY, V139, P1462, DOI 10.1210/en.139.3.1462	30	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26036	26041		10.1074/jbc.273.40.26036	http://dx.doi.org/10.1074/jbc.273.40.26036			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748282	hybrid			2022-12-25	WOS:000076263100073
J	Gomez, J; Martinez, C; Gonzalez, A; Garcia, A; Rebollo, A				Gomez, J; Martinez, C; Gonzalez, A; Garcia, A; Rebollo, A			The Bcl-2 gene is differentially regulated by IL-2 and IL-4: role of the transcription factor NF-AT	ONCOGENE			English	Article						Bcl-2; calcineurin; IL-4; IL-2; NF-AT	PROTEIN-KINASE-C; HUMAN INTERLEUKIN-2 RECEPTOR; T-CELL LINE; CYCLOSPORINE-A; B-CELLS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; HIGH-AFFINITY; GAMMA-CHAIN; EXPRESSION	The murine TS1 alpha beta T cell line expresses the anti-apoptotic protein Bcl-2 upon IL-2 stimulation, whereas IL-4-mediated growth of this cell line proceeds in the absence of Bcl-2 expression. In addition, IL-4 stimulation inhibits Bcl-2 expression and modulates its mRNA level. IL-2-induced DNA binding activity for these transcription factors is sensitive to phosphatidylinositol 3 kinase inhibitor wortmannin and to Rho inhibitor Clostridium difficile toxin B, which inhibit IL-2-induced Bcl-2 expression. IVF-AT transcription factor appears to be the most important in the control Bcl-2 expression, since inhibition of the calcium-calmodulin-dependent phosphatase calcineurin, which regulates NF-AT activity, downregulates Bcl-2 expression in IL-2-stimulated cells, Constitutive expression of this phosphatase also upregulates Bcl-2 expression in IL-4-stimulated cells. In addition, a dominant negative NF-AT expression vector downregulates Bcl-2 expression in IL-2-stimulated cells. These results suggest that IL-2 induction of Bcl-2 expression may be directly or indirectly mediated by NF-AT.	Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Inst Pasteur, Grp Dev Cellulaire, F-75015 Paris, France	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Rebollo, A (corresponding author), Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Rebollo, Angelita/P-2118-2017	Rebollo, Angelita/0000-0002-1293-9686				Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204; BROOME HE, 1995, IMMUNOLOGY, V84, P375; BROOME HE, 1995, J IMMUNOL, V155, P2311; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Cohen SBA, 1997, IMMUNOLOGY, V92, P1, DOI 10.1046/j.1365-2567.1997.00348.x; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DEJONG D, 1994, CANCER RES, V54, P256; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1824; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOMEZ J, 1994, EXP CELL RES, V213, P178, DOI 10.1006/excr.1994.1188; Gomez J, 1997, J IMMUNOL, V158, P1516; Gomez J, 1997, EUR J IMMUNOL, V27, P1610, DOI 10.1002/eji.1830270704; Gomez J, 1997, EUR J IMMUNOL, V27, P2793, DOI 10.1002/eji.1830271108; GOMEZ J, 1995, EXP CELL RES, V218, P105, DOI 10.1006/excr.1995.1136; GOMEZ J, 1995, EUR J IMMUNOL, V25, P2673, DOI 10.1002/eji.1830250941; GOMEZ J, 1996, J IMMUNOL, V157, P2772; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; HANADA M, 1993, CANCER RES, V53, P4978; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; Katoh S, 1997, NEUROSCI LETT, V232, P71, DOI 10.1016/S0304-3940(97)00582-X; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; KRAJEWSKI S, 1993, CANCER RES, V53, P47017; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MAKOVER D, 1991, ONCOGENE, V6, P455; MANIATIS T, 1989, MOL CLONING LAB HDB; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MINAMI Y, 1995, CURR OPIN CELL BIOL, V7, P156, DOI 10.1016/0955-0674(95)80023-9; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLIVER FJ, 1993, BIOCHEM BIOPH RES CO, V194, P126, DOI 10.1006/bbrc.1993.1794; PITTON C, 1993, CYTOKINE, V5, P362, DOI 10.1016/1043-4666(93)90069-H; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rebollo A, 1996, ADV IMMUNOL, V63, P127, DOI 10.1016/S0065-2776(08)60856-1; REBOLLO A, 1995, CYTOKINE, V7, P277, DOI 10.1006/cyto.1995.0033; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; Sekiya M, 1997, BIOCHEM BIOPH RES CO, V239, P401, DOI 10.1006/bbrc.1997.7478; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SENTMAN CL, 1991, CELL, V67, P878; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8	74	32	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1235	1243		10.1038/sj.onc.1202049	http://dx.doi.org/10.1038/sj.onc.1202049			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771966				2022-12-25	WOS:000075803300005
J	Taylor, GA; Jeffers, M; Webb, CP; Koo, HM; Anver, M; Sekiguchi, K; Woude, GFV				Taylor, GA; Jeffers, M; Webb, CP; Koo, HM; Anver, M; Sekiguchi, K; Woude, GFV			Decreased fibronectin expression in Met/HGF-mediated tumorigenesis	ONCOGENE			English	Article						Met; HGF; fibronectin; TGF beta	HEPATOCYTE GROWTH-FACTOR; C-MET RECEPTOR; SCATTER FACTOR; EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; PROTOONCOGENE; INDUCTION; MUTATIONS; METASTASIS; ADHESION	The tyrosine kinase receptor Met and its ligand, hepatocyte growth factor (HGF)/scatter factor are involved in the etiology and progression of a number of human cancers. Coexpression of Met and HGF in mesenchymal cells increases the tumorigenic and metastatic potential of the cells. In the studies described here, we used differential display screening to identify changes in gene expression that are initiated by Met/HGF, and that may lead to these phenotypes. We learned that Met/HGF signaling resulted in greatly decreased fibronectin mRNA production in three different human and mouse tumor cell lines; these decreases in fibronectin mRNA were paralleled by decreases in fibronectin protein. We also found a progressive decrease in fibronectin in tumor explants and metastases derived from the Met/HGF transformed cells. The absence of fibronectin expression is a frequent cancer phenotype; our results indicate that decreases in fibronectin correlate with, but are not essential for, MetHGF/SF-mediated tumorigenesis.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Sci Applicat Int Corp, Frederick, MD 21702 USA; Osaka Med Ctr Maternal & Child Hlth, Inst Res, Osaka 59002, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Woude, GFV (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA.		Webb, Craig/I-8123-2012					Akamatsu H, 1996, CANCER RES, V56, P4541; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998; Faletto D L, 1993, EXS, V65, P107; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HYNES RO, 1990, FIBRONECTINS, P301; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Koochekpour S, 1997, CANCER RES, V57, P5391; Laterra J, 1997, LAB INVEST, V76, P565; Matsumoto K, 1993, EXS, V65, P225; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUOSLAHTI E, 1984, CANCER METAST REV, V3, P43, DOI 10.1007/BF00047692; SAITOH K, 1994, J PATHOL, V174, P191, DOI 10.1002/path.1711740308; SANTOS OFP, 1993, DEV BIOL, V160, P293, DOI 10.1006/dbio.1993.1308; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; STREIT A, 1995, DEVELOPMENT, V121, P813; Taipale J, 1996, J BIOL CHEM, V271, P4342; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597	31	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1179	1183		10.1038/sj.onc.1202004	http://dx.doi.org/10.1038/sj.onc.1202004			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764829				2022-12-25	WOS:000075598400014
J	Hayashi, K; Saga, H; Chimori, Y; Kimura, K; Yamanaka, Y; Sobue, K				Hayashi, K; Saga, H; Chimori, Y; Kimura, K; Yamanaka, Y; Sobue, K			Differentiated phenotype of smooth muscle cells depends on signaling pathways through insulin-like growth factors and phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I-RECEPTOR; MOLECULAR-BASIS; CALDESMON GENE; EXPRESSION; PROTEIN; ACTIVATION; ISOFORMS; SHC; TROPOMYOSIN; ELEMENTS	Under conventional culture conditions, smooth muscle cells display their phenotypic modulation from a differentiated to a dedifferentiated state. Here, we established a primary culture system of smooth muscle cells maintaining a differentiated phenotype, as characterized by expression of smooth muscle-specific marker genes such as h-caldesmon and calponin, cell morphology, and ligand-induced contractility. Laminin retarded the progression of dedifferentiation of smooth muscle cells. Insulin-like growth factors (IGF-I and IGF-II) and insulin markedly prolonged the differentiated phenotype, with IGF-I being the more potent, In contrast, serum, epidermal growth factor, transforming growth factors, and platelet-derived growth factors potently induced dedifferentiation compared with angiotensin II, arginine-vasopressin, and basic fibroblast growth factor. Using the present culture system, we investigated signaling pathways regulating a phenotype of smooth muscle cells. In cultured cells, IGF-I specifically activated phosphatidylinositol 3-kinase (PI3-kinase) and its downstream target, protein kinase B, but not mitogen-activated protein kinases. Specific inhibitors of PIS-kinase (wortmannin and LY294002) induced dedifferentiation of smooth muscle cells even when they were cultured on laminin under IGF-I-stimulated conditions. The sole effect of laminin to retard the dedifferentiation was completely blocked by anti-IGF-I antibody, and laminin promoted the endogenous expression of IGF-I in cultured cells. The reduced promoter activity of the caldesmon gene induced by platelet-derived growth factor BE was overcome by the forced expression of the constitutive active form of PI3-kinase p110 alpha catalytic subunit. These findings suggest that an IGF-I signaling pathway through PI3-kinase plays a critical role in maintaining a differentiated phenotype of smooth muscle cells.	Osaka Univ, Sch Med, Dept Neurochem & Neuropharmacol, Biomed Res Ctr, Suita, Osaka 5650871, Japan	Osaka University	Sobue, K (corresponding author), Osaka Univ, Sch Med, Dept Neurochem & Neuropharmacol, Biomed Res Ctr, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							BLANK RS, 1992, J BIOL CHEM, V267, P984; BORNFELDT KE, 1990, J ENDOCRINOL, V125, P381, DOI 10.1677/joe.0.1250381; BRONFELDT KE, 1993, J CLIN INVEST, V93, P1266; CAMPBELL JH, 1989, ARTERIOSCLEROSIS, V9, P633, DOI 10.1161/01.ATV.9.5.633; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CLEMMONS DR, 1985, CIRC RES, V56, P418, DOI 10.1161/01.RES.56.3.418; CRECK B, 1990, CIRC RES, V66, P1755; Dardevet D, 1996, ENDOCRINOLOGY, V137, P4087, DOI 10.1210/en.137.10.4087; DELAFONTAINE P, 1991, HYPERTENSION, V18, P724; DU J, 1995, CIRC RES, V76, P963, DOI 10.1161/01.RES.76.6.963; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GIMONA M, 1992, EUR J BIOCHEM, V205, P1067, DOI 10.1111/j.1432-1033.1992.tb16875.x; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GLUKHOVA M, 1993, DEV BIOL, V157, P437, DOI 10.1006/dbio.1993.1147; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HAYASHI K, 1992, P NATL ACAD SCI USA, V89, P12122, DOI 10.1073/pnas.89.24.12122; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P503, DOI 10.1016/0006-291X(89)91748-8; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HEDIN U, 1988, J CELL BIOL, V107, P307, DOI 10.1083/jcb.107.1.307; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Kashiwada K, 1997, J BIOL CHEM, V272, P15396, DOI 10.1074/jbc.272.24.15396; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; NAGAI R, 1989, J BIOL CHEM, V264, P9734; OBATA H, 1997, J BIOL CHEM, V272, P26638; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SMALL JV, 1977, J CELL SCI, V24, P327; Sobue K, 1998, HORM RES, V50, P15, DOI 10.1159/000053119; TAKAHASHI K, 1987, LIFE SCI, V41, P291, DOI 10.1016/0024-3205(87)90151-2; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661	36	147	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28860	28867		10.1074/jbc.273.44.28860	http://dx.doi.org/10.1074/jbc.273.44.28860			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786887	hybrid			2022-12-25	WOS:000076691800048
J	Kasahara, T; Kasahara, M				Kasahara, T; Kasahara, M			Tryptophan 388 in putative transmembrane segment 10 of the rat glucose transporter Glut1 is essential for glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; SUGAR TRANSPORTERS; SUBSTRATE RECOGNITION; FORSKOLIN; RESIDUES; SUBSTITUTION; BINDING; MEMBRANE; GENE	The molecular mechanism of substrate recognition in membrane transport is not well understood. Two amino acid residues, Tyr(446) and Trp(455) in transmembrane segment 10 (TM10), have been shown to be important for galactose recognition by the yeast Gal2 transporter; Tyr(446) was found to be essential in that its replacement by any of the other 19 amino acids abolished transport activity (Kasahara, M., Shimoda, E., and Maeda, M. (1997) J. Biol. Chem. 272, 16121-16724). The Glut1 glucose transporter of animal cells belongs to the same Glut transporter family as does Gal2 and thus might be expected to show a similar mechanism of substrate recognition. The role of the two amino acids, Phe(379) and Trp(388), in rat Glut1 corresponding to Tyr(446) and Trp(455) Of Gal2 was therefore studied. Phe(379) and Trp(388) were individually replaced with each of the other 19 amino acids, and the mutant Glut1 transporters were expressed in yeast. The expression level of most mutants was similar to that of the wild-type Glut1, as revealed by immunoblot analysis. Glucose transport activity was assessed by reconstituting a crude membrane fraction of the yeast cells in liposomes. No significant glucose transport activity was observed with any of Trp(388) mutants,whereas the Phe(379) mutants showed reduced or no activity. These results indicate that the two aromatic amino acids in TM10 of Glut1 are important for glucose transport. However, unlike Gal2, the residue at the cytoplasmic end of TM10 (Trp(388), corresponding to Trp(455) of Gal2), rather than that in the middle of TM10 (Phe(379), corresponding to Tyr(446) Of Gal2), is essential for transport activity.	Teikyo Univ, Sch Med, Biophys Lab, Hachioji, Tokyo 1920395, Japan	Teikyo University	Kasahara, M (corresponding author), Teikyo Univ, Sch Med, Biophys Lab, Hachioji, Tokyo 1920395, Japan.	kasahara@main.teikyo-u.ac.jp						ASANO T, 1991, J BIOL CHEM, V266, P24632; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BELL GI, 1993, J BIOL CHEM, V268, P19161; BISSON LF, 1993, CRIT REV BIOCHEM MOL, V28, P259, DOI 10.3109/10409239309078437; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; Doege H, 1998, BIOCHEM J, V329, P289, DOI 10.1042/bj3290289; Dutzler R, 1996, STRUCTURE, V4, P127, DOI 10.1016/S0969-2126(96)00016-0; Forst D, 1998, NAT STRUCT BIOL, V5, P37, DOI 10.1038/nsb0198-37; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; INUKAI K, 1994, BIOCHEM J, V302, P355, DOI 10.1042/bj3020355; Kasahara M, 1996, FEBS LETT, V389, P174, DOI 10.1016/0014-5793(96)00567-4; Kasahara M, 1997, J BIOL CHEM, V272, P16721, DOI 10.1074/jbc.272.27.16721; Kasahara T, 1996, BIOCHEM J, V315, P177, DOI 10.1042/bj3150177; Kasahara T, 1997, BBA-BIOMEMBRANES, V1324, P111, DOI 10.1016/S0005-2736(96)00217-9; KATAGIRI H, 1993, BIOCHEM J, V291, P861, DOI 10.1042/bj2910861; KRUCKEBERG AL, 1990, MOL CELL BIOL, V10, P5903, DOI 10.1128/MCB.10.11.5903; MORI H, 1994, J BIOL CHEM, V269, P11578; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1994, J BIOL CHEM, V269, P17765; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; Schurmann A, 1997, BIOCHEMISTRY-US, V36, P12897, DOI 10.1021/bi971173c; SCHURMANN A, 1993, BIOCHEM J, V290, P497, DOI 10.1042/bj2900497; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; TAMORI Y, 1994, J BIOL CHEM, V269, P2982; WADZINSKI BE, 1990, BIOCHEM J, V272, P151, DOI 10.1042/bj2720151; WANDEL S, 1994, FEBS LETT, V348, P114, DOI 10.1016/0014-5793(94)00558-3	28	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29113	29117		10.1074/jbc.273.44.29113	http://dx.doi.org/10.1074/jbc.273.44.29113			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786919	hybrid			2022-12-25	WOS:000076691800080
J	Binstadt, BA; Billadeau, DD; Jevremovic, D; Williams, BL; Fang, N; Yi, TL; Koretzky, GA; Abraham, RT; Leibson, PJ				Binstadt, BA; Billadeau, DD; Jevremovic, D; Williams, BL; Fang, N; Yi, TL; Koretzky, GA; Abraham, RT; Leibson, PJ			SLP-76 is a direct substrate of SHP-1 recruited to killer cell inhibitory receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; FC-RECEPTOR; NK CELLS; ACTIVATION; ZAP-70; SYK; KINASES; RECOGNITION	Activation of immune system cells via antigen-, Fc-, or natural killer cell-triggering-receptor stimulation is aborted by co-engagement of inhibitory receptors, Negative signaling by killer cell inhibitory receptors and related receptors depends on the Src homology 2 (SH2)-containing protein tyrosine phosphatase SHP-1, Using a combination of direct binding and functional assays, we demonstrated that the SH2 domain-containing leukocyte protein 76 (SLP-76) is a specific target for dephosphorylation by SHP-1 in T cells and natural killer cells. Furthermore, we showed that tyrosine-phosphorylated SLP-76 is required for optimal activation of cytotoxic lymphocytes, suggesting that the targeted dephosphorylation of SLP-76 by SHP-1 is an important mechanism for the negative regulation of immune cell activation by inhibitory receptors.	Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Interdisciplinary Grad Program Immunol, Iowa City, IA 52242 USA; Cleveland Clin Fdn, Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Mayo Clinic; University of Iowa; University of Iowa; University of Iowa; Cleveland Clinic Foundation	Leibson, PJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA.	leibson.paul@mayo.edu	Binstadt, Bryce/N-1305-2013; Koretzky, Gary/AAU-5381-2021	Binstadt, Bryce/0000-0003-3127-3856; Jevremovic, Dragan/0000-0002-1792-5822	NATIONAL CANCER INSTITUTE [R01CA047752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053256, R01GM047286, R01GM053256] Funding Source: NIH RePORTER; NCI NIH HHS [CA47752] Funding Source: Medline; NIGMS NIH HHS [GM47286, GM53256] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Blery M, 1997, J BIOL CHEM, V272, P8989; Brown MG, 1997, IMMUNOL REV, V155, P53, DOI 10.1111/j.1600-065X.1997.tb00939.x; Brumbaugh KM, 1997, J EXP MED, V186, P1965, DOI 10.1084/jem.186.12.1965; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Burshtyn DN, 1997, TRENDS CELL BIOL, V7, P473, DOI 10.1016/S0962-8924(97)01167-7; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Colonna M, 1997, IMMUNOL REV, V155, P127, DOI 10.1111/j.1600-065X.1997.tb00945.x; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DANDREA A, 1995, J IMMUNOL, V155, P2306; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Fang N, 1996, J IMMUNOL, V157, P3769; FARGNOLI J, 1995, J BIOL CHEM, V270, P26533, DOI 10.1074/jbc.270.44.26533; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Gupta N, 1997, J EXP MED, V186, P473, DOI 10.1084/jem.186.3.473; HendricksTaylor LR, 1997, J BIOL CHEM, V272, P1363, DOI 10.1074/jbc.272.2.1363; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JAIO H, 1996, MOL CELL BIOL, V16, P6985; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; Law CL, 1996, MOL CELL BIOL, V16, P1305; Leibson PJ, 1997, IMMUNITY, V6, P655, DOI 10.1016/S1074-7613(00)80441-0; Long EO, 1997, CURR OPIN IMMUNOL, V9, P344, DOI 10.1016/S0952-7915(97)80080-5; Mizuno K, 1996, J EXP MED, V184, P457, DOI 10.1084/jem.184.2.457; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; Olcese L, 1996, J IMMUNOL, V156, P4531; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PERUSSIA B, 1984, J IMMUNOL, V132, P1410; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TING AT, 1995, J BIOL CHEM, V270, P16415, DOI 10.1074/jbc.270.27.16415; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; Vely F, 1997, J IMMUNOL, V159, P2075; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; WINDEBANK KP, 1988, J IMMUNOL, V141, P3951; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040	59	103	107	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27518	27523		10.1074/jbc.273.42.27518	http://dx.doi.org/10.1074/jbc.273.42.27518			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765283	hybrid			2022-12-25	WOS:000076448000070
J	Ko, JL; Liu, HC; Minnerath, SR; Loh, HH				Ko, JL; Liu, HC; Minnerath, SR; Loh, HH			Transcriptional regulation of mouse mu-opioid receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORPHINE-INDUCED ANALGESIA; BOX-BINDING-PROTEINS; TATA-LESS PROMOTER; MESSENGER-RNA; MOLECULAR-CLONING; CONTROL ELEMENT; TFIID COMPLEX; MICE LACKING; EXPRESSION; SP1	Previously, the existence of dual promoters was reported in mouse CL-opioid receptor (mor) gene, with mor transcription in the mouse brain predominantly initiated by the proximal promoter. In this study, we further analyzed the proximal promoter region, base pairs -450 to -249, to identify cis-DNA regulatory elements and trans-acting protein factors that are important for mor promoter activity. The results revealed that a mor inverted GA (iGA) motif and a canonical Spl binding site are required for the promoter activity. Using electrophoretic mobility shift analysis, we identified nuclear proteins that specifically bind to the mor iGA motif and that are immunologically related to Spl and Sp3. Mutation of the mor iGA motif, resulting in a loss of Sp binding, led to a 50% decrease in activity. Mutation of the canonical Spl binding site yielded a lesser (approximately 25%) loss of activity. Mutation of both motifs together resulted in an approximately 70% decrease in activity. In cotransfection assays using Drosophila SL2 cells, Spl trans-activated the promoter in a manner dependent on the presence of mor iGA and canonical Spl binding motifs. Sp3 can also trans-activate the promoter, and furthermore, Spl and Sp3 can trans-activate the mor promoter additively. Our results suggest that combined or cooperative interaction of Sp transcription factors within the proximal promoter is necessary for activation of mor gene transcription.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Ko, JL (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 3-249 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.	koxxx001@maroon.tc.umn.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA001583, P01DA005695, R37DA001583] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00546, DA-01583, DA-05695] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Azaryan AV, 1996, NEUROCHEM RES, V21, P1411, DOI 10.1007/BF02532382; BALL HJ, 1995, J BIOL CHEM, V270, P27272, DOI 10.1074/jbc.270.45.27272; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DELFS JM, 1994, J NEUROCHEM, V63, P777; DELFS JM, 1994, J COMP NEUROL, V345, P46, DOI 10.1002/cne.903450104; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hyman SE, 1996, SCIENCE, V273, P611, DOI 10.1126/science.273.5275.611; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JOHNSON DR, 1995, BIOTECHNIQUES, V19, P190; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Ko JL, 1997, BIOCHEM BIOPH RES CO, V234, P351, DOI 10.1006/bbrc.1997.6640; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; Kovarik A, 1996, J BIOL CHEM, V271, P18140, DOI 10.1074/jbc.271.30.18140; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; KRAUS J, 1995, BIOCHEM BIOPH RES CO, V215, P591, DOI 10.1006/bbrc.1995.2505; Lee SH, 1996, J BIOL CHEM, V271, P25292, DOI 10.1074/jbc.271.41.25292; LIANG YB, 1995, BRAIN RES, V679, P82, DOI 10.1016/0006-8993(95)00222-C; Maekawa K, 1996, PAIN, V64, P365, DOI 10.1016/0304-3959(95)00132-8; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MIN BH, 1994, P NATL ACAD SCI USA, V91, P9081, DOI 10.1073/pnas.91.19.9081; MINAMI M, 1995, NEUROSCI RES, V23, P121, DOI 10.1016/0168-0102(95)00933-K; MOTEJLEK K, 1994, J BIOL CHEM, V269, P15265; NESTLER EJ, 1994, BRAIN RES BULL, V35, P521, DOI 10.1016/0361-9230(94)90166-X; Parks CL, 1996, J BIOL CHEM, V271, P4417; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Ronnekleiv OK, 1996, NEUROSCI LETT, V216, P129; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Solecki D, 1997, J BIOL CHEM, V272, P5579, DOI 10.1074/jbc.272.9.5579; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Wood P. L., 1988, OPIATE RECEPTORS, P307	45	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27678	27685		10.1074/jbc.273.42.27678	http://dx.doi.org/10.1074/jbc.273.42.27678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765304	hybrid			2022-12-25	WOS:000076448000091
J	Koussevitzky, S; Ne'eman, E; Sommer, A; Steffens, JC; Harel, E				Koussevitzky, S; Ne'eman, E; Sommer, A; Steffens, JC; Harel, E			Purification and properties of a novel chloroplast stromal peptidase - Processing of polyphenol oxidase and other imported precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A/B PROTEIN; OXYGEN-EVOLVING COMPLEX; PEA-CHLOROPLASTS; MOLECULAR-CLONING; ESCHERICHIA-COLI; TRANSFER SIGNALS; TRANSPORT; PATHWAY; PLANTS; IDENTIFICATION	Polyphenol oxidases (PPOs) are nuclear-encoded chloroplast proteins that are targeted to the thylakoid lumen by a bipartite presequence. The N-terminal part of this sequence is removed by a stromal processing peptidase (SPP), and the resulting intermediate is translocated across the thylakoid and processed to the mature protein. A 4800-fold-purified SPP processed a PPO precursor (pPPO) at a site identical to that occurring in organelle, The in vitro product of SPP action on pPPO was further processed and translocated by thylakoids. This SPP processed other precursors but was inactive toward those of light-harvesting chlorophyll binding proteins. The enzyme appeared to be a metalloendopeptidase, like previously reported SPPs, However, it differed in substrate specificity, apparent size, and, most significantly, cleavage site of pPPO. Whereas the processing sites of lumen proteins determined so far were relatively distant from the hydrophobic core of the thylakoid targeting domain, pPPO was cleaved immediately before this domain, Cleavage removed the twin arginine motif characteristic of thylakoid targeting domains of lumen proteins, which are translocated by the Delta pH-dependent pathway, The possible significance of these observations to PPO translocation mechanism is discussed. It is suggested that several SPPs may exist in chloroplasts with preferences for different subsets of precursors.	Hebrew Univ Jerusalem, Dept Plant Sci, IL-91904 Jerusalem, Israel; Cornell Univ, Dept Plant Breeding, Ithaca, NY 14853 USA	Hebrew University of Jerusalem; Cornell University	Harel, E (corresponding author), Hebrew Univ Jerusalem, Dept Plant Sci, IL-91904 Jerusalem, Israel.	eitanamm@vms.huji.ac.il						ABAD MS, 1991, PLANT PHYSIOL, V96, P1220, DOI 10.1104/pp.96.4.1220; ABAD MS, 1989, PLANT PHYSIOL, V90, P117, DOI 10.1104/pp.90.1.117; BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; BASSHAM DC, 1994, EUR J BIOCHEM, V221, P523, DOI 10.1111/j.1432-1033.1994.tb18764.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bogsch E, 1997, EMBO J, V16, P3851, DOI 10.1093/emboj/16.13.3851; BOSS PK, 1995, PLANT MOL BIOL, V27, P429, DOI 10.1007/BF00020197; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CHITNIS PR, 1986, J CELL BIOL, V102, P982, DOI 10.1083/jcb.102.3.982; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; COHEN Y, 1992, FEBS LETT, V302, P15, DOI 10.1016/0014-5793(92)80273-J; CONSTABEL CP, 1995, P NATL ACAD SCI USA, V92, P407, DOI 10.1073/pnas.92.2.407; CREIGHTON AM, 1995, J BIOL CHEM, V270, P1663, DOI 10.1074/jbc.270.4.1663; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DRY IB, 1994, PLANT MOL BIOL, V26, P495, DOI 10.1007/BF00039560; HIND G, 1995, BIOCHEMISTRY-US, V34, P8157, DOI 10.1021/bi00025a022; JAMES HE, 1989, J BIOL CHEM, V264, P19573; JOY RW, 1995, PLANT PHYSIOL, V107, P1083, DOI 10.1104/pp.107.4.1083; KOHORN BD, 1986, J CELL BIOL, V102, P972, DOI 10.1083/jcb.102.3.972; LAMPPA GK, 1987, J CELL BIOL, V105, P2641, DOI 10.1083/jcb.105.6.2641; Leheny EA, 1998, PLANT PHYSIOL, V116, P805, DOI 10.1104/pp.116.2.805; Lindahl M, 1996, J BIOL CHEM, V271, P29329, DOI 10.1074/jbc.271.46.29329; LIU XQ, 1986, PLANT PHYSIOL, V81, P603, DOI 10.1104/pp.81.2.603; LUBBEN TH, 1986, P NATL ACAD SCI USA, V83, P5502, DOI 10.1073/pnas.83.15.5502; MAYER AM, 1987, PHYTOCHEMISTRY, V26, P11; MAYER AM, 1979, PHYTOCHEMISTRY, V18, P193, DOI 10.1016/0031-9422(79)80057-6; MAYER AM, 1991, FOOD ENZYMOLOGY, P373; MEADOWS JW, 1991, PLANT MOL BIOL, V16, P1085, DOI 10.1007/BF00016082; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; NEWMAN SM, 1993, PLANT MOL BIOL, V21, P1035, DOI 10.1007/BF00023601; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; Ostersetzer O, 1996, EUR J BIOCHEM, V236, P932, DOI 10.1111/j.1432-1033.1996.00932.x; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PECKER I, 1992, P NATL ACAD SCI USA, V89, P4962, DOI 10.1073/pnas.89.11.4962; PICHERSKY E, 1988, PLANT MOL BIOL, V11, P69, DOI 10.1007/BF00016015; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; Robinson C, 1997, TRENDS PLANT SCI, V2, P431, DOI 10.1016/S1360-1385(97)90027-3; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; Sommer A, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL III, P827; SOMMER A, 1994, PLANT PHYSIOL, V105, P1301, DOI 10.1104/pp.105.4.1301; Steffens J. C., 1994, Genetic engineering of plant secondary metabolism., P275; SU QX, 1994, BIOCHEM J, V300, P787, DOI 10.1042/bj3000787; SU QX, 1993, EUR J BIOCHEM, V217, P1039, DOI 10.1111/j.1432-1033.1993.tb18335.x; Thipyapong P, 1997, PLANT PHYSIOL, V115, P409, DOI 10.1104/pp.115.2.409; VAUGHN KC, 1988, PHYSIOL PLANTARUM, V72, P659, DOI 10.1111/j.1399-3054.1988.tb09180.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; YALOVSKY S, 1992, J BIOL CHEM, V267, P20689	49	36	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27064	27069		10.1074/jbc.273.42.27064	http://dx.doi.org/10.1074/jbc.273.42.27064			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765221	hybrid			2022-12-25	WOS:000076448000008
J	Tang, Y; Tie, F; Boros, I; Harrod, R; Glover, M; Giam, CZ				Tang, Y; Tie, F; Boros, I; Harrod, R; Glover, M; Giam, CZ			An extended alpha-helix and specific amino acid residues opposite the DNA-binding surface of the cAMP response element binding protein basic domain are important for human T cell lymphotropic retrovirus type I Tax binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-I; CYCLIC-AMP; TRANSACTIVATOR TAX; 21-BASE-PAIR REPEATS; CRYSTAL-STRUCTURE; CREB BINDING; TRANSCRIPTIONAL ACTIVATOR; BZIP PROTEINS; ENHANCER; COMPLEX	The human T cell lymphotropic retrovirus type I (HTLV-I) trans-activator, Tax, interacts specifically with the basic-domain/leucine-zipper (bZip) protein, cAMP response element binding protein (CREB), bound to the viral Tax-responsive element consisting of three imperfect 21-base pair repeats, each with a cAMP response element core flanked by G/C-rich sequences. Here, the minimal CREB-bZip necessary for Tax binding is shown to be composed of amino acid residues 280 341, The Tax-CREB interaction involves an uninterrupted and extended a-helix in CREB that spans most of its basic domain to include amino acid residues localized to the NH, terminus of the DNA binding region. Mutational analyses indicate that three residues, Arg(284), Met(291), and Glu(299) unique to this region of the CREB/activating transcription factor-1 subfamily of bZip proteins, constitute the contact surface for Tax, Amino acid substitutions in these positions had little impact on CREB-bZip binding to DNA but abrogated its binding to Tax. Each of the contact residues for Tax are spaced approximately two helical turns apart on the side of the bZip helix directly opposite to that of the invariant DNA-binding residues. Molecular modeling reveals the Tax-contact residues to be near the minor groove of the G/C-rich DNA in the al-base pair repeat. They most likely position Tax for minor groove contact with the G/C-rich sequences.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	Uniformed Services University of the Health Sciences - USA; University of Alberta	Giam, CZ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.			Boros, Imre/0000-0001-8504-9687	NATIONAL CANCER INSTITUTE [R01CA075688, R01CA048709] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA48709, R0 CA/GM 75688] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; Adya N, 1994, MOL CELL BIOL, V14, P456; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BOROS IM, 1995, VIROLOGY, V214, P207, DOI 10.1006/viro.1995.9939; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CANN AJ, 1996, VIROLOGY, P1849; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLER W, 1995, J MOL BIOL, V254, P657, DOI 10.1006/jmbi.1995.0645; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; Shnyreva M, 1996, J VIROL, V70, P7478, DOI 10.1128/JVI.70.11.7478-7484.1996; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Yin MJ, 1996, J MOL BIOL, V264, P20, DOI 10.1006/jmbi.1996.0620; YIN MJ, 1995, J VIROL, V69, P6209, DOI 10.1128/JVI.69.10.6209-6218.1995; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	38	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27339	27346		10.1074/jbc.273.42.27339	http://dx.doi.org/10.1074/jbc.273.42.27339			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765261	hybrid			2022-12-25	WOS:000076448000048
J	Ten Hagen, BG; Hagen, FK; Balys, MM; Beres, TM; Van Wuyckhuyse, B; Tabak, LA				Ten Hagen, BG; Hagen, FK; Balys, MM; Beres, TM; Van Wuyckhuyse, B; Tabak, LA			Cloning and expression of a novel, tissue specifically expressed member of the UDP-GalNAc : polypeptide N-acetylgalactosaminyltransferase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; ACETYL-D-GALACTOSAMINE; MOLECULAR-CLONING; CHROMOSOMAL LOCALIZATION; CDNA CLONING; MUCIN; IDENTIFICATION; GENE; SITE; MUTAGENESIS	We report the cloning and expression of the fifth member of the mammalian UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (ppGaNTase) family. Degenerate polymerase chain reaction amplification and hybridization screening of a rat sublingual gland (RSLG) cDNA library were used to identify a novel iso form termed ppGaNTase-T5. Conceptual translation of the cDNA reveals a uniquely long stem region not observed for other members of this enzyme family. Recombinant proteins expressed transiently in COS7 cells displayed transferase activity in vitro, Relative activity and substrate preferences of ppGaNTase-T5 were compared with previously identified isoforms (ppGaNTase-T1, -T3, and -T4); ppGaNTase-T5 and -T4 glycosylated a restricted subset of peptides whereas ppGaNTase-T1 and -T3 glycosylated a broader range of substrates. Northern blot analysis revealed that ppGaNTase TB is expressed in a highly tissue-specific manner; abundant expression was seen in the RSLG, with lesser amounts of message in the stomach, small intestine, and colon. Therefore, the pattern of expression of ppGaNTase-T5 is the most restricted of all isoforms examined thus far. The identification of this novel isoform underscores the diversity and complexity of the family of genes controlling O-linked glycosylation.	Univ Rochester, Med Ctr, Ctr Oral Biol, Rochester Inst Biomed Sci, Rochester, NY 14642 USA	University of Rochester	Tabak, LA (corresponding author), Univ Rochester, Med Ctr, Ctr Oral Biol, Rochester Inst Biomed Sci, 601 Elmwood Ave,Box 611, Rochester, NY 14642 USA.				NIDCR NIH HHS [DE-08108] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008108, R01DE008108] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBONE EF, 1994, J BIOL CHEM, V269, P16845; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; DOWBENKO D, 1993, J BIOL CHEM, V268, P4525; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HOMA FL, 1993, J BIOL CHEM, V268, P12609; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KINLOCH RA, 1995, P NATL ACAD SCI USA, V92, P263, DOI 10.1073/pnas.92.1.263; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Moore DD, 1995, GLOB MOB SURV; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; OHMORI H, 1994, J BIOL CHEM, V269, P17833; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHEKELS LL, 1995, BIOCHEM J, V311, P775, DOI 10.1042/bj3110775; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; Wragg S, 1997, BIOCHEM J, V328, P193, DOI 10.1042/bj3280193; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	25	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27749	27754						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765313				2022-12-25	WOS:000076448000100
J	Wang, SF; Miura, K; Miksicek, RJ; Segraves, WA; Raikhel, AS				Wang, SF; Miura, K; Miksicek, RJ; Segraves, WA; Raikhel, AS			DNA binding and transactivation characteristics of the mosquito ecdysone receptor-Ultraspiracle complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; RESPONSE ELEMENTS; DROSOPHILA-MELANOGASTER; DIRECT REPEATS; GLUCOCORTICOID RECEPTOR; ECDYSTEROID RECEPTOR; SUPERFAMILY MEMBERS; NUCLEAR RECEPTOR; AEDES-AEGYPTI; RETINOIC ACID	The steroid hormone 20-hydroxyecdysone is a key regulatory factor, controlling blood-meal triggered egg maturation in mosquitoes. To elucidate the ecdysone hierarchy governing this event, we cloned and characterized the ecdysone receptor (AaEcR) and the nuclear receptor Ultraspiracle (AaUSP), a retinoid X receptor homologue, from the mosquito, Aedes aegypti, which form a functional complex capable of ligand and DNA binding. Here we analyzed the DNA-binding properties of the AaEcR AaUSP heterodimer with respect to the effects of nucleotide sequence, orientation, and spacing between half-sites in natural Drosophila and synthetic ecdysone response element (EcREs). By using an electrophoretic gel mobility shift assay, we showed that AaEcR AaUSP exhibits a broad binding specificity, forming complexes with inverted (IR) and direct (DR) repeats of the nuclear receptor response element half-site consensus sequence AGGTCA separated by spacers of variable length. A single nucleotide spacer was optimal for both imperfect (IRhsp-1) and perfect (IRper-1) inverted repeats; adding or removing 1 base pair in an IRhsp-1 spacer practically abolished binding. However, changing the half-site to the consensus sequence AG;GTCA (IRper-1) increased binding of AaEcR AaUSP 10-fold over IRhsp-1 and, at the same time, reduced the stringency of the spacer length requirement, with IRper-1 to IRper-5 showing detectable binding. Spacer length was less important in DRs of AGGTCA (DR-0 to DR-5); although 4 bp was optimal, DR-3 and DR-5 bound AaEcR AaUSP almost as efficiently as DR-4. Furthermore, AaEcR AaUSP also bound DRs separated by 11-13 nucleotide spacers. Competition experiments and direct estimation of binding affinity (K-d) indicated that, given identical consensus half-sites and an optimal spacer, the AaEcR AaUSP heterodimer bound an Tl with higher affinity than a DR. Co-transfection assays utilizing CV-1 cells demonstrated that the mosquito EcR.USP heterodimer is capable of transactivating reporter constructs containing either IR-1 or DR-4. The levels of transactivation are correlated with the respective binding affinities of the response elements (IRper-1 > DR-4 > IRhsp-1). Taken together, these analyses predict broad variability in the EcREs of mosquito ecdysone-responsive genes.	Michigan State Univ, Dept Entomol, Genet Program, E Lansing, MI 48824 USA; Michigan State Univ, Dept Entomol, Cell & Mol Biol Program, E Lansing, MI 48824 USA; Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Yale Univ, Dept Biol, New Haven, CT 06520 USA	Michigan State University; Michigan State University; Michigan State University; Yale University	Raikhel, AS (corresponding author), Michigan State Univ, Dept Entomol, Genet Program, S-150 Plant Biol Bldg, E Lansing, MI 48824 USA.	araikhel@pilot.cl.msu.edu	Miksicek, Richard/AAC-7319-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036959] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-36959] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTONIEWSKI C, 1994, MOL CELL BIOL, V14, P4465, DOI 10.1128/MCB.14.7.4465; ANTONIEWSKI C, 1993, INSECT BIOCHEM MOLEC, V23, P105, DOI 10.1016/0965-1748(93)90088-A; Antoniewski C, 1995, MOL GEN GENET, V249, P545, DOI 10.1007/BF00290580; Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOWNES M, 1986, ANNU REV ENTOMOL, V31, P507, DOI 10.1146/annurev.en.31.010186.002451; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; Cherbas P, 1996, METAMORPHOSIS POSTEM, P175; CHO WL, 1991, P NATL ACAD SCI USA, V88, P10821, DOI 10.1073/pnas.88.23.10821; CHO WL, 1995, INSECT BIOCHEM MOLEC, V25, P19, DOI 10.1016/0965-1748(94)00045-J; CHRISTIANSON AMK, 1992, P NATL ACAD SCI USA, V89, P11503, DOI 10.1073/pnas.89.23.11503; COONEY AJ, 1994, MECHANISM STEROID HO, P25; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DAVINO PP, 1995, MOL CELL ENDOCRINOL, V113, P1; DEITSCH KW, 1995, INSECT BIOCHEM MOLEC, V25, P449, DOI 10.1016/0965-1748(94)00082-A; DHADIALLA TS, 1994, PERSPECTIVES IN COMPARATIVE ENDOCRINOLOGY, P275; DHADIALLA TS, 1990, J BIOL CHEM, V265, P9924; Elke C, 1997, ARCH INSECT BIOCHEM, V35, P59, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<59::AID-ARCH6>3.3.CO;2-O; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Hagedorn H.H., 1989, P279; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORNER MA, 1995, DEV BIOL, V168, P490, DOI 10.1006/dbio.1995.1097; Kapitskaya M, 1996, MOL CELL ENDOCRINOL, V121, P119, DOI 10.1016/0303-7207(96)03847-6; KATO S, 1995, MOL CELL BIOL, V15, P5858; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; LEHMANN M, 1995, EMBO J, V14, P716, DOI 10.1002/j.1460-2075.1995.tb07050.x; LIN YG, 1993, DEV BIOL, V155, P558, DOI 10.1006/dbio.1993.1052; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; RAIKHEL AS, 1998, IN PRESS AM ZOOL; Riddiford L.M., 1985, P37; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Segraves William A., 1994, Seminars in Cell Biology, V5, P105, DOI 10.1006/scel.1994.1014; SOKAL RR, 1987, INTRO BIOSTATISTICS, P437; Swevers L, 1996, INSECT BIOCHEM MOLEC, V26, P217, DOI 10.1016/0965-1748(95)00097-6; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; Thummel CS, 1996, TRENDS GENET, V12, P306, DOI 10.1016/0168-9525(96)10032-9; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vogtli M, 1998, NUCLEIC ACIDS RES, V26, P2407, DOI 10.1093/nar/26.10.2407; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	54	65	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27531	27540		10.1074/jbc.273.42.27531	http://dx.doi.org/10.1074/jbc.273.42.27531			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765285	hybrid			2022-12-25	WOS:000076448000072
J	Klenova, EM; Fagerlie, S; Filippova, GN; Kretzner, L; Goodwin, GH; Loring, G; Neiman, PE; Lobanenkov, VV				Klenova, EM; Fagerlie, S; Filippova, GN; Kretzner, L; Goodwin, GH; Loring, G; Neiman, PE; Lobanenkov, VV			Characterization of the chicken CTCF genomic locus, and initial study of the cell cycle-regulated promoter of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC GENE; TRANSCRIPTIONAL REPRESSION; MESSENGER-RNA; SEQUENCE REQUIREMENTS; FUNCTIONAL-ANALYSIS; BINDING-SITES; EXPRESSION; PROTEIN; YY1; IDENTIFICATION	CTCF is a multifunctional transcription factor encoded by a novel candidate tumor suppressor gene (Filippova, G. N., Lindblom, A., Meinke, L. J., Klenova, E. M., Neiman, P. E., Collins, S. J., Doggett, N. D., and Lobanenkov, V, V, (1998) Genes Chromosomes Cancer 22, 26-36), We characterized genomic organization of the chicken CTCF (chCTCF) gene, and studied the chCTCF promoter, Genomic locus of chCTCF contains a CC-rich untranslated exon separated from seven coding exons by a long intron, The 2-kilobase pair region upstream of the major transcription start site contains a CpG island marked by a "Not-knot" that includes sequence motifs characteristic of a TATA-less promoter of housekeeping genes. When fused upstream of a reporter chloramphenicol acetyltransferase gene, it acts as a strong transcriptional promoter in transient transfection experiments. The minimal 180-base pair chCTCF promoter region that is fully sufficient to confer high level transcriptional activity to the reporter contains high affinity binding element for the transcription factor YY1, This element is strictly conserved in chicken, mouse, and human CTCF genes. Mutations in the core nucleotides of the YY1 element reduce transcriptional activity of the minimal chCTCF promoter, indicating that the conserved YY1-binding sequence is critical for transcriptional regulation of vertebrate CTCF genes, We also noted in the chCTCF promoter several elements previously characterized in cell cycle-regulated genes, including the "cell cycle-dependent element" and "cell cycle gene homology region" motifs shown to be important for S/G(2)-specific up-regulation of cdc25C, cdc2, cyclin A, and Plk (polo-like kinase) gene promoters, Presence of the cell cycle-dependent element/cell cycle gene homology region element suggested that chCTCF expression may be cell cycle-regulated. We show that both levels of the endogenous chCTCF mRNA, and the activity of the stably transfected chCTCF promoter constructs, increase in S/G(2) cells.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ S Dakota, Sch Med, Vermillion, SD 57069 USA; Inst Canc Res, McElwain Labs, Sutton SM2 5NG, Surrey, England	Fred Hutchinson Cancer Center; University of Oxford; University of South Dakota; University of London; Institute of Cancer Research - UK	Lobanenkov, VV (corresponding author), Fred Hutchinson Canc Res Ctr, Suite C2-023,1100 Fairview Ave N, Seattle, WA 98109 USA.	vlobanen@fred.fhcrc.org	Lobanenkov, Victor V./AGQ-8903-2022; Lobanenkov, Victor/ABD-5710-2021	Lobanenkov, Victor/0000-0001-6665-3635	NCI NIH HHS [R01 CA68360, CA20068, CA71732] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020068, R01CA071732, R01CA068360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BEUG H, 1982, J CELL PHYSIOL, P195; BIEGALKE BJ, 1991, VIROLOGY, V183, P381, DOI 10.1016/0042-6822(91)90151-Z; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; CHALLONER PB, 1989, MOL CELL BIOL, V9, P902, DOI 10.1128/MCB.9.3.902; Chang CS, 1997, J LIGHTWAVE TECHNOL, V15, P1225; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHEN D, 1991, J BIOL CHEM, V266, P2239; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GUPTA KC, 1984, NUCLEIC ACIDS RES, V12, P3829, DOI 10.1093/nar/12.9.3829; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; ICHINOSE H, 1992, BIOCHEMISTRY-US, V31, P11546, DOI 10.1021/bi00161a036; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; LABASTIE MC, 1994, GENOMICS, V21, P1, DOI 10.1006/geno.1994.1217; LANFRANCONE L, 1992, GENOMICS, V12, P720, DOI 10.1016/0888-7543(92)90301-8; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; LOBANENKOV VV, 1986, EUR J BIOCHEM, V159, P181, DOI 10.1111/j.1432-1033.1986.tb09850.x; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; LOBANENKOV VV, 1989, GENE REGULATION AIDS, P45; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; NAZERIAN K, 1975, J NATL CANCER I, V54, P453; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanger F, 1992, Biotechnology, V24, P104; Schug J., 1997, TESS TRANSCRIPTION E; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; SOLOVYEV V, 1997, ISMB, V5, P294; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; YE JP, 1994, NUCLEIC ACIDS RES, V22, P5672, DOI 10.1093/nar/22.25.5672; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	57	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26571	26579		10.1074/jbc.273.41.26571	http://dx.doi.org/10.1074/jbc.273.41.26571			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756895	hybrid			2022-12-25	WOS:000076373300049
J	Miquel, K; Pradines, A; Terce, F; Selmi, S; Favre, G				Miquel, K; Pradines, A; Terce, F; Selmi, S; Favre, G			Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PROTEIN-KINASE-C; MITOGENIC GROWTH-FACTORS; HAMSTER OVARY CELLS; HMG-COA REDUCTASE; MEVALONATE METABOLISM; HL-60 CELLS; TYROSINE PHOSPHORYLATION; TRANSFORMED-CELLS; NUCLEAR RECEPTOR	We have previously shown that, among various isoprenoids, farnesol and geranylgeraniol specifically induced actin fiber disorganization, growth inhibition, and apoptosis in human lung adenocarcinoma A549 cells (Miquel, K., Pradines, A. and Favre, G. (1996) Biochem. Biophys. Res. Commun. 225, 869-876). Here we demonstrate that isoprenoid-induced apoptosis was preceded by an arrest in G(0)/G(1) phase. The isoprenoid effects were independent of protein prenylation and of mitogen-activated protein kinase activity. Moreover, geranylgeraniol and farnesol induced a rapid inhibition of phosphatidylcholine biosynthesis at the last step of the CDP-choline pathway controlled by choline phosphotransferase and not at the level of CTP:phosphocholine cytidylyltransferase, the key enzyme of the pathway. Inhibition of choline phosphotransferase was confirmed by in vitro assays on microsomal fractions, which clearly showed that the isoprenoids acted by competitive inhibition with the diacylglycerol binding. Exogenous phosphatidylcholine addition prevented all the biological effects of the isoprenoids, including actin fiber disorganization and apoptosis, suggesting that inhibition of phosphatidylcholine biosynthesis might be the primary event of the isoprenoid action. These data demonstrate the molecular mechanism of geranylgeraniol and farnesol effects and suggest that the mevalonate pathway, leading notably to prenylated proteins, might be linked to the control of cell proliferation through the regulation of phosphatidylcholine biosynthesis.	Inst Claudius Regaud, Lab Oncol Cellulaire & Mol, Fac Pharmaceut Sci, F-31052 Toulouse, France; Inst Claudius Regaud, Ctr Lutte Contre Canc, F-31052 Toulouse, France; Hop Purpan, INSERM, U326, F-31059 Toulouse, France	UNICANCER; Institut Claudius Regaud; UNICANCER; Institut Claudius Regaud; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Favre, G (corresponding author), Inst Claudius Regaud, Lab Oncol Cellulaire & Mol, Fac Pharmaceut Sci, 20-24 Rue Pont St Pierre,EA 2048, F-31052 Toulouse, France.		FAVRE, Gilles/K-9189-2014; Tercé, François/M-5863-2018; Pradines, Anne/M-3935-2014	FAVRE, Gilles/0000-0002-2344-1883; Tercé, François/0000-0003-4488-2167; Pradines, Anne/0000-0002-2449-678X				BANSAL VS, 1994, ARCH BIOCHEM BIOPHYS, V315, P393, DOI 10.1006/abbi.1994.1516; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; BRADFUTE DL, 1992, J BIOL CHEM, V267, P18308; BROWN MS, 1980, J LIPID RES, V21, P505; Burke YD, 1997, LIPIDS, V32, P151, DOI 10.1007/s11745-997-0019-y; CHAKRABARTI R, 1991, J BIOL CHEM, V266, P12216; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Cuthbert JA, 1997, CANCER RES, V57, P3498; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GanaWeisz ML, 1997, BIOCHEM BIOPH RES CO, V239, P900, DOI 10.1006/bbrc.1997.7582; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAUG JS, 1994, BBA-MOL CELL RES, V1223, P133, DOI 10.1016/0167-4889(94)90082-5; HOUWELING M, 1991, BIOCHEM J, V278, P347, DOI 10.1042/bj2780347; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; JONES KD, 1994, BIOCHEM BIOPH RES CO, V205, P1681, DOI 10.1006/bbrc.1994.2861; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KOTHAPALLI R, 1993, LIPIDS, V28, P969, DOI 10.1007/BF02537116; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; Masuda Y, 1997, INT J CANCER, V71, P691, DOI 10.1002/(SICI)1097-0215(19970516)71:4<691::AID-IJC29>3.0.CO;2-D; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; Meigs TE, 1997, ARCH BIOCHEM BIOPHYS, V345, P1, DOI 10.1006/abbi.1997.0200; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; MEIGS TE, 1995, EXP CELL RES, V219, P461, DOI 10.1006/excr.1995.1253; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MELNYKOVYCH G, 1992, BIOCHEM BIOPH RES CO, V186, P543, DOI 10.1016/S0006-291X(05)80842-3; Miquel K, 1996, BIOCHEM BIOPH RES CO, V225, P869, DOI 10.1006/bbrc.1996.1265; Miquel K, 1997, CANCER RES, V57, P1846; Nakajo S, 1996, BIOCHEM BIOPH RES CO, V226, P741, DOI 10.1006/bbrc.1996.1423; OHIZUMI H, 1995, J BIOCHEM-TOKYO, V117, P11, DOI 10.1093/oxfordjournals.jbchem.a124695; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; REEDQUIST KA, 1995, BIOCHEM BIOPH RES CO, V211, P665, DOI 10.1006/bbrc.1995.1863; Rusnak JM, 1996, EXP CELL RES, V224, P189, DOI 10.1006/excr.1996.0127; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; TERCE F, 1994, J LIPID RES, V35, P2130; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; VANCE DE, 1981, METHOD ENZYMOL, V71, P571; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; Vogt A, 1996, ONCOGENE, V13, P1991; VOZIYAN PA, 1993, BIOCHEM J, V295, P757, DOI 10.1042/bj2950757; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WARDEN CH, 1984, BIOCHIM BIOPHYS ACTA, V792, P270, DOI 10.1016/0005-2760(84)90194-2; YASUGI E, 1995, BIOCHEM BIOPH RES CO, V216, P848, DOI 10.1006/bbrc.1995.2699; YAZLOVITSKAYA EM, 1995, CANCER LETT, V88, P179, DOI 10.1016/0304-3835(94)03635-V	54	117	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26179	26186		10.1074/jbc.273.40.26179	http://dx.doi.org/10.1074/jbc.273.40.26179			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748300	hybrid			2022-12-25	WOS:000076263100091
J	Nomura, H; Turco, AE; Pei, Y; Kalaydjieva, L; Schiavello, T; Weremowicz, S; Ji, WZ; Morton, CC; Meisler, M; Reeders, ST; Zhou, J				Nomura, H; Turco, AE; Pei, Y; Kalaydjieva, L; Schiavello, T; Weremowicz, S; Ji, WZ; Morton, CC; Meisler, M; Reeders, ST; Zhou, J			Identification of PKDL, a novel polycystic kidney disease 2-like gene whose murine homologue is deleted in mice with kidney and retinal defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTING COILED COILS; HAJDU-CHENEY-SYNDROME; CA2+ CHANNELS; PROTEIN; ENCODES; LOCUS; SEQUENCES; FAMILY; MODELS; FORM	Polycystin-1 and polycystin-2 are the products of PKD1 and PKD2, genes that are mutated in most cases of autosomal dominant polycystic kidney disease. Polycystin-2 shares similar to 46% homology with pore-forming domains of a number of cation channels. It has been suggested that polycystin-2 may function as a subunit of an ion channel whose activity is regulated by polycystin-1, Here we report the identification of a human gene, PKDL, which encodes a new member of the polycystin protein family designated polycystin-L, Polycystin-L has 50% amino acid sequence identity and 71% homology to polycystin-2 and has striking sequence and structural resemblance to the pore-forming alpha 1 subunits of Ca2+ channels, suggesting that polycystin-L may function as a subunit of an ion channel. The full-length transcript of PKDL is expressed at high levels in fetal tissues, including kidney and liver, and down-regulated in adult tissues. PKDL was assigned to 10q24 by fluorescence in situ hybridization and is linked to D10S603 by radiation hybrid mapping. There is no evidence of linkage to PKDL in six ADPKD families that are unlinked to PKD1 or PKD2, The mouse homologue of PKDL is deleted in Krd mice, a deletion mutant with defects in the kidney and eye. We propose that PKDL is an excellent candidate for as yet unmapped cystic diseases in man and animals.	Brigham & Womens Hosp, Div Renal, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Verona, Sch Med, Inst Genet, I-37134 Verona, Italy; Univ Toronto, Toronto, ON, Canada; Toronto Hosp, Dept Med, Div Nephrol, Toronto, ON, Canada; Edith Cowan Univ, Dept Human Biol, Perth, WA 6027, Australia; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Verona; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Edith Cowan University; University of Michigan System; University of Michigan	Zhou, J (corresponding author), Brigham & Womens Hosp, Div Renal, Dept Med, HIM 522,77 Ave Louis Pasteur, Boston, MA 02115 USA.	zhou@rics.bwh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK051050, R01DK040703, R01DK051050] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51050, DK40703] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ariza M, 1997, J MED GENET, V34, P587, DOI 10.1136/jmg.34.7.587; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bihoreau MT, 1997, HUM MOL GENET, V6, P609, DOI 10.1093/hmg/6.4.609; BOGDANOVA N, 1995, HUM GENET, V95, P645; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Fryns JP, 1997, CLIN GENET, V51, P271; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Gretz N, 1996, NEPHROL DIAL TRANSPL, V11, P46; GUAYWOODFORD LM, 1995, AM J HUM GENET, V56, P1101; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; KAPLAN P, 1995, AM J MED GENET, V56, P25, DOI 10.1002/ajmg.1320560108; KELLER SA, 1994, GENOMICS, V23, P309, DOI 10.1006/geno.1994.1506; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Pirson Y, 1996, HEPATOLOGY, V23, P249, DOI 10.1002/hep.510230208; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Schieren G, 1996, NEPHROL DIAL TRANSPL, V11, P38; Schneider MC, 1996, GENOMICS, V38, P1, DOI 10.1006/geno.1996.0584; Sharp CK, 1997, J AM SOC NEPHROL, V8, P77; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; STULTZ CM, 1993, PROTEIN SCI, V2, P305; Torres M, 1995, DEVELOPMENT, V121, P4057; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Turco AE, 1996, AM J KIDNEY DIS, V28, P759, DOI 10.1016/S0272-6386(96)90261-9; WHITE JV, 1994, MATH BIOSCI, V119, P35, DOI 10.1016/0025-5564(94)90004-3; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353; [No title captured]	39	128	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25967	25973		10.1074/jbc.273.40.25967	http://dx.doi.org/10.1074/jbc.273.40.25967			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748274	hybrid			2022-12-25	WOS:000076263100065
J	Apanovitch, DM; Iiri, T; Karasawa, T; Bourne, HR; Dohlman, HG				Apanovitch, DM; Iiri, T; Karasawa, T; Bourne, HR; Dohlman, HG			Second site suppressor mutations of a GTPase-deficient G-protein alpha-subunit - Selective inhibition of G beta gamma-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; PHEROMONE RESPONSE; ESCHERICHIA-COLI; ACTIVATION; YEAST; MUTANT; RECEPTORS	G proteins transmit signals from cell surface receptors to intracellular effectors, The intensity of the signal is governed by the rates of GTP binding (leading to subunit dissociation) and hydrolysis. Mutants that cannot hydrolyze GTP (e.g. G(s)alpha(Q227L), G(i2)alpha(Q205L)) are constitutively activated and can lead to cell transformation and cancer. Here we have used a genetic screen to identify intragenic suppressors of a GTPase-deficient form of the G alpha in yeast, Gpal(Q323L). Sequencing revealed second-site mutations in three conserved residues, K54E, R327S, and L353 Delta (codon deletion). Each mutation alone results in a complete loss of the beta gamma-mediated mating response in yeast, indicating a dominant-negative mode of inhibition. Likewise, the corresponding mutations in a mammalian G(i2)alpha (K46E, R209S, L235 Delta) lead to inhibition of G beta gamma-mediated mitogen-activated protein (MAP) kinase phosphorylation in cultured cells. The most potent of these beta gamma inhibitors (R209S) has no effect on G(i2)alpha-mediated regulation of adenylyl cyclase, Despite its impaired ability to release py, purified recombinant Gpal(R327S) is, fully competent to bind and hydrolyze GTP. These mutants will be useful for uncoupling G beta gamma- and G alpha-mediated signaling events in whole cells and animals. In addition, they serve as a model for drugs that could directly inhibit G protein activity and cell transformation.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Interdepartmental Neurosci Program, New Haven, CT 06520 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	Yale University; Yale University; University of California System; University of California San Francisco	Dohlman, HG (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 295 Congress Ave, New Haven, CT 06536 USA.			Dohlman, Henrik/0000-0003-2443-0729	NCI NIH HHS [CA54427] Funding Source: Medline; NIGMS NIH HHS [GM27800, R01 GM055316, GM 55316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM055316, R01GM027800, R29GM055316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOURNE HR, 1981, MOL PHARMACOL, V20, P435; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; FAURE M, 1994, J BIOL CHEM, V269, P7851; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; HEWLETT EL, 1997, PEDIAT INFECT DIS S, V16, P78; HIRSCH JP, 1992, BIOESSAYS, V14, P367, DOI 10.1002/bies.950140604; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE E, 1992, J BIOL CHEM, V267, P1212; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MIYAJIMA I, 1989, MOL CELL BIOL, V9, P2289, DOI 10.1128/MCB.9.6.2289; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OSAWA S, 1991, J BIOL CHEM, V266, P4673; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; SALOMON MR, 1981, MOL PHARMACOL, V19, P109; SIKORSKI RS, 1989, GENETICS, V122, P19; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; SPIEGEL AM, 1993, J CLIN INVEST, V92, P1119, DOI 10.1172/JCI116680; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P21; STONE DE, 1990, MOL CELL BIOL, V10, P4439, DOI 10.1128/MCB.10.9.4439; Stratton HF, 1996, MOL CELL BIOL, V16, P6325; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924	45	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28597	28602		10.1074/jbc.273.44.28597	http://dx.doi.org/10.1074/jbc.273.44.28597			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786851	hybrid			2022-12-25	WOS:000076691800012
J	Bockamp, EO; Fordham, JL; Gottgens, B; Murrell, AM; Sanchez, MJ; Green, AR				Bockamp, EO; Fordham, JL; Gottgens, B; Murrell, AM; Sanchez, MJ; Green, AR			Transcriptional regulation of the stem cell leukemia gene by PU.1 and Elf-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMITIVE MYELOID CELLS; LOOP-HELIX GENE; MAST-CELLS; BINDING-SITES; SCL GENE; T-CELLS; ERYTHROID-DIFFERENTIATION; GATA-BINDING; DNA-BINDING; HEMATOPOIETIC LINEAGES	The SCL gene, also known as tal-1, encodes a basic helix-loop-helix transcription factor that is pivotal for the normal development of all hematopoietic lineages. SCL is expressed in committed erythroid, mast, and megakaryocytic cells as well as in hematopoietic stem cells. Nothing is known about the regulation of SCL transcription in mast cells, and in other lineages GATA-1 is the only tissue-specific transcription factor recognized to regulate the SCL gene. We have therefore analyzed the molecular mechanisms underlying SCL expression in mast cells. In this paper, we demonstrate that SCL promoter la was regulated by GATA-1 together with Spl and Sp3 in a manner similar to the situation in erythroid cells. However, SCL promoter Ib was strongly active in mast cells, in marked contrast to the situation in erythroid cells. Full activity of promoter Ib was dependent on ETS and Sp1/3 motifs, Transcription factors PU.1, Elf-1, Spl, and Sp3 were all present in mast cell extracts, bound to promoter Ib and transactivated promoter Ib reporter constructs. These data provide the first evidence that the SCL gene is a direct target for PU.1, Elf-1, and Sp3.	Univ Cambridge, Dept Haematol, MRC Ctr, Cambridge CB2 2QH, England; Univ Mainz, Lab Mouse Genet, Inst Toxikol, D-55131 Mainz, Germany	MRC Laboratory Molecular Biology; University of Cambridge; Johannes Gutenberg University of Mainz	Green, AR (corresponding author), Univ Cambridge, Dept Haematol, MRC Ctr, Hills Ctr, Cambridge CB2 2QH, England.	arg1000@cam.ac.uk	Sanchez, Maria Jose/P-4716-2016	Sanchez, Maria Jose/0000-0003-3464-6224; Green, Anthony/0000-0002-9795-0218; Gottgens, Berthold/0000-0001-6302-5705; Bockamp, Ernesto/0000-0002-6181-1734	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akbarali Y, 1996, J BIOL CHEM, V271, P26007, DOI 10.1074/jbc.271.42.26007; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; ASSELIN C, 1989, ONCOGENE, V4, P549; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BIEBER T, 1994, IMMUNOL TODAY, V15, P52, DOI 10.1016/0167-5699(94)90132-5; Bockamp EO, 1997, J BIOL CHEM, V272, P8781, DOI 10.1074/jbc.272.13.8781; BOCKAMP EO, 1994, BIOESSAYS, V16, P481, DOI 10.1002/bies.950160707; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; CHEN HM, 1995, ONCOGENE, V11, P1549; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Costello PS, 1996, ONCOGENE, V13, P2595; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROSS MA, 1994, ONCOGENE, V9, P3013; Davis JN, 1996, GENE, V171, P265, DOI 10.1016/0378-1119(96)00013-3; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; ELEFANTY AG, 1992, BLOOD, V79, P1271; Ernst P, 1996, MOL CELL BIOL, V16, P6121; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; Gao JG, 1996, MOL ENDOCRINOL, V10, P613, DOI 10.1210/me.10.6.613; Gottgens B, 1997, ONCOGENE, V15, P2419, DOI 10.1038/sj.onc.1201426; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; Green T, 1996, NATURE, V383, P575, DOI 10.1038/383575a0; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; Henkel GW, 1996, BLOOD, V88, P2917, DOI 10.1182/blood.V88.8.2917.bloodjournal8882917; HWANG LY, 1993, ONCOGENE, V8, P3043; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jippo T, 1997, BLOOD, V90, P2601, DOI 10.1182/blood.V90.7.2601.2601_2601_2608; John S, 1996, J EXP MED, V183, P743, DOI 10.1084/jem.183.3.743; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KALLIANPUR AR, 1994, BLOOD, V83, P1220; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P482; LECOINTE N, 1994, ONCOGENE, V9, P2623; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; Liao YB, 1997, J BIOL CHEM, V272, P2969, DOI 10.1074/jbc.272.5.2969; Lodie TA, 1997, J IMMUNOL, V158, P1848; Mao C, 1996, ONCOGENE, V12, P863; Marone G, 1997, INT ARCH ALLERGY IMM, V114, P207, DOI 10.1159/000237670; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; Maxam A M, 1980, Methods Enzymol, V65, P499; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MIYAJIMA I, 1995, BLOOD, V85, P1246, DOI 10.1182/blood.V85.5.1246.bloodjournal8551246; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; MORRIS JF, 1994, MOL CELL BIOL, V14, P1756; MOUTHON MA, 1993, BLOOD, V81, P647; MURRELL AM, 1995, ONCOGENE, V11, P131; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; OFarrell AM, 1996, BLOOD, V87, P3655, DOI 10.1182/blood.V87.9.3655.bloodjournal8793655; Oh CK, 1997, BIOCHEM J, V323, P511, DOI 10.1042/bj3230511; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; Plumb M A, 1988, Methods Mol Biol, V4, P139, DOI 10.1385/0-89603-127-6:139; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Silver L, 1997, BLOOD, V89, P1154, DOI 10.1182/blood.V89.4.1154; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; VISVADER J, 1991, ONCOGENE, V6, P195; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Weiss DL, 1996, MOL CELL BIOL, V16, P228; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WONG F, 1995, BIOTECHNIQUES, V18, P1034; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; ZON LI, 1991, J BIOL CHEM, V266, P22948	95	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29032	29042		10.1074/jbc.273.44.29032	http://dx.doi.org/10.1074/jbc.273.44.29032			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786909	hybrid			2022-12-25	WOS:000076691800070
J	Linnertz, H; Urbanova, P; Obsil, T; Herman, P; Amler, E; Schoner, W				Linnertz, H; Urbanova, P; Obsil, T; Herman, P; Amler, E; Schoner, W			Molecular distance measurements reveal an (alpha beta)(2) dimeric structure of Na+/K+-ATPase - High affinity ATP binding site and K+-activated phosphatase reside on different alpha-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; ISOTHIOCYANATE REACTIVE SITE; FLUORESCENCE ENERGY-TRANSFER; COMPLEX ANALOG CO(NH3)4PO4; CARDIAC GLYCOSIDE SITE; AMINO-ACID-SEQUENCE; CONFORMATIONAL-CHANGES; TRANSPORTING ATPASE; MAMMALIAN KIDNEY; BETA-SUBUNIT	ATP hydrolysis by Na+/K+-ATPase proceeds via the interaction of simultaneously existing and cooperating high (E(1)ATP) and low (E(2)ATP) substrate binding sites, It is unclear whether both ATP sites reside on the same or on different catalytic cu-subunits, To answer this question, we looked for a fluorescent label for the E(2)ATP site that would be suitable for distance measurements by Forster energy transfer after affinity labeling of the E(1)ATP site by fluorescein 5'-isothiocyanate (FITC), Erythrosin 5'-isothiocyanate (ErITC) inactivated, in an E(1)ATP site-blocked enzyme (by FITC), the residual activity of the E(2)ATP site, namely K+-activated p-nitrophenylphosphatase in a concentration-dependent way that was ATP-protectable. The molar ratios of FITC/alpha-subunit of 0.6 and of ErITC/alpha-subunit of 0.48 indicate 2 ATP sites per (alpha beta)(2) diprotomer. Measurements of Forster energy transfer between the FITC-labeled E(1)ATP and the ErITC-labeled or Co(NH3)(4)ATP-inactivated E(2)ATP sites gave a distance of 6.45 +/- 0.64 nm, This distance excludes 2 ATP sites per a-subunit since the diameter of alpha is 4-5 nm, Forster energy transfer between cardiac glycoside binding sites labeled with anthroylouabain and fluoresceinylethylenediamino ouabain gave a distance of 4.9 +/- 0.5 nm, Hence all data are consistent with the hypothesis that Na+/K+-ATPase in cellular membranes is an (alpha beta)(2) diprotomer and works as a functional dimer (Thoenges, D., and Schoner, W. (1997) J. Biol. Chem, 272, 16315-16321).	Univ Giessen, Inst Biochem & Endokrinol, D-35392 Giessen, Germany; Czech Acad Sci, Inst Physiol, CZ-14220 Prague 4, Czech Republic; Charles Univ, Inst Phys, CZ-12116 Prague 2, Czech Republic	Justus Liebig University Giessen; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Charles University Prague	Schoner, W (corresponding author), Univ Giessen, Inst Biochem & Endokrinol, Frankfurter Str 100, D-35392 Giessen, Germany.	wilhelm.schoner@vetmed.uni-giessen.de	Amler, Evzen/H-3588-2014; Herman, Petr/A-2626-2008; Obsil, Tomas/B-7142-2012	Herman, Petr/0000-0001-6918-2576; Obsil, Tomas/0000-0003-4602-1272				ABBOTT AJ, 1991, BIOCHEMISTRY-US, V30, P1692, DOI 10.1021/bi00220a035; AMLER E, 1992, BIOPHYS J, V61, P553, DOI 10.1016/S0006-3495(92)81859-3; Amler E, 1996, BIOPHYS J, V70, P182, DOI 10.1016/S0006-3495(96)79562-0; Askari A, 1988, Prog Clin Biol Res, V268A, P149; Brinkmann K, 1997, EUR J BIOCHEM, V249, P301, DOI 10.1111/j.1432-1033.1997.t01-2-00301.x; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; BUXBAUM E, 1990, EUR J BIOCHEM, V193, P355, DOI 10.1111/j.1432-1033.1990.tb19346.x; BUXBAUM E, 1991, EUR J BIOCHEM, V195, P407, DOI 10.1111/j.1432-1033.1991.tb15720.x; CAMPOS M, 1994, J BIOL CHEM, V269, P18028; CARILLI CT, 1982, J BIOL CHEM, V257, P5601; CAVIERES JD, 1987, FEBS LETT, V225, P145, DOI 10.1016/0014-5793(87)81147-X; CLELAND WW, 1982, METHOD ENZYMOL, V87, P159; DALE RE, 1976, P NATL ACAD SCI USA, V73, P271, DOI 10.1073/pnas.73.2.271; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FORSTER T, 1951, FLUORESZENZ ORGANISC, P67; FORTES PAG, 1988, NA PLUS K PLUS PUM A, P197; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; HAMER E, 1993, EUR J BIOCHEM, V213, P743, DOI 10.1111/j.1432-1033.1993.tb17815.x; HERMAN P, 1994, BBA-BIOMEMBRANES, V1190, P1, DOI 10.1016/0005-2736(94)90028-0; HINZ HR, 1990, J BIOL CHEM, V265, P10260; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KAPAKOS JG, 1986, J BIOL CHEM, V261, P2090; KAPAKOS JG, 1982, BIOCHIM BIOPHYS ACTA, V693, P493, DOI 10.1016/0005-2736(82)90458-8; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; KLODOS I, 1987, BIOCHIM BIOPHYS ACTA, V897, P302, DOI 10.1016/0005-2736(87)90426-3; LAKOWICZ JR, 1984, BIOPHYS J, V46, P463, DOI 10.1016/S0006-3495(84)84043-6; LEE JA, 1986, BIOCHEMISTRY-US, V25, P8133, DOI 10.1021/bi00373a002; Lin SH, 1996, BIOCHEMISTRY-US, V35, P8419, DOI 10.1021/bi960407+; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Linnertz H, 1997, FEBS LETT, V419, P227, DOI 10.1016/S0014-5793(97)01460-9; LINNERTZ H, 1995, EUR J BIOCHEM, V232, P420, DOI 10.1111/j.1432-1033.1995.tb20827.x; Linnertz H, 1998, EUR J BIOCHEM, V251, P522, DOI 10.1046/j.1432-1327.1998.2510522.x; Linnertz H, 1997, PHYSIOL RES, V46, P345; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P111, DOI 10.1016/0014-5793(87)81253-X; PAULS H, 1980, EUR J BIOCHEM, V109, P523, DOI 10.1111/j.1432-1033.1980.tb04824.x; PELUFFO RD, 1992, J BIOL CHEM, V267, P6596; PISZKIEWICZ D, 1971, BIOCHEMISTRY-US, V10, P4544, DOI 10.1021/bi00800a031; PLESNER IW, 1987, BIOPHYS J, V51, P69, DOI 10.1016/S0006-3495(87)83312-X; REPKE KRH, 1973, ACTA BIOL MED GER, V31, pK19; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SCHEINERBOBIS G, 1987, EUR J BIOCHEM, V168, P123, DOI 10.1111/j.1432-1033.1987.tb13396.x; SCHONER W, 1967, EUR J BIOCHEM, V1, P334, DOI 10.1111/j.1432-1033.1967.tb00078.x; Schoner W, 1998, EUR J BIOCHEM, V253, P245, DOI 10.1046/j.1432-1327.1998.2530245.x; SCHONER W, 1994, SODIUM PUMP, P332; SKOU JC, 1980, BIOCHIM BIOPHYS ACTA, V601, P386, DOI 10.1016/0005-2736(80)90543-X; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; SKOU JC, 1988, METHOD ENZYMOL, V156, P278; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; SKOU JC, 1981, BIOCHIM BIOPHYS ACTA, V647, P232, DOI 10.1016/0005-2736(81)90251-0; THOENGES D, 1997, ANN NY ACAD SCI, V834, P321; TINGBEALL HP, 1990, FEBS LETT, V265, P121, DOI 10.1016/0014-5793(90)80899-T; TOSA H, 1993, SODIUM PUMP, P649; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; TYSON PA, 1989, J BIOL CHEM, V264, P726; VECER J, 1993, REV SCI INSTRUM, V64, P3413, DOI 10.1063/1.1144312; Ward DG, 1996, J BIOL CHEM, V271, P12317, DOI 10.1074/jbc.271.21.12317; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; YAMAZAKI A, 1994, J BIOCHEM, V116, P1360, DOI 10.1093/oxfordjournals.jbchem.a124688	62	46	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28813	28821		10.1074/jbc.273.44.28813	http://dx.doi.org/10.1074/jbc.273.44.28813			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786881	hybrid			2022-12-25	WOS:000076691800042
J	Renganathan, M; Messi, ML; Delbono, O				Renganathan, M; Messi, ML; Delbono, O			Overexpression of IGF-1 exclusively in skeletal muscle prevents age-related decline in the number of dihydropyridine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; CONTRACTILE PROPERTIES; TRANSGENIC MICE; CALCIUM-RELEASE; CA2+ RELEASE; C-FOS; FIBERS; CHANNEL; ADULT; JUN	Excitation-contraction uncoupling has been identified as a mechanism underlying skeletal muscle weakness in aging mammals (sarcopenia). The basic mechanism for excitation-contraction uncoupling is a larger number of ryanodine receptors (RyR1) uncoupled to dihydropyridine receptors (DHPRs) (Delbono, O., O'Rourke, K, S,, and Ettinger, W. H, (1995) J, Membr. Biol. 148, 211-222), In the present study, we used transgenic mice overexpressing human insulin-like growth factor-1 exclusively in skeletal muscle to test the hypothesis that a high concentration of IGF-1 prevents age-related decreases in DHPR number and in muscle force. Transgenic mice express 10-20-fold higher IGF-1 concentrations than nontransgenic mice at all ages (1-24 months). The number of DHPRs is 50-100% higher, and the DHPR/RyR1 ratio is 40% higher in transgenic soleus (predominantly type I fiber muscles), extensor digitorum longus (predominantly type II fiber muscles), and the pool of type I and type II fiber muscles than in nontransgenic young (6 months), adult (12 months), and old (24 months) mice. Furthermore, no age-related changes in DHPRs and the DHPR/RyR1 ratio were observed in transgenic muscles. The specific single twitch and tetanic muscle force in old transgenic soleus and extensor digitorum longus muscles are 50% higher than in old nontransgenic muscles, Taken together, these results support the concept that IGF-1- dependent prevention of age-related decline in DHPR expression is associated with stronger muscle contraction in older transgenic mice.	Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Sticht Ctr Aging, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med Gerontol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University	Delbono, O (corresponding author), Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	odelbono@wfubmc.edu			NATIONAL INSTITUTE ON AGING [R29AG013934, P60AG010484, K01AG000692] Funding Source: NIH RePORTER; NIA NIH HHS [R29AG13934, K01AG00692, P60AG10484] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON K, 1994, AM J PHYSIOL, V266, pC462, DOI 10.1152/ajpcell.1994.266.2.C462; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ASHLEY CC, 1991, Q REV BIOPHYS, V24, P1, DOI 10.1017/S0033583500003267; Balnave CD, 1996, J PHYSIOL-LONDON, V492, P705, DOI 10.1113/jphysiol.1996.sp021339; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BROOKS SV, 1988, J PHYSIOL-LONDON, V404, P71, DOI 10.1113/jphysiol.1988.sp017279; BROOKS SV, 1994, AM J PHYSIOL, V267, pC507, DOI 10.1152/ajpcell.1994.267.2.C507; CARTER WJ, 1995, CLIN GERIATR MED, V11, P735, DOI 10.1016/S0749-0690(18)30268-4; CAVALIE A, 1994, J PHYSIOL-LONDON, V479, P11, DOI 10.1113/jphysiol.1994.sp020274; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; DELBONO O, 1987, PFLUG ARCH EUR J PHY, V410, P394, DOI 10.1007/BF00586516; Delbono O, 1997, MUSCLE NERVE, pS88; Delbono O, 1996, J MEMBRANE BIOL, V151, P123, DOI 10.1007/s002329900063; Delbono O, 1995, J MEMBRANE BIOL, V148, P211; Delbono O, 1997, J NEUROSCI, V17, P6918; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1993, ADV EXP MED BIOL, V343, P319; GRIMBY G, 1983, CLIN PHYSIOL, V3, P209, DOI 10.1111/j.1475-097X.1983.tb00704.x; HOCHBERG MC, 1994, ARTHRITIS RHEUM, V37, P1177, DOI 10.1002/art.1780370811; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; LARSSON L, 1979, J APPL PHYSIOL, V46, P451, DOI 10.1152/jappl.1979.46.3.451; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MONNIER D, 1994, MOL CELL ENDOCRINOL, V104, P139, DOI 10.1016/0303-7207(94)90116-3; OZ M, 1991, J PHARMACOL EXP THER, V257, P575; PAZ CAO, 1986, EXP NEUROL, V94, P509, DOI 10.1016/0014-4886(86)90234-7; Renganathan M, 1997, J MEMBRANE BIOL, V157, P247, DOI 10.1007/s002329900233; Renganathan M, 1997, FEBS LETT, V417, P13, DOI 10.1016/S0014-5793(97)01225-8; Renganathan M, 1997, BIOCHEM BIOPH RES CO, V235, P784, DOI 10.1006/bbrc.1997.6881; SABORIDO A, 1995, PFLUG ARCH EUR J PHY, V429, P364, DOI 10.1007/BF00374151; SCHMID A, 1985, J BIOL CHEM, V260, P3041; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; SEGAL SS, 1985, AM J PHYSIOL, V248, pC265, DOI 10.1152/ajpcell.1985.248.3.C265; SONNTAG WE, 1980, ENDOCRINOLOGY, V107, P1875, DOI 10.1210/endo-107-6-1875	35	84	85	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28845	28851		10.1074/jbc.273.44.28845	http://dx.doi.org/10.1074/jbc.273.44.28845			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786885	hybrid			2022-12-25	WOS:000076691800046
J	Ventoso, I; Barco, A; Carrasco, L				Ventoso, I; Barco, A; Carrasco, L			Mutational analysis of poliovirus 2A(pro) - Distinct inhibitory functions of 2A(pro) on translation and transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-4F; CAP-INDEPENDENT TRANSLATION; CELL PROTEIN-SYNTHESIS; POLYMERASE-II TRANSCRIPTION; TATA-BINDING PROTEIN; MAMMALIAN-CELLS; HELA-CELLS; IN-VITRO; HOST TRANSLATION; GENE-EXPRESSION	Transient expression of poliovirus 2A(pro) in mammalian cells by means of the recombinant vaccinia virus vT7 expression system leads to drastic inhibition of both cellular and vaccinia virus gene expression (Aldabe, R., Feduchi, E., Novoa, I., and Carrasco, L. (1995) FEBS Lett. 377, 1-5; Aldabe, R., Feduchi, E., Novoa, I., and Carrasco, L. (1995) Biochem. Biophys. Res. Commun. 215, 928-936). To obtain further insights into the molecular basis of this inhibition, a number of 2A(pro) variants were generated and expressed in COS-1 cells. The effect of these variants on cellular translation, on vaccinia virus-specific translation, and on transcription of the reporter gene luciferase was analyzed. The ability of the different 2A(pro) variants to block cellular translation depends on their capacities to cleave eIF-4G. The blockade exerted by 2A(pro) on transcription of the luciferase gene reinforces the notion that this protease is a potent inhibitor of RNA polymerase II-mediated transcription. Some of the 2A(pro) variants tested failed to block luciferase transcription, despite the fact that eIF-4G cleavage and inhibition of translation were observed. Two reconstituted polioviruses mutated in 2A(pro) were defective in inhibiting luciferase transcription, yet were still able to cleave eIF-4G and block translation. These findings indicate that 2A(pro) interferes with cellular gene expression at both the transcriptional and translational levels. Moreover, these two effects probably reflect the inactivation of different host proteins by poliovirus 2A(pro).	Univ Autonoma Madrid, CSIC, Ctr Biol Mol, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Ventoso, I (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol, Canto Blanco, Madrid 28049, Spain.		Carrasco, Luis/H-3001-2017; Barco, Angel/ABF-1864-2021; Carrasco, Luis/E-2435-2012; Barco, Angel/C-3062-2008; Ventoso, Iván/N-4018-2014	Carrasco, Luis/0000-0003-3833-8835; Barco, Angel/0000-0002-0653-3751; Barco, Angel/0000-0002-0653-3751; Ventoso, Iván/0000-0001-7887-3520				ALDABE R, 1995, BIOCHEM BIOPH RES CO, V215, P928, DOI 10.1006/bbrc.1995.2553; Aldabe R, 1995, FEBS LETT, V377, P1, DOI 10.1016/0014-5793(95)01269-9; Barco A, 1997, J BIOL CHEM, V272, P12683, DOI 10.1074/jbc.272.19.12683; BARCO A, 1995, FEBS LETT, V371, P4, DOI 10.1016/0014-5793(95)00841-V; BERNSTEIN HD, 1985, MOL CELL BIOL, V5, P2913, DOI 10.1128/MCB.5.11.2913; BONNEAU AM, 1987, J VIROL, V61, P986, DOI 10.1128/JVI.61.4.986-991.1987; CLARK ME, 1993, MOL CELL BIOL, V13, P1232, DOI 10.1128/MCB.13.2.1232; CLARK ME, 1991, EMBO J, V10, P2941, DOI 10.1002/j.1460-2075.1991.tb07844.x; CRAWFORD N, 1981, CELL, V27, P555, DOI 10.1016/0092-8674(81)90397-4; DAVIES MV, 1991, J BIOL CHEM, V266, P14714; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; Favaloro J, 1980, Methods Enzymol, V65, P718; Feduchi E, 1995, EUR J BIOCHEM, V234, P849, DOI 10.1111/j.1432-1033.1995.849_a.x; FERNANDEZTOMAS C, 1982, VIROLOGY, V116, P629, DOI 10.1016/0042-6822(82)90154-4; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; HAMBIDGE SJ, 1992, P NATL ACAD SCI USA, V89, P10272, DOI 10.1073/pnas.89.21.10272; HELLEN CUT, 1991, J VIROL, V65, P4226, DOI 10.1128/JVI.65.8.4226-4231.1991; IRURZUN A, 1995, J VIROL, V69, P7453, DOI 10.1128/JVI.69.12.7453-7460.1995; JEWELL JE, 1990, J VIROL, V64, P1388, DOI 10.1128/JVI.64.3.1388-1393.1990; Keiper BD, 1997, NUCLEIC ACIDS RES, V25, P395, DOI 10.1093/nar/25.2.395; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LEE CK, 1988, VIROLOGY, V166, P405, DOI 10.1016/0042-6822(88)90511-9; LEIBOWITZ R, 1971, J VIROL, V8, P661, DOI 10.1128/JVI.8.5.661-668.1971; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; LU HH, 1994, J VIROL, V68, P7507, DOI 10.1128/JVI.68.11.7507-7515.1994; MACADAM AJ, 1994, EMBO J, V13, P924, DOI 10.1002/j.1460-2075.1994.tb06336.x; MOLLA A, 1993, VIROLOGY, V196, P739, DOI 10.1006/viro.1993.1531; Novoa I, 1996, J VIROL, V70, P3319, DOI 10.1128/JVI.70.5.3319-3324.1996; Novoa I, 1997, BIOCHEMISTRY-US, V36, P7802, DOI 10.1021/bi9631172; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; PEREZ L, 1992, VIROLOGY, V189, P178, DOI 10.1016/0042-6822(92)90693-J; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNIERLE BS, 1992, VIROLOGY, V188, P931, DOI 10.1016/0042-6822(92)90556-5; Shen YH, 1996, MOL CELL BIOL, V16, P4163; SUN XH, 1989, P NATL ACAD SCI USA, V86, P2143, DOI 10.1073/pnas.86.7.2143; TOYODA H, 1986, CELL, V45, P761, DOI 10.1016/0092-8674(86)90790-7; TURNER PC, 1989, VIROLOGY, V173, P509, DOI 10.1016/0042-6822(89)90563-1; URZAINQUI A, 1989, J VIROL, V63, P4729, DOI 10.1128/JVI.63.11.4729-4735.1989; VENTOSO I, 1995, J VIROL, V69, P6280, DOI 10.1128/JVI.69.10.6280-6288.1995; WET JR, 1987, MOL CELL BIOL, V7, P725; WYCKOFF EE, 1990, P NATL ACAD SCI USA, V87, P9529, DOI 10.1073/pnas.87.24.9529; Yalamanchili P, 1997, J VIROL, V71, P1220, DOI 10.1128/JVI.71.2.1220-1226.1997; Yalamanchili P, 1997, J VIROL, V71, P6881, DOI 10.1128/JVI.71.9.6881-6886.1997; Yalamanchili P, 1996, J VIROL, V70, P2922, DOI 10.1128/JVI.70.5.2922-2929.1996; YU SF, 1991, VIROLOGY, V182, P615, DOI 10.1016/0042-6822(91)90602-8	50	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27960	27967		10.1074/jbc.273.43.27960	http://dx.doi.org/10.1074/jbc.273.43.27960			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774410	hybrid			2022-12-25	WOS:000076549800030
J	Suo, ZC; Johnson, KA				Suo, ZC; Johnson, KA			DNA secondary structure effects on DNA synthesis catalyzed by HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED DNA; POLYMERASE-ALPHA; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; INVITRO; REPLICATION; MECHANISM; STABILITY; SPECIFICITY	The effect of DNA secondary structure on polymerization catalyzed by human immunodeficiency virus (HIV-1) reverse transcriptase (RT) was studied using a synthetic 66-nucleotide DNA template containing a stable hairpin structure. Four RT pause sites were identified within the first half of the hairpin stem. Additionally, five weak pause sites within the second half of the stem and the loop of the hairpin were identified at low temperatures. These weak pause sites were relocated to the site of the first few stem base pairs of two new hairpins formed due to a change in DNA secondary structure. Each pause site was correlated with a high free energy barrier of melting the stem base pair. Pre-steady state kinetic analysis of single nucleotide incorporation showed that polymerization at each pause site occurred by both a fast phase (10-20 s(-1)) and a slow phase (0.02-0.07 s(-1)) during a single binding event. The reaction amplitudes of the fast phase were small (4-10% of enzyme sites), whereas the amplitudes of the slow phase were large (14-40%) at the pause sites. In contrast, only a single phase with a large reaction amplitude (32-50%) and a fast nucleotide incorporation rate (33-87 s(-1)) was observed at the non-pause sites. DNA substrates at all sites had similar dissociation rates (0.14-0.29 s(-1)) and overall binding affinity (16-86 nM). These results suggest that the DNA substrates at pause sites were bound in both productive and non-productive states at the polymerase site of RT. The non-productively bound DNA was slowly converted into a productive state upon melting of the next stem base pair without dissociation of the DNA from RT.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Johnson, KA (corresponding author), Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA.	kajl@psu.edu			FDA HHS [BM44613] Funding Source: Medline	FDA HHS		BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BEDINGER P, 1989, J BIOL CHEM, V264, P16880; DUDDING LR, 1991, BIOCHEMISTRY-US, V30, P10498, DOI 10.1021/bi00107a019; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; Hottiger M, 1996, BIOL CHEM H-S, V377, P97; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JI JP, 1994, NUCLEIC ACIDS RES, V22, P47, DOI 10.1093/nar/22.1.47; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KAGUNI LS, 1982, P NATL ACAD SCI-BIOL, V79, P983, DOI 10.1073/pnas.79.4.983; KATI WM, 1992, J BIOL CHEM, V267, P25988; KIELECZAWA J, 1992, SCIENCE, V258, P1787, DOI 10.1126/science.1465615; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LEONTIS NB, 1991, NUCLEIC ACIDS RES, V19, P759, DOI 10.1093/nar/19.4.759; LU M, 1992, J MOL BIOL, V223, P781, DOI 10.1016/0022-2836(92)90989-W; PAPANICOLAOU C, 1991, J MOL BIOL, V221, P805, DOI 10.1016/0022-2836(91)80177-V; SantaLucia J, 1996, BIOCHEMISTRY-US, V35, P3555, DOI 10.1021/bi951907q; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P14778, DOI 10.1021/bi971963m; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; TRINH TQ, 1993, GENETICS, V134, P409; WEAVER DT, 1982, J BIOL CHEM, V257, P2075; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	35	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27259	27267		10.1074/jbc.273.42.27259	http://dx.doi.org/10.1074/jbc.273.42.27259			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765249	hybrid			2022-12-25	WOS:000076448000036
J	Mazella, J; Zsurger, N; Navarro, V; Chabry, J; Kaghad, M; Caput, D; Ferrara, P; Vita, N; Gully, D; Maffrand, JP; Vincent, JP				Mazella, J; Zsurger, N; Navarro, V; Chabry, J; Kaghad, M; Caput, D; Ferrara, P; Vita, N; Gully, D; Maffrand, JP; Vincent, JP			The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; MOUSE-BRAIN; AFFINITY-CHROMATOGRAPHY; BINDING-PROPERTIES; SORTING RECEPTOR; INTERNALIZATION; SOLUBILIZATION; PURIFICATION; ANTAGONIST; CLONING	In this work, the 100-kDa neurotensin (NT) receptor previously purified from human brain by affinity chromatography (Zsurger, N., Mazella, J., and Vincent, J. P. (1994) Brain Res. 639, 245-252) was cloned from a human brain cDNA library. This cDNA encodes a 833-amino acid protein 100% identical to the recently cloned gp95/sortilin and was then designated NT3 receptor-gp95/sortilin. The N terminus of the purified protein is identical to the sequence of the purified gp95/sortilin located immediately after the furin cleavage site. The binding of iodinated NT to 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonic acid-solubilized extracts of COS-7 cells transfected with the cloned cDNA was saturable and reversible with an affinity of 10-15 nM. The localization of the NT3 receptor-gp95/sortilin into intracellular vesicles was in agreement with previous results obtained with the purified receptor and with gp95/sortilin. Affinity labeling and binding experiments showed that the 110-kDa NT3 receptor can be partly transformed into a higher affinity (K-d = 0.3 nM) 100-kDa protein receptor by cotransfection with furin. This 100-kDa NT receptor corresponded to the mature form of the receptor. The NT3/gp95/sortilin protein is the first transmembrane neuropeptide receptor that does not belong to the superfamily of G-protein-coupled receptors.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 0411, F-06560 Valbonne, France; Sanofi Rech, F-31676 Labege, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Sanofi-Aventis; Sanofi France	Mazella, J (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 0411, 660 Route Lucioles, F-06560 Valbonne, France.		Chabry, Joelle/O-2101-2016; Mazella, Jean/A-6767-2012					BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CHABRY J, 1993, J BIOL CHEM, V268, P17138; CHABRY J, 1994, J NEUROCHEM, V63, P19; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DUBUC I, 1994, BRIT J PHARMACOL, V112, P352, DOI 10.1111/j.1476-5381.1994.tb13077.x; FEHLMANN M, 1981, ENDOCRINOLOGY, V109, P253, DOI 10.1210/endo-109-1-253; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin BZ, 1997, J BIOL CHEM, V272, P24145, DOI 10.1074/jbc.272.39.24145; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MAZELLA J, 1988, J BIOL CHEM, V263, P144; MAZELLA J, 1989, J BIOL CHEM, V264, P5559; Mazella J, 1996, J NEUROSCI, V16, P5613; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; Vincent JP, 1995, CELL MOL NEUROBIOL, V15, P501, DOI 10.1007/BF02071313; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; ZSURGER N, 1994, BRAIN RES, V639, P245, DOI 10.1016/0006-8993(94)91737-X	22	323	339	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26273	26276		10.1074/jbc.273.41.26273	http://dx.doi.org/10.1074/jbc.273.41.26273			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756851	hybrid			2022-12-25	WOS:000076373300005
J	Wilkens, S; Capaldi, RA				Wilkens, S; Capaldi, RA			Solution structure of the epsilon subunit of the F-1-ATPase from Escherichia coli and interactions of this subunit with beta subunits in the complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; BACKBONE DYNAMICS; NMR-SPECTROSCOPY; ADENOSINE-TRIPHOSPHATASE; CRYOELECTRON MICROSCOPY; F1F0-TYPE ATPASE; TERMINAL DOMAIN; CATALYTIC SITES; GAMMA-SUBUNITS; DELTA-SUBUNIT	The solution structure of the epsilon subunit of the Escherichia coli F-1-ATPase has been determined by NMR spectroscopy. This subunit has a two-domain structure with an N-terminal 10-stranded beta sandwich and a C-terminal antiparallel two alpha-helix hairpin, as described previously (Wilkens, S., Dahlquist, F. W., McIntosh, L. P., Donaldson, L, W,, and Capaldi, R. A. (1995) Nat, Struct. Biol. 2, 961-967). New data show that the two domains interact in solution in an interface formed by beta strand 7 and the very C-terminal alpha-helix. This interface involves only hydrophobic interactions. The dynamics of the epsilon subunit in solution were examined. The two domains are relatively tightly associated with little or no flexibility relative to one another. The epsilon subunit can exist in two states in the ECF1F0 complex depending on whether ATP or ADP occupies catalytic sites. Proteolysis of the epsilon subunit in solution and when bound to the core F-1 complex indicates that the conformation of the polypeptide in solution closely resembles the conformation of epsilon when bound to the F, in the ADP state. Chemical and photo-cross-linking show that the epsilon subunit spans and interacts with two beta subunits in the ADP state. These interactions are disrupted on binding of ATP + Mg2+, as is the interaction between the N- and C-terminal domains of the epsilon subunit.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Capaldi, RA (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.				PHS HHS [58671] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BRUNGER A, 1993, XPLOR VERSION 3 1; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; Haughton MA, 1996, BBA-BIOENERGETICS, V1276, P154, DOI 10.1016/0005-2728(96)00073-4; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PATEL AM, 1990, MOL MICROBIOL, V4, P1941, DOI 10.1111/j.1365-2958.1990.tb02043.x; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; ZHANG Y, 1994, J BIOL CHEM, V269, P10221; ZHOU HJ, 1995, BIOCHEMISTRY-US, V34, P13858, DOI 10.1021/bi00042a018	38	90	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26645	26651		10.1074/jbc.273.41.26645	http://dx.doi.org/10.1074/jbc.273.41.26645			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756905	hybrid			2022-12-25	WOS:000076373300059
J	Ahmadian, A; Ren, ZP; Williams, C; Ponten, F; Odeberg, J; Ponten, J; Uhlen, M; Lundeberg, J				Ahmadian, A; Ren, ZP; Williams, C; Ponten, F; Odeberg, J; Ponten, J; Uhlen, M; Lundeberg, J			Genetic instability in the 9q22.3 region is a late event in the development of squamous cell carcinoma	ONCOGENE			English	Article						p53; 9q22.3; loss of heterozygosity; squamous cell carcinoma; dysplasia	HUMAN P53 GENE; HUMAN HOMOLOG; HUMAN SKIN; ALLELE LOSS; BASAL; CANCER; MUTATIONS; CHROMOSOME-9; HETEROZYGOSITY; POLYMORPHISM	Squamous cell carcinoma (SCC) of the skin represents a group of neoplasms which is associated with exposure to UV light. Recently, we obtained data suggesting that invasive skin cancer and its precursors derive from one original neoplastic clone. Here, the analysis were extended by loss of heterozygosity (LOH) analysis in the chromosome 9q22.3 region. A total of 85 samples, taken from twenty-two sections of sun-exposed sites, corresponding to normal epidermis, morphological normal cells with positive immune-staining for the p53 protein (p53 patches), dysplasias, cancer in situ (CIS) and squamous cell carcinomas (SCC) of the skin were analysed. Overall, about 70% of p53 patches had mutations in the p53 gene but not LOH in the p53 gene or 9q22.3 region. Approximately 70% of the dysplasias showed p53 mutations of which about 40% had LOH in the p53 region but not in the 9q22.3 region. In contrast, about 65% of SCC and CIS displayed LOH in the 9q22.3 region, as well as frequent (80%) mutations and/or LOH in the p53 gene. These findings strongly suggest that alterations in the p53 gene is an early event in the progression towards SCC, whereas malignant development involves LOH and alterations in at least one (or several) tumor suppressor genes located in chromosome 9q22.3.	Royal Inst Technol, Dept Biochem & Biotechnol, S-10044 Stockholm, Sweden; Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden	Royal Institute of Technology; Uppsala University; Uppsala University Hospital	Lundeberg, J (corresponding author), Royal Inst Technol, Dept Biochem & Biotechnol, S-10044 Stockholm, Sweden.		Williams, Cecilia/A-6677-2009; Uhlen, Mathias/B-3262-2016; Odeberg, Jacob O/O-3336-2014; Uhlen, Mathias/AAV-8746-2021; Odeberg, Jacob/I-8314-2016	Williams, Cecilia/0000-0002-0602-2062; Uhlen, Mathias/0000-0002-4858-8056; Odeberg, Jacob O/0000-0003-0996-1644; Odeberg, Jacob/0000-0003-0996-1644				BERG C, 1995, CLIN CHEM, V41, P1461; EKLUND LK, 1997, IN PRESS MOL CARCINO; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holmberg E, 1996, BRIT J CANCER, V74, P246, DOI 10.1038/bjc.1996.345; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Ponten F, 1997, MUTAT RES-GENOMICS, V382, P45, DOI 10.1016/S1383-5726(97)00008-3; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; QUINN AG, 1994, J INVEST DERMATOL, V102, P300, DOI 10.1111/1523-1747.ep12371786; QUINN AG, 1994, CANCER RES, V54, P4756; REHMAN I, 1994, LANCET, V344, P788, DOI 10.1016/S0140-6736(94)92343-4; Ren ZP, 1996, ONCOGENE, V12, P765; Ren ZP, 1997, AM J PATHOL, V150, P1791; Unden AB, 1997, CANCER RES, V57, P2336; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; ZAPHIROPOULOS PG, 1994, BIOCHEM BIOPH RES CO, V201, P1495, DOI 10.1006/bbrc.1994.1873	25	40	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1837	1843		10.1038/sj.onc.1202080	http://dx.doi.org/10.1038/sj.onc.1202080			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778050				2022-12-25	WOS:000076303300010
J	Hansen, PA; Han, DH; Marshall, BA; Nolte, LA; Chen, MM; Mueckler, M; Holloszy, JO				Hansen, PA; Han, DH; Marshall, BA; Nolte, LA; Chen, MM; Mueckler, M; Holloszy, JO			A high fat diet impairs stimulation of glucose transport in muscle - Functional evaluation of potential mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; AMINO-ACID-TRANSPORT; INSULIN-RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; TISSUE DISTRIBUTION; RESPONSIVE TISSUES; TYROSINE KINASE; OBESE SUBJECTS; RAT; RESISTANCE	A high fat diet causes resistance of skeletal muscle glucose transport to insulin and contractions. We tested the hypothesis that fat feeding causes a change in plasma membrane composition that interferes with functioning of glucose transporters and/or insulin receptors, Epitrochlearis muscles of rats fed a high (50% of calories) fat diet for 8 weeks showed similar to 50% decreases in insulin- and contraction-stimulated 3-O-methylglucose transport. Similar decreases in stimulated glucose transport activity occurred in muscles of wild-type mice with 4 weeks of fat feeding. In contrast, GLUT1 overexpressing muscles of transgenic mice fed a high fat diet showed no decreases in their high rates of glucose transport, providing evidence against impaired glucose transporter function. Insulin-stimulated system A amino acid transport, insulin receptor (IR) tyrosine kinase activity, and insulin-stimulated IR and IRS-1 tyrosine phosphorylation were all normal in muscles of rats fed the high fat diet for 8 weeks. However, after 30 weeks on the high fat diet, there was a significant reduction in insulin-stimulated tyrosine phosphorylation in muscle. The increases in GLUT4 at the cell surface induced by insulin or muscle contractions, measured with the H-3-labeled 2-N-4-(1-azi-2,2,2-trifluoroethyl) -benzoyl-1,3-bis-(D-mannose-4-yloxy)-2-propylamine photolabel, were 26-36% smaller in muscles of the 8-week high fat-fed rats as compared with control rats. Our findings provide evidence that (a) impairment of muscle glucose transport by 8 weeks of high fat feeding is not due to plasma membrane composition-related reductions in glucose transporter or insulin receptor function, (b) a defect in insulin receptor signaling is a late event, not a primary cause, of the muscle insulin resistance induced by fat feeding, and (c) impaired GLUT4 translocation to the cell surface plays a major role in the decrease in stimulated glucose transport.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Hansen, PA (corresponding author), Washington Univ, Sch Med, Dept Med, 4566 Scott Ave,Campus Box 8113, St Louis, MO 63110 USA.	phansen@imgate.wustl.edu	Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038495, K08DK002339, R01DK018986] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18986, DK02339, DK38495] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNER P, 1987, DIABETOLOGIA, V30, P437, DOI 10.1007/BF00292549; BAK JF, 1990, BIOCHIM BIOPHYS ACTA, V1052, P306, DOI 10.1016/0167-4889(90)90226-4; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; BOYD JJ, 1990, AM J PHYSIOL, V259, pE111, DOI 10.1152/ajpendo.1990.259.1.E111; BURANT CF, 1984, DIABETES, V33, P704, DOI 10.2337/diabetes.33.7.704; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CARRUTHERS A, 1984, BIOCHEMISTRY-US, V23, P6901, DOI 10.1021/bi00321a096; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CLANDININ MT, 1991, FASEB J, V5, P2761, DOI 10.1096/fasebj.5.13.1916101; DESPRES JP, 1989, DIABETES, V38, P304, DOI 10.2337/diabetes.38.3.304; FIELD CJ, 1990, J BIOL CHEM, V265, P11143; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; GOULD RJ, 1982, J BIOL CHEM, V257, P477; GULVE EA, 1991, AM J PHYSIOL, V260, pC88, DOI 10.1152/ajpcell.1991.260.1.C88; Han DH, 1997, DIABETES, V46, P1761, DOI 10.2337/diabetes.46.11.1761; Hansen PA, 1997, AM J PHYSIOL-ENDOC M, V273, pE28, DOI 10.1152/ajpendo.1997.273.1.E28; Holloszy JO, 1996, REV PHYSIOL BIOCH P, V128, P99; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KISSEBAH AH, 1991, INT J OBESITY, V15, P109; KRAEGEN EW, 1986, DIABETOLOGIA, V29, P192, DOI 10.1007/BF02427092; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LEMARCHANDBRUSTEL Y, 1985, NATURE, V315, P676, DOI 10.1038/315676a0; LIU S, 1994, BIOCHEM J, V299, P831, DOI 10.1042/bj2990831; LUND S, 1993, FEBS LETT, V330, P312, DOI 10.1016/0014-5793(93)80895-2; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; MARETTE E, 1992, AM J PHYSIOL, V263, pC443; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NESHER R, 1985, AM J PHYSIOL, V249, pC226, DOI 10.1152/ajpcell.1985.249.3.C226; OKAMOTO M, 1992, J NUTR BIOCHEM, V3, P241, DOI 10.1016/0955-2863(92)90046-L; PAGLIASSOTTI MJ, 1994, AM J PHYSIOL, V267, pR659, DOI 10.1152/ajpregu.1994.267.3.R659; REN JM, 1993, J BIOL CHEM, V268, P16113; RIGGS TR, 1973, J BIOL CHEM, V248, P6450; ROSHOLT MN, 1994, AM J PHYSIOL, V266, pR95, DOI 10.1152/ajpregu.1994.266.1.R95; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SANDRA A, 1984, BIOCHIM BIOPHYS ACTA, V778, P511, DOI 10.1016/0005-2736(84)90401-2; Stevenson RW, 1996, DIABETES, V45, P60, DOI 10.2337/diabetes.45.1.60; STORLIEN LH, 1986, AM J PHYSIOL, V251, pE576, DOI 10.1152/ajpendo.1986.251.5.E576; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; VANAMELSVOORT JMM, 1986, ANN NUTR METAB, V30, P273, DOI 10.1159/000177204; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; WILSON CM, 1994, BIOCHEM J, V299, P755, DOI 10.1042/bj2990755; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; YOUNG DA, 1986, J BIOL CHEM, V261, P6049; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215; ZORZANO A, 1986, AM J PHYSIOL, V251, pE21, DOI 10.1152/ajpendo.1986.251.1.E21	52	117	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26157	26163		10.1074/jbc.273.40.26157	http://dx.doi.org/10.1074/jbc.273.40.26157			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748297	hybrid			2022-12-25	WOS:000076263100088
J	Leidich, SD; Ibrahim, AS; Fu, Y; Koul, A; Jessup, C; Vitullo, J; Fonzi, W; Mirbod, F; Nakashima, S; Nozawa, Y; Ghannoum, MA				Leidich, SD; Ibrahim, AS; Fu, Y; Koul, A; Jessup, C; Vitullo, J; Fonzi, W; Mirbod, F; Nakashima, S; Nozawa, Y; Ghannoum, MA			Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OROTIDINE-5'-PHOSPHATE DECARBOXYLASE; LYSOPHOSPHOLIPASE-TRANSACYLASE; ESCHERICHIA-COLI; ALPHA-AGGLUTININ; CELL-WALL; VIRULENCE; PROTEIN; YEAST; MUTANTS; ACID	The Candida albicans PLB1 gene was cloned using a polymerase chain reaction-based approach relying on degenerate oligonucleotide primers designed according to the amino acid sequences of two peptide fragments obtained from a purified candidal enzyme displaying phospholipase activity (Mirbod, F., Banno, Y., Ghannoum, M. A, Ibrahim, A. S., Nakashima, S., Yasuo, It., Cole, G. T., and Nozawa, Y. (1995) Biochim. Biophys. Acta 1257, 181-188). Sequence analysis of a 6.7-kilobase pair EcoRI-ClaI genomic clone revealed a single open reading frame of 1818 base pairs that predicts for a preprotein of 605 residues. Comparison of the putative candidal phospholipase with those of other proteins in data base revealed significant homology to known fungal phospholipase Bs from Saccharomyces cerevisiae (45%), Penicillium notatum (42%), Torulaspora delbrueckii (48%), and Schizosaccharomyces pombe (38%). Thus, we have cloned the gene encoding a C. albicans phospholipase B homolog. This gene, designated caPLB1, was mapped to chromosome 6. Disruption experiments revealed that the caplb1 null mutant is viable and displays no obvious phenotype. However, the virulence of strains deleted for caPLB1, as assessed in a murine model for hematogenously disseminated candidiasis, was significantly attenuated compared with the isogenic mild-type parental strain. Although deletion of caPLB1 did not produce any detectable effects on candidal adherence to human endothelial or epithelial cells, the ability of the caplb1 null mutant to penetrate host cells was dramatically reduced. Thus, phospholipase B may well contribute to the pathogenicity of C. albicans by abetting the fungus in damaging and traversing host cell membranes, processes which likely increase the rapidity of disseminated infection.	Univ Hosp Cleveland, Ctr Med Mycol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ Calif Los Angeles, Harbor Med Ctr, Dept Med, Div Infect Dis,St Johns Cardiovasc Res Ctr, Torrance, CA 90509 USA; Georgetown Univ, Med Ctr, Sch Med, Dept Microbiol & Immunol, Washington, DC 20007 USA; Gifu Univ, Sch Med, Dept Biochem, Gifu 500, Japan	University Hospitals of Cleveland; Case Western Reserve University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Georgetown University; Gifu University	Ghannoum, MA (corresponding author), Univ Hosp Cleveland, Ctr Med Mycol, 11100 Euclid Ave, Cleveland, OH 44106 USA.	mag3@po.cwru.edu	Galgiani, John/GLT-7012-2022	Mirbod Donovan, Fariba/0000-0002-6203-5693	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035097] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35097] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALLEN G, 1990, LAB TECHNIQUES BIOCH; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARRETTBEE K, 1985, J GEN MICROBIOL, V131, P1217; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CARLO LHP, 1997, YEAST, V13, P1477; CUTLER JE, 1991, ANNU REV MICROBIOL, V45, P187, DOI 10.1146/annurev.mi.45.100191.001155; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DiezOrejas R, 1997, INFECT IMMUN, V65, P833, DOI 10.1128/IAI.65.2.833-837.1997; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FONZI WA, 1993, GENETICS, V134, P717; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GILLUM AM, 1984, MOL GEN GENET, V198, P179, DOI 10.1007/BF00328721; GOW NAR, 1994, P NATL ACAD SCI USA, V91, P6216, DOI 10.1073/pnas.91.13.6216; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hube B, 1997, INFECT IMMUN, V65, P3529, DOI 10.1128/IAI.65.9.3529-3538.1997; IBRAHIM AS, 1995, INFECT IMMUN, V63, P1993, DOI 10.1128/IAI.63.5.1993-1998.1995; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JARVIS WR, 1995, CLIN INFECT DIS, V20, P1526, DOI 10.1093/clinids/20.6.1526; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE JD, 1995, INFECT IMMUN, V63, P3796, DOI 10.1128/IAI.63.10.3796-3803.1995; LEE KS, 1994, J BIOL CHEM, V269, P19725; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; LU CF, 1994, MOL CELL BIOL, V14, P4825, DOI 10.1128/MCB.14.7.4825; MACDONALD F, 1983, J GEN MICROBIOL, V129, P431; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MASUDA N, 1991, EUR J BIOCHEM, V202, P783, DOI 10.1111/j.1432-1033.1991.tb16433.x; MIRBOD F, 1995, BBA-LIPID LIPID MET, V1257, P181, DOI 10.1016/0005-2760(95)00072-K; PRICE MF, 1977, SABOURAUDIA, V15, P179; PUGH D, 1977, SABOURAUDIA, V15, P29; RADVIN JI, 1985, J INFECT DIS, V152, P542; Rose MD., 1990, METHODS YEAST GENETI; ROSS IK, 1990, J GEN MICROBIOL, V136, P687, DOI 10.1099/00221287-136-4-687; SABITINI D, 1962, ANAT REC, V142, P274; SAFFER LD, 1991, J PROTOZOOL, V38, P454, DOI 10.1111/j.1550-7408.1991.tb04816.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sanglard D, 1997, INFECT IMMUN, V65, P3539, DOI 10.1128/IAI.65.9.3539-3546.1997; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SHIMIZU S, 1980, ANAL BIOCHEM, V107, P193, DOI 10.1016/0003-2697(80)90511-4; SILVERMAN DJ, 1992, INFECT IMMUN, V60, P2733, DOI 10.1128/IAI.60.7.2733-2740.1992; SMITH GA, 1995, INFECT IMMUN, V63, P4231, DOI 10.1128/IAI.63.11.4231-4237.1995; SUGIMOTO H, 1994, J BIOL CHEM, V269, P6252; Verheij HM, 1994, LIPASES THEIR STRUCT, P119; WATANABE Y, 1994, FEMS MICROBIOL LETT, V124, P29, DOI 10.1111/j.1574-6968.1994.tb07257.x; WENZEL RP, 1991, INFECT CONT HOSP EP, V12, P523, DOI 10.1086/646403; WINKLER HH, 1989, INFECT IMMUN, V57, P36, DOI 10.1128/IAI.57.1.36-40.1989; Wysong DR, 1998, INFECT IMMUN, V66, P1953, DOI 10.1128/IAI.66.5.1953-1961.1998; Zhao XJ, 1997, INFECT IMMUN, V65, P829, DOI 10.1128/IAI.65.2.829-832.1997	52	176	190	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26078	26086		10.1074/jbc.273.40.26078	http://dx.doi.org/10.1074/jbc.273.40.26078			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748287	hybrid			2022-12-25	WOS:000076263100078
J	Singh, AK; Shichi, H				Singh, AK; Shichi, H			A novel glutathione peroxidase in bovine eye - Sequence analysis, mRNA level, and translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; SALMONELLA-TYPHIMURIUM; ANTIOXIDANT ENZYMES; NUCLEOTIDE-SEQUENCE; S-TRANSFERASES; TISSUE-REPAIR; CILIARY BODY; RAT-LIVER; SELENIUM; CDNA	Bovine ciliary body contains a selenium-independent glutathione peroxidase (GPX) with a molecular mass of about 100 kDa that is composed of four identical subunits and exhibits no glutathione S-transferase activity. In this study, we isolated cDNA clones and determined the nucleotide sequence to deduce the primary structure of the enzyme. The cDNA contained 672 base pairs encoding a polypeptide with an estimated molecular mass of 25,064 Da, Translation of bovine ciliary mRNA produced a protein which was immunologically indistinguishable from GPX and showed high enzyme activity. The encoded amino acid sequence of the protein was 95% identical with that of a human keratinocyte gene product expressed in response to keratinocyte growth factor. It also showed sequence identity to bacterial alkyl hydroperoxide reductases and thiol specific antioxidant enzymes. GPX mRNA level was highest in the ciliary body, followed by the retina and iris, In various rat organs, the level of GPX mRNA was highest in the lung, followed by the muscle, liver, eye, heart, testis, thymus, kidney, and spleen. A very low level of mRNA was detected in the brain. Enzyme-linked immunosorbent assay with an antibody raised against the NH2-terminal sequence of GPX detected GPX protein in all rat tissues examined.	Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, Detroit, MI 48201 USA	Wayne State University	Shichi, H (corresponding author), Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, 4717 St Antoine, Detroit, MI 48201 USA.		Singh, Ashok/HGF-2506-2022		NATIONAL EYE INSTITUTE [R01EY004694] Funding Source: NIH RePORTER; NEI NIH HHS [EY04694] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHU FF, 1993, J BIOL CHEM, V268, P2571; DAS ND, 1981, EXP EYE RES, V33, P525, DOI 10.1016/S0014-4835(81)80127-3; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Engvall E, 1980, Methods Enzymol, V70, P419; ESWORTHY RS, 1994, GENE, V144, P317, DOI 10.1016/0378-1119(94)90400-6; Frank S, 1997, ONCOGENE, V14, P915, DOI 10.1038/sj.onc.1200905; Harlow E., 1988, ANTIBODIES LAB MANUA; HAWKER FH, 1993, EUR RESPIR J, V6, P1317; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; ISHIDA K, 1987, NUCLEIC ACIDS RES, V15, P10051, DOI 10.1093/nar/15.23.10051; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; Kishida K, 1985, J Ocul Pharmacol, V1, P85, DOI 10.1089/jop.1985.1.85; Mehlotra RK, 1996, CRIT REV MICROBIOL, V22, P295, DOI 10.3109/10408419609105484; NG MC, 1988, EXP EYE RES, V46, P919, DOI 10.1016/S0014-4835(88)80043-5; PENG B, 1992, CURR EYE RES, V11, P1087, DOI 10.3109/02713689209015080; PROHASKA JR, 1977, BIOCHEM BIOPH RES CO, V76, P437, DOI 10.1016/0006-291X(77)90744-6; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; SCHWARTZMAN ML, 1987, CURR EYE RES, V6, P623, DOI 10.3109/02713688709025223; SHICHI H, 1990, EXP EYE RES, V50, P513, DOI 10.1016/0014-4835(90)90040-2; Shichi H, 1986, J Ocul Pharmacol, V2, P59, DOI 10.1089/jop.1986.2.59; SHICHI H, 1980, EXTRAHEPATIC METABOL, P333; SHICHI H, 1984, PHARM EYE, P117; Singh AK, 1996, EXP EYE RES, V62, P299, DOI 10.1006/exer.1996.0036; Spector A, 1996, EXP EYE RES, V62, P521, DOI 10.1006/exer.1996.0063; STONE WL, 1982, EXP EYE RES, V35, P405, DOI 10.1016/0014-4835(82)90039-2; TAKAHASHI K, 1986, BLOOD, V68, P640; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; Vuilleumier S, 1997, J BACTERIOL, V179, P1431, DOI 10.1128/jb.179.5.1431-1441.1997; Wan XY, 1997, FEBS LETT, V407, P32, DOI 10.1016/S0014-5793(97)00302-5; Wang JM, 1995, EXP MOL PATHOL, V63, P41, DOI 10.1006/exmp.1995.1029; YOSHIMURA S, 1988, BIOCHEM BIOPH RES CO, V154, P1024, DOI 10.1016/0006-291X(88)90242-2	36	67	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26171	26178		10.1074/jbc.273.40.26171	http://dx.doi.org/10.1074/jbc.273.40.26171			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748299	hybrid			2022-12-25	WOS:000076263100090
J	Tanaka, K; Pracyk, JB; Takeda, K; Yu, ZX; Ferrans, VJ; Deshpande, SS; Ozaki, M; Hwang, PM; Lowenstein, CJ; Irani, K; Finkel, T				Tanaka, K; Pracyk, JB; Takeda, K; Yu, ZX; Ferrans, VJ; Deshpande, SS; Ozaki, M; Hwang, PM; Lowenstein, CJ; Irani, K; Finkel, T			Expression of Id1 results in apoptosis of cardiac myocytes through a redox-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; SENESCENT HUMAN FIBROBLASTS; MEDIATED GENE-TRANSFER; PROGRAMMED CELL-DEATH; DNA-BINDING PROTEINS; RETINOBLASTOMA PROTEIN; HYDROGEN-PEROXIDE; ADENOVIRUS TYPE-5; HEART-FAILURE; MUSCLE	We have constructed a recombinant adenovirus (Ad.Id1) that allows for efficient expression of the helix-loop-helix protein Idl, After infection with Ad.Id1, neonatal cardiac myocytes display a significant reduction in viability, which was proportional to the level of Idl expression, A similar effect was observed in adult myocytes, Morphological and biochemical assays demonstrated that Id1 expression resulted in myocyte apoptosis. In contrast, expression of Idl in endothelial cells, vascular smooth muscle cells, or fibroblasts did not affect the viability of these cells, Along with the induction of apoptosis, the expression of Idl in neonatal cardiac myocytes resulted in an increase in the level of intracellular reactive oxygen species. The source of these reactive oxygen species appears to be the mitochondria, Reducing the ambient oxygen concentration or treatment with a cell-permeant H2O2 scavenger prevented Id1-stimulated apoptosis in cardiac myocytes, These results suggest that the expression of Idl leads to the induction of apoptosis in cardiac myocytes through a redox-dependent mechanism.	NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA; Johns Hopkins Sch Med, Div Cardiol, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University; Johns Hopkins Medicine	Finkel, T (corresponding author), NHLBI, Cardiol Branch, NIH, 10 Ctr Dr,Bldg 10,Rm 7B15, Bethesda, MD 20892 USA.			Irani, Kaikobad/0000-0001-9194-7387; Lowenstein, Charles/0000-0003-0485-7514				BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; Desagher S, 1997, J NEUROSCI, V17, P9060; DHALLA AK, 1994, AM J PHYSIOL, V266, pH1280, DOI 10.1152/ajpheart.1994.266.4.H1280; Dhalla AK, 1996, J AM COLL CARDIOL, V28, P506, DOI 10.1016/0735-1097(96)00140-4; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; EVANS SM, 1993, CIRC RES, V73, P569, DOI 10.1161/01.RES.73.3.569; Giandomenico AR, 1997, FREE RADICAL BIO MED, V23, P426, DOI 10.1016/S0891-5849(97)00113-5; Guidarelli A, 1996, BIOCHEM BIOPH RES CO, V226, P70, DOI 10.1006/bbrc.1996.1312; GUZMAN RJ, 1994, P NATL ACAD SCI USA, V91, P10732, DOI 10.1073/pnas.91.22.10732; GUZMAN RJ, 1993, CIRC RES, V73, P1202, DOI 10.1161/01.RES.73.6.1202; Hara E, 1996, DEV GENET, V18, P161; HARA E, 1994, J BIOL CHEM, V269, P2139; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON SL, 1986, J MOL CELL CARDIOL, V18, P661, DOI 10.1016/S0022-2828(86)80939-7; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KassEisler A, 1997, METHOD CELL BIOL, V52, P423, DOI 10.1016/S0091-679X(08)60390-8; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KRISHENBAUM LA, 1993, J CLIN INVEST, V92, P381, DOI 10.1172/JCI116577; KURABAYASHI M, 1993, J BIOL CHEM, V268, P5524; KURABAYASHI M, 1994, J BIOL CHEM, V269, P6031; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Mallat Z, 1996, NEW ENGL J MED, V335, P1190, DOI 10.1056/NEJM199610173351604; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pracyk JB, 1997, SURGERY, V122, P404, DOI 10.1016/S0039-6060(97)90033-7; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; ROTHE G, 1991, J IMMUNOL METHODS, V138, P133, DOI 10.1016/0022-1759(91)90074-P; SHIGEOMI S, 1995, NATURE, V374, P811; Silverman HS, 1997, CIRC RES, V80, P699, DOI 10.1161/01.RES.80.5.699; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tsai JC, 1996, J BIOL CHEM, V271, P3667; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; WANG YQ, 1992, DEV DYNAM, V194, P222, DOI 10.1002/aja.1001940307; Zhong WX, 1996, CELL GROWTH DIFFER, V7, P1175	46	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					25922	25928		10.1074/jbc.273.40.25922	http://dx.doi.org/10.1074/jbc.273.40.25922			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748268	hybrid			2022-12-25	WOS:000076263100059
J	McGarvey, TW; Maruta, Y; Tomaszewski, JE; Linnenbach, AJ; Malkowicz, SB				McGarvey, TW; Maruta, Y; Tomaszewski, JE; Linnenbach, AJ; Malkowicz, SB			PTCH gene mutations in invasive transitional cell carcinoma of the bladder	ONCOGENE			English	Article						PTCH; transitional cell carcinoma of the bladder; mutations	DROSOPHILA PATCHED GENE; TUMOR-SUPPRESSOR LOCI; SONIC HEDGEHOG; HUMAN HOMOLOG; MICROSATELLITE ALTERATIONS; REGULATES EXPRESSION; MEMBRANE-PROTEIN; ALLELIC LOSSES; CANCER; CHROMOSOME-9	LOH analysis suggests that multiple tumor suppressor genes play a role in the development of human TCC. The human homolog of the Drosophila PTCH was recently cloned and mapped to the BCNS locus on 9q22.3, a chromosomal region commonly deleted in TCCs. We first examined the steady state mRNA transcription of the PTCH, SMOH and GL13 genes of the HH signal transduction pathway in TCC cell lines and normal urothelium. Normal urothelium and TCC cell lines express these three genes within the PTCH signal transduction pathway. We then screened for PTCH mutations in 'hot spot' exons 6, 8, 13 and 16 by PCR/SSCP analysis of genomic DNAs from 54 TCC tumor samples and control autologous peripheral blood lymphocytes. DNA sequence analysis confirmed TCC-specific mutations in two of 54 patients (3.7%). These mutations resulted a single amino acid substitution and two frame shifts. One tumor had PTCH mutations in exon 16 as well as exon 13 and one tumor had a mutation in exon 13 alone. Both TCC tumors that contained PTCH mutations had a loss of heterozygosity at 9q. Although the PTCH protein has an unknown function in urothelial cells, the detection of the PTCH, SMOH and GL13 transcripts in normal urothelium and TCC cell lines and rare PTCH mutations in tumor samples suggest that the HH pathway may have a role in controlling the proliferation of urothelial cells and that PTCH mutations may contribute to the development of a subset of TCCs.	Univ Penn, Med Ctr, Dept Surg, Div Urol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pathol, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); The Wistar Institute	Malkowicz, SB (corresponding author), Univ Penn, Med Ctr, Dept Surg, Div Urol, 1 Rhoads,3400 Spruce St, Philadelphia, PA 19104 USA.							Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; CATALONA WJ, 1988, CAMPBELLS UROLOGY, P1094; CHANG WYH, 1995, CANCER RES, V55, P3246; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chidambaram A, 1996, CANCER RES, V56, P4599; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; DOMINGUEZ M, 1996, NATURE, V372, P1621; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hepker J, 1997, DEVELOPMENT, V124, P549; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kallassy M, 1997, CANCER RES, V57, P4731; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KNOWLES MA, 1994, CANCER RES, V54, P531; Li MM, 1996, AM J PATHOL, V149, P229; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; Maesawa C, 1998, GENE CHROMOSOME CANC, V21, P276, DOI 10.1002/(SICI)1098-2264(199803)21:3<276::AID-GCC15>3.3.CO;2-H; MALKOWICZ SB, 1994, CLIN MANUAL UROLOGY, P419; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; ORLOW I, 1994, CANCER RES, V54, P2848; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Raffel C, 1997, CANCER RES, V57, P842; RUPPERT JM, 1993, CANCER RES, V53, P5093; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; Simoneau AR, 1996, CANCER RES, V56, P5039; SPRUCK CH, 1994, CANCER RES, V54, P784; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Unden AB, 1996, CANCER RES, V56, P4562; Unden AB, 1997, CANCER RES, V57, P2336; WALDMAN FM, 1991, CANCER RES, V51, P3807; WINGO PA, 1997, CA CANC J CLIN, V45, P8; Xie JW, 1997, CANCER RES, V57, P2369; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	45	74	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1167	1172		10.1038/sj.onc.1202045	http://dx.doi.org/10.1038/sj.onc.1202045			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764827				2022-12-25	WOS:000075598400012
J	Wood, DE; Thomas, A; Devi, LA; Berman, Y; Beavis, RC; Reed, JC; Newcomb, EW				Wood, DE; Thomas, A; Devi, LA; Berman, Y; Beavis, RC; Reed, JC; Newcomb, EW			Bax cleavage is mediated by calpain during drug-induced apoptosis	ONCOGENE			English	Article						drug-induced apoptosis; calpain; Bax cleavage; HL-60 cells; mitochondrial membranes	PROGRAMMED CELL-DEATH; RAT-LIVER MITOCHONDRIA; CYTOCHROME-C; ENDOPLASMIC-RETICULUM; LIMITED PROTEOLYSIS; NEUTRAL PROTEASE; HL-60 CELLS; ION-CHANNEL; BCL-2; INHIBITION	The anti-apoptotic molecule Bcl-2 is located in the mitochondrial and endoplasmic reticulum membranes as well as the nuclear envelope. Although its location has not been as rigorously defined, the pro-apoptotic molecule Pax appears to be mainly a cytosolic protein which translocates to the mitochondria upon induction of apoptosis, Here me identify a protease activity in mitochondria-enriched membrane fractions from HL-60 cells capable of cleaving Pax which is absent from the cytosolic fraction, Pax protease activity is blocked in vitro by cysteine protease inhibitors including E-64 which distinguishes it from all known caspases and granzyme B, both of which are involved in apoptosis, Protease activity is also blocked by inhibitors against the calcium-activated neutral cysteine endopeptidase calpain, Partial purification of the Pax protease activity from HL-60 cell membrane fractions by column chromatography revealed that a calpain-like activity was the protease responsible for Pax cleavage, In addition, purified calpain enzymes cleaved Pax in a calcium-dependent manner. Pretreatment of HL-60 cells with the specific calpain inhibitor calpeptin effectively blocked both drug-induced Pax cleavage and calpain activation, but not PARP cleavage or cell death. These results suggest that calpains and caspases are activated during drug-induced apoptosis and that calpains, along with caspases, may be involved in modulating cell death by acting selectively on cellular substrates.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA; Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Burnham Inst, La Jolla, CA 92037 USA	New York University; New York University; Sanford Burnham Prebys Medical Discovery Institute	Newcomb, EW (corresponding author), NYU, Med Ctr, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.		Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001788, R01NS026880, R29NS026880] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 01788, NS 26880] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguilar HI, 1996, GASTROENTEROLOGY, V110, P558, DOI 10.1053/gast.1996.v110.pm8566604; AKAO Y, 1994, CANCER RES, V54, P2468; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BEER DG, 1982, BIOCHEM BIOPH RES CO, V109, P1276, DOI 10.1016/0006-291X(82)91915-5; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BOYD JM, 1995, ONCOGENE, V11, P1921; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CROALL DE, 1986, BIOCHIM BIOPHYS ACTA, V882, P287, DOI 10.1016/0304-4165(86)90250-3; Decaudin D, 1997, CANCER RES, V57, P62; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; GEERAERTS MD, 1991, AM J PHYSIOL, V261, pC889, DOI 10.1152/ajpcell.1991.261.5.C889; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; JURGENSMEIER JM, 1998, IN PRESS P NATL ACAD; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; KENNEY DM, 1994, BRIT J HAEMATOL, V87, P773, DOI 10.1111/j.1365-2141.1994.tb06737.x; Kim CN, 1997, CANCER RES, V57, P3115; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NICHOLS JC, 1994, GASTROENTEROLOGY, V106, P168, DOI 10.1016/S0016-5085(94)95147-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PINTER M, 1992, BIOCHEMISTRY-US, V31, P8201, DOI 10.1021/bi00150a012; POE M, 1991, J BIOL CHEM, V266, P98; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Squier MKT, 1997, J IMMUNOL, V158, P3690; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TAVARES A, 1991, BIOMED BIOCHIM ACTA, V50, P523; Thomas A, 1996, ONCOGENE, V12, P1055; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zhao H, 1997, J BIOL CHEM, V272, P21625, DOI 10.1074/jbc.272.34.21625	71	299	309	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1069	1078		10.1038/sj.onc.1202034	http://dx.doi.org/10.1038/sj.onc.1202034			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764817	Green Published			2022-12-25	WOS:000075598400002
J	Rose, DW; Xiao, S; Pillay, TS; Kolch, W; Olefsky, JM				Rose, DW; Xiao, S; Pillay, TS; Kolch, W; Olefsky, JM			Prolonged vs transient roles for early cell cycle signaling components	ONCOGENE			English	Article						insulin IGF-I; DNA synthesis; microinjection	INSULIN-RECEPTOR SUBSTRATE-1; EPIDERMAL GROWTH-FACTOR; NUCLEOTIDE-RELEASING-FACTOR; PHOSPHOTYROSINE PHOSPHATASE SYP; PROTEIN-TYROSINE-PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; SH2 DOMAIN; FACTOR-I; C-FOS	Both p21ras and phosphatidylinositol 3-kinase (PI 3-k) are critical elements in signaling pathways mediating insulin/IGF-I induced cell cycle progression. For example, microinjection of antibodies, peptides, or recombinant proteins which block the interaction of the SH2 domains of the PI 3-k p85 alpha subunit with tyrosine phosphorylated intracellular targets blocks insulin mediated DNA synthesis. We report here that this inhibitory phenotype is observed whether the injections are made into quiescent cells (the standard approach), or at any time point during G(1) phase subsequent to stimulation. This observation is not true, however, for the major substrate of the insulin/IGF-I receptor (IRS-1) despite the well known interaction of p85 with IRS-1, Antibodies to IRS-1 are inhibitory only when injected during the first 15 min of G(1) phase, as are antibodies to another major IRS-1 binding protein, the tyrosine phosphatase SHP2. We also have microinjected reagents which target proteins involved in the formation of rasGTP and which mediate some of the downstream effects of ras activation. Reagents which target the formation of rasGTP (Shc and dominant negative ras protein) inhibit DNA synthesis only at points early in G(1), as do reagents which target components of the MAP kinase pathway. Injection of antibodies to p21ras itself, or a recombinant Raf-l protein domain which binds to the effector region of ras in a GTP-dependent manner, results in the inhibition of cell cycle progression throughout G(1) phase. The results point to a continuous requirement for both PI 3-k and ras activity until cellular commitment to DNA synthesis, although some of the molecules which are both upstream and downstream of these activities are only required transiently. Our results are also consistent with a Raf-l independent ras activity late in G(1), as well as IRS-1 independent effects of PI 3-kinase.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Vet Adm Med Ctr, San Diego, CA 92161 USA; Haematologikum, GSF, Whittier Diabet Res Program, D-81377 Munich, Germany; Haematologikum, GSF, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Rose, DW (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA.		Admin, SBI/HGB-2738-2022; Kolch, Walter/ABF-2102-2021	pillay, tahir/0000-0002-9982-9710; Kolch, Walter/0000-0001-5777-5016	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 1996, CELL, V85, P15; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; FENG GS, 1994, ONCOGENE, V9, P1545; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAPLAN JB, 1994, ONCOL RES, V6, P611; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KODAKI T, 1995, BIOCHEM SOC T, V23, pS195, DOI 10.1042/bst023195s; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOLCH W, 1990, ONCOGENE, V5, P713; Kolch W, 1996, ONCOGENE, V13, P1305; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANGLOIS WJ, 1994, ENDOCRINOLOGY, V135, P2412, DOI 10.1210/en.135.6.2412; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	62	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	1998	17	7					889	899		10.1038/sj.onc.1201997	http://dx.doi.org/10.1038/sj.onc.1201997			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780005				2022-12-25	WOS:000075448800010
J	Santos, J; Herranz, M; Perez de Castro, I; Pellicer, A; Fernandez-Piqueras, J				Santos, J; Herranz, M; Perez de Castro, I; Pellicer, A; Fernandez-Piqueras, J			A new candidate site for a tumor suppressor gene involved in mouse thymic lymphomagenesis is located on the distal part of chromosome 4	ONCOGENE			English	Article						mouse thymic lymphomas; gamma-irradiation; loss of heterozygosity; microsatellites; distal chromosome 4 region; tumor suppressor genes	ALLELIC LOSS; INTESTINAL NEOPLASIA; MAJOR MODIFIER; HETEROZYGOSITY; NEUROBLASTOMA; ABNORMALITIES; DELETION; REGION; 1P36; PHEOCHROMOCYTOMAS	In a previous work we provided preliminary evidence of the existence of a putative tumor suppressor gene region on the distal part of chromosome 4 in gamma-radiation-induced T-cell lymphomas of (C57BL/6JxRF/J) Fl hybrid mice. This region, named as TLSR2 (Thymic Lymphoma Suppressor Region 2), was located centered at D4Mit54. A more detailed allelotype analysis in the mentioned tumors with new informative microsatellites on distal chromosome 4 region, as well as in thymic lymphomas induced with gamma-rays in Fl hybrids generated from reciprocal crosses between the strains C57BL/6J and BALB/cJ, and having in mind the new map position of D4Mit205b, allowed us to confirm the existence of TLSR2 and to define it more precisely as centered at D4Mit205b, In addition, we identified a new candidate region, named as TLSR3 (Thymic Lymphoma Suppressor Re,Region 3), located between the Mom-l locus and D4Mit68, as the site of another putative tumor suppressor region involved in thymic lymphomagenesis.	Univ Autonoma Madrid, Fac Ciencias, Lab Genet Mol Humana, Dept Biol, E-28049 Madrid, Spain; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	Autonomous University of Madrid; New York University	Fernandez-Piqueras, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Lab Genet Mol Humana, Dept Biol, E-28049 Madrid, Spain.		MARTINEZ, ANTONIO PELLICER/C-4832-2015; de Castro, Ignacio Pérez/A-6260-2012; Santos, Javier/ABF-5755-2021	de Castro, Ignacio Pérez/0000-0002-8822-8274; Santos, Javier/0000-0002-4168-6251; Pellicer, Angel/0000-0002-5062-0692				ABBOTT CM, 1994, MAMM GENOME, V5, pS51; BARDI G, 1993, CANCER RES, V53, P1895; BELLO MJ, 1994, INT J CANCER, V57, P172, DOI 10.1002/ijc.2910570207; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P296, DOI 10.1002/gcc.2870090411; BIECHE I, 1994, CANCER RES, V54, P4274; CHENG NC, 1995, ONCOGENE, V10, P291; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DING SF, 1992, BRIT J CANCER, V65, P809, DOI 10.1038/bjc.1992.173; DOVE WF, 1994, COLD SPRING HARB SYM, V59, P501, DOI 10.1101/SQB.1994.059.01.055; FONG CT, 1992, CANCER RES, V52, P1780; HERZOG CR, 1995, ONCOGENE, V11, P1811; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KHOSLA S, 1991, J CLIN INVEST, V87, P1691, DOI 10.1172/JCI115186; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; MATHEW S, 1994, CANCER RES, V54, P6265; Mock BA, 1996, MAMM GENOME, V6, pS73; MOLEY JF, 1992, CANCER RES, V52, P770; QUELLE DE, 1995, ONCOGENE, V11, P635; Radany EH, 1997, P NATL ACAD SCI USA, V94, P8664, DOI 10.1073/pnas.94.16.8664; Santos J, 1996, ONCOGENE, V12, P669; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SIMON D, 1991, ONCOGENE, V6, P765; SOKOVA OI, 1992, CANCER GENET CYTOGEN, V58, P24, DOI 10.1016/0165-4608(92)90128-U; SREEKANTAIAH C, 1993, AM J PATHOL, V142, P293; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Zhuang SM, 1996, CANCER RES, V56, P3338	27	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					925	929		10.1038/sj.onc.1202009	http://dx.doi.org/10.1038/sj.onc.1202009			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780010				2022-12-25	WOS:000075448800015
J	Borowsky, B; Hoffman, BJ				Borowsky, B; Hoffman, BJ			Analysis of a gene encoding two glycine transporter variants reveals alternative promoter usage and a novel gene structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-TROPOMYOSIN GENE; NEUROTRANSMITTER TRANSPORTERS; NMDA ANTAGONISTS; MOUSE-BRAIN; RAT-BRAIN; EXPRESSION; CLONING; LOCALIZATION; RECEPTOR; CNS	The rat GLYT-1 gene encodes two glycine transporter variants, GLYT-1a and GLYT-1b, that differ in NH2 termini and 5'-noncoding regions as well as in tissue distribution. The GLYT-1 gene contains 15 exons, with the first two specific for GLYT-1a and the third specific for GLYT-1b. By combining RNase protection and rapid amplification of cDNA ends analysis, we have determined transcription start sites for GLYT-1a and GLYT-1b. By using a functional luciferase reporter assay, we demonstrate that distinct promoters regulate the expression of these transporters in several cell lines. Serially truncated GLYT-1b promoter constructs reveal a basal promoter within 304 base pairs of the transcription start site, possible negative regulatory elements between -304 and -1310, and additional positive regulatory elements between -1310 and -5264. The GLYT-1 gene contains three sets of dinucleotide repeats, two AC repeats, and one TG repeat which may form stem-loop structures to either facilitate or interfere with transcription of one of the transporter isoforms. The potential use of dinucleotide repeats in this manner would represent a novel mechanism for gene splicing. The use of distinct promoters for GLYT-1a and GLYT-1b suggests that these transporters have unique regulatory requirements that may reflect the differential tissue-specific expression patterns in white matter (GLYT-1b) and gray matter (GLYT-1a).	NIMH, Unit Mol Pharmacol, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Hoffman, BJ (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Crop Code 8510, Indianapolis, IN 46285 USA.	Hoffman_Beth@Lilly.com						ADAMS RH, 1995, J NEUROSCI, V15, P2524, DOI 10.1523/JNEUROSCI.15-03-02524.1995; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Attwell David, 1994, Current Opinion in Neurobiology, V4, P353, DOI 10.1016/0959-4388(94)90096-5; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BERNSTEIN SI, 1997, MRNA METABOLISM POST, P43; BOROWSKY B, 1993, NEURON, V10, P851, DOI 10.1016/0896-6273(93)90201-2; Borowsky B, 1995, INT REV NEUROBIOL, V38, P139, DOI 10.1016/S0074-7742(08)60526-7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Fossom LH, 1997, J NEURAL TRANSM-SUPP, P235; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; Hirsch SR, 1997, PHARMACOL BIOCHEM BE, V56, P797, DOI 10.1016/S0091-3057(96)00428-5; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JURSKY F, 1995, J NEUROCHEM, V64, P1026; KIM CH, 1987, P NATL ACAD SCI USA, V84, P6025, DOI 10.1073/pnas.84.17.6025; KIM KM, 1994, MOL PHARMACOL, V45, P608; Lees KR, 1997, NEUROLOGY, V49, pS66, DOI 10.1212/WNL.49.5_Suppl_4.S66; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; LIBRI D, 1990, J BIOL CHEM, V265, P3471; LIU QR, 1992, P NATL ACAD SCI USA, V89, P12145, DOI 10.1073/pnas.89.24.12145; LIU QR, 1992, P NATL ACAD SCI USA, V89, P6639, DOI 10.1073/pnas.89.14.6639; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; LUQUE JM, 1995, NEUROSCIENCE, V64, P525, DOI 10.1016/0306-4522(94)00404-S; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; Small DL, 1997, INT REV NEUROBIOL, V40, P137; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; Supplisson S, 1997, J NEUROSCI, V17, P4580; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; ZAFRA F, 1995, EUR J NEUROSCI, V7, P1342, DOI 10.1111/j.1460-9568.1995.tb01125.x; ZAFRA F, 1995, J NEUROSCI, V15, P3952; Zhang L, 1997, J NEUROPHYSIOL, V78, P582, DOI 10.1152/jn.1997.78.2.582	33	57	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29077	29085		10.1074/jbc.273.44.29077	http://dx.doi.org/10.1074/jbc.273.44.29077			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786914	hybrid			2022-12-25	WOS:000076691800075
J	Bose, R; Chen, P; Loconti, A; Grullich, C; Abrams, JM; Kolesnick, RN				Bose, R; Chen, P; Loconti, A; Grullich, C; Abrams, JM; Kolesnick, RN			Ceramide generation by the reaper protein is not blocked by the caspase inhibitor, p35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; DROSOPHILA-MELANOGASTER; INTERLEUKIN-1-BETA-CONVERTING ENZYME; SACCHAROMYCES-CEREVISIAE; FAMILY PROTEASES; ACTIVATION; KINASE; BCL-2; GENE	The Reaper (Rpr) gene encodes a 65-amino acid protein that induces apoptosis in Drosophila by an unknown mechanism. A previous study reported that Rpr expression induced generation of the lipid second messenger ceramide and through use of the peptide caspase inhibitor N-benzyloxycarbonyl-VAD-fluoromethylketone (zVAD.fmk) ordered ceramide generation downstream of caspases in SL2 cells (Pronk, G, J., Ramer, K,, Amiri, P,, and Williams, L, T. (1996) Science 271, 808-810), The present study re-evaluates these events in SL2 cells transfected with cDNA for Rpr, with or without the baculovirus caspase inhibitor p35, under the control of the metallothionein promoter. Following copper addition, Rpr protein was detected at 1.5 h and maximal at 2.5 h, Ceramide generation and caspase activation occurred nearly simultaneously, each detectable at 2-2.5 h and maximal at 6 h. Ceramide levels increased from a base line of 5 pmol/nmol lipid phosphorus to a maximum of 10 pmol/nmol lipid phosphorus, Identical increases in ceramide were detected using the enzymatic 1,2-diacylglycerol kinase assay or the non-enzymatic o-phthalaldehyde derivatization high pressure liquid chromatography assay. In contrast, diacylglycerol levels were not increased by Rpr expression. Apoptosis, first detected at 4 h, was maximal at 16 h, Go-expression of p35 did not affect Rpr-induced ceramide generation, whereas caspase activation and apoptosis were abolished. In contrast, zVAD.fmk inhibited ceramide generation and apo ptosis. These data show that Rpr-induced ceramide generation is upstream or independent of p35-inhibitable caspases and demonstrate differences in the actions of peptide and p35 caspase inhibitors.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	Memorial Sloan Kettering Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kolesnick, RN (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.			Grullich, Carsten/0000-0002-2783-8220	NIA NIH HHS [AG12466] Funding Source: Medline; NIGMS NIH HHS [GM18215, GM07739] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012466] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chen P, 1996, J BIOL CHEM, V271, P25735, DOI 10.1074/jbc.271.42.25735; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Farschon DM, 1997, J CELL BIOL, V137, P1117, DOI 10.1083/jcb.137.5.1117; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HAY BA, 1994, DEVELOPMENT, V120, P2121; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; Kondo T, 1997, P NATL ACAD SCI USA, V94, P11951, DOI 10.1073/pnas.94.22.11951; LIU J, 1994, J BIOL CHEM, V269, P3047; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; LOZANO J, 1994, J BIOL CHEM, V269, P19200; LUUKKONEN A, 1976, BIOCHIM BIOPHYS ACTA, V450, P109, DOI 10.1016/0005-2760(76)90082-5; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; MARTIN SJ, 1995, CELL, V82, P342; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sambrook J., 2002, MOL CLONING LAB MANU; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHEA TB, 1994, BIOTECHNIQUES, V16, P1126; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; STARK WS, 1993, LIPIDS, V28, P23, DOI 10.1007/BF02536355; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Witty JP, 1996, ENDOCRINOLOGY, V137, P5269, DOI 10.1210/en.137.12.5269; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	62	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28852	28859		10.1074/jbc.273.44.28852	http://dx.doi.org/10.1074/jbc.273.44.28852			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786886	hybrid			2022-12-25	WOS:000076691800047
J	Litovchick, L; Chestukhin, A; Shaltiel, S				Litovchick, L; Chestukhin, A; Shaltiel, S			The carboxyl-terminal tail of kinase splitting membranal proteinase meprin beta is involved in its intracellular trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBENZOIC ACID HYDROLASE; ENDOPLASMIC-RETICULUM; ALPHA-SUBUNIT; TRANSMEMBRANE PROTEINS; TRANSPORT VESICLES; CATALYTIC SUBUNIT; ASTACIN FAMILY; EXPRESSION; COPII; METALLOENDOPEPTIDASES	The kinase splitting membranal proteinase (KSMP), was recently shown to be identical with the beta-subunit of meprin. Meprin is a metalloendoproteinase located in brush border membranes and composed of the two types of subunits, alpha and beta. Despite their high sequence homology and similar domain organization, meprin subunits are differently processed during maturation; meprin ct is retained in the endoplasmic reticulum (ER), and undergoes a proteolytic removal of the transmembrane and cytoplasmic domains, prior to its export from this organelle, In contrast, meprin beta retains these domains even after reaching its final destination in the plasma membrane. Using truncated mutants of rat meprin beta expressed in Cos-7 and human embryonic kidney (HEK) 293 cells, we show here that the cytoplasmic tail is indispensable for its exit from the ER, A meprin beta mutant lacking the last 25 amino acids is shown to be transport-incompetent, although it does not contain any of the known ER retention signals, Systematic analysis of the rate of the ER to Golgi transport using a series of mutants with Ala or Pro substitutions in the tail, suggests that while no specific amino acid residue by itself is imperative for normal intracellular trafficking of meprin beta, the insertion of a bend at a distinct position in the tail (specifically by a Y685P mutation) suffices to retain this protein in the ER. We propose that the very length of the cytoplasmic tail, as well as its secondary structure are essential for the ER to Golgi transport of meprin beta, possibly by allowing an interaction with a cargo receptor.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaltiel, S (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	lishalt@wiccmail.weizmann.ac.il		Litovchick, Larisa/0000-0002-9540-597X				ALHANATY E, 1979, BIOCHEM BIOPH RES CO, V89, P323, DOI 10.1016/0006-291X(79)90633-8; ALHANATY E, 1981, P NATL ACAD SCI-BIOL, V78, P3492, DOI 10.1073/pnas.78.6.3492; ALHANATY E, 1985, CURR TOP CELL REGUL, V27, P267; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BOND JS, 1986, CURR TOP CELL REGUL, V28, P263; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Chestukhin A, 1996, J BIOL CHEM, V271, P30272, DOI 10.1074/jbc.271.47.30272; Chestukhin A, 1997, J BIOL CHEM, V272, P3153, DOI 10.1074/jbc.272.6.3153; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; Eldering JA, 1997, EUR J BIOCHEM, V247, P920, DOI 10.1111/j.1432-1033.1997.00920.x; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; GORBEA CM, 1994, MAMMALIAN BRUSH BORD, P89; GRUNBERG J, 1993, FEBS LETT, V335, P376, DOI 10.1016/0014-5793(93)80422-Q; Hahn D, 1997, EUR J BIOCHEM, V247, P933, DOI 10.1111/j.1432-1033.1997.00933.x; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HIMMELHOCH S, 1994, MICROSC RES TECHNIQ, V29, P23, DOI 10.1002/jemt.1070290104; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; MILHIET PE, 1995, BIOCHEM J, V309, P683, DOI 10.1042/bj3090683; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P119, DOI 10.1016/0003-9861(88)90377-3; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325	36	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29043	29051		10.1074/jbc.273.44.29043	http://dx.doi.org/10.1074/jbc.273.44.29043			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786910	hybrid			2022-12-25	WOS:000076691800071
J	Roldan, MD; Sears, HJ; Cheesman, MR; Ferguson, SJ; Thomson, AJ; Berks, BC; Richardson, DJ				Roldan, MD; Sears, HJ; Cheesman, MR; Ferguson, SJ; Thomson, AJ; Berks, BC; Richardson, DJ			Spectroscopic characterization of a novel multiheme c-type cytochrome widely implicated in bacterial electron transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPLASMIC NITRATE REDUCTASE; MAGNETIC CIRCULAR-DICHROISM; PARACOCCUS-DENITRIFICANS; ESCHERICHIA-COLI; THIOSPHAERA-PANTOTROPHA; STRUCTURAL GENE; SEQUENCE; IDENTIFICATION; CLONING; CLUSTER	lNapC is a member of a family of bacterial membrane-anchored tetra-heme c-type cytochromes that participate in a number of respiratory electron transport pathways. They are postulated to mediate electron transfer between membrane quinols/quinones and soluble periplasmic enzymes. The water-soluble heme domain of NapC has been expressed as a periplasmic protein, Mediated redox potentiometry and characterization by UV-visible, magnetic circular dichroism, and electron paramagnetic resonance spectroscopies demonstrates that soluble NapC contains four low spin hemes, each with bis-histidine axial ligation and with midpoint reduction potentials of -56, -181, -207, and -235 mV.	Univ E Anglia, Ctr Metalloprot Spect & Biol, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Ctr Metalloprot Spect & Biol, Sch Chem Sci, Norwich NR4 7TJ, Norfolk, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of East Anglia; University of East Anglia; University of Oxford	Richardson, DJ (corresponding author), Univ E Anglia, Ctr Metalloprot Spect & Biol, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	d.richardson@uea.ac.uk	Sears, Heather J/A-2950-2015; Richardson, David J/E-2275-2011; Roldán Ruiz, María Dolores/K-4370-2014	Sears, Heather J/0000-0003-3480-0543; Roldán Ruiz, María Dolores/0000-0001-7173-8641; Berks, Ben/0000-0001-9685-4067				ALLEN LN, 1985, J BACTERIOL, V161, P955, DOI 10.1128/JB.161.3.955-962.1985; BELL LC, 1993, J GEN MICROBIOL, V139, P3205, DOI 10.1099/00221287-139-12-3205; BERGMANN DJ, 1994, J BACTERIOL, V176, P3148, DOI 10.1128/jb.176.11.3148-3153.1994; BERKS BC, 1995, BIOCHEM J, V309, P983, DOI 10.1042/bj3090983; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BERKS BC, 1994, EUR J BIOCHEM, V220, P117, DOI 10.1111/j.1432-1033.1994.tb18605.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Braterman P. S., 1964, ADV CHEM PHYS, V7, P359; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; CHEESMAN MR, 1992, BIOCHEM J, V286, P361, DOI 10.1042/bj2860361; CHEESMAN MR, 1991, ADV INORG CHEM, V36, P201, DOI 10.1016/S0898-8838(08)60040-9; CHENG JC, 1973, NATURE, V241, P193, DOI 10.1038/241193a0; DEVRIES GE, 1989, ARCH MICROBIOL, V152, P52, DOI 10.1007/BF00447011; DOLATA MM, 1993, J BIOL CHEM, V268, P14426; Dutton P L, 1978, Methods Enzymol, V54, P411; EATON WA, 1967, J CHEM PHYS, V46, P2533, DOI 10.1063/1.1841081; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; GADSBY PMA, 1987, BIOCHEM J, V246, P43, DOI 10.1042/bj2460043; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; JUNGST A, 1991, FEBS LETT, V279, P205, DOI 10.1016/0014-5793(91)80150-2; MCKNIGHT J, 1993, EUR J BIOCHEM, V213, P683, DOI 10.1111/j.1432-1033.1993.tb17808.x; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; MOIR JWB, 1994, MICROBIOL-SGM, V140, P389, DOI 10.1099/13500872-140-2-389; Moore G. R., 1990, CYTOCHROMES C EVOLUT; MOORE GR, 1985, BIOCHIM BIOPHYS ACTA, V829, P83, DOI 10.1016/0167-4838(85)90071-8; Myers CR, 1997, J BACTERIOL, V179, P1143, DOI 10.1128/jb.179.4.1143-1152.1997; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; PARSONAGE D, 1983, FEBS LETT, V153, P108, DOI 10.1016/0014-5793(83)80128-8; PARSONAGE D, 1985, BIOCHIM BIOPHYS ACTA, V807, P81, DOI 10.1016/0005-2728(85)90055-6; Reyes F, 1996, MOL MICROBIOL, V19, P1307, DOI 10.1111/j.1365-2958.1996.tb02475.x; RIGBY SEJ, 1988, BIOCHEM J, V256, P571, DOI 10.1042/bj2560571; Sambongi Y, 1996, MOL MICROBIOL, V19, P1193, DOI 10.1111/j.1365-2958.1996.tb02465.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shaw AL, 1996, BBA-BIOENERGETICS, V1276, P176, DOI 10.1016/0005-2728(96)00092-8; SIDDIQUI RA, 1993, J BACTERIOL, V175, P5867, DOI 10.1128/JB.175.18.5867-5876.1993; Simon J, 1998, ARCH MICROBIOL, V169, P424, DOI 10.1007/s002030050593; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; UJIIYE T, 1996, BIOCHIM BIOPHYS ACTA, V1227, P1; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038	41	110	111	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28785	28790		10.1074/jbc.273.44.28785	http://dx.doi.org/10.1074/jbc.273.44.28785			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786877	hybrid			2022-12-25	WOS:000076691800038
J	Sakaue, H; Ogawa, W; Matsumoto, M; Kuroda, S; Takata, M; Sugimoto, T; Spiegelman, BM; Kasuga, M				Sakaue, H; Ogawa, W; Matsumoto, M; Kuroda, S; Takata, M; Sugimoto, T; Spiegelman, BM; Kasuga, M			Posttranscriptional control of adipocyte differentiation through activation of phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 PREADIPOCYTES; GENE-EXPRESSION; PPAR-GAMMA; PROTEIN; INSULIN; CELLS; PHOSPHORYLATION; TRANSLATION; INHIBITION	Differentiation of adipocytes is an important aspect of energy homeostasis. Although the transcriptional regulation of adipocyte differentiation is relatively well characterized, the subsequent molecular events remain unclear. The activity of phosphoinositide (PI) 3-kinase precipitated with antibodies to phosphotyrosine has now been shown to increase transiently during adipocyte differentiation of 3T3-F442A and of 3T3-L1 cells. PI 3-kinase activity precipitated with antibodies to insulin receptor substrate 1 (IRS1) and association of subunits of PI 3-kinase with IRS1 were also increased at this stage of differentiation, suggesting that IRS1 contributes to PI 3-kinase activation. Inhibition of the activation of PI 3-kinase by expression of dominant negative mutant subunits of the enzyme prevented adipogenesis, as assessed by lipid accumulation and expression of key adipocyte proteins such as GLUT4, adipsin, and aP2, suggesting that PI 3-kinase activation is essential for adipocyte differentiation. However, these mutant proteins did not affect either the expression of the transcription factor PPAR gamma at the mRNA or protein level or the increase in the abundance of mRNAs encoding the adipocyte marker proteins. These results demonstrate that adipocyte differentiation is regulated at the posttranscriptional level and that activation of PI 3-kinase is required for this regulation.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 6500017, Japan; Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA	Kobe University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Ogawa, W (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.		Sakaue, Hiroshi/ABE-2337-2021; OGAWA, Wataru/AAQ-9586-2020	Sakaue, Hiroshi/0000-0002-2468-2363; 				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kitamura Y, 1997, BIOCHEM J, V322, P873, DOI 10.1042/bj3220873; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; MCDONALD OA, 1995, J BIOL CHEM, V269, P19041; MCDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; RICE KM, 1992, J BIOL CHEM, V267, P10163; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONZTOZ P, 1994, CELL, V79, P1147; VANHAESEBROECK B, 1997, TRENDS BIOCHEM SCI, V22, P269; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; WHITE MF, 1997, DIABETOLOGIA, V40, P2; WU Z, 1996, MOL CELL BIOL, V16, P4126; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	40	136	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28945	28952		10.1074/jbc.273.44.28945	http://dx.doi.org/10.1074/jbc.273.44.28945			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786898	Green Published, hybrid			2022-12-25	WOS:000076691800059
J	Smith, KE; Voziyan, PA; Fisher, MT				Smith, KE; Voziyan, PA; Fisher, MT			Partitioning of rhodanese onto GroEL - Chaperonin binds a reversibly oxidized form derived from the native protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DODECAMERIC GLUTAMINE-SYNTHETASE; ASSISTED FOLDING REACTION; ESCHERICHIA-COLI; OXIDATIVE MODIFICATION; CONFORMATIONAL-CHANGES; ENZYME RHODANESE; IN-VIVO; INACTIVATION; SUBSTRATE; RELEASE	The mammalian mitochondrial enzyme, rhodanese, can form stable complexes with the Escherichia coli chaperonin GroEL if it is either refolded from 8 as urea in the presence of chaperonin or is simply added to the chaperonin as the folded conformer at 37 degrees C, In the presence of GroEL, the kinetic profile of the inactivation of native rhodanese followed a single exponential decay. Initially, the inactivation rates showed a dependence on the chaperonin concentration but reached a constant maximum value as the GroEL concentration increased. Over the same time period, in the absence of GroEL, native rhodanese showed only a small decline in activity. The addition of a non-denaturing concentration of urea accelerated the inactivation and partitioning of rhodanese onto GroEL, These results suggest that the GroEL chaperonin may facilitate protein unfolding indirectly by interacting with intermediates that exist in equilibrium with native rhodanese. The activity of GroEL-bound rhodanese can be completely recovered upon addition of GroES and ATP, The reactivation kinetics and commitment rates for GroEL-rhodanese complexes prepared from either unfolded or native rhodanese were identical, However, when rhodanese was allowed to inactivate spontaneously in the absence of GroEL, no recovery of activity was observed upon addition of GroEL, GroES, and ATP, Interestingly, the partitioning of rhodanese and its subsequent inactivation did not occur when native rhodanese and GroEL were incubated under anaerobic conditions. Thus, our results strongly suggest that the inactive intermediate that partitions onto GroEL is the reversibly oxidized form of rhodanese.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Fisher, MT (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	mfisher1@kumc.edu			NIGMS NIH HHS [GM49309] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049309] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; CANNELLA C, 1983, FEBS LETT, V162, P180, DOI 10.1016/0014-5793(83)81074-6; Clark AC, 1997, J MOL BIOL, V268, P512, DOI 10.1006/jmbi.1997.0969; Eisenstein E, 1998, METHOD ENZYMOL, V290, P119, DOI 10.1016/S0076-6879(98)90011-8; Fenton WA, 1997, PROTEIN SCI, V6, P743; FISHER MT, 1992, J BIOL CHEM, V267, P1872; FISHER MT, 1994, J BIOL CHEM, V269, P13629; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; FISHER MT, 1994, J BIOL CHEM, V269, P29598; GOLDBERG MS, 1997, P NATL ACAD SCI USA, V93, P12189; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; Gross M, 1996, PROTEIN SCI, V5, P2506, DOI 10.1002/pro.5560051213; HOROWITZ PM, 1988, J BIOL CHEM, V263, P10278; HOROWITZ PM, 1992, J BIOL CHEM, V267, P23596; HOROWITZ PM, 1995, BBA-PROTEIN STRUCT M, V1249, P161, DOI 10.1016/0167-4838(95)00037-U; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; PERRY LJ, 1987, PROTEIN ENG, V1, P101, DOI 10.1093/protein/1.2.101; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Reid BG, 1996, J BIOL CHEM, V271, P7212, DOI 10.1074/jbc.271.12.7212; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; SZWEDA LI, 1992, J BIOL CHEM, V267, P3096; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	41	10	11	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28677	28681		10.1074/jbc.273.44.28677	http://dx.doi.org/10.1074/jbc.273.44.28677			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786862	hybrid			2022-12-25	WOS:000076691800023
J	Spencer, VA; Coutts, AS; Samuel, SK; Murphy, LC; Davie, JR				Spencer, VA; Coutts, AS; Samuel, SK; Murphy, LC; Davie, JR			Estrogen regulates the association of intermediate filament proteins with nuclear DNA in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; CROSS-LINKING; MATRIX PROTEINS; ELECTRON-MICROSCOPY; IN-VIVO; INVIVO; CIS-DIAMMINEDICHLOROPLATINUM(II); CYTOSKELETAL; BINDING; EXPRESSION	In a previous study we showed that the levels of the intermediate filament proteins, cytokeratins 8, 18, and 19, in the nuclear matrix-intermediate filament (NM-IF) fraction from the hormone-dependent and estrogen receptor (ER)-positive human breast cancer cell line T-47D5 were regulated by estrogens. In contrast, estrogens did not regulate the cytokeratins in the NM-IF fraction of the hormone-independent and ER-positive cell line, T5-PRF. In this study, human breast cancer cells were treated with cis-diamminedichloroplatinum to cross-link protein to nuclear DNA in situ, and proteins bound to DNA were isolated. We show that cytokeratins 8, 18, and 19 of T-47D5 and T5-PRF were associated with nuclear DNA in situ. The levels of the cytokeratins 8, 18, and 19 bound to nuclear DNA or associated with the cytoskeleton of T-47D5 human breast cancer cells decreased when estrogens were depleted or the pure antiestrogen ICI 164,384 was added. In contrast, the cytokeratin levels associated with nuclear DNA or cytoskeleton were not significantly affected by estrogen withdrawal or antiestrogen administration in TB-PRF cells. These observations suggest that estrogen regulates the organization of nuclear DNA by rearrangement of the cytokeratin filament network in hormone-dependent, ER-positive human breast cancer cells and that this regulation is lost in hormone-independent, ER-positive breast cancer cells.	Univ Manitoba, Fac Med, Dept Biochem & Mol Biol, Winnipeg, MB R3E 0W3, Canada	University of Manitoba	Davie, JR (corresponding author), Univ Manitoba, Fac Med, Dept Biochem & Mol Biol, 770 Bannatyne Ave, Winnipeg, MB R3E 0W3, Canada.			Coutts, Amanda/0000-0002-5005-1864; Davie, James/0000-0002-0420-6888; Murphy, Leigh C/0000-0002-7676-6032				Bidwell JP, 1998, J BONE MINER RES, V13, P155, DOI 10.1359/jbmr.1998.13.2.155; Bode J, 1995, INT REV CYTOL, V162A, P389; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; Bubley GJ, 1996, BIOCHEM PHARMACOL, V51, P717, DOI 10.1016/S0006-2952(95)02256-2; CHOU CF, 1993, J CELL SCI, V105, P433; Coutts AS, 1996, J CELL BIOCHEM, V63, P174, DOI 10.1002/(SICI)1097-4644(19961101)63:2<174::AID-JCB5>3.0.CO;2-V; Davie JR, 1997, MOL BIOL REP, V24, P197, DOI 10.1023/A:1006811817247; Davie JR, 1995, INT REV CYTOL, V162A, P191; DAVIE JR, 1998, GENE THER MOL BIOL, V1, P509; FERRARO A, 1995, ACTA BIOCHIM POL, V42, P145; FERRARO A, 1991, BIOCHEM BIOPH RES CO, V178, P1365, DOI 10.1016/0006-291X(91)91044-D; FERRARO A, 1992, FEBS LETT, V307, P383, DOI 10.1016/0014-5793(92)80718-V; Georgatos S D, 1996, Int Rev Cytol, V164, P91; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; Hendrix MJC, 1996, CANCER METAST REV, V15, P413, DOI 10.1007/BF00054009; INGBER DE, 1993, J CELL SCI, V104, P613; JACKSON DA, 1988, EMBO J, V7, P3667, DOI 10.1002/j.1460-2075.1988.tb03248.x; KHAN MUA, 1978, CHEM-BIOL INTERACT, V21, P227, DOI 10.1016/0009-2797(78)90021-2; Klymkowsky MW, 1996, CANCER METAST REV, V15, P417, DOI 10.1007/BF00054010; Kuang WW, 1998, NUCLEIC ACIDS RES, V26, P1116, DOI 10.1093/nar/26.4.1116; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Mattia E, 1998, EXP CELL RES, V238, P216, DOI 10.1006/excr.1997.3833; McNeil S, 1998, J CELL BIOCHEM, V68, P500, DOI 10.1002/(SICI)1097-4644(19980315)68:4<500::AID-JCB9>3.3.CO;2-T; NICKERSON JA, 1990, P NATL ACAD SCI USA, V87, P2259, DOI 10.1073/pnas.87.6.2259; OLINSKI R, 1987, CANCER RES, V47, P201; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; PENMAN S, 1995, P NATL ACAD SCI USA, V92, P5251, DOI 10.1073/pnas.92.12.5251; ReplogleSchwab TS, 1996, CRIT REV EUKAR GENE, V6, P103, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.10; Samuel SK, 1997, CANCER RES, V57, P147; SAPINO A, 1986, CANCER RES, V46, P2526; SOMMERS CL, 1989, CANCER RES, V49, P4258; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; Walter J, 1997, METHODS, V11, P215, DOI 10.1006/meth.1996.0408; Wang X, 1996, DNA CELL BIOL, V15, P209, DOI 10.1089/dna.1996.15.209; WARD WS, 1984, P NATL ACAD SCI-BIOL, V81, P419, DOI 10.1073/pnas.81.2.419; WATTS CKW, 1992, J STEROID BIOCHEM, V41, P529, DOI 10.1016/0960-0760(92)90378-V; WEDRYCHOWSKI A, 1986, J BIOL CHEM, V261, P3370; WEDRYCHOWSKI A, 1986, BIOCHEMISTRY-US, V25, P1, DOI 10.1021/bi00349a001; WEDRYCHOWSKI A, 1989, EXP CELL RES, V183, P376, DOI 10.1016/0014-4827(89)90398-4; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585	40	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29093	29097		10.1074/jbc.273.44.29093	http://dx.doi.org/10.1074/jbc.273.44.29093			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786916	hybrid			2022-12-25	WOS:000076691800077
J	Xu, YJ; Kim, EY; Demple, B				Xu, YJ; Kim, EY; Demple, B			Excision of C-4 '-oxidized deoxyribose lesions from double-stranded DNA by human Apurinic/Apyrimidinic endonuclease (Ape1 protein) and DNA polymerase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC ENDONUCLEASE; ESCHERICHIA-COLI; ABASIC SITES; PHOSPHATE RESIDUES; OXIDATIVE DAMAGE; REPAIR; BLEOMYCIN; IV; NEOCARZINOSTATIN; RECOGNITION	Oxidative damage to DNA deoxyribose generates oxidized abasic sites (OAS) that may constitute one-third of ionizing radiation damage. The antitumor drug bleomycin produces exclusively OAS in the farm of C-4-keto-C-1-aldehydes in unbroken DNA strands and 3'-phosphoglycolate esters terminating strand breaks. We investigated whether two human DNA repair enzymes can mediate OAS excision in vitro: Ape1 protein (the main human abasic endonuclease (also called Hap1, Apex, or Ref1)) and DNA polymerase beta, which carries out both the abasic excision and the resynthesis steps. We used a duplex oligonucleotide substrate with one main target for bleomycin-induced damage. Ape1 catalyzed effective incision at the C-4-keto-C-1-aldehyde sites at a rate that may be only a few-fold lower than incision of hydrolytic abasic sites at the same location. Consistent with several previous studies, Ape1 hydrolyzed 3'-phosphoglycolates 25-fold more slowly than C-4-keto-C-1-aldehydes. DNA polymerase beta excised the 5'-terminal OAS formed by Ape1 incision at a rate similar to its removal of unmodified abasic residues. Polymerase beta-mediated excision of 5'-terminal OAS was stimulated by Ape1 as it is for unmodified abasic sites. Escherichia coli Fpg (MutM) protein also excised 5'-terminal GAS, but in our hands, the RecJ protein did not. These observations help define mammalian pathways of OAS repair, point to interactions that might coordinate functional steps, and suggest that still unknown factors may contribute to removal of 3'-phosphoglycolate esters.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.	bdemple@hsph.harvard.edu			NCI NIH HHS [CA71993] Funding Source: Medline; NIGMS NIH HHS [GM40000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABSALON MJ, 1995, BIOCHEMISTRY-US, V34, P2076, DOI 10.1021/bi00006a030; ABSALON MJ, 1995, BIOCHEMISTRY-US, V34, P2056; AKIYAMA K, 1995, GENOMICS, V26, P63, DOI 10.1016/0888-7543(95)80083-X; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; BLACKBURN GM, 1990, NUCLEIC ACIDS CHEM B, P71; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; DEDON PC, 1992, CHEM RES TOXICOL, V5, P311, DOI 10.1021/tx00027a001; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; Goldberg IH, 1996, NATO ADV SCI I C-MAT, V479, P1; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HARING M, 1994, NUCLEIC ACIDS RES, V22, P2010, DOI 10.1093/nar/22.11.2010; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KUBOTA Y, 1996, EMBO J, V15, P662; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; Levin JD, 1996, NUCLEIC ACIDS RES, V24, P885, DOI 10.1093/nar/24.5.885; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MIASKIEWICZ K, 1994, J AM CHEM SOC, V116, P232, DOI 10.1021/ja00080a027; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; POVIRK LF, 1989, BIOCHEMISTRY-US, V28, P5808, DOI 10.1021/bi00440a016; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; ROTHWELL DG, BASE EXCISION REPAIR, P67; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SUGIYAMA H, 1990, J AM CHEM SOC, V112, P5252, DOI 10.1021/ja00169a037; Suh D, 1997, NUCLEIC ACIDS RES, V25, P2495, DOI 10.1093/nar/25.12.2495; Vanderwall DE, 1997, CHEM BIOL, V4, P373, DOI 10.1016/S1074-5521(97)90128-9; VONSONNTAG C, 1987, CHE BASIS RAD BIOL; Weinfeld M, 1997, MUTAT RES-FUND MOL M, V378, P127, DOI 10.1016/S0027-5107(97)00103-6; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; WINTERS TA, 1994, NUCLEIC ACIDS RES, V22, P1866, DOI 10.1093/nar/22.10.1866; WINTERS TA, 1992, NUCLEIC ACIDS RES, V20, P933; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xu YJ, 1997, BIOCHEMISTRY-US, V36, P14975, DOI 10.1021/bi972101o	40	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28837	28844		10.1074/jbc.273.44.28837	http://dx.doi.org/10.1074/jbc.273.44.28837			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786884	hybrid			2022-12-25	WOS:000076691800045
J	Janciauskiene, S; Rubin, H; Lukacs, CM; Wright, HT				Janciauskiene, S; Rubin, H; Lukacs, CM; Wright, HT			Alzheimer's peptide A beta(1-42) binds to two beta-sheets of alpha(1)-antichymotrypsin and transforms it from inhibitor to substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-INHIBITORS; CONFORMATIONAL STABILITY; SERPINS; ANTICHYMOTRYPSIN; DISEASE; ALPHA-1-ANTICHYMOTRYPSIN; ALPHA-1-ANTITRYPSIN; TRANSITION; MECHANISM; COMPLEX	The serpin alpha(1)-antichymotrypsin is a major component of brain amyloid plaques in Alzheimer's disease. In vitro alpha(1)-antichymotrypsin interacts with the Alzheimer's amyloid peptide A beta(1-42) and stimulates both formation and disruption of neurotoxic A beta(1-42) fibrils in a concentration-dependent manner. We have constructed a new hybrid model of the complex between A beta(1-42) and alpha(1)-antichymotrypsin in which both amino and carboxyl sequences of A beta(1-42) insert into two different beta-sheets of alpha(1)-antichymotrypsin. We have tested this model and shown experimentally that full-length and amino-terminal segments of A beta(1-42) bind to alpha(1)-antichymotrypsin as predicted. We also show that A beta(1-42) forms both intra- and intermolecular SDS-stable complexes with alpha(1)-antichymotrypsin and that the binding of A beta(1-42) to alpha(1)-antichymotrypsin abolishes the inhibitory activity of the latter and its ability to form stable complex with chymotrypsin. The existence of both inter- as well as intramolecular complexes of A beta(1-42) explains the nonlinear concentration-dependent effects of alpha(1)-antichymotrypsin on A beta(1-42) fibril formation, which we have reinvestigated here over a broad range of A beta(1-42):alpha(1)-antichymotrypsin ratios. These data suggest a molecular basis for the distinction between amorphous and fibrillar A beta(1-42) in vivo. The reciprocal effects of A beta(1-42) and alpha(1)-antichymotrypsin could play a role in the etiology of Alzheimer's disease.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Lund, Malmo Univ Hosp, Dept Med, S-20502 Malmo, Sweden; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Virginia Commonwealth Univ, Inst Struct Biol & Drug Discovery, Richmond, VA 23219 USA	University of Pennsylvania; Lund University; Skane University Hospital; University of Pennsylvania; Virginia Commonwealth University	Rubin, H (corresponding author), Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [HL50523] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050523] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BJORK I, 1992, J BIOL CHEM, V267, P1976; BRUCH M, 1988, J BIOL CHEM, V263, P16626; Carrell RW, 1996, BIOL CHEM H-S, V377, P1; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; EITZMAN DT, 1995, J CLIN INVEST, V95, P2416, DOI 10.1172/JCI117937; ERIKSSON S, 1995, P NATL ACAD SCI USA, V92, P2313, DOI 10.1073/pnas.92.6.2313; FRASER PE, 1993, J NEUROCHEM, V61, P298, DOI 10.1111/j.1471-4159.1993.tb03568.x; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Janciauskiene S, 1996, NAT STRUCT BIOL, V3, P668, DOI 10.1038/nsb0896-668; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lukacs CM, 1996, PROTEINS, V25, P420, DOI 10.1002/(SICI)1097-0134(199608)25:4<420::AID-PROT2>3.3.CO;2-I; Ma JY, 1996, NEUROBIOL AGING, V17, P773; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; RUBIN H, 1990, J BIOL CHEM, V265, P1199; RUBIN H, 1992, BIOL CHEM H-S, V373, P497, DOI 10.1515/bchm3.1992.373.2.497; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WISNIEWSKI T, 1994, NEUROBIOL AGING, V15, P420; Wright HT, 1996, BIOESSAYS, V18, P453, DOI 10.1002/bies.950180607; WRIGHT HT, 1994, PROTEIN-STRUCT FUNCT, V22, P210	31	59	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28360	28364		10.1074/jbc.273.43.28360	http://dx.doi.org/10.1074/jbc.273.43.28360			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774461	hybrid			2022-12-25	WOS:000076549800081
J	Trapani, JA; Jans, DA; Jans, PJ; Smyth, MJ; Browne, KA; Sutton, VR				Trapani, JA; Jans, DA; Jans, PJ; Smyth, MJ; Browne, KA; Sutton, VR			Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perforin are caspase-dependent, but cell death is caspase-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; CYTOTOXICITY; FAMILY; PURIFICATION; LOCALIZATION; SPECIFICITY; SUBSTRATE; PROTEASES; CLEAVAGE; PROTEIN	The secretory lysosomes of cytolytic lymphocytes house the principal apoptotic molecules for eliminating virus-infected cells: a membranolytic agent, perforin, and the serine protease, granzyme B. Perforin allows granzyme B access to cytosolic and nuclear substrates that, when cleaved, result in the characteristic apoptotic phenotype. Key among these substrates is a family of cytoplasmic caspases that mediate cell suicide. We have examined the caspase dependence of several nuclear and cytoplasmic parameters of apoptosis induced by purified perforin and granzyme B. Cell membrane leakage in response to perforin and granzyme B was independent of caspase activation; however, nuclear events such as DNA fragmentation and nuclear condensation and disintegration were abolished by the broad-acting caspase inhibitor, z-VAD-fmk, Despite being spared from nuclear damage, z-VAD-fmk-treated cells exposed to both cytotoxins uniformly died when they were re-cultured, while cells exposed to perforin or granzyme alone survived and proliferated as readily as untreated cells. Pretreatment of cells with z-VAD-fmk also resulted in reduced granzyme B nuclear uptake following addition of perforin; however, its uptake into the cytoplasm in the absence of perforin was unaffected. We conclude that cell death in response to perforin and granzyme B does not require caspase activation and still proceeds efficiently through non-nuclear pathways when nuclear substrate cleavage is inhibited.	Austin Res Inst, John Connell Lab, Heidelberg, Vic 3084, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Nucl Targeting Lab, Canberra, ACT 2601, Australia	Austin Research Institute; Australian National University; John Curtin School of Medical Research	Trapani, JA (corresponding author), Austin Res Inst, John Connell Lab, Studley Rd, Heidelberg, Vic 3084, Australia.	j.trapani@ari.unimelb.edu.au	Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240; Trapani, Joseph/0000-0003-0983-1532				Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V227, P658, DOI 10.1006/bbrc.1996.1565; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Miller LK, 1997, J CELL PHYSIOL, V173, P178, DOI 10.1002/(SICI)1097-4652(199711)173:2<178::AID-JCP17>3.3.CO;2-Z; Nagata S, 1996, ADV EXP MED BIOL, V406, P119; NAKAJIMA H, 1995, J EXP MED, V181, P1905, DOI 10.1084/jem.181.5.1905; Pinkoski MJ, 1996, J BIOL CHEM, V271, P10225, DOI 10.1074/jbc.271.17.10225; POE M, 1991, J BIOL CHEM, V266, P98; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; Sutton VR, 1997, J IMMUNOL, V158, P5783; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; Trapani JA, 1998, CELL DEATH DIFFER, V5, P488, DOI 10.1038/sj.cdd.4400373; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	26	135	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27934	27938		10.1074/jbc.273.43.27934	http://dx.doi.org/10.1074/jbc.273.43.27934			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774406	hybrid			2022-12-25	WOS:000076549800026
J	Hui, TY; Frohnert, BI; Smith, AJ; Schaffer, JE; Bernlohr, DA				Hui, TY; Frohnert, BI; Smith, AJ; Schaffer, JE; Bernlohr, DA			Characterization of the murine fatty acid transport protein gene and its insulin response sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; FACTOR-BINDING PROTEIN-1; RNA-POLYMERASE-II; MESSENGER-RNA; PHOSPHOENOLPYRUVATE CARBOXYKINASE; REGULATED EXPRESSION; MEMBRANE-PROTEIN; HEPATOMA-CELLS; LESS PROMOTER; C-FOS	Fatty acid transport protein (FATP) was identified by expression cloning strategies (Schaffer, J. E., and Lodish, H. F. (1994) Cell 79, 427-436) and shown by transfection analysis to catalyze the transfer of long-chain fatty acids across the plasma membrane of cells. It is expressed highly in tissues exhibiting rapid fatty acid metabolism such as skeletal muscle, heart, and adipose. FATP mRNA levels are down-regulated by insulin in cultured 3T3-L1 adipocytes and up-regulated by nutrient depletion in murine adipose tissue (Man, M. Z., Hui, T. Y., Schaffer, J. E., Lodish, H. F., and Bernlohr, D. A. (1996) Mol.. Endocrinol. 10, 1021-1028). To determine the molecular mechanism of insulin regulation of FATP transcription, we have isolated the murine FATP gene and its 5'-flanking sequences. The FATP gene spans similar to 16 kilobases and contains 13 exons, of which exon 2 is alternatively spliced. S1 nuclease and RNase protection assays revealed the presence of multiple transcription start sites; the DNA sequence upstream of the predominant transcription start sites lacks a typical TATA box. By transient transfection assays in 3T3-L1 adipocytes, the inhibitory action of insulin on FATP transcription was localized to a cis-acting element with the sequence 5'-TGTTTTC-3' from -1347 to -1353, This sequence is very similar to the insulin response sequence found in the regulatory region of other genes negatively regulated by insulin such as those encoding phosphoenolpyruvate carboxykinase, tyrosine aminotransferase, and insulin-like growth factor-binding protein 1. Fluorescence in situ hybridization analysis revealed that the murine FATP gene is localized to chromosome 8, band 8B3.3. Interestingly, this region of chromosome 8 contains a cluster of three other genes important for fatty acid homeostasis, lipoprotein lipase, the mitochondrial uncoupling protein 1 (UCP1) and sterol regulatory element-binding protein 1. These results characterize the murine FATP gene and its insulin responsiveness as well as present a framework for future studies of its role in lipid metabolism, obesity, and type II diabetes mellitus.	Univ Minnesota, Dept Biochem, St Paul, MN 55108 USA; Univ Minnesota, Inst Human Genet, St Paul, MN 55108 USA; Washington Univ, Sch Med, St Louis, MO 63110 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Washington University (WUSTL)	Bernlohr, DA (corresponding author), Univ Minnesota, Dept Biochem, 1479 Gortner Ave, St Paul, MN 55108 USA.	david-b@biosci.cbs.umn.edu		Frohnert, Brigitte/0000-0002-6636-4048	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049807] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 49807] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; Berk PD, 1997, J BIOL CHEM, V272, P8830, DOI 10.1074/jbc.272.13.8830; BERK PD, 1998, IN PRESS MOL CELL BI; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOODY MC, 1980, BIOCHEMISTRY-US, V19, P108, DOI 10.1021/bi00542a017; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FUJII S, 1987, J BIOCHEM-TOKYO, V101, P679, DOI 10.1093/jb/101.3.679; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; HEDIGER MA, 1994, J EXP BIOL, V196, P15; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; JACOB M, 1989, NUCLEIC ACIDS RES, V17, P2159, DOI 10.1093/nar/17.6.2159; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; KIM SJ, 1994, J BIOL CHEM, V269, P11887; Kinne R K, 1995, Curr Opin Nephrol Hypertens, V4, P412, DOI 10.1097/00041552-199509000-00007; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MA L, 1992, NUCLEIC ACIDS RES, V20, P217, DOI 10.1093/nar/20.2.217; MAHADEVAN S, 1974, ARCH BIOCHEM BIOPHYS, V164, P185, DOI 10.1016/0003-9861(74)90021-6; Man MZ, 1996, MOL ENDOCRINOL, V10, P1021, DOI 10.1210/me.10.8.1021; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MIRA E, 1989, J BIOL CHEM, V264, P18209; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Parks CL, 1996, J BIOL CHEM, V271, P4417; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; STRAUS DS, 1987, J BIOL CHEM, V262, P1955; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1988, J CLIN INVEST, V81, P844, DOI 10.1172/JCI113393; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794	51	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27420	27429		10.1074/jbc.273.42.27420	http://dx.doi.org/10.1074/jbc.273.42.27420			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765271	hybrid			2022-12-25	WOS:000076448000058
J	Feng, X; Hannun, YA				Feng, X; Hannun, YA			An essential role for autophosphorylation in the dissociation of activated protein kinase C from the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; PHOSPHORYLATION; ALPHA; BINDING	The cellular localization of protein kinase C (PKC) is intimately associated with the regulation of its biological activity. Previously we have demonstrated that the redistribution of PKC to the plasma membrane in response to physiological stimuli is followed by a rapid returning of PKC back to the cytoplasm (Feng, X., Zhang, J,, Barak, L, S., Meyer, T,, Caron, M. G., and Hannun, Y, A. (1998) J. Biol Chem. 273, 10755-10762), Although the process of PKC membrane targeting has been extensively studied, the molecular mechanism underlying the dissociation of membrane-bound PKC remains unclear, In the present study, by examining the dynamic distribution of wild-type PKC PIP and its kinase-deficient mutant (K371R), we demonstrate that kinase activity is required for PKC membrane dissociation. Moreover, the inability of PKC PII(K371R) to dissociate from the plasma membrane in cells overexpressing wild-type PKC Pll suggests that autophosphorylation activity of the kinase might be essential for its membrane dissociation. This was further supported by mutational analysis of two lit vivo autophosphorylation sites on PKC beta II. The replacement of Ser(660) or Thr(641) by alanine (S660A or T641A) was found to synergistically reduce the reversal of PKC beta II membrane translocation, whereas the replacement of the same amino acids by glutamic acid (S660E or T641E), an amino acid commonly used to mimic phosphate, results in mutants behaving similar to wild-type PKC PHI, These findings point to an essential role for autophosphorylation in the dissociation of activated PKC from the plasma membrane and suggest that, like PKC membrane translocation, the returning of PBC to the cytoplasm after its activation is also delicately regulated.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem, 171 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blobe GC, 1996, CANCER SURV, V27, P213; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; BORNER C, 1989, J BIOL CHEM, V264, P13902; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Dembinsky A, 1997, J BIOL CHEM, V272, P828, DOI 10.1074/jbc.272.2.828; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; FARRAR WL, 1985, NATURE, V315, P235, DOI 10.1038/315235a0; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HUANG KP, 1986, J BIOL CHEM, V261, P2134; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; OHNO S, 1990, J BIOL CHEM, V265, P6296; ORR JW, 1994, J BIOL CHEM, V269, P27715; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; WARD NE, 1992, MOL PHARMACOL, V41, P387	27	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26870	26874		10.1074/jbc.273.41.26870	http://dx.doi.org/10.1074/jbc.273.41.26870			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756933	hybrid			2022-12-25	WOS:000076373300087
J	Guffanti, AA; Cheng, JB; Krulwich, TA				Guffanti, AA; Cheng, JB; Krulwich, TA			Electrogenic antiport activities of the gram-positive tet proteins include a Na+(K+)/K+ mode that mediates net K+ uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; BACILLUS-SUBTILIS TETA(L); ESCHERICHIA-COLI; NA+/H+ ANTIPORTER; STAPHYLOCOCCUS-AUREUS; POTASSIUM-TRANSPORT; RESISTANCE PROTEIN; MEMBRANE-VESICLES; ACTIVE-TRANSPORT; GENE	Two Gram-positive Tet proteins, TetA(L) from Bacillus subtilis and TetK from a Staphylococcus aureus plasmid, have previously been suggested to have multiple catalytic modes and roles. These include: tetracycline (Tc)-metal/H+ antiport for both proteins (Yamaguchi, A., Shiina, Y,, Fujihira, E., Sawai, T., Noguchi, N., and Sasatsu, M. (1995) FEES Lett. 365, 193-197; Cheng, J. Guffanti, A A., Wang, W., Krulwich, T. A., and Bechhofer, D. H. (1996) J. Bacteriol. 178, 2853-2860); Na+(K+)/H+ antiport for both proteins (Cheng ct at. (1996)); and an electrical potential-dependent K+ leak mode for TetK and highly truncated segments thereof that can facilitate net K+ uptake (Guay, G. G., Tuckman, M., McNicholas, P., and Rothstein, D. M. (1993) J. Bacteriol. 175, 4927-4929). Studies of membrane vesicles from Escherichia coli expressing low levels of complete and 3'-truncated versions of tetA(L) or tetK, now show that the full-length versions of both transporters catalyze electrogenic antiport and that demonstration of electrogenicity depends upon use of a low chloride buffer for the assay. The K+ uptake mode, assayed via Rb-86(+) uptake, was also catalyzed by both full-length TetA(L) and TetK. This mode does not represent a potential-dependent leak. Such a leak was not demonstrable in energized membrane vesicles. Rather, Rb+ uptake occurred in right-side-out vesicles when the intravesicular space contained either Na+ or K+ but not choline. If an outwardly directed gradient of Na+ or K+ was present, Rbi uptake occurred without energization in vesicles from cells transformed with a plasmid containing tetA(L) or tetK but not a control plasmid. Experiments in which a comparable exchange was carried out in low chloride buffers to which oxonol was added confirmed that the exchange was electrogenic. Thus, the K+ uptake mode is proposed to be a mode of the electrogenic monovalent cation/H+ antiport activity of TetA(L) and TetK in which K+ takes the place of the external protons. Truncated TetK and TetA(L) failed to catalyze either Tc-metal/H+ or Na+/H+ antiport in energized everted vesicles. Truncated TetK, but not TetA(L), did, however, exhibit modest, electrogenic Na+(K+)/Rb+ exchange as well as a small, potential-dependent leak of Rb+. The C-terminal halves of the TetA(L) and TetK proteins are thus required both for proton-coupled active transport activities of the multifunctional transporter and, perhaps, for minimizing cation leakiness.	CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Krulwich, TA (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem, Box 1020,1 Gustave L Levy Pl, New York, NY 10029 USA.				NIGMS NIH HHS [GM52837] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cheng JB, 1996, P NATL ACAD SCI USA, V93, P14446, DOI 10.1073/pnas.93.25.14446; CHENG JB, 1994, J BIOL CHEM, V269, P27365; Cheng JB, 1996, J BACTERIOL, V178, P2853, DOI 10.1128/jb.178.10.2853-2860.1996; Cheng JB, 1996, ANTIMICROB AGENTS CH, V40, P852, DOI 10.1128/AAC.40.4.852; DOSCH DC, 1984, J BACTERIOL, V160, P1188, DOI 10.1128/JB.160.3.1188-1190.1984; EPSTEIN W, 1993, BIOCHEM SOC T, V21, P1006, DOI 10.1042/bst0211006; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; FIJIHIRA E, 1997, FEBS LETT, V419, P211; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GRIFFITH JK, 1988, J BACTERIOL, V170, P598, DOI 10.1128/jb.170.2.598-604.1988; GRIFFITH JK, 1994, MOL MEMBR BIOL, V11, P271, DOI 10.3109/09687689409160437; GUAY GG, 1993, J BACTERIOL, V175, P4927, DOI 10.1128/JB.175.15.4927-4929.1993; GUFFANTI AA, 1995, J BACTERIOL, V177, P4557, DOI 10.1128/jb.177.15.4557-4561.1995; HARRINGTON CR, 1984, J BACTERIOL, V159, P925, DOI 10.1128/JB.159.3.925-933.1984; Hirata T, 1997, FEBS LETT, V412, P337, DOI 10.1016/S0014-5793(97)00796-5; IVEY DM, 1992, J BACTERIOL, V174, P4878, DOI 10.1128/JB.174.15.4878-4884.1992; JOLLIFFE LK, 1981, CELL, V25, P753, DOI 10.1016/0092-8674(81)90183-5; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KABACK HR, 1971, J BIOL CHEM, V246, P5523; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; KEYES SR, 1982, J BIOL CHEM, V257, P1172; LENSKI RE, 1994, J BACTERIOL, V176, P3140, DOI 10.1128/jb.176.11.3140-3147.1994; LEVY SB, 1992, ANTIMICROB AGENTS CH, V24, P1; MCMURRY LM, 1992, J BACTERIOL, V174, P6294, DOI 10.1128/JB.174.19.6294-6297.1992; MCNAB RM, 1987, BIOPHYS J, V52, P637; NAKAMURA T, 1986, J BIOL CHEM, V261, P678; NAKAMURA T, 1995, BIOL PHARM BULL, V18, P1189; PADAN E, 1989, J BIOL CHEM, V264, P20297; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; SCHULDINER S, 1975, BIOCHEMISTRY-US, V14, P5451, DOI 10.1021/bi00696a011; WAGGONER AS, 1979, ANNU REV BIOPHYS BIO, V8, P47, DOI 10.1146/annurev.bb.08.060179.000403; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1995, FEBS LETT, V365, P193, DOI 10.1016/0014-5793(95)00455-I; YAMAGUCHI A, 1991, ANTIMICROB AGENTS CH, V35, P53, DOI 10.1128/AAC.35.1.53; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490	35	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26447	26454		10.1074/jbc.273.41.26447	http://dx.doi.org/10.1074/jbc.273.41.26447			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756879	hybrid			2022-12-25	WOS:000076373300033
J	Huang, ZS; Wu, HN				Huang, ZS; Wu, HN			Identification and characterization of the RNA chaperone activity of hepatitis delta antigen peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMMERHEAD RIBOZYME CATALYSIS; VIRUS-RNA; SELF-CLEAVAGE; REPLICATION; PROTEIN; BINDING; GENOME; ASSOCIATION; EXPRESSION; SEQUENCES	In this study, we identified an activity of the hepatitis delta antigen that both modulates the cis-cleaving activities of hepatitis delta virus (HDV) genomic RNA fragments and facilitates the trans-cleavage reactions between hammerhead ribozymes and the cognate substrates of various lengths in vitro. Hepatitis delta antigen peptides exert their effect by accelerating the unfolding and refolding of RNA molecules and by promoting strand annealing and strand dissociation. In addition, the stimulatory effect of hepatitis delta antigen peptide on hammerhead catalysis is observed whether the peptide is removed or not by phenol/chloroform extraction prior to the initiation of trans-cleavage reaction. Therefore, hepatitis delta antigen peptide acts as an RNA chaperone. The RNA chaperone domain of hepatitis delta antigen overlaps with the coiled-coil domain that is rich in lysine residues. The RNA binding domains of hepatitis delta antigen previously identified are not required for the RNA chaperone activity identified herein. The RNA chaperone activity of hepatitis delta antigen may be important for the regulation of HDV replication in vivo.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Wu, HN (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.	hnwu@gate.sinica.edu.tw	Wu, Huey Nan/ABA-4484-2021	Wu, Huey Nan/0000-0002-1538-7776				BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; BONINO F, 1986, J VIROL, V58, P945, DOI 10.1128/JVI.58.3.945-950.1986; BONINO F, 1984, INFECT IMMUN, V43, P1000, DOI 10.1128/IAI.43.3.1000-1005.1984; CHANG MF, 1993, J VIROL, V67, P2529, DOI 10.1128/JVI.67.5.2529-2536.1993; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; COETZEE T, 1994, GENE DEV, V8, P1575, DOI 10.1101/gad.8.13.1575; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; Jeng KS, 1996, J VIROL, V70, P4205, DOI 10.1128/JVI.70.7.4205-4209.1996; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; LAZINSKI DW, 1993, J VIROL, V67, P2672, DOI 10.1128/JVI.67.5.2672-2680.1993; LEE CZ, 1995, J VIROL, V69, P5332, DOI 10.1128/JVI.69.9.5332-5336.1995; LEE CZ, 1993, J VIROL, V67, P2221, DOI 10.1128/JVI.67.4.2221-2227.1993; LIN JH, 1990, J VIROL, V64, P4051, DOI 10.1128/JVI.64.9.4051-4058.1990; MACNAUGHTON TB, 1993, J VIROL, V67, P2228, DOI 10.1128/JVI.67.4.2228-2234.1993; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; POISSON F, 1993, J GEN VIROL, V74, P2473, DOI 10.1099/0022-1317-74-11-2473; RIZZETTO M, 1980, P NATL ACAD SCI-BIOL, V77, P6124, DOI 10.1073/pnas.77.10.6124; ROSENSTEIN SP, 1991, NUCLEIC ACIDS RES, V19, P5409, DOI 10.1093/nar/19.19.5409; ROZZELLE JE, 1995, P NATL ACAD SCI USA, V92, P382, DOI 10.1073/pnas.92.2.382; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; WANG JG, 1993, J VIROL, V67, P446, DOI 10.1128/JVI.67.1.446-454.1993; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WEINER AJ, 1988, J VIROL, V62, P594, DOI 10.1128/JVI.62.2.594-599.1988; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831; WU HN, 1990, MOL CELL BIOL, V10, P5575, DOI 10.1128/MCB.10.10.5575	30	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26455	26461		10.1074/jbc.273.41.26455	http://dx.doi.org/10.1074/jbc.273.41.26455			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756880	hybrid			2022-12-25	WOS:000076373300034
J	Ishikawa, R; Yamashiro, S; Kohama, K; Matsumura, F				Ishikawa, R; Yamashiro, S; Kohama, K; Matsumura, F			Regulation of actin binding and actin bundling activities of fascin by caldesmon coupled with tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CULTURED-CELLS; SEA-URCHIN EGGS; NONMUSCLE CALDESMON; SMOOTH-MUSCLE; MULTIPLE ISOFORMS; TRANSFORMED-CELLS; ALPHA-ACTININ; CROSS-LINKS; PROTEIN; LOCALIZATION	Human fascin is an actin-bundling protein and is thought to play a role in the formation of microfilament bundles of microspikes and stress fibers in cultured cells. To explore the regulation of fascin-actin interaction, we have examined the effects of culture cell caldesmon and tropomyosin (TM) on actin binding activity of human fascin, Caldesmon alone or TM alone has little or no effect on the actin binding of fascin, However, caldesmon together with TM completely inhibits actin binding of human fascin, When calmodulin is added, the inhibition of fascin-actin interaction by caldesmon and TM becomes Ca2+ dependent because Ca2+/calmodulin blocks actin binding of caldesmon, Furthermore, as phosphorylation of caldesmon by cdc2 kinase inhibits actin binding of caldesmon, phosphorylation can also control actin binding of fascin in the presence of TM. As expected by the inhibition of fascin-actin binding, caldesmon coupled with TM also inhibits actin bundling activity of fascin, Whereas smooth muscle caldesmon alone or TM alone shows no effect, caldesmon together with TM completely inhibits actin bundling activity of fascin. This inhibition is again Ca2+ dependent when calmodulin is added to the system. These results suggest important roles for caldesmon and TM in the regulation of the function of human fascin.	Rutgers State Univ, Dept Mol Biol & Biochem, Nelson Lab, Piscataway, NJ 08854 USA; Gunma Univ, Sch Med, Dept Pharmacol, Maebashi, Gumma 3718511, Japan	Rutgers State University New Brunswick; Gunma University	Matsumura, F (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Nelson Lab, Busch Campus, Piscataway, NJ 08854 USA.	matsumura@mbcl.rutgers.edu		Matsumura, Fumio/0000-0002-8204-153X; Yamashiro, Shigeko/0000-0001-7207-9406	NCI NIH HHS [CA42742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042742, R01CA042742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRETSCHER A, 1985, J CELL BIOL, V100, P1656, DOI 10.1083/jcb.100.5.1656; BRYAN J, 1986, METHOD ENZYMOL, V134, P13; BRYAN J, 1993, P NATL ACAD SCI USA, V90, P9115, DOI 10.1073/pnas.90.19.9115; Cant K, 1996, GENETICS, V143, P249; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; CASTELLINO F, 1995, J CELL BIOL, V131, P1223, DOI 10.1083/jcb.131.5.1223; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; DEROSIER DJ, 1980, EXP CELL RES, V126, P490, DOI 10.1016/0014-4827(80)90295-5; EDWARDS RA, 1995, CELL MOTIL CYTOSKEL, V32, P1, DOI 10.1002/cm.970320102; FRANZA BR, 1984, CANCER CELL, P137; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KANE RE, 1975, J CELL BIOL, V66, P305, DOI 10.1083/jcb.66.2.305; KOJIOWADA M, 1984, P NATL ACAD SCI USA, V81, P3133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb NJC, 1996, EUR J CELL BIOL, V69, P36; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; Lehman W, 1997, J MOL BIOL, V274, P310, DOI 10.1006/jmbi.1997.1422; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; LIN JJC, 1988, J CELL BIOL, V107, P563, DOI 10.1083/jcb.107.2.563; LIN JJC, 1984, CANCER CELL, V1, P57; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MATSUMURA F, 1985, J BIOL CHEM, V260, P3851; MATSUMURA F, 1986, J BIOL CHEM, V261, P4655; MATSUMURA F, 1983, J BIOL CHEM, V258, P6636; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MOSIALOS G, 1994, J VIROL, V68, P7320, DOI 10.1128/JVI.68.11.7320-7328.1994; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; NOVY RE, 1991, J BIOL CHEM, V266, P16917; OKAGAKI T, 1991, J BIOCHEM, V109, P858, DOI 10.1093/oxfordjournals.jbchem.a123471; Ono S, 1997, J BIOL CHEM, V272, P2527; OTTO JJ, 1979, CELL, V17, P285, DOI 10.1016/0092-8674(79)90154-5; OTTO JJ, 1994, CURR OPIN CELL BIOL, V6, P105, DOI 10.1016/0955-0674(94)90123-6; OTTO JJ, 1980, CELL MOTIL CYTOSKEL, V1, P31, DOI 10.1002/cm.970010104; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; Sasaki Y, 1996, J NEUROCHEM, V66, P980; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1991, J BIOL CHEM, V266, P12115; STEINHARDT R, 1977, DEV BIOL, V58, P185, DOI 10.1016/0012-1606(77)90084-7; TemmGrove CJ, 1996, CELL MOTIL CYTOSKEL, V33, P223, DOI 10.1002/(SICI)1097-0169(1996)33:3<223::AID-CM6>3.0.CO;2-B; TILNEY LG, 1995, J CELL BIOL, V130, P629, DOI 10.1083/jcb.130.3.629; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; VEIGL ML, 1983, BIOCHIM BIOPHYS ACTA, V738, P21, DOI 10.1016/0304-419X(84)90018-0; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WARREN KS, 1994, J CELL BIOL, V125, P359, DOI 10.1083/jcb.125.2.359; Warren KS, 1996, CELL MOTIL CYTOSKEL, V34, P215, DOI 10.1002/(SICI)1097-0169(1996)34:3<215::AID-CM5>3.0.CO;2-8; Yamakita Y, 1996, J BIOL CHEM, V271, P12632, DOI 10.1074/jbc.271.21.12632; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; YAMASHIRO S, 1994, INT C BIOPH BIOCH CE, P113; YAMASHIRO-MATSUMURA S, 1988, Protoplasma Supplementum, V2, P9; YAMASHIROMATSUMURA S, 1988, J CELL BIOL, V106, P1973, DOI 10.1083/jcb.106.6.1973; YAMASHIROMATSUMURA S, 1986, J CELL BIOL, V103, P631, DOI 10.1083/jcb.103.2.631; YAMASHIROMATSUMURA S, 1985, J BIOL CHEM, V260, P5087	59	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26991	26997		10.1074/jbc.273.41.26991	http://dx.doi.org/10.1074/jbc.273.41.26991			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756949	hybrid			2022-12-25	WOS:000076373300103
J	Discher, DJ; Bishopric, NH; Wu, XS; Peterson, CA; Webster, KA				Discher, DJ; Bishopric, NH; Wu, XS; Peterson, CA; Webster, KA			Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN GENE-EXPRESSION; DEPENDENT PROTEIN-KINASE; RESPONSIVE ELEMENT; TRANSCRIPTIONAL REGULATION; INDUCIBLE FACTOR-1; CARDIAC MYOCYTES; NUCLEAR-PROTEIN; MAIZE ADH1; ACTIVATION; SP3	The transcription rates of glycolytic enzyme genes are coordinately induced when cells are exposed to low oxygen tension. This effect has been described in many cell types and is not restricted to species or phyla. In mammalian cells, there are 11 distinct glycolytic enzymes, at least 9 of which are induced by hypoxia. Recent reports described a role for the hypoxia-inducible factor-1 (HIF-1) in the transcriptional activation of lactate dehydrogenase A, aldolase-A, phosphoglycerate kinase, and enolase-l genes. It is not known whether the HIF-1 factor acts exclusively to regulate these genes during hypoxia, or how the other genes of the pathway are regulated. In this paper, we describe analyses of the muscle-specific pyruvate kinase-M and beta-enolase promoters that implicate additional mechanisms for the regulation of glycolytic enzyme gene transcription by hypoxia, Transient transcription of a reporter gene directed by either promoter was activated when transfected muscle cells were exposed to hypoxia. Neither of these promoters contain HIF-1 binding sites. Instead, the hypoxia response was localized to a conserved GC-rich element positioned immediately upstream of a GATAA site in the proximal promoter regions of both genes. The GC element was essential for both basal and hypoxia-induced expression and bound the transcription factors Spl and Sp3. Hypoxia caused the progressive depletion of Sp3 determined by DNA binding studies and Western analyses, whereas Spl protein levels remained unchanged, Overexpression of Sp3 repressed expression of p-enolase promoters. It is concluded that hypoxia activates these glycolytic enzyme gene promoters by down-regulating Sp3, thereby removing the associated transcriptional repression.	Univ Miami, Med Ctr, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; SRI Int, Pharmaceut Discovery, Menlo Park, CA 94025 USA; Univ Arkansas Med Sch, Vet Adm Hosp, Dept Med, Little Rock, AR 72205 USA	University of Miami; SRI International; University of Arkansas System; University of Arkansas Medical Sciences	Webster, KA (corresponding author), Univ Miami, Med Ctr, Dept Mol Pharmacol, Rosenstiel Med Sci Bldg,Rm 6038,1600 NW 10th Av, Miami, FL 33136 USA.	kwebster@chroma.med.miami.edu		Webster, Keith A/0000-0002-6431-3642	NHLBI NIH HHS [HL44578, HL49891] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044578, R01HL044578, R01HL049891] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARONSON RM, 1995, J BIOL CHEM, V270, P27752, DOI 10.1074/jbc.270.46.27752; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bodi I, 1995, CARDIOVASC RES, V30, P975, DOI 10.1016/S0008-6363(95)00164-6; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DENNIS ES, 1988, J MOL BIOL, V202, P759, DOI 10.1016/0022-2836(88)90556-6; FERL RJ, 1987, J BIOL CHEM, V262, P7947; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GOOD AG, 1992, PLANT MOL BIOL, V19, P693, DOI 10.1007/BF00026795; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Ho VT, 1996, BIOCHEM BIOPH RES CO, V223, P175, DOI 10.1006/bbrc.1996.0865; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KOIZUMI S, 1992, EUR J BIOCHEM, V210, P555, DOI 10.1111/j.1432-1033.1992.tb17454.x; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; OLIVE MR, 1991, NUCLEIC ACIDS RES, V19, P7053, DOI 10.1093/nar/19.25.7053; Prentice H, 1997, CARDIOVASC RES, V35, P567, DOI 10.1016/S0008-6363(97)00158-2; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHANNA YL, 1995, CIRC RES, V77, P638; SMITH A, 1993, J BIOL CHEM, V268, P7365; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; TAYLOR JM, 1995, J BIOL CHEM, V270, P2535, DOI 10.1074/jbc.270.6.2535; WALKER JC, 1987, P NATL ACAD SCI USA, V84, P6624, DOI 10.1073/pnas.84.19.6624; WEBSTER KA, 1990, MOL CELL BIOL, V10, P2402, DOI 10.1128/MCB.10.5.2402; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WEBSTER KA, 1988, CAN J ZOOL, V66, P1046, DOI 10.1139/z88-155; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WEBSTER KA, 1992, J MOL CELL CARDIOL, V24, P741, DOI 10.1016/0022-2828(92)93388-Z; Wu XS, 1996, MOL CELL BIOL, V16, P1035; YOUSSOUFIAN H, 1994, BLOOD, V83, P1428	44	146	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26087	26093		10.1074/jbc.273.40.26087	http://dx.doi.org/10.1074/jbc.273.40.26087			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748288	hybrid			2022-12-25	WOS:000076263100079
J	Glick, JL; Meigs, TE; Miron, A; Casey, PJ				Glick, JL; Meigs, TE; Miron, A; Casey, PJ			RGSZ1, a G(z)-selective regulator of G protein signaling whose action is sensitive to the phosphorylation state of G(z)alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; ALPHA-SUBUNITS; BINDING PROTEIN; PERTUSSIS TOXIN; HUMAN-PLATELETS; 2-HYBRID SYSTEM; BOVINE BRAIN; BETA-GAMMA; RAT-BRAIN	Regulators of G protein signaling (RGS) are a family of proteins that attenuate the activity of the trimeric G proteins, RGS proteins act as GTPase-activating proteins (GAPs) for the alpha subunits of several trimeric G proteins, much like the GAPs that regulate the activity of monomeric G proteins such as Ras. RGS proteins have been cloned from many eukaryotes, and those whose biochemical activity has been characterized regulate the members of the G(i) family of G proteins; some forms can also act on G(q) proteins. In an ongoing effort to elucidate the role of G(z)alpha in cell signaling, the yeast two-hybrid system was employed to identify proteins that could interact with a mutationally activated form of G(z)alpha. A novel RGS, termed RGSZ1, was identified that is most closely related to two existing RGS proteins termed RetRGS1 and GAIP. Northern blot analysis revealed that expression of RGSZ1 was Limited to brain, and expression was particularly high in the caudate nucleus. Biochemical characterization of recombinant RGSZ1 protein revealed that RGSZ1 was indeed a GAP and, most significantly, showed a marked preference for G(z)alpha over other members of the G(i)alpha family. Phosphorylation of G(z)alpha by protein kinase C, an event known to occur in cells and that was previously shown to influence alpha-beta gamma interactions of G(z), rendered the G protein much less susceptible to RGSZ1 action.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Expt Surg, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	pjc@galactose.mc.duke.edu		Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Bai C, 1997, METHOD ENZYMOL, V283, P141; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DOHLMAN HG, 1998, BIOCHEMISTRY-US, V37, P4815; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Fields TA, 1998, CELL SIGNAL, V10, P43, DOI 10.1016/S0898-6568(97)00071-5; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GAGNON AW, 1991, BLOOD, V78, P1247; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gold SJ, 1997, J NEUROSCI, V17, P8024; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; HALL A, 1986, J BIOL CHEM, V261, P963; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; JONES DT, 1987, J BIOL CHEM, V262, P14241; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Nomoto S, 1997, BIOCHEM BIOPH RES CO, V241, P281, DOI 10.1006/bbrc.1997.7802; Pupier S, 1997, J NEUROSCI, V17, P2722; SCHIMPFF SC, 1993, SUPPORT CARE CANCER, V1, P5, DOI 10.1007/BF00326634; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	47	110	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26008	26013		10.1074/jbc.273.40.26008	http://dx.doi.org/10.1074/jbc.273.40.26008			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748279	hybrid			2022-12-25	WOS:000076263100070
J	Komarova, EA; Diatchenko, L; Rokhlin, OW; Hill, JE; Wang, ZJ; Krivokrysenko, VI; Feinstein, E; Gudkov, AV				Komarova, EA; Diatchenko, L; Rokhlin, OW; Hill, JE; Wang, ZJ; Krivokrysenko, VI; Feinstein, E; Gudkov, AV			Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53	ONCOGENE			English	Article						p53; transcription; secretion; growth inhibition; radiation; chemotherapy	CELL-CYCLE; IN-VIVO; APOPTOSIS; FIBROBLASTS; GENE; RADIATION; ANGIOGENESIS; MICE	p53 tumor suppressor gene controls cell response to a variety of stresses inducing growth arrest or apoptosis in damaged cells. It largely determines the sensitivity of tumor and normal cells to radiation and chemotherapy, and, therefore, defines both the efficacy and limitations of anti-cancer treatment. To determine molecular mechanisms of p53-dependent stress response in normal tissues we identified and compared the spectra of radiation-responsive genes in cells of different origin and p53 status using a cDNA array hybridization technique. The majority of genes identified were p53-dependent and cell type specific, Several of the new p53 responders encode known secreted growth inhibitory factors, This suggests that p53, in addition to its intrinsic antiproliferation activity, can cause 'bystander effect' by inducing export of growth suppressive stimuli from damaged cells to neighboring cells. Consistently, a p53-dependent accumulation of factors, which causes growth inhibitory effects in a variety of cell lines, was found after gamma irradiation in the media from established and primary cell cultures and in the urine of irradiated mice. Moreover, p53-dependent factors released by normal human fibroblasts potentiated the cytotoxic effect of a chemotherapeutic drug on co-cultivated tumor cells. This suggests a previously unknown role for normal cells in chemo- and radiation therapy of cancer.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; CLONTECH Labs Inc, Palo Alto, CA 94303 USA; Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; QBI Enterprises Ltd, IL-74106 Ness Ziona, Israel	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Iowa	Gudkov, AV (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154; Hill, Jason/0000-0003-2512-1661	NATIONAL CANCER INSTITUTE [R01CA060730, R01CA075179] Funding Source: NIH RePORTER; NCI NIH HHS [CA60730, CA75179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adolph KW, 1997, GENE, V193, P5, DOI 10.1016/S0378-1119(97)00070-X; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GULLINO PM, 1995, ACTA ONCOL, V34, P439, DOI 10.3109/02841869509094005; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HERMEKING H, 1997, MOL CELL, V1, P1; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACCALLUM DE, 1996, ONCOGENE, V13, P2545; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MIYASHITA T, 1995, CELL, V80, P293; Nikiforov MA, 1997, ONCOGENE, V15, P3007, DOI 10.1038/sj.onc.1201723; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; OBRIEN PM, 1960, CANCER, V23, P451; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Qazilbash MH, 1997, GENE THER, V4, P675, DOI 10.1038/sj.gt.3300444; Rokhlin OW, 1997, CANCER RES, V57, P1758; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	32	120	126	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1089	1096		10.1038/sj.onc.1202303	http://dx.doi.org/10.1038/sj.onc.1202303			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764819				2022-12-25	WOS:000075598400004
J	Holmgren, L; Jackson, G; Arbiser, J				Holmgren, L; Jackson, G; Arbiser, J			P53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma	ONCOGENE			English	Article						angiogenesis; dormancy; neoplasia	WILD-TYPE P53; ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; IN-VIVO; EXPRESSION; CANCER; CELLS; APOPTOSIS; INHIBITOR; SUPPRESSION	The p53 tumor-suppressor gene is inactivated in over 50% of all human cancers, In normal cells, p53 induces growth arrest and apoptosis in response to DNA damage. We show that p53 acts as potent tumor-suppressor gene independent of its well-documented effects on tumor-cell proliferation and apoptosis. p53 activates target genes in a murine fibrosarcoma cell-line but does not affect tumor cell-cycle progression or survival. Exogenous expression of wt-p53 does, however, block the angiogenic potential of the tumor cells resulting in formation of dormant tumors in vivo. These data provide evidence that: (1) p53 acts as a tumor suppressor gene independent of its anti-proliferative effects; (2) By inhibiting angiogenesis p53 can indirectly induce apoptosis in vivo but not in vitro; (3) p53-gene therapy which alters a tumors angiogenic potential, can revert tumors to a dormant phenotype.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Harvard Univ, Childrens Hosp, Sch Med, Surg Res Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA	Karolinska Institutet; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Holmgren, L (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.							Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Folkman J, 1995, MOL BASIS CANC, P206; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Holmgren L, 1996, CANCER METAST REV, V15, P241, DOI 10.1007/BF00437478; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEYER JL, 1985, INT J RADIAT ONCOL, V11, P973, DOI 10.1016/0360-3016(85)90120-8; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; RAK J, 1995, CANCER RES, V55, P4575; Sambrook J., 2002, MOL CLONING LAB MANU; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TANAKA T, 1996, ANGIOGENESIS ANTAGON; TEICHER BA, 1992, CANCER RES, V52, P6702; Teicher BA, 1994, RADIAT ONCOL INVEST, V2, P269, DOI DOI 10.1002/ROI.2970020604; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG WW, 1994, CANCER GENE THER, V1, P5	28	40	42	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					819	824		10.1038/sj.onc.1201993	http://dx.doi.org/10.1038/sj.onc.1201993			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9779998				2022-12-25	WOS:000075448800003
J	Koga, H; Araki, N; Takeshima, H; Nishi, T; Hirota, T; Kimura, Y; Nakao, M; Saya, H				Koga, H; Araki, N; Takeshima, H; Nishi, T; Hirota, T; Kimura, Y; Nakao, M; Saya, H			Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain	ONCOGENE			English	Article						NF2 gene; MBPs binding domain; exon-missing; protein truncation test (PTT); nuclear microinjection	PROTEIN TRUNCATION TEST; COLI APC GENE; TUMOR-SUPPRESSOR; ADENOMATOUS POLYPOSIS; MUTATION; PRODUCT; MEMBRANE; MERLIN; CYTOSKELETON; SCHWANNOMAS	Neurofibromatosis 2 (NF2) is an inherited disorder characterized by a predisposition to multiple intracranial tumors. The protein encoded by the NF2 gene has striking similarities to ezrin, radixin and moesin (ERM) proteins which link membrane proteins to the cytoskeleton, Therefore, it can be speculated that the disruption of cytoskeletal organization by alterations in the Nn gene is involved in the development of tumors. It has been reported that the majority of NF2 mutations were nonsense or frameshift mutations that result in premature termination of translation. To facilitate the detection of these mutations, we performed protein truncation test and found that 11 of 14 NF2 patients had truncational mutations (79%). Seven of the 11 patients (64%) had a splicing abnormality which lead to absence of exons in the ERM homology domain. To examine the biological significance of the exon-missing mutations in the ERM homology domain, we expressed the wild-type (wt-NF2) and the various mutant NF2s (mu-NF2s) in a fibroblast cell line by using both liposome-mediated transfection and nuclear microinjection of the expression plasmids, The wt-NF2 showed intense punctate staining in the perinuclear cytoplasm in addition to overall staining of the submembranous area, whereas the mu-NF2s lacking exons in the ERM homology domain showed granular staining at the perinuclear region without any accumulation at the submembrane region. Microinjection of wt-NF2 cDNA into the nucleus of VA13 cells revealed that wt-NF2 protein induced a progressive elongation of cell processes. Furthermore, cells that expressed mu-NF2 had decreased adhesion, which resulted in detachment from the substratum. These findings suggested that the exon-missing mutations in the ERM-homology domain may affect cell membrane-cytoskeleton signaling and consequently disrupt cell-to-cell or cell-to-matrix interaction.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 860, Japan; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 860, Japan	Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 860, Japan.		Saya, Hideyuki/J-4325-2013					ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; Bala S, 1996, HUM GENET, V98, P528, DOI 10.1007/s004390050254; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; DENBAKKER MA, 1995, ONCOGENE, V10, P757; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; DeVitis LR, 1996, HUM GENET, V97, P632; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MACCOLLIN M, 1994, AM J HUM GENET, V55, P314; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; Nishi T, 1997, INT J ONCOL, V10, P1025; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBIO MP, 1994, CANCER RES, V54, P45; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.3.CO;2-2; SIEBERT PD, 1993, NUCLEIC ACIDS RES, V21, P2019, DOI 10.1093/nar/21.8.2019; StemmerRachamimov AO, 1997, J NEUROPATH EXP NEUR, V56, P735; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; Welling DB, 1996, HUM GENET, V98, P189, DOI 10.1007/s004390050188	26	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					801	810		10.1038/sj.onc.1202010	http://dx.doi.org/10.1038/sj.onc.1202010			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9779996				2022-12-25	WOS:000075448800001
J	Sanjo, H; Kawai, T; Akira, S				Sanjo, H; Kawai, T; Akira, S			DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DAP-KINASE; EXPRESSION; INDUCTION; IDENTIFICATION; CASPASES; SAPK/JNK; GENE	The present study describes the cloning of two novel serine/threonine kinases termed DRAK1 and DRAK2, whose catalytic domains are related to that of death-associated protein kinase, a serine/threonine kinase involved in apoptosis, Both DRAKs are composed of the N-terminal catalytic domain and the C-terminal domain that is responsible for regulation of kinase activity. DRAK1 and DRAK2 show 59.7% identity and display ubiquitous expression. An in vitro kinase assay revealed that both DRAKs are autophosphorylated and phosphorylate myosin light chain as an exogenous substrate, although the kinase activity of DRAK2 is significantly lower than that of DRAK1. Both DRAKs are exclusively localized to the nucleus. Furthermore, overexpression of both DRAKs induces the morphological changes of apoptosis in NIH 3T3 cells, suggesting the role of DRAKs in apoptotic signaling.	Hyogo Coll Med, Dept Biochem, Nishinomiya, Hyogo 6638501, Japan	Hyogo College of Medicine	Akira, S (corresponding author), Hyogo Coll Med, Dept Biochem, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	akira@hyo-med.ac.jp	Akira, Shizuo/C-3134-2009	Kawai, Taro/0000-0001-7510-4662				Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; ASKEW DS, 1991, ONCOGENE, V6, P1915; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SYMONDS H, 1994, CELL, V78, P708; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Wright SC, 1997, FASEB J, V11, P843, DOI 10.1096/fasebj.11.11.9285482; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	26	159	170	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29066	29071		10.1074/jbc.273.44.29066	http://dx.doi.org/10.1074/jbc.273.44.29066			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786912	hybrid			2022-12-25	WOS:000076691800073
J	Szymanska, G; Leszyk, JD; O'Connor, CM				Szymanska, G; Leszyk, JD; O'Connor, CM			Carboxyl methylation of deamidated calmodulin increases its stability in Xenopus oocyte cytoplasm - Implications for protein repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ISOASPARTYL RESIDUES; MULTIPLE UBIQUITINATION; SPONTANEOUS DEGRADATION; VERTEBRATE CALMODULIN; COVALENT MODIFICATION; ASPARAGINYL RESIDUES; O-METHYLTRANSFERASE; ASPARTYL RESIDUES; LAEVIS OOCYTES; BINDING DOMAIN	The widely distributed protein-L-isoaspartate(D-aspartate) O-methyltransferase (PIMT; EC 2.1.1.77) is postulated to play a role in the repair or metabolism of damaged cellular proteins containing L-isoaspartyl residues derived primarily from the spontaneous deamidation of protein asparaginyl residues. To evaluate the functional consequence of PIMT-catalyzed methylation on the stability of isoaspartyl-containing proteins in cells, Xenopus laevis oocytes were microinjected with both deamidated and nondeamidated forms of recombinant chicken calmodulin (CaM) containing a hemagglutinin (HA) epitope at its N terminus. Processing of HA-CaM was monitored by electrophoretic analysis and Western blotting of oocyte extracts. The experiments indicate that deamidated HA-CaM is degraded after microinjection, while nondeamidated HA-CaM is stable. Kinetic analysis is consistent with the entry of microinjected HA-CaM into two intracellular pools with distinct hydrolytic stabilities. The larger, more stable pool may consist of HA CaM bound to the heterogeneous pool of oocyte CaM binding proteins detected by an overlay procedure. Enzymatic methylation of deamidated HA-CaM with purified PIMT prior to injection results in its stabilization. Conversely, inhibition of endogenous oocyte PIMT with sinefungin, a nonhydrolyzable analog of S-adenosylhomocysteine, increases the rate of deamidated HA-CaM degradation. These results are consistent with a role for PIMT-catalyzed methylation in the repair of damaged cellular proteins.	Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA; Univ Massachusetts, Med Ctr, Core Lab Prot Sequencing & Mass Spectrometry, Shrewsbury, MA 01545 USA	Boston College; University of Massachusetts System	O'Connor, CM (corresponding author), Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA.		O'Connor, Clare/A-1679-2010	O'Connor, Clare/0000-0002-7201-647X	NATIONAL INSTITUTE ON AGING [R01AG008109] Funding Source: NIH RePORTER; NIA NIH HHS [AG08109] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARTIGUES A, 1993, J BIOL CHEM, V268, P13784; Aswad DW, 1989, CURR OPIN CELL BIOL, V1, P1182, DOI 10.1016/S0955-0674(89)80069-9; ASWAD DW, 1983, J NEUROCHEM, V41, P1702, DOI 10.1111/j.1471-4159.1983.tb00883.x; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BISCHOFF R, 1994, J CHROMATOGR B, V662, P261, DOI 10.1016/0378-4347(94)00203-7; BORCHARDT RT, 1979, BIOCHEM BIOPH RES CO, V89, P919, DOI 10.1016/0006-291X(79)91866-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN TV, 1994, J BIOL CHEM, V269, P24586; BRUNAUER LS, 1986, BIOCHEM J, V236, P811, DOI 10.1042/bj2360811; CHAZIN WJ, 1989, BIOCHEMISTRY-US, V28, P8646, DOI 10.1021/bi00447a055; CICERELLI MF, 1908, DEV BIOL, V113, P174; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; DESROSIERS RR, 1990, J BIOL CHEM, V265, P21368; GEIGER T, 1987, J BIOL CHEM, V262, P785; GEORGENASCIMENTO C, 1990, BIOCHEMISTRY-US, V29, P9584, DOI 10.1021/bi00493a012; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREGORI L, 1987, J BIOL CHEM, V262, P2562; JOHNSON BA, 1991, BIOCHEM INT, V24, P841; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1989, ARCH BIOCHEM BIOPHYS, V268, P276, DOI 10.1016/0003-9861(89)90589-4; JOHNSON BA, 1989, J BIOL CHEM, V264, P14262; Kagan RM, 1997, COMP BIOCHEM PHYS B, V117, P379, DOI 10.1016/S0305-0491(96)00333-1; KELLY GM, 1991, J BIOL CHEM, V266, P12469; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LIU DTY, 1992, TRENDS BIOTECHNOL, V10, P364, DOI 10.1016/0167-7799(92)90269-2; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MURTAUGH TJ, 1986, J NEUROCHEM, V47, P164; OCONNOR CM, 1987, J BIOL CHEM, V262, P10404; OCONNOR CM, 1987, J BIOL CHEM, V262, P10398; OTA IM, 1990, ARCH BIOCHEM BIOPHYS, V279, P320, DOI 10.1016/0003-9861(90)90498-N; OTA IM, 1989, J BIOL CHEM, V264, P54; OTA IM, 1989, BIOCHEMISTRY-US, V28, P4020, DOI 10.1021/bi00435a058; POTTER SM, 1993, PROTEIN SCI, V2, P1648, DOI 10.1002/pro.5560021011; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; ROMANIK EA, 1989, J BIOL CHEM, V264, P14050; RUNTE L, 1982, FEBS LETT, V147, P125, DOI 10.1016/0014-5793(82)81025-9; Schrama LH, 1997, NEUROSCIENCE, V76, P635, DOI 10.1016/S0306-4522(96)00400-9; Siegel F.L., 1988, Advances in Experimental Medicine and Biology, V231, P341; SLAUGHTER GR, 1987, METHOD ENZYMOL, V139, P133; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; Szymanska G, 1997, ANAL BIOCHEM, V252, P96, DOI 10.1006/abio.1997.2319; WALLACE RA, 1973, J EXP ZOOL, V184, P321, DOI 10.1002/jez.1401840305; WALSH M, 1977, J BIOL CHEM, V252, P7440; ZIEGENHAGEN R, 1988, BIOL CHEM H-S, V369, P1317, DOI 10.1515/bchm3.1988.369.2.1317; ZIEGENHAGEN R, 1990, FEBS LETT, V271, P71, DOI 10.1016/0014-5793(90)80374-R	49	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28516	28523		10.1074/jbc.273.43.28516	http://dx.doi.org/10.1074/jbc.273.43.28516			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774482	hybrid			2022-12-25	WOS:000076549800102
J	Corey, S; Clapham, DE				Corey, S; Clapham, DE			Identification of native atrial G-protein-regulated inwardly rectifying K(+) (GIRK4) channel homomultimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; BETA-GAMMA-SUBUNITS; ADULT-RAT BRAIN; POTASSIUM CHANNELS; I-KACH; RECTIFIER; LOCALIZATION; EXPRESSION; CIR; STOICHIOMETRY	G-protein-regulated inwardly rectifying K(+) (GIRK) channels play critical inhibitory roles throughout the nervous system, heart, and pancreas. They are believed to be heterotetramers consisting of GIRK1 (Kir3.1) and either GIRK2 (Kir3.2), GIRKB (Kir3.3), or GIRK4 (Kir3.4) subunits. The GIRK1 subunit is hypothesized to be critical to form GIRK channels with normal channel kinetics based on heterologous expression studies. However, GIRK2 and GIRK3 proteins are present in areas of the brain where no GIRK1 has been detected. Here we demonstrate that GIRK tetramers lacking GIRK1 can be purified from bovine heart atria. We have found that only half of GIRK4 is purified as the GIRK1-GIRK4 heterotetramer, whereas the remaining GIRK4 forms a high molecular weight, SDS-resistant complex that does not contain GIRK1. These GIRK4 complexes, most likely GIRK4 homotetramers, were previously not seen because of their aberrant migration on SDS-polyacrylamide gels. We propose that all of GIRK1 and half of GIRK4 proteins in atria combine to form the heterotetramer I(KACh), whereas the remaining GIRK4 forms a novel tetrameric complex. GIRK4 homotetramers form channels with unusual single channel behavior, and their contribution to native currents requires further investigation.	Harvard Univ, Childrens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA; Mayo Clin & Mayo Fdn, Program Neurosci, Rochester, MN 55905 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Mayo Clinic	Clapham, DE (corresponding author), Howard Hughes Med Inst, 1309 Enders,320 Longwood Ave, Boston, MA 02115 USA.	clapham@rascal.med.harvard.edu	Clapham, David/S-1123-2019; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; 				Arkin IT, 1998, BBA-BIOMEMBRANES, V1369, P131, DOI 10.1016/S0005-2736(97)00219-8; Barry DM, 1996, ANNU REV PHYSIOL, V58, P363, DOI 10.1146/annurev.ph.58.030196.002051; Bausch SB, 1995, RECEPTOR CHANNEL, V3, P221; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; Dissmann E, 1996, BIOCHEM BIOPH RES CO, V223, P474, DOI 10.1006/bbrc.1996.0918; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FUJII J, 1989, J BIOL CHEM, V264, P12950; HALTIA T, 1995, BBA-BIOENERGETICS, V1228, P1, DOI 10.1016/0005-2728(94)00161-W; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Iizuka M, 1997, NEUROSCIENCE, V77, P1, DOI 10.1016/S0306-4522(96)00460-5; Iizuka M, 1995, RECEPTOR CHANNEL, V3, P299; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Ji S, 1998, J BIOL CHEM, V273, P1324, DOI 10.1074/jbc.273.3.1324; Karschin C, 1996, J NEUROSCI, V16, P3559; KARSCHIN C, 1994, FEBS LETT, V348, P139, DOI 10.1016/0014-5793(94)00590-7; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; Liao YJ, 1996, J NEUROSCI, V16, P7137; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Murer G, 1997, NEUROSCIENCE, V80, P345, DOI 10.1016/S0306-4522(97)00001-8; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; Ponce A, 1996, J NEUROSCI, V16, P1990; Signorini S, 1997, P NATL ACAD SCI USA, V94, P923, DOI 10.1073/pnas.94.3.923; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; Tucker SJ, 1996, AM J PHYSIOL-HEART C, V271, pH379, DOI 10.1152/ajpheart.1996.271.1.H379; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614	46	77	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27499	27504		10.1074/jbc.273.42.27499	http://dx.doi.org/10.1074/jbc.273.42.27499			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765280	hybrid			2022-12-25	WOS:000076448000067
J	Little, MJ; Zappia, C; Gilles, N; Connor, M; Tyler, MI; Martin-Eauclaire, MF; Gordon, D; Nicholson, GM				Little, MJ; Zappia, C; Gilles, N; Connor, M; Tyler, MI; Martin-Eauclaire, MF; Gordon, D; Nicholson, GM			delta-atracotoxins from Australian funnel-web spiders compete with scorpion alpha-toxin binding but differentially modulate alkaloid toxin activation of voltage-gated sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE-ENDING PARTICLES; HIGH-AFFINITY BINDING; AMINO-ACID SEQUENCE; RAT-BRAIN; RECEPTOR-SITE; CURRENT INACTIVATION; LETHAL NEUROTOXIN; NA+ CHANNELS; VENOM; VERATRIDINE	delta-Atracotoxins from the venom of Australian funnel-web spiders are a unique group of peptide toxins that slow sodium current inactivation in a manner similar to scorpion alpha-toxins. To analyze their interaction with known sodium channel neurotoxin receptor sites, we studied their effect on [H-3]batrachotoxin and I-125-Lqh II (where Lqh is alpha-toxin II from the venom of the scorpion Leiurus quinquestriatus hebraeus) binding and on alkaloid toxin-stimulated Na-22(+) uptake in rat brain synaptosomes. delta-Atracotoxins significantly increased [H-3]batrachotoxin binding yet decreased maximal batrachotoxin-activated Na-22(+) uptake by 70-80%, the latter in marked contrast to the effect of scorpion alpha-toxins, Unlike the inhibition of batrachotoxin-activated Na-22(+) uptake, delta-atracotoxins increased veratridine-stimulated Na-22(+) uptake by converting veratridine from a partial to a full agonist, analogous to scorpion alpha-toxins. Hence, delta-atracotoxins are able to differentiate between the open state of the sodium channel stabilized by batrachotoxin and veratridine and suggest a distinct sub-conductance state stabilized by delta-atracotoxins. Despite these actions, low concentrations of delta-atracotoxins completely inhibited the binding of the scorpion alpha-toxin, I-125-Lqh Ht indicating that they bind to similar, or partially overlapping, receptor sites. The apparent uncoupling between the increase in binding but inhibition of the effect of batrachotoxin induced by delta-atracotoxins suggests that the binding and action of certain alkaloid toxins may represent at least two distinguishable steps. These results further contribute to the understanding of the complex dynamic interactions between neurotoxin receptor site areas related to sodium channel gating.	Univ Technol Sydney, Dept Hlth Sci, Broadway, NSW 2007, Australia; Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia; CSIRO, Div Food Proc, N Ryde, NSW 2113, Australia; Univ Mediterranee, Biochim Lab, UMR 6560 CNRS, IFR Jean Roche, F-13916 Marseille 20, France; CENS, CEA, Dept Ingn & Etud Prot, F-91911 Gif Sur Yvette, France	University of Technology Sydney; University of Sydney; Commonwealth Scientific & Industrial Research Organisation (CSIRO); UDICE-French Research Universities; Aix-Marseille Universite; CEA; UDICE-French Research Universities; Universite Paris Saclay	Nicholson, GM (corresponding author), Univ Technol Sydney, Dept Hlth Sci, POB 123, Broadway, NSW 2007, Australia.	Graham.Nicholson@uts.edu.au	Nicholson, Graham M/E-8136-2010; Connor, Mark/A-4197-2008	Nicholson, Graham M/0000-0002-4277-4296; Connor, Mark/0000-0003-2538-2001				BROWN MR, 1988, BIOCHEM J, V250, P401, DOI 10.1042/bj2500401; CATTERALL WA, 1981, J BIOL CHEM, V256, P8922; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CATTERALL WA, 1977, J BIOL CHEM, V252, P8669; CESTELE S, 1995, J BIOL CHEM, V270, P15153, DOI 10.1074/jbc.270.25.15153; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Connor M, 1998, J PHYSIOL-LONDON, V509, P47, DOI 10.1111/j.1469-7793.1998.047bo.x; CORREA AM, 1991, J GEN PHYSIOL, V97, P605, DOI 10.1085/jgp.97.3.605; COURAUD F, 1986, J NEUROSCI, V6, P192; EITAN M, 1990, BIOCHEMISTRY-US, V29, P5941, DOI 10.1021/bi00477a009; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; Felts PA, 1997, MOL BRAIN RES, V45, P71, DOI 10.1016/S0169-328X(96)00241-0; Fletcher JI, 1997, STRUCTURE, V5, P1525, DOI 10.1016/S0969-2126(97)00301-8; Fletcher JI, 1997, NAT STRUCT BIOL, V4, P559, DOI 10.1038/nsb0797-559; FLETCHER JI, 1998, IN PRESS PERSPECTIVE; FONTECILLACAMPS JC, 1982, TOXICON, V20, P1, DOI 10.1016/0041-0101(82)90137-4; GARBER SS, 1987, J GEN PHYSIOL, V89, P459, DOI 10.1085/jgp.89.3.459; GONOI T, 1984, J NEUROSCI, V4, P2836; GORDON D, 1993, FEBS LETT, V315, P125, DOI 10.1016/0014-5793(93)81147-R; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; Gordon D, 1997, TOXINS SIGNAL TRANSD, P119; GRAY EG, 1962, J ANAT, V96, P79; Hille B, 1987, Soc Gen Physiol Ser, V41, P109; HILLE B, 1992, IONIC CHANNELS EXCIT, P308; Ingram S, 1997, MOL PHARMACOL, V52, P136, DOI 10.1124/mol.52.1.136; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; MIRANDA F, 1970, EUR J BIOCHEM, V16, P514, DOI 10.1111/j.1432-1033.1970.tb01111.x; NICHOLSON GM, 1994, PFLUG ARCH EUR J PHY, V428, P400, DOI 10.1007/BF00724524; Nicholson GM, 1998, PFLUG ARCH EUR J PHY, V436, P117, DOI 10.1007/s004240050612; Pallaghy PK, 1997, FEBS LETT, V419, P191, DOI 10.1016/S0014-5793(97)01452-X; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; RAY R, 1978, J BIOL CHEM, V253, P7307; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Sautiere P, 1998, TOXICON, V36, P1141, DOI 10.1016/S0041-0101(98)00080-4; SHEUMACK DD, 1985, FEBS LETT, V181, P154, DOI 10.1016/0014-5793(85)81132-7; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; STRICHARTZ GR, 1986, J GEN PHYSIOL, V88, P413, DOI 10.1085/jgp.88.3.413; TAMKUN MM, 1981, MOL PHARMACOL, V19, P78; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; Trainer VL, 1997, MOL PHARMACOL, V51, P651, DOI 10.1124/mol.51.4.651; Tugarinov V, 1997, BIOCHEMISTRY-US, V36, P2414, DOI 10.1021/bi961497l; WANG G, 1990, MOL PHARMACOL, V37, P144; Wang SY, 1998, P NATL ACAD SCI USA, V95, P2653, DOI 10.1073/pnas.95.5.2653	43	43	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27076	27083		10.1074/jbc.273.42.27076	http://dx.doi.org/10.1074/jbc.273.42.27076			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765223	hybrid			2022-12-25	WOS:000076448000010
J	Ajouz, B; Berrier, C; Garrigues, A; Besnard, M; Ghazi, E				Ajouz, B; Berrier, C; Garrigues, A; Besnard, M; Ghazi, E			Release of thioredoxin via the mechanosensitive channel MscL during osmotic downshock of Escherichia coli cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION CHANNELS; SENSITIVE COMPARTMENT; ACTIVATED CHANNELS; BACILLUS-SUBTILIS; MEMBRANE; SHOCK; LOCALIZATION; ACCUMULATION; PRESSURE; BETAINE	Escherichia cold cells possess several mechanosensitive ion channels but only MscL, the channel with the highest conductance, which is activated at the highest membrane tension, has been cloned. We investigated the putative involvement of MscL in the effluxes caused by osmotic downshock, Osmotic shock caused the release of potassium glutamate, trehalose, and glycine betaine from wild type cells and cells lacking MscL. These was no difference between the two strains, brat the extreme rapidity of the efflux process, as shown herein for glycine betaine, suggests that it is channel-mediated. Osmotic downshock also induces the release of some cytosolic proteins from EDTA-treated cells. We investigated the release of thioredoxin, This protein was totally released from wild type cells but was retained by MscL(-) cells. Release was restored by expression of the gene coding for MscL, Thus MscL is not necessary for the excretion of osmoprotectants, but it does open in vivo during shock and catalyzes the efflux of thioredoxin and possibly other small cytosolic proteins. It follows that the other mechanosensitive channels, which are known to be activated at lower tension, must also open during osmotic shock, Their opening and that of MscL could account for the rapid release of osmolytes.	Univ Paris Sud, Lab Biomembranes, CNRS, ERS 571, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Ghazi, E (corresponding author), Univ Paris Sud, Lab Biomembranes, CNRS, ERS 571, Bat 430, F-91405 Orsay, France.	alexandre.ghazi@biomembr.u-psud.fr						ARMSTRONG JB, 1967, J BACTERIOL, V93, P390, DOI 10.1128/JB.93.1.390-398.1967; BEACHAM IR, 1979, INT J BIOCHEM, V10, P877, DOI 10.1016/0020-711X(79)90117-4; Beautler HO, 1990, METHOD ENZYMAT AN, V8, P369; Berrier C, 1996, J MEMBRANE BIOL, V151, P175, DOI 10.1007/s002329900068; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; Csonka L. N., 1996, ESCHERICHIA COLI SAL, P1210; DINNIBIER U, 1988, ARCH MICROBIOL, V150, P348, DOI 10.1007/BF00408306; ELYAAGOUBI A, 1994, J BACTERIOL, V176, P7074, DOI 10.1128/JB.176.22.7074-7078.1994; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; Glaasker E, 1996, J BIOL CHEM, V271, P10060, DOI 10.1074/jbc.271.17.10060; Hase CC, 1997, BIOCHEM BIOPH RES CO, V232, P777, DOI 10.1006/bbrc.1997.6370; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1978, J BIOL CHEM, V253, P430; HOUSSIN C, 1991, BIOCHIM BIOPHYS ACTA, V1056, P76, DOI 10.1016/S0005-2728(05)80075-1; IKUTA S, 1977, J BIOCHEM-TOKYO, V82, P157, DOI 10.1093/oxfordjournals.jbchem.a131664; JACOBSON GR, 1976, NATURE, V261, P23, DOI 10.1038/261023a0; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KOO SP, 1991, J GEN MICROBIOL, V137, P2617, DOI 10.1099/00221287-137-11-2617; LAMARK T, 1992, FEMS MICROBIOL LETT, V96, P149; LARSEN PI, 1987, ARCH MICROBIOL, V147, P1, DOI 10.1007/BF00492896; Le Dain AC, 1998, J BIOL CHEM, V273, P12116, DOI 10.1074/jbc.273.20.12116; LUNN CA, 1982, J BIOL CHEM, V257, P1424; MCLAGGAN D, 1994, J BIOL CHEM, V269, P1911; MEURY J, 1985, EUR J BIOCHEM, V151, P613, DOI 10.1111/j.1432-1033.1985.tb09148.x; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; PERROUD B, 1985, J BACTERIOL, V161, P393, DOI 10.1128/JB.161.1.393-401.1985; Ruffert S, 1997, EUR J BIOCHEM, V247, P572, DOI 10.1111/j.1432-1033.1997.00572.x; Saint N, 1998, J BIOL CHEM, V273, P14667, DOI 10.1074/jbc.273.24.14667; SCHLEYER M, 1993, ARCH MICROBIOL, V160, P424, DOI 10.1007/BF00245302; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Szabo I, 1997, J BIOL CHEM, V272, P25275, DOI 10.1074/jbc.272.40.25275; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAPIS A, 1977, BIOCHIM BIOPHYS ACTA, V469, P1, DOI 10.1016/0005-2736(77)90320-0; Verheul A, 1997, J BACTERIOL, V179, P6979, DOI 10.1128/jb.179.22.6979-6985.1997; ZORATTI M, 1988, FEBS LETT, V240, P105, DOI 10.1016/0014-5793(88)80348-X; ZORATTI M, 1990, BIOCHEM BIOPH RES CO, V168, P443, DOI 10.1016/0006-291X(90)92341-V; ZORATTI M, 1993, ALKALI TRANSPORT SYS, P349	43	126	135	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26670	26674		10.1074/jbc.273.41.26670	http://dx.doi.org/10.1074/jbc.273.41.26670			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756908	hybrid			2022-12-25	WOS:000076373300062
J	Couve, A; Filippov, AK; Connolly, CN; Bettler, B; Brown, DA; Moss, SJ				Couve, A; Filippov, AK; Connolly, CN; Bettler, B; Brown, DA; Moss, SJ			Intracellular retention of recombinant GABA(B) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPERIOR CERVICAL-GANGLION; GAMMA-AMINOBUTYRIC-ACID; METABOTROPIC GLUTAMATE RECEPTORS; RAT SYMPATHETIC NEURONS; PUTATIVE PHEROMONE RECEPTORS; A RECEPTORS; INHIBITION; CURRENTS; PROTEIN; PHARMACOLOGY	gamma-Aminobutyric acid type B (GABA(B)) receptors mediate the transmission of slow and prolonged inhibitory signals in the central nervous system, Two splice variants of GABA(B) receptors, GABA(B)R1a and GABA(B)R1b, were recently cloned from a mouse cortical and cerebellar cDNA library. As predicted, these receptors belong to the G protein-coupled receptor superfamily. We have used epitope-tagged versions of GABA(B)R1a receptors to study the cellular distribution of these proteins in a variety of non-neuronal and neuronal cell types. Here we report that recombinant GABA(B) receptors fail to reach the cell surface when expressed in heterologous systems and are retained in the endoplasmic reticulum when introduced into COS cells. In addition, we prove that recombinant GABA(B) receptors are excluded from the cell surface when overexpressed in ganglion neurons and we further demonstrate that they fail to activate in superior cervical ganglion neurons. Together our observations suggest that recombinant GABA(B) receptors require additional information for functional targeting to the plasma membrane.	Univ London Univ Coll, Mol Cell Biol Lab, MRC, London WC1E 6BT, England; Univ London Univ Coll, Dept Pharmacol, London WC1E 6BT, England; Novartis Pharma Inc, Res Dept, Therapeut Area Nervous Syst, CH-4002 Basel, Switzerland	University of London; University College London; University of London; University College London; Novartis	Moss, SJ (corresponding author), Univ London Univ Coll, Mol Cell Biol Lab, MRC, Gower St, London WC1E 6BT, England.		Brown, David A/J-9019-2012; bettler, bernhard/AAO-8018-2020; couve, andres/I-2249-2013	couve, andres/0000-0003-4216-8672; Connolly, Christopher/0000-0002-0445-8874; Bettler, Bernhard/0000-0003-0842-8207	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALKADHI KA, 1993, ARCH INT PHARMACOD T, V322, P66; [Anonymous], [No title captured]; BOWERY NG, 1993, ANNU REV PHARMACOL, V33, P109, DOI 10.1146/annurev.pa.33.040193.000545; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BURGOS GRG, 1994, BRAIN RES, V658, P1; Caddick SJ, 1996, NEUROSCI LETT, V205, P29, DOI 10.1016/0304-3940(96)12362-4; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connolly CN, 1996, P NATL ACAD SCI USA, V93, P9899, DOI 10.1073/pnas.93.18.9899; Davies PA, 1997, BRIT J PHARMACOL, V120, P899, DOI 10.1038/sj.bjp.0700987; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Filippov AK, 1997, BRIT J PHARMACOL, V121, P849, DOI 10.1038/sj.bjp.0701270; Filippov AK, 1998, J NEUROSCI, V18, P5170, DOI 10.1523/JNEUROSCI.18-14-05170.1998; FUKUDA A, 1993, J NEUROPHYSIOL, V70, P448, DOI 10.1152/jn.1993.70.1.448; GAIARSA JL, 1995, J NEUROPHYSIOL, V73, P246, DOI 10.1152/jn.1995.73.1.246; HELM R, 1995, NATURE, V373, P663; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; JOLY C, 1995, J NEUROSCI, V15, P3970; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Luebke AE, 1996, P NATL ACAD SCI USA, V93, P3455, DOI 10.1073/pnas.93.8.3455; LUHMANN HJ, 1991, J NEUROPHYSIOL, V65, P247, DOI 10.1152/jn.1991.65.2.247; MARRION NV, 1987, NEUROSCI LETT, V77, P55, DOI 10.1016/0304-3940(87)90606-9; MARRION NV, 1989, BRIT J PHARMACOL, V98, P557, DOI 10.1111/j.1476-5381.1989.tb12630.x; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; McLean HA, 1996, J NEUROPHYSIOL, V76, P1036, DOI 10.1152/jn.1996.76.2.1036; MOTT DD, 1994, INT REV NEUROBIOL, V36, P97, DOI 10.1016/S0074-7742(08)60304-9; NEWBERRY NR, 1989, EUR J PHARMACOL, V163, P245, DOI 10.1016/0014-2999(89)90193-3; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PARDUCZ A, 1990, NEUROSCIENCE, V36, P239, DOI 10.1016/0306-4522(90)90365-B; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SMART TG, 1987, J PHYSIOL-LONDON, V389, P337, DOI 10.1113/jphysiol.1987.sp016660; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TURGEON SM, 1994, NEUROSCIENCE, V62, P601, DOI 10.1016/0306-4522(94)90392-1; Wasterlain CG, 1996, EPILEPSY RES, V26, P255, DOI 10.1016/S0920-1211(96)00058-7; Wooltorton JRA, 1997, EUR J NEUROSCI, V9, P2225, DOI 10.1111/j.1460-9568.1997.tb01641.x; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162	41	171	177	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26361	26367		10.1074/jbc.273.41.26361	http://dx.doi.org/10.1074/jbc.273.41.26361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756866	hybrid			2022-12-25	WOS:000076373300020
J	Delot, E; Brodie, SG; King, LM; Wilcox, WR; Cohn, DH				Delot, E; Brodie, SG; King, LM; Wilcox, WR; Cohn, DH			Physiological and pathological secretion of cartilage oligomeric matrix protein by cells in culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; ENDOPLASMIC-RETICULUM; EXTRACELLULAR-MATRIX; ARTICULAR-CARTILAGE; PSEUDOACHONDROPLASIA; COMP; GENE; MUTATIONS; THROMBOSPONDIN; FAMILY	Abnormalities in cartilage oligomeric matrix protein (COMP), a pentameric structural protein of the cartilage extracellular matrix, have been identified in pseudoachondroplasia and multiple epiphyseal dysplasia, two human autosomal dominant osteochondrodysplasias. However, the function of the protein remains unknown. With the goal of establishing a model to study the mechanisms by which COMP mutations cause disease, we have analyzed synthesis and secretion of COMP in cultured chondrocytes, tendon, and ligament cells. Pentameric protein detected inside of control cells suggested that pentamerization is an intracellular process. Patient cells expressed mutant and normal RNA and secreted COMP at levels similar to controls, suggesting that abnormal pentamers are likely to be found in the extracellular matrix. Inclusions within patient cartilage stained with anti-COMP antibodies, and cultured cells presented similar inclusions, indicating that presumably abnormal COMP pentamers are less efficiently secreted than normal molecules. We conclude that the COMP disorders are likely to result from a combination of a decreased amount of COMP in the matrix and a dominant negative effect due to the presence of abnormal pentamers in cartilage.	Univ Calif Los Angeles, Sch Med,Ahmanson Dept Pediat, Burns & Allen Cedars Sinai Res Inst, Steven Spielberg Pediat Res Ctr, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cohn, DH (corresponding author), Cedars Sinai Med Ctr, SSB-3,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	dcohn@xchg.peds.csmc.edu		Delot, Emmanuele/0000-0003-3541-3190	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043139] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43139] Funding Source: Medline; NICHD NIH HHS [HD22567] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ballo R, 1997, AM J MED GENET, V68, P396, DOI 10.1002/(SICI)1096-8628(19970211)68:4<396::AID-AJMG4>3.3.CO;2-R; BARRON EJ, 1995, GEOTIMES, V40, P12; BRIGGS MD, 1993, GENOMICS, V18, P656, DOI 10.1016/S0888-7543(05)80369-6; BRIGGS MD, 1994, AM J HUM GENET, V55, P678; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; BRODIE SG, 1998, IN PRESS AM J MED GE; DICESARE PE, 1995, J ORTHOPAED RES, V13, P422, DOI 10.1002/jor.1100130316; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; EFIMOV VP, 1994, FEBS LETT, V341, P54, DOI 10.1016/0014-5793(94)80239-4; FRANZEN A, 1987, DIFFERENTIATION, V36, P199, DOI 10.1111/j.1432-0436.1987.tb00194.x; HAUSER N, 1995, FEBS LETT, V368, P307, DOI 10.1016/0014-5793(95)00675-Y; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Loughlin J, 1998, HUM MUTAT, pS10; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; MAYNARD JA, 1972, LAB INVEST, V26, P40; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; MURAD S, 1981, P NATL ACAD SCI-BIOL, V78, P2879, DOI 10.1073/pnas.78.5.2879; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Prabakaran D, 1996, EUR J CELL BIOL, V70, P134; Recklies AD, 1998, ARTHRITIS RHEUM, V41, P997, DOI 10.1002/1529-0131(199806)41:6<997::AID-ART6>3.0.CO;2-G; RIMOIN DL, 1994, HUM GENET, V93, P236, DOI 10.1007/BF00212015; SAXNE T, 1992, BR J RHEUM, V31, P573; SHARIF M, 1995, BRIT J RHEUMATOL, V34, P306; Shen ZX, 1995, MATRIX BIOL, V14, P773, DOI 10.1016/S0945-053X(05)80020-4; Smith RKW, 1997, MATRIX BIOL, V16, P255, DOI 10.1016/S0945-053X(97)90014-7; STANESCU R, 1993, AM J MED GENET, V45, P501, DOI 10.1002/ajmg.1320450420; STANESCU V, 1982, EUR J PEDIATR, V138, P221, DOI 10.1007/BF00441206; Susic S, 1997, CLIN GENET, V51, P219; VANMOURIK JBA, 1998, IN PRESS ULTRASTRUC	33	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26692	26697		10.1074/jbc.273.41.26692	http://dx.doi.org/10.1074/jbc.273.41.26692			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756911	hybrid			2022-12-25	WOS:000076373300065
J	Pedram, A; Razandi, M; Levin, ER				Pedram, A; Razandi, M; Levin, ER			Extracellular signal-regulated protein kinase Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; SMOOTH-MUSCLE CELLS; TYROSINE KINASE; CYCLE PROGRESSION; TRANSDUCTION PATHWAYS; MAP KINASES; IN-VIVO; ACTIVATION; MITOGEN; EXPRESSION	Ligand binding to vascular endothelial cell growth factor (VEGF) receptors activates the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK) and c-Jun N-terminal protein kinase (JNK). Possible cross-communication of ERK and JNK effecting endothelial cell (EC) actions of VEGF is poorly understood. Incubation of EC with PD 98059, a specific nitrogen-activated protein kinase kinase inhibitor, or transfection with Y185F, a dominant negative ERK2, strongly inhibited VEGF-activated JNK. JNK was also activated by ERK2 expression in the absence of VEGF, inhibited 82% by co-transfection with dominant negative SEK-1, indicating upstream activation of JNK by ERK. VEGF-stimaulated JNK activity was also reversed by dominant negative SEK-1. Other EC growth factors exhibited similar cross-activation of JNK through ERK. VEGF stimulated the nuclear incorporation of thymidine, reversed 89% by PD 98059 and 72% by Y185F. Dominant negative SEK-1 or JNK-1 also significantly reduced VEGF-stimulated thymidine incorporation Expression of wild type Jip-1, which prevents JNK nuclear translocation, inhibited VEGF-induced EC proliferation by 75%. VEGF stimulated both cyclin D1 synthesis and Cdk4 kinase activity, inhibited by PD 98059 and dominant negative JNK-1. Important events for VEGF-induced G(1)/S progression and cell proliferation are enhanced through a novel ERK to JNK cross-activation and subsequent JNK action.	Long Beach Vet Affairs Med Ctr, Med Serv, Div Endocrinol, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine	Levin, ER (corresponding author), Long Beach Vet Affairs Med Ctr, Med Serv, Div Endocrinol, 111-I,5901 E 7th St, Long Beach, CA 90822 USA.	elevin@pop.long-beach.va.gov			NINDS NIH HHS [NS-30521] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030521] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Higashita R, 1997, J BIOL CHEM, V272, P25845, DOI 10.1074/jbc.272.41.25845; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Morey AK, 1997, ENDOCRINOLOGY, V138, P3330, DOI 10.1210/en.138.8.3330; Morey AK, 1998, BIOCHEM J, V330, P1097; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pedram A, 1997, J BIOL CHEM, V272, P17097, DOI 10.1074/jbc.272.27.17097; Pedram A, 1998, J BIOL CHEM, V273, P13966, DOI 10.1074/jbc.273.22.13966; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PRINS BA, 1994, J BIOL CHEM, V269, P11938; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; SHIBUYA M, 1990, ONCOGENE, V5, P519; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	58	186	193	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26722	26728		10.1074/jbc.273.41.26722	http://dx.doi.org/10.1074/jbc.273.41.26722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756915	hybrid			2022-12-25	WOS:000076373300069
J	Roush, DL; Gottardi, CJ; Naim, HY; Roth, MG; Caplan, MJ				Roush, DL; Gottardi, CJ; Naim, HY; Roth, MG; Caplan, MJ			Tyrosine-based membrane protein sorting signals are differentially interpreted by polarized Madin-Darby canine kidney and LLC-PK1 epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; POLYMERIC IMMUNOGLOBULIN RECEPTOR; CYTOPLASMIC DOMAIN DETERMINANT; COATED PIT LOCALIZATION; AMINO-ACID CHANGE; MDCK CELLS; FC-RECEPTORS; TRANSFERRIN RECEPTOR; BASOLATERAL SURFACE; TRANSPORTING ATPASE	Tyrosine-dependent sequence motifs are implicated in sorting membrane proteins to the basolateral domain of Madin-Darby canine kidney (MDCK) cells. We find that these motifs are interpreted differentially in various polarized epithelial cell types. The H,K-ATPase beta subunit, which contains a tyrosine-based motif in its cytoplasmic tail, was expressed in MDCK and LLC-PK1 cells. This protein was restricted to the basolateral membrane in MDCK cells, but was localized to the apical membrane in LLC-PK1 cells. Similarly, HA-Y543, a construct in which a tyrosine-based motif was introduced into the cytoplasmic tail of influenza hemagglutinin, was sorted to the basolateral membrane of MDCK cells and retained at the epical membrane of LLC-PK1 cells. A chimera in which the cytoplasmic tail of the IP,K-ATPase beta subunit protein was replaced with the analogous region of the Na,R-ATPase beta subunit polypeptide was localized to both surface domains of MDCK cells. Mutation of tyrosine-20 of the H,K-ATPase beta subunit cytoplasmic sequence to an alanine was sufficient to disrupt basolateral localization of this polypeptide. In contrast, these constructs all remain localized to the apical membrane in LLC-PK1 cells. The FcRII-B2 protein bears a di-leucine motif and is found at the basolateral membrane of both MDCK and LLC-PK1 cells. These results demonstrate that polarized epithelia are able to discriminate between different classes of specifically defined membrane protein sorting signals.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Roush, DL (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06510 USA.		Gottardi, Cara J./AAU-4691-2021	Gottardi, Cara J./0000-0003-0912-7617; Roth, Michael/0000-0002-9056-332X; Caplan, Michael/0000-0001-5768-4405	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-17433] Funding Source: Medline; NIGMS NIH HHS [GM-42136] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1993, BIOCHEM J, V267, P31; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BUTOR C, 1992, EXP CELL RES, V203, P115, DOI 10.1016/0014-4827(92)90046-B; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CourtoisCoutry N, 1997, CELL, V90, P501, DOI 10.1016/S0092-8674(00)80510-3; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DeStrooper B, 1995, J BIOL CHEM, V270, P30310, DOI 10.1074/jbc.270.51.30310; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HALLER C, 1993, AM J PHYSIOL, V265, pC1069, DOI 10.1152/ajpcell.1993.265.4.C1069; HERZLINGER DA, 1982, J CELL BIOL, V93, P269, DOI 10.1083/jcb.93.2.269; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MASUZAWA T, 1984, BRAIN RES, V302, P357, DOI 10.1016/0006-8993(84)90250-6; MATLIN KS, 1992, KIDNEY PHYSL PATHOPH, P447; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCQUEEN N, 1986, P NATL ACAD SCI USA, V83, P9318, DOI 10.1073/pnas.83.24.9318; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; NAIM HY, 1994, J BIOL CHEM, V269, P3928; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PFALLER W, 1990, J CELL PHYSIOL, V142, P247, DOI 10.1002/jcp.1041420205; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHWARTZ GJ, 1985, J CLIN INVEST, V75, P1638, DOI 10.1172/JCI111871; STEPHENS EB, 1986, EMBO J, V5, P237, DOI 10.1002/j.1460-2075.1986.tb04204.x; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL LK, 1995, J BIOL CHEM, V270, P22933, DOI 10.1074/jbc.270.39.22933; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	52	94	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26862	26869		10.1074/jbc.273.41.26862	http://dx.doi.org/10.1074/jbc.273.41.26862			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756932	hybrid			2022-12-25	WOS:000076373300086
J	Treger, JM; Schmitt, AP; Simon, JR; McEntee, K				Treger, JM; Schmitt, AP; Simon, JR; McEntee, K			Transcriptional factor mutations reveal regulatory complexities of heat shock and newly identified stress genes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENT STRE; PROTEIN-KINASE-A; RNA-POLYMERASE; HSP70 GENE; DNA DAMAGE; PATHWAY; TEMPERATURE; ACTIVATOR; SEQUENCE; FAMILY	A computer-aided pattern search of the entire yeast genome was designed and used to identify 186 putative stress response element-regulated genes in Saccharomyces cerevisiae. Transcript levels of eight of these candidate genes were examined, and three (37%) were shown to be heat shock- and DNA damage-inducible and to require the Msn2p and Msn4p transcriptional activators for stress regulation. Significantly, several heat shock protein (HSP) genes were identified in this computer search. Using a series of single and multiple regulatory mutants, we demonstrate unexpected regulatory complexities among the HSP genes from S. cerevisiae following heat shock.	Univ Calif Los Angeles, Ctr Hlth Sci, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	McEntee, K (corresponding author), Univ Calif Los Angeles, Ctr Hlth Sci, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.			Schmitt, Anthony/0000-0001-9272-058X	NIGMS NIH HHS [GM38456] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BOORSTEIN WR, 1990, EMBO J, V9, P2543, DOI 10.1002/j.1460-2075.1990.tb07435.x; BOORSTEIN WR, 1990, MOL CELL BIOL, V10, P3262, DOI 10.1128/MCB.10.6.3262; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; FARRELLY FW, 1984, J BIOL CHEM, V259, P5745; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; GROSS DS, 1990, ANTON LEEUW INT J G, V58, P175, DOI 10.1007/BF00548930; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; LEONHARDT SA, 1993, MOL CELL BIOL, V13, P6304, DOI 10.1128/MCB.13.10.6304; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MCCLANAHAN T, 1984, MOL CELL BIOL, V4, P2356, DOI 10.1128/MCB.4.11.2356; NI HT, 1995, MOL MICROBIOL, V16, P1197, DOI 10.1111/j.1365-2958.1995.tb02342.x; OH D, 1990, MOL CELL BIOL, V10, P1415, DOI 10.1128/MCB.10.4.1415; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; Rose MD., 1990, METHODS YEAST GENETI; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SMID A, 1995, J BIOL CHEM, V270, P13534, DOI 10.1074/jbc.270.22.13534; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; Treger JM, 1998, BIOCHEM BIOPH RES CO, V243, P13, DOI 10.1006/bbrc.1997.8061; TREGER JM, 1990, MOL CELL BIOL, V10, P3174, DOI 10.1128/MCB.10.6.3174; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; Wotton D, 1996, J BIOL CHEM, V271, P2717, DOI 10.1074/jbc.271.5.2717; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854	31	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26875	26879		10.1074/jbc.273.41.26875	http://dx.doi.org/10.1074/jbc.273.41.26875			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756934	hybrid			2022-12-25	WOS:000076373300088
J	DiGiovanna, MP; Lerman, MA; Coffey, RJ; Muller, WJ; Cardiff, RD; Stern, DF				DiGiovanna, MP; Lerman, MA; Coffey, RJ; Muller, WJ; Cardiff, RD; Stern, DF			Active signaling by Neu in transgenic mice	ONCOGENE			English	Article						HER-2/Neu/ErbB-2; transgenic mice; phosphorylation; breast cancer; activation; transforming growth factor-alpha (TGF alpha)	EPIDERMAL GROWTH-FACTOR; HUMAN BREAST-TUMORS; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; POINT MUTATION; MAMMARY-TUMORS; PROTOONCOGENE PRODUCT; ONCOGENIC ACTIVATION; METASTATIC DISEASE; CELLULAR-RESPONSE	Transgenic mice engineered to overexpress the HER-2/neu/erbB-2 protooncogene under the control of a mammary-specific promoter develop mammary tumors and are a model for human breast cancer. Signal transduction by Neu was examined in situ in the tumors of these transgenic mice. This was accomplished using the PN2A monoclonal antibody, which recognizes Neu only in the phosphorylated, and therefore actively signaling, state. Immunohistochemistry using PN2A demonstrated that Neu actively signals in the tumors of Neu transgenic mice. Expression of Neu was always accompanied by co-overexpression of the endogenous epidermal growth factor receptor. Qualitatively similar results were found in mammary tumors from mice bitransgenic for the neu and transforming growth factor-alpha genes (both driven by the mouse mammary tumor virus promoter). Early mammary lesions demonstrated distinctive patterns of Neu activation relative to expression levels. Overexpression and activation were separable both temporally and spatially. These results refine the multi-step model for the role of Neu in mammary neoplasia and establish phosphorylation-state specific antibodies as a powerful tool for investigating tumor progression.	Yale Univ, Sch Med, Dept Internal Med, Sect Med Oncol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06510 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; McMaster Univ, Inst Mol Biol, Hamilton, ON L8S 4K1, Canada; Univ Calif Davis, Sch Med, Dept Pathol, Livermore, CA 95616 USA	Yale University; Yale University; Yale University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; McMaster University; University of California System; University of California Davis	DiGiovanna, MP (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Med Oncol, 333 Cedar St, New Haven, CT 06510 USA.		Lerman, Melissa/AGG-2451-2022	Lerman, Melissa/0000-0003-1378-5292	NATIONAL CANCER INSTITUTE [R01CA046413, R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA45708, R01-CA46413] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DeckardJanatpour K, 1997, INT J ONCOL, V11, P235; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; DiGiovanna MP, 1996, BRIT J CANCER, V74, P802, DOI 10.1038/bjc.1996.439; DiGiovanna MP, 1997, ANAL BIOCHEM, V247, P167, DOI 10.1006/abio.1997.9919; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gulliford TJ, 1997, ONCOGENE, V15, P2219, DOI 10.1038/sj.onc.1201595; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KAPLAN PL, 1982, VIROLOGY, V123, P372, DOI 10.1016/0042-6822(82)90270-7; Krane IM, 1996, ONCOGENE, V12, P1781; LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MIKAMI Y, 1992, P NATL ACAD SCI USA, V89, P7335, DOI 10.1073/pnas.89.16.7335; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRESS MF, 1990, ONCOGENE, V5, P953; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; RIESE DJ, IN PRESS BIOESSAYS; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHIMMELPENNING H, 1992, VIRCHOWS ARCH A, V420, P433, DOI 10.1007/BF01600515; SEGATTO O, 1990, New Biologist, V2, P187; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUDA Y, 1990, EMBO J, V9, P181, DOI 10.1002/j.1460-2075.1990.tb08094.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	49	51	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1877	1884		10.1038/sj.onc.1202091	http://dx.doi.org/10.1038/sj.onc.1202091			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778054				2022-12-25	WOS:000076303300014
J	Kato, M; Takahashi, M; Akhand, AA; Liu, W; Dai, Y; Shimizu, S; Iwamoto, T; Suzuki, H; Nakashima, I				Kato, M; Takahashi, M; Akhand, AA; Liu, W; Dai, Y; Shimizu, S; Iwamoto, T; Suzuki, H; Nakashima, I			Transgenic mouse model for skin malignant melanoma	ONCOGENE			English	Article						malignant melanoma; Ret; transgenic mouse	METASTATIC CELL-LINES; MATRIX METALLOPROTEINASES; TUMOR PROGRESSION; RET; EXPRESSION; MICE; GENE; ESTABLISHMENT; ACTIVATION; MECHANISM	We report here on a novel metallothionein-I (MT)/ret transgenic mouse line in which skin melanosis, benign melanocytic tumor and malignant melanoma metastasizing to distant organs develop stepwise. The process of tumor development and its malignant transformation in this line may resemble that of the human giant congenital melanocytic nevus that is present at birth and that frequently gives rise to malignant melanoma during aging. We observed an increase in the expression level and activity of the ret transgene during the disease progression. That increase in transgene expression accompanied an activation of mitogen-activated protein kinases (MAPKs) and c-Jun as well as matrix metalloproteinases. These results suggest that progressive dysregulation of the expression level of the ret transgene might play a crucial role in the malignant transformation of melanocytic tumors developed in the MT/ret transgenic mouse line.	Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 4640021, Japan	Nagoya University; Nagoya University; Aichi Cancer Center	Nakashima, I (corresponding author), Nagoya Univ, Sch Med, Dept Immunol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020; KATO, Masashi/I-7250-2014	Takahashi, Masahide/0000-0002-2803-2683; 				BALCH CM, 1989, PRINCIPLES PRACTICE, P1519; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; Chen S, 1996, J INVEST DERMATOL, V106, P1145, DOI 10.1111/1523-1747.ep12340194; CRAWFORD HC, 1994, INVAS METAST, V14, P234; DAVIES B, 1993, CANCER RES, V53, P5365; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; Iwata H, 1996, JPN J CANCER RES, V87, P602, DOI 10.1111/j.1349-7006.1996.tb00266.x; KATO M, 1994, CELL IMMUNOL, V159, P15, DOI 10.1006/cimm.1994.1291; KOH HK, 1992, TUMORS SKIN DERMATOL, P1753; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; OHMIYA N, 1995, CLIN EXP IMMUNOL, V100, P151; Pu MY, 1996, ONCOGENE, V13, P2615; Sakata K, 1996, JPN J CANCER RES, V87, P78, DOI 10.1111/j.1349-7006.1996.tb00203.x; SATO H, 1993, J BIOL CHEM, V268, P23460; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TANIGUCHI M, 1992, ONCOGENE, V7, P1491; YAMAGATA S, 1988, BIOCHEM BIOPH RES CO, V151, P158, DOI 10.1016/0006-291X(88)90573-6; YAMAMOTO K, 1989, CHEM RES TOXICOL, V2, P234, DOI 10.1021/tx00010a004	20	171	172	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1885	1888		10.1038/sj.onc.1202077	http://dx.doi.org/10.1038/sj.onc.1202077			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778055				2022-12-25	WOS:000076303300015
J	Guadiz, G; Haidaris, CG; Maine, GN; Simpson-Haidaris, PJ				Guadiz, G; Haidaris, CG; Maine, GN; Simpson-Haidaris, PJ			The carboxyl terminus of Pneumocystis carinii glycoprotein A encodes a functional glycosylphosphatidylinositol signal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SURFACE GLYCOPROTEIN; CULTURED LUNG-CELLS; SACCHAROMYCES-CEREVISIAE; GLYCOSYL-PHOSPHATIDYLINOSITOL; ALPHA-AGGLUTININ; ANTIGENIC VARIATION; CANDIDA-ALBICANS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; GPI-ANCHORS	Pneumocystis carinii pneumonia is a hallmark disease associated with AIDS. An abundant glycoprotein, termed gpA, on the surface of P. carinii is considered an important factor in host-parasite interactions. The primary structure of ferret P. carinii gpA contains a carboxyl-terminal sequence characteristic of a signal for glycosylphosphatidylinositol (GPI) anchors. Here we report the capacity for this gpA carboxyl sequence to direct attachment of a secreted protein, human growth hormone (hGH), to the membranes of COS cells. A control fusion protein (hGHDAF37) was obtained which, under the direction of the GPI signal from decay accelerating factor, directs hGR cell surface expression. A construct (phGH2-1A30) was created similar to hGHDAF37 by fusing hGH to the putative GPI signal sequence encoded in the terminal 30 residues from a ferret P. carinii gpA cDNA clone. By indirect immunofluorescent staining, hGH was detected on the surface of COS cells transfected with phGH2-1A30; this surface location was confirmed by confocal laser cytometry. Metabolic labeling with [H-3]ethanolamine and subsequent immunopurification of hGH from cells transfected with phGH2-1A30 confirmed that a lipid moiety characteristic of a conventional GPI anchor was linked covalently to hGH, and cell surface hGH2-1A30 fusion protein was sensitive to enzymatic cleavage by phosphatidylinositol-phospholipase C. Furthermore, hGH2-1A30 recombinant protein cofractionated with 5'-nucleotidase, a classical GPI-anchored membrane marker. Together, these results indicate that the carboxyl-terminal residues of ferret P. carinii gpA constitute a biologically functional GPI consensus domain, thus providing a potential mechanism for antigenic variation of P. carinii gpA during P. carinii pneumonia.	Univ Rochester, Dept Med, Vasc Med Unit, Rochester, NY 14642 USA; Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Dept Dent Res, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Simpson-Haidaris, PJ (corresponding author), Univ Rochester, Dept Med, Vasc Med Unit, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.			, PJ/0000-0003-2778-2500	NHLBI NIH HHS [HL50615, HL49610] Funding Source: Medline; NIAID NIH HHS [AI07362] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050615, R01HL049610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007362] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG MYK, 1994, PNEUMOCYSTIS CARINII, P189; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BAUER NL, 1993, INFECT IMMUN, V61, P1315, DOI 10.1128/IAI.61.4.1315-1319.1993; BERGELSON JM, 1994, P NATL ACAD SCI USA, V91, P6245, DOI 10.1073/pnas.91.13.6245; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; CEZANNE L, 1992, BIOCHIM BIOPHYS ACTA, V1112, P205, DOI 10.1016/0005-2736(92)90393-Z; CHEN WX, 1992, INT J EXP PATHOL, V73, P709; CONZELMANN A, 1991, CELL BIOL INT REP, V15, P863, DOI 10.1016/0309-1651(91)90038-K; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CUSHION MT, 1994, J MED VET MYCOL, V32, P217; De Nobel Hans, 1994, Trends in Cell Biology, V4, P42, DOI 10.1016/0962-8924(94)90003-5; DESTEFANO JA, 1990, J PROTOZOOL, V37, P428; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FISHER DJ, 1991, INFECT IMMUN, V59, P3372, DOI 10.1128/IAI.59.10.3372-3376.1991; FLORINCHRISTENSEN M, 1994, BIOCHEM BIOPH RES CO, V198, P236, DOI 10.1006/bbrc.1994.1033; GARBE TR, 1994, INFECT IMMUN, V62, P3092, DOI 10.1128/IAI.62.8.3092-3101.1994; GIGLIOTTI F, 1988, J CLIN INVEST, V81, P1666, DOI 10.1172/JCI113503; GIGLIOTTI F, 1986, J INFECT DIS, V154, P315, DOI 10.1093/infdis/154.2.315; GIGLIOTTI F, 1992, J INFECT DIS, V165, P329, DOI 10.1093/infdis/165.2.329; Gigliotti F, 1996, INFECT IMMUN, V64, P1892, DOI 10.1128/IAI.64.6.1892-1899.1996; Guadiz G, 1997, BLOOD, V90, P2644, DOI 10.1182/blood.V90.7.2644.2644_2644_2653; GUO ZK, 1995, INFECT IMMUN, V63, P1286, DOI 10.1128/IAI.63.4.1286-1290.1995; Haidaris C G, 1998, DNA Res, V5, P77, DOI 10.1093/dnares/5.2.77; HAIDARIS PJ, 1993, MOL MICROBIOL, V7, P647, DOI 10.1111/j.1365-2958.1993.tb01156.x; HAIDARIS PJ, 1992, J INFECT DIS, V166, P1113, DOI 10.1093/infdis/166.5.1113; HERALD D, 1986, J BIOL CHEM, V261, P13813; HONG ST, 1990, J CLIN MICROBIOL, V28, P1785, DOI 10.1128/JCM.28.8.1785-1795.1990; HOPKIN JM, 1991, PNEUMOCYSTIS CARINII, P1; KANESHIRO ES, 1994, PNEUMOCYSTIS CARINII, P45; KAPTEYN JC, 1994, EUR J CELL BIOL, V65, P402; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; KOVACS JA, 1993, J BIOL CHEM, V268, P6034; LIMPER AH, 1993, INFECT IMMUN, V61, P4302, DOI 10.1128/IAI.61.10.4302-4309.1993; LIMPER AH, 1991, J LAB CLIN MED, V118, P492; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; LU CF, 1994, MOL CELL BIOL, V14, P4825, DOI 10.1128/MCB.14.7.4825; MATSUMOTO Y, 1989, J PROTOZOOL, V36, pS21, DOI 10.1111/j.1550-7408.1989.tb05814.x; MORAN P, 1994, J CELL BIOL, V125, P333, DOI 10.1083/jcb.125.2.333; MULLER G, 1992, J BIOL CHEM, V267, P25337; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; PESANTI EL, 1987, INFECT IMMUN, V55, P736, DOI 10.1128/IAI.55.3.736-741.1987; POTTRATZ ST, 1991, J CLIN INVEST, V88, P403, DOI 10.1172/JCI115318; ROSSE WF, 1995, BLOOD, V86, P3277, DOI 10.1182/blood.V86.9.3277.bloodjournal8693277; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; SCHREUDER MP, 1993, YEAST, V9, P399, DOI 10.1002/yea.320090410; SPECTOR DL, 1998, CELLS LAB MANUAL, V1; Sunkin SM, 1996, MOL MICROBIOL, V19, P283, DOI 10.1046/j.1365-2958.1996.375905.x; VOSSEN JH, 1995, BBA-GEN SUBJECTS, V1243, P549, DOI 10.1016/0304-4165(95)00002-S; Wada M, 1996, DNA Res, V3, P55, DOI 10.1093/dnares/3.2.55; WADA M, 1995, J INFECT DIS, V171, P1563, DOI 10.1093/infdis/171.6.1563; WALZER PD, 1980, J INFECT DIS, V142, P449, DOI 10.1093/infdis/142.3.449; WEBSTER P, 1991, CELL BIOL INT REP, V15, P799; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554; Wright T W, 1995, DNA Res, V2, P77, DOI 10.1093/dnares/2.2.77; WRIGHT TW, 1994, INFECT IMMUN, V62, P1513, DOI 10.1128/IAI.62.5.1513-1519.1994; YONEDA K, 1980, INFECT IMMUN, V29, P692; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	61	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26202	26209		10.1074/jbc.273.40.26202	http://dx.doi.org/10.1074/jbc.273.40.26202			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748303	hybrid			2022-12-25	WOS:000076263100094
J	Meierhans, D; Allemann, RK				Meierhans, D; Allemann, RK			The N-terminal methionine is a major determinant of the DNA binding specificity of MEF-2C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; BOX TRANSCRIPTION FACTORS; BENDING PROPENSITY; MYOGENIC LINEAGE; GENE-EXPRESSION; ADENINE TRACT; B-DNA; PROTEIN; MEF2; ACTIVATION	Members of the MEF-S family of transcriptional regulators positively modulate the activity of basic helix-loop-helix proteins in both myogenic and neurogenic cell lineages. Previous work had shown that MEF-2C(2-117), a protein fragment comprising the dimerization and DNA-binding domains of MEF-2C but lacking the N-terminal methionine, bound to AT-rich DNA sequences with high affinity. MEF-2C(2-117) did not discriminate between different AT-rich sequences. We now report the in vitro DNA binding properties of a MEF-2C fragment containing the N-terminal methionine. Measurements of the apparent dissociation constants of the complexes of GG-MEF-2C(1-117) revealed that different AT-rich sequences are bound with different affinities; in particular MEF site containing DNA (CTATAAATAG) is bound preferentially to DNA containing a SRF site (CATAAATG). Strikingly, when the shorter AT run consisted of six alternating thymines and adenines, almost wild-type affinity was observed. Irrespective of the particular DNA sequence, all circular dichroism spectra of the DNA complexes of GG-MEF-2C(1-117) were superimposable and characterized by an identical maximal ellipticity at 269.5 nm, suggesting similar DNA conformations. Bending analysis by circular permutation assay revealed that on complex formation MEF-2C(2-117) induced cognate DNA to bend by 49 degrees, while heterologous DNA remained unbent. In the presence of the N-terminal methionine, however, all DNA sequences were bent by 70 degrees. The above results suggest an important function for the N-terminal methionine in properly orientating MEF-2C on the DNA.	Swiss Fed Inst Technol, Dept Chem, CH-8092 Zurich, Switzerland	ETH Zurich	Allemann, RK (corresponding author), Univ Birmingham, Sch Chem, Birmingham B15 2TT, W Midlands, England.							Allemann RK, 1997, CHEM BIOL, V4, P643, DOI 10.1016/S1074-5521(97)90218-0; Berman HM, 1997, BIOPOLYMERS, V44, P23, DOI 10.1002/(SICI)1097-0282(1997)44:1<23::AID-BIP3>3.0.CO;2-1; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BRUKNER I, 1995, EMBO J, V14, P1812, DOI 10.1002/j.1460-2075.1995.tb07169.x; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; DELCOURT SG, 1991, J BIOL CHEM, V266, P15160; Dickerson RE, 1996, J MOL BIOL, V256, P108, DOI 10.1006/jmbi.1996.0071; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; DIGABRIELE AD, 1993, J MOL BIOL, V231, P1024, DOI 10.1006/jmbi.1993.1349; ERIE DA, 1994, SCIENCE, V266, P1562, DOI 10.1126/science.7985026; ERIE DA, 1995, SCIENCE, V269, P989, DOI 10.1126/science.269.5226.989-a; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; Gabrielian A, 1996, FEBS LETT, V393, P65, DOI 10.1016/0014-5793(96)00855-1; Gabrielian A, 1996, FEBS LETT, V393, P124, DOI 10.1016/0014-5793(96)00837-X; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GOTOH O, 1981, BIOPOLYMERS, V20, P1043, DOI 10.1002/bip.1981.360200514; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kunne AGE, 1996, FEBS LETT, V391, P79, DOI 10.1016/0014-5793(96)00707-7; Mao ZX, 1996, J BIOL CHEM, V271, P14371, DOI 10.1074/jbc.271.24.14371; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; Meierhans D, 1997, NUCLEIC ACIDS RES, V25, P4537, DOI 10.1093/nar/25.22.4537; Meierhans D, 1997, PROTEIN EXPRES PURIF, V11, P297, DOI 10.1006/prep.1997.0795; MEIERHANS D, 1995, BIOCHEMISTRY-US, V34, P11026, DOI 10.1021/bi00035a008; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; QUINTANA JR, 1992, J MOL BIOL, V225, P379, DOI 10.1016/0022-2836(92)90928-D; Riechmann JL, 1997, BIOL CHEM, V378, P1079; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEPARTZ A, 1995, SCIENCE, V269, P989, DOI 10.1126/science.7638626; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Sieber M, 1998, BIOL CHEM, V379, P731; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; SUZUKI M, 1995, NUCLEIC ACIDS RES, V23, P2083, DOI 10.1093/nar/23.12.2083; Suzuki M, 1996, FEBS LETT, V379, P148, DOI 10.1016/0014-5793(95)01506-X; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	49	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26052	26060		10.1074/jbc.273.40.26052	http://dx.doi.org/10.1074/jbc.273.40.26052			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748284	hybrid			2022-12-25	WOS:000076263100075
J	Ranganathan, S; Kern, PA				Ranganathan, S; Kern, PA			Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADIPOSE-TISSUE; PEROXISOME PROLIFERATOR; 3T3-L1 ADIPOCYTES; PPAR-GAMMA; GENE-EXPRESSION; GLUCOSE-UPTAKE; INSULIN; DIFFERENTIATION; CELLS; TROGLITAZONE	The thiazolidinediones troglitazone and BRL 49653 improve insulin sensitivity in humans and animals with insulin resistance. Adipose tissue lipoprotein lipase is an insulin-sensitive enzyme. We examined the effects of thiazolidinediones on lipoprotein lipase expression in adipocytes. When added to 3T3-F442A, 3T3-L1, and rat adipocytes in culture, troglitazone and BRL 49653 inhibited lipoprotein lipase activity. This inhibition was observed at concentrations as low as 0.1 mu M and within 2 h after addition of the drug. Lipoprotein lipase activity was inhibited in differentiated adipocytes as well as the differentiating cells. Despite this decrease in enzyme activity, these drugs increased mRNA levels in undifferentiated 3T3-F442A and 3T3-L1 cells and had no effect on mRNA expression or synthesis of lipoprotein lipase in differentiated cells. Western blot analysis showed that these drugs did not affect the mass of the enzyme protein. Lipoprotein lipase activity in cultured Chinese hamster ovary cells was not inhibited by troglitazone. Glucose transport, biosynthesis of lipids from glucose or the biosynthesis of proteins were unaffected by thiazolidinediones in differentiated cells, whereas glucose transport and lipid biosynthesis were increased when these drugs were added during differentiation. These results show that troglitazone and BRL 49653 have a specific, post-translational inhibitory effect on lipoprotein lipase in adipocytes, yet they promote lipid accumulation and differentiation in preadipocytes.	Univ Arkansas Med Sci, Div Endocrinol, Dept Med, Little Rock, AR 72205 USA; John L McClellan Mem Vet Affairs Med Ctr, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Kern, PA (corresponding author), John L McClellan Mem Vet Hosp, ACOS Res,4300 W 7th St, Little Rock, AR 72205 USA.	KernPhilipA@exchange.UAMS.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039176] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK/HL 39176] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELFRAGE P, 1969, J LIPID RES, V10, P341; BENZEEV O, 1992, J BIOL CHEM, V267, P6219; BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; Cominacini L, 1997, DIABETOLOGIA, V40, P165, DOI 10.1007/s001250050658; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fulgencio JP, 1996, DIABETES, V45, P1556, DOI 10.2337/diabetes.45.11.1556; HARRIS PKW, 1993, MOL PHARMACOL, V45, P439; HOLLENBERG CH, 1966, J CLIN INVEST, V45, P205, DOI 10.1172/JCI105333; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KERN PA, 1985, J CLIN INVEST, V75, P199, DOI 10.1172/JCI111675; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Lefebvre AM, 1997, ARTERIOSCL THROM VAS, V17, P1756, DOI 10.1161/01.ATV.17.9.1756; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIMA FB, 1994, DIABETES, V43, P53, DOI 10.2337/diabetes.43.1.53; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; OLIVECRONA T, 1987, J BIOL CHEM, V262, P10748; ONG JM, 1989, J CLIN INVEST, V84, P305, DOI 10.1172/JCI114155; ONG JM, 1988, J BIOL CHEM, V263, P12933; PFEIFER MA, 1983, DIABETES, V32, P525, DOI 10.2337/diabetes.32.6.525; PYKALISTO OJ, 1975, J CLIN INVEST, V56, P1108, DOI 10.1172/JCI108185; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SHRAGO E, 1969, J BIOL CHEM, V244, P2761; SIMSOLO RB, 1992, J LIPID RES, V33, P89; SIMSOLO RB, 1992, J LIPID RES, V33, P1777; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STEVENSON RW, 1990, DIABETES, V39, P1218, DOI 10.2337/diabetes.39.10.1218; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; Tafuri SR, 1996, ENDOCRINOLOGY, V137, P4706, DOI 10.1210/en.137.11.4706; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WILSON JPD, 1973, METABOLISM, V22, P913, DOI 10.1016/0026-0495(73)90063-2; YUKHT A, 1995, J CLIN INVEST, V96, P2438, DOI 10.1172/JCI118301	41	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26117	26122		10.1074/jbc.273.40.26117	http://dx.doi.org/10.1074/jbc.273.40.26117			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748292	hybrid			2022-12-25	WOS:000076263100083
J	Nadal, A; Rovira, JM; Laribi, O; Leon-Quinto, T; Andreu, E; Ripoll, C; Soria, B				Nadal, A; Rovira, JM; Laribi, O; Leon-Quinto, T; Andreu, E; Ripoll, C; Soria, B			Rapid insulinotropic effect of 17 beta-estradiol via a plasma membrane receptor	FASEB JOURNAL			English	Article						intracellular calcium; K-ATP channels; insulin secretion; confocal microscopy; membrane estrogen receptor	PANCREATIC BETA-CELL; BURSTING ELECTRICAL-ACTIVITY; VASCULAR SMOOTH-MUSCLE; REPLACEMENT THERAPY; GLUCOSE; ISLETS; ESTROGEN; CALCIUM; OSCILLATIONS; SECRETION	Impaired insulin secretion is a hallmark in both type I and type II diabetic individuals. Whereas type I (insulin-dependent diabetes mellitus) implies p-cen destruction, type II (non-insulin dependent diabetes mellitus), responsible for 75% of diabetic syndromes, involves diminished glucose-dependent secretion of insulin from pancreatic beta-cells. Although a clear demonstration of a direct effect of 17 beta-estradiol on the pancreatic P-cen is lacking, an in vivo insulinotropic effect has been suggested. In this report we describe the effects of 17 beta-estradiol in mouse pancreatic p-cells. 17 beta-Estradiol, at physiological concentrations, closes K-ATP channels, which are also targets for antidiabetic sulfonylureas, in a rapid and reversible manner. Furthermore, in synergy with glucose, 17 beta-estradiol depolarizes the plasma membrane, eliciting electrical activity and intracellular calcium signals, which in turn enhance insulin secretion. These effects occur through a receptor located at the plasma membrane, distinct from the classic cytosolic estrogen receptor. Specific competitive binding and localization of 17 beta-estradiol receptors at the plasma membrane was demonstrated using confocal reflective microscopy and immunocytochemistry. Gaining deeper knowledge of the effect induced by 17 beta-estradiol may be important in order to better understand the hormonal regulation of insulin secretion and for the treatment of NIDDM.	Miguel Hernandez Univ, Sch Med, Inst Bioengn, Alicante 03550, Spain; Miguel Hernandez Univ, Dept Physiol, Alicante 03550, Spain	Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche	Nadal, A (corresponding author), Miguel Hernandez Univ, Sch Med, Inst Bioengn, San Juan Campus,Carretera Alicante Valencia Km 87, Alicante 03550, Spain.	nadal@umh.es	Andreu, Etelvina/M-1623-2014; , Bernat/AAL-6470-2021; Ripoll, Cristina/F-3324-2016; Nadal, Angel/G-6721-2014	Andreu, Etelvina/0000-0003-0156-8944; Ripoll, Cristina/0000-0003-0935-8722; Nadal, Angel/0000-0003-4178-2152; Soria, Bernat/0000-0002-2356-0380				Alonso R, 1998, NEUROCHEM RES, V23, P675, DOI 10.1023/A:1022442922931; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Barbosa RM, 1996, BIOCHEM BIOPH RES CO, V228, P100, DOI 10.1006/bbrc.1996.1622; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; Brussaard HE, 1997, DIABETOLOGIA, V40, P843, DOI 10.1007/s001250050758; EFRAT S, 1991, ENDOCRINOLOGY, V128, P897, DOI 10.1210/endo-128-2-897; HARDY SP, 1994, FASEB J, V8, P760, DOI 10.1096/fasebj.8.10.8050676; HOLTZ GG, 1993, NATURE, V361, P362; JENSEN SL, 1978, AM J PHYSIOL, V235, pE387, DOI 10.1152/ajpendo.1978.235.4.E387; Kitazawa T, 1997, J PHYSIOL-LONDON, V499, P497, DOI 10.1113/jphysiol.1997.sp021944; KUZNETSOVA VA, 1990, PEDIATRIA, V10, P12; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; MARTIN F, 1995, DIABETES, V44, P300, DOI 10.2337/diabetes.44.3.300; Mermelstein PG, 1996, J NEUROSCI, V16, P595; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; NADAL A, 1994, AM J PHYSIOL-ENDOC M, V267, pE769, DOI 10.1152/ajpendo.1994.267.5.E769; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Ramirez VD, 1996, CELL MOL NEUROBIOL, V16, P175, DOI 10.1007/BF02088175; RAMIREZ VD, 1992, NEUROPROTOCOLS, V1, P35; Ripoll C, 1996, DIABETES, V45, P1431, DOI 10.2337/diabetes.45.10.1431; SANCHEZANDRES JV, 1991, EUR J PHARMACOL, V205, P89, DOI 10.1016/0014-2999(91)90775-L; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; STEVENSON JC, 1994, DRUGS, V47, P35, DOI 10.2165/00003495-199400472-00007; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; VALDEOLMILLOS M, 1992, J PHYSIOL-LONDON, V455, P173, DOI 10.1113/jphysiol.1992.sp019295; WAHL MA, 1991, ENDOCRINOLOGY, V128, P3247, DOI 10.1210/endo-128-6-3247; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; ZHANG F, 1994, AM J PHYSIOL, V266, pC975, DOI 10.1152/ajpcell.1994.266.4.C975	31	189	201	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1998	12	13					1341	1348		10.1096/fasebj.12.13.1341	http://dx.doi.org/10.1096/fasebj.12.13.1341			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761777				2022-12-25	WOS:000076402000009
J	Kadowaki, T; Nakayama, K; Yoshimura, F; Okamoto, K; Abe, N; Yamamoto, K				Kadowaki, T; Nakayama, K; Yoshimura, F; Okamoto, K; Abe, N; Yamamoto, K			Arg-gingipain acts as a major processing enzyme for various cell surface proteins in Porphyromonas gingivalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBE BACTEROIDES-GINGIVALIS; TRYPSIN-LIKE PROTEASE; CYSTEINE PROTEINASE; MOLECULAR-CLONING; PERIODONTAL-DISEASE; STRUCTURAL CHARACTERIZATION; POSSIBLE INVOLVEMENT; LYS-GINGIPAIN; GENE PRTR; PURIFICATION	Arg-gingipain (RGP) is an Arg-X-specific cysteine proteinase produced by the Gram-negative anaerobe Porphyromonas gingivalis and has been shown to be a potent virulence factor in progressive periodontal disease (Nakayama, K., Kadowaki, T,, Okamoto, K,, and Yamamoto, K, (1995) J, Biol, Chem, 270, 23619-23626), In this study, we provide evidence that RGP acts as a major processing enzyme for various cell surface and secretory proteins in P, gingivalis. Fimbrilin, a major component of fimbriae, remained in the precursor form in the RGP-null mutant. Prefimbrilin expressed in Escherichia coli was converted to the mature fimbrilin in vitro when incubated with purified RGP, but its conversion was suppressed by potent RGP inhibitors. The results were consistent with the electron microscopic observation indicating little or no fimbriation in the RGP-null mutant. The immunogenic 75-kDa cell surface protein was also shown to retain its preform in the RGP-null mutant. In addition, Lys-gingipain (KGP) was found to be abnormally processed in the RGP-null mutant, In contrast, both prefimbrilin and the 75-kDa protein precursor were processed to their respective mature forms in the KG;P-null mutant, suggesting that KGP is not involved in the normal processing mechanisms of these proteins. These results suggest that RGP not only acts as a direct virulence factor but also makes a significant contribution as a major processing enzyme to the virulence of P. gingivalis,	Kyushu Univ, Fac Dent, Dept Pharmacol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Dent, Dept Microbiol, Higashi Ku, Fukuoka 8128582, Japan; Aichi Gakuin Univ, Sch Dent, Dept Microbiol, Nagoya, Aichi 4648650, Japan	Kyushu University; Kyushu University; Aichi Gakuin University	Yamamoto, K (corresponding author), Kyushu Univ, Fac Dent, Dept Pharmacol, Higashi Ku, Fukuoka 8128582, Japan.	kyama@dent.kyushu-u.ac.jp						Abe N, 1998, J BIOCHEM, V123, P305; ADUSEOPOKU J, 1995, INFECT IMMUN, V63, P4744, DOI 10.1128/IAI.63.12.4744-4754.1995; BarkocyGallagher GA, 1996, J BACTERIOL, V178, P2734, DOI 10.1128/jb.178.10.2734-2741.1996; BOYD J, 1984, INFECT IMMUN, V45, P403, DOI 10.1128/IAI.45.2.403-409.1984; DENARDIN AM, 1991, INFECT IMMUN, V59, P4363, DOI 10.1128/IAI.59.12.4363-4370.1991; DICKINSON DP, 1988, J BACTERIOL, V170, P1658, DOI 10.1128/jb.170.4.1658-1665.1988; FLETCHER HM, 1994, INFECT IMMUN, V62, P4279, DOI 10.1128/IAI.62.10.4279-4286.1994; FRANDSEN EVG, 1987, INFECT IMMUN, V55, P631, DOI 10.1128/IAI.55.3.631-638.1987; GRENIER D, 1992, INFECT IMMUN, V60, P1854, DOI 10.1128/IAI.60.5.1854-1857.1992; Han NM, 1996, INFECT IMMUN, V64, P4000, DOI 10.1128/IAI.64.10.4000-4007.1996; IMAMURA T, 1994, J CLIN INVEST, V94, P361, DOI 10.1172/JCI117330; KADOWAKI T, 1994, J BIOL CHEM, V269, P21371; KIRSZBAUM L, 1995, BIOCHEM BIOPH RES CO, V207, P424, DOI 10.1006/bbrc.1995.1205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTZ MS, 1991, J PERIODONTAL RES, V26, P283, DOI 10.1111/j.1600-0765.1991.tb01659.x; LEE JY, 1991, INFECT IMMUN, V59, P383, DOI 10.1128/IAI.59.1.383-389.1991; Nakayama K, 1996, J BACTERIOL, V178, P2818, DOI 10.1128/jb.178.10.2818-2824.1996; NAKAYAMA K, 1995, J BIOL CHEM, V270, P23619, DOI 10.1074/jbc.270.40.23619; Nakayama K, 1997, MICROBIOL IMMUNOL, V41, P185, DOI 10.1111/j.1348-0421.1997.tb01189.x; Nakayama K, 1998, MOL MICROBIOL, V27, P51, DOI 10.1046/j.1365-2958.1998.00656.x; NIEKRASH CE, 1986, J PERIODONTAL RES, V21, P233; OGAWA T, 1990, IMMUNOLOGY, V69, P8; OGAWA T, 1994, FEMS MICROBIOL LETT, V120, P23; Okamoto K, 1998, J BIOL CHEM, V273, P21225, DOI 10.1074/jbc.273.33.21225; Okamoto K, 1996, J BIOCHEM-TOKYO, V120, P398; OKAMOTO K, 1995, ARCH BIOCHEM BIOPHYS, V316, P917, DOI 10.1006/abbi.1995.1123; OKUDA K, 1981, CURR MICROBIOL, V6, P7, DOI 10.1007/BF01566718; Onoe T, 1995, MICROB PATHOGENESIS, V19, P351, DOI 10.1016/S0882-4010(96)80006-4; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; Pavloff N, 1997, J BIOL CHEM, V272, P1595, DOI 10.1074/jbc.272.3.1595; POTEMPA J, 1995, INFECT IMMUN, V63, P1176, DOI 10.1128/IAI.63.4.1176-1182.1995; Rangarajan M, 1997, MOL MICROBIOL, V23, P955, DOI 10.1046/j.1365-2958.1997.2831647.x; SATO M, 1987, ARCH ORAL BIOL, V32, P235, DOI 10.1016/0003-9969(87)90016-1; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; Slakeski N, 1996, BIOCHEM BIOPH RES CO, V224, P605, DOI 10.1006/bbrc.1996.1073; SLOTS J, 1984, J DENT RES, V63, P412, DOI 10.1177/00220345840630031101; SLOTS J, 1978, INFECT IMMUN, V19, P254, DOI 10.1128/IAI.19.1.254-264.1978; WATANABE K, 1992, FEMS MICROBIOL LETT, V92, P47, DOI 10.1016/0378-1097(92)90540-5; WINGROVE JA, 1992, J BIOL CHEM, V267, P18902; YAMAMOTO K, 1985, J BIOCHEM-TOKYO, V97, P821, DOI 10.1093/oxfordjournals.jbchem.a135122; YAMAMOTO K, 1997, MED ASPECTS PROTEASE, P19; YOSHIMURA F, 1993, INFECT IMMUN, V61, P5181, DOI 10.1128/IAI.61.12.5181-5189.1993; YOSHIMURA F, 1985, J BACTERIOL, V163, P730, DOI 10.1128/JB.163.2.730-734.1985; YOSHIMURA F, 1984, J BACTERIOL, V160, P949, DOI 10.1128/JB.160.3.949-957.1984; YOSHIMURA F, 1989, INFECT IMMUN, V57, P3646, DOI 10.1128/IAI.57.11.3646-3652.1989	45	140	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					29072	29076		10.1074/jbc.273.44.29072	http://dx.doi.org/10.1074/jbc.273.44.29072			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786913	hybrid			2022-12-25	WOS:000076691800074
J	Lim, KL; Kolatkar, PR; Ng, KP; Ng, CH; Pallen, CJ				Lim, KL; Kolatkar, PR; Ng, KP; Ng, CH; Pallen, CJ			Interconversion of the kinetic identities of the tandem catalytic domains of receptor-like protein-tyrosine phosphatase PTP alpha by two point mutations is synergistic and substrate-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; STRUCTURAL BASIS; PURIFICATION; CD45; LAR; INTERMEDIATE; SPECIFICITY; EXPRESSION; MECHANISM; FORM	The two tandem homologous catalytic domains of PTP alpha possess different kinetic properties, with the membrane proximal domain (D1) exhibiting much higher activity than the membrane distal (D2) domain. Sequence alignment of PTP alpha-D1 and -D2 with the D1 domains of other receptor-like PTPs, and modeling of the PTP alpha-D1 and -D2 structures, identified two nonconserved amino acids in PTP alpha-D2 that may account for its low activity. Mutation of each residue (Val-536 or Glu-671) to conform to its invariant counterpart in PTP alpha-D1 positively affected the catalytic efficiency of PTP alpha-D2 toward the in vitro substrates para-nitrophenylphosphate and the phosphotyrosyl-peptide RR-src. Together, they synergistically transformed PTP alpha-D2 into a phosphatase with catalytic efficiency for para-nitrophenylphosphate equal to PTP alpha-D1 but not approaching that of PTP alpha-D1 for the more complex substrate RR-src, In vivo, no gain in D2 activity toward p59(fyn) was effected by the double mutation. Alteration of the two corresponding invariant residues in PTPa-D1 to those in D2 conferred Da-like kinetics toward all substrates, Thus, these two amino acids are critical for interaction with phosphotyrosine but not sufficient to supply PTP alpha-D2 with a D1-like substrate specificity for elements of the phosphotyrosine microenvironment present in RR-src and p59(fyn). Whether the structural features of D2 can uniquely accommodate a specific phosphoprotein substrate or whether D2 has an alternate function in PTP alpha remains an open question.	Inst Cell & Mol Biol, Cell Regulat Lab, Singapore 117609, Singapore; Natl Univ Singapore Hosp, Bioinformat Ctr, Singapore 119074, Singapore	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Pallen, CJ (corresponding author), Inst Cell & Mol Biol, Cell Regulat Lab, 30 Med Dr, Singapore 117609, Singapore.		Lim, Kah-Leong/AAY-3308-2020; Lim, Kah/L-5426-2019	Lim, Kah-Leong/0000-0002-5440-2588; Pallen, Catherine/0000-0002-3576-5295; Ng, Chee Hoe/0000-0001-8545-0497; kolatkar, prasanna/0000-0003-4970-5944				BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; CHO HJ, 1992, J AM CHEM SOC, V114, P7206; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GEBBINK MFBG, 1993, BIOCHEMISTRY-US, V32, P13516, DOI 10.1021/bi00212a017; GUAN KL, 1991, J BIOL CHEM, V266, P17026; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LEE C, 1991, J MOL BIOL, V217, P373, DOI 10.1016/0022-2836(91)90550-P; Lim KL, 1997, EUR J BIOCHEM, V245, P693, DOI 10.1111/j.1432-1033.1997.00693.x; POT DA, 1991, J BIOL CHEM, V266, P19688; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	29	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28986	28993		10.1074/jbc.273.44.28986	http://dx.doi.org/10.1074/jbc.273.44.28986			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786903	hybrid			2022-12-25	WOS:000076691800064
J	Luzzi, V; Sims, CE; Soughayer, JS; Allbritton, NL				Luzzi, V; Sims, CE; Soughayer, JS; Allbritton, NL			The physiologic concentration of inositol 1,4,5-trisphosphate in the oocytes of Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; PHOSPHOLIPASE-C; CAPILLARY ELECTROPHORESIS; CA2+ MOBILIZATION; CALCIUM-RELEASE; CELLS; TRISPHOSPHATE; MASS; PROTEIN; OSCILLATIONS	To measure the concentration of inositol 1,4,5-trisphosphate ([IP3]) in small regions of single Xenopus oocytes, a biological detector cell was combined with capillary electrophoresis, This method is 10,000 times more sensitive than all existing assays enabling subcellular measurement of [IP3] in Xenopus oocytes. Upon addition of lysophosphatidic acid to an oocyte, [IP3] increased from 40 to 650 nM within 2 min. IP3 concentrations as high as 1.8 mu M were measured after activation with lysophosphatidic acid, suggesting that the physiologic concentration of IP3 ranges from the tens of nanomolar to a few micromolar in Xenopus oocytes. Since the IP3 receptor in Xenopus oocytes is nearly identical to the type I receptor of mammalian cells, the range of [IP3] in most mammalian cells is likely to be similar to that in the oocyte. By selecting or engineering the appropriate detector cell, this strategy should be applicable to cyclic adenosine diphosphate ribose and nicotinic acid adenine dinucleotide phosphate, and to the discovery of new Ca2+-releasing second messengers.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Allbritton, NL (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	nlallbri@uci.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057015] Funding Source: NIH RePORTER; NIAID NIH HHS [K08AI01513] Funding Source: Medline; NIGMS NIH HHS [GM57015] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GSJ, 1991, BIOCHEM J, V273, P541, DOI 10.1042/bj2730541; BRADFORD PG, 1986, J BIOL CHEM, V261, P5644; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; CALLAMARAS N, 1994, CELL CALCIUM, V15, P56; CHALLISS RAJ, 1988, BIOCHEM BIOPH RES CO, V157, P684, DOI 10.1016/S0006-291X(88)80304-8; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CRANK J, 1989, MATH DIFFUSION, P2; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FISHMAN HA, 1994, ANAL CHEM, V66, P2318, DOI 10.1021/ac00086a018; FISHMAN HA, 1994, J CHROMATOGR A, V680, P99, DOI 10.1016/0021-9673(94)80057-X; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; GIOVANNELLI A, 1995, CELL CALCIUM, V18, P41, DOI 10.1016/0143-4160(95)90044-6; GROMADA J, 1993, CELL CALCIUM, V14, P711, DOI 10.1016/0143-4160(93)90097-P; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; HAUGLAND R, 1996, HDB FLUORESCENT PROB, P527; HJERTEN S, 1985, J CHROMATOGR, V347, P191, DOI 10.1016/S0021-9673(01)95485-8; HOFER AM, 1995, FASEB J, V9, P788, DOI 10.1096/fasebj.9.9.7601343; HORSTMAN DA, 1988, J BIOL CHEM, V263, P15297; HUANG XH, 1990, J CHROMATOGR, V516, P185, DOI 10.1016/S0021-9673(01)90216-X; Kaftan EJ, 1997, J GEN PHYSIOL, V110, P529, DOI 10.1085/jgp.110.5.529; KEIZER J, 1992, BIOPHYS J, V61, P649, DOI 10.1016/S0006-3495(92)81870-2; KHODAKHAH K, 1993, P NATL ACAD SCI USA, V90, P4976, DOI 10.1073/pnas.90.11.4976; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; Luzzi V, 1997, ANAL CHEM, V69, P4761, DOI 10.1021/ac970550o; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PRENTKI M, 1984, NATURE, V309, P562, DOI 10.1038/309562a0; RYU SH, 1987, J BIOL CHEM, V262, P12511; SAFRANY ST, 1992, EUR J PHARM-MOLEC PH, V226, P265, DOI 10.1016/0922-4106(92)90071-3; SAKUTA H, 1991, EUR J PHARMACOL, V12, P31; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SHAYMAN JA, 1987, BIOCHEM BIOPH RES CO, V145, P1119, DOI 10.1016/0006-291X(87)91553-1; SHEAR JB, 1995, SCIENCE, V267, P74, DOI 10.1126/science.7809609; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; Sims CE, 1998, J BIOL CHEM, V273, P4052, DOI 10.1074/jbc.273.7.4052; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STITH BJ, 1993, MOL BIOL CELL, V4, P435, DOI 10.1091/mbc.4.4.435; SULPICE JC, 1990, METHODS INOSITIDE RE, P45; SWEDBERG SA, 1990, ANAL BIOCHEM, V185, P51, DOI 10.1016/0003-2697(90)90253-6; TARVER AP, 1987, J BIOL CHEM, V262, P17268; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TIGYI G, 1990, P NATL ACAD SCI USA, V87, P1521, DOI 10.1073/pnas.87.4.1521; UNDERWOOD RH, 1988, ENDOCRINOLOGY, V123, P211, DOI 10.1210/endo-123-1-211; WEINBERGER R, 1993, PRACTICAL CAPILLARY, P200; WILSON DB, 1984, J BIOL CHEM, V259, P1718; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	56	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28657	28662		10.1074/jbc.273.44.28657	http://dx.doi.org/10.1074/jbc.273.44.28657			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786859	hybrid			2022-12-25	WOS:000076691800020
J	Macq, AF; Czech, C; Essalmani, R; Brion, JP; Maron, A; Mercken, L; Pradier, L; Octave, JN				Macq, AF; Czech, C; Essalmani, R; Brion, JP; Maron, A; Mercken, L; Pradier, L; Octave, JN			The long term adenoviral expression of the human amyloid precursor protein shows different secretase activities in rat cortical neurons and astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; TRANSGENIC MICE; BETA; PEPTIDES; CELLS; GENE; COMPARTMENT; CEREBELLUM; METABOLISM	Recombinant adenoviruses were used for the expression of human amyloid precursor protein (APP) of Alzheimer's disease in primary cultures of rat cortical neurons and astrocytes, The catabolic pathways of human APP were studied 3 to 4 days after infection, when the equilibrium of APP production was reached, Although the expression of human wild type APP (WtAPP) by rat neurons induced the production of both extracellular and intraneuronal amyloid peptide (A beta), A beta was not detected in the culture medium of rat astrocytes producing human WtAPP. Because a low beta-secretase activity was previously reported in rodent astrocytes, we wondered whether modifications of the APP amino acid sequence at the beta-secretase clipping site would modify the astrocytic production of A beta. Interestingly, rat astrocytes produced high amounts of A beta after expression of human APP carrying a double amino acid substitution responsible for Alzheimer's disease in a large Swedish family (SwAPP), In both rat cortical neurons and astrocytes, the beta-secretase cleavage of the human SwAPP occurred very early in the secretion process in a cellular compartment in which a different sorting of SwAPP and WtAPP seems unlikely, These results suggest that human WtAPP and SwAPP could be processed by different beta-secretase activities.	Catholic Univ Louvain, Lab Expt Pharmacol, FARL 5410, B-1200 Brussels, Belgium; Rhone Poulenc Rorer, F-94400 Vitry Sur Seine, France; Free Univ Brussels, Lab Pathol & Elect Microscopy, B-1070 Brussels, Belgium	Universite Catholique Louvain; Sanofi-Aventis; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Octave, JN (corresponding author), Catholic Univ Louvain, Lab Expt Pharmacol, FARL 5410, 54 Ave Hippocrate, B-1200 Brussels, Belgium.	cctave@nchm.ucl.ac.be	Brion, Jean-Pierre/C-6467-2009	Brion, Jean-Pierre/0000-0002-1917-775X; Czech, Christian/0000-0001-7746-0134				Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; BRION JP, 1988, DEV BRAIN RES, V44, P221, DOI 10.1016/0165-3806(88)90220-9; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Czech C, 1997, MOL BRAIN RES, V47, P108, DOI 10.1016/S0169-328X(97)00039-9; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; Essalmani R, 1996, BIOCHEM BIOPH RES CO, V218, P89, DOI 10.1006/bbrc.1996.0017; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HEUSCHLING P, 1995, J NEUROIMMUNOL, V57, P63, DOI 10.1016/0165-5728(94)00162-H; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LeBlanc AC, 1997, J NEUROCHEM, V68, P1183; Maron A, 1997, GENE THER, V4, P25, DOI 10.1038/sj.gt.3300353; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McPhie DL, 1997, J BIOL CHEM, V272, P24743, DOI 10.1074/jbc.272.40.24743; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Octave JN, 1995, REV NEUROSCIENCE, V6, P287; OLKKONEN VM, 1993, J NEUROSCI RES, V35, P445, DOI 10.1002/jnr.490350412; Philippe B, 1996, J NEUROSCI RES, V46, P709, DOI 10.1002/jnr.490460602; PIKE CJ, 1995, EXP NEUROL, V132, P172, DOI 10.1016/0014-4886(95)90022-5; Simons M, 1996, J NEUROSCI, V16, P899; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tienari PJ, 1996, EMBO J, V15, P5218, DOI 10.1002/j.1460-2075.1996.tb00907.x; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Zhao J, 1996, J BIOL CHEM, V271, P31407, DOI 10.1074/jbc.271.49.31407	32	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28931	28936		10.1074/jbc.273.44.28931	http://dx.doi.org/10.1074/jbc.273.44.28931			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786896	hybrid			2022-12-25	WOS:000076691800057
J	Stuhlsatz-Krouper, SM; Bennett, NE; Schaffer, JE				Stuhlsatz-Krouper, SM; Bennett, NE; Schaffer, JE			Substitution of alanine for serine 250 in the murine fatty acid transport protein inhibits long chain fatty acid transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; NUCLEOTIDE-BINDING; MEMBRANE-PROTEIN; PREADIPOCYTE DIFFERENTIATION; PEPTIDE SYNTHETASES; MOLECULAR-CLONING; ATP-BINDING; H+-ATPASE; RAT; ADIPOCYTE	The murine fatty acid transport protein (FATP) was identified on the basis of its ability to facilitate uptake of long chain fatty acids (LCFAs) when expressed in mammalian cells. To delineate FATP domains important for transport function, we cloned the human heart FATP ortholog, Comparison of the human, murine, and yeast amino acid sequences identified a highly conserved motif, IYTSGTTGXPK, also found in a number of proteins that form adenylated intermediates. We demonstrate that depletion of intracellular ATP dramatically reduces FATP-mediated LCFA uptake. Furthermore, wildtype FATP specifically binds [alpha-P-32]azido-ATP. Introduction of a serine to alanine substitution (S250A) in the IYTSGTTGXPK motif produces an appropriately expressed and metabolized mutant FATP that demonstrates diminished LCFA transport function and decreased [alpha-P-32]azido-ATP binding. These results are consistent with a mechanism of action for FATP involving ATP binding that is dependent on serine 250 of the IYTSGTTGXPK motif.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Schaffer, JE (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Internal Med, 660 S Euclid Ave,Box 8086, St Louis, MO 63110 USA.							ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; ABUMRAD NA, 1986, J BIOL CHEM, V261, P2999; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Blobel F, 1996, EUR J BIOCHEM, V240, P468, DOI 10.1111/j.1432-1033.1996.0468h.x; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; FANESTIL DD, 1981, AM J PHYSIOL, V240, pC201, DOI 10.1152/ajpcell.1981.240.5.C201; GOCHT M, 1994, J BACTERIOL, V176, P2654, DOI 10.1128/JB.176.9.2654-2662.1994; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; ISOLA LM, 1995, P NATL ACAD SCI USA, V92, P9866, DOI 10.1073/pnas.92.21.9866; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; Man MZ, 1996, MOL ENDOCRINOL, V10, P1021, DOI 10.1210/me.10.8.1021; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P11935, DOI 10.1021/bi00205a032; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PAVELAVRANCIC M, 1994, BIOCHEMISTRY-US, V33, P6276, DOI 10.1021/bi00186a030; PAVELAVRANCIC M, 1994, EUR J BIOCHEM, V220, P535, DOI 10.1111/j.1432-1033.1994.tb18653.x; RAO R, 1993, J BIOL CHEM, V268, P6708; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schaap FG, 1997, BBA-GENE STRUCT EXPR, V1354, P29, DOI 10.1016/S0167-4781(97)00121-8; Schaffer JE, 1995, TRENDS CARDIOVAS MED, V5, P218, DOI 10.1016/1050-1738(95)00102-6; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHULTZ BD, 1996, J MEMBRANE BIOL, V151, P93; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, BIOCHIM BIOPHYS ACTA, V877, P191, DOI 10.1016/0005-2760(86)90134-7; STREMMEL W, 1988, J CLIN INVEST, V82, P2001, DOI 10.1172/JCI113820; STREMMEL W, 1988, J CLIN INVEST, V81, P844, DOI 10.1172/JCI113393; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; Thompson JF, 1997, J BIOL CHEM, V272, P18766, DOI 10.1074/jbc.272.30.18766; TOH H, 1991, Protein Sequences and Data Analysis, V4, P111; TOH H, 1990, PROTEIN SEQ DATA ANA, V3, P57; TOKITA K, 1993, J BIOCHEM-TOKYO, V114, P522, DOI 10.1093/oxfordjournals.jbchem.a124210; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	42	67	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28642	28650		10.1074/jbc.273.44.28642	http://dx.doi.org/10.1074/jbc.273.44.28642			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786857	hybrid			2022-12-25	WOS:000076691800018
J	Biwa, T; Hakamata, H; Sakai, M; Miyazaki, A; Suzuki, H; Kodama, T; Shichiri, M; Horiuchi, S				Biwa, T; Hakamata, H; Sakai, M; Miyazaki, A; Suzuki, H; Kodama, T; Shichiri, M; Horiuchi, S			Induction of murine macrophage growth by oxidized low density lipoprotein is mediated by granulocyte macrophage colony-stimulating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERITONEAL-MACROPHAGES; SCAVENGER RECEPTOR; CELL-LINE; GM-CSF; ATHEROSCLEROTIC LESIONS; MESSENGER-RNA; DNA-SYNTHESIS; FACTOR GENE; PROLIFERATION; EXPRESSION	We have examined whether certain secreted factor(s) is involved in oxidized low density lipoprotein (Ox-LDL)-induced murine macrophage growth. An antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) effectively inhibited Ox-LDL-induced macrophage growth by >80%. Ox-LDL as well as phospholipase A(2)-treated acetylated LDL enhanced mRNA levels and protein release of GM-CSF from macrophages, while neither acetylated LDL nor lysophosphatidylcholine (lyso-PC) showed such effects. The maximal induction of GM-CSF by Ox-LDL was noted at 4 h, followed by a time-dependent decrease to a basal level within 24 h. Ox-LDL-induced macrophage growth was inhibited by 75% by replacement of the culture medium at 24 h by a fresh medium containing the same concentration of Ox-LDL, when GM-CSF had already returned to the basal level. Thus, a cytokine(s) other than GMCSF is also expected to participate in Ox-LDL-induced macrophage growth in a later phase. The Ox-LDL-induced GM-CSF release was inhibited by calphostin C, a protein kinase C inhibitor, and was significantly reduced in macrophages from the knockout mice lacking class A, type I and type II macrophage scavenger receptors (MSR-AI/AII). These results taken together indicate that effective endocytosis of lyse-PC of Ox-LDL by macrophages through MSR-AI/AII and subsequent protein kinase C activation have led to GM-CSF release into the medium which may play a priming role in conjunction with other cytokines in Ox-LDL-induced macrophage growth.	Kumamoto Univ, Sch Med, Dept Biochem, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Metab Med, Kumamoto 8600811, Japan; Chugai Pharmaceut Co Ltd, Shizuoka 4120038, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Dept Mol Biol & Med, Tokyo 1530041, Japan	Kumamoto University; Kumamoto University; Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Tokyo	Horiuchi, S (corresponding author), Kumamoto Univ, Sch Med, Dept Biochem, Honjo 2-2-1, Kumamoto 8600811, Japan.	horiuchi@gpo.kumamoto-u.ac.jp						ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CAMPBELL HD, 1988, EUR J BIOCHEM, V174, P345, DOI 10.1111/j.1432-1033.1988.tb14104.x; CHEN BDM, 1986, J IMMUNOL, V137, P563; CHEN BDM, 1988, BLOOD, V71, P997; CHODAKEWITZ JA, 1988, J IMMUNOL, V140, P832; CLINTON SK, 1992, AM J PATHOL, V140, P301; FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; Hakamata H, 1998, J LIPID RES, V39, P482; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Kodama T, 1996, CURR OPIN LIPIDOL, V7, P287, DOI 10.1097/00041433-199610000-00005; LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706; LEE JC, 1982, J IMMUNOL, V128, P2393; Lougheed M, 1997, J BIOL CHEM, V272, P12938, DOI 10.1074/jbc.272.20.12938; Martens JS, 1998, J BIOL CHEM, V273, P4915, DOI 10.1074/jbc.273.9.4915; Matsuda H, 1996, BBA-LIPID LIPID MET, V1301, P76, DOI 10.1016/0005-2760(96)00020-3; Matsumura T, 1997, ARTERIOSCL THROM VAS, V17, P3013, DOI 10.1161/01.ATV.17.11.3013; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MIYATAKE S, 1985, P NATL ACAD SCI USA, V82, P316, DOI 10.1073/pnas.82.2.316; MURAKAMI M, 1987, J BIOCHEM-TOKYO, V101, P729, DOI 10.1093/jb/101.3.729; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PESSINA A, 1992, CYTOTECHNOLOGY, V8, P93, DOI 10.1007/BF02525491; QUINN MT, 1985, P NATL ACAD SCI USA, V82, P5949, DOI 10.1073/pnas.82.17.5949; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; RALPH P, 1977, J IMMUNOL, V119, P950; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSENFELD ME, 1992, AM J PATHOL, V140, P291; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakai M, 1998, TRENDS CARDIOVAS MED, V8, P119, DOI 10.1016/S1050-1738(97)00139-4; Sakai M, 1996, J BIOL CHEM, V271, P27346, DOI 10.1074/jbc.271.44.27346; SAKAI M, 1994, J BIOL CHEM, V269, P31430; Sakai M, 1996, ARTERIOSCL THROM VAS, V16, P600, DOI 10.1161/01.ATV.16.4.600; Sambrook J., 2002, MOL CLONING LAB MANU; Sasaki T, 1996, BIOL PHARM BULL, V19, P449; Sato Y, 1996, ATHEROSCLEROSIS, V125, P15, DOI 10.1016/0021-9150(96)05829-7; SPAGNOLI LG, 1991, ATHEROSCLEROSIS, V88, P87, DOI 10.1016/0021-9150(91)90260-A; STANLEY ER, 1976, J EXP MED, V143, P631, DOI 10.1084/jem.143.3.631; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEWART CC, 1978, J RETICULOENDOTH SOC, V23, P269; Suginohara Y, 1996, ATHEROSCLEROSIS, V120, P167, DOI 10.1016/0021-9150(95)05698-X; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WANG J, 1994, EXP MOL PATHOL, V61, P109, DOI 10.1006/exmp.1994.1030; Yia-Herttuala S, 1989, J CLIN INVEST, V84, P1086; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331	55	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28305	28313		10.1074/jbc.273.43.28305	http://dx.doi.org/10.1074/jbc.273.43.28305			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774454	hybrid			2022-12-25	WOS:000076549800074
J	Stewart, C; Bailey, J; Manoil, C				Stewart, C; Bailey, J; Manoil, C			Mutant membrane protein toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LACTOSE PERMEASE; LAC PERMEASE; RETINITIS-PIGMENTOSA; TRANSPORT PROTEIN; MUTATIONS; SEQUENCES; STABILITY; TOPOLOGY; RESIDUES	This report describes an extensive mutational analysis of the most carboxyl-terminal membrane-spanning sequence of Escherichia coli lac permease (TM12), In addition to identifying residues important for lactose transport function, the analysis revealed that numerous mutations made lac permease highly toxic to cells. In the most extreme cases, production of such proteins at very low steady-state levels reduced cell viability greater than 10(4)-fold. Both frameshift and missense mutations led to toxicity, with the frameshift mutations having the strongest effects observed. The toxic missense mutations corresponded to changes in TM12 expected to interfere with membrane insertion or folding, such as the introduction of charged residues or prolines in the putative helix, The results suggest that cellular toxicity may be a relatively common consequence of mutations altering integral membrane protein folding. An analogous toxicity might contribute to the pathogenesis of several degenerative diseases caused by mutant membrane proteins, such as retinitis pigmentosa, Charcot-Marie-Tooth syndrome, and Alzheimer's disease.	Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Manoil, C (corresponding author), Univ Washington, Dept Genet, Box 357360, Seattle, WA 98195 USA.							ALMAGHTHEH M, 1993, HUM MUTAT, V2, P249, DOI 10.1002/humu.1380020403; Bailey J, 1998, J MOL BIOL, V277, P199, DOI 10.1006/jmbi.1998.1627; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Goswitz VC, 1996, J BIOL CHEM, V271, P21927, DOI 10.1074/jbc.271.36.21927; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; HINKLE PC, 1990, BIOCHEMISTRY-US, V29, P10989, DOI 10.1021/bi00501a017; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; JUNG K, 1995, BIOCHEMISTRY-US, V34, P1030, DOI 10.1021/bi00003a038; KABACK HR, 1996, HDB BIOL PHYSICS TRA, P203; Lee MH, 1997, PROTEIN ENG, V10, P715, DOI 10.1093/protein/10.6.715; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; Manoil C, 1995, ANNU REV GENET, V29, P131; Manoil C, 1997, J MOL BIOL, V267, P250, DOI 10.1006/jmbi.1996.0881; MCKENNA E, 1992, J BIOL CHEM, V267, P6471; MCKENNA E, 1991, P NATL ACAD SCI USA, V88, P2969, DOI 10.1073/pnas.88.8.2969; Miller JH., 1972, EXPT BACTERIAL GENET; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; SABERWAL G, 1994, BBA-REV BIOMEMBRANES, V1197, P109, DOI 10.1016/0304-4157(94)90002-7; SELIGMAN L, 1995, J BACTERIOL, V177, P2315, DOI 10.1128/jb.177.9.2315-2320.1995; SUTER U, 1994, HUM MUTAT, V3, P95, DOI 10.1002/humu.1380030203; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; Varela MF, 1996, BBA-BIOENERGETICS, V1276, P21, DOI 10.1016/0005-2728(96)00030-8	27	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28078	28084		10.1074/jbc.273.43.28078	http://dx.doi.org/10.1074/jbc.273.43.28078			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774425	hybrid			2022-12-25	WOS:000076549800045
J	Vince, JW; Reithmeier, RAF				Vince, JW; Reithmeier, RAF			Carbonic anhydrase II binds to the carboxyl terminus of human band 3, the erythrocyte Cl-/HCO3- exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSPORT PROTEIN; RED-BLOOD-CELL; PROTEOLYTIC DISSECTION; TRANSMEMBRANE POLYPEPTIDE; MONOCLONAL-ANTIBODIES; CYTOPLASMIC DOMAIN; PLASMA-MEMBRANE; NH2 TERMINUS; LOCALIZATION; ASSOCIATION	In this study, we provide evidence that the 33-residue carboxyl-terminal (Ct) region of the human erythrocyte chloride/bicarbonate exchanger, band 3, binds carbonic anhydrase II (CAII), Immunofluorescence showed that tomato lectin-mediated clustering of band 3 in ghost membranes caused a similar clustering of CAII, indicating an in situ association. CAII cosolubilized and coimmunoprecipitated with band 3, suggesting that the two proteins form a complex. Band 3 (K-1/2 = 70 nM) or the membrane domain of band 3 (K-1/2 = 100 nM) bound saturably to immobilized CAII in a solid phase binding assay. The interaction with CAII was specifically blocked by an antibody to the Ct of band 3, Affinity blotting showed that a glutathione S-transferase (GST)-fusion protein (GST-Ct) containing the last 33 residues of human band 3 bound to CAII, The solid phase binding assay showed that binding of GST-Ct to immobilized CAII was saturable (K-1/2 = 20 nM). The binding rate was slow (t(1/2) = 12 h) at physiological ionic strength and pH but was enhanced at low ionic strength or acidic pH. Intact band 3 (K-i = 15 nM), the membrane domain of band 3 (K-i = 100 nM), or antibodies to the Ct of band 3 were able to block GST-Ct binding to CAII, confirming the specificity of the interaction. Affinity chromatography showed that CAII bound to immobilized GST-Ct with a 1:1 stoichiometry. This work indicates that CAII, the bicarbonate supplier, is directly coupled to band 3, the chloride/bicarbonate exchanger in red blood cells.	Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Reithmeier, RAF (corresponding author), Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Rm 7344,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	r.reithmeier@utoronto.ca						BENNETT V, 1983, METHOD ENZYMOL, V96, P313; CASEY JR, 1989, METHOD ENZYMOL, V173, P494; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CASEY JR, 1992, J BIOL CHEM, V267, P11940; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; DRICKAMER LK, 1976, J BIOL CHEM, V251, P5115; EDELMAN GM, 1971, P NATL ACAD SCI USA, V68, P2153, DOI 10.1073/pnas.68.9.2153; ENGLAND BJ, 1980, BIOCHIM BIOPHYS ACTA, V623, P171, DOI 10.1016/0005-2795(80)90019-7; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; GUY D, 1979, EXP CELL BIOL, V47, P312; HARRISON ML, 1991, J BIOL CHEM, V266, P4106; HIGASHI T, 1979, J BIOL CHEM, V254, P9542; Hoffman J F, 1997, Curr Opin Hematol, V4, P112; HOLTHOFER H, 1987, LAB INVEST, V57, P150; JENNINGS ML, 1986, J BIOL CHEM, V261, P9002; KENDALL AG, 1977, SCIENCE, V197, P471, DOI 10.1126/science.406674; KIFOR G, 1993, J MEMBRANE BIOL, V134, P169; KIM J, 1992, AM J PHYSIOL, V262, pF288, DOI 10.1152/ajprenal.1992.262.2.F288; KOLLERTJONS A, 1993, AM J PHYSIOL, V265, pF813, DOI 10.1152/ajprenal.1993.265.6.F813; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KORSGREN C, 1988, J BIOL CHEM, V263, P10212; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN DM, 1987, BIOCHIM BIOPHYS ACTA, V903, P37, DOI 10.1016/0005-2736(87)90153-2; LIEBERMAN DM, 1988, J BIOL CHEM, V263, P10022; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; McCoy AJ, 1997, J MOL BIOL, V268, P570, DOI 10.1006/jmbi.1997.0987; MERCER RW, 1981, J GEN PHYSIOL, V78, P547, DOI 10.1085/jgp.78.5.547; MORI A, 1995, J BIOCHEM-TOKYO, V118, P1192, DOI 10.1093/oxfordjournals.jbchem.a125006; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; NASSEEM A, 1989, METHOD ENZYMOL, V173, P513; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; PARKES JL, 1989, ARCH BIOCHEM BIOPHYS, V275, P459, DOI 10.1016/0003-9861(89)90392-5; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; POWER GG, 1970, J APPL PHYSIOL, V29, P145, DOI 10.1152/jappl.1970.29.2.145; PROVERBIO F, 1977, J GEN PHYSIOL, V69, P605, DOI 10.1085/jgp.69.5.605; Reithmeier R.A.F., 1996, HDB BIOL PHYS, V2, P281; ROGALSKI AA, 1989, J BIOL CHEM, V264, P6438; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SHIP S, 1977, J MEMBRANE BIOL, V33, P311, DOI 10.1007/BF01869522; SLY WS, 1985, NEW ENGL J MED, V313, P139, DOI 10.1056/NEJM198507183130302; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STECK TL, 1971, BIOCHEMISTRY-US, V10, P2617, DOI 10.1021/bi00789a031; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; STRAPAZON E, 1977, BIOCHEMISTRY-US, V16, P2966, DOI 10.1021/bi00632a025; SWENSON ER, 1993, J APPL PHYSIOL, V74, P838, DOI 10.1152/jappl.1993.74.2.838; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; Tashian R E, 1976, Adv Hum Genet, V7, P1; THORSLUND A, 1967, EUR J BIOCHEM, V3, P117, DOI 10.1111/j.1432-1033.1967.tb19504.x; Vince JW, 1997, BBA-BIOMEMBRANES, V1326, P295, DOI 10.1016/S0005-2736(97)00033-3; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211; YANNOUKAKOS D, 1991, BIOCHIM BIOPHYS ACTA, V1066, P70, DOI 10.1016/0005-2736(91)90252-4; YU J, 1975, J BIOL CHEM, V250, P9176; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	57	191	195	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28430	28437		10.1074/jbc.273.43.28430	http://dx.doi.org/10.1074/jbc.273.43.28430			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774471	hybrid			2022-12-25	WOS:000076549800091
J	Keely, SJ; Uribe, JM; Barrett, KE				Keely, SJ; Uribe, JM; Barrett, KE			Carbachol stimulates transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T-84 cells - Implications for carbachol-stimulated chloride secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; MAP KINASE; COUPLED RECEPTORS; ANGIOTENSIN-II; ION-CHANNEL; CASCADE; CALCIUM; PYK2; INHIBITION; PATHWAYS	We have examined the role of tyrosine phosphorylation in regulation of calcium-dependent chloride secretion across T-84 colonic epithelial cells. The calcium-mediated agonist carbachol (CCh, 100 mu M) stimulated a time dependent increase in tyrosine phosphorylation of a range of proteins (with molecular masses ranging up to 180 kDa) in T-84 cells. The tyrosine kinase inhibitor, genistein (5 mu M), significantly potentiated chloride secretory responses to CCh, indicating a role for CCh-stimulated tyrosine phosphorylation in negative regulation of CCh-stimulated secretory responses. Further studies revealed that CCh stimulated an increase in both phosphorylation and activity of the extracellular signal-regulated kinase (ERK) isoforms of mitogen-activated protein kinase, Chloride secretory responses to CCh were also potentiated by the mitogen-activated protein kinase inhibitor, PD98059 (20 mu M), Phosphorylation of ERK in response to CCh was mimicked by the protein kinase C (PKC) activator, phorbol myristate acetate (100 nM), but was not altered by the PKC inhibitor GF 109203X (1 mu M). ERK phosphorylation was also induced by epidermal growth factor (EGF) (100 ng/ml), Immunoprecipitation/Western blot studies revealed that CCh stimulated tyrosine phosphorylation of the EGF receptor (EGFr) and increased co immunoprecipitation of the adapter proteins, Shc and Grb2, with the EGFr, An inhibitor of EGFr phosphorylation, tyrphostin AG1478 (1 mu M), reversed CCh-stimulated phosphorylation of both EGFr and ERK, Tyrphostin AG1478 also potentiated chloride secretory responses to CCh, We conclude that CCh activates ERK in T-84 cells via a mechanism involving transactivation of the EGFr, and that this pathway constitutes an inhibitory signaling pathway by which chloride secretory responses to CCh may be negatively regulated.	Univ Calif San Diego, Med Ctr, Dept Med, Sch Med, San Diego, CA 92103 USA	University of California System; University of California San Diego	Barrett, KE (corresponding author), Univ Calif San Diego, Med Ctr, Dept Med, Sch Med, 8414,200 W Arbor Dr, San Diego, CA 92103 USA.	kbarrett@ucsd.edu	Barrett, Kim/AAE-2794-2022; Barrett, Kim Elaine/AAE-7762-2019	Barrett, Kim Elaine/0000-0002-6704-998X; Keely, Stephen/0000-0002-6315-3587	NIDDK NIH HHS [DK28305, DK07202] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028305, T32DK007202] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barrett KE, 1997, AM J PHYSIOL-CELL PH, V272, pC1069, DOI 10.1152/ajpcell.1997.272.4.C1069; BISCHOF G, 1995, AM J PHYSIOL-CELL PH, V268, pC154, DOI 10.1152/ajpcell.1995.268.1.C154; Dabrowski A, 1997, AM J PHYSIOL-CELL PH, V273, pC1472, DOI 10.1152/ajpcell.1997.273.5.C1472; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; DICKINSON KEJ, 1992, EUR J PHARM-MOLEC PH, V225, P291, DOI 10.1016/0922-4106(92)90102-2; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Gerthoffer WT, 1997, AM J PHYSIOL-LUNG C, V272, pL244, DOI 10.1152/ajplung.1997.272.2.L244; HEASLEY LE, 1994, AM J PHYSIOL, V267, pF366, DOI 10.1152/ajprenal.1994.267.3.F366; Illek B, 1996, AM J PHYSIOL-CELL PH, V270, pC265, DOI 10.1152/ajpcell.1996.270.1.C265; ILLEK B, 1995, AM J PHYSIOL-CELL PH, V268, pC886, DOI 10.1152/ajpcell.1995.268.4.C886; LEHRICH RW, 1995, AM J PHYSIOL-RENAL, V269, pF594, DOI 10.1152/ajprenal.1995.269.4.F594; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Luttrell L M, 1998, Adv Pharmacol, V42, P466; MANDEL KG, 1986, AM J PHYSIOL, V250, pC486, DOI 10.1152/ajpcell.1986.250.3.C486; MANDEL KG, 1986, J BIOL CHEM, V261, P704; Nakamura K, 1996, AM J PHYSIOL-GASTR L, V271, pG640, DOI 10.1152/ajpgi.1996.271.4.G640; OFFERMANNS S, 1993, BIOCHEM J, V294, P545, DOI 10.1042/bj2940545; OMALLEY KE, 1995, EUR J PHARMACOL, V275, P83, DOI 10.1016/0014-2999(94)00758-Y; Reenstra WW, 1996, AM J PHYSIOL-CELL PH, V271, pC650, DOI 10.1152/ajpcell.1996.271.2.C650; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SEARS CL, 1995, AM J PHYSIOL, V269, pC874; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Uribe JM, 1996, AM J PHYSIOL-CELL PH, V271, pC914, DOI 10.1152/ajpcell.1996.271.3.C914; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; VAJANAPHANICH M, 1993, GASTROENTEROLOGY, V104, pA286; VAJANAPHANICH M, 1995, J CLIN INVEST, V96, P386, DOI 10.1172/JCI118046; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175; Wilkie N, 1996, J BIOL CHEM, V271, P32447, DOI 10.1074/jbc.271.50.32447; Yamada T., 1995, GASTROENTEROLOGY, P326; YANG I, 1996, AM J PHYSIOL, V272, pC142; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	41	149	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27111	27117		10.1074/jbc.273.42.27111	http://dx.doi.org/10.1074/jbc.273.42.27111			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765228	hybrid			2022-12-25	WOS:000076448000015
J	Palomino, T; Barettino, D; Aranda, A				Palomino, T; Barettino, D; Aranda, A			Role of GHF-1 in the regulation of the rat growth hormone gene promoter by thyroid hormone and retinoic acid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENTS; TRANSCRIPTIONAL ACTIVATION; SYNERGISTIC INTERACTIONS; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; EXPRESSION; PIT-1; BINDING; DOMAIN; TRANSACTIVATION	In non-pituitary HeLa cells the unliganded thyroid hormone or retinoic acid receptors cause a strong activation of the rat growth hormone promoter that is repressed by their ligands, In contrast, after expression of the pituitary-specific transcription factor GHF-1, thyroid hormone and retinoic acid produce a stimulation similar to that found in pituitary cells. Therefore, GHF-1 changes a ligand-dependent inhibition into a ligand-dependent activation. The essential role of GHF-1 on the rat growth hormone promoter was also demonstrated with AF-2-defective T-3 receptor mutants that show a normal activation of this promoter in the presence of GHF-1. Furthermore, a truncated T-3 receptor, which lacks the N-terminus and the DNA binding domain, was able to stimulate this promoter in the presence of GHF-1 and exogenous RXR receptors, suggesting the importance of protein to protein interactions in this regulation, This study shows that the final transcriptional effect depends not only on the type of regulatory promoter response elements but also on the presence of other transcriptional activators, in the case of the growth hormone promoter, the tissue-specific transcription factor GHF-1, which plays a coactivator-like role in this promoter.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	aaranda@biomed.iib.uam.es	Aranda, Ana/ABG-8820-2020	Aranda, Ana/0000-0002-8338-9589				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chang W, 1996, J BIOL CHEM, V271, P17733, DOI 10.1074/jbc.271.30.17733; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CRONE DE, 1990, J BIOL CHEM, V265, P10851; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; FLUG F, 1987, J BIOL CHEM, V262, P6373; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GarciaVillalba P, 1996, MOL CELL BIOL, V16, P318; GARCIAVILLALBA P, 1993, BIOCHEM BIOPH RES CO, V191, P580, DOI 10.1006/bbrc.1993.1257; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Helmer EB, 1996, ENDOCRINOLOGY, V137, P390, DOI 10.1210/en.137.2.390; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LIRA SA, 1993, MOL ENDOCRINOL, V7, P694, DOI 10.1210/me.7.5.694; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; PALOMINO T, 1998, IN PRESS FASEB J; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Sanchez-Pacheco A, 1998, FEBS LETT, V422, P103, DOI 10.1016/S0014-5793(97)01609-8; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WIGHT PA, 1987, J BIOL CHEM, V262, P5659; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P206; YE ZS, 1988, J BIOL CHEM, V263, P7821	51	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27541	27547		10.1074/jbc.273.42.27541	http://dx.doi.org/10.1074/jbc.273.42.27541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765286	hybrid, Green Published			2022-12-25	WOS:000076448000073
J	Pourquier, P; Bjornsti, MA; Pommier, Y				Pourquier, P; Bjornsti, MA; Pommier, Y			Induction of topoisomerase I cleavage complexes by the vinyl chloride adduct 1,N-6-ethenoadenine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; METABOLITE CHLOROACETALDEHYDE; DNA CLEAVAGE; CAMPTOTHECIN; CELLS; 1,N-6-ETHENODEOXYADENOSINE; MUTAGENESIS; OXIDATION; INVITRO; GENOME	We used purified mammalian topoisomerases I (top1) and oligonucleotides to study top1-mediated cleavage and religation in the presence of a potent carcinogenic adduct, 1,N-6-ethenoadenosine (EA) incorporated immediately downstream of a unique top1 cleavage site. We found tha epsilon A markedly enhanced top1 cleavage complexes when it was incorporated at the +1 position of the top1 cleavage. This enhancement was due to a reduction of the religation step of the top1 reaction. In addition, epsilon A reduced the top1-mediated cleavage and decreased binding of the enzyme to DNA. We also studied the effects of the epsilon A adduct on top1 trapping by camptothecin (CPT), a web known top1 inhibitor. CPT was inactive when epsilon A was present at the +1 position. Alkylation of the top1 cleavage complex by 7-chloromethyl-10,11-methylenedioxycamptothecin (7-ClMe-MDO-CPT) was also blocked by the epsilon A adduct. Altogether, these results demonstrate that the epsilon A carcinogenic ad duct can efficiently trap human top1 and mimic CPT effects. Normal hydrogen bonding of the base pairs immediately downstream from the top1 cleavage site is probably essential for efficient DNA religation and binding of camptothecins in the top1 cleavage complex.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37,Rm 5D02, Bethesda, MD 20892 USA.	pommier@nih.gov	Pourquier, Philippe/O-8030-2018	Pourquier, Philippe/0000-0001-5326-3005				BASU AK, 1993, BIOCHEMISTRY-US, V32, P12793, DOI 10.1021/bi00210a031; BASU AK, 1987, BIOCHEMISTRY-US, V26, P5626, DOI 10.1021/bi00392a007; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; Cheng CH, 1998, J BIOL CHEM, V273, P11589, DOI 10.1074/jbc.273.19.11589; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; CHENG KC, 1991, P NATL ACAD SCI USA, V88, P9974, DOI 10.1073/pnas.88.22.9974; DOSANJH MK, 1994, P NATL ACAD SCI USA, V91, P1024, DOI 10.1073/pnas.91.3.1024; ENG WK, 1989, J BIOL CHEM, V264, P13373; Fan Y, 1998, J MED CHEM, V41, P2216, DOI 10.1021/jm9605445; Ghissassi F. E., 1995, CHEM RES TOXICOL, V8, P278; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; GUENGERICH FP, 1992, CHEM RES TOXICOL, V5, P2, DOI 10.1021/tx00025a001; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; Hang B, 1996, CARCINOGENESIS, V17, P155, DOI 10.1093/carcin/17.1.155; JACOBSEN JS, 1990, BIOCHEMISTRY-US, V29, P496, DOI 10.1021/bi00454a025; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Kingma PS, 1997, J BIOL CHEM, V272, P7488, DOI 10.1074/jbc.272.11.7488; Langouet S, 1998, BIOCHEMISTRY-US, V37, P5184, DOI 10.1021/bi972327r; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; NAIR J, 1995, CARCINOGENESIS, V16, P613, DOI 10.1093/carcin/16.3.613; Pandya GA, 1996, BIOCHEMISTRY-US, V35, P11487, DOI 10.1021/bi960170h; PARK KK, 1993, CARCINOGENESIS, V14, P441, DOI 10.1093/carcin/14.3.441; POMMIER Y, 1995, MUTAT RES-DNA REPAIR, V337, P135, DOI 10.1016/0921-8777(95)00019-G; Pommier Y, 1996, SEMIN ONCOL, V23, P3; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; SINGER B, 1988, CHEM CARCINOGENS ACT, P188; Subramanian D, 1998, CANCER RES, V58, P976; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TANIZAWA A, 1995, BIOCHEMISTRY-US, V34, P7200, DOI 10.1021/bi00021a035; Valenti M, 1997, MOL PHARMACOL, V52, P82, DOI 10.1124/mol.52.1.82; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; YEH YC, 1994, J BIOL CHEM, V269, P15498; ZHELKOVSKY AM, 1994, PROTEIN EXPRES PURIF, V5, P364, DOI 10.1006/prep.1994.1053	39	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27245	27249		10.1074/jbc.273.42.27245	http://dx.doi.org/10.1074/jbc.273.42.27245			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765247	Green Published, hybrid			2022-12-25	WOS:000076448000034
J	Suen, CS; Berrodin, TJ; Mastroeni, R; Cheskis, BJ; Lyttle, CR; Frail, DE				Suen, CS; Berrodin, TJ; Mastroeni, R; Cheskis, BJ; Lyttle, CR; Frail, DE			A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; HUMAN ESTROGEN-RECEPTOR; NUCLEAR-RECEPTOR; FACTOR TFIIB; CONSERVED REGION; BINDING PROTEIN; CO-REPRESSOR; ACTIVATION; SUPERFAMILY; COMPLEX	Estrogen receptors ER alpha and ER beta are members of the family of nuclear hormone receptors and act as ligand-inducible transcriptional factors, which regulate the expression of target genes on binding to cognate response elements. We report here the characterization of steroid receptor coactivator-3 (SRC-3), a coactivator of nuclear receptor transcription that is a member of a family of steroid receptor coactivators that includes SRC-1 and transcription intermediate factor-2, SRC-3 enhanced ER alpha and progesterone receptor-stimulated gene transcription in a ligand dependent manner, but stimulation of ER beta-mediated transcription was not observed. Protein-protein interaction assays, including real-time interaction analyses with BIAcore, demonstrated that the affinity of the ERa interaction with SRC-3 was much higher than that observed for the ERP interaction with SRC-S. Mutational analysis suggests a potential interplay between the transactivation function-1 and -2 do mains of ER alpha and SRC-3, Furthermore, an intrinsic transactivation function was observed in the C-terminal half of SRC-3. Finally, SRC-3 was differentially expressed in various tissues and, among several tumor cells examined, was most abundant in the nuclear fraction of MCF-7 breast cancer cells. Therefore, SRC-S, a third member of a family of steroid receptor coactivators, has a distinct tissue distribution and intriguing selectivity between ER alpha and ER beta.	Wyeth Ayerst Res, Womens Hlth Res Inst, Radnor, PA 19087 USA	Pfizer	Frail, DE (corresponding author), Wyeth Ayerst Res, Womens Hlth Res Inst, 145 King Of Prussia Rd,R-4, Radnor, PA 19087 USA.	Fraild@WAR.wyeth.com						Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cheskis BJ, 1997, J BIOL CHEM, V272, P11384; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Norris JD, 1998, J BIOL CHEM, V273, P6679, DOI 10.1074/jbc.273.12.6679; ONATE SA, 1995, SCIENCE, V270, P1354; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; SCHWERK C, 1995, J BIOL CHEM, V270, P21331, DOI 10.1074/jbc.270.36.21331; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; SUEN CS, 1993, MOL CELL BIOL, V13, P1719, DOI 10.1128/MCB.13.3.1719; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	44	202	206	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27645	27653		10.1074/jbc.273.42.27645	http://dx.doi.org/10.1074/jbc.273.42.27645			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765300	hybrid			2022-12-25	WOS:000076448000087
J	Kadrmas, JL; Allaway, D; Studholme, RE; Sullivan, JT; Ronson, CW; Poole, PS; Raetz, CRH				Kadrmas, JL; Allaway, D; Studholme, RE; Sullivan, JT; Ronson, CW; Poole, PS; Raetz, CRH			Cloning and overexpression of glycosyltransferases that generate the lipopolysaccharide core of Rhizobium leguminosarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DEOXY-D-MANNO-OCTULOSONIC ACID TRANSFERASE; ESCHERICHIA-COLI K-12; ACYL CARRIER PROTEIN; T7 RNA-POLYMERASE; LIPID-A; SALMONELLA-TYPHIMURIUM; OUTER MEMBRANE; CLONED GENES; BIOSYNTHESIS; MUTANTS	The lipopolysaccharide (LPS) core of the Gram-negative bacterium Rhizobium leguminosarum is more amenable to enzymatic study than that of Escherichia coli because much of it is synthesized from readily available sugar nucleotides. The inner portion of the R. leguminosarum core contains mannose, galactose, and three 3-deoxy-D-manno-octulosonate (Kdo) residues, arranged in the order: lipid A-(Kdo)(2)-Man-Gal-Kdo-[O antigen], A mannosyltransferase. ase that uses GDP-mannose and the conserved precursor Kdo(2)-[4'-P-32]lipid IVA (Kadrmas, J. L., Brozek, H. A., and Raetz, C. R. H. (1996) J. Biol. Chem. 271, 32119-32125) is proposed to represent a key early enzyme in R. leguminosarum core assembly, Conditions for demonstrating efficient galactosyl- and distal Kdo-transferase activities are now described using a coupled assay system that starts with GDP-mannose and Kdo(2)-[4'-P-32]lipid IVA. As predicted, mannose incorporation precedes galactose addition, which in turn precedes distal Kdo transfer, LPS core mutants with Tn5 insertions in the genes encoding the putative galactosyltransferase (lpcA) and the distal Kdo-transferase (lpcB) are shown to be defective in the corresponding in vitro glycosylation of Kdo(2)-[4'-P-32]lipid IVA. We have also discovered the new gene (lpcC) that encodes the mannosyltransferase, The gene is separated by several kilobase pairs from the lpcAB cluster, All three glycosyltransferases are carried on cosmid pIJ1848, which contains at least 20 kilobase pairs of R. leguminosarum DNA, Transfer of pIJ1848 into R. meliloti 1021 results in heterologous expression of all three enzymes, which are not normally present in strain 1021, Expression of the lpc genes individually behind the T7 promoter results in the production of each R. leguminosarum glycosyltransferase in E. coli membranes in a catalytically active form, demonstrating that lpcA, lpcB, and lpcC are structural genes.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Otago, Dept Microbiol, Dunedin, New Zealand; Univ Reading, Sch Anim & Microbiol Sci, Div Microbiol, Whiteknights, England	Duke University; University of Otago; University of Reading	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Allaway, David/0000-0003-4602-8933; sullivan, john/0000-0001-7716-4159; Ronson, Clive/0000-0002-2217-9676	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796, R01GM051796] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51796, 5T32GM017105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allaway D, 1996, J BACTERIOL, V178, P6403, DOI 10.1128/jb.178.21.6403-6406.1996; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMES GF, 1974, J BACTERIOL, V117, P406, DOI 10.1128/JB.117.2.406-416.1974; ANTELMANN H, 1995, J BACTERIOL, V177, P3540, DOI 10.1128/jb.177.12.3540-3545.1995; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BELUNIS CJ, 1992, J BIOL CHEM, V267, P18702; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BREWIN NJ, 1982, J GEN MICROBIOL, V128, P1817; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CAVA JR, 1990, MOL GEN GENET, V221, P125, DOI 10.1007/BF00280377; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; DENARIE J, 1993, CELL, V74, P951, DOI 10.1016/0092-8674(93)90717-5; FINAN TM, 1986, J BACTERIOL, V167, P66, DOI 10.1128/jb.167.1.66-72.1986; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GLAZEBROOK J, 1991, METHOD ENZYMOL, V204, P398; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JOHNSTON AWB, 1975, J GEN MICROBIOL, V87, P343, DOI 10.1099/00221287-87-2-343; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KOPLOW J, 1974, J BACTERIOL, V117, P527, DOI 10.1128/JB.117.2.527-543.1974; LAIRD MW, 1994, J BACTERIOL, V176, P2259, DOI 10.1128/JB.176.8.2259-2264.1994; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; Miller J.H., 1972, EXPT MOL GENETICS; MORRISON DC, 1992, BACTERIAL ENDOTOXIC, V1; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; POCLE PS, 1994, MICROBIOLOGY, V140, P2797; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; PRIEFER UB, 1989, J BACTERIOL, V171, P6161, DOI 10.1128/jb.171.11.6161-6168.1989; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RONCERO C, 1992, J BACTERIOL, V174, P3250, DOI 10.1128/jb.174.10.3250-3260.1992; RONSON CW, 1984, J BACTERIOL, V160, P903, DOI 10.1128/JB.160.3.903-909.1984; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SIRISENA DM, 1992, J BIOL CHEM, V267, P18874; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; White KA, 1997, J BIOL CHEM, V272, P16555, DOI 10.1074/jbc.272.26.16555; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; ZHANG Y, 1992, CARBOHYD RES, V231, P261, DOI 10.1016/0008-6215(92)84024-M	56	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26432	26440		10.1074/jbc.273.41.26432	http://dx.doi.org/10.1074/jbc.273.41.26432			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756877	hybrid, Green Submitted			2022-12-25	WOS:000076373300031
J	Kampranis, SC; Maxwell, A				Kampranis, SC; Maxwell, A			Hydrolysis of ATP at only one GyrB subunit is sufficient to promote supercoiling by DNA gyrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; B-PROTEIN; NUCLEOTIDE-BINDING; BASE-PAIRS	Mutation of Glu(42) to Ala in the B subunit of DNA gyrase abolishes ATP hydrolysis but not nucleotide binding. Gyrase complexes that contain one wild-type and one Ala(42) mutant B protein were formed, and the ability of such complexes to hydrolyze ATP was investigated. We found that ATP hydrolysis was able to proceed independently only in the wild-type subunit, albeit at a lower rate. With only one ATP molecule hydrolyzed at a time, gyrase could still perform supercoiling, but the limit of this reaction was lower than that observed when both subunits can hydrolyze the nucleotide.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Maxwell, A (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	ony@le.ac.uk	Kampranis, Sotirios C/G-8374-2016	Kampranis, Sotirios C/0000-0001-6208-1684; Maxwell, Anthony/0000-0002-5756-6430				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; BATES AD, 1989, EMBO J, V8, P1861, DOI 10.1002/j.1460-2075.1989.tb03582.x; CULLIS PM, 1992, BIOCHEMISTRY-US, V31, P9642, DOI 10.1021/bi00155a017; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; Kampranis SC, 1998, J BIOL CHEM, V273, P22615, DOI 10.1074/jbc.273.35.22615; Kampranis SC, 1998, J BIOL CHEM, V273, P22606, DOI 10.1074/jbc.273.35.22606; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KLEVAN L, 1980, BIOCHEMISTRY-US, V19, P5229, DOI 10.1021/bi00564a012; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MAXWELL A, 1999, PROTOCOLS DNA TOPOIS, V1, P135; MAXWELL A, 1986, 4TH P CONV BIOM STER, V3, P137; ODea MH, 1996, J BIOL CHEM, V271, P9723, DOI 10.1074/jbc.271.16.9723; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; TAMURA JK, 1992, J BIOL CHEM, V267, P9214; WESTERHOFF HV, 1988, CELL BIOPHYS, V12, P157, DOI 10.1007/BF02918357; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	21	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26305	26309		10.1074/jbc.273.41.26305	http://dx.doi.org/10.1074/jbc.273.41.26305			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756859	hybrid			2022-12-25	WOS:000076373300013
J	Sarmiento, M; Zhao, Y; Gordon, SJ; Zhang, ZY				Sarmiento, M; Zhao, Y; Gordon, SJ; Zhang, ZY			Molecular basis for substrate specificity of protein-tyrosine phosphatase 1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TRANSITION-STATE; KINETIC-ANALYSIS; FOCAL ADHESIONS; YERSINIA; P130(CAS); IDENTIFICATION; PURIFICATION; PEPTIDES; PHOSPHORYLATION	Protein-tyrosine phosphatases can exhibit stringent substrate specificity in vivo, although the molecular basis for this is not well understood. The three-dimensional structure of the catalytically inactive protein-tyrosine phosphate 1B (PTP1B)/C215S complexed with an optimal substrate, DADEpYL-NH2, reveals specific interactions between amino acid residues in the substrate and PTP1B. The goal of this work is to rigorously evaluate the functional significance of Tyr(46), Arg(47), Asp(48) Phe(182), and Gln(262) in substrate binding and catalysis, using site-directed mutagenesis. Combined with structural information, kinetic analysis of the wild type and mutant PTP1B using p-nitrophenyl phosphate and phosphotyrosine-containing peptides has yielded further insight into PTP1B residues, which recognize general features, as well, as specific properties, in peptide substrates, In addition, the kinetic results suggest roles of these residues in E-P hydrolysis, which are not obvious from the structure of PTP1B/peptide complex. Thus, Tyr(46) and Asp(48) recognize common features of peptide substrates and are important for peptide substrate binding and/or E-P formation. Arg47 acts as a determinant of substrate specificity and is responsible for the modest preference of PTP1B for acidic residues NH2-terminal to phosphotyrosine, Phe(182) and the invariant Gln2G2 are not only important for substrate binding and/or E-P formation but also important for the E-P hydrolysis step.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [CA69202] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07491-21, 5T32 GM07260-22] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007260, T32GM007491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; DECHERT U, 1995, EUR J BIOCHEM, V231, P673, DOI 10.1111/j.1432-1033.1995.0673d.x; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Juszczak LJ, 1997, BIOCHEMISTRY-US, V36, P2227, DOI 10.1021/bi9622130; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; PALLEN CJ, 1991, BIOCHEM J, V276, P315, DOI 10.1042/bj2760315; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; Zhang M, 1997, BIOCHEMISTRY-US, V36, P15, DOI 10.1021/bi961804n; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; Zhao Y, 1998, J BIOL CHEM, V273, P5484, DOI 10.1074/jbc.273.10.5484	33	96	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26368	26374		10.1074/jbc.273.41.26368	http://dx.doi.org/10.1074/jbc.273.41.26368			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756867	hybrid			2022-12-25	WOS:000076373300021
J	Thiel, G; Lietz, M; Cramer, M				Thiel, G; Lietz, M; Cramer, M			Biological activity and modular structure of RE-1-silencing transcription factor (REST), a repressor of neuronal genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR GENE; RESTRICTIVE SILENCER ELEMENT; CELL-ADHESION MOLECULE; SYNAPSIN-I; MAMMALIAN-CELLS; EXPRESSION; PROMOTER; ENHANCER; DOMAINS; ACTIVATION	The zinc finger protein RE-1-silencing transcription factor (REST)(1) is a transcriptional repressor that represses neuronal genes in nonneuronal tissues. Transfection experiments of neuroblastoma cells using a REST expression vector revealed that synapsin I promoter activity is controlled by REST. The biological activity of REST was further investigated using a battery of model promoters containing strong promoters/enhancers and REST binding sites. REST functioned as a transcriptional repressor when REST binding motifs derived from the genes encoding synapsin I, SCG10, alpha(1)-glycine receptor, the beta 2-subunit of the neuronal nicotinic acetylcholine receptor, and the m4-subunit of the muscarinic acetylcholine receptor were present in the promoter region. No differences in the biological activity of these REST binding motifs tested were detected. Moreover, we found that REST functioned very effectively as a transcriptional repressor at a distance. Thus, REST represents a general transcriptional repressor that blocks transcription regardless of the location or orientation of its binding site relative to the enhancer and promoter. This biological activity could also be attributed to isolated domains of REST. Both repressor domains identified at the N and C termini of REST were transferable to a heterologous DNA binding domain and functioned from proximal and distal positions, similar to the REST protein.	Univ Saarland, Sch Med, D-66421 Homburg, Germany; Univ Cologne, Inst Genet, D-50674 Cologne, Germany	Saarland University; University of Cologne	Thiel, G (corresponding author), Univ Saarland, Sch Med, Bldg 44, D-66421 Homburg, Germany.	bcgthi@med-rz.uni-sb.de						BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; BLESSIS A, 1997, P NATL ACAD SCI USA, V94, P5906; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Cibelli G, 1996, EUR J BIOCHEM, V237, P311, DOI 10.1111/j.1432-1033.1996.0311n.x; Cibelli G, 1996, EUR J BIOCHEM, V236, P171, DOI 10.1111/j.1432-1033.1996.00171.x; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; Harlow E., 1988, ANTIBODIES LAB MANUA; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; Kallunki P, 1997, J CELL BIOL, V138, P1343, DOI 10.1083/jcb.138.6.1343; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LIN AY, 1996, MOL CELL BIOL, V6, P1235; Lonnerberg P, 1996, J BIOL CHEM, V271, P33358, DOI 10.1074/jbc.271.52.33358; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Mieda M, 1996, J BIOL CHEM, V271, P5177; Mieda M, 1997, J BIOL CHEM, V272, P5854, DOI 10.1074/jbc.272.9.5854; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Palm K, 1998, J NEUROSCI, V18, P1280; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Scholl T, 1996, J IMMUNOL, V156, P1448; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; THIEL G, 1994, J BIOL CHEM, V269, P15294; THIEL G, 1991, P NATL ACAD SCI USA, V88, P3431, DOI 10.1073/pnas.88.8.3431; Thiel G, 1996, GENE, V168, P173, DOI 10.1016/0378-1119(95)00739-3; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; Wood IC, 1996, J BIOL CHEM, V271, P14221, DOI 10.1074/jbc.271.24.14221	35	81	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26891	26899		10.1074/jbc.273.41.26891	http://dx.doi.org/10.1074/jbc.273.41.26891			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756936	hybrid			2022-12-25	WOS:000076373300090
J	Krainc, D; Bai, G; Okamoto, S; Carles, M; Kusiak, JW; Brent, RN; Lipton, SA				Krainc, D; Bai, G; Okamoto, S; Carles, M; Kusiak, JW; Brent, RN; Lipton, SA			Synergistic activation of the N-methyl-D-aspartate receptor subunit 1 promoter by myocyte enhancer factor 2C and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM REGULATORY ELEMENTS; NEURON-SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR SP1; SODIUM-CHANNEL GENE; NMDA RECEPTOR; DNA-BINDING; RAT-BRAIN; EMBRYONIC-DEVELOPMENT; CORTICAL-NEURONS; NERVOUS-SYSTEM	The N-methyl-D-aspartate (NMDA) subtype of glutamate receptor plays important roles in neuronal development, plasticity, and cell death. NMDA receptor subunit 1 (NR1) is an essential subunit of the NMDA receptor and is developmentally expressed in postnatal neurons of the central nervous system. Here we identify on the NR1 promoter a binding site for myocyte enhancer factor 2C (MEF2C), a developmentally expressed neuron/muscle transcription factor found in cerebrocortical neurons, and study its regulation of the NR1 gene. Co-expression of MEF2C and Sp1 cDNAs in primary neurons or cell lines synergistically activates the NR1 promoter. Disruption of the MEF2 site or the MEF2C DNA binding domain moderately reduces this synergism. Mutation of the Sp1 sites or the activation domains of Sp1 protein strongly reduces the synergism. Results of yeast two-hybrid and co-immunoprecipitation experiments reveal a physical interaction between MEF2C and Sp1 proteins. The MEF2C DNA binding domain is sufficient for this interaction. Dominant-negative MEF2C interferes with expression of NR1 mRNA in neuronally differentiated P19 cells. Growth factors, including epidermal growth factor and basic fibroblast growth factor, can up-regulate NR1 promoter activity in stably transfected PC12 cells, even in the absence of the MEF2 site, but the Sp1 sites are necessary for this growth factor regulation, suggesting that Spl sites may mediate these effects.	Brigham & Womens Hosp, CNS Res Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; NIA, Mol Neurobiol Unit, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Lipton, SA (corresponding author), Brigham & Womens Hosp, CNS Res Inst, 221 Longwood Ave,LMRC 1st Floor, Boston, MA 02115 USA.		Carles, Michel/CAH-0065-2022	Lipton, Stuart/0000-0002-3490-1259	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD029587] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY006087, R01EY005477] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY06087, R01 EY05477] Funding Source: Medline; NICHD NIH HHS [P01 HD29587] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bai G, 1997, J BIOL CHEM, V272, P5936, DOI 10.1074/jbc.272.9.5936; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; BOECKMAN FA, 1996, NEURAL NOTES, V11, P13; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CHIN LS, 1994, J BIOL CHEM, V269, P18507; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DICHTER MA, 1978, BRAIN RES, V149, P279, DOI 10.1016/0006-8993(78)90476-6; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HOCHSCHILD A, 1988, NATURE, V336, P353, DOI 10.1038/336353a0; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MORLEY P, 1995, J NEUROCHEM, V65, P1093; MOTEJLEK K, 1994, J BIOL CHEM, V269, P15265; NEMER M, 1993, P NATL ACAD SCI USA, V90, P10851, DOI 10.1073/pnas.90.22.10851; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAY WJ, 1993, BIOCHEM BIOPH RES CO, V197, P1475, DOI 10.1006/bbrc.1993.2643; SATO T, 1995, J BIOL CHEM, V270, P10314, DOI 10.1074/jbc.270.17.10314; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; STANDAERT DG, 1994, J COMP NEUROL, V343, P1, DOI 10.1002/cne.903430102; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHONG J, 1995, J NEUROCHEM, V64, P531	71	77	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26218	26224		10.1074/jbc.273.40.26218	http://dx.doi.org/10.1074/jbc.273.40.26218			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748305	hybrid			2022-12-25	WOS:000076263100096
J	Lum, L; Reid, MS; Blobel, CP				Lum, L; Reid, MS; Blobel, CP			Intracellular maturation of the mouse metalloprotease disintegrin MDC15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SPERM-EGG FUSION; SUBTILISIN-LIKE ENDOPROTEASE; PLASMA-MEMBRANE; POTENTIAL ROLE; BREFELDIN-A; CYSTEINE SWITCH; SURFACE PROTEIN; CELL-ADHESION; ADAM FAMILY	Metalloprotease disintegrins are a family of membrane-anchored glycoproteins that play a role in fertilization, myoblast fusion, neuronal development, and cleavage of the membrane-anchored cytokine tumor necrosis factor-cu. Here, we report the cloning and cDNA sequencing of the mouse metalloprotease disintegrin MDC15 and an analysis of its processing in the secretory pathway. A notable difference between mMDC15 and its putative human orthologue (hMDC15, metargidin) is the presence of the peptide sequence TDDC instead of the RGDC found in the disintegrin domain of hMDC15. In a Western blot analysis the majority of mMDC15 was found to lack the pro-domain in all mouse tissues examined. Pulse-chase experiments in transiently transfected COS-7 cells suggest that mMDC15 is processed by a pro-protein convertase in a late Golgi compartment, since (i) addition of brefeldin A or monensin blocks prodomain removal, (ii) all detectable processed mMDC15 is endoglycosidase H -resistant, and (iii) a recombinant soluble form of the trans-Golgi network pro-protein convertase furin can mimic mMDC15 processing in vitro. Cell-surface trypsinization revealed that more than half of mature mMDC15 is intracellular. Immunolocalization provided evidence for a strong perinuclear accumulation in a region resembling the trans-Golgi network and/or endosomal compartments. This study provides the first characterization of the intracellular processing of a metalloprotease disintegrin, and highlights the potential role of pro-protein convertases in removal of the inhibitory pro-domain. These results further suggest possible intracellular functions for mMDC15, such as in protein maturation, in addition to a potential role in cell-surface proteolysis or cell adhesion.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Blobel, CP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, Box 368,1275 York Ave, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NIGMS NIH HHS [5T32GM07739-17] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Bradbury FA, 1997, J BIOL CHEM, V272, P5921, DOI 10.1074/jbc.272.9.5921; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; Decroly E, 1997, FEBS LETT, V405, P68, DOI 10.1016/S0014-5793(97)00156-7; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Evans JP, 1997, DEV BIOL, V187, P94, DOI 10.1006/dbio.1997.8612; Evans JP, 1997, DEV BIOL, V187, P79, DOI 10.1006/dbio.1997.8611; EVANS JP, 1995, J CELL SCI, V108, P3267; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Lehmann M, 1996, BIOCHEM J, V317, P803, DOI 10.1042/bj3170803; Linder B, 1997, DEV GROWTH DIFFER, V39, P243; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; Mbikay M, 1997, P NATL ACAD SCI USA, V94, P6842, DOI 10.1073/pnas.94.13.6842; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PATEL YC, 1995, CIBA F SYMP, V190, P26; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	52	135	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26236	26247		10.1074/jbc.273.40.26236	http://dx.doi.org/10.1074/jbc.273.40.26236			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748307	hybrid			2022-12-25	WOS:000076263100098
J	Otero, AS; Xu, L; Ni, YJ; Szabo, G				Otero, AS; Xu, L; Ni, YJ; Szabo, G			Receptor-independent activation of atrial muscarinic potassium channels in the absence of nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-CHANNEL; G-PROTEINS; GAMMA-SUBUNIT; CELL-MEMBRANE; BETA-GAMMA; MECHANISM; BINDING; HEART; HYDROLYSIS; MYOCYTES	The removal of nucleotides from the solution bathing the inner face of excised patches of frog atrial membranes was found to activate muscarinic K+ channels in the absence of agonists, Channel activation was also observed in Mg2+-free solutions and blocked by low (0.1-10 mu M) concentrations Of GDP or GTP. After full activation was achieved, channel openings were abolished by the application of GDP-bound G alpha(i2), but were not affected by exogenous G beta gamma dimers, suggesting that effector activation is a consequence of the liberation of beta gamma subunits from endogenous G proteins. The process of channel activation in the absence of nucleotides seems to be receptor-independent, because it is not influenced by muscarinic receptor agonists and antagonists or by treatment with uncoupling agents such as pertussis toxin or N-ethyl maleimide, Taken together, these results suggest that the loss of GDP from the G protein nucleotide binding site promotes its uncoupling from receptors and destabilizes the G alpha((empty))beta gamma heterotrimer. Therefore, the nucleotide-free form of G proteins has some of the characteristics of the GTP-bound, activated form.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA	University of Virginia	Otero, AS (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, Box 10011, Charlottesville, VA 22906 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037127, R01HL048726, R37HL037127] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37127, HL48726] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOURNE HR, 1995, SCIENCE, V270, P933, DOI 10.1126/science.270.5238.933; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CLARK RB, 1990, J PHYSIOL-LONDON, V424, P229, DOI 10.1113/jphysiol.1990.sp018064; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FINDLAY I, 1986, PFLUG ARCH EUR J PHY, V407, P238, DOI 10.1007/BF00580683; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; ILRI T, 1994, NATURE, V371, P164; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KIRSCH GE, 1989, AM J PHYSIOL, V257, pH334, DOI 10.1152/ajpheart.1989.257.1.H334; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1986, AM J PHYSIOL, V251, pH681, DOI 10.1152/ajpheart.1986.251.3.H681; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P572, DOI 10.1007/BF00657521; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1988, J BIOL CHEM, V263, P8996; OKABE K, 1991, J GEN PHYSIOL, V97, P1279, DOI 10.1085/jgp.97.6.1279; OTERO AD, 1993, MOL PHARMACOL, V44, P595; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; SZABO G, 1993, GTPASES BIOL HDB EXP, V108, P291; Valenzuela D, 1997, P NATL ACAD SCI USA, V94, P1727, DOI 10.1073/pnas.94.5.1727; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Xu L, 1996, J BIOL CHEM, V271, P21120, DOI 10.1074/jbc.271.35.21120	31	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28868	28872		10.1074/jbc.273.44.28868	http://dx.doi.org/10.1074/jbc.273.44.28868			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786888	hybrid			2022-12-25	WOS:000076691800049
J	Rich, RC; Schulman, H				Rich, RC; Schulman, H			Substrate-directed function of calmodulin in autophosphorylation of Ca2+/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL CAM KINASE; MUTATIONAL ANALYSIS; CA-2+ CALMODULIN; CA-2+-INDEPENDENT ACTIVITY; EXPRESSION; MECHANISM; GENERATION; BINDING; DOMAIN; CELLS	Autophosphorylation of Thr(286) in Ca2+/calmodulin-dependent protein kinase II occurs within each holoenzyme by an intersubunit reaction and is essential for kinase function in vivo, In addition to a kinase-directed function of calmodulin to activate the kinase, a second calmodulin is required for the autophosphorylation of each Thr(286) (Hanson, P. I., Meyer, T., Stryer, L., and Schulman, H. (1994) Neuron 12, 943-956), We have engineered heteromeric holoenzymes comprising distinct "kinase" and "substrate" subunits to test for kinase- and substrate-directed functions of calmodulin, The obligate kinase subunits have aspartate residues substituted for threonine at positions 286, 305, and 306 (the autophosphorylation and calmodulin-binding sites), making it constitutively active but unable to bind calmodulin, Obligate substrate subunits are catalytically inactive (K42M mutation) but are able to bind calmodulin, Phosphorylation of substrate subunits occurs specifically at Thr(286) and is completely dependent upon the presence of calmodulin, Blocking the ability of the substrate subunit to bind calmodulin, either with inhibitor KN-93 or by mutagenesis of the calmodulin-binding domain of the substrate subunit, prevents its phosphorylation, consistent with a substrate-directed function of calmodulin that requires its direct binding to the subunit being phosphorylated.	Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA	Stanford University	Schulman, H (corresponding author), Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA.	schulman@cmgm.stanford.edu			NINDS NIH HHS [5T32-NS07280-11] Funding Source: Medline; PHS HHS [4060] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007280] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; BROCKE L, 1995, J NEUROSCI, V15, P6797; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cho YH, 1998, SCIENCE, V279, P867, DOI 10.1126/science.279.5352.867; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; FONG YL, 1989, J BIOL CHEM, V264, P16759; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; IKEDA A, 1991, J BIOL CHEM, V266, P11582; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KATOH T, 1991, BIOCHIM BIOPHYS ACTA, V1091, P205, DOI 10.1016/0167-4889(91)90063-4; KURET J, 1985, J BIOL CHEM, V260, P6427; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEVINE H, 1986, P NATL ACAD SCI USA, V83, P2253; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LOU LL, 1989, J NEUROSCI, V9, P2020; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MUKHERJI S, 1994, J BIOL CHEM, V269, P20733; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; PATTON BL, 1990, J BIOL CHEM, V265, P11204; Rotenberg A, 1996, CELL, V87, P1351, DOI 10.1016/S0092-8674(00)81829-2; SCHOLZ WK, 1988, J NEUROSCI, V8, P1039; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002	41	123	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28424	28429		10.1074/jbc.273.43.28424	http://dx.doi.org/10.1074/jbc.273.43.28424			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774470	hybrid			2022-12-25	WOS:000076549800090
J	Decker, EL; Skerka, C; Zipfel, PF				Decker, EL; Skerka, C; Zipfel, PF			The early growth response protein (EGR-1) regulates interleukin-2 transcription by synergistic interaction with the nuclear factor of activated T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; IL-2 GENE-EXPRESSION; DNA-BINDING DOMAINS; NGFI-A; NF-AT; CULTURED-CELLS; PROMOTER; FAMILY; ENCODES; ELEMENT	The early growth response-1 gene (EGR-1) is induced by a wide range of stimuli in diverse cell types; however, EGR-1-regulated genes display a highly restricted pattern of expression. Recently, an overlapping Sp1.EGR-1 binding site has been identified within the interleukin-2 (IL-2) gene promoter directly upstream of the binding site for the nuclear factor of activated T cells (NFAT), We used transfection assays to study how the abundantly and constitutively expressed Sp1 protein and the immediate early EGR-1 zinc finger protein regulate IL-2 gene expression. Here, we identify EGR-1 as an important activator of the IL-2 gene. In Jurkat T cells, EGR-1 but not Sp1 acts as a potent coactivator for IL-2 transcription, and in combination with NFATc, EGR-1 increases transcription of an IL-2 reporter construct 200-fold. Electrophoretic mobility shift assays reveal that recombinant EGR-1 and NFATc bind independently to their target sites within the IL-2 promoter, and the presence of both sites on the same DNA molecule is required for EGR-1.NFATc.DNA complex formation. The transcriptional synergy observed here for EGR-1 and NFATc explains how the abundant nuclear factor EGR-1 contributes to the expression of restrictively expressed genes.	Bernhard Nocht Inst Trop Med, Res Grp Biomol Med, D-20359 Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin	Zipfel, PF (corresponding author), Bernhard Nocht Inst Trop Med, Res Grp Biomol Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	zipfel@uke.uni-hamburg.de						ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Avots A, 1997, MOL CELL BIOL, V17, P4381, DOI 10.1128/MCB.17.8.4381; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; Dinkel A, 1997, J IMMUNOL, V159, P2678; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MAGES HW, 1993, INT IMMUNOL, V5, P63, DOI 10.1093/intimm/5.1.63; Maltzman JS, 1996, J EXP MED, V183, P1747, DOI 10.1084/jem.183.4.1747; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MULLER HJ, 1991, P NATL ACAD SCI USA, V88, P10079, DOI 10.1073/pnas.88.22.10079; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PATWARDHAN S, 1991, ONCOGENE, V6, P917; RAIZIS AM, 1993, BIOCHEM J, V289, P133, DOI 10.1042/bj2890133; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Sambrook J., 2002, MOL CLONING LAB MANU; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; Skerka C, 1997, IMMUNOBIOLOGY, V198, P179, DOI 10.1016/S0171-2985(97)80039-3; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; Svaren J, 1996, MOL CELL BIOL, V16, P3545; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Timmerman LA, 1997, J IMMUNOL, V159, P2735; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; WILLIAMS TM, 1991, SCIENCE, V254, P1791, DOI 10.1126/science.1840704; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; ZHANG LQ, 1994, CYTOKINE, V6, P221, DOI 10.1016/1043-4666(94)90016-7; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041; Zipfel PF, 1997, BBA-GENE STRUCT EXPR, V1354, P134, DOI 10.1016/S0167-4781(97)00084-5	62	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26923	26930		10.1074/jbc.273.41.26923	http://dx.doi.org/10.1074/jbc.273.41.26923			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756940	hybrid			2022-12-25	WOS:000076373300094
J	Kudo, T; Ikehara, Y; Togayachi, A; Kaneko, M; Hiraga, T; Sasaki, K; Narimatsu, H				Kudo, T; Ikehara, Y; Togayachi, A; Kaneko, M; Hiraga, T; Sasaki, K; Narimatsu, H			Expression cloning and characterization of a novel murine alpha 1,3-fucosyltransferase, mFuc-TIX, that synthesizes the Lewis x (CD15) epitope in brain and kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; FUCOSYL-TRANSFERASE GENES; EMBRYONIC ANTIGEN SSEA-1; BLOOD GROUP SYSTEM; MOLECULAR-CLONING; SIALYL-LEWIS; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; SUBSTRATE SPECIFICITIES; ALPHA-1,3-FUCOSYL-TRANSFERASE GENE; DETERMINES EXPRESSION	The 3-fucosyl-N-acetyllactosamine (Lewis x, CD15, SSEA-1) carbohydrate epitope is widely distributed in many tissues and is developmentally expressed in some rodent and human tissues, i.e. brain and lung, and mouse early embryo. In such tissues, the Lewis x epitope is considered to be involved in cell-cell interactions. We isolated a novel mouse alpha 1,3-fucosyltransferase gene, named mFuc-TIX, from an adult mouse brain cDNA library using the expression cloning method. On flow cytometric analysis, Namalwa cells transfected stably with the mFuc-TIX gene showed a marked increase in Lewis x epitopes but not sialyl Lewis x epitopes. As seen experiments involving oligosaccharides as acceptor substrates, mFuc-TIX transfers a fucose to lacto-N-neotetraose but not to either alpha 2,3-sialyl lacto-N-neotetraose or lacto-N-tetraose. The substrate specificity of mFuc-TIX was similar to that of mouse myeloid-type alpha 1,3-fucosyltransferase (mFuc-TIV). The deduced amino acid sequence of mFuc-TIX, consisting of 359 residues, indicated a type II membrane protein and shows low degrees of homology to the previously cloned alpha 1,3-fucosyltransferases, i.e. mFuc-TIV (48.4%), mouse Fuc-TVII (39.1%), and human Fuc-TIII (43.0%), at the amino acid sequence level. A phylogenetic tree of the alpha 1,3-fucosyltransferases constructed by the neighbor-joining method showed that mFuc-TIX is quite distant from the other alpha 1,3-fucosyltransferases. Thus, mFuc-TIX does not belong to any subfamilies of known alpha 1,3Fuc-Ts. The mFuc-TIX transcript was mainly detected in brain and kidney with the Northern blotting and competitive re verse transcription-polymerase chain reaction methods, whereas the mFuc-TIV transcript was not detected in brain with these methods. On in situ hybridization, the mFuc-TIX transcript was detected in neuronal cells but not in the glial cells including astrocytes. These results strongly indicated that mFuc-TIX participates in the Lewis x synthesis in neurons of the brain and may be developmentally regulated.	Soka Univ, Inst Life Sci, Div Cell Biol, Hachioji, Tokyo 1928577, Japan; Natl Inst Genet, Grad Univ Adv Studies, Sch Life Sci, Dept Genet, Mishima, Shizuoka 4110801, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 1948533, Japan	Soka University; Graduate University for Advanced Studies - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Kyowa Kirin Ltd	Narimatsu, H (corresponding author), Soka Univ, Inst Life Sci, Div Cell Biol, 1-236 Tangi-cho, Hachioji, Tokyo 1928577, Japan.		Ikehara, yuzuru/L-7696-2018; Ikehara, yuzuru/R-2239-2019	Ikehara, yuzuru/0000-0002-1915-9172; Ikehara, yuzuru/0000-0002-1915-9172; K. Kaneko, Mika/0000-0002-4158-9208				Ashwell KWS, 1997, CELL TISSUE RES, V289, P17, DOI 10.1007/s004410050848; BARTSCH D, 1991, CELL TISSUE RES, V263, P353, DOI 10.1007/BF00318777; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costache M, 1997, J BIOL CHEM, V272, P29721, DOI 10.1074/jbc.272.47.29721; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; FOX N, 1981, DEV BIOL, V83, P391, DOI 10.1016/0012-1606(81)90487-5; Ge ZM, 1997, J BIOL CHEM, V272, P21357, DOI 10.1074/jbc.272.34.21357; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HAKOMORI SI, 1992, HISTOCHEM J, V24, P771, DOI 10.1007/BF01046348; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; Ito H, 1997, INT J CANCER, V71, P556, DOI 10.1002/(SICI)1097-0215(19970516)71:4<556::AID-IJC9>3.3.CO;2-J; ITZKOWITZ SH, 1986, CANCER RES, V46, P2627; Kaneko M, 1997, BLOOD, V90, P839, DOI 10.1182/blood.V90.2.839.839_839_849; KIMURA H, 1995, GLYCOCONJUGATE J, V12, P802, DOI 10.1007/BF00731242; Kimura H, 1997, BIOCHEM BIOPH RES CO, V237, P131, DOI 10.1006/bbrc.1997.7100; KODA Y, 1993, BLOOD, V82, P2915; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kudo T, 1996, J BIOL CHEM, V271, P9830, DOI 10.1074/jbc.271.16.9830; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; Lee KP, 1996, J BIOL CHEM, V271, P32960, DOI 10.1074/jbc.271.51.32960; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MAI JK, 1992, HISTOCHEM J, V24, P878, DOI 10.1007/BF01046359; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MARANI E, 1992, HISTOCHEM J, V24, P852, DOI 10.1007/BF01046357; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; Martin SL, 1997, J BIOL CHEM, V272, P21349, DOI 10.1074/jbc.272.34.21349; MCCURLEY RS, 1995, GENOMICS, V26, P142, DOI 10.1016/0888-7543(95)80094-3; MIYAKE M, 1988, CANCER RES, V48, P7150; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MORRES SA, 1992, HISTOCHEM J, V24, P902, DOI 10.1007/BF01046361; MURAMATSU H, 1983, FEBS LETT, V163, P181, DOI 10.1016/0014-5793(83)80814-X; Narimatsu H, 1998, CANCER RES, V58, P512; Narimatsu H, 1996, CANCER RES, V56, P330; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; Orntoft TF, 1996, J BIOL CHEM, V271, P32260, DOI 10.1074/jbc.271.50.32260; OUDEGA M, 1992, HISTOCHEM J, V24, P869, DOI 10.1007/BF01046358; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; Ozawa M, 1996, J BIOCHEM-TOKYO, V119, P302; PENNINGTON JE, 1985, J EMBRYOL EXP MORPH, V90, P335; REGUIGNE I, 1994, CYTOGENET CELL GENET, V66, P104, DOI 10.1159/000133677; REGUIGNEARNOULD I, 1995, CYTOGENET CELL GENET, V71, P158, DOI 10.1159/000134098; REIFENBERGER G, 1992, HISTOCHEM J, V24, P890, DOI 10.1007/BF01046360; ROBINSON NE, 1994, GLYCOBIOLOGY, V4, P317, DOI 10.1093/glycob/4.3.317; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SajdelSulkowska EM, 1997, GLYCOCONJUGATE J, V14, P249, DOI 10.1023/A:1018550023637; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SATOH J, 1994, J NEUROSCI RES, V37, P466, DOI 10.1002/jnr.490370406; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; Streit A, 1996, J NEUROCHEM, V66, P834; TETTEROO P, 1992, HISTOCHEM J, V24, P777, DOI 10.1007/BF01046349; Uozumi N, 1996, J BIOL CHEM, V271, P27810, DOI 10.1074/jbc.271.44.27810; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Yanagidani S, 1997, J BIOCHEM-TOKYO, V121, P626	66	87	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26729	26738		10.1074/jbc.273.41.26729	http://dx.doi.org/10.1074/jbc.273.41.26729			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756916	hybrid			2022-12-25	WOS:000076373300070
J	Misra, S; Ujhazy, P; Gatmaitan, Z; Varticovski, L; Arias, IM				Misra, S; Ujhazy, P; Gatmaitan, Z; Varticovski, L; Arias, IM			The role of phosphoinositide 3-kinase in taurocholate-induced trafficking of ATP-dependent canalicular transporters in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE PLASMA-MEMBRANE; ORGANIC ANION TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; BILE SECRETION; GENE FAMILY; VESICLES; KINASE; SYSTEM; TRANSLOCATION	Recent studies indicate that wortmannin, a potent inhibitor of phosphatidylinositol (PI) 3-kinase, interferes with bile acid secretion in rat liver; taurocholate induces recruitment of ATP-dependent transporters to the bile canalicular membrane, and PI 3-kinase products are important in intracellular trafficking. We investigated the role of PI 3-kinase in bile acid secretion by studying the in vivo effect of taurocholate, colchicine, and wortmannin on bile acid secretion, kinase activity, and protein levels in canalicular membrane vesicle (CMV) and sinusoidal membrane vesicle (SMV) fractions from rat lives. Treatment of rats or perfusion of isolated liver with taurocholate significantly increased PI 3-kinase activity in both membrane fractions, Taurocholate increased protein content of ATP-dependent transporters, which were detected only in CMVs, whereas increased levels of p85 and a cell adhesion molecule, cCAM 105, were observed in both fractions. Colchicine prevented taurocholate-induced changes in all proteins studied, as well as the increase in PI 3-kinase activity in CMVs, but it resulted in further accumulation of PI 3-kinase activity, p85, and cCAM 105 in SMVs. These results indicate that taurocholale-mediated changes involve a microtubular system. Wortmannin blocked taurocholate-induced bile acid secretion. The effect was more profound when wortmannin was administered prior to treatment with taurocholate. When wortmannin was given after taurocholate, the protein levels of each ATP-dependent transporter were maintained in CMVs, whereas the levels of p85 and cCAM decreased in both membrane fractions. Perfusion of liver with wortmannin before taurocholate administration blocked accumulation of all proteins studied in CMVs and SMVs. These results indicate that PI 3-kinase is required for intracellular trafficking of itself, as weal as of ATP-dependent canalicular transporters.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; St Elizabeth Med Ctr, Dept Biomed Res, Brighton, MA 02135 USA	Tufts University; St. Elizabeth's Medical Center	Misra, S (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.		Ujhazy, Peter/AAF-9507-2021	Varticovski, Lyuba/0000-0002-5105-9008	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928, R01DK035652, R37DK035652] Funding Source: NIH RePORTER; NCI NIH HHS [CA 94536] Funding Source: Medline; NIDDK NIH HHS [30DK34928, DK35652] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARR VA, 1993, GASTROENTEROLOGY, V105, P554, DOI 10.1016/0016-5085(93)90734-T; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; CRAWFORD JM, 1988, J LIPID RES, V29, P144; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Endicott J A, 1991, DNA Seq, V2, P89, DOI 10.3109/10425179109039677; Erlinger Serge, 1994, P769; Folli F, 1997, GASTROENTEROLOGY, V113, P954, DOI 10.1016/S0016-5085(97)70192-6; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Gatmaitan ZC, 1997, AM J PHYSIOL-GASTR L, V272, pG1041, DOI 10.1152/ajpgi.1997.272.5.G1041; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; HEMS R, 1966, BIOCHEM J, V101, P284, DOI 10.1042/bj1010284; Hofmann Alan F., 1994, P677; INOUE M, 1982, HEPATOLOGY, V2, P572; INOUE M, 1983, J BIOL CHEM, V258, P5183; Ito K, 1997, AM J PHYSIOL-GASTR L, V272, pG16, DOI 10.1152/ajpgi.1997.272.1.G16; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; LINCKE CR, 1992, J MOL BIOL, V228, P701, DOI 10.1016/0022-2836(92)90855-E; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MULLER M, 1991, J BIOL CHEM, V266, P18920; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; Nies AT, 1996, J LIPID RES, V37, P1125; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; Noe B, 1996, GASTROENTEROLOGY, V110, P858, DOI 10.1053/gast.1996.v110.pm8608896; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P679; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; STOLZ A, 1993, J BIOL CHEM, V268, P10448; SUSA M, 1992, J BIOL CHEM, V267, P22951; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VONDIPPE P, 1993, AM J PHYSIOL, V264, pG528, DOI 10.1152/ajpgi.1993.264.3.G528; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wolkoff AW, 1996, SEMIN LIVER DIS, V16, P121, DOI 10.1055/s-2007-1007225	41	113	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26638	26644		10.1074/jbc.273.41.26638	http://dx.doi.org/10.1074/jbc.273.41.26638			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756904	hybrid			2022-12-25	WOS:000076373300058
J	Pacheco-Rodriguez, G; Meacci, E; Vitale, N; Moss, J; Vaughan, M				Pacheco-Rodriguez, G; Meacci, E; Vitale, N; Moss, J; Vaughan, M			Guanine nucleotide exchange on ADP-ribosylation factors catalyzed by cytohesin-1 and its Sec7 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-D; BREFELDIN-A; BINDING PROTEIN; CHOLERA-TOXIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; SACCHAROMYCES-CEREVISIAE; HOMOLOGY DOMAINS; BOVINE BRAIN; FACTOR ARF	ADP-ribosylation factors (ARFs) are 20-kDa guanine nucleotide-binding proteins that require specific guanine nucleotide-exchange proteins (GEPs) to accelerate the conversion of inactive ARF-GDP to active ARF-GTP, Cytohesin-1, a 46-kDa ARF GEP, contains a central Sec7 domain of 188 amino acids similar in sequence to a region of the yeast Sec7 protein. Cytohesin-1 and its 22-kDa Sec7 domain (C-1 Sec7), synthesized in Escherichia coli, were assayed with recombinant non-myristoylated ARFs and related proteins to compare their GEP activities. Both were effective with native mammalian ARFs 1 and 3. Cytohesin-1 accelerated GTP gamma S (guanosine 5'-3-O-(thio)triphosphate) binding to recombinant human ARF1 (rARF1), yeast ARF3, and ARD1 (a 64-kDa guanine nucleotide-binding protein containing a C-terminal ARF domain). In contrast, C-1 Sec7 enhanced GTP gamma S binding to recombinant human ARFs 1, 5, and 6; yeast ARFs 1, 2, and 3; ARD1; two ARD1 mutants that contain the ARF domain; and Delta 13ARF1, which lacks the N-terminal alpha-helix. Neither C-1 Sec7 nor cytohesin-1 increased GTP gamma S binding to human ARF-like ARL proteins 1, 2, and 3. Thus, ARLs, initially differentiated from ARFs because of their inability to activate cholera toxin, differ also in their failure to interact functionally with C-1 Sec7 or cytohesin-1. As C-1 Sec7 was much less substrate-specific than cytohesin-1, it appears that structure outside of the Sec7 domain is important for ARF specificity. Data obtained with mutant ARF constructs are all consistent with the conclusion that the ARF N terminus is an important determinant of cytohesin-1 specificity.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Pacheco-Rodriguez, G (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Rm 5N-307,Bldg 10,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.		Vitale, Nicolas/G-5967-2014; Pacheco, Gustavo/Q-6956-2019	Vitale, Nicolas/0000-0002-4752-4907; 				ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HONG JX, 1994, J BIOL CHEM, V269, P9743; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LEE FJS, 1994, J BIOL CHEM, V269, P20931; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PATTON WA, 1997, BACTERIAL TOXINS TOO, P15; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sata M, 1998, P NATL ACAD SCI USA, V95, P4204, DOI 10.1073/pnas.95.8.4204; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TERUI T, 1994, J BIOL CHEM, V269, P28130; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; Vitale N, 1997, J BIOL CHEM, V272, P25077, DOI 10.1074/jbc.272.40.25077; Vitale N, 1996, P NATL ACAD SCI USA, V93, P1941, DOI 10.1073/pnas.93.5.1941; WELSH CF, 1994, J BIOL CHEM, V269, P15583; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	47	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26543	26548		10.1074/jbc.273.41.26543	http://dx.doi.org/10.1074/jbc.273.41.26543			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756891	hybrid			2022-12-25	WOS:000076373300045
J	Parsons, MA; Sinden, RR; Izban, MG				Parsons, MA; Sinden, RR; Izban, MG			Transcriptional properties of RNA polymerase II within triplet repeat-containing DNA from the human myotonic dystrophy and fragile X loci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DISEASE GENES; C-TERMINAL DOMAIN; ELONGATION COMPLEX; TERNARY COMPLEXES; ESCHERICHIA-COLI; MESSENGER-RNA; TRINUCLEOTIDE REPEAT; CHAIN ELONGATION; NASCENT RNA; SITES INVITRO	Expansion of a (CTG)(n) segment within the 3'-untranslated region of the myotonic dystrophy protein kinase gene alters mRNA production. The inherent ability of RNA polymerase II to transcribe (CTG)(17-255) tracts corresponding to DNA from normal, unstable, and affected individuals, and the normal (CGG)(54) fragile X repeat tract, was analyzed using a synchronized in vitro transcription system. Core RNA polymerase II transcribed all repeat units irrespective of repeat length or orientation. However, approximately 50% of polymerases transiently halted transcription (with a half-life of approximately 10 +/- 1 s) within the first and second CTG repeat unit and a more transient barrier to elongation was observed roughly centered within repeats 6-9. Transcription within the remainder of the CTG tracts and within the CCG, CGG, and CAG tracts appeared uniform with average transcription rates of 170, 250, 300, and 410 nucleotides/min, respectively. These differences correlated with changes in the sequence-specific transient pausing pattern within the CNG repeat tracts; individual incorporation rates were slower after incorporation of pyrimidine residues. Unexpectedly, approximately 4% of the run-off transcripts were, depending on the repeat sequence, either 15 or 18 nucleotides longer than expected, However, these products were not produced by transcriptional slippage within the repeat tract.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Dept Obstet & Gynecol, Galveston, TX 77555 USA; Texas A&M Univ, Ctr Genome Res, Inst Biosci & Technol, Dept Biochem & Biophys, Houston, TX 77030 USA	University of Texas System; University of Texas Medical Branch Galveston; Texas A&M University System	Sinden, RR (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Dept Obstet & Gynecol, Galveston, TX 77555 USA.		Sinden, Richard/AAE-3086-2019		NIGMS NIH HHS [GM50719, GM52982] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIVAZASHVILI VA, 1982, MOL BIOL, V15, P711; Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENGAL E, 1989, J BIOL CHEM, V264, P9791; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CHAFIN DR, 1995, J BIOL CHEM, V270, P19114, DOI 10.1074/jbc.270.32.19114; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; Chastain PD, 1998, J MOL BIOL, V275, P405, DOI 10.1006/jmbi.1997.1502; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; ENRIQUEZHARRIS P, 1991, EMBO J, V10, P1833, DOI 10.1002/j.1460-2075.1991.tb07709.x; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; Godde JS, 1996, J BIOL CHEM, V271, P15222, DOI 10.1074/jbc.271.25.15222; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; Hamshere MG, 1997, P NATL ACAD SCI USA, V94, P7394, DOI 10.1073/pnas.94.14.7394; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; Izban MG, 1998, J BIOL CHEM, V273, P27009, DOI 10.1074/jbc.273.41.27009; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; NOVELLI G, 1993, BIOCHEM MOL BIOL INT, V29, P291; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PRICE DH, 1987, J BIOL CHEM, V262, P3244; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; RHODES G, 1974, J BIOL CHEM, V249, P6675; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; SMEETS HJM, 1995, HUM MOL GENET, V4, P2103, DOI 10.1093/hmg/4.11.2103; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WIEST DK, 1992, J BIOL CHEM, V267, P7733; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975	66	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26998	27008		10.1074/jbc.273.41.26998	http://dx.doi.org/10.1074/jbc.273.41.26998			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756950	hybrid			2022-12-25	WOS:000076373300104
J	Rhodes, K; Oshima, RG				Rhodes, K; Oshima, RG			A regulatory element of the human keratin 18 gene with AP-1-dependent promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; MESSENGER-RNA; TRANSCRIPTIONAL INSULATION; CRYPTIC PROMOTER; INTRON ENHANCER; C-FOS; EXPRESSION; CELLS; ACTIVATION; SEQUENCES	The human keratin 18 (K18) gene is expressed in a restricted but diverse subset of differentiated epithelial tissues and carcinomas, The 10-kilobase pair K18 gene contains all of the genetic information necessary for tissue-specific, copy number-dependent and integration site-independent expression in transgenic mice. We identified a 100-base pair regulatory element that activates the K18 proximal promoter in the presence of the previously identified first intron enhancer. Deletion of the element greatly diminished K18 expression. This regulatory element also has cryptic, AP-1-dependent promoter activity in the absence of the normal promoter, which results in 10-40-fold higher levels of K18 RNA expression in transgenic mice. The high activity of this cryptic promoter is dependent upon the first intron enhancer. These experiments define interactive regulatory regions of the K18 gene that modulate expression in diverse epithelial cell types and identify an unusual regulatory element with promoter activity that may be useful for high level heterologous gene expression in transgenic animals.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Oshima, RG (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rgoshima@ljcrf.edu			NCI NIH HHS [5 R01 CA42302, 5 P30 CA30199] Funding Source: Medline; NICHD NIH HHS [N01 HD-0-2911] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002911] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042302, P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1990, J CELL BIOL, V111, P1197, DOI 10.1083/jcb.111.3.1197; ALSHAWI R, 1991, MOL CELL BIOL, V11, P4207, DOI 10.1128/MCB.11.8.4207; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P29; GUNTHER M, 1995, MOL CELL BIOL, V15, P2490; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; HOGAN B, 1987, MANIPULATING MOUSE E; HSU J, 1991, P NATL ACAD SCI USA, V38, P3511; IRNIGER S, 1992, NUCLEIC ACIDS RES, V20, P4733, DOI 10.1093/nar/20.18.4733; KULESH DA, 1988, MOL CELL BIOL, V8, P1540, DOI 10.1128/MCB.8.4.1540; KULESH DA, 1989, GENOMICS, V4, P339, DOI 10.1016/0888-7543(89)90340-6; LEPAGE P, 1995, VIROLOGY, V210, P244, DOI 10.1006/viro.1995.1341; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MULLICK J, 1995, BIOCHEMISTRY-US, V34, P13729, DOI 10.1021/bi00042a003; Neznanov N, 1997, J BIOL CHEM, V272, P27549, DOI 10.1074/jbc.272.44.27549; NEZNANOV N, 1993, MOL CELL BIOL, V13, P2214, DOI 10.1128/MCB.13.4.2214; Neznanov N, 1996, MOL BIOL CELL, V7, P541, DOI 10.1091/mbc.7.4.541; NEZNANOV NS, 1993, MOL CELL BIOL, V13, P1815, DOI 10.1128/MCB.13.3.1815; OSBALDESTON NJ, 1995, BIOCHEM J, V308, P465, DOI 10.1042/bj3080465; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; OSHIMA RG, 1988, GENE DEV, V2, P505, DOI 10.1101/gad.2.5.505; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Sambrook J, 1989, MOL CLONING LAB MANU, P165; TAYLOR JM, 1995, J BIOL CHEM, V270, P2535, DOI 10.1074/jbc.270.6.2535; TEE MK, 1995, HUM MOL GENET, V4, P2109, DOI 10.1093/hmg/4.11.2109; THOREY IS, 1993, DEV BIOL, V160, P519, DOI 10.1006/dbio.1993.1326; THOREY IS, 1993, MOL CELL BIOL, V13, P6742, DOI 10.1128/MCB.13.11.6742; TURPEN T H, 1986, Biotechniques, V4, P14; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315	41	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26534	26542		10.1074/jbc.273.41.26534	http://dx.doi.org/10.1074/jbc.273.41.26534			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756890	hybrid			2022-12-25	WOS:000076373300044
J	Rizzo, V; Sung, A; Oh, P; Schnitzer, JE				Rizzo, V; Sung, A; Oh, P; Schnitzer, JE			Rapid mechanotransduction in situ at the luminal cell surface of vascular endothelium and its caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	13th Bodensee Symposium on Microcirculation	JUN 09-10, 1995	BAD SCHACHEN, GERMANY	Medisan AB, Uppsala			FLUID SHEAR-STRESS; NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; PROSTACYCLIN PRODUCTION; INOSITOL TRISPHOSPHATE; SIGNAL-TRANSDUCTION; RAF-1 KINASE; KAPPA-B	The vascular endothelium is uniquely positioned between the blood and tissue compartments to receive directly the fluid forces generated by the blood flowing through the vasculature. These forces invoke specific responses within endothelial cells and serve to modulate their intrinsic structure and function. The mechanisms by which hemodynamic forces are detected and converted by endothelia into a sequence of biological and even pathological responses are presently unknown. By purifying and subfractionating the luminal endothelial cell plasma membrane from tissue, we show, for the first time, that not only does mechanotransduction occur at the endothelial cell surface directly exposed to vascular flow in, vivo but also increased flow in situ induces rapid tyrosine phosphorylation of luminal endothelial cell surface proteins located primarily in the plasmalemmal invaginations called caveolae. Increased flow induces the translocation of signaling molecules primarily to caveolae, ultimately activating the Ras-Raf-mitogen-activated protein kinase pathway. This signaling appears to require intact caveolae. Filipin-induced disassembly of caveolae inhibits both proximal signaling events at the cell surface and downstream activation of the mitogen-activated protein kinase pathway. With the molecular machinery required for mediating rapid flow-induced responses as seen in endothelium, caveolae may be flow-sensing organelles converting mechanical stimuli into chemical signals transmitted into the cell.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Schnitzer, JE (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA.	jschnitz@bidmc.harvard.edu			NHLBI NIH HHS [HL52766, HL58216, HL09857-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058216, R01HL052766, F32HL009857] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Berk BC, 1995, J BIOMECH, V28, P1439, DOI 10.1016/0021-9290(95)00092-5; BERTHIAUME F, 1992, FEBS LETT, V308, P277, DOI 10.1016/0014-5793(92)81292-T; BHAGYALAKSHMI A, 1992, J VASC RES, V29, P443, DOI 10.1159/000158963; COLLINS T, 1993, LAB INVEST, V68, P499; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Du W, 1995, J BIOMECH, V28, P1485, DOI 10.1016/0021-9290(95)00096-8; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FRANKE RP, 1984, NATURE, V307, P648, DOI 10.1038/307648a0; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; Gimbrone MA, 1997, ANN NY ACAD SCI, V811, P1, DOI 10.1111/j.1749-6632.1997.tb51983.x; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; LEE J, 1995, ANN BIOMED ENG, V23, P226, DOI 10.1007/BF02584425; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lindner V, 1996, AM J PATHOL, V148, P427; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Malek AM, 1995, J BIOMECH, V28, P1515, DOI 10.1016/0021-9290(95)00099-2; MELKUMYANTS AM, 1995, NEWS PHYSIOL SCI, V10, P204; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; RESNICK N, 1995, FASEB J, V9, P874, DOI 10.1096/fasebj.9.10.7615157; Rizzo V, 1998, FASEB J, V12, pA187; ROSALES OR, 1992, AM J PHYSIOL, V262, pC956, DOI 10.1152/ajpcell.1992.262.4.C956; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Schnitzer J. E., 1997, VASCULAR ENDOTHELIUM, P77; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHNITZER JE, 1995, ANN BIOMED ENG, V23, pS34; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; SIMIONESCU M, 1984, HDB PHYSL, V4; Skalak Thomas C., 1996, Microcirculation (Philadelphia), V3, P143, DOI 10.3109/10739689609148284; SUMPIO BE, 1994, J CELL PHYSIOL, V158, P133, DOI 10.1002/jcp.1041580117; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922	56	135	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26323	26329		10.1074/jbc.273.41.26323	http://dx.doi.org/10.1074/jbc.273.41.26323			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	127WJ	9756862	hybrid			2022-12-25	WOS:000076373300016
J	Yokoyama, K; Trobridge, P; Buckner, FS; Van Voorhis, WC; Stuart, KD; Gelb, MH				Yokoyama, K; Trobridge, P; Buckner, FS; Van Voorhis, WC; Stuart, KD; Gelb, MH			Protein farnesyltransferase from Trypanosoma brucei - A heterodimer of 61- and 65-kDa subunits as a new target for antiparasite therapeutics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAB GERANYLGERANYL TRANSFERASE; BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; TRICYCLIC INHIBITORS; METAL REQUIREMENTS; ALPHA-SUBUNIT; CDNA CLONING; GENE-PRODUCT; ANIMAL-CELLS; COMPONENT-A	We have previously shown that protein prenylation occurs in the Trypanosomatids Trypanosoma brucei (T, brucei), Trypanosoma cruzi, and Leishmania mexicana and that protein farnesyltransferase (PFT) activity can be detected in cytosolic extracts of insect (procyclic) form T, brucei, A PFT that transfers the farnesyl group from farnesyl pyrophosphate to a cysteine that is 4 residues upstream of the C terminus of the Ras GTP-binding protein RAS1-CVIM has now been purified 60,000-fold to near homogeneity from procyclic T, brucei. By screening a mixture of hexapeptides SSCALX (X is 20 different amino acids), it was found that SSCALM binds to T, brucei PFT with sub-micromolar affinity, and affinity chromatography using this peptide was a key step in the purification of this enzyme. On SDS-polyacrylamide gel electrophoresis, the enzyme migrates as a pair of bands with apparent molecular masses of 61 and 65 kDa, and thus its subunits are similar to 30% larger than those of the mammalian homolog, The 61-kDa band was identified as the putative beta-subunit by photoaffinity labeling with a P-32-labeled analog of farnesyl pyrophosphate, Mimetics of the C-terminal tetrapeptide of prenyl accepters have been previously shown to inhibit mammalian PFT, and these compounds also inhibit T. brucei PFT with affinities in the nanomolar to micromolar range, although the structure-activity relationship is very different for parasite versus mammalian enzyme. Unlike mammalian cells, the growth of bloodstream T, brucei is completely inhibited by low micromolar concentrations of two of the PFT inhibitors, and these compounds also block protein farnesylation in cultured parasites. These compounds also potently block the growth of the intracellular (amastigote) form of T, cruzi grown in fibroblast host cells. The results suggest that protein farnesylation is a target for the development of anti-trypanosomatid chemotherapeutics.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Seattle Biomed Res Inst, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Center for Infectious Disease Research; University of Washington; University of Washington Seattle	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.		Buckner, Frederick/AAF-3938-2020	gelb, michael/0000-0001-7000-5219; Buckner, Frederick/0000-0001-7796-6477	NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014102, R01AI014102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042188] Funding Source: NIH RePORTER; NCI NIH HHS [CA52874] Funding Source: Medline; NIAID NIH HHS [R01 AI014102, AI14102] Funding Source: Medline; NIGMS NIH HHS [R01 GM042188, GM42188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN CM, 1985, METHOD ENZYMOL, V110, P117; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; Bubis Jose, 1993, Biological Research, V26, P177; Buckner FS, 1996, ANTIMICROB AGENTS CH, V40, P2592, DOI 10.1128/AAC.40.11.2592; CAPPAI R, 1993, MOL BIOCHEM PARASIT, V62, P73, DOI 10.1016/0166-6851(93)90179-2; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASSEL D, 1991, EXP PARASITOL, V72, P411, DOI 10.1016/0014-4894(91)90087-D; CHEN GZ, 1993, MOL BIOCHEM PARASIT, V59, P287, DOI 10.1016/0166-6851(93)90226-N; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COSO OA, 1992, BIOCH J; COULTER LJ, 1995, EXP PARASITOL, V80, P308, DOI 10.1006/expr.1995.1037; EISENSCHLOS CD, 1986, BIOCHEM J, V237, P913, DOI 10.1042/bj2370913; ELSAYED NMA, 1995, MOL BIOCHEM PARASIT, V73, P75, DOI 10.1016/0166-6851(95)00098-L; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; Field H, 1996, MOL BIOCHEM PARASIT, V82, P67, DOI 10.1016/0166-6851(96)02723-5; Field H, 1997, J BIOL CHEM, V272, P10498, DOI 10.1074/jbc.272.16.10498; Field MC, 1995, EXP PARASITOL, V81, P313, DOI 10.1006/expr.1995.1122; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; Gelb MH, 1998, CURR OPIN CHEM BIOL, V2, P40, DOI 10.1016/S1367-5931(98)80034-3; GLOMSET JA, 1992, BIOCHEM SOC T, V20, P479, DOI 10.1042/bst0200479; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GONZALESPERDOMO M, 1988, EXP PARASITOL, V66, P205, DOI 10.1016/0014-4894(88)90092-6; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Koblan KS, 1996, BIOCHEM SOC T, V24, P688, DOI 10.1042/bst0240688; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; Leonard DM, 1997, J MED CHEM, V40, P2971, DOI 10.1021/jm970226l; LUJAN HD, 1995, MOL BIOCHEM PARASIT, V72, P121, DOI 10.1016/0166-6851(94)00070-4; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MCGEADY P, 1995, J BIOL CHEM, V270, P26347, DOI 10.1074/jbc.270.44.26347; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; Mendonca Sergio M., 1993, Biological Research, V26, P3; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUSHA T, 1992, J BIOL CHEM, V267, P9821; Njoroge FG, 1997, BIOORGAN MED CHEM, V5, P101, DOI 10.1016/S0968-0896(96)00206-4; Noguchi Y, 1998, J BIOL CHEM, V273, P3649, DOI 10.1074/jbc.273.6.3649; OLIVEIRA MM, 1993, MOL CELL BIOCHEM, V124, P91, DOI 10.1007/BF00929200; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; Otto JC, 1996, J BIOL CHEM, V271, P4569; OZ HS, 1994, AM J TROP MED HYG, V50, P620, DOI 10.4269/ajtmh.1994.50.620; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; POMPLIANO DL, 1993, BIOCHEMISTRY-US, V32, P8341, DOI 10.1021/bi00083a038; Qian YM, 1997, BIOPOLYMERS, V43, P25, DOI 10.1002/(SICI)1097-0282(1997)43:1<25::AID-BIP4>3.0.CO;2-2; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SAKAGAMI Y, 1978, AGR BIOL CHEM TOKYO, V42, P1093, DOI 10.1080/00021369.1978.10863118; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Williams TM, 1996, J MED CHEM, V39, P1345, DOI 10.1021/jm9508090; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; Yokoyama K, 1997, MOL BIOCHEM PARASIT, V87, P61, DOI 10.1016/S0166-6851(97)00043-1; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; YOKOYAMA K, 1998, IN PRESS MOL BIOCH P; YOKOYAMA K, 1992, BIOCHEM SOC T, V20, P479; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	70	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26497	26505		10.1074/jbc.273.41.26497	http://dx.doi.org/10.1074/jbc.273.41.26497			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756885	hybrid			2022-12-25	WOS:000076373300039
J	Esteve, P; Embade, N; Perona, R; Jimenez, B; del Peso, L; Leon, J; Arends, M; Miki, T; Lacal, JC				Esteve, P; Embade, N; Perona, R; Jimenez, B; del Peso, L; Leon, J; Arends, M; Miki, T; Lacal, JC			Rho-regulated signals induce apoptosis in vitro and in vivo by a p53-independent, but Bcl2 dependent pathway	ONCOGENE			English	Article						apoptosis; Rho proteins; p53; Bcl2; ceramides; TNF alpha	GTP-BINDING PROTEIN; NF-KAPPA-B; FAS-INDUCED APOPTOSIS; MYC-INDUCED APOPTOSIS; ACTIN STRESS FIBERS; CELL-DEATH; C-MYC; RAS TRANSFORMATION; GROWTH-FACTOR; ADP-RIBOSYLTRANSFERASE	Rho proteins are a branch of GTPases that belongs to the Ras superfamily which are critical elements of signal transduction pathways leading to a variety of cellular responses. This family of small GTPases has been involved in diverse biological functions such as cytoskeleton organization, cell growth and transformation, cell motility, migration, metastasis, and responses to stress. We report that several human Rho proteins including Rho A, Rho C and Rac I, are capable of inducing apoptosis in different cell systems like murine NIH3T3 fibroblasts and the human erythroleukemia K562 cell line, Since K562 cells are devoid of p53, apoptosis induced by Rho in this system is independent of p53, Rho-dependent apoptosis is mediated by the generation of ceramides, and it is drastically inhibited by ectopic expression of Bcl2, both under in vitro and in vivo conditions. Furthermore, the human oncogenes vav and ost that have been shown to function as guanine exchange factors for Rho proteins, were also able to induce apoptosis under similar conditions. Finally, we also report that the levels of endogenous Rho proteins are increased when U937 myeloid leukemia cells are exposed to apoptosis-inducing conditions such as TNF alpha treatment. Furthermore, TNF alpha-induced apoptosis in these cells is inhibited by expression of a dominant negative mutant of Rac 1 but it is not affected by a similar mutant of Rho A. These results suggest that Rho proteins play an important role in the physiological regulation of the apoptotic response to stress-inducing agents.	Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, Madrid, Spain; Univ Autonoma Madrid, Fac Med, Dept Bioquim, Madrid, Spain; Univ Cantabria, Dept Biol Mol, E-39005 Santander, Spain; Univ Edinburgh, Dept Pathol, Edinburgh, Midlothian, Scotland; NCI, LCMB, Bethesda, MD 20892 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Universidad de Cantabria; University of Edinburgh; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lacal, JC (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, Madrid, Spain.		Cuenca, Benilde Jimenez/K-9959-2014; Lacal, Juan Carlos/AAL-2235-2020; embade, Nieves/K-5190-2014; Leon, Javier/K-4615-2014; del Peso, Luis/K-9391-2014; Lacal, Juan Carlos/N-9064-2015	embade, Nieves/0000-0001-9878-3290; del Peso, Luis/0000-0003-4014-5688; Lacal, Juan Carlos/0000-0002-1908-2777; Leon, Javier/0000-0001-5803-0112; Jimenez Cuenca, Benilde/0000-0002-1806-6636				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; ARENDS MJ, 1994, MOL BIOL HISTOPATHOL, P151; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Bettaieb A, 1996, BLOOD, V88, P1465, DOI 10.1182/blood.V88.4.1465.bloodjournal8841465; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; del Peso L, 1997, ONCOGENE, V15, P3047; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Esteve P, 1995, ONCOGENE, V11, P2657; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; JIMENEZ B, 1995, ONCOGENE, V10, P811; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moorman JP, 1996, J IMMUNOL, V156, P4146; MORII N, 1992, J BIOL CHEM, V267, P20921; MOSCOW JA, 1994, GENE, V144, P229, DOI 10.1016/0378-1119(94)90382-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; PERONA R, 1993, ONCOGENE, V8, P1285; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Preston GA, 1996, MOL CELL BIOL, V16, P211; PROKOCIMER M, 1986, BLOOD, V68, P113; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAEZ R, 1994, ONCOGENE, V9, P2977; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	78	93	95	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1855	1869		10.1038/sj.onc.1202082	http://dx.doi.org/10.1038/sj.onc.1202082			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778052				2022-12-25	WOS:000076303300012
J	Kasus-Jacobi, A; Perdereau, D; Auzan, C; Clauser, E; Van Obberghen, E; Mauvais-Jarvis, F; Girard, J; Burnol, AF				Kasus-Jacobi, A; Perdereau, D; Auzan, C; Clauser, E; Van Obberghen, E; Mauvais-Jarvis, F; Girard, J; Burnol, AF			Identification of the rat adapter Grb14 as an inhibitor of insulin actions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; IGF-I RECEPTOR; STIMULATES TYROSINE PHOSPHORYLATION; YEAST 2-HYBRID SYSTEM; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-HORMONE; CARBOXYL-TERMINUS; CRYSTAL-STRUCTURE; BINDING-PROTEIN	We cloned by interaction with the beta-subunit of the insulin receptor the rat variant of the human adapter Grb14 (rGrb14). rGrb14 is specifically expressed in rat insulin-sensitive tissues and in the brain. The binding of rGrb14 to insulin receptors is insulin-dependent in vivo in Chinese hamster ovary (CHO) cells overexpressing both proteins and importantly, in rat liver expressing physiological levels of proteins. However, rGrbl4 is not a substrate of the tyrosine kinase of the receptor. In the two-hybrid system, two domains of rGrbl4 can mediate the interaction with insulin receptors: the Src homology 2 (SH2) domain and a region between the PH and SH2 domains that we named PIR (for (p) under bar hosphorylated insulin receptor-(i) under bar nteracting (r) under bar egion). In vitro interaction assays using deletion mutants of rGrbl4 show that the PIR, but not the SH2 domain, is able to coprecipitate insulin receptors, suggesting that the PIR is the major binding domain of rGrb14. The interaction between rGrb14 and the insulin receptors is almost abolished by mutating tyrosine residue Tyr(1150) Or Tyr(1151) Of the receptor. The overexpression of rGrb14 in CHO-IR cells decreases insulin stimulation of both DNA and glycogen synthesis. These effects are accompanied by a decrease in insulin-stimulated tyrosine phosphorylation of IRS-1, but insulin receptor autophosphorylation is unaltered. These findings suggest that rGrbl4 could be a new downstream signaling component of the insulin-mediated pathways.	CNRS, UPR 1524, F-92190 Meudon, France; Coll France, INSERM, U36, F-75005 Paris, France; INSERM, U145, F-06107 Nice, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Burnol, AF (corresponding author), CNRS, UPR 1524, 9 Rue Jules Hetzel, F-92190 Meudon, France.	burnol@cnrs-bellevue.fr	Burnol, Anne-Francoise/P-2181-2017; KASUS-JACOBI, Anne/V-7799-2019	KASUS-JACOBI, Anne/0000-0003-3844-0450				ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BELL GI, 1993, J BIOL CHEM, V268, P19161; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; BURNOL AF, 1990, BIOCHEM J, V270, P277, DOI 10.1042/bj2700277; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; KasusJacobi A, 1997, J BIOL CHEM, V272, P17166, DOI 10.1074/jbc.272.27.17166; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMOTHE B, 1995, FEBS LETT, V373, P51, DOI 10.1016/0014-5793(95)01011-3; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; LECONTE I, 1992, J BIOL CHEM, V267, P17415; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONeill TJ, 1997, J BIOL CHEM, V272, P10035; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OOI J, 1995, ONCOGENE, V10, P1621; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; REED BC, 1977, P NATL ACAD SCI USA, V74, P4876, DOI 10.1073/pnas.74.11.4876; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SAAD MJA, 1994, MOL ENDOCRINOL, V8, P545, DOI 10.1210/me.8.5.545; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; Velloso LA, 1996, P NATL ACAD SCI USA, V93, P12490, DOI 10.1073/pnas.93.22.12490; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942	68	94	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26026	26035		10.1074/jbc.273.40.26026	http://dx.doi.org/10.1074/jbc.273.40.26026			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748281	hybrid			2022-12-25	WOS:000076263100072
J	Dirks, PB; Rutka, JT; Hubbard, SL; Mondal, S; Hamel, PA				Dirks, PB; Rutka, JT; Hubbard, SL; Mondal, S; Hamel, PA			The E2P-family proteins induce distinct cell cycle regulatory factors in pl6-arrested, U343 astrocytoma cells	ONCOGENE			English	Article						E2F-family; p16; astrocytomas; cell cycle; apoptosis	DIHYDROFOLATE-REDUCTASE GENE; E2F TRANSCRIPTION FACTOR; HUMAN MYC PROMOTER; RETINOBLASTOMA-PROTEIN; GROWTH SUPPRESSION; IN-VIVO; EXPRESSION PATTERNS; TRANS-ACTIVATION; BINDING PROTEIN; FAMILY PROTEINS	We previously demonstrated that P16(Ink4a) (p16) expression in p16-deficient U343 astrocytoma cells causes a G(1) cell cycle arrest, profound changes in cytoskeletal proteins and alterations in expression and activity of the pRB and E2F family proteins, We examine here the effects of expressing wild type or mutant versions of the downstream targets of p16 in U343 astrocytomas, We first attempted to block proliferation of U343 cells using the dominant mutant of pRB, Delta p34. Expression of this mutant in the human osteosarcoma, SAOS-2, potently blocked proliferation but did not affect the cell cycle of U343 cells. We next showed that expression of E2F-1, E2F-2, E2F-3 and E2F-4 are each able to overcome this p16-dependent cell cycle arrest but exhibit distinct biological activities, Adenoviral-mediated expression of E2F-1, E2F-2, E2F-3, or E2F-4 overcame the p16-dependent cell cycle block and induced alterations in cell morphology, E2F-5, only in conjunction with DP1, promoted cell cycle progression. For both E2F-1 and E2F-2, bat not E2F-3 or E2F-5/DP1, cell cycle re-entry was associated with almost quantitative cell death, Only small numbers of dying cells were observed in E2F-4-expressing cultures. Expression of the different E2F's altered the expression of distinct sets of cell cycle regulatory proteins. E2F-1 induced endogenous E2F-4 expression and also caused an increase in pRB, p107 and cyclin E levels. Expression of E2F-4 caused a weak increase in E2F-1 levels but also strongly induced pRB, p107, p130 and cyclin E, However, E2F-1 and E2F-4 clearly regulate expression of distinct genes, demonstrated when E2F-4 caused a threefold increase in the levels of cdk2 whereas E2F-1 failed to increase in this cyclin dependent kinase, Similarly, expression of E2F-1 or E2F-2 were shown to have distinct effects on the expression of cdk2, cyclin E and pRB despite both of these closely related E2F-family members potently inducing cell death, Thus, E2F-1, E2F-2, E2F-3 and E2F-4 are able to overcome the p16-dependent proliferative block in U343 astrocytoma cells, While overcoming this cell cycle block, each of the E2F's uniquely affect the expression of a number of cell cycle regulatory proteins and have distinct abilities to promote cell death.	Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Hosp Sick Children, Div Neurosurg, Toronto, ON M5S 1A8, Canada; Univ Toronto, Hosp Sick Children, Div Surg Res, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Hamel, PA (corresponding author), Univ Toronto, Dept Lab Med & Pathol, 100 Coll St, Toronto, ON M5S 1A8, Canada.							BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Botz J, 1996, MOL CELL BIOL, V16, P3401; BUCK V, 1995, ONCOGENE, V11, P31; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dirks PB, 1997, ONCOGENE, V15, P2037, DOI 10.1038/sj.onc.1201392; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1992, ONCOGENE, V7, P693; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hirai H, 1996, MOL CELL BIOL, V16, P6457; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KIESS M, 1995, ONCOGENE, V10, P159; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEE WH, 1988, J CELL BIOCHEM, V38, P213, DOI 10.1002/jcb.240380309; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUKAS J, 1995, CANCER RES, V55, P4818; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MUNCASTER MM, 1992, CANCER RES, V52, P654; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIMIZU M, 1995, MOL CELL BIOL, V15, P2882; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V12, P5620; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; Ueki K, 1996, CANCER RES, V56, P150; WADE M, 1995, J BIOL CHEM, V270, P9783, DOI 10.1074/jbc.270.17.9783; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU CL, 1995, MOL CELL BIOL, V15, P2536; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; YEAGER T, 1995, CANCER RES, V55, P493; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	69	46	50	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					867	876		10.1038/sj.onc.1202008	http://dx.doi.org/10.1038/sj.onc.1202008			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780003				2022-12-25	WOS:000075448800008
J	Bianco, A; Brock, C; Zabel, C; Walk, T; Walden, P; Jung, G				Bianco, A; Brock, C; Zabel, C; Walk, T; Walden, P; Jung, G			New synthetic non-peptide ligands for classical major histocompatibility complex class I molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL PEPTIDES; DRUG DISCOVERY; MHC; BINDING; LIBRARIES; HLA-A2; AMINO; PSEUDOPEPTIDES; STABILITY; EPITOPES	Poly-N-acylated amines, as a new class of synthetic non-peptide ligands for the murine major histocompatibility complex (MHC) class I molecule H-2K(b), were developed on the basis of the ovalbumin-derived peptide epitope SIINFEKL. Non-peptidic structural elements were introduced at the C-terminal part of the ligand and include the two dominant anchors at positions 5 and 8, Several oligomers and five different combinatorial libraries were synthesized and tested for their H-2K(b)-binding capacities in an MHC stabilization assay. First, the optimal spacing and geometry of the side chains were determined using a series of oligomers with different main chain modifications. Then, based on the structure with the highest binding efficiency, randomized libraries were designed that contain 26 different aromatic, heteroaromatic, or pseudoaromatic side chains for the dominant anchor at position 5, which is deeply buried inside the MHC peptide-binding groove and is crucial for the conformational stability of the entire peptide-MHC complex. Similarly, a series of aliphatic side chains were tested for the second dominant anchor at position 8, MHC-binding and MHC-stabilizing oligomers with defined structures were derived from these libraries by deconvolution.	Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; Humboldt Univ, Dermatol Klin, D-10089 Berlin, Germany	Eberhard Karls University of Tubingen; Humboldt University of Berlin	Bianco, A (corresponding author), Univ Padua, Dept Organ Chem, Via Marzolo 1, I-35131 Padua, Italy.							ANDERSON GW, 1960, J AM CHEM SOC, V82, P3359, DOI 10.1021/ja01498a032; Augustyns K, 1998, J PEPT RES, V51, P127; BARBER LD, 1993, ANNU REV CELL BIOL, V9, P163; BIANCO A, 1998, IN PRESS J PEPT SCI; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CHO CY, 1993, SCIENCE, V261, P1303, DOI 10.1126/science.7689747; DURR H, 1992, ANGEW CHEM INT EDIT, V31, P785, DOI 10.1002/anie.199207851; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FRANCO A, 1994, EUR J IMMUNOL, V24, P940, DOI 10.1002/eji.1830240424; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GUICHARD G, 1995, J BIOL CHEM, V270, P26057, DOI 10.1074/jbc.270.44.26057; Guichard G, 1996, J MED CHEM, V39, P2030, DOI 10.1021/jm9509511; JAMESON SC, 1992, EUR J IMMUNOL, V22, P2663, DOI 10.1002/eji.1830221028; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; JUNG G, 1996, COMBINATORIAL PEPTID; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; METZGER JW, 1994, ANAL BIOCHEM, V219, P261, DOI 10.1006/abio.1994.1266; MORAN EJ, 1995, BIOPOLYMERS, V37, P213, DOI 10.1002/bip.360370305; Nash IA, 1996, TETRAHEDRON LETT, V37, P2625, DOI 10.1016/0040-4039(96)00344-9; ROGNAN D, 1995, P NATL ACAD SCI USA, V92, P753, DOI 10.1073/pnas.92.3.753; SIMON RJ, 1992, P NATL ACAD SCI USA, V89, P9367, DOI 10.1073/pnas.89.20.9367; UDAKA K, 1995, J BIOL CHEM, V270, P24130, DOI 10.1074/jbc.270.41.24130; UDAKA K, 1995, J EXP MED, V181, P2097, DOI 10.1084/jem.181.6.2097; WALDEN P, 1995, BIOCHEM SOC T, V23, P678, DOI 10.1042/bst0230678; WEISS GA, 1995, CHEM BIOL, V2, P401, DOI 10.1016/1074-5521(95)90221-X; ZUCKERMANN RN, 1993, CURR OPIN STRUC BIOL, V3, P580, DOI 10.1016/0959-440X(93)90086-Z	31	14	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28759	28765		10.1074/jbc.273.44.28759	http://dx.doi.org/10.1074/jbc.273.44.28759			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786873	hybrid			2022-12-25	WOS:000076691800034
J	Chan, YR; Gallo, RL				Chan, YR; Gallo, RL			PR-39, a syndecan-inducing antimicrobial peptide, binds and affects p130(Cas)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH ANTIBACTERIAL PEPTIDE; MEDIATED CELL-ADHESION; TYROSINE PHOSPHORYLATION; PIG INTESTINE; V-CRK; SUBSTRATE P130(CAS); SIGNALING COMPLEX; INNATE IMMUNITY; GROWTH-FACTOR; PROLINE	PR-39 is a proline-arginine-rich antimicrobial peptide and an important component of innate immunity, In addition to its antimicrobial effects, PR-39 can alter mammalian cell gene expression and behavior. To determine the mechanism through which PR-39 affects mesenchymal cells, we identify a number of binding targets for PR-39 using a biologically active fragment of PR-39 (PR-39(15)), We found that PR-39 binds NIH 3T3 in a saturable manner consistent with the existence of a binding target. Similar to full-length PR-39, PR-39(15) interacts with lipid bilayers, After interacting with the membrane, PR-39(15) rapidly enters human microvascular endothelial cells and binds a number of cytoplasmic proteins, PR-39 selectively binds recombinant SH3-containing proteins and was also found to bind a native SH3-containing protein, p130(Cas). PR-39(15) treatment of endothelial cells results in altered p130 localization, These results show that PR-39(15) binds an SH3-containing signal transduction molecule that has the potential to explain a myriad of effects PR-39 has on mammalian cell behaviors.	Harvard Univ, Sch Med, Childrens Hosp, Dept Dermatol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Dev & Newborn Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Gallo, RL (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Dermatol, 300 Longwood Ave,Enders 961, Boston, MA 02115 USA.	gallo@a1.tch.harvard.edu	Gallo, Richard L/A-8931-2009; Chan, Yvonne R/A-2513-2011	Gallo, Richard L/0000-0002-1401-7861; 				AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; Aspedon A, 1996, MICROBIOL-SGM, V142, P3389, DOI 10.1099/13500872-142-12-3389; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BEVINS CL, 1994, CIBA F SYMP, V186, P250; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Boman HG, 1996, SCAND J IMMUNOL, V43, P475, DOI 10.1046/j.1365-3083.1996.d01-76.x; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; BONIFACINO J, 1997, ANAL PROTEINS, V2; Burnham MR, 1996, ONCOGENE, V12, P2467; CABIAUX V, 1994, EUR J BIOCHEM, V224, P1019, DOI 10.1111/j.1432-1033.1994.01019.x; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Fujimoto Y, 1998, Rinsho Byori, V46, P9; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; GALLO R, IN PRESS J INVEST DE; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GALLO RL, 1995, MOL CELLULAR BIOL WO, P475; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Huang HJ, 1997, J LEUKOCYTE BIOL, V61, P624, DOI 10.1002/jlb.61.5.624; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; Kenakin TP., 1993, PHARM ANAL DRUG RECE, V2; Khwaja A, 1996, ONCOGENE, V12, P2491; Kobayashi S, 1998, J BIOCHEM-TOKYO, V123, P624; Ladokhin AS, 1997, BIOPHYS J, V72, P794, DOI 10.1016/S0006-3495(97)78713-7; LARRICK JW, 1994, J IMMUNOL, V152, P231; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; Lencer WI, 1997, P NATL ACAD SCI USA, V94, P8585, DOI 10.1073/pnas.94.16.8585; Mahoney MM, 1995, FEBS LETT, V377, P519, DOI 10.1016/0014-5793(95)01390-3; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Shi JH, 1996, ANTIMICROB AGENTS CH, V40, P115, DOI 10.1128/AAC.40.1.115; SHI JS, 1994, J LEUKOCYTE BIOL, V56, P807, DOI 10.1002/jlb.56.6.807; Shi JS, 1996, P NATL ACAD SCI USA, V93, P6014, DOI 10.1073/pnas.93.12.6014; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1363, DOI 10.1006/bbrc.1993.2403; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1058, DOI 10.1006/bbrc.1993.2358; TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4; Vunnam S, 1997, J PEPT RES, V49, P59; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O	53	97	104	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28978	28985		10.1074/jbc.273.44.28978	http://dx.doi.org/10.1074/jbc.273.44.28978			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786902	hybrid			2022-12-25	WOS:000076691800063
J	de Vega, M; Blanco, L; Salas, M				de Vega, M; Blanco, L; Salas, M			o29 DNA polymerase residue Ser(122), a single-stranded DNA ligand for 3 '-5 ' exonucleolysis, is required to interact with the terminal protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; EXONUCLEASE ACTIVE-SITE; SLIDING-BACK MECHANISM; EXO-III MOTIF; ESCHERICHIA-COLI; AMINO-ACID; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; 3'-5'-EXONUCLEASE DOMAIN; SACCHAROMYCES-CEREVISIAE	Three amino acid residues highly conserved in most proofreading DNA polymerases, a phenylalanine contained in the Exo II motif and a serine and a leucine belonging to the S/TLx(2)h motif, were recently shown to be critical for 3'-5' exonucleolysis by acting as single-stranded DNA ligands (de Vega, M., Lazaro, J.M., Salas, M. and Blanco, L. (1998) J. Mol. Biol. 279, 807-822). In this paper, site-directed mutants at these three residues were used to analyze their functional importance for the synthetic activities of phi 29 DNA polymerase, an enzyme able to start linear phi 29 DNA replication using a terminal protein (TP) as primer. Mutations introduced at Phe(65), Ser(122), and Leu(123) residues of phi 29 DNA polymerase severely affected the replication capacity of the enzyme. Three mutants, F65S, S122T, and S122N, were strongly affected in their capacity to interact with a DNA primer/template structure, suggesting a dual role during both polymerization and proofreading. Interestingly, mutant S122N was not able to maintain a stable interaction with the TP primer, thus impeding the firsts steps (initiation and transition) of phi 29 DNA replication. The involvement of Ser(122) in the consecutive binding of TP and DNA is compatible with the finding that the TP/DNA polymerase heterodimer was not able to use a DNA primer/template structure. Assuming a structural conservation among the eukaryotic-type DNA polymerases, a model for the interactions of phi 29 DNA polymerase with both TP and DNA primers is presented.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Canto Blanco, E-28049 Madrid, Spain.		de Vega, Miguel/K-2878-2014; Blanco, Luis/I-1848-2015; Salas, Margarita/J-9873-2014	de Vega, Miguel/0000-0003-1285-7549; Salas, Margarita/0000-0001-5939-3441	NIGMS NIH HHS [5R01 GM27242-19] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES MH, 1995, GENE, V165, P45, DOI 10.1016/0378-1119(95)00530-J; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BLANCO L, 1986, VIROLOGY, V153, P179, DOI 10.1016/0042-6822(86)90021-8; Blanco L, 1996, J BIOL CHEM, V271, P8509, DOI 10.1074/jbc.271.15.8509; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1993, J BIOL CHEM, V268, P24106; BLASCO MA, 1995, J BIOL CHEM, V270, P2735, DOI 10.1074/jbc.270.6.2735; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Derbyshire V, 1995, METHOD ENZYMOL, V262, P363; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; ESTEBAN JA, 1994, J BIOL CHEM, V269, P31946; ESTEBAN JA, 1993, J BIOL CHEM, V268, P2719; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GIBBS JS, 1991, MOL CELL BIOL, V11, P4786, DOI 10.1128/MCB.11.9.4786; HALL JD, 1995, J GEN VIROL, V76, P2999, DOI 10.1099/0022-1317-76-12-2999; HU JP, 1995, GENE, V160, P105, DOI 10.1016/0378-1119(95)00215-R; Hwang YT, 1997, J VIROL, V71, P7791, DOI 10.1128/JVI.71.10.7791-7798.1997; Illana B, 1996, J MOL BIOL, V264, P453, DOI 10.1006/jmbi.1996.0653; INCIARTE MR, 1976, VIROLOGY, V74, P314, DOI 10.1016/0042-6822(76)90338-X; ISHINO Y, 1994, J BIOL CHEM, V269, P14655; KHAN NN, 1991, NUCLEIC ACIDS RES, V19, P1627, DOI 10.1093/nar/19.7.1627; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KONG HM, 1993, J BIOL CHEM, V268, P1965; Kuhn FJP, 1996, J BIOL CHEM, V271, P29245; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; MCDONELL MW, 1977, J MOL BIOL, V110, P119, DOI 10.1016/S0022-2836(77)80102-2; Mendez J, 1997, EMBO J, V16, P2519, DOI 10.1093/emboj/16.9.2519; MENDEZ J, 1994, J BIOL CHEM, V269, P30030; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PASTRANA R, 1985, NUCLEIC ACIDS RES, V13, P3083, DOI 10.1093/nar/13.9.3083; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; ROHE M, 1991, CURR GENET, V20, P527, DOI 10.1007/BF00334782; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SALAS M, 1996, DNA REPLICATION EUKA, P131; Sattar AKMA, 1996, BIOCHEMISTRY-US, V35, P16621, DOI 10.1021/bi961552q; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SOENGAS MS, 1992, EMBO J, V11, P4227, DOI 10.1002/j.1460-2075.1992.tb05517.x; Southworth MW, 1996, P NATL ACAD SCI USA, V93, P5281, DOI 10.1073/pnas.93.11.5281; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r; WANG Y, 1992, J VIROL, V66, P1814, DOI 10.1128/JVI.66.3.1814-1816.1992; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; ZHU WG, 1994, NUCLEIC ACIDS RES, V22, P5177, DOI 10.1093/nar/22.24.5177	60	27	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28966	28977		10.1074/jbc.273.44.28966	http://dx.doi.org/10.1074/jbc.273.44.28966			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786901	hybrid			2022-12-25	WOS:000076691800062
J	Romano, M; Ricci, V; Memoli, A; Tuccillo, C; Di Popolo, A; Sommi, P; Acquaviva, AM; Blanco, CD; Bruni, CB; Zarrilli, R				Romano, M; Ricci, V; Memoli, A; Tuccillo, C; Di Popolo, A; Sommi, P; Acquaviva, AM; Blanco, CD; Bruni, CB; Zarrilli, R			Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E-2 synthesis in MKN 28 gastric mucosal cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CANCER; VACUOLATING TOXIN; EPITHELIAL-CELLS; PROLIFERATION; PREVENTION; APOPTOSIS; DAMAGE	Helicobacter pylori has been suggested to play a role in the development of gastric carcinoma in humans. Also, mounting evidence indicates that cyclooxygenase-a overexpression is associated with gastrointestinal carcinogenesis. We studied the effect of H. pylori on the expression and activity of cyclooxygenase-l and cyclooxygenase-a in MKN 28 gastric mucosal cells. H. pylori did not affect cyclooxygenase-l expression, whereas cyclooxygenase-2 mRNA levels increased by 5-fold at 24 h after incubation of MKN 28 cells with broth culture filtrates or bacterial suspensions from wild-type H. pylori strain. Also, H. pylori caused a S-fold increase in the release of prostaglandin E-2, the main product of cyclooxygenase activity. This effect was specifically related to H. pylori because it was not observed with Escherichia coli and was independent of VacA, CagA, or ammonia. H. pylori isogenic mutants specifically lacking picA or picB, which are responsible for cytokine production by gastric cells, were less effective in the up-regulation of cyclooxygenase-a mRNA expression and in the stimulation of prostaglandin E-2 release compared with the parental wild-type strain. This study suggests that development of gastric carcinoma associated with H. pylori infection may depend on the activation of cyclooxygenase-2-related events.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale G Salvatore, I-80131 Naples, Italy; Univ Naples Federico II, Policlin 2, Dipartimento Internist Clin & Sperimentale Gastro, I-80131 Naples, Italy; Univ Pavia, Ist Fisiol Umana, I-27100 Pavia, Italy; Univ Pavia, Ist Patol Gen, I-27100 Pavia, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II; University of Pavia; University of Pavia	Zarrilli, R (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Via Pansini 5, I-80131 Naples, Italy.	rafzarri@unina.it	Zarrilli, Raffaele/F-5067-2012	Zarrilli, Raffaele/0000-0003-4191-9032; ACQUAVIVA, Angela Maria/0000-0001-9538-2766; ROMANO, Marco/0000-0002-3271-349X				Baik SC, 1996, CANCER RES, V56, P1279; BLASER MJ, 1994, J CLIN INVEST, V94, P4, DOI 10.1172/JCI117336; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; COVER TL, 1992, J BIOL CHEM, V267, P10570; EBERHART CE, 1995, GASTROENTEROLOGY, V109, P285, DOI 10.1016/0016-5085(95)90296-1; Elder DJE, 1997, GASTROENTEROLOGY, V113, P1999; GHIRA P, 1995, INFECT IMMUN, V63, P4154, DOI 10.1128/IAI.63.10.4154-4160.1995; Huang JQ, 1998, GASTROENTEROLOGY, V114, P1169, DOI 10.1016/S0016-5085(98)70422-6; Mannick EE, 1996, CANCER RES, V56, P3238; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; Peek RM, 1997, JNCI-J NATL CANCER I, V89, P863, DOI 10.1093/jnci/89.12.863; Ricci V, 1996, INFECT IMMUN, V64, P2829, DOI 10.1128/IAI.64.7.2829-2833.1996; Ricci V, 1997, J PATHOL, V183, P453; Ristimaki A, 1997, CANCER RES, V57, P1276; ROBERT A, 1979, GASTROENTEROLOGY, V77, P433; Romano M, 1998, J CLIN INVEST, V101, P1604, DOI 10.1172/JCI1174; ROMANO M, 1988, J LAB CLIN MED, V111, P430; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; To KF, 1998, GASTROENTEROLOGY, V114, pA310, DOI 10.1016/S0016-5085(98)81260-2; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Wu KC, 1998, GASTROENTEROLOGY, V114, pA334, DOI 10.1016/S0016-5085(98)81355-3; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	26	163	184	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	1998	273	44					28560	28563		10.1074/jbc.273.44.28560	http://dx.doi.org/10.1074/jbc.273.44.28560			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	133NC	9786845	hybrid			2022-12-25	WOS:000076691800006
J	Colby, G; Tu, M; Tzagoloff, A				Colby, G; Tu, M; Tzagoloff, A			MTO1 codes for a mitochondrial protein required for respiration in paromomycin-resistant mutants of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MEMBRANE SYSTEM; YEAST; GENES; DNA; TRANSFORMATION; CLONING; CONSTRUCTION; EXPRESSION; MUTATION	Mutations in MTO1 express a respiratory defect only in the context of a mitochondrial genome with a paromomycin-resistance allele, This phenotype is similar to that described previously for mss1 mutants by Decoster, E. Vassal, A., and Faye, G.(1993) J. Mol. Biol, 232, 79-88, We present evidence that Mto1p and Mss1p are mitochondrial proteins and that they form a heterodimer complex. In a paromomycin-resistant background, mss1 and mto1 mutants are inefficient in processing the mitochondrial COX1 transcript for subunit 1 of cytochrome oxidase, The mutants also fail to synthesize subunit 1 and show a pleiotropic absence of cytochromes a, a(3), and b. In vivo pulse labeling of an mto1 mutant, however, indicate increased rates of synthesis of other mitochondrial translation products. The respiratory defective phenotype of mto1 and mss1 mutants is not seen in a paromomycin-sensitive genetic background. The visible absorption spectra of such strains indicate a higher ratio of cytochromes bla and elevated NADH- and succinate-cytochrome c reductase activities. To explain these phenotypic characteristics, we proposed that the Mto1p.Mss1p complex plays a role in optimizing mitochondrial protein synthesis in yeast, possibly by a proofreading mechanism.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.		Colby, Geoffrey/G-2526-2017	Colby, Geoffrey/0000-0002-3376-0933; Wu, Mian/0000-0002-2714-0500	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL022174, R01HL022174, R37HL022174] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL022174, HL22174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; DECOSTER E, 1993, J MOL BIOL, V232, P79, DOI 10.1006/jmbi.1993.1371; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HILL J, 1985, J BIOL CHEM, V260, P3235; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1982, J BIOL CHEM, V257, P5921; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU; Mashkevich G, 1997, J BIOL CHEM, V272, P14356, DOI 10.1074/jbc.272.22.14356; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MESSER W, 1992, CHROMOSOMA, V102, pS1, DOI 10.1007/BF02451779; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; PINKHAM JL, 1985, MOL CELL BIOL, V5, P3410, DOI 10.1128/MCB.5.12.3410; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SERAPHIN B, 1987, P NATL ACAD SCI USA, V84, P6810, DOI 10.1073/pnas.84.19.6810; SOR F, 1982, MITOCHONDRIAL GENES, P255; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228	29	76	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27945	27952		10.1074/jbc.273.43.27945	http://dx.doi.org/10.1074/jbc.273.43.27945			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774408	hybrid			2022-12-25	WOS:000076549800028
J	Datta, K; Biswal, SS; Xu, J; Towndrow, KM; Feng, X; Kehrer, JP				Datta, K; Biswal, SS; Xu, J; Towndrow, KM; Feng, X; Kehrer, JP			A relationship between 5-lipoxygenase-activating protein and bcl-x(L) expression in murine pro-B lymphocytic FL5.12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; MEDIATED APOPTOSIS; N-ACETYLCYSTEINE; GENE-EXPRESSION; FATTY-ACIDS; BCL-2; DEATH; ACTIVATION; PATHWAY; ANTIOXIDANT	Inhibitors of 5-lipoxygenase-activating protein (FLAP) have been found to induce apoptosis, The current study examined the expression of FLAP and bcl family proteins and the induction of apoptosis in interleukin-3-dependent control and bcl-x(L)-overexpressing FL5.12 cell lines after treatment with MK886, a specific FLAP inhibitor. FL5.12 cells contained a substantial amount of FLAP protein and mRNA but surprisingly had no measurable 5-lipoxygenase protein or 5-, 12-, or 15-lipoxygenase activity. The basal level of FLAP protein in cells overexpressing bcLx(L) was 70% less than in controls. FLAP disappeared 4 h after withdrawal of interleukin-3 in bcl-x(L) cells but not in control cells, which underwent apoptosis, A dose- and time-response study revealed that 5 nmol of MK886/10(6) cells was sufficient to induce apoptosis both in control and bcl-x(L) cells, respectively, but to different degrees, bcl-x(L) and bcl-2 proteins, but not bar or FLAP, were decreased by 4 h after 5 nmol of MK886/10(6) cells in both cell lines, although the higher levels of bcl-x(L) in overexpressors took longer to disappear. This early loss of bcl-x(L) and bcl-2 was not attributable to generalized proteoIysis, as shown by Coomassie Blue staining and by the maintenance of bar. Caspase-3 was activated 2 h after MK886 treatment in control cells but not in bcl-x(L) cells. Inhibition of caspase-3 decreased MK886-induced apoptosis by 50% in control cells. Inhibition of this caspase after MK886 treatment was unable to prevent the loss of bcl-x(L) in control cells but did provide partial protection for the loss of the transfected form, but not the endogenous form, in overexpressing cells. These data indicate that MK886 induces extensive apoptosis that is partially caspase-3 dependent and may be related to a rapid loss of bcl-x(L). Although caspase-3 inhibitors had no effect on the loss of bcl-x(L), other caspases or protease systems may still be involved. The absence of 5- lipoxygenase in cells containing FLAP, the lower level of FLAP in bcl-x(L) cells, the apoptosis-inducing activity of MK886, and the rapid loss of bcl-x(L) and bcl-2 proteins after treatment with MK886 strongly indicate that FLAP has activities unrelated to lipoxygenase and suggest a possible functional or regulatory link between these proteins, which share similar subcellular localizations.	Univ Texas, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Datta, K (corresponding author), Univ Texas, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78712 USA.	kaushik@mail.utexas.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51005] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson KM, 1996, ANTICANCER RES, V16, P2589; Aoshima H, 1997, BBA-LIPID LIPID MET, V1345, P35, DOI 10.1016/S0005-2760(96)00159-2; Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; Bojes HK, 1997, BIOCHEM J, V325, P315, DOI 10.1042/bj3250315; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CLAESSON HE, 1993, J LIPID MEDIATOR, V6, P15; CORCORAN GB, 1994, TOXICOL APPL PHARM, V128, P169, DOI 10.1006/taap.1994.1195; DUKE RC, 1992, CURRENT PROTOCOLS IM; ELMAKHOURHOJEIJ Y, 1994, PROSTAGLANDINS, V48, P21, DOI 10.1016/0090-6980(94)90093-0; FAIR A, 1994, BIOCHEM BIOPH RES CO, V201, P1014, DOI 10.1006/bbrc.1994.1803; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FENG W, 1995, J IMMUNOL, V155, P66; Ford-Hutchinson A W, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P13; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Ioannou YA, 1996, NUCLEIC ACIDS RES, V24, P992; KARGMAN S, 1993, J LIPID MEDIATOR, V7, P31; KLUCK RM, 1994, BBA-MOL CELL RES, V1223, P247, DOI 10.1016/0167-4889(94)90233-X; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; Korystov YN, 1996, FEBS LETT, V388, P238, DOI 10.1016/0014-5793(96)00538-8; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; LEE JC, 1982, J IMMUNOL, V128, P2393; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maccarrone M, 1997, CELL DEATH DIFFER, V4, P396, DOI 10.1038/sj.cdd.4400255; Marin MC, 1996, ONCOGENE, V12, P2259; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; Nishio E, 1997, BRIT J PHARMACOL, V121, P665, DOI 10.1038/sj.bjp.0701171; NOGUCHI M, 1995, ONCOLOGY-BASEL, V52, P265; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; Ondrey FG, 1996, LARYNGOSCOPE, V106, P129, DOI 10.1097/00005537-199602000-00003; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; Pouliot M, 1996, EUR J BIOCHEM, V238, P250, DOI 10.1111/j.1432-1033.1996.0250q.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SANDSTROM PA, 1995, FEBS LETT, V365, P66, DOI 10.1016/0014-5793(95)00443-D; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shirahama T, 1997, FEBS LETT, V407, P97, DOI 10.1016/S0014-5793(97)00304-9; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Tang DG, 1997, INT J CANCER, V72, P1078, DOI 10.1002/(SICI)1097-0215(19970917)72:6<1078::AID-IJC24>3.0.CO;2-#; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; Tang DG, 1997, J CELL PHYSIOL, V172, P155, DOI 10.1002/(SICI)1097-4652(199708)172:2<155::AID-JCP3>3.0.CO;2-N; Tsai JC, 1996, J BIOL CHEM, V271, P3667; Um HD, 1996, J IMMUNOL, V156, P3469; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VICKERS PJ, 1995, J LIPID MEDIAT CELL, V12, P185, DOI 10.1016/0929-7855(95)00018-L; Wagenknecht B, 1997, FEBS LETT, V409, P17, DOI 10.1016/S0014-5793(97)00468-7; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; Zhivotovsky B, 1996, EXPERIENTIA, V52, P968, DOI 10.1007/BF01920106; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	56	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28163	28169		10.1074/jbc.273.43.28163	http://dx.doi.org/10.1074/jbc.273.43.28163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774436	hybrid			2022-12-25	WOS:000076549800056
J	Ghoshal, K; Wang, YJ; Sheridan, JF; Jacob, ST				Ghoshal, K; Wang, YJ; Sheridan, JF; Jacob, ST			Metallothionein induction in response to restraint stress - Transcriptional control, adaptation to stress, and role of glucocorticoid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA VIRAL-INFECTION; MESSENGER-RNA LEVELS; LIVER METALLOTHIONEIN; FACTOR MTF-1; RAT-LIVER; I GENE; DIFFERENTIALLY AFFECTS; OXIDATIVE STRESS; BINDING-ACTIVITY; INBRED STRAINS	Metallothioneins (MT) have been implicated in the protection of cells from oxidative stress. We studied the molecular mechanism of induction of MT-I and MT-II in response to restraint stress using a mouse model system in which the animals were restrained in well ventilated polypropylene tubes for 12 h each day (one cycle). Here, we show that MT-I and MT-II mRNA levels were elevated as much as 10-20-fold after just one cycle of this simple stress. Stress-mediated MT induction occurred at the transcriptional level. The level of MT mRNA correlated with the stress-induced increase, and not with the diurnal variation, in the level of serum glucocorticoid. Treatment of the mice with RU 486, a glucocorticoid receptor antagonist, prior to restraint stress inhibited MT induction by at least 50%. Furthermore, the glucocorticoid responsive element-binding activity in the liver nuclear extracts from the stressed mice was significantly higher than that in the control mice. The complex formations between the transcription factor Sp1, MTF1, or MLTF/ARE and the respective specific oligonucleotides were not altered in the liver from the stressed mouse. The MT mRNA levels returned to the basal level at the end of nine cycles of stress, indicating habituation of the animals to restraint stress. At this stage, exposure of the animals to another type of stress, treatment with heavy metals, resulted in further induction of MT. These data indicate that glucocorticoid is the primary physiological factor responsible for MT induction following restraint stress, and the glucocorticoid receptor is the major transcription factor involved in this process.	Ohio State Univ, Coll Med, Dept Med Biochem, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Med Microbiol & Immunol, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Comprehens Canc Ctr, Columbus, OH 43210 USA; Ohio State Univ, Coll Dent, Sect Oral Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Jacob, ST (corresponding author), Ohio State Univ, Coll Med, Dept Med Biochem, 333 Hmailton Hall,1645 Neil Ave, Columbus, OH 43210 USA.			Sheridan, John/0000-0002-6927-0266	NCI NIH HHS [R01 CA061321-05, CA 61321] Funding Source: Medline; NIA NIH HHS [P01 AG011585-040001, P01 AG011585-040004, P01-AG 11585, P01 AG011585-040003] Funding Source: Medline; NIMH NIH HHS [R01 MH046801, R01 MH046801-08, R01-MH 46801] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aniskovitch LP, 1997, ARCH BIOCHEM BIOPHYS, V341, P337, DOI 10.1006/abbi.1997.9976; Aniskovitch LP, 1998, ONCOGENE, V16, P1475, DOI 10.1038/sj.onc.1201659; Belloso E, 1996, NEUROENDOCRINOLOGY, V64, P430, DOI 10.1159/000127149; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; BREMNER I, 1991, METHOD ENZYMOL, V205, P584; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHOUDHURI S, 1995, TOXICOL APPL PHARM, V131, P144, DOI 10.1006/taap.1995.1056; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; DOBBS CM, 1993, J NEUROIMMUNOL, V48, P151, DOI 10.1016/0165-5728(93)90187-4; Dobbs CM, 1996, J IMMUNOL, V157, P1870; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HAGER LJ, 1981, NATURE, V291, P340, DOI 10.1038/291340a0; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HERMANN G, 1993, J NEUROIMMUNOL, V47, P83, DOI 10.1016/0165-5728(93)90287-9; HERMANN G, 1994, J NEUROIMMUNOL, V49, P25, DOI 10.1016/0165-5728(94)90177-5; HERMANN G, 1994, J NEUROIMMUNOL, V53, P173, DOI 10.1016/0165-5728(94)90027-2; HERMANN G, 1995, J NEUROIMMUNOL, V56, P179, DOI 10.1016/0165-5728(94)00145-E; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; HIDALGO J, 1990, J NEUROCHEM, V55, P651, DOI 10.1111/j.1471-4159.1990.tb04182.x; HIDALGO J, 1988, AM J PHYSIOL, V254, pE71, DOI 10.1152/ajpendo.1988.254.1.E71; HIDALGO J, 1986, EXPERIENTIA, V42, P1006, DOI 10.1007/BF01940708; HIDALGO J, 1992, HORM METAB RES, V24, P233, DOI 10.1055/s-2007-1003300; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KASAHARA K, 1991, CANCER RES, V51, P3237; Kelly EJ, 1997, P NATL ACAD SCI USA, V94, P10045, DOI 10.1073/pnas.94.19.10045; KELLY SL, 1990, SCIENCE, V35, P1813; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MAYO KE, 1981, J BIOL CHEM, V256, P2621; Moffatt P, 1997, DRUG METAB REV, V29, P261, DOI 10.3109/03602539709037585; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; Palmiter R D, 1987, Experientia Suppl, V52, P63; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Pitt BR, 1997, AM J PHYSIOL-LUNG C, V273, pL856, DOI 10.1152/ajplung.1997.273.4.L856; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; SCHILDER RJ, 1990, INT J CANCER, V45, P416, DOI 10.1002/ijc.2910450306; SCHWARZ MA, 1994, J BIOL CHEM, V269, P15238; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; SHERIDAN JF, 1991, J NEUROIMMUNOL, V31, P245, DOI 10.1016/0165-5728(91)90046-A; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; VALLEE BL, 1995, NEUROCHEM INT, V27, P23, DOI 10.1016/0197-0186(94)00165-Q; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822	52	68	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					27904	27910		10.1074/jbc.273.43.27904	http://dx.doi.org/10.1074/jbc.273.43.27904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774402	hybrid, Green Accepted			2022-12-25	WOS:000076549800022
J	Rawson, RB; Cheng, D; Brown, MS; Goldstein, JL				Rawson, RB; Cheng, D; Brown, MS; Goldstein, JL			Isolation of cholesterol-requiring mutant Chinese hamster ovary cells with defects in cleavage of sterol regulatory element-binding proteins at site 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-MEDIATED ENDOCYTOSIS; COENZYME-A REDUCTASE; ACTIVATING PROTEIN; BIOCHEMICAL-CHARACTERIZATION; TRANSCRIPTIONAL ACTIVATION; TRANSGENIC MICE; CULTURED-CELLS; PROMOTER; GENE	The synthesis and uptake of cholesterol requires transcription factors designated sterol regulatory element-binding proteins (SREBPs). SREBPs are bound to membranes in a hairpin orientation with their transcriptionally active NH2-terminal segments facing the cytosol, The NH2-terminal segments are released from membranes by two-step proteolysis initiated by site 1 protease (S1P), which cleaves in the luminal loop between two membrane-spanning segments, Next, site 2 protease (S2P) releases the NH2-terminal fragment of SREBP. The S2P gene was recently isolated by complementation cloning using Chinese hamster ovary cells that require cholesterol for growth, due to a mutation in the S2P gene. A similar approach cannot be used for S1P because all previous cholesterol auxotrophs manifest defects in S2P, which is encoded by a single copy gene. To circumvent this problem, in the current studies we transfected Chinese hamster ovary cells with the S2P cDNA, assuring multiple copies. We mutagenized the cells, selected for cholesterol auxotrophy, and identified two mutant cell lines (SRD-12A and -12B) that fail to cleave SREBPs at site 1, Complementation analysis demonstrated that the defects in both cell lines are recessive and noncomplementing, indicating a mutation in the same gene. These cells should now be useful for expression cloning of the sterol-regulated SIP gene.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rawson, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1978, J BIOL CHEM, V253, P1121; CHANG TY, 1982, BIOCHEMISTRY-US, V21, P5316, DOI 10.1021/bi00264a030; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; EVANS MJ, 1993, MOL CELL BIOL, V13, P5175, DOI 10.1128/MCB.13.9.5175; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Guan GM, 1998, J BIOL CHEM, V273, P12526, DOI 10.1074/jbc.273.20.12526; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KRIEGER M, 1979, J SUPRAMOL STR CELL, V10, P467, DOI 10.1002/jss.400100409; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magana MM, 1997, J LIPID RES, V38, P1630; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152	38	81	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28261	28269		10.1074/jbc.273.43.28261	http://dx.doi.org/10.1074/jbc.273.43.28261			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774448	hybrid			2022-12-25	WOS:000076549800068
J	Snajdrova, L; Xu, AD; Narayanan, N				Snajdrova, L; Xu, AD; Narayanan, N			Clotrimazole, an antimycotic drug, inhibits the sarcoplasmic reticulum calcium pump and contractile function in heart muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST SKELETAL-MUSCLE; CYCLOPIAZONIC ACID; RYANODINE RECEPTORS; IMIDAZOLE; THAPSIGARGIN; BINDING; ATPASE; CA2+-ATPASE; CA2+; CA-2+-ATPASE	Clotrimazole (CLT), an antimycotic drug, has been shown to inhibit proliferation of normal and cancer cell lines and its systemic use as a new tool in the treatment of proliferative disorders is presently under scrutiny (Benzaquen, L. R., Brugnara, C., Byers, H. R., Gattoni-Celli, S., and Halperin, J. A. (1995) Nature Med. 1, 534-540), The action of CLT is thought to involve depletion of intracellular Ca2+ stores but the underlying mechanism has not been defined. The present study utilized membrane vesicles of rabbit cardiac sarcoplasmic reticulum (SR) to determine the mechanism by which CLT depletes intracellular Ca2+ stores. The results revealed a strong, concentration-dependent inhibitory action of CLT on the ATP-energized Ca2+ uptake activity of SR (50% inhibition with similar to 35 mu M CLT). The inhibition was of rapid onset (manifested in <15 s), and was accompanied by a 7-fold decrease in the apparent affinity of the SR Ca2+-ATPase for Ca2+ and a minor decrement in the enzyme's apparent affinity toward ATP. Exposure of SR to CLT in the absence or presence of Ca2+ resulted in irreversible inhibition of Ca2+ uptake demonstrating that the Ca2+-bound and Ca2+-free conformations of the Ca2+-ATPase are CLT-sensitive. Introduction of CLT to the reaction medium subsequent to induction of enzyme turnover with Ca2+ and ATP resulted in instantaneous cessation of Ca2+ transport indicating that an intermediate enzyme species generated during turnover undergoes rapid inactivation by CLT. The inhibition of Ca2+ uptake by CLT was accompanied by inhibition of Ca2+ stimulated ATP hydrolysis and Ca2+-induced phosphoenzyme intermediate formation from ATP in the ATPase catalytic cycle. Phosphorylation of the Ca2+-deprived enzyme with P-i in the reverse direction of catalytic cycle and Ca2+ release from Ca2+-preloaded SR vesicles were unaffected by CLT. It is concluded that CLT depletes intracellular Ca2+ stores by inhibiting Ca2+ sequestration by the Ca2+-ATPase. The mechanism of ATPase inhibition involves a drug-induced alteration in the Ca2+-binding site(s) resulting in paralysis of the enzyme's catalytic and ion transport cycle. CLT (50 mu M) caused marked depression of contractile function in isolated perfused, electrically paced rabbit heart preparations. The contractile function recovered gradually following withdrawal of CLT from the perfusate indicating the existence of mechanisms in the intact cell to inactivate, metabolize, or clear CLT from its target site.	Univ Western Ontario, Dept Physiol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Narayanan, N (corresponding author), Univ Western Ontario, Dept Physiol, London, ON N6A 5C1, Canada.	nnarayan@physiology.uwo.ca						ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; ALVAREZ J, 1990, BIOCHEM J, V274, P193; AYUB M, 1988, J STEROID BIOCHEM, V31, P65, DOI 10.1016/0022-4731(88)90207-5; BALLARD SA, 1988, BIOCHEM PHARMACOL, V37, P4643, DOI 10.1016/0006-2952(88)90333-4; BENZAQUEN LR, 1995, NAT MED, V1, P534, DOI 10.1038/nm0695-534; BRUGNARA C, 1995, J PHARMACOL EXP THER, V273, P266; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FEHER JJ, 1990, CALCIUM HEART, P199; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; GUILLAIN F, 1997, BIOCHIM BIOPHYS ACTA, V1318, P52; HAWKINS C, 1994, BBA-BIOMEMBRANES, V1191, P231, DOI 10.1016/0005-2736(94)90174-0; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; KARON BS, 1994, BIOCHEMISTRY-US, V33, P13928, DOI 10.1021/bi00250a048; KoskKosicka D, 1997, FEBS LETT, V402, P189, DOI 10.1016/S0014-5793(96)01526-8; LOPEZ MM, 1995, J BIOL CHEM, V270, P28239; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1992, HEART CARDIOVASCULAR, V2, P1203; Nakamura S, 1997, J BIOL CHEM, V272, P6232, DOI 10.1074/jbc.272.10.6232; Narayanan N, 1996, AM J PHYSIOL-CELL PH, V271, pC1032, DOI 10.1152/ajpcell.1996.271.4.C1032; NARAYANAN N, 1983, BIOCHIM BIOPHYS ACTA, V735, P53, DOI 10.1016/0005-2736(83)90260-2; NARAYANAN N, 1981, BIOCHIM BIOPHYS ACTA, V678, P442, DOI 10.1016/0304-4165(81)90126-4; NARAYANAN N, 1991, BIOCHIM BIOPHYS ACTA, V1070, P83, DOI 10.1016/0005-2736(91)90149-3; NORREGAARD A, 1993, FEBS LETT, V336, P248, DOI 10.1016/0014-5793(93)80813-A; PlengeTellechea F, 1997, J BIOL CHEM, V272, P2794, DOI 10.1074/jbc.272.5.2794; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SHEETS JJ, 1986, BIOCHEM PHARMACOL, V35, P487, DOI 10.1016/0006-2952(86)90224-8; SULAKHE PV, 1978, BIOCHEM J, V261, P171; SULAKHE SJ, 1979, GEN PHARMACOL, V10, P103, DOI 10.1016/0306-3623(79)90044-2; SUMBILLA C, 1991, J BIOL CHEM, V266, P12682; VANDENBOSSCHE H, 1983, BIOCHEM SOC T, V11, P665, DOI 10.1042/bst0110665; VILLALOBOS C, 1992, FASEB J, V6, P2742, DOI 10.1096/fasebj.6.9.1319362; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; YOSHIDA Y, 1987, BIOCHEM PHARMACOL, V36, P229, DOI 10.1016/0006-2952(87)90694-0	39	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28032	28039		10.1074/jbc.273.43.28032	http://dx.doi.org/10.1074/jbc.273.43.28032			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774419	hybrid			2022-12-25	WOS:000076549800039
J	Vinogradov, EV; Petersen, BO; Thomas-Oates, JE; Duus, JO; Brade, H; Holst, O				Vinogradov, EV; Petersen, BO; Thomas-Oates, JE; Duus, JO; Brade, H; Holst, O			Characterization of a novel branched tetrasaccharide of 3-deoxy-D-manno-oct-2-ulopyranosonic acid - The structure of the carbohydrate backbone of the lipopolysaccharide from Acinetobacter baumannii strain NCTC 10303 (ATCC 17904)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ESCHERICHIA-COLI; LIPID-A; CONFORMATIONAL-ANALYSIS; CHEMICAL-ANALYSIS; VIBRIO-CHOLERAE; FORCE-FIELDS; IDENTIFICATION; KDO; OLIGOSACCHARIDE	For the first time, the tetrasaccharide Kdo alpha 2-->5Kdo alpha 2-->5(Kdo alpha 2-->4)Kdo (Kdo is 3-deoxy-D-manno-oct-2-ulopyranosonic acid) has been identified in a bacterial lipopolysaccharide (LPS), i.e. in the core region of LPS from Acinetobacter baumannii NCTC 10303, The LPS was analyzed using compositional analysis, mass spectrometry, and NMR spectroscopy. The disaccharide D-GlcpN beta 1-->6D-GlcpN, phosphorylated at O-1 and O-4', was identified as the carbohydrate backbone of the lipid A. The Kdo tetrasaccharide is attached to O-6' of this disaccharide and is further substituted by short L-rhamnoglycans of varying length and by the disaccharide D-GlcpNAc alpha 1-->4D-GlcpNA (GlcpNA, 2-amino-2-deoxy-glucopyranosuronic acid). The core region is not substituted by phosphate residues and represents a novel core type of bacterial LPS, The complete carbohydrate backbone of the LPS is shown in Structure I as follows: [GRAPHICS] where Rha is rhamnose, Except were indicated, monosaccharides possess the D-configuration. Sugars marked with an asterisk are present in non-stoichiometric amounts.	Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, D-23845 Borstel, Germany; Carlsberg Lab, Dept Chem, DK-2500 Valby, Denmark; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Mass Spectrometry, NL-3584 CA Utrecht, Netherlands	Forschungszentrum Borstel; Utrecht University	Holst, O (corresponding author), Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, Parkallee 22, D-23845 Borstel, Germany.	oholst@fz-borstel.de	Duus, Jens Øllgaard/N-4279-2013	Duus, Jens Øllgaard/0000-0003-3625-1250				ASENSIO JL, 1995, INT J BIOL MACROMOL, V17, P137, DOI 10.1016/0141-8130(95)92680-O; Aspinall GO, 1995, CARBOHYD RES, V279, P245, DOI 10.1016/0008-6215(95)00284-7; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BergogneBerezin E, 1996, CLIN MICROBIOL REV, V9, P148, DOI 10.1128/CMR.9.2.148; BIRNBAUM GI, 1987, J CARBOHYD CHEM, V6, P17, DOI 10.1080/07328308708058858; BOCK K, 1992, CARBOHYD RES, V229, P213, DOI 10.1016/S0008-6215(00)90571-8; Bode CE, 1998, EUR J BIOCHEM, V254, P404, DOI 10.1046/j.1432-1327.1998.2540404.x; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRADE H, 1982, EUR J BIOCHEM, V122, P233, DOI 10.1111/j.1432-1033.1982.tb05871.x; BRADE H, 1987, CARBOHYD RES, V167, P295, DOI 10.1016/0008-6215(87)80287-2; BRADE H, 1988, ZBL BAKT-INT J MED M, V268, P151; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; DIJKSHOORN L, 1996, ACINETOBACTER MICROB, P37; Ehrenstein B, 1996, J CLIN MICROBIOL, V34, P2414, DOI 10.1128/JCM.34.10.2414-2420.1996; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; GRONBERG G, 1994, CARBOHYD RES, V257, P35, DOI 10.1016/0008-6215(94)84106-3; HAGLER AT, 1979, J AM CHEM SOC, V101, P5122, DOI 10.1021/ja00512a002; Haseley SR, 1998, EUR J BIOCHEM, V251, P189, DOI 10.1046/j.1432-1327.1998.2510189.x; HOLST O, 1995, EUR J BIOCHEM, V229, P194, DOI 10.1111/j.1432-1033.1995.tb20455.x; HOLST O, 1993, EUR J BIOCHEM, V214, P703, DOI 10.1111/j.1432-1033.1993.tb17971.x; HOLST O, 1998, CARBOHYDRATES EUROPE, V21, P30; HOLST O, 1998, ENDOTOXIN HLTH DIS; KACA W, 1988, CARBOHYD RES, V179, P289, DOI 10.1016/0008-6215(88)84125-9; KAWAHARA K, 1987, EUR J BIOCHEM, V163, P489, DOI 10.1111/j.1432-1033.1987.tb10895.x; KJAER M, 1994, METHODS ENZYMOL, V239, P288; LEVI I, 1996, ACINETOBACTER MICROB, P101; LEVITT MH, 1982, J MAGN RESON, V47, P328, DOI 10.1016/0022-2364(82)90124-X; LUDERITZ O, 1982, CURR TOP MEMBR TRANS, V17, P79; MCNICHOLAS PA, 1987, CARBOHYD RES, V165, P17, DOI 10.1016/0008-6215(87)80073-3; PETERS T, 1993, CARBOHYD RES, V238, P49, DOI 10.1016/0008-6215(93)87005-D; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; RAINEY FA, 1994, FEMS MICROBIOL LETT, V124, P349, DOI 10.1016/0378-1097(94)00453-6; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Seifert H, 1997, J CLIN MICROBIOL, V35, P2819, DOI 10.1128/JCM.35.11.2819-2825.1997; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STUIKEPRILL R, 1990, EUR J BIOCHEM, V194, P903, DOI 10.1111/j.1432-1033.1990.tb19485.x; Vinogradov E.V., 1994, J ENDOTOXIN RES, V1, P199, DOI [10.1177/096805199400100401, DOI 10.1177/096805199400100401]; VINOGRADOV EV, 1992, EUR J BIOCHEM, V210, P491, DOI 10.1111/j.1432-1033.1992.tb17447.x; Vinogradov EV, 1996, EUR J BIOCHEM, V239, P602, DOI 10.1111/j.1432-1033.1996.0602u.x; ZAHRINGER U, 1993, TETRAHEDRON, V49, P4193, DOI 10.1016/S0040-4020(01)85737-9; [No title captured]	42	31	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28122	28131		10.1074/jbc.273.43.28122	http://dx.doi.org/10.1074/jbc.273.43.28122			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774431	hybrid			2022-12-25	WOS:000076549800051
J	Williams, MD; Van Remmen, H; Conrad, CC; Huang, TT; Epstein, CJ; Richardson, A				Williams, MD; Van Remmen, H; Conrad, CC; Huang, TT; Epstein, CJ; Richardson, A			Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; PERMEABILITY TRANSITION; GLUTAMINE-SYNTHETASE; MAMMALIAN-CELLS; COENZYME-Q; RAT-HEART; COMPLEX-I; ACONITASE; TRANSCRIPTION; ACTIVATION	This study characterizes mitochondria isolated from livers of Sod2(-/+) and Sod2(+/+) mice. A 50% decrease in manganese superoxide dismutase (MnSOD) activity was observed in mitochondria isolated from Sod2(-/+) mice compared with Sod2(+/+) mice, with no change in the activities of either glutathione peroxidase or copper/zinc superoxide dismutase, However, the level of total glutathione was 30% less in liver mitochondria of the Sod2(-/+) mice. The reduction in MnSOD activity in Sod2(-/+) mice was correlated to an increase in oxidative damage to mitochondria: decreased activities of the Fe-S proteins (aconitase and NADH oxidoreductase), increased carbonyl groups in proteins, and increased levels of 8-hydroxydeoxyguanosine in mitochondrial DNA. In contrast, there were no significant changes in oxidative damage in the cytosolic proteins or nuclear DNA. The increase in oxidative damage in mitochondria was correlated to altered mitochondrial function. A significant decrease in the respiratory control ratio was observed in mitochondria isolated from Sod2(-/+) mice compared with Sod2(+/+) mice for substrates metabolized by complexes I, II, and III. In addition, mitochondria isolated from Sod2(-/+) mice showed an increased rate of induction of the permeability transition. Therefore, this study provides direct evidence correlating reduced MnSOD activity in vivo to increased oxidative damage in mitochondria and alterations in mitochondrial function.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Div, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of California System; University of California San Francisco	Richardson, A (corresponding author), Audie L Murphy Mem Vet Adm Med Ctr, GRECC 182, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA.	richardsona@uthscsa.edu			NATIONAL INSTITUTE ON AGING [R01AG015908, P01AG008938] Funding Source: NIH RePORTER; NIA NIH HHS [AG15908, AG08938] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; Anderson ME, 1985, HDB METHODS OXYGEN R, P317; BEAL MF, 1990, J NEUROCHEM, V55, P1327, DOI 10.1111/j.1471-4159.1990.tb03143.x; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BEYER RE, 1992, BIOCHEM CELL BIOL, V70, P390, DOI 10.1139/o92-061; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Chan PH, 1996, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1996, P573; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DUAN JM, 1992, EUR J PHARMACOL, V210, P149, DOI 10.1016/0014-2999(92)90665-Q; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; FLOYD RA, 1990, ANAL BIOCHEM, V188, P155, DOI 10.1016/0003-2697(90)90544-J; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GAULTON GN, 1988, IMMUNOL RES, V7, P113, DOI 10.1007/BF02918096; HALLIWELL B, 1995, FREE RADICAL BIO MED, P86; HANSFORD RG, 1983, BIOCHIM BIOPHYS ACTA, V726, P41, DOI 10.1016/0304-4173(83)90010-1; HARDY L, 1991, BIOCHEM J, V274, P133, DOI 10.1042/bj2740133; Hausladen A, 1996, METHOD ENZYMOL, V269, P37; Heydari AR, 1996, DEV GENET, V18, P114, DOI 10.1002/(SICI)1520-6408(1996)18:2&lt;114::AID-DVG4&gt;3.0.CO;2-C; HILL BT, 1978, GERONTOLOGY, V24, P326, DOI 10.1159/000212267; Hill RL, 1969, METHOD ENZYMOL, V8, P91, DOI 10.1016/0076-6879(69)13021-9; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; Huang TT, 1998, AGE, V21, P83, DOI 10.1007/s11357-998-0011-y; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KATES J, 1970, COLD SPRING HARB SYM, V35, P743, DOI 10.1101/SQB.1970.035.01.090; KELLER RJ, 1993, CHEM RES TOXICOL, V6, P430, DOI 10.1021/tx00034a007; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KOEN AL, 1969, BIOCHIM BIOPHYS ACTA, V191, P698, DOI 10.1016/0005-2744(69)90363-5; Kristal BS, 1996, BIOCHEM BIOPH RES CO, V222, P519, DOI 10.1006/bbrc.1996.0776; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; Liochev SI, 1996, FREE RADICAL RES, V25, P369, DOI 10.3109/10715769609149059; MOREADITH RW, 1984, J CLIN INVEST, V74, P685, DOI 10.1172/JCI111484; MURIANA FJG, 1993, J BIOCHEM, V113, P738, DOI 10.1093/oxfordjournals.jbchem.a124113; PACIFICI RE, 1991, GERONTOLOGY, V37, P166; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; PEETERSJORIS C, 1975, BIOCHEM J, V150, P31, DOI 10.1042/bj1500031; RAGAN CI, 1976, BIOCHEM J, V154, P295, DOI 10.1042/bj1540295; Singer T P, 1974, Methods Biochem Anal, V22, P123, DOI 10.1002/9780470110423.ch3; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; TAKEYAMA N, 1993, BIOCHEM J, V294, P719, DOI 10.1042/bj2940719; Tappel A L, 1978, Methods Enzymol, V52, P506; VEITCH K, 1992, BIOCHEM J, V281, P709, DOI 10.1042/bj2810709; WOODS SA, 1988, BIOCHIM BIOPHYS ACTA, V954, P14, DOI 10.1016/0167-4838(88)90050-7; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	48	384	393	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	1998	273	43					28510	28515		10.1074/jbc.273.43.28510	http://dx.doi.org/10.1074/jbc.273.43.28510			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	130ZD	9774481	hybrid			2022-12-25	WOS:000076549800101
J	Cooper, DMF; Schell, MJ; Thorn, P; Irvine, RF				Cooper, DMF; Schell, MJ; Thorn, P; Irvine, RF			Regulation of adenylyl cyclase by membrane potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; CALCIUM CHANNELS; GRANULE CELLS; CA2+; ENTRY; EXPRESSION; FORSKOLIN; CURRENTS; DOMAINS; VOLTAGE	Mammalian adenylyl cyclases possess 12 transmembrane-spanning domains and bear a superficial resemblance to certain classes of ion channels. Some evidence suggests that bacterial and sea urchin sperm adenylyl cyclases can be regulated by membrane depolarization. In the present study, we explored the effect of altering membrane potential on the adenylyl cyclase activity of cerebellar granule cells with acute potassium depolarization. A biphasic stimulatory and then inhibitory response is evoked by progressive increases in the extracellular [K]:[Na] ratio in the absence of-extracellular Ca2+. This effect does not mimic the linear increase in membrane potential elicited under the same conditions. Instead it appears as though membrane depolarization opens L-type (nimodipine-sensitive) Ca2+ channels, allowing the entry of Na+, which directly stimulates adenylyl cyclase activity. Gramicidin, which generates pores that are permeable to monovalent cations, and concurrently eliminates the membrane potential, permits a similar stimulation by extracellularly applied Na+. Although the results indicate no direct sensitivity of cerebellar granule cell adenylyl cyclase to membrane potential, they do demonstrate that, as a result of membrane depolarization, the influx of Na+, as well as Ca2+, will elevate cAMP levels.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England	University of Cambridge	Cooper, DMF (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Box C-236,4200 E 9th Ave, Denver, CO 80262 USA.		Thorn, Peter/F-7030-2010	Thorn, Peter/0000-0002-3228-770X; Schell, Michael/0000-0003-1553-3582	FOGARTY INTERNATIONAL CENTER [F06TW002185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH011609] Funding Source: NIH RePORTER; FIC NIH HHS [TW02185] Funding Source: Medline; NIMH NIH HHS [F32 MH11609] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Beltran C, 1996, BIOCHEMISTRY-US, V35, P7591, DOI 10.1021/bi952806v; BYRON KL, 1993, J BIOL CHEM, V268, P6945; CALDWELL KK, 1992, CELL CALCIUM, V13, P107, DOI 10.1016/0143-4160(92)90004-C; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; EVANS T, 1984, MOL PHARMACOL, V26, P395; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Harrold J, 1997, NEUROSCIENCE, V77, P683, DOI 10.1016/S0306-4522(97)86659-6; JACOBOWITZ O, 1994, METHOD ENZYMOL, V238, P108; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; MONS N, 1993, SYNAPSE, V14, P51, DOI 10.1002/syn.890140108; MONS N, 1995, P NATL ACAD SCI USA, V92, P8473, DOI 10.1073/pnas.92.18.8473; RANDALL A, 1995, J NEUROSCI, V15, P2995; REDDY R, 1995, J BIOL CHEM, V270, P14340, DOI 10.1074/jbc.270.24.14340; SCHULTZ JE, 1992, SCIENCE, V255, P600, DOI 10.1126/science.1371017; SLESINGER PA, 1991, J PHYSIOL-LONDON, V435, P101, DOI 10.1113/jphysiol.1991.sp018500; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; WANG KW, 1995, J MEMBRANE BIOL, V143, P247; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zimprich F, 1996, EUR J NEUROSCI, V8, P467, DOI 10.1111/j.1460-9568.1996.tb01230.x	28	53	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27703	27707		10.1074/jbc.273.42.27703	http://dx.doi.org/10.1074/jbc.273.42.27703			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765307	hybrid			2022-12-25	WOS:000076448000094
J	Hosfield, DJ; Frank, G; Weng, YH; Tainer, JA; Shen, B				Hosfield, DJ; Frank, G; Weng, YH; Tainer, JA; Shen, B			Newly discovered archaebacterial flap endonucleases show a structure-specific mechanism for DNA substrate binding and catalysis resembling human flap endonuclease-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; ESCHERICHIA-COLI; POLYMERASE-I; SACCHAROMYCES-CEREVISIAE; MUTATION AVOIDANCE; REPLICATION; FEN-1; EXONUCLEASE; RAD2	Mammalian flap endonuclease-l (FEN-1) is a structure-specific metalloenzyme that acts in processing of both the Okazaki fragments during lagging strand DNA synthesis and flap intermediates during DNA damage repair. We identified and cloned three open reading frames encoding a flap endonuclease from Archaeglobus fulgidus,,Methanococcus jannaschii, and Pyrococcus furiosus, respectively. The deduced FEN-1 protein sequences share approximately 75% similarity with the human FEN-1 nuclease in the conserved nuclease domains, and extensive biochemical experiments indicate that the substrate specificities and catalytic activities of these enzymes have overall similarities with those of the human enzyme, Thus, FEN-1 enzymes and likely reaction mechanisms are conserved across the eukaryotic and archaeal kingdoms. Detailed comparative analysis, however, reveals subtle differences among these four enzymes including distinctive substrate specificity, tolerance of the archaebacterial enzymes for acidic pHs and elevated temperatures, and variations in the metalion dependence of substrate cleavage. Although the archaebacterial enzymes were inactive at temperatures below 30 degrees C, DNA binding occurred at temperatures as low as 4 degrees C and with or without metal ions. Thus, these archaeal enzymes mag provide a means to dissect the specific binding and catalytic mechanisms of the entire FEN-1 family of structure-specific nucleases.	Scripps Res Inst, Skaggs Inst Chem Biol, Dept Biol Mol, La Jolla, CA 92037 USA; City Hope Natl Med Ctr, Dept Cell & Tumor Biol, Duarte, CA 91010 USA	Scripps Research Institute; City of Hope	Tainer, JA (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, Dept Biol Mol, La Jolla, CA 92037 USA.	jat@scripps.edu	Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Shen, Binghui/0000-0002-4408-407X	NATIONAL CANCER INSTITUTE [R01CA073764, R29CA073764] Funding Source: NIH RePORTER; NCI NIH HHS [CA57348, CA 73764-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BORGES KM, 1996, GENOME SCI TECHNOL, V1, P37; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DOETSCH PW, 1995, TRENDS BIOCHEM SCI, V20, P384, DOI 10.1016/S0968-0004(00)89084-2; FRANK G, 1998, IN PRESS J BIOL CHEM, V273; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FRIEDBERG EC, 1992, TRENDS BIOCHEM SCI, V17, P347, DOI 10.1016/0968-0004(92)90312-W; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Goldman A, 1995, STRUCTURE, V3, P1277, DOI 10.1016/S0969-2126(01)00263-5; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hennig M, 1995, STRUCTURE, V3, P1295, DOI 10.1016/S0969-2126(01)00267-2; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Knauf JA, 1996, MUTAT RES-DNA REPAIR, V363, P67, DOI 10.1016/0921-8777(95)00062-3; Kornberg A., 1992, DNA REPLICATION; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LINDAHL T, 1969, P NATL ACAD SCI USA, V62, P597, DOI 10.1073/pnas.62.2.597; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Xu Y, 1997, J MOL BIOL, V268, P284, DOI 10.1006/jmbi.1997.0967; Zhu FX, 1997, BIOCHEMISTRY-US, V36, P5947, DOI 10.1021/bi962889v; [No title captured]	54	66	78	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27154	27161		10.1074/jbc.273.42.27154	http://dx.doi.org/10.1074/jbc.273.42.27154			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765234	hybrid			2022-12-25	WOS:000076448000021
J	Kakuta, Y; Petrotchenko, EV; Pedersen, LC; Negishi, M				Kakuta, Y; Petrotchenko, EV; Pedersen, LC; Negishi, M			The sulfuryl transfer mechanism - Crystal structure of a vanadate complex of estrogen sulfotransferase and mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE; FLAVONOL 3-SULFOTRANSFERASE; SULFATION; PHOSPHATASE; ENZYMOLOGY; ACTIVATION; ANALOGS; BINDING; BIOLOGY; DOMAIN	Estrogen sulfotransferase (EST) catalyzes transfer of the 5'-sulfuryl group of adenosine 3'-phosphate 5'-phosphosulfate (PAPS) to the 3 alpha-phenol group of estrogenic steroids such as estradiol (E-2), The recent crystal structure of EST adenosine 3',5'-diphosphate (PAP)- E-2 complex has revealed that residues Lys(48), Thr(45) Thr(51), Thr(52), Lys(106), His(108), and Try(240) are in position to play a catalytic role in the sulfuryl transfer reaction of EST (Kakuta Y., Pedersen, L. G., Carter, C. W., Negishi, M., and Pedersen, L. C. (1997) Nat. Struct. BioL. 4, 904-908). Mutation of Lys(48), Lys(106), or His(108) nearly abolishes EST activity, indicating that they play a critical role in catalysis, A present 2.2-A resolution structure of EST-PAP-vanadate complex indicates that the vanadate molecule adopts a trigonal bipyramidal geometry with its equatorial oxygens coordinated to these three residues. The apical positions of the vanadate molecule are occupied by a terminal oxygen of the 5'-phosphate of PAP (2.1 ) and a possible water molecule (2.3 Angstrom), This water molecule superimposes well to the 3 alpha-phenol group of E-2 in the crystal structure of the EST . PAP . E-2 complex. These structures are characteristic of the transition state for an in-line sulfuryl transfer reaction from PAPS to E-2. Moreover, residues Lys(48), Lys(106), His(108) are found to be coordinated with the vanadate molecule at the transition state of EST.	NIEHS, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Negishi, Masahiko/F-7805-2019; Pedersen, Lars/C-6173-2019	Negishi, Masahiko/0000-0002-2076-8928; Pedersen, Lars/0000-0002-4488-4077				BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHAI CLL, 1992, BIOORG CHEM, V20, P1981; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; DUFFEL MW, 1981, J BIOL CHEM, V256, P1123; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; Glatt H, 1997, FASEB J, V11, P314, DOI 10.1096/fasebj.11.5.9141497; HOBKIRK R, 1993, TRENDS ENDOCRIN MET, V4, P69, DOI 10.1016/S1043-2760(05)80018-9; HOMMA H, 1996, BIOCHIM BIOPHYS ACTA, V1296, P156; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, BIOCHEM PHARMACOL, V55, P313, DOI 10.1016/S0006-2952(97)00465-6; KOBASHI K, 1986, BIOCHEM BIOPH RES CO, V140, P38, DOI 10.1016/0006-291X(86)91054-5; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Marsolais F, 1997, EUR J BIOCHEM, V247, P1056, DOI 10.1111/j.1432-1033.1997.01056.x; Matsubayashi Y, 1997, P NATL ACAD SCI USA, V94, P13357, DOI 10.1073/pnas.94.24.13357; MEAGLEY KA, 1996, P NATL ACAD SCI USA, V93, P8160; MEISHERI KD, 1988, J PHARMACOL EXP THER, V245, P751; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Nelson RM, 1995, ANNU REV CELL DEV BI, V11, P601, DOI 10.1146/annurev.cellbio.11.1.601; NULLERDIECKMANN H, 1994, J MOL BIOL, V236, P361; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; ROTH JA, 1986, TRENDS BIOCHEM SCI, V11, P404; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; STANKIEWICZ PJ, 1988, BIOCHEMISTRY-US, V27, P206, DOI 10.1021/bi00401a031; Strott CA, 1996, ENDOCR REV, V17, P670, DOI 10.1210/er.17.6.670; SUPERTIFURGA A, 1994, AM J HUM GENET, V55, P1137; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; Zhang M, 1997, BIOCHEMISTRY-US, V36, P15, DOI 10.1021/bi961804n	35	107	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27325	27330		10.1074/jbc.273.42.27325	http://dx.doi.org/10.1074/jbc.273.42.27325			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765259	hybrid			2022-12-25	WOS:000076448000046
J	Liao, W; Yeung, SCJ; Chan, L				Liao, W; Yeung, SCJ; Chan, L			Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; CULTURED LIVER-CELLS; I HEAVY-CHAINS; INTRACELLULAR DEGRADATION; HEPG2 CELLS; SECRETION; PATHWAY; CONFORMATION; DETERMINES; CALNEXIN	A major portion of newly synthesized apolipoprotein B (apoB) is degraded intracellularly, This degradation has been demonstrated to be mediated largely by the ubiquitin-proteasome pathway. We examined whether nascent apoB polypeptides or full-length apoB is selectively retrotranslocated from the endoplasmic reticulum into the cytosol for degradation. Herein, we found that full-length apoB as well as partial-length apoB peptides are ubiquitinated in HepG2 cells, and ubiquitination is an exclusively cytosolic process. Calnexin, which binds specifically to glycoproteins, has been postulated to promote apoB folding and complete translocation; me found that ubiquitinated apoB is bound to calnexin, suggesting that ubiquitinated apoB is glycosylated. In addition to calnexin binding, we have other pieces of evidence that the full-length intracellular ubiquitinated apoB is glycosylated, because (i) it binds to concanavalin A, and (ii) glycan can be demonstrated in the full-length ubiquitinated apoB by a chemical detection method involving oxidation of adjacent hydroxyl groups in the glycan moiety. Because glycosylation occurs inside the endoplasmic reticulum, the full-length glycosylated apoB must have been retrotranslocated into the cytosol for ubiquitination and proteasome-mediated degradation. Next we synchronized translation in HepG2 cells by puromycin treatment. A pulse-chase experiment using [S-35]methionine labeling of intracellular apoB in these synchronized cells demonstrated that nascent partial-length apoB peptides are also ubiquitinated cotranslationally, We conclude that the ubiquitin proteasome mediated degradation of apoB targets both nascent peptides cotranslationally before translocation as well as full-length apoB after its translocation into the endoplasmic reticulum.	Baylor Coll Med, Dept Cell Biol, Div Endocrinol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Div Endocrinol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Chan, L (corresponding author), Baylor Coll Med, Dept Cell Biol, Div Endocrinol, 1 Baylor Plaza, Houston, TX 77030 USA.		Yeung, Sai-Ching/AAP-8079-2020; Yeung, Sai-Ching/AAI-6178-2021	Yeung, Sai-Ching/0000-0001-5170-0822	NHLBI NIH HHS [HL-16512] Funding Source: Medline; NIGMS NIH HHS [GM 17159] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016512, R37HL016512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017159] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumeister W, 1997, CURR OPIN STRUC BIOL, V7, P273, DOI 10.1016/S0959-440X(97)80036-X; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN PF, 1988, EUR J BIOCHEM, V175, P111, DOI 10.1111/j.1432-1033.1988.tb14172.x; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; COSGROVE PG, 1993, J LIPID RES, V34, P1983; DIXON JL, 1993, J LIPID RES, V34, P167; DU EZ, 1994, J BIOL CHEM, V269, P24169; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; KANE JP, 1995, METABOLIC MOL BASES, P1853; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	24	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 16	1998	273	42					27225	27230		10.1074/jbc.273.42.27225	http://dx.doi.org/10.1074/jbc.273.42.27225			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	129DM	9765244	hybrid			2022-12-25	WOS:000076448000031
J	Gardner, PR; Costantino, G; Salzman, AL				Gardner, PR; Costantino, G; Salzman, AL			Constitutive and adaptive detoxification of nitric oxide in Escherichia coli - Role of nitric-oxide dioxygenase in the protection of aconitase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; PARACOCCUS-DENITRIFICANS; L-ARGININE; REDUCTASE; SUPEROXIDE; PEROXYNITRITE; REACTIVATION; MACROPHAGES; INHIBITION; ACTIVATION	Nitric oxide (NO.) is a naturally occurring toxin that some organisms adaptively resist. In aerobic or anaerobic Escherichia coli, low levels of NO. exposure inactivated the NO.-sensitive citric acid cycle enzyme aconitase, and inactivation was more effective when the adaptive synthesis of NO.-defensive proteins was blocked with chloramphenicol. Protection of aconitase in aerobically grown E. coli, was dependent upon O-2, was potently inhibited by cyanide, and was correlated with an induced rate of cellular NO. consumption. Constitutive and adaptive cellular NO. consumption in aerobic cells was also dependent upon O-2 and inhibited by cyanide. Exposure of aerobic cells to NO. accordingly elevated the activity of the O-2-dependent and cyanide-sensitive NO. dioxygenase (NOD). Anaerobic E. coli exposed to NO. or nitrate induced a modest O-2-independent and cyanide-resistant NO.-metabolizing activity and a more robust O-2-stimulated cyanide-sensitive activity. The latter activity was attributed to NOD. The results support a role for NOD in the aerobic detoxification of NO. and suggest functions for NOD and a cyanide-resistant NO. scavenging activity in anaerobic cells.	Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Gardner, PR (corresponding author), Childrens Hosp, Med Ctr, Div Crit Care, R045,3333 Burnet Ave, Cincinnati, OH 45229 USA.	gardp0@chmcc.org		Gardner, Paul/0000-0001-8189-0903				Borutaite V, 1996, BIOCHEM J, V315, P295, DOI 10.1042/bj3150295; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; CARR GJ, 1989, EUR J BIOCHEM, V179, P683, DOI 10.1111/j.1432-1033.1989.tb14601.x; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; Cooper CE, 1997, FEBS LETT, V414, P281, DOI 10.1016/S0014-5793(97)01009-0; COSTA C, 1990, FEBS LETT, V276, P67, DOI 10.1016/0014-5793(90)80508-G; DERMASTIA M, 1991, J BIOL CHEM, V266, P10899; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Fujiwara T, 1996, J BACTERIOL, V178, P1866, DOI 10.1128/jb.178.7.1866-1871.1996; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; Gardner PR, 1997, BIOSCIENCE REP, V17, P33, DOI 10.1023/A:1027383100936; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hurst JK, 1997, CHEM RES TOXICOL, V10, P802, DOI 10.1021/tx970008v; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; IMLAY JA, 1995, J BIOL CHEM, V270, P19767; IUCHI S, 1990, J BACTERIOL, V172, P6020, DOI 10.1128/jb.172.10.6020-6025.1990; JI XB, 1988, BIOCHEM BIOPH RES CO, V157, P106, DOI 10.1016/S0006-291X(88)80018-4; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Kwiatkowski AV, 1996, J BIOL CHEM, V271, P24382, DOI 10.1074/jbc.271.40.24382; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; MANCINELLI RL, 1983, APPL ENVIRON MICROB, V46, P198, DOI 10.1128/AEM.46.1.198-202.1983; Morita H, 1997, J BACTERIOL, V179, P7812, DOI 10.1128/jb.179.24.7812-7815.1997; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794, DOI 10.1128/IAI.63.3.794-798.1995; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; PACELLI R, 1995, J EXP MED, V182, P1469, DOI 10.1084/jem.182.5.1469; SHANK JL, 1962, APPL MICROBIOL, V10, P185, DOI 10.1128/AEM.10.3.185-189.1962; Stenger S, 1996, J EXP MED, V183, P1501, DOI 10.1084/jem.183.4.1501; Taylor-Robinson AW, 1998, LANCET, V351, P1630, DOI 10.1016/S0140-6736(05)77685-6	32	69	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26528	26533		10.1074/jbc.273.41.26528	http://dx.doi.org/10.1074/jbc.273.41.26528			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756889	hybrid			2022-12-25	WOS:000076373300043
J	Soler, C; Felipe, A; Mata, JF; Casado, FJ; Celada, A; Pastor-Anglada, M				Soler, C; Felipe, A; Mata, JF; Casado, FJ; Celada, A; Pastor-Anglada, M			Regulation of nucleoside transport by lipopolysaccharide, phorbol esters, and tumor necrosis factor-alpha in human B-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GUANINE RIBONUCLEOSIDES; FUNCTIONAL EXPRESSION; URIDINE-TRANSPORT; LEUKEMIA-CELLS; HL-60 CELLS; RAT-LIVER; ACTIVATION; MOUSE; DIFFERENTIATION	Nucleoside transport systems and their regulation in human B-lymphocytes have been characterized using the cell lines Raji and Bare lymphoma syndrome-1 (BLS-1) as experimental models. These cells express at least three different nucleoside transport systems as follows: a nitrobenzylthioinosine-sensitive equilibrative transport system of the es-type, which appears to be associated with hENT1 expression, and two Na+-dependent transport systems that may correspond to N1 and to the recently characterized NS-type, which is nitrobenzylthioinosine-sensitive and guanosine-preferring. B cell activators such as phorbol 12-myristate 13-acetate and lipopolysaccharide (LPS) up-regulate both concentrative transport systems but down-regulate the equilibrative es-type transporter, which correlates with lower hENT1 mRNA levels. These effects are dependent on protein kinase C activity. Phorbol 12-myristate 13-acetate and LPS also induce an increase in tumor necrosis factor-alpha (TNF-alpha) mRNA levels, which suggest that this cytokine may mediate some of the effects triggered by these agents, since addition of TNF-alpha alone can increase N1 and N5 transport activities by a mechanism that also depends on protein kinase C activation. Interestingly, TNF-alpha down-regulates es activity, but this effect cannot be abolished by inhibiting protein kinase C, This study reveals differential regulation of nucleoside transport systems following activation of human B-lymphocyte cell lines by agents of physiological relevance such as TNF-alpha and LPS, Moreover, it indicates that the recently characterized N5 transport system can also be regulated following B cell activation, which may be relevant to lymphocyte physiology and to the treatment of lymphocyte malignancies.	Univ Barcelona, Dept Bioquim & Biol Mol, Inst Invest Biomed August Pi & Sunyer, Barcelona 08071, Spain; Univ Barcelona, Dept Fisiol Immunol, E-08007 Barcelona, Spain; Univ Barcelona, Fdn Pi & Sunyer, E-08007 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; University of Barcelona	Pastor-Anglada, M (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Inst Invest Biomed August Pi & Sunyer, Avda Diagonal 645, Barcelona 08071, Spain.	mpastor@porthos.bio.ub.es	Soler, Concepció/L-1185-2014; Felipe, Antonio/M-8297-2015; Celada, Antonio/I-1714-2016	Soler, Concepció/0000-0001-6502-5012; Felipe, Antonio/0000-0002-7294-6431; Mata, Joao/0000-0002-6988-9069; Casado Merediz, Francisco Javier/0000-0003-0192-841X; Celada, Antonio/0000-0003-3883-2171				Anderson CM, 1996, MOL BRAIN RES, V42, P358, DOI 10.1016/S0169-328X(96)00244-6; Boleti H, 1997, NEUROPHARMACOLOGY, V36, P1167, DOI 10.1016/S0028-3908(97)00136-6; Borgland SL, 1997, J PHARMACOL EXP THER, V281, P347; BOUSSIOTIS VA, 1994, P NATL ACAD SCI USA, V91, P7007, DOI 10.1073/pnas.91.15.7007; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CRAWFORD CR, 1990, J BIOL CHEM, V265, P9732; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; CRAWFORD DH, 1994, IMMUNOLOGY, V82, P357; DAGNINO L, 1991, J BIOL CHEM, V266, P6308; DELICADO EG, 1991, BIOCHEM J, V279, P851; Falzarano G, 1996, BLOOD, V87, P2853, DOI 10.1182/blood.V87.7.2853.bloodjournal8772853; Felipe A, 1998, BIOCHEM J, V330, P997, DOI 10.1042/bj3300997; FELIPE A, 1994, J BIOL CHEM, V269, P30125; FELIPE A, 1993, AM J PHYSIOL, V265, pC1230, DOI 10.1152/ajpcell.1993.265.5.C1230; Flanagan SA, 1997, J BIOL CHEM, V272, P18026, DOI 10.1074/jbc.272.29.18026; GOMEZANGELATS M, 1995, AM J PHYSIOL-ENDOC M, V268, pE368, DOI 10.1152/ajpendo.1995.268.2.E368; GomezAngelats M, 1996, BIOCHEM J, V313, P915, DOI 10.1042/bj3130915; GOODMAN MG, 1983, J IMMUNOL, V130, P551; GOODMAN MG, 1983, P NATL ACAD SCI-BIOL, V80, P3452, DOI 10.1073/pnas.80.11.3452; GOODMAN MG, 1983, J IMMUNOL, V130, P2042; GOODMAN MG, 1983, J IMMUNOL, V130, P2580; GOODMAN MG, 1981, P NATL ACAD SCI-BIOL, V78, P7604, DOI 10.1073/pnas.78.12.7604; GOODMAN MG, 1984, P NATL ACAD SCI-BIOL, V81, P862, DOI 10.1073/pnas.81.3.862; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; Lee Chee-Wee, 1994, In Vivo (Attiki), V8, P795; LEE CW, 1991, BIOCHEM J, V274, P85, DOI 10.1042/bj2740085; LEE CW, 1994, BIOCHEM J, V300, P407, DOI 10.1042/bj3000407; MACLEOD CL, 1990, CELL GROWTH DIFFER, V1, P271; MARTINEZMAS JV, 1993, BIOCHEM J, V293, P819, DOI 10.1042/bj2930819; MCGIVAN JD, 1989, METHOD ENZYMOL, V172, P346; MOND JJ, 1994, CIRC SHOCK, V44, P57; PASTORANGLADA M, 1998, IN PRESS TRENDS PHAR; Paterson A. R. P., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P14; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1028, P289, DOI 10.1016/0005-2736(90)90178-Q; PLAGEMANN PGW, 1991, BIOCHEM PHARMACOL, V42, P247, DOI 10.1016/0006-2952(91)90710-M; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Roovers KI, 1996, J CELL PHYSIOL, V166, P593, DOI 10.1002/(SICI)1097-4652(199603)166:3<593::AID-JCP14>3.0.CO;2-8; RUIZMONTASELL B, 1993, FEBS LETT, V316, P85, DOI 10.1016/0014-5793(93)81741-H; Schaner ME, 1997, PHARMACEUT RES, V14, P1316, DOI 10.1023/A:1012148016794; SCHMID M, 1994, LEUKEMIA LYMPHOMA, V15, P317, DOI 10.3109/10428199409049730; Tangye SG, 1997, IMMUNOL CELL BIOL, V75, P561, DOI 10.1038/icb.1997.87; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; WOODLOCK TJ, 1993, J BIOL CHEM, V268, P16020; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	48	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26939	26945		10.1074/jbc.273.41.26939	http://dx.doi.org/10.1074/jbc.273.41.26939			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756942	hybrid, Green Published			2022-12-25	WOS:000076373300096
J	Tanaka, T; Tatsuno, I; Noguchi, Y; Uchida, D; Oeda, T; Narumiya, S; Yasuda, T; Higashi, H; Kitagawa, M; Nakayama, K; Saito, Y; Hirai, A				Tanaka, T; Tatsuno, I; Noguchi, Y; Uchida, D; Oeda, T; Narumiya, S; Yasuda, T; Higashi, H; Kitagawa, M; Nakayama, K; Saito, Y; Hirai, A			Activation of cyclin-dependent kinase 2 (Cdk2) in growth-stimulated rat astrocytes - Geranylgeranylated Rho small GTPase(s) are essential for the induction of cyclin E gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; PRIMARY CULTURES; CHOLESTEROL-BIOSYNTHESIS; ADP-RIBOSYLATION; FRTL-5 CELLS; G(1) PHASE; S-PHASE; LATE G1; PROTEIN; PHOSPHORYLATION	The role of the mevalonate cascade in the control of cell cycle progression in astrocytes has been investigated. Serum stimulation of rat astrocytes in primary culture induces the expression of cyclin E followed by the activation of cyclin-dependent kinase 2 (Cdk2) during G(1)/S transition. The expression of p27(hip1) cyclin D1, and the activities of Cdk4 and Cdk-activating kinase (CAB), composed of Cdk7 and cyclin H, mere not affected. Serum did, however, stimulate the expression of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase mRNA at mid-G(1) phase. Moreover, an inhibitor of HMG-CoA reductase, pravastatin, reduced cyclin E expression and Cdk2 activation and caused G(1) arrest in the astro cytes. In contrast, mevalonate and its metabolite, geranylgeranylpyrophosphate (GGPP) but not farnesylpyrophosphate (FPP), reversed the inhibitory effects of pravastatin on cyclin E expression and Cdk2 activation and allowed G(1)/S transition. Rho small GTPase(s) were geranylgeranylated and translocated to membranes in the presence of GGPP during G(1)/S transition. The effect of GGPP on cyclin E expression was abolished by botulinum C3 exoenzyme, which specifically inactivates Rho. These data indicate that geranylgeranylated Rho small GTPase(s) are essential for the induction of cyclin E expression, Cdk2 activation, and G(1)/S transition in rat astrocytes.	Chiba Univ, Sch Med, Dept Internal Med 2, Chiba 260, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan; Okayama Univ, Sch Med, Inst Cellular & Mol Biol, Dept Cell Chem, Okayama 700, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 81282, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan; Merck Res Labs, Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan	Chiba University; Kyoto University; Okayama University; Kyushu University; Japan Science & Technology Agency (JST); Merck & Company	Tanaka, T (corresponding author), Chiba Univ, Sch Med, Dept Internal Med 2, 1-8-1 Inohana, Chiba 260, Japan.	tomoaki@intmed02.m.chiba-u.ac.jp	Higashi, Hideaki/F-6872-2012					BATES S, 1994, ONCOGENE, V9, P71; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DOBBING J, 1973, ARCH DIS CHILD, V48, P757, DOI 10.1136/adc.48.10.757; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Higashi H, 1996, EUR J BIOCHEM, V237, P460, DOI 10.1111/j.1432-1033.1996.0460k.x; Hirai A, 1997, J BIOL CHEM, V272, P13; JONES JP, 1975, J NEUROCHEM, V24, P123, DOI 10.1111/j.1471-4159.1975.tb07637.x; Kabara J J, 1973, Prog Brain Res, V40, P363; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KIMELBERG HK, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0489-66; KITAGAWA M, 1995, ONCOGENE, V10, P229; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KITAGAWA M, 1993, ONCOGENE, V8, P2425; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LANGAN TJ, 1991, J NEUROCHEM, V56, P1058, DOI 10.1111/j.1471-4159.1991.tb02029.x; LANGAN TJ, 1991, BRAIN RES, V548, P9, DOI 10.1016/0006-8993(91)91099-M; LANGAN TJ, 1986, J NEUROCHEM, V46, P1283, DOI 10.1111/j.1471-4159.1986.tb00651.x; LANGAN TJ, 1991, J CELL PHYSIOL, V149, P284, DOI 10.1002/jcp.1041490215; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MILLER RH, 1986, J NEUROSCI, V6, P22; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; Noguchi Y, 1998, J BIOL CHEM, V273, P3649, DOI 10.1074/jbc.273.6.3649; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTUBO M, 1995, MOL CELL BIOL, V15, P2612; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TATSUNO I, 1990, BIOCHEM BIOPH RES CO, V168, P1027, DOI 10.1016/0006-291X(90)91132-C; Tatsuno I, 1997, BIOCHEM BIOPH RES CO, V241, P376, DOI 10.1006/bbrc.1997.7825; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Vogt A, 1996, ONCOGENE, V13, P1991; VOLPE JJ, 1977, BIOCHIM BIOPHYS ACTA, V486, P408, DOI 10.1016/0005-2760(77)90090-X; VOLPE JJ, 1985, J NEUROCHEM, V45, P536, DOI 10.1111/j.1471-4159.1985.tb04021.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	56	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26772	26778		10.1074/jbc.273.41.26772	http://dx.doi.org/10.1074/jbc.273.41.26772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756921	hybrid			2022-12-25	WOS:000076373300075
J	Tigue, NJ; Kay, J				Tigue, NJ; Kay, J			Autoprocessing and peptide substrates for human herpesvirus 6 proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOMEGALOVIRUS PROTEASE; CRYSTAL-STRUCTURE; IDENTIFICATION; AGENT; FOLD	Autoprocessing of the precursor form of human herpesvirus 6 (HHV-6) proteinase at two sites (termed M and R) is required to generate the mature enzyme, Kinetic constants were determined for the hydrolysis of a series of synthetic peptide substrates by mature HHV-6 proteinase, purified to homogeneity, Truncation or replacement of individual residues in peptides mimicking the R-site sequence, indicated that the minimum length for effective hydrolysis by the viral enzyme was P-4-P-3-P-2-Ala*Ser-P-2'-P-3'-P-4' and revealed the importance of the P-1 Ala and P-4 Tyr residues. Consequently, relevant (P-1 or P-4) mutations were introduced into the precursor form of the proteinase and the ability of these altered proteins to autoprocess was examined. Introduction of Val in place of the P-1 Ala at the M-site essentially abrogated cleavage but mature HHV-6 proteinase was still generated by cleavage at the R-site, indicating that processing of the M-site is not a prerequisite for cleavage of the R-site in the precursor. At the R-site, mutation of the P-1 Ala, or of the preceding P-4 Tyr residue, prevented processing at the R-site in the precursor so that the mature form of HHV-6 proteinase was not generated. The accumulated data suggest a possible new approach to the design of inhibitors for therapeutic intervention in the life cycle of herpesviruses.	Univ Wales, Sch Mol & Med Biosci, Cardiff CF1 3US, S Glam, Wales	Cardiff University	Kay, J (corresponding author), Univ Wales, Sch Mol & Med Biosci, POB 911, Cardiff CF1 3US, S Glam, Wales.			Tigue, Natalie/0000-0001-9916-0255				BUCHWALD D, 1992, ANN INTERN MED, V116, P103, DOI 10.7326/0003-4819-116-2-103; Chen P, 1996, CELL, V86, P835, DOI 10.1016/S0092-8674(00)80157-9; DILANNI CL, 1993, J BIOL CHEM, V268, P25449; Gibson W., 1995, PERSPECT DRUG DISCOV, V2, P413; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoog SS, 1997, BIOCHEMISTRY-US, V36, P14023, DOI 10.1021/bi9712697; KRAFFT GA, 1994, METHOD ENZYMOL, V241, P70; McMillan DJ, 1997, J GEN VIROL, V78, P2153, DOI 10.1099/0022-1317-78-9-2153; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; PINKO C, 1995, J BIOL CHEM, V270, P23634, DOI 10.1074/jbc.270.40.23634; PRESTON VG, 1992, VIROLOGY, V186, P87, DOI 10.1016/0042-6822(92)90063-U; QUI X, 1996, NATURE, V383, P275; QUI XY, 1997, P NATL ACAD SCI USA, V94, P287; Roizman B, 1993, HUMAN HERPESVIRUSES, P1795; Shieh HS, 1996, NATURE, V383, P279, DOI 10.1038/383279a0; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; STEVENS JT, 1994, EUR J BIOCHEM, V226, P361, DOI 10.1111/j.1432-1033.1994.tb20060.x; Tigue NJ, 1996, J VIROL, V70, P4136, DOI 10.1128/JVI.70.6.4136-4141.1996; Tong L, 1996, NATURE, V383, P272, DOI 10.1038/383272a0; YAMANISHI K, 1988, LANCET, V1, P1065	20	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26441	26446		10.1074/jbc.273.41.26441	http://dx.doi.org/10.1074/jbc.273.41.26441			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756878	hybrid			2022-12-25	WOS:000076373300032
J	Yethon, JA; Heinrichs, DE; Monteiro, MA; Perry, MB; Whitfield, C				Yethon, JA; Heinrichs, DE; Monteiro, MA; Perry, MB; Whitfield, C			Involvement of waaY, waaQ, and waaP in the modification of Escherichia coli lipopolysaccharide and their role in the formation of a stable outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; KLEBSIELLA-PNEUMONIAE; CORE TYPES; LIPID-A; GENES; K-12; RFAP; SUBSTITUTION; BIOSYNTHESIS; PERMEABILITY	The waaY, waaQ, and waaP genes are located in the central operon of the waa (formerly rfa.) locus on the chromosome of Escherichia coli. This locus contains genes whose products are involved in the assembly of the core region of the lipopolysaccharide molecule. In the R1 core prototype strain, E. coli F470, there are nine genes in this operon, and all but waaY, waaQ, and waaP have been assigned function, In this study, the waaY, waaQ, and waaP genes were independently mutated by insertion of a non-polar antibiotic resistance cassette, and the structures of the resulting mutant core oligosaccharides were determined by chemical analyses and phosphorus-nuclear magnetic resonance spectroscopy. All three of these mutations were shown to affect the modification of the heptose region of the core, a region whose structure is critical to outer membrane stability. Mutation of waaY resulted in a core oligosaccharide devoid of phosphate on HepII. Mutation of waaQ resulted in loss of the branch HepIII residue on HepII and impeded the activity of WaaY. Mutation of waaP resulted in loss of phosphoryl substituents on HepI and obviated WaaQ and WaaY activity. Only mutation of waaP resulted in hypersensitivity to novobiocin and sodium dodecyl sulfate, a characteristic of deep-rough mutations.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Whitfield, C (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.		Heinrichs, David/ABD-5702-2021	Heinrichs, David/0000-0002-7217-2456				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amor PA, 1997, MOL MICROBIOL, V26, P145, DOI 10.1046/j.1365-2958.1997.5631930.x; APPELMELK BJ, 1994, MICROBIOL-UK, V140, P1119, DOI 10.1099/13500872-140-5-1119; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DROGE W, 1968, EUR J BIOCHEM, V4, P134, DOI 10.1111/j.1432-1033.1968.tb00183.x; GIBB AP, 1992, J INFECT DIS, V166, P1051, DOI 10.1093/infdis/166.5.1051; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HASIN M, 1982, J BIOL CHEM, V257, P2475; HELANDER IM, 1989, EUR J BIOCHEM, V185, P541, DOI 10.1111/j.1432-1033.1989.tb15147.x; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; HOLST O, 1992, BACTERIAL ENDOTOXIC, V1, P134; JANSSON PE, 1981, EUR J BIOCHEM, V115, P571; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; MUHLRADT P, 1968, EUR J BIOCHEM, V4, P139, DOI 10.1111/j.1432-1033.1968.tb00184.x; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; Olsthoorn MMA, 1998, J BIOL CHEM, V273, P3817, DOI 10.1074/jbc.273.7.3817; PARKER CT, 1992, J BACTERIOL, V174, P2525, DOI 10.1128/jb.174.8.2525-2538.1992; PARKER CT, 1992, J BACTERIOL, V174, P930, DOI 10.1128/jb.174.3.930-934.1992; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; Sambrook J., 2002, MOL CLONING LAB MANU; SAWARDEKER JH, 1967, ANAL CHEM, V39, P1602; SCHMIDT G, 1969, EUR J BIOCHEM, V10, P501, DOI 10.1111/j.1432-1033.1969.tb00717.x; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHWEIZER HP, 1993, BIOTECHNIQUES, V15, P831; Severn WB, 1996, J BACTERIOL, V178, P1731, DOI 10.1128/jb.178.6.1731-1741.1996; SIRISENA DM, 1994, J BACTERIOL, V176, P2379, DOI 10.1128/JB.176.8.2379-2385.1994; SUSSKIND M, 1995, CARBOHYD RES, V269, pC1, DOI 10.1016/0008-6215(95)00002-B; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; Whitfield C., 1994, P437	35	122	133	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 9	1998	273	41					26310	26316		10.1074/jbc.273.41.26310	http://dx.doi.org/10.1074/jbc.273.41.26310			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	127WJ	9756860	hybrid			2022-12-25	WOS:000076373300014
J	Ichaso, N; Rodriguez, RE; Martin-Zanca, D; Gonzalez-Sarmiento, R				Ichaso, N; Rodriguez, RE; Martin-Zanca, D; Gonzalez-Sarmiento, R			Genomic characterization of the human trkC gene	ONCOGENE			English	Article						trkC gene; intron/exon structure; promoter sequence	NEUROTROPHIN RECEPTOR TRKC; MESSENGER-RNA; MOLECULAR-CLONING; RAT TRKC; EXPRESSION; NEUROBLASTOMAS; AFFERENTS; MUTATIONS; ONCOGENE; FAMILY	The trkC gene encodes the high-affinity receptor for neurotrophin 3 and plays an important role in the regulation of the survival and differentiation of the mammalian nervous system and in heart development. Chromosomal rearrangements of trkC have been recently reported in congenital fibrosarcoma and it has been proposed that abnormal activation of this gene might be involved in tumor development. To facilitate the search for new mutations and rearrangements in the human trkC locus we have partially characterized its genomic organization by restriction mapping and have obtained the complete intron-exon structure. Our results show that human trkC consists of 20 exons, including two that encode the inserts present in the extracellular and tyrosine kinase domains, and another two that encode the carboxyl-terminal tail of the truncated TRKC isoform. Analysis of the 5' flanking region revealed the absence of TATA box, a very high content in C/G compatible with a CpG island and the presence of putative binding sites for the AP1, AP2, GC, ATF, BRN2, AML1 and Nkx2.5 transcription factors.	Univ Salamanca, Dept Med, Unidad Med Mol, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain; Univ Salamanca, CSIC, Inst Microbiol Bioquim, E-37008 Salamanca, Spain	University of Salamanca; University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Gonzalez-Sarmiento, R (corresponding author), Univ Salamanca, Dept Med, Unidad Med Mol, Avda Campo Charro S-N, Salamanca 37007, Spain.		Gonzalez-Sarmiento, Rogelio/V-5526-2019	Gonzalez-Sarmiento, Rogelio/0000-0002-2726-6795; Rodriguez Rodriguez, Raquel/0000-0003-1805-3066				AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARKER PA, 1993, J BIOL CHEM, V268, P15150; Chang BB, 1998, J BIOL CHEM, V273, P39, DOI 10.1074/jbc.273.1.39; Donovan MJ, 1996, NAT GENET, V14, P210, DOI 10.1038/ng1096-210; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; Greco A, 1996, ONCOGENE, V13, P2463; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCGREGOR LM, 1994, GENOMICS, V22, P267, DOI 10.1006/geno.1994.1383; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ryden M, 1996, BRIT J CANCER, V74, P773, DOI 10.1038/bjc.1996.435; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SEGAL RA, 1994, P NATL ACAD SCI USA, V91, P12867, DOI 10.1073/pnas.91.26.12867; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; Tessarollo L, 1997, P NATL ACAD SCI USA, V94, P14776, DOI 10.1073/pnas.94.26.14776; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; Yamashiro DJ, 1996, ONCOGENE, V12, P37	30	26	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1871	1875		10.1038/sj.onc.1202100	http://dx.doi.org/10.1038/sj.onc.1202100			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778053				2022-12-25	WOS:000076303300013
J	Morton, NM; Emilsson, V; Liu, YL; Cawthorne, MA				Morton, NM; Emilsson, V; Liu, YL; Cawthorne, MA			Leptin action in intestinal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; OBESE GENE; FOOD-INTAKE; OB/OB MICE; DIABETIC MICE; OB PROTEIN; DB/DB MICE; RECEPTOR; ACTIVATION; IDENTIFICATION	The adipocyte hormone leptin activates signal transducer and activator of transcription 3 (STAT3) in the hypothalamus, mediating increased satiety and increased energy expenditure. To date, leptin-mediated activation of the STAT pathway in vivo has not been established in tissues other than hypothalamus. We now describe leptin receptor expression and in vivo signaling in discrete regions of the mouse gastrointestinal tract. Expression of the functional isoform leptin receptor (OB-Rb) is restricted to the jejunum and is readily detected by RT-PCR in isolated enterocytes from this site. Intravenous injection of leptin rapidly induced nuclear STATE DNA binding activity in jejunum of +/+ and obese (ob/ob) mice but had no effect in the diabetic (db/db) mouse that lacks the OB-Rb isoform. In addition, an induction of the immediate-early gene c-fos is observed in jejunum in vitro. Leptin-mediated induction of a number of immediate-early genes and activation of STAT3 and STATE in a human model of small intestine epithelium, CACO-2 cells, corroborate this effect. Furthermore, intravenous leptin administration caused a significant a-fold reduction in the apolipoprotein AIV transcript levels in jejunum 90 min after a fat load. Our results suggest that the epithelium of jejunum is a direct target of leptin action, and this activity is dependent on the presence of OB-Rb. Lack of leptin or resistance to leptin action in this site may contribute to obesity and its related syndromes by directly affecting lipid handling.	Univ Buckingham, Clore Lab, Buckingham MK18 1EG, England	University of Buckingham	Emilsson, V (corresponding author), Univ Buckingham, Clore Lab, Hunter St, Buckingham MK18 1EG, England.	valur.emilsson@buck.ac.uk	Morton, NICHOLAS/ABF-3774-2020	Emilsson, Valur/0000-0001-9982-0524				Angelin B, 1997, CURR OPIN LIPIDOL, V8, P337, DOI 10.1097/00041433-199712000-00003; BARRACHINA MD, 1997, AM J PHYSIOL-REG I, V41, pR1007; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EMILSSON V, 1997, DIABETES, V4, P17; FEINGOLD KR, 1990, ENDOCRINOLOGY, V127, P2247, DOI 10.1210/endo-127-5-2247; FLINT N, 1991, BIOCHEM J, V280, P331, DOI 10.1042/bj2800331; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hamann A, 1997, DIABETOLOGIA, V40, P810, DOI 10.1007/s001250050753; Islam MS, 1997, BIOCHEM BIOPH RES CO, V238, P851, DOI 10.1006/bbrc.1997.7399; Kalogeris TJ, 1996, AM J PHYSIOL-GASTR L, V270, pG277, DOI 10.1152/ajpgi.1996.270.2.G277; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; Liu YL, 1997, FEBS LETT, V411, P351, DOI 10.1016/S0014-5793(97)00732-1; Lostao MP, 1998, FEBS LETT, V423, P302, DOI 10.1016/S0014-5793(98)00110-0; Mercer JG, 1996, J NEUROENDOCRINOL, V8, P733, DOI 10.1046/j.1365-2826.1996.05161.x; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; STREAMSON CC, 1996, SCIENCE, V271, P994; Takahashi Y, 1997, J BIOL CHEM, V272, P12897, DOI 10.1074/jbc.272.20.12897; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; White DW, 1997, P NATL ACAD SCI USA, V94, P10657, DOI 10.1073/pnas.94.20.10657; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	34	205	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 2	1998	273	40					26194	26201		10.1074/jbc.273.40.26194	http://dx.doi.org/10.1074/jbc.273.40.26194			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125XU	9748302	hybrid			2022-12-25	WOS:000076263100093
J	Thomas, SC; Ryan, MA; Shanley, TP; Wong, HR				Thomas, SC; Ryan, MA; Shanley, TP; Wong, HR			Induction of the stress response with prostaglandin A(1) increases I-kappa B alpha gene expression	FASEB JOURNAL			English	Article						PGA(1); NF-kappa B; interleukin 8; inflammation	HEAT-SHOCK RESPONSE; TRANSCRIPTION FACTOR; NUCLEAR TRANSLOCATION; ENDOTHELIAL-CELLS; MORTALITY-RATE; ACTIVATION; INHIBITION; PROMOTER; APOPTOSIS; PROTEINS	I-kappa B alpha is an intracellular protein that functions as a primary inhibitor of the proinflammatory transcription factor NF-KB. Induction of the stress response with heat shock was previously demonstrated to induce I-kappa B alpha gene expression. Because the stress response can also be induced by nonthermal stimuli, we determined whether induction of the stress response with prostaglandin A(1) (PGA(1)) would induce I-kappa B alpha gene expression. Treatment of human bronchial epithelium (BEAS-2B cells) with PGA(1) induced nuclear translocation of heat shock factor 1, thus confirming that PGA(1) induces the stress response in BEAS-2B cells. Induction of the stress response with PGA(1) increased I-kappa B alpha mRNA expression in a time-dependent manner and increased I-kappa B alpha peptide expression. Transient transfection assays involving a human I-kappa B alpha promoter-luciferase reporter construct demonstrated that induction of the stress response with PGA1 activated the I-kappa B alpha promoter. Induction of the stress response with PGA1 and concomitant induction of I-kappa B alpha were associated with inhibition of TNF-alpha-mediated secretion of interleukin 8 and with inhibition of TNF-alpha-mediated nuclear translocation and activation of NF-kappa B. These data demonstrate that induction of the stress response, by a nonthermal stimulus, increases I-kappa B alpha gene expression by a mechanism involving activation of the I-kappa B alpha promoter. Coupled with previous data demonstrating heat shock-mediated induction of I-kappa B alpha gene expression, these data suggest that I-kappa B alpha may be considered to be one of the stress proteins. The functional consequences of stress response-mediated I-kappa B alpha gene expression may involve attenuation of cellular proinflammatory responses.	Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Wong, HR (corresponding author), Childrens Hosp, Med Ctr, Div Crit Care Med, OSB5,3333 Burnet Ave, Cincinnati, OH 45229 USA.	wonghr@chmcc.org		Wong, Hector/0000-0001-7989-1173; Shanley, Thomas/0000-0001-8936-377X	NICHD NIH HHS [HD-28827-05] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; BOND U, 1985, MOL CELL BIOL, V5, P949, DOI 10.1128/MCB.5.5.949; Chen CG, 1996, MOL IMMUNOL, V33, P57, DOI 10.1016/0161-5890(95)00128-X; CONWAY EM, 1994, J BIOL CHEM, V269, P22804; CONWAY EM, 1995, J BIOL CHEM, V270, P17011, DOI 10.1074/jbc.270.28.17011; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DeMeester SL, 1997, ARCH SURG-CHICAGO, V132, P1283; deVera ME, 1996, HEPATOLOGY, V24, P1238; Feinstein D.L., 1996, J BIOL CHEM, V271, P17224; GOLDENBERG CJ, 1988, J BIOL CHEM, V263, P19734; Hauser GJ, 1996, AM J PHYSIOL-HEART C, V271, pH2529, DOI 10.1152/ajpheart.1996.271.6.H2529; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Klosterhalfen B, 1997, SHOCK, V7, P254, DOI 10.1097/00024382-199704000-00003; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KWON OJ, 1994, AM J PHYSIOL, V267, P6398; LANKS KW, 1986, EXP CELL RES, V165, P1, DOI 10.1016/0014-4827(86)90528-8; MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SCHMIDT JA, 1988, J IMMUNOL, V141, P2027; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SNYDER YM, 1992, J LEUKOCYTE BIOL, V51, P181, DOI 10.1002/jlb.51.2.181; VILLAR J, 1994, CRIT CARE MED, V22, P914; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; Wong HR, 1996, AM J RESP CELL MOL, V15, P745, DOI 10.1165/ajrcmb.15.6.8969269; Wong HR, 1997, J CLIN INVEST, V99, P2423, DOI 10.1172/JCI119425; Wong HR, 1997, AM J PHYSIOL-LUNG C, V272, pL132, DOI 10.1152/ajplung.1997.272.1.L132; Wong HR, 1997, BIOCHEM BIOPH RES CO, V231, P257, DOI 10.1006/bbrc.1997.6076; Wong HR, 1995, AM J PHYSIOL-LUNG C, V269, pL843, DOI 10.1152/ajplung.1995.269.6.L843; Wong HR, 1997, AM J PHYSIOL-LUNG C, V273, pL1, DOI 10.1152/ajplung.1997.273.1.L1; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013	37	41	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1371	1378		10.1096/fasebj.12.13.1371	http://dx.doi.org/10.1096/fasebj.12.13.1371			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761780				2022-12-25	WOS:000076402000012
